PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Stutchfield, P; Whitaker, R; Russell, I				Stutchfield, P; Whitaker, R; Russell, I		ASTECS Res Team	Antenatal betamethasone and incidence of neonatal respiratory distress after elective caesarean section: pragmatic randomised trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TRANSIENT TACHYPNEA; MORBIDITY; DELIVERY; NEWBORN; FLUID	Objective To test whether steroids reduce respiratory distress in babies born by elective caesarean section at term. Design Multicentre pragmatic randomised trial. Setting Ten maternity units. Participants 998 consenting women randomised at decision to deliver by elective caesarean section; 503 randomised to treatment. group. Interventions The treatment group received two intramuscular doses of 12 mg betamethasone in the 48 hours before delivery. The control group received treatment as usual. Outcome measures The primary outcome was admission to special care baby unit with respiratory distress. Secondary outcomes were severity of respiratory distress and level of care in response. Results Sex, birth weight, and gestation were not different between the two groups. Of the 35 babies admitted to special baby units with respiratory distress, 24 were in the control group and 11 in the intervention group (P = 0.02). The incidence of admission with respiratory distress was 0.051 in the control group and 0.024 in the treatment group (relative risk 0.46, 95% confidence interval 0.23 to 0.93). The incidence of transient tachypnoea of the newborn was 0.040 in the control group and 0.021 in the treatment group (0.54, 0.26 to 1.12). The incidence of respiratory distress syndrome was 0.011 in the control group and 0.002 in the treatment group (0.21, 0.03 to 1.32). Conclusions Antenatal betamethasone and delaying delivery until 39 weeks both reduce admissions to a special care baby unit with respiratory distress after elective caesarean section at term.	Glan Clwyd Gen Hosp, Conwy & Denbighshire NHS Trust, Rhyl LL18 5UJ, Denbighshire, Wales; Univ Wales, Inst Med & Social Care Res, Bangor LL57 2PX, Gwynedd, Wales	Bangor University	Stutchfield, P (corresponding author), Glan Clwyd Gen Hosp, Conwy & Denbighshire NHS Trust, Rhyl LL18 5UJ, Denbighshire, Wales.	DrPeter.Stutchfleld@cd-tr.wales.nhs.uk	Whitaker, Rhiannon/G-6278-2012; Russell, Ian T/H-1181-2012	Whitaker, Rhiannon/0000-0003-4305-3236				AVERY ME, 1966, AM J DIS CHILD, V111, P380, DOI 10.1001/archpedi.1966.02090070078010; COOKE RWI, 1992, ARCH DIS CHILD-FETAL, V67, P868; Cotzias CS, 2001, EUR J OBSTET GYN R B, V97, P15, DOI 10.1016/S0301-2115(00)00360-2; CROWLEY P, 1990, BRIT J OBSTET GYNAEC, V97, P11, DOI 10.1111/j.1471-0528.1990.tb01711.x; Crowley P, 2007, COCHRANE DB SYST REV, V18, DOI [10.1002/14651858.CD000065, DOI 10.1002/14651858.CD000065, 10.1002/14651858.CD000065.pub2, DOI 10.1002/14651858.CD000065.PUB2]; Demissie K, 1998, PEDIATRICS, V102, P84, DOI 10.1542/peds.102.1.84; *DEP HLTH, 2004, NHS MAT STAT ENGL 20; HILLAN EM, 1995, J ADV NURS, V22, P1035; Madar J, 1999, ACTA PAEDIATR, V88, P1244, DOI 10.1080/080352599750030365; MCCARTHY M, 1994, LANCET, V343, P726, DOI 10.1016/S0140-6736(94)91598-9; MORRISON JJ, 1995, BRIT J OBSTET GYNAEC, V102, P101, DOI 10.1111/j.1471-0528.1995.tb09060.x; National Collaborating Centre for Women's and Children's Health, 2004, CAES SECT CLIN GUID; OBrodovich HM, 1996, P ASSOC AM PHYSICIAN, V108, P345; Quist-Therson EC, 1999, ACTA OBSTET GYN SCAN, V78, P388, DOI 10.1034/j.1600-0412.1999.780508.x; RIMMER S, 1982, ARCH DIS CHILD, V57, P63; ROBERT MF, 1976, NEW ENGL J MED, V294, P357, DOI 10.1056/NEJM197602122940702; *ROYAL COLL OBST G, 2001, NAT SENT CAES SECT A; *ROYAL COLL OBST G, 2004, ECOG GUID, P1; SCHATZ M, 1991, AM J DIS CHILD, V145, P156, DOI 10.1001/archpedi.1991.02160020046013; Smith GCS, 2004, ARCH DIS CHILD, V89, P956, DOI 10.1136/adc.2003.045971; SYMANSKI ME, 1992, J NURSE-MIDWIFERY, V37, pS67, DOI 10.1016/0091-2182(92)90010-Z; WALTERS DV, 1978, PEDIATR RES, V12, P239, DOI 10.1203/00006450-197803000-00017; WATLERS DV, 1978, PEDIATR RES, V12, P239; 2004, SUNDAY TIMES    0425, P14	24	253	270	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 24	2005	331	7518					662	664A		10.1136/bmj.38547.416493.06	http://dx.doi.org/10.1136/bmj.38547.416493.06			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970HH	16115831	Bronze, Green Published			2022-12-28	WOS:000232295400016
J	Varela, I; Cadinanos, J; Pendas, AM; Gutierrez-Fernandez, A; Folgueras, AR; Sanchez, LM; Zhou, ZJ; Rodriguez, FJ; Stewart, CL; Vega, JA; Tryggvason, K; Freije, JMP; Lopez-Otin, C				Varela, I; Cadinanos, J; Pendas, AM; Gutierrez-Fernandez, A; Folgueras, AR; Sanchez, LM; Zhou, ZJ; Rodriguez, FJ; Stewart, CL; Vega, JA; Tryggvason, K; Freije, JMP; Lopez-Otin, C			Accelerated ageing in mice deficient in Zmpste24 protease is linked to p53 signalling activation	NATURE			English	Article							A-TYPE LAMINS; HUTCHINSON-GILFORD PROGERIA; LIFE-SPAN; IN-VIVO; METALLOPROTEINASE; SENESCENCE; PHENOTYPES; MUTATIONS; CANCER; CELLS	Zmpste24 ( also called FACE- 1) is a metalloproteinase involved in the maturation of lamin A ( Lmna), an essential component of the nuclear envelope(1 - 3). Both Zmpste24- and Lmna- deficient mice exhibit profound nuclear architecture abnormalities and multiple histopathological defects that phenocopy an accelerated ageing process(1,2,4,5). Similarly, diverse human progeroid syndromes are caused by mutations in ZMPSTE24 or LMNA genes(6 - 10). To elucidate the molecular mechanisms underlying these devastating diseases, we have analysed the transcriptional alterations occurring in tissues from Zmpste24- deficient mice. We demonstrate that Zmpste24 deficiency elicits a stress signalling pathway that is evidenced by a marked upregulation of p53 target genes, and accompanied by a senescence phenotype at the cellular level and accelerated ageing at the organismal level. These phenotypes are largely rescued in Zmpste24 (-/-) Lmna (+/-) mice and partially reversed in Zmpste24 (-/-) p53 (-/-) mice. These findings provide evidence for the existence of a checkpoint response activated by the nuclear abnormalities caused by prelamin A accumulation, and support the concept that hyperactivation of the tumour suppressor p53 may cause accelerated ageing(11).	Inst Univ Oncol, Fac Med, Dept Bioquim & Biol Mol, Oviedo, Spain; Univ Oviedo, Dept Morfol & Biol Celular, E-33006 Oviedo, Spain; Karolinska Inst, Dept Biochem & Biophys, Div Matrix Biol, S-17177 Stockholm, Sweden; NCI, Frederick, MD 21702 USA	University of Oviedo; Instituto Universitario de Oncologia de Asturias; University of Oviedo; Karolinska Institutet; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lopez-Otin, C (corresponding author), Inst Univ Oncol, Fac Med, Dept Bioquim & Biol Mol, Oviedo, Spain.	clo@uniovi.es	Varela, Ignacio/G-1699-2016; Vega, Jose A/AAG-3209-2021; Freije, José M.P./A-6535-2008; Gutierrez-Fernandez, Ana/AAS-9954-2021; López-Otín, Carlos/AAB-2106-2020; Gutierrez-Fernandez, Ana/ABG-6678-2020; Varela, Ignacio/AAA-7680-2021; zhou, zhongjun/D-4818-2012; Pendas, Alberto M/L-1017-2014; Folgueras, Alicia/B-3281-2017; Zhou, Zhongjun/C-4476-2009	Varela, Ignacio/0000-0002-0969-506X; Freije, José M.P./0000-0002-4688-8266; Gutierrez-Fernandez, Ana/0000-0002-9287-8843; López-Otín, Carlos/0000-0001-6964-1904; Varela, Ignacio/0000-0002-0969-506X; Folgueras, Alicia/0000-0003-3426-9502; Pendas, Alberto M/0000-0001-9264-3721; Cadinanos, Juan/0000-0001-7561-7759; Zhou, Zhongjun/0000-0001-7092-8128	NATIONAL CANCER INSTITUTE [Z01BC010377] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal AK, 2003, HUM MOL GENET, V12, P1995, DOI 10.1093/hmg/ddg213; Bergo MO, 2002, P NATL ACAD SCI USA, V99, P13049, DOI 10.1073/pnas.192460799; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Campisi J, 2003, NAT REV CANCER, V3, P339, DOI 10.1038/nrc1073; Chen LS, 2003, LANCET, V362, P440, DOI 10.1016/S0140-6736(03)14069-X; Corrigan DP, 2005, BIOCHEM J, V387, P129, DOI 10.1042/BJ20041359; De Sandre-Giovannoli A, 2003, SCIENCE, V300, P2055, DOI 10.1126/science.1084125; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; Fei PW, 2002, CANCER RES, V62, P7316; Fong LG, 2004, P NATL ACAD SCI USA, V101, P18111, DOI 10.1073/pnas.0408558102; Hutchison CJ, 2004, NAT CELL BIOL, V6, P1062, DOI 10.1038/ncb1104-1062; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Johnson BR, 2004, P NATL ACAD SCI USA, V101, P9677, DOI 10.1073/pnas.0403250101; LIU B, 2005, NAT MED, V111, P780; Maier B, 2004, GENE DEV, V18, P306, DOI 10.1101/gad.1162404; Mounkes LC, 2003, NATURE, V423, P298, DOI 10.1038/nature01631; Navarro CL, 2005, HUM MOL GENET, V14, P1503, DOI 10.1093/hmg/ddi159; Pendas AM, 2002, NAT GENET, V31, P94, DOI 10.1038/ng871; Petriv OI, 2004, J BIOL CHEM, V279, P19996, DOI 10.1074/jbc.M400207200; Qiu WH, 2004, AM J PATHOL, V165, P1689, DOI 10.1016/S0002-9440(10)63425-6; Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Sharpless NE, 2004, J CLIN INVEST, V113, P160, DOI 10.1172/JCI200420761; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Yan T, 1999, BIOCHEM BIOPH RES CO, V257, P163, DOI 10.1006/bbrc.1999.0423; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517	30	339	355	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 22	2005	437	7058					564	568		10.1038/nature04019	http://dx.doi.org/10.1038/nature04019			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	966FF	16079796				2022-12-28	WOS:000232004800053
J	Huang, T; Bohlenius, H; Eriksson, S; Parcy, F; Nilsson, O				Huang, T; Bohlenius, H; Eriksson, S; Parcy, F; Nilsson, O			RETRACTED: The mRNA of the Arabidopsis gene FT moves from leaf to shoot apex and induces flowering (Retracted Article. See vol 316, pg 367, 2007)	SCIENCE			English	Article; Retracted Publication							CONSTANS; PROTEIN; PLANTS; THALIANA; MOVEMENT; SIGNALS; PHLOEM	Day length controls flowering time in many plants. The day-length signal is perceived in the leaf, but how this signal is transduced to the shoot apex, where floral initiation occurs, is not known. In Arabidopsis, the day-length response depends on the induction of the FLOWERING LOCUS T (FT) gene. We show here that local induction of FT in a single Arabidopsis leaf is sufficient to trigger flowering. The FT messenger RNA is transported to the shoot apex, where downstream genes are activated. These data suggest that the FT mRNA is an important component of the elusive "florigen" signal that moves from leaf to shoot apex.	Swedish Univ Agr Sci, Dept Forest Genet & Plant Physiol, Umea Plant Sci Ctr, S-90183 Umea, Sweden; Univ Grenoble 1, INRA, CEA,Lab Physiol Cellulaire Vegetale, CNRS,UMR 5168,DRDC PCV, F-38054 Grenoble, France	Swedish University of Agricultural Sciences; Umea University; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); CNRS - National Institute for Biology (INSB); INRAE; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA	Nilsson, O (corresponding author), Swedish Univ Agr Sci, Dept Forest Genet & Plant Physiol, Umea Plant Sci Ctr, S-90183 Umea, Sweden.	Ove.Nilsson@genfys.slu.se		Parcy, Francois/0000-0003-2191-500X				Abe M, 2005, SCIENCE, V309, P1052, DOI 10.1126/science.1115983; An HL, 2004, DEVELOPMENT, V131, P3615, DOI 10.1242/dev.01231; Ayre BG, 2004, PLANT PHYSIOL, V135, P2271, DOI 10.1104/pp.104.040592; CHAILAKHYAN MKH, 1936, DOKL ACAD SCI URSS, V13, P77; Colasanti J, 2000, TRENDS BIOCHEM SCI, V25, P236, DOI 10.1016/S0968-0004(00)01542-5; Corbesier L, 2005, PLANT CELL ENVIRON, V28, P54, DOI 10.1111/j.1365-3040.2005.01283.x; Ding B, 2003, CURR OPIN PLANT BIOL, V6, P596, DOI 10.1016/j.pbi.2003.09.010; Hempel FD, 1997, DEVELOPMENT, V124, P3845; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; Kim M, 2001, SCIENCE, V293, P287, DOI 10.1126/science.1059805; KNOTT JAMES E., 1934, PROC AMER SOC HORT SCI, V31, P152; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; MANDEL MA, 1992, NATURE, V360, P273, DOI 10.1038/360273a0; SEVERIN K, 1990, PLANT MOL BIOL, V15, P827, DOI 10.1007/BF00039423; Takada S, 2003, PLANT CELL, V15, P2856, DOI 10.1105/tpc.016345; Valverde F, 2004, SCIENCE, V303, P1003, DOI 10.1126/science.1091761; Wigge PA, 2005, SCIENCE, V309, P1056, DOI 10.1126/science.1114358; Xoconostle-Cazares B, 1999, SCIENCE, V283, P94, DOI 10.1126/science.283.5398.94; Yanovsky MJ, 2003, NAT REV MOL CELL BIO, V4, P265, DOI 10.1038/nrm1077; Yoo BC, 2004, PLANT CELL, V16, P1979, DOI 10.1105/tpc.104.023614; ZEEVAART JAD, 1976, ANNU REV PLANT PHYS, V27, P321, DOI 10.1146/annurev.pp.27.060176.001541; ZEEVAART JAD, 1985, HDB FLOWERING, P239	22	176	224	3	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 9	2005	309	5741					1694	1696		10.1126/science.1117768	http://dx.doi.org/10.1126/science.1117768			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	963WK	16099949				2022-12-28	WOS:000231836700035
J	Faiz, MA; Bin Yunus, E; Rahman, MR; Islam, F; Hoque, MG; Hasan, MU; Samad, R; Aung, S; Thein, S; Than, M; Thwe, Y; Ohn, KM; Hla, S; Lwin, S; Htut, Y; Lin, K; Kyaw, MP; Win, N; Aung, WN; Win, M; Oo, AZ; Aung, Z; Shein, OM; Kyi, MM; Myint, WW; Pyar, KP; Nyein, K; Win, KK; Mishra, SK; Mohanty, S; Pattnaik, RB; Acharya, SK; Mohanty, A; Mohapatra, D; Tijtra, E; Anstey, N; Price, R; Handoyo, T; Gampamola, D; Kenangalem, E; Takaendengan, D; Hardiyanto; Lampat, A; Harijanto, P; Dondorp, AE; Nosten, F; Day, N; Stepniewska, K; Tipmanee, P; Douthwaite, S; Silamut, K; Proux, S; Pongsawat, K; White, N				Faiz, MA; Bin Yunus, E; Rahman, MR; Islam, F; Hoque, MG; Hasan, MU; Samad, R; Aung, S; Thein, S; Than, M; Thwe, Y; Ohn, KM; Hla, S; Lwin, S; Htut, Y; Lin, K; Kyaw, MP; Win, N; Aung, WN; Win, M; Oo, AZ; Aung, Z; Shein, OM; Kyi, MM; Myint, WW; Pyar, KP; Nyein, K; Win, KK; Mishra, SK; Mohanty, S; Pattnaik, RB; Acharya, SK; Mohanty, A; Mohapatra, D; Tijtra, E; Anstey, N; Price, R; Handoyo, T; Gampamola, D; Kenangalem, E; Takaendengan, D; Hardiyanto; Lampat, A; Harijanto, P; Dondorp, AE; Nosten, F; Day, N; Stepniewska, K; Tipmanee, P; Douthwaite, S; Silamut, K; Proux, S; Pongsawat, K; White, N		SEAQUAMAT Grp	Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial	LANCET			English	Article							PLASMODIUM-FALCIPARUM; INTRAMUSCULAR ARTESUNATE; INTRAVENOUS QUININE; ANTIMALARIAL-DRUGS; ARTEMETHER; CHILDREN; DIHYDROARTEMISININ; PHARMACOKINETICS; TETRACYCLINE	Background In the treatment of severe malaria, intravenous artesunate is more rapidly acting than intravenous quinine in terms of parasite clearance, is safer, and is simpler to administer, but whether it can reduce mortality is uncertain. Methods We did an open-label randomised controlled trial in patients admitted to hospital with severe falciparum malaria in Bangladesh, India, Indonesia, and Myanmar. We assigned individuals intravenous artesunate 2.4 mg/kg bodyweight given as a bolus (n=730) at 0, 12, and 24 h, and then daily, or intravenous quinine (20 mg salt per kg loading dose infused over 4 h then 10 mg/kg infused over 2-8 h three times a day; n=731). Oral medication was substituted when possible to complete treatment. Our primary endpoint was death from severe malaria, and analysis was by intention to treat. Findings We assessed all patients randomised for the primary endpoint. Mortality in artesunate recipients was 15% (107 of 730) compared with 22% (164 of 731) in quinine recipients; an absolute reduction of 34.7% (95% CI 18.5-47.6%; p=0.0002). Treatment with artesunate was well tolerated, whereas quinine was associated with hypoglycaemia (relative risk 3.2, 1.3-7.8; p=0.009). Interpretation Artesunate should become the treatment of choice for severe falciparum malaria in adults.	Mahidol Univ, Fac Trop Med, Bangkok 10400, Thailand	Mahidol University	White, N (corresponding author), Mahidol Univ, Fac Trop Med, 420-6 Rajvithi Rd, Bangkok 10400, Thailand.	niclcw@tropmedres.ac	Nosten, Francois/AAC-5509-2019; White, Nicholas J/I-4629-2012; , Myat-Phone-Kyaw/P-1750-2019; White, Nick/AAC-6527-2019	Nosten, Francois/0000-0002-7951-0745; White, Nick/0000-0002-1897-1978; Stepniewska, Kasia/0000-0002-1713-6209; Price, Richard/0000-0003-2000-2874; , KHIN PHYU PYAR/0000-0003-3700-2838	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adjuik M, 2004, LANCET, V363, P9, DOI 10.1016/S0140-6736(03)15162-8; Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219; [Anonymous], 1990, Trans R Soc Trop Med Hyg, V84 Suppl 2, P1; Beales PF, 2000, T ROY SOC TROP MED H, V94, pS1; Brockman A, 2000, T ROY SOC TROP MED H, V94, P537, DOI 10.1016/S0035-9203(00)90080-4; *CHIN COOP RES GRO, 1979, CHIN MED J, V92, P811; Chotivanich K, 2002, J INFECT DIS, V185, P1538, DOI 10.1086/340213; CLYDE DF, 1970, J AMER MED ASSOC, V213, P2041, DOI 10.1001/jama.213.12.2041; Dondorp AM, 2000, PARASITOL TODAY, V16, P228, DOI 10.1016/S0169-4758(00)01666-5; Faiz Md. Abul, 2001, Indian Journal of Malariology, V38, P9; GIBODA M, 1988, J TROP MED HYG, V91, P205; Gravenor MB, 1998, P NATL ACAD SCI USA, V95, P7620, DOI 10.1073/pnas.95.13.7620; HIEN TT, 1992, T ROY SOC TROP MED H, V86, P582, DOI 10.1016/0035-9203(92)90137-2; Hien TT, 2004, ANTIMICROB AGENTS CH, V48, P4234, DOI 10.1128/AAC.48.11.4234-4239.2004; Hien TT, 1996, NEW ENGL J MED, V335, P76, DOI 10.1056/NEJM199607113350202; Ilett KF, 2002, BRIT J CLIN PHARMACO, V53, P23, DOI 10.1046/j.0306-5251.2001.01519.x; Jaroonvesama N, 1974, Southeast Asian J Trop Med Public Health, V5, P504; Leonardi E, 2001, T ROY SOC TROP MED H, V95, P182, DOI 10.1016/S0035-9203(01)90157-9; LI G, 1982, Journal of Traditional Chinese Medicine, V2, P125; LOOAREESUWAN S, 1990, J INFECT DIS, V161, P577, DOI 10.1093/infdis/161.3.577; Mithwani S, 2004, BRIT J CLIN PHARMACO, V57, P146, DOI 10.1046/j.1365-2125.2003.01986.x; Murphy SA, 1997, T ROY SOC TROP MED H, V91, P331, DOI 10.1016/S0035-9203(97)90097-3; Nealon C, 2002, ANTIMICROB AGENTS CH, V46, P3933, DOI 10.1128/AAC.46.12.3933-3939.2002; Newton PN, 2003, CLIN INFECT DIS, V37, P7, DOI 10.1086/375059; Phuong CXT, 1997, T ROY SOC TROP MED H, V91, P335, DOI 10.1016/S0035-9203(97)90099-7; PUKRITTAYAKAMEE S, 1994, T ROY SOC TROP MED H, V88, P324, DOI 10.1016/0035-9203(94)90102-3; RASHID R, 2000, BANGLADESH J MED, V11, P132; Silamut K, 2003, ANTIMICROB AGENTS CH, V47, P3795, DOI 10.1128/AAC.47.12.3795-3798.2003; Stepniewska K, 2001, T ROY SOC TROP MED H, V95, P637, DOI 10.1016/S0035-9203(01)90104-X; TERKUILE F, 1993, EXP PARASITOL, V76, P85, DOI 10.1006/expr.1993.1010; Udomsangpetch R, 1996, J INFECT DIS, V173, P691, DOI 10.1093/infdis/173.3.691; vanHensbroek MB, 1996, NEW ENGL J MED, V335, P69, DOI 10.1056/NEJM199607113350201; WATKINS WM, 1993, AM J TROP MED HYG, V49, P106, DOI 10.4269/ajtmh.1993.49.106; White NJ, 1996, NEW ENGL J MED, V335, P800, DOI 10.1056/NEJM199609123351107; WHITE NJ, 1983, NEW ENGL J MED, V309, P61, DOI 10.1056/NEJM198307143090201; WHITE NJ, 1995, T ROY SOC TROP MED H, V89, P462, DOI 10.1016/0035-9203(95)90063-2; WIN K, 1992, B WORLD HEALTH ORGAN, V70, P777; YEN LM, 1994, LANCET, V344, P786, DOI 10.1016/S0140-6736(94)92342-6	38	706	721	1	81	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 27	2005	366	9487					717	725						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958UV	16125588				2022-12-28	WOS:000231474600027
J	Dlott, DD				Dlott, DD			Ultrafast chemical exchange seen with 2D vibrational echoes	SCIENCE			English	Editorial Material							SPECTROSCOPY		Univ Illinois, Sch Chem Sci, Urbana, IL 61801 USA; Univ Illinois, Fredrick Seitz Mat Res Lab, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Dlott, DD (corresponding author), Univ Illinois, Sch Chem Sci, Urbana, IL 61801 USA.	dlott@scs.uiuc.edu		Dlott, Dana/0000-0001-8719-7093				BREWER RG, 1971, PHYS REV LETT, V27, P631, DOI 10.1103/PhysRevLett.27.631; EIGEN M, 1960, ANNU REV PHYS CHEM, V11, P307, DOI 10.1146/annurev.pc.11.100160.001515; GUTOWSKY HS, 1953, J CHEM PHYS, V21, P279, DOI 10.1063/1.1698874; GUTOWSKY HS, 1953, J CHEM PHYS, V21, P1688, DOI 10.1063/1.1698644; Kim YS, 2005, P NATL ACAD SCI USA, V102, P11185, DOI 10.1073/pnas.0504865102; MEIER BH, 1979, J AM CHEM SOC, V101, P6441, DOI 10.1021/ja00515a053; TOKMAKOFF A, 1995, ACCOUNTS CHEM RES, V28, P437, DOI 10.1021/ar00059a001; Zanni MT, 2001, CURR OPIN STRUC BIOL, V11, P516, DOI 10.1016/S0959-440X(00)00243-8; Zheng JR, 2005, SCIENCE, V309, P1338, DOI 10.1126/science.1116213	9	7	7	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 26	2005	309	5739					1333	1334		10.1126/science.1117435	http://dx.doi.org/10.1126/science.1117435			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TX	16123291				2022-12-28	WOS:000231543300032
J	Tsuda, H; Jafar-Nejad, H; Patel, AJ; Sun, Y; Chen, HK; Rose, MF; Venken, KJT; Botas, J; Orr, HT; Bellen, HJ; Zoghbi, HY				Tsuda, H; Jafar-Nejad, H; Patel, AJ; Sun, Y; Chen, HK; Rose, MF; Venken, KJT; Botas, J; Orr, HT; Bellen, HJ; Zoghbi, HY			The AXH domain of Ataxin-1 mediates neurodegeneration through its interaction with Gfi-1/senseless proteins	CELL			English	Article							FINGER TRANSCRIPTION FACTOR; SCA1 TRANSGENIC MICE; POLYGLUTAMINE-INDUCED DISEASE; FAMILIAL PARKINSONS-DISEASE; GREEN FLUORESCENT PROTEIN; SENSORY ORGAN; GENE-EXPRESSION; CELL-TYPES; DROSOPHILA; DIFFERENTIATION	Spinocerebellar ataxia type 1 (SCA1) is a neurodegenerative disease caused by an expanded glutamine tract in human Ataxin-1 (hAtx-1). The expansion stabilizes hAtx-1, leading to its accumulation. To understand how stabilized hAtx-1 induces selective neuronal degeneration, we studied Drosophila Atx-1 (dAtx-1), which has a conserved AXH domain but lacks a polyglutamine tract. Overexpression of hAtx-1 in fruit flies produces phenotypes similar to those of dAtx-1 but different from the polyglutamine peptide alone. We show that the Drosophila and mammalian transcription factors Senseless/Gfi-1 interact with Atx-1's AXH domain. In flies, overexpression of Atx-1 inhibits sensory-organ development by decreasing Senseless protein. Similarly, overexpression of wildtype and glutamine-expanded hAtx-1 reduces Gfi-1 levels in Purkinje cells. Deletion of the AXH domain abolishes the effects of glutamine-expanded hAtx-1 on Senseless/Gfi-1. Interestingly, loss of Gfi-1 mimics SCA1 phenotypes in Purkinje cells. These results indicate that the Atx-1/Gfi-1 interaction contributes to the selective Purkinje cell degeneration in SCA1.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Biochem, Minneapolis, MN 55455 USA; Univ Minnesota, Inst Human Genet, Minneapolis, MN 55455 USA	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Zoghbi, HY (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.	hzoghbi@bcm.tmc.edu	Venken, Koen/B-9909-2013; Jafar-Nejad, Hamed/B-9216-2008	Venken, Koen/0000-0003-0741-4698; Chen, Hung-Kai/0000-0002-2169-4924; Rose, Matthew/0000-0002-1148-4130; Zoghbi, Huda/0000-0002-0700-3349; Bellen, Hugo/0000-0001-5992-5989; Orr, Harry/0000-0001-6118-741X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS042179, R01NS042179, R01NS027699, R37NS022920, R01NS022920] Funding Source: NIH RePORTER; NICHD NIH HHS [HD024064, HD24064] Funding Source: Medline; NIGMS NIH HHS [T32-GM07526] Funding Source: Medline; NINDS NIH HHS [NS42179, NS27699, NS22920] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abdelilah-Seyfried S, 2000, GENETICS, V155, P733; Banfi S, 1996, HUM MOL GENET, V5, P33, DOI 10.1093/hmg/5.1.33; Bertrand N, 2002, NAT REV NEUROSCI, V3, P517, DOI 10.1038/nrn874; BRAND AH, 1993, DEVELOPMENT, V118, P401; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; Chartier-Harlin MC, 2004, LANCET, V364, P1167, DOI 10.1016/S0140-6736(04)17103-1; Chen HK, 2003, CELL, V113, P457, DOI 10.1016/S0092-8674(03)00349-0; Chen YW, 2004, J BIOL CHEM, V279, P3758, DOI 10.1074/jbc.M309817200; Clark HB, 1997, J NEUROSCI, V17, P7385; Dubruille R, 2002, DEVELOPMENT, V129, P5487, DOI 10.1242/dev.00148; Emamian ES, 2003, NEURON, V38, P375, DOI 10.1016/S0896-6273(03)00258-7; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; Frankfort BJ, 2001, NEURON, V32, P403, DOI 10.1016/S0896-6273(01)00480-9; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Gustafson K, 1996, GENOME, V39, P174, DOI 10.1139/g96-023; Hassan BA, 2000, NEURON, V25, P549, DOI 10.1016/S0896-6273(00)81059-4; Hock H, 2003, IMMUNITY, V18, P109, DOI 10.1016/S1074-7613(02)00501-0; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Ibanez P, 2004, LANCET, V364, P1169, DOI 10.1016/S0140-6736(04)17104-3; Jafar-Nejad H, 2004, MOL CELL BIOL, V24, P8803, DOI 10.1128/MCB.24.20.8803-8812.2004; Jafar-Nejad H, 2003, GENE DEV, V17, P2966, DOI 10.1101/gad.1122403; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Lieberman AP, 1999, ANN NEUROL, V46, P271, DOI 10.1002/1531-8249(199908)46:2<271::AID-ANA21>3.0.CO;2-M; Lin X, 2000, NAT NEUROSCI, V3, P157, DOI 10.1038/72101; Marsh JL, 2000, HUM MOL GENET, V9, P13, DOI 10.1093/hmg/9.1.13; Matilla A, 1998, J NEUROSCI, V18, P5508, DOI 10.1523/JNEUROSCI.18-14-05508.1998; Matilla A, 1997, NATURE, V389, P974, DOI 10.1038/40159; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; Mollereau B, 2000, MECH DEVELOP, V93, P151, DOI 10.1016/S0925-4773(00)00287-2; Mrak RE, 2004, J NEUROPATH EXP NEUR, V63, P679, DOI 10.1093/jnen/63.7.679; Nolo R, 2000, CELL, V102, P349, DOI 10.1016/S0092-8674(00)00040-4; Nolo R, 2001, GENETICS, V157, P307; Okazawa H, 2002, NEURON, V34, P701, DOI 10.1016/S0896-6273(02)00697-9; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; Parker DS, 2002, DEVELOPMENT, V129, P2565; Serra HG, 2004, HUM MOL GENET, V13, P2535, DOI 10.1093/hmg/ddh268; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Taroni F, 2004, NAT REV NEUROSCI, V5, P641, DOI 10.1038/nrn1474; Tsai CC, 2004, P NATL ACAD SCI USA, V101, P4047, DOI 10.1073/pnas.0400615101; Vila M, 2004, NAT MED, V10, pS58, DOI 10.1038/nm1068; Wallis D, 2003, DEVELOPMENT, V130, P221, DOI 10.1242/dev.00190; Yee AS, 2004, GENE, V336, P1, DOI 10.1016/j.gene.2004.04.004; YEH E, 1995, P NATL ACAD SCI USA, V92, P7036, DOI 10.1073/pnas.92.15.7036; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217; Zoghbi HY, 2001, METABOLIC MOL BASES, P5741	48	155	157	1	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 26	2005	122	4					633	644		10.1016/j.cell.2005.06.012	http://dx.doi.org/10.1016/j.cell.2005.06.012			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	959YI	16122429	Bronze			2022-12-28	WOS:000231555100017
J	Zhang, J; Song, XD; Li, YC; Richards, PG; Sun, XL; Waldhauser, F				Zhang, J; Song, XD; Li, YC; Richards, PG; Sun, XL; Waldhauser, F			Inner core differential motion confirmed by earthquake waveform doublets	SCIENCE			English	Article							SUPER-ROTATION; SCALE HETEROGENEITY; EXISTENCE; FAULT; TIMES	We analyzed 18 high-quality waveform doublets with time separations of up to 35 years in the South Sandwich Islands region, for which the seismic signals have traversed the inner core as PKP(DF). The doublets show a consistent temporal change of travel times at up to 58 stations in and near Alaska, and they show a dissimilarity of PKP(DF) coda. Using waveform doublets avoids artifacts of earthquake mislocations and contamination from small-scale heterogeneities. Our results confirm that Earth's inner core is rotating faster than the mantle and crust at about 0.3 degrees to 0.5 degrees per year.	Univ Illinois, Dept Geol, Urbana, IL 61801 USA; Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA	University of Illinois System; University of Illinois Urbana-Champaign; Columbia University	Song, XD (corresponding author), Univ Illinois, Dept Geol, Urbana, IL 61801 USA.	xsong@uiuc.edu	Zhang, Jian/F-2090-2011	Song, Xiaodong/0000-0002-5932-6916				Buffett BA, 2000, GEOPHYS RES LETT, V27, P3125, DOI 10.1029/2000GL011705; Collier JD, 2001, EARTH PLANET SC LETT, V193, P523, DOI 10.1016/S0012-821X(01)00520-9; Cormier VF, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2002JB001796; Creager KC, 1997, SCIENCE, V278, P1284, DOI 10.1126/science.278.5341.1284; GLATZMAIER GA, 1995, PHYS EARTH PLANET IN, V91, P63, DOI 10.1016/0031-9201(95)03049-3; GUBBINS D, 1981, J GEOPHYS RES, V86, P1695, DOI 10.1029/JB086iB12p11695; Laske G, 2003, GEODYNAMICS, V31, P5; Li AY, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2002GC000379; Li AY, 2003, GEODYNAMICS, V31, P23; Poupinet G, 2000, PHYS EARTH PLANET IN, V118, P77, DOI 10.1016/S0031-9201(99)00129-6; POUPINET G, 1984, J GEOPHYS RES, V89, P5719, DOI 10.1029/JB089iB07p05719; Schaff DP, 2004, SCIENCE, V303, P1176, DOI 10.1126/science.1093422; Song XD, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013822; Song XD, 2000, J GEOPHYS RES-SOL EA, V105, P7931, DOI 10.1029/1999JB900436; Song XD, 2000, J GEOPHYS RES-SOL EA, V105, P623, DOI 10.1029/1999JB900341; Song XD, 2001, PHYS EARTH PLANET IN, V124, P269, DOI 10.1016/S0031-9201(01)00182-0; Song XD, 2000, PHYS EARTH PLANET IN, V122, P221, DOI 10.1016/S0031-9201(00)00195-3; Song XD, 1996, NATURE, V382, P221, DOI 10.1038/382221a0; Souriau A, 2000, PHYS EARTH PLANET IN, V118, P13, DOI 10.1016/S0031-9201(99)00131-4; Souriau A, 1997, GEOPHYS RES LETT, V24, P2103, DOI 10.1029/97GL01933; Souriau A, 2003, GEODYNAMICS-US, V31, P65; Souriau A, 1998, SCIENCE, V281, P55, DOI 10.1126/science.281.5373.55; Vidale JE, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021240; Vidale JE, 2000, NATURE, V405, P445, DOI 10.1038/35013039; Vidale JE, 2000, NATURE, V404, P273, DOI 10.1038/35005059; Waldhauser F, 2000, B SEISMOL SOC AM, V90, P1353, DOI 10.1785/0120000006; Xu XX, 2003, GEOPHYS J INT, V152, P509, DOI 10.1046/j.1365-246X.2003.01852.x	27	92	105	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 26	2005	309	5739					1357	1360		10.1126/science.1113193	http://dx.doi.org/10.1126/science.1113193			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TX	16123296				2022-12-28	WOS:000231543300039
J	Donlan, J; Berger, J; Bock, CE; Bock, JH; Burney, DA; Estes, JA; Foreman, D; Martin, PS; Roemer, GW; Smith, FA; Soule, ME; Greene, HW				Donlan, J; Berger, J; Bock, CE; Bock, JH; Burney, DA; Estes, JA; Foreman, D; Martin, PS; Roemer, GW; Smith, FA; Soule, ME; Greene, HW			Re-wilding North America	NATURE			English	Editorial Material									Cornell Univ, Dept Ecol & Evolut Biol, Ithaca, NY 14853 USA; Wildlife Conservat Soc, Teton Field Off, Bronx, NY 10460 USA; Univ Colorado, Boulder, CO 80309 USA; Fordham Univ, New York, NY 10023 USA; Univ Calif Santa Cruz, US Geol Survey, Santa Cruz, CA 95064 USA; Rewilding Inst, Albuquerque, NM USA; Univ Arizona, Dept Geosci, Tucson, AZ USA; Univ New Mexico, Albuquerque, NM 87131 USA; New Mexico State Univ, Dept Fishery & Wildlife Sci, Las Cruces, NM 88003 USA	Cornell University; Wildlife Conservation Society; University of Colorado System; University of Colorado Boulder; Fordham University; United States Department of the Interior; United States Geological Survey; University of California System; University of California Santa Cruz; University of Arizona; University of New Mexico; New Mexico State University	Donlan, J (corresponding author), Cornell Univ, Dept Ecol & Evolut Biol, Ithaca, NY 14853 USA.		Smith, Felisa/ABE-6160-2021	Smith, Felisa/0000-0001-6262-436X				Byers J.A., 1997, AM PRONGHORN SOCIAL; DUFFIELD WJ, 1996, T 61 N AM WILDL NAT, P285; JANZEN DH, 1982, SCIENCE, V215, P19, DOI 10.1126/science.215.4528.19; Lonsdale RE, 1998, J GEOGR, V97, P108, DOI 10.1080/00221349808978835; Phillips A., 2001, COGRAZING CATTLE CAM; Schmidly, 2002, TEXAS NATURAL HIST C; Tordoff HB, 2001, CONSERV BIOL, V15, P528, DOI 10.1046/j.1523-1739.2001.015002528.x	7	215	223	10	326	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 18	2005	436	7053					913	914		10.1038/436913a	http://dx.doi.org/10.1038/436913a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955XQ	16107817				2022-12-28	WOS:000231263900020
J	Kastrati, A; Dibra, A; Eberle, S; Mehilli, J; de Lezo, JS; Goy, JJ; Ulm, K; Schomig, A				Kastrati, A; Dibra, A; Eberle, S; Mehilli, J; de Lezo, JS; Goy, JJ; Ulm, K; Schomig, A			Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease - Meta-analysis of randomized trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CLINICAL-TRIALS; RESTENOSIS; CARDIOLOGY; PREVENTION; FRONTIERS; RAPAMYCIN; QUALITY; LESIONS	Context Placement of sirolimus-eluting stents or paclitaxel-eluting stents has emerged as the predominant percutaneous treatment strategy in patients with coronary artery disease (CAD). Whether there are any differences in efficacy and safety between these 2 drug-eluting stents is unclear. Objective To compare outcomes of sirolimus-eluting and paclitaxel-eluting coronary stents on the basis of data generated by randomized head-to-head clinical trials. Data Sources PubMed and the Cochrane Central Register of Controlled Trials, conference proceedings from major cardiology meetings, and Internet-based sources of information on clinical trials in cardiology from January 2003 to April 2005. Study Selection Randomized trials comparing the sirolimus-eluting stent with the paclitaxel-eluting stent in patients with CAD reporting the outcomes of interest (target lesion revascularization, angiographic restenosis, stent thrombosis, myocardial infarction [MI] death, and the composite of death or MI) during a follow-up of at least 6 months. Data Extraction Two reviewers independently identified studies and abstracted data on sample size, baseline characteristics, and outcomes of interest. Data Synthesis Six trials, including 3669 patients, met the selection criteria. No significant heterogeneity was found across trials. Target lesion revascularization, the primary outcome of interest, was less frequently performed in patients who were treated with the sirolimus-eluting stent (5.1 %) vs the paclitaxel-eluting stent (7.8%) (odds ratio [OR], 0.64; 95% confidence interval [CI], 0.49-0,84; P=.001). Similarly, angiographic restenosis was less frequently observed among patients assigned to the sirolimus-eluting stent (9.3 %) vs the paclitaxel-eluting stent (13.1%) (OR, 0.68; 95% Cl, 0.55-0.86; P=.001). Event rates for sirolimus-eluting vs paclitaxel-eluting stents were 0.9% and 1.1 %, respectively, for stent thrombosis (P=.62); 1.4% and 1.6%, respectively, for death (P=.56); and 4.9% and 5.8%, respectively, for the composite of death or MI (P=.23). Conclusions Patients receiving sirolimus-eluting stents had a significantly lower risk of restenosis and target vessel revascularization compared with those receiving paclitaxel-eluting stents. Rates of death, death or MI, and stent thrombosis were similar.	Deutsch Herzzentrum Munich, D-80636 Munich, Germany; Tech Univ Munich, Inst Med Stat & Epidemiol, D-8000 Munich, Germany; Reina Sofia Hosp, Cordoba, Spain; Clin Cecil, Serv Cardiol, Lausanne, Switzerland	German Heart Centre Munich; Technical University of Munich; Hospital Universitario Reina Sofia - Cordoba	Kastrati, A (corresponding author), Deutsch Herzzentrum Munich, Lazarettstr 36, D-80636 Munich, Germany.	kastrati@dhm.mhn.de	Mehilli, Julinda/F-2629-2016; , Kastrati/Y-2389-2019; Suárez de Lezo, José/AAX-9084-2021	Suárez de Lezo, José/0000-0002-7621-3235				Altman DG, 2001, BRIT MED J, V323, P446, DOI 10.1136/bmj.323.7310.446; Ardissino D, 2004, JAMA-J AM MED ASSOC, V292, P2727, DOI 10.1001/jama.292.22.2727; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Colombo A, 2003, CIRCULATION, V108, P788, DOI 10.1161/01.CIR.0000086926.62288.A6; de Lezo JS, 2005, J AM COLL CARDIOL, V45, p75A; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dibra A, 2005, NEW ENGL J MED, V353, P663, DOI 10.1056/NEJMoa044372; Egger M, 1997, BMJ-BRIT MED J, V315, P1533, DOI 10.1136/bmj.315.7121.1533; Elezi S, 1998, J AM COLL CARDIOL, V32, P1866, DOI 10.1016/S0735-1097(98)00467-7; Goy JJ, 2005, J AM COLL CARDIOL, V45, P308, DOI 10.1016/j.jacc.2004.10.062; GREENLAND S, 1994, AM J EPIDEMIOL, V140, P290, DOI 10.1093/oxfordjournals.aje.a117248; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Iakovou I, 2005, JAMA-J AM MED ASSOC, V293, P2126, DOI 10.1001/jama.293.17.2126; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Juni P, 1999, JAMA-J AM MED ASSOC, V282, P1054, DOI 10.1001/jama.282.11.1054; Kastrati A, 1997, J AM COLL CARDIOL, V30, P1428, DOI 10.1016/S0735-1097(97)00334-3; Kastrati A, 2005, JAMA-J AM MED ASSOC, V293, P165, DOI 10.1001/jama.293.2.165; KASTRATI A, 2005, 2005 SCI SESS AM COL; Kereiakes DJ, 2005, J AM COLL CARDIOL, V45, P1206, DOI 10.1016/j.jacc.2005.01.005; Levin AD, 2004, P NATL ACAD SCI USA, V101, P9463, DOI 10.1073/pnas.0400918101; Macdonald GM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub2; MANTEL N, 1959, J NATL CANCER I, V22, P719; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; MORICE MC, 2005 SCI SESS AM COL; Moses JW, 2003, NEW ENGL J MED, V349, P1315, DOI 10.1056/NEJMoa035071; Perin Emerson C, 2005, Rev Cardiovasc Med, V6 Suppl 1, pS13; Rogers Campbell D K, 2005, Rev Cardiovasc Med, V6 Suppl 1, pS3; Schofer J, 2003, LANCET, V362, P1093, DOI 10.1016/S0140-6736(03)14462-5; Smith Elliot J, 2003, J Interv Cardiol, V16, P475, DOI 10.1046/j.1540-8183.2003.01058.x; Sousa JE, 2003, CIRCULATION, V107, P2383, DOI 10.1161/01.CIR.0000069331.67148.2F; Sousa JE, 2003, CIRCULATION, V107, P2274, DOI 10.1161/01.CIR.0000069330.41022.90; Stone GW, 2004, NEW ENGL J MED, V350, P221, DOI 10.1056/NEJMoa032441; Windecker S, 2005, NEW ENGL J MED, V353, P653, DOI 10.1056/NEJMoa051175; WINDECKER S, 2005, 2005 SCI SESS AM COL	35	245	267	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	2005	294	7					819	825		10.1001/jama.294.7.819	http://dx.doi.org/10.1001/jama.294.7.819			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955LI	16106007				2022-12-28	WOS:000231227000022
J	Balabanova, Y; Coker, R; Fedorin, I; Zakharova, S; Plavinskij, S; Krukov, N; Atun, R; Drobniewski, F				Balabanova, Y; Coker, R; Fedorin, I; Zakharova, S; Plavinskij, S; Krukov, N; Atun, R; Drobniewski, F			Variability in interpretation of chest radiographs among Russian clinicians and implications for screening programmes: observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OBSERVER VARIATION; TUBERCULOSIS; PERFORMANCE; AGREEMENT; ACCURACY	Objective To determine variability in interpretation of chest radiographs among tuberculosis specialists, radiologists, and respiratory specialists. Design Observational study. Setting Tuberculosis and respiratory disease services, Samara region, Russian Federation. Participants 10 1 clinicians involved in the diagnosis and management of pulmonary tuberculosis and respiratory diseases. Main outcome measures Interobserver and intraobserver agreement on the interpretation of 50 digital chest radiographs, using a scale of poor to very good agreement (kappa coefficient: <= 0.20 poor, 0.21-0.40 fair, 0.41-0.60 moderate, 0.61-0.80 good, and 0.81-1.00 very good). Results Agreement on the presence or absence of an abnormality was fair only (kappa = 0.380,95% confidence interval 0.376 to 0.384), moderate for localisation of the abnormality (0.448, 0.444 to 0.452), and fair for a diagnosis of tuberculosis (0.387, 0.382 to 0.391). The highest levels of agreement were among radiologists. Level of experience (years of work in the specialty) influenced agreement on presence of abnormalities and cavities. Levels of intraobserver agreement were fair. Conclusions Population screening for tuberculosis in Russia may be less than optimal owing to limited agreement on interpretation of chest radiographs, and may have implications for radiological screening programmes in other countries.	Guys Kings & St Thomas Med Sch, Dept Microbiol & Infect, Hlth Protect Agcy Natl Mycobacterium Reference Un, London, England; Samara Oblast Dispensary, Samara Reg TB Serv, Samara, Russia; Samara City TB Serv, Samara, Russia; St Petersburg Acad Postgrad Sci, Coll Publ Hlth, St Petersburg, Russia; Samara State Med Univ, Dept Internal Med, Samara, Russia; London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London, England; Univ London Imperial Coll Sci Technol & Med, Tanaka Business Sch, Ctr Hlth Management, London SW7 2AZ, England	University of London; King's College London; Samara State Medical University; University of London; London School of Hygiene & Tropical Medicine; Imperial College London	Drobniewski, F (corresponding author), Queen Marys Sch Med, Inst Cell & Mol Sci, Hlth Protect Agcy Natl Mycobacterium Reference Un, London E1 2AT, England.	francis.drobniewski@kcl.ac.uk	Plavinskij, Sviatoslav/C-8421-2014; Plavinskii, Sviatoslav/P-3194-2014; Atun, Rifat/AAH-5537-2021	Plavinskij, Sviatoslav/0000-0001-9159-6177; Plavinskii, Sviatoslav/0000-0001-9159-6177; Atun, Rifat/0000-0002-1531-5983				Albaum MN, 1996, CHEST, V110, P343, DOI 10.1378/chest.110.2.343; ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; Altman D.G., 1991, PRACTICAL STAT MED R; Brealey S, 2001, BRIT J RADIOL, V74, P307, DOI 10.1259/bjr.74.880.740307; Brealey S, 2001, CLIN RADIOL, V56, P341, DOI 10.1053/crad.2001.0678; COBLENTZ CL, 1991, INVEST RADIOL, V26, P115, DOI 10.1097/00004424-199102000-00004; COKER R, 2003, 1 I PUBL POL RES; Coker RJ, 2003, INT J TUBERC LUNG D, V7, P920; Dhingsa R, 2002, BRIT J RADIOL, V75, P136, DOI 10.1259/bjr.75.890.750136; Drobniewski F, 2003, CLIN INFECT DIS, V36, P234, DOI 10.1086/345530; Drobniewski F, 1996, TUBERCLE LUNG DIS, V77, P297, DOI 10.1016/S0962-8479(96)90092-1; Du Toit G, 2002, INT J TUBERC LUNG D, V6, P814; Erokhin V V, 2003, Probl Tuberk, P48; Kwong JS, 1996, CHEST, V110, P339, DOI 10.1378/chest.110.2.339; Pillay V, 2001, INT J TUBERC LUNG D, V5, P946; Potchen EJ, 2000, RADIOLOGY, V217, P456, DOI 10.1148/radiology.217.2.r00nv14456; PRIKAZ, 2003, INPROVEMENT TB CONTR; Quekel LGBA, 2001, EUR J RADIOL, V39, P111, DOI 10.1016/S0720-048X(01)00301-1; SHAW NJ, 1990, SCOT MED J, V35, P140, DOI 10.1177/003693309003500505; Tudor GR, 1997, CLIN RADIOL, V52, P235, DOI 10.1016/S0009-9260(97)80280-2; Tudor GR, 2001, CLIN RADIOL, V56, P751, DOI 10.1053/crad.2001.0760; *WHO, DIV EN OTH COMM DIS; *WHO, DIV EM OTH COMM DIS; ZITTING AJ, 1995, CHEST, V107, P126, DOI 10.1378/chest.107.1.126	24	50	51	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 13	2005	331	7513					379	+		10.1136/bmj.331.7513.379	http://dx.doi.org/10.1136/bmj.331.7513.379			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	956SK	16096305	Green Published, Green Accepted			2022-12-28	WOS:000231319900014
J	Tsang, KWT; Eng, P; Liam, CK; Shim, YS; Lam, WK				Tsang, KWT; Eng, P; Liam, CK; Shim, YS; Lam, WK			H5N1 influenza pandemic: contingency plans	LANCET			English	Editorial Material							ZANAMIVIR; EFFICACY; ASTHMA; SAFETY		Univ Hong Kong, Queen Mary Hosp, Univ Dept Med, Pokfulam, Hong Kong, Peoples R China; Singapore Gen Hosp, Dept Resp & Crit Care Med, Singapore, Singapore; Univ Malaya, Med Ctr, Dept Med, Kuala Lumpur, Malaysia; Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea	University of Hong Kong; Singapore General Hospital; Universiti Malaya; Seoul National University (SNU)	Tsang, KWT (corresponding author), Univ Hong Kong, Queen Mary Hosp, Univ Dept Med, Pokfulam, Hong Kong, Peoples R China.	kwttsang@hku.hk	Liam, Chong-Kin/AAC-8475-2022	Liam, Chong-Kin/0000-0002-3639-9231				Cass LMR, 1999, CLIN PHARMACOKINET, V36, P1, DOI 10.2165/00003088-199936001-00001; *GLAXOSMITHKLINE, 2000, REL DAT; Hien TT, 2004, NEW ENGL J MED, V350, P1179, DOI 10.1056/NEJMoa040419; Hill LS, 1998, RESP MED, V92, P105, DOI 10.1016/S0954-6111(98)90040-3; *HOFFM LAR, 2004, TAM DAT COR DAT SHEE; Imuta F, 2003, PEDIATR INT, V45, P366, DOI 10.1046/j.1442-200X.2003.01724.x; Kirkbride H A, 2003, Commun Dis Public Health, V6, P123; Kiso M, 2004, LANCET, V364, P759, DOI 10.1016/S0140-6736(04)16934-1; McKimm-Breschkin Jennifer L, 2005, Treat Respir Med, V4, P107, DOI 10.2165/00151829-200504020-00004; Murphy KR, 2000, CLIN DRUG INVEST, V20, P337, DOI 10.2165/00044011-200020050-00005; Silagy C, 1998, LANCET, V352, P1877, DOI 10.1016/S0140-6736(98)10190-3; Treanor JJ, 2000, JAMA-J AM MED ASSOC, V283, P1016, DOI 10.1001/jama.283.8.1016; Tzeng HM, 2004, NURS ETHICS, V11, P277, DOI 10.1191/096733004ne695oa; Ungchusak K, 2005, NEW ENGL J MED, V352, P333, DOI 10.1056/NEJMoa044021; Webby RJ, 2003, SCIENCE, V302, P1519, DOI 10.1126/science.1090350; *WHO, 2005, NAT INFL PAND PLANS; *WHO, 2005, CUM NUMB CONF HUM CA; Zeitlin Gary Adam, 2005, Curr Infect Dis Rep, V7, P193, DOI 10.1007/s11908-005-0034-9	18	16	18	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 13	2005	366	9485					533	534		10.1016/S0140-6736(05)67080-8	http://dx.doi.org/10.1016/S0140-6736(05)67080-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955LL	16099278	Green Published, Bronze			2022-12-28	WOS:000231227300010
J	Gunton, JE; Kulkarni, RN; Yim, SH; Okada, T; Hawthorne, WJ; Tseng, YH; Roberson, RS; Ricordi, C; O'Connell, PJ; Gonzalez, FJ; Kahn, CR				Gunton, JE; Kulkarni, RN; Yim, SH; Okada, T; Hawthorne, WJ; Tseng, YH; Roberson, RS; Ricordi, C; O'Connell, PJ; Gonzalez, FJ; Kahn, CR			Loss of ARNT/HIF1 beta mediates altered gene expression and pancreatic-islet dysfunction in human type 2 diabetes	CELL			English	Article							ARYL-HYDROCARBON RECEPTOR; INSULIN-RESISTANCE; BETA-CELLS; SKELETAL-MUSCLE; MICE LACKING; MELLITUS; TRANSCRIPTION; PATHOGENESIS; HYPOXIA; GLUCOSE	beta cell dysfunction is a central component of the pathogenesis of type 2 diabetes. Using oligonucleotide microarrays and real-time PCR of pancreatic islets isolated from humans with type 2 diabetes versus normal glucose-tolerant controls, we identified multiple changes in expression of genes known to be important in beta cell function, including major decreases in expression of HNF4 alpha, insulin receptor, IRS2, Akt2, and several glucose-metabolic-pathway genes. There was also a 90% decrease in expression of the transcription factor ARNT Reducing ARNT levels in Min6 cells with small interfering RNA (siRNA) resulted in markedly impaired glucose-stimulated insulin release and changes in gene expression similar to those in human type 2 islets. Likewise, beta cell-specific ARNT knockout mice exhibited abnormal glucose tolerance, impaired insulin secretion, and changes in islet gene expression that mimicked those in human diabetic islets. Together, these data suggest an important role for decreased ARNT and altered gene expression in the impaired islet function of human type 2 diabetes.	Joslin Diabet Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; NCI, Lab Metab, Bethesda, MD 20892 USA; Univ Sydney, Westmead Hosp, Natl Pancreas Transplant Unit, Sydney, NSW 2145, Australia; Univ Miami, Diabet Res Inst, Miami, FL 33136 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Sydney; University of Miami	Kahn, CR (corresponding author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.	c.ronald.kahn@joslin.harvard.edu	RICORDI, CAMILLO/AAA-4740-2019; Tseng, Yu-Hua/AAE-6471-2021; Gunton, Jenny E/AAH-7719-2021; Kahn, Ronald/AAY-2435-2021	Tseng, Yu-Hua/0000-0003-2053-9559; Kahn, Ronald/0000-0002-7583-9228; Ricordi, Camillo/0000-0001-8092-7153	NATIONAL CANCER INSTITUTE [Z01BC005708, ZIABC005708] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [U42RR016603] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033201, R01DK060837, K08DK002885, R01DK067536] Funding Source: NIH RePORTER; NCRR NIH HHS [RR16603] Funding Source: Medline; NIDDK NIH HHS [DK60837-02, R01 DK33201, K08 DK02885, R01 DK67536] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbott BD, 2000, DEV DYNAM, V219, P526, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1080>3.0.CO;2-N; Anello M, 2005, DIABETOLOGIA, V48, P282, DOI 10.1007/s00125-004-1627-9; Bell GI, 2001, NATURE, V414, P788, DOI 10.1038/414788a; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Carlsson PO, 1998, DIABETES, V47, P1027, DOI 10.2337/diabetes.47.7.1027; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; CLARK A, 1988, DIABETES RES CLIN EX, V9, P151; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; Cras-Meneur C, 2004, DIABETOLOGIA, V47, P284, DOI 10.1007/s00125-003-1300-8; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; Del Prato S, 2002, DIABETES, V51, pS109, DOI 10.2337/diabetes.51.2007.S109; DEVOS A, 1995, J CLIN INVEST, V96, P2489, DOI 10.1172/JCI118308; EDLUND H, 2001, DIABETES S1, V50, P5; Entingh AJ, 2003, J BIOL CHEM, V278, P33377, DOI 10.1074/jbc.M303056200; Fierens S, 2003, BIOMARKERS, V8, P529, DOI 10.1080/1354750032000158420; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Froguel P, 2001, RECENT PROG HORM RES, V56, P91, DOI 10.1210/rp.56.1.91; Gerich JE, 1998, ENDOCR REV, V19, P491, DOI 10.1210/er.19.4.491; Gumbiner B, 1996, J CLIN ENDOCR METAB, V81, P2061, DOI 10.1210/jc.81.6.2061; Gupta RK, 2005, J CLIN INVEST, V115, P1006, DOI 10.1172/JCI22365; Habener JF, 1998, P ASSOC AM PHYSICIAN, V110, P12; Kellerer M, 2001, DIABETOLOGIA, V44, P1125, DOI 10.1007/s001250100614; Kewley RJ, 2004, INT J BIOCHEM CELL B, V36, P189, DOI 10.1016/S1357-2725(03)00211-5; KIKUTANI H, 1992, ADV IMMUNOL, V51, P285, DOI 10.1016/S0065-2776(08)60490-3; Kim JS, 2003, IND HEALTH, V41, P149, DOI 10.2486/indhealth.41.149; KLOPPEL G, 1985, SURV SYN PATHOL RES, V4, P110; Kozak KR, 1997, DEV BIOL, V191, P297, DOI 10.1006/dbio.1997.8758; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Kulkarni RN, 1999, J CLIN INVEST, V104, pR69, DOI 10.1172/JCI8339; Lauro D, 1998, NAT GENET, V20, P294, DOI 10.1038/3112; Lee CS, 2002, DIABETES, V51, P2546, DOI 10.2337/diabetes.51.8.2546; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; Mauvais-Jarvis F, 2000, DIABETES METAB, V26, P433; McCarthy MI, 2002, AM J PHYSIOL-ENDOC M, V283, pE217, DOI 10.1152/ajpendo.00099.2002; Michalek JE, 2003, J TOXICOL ENV HEAL A, V66, P211, DOI 10.1080/15287390306373; Nandi A, 2004, PHYSIOL REV, V84, P623, DOI 10.1152/physrev.00032.2003; NORGREN S, 1993, DIABETES, V42, P675, DOI 10.2337/diabetes.42.5.675; Okino ST, 1998, J BIOL CHEM, V273, P23837, DOI 10.1074/jbc.273.37.23837; Pesatori AC, 2003, IND HEALTH, V41, P127, DOI 10.2486/indhealth.41.127; Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314; POLONSKY KS, 1995, DIABETES, V44, P705, DOI 10.2337/diabetes.44.6.705; Porte D, 2001, DIABETES, V50, pS160, DOI 10.2337/diabetes.50.2007.S160; RICORDI C, 1988, DIABETES, V37, P413, DOI 10.2337/diabetes.37.4.413; Salceda S, 1996, ARCH BIOCHEM BIOPHYS, V334, P389, DOI 10.1006/abbi.1996.0469; Sreekumar R, 2002, DIABETES, V51, P1913, DOI 10.2337/diabetes.51.6.1913; Thackaberry EA, 2003, TOXICOL SCI, V76, P407, DOI 10.1093/toxsci/kfg229; Tomita S, 2000, MOL ENDOCRINOL, V14, P1674, DOI 10.1210/me.14.10.1674; Weyer C, 1999, J CLIN INVEST, V104, P787, DOI 10.1172/JCI7231; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Wolfrum C, 2003, P NATL ACAD SCI USA, V100, P11624, DOI 10.1073/pnas.1931483100; Yechoor VK, 2002, P NATL ACAD SCI USA, V99, P10587, DOI 10.1073/pnas.142301999; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	56	383	394	1	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 12	2005	122	3					337	349		10.1016/j.cell.2005.05.027	http://dx.doi.org/10.1016/j.cell.2005.05.027			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	955UZ	16096055	Bronze			2022-12-28	WOS:000231254400007
J	Weiner, S; Sagi, I; Addadi, L				Weiner, S; Sagi, I; Addadi, L			Choosing the crystallization path less traveled	SCIENCE			English	Editorial Material							AMORPHOUS CALCIUM-CARBONATE; RADULAR TEETH; MINERALIZATION; TRANSFORMATION; PHOSPHATE; PHASE		Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Weiner, S (corresponding author), Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel.	steve.weiner@weizmann.ac.il						Addadi L, 2003, ADV MATER, V15, P959, DOI 10.1002/adma.200300381; Aizenberg J, 1996, ADV MATER, V8, P222, DOI 10.1002/adma.19960080307; Beniash E, 1997, P ROY SOC B-BIOL SCI, V264, P461, DOI 10.1098/rspb.1997.0066; Dillaman R, 2005, J MORPHOL, V263, P356, DOI 10.1002/jmor.10311; GLIMCHER MJ, 1984, PHILOS T R SOC B, V304, P479, DOI 10.1098/rstb.1984.0041; Li M, 2002, ADV FUNCT MATER, V12, P773, DOI 10.1002/adfm.200290006; Loste E, 2004, ADV FUNCT MATER, V14, P1211, DOI 10.1002/adfm.200400268; LOWENSTAM HA, 1985, SCIENCE, V227, P51, DOI 10.1126/science.227.4682.51; LOWENSTAM HA, 1962, GEOL SOC AM BULL, V73, P435, DOI 10.1130/0016-7606(1962)73[435:MIDCIR]2.0.CO;2; MANN S, 1985, MAGNETITE BIOMINERAL, P311, DOI DOI 10.1007/978-1-4613-0313-8_15; Marxen JC, 2003, J MOLLUS STUD, V69, P113, DOI 10.1093/mollus/69.2.113; Meibom A, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL021313; Politi Y, 2004, SCIENCE, V306, P1161, DOI 10.1126/science.1102289; TOWE KM, 1967, J ULTRA MOL STRUCT R, V17, P1, DOI 10.1016/S0022-5320(67)80015-7; Weiss IM, 2002, J EXP ZOOL, V293, P478, DOI 10.1002/jez.90004	15	266	272	5	115	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 12	2005	309	5737					1027	1028		10.1126/science.1114920	http://dx.doi.org/10.1126/science.1114920			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955MN	16099970				2022-12-28	WOS:000231230100030
J	Kuwayama, Y; Hirose, K; Sata, N; Ohishi, Y				Kuwayama, Y; Hirose, K; Sata, N; Ohishi, Y			The pyrite-type high-pressure form of silica	SCIENCE			English	Article							STISHOVITE; PHASE; SIO2; SYSTEM	Silica (SiO2) exhibits extensive polymorphism at elevated pressures. X-ray diffraction measurements showed that a high-pressure form with a pyrite-type structure, denser than other known silica phases, is stable above 268 gigapascals and 1800 kelvin. The silicon coordination number increases from 6 in the alpha-PbO2-type phase to 6+2 in the pyrite-type phase, leading to a large increase in density by about 5% at the phase transition.	Tokyo Inst Technol, Dept Earth & Planetary Sci, Meguro Ku, Tokyo 1528551, Japan; Japan Agcy Marine Earth Sci & Technol, Inst Res Earth Evolut, Kanagawa 2370061, Japan; Japan Synchrotron Radiat Res Inst, Mikazuki, Hyogo 6795198, Japan	Tokyo Institute of Technology; Japan Agency for Marine-Earth Science & Technology (JAMSTEC); Japan Synchrotron Radiation Research Institute	Kuwayama, Y (corresponding author), Tokyo Inst Technol, Dept Earth & Planetary Sci, Meguro Ku, 2-12-1 Ookayama, Tokyo 1528551, Japan.	ykuwayam@geo.titech.ac.jp	Hirose, Kei/C-2165-2009	Hirose, Kei/0000-0003-4366-7721; Kuwayama, Yasuhiro/0000-0002-0077-3877				Andrault D, 1998, SCIENCE, V282, P720, DOI 10.1126/science.282.5389.720; Dubrovinsky LS, 2004, PHYS EARTH PLANET IN, V143, P231, DOI 10.1016/j.pepi.2003.06.006; Dubrovinsky LS, 1997, NATURE, V388, P362, DOI 10.1038/41066; Guillot T, 1999, SCIENCE, V286, P72, DOI 10.1126/science.286.5437.72; Haines J, 1996, SCIENCE, V271, P629, DOI 10.1126/science.271.5249.629; Haines J, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.155503; Hammersley A. P., 1997, ESRF97HA02T; HEMLEY RJ, 1994, REV MINERAL, V29, P41; HOLMES NC, 1989, J APPL PHYS, V66, P2962, DOI 10.1063/1.344177; Izumi F, 2000, MATER SCI FORUM, V321-3, P198, DOI 10.4028/www.scientific.net/MSF.321-324.198; Karki BB, 1997, PHYS REV B, V55, P3465, DOI 10.1103/PhysRevB.55.3465; KINGMA KJ, 1995, NATURE, V374, P243, DOI 10.1038/374243a0; Murakami M, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016722; Oganov AR, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.064104; Ono S, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.014103; Ono S, 2002, EARTH PLANET SC LETT, V197, P187, DOI 10.1016/S0012-821X(02)00479-X; PARK KT, 1988, NATURE, V336, P670, DOI 10.1038/336670a0; POLLACK JB, 1994, ASTROPHYS J, V421, P615, DOI 10.1086/173677; Shen G., 1996, P 3 NIRIM INT S ADV, P149; Teter DM, 1998, PHYS REV LETT, V80, P2145, DOI 10.1103/PhysRevLett.80.2145; TSUCHIDA Y, 1989, NATURE, V340, P217, DOI 10.1038/340217a0; Watanuki T, 2001, REV SCI INSTRUM, V72, P1289, DOI 10.1063/1.1343869	22	119	125	1	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 5	2005	309	5736					923	925		10.1126/science.1114879	http://dx.doi.org/10.1126/science.1114879			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953SS	16081734				2022-12-28	WOS:000231101400043
J	Karsenty, G				Karsenty, G			An aggrecanase and osteoarthritis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ADAMTS5		Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine	Karsenty, G (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.							Glasson SS, 2005, NATURE, V434, P644, DOI 10.1038/nature03369; Stanton H, 2005, NATURE, V434, P648, DOI 10.1038/nature03417	2	21	23	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 4	2005	353	5					522	523		10.1056/NEJMcibr051399	http://dx.doi.org/10.1056/NEJMcibr051399			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	951OB	16079379				2022-12-28	WOS:000230939000015
J	Scott, RS; Ungar, PS; Bergstrom, TS; Brown, CA; Grine, FE; Teaford, MF; Walker, A				Scott, RS; Ungar, PS; Bergstrom, TS; Brown, CA; Grine, FE; Teaford, MF; Walker, A			Dental microwear texture analysis shows within-species diet variability in fossil hominins	NATURE			English	Article							FRACTAL ANALYSIS; IMAGE-ANALYSIS; QUANTIFICATION	Reconstructing the diets of extinct hominins is essential to understanding the paleobiology and evolutionary history of our lineage. Dental microwear, the study of microscopic tooth-wear resulting from use(1-4), provides direct evidence of what an individual ate in the past. Unfortunately, established methods(5-10) of studying microwear are plagued with low repeatability and high observer error(11). Here we apply an objective, repeatable approach for studying three-dimensional microwear surface texture to extinct South African hominins. Scanning confocal microscopy(12,13) together with scale-sensitive fractal analysis(14-19) are used to characterize the complexity and anisotropy of microwear. Results for living primates show that this approach can distinguish among diets characterized by different fracture properties. When applied to hominins(20), microwear texture analysis indicates that Australopithecus africanus microwear is more anisotropic, but also more variable in anisotropy than Paranthropus robustus. This latter species has more complex microwear textures, but is also more variable in complexity than A. africanus. This suggests that A. africanus ate more tough foods and P. robustus consumed more hard and brittle items, but that both had variable and overlapping diets.	Univ Arkansas, Dept Anthropol, Fayetteville, AR 72701 USA; Worcester Polytech Inst, Dept Mech Engn, Surface Metrol Lab, Worcester, MA 01609 USA; SUNY Stony Brook, Dept Anthropol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Anat Sci, Stony Brook, NY 11794 USA; Johns Hopkins Univ, Sch Med, Ctr Funct Anat & Evolut, Baltimore, MD 21205 USA; Penn State Univ, Dept Anthropol, University Pk, PA 16802 USA; Penn State Univ, Dept Biol, University Pk, PA 16802 USA	University of Arkansas System; University of Arkansas Fayetteville; Worcester Polytechnic Institute; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Ungar, PS (corresponding author), Univ Arkansas, Dept Anthropol, Fayetteville, AR 72701 USA.	pungar@uark.edu	Scott, Robert S/B-5960-2008	Scott, Robert S/0000-0003-2573-533X				*AM SOC MECH ENG, 2002, B461 AM SOC MECH ENG; Bergstrom TS, 2001, INT J MACH TOOL MANU, V41, P1995, DOI 10.1016/S0890-6955(01)00063-3; BOYDE A, 1991, SCANNING, V13, P429, DOI 10.1002/sca.4950130608; Brown CA, 2001, INT J MACH TOOL MANU, V41, P1927, DOI 10.1016/S0890-6955(01)00057-8; BROWN CA, 1993, WEAR, V161, P61, DOI 10.1016/0043-1648(93)90453-S; Brown CA, 1998, INT J MACH TOOL MANU, V38, P633, DOI 10.1016/S0890-6955(97)00111-9; BROWN CA, 1991, WEAR, V141, P211, DOI 10.1016/0043-1648(91)90269-Z; Conklin-Brittain NL, 1998, INT J PRIMATOL, V19, P971, DOI 10.1023/A:1020370119096; Crompton RH, 1998, FOLIA PRIMATOL, V69, P41; De Chiffre L, 2000, CIRP ANNALS 2000: MANUFACTURING TECHNOLOGY, VOL 49/2/2000, P635; EISENBERG JF, 1989, MAMMALS NEOTROPICS, V1, P233; ESTRADA A, 1984, INT J PRIMATOL, V5, P105, DOI 10.1007/BF02735736; GORDON KD, 1982, AM J PHYS ANTHROPOL, V59, P195, DOI 10.1002/ajpa.1330590208; Grine FE, 2002, SCANNING, V24, P144, DOI 10.1002/sca.4950240307; GRINE FE, 1988, NATURE, V333, P765, DOI 10.1038/333765a0; GRINE FE, 1986, J HUM EVOL, V15, P783, DOI 10.1016/S0047-2484(86)80010-0; KAY RF, 1977, AM J PHYS ANTHROPOL, V46, P327, DOI 10.1002/ajpa.1330460213; Lambert JE, 2004, AM J PHYS ANTHROPOL, V125, P363, DOI 10.1002/ajpa.10403; MOLLESON T, 1993, J HUM EVOL, V24, P455, DOI 10.1006/jhev.1993.1031; Neville M.K., 1988, P349; PASTOR RF, 1992, J HUM ECOL, V2, P215; Rensberger J.M., 1978, P415; RYAN A S, 1981, Primates, V22, P533, DOI 10.1007/BF02381245; SOLOUNIAS N, 1988, PALEOBIOLOGY, V14, P287, DOI 10.1017/S009483730001201X; Stanford CB, 2003, INT J PRIMATOL, V24, P901, DOI 10.1023/A:1024689008159; STRAIT SG, 1993, AM J PHYS ANTHROPOL, V92, P63, DOI 10.1002/ajpa.1330920106; TEAFORD MF, 1988, SCANNING MICROSCOPY, V2, P1149; Ungar PS, 2003, SCANNING, V25, P185, DOI 10.1002/sca.4950250405; UNGAR PS, 1991, SCANNING, V13, P31, DOI 10.1002/sca.4950130107; WALKER A, 1978, SCIENCE, V201, P908, DOI 10.1126/science.684415	30	398	419	2	85	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 4	2005	436	7051					693	695		10.1038/nature03822	http://dx.doi.org/10.1038/nature03822			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	951XA	16079844				2022-12-28	WOS:000230964500042
J	Truog, RD				Truog, RD			The ethics of organ donation by living donors	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Harvard Univ, Sch Med, Dept Social Med, Cambridge, MA 02138 USA; Childrens Hosp, Div Crit Care Med, Boston, MA 02115 USA	Harvard University; Harvard University; Boston Children's Hospital	Truog, RD (corresponding author), Harvard Univ, Sch Med, Dept Social Med, Cambridge, MA 02138 USA.							Abecassis M, 2000, JAMA-J AM MED ASSOC, V284, P2919; KLUGE EHW, 1989, HASTINGS CENT REP, V19, P10, DOI 10.2307/3562635; Kolata Gina, 1991, N Y Times Web, pA11; Parker Ian, 2004, THE NEW YORKER, V80, P54; Veatch R. M., 2000, TRANSPLANTATION ETHI	5	94	95	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 4	2005	353	5					444	446		10.1056/NEJMp058155	http://dx.doi.org/10.1056/NEJMp058155			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	951OB	16079366				2022-12-28	WOS:000230939000002
J	Titov, V; Rabinovich, AB; Mofjeld, HO; Thomson, RE; Gonzalez, FI				Titov, V; Rabinovich, AB; Mofjeld, HO; Thomson, RE; Gonzalez, FI			The global reach of the 26 December 2004 Sumatra tsunami	SCIENCE			English	Article								Numerical model simulations, combined with tide-gauge and satellite altimetry data, reveal that wave amplitudes, directionatity, and global propagation patterns of the 26 December 2004 Sumatra tsunami were primarily determined by the orientation and intensity of the offshore seismic line source and subsequently by the trapping effect of mid-ocean ridge topographic waveguides.	NOAA, Pacific Marine Environm Lab, Seattle, WA 98115 USA; Dept Fisheries & Oceans Canada, Inst Ocean Sci, Sidney, BC V8L 4B2, Canada; Russian Acad Sci, PP Shirshov Oceanol Inst, Moscow 117997, Russia	National Oceanic Atmospheric Admin (NOAA) - USA; Fisheries & Oceans Canada; Russian Academy of Sciences; Shirshov Institute of Oceanology	Titov, V (corresponding author), NOAA, Pacific Marine Environm Lab, 7600 Sand Point Way NE, Seattle, WA 98115 USA.	Vasity.Titov@noaa.gov	Gonzalez, Frank/ABG-8903-2021; Titov, Vasily V/P-9579-2017; Rabinovich, Alexander/ABD-5745-2020	Titov, Vasily V/0000-0002-1630-3829; 				Ammon CJ, 2005, SCIENCE, V308, P1133, DOI 10.1126/science.1112260; Bilham R, 2005, SCIENCE, V308, P1126, DOI 10.1126/science.1113363; Emery W.J., 2001, DATA ANAL METHODS PH, P159, DOI DOI 10.1016/C2010-0-66362-0; GONZALEZ FI, 1995, PURE APPL GEOPHYS, V144, P409, DOI 10.1007/BF00874375; Gower J, 2005, EOS T AGU, V86, P37, DOI DOI 10.1029/2005E0040002; HIRATA K, UNPUB; KOSHIMURA S, 1999, COAST ENG J, V41, P167; Liu PLF, 2005, SCIENCE, V308, P1595, DOI 10.1126/science.1110730; MARCHUK AG, 1989, P IUGG IOC INT TSUN, P11; Smith W.H., 2005, OCEANOGRAPHY, DOI 10.5670/oceanog.2005.62; Stein S, 2005, NATURE, V434, P581, DOI 10.1038/434581a; SUBARYA C, 2005, EOS T AGU, V86; Titov V.V., 2001, ADV NAT TECHNOL HAZ, P75; Titov VV, 1997, GEOPHYS RES LETT, V24, P1315, DOI 10.1029/97GL01128; TITOV VV, 1998, J WATERWAYS PORTS CO, V124, P57	15	330	350	2	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 23	2005	309	5743					2045	2048		10.1126/science.1114576	http://dx.doi.org/10.1126/science.1114576			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968SF	16123264				2022-12-28	WOS:000232181900047
J	Harris, GC; Wimmer, M; Aston-Jones, G				Harris, GC; Wimmer, M; Aston-Jones, G			A role for lateral hypothalamic orexin neurons in reward seeking	NATURE			English	Article							VENTRAL TEGMENTAL AREA; RECEPTOR ANTAGONIST; RAT-BRAIN; HYPOCRETIN OREXIN; FEEDING-BEHAVIOR; FOS EXPRESSION; PREFERENCE; STRESS; NEUROPEPTIDES; ENVIRONMENT	The lateral hypothalamus is a brain region historically implicated in reward and motivation(1 - 4), but the identity of the neurotransmitters involved are unknown. The orexins ( or hypocretins) are neuropeptides recently identified as neurotransmitters in lateral hypothalamus neurons(5,6). Although knockout and transgenic overexpression studies have implicated orexin neurons in arousal and sleep(7), these cells also project to reward- associated brain regions, including the nucleus accumbens and ventral tegmental area(8,9). This indicates a possible role for these neurons in reward function and motivation(3,10), consistent with previous studies implicating these neurons in feeding(6). Here we show that activation of lateral hypothalamus orexin neurons is strongly linked to preferences for cues associated with drug and food reward. In addition, we show that chemical activation of lateral hypothalamus orexin neurons reinstates an extinguished drug- seeking behaviour. This reinstatement effect was completely blocked by prior administration of an orexin A antagonist. Moreover, administration of the orexin A peptide directly into the ventral tegmental area also reinstated drug- seeking. These data reveal a new role for lateral hypothalamus orexin neurons in reward- seeking, drug relapse and addiction.	Univ Penn, Dept Psychiat, Lab Neuromodulat & Behav, Philadelphia, PA 19104 USA	University of Pennsylvania	Harris, GC (corresponding author), Univ Penn, Dept Psychiat, Lab Neuromodulat & Behav, 705 Stellar Chance 6100,422 Curie Blvd, Philadelphia, PA 19104 USA.	glenda@dolphin.upenn.edu	Jansen, Heiko T./A-5770-2008; Wimmer, Mathieu E/P-8091-2018	Jansen, Heiko T./0000-0003-0178-396X; 				ANAND BK, 1951, YALE J BIOL MED, V24, P123; Baldo BA, 2004, EUR J NEUROSCI, V19, P376, DOI 10.1111/j.1460-9568.2004.03093.x; Baldo BA, 2003, J COMP NEUROL, V464, P220, DOI 10.1002/cne.10783; Bevins RA, 2002, BEHAV BRAIN RES, V129, P41, DOI 10.1016/S0166-4328(01)00326-6; Campbell RE, 2003, J NEUROSCI, V23, P1487, DOI 10.1523/JNEUROSCI.23-04-01487.2003; Carr KD, 2002, PHYSIOL BEHAV, V76, P353, DOI 10.1016/S0031-9384(02)00759-X; Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; DiLeone RJ, 2003, LIFE SCI, V73, P759, DOI 10.1016/S0024-3205(03)00408-9; Espana RA, 2003, NEUROSCIENCE, V121, P201, DOI 10.1016/S0306-4522(03)00334-8; Estabrooke IV, 2001, J NEUROSCI, V21, P1656, DOI 10.1523/JNEUROSCI.21-05-01656.2001; Fadel J, 2002, NEUROSCIENCE, V111, P379, DOI 10.1016/S0306-4522(02)00017-9; Georgescu D, 2003, J NEUROSCI, V23, P3106; Harris GC, 2003, NEUROPSYCHOPHARMACOL, V28, P865, DOI 10.1038/sj.npp.1300122; Harris GC, 2003, NEUROPSYCHOPHARMACOL, V28, P292, DOI 10.1038/sj.npp.1300037; Harris GC, 2003, NEUROPSYCHOPHARMACOL, V28, P73, DOI 10.1038/sj.npp.1300011; Haynes AC, 2000, REGUL PEPTIDES, V96, P45, DOI 10.1016/S0167-0115(00)00199-3; Herrera DG, 1996, PROG NEUROBIOL, V50, P83, DOI 10.1016/S0301-0082(96)00021-4; Korotkova TM, 2003, J NEUROSCI, V23, P7; Marcus JN, 2001, J COMP NEUROL, V435, P6, DOI 10.1002/cne.1190; OLDS J, 1954, J COMP PHYSIOL PSYCH, V47, P419, DOI 10.1037/h0058775; Petrovich GD, 2003, ANN NY ACAD SCI, V985, P251; Peyron C, 1998, J NEUROSCI, V18, P9996; Rodgers RJ, 2001, EUR J NEUROSCI, V13, P1444, DOI 10.1046/j.0953-816x.2001.01518.x; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Shalev U, 2002, PHARMACOL REV, V54, P1, DOI 10.1124/pr.54.1.1; Siegel JM, 2004, ANNU REV PSYCHOL, V55, P125, DOI 10.1146/annurev.psych.55.090902.141545; Smart D, 2001, BRIT J PHARMACOL, V132, P1179, DOI 10.1038/sj.bjp.0703953; Swanson L. W., 1992, BRAIN MAPS STRUCTURE; Trivedi P, 1998, FEBS LETT, V438, P71, DOI 10.1016/S0014-5793(98)01266-6; Wang B, 2000, NEUROREPORT, V11, P2781, DOI 10.1097/00001756-200008210-00034	31	973	1009	1	69	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 22	2005	437	7058					556	559		10.1038/nature04071	http://dx.doi.org/10.1038/nature04071			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	966FF	16100511				2022-12-28	WOS:000232004800051
J	Chebli, JMF; Gaburri, PD; Morais, JMM				Chebli, JMF; Gaburri, PD; Morais, JMM			Choledocholithiasis	LANCET			English	Editorial Material									Santa Casa Misericordia Hosp, Dept Med, Div Gastroenterol, Juiz De Fora, Brazil		Chebli, JMF (corresponding author), Santa Casa Misericordia Hosp, Dept Med, Div Gastroenterol, Juiz De Fora, Brazil.	chebli@hu.ufjf.br	Chebli, Julio MF/I-1528-2014	Chebli, Julio MF/0000-0003-1527-0663					0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 27	2005	366	9487					748	748		10.1016/S0140-6736(05)67180-2	http://dx.doi.org/10.1016/S0140-6736(05)67180-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958UV	16125593	Bronze			2022-12-28	WOS:000231474600032
J	Sachedina, A				Sachedina, A			End-of-life: the Islamic view	LANCET			English	Editorial Material									Univ Virginia, Dept Religious Studies, Charlottesville, VA 22904 USA	University of Virginia	Sachedina, A (corresponding author), Univ Virginia, Dept Religious Studies, POB 400126, Charlottesville, VA 22904 USA.	aas@cms.mail.virginia.edu						AHMAD B, 1965, KITAB ALMAHASIN, P123; *ALQ ALTH BISH MAW, 1990, MAJALLA ALBUHUTH ALF, V4, P159; HABIBI H, 2001, MARGI MAGHZI DIDGAHI; HAYYAN AA, 1992, ALMUQABASAT, P132; MUHAMMAD B, 1979, JAMI ALSAHIHI KITAB, P373; RISPLERCHAIM V, 1993, ISLAMIC MED ETHICS 2, P63; Sachedina A., 1995, ENCY BIOETHICS, P1289	7	113	114	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 27	2005	366	9487					774	779		10.1016/S0140-6736(05)67183-8	http://dx.doi.org/10.1016/S0140-6736(05)67183-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	958UV	16125596				2022-12-28	WOS:000231474600035
J	Littlewood, S; Ypinazar, V; Margolis, SA; Scherpbier, A; Spencer, J; Dornan, T				Littlewood, S; Ypinazar, V; Margolis, SA; Scherpbier, A; Spencer, J; Dornan, T			Early practical experience and the social responsiveness of clinical education: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							1ST-YEAR MEDICAL-STUDENTS; PRIMARY-CARE; PRECLINICAL PRECEPTORSHIP; FAMILY MEDICINE; PROGRAM; SKILLS; EXPOSURE; IMPACT; PROFESSIONALISM; PERFORMANCE	Objectives To find how early experience in clinical and community settings ("early experience") affects medical education, and identify strengths and limitations of the available evidence. Design A systematic review rating, by consensus, the strength and importance of outcomes reported in the decade 1992-2001. Data sources Bibliographical databases and journals were searched for publications on the topic, reviewed under the auspices of the recently formed Best Evidence Medical Education (BEME) collaboration. Selection of studies All empirical studies (verifiable, observational data) were included, whatever their design, method, or language of publication. Results Early experience was most commonly provided in community settings, aiming to recruit primary care practitioners for underserved populations. It increased the popularity of primary care residencies, albeit among self selected students. It fostered self awareness and empathic attitudes towards ill people, boosted students' confidence, motivated them, gave them satisfaction, and helped them develop a professional identity. By helping develop interpersonal skills, it made entering clerkships a less stressful experience. Early experience helped students learn about professional roles and responsibilities, healthcare systems, and health needs of a population. It made biomedical, behavioural, and social sciences more relevant and easier to learn. It motivated and rewarded teachers and patients and enriched curriculums. In some countries,junior students provided preventive health care directly to underserved populations. Conclusion Early experience helps medical students learn, helps them develop appropriate attitudes towards their studies and future practice, and orientates medical curriculums towards society's needs. Experimental evidence of its benefit is unlikely to be forthcoming and yet more medical schools are likely to provide it. Effort could usefully be concentrated on evaluating the methods and outcomes of early experience provided within non-experimental research designs, and using that evaluation to improve the quality of curriculums.	Univ Manchester, Hope Hosp, Sch Med, Manchester M6 8HD, Lancs, England; Univ Queensland, Sch Med, Rural Clin Div CQ Reg, Rockhampton, Qld 4700, Australia; Univ Maastricht, Inst Med Educ, NL-6200 MD Maastricht, Netherlands; Univ Newcastle Upon Tyne, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of Manchester; University of Queensland; Maastricht University; Newcastle University - UK	Dornan, T (corresponding author), Univ Manchester, Hope Hosp, Sch Med, Manchester M6 8HD, Lancs, England.	tim.dornan@manchester.ac.uk	Margolis, Stephen A/G-7541-2011	Margolis, Stephen A/0000-0002-8954-1019				Albanese M, 2002, ADV HEALTH SCI EDUC, V7, P147, DOI 10.1023/A:1015786920642; Alford CL, 2001, J AM GERIATR SOC, V49, P782, DOI 10.1046/j.1532-5415.2001.49156.x; ALLEN SS, 1991, MED TEACH, V13, P177, DOI 10.3109/01421599109029028; Barley G, 2001, ACAD MED, V76, pS68, DOI 10.1097/00001888-200104001-00013; Brennan T, 2002, LANCET, V359, P520, DOI 10.1016/s0140-6736(02)07684-5; BUCCI KK, 1993, AM J PHARM EDUC, V57, P44; Carney P A, 1999, Acad Med, V74, pS59, DOI 10.1097/00001888-199901000-00033; Chisholm MA, 1997, AM J PHARM EDUC, V61, P364; Cooper HC, 2001, MED TEACH, V23, P295, DOI 10.1080/01421590120043071; Dahle LO, 2002, MED TEACH, V24, P280, DOI 10.1080/01421590220134097; DOBIE SA, 1996, ADV HLTH SCI ED THEO, V2, P35; Dornan T, 2005, J ROY SOC MED, V98, P91, DOI 10.1258/jrsm.98.3.91; Dornan T, 2004, BMJ-BRIT MED J, V329, P834, DOI 10.1136/bmj.329.7470.834; DORNAN TL, CAN EXPERIENCE CLIN; Elnicki DM, 1999, J GEN INTERN MED, V14, P341, DOI 10.1046/j.1525-1497.1999.00352.x; Fernald DH, 2001, TEACH LEARN MED, V13, P13, DOI 10.1207/S15328015TLM1301_4; Frank D, 1996, TEACH LEARN MED, V8, P4, DOI 10.1080/10401339609539756; FREEMAN J, 1995, ACAD MED, V70, pS64, DOI 10.1097/00001888-199501000-00027; FRIEDBERG M, 1997, ED HLTH, V10, P205; General Medical Council, 2002, TOM DOCT; Grayson MS, 2001, J GEN INTERN MED, V16, P860, DOI 10.1046/j.1525-1497.2001.10117.x; Hampshire AJ, 1998, MED EDUC, V32, P495; HARDEN RM, 1998, MED EDUC, V32, P216; Irvine D, 1999, LANCET, V353, P1174, DOI 10.1016/S0140-6736(99)91160-1; Johnson AK, 1998, ACAD MED, V73, P430, DOI 10.1097/00001888-199804000-00018; KENT GG, 1991, MED EDUC, V25, P23, DOI 10.1111/j.1365-2923.1991.tb00022.x; Kirkpatrick D. L., 1967, TRAINING DEV HDB; Levy BT, 2001, FAM MED, V33, P683; LINDER BMW, 1992, MED EDUC, V26, P282, DOI 10.1111/j.1365-2923.1992.tb00170.x; Lynch DC, 2001, TEACH LEARN MED, V13, P36, DOI 10.1207/S15328015TLM1301_7; Madray H, 2000, MED EDUC, V34, P404, DOI 10.1046/j.1365-2923.2000.00459.x; MANN MP, 1994, ANN M AM ED RES ASS; Mengel M B, 1995, Fam Med, V27, P652; Murray E, 2002, MED EDUC, V36, P110, DOI 10.1046/j.1365-2923.2002.01155.x; Nieman LZ, 2001, ACAD MED, V76, P478, DOI 10.1097/00001888-200105000-00022; Niemi PM, 1997, MED EDUC, V31, P408, DOI 10.1046/j.1365-2923.1997.00697.x; NOVACK DH, 1992, ARCH INTERN MED, V152, P1814, DOI 10.1001/archinte.152.9.1814; ORBELL S, 1993, MED EDUC, V27, P218, DOI 10.1111/j.1365-2923.1993.tb00260.x; PAMIES RJ, 1994, J NATL MED ASSOC, V86, P594; QUINBY PM, 1995, MED TEACH, V17, P47, DOI 10.3109/01421599509008288; RILEY K, 1991, ACAD MED, V66, P776, DOI 10.1097/00001888-199112000-00015; ROGERS JC, 1991, MED TEACH, V13, P157, DOI 10.3109/01421599109029025; Rogers JC, 2001, ACAD MED, V76, P1065, DOI 10.1097/00001888-200110000-00019; Rooks L, 2001, ACAD MED, V76, P489, DOI 10.1097/00001888-200105000-00024; SATRAN L, 1993, ACAD MED, V68, P380, DOI 10.1097/00001888-199305000-00024; Steele D, 2001, ACAD MED, V76, pS121, DOI 10.1097/00001888-200104001-00024; Thomas EJ, 1999, MED TEACH, V21, P311; VAZ R, 1992, MED EDUC, V26, P27, DOI 10.1111/j.1365-2923.1992.tb00118.x; Waddell R F, 2000, Educ Health (Abingdon), V13, P69	49	196	207	2	45	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 13	2005	331	7513					387	391		10.1136/bmj.331.7513.387	http://dx.doi.org/10.1136/bmj.331.7513.387			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	956SK	16096306	Green Published			2022-12-28	WOS:000231319900017
J	LaFever, L; Drummond-Barbosa, D				LaFever, L; Drummond-Barbosa, D			Direct control of germline stem cell division and cyst growth by neural insulin in Drosophila	SCIENCE			English	Article							RECEPTOR; PEPTIDES; OVARY; FLIES	Stem cells reside in specialized niches that provide signals required for their maintenance and division. Tissue-extrinsic signals can also modify stem cell activity, although this is poorly understood. Here, we report that neural-derived Drosophila insulin-like peptides (DILPs) directly regulate germline stem cell division rate, demonstrating that signals mediating the ovarian response to nutritional input can modify stem cell activity in a niche-independent manner. We also reveal a crucial direct role of DILPs in controlling germline cyst growth and vitellogenesis.	Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN 37232 USA	Vanderbilt University	Drummond-Barbosa, D (corresponding author), Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, 4120B Med Res Bldg 3,465 21st Ave S, Nashville, TN 37232 USA.	daniela.drummond-barbosa@vanderbilt.edu			NICHD NIH HHS [T32 HD007502] Funding Source: Medline; NIGMS NIH HHS [R01 GM069875, GM 069875] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069875] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brogiolo W, 2001, CURR BIOL, V11, P213, DOI 10.1016/S0960-9822(01)00068-9; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Cao C, 2001, CELL TISSUE RES, V304, P317, DOI 10.1007/s004410100367; Chen C, 1996, ENDOCRINOLOGY, V137, P846, DOI 10.1210/en.137.3.846; Drummond-Barbosa D, 2001, DEV BIOL, V231, P265, DOI 10.1006/dbio.2000.0135; Garofalo RS, 2002, TRENDS ENDOCRIN MET, V13, P156, DOI 10.1016/S1043-2760(01)00548-3; Goberdhan DCI, 2003, DIFFERENTIATION, V71, P375, DOI 10.1046/j.1432-0436.2003.7107001.x; Ikeya T, 2002, CURR BIOL, V12, P1293, DOI 10.1016/S0960-9822(02)01043-6; LAFEVER L, UNPUB; Maines JZ, 2004, DEVELOPMENT, V131, P775, DOI 10.1242/dev.00932; Rulifson EJ, 2002, SCIENCE, V296, P1118, DOI 10.1126/science.1070058; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; Spradling AC, 1997, COLD SPRING HARB SYM, V62, P25; Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987; Wynn Arthur, 1993, Nutrition and Health (Bicester), V9, P43; Xie T, 1998, CELL, V94, P251, DOI 10.1016/S0092-8674(00)81424-5; XU T, 1993, DEVELOPMENT, V117, P1223	17	232	238	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 12	2005	309	5737					1071	1073		10.1126/science.1111410	http://dx.doi.org/10.1126/science.1111410			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955MN	16099985				2022-12-28	WOS:000231230100045
J	O'Neal, CJ; Jobling, MG; Holmes, RK; Hol, WGJ				O'Neal, CJ; Jobling, MG; Holmes, RK; Hol, WGJ			Structural basis for the activation of cholera toxin by human ARF6-GTP	SCIENCE			English	Article							HEAT-LABILE ENTEROTOXIN; RIBOSYLATING BACTERIAL TOXINS; CRYSTAL-STRUCTURE; CLOSTRIDIUM-BOTULINUM; ADP-RIBOSYLATION; BINDING; SUBUNIT; MECHANISM; ARF; RECOGNITION	The Vibrio cholerae bacterium causes devastating diarrhea when it infects the human intestine. The key event is adenosine diphosphate (ADP)-ribosylation of the human signaling protein G(S alpha), catalyzed by the cholera toxin A1 subunit (CTA1). This reaction is ailostericaliy activated by human ADP-ribosylation factors (ARFs), a family of essential and ubiquitous G proteins. Crystal structures of a CTA1:ARF6-GTP (guanosine triphosphate) complex reveal that binding of the human activator elicits dramatic changes in CTA1 loop regions that allow nicotinamide adenine dinucleotide (NAD(+)) to bind to the active site. The extensive toxin:ARF-GTP interface surface mimics ARF-GTP recognition of normal cellular protein partners, which suggests that the toxin has evolved to exploit promiscuous binding properties of ARFs.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Aurora, CO 80045 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Colorado System; University of Colorado Anschutz Medical Campus	Hol, WGJ (corresponding author), Univ Washington, Dept Biochem, Seattle, WA 98195 USA.	wghol@u.washington.edu	Jobling, Michael G/AAJ-3814-2021	Jobling, Michael/0000-0001-7689-3093	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI034501, R01AI031940, R01AI034501] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-31940, R01 AI031940, AI-34501] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agren L, 1999, PROTEIN ENG, V12, P173, DOI 10.1093/protein/12.2.173; Bell CE, 1996, BIOCHEMISTRY-US, V35, P1137, DOI 10.1021/bi9520848; Biou V, 2004, BIOCHEMISTRY-US, V43, P6833, DOI 10.1021/bi049630u; Cieplak W, 1995, J BIOL CHEM, V270, P30545, DOI 10.1074/jbc.270.51.30545; de Haan L, 2004, MOL MEMBR BIOL, V21, P77, DOI 10.1080/09687680410001663267; Evans HR, 2003, J BIOL CHEM, V278, P45924, DOI 10.1074/jbc.M307719200; Hacker J, 2000, ANNU REV MICROBIOL, V54, P641, DOI 10.1146/annurev.micro.54.1.641; Han S, 2002, INT J MED MICROBIOL, V291, P523; Han S, 1999, NAT STRUCT BIOL, V6, P932, DOI 10.1038/13300; Han SI, 2001, J MOL BIOL, V305, P95, DOI 10.1006/jmbi.2000.4292; Hanzal-Bayer M, 2002, EMBO J, V21, P2095, DOI 10.1093/emboj/21.9.2095; Jobling MG, 2001, J BACTERIOL, V183, P4024, DOI 10.1128/JB.183.13.4024-4032.2001; KAHN RA, 1986, J BIOL CHEM, V261, P7906; LEE CM, 1991, J CLIN INVEST, V87, P1780, DOI 10.1172/JCI115197; Li M, 1996, P NATL ACAD SCI USA, V93, P6902, DOI 10.1073/pnas.93.14.6902; LOBET Y, 1991, INFECT IMMUN, V59, P2870, DOI 10.1128/IAI.59.9.2870-2879.1991; Masignani V, 2000, HANDB EXP PHARM, V145, P21; MEKALANOS JJ, 1979, J BIOL CHEM, V254, P5855; Menetrey J, 2000, NAT STRUCT BIOL, V7, P466; Menetrey J, 2002, J BIOL CHEM, V277, P30950, DOI 10.1074/jbc.M201844200; Nagahama M, 2000, J BACTERIOL, V182, P2096, DOI 10.1128/JB.182.8.2096-2103.2000; NODA M, 1990, BIOCHIM BIOPHYS ACTA, V1034, P195, DOI 10.1016/0304-4165(90)90076-9; O'Neal CJ, 2004, BIOCHEMISTRY-US, V43, P3772, DOI 10.1021/bi0360152; Panic B, 2003, MOL CELL, V12, P863, DOI 10.1016/S1097-2765(03)00356-3; Pasqualato S, 2002, EMBO REP, V3, P1035, DOI 10.1093/embo-reports/kvf221; Sack DA, 2004, LANCET, V363, P223, DOI 10.1016/S0140-6736(03)15328-7; Shiba T, 2003, NAT STRUCT BIOL, V10, P386, DOI 10.1038/nsb920; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Sun JJ, 2004, NAT STRUCT MOL BIOL, V11, P868, DOI 10.1038/nsmb818; Tsuge H, 2003, J MOL BIOL, V325, P471, DOI 10.1016/S0022-2836(02)01247-0; vandenAkker F, 1996, STRUCTURE, V4, P665, DOI 10.1016/S0969-2126(96)00073-1; VANDENAKKER F, 1995, BIOCHEMISTRY-US, V34, P10996, DOI 10.1021/bi00035a005; Widdus R, 2001, B WORLD HEALTH ORGAN, V79, P713; Wilde C, 2002, BIOCHEMISTRY-US, V41, P1539, DOI 10.1021/bi015809i; ZHANG RG, 1995, J MOL BIOL, V251, P563, DOI 10.1006/jmbi.1995.0456; Zhou GC, 2004, J AM CHEM SOC, V126, P5690, DOI 10.1021/ja038159+; Zhu XJ, 2001, BIOCHEMISTRY-US, V40, P4560, DOI 10.1021/bi002628s; Zhu XJ, 2001, J BIOL CHEM, V276, P25014, DOI 10.1074/jbc.M100923200	39	116	120	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 12	2005	309	5737					1093	1096		10.1126/science.1113398	http://dx.doi.org/10.1126/science.1113398			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955MN	16099990				2022-12-28	WOS:000231230100051
J	Hemann, MT; Bric, A; Teruya-Feldstein, J; Herbst, A; Nilsson, JA; Cordon-Cardo, C; Cleveland, JL; Tansey, WP; Lowe, SW				Hemann, MT; Bric, A; Teruya-Feldstein, J; Herbst, A; Nilsson, JA; Cordon-Cardo, C; Cleveland, JL; Tansey, WP; Lowe, SW			Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants	NATURE			English	Article							BURKITT-LYMPHOMA CELLS; N-TERMINAL DOMAIN; C-MYC; TRANSACTIVATION DOMAIN; TRANSFORMING ACTIVITY; IN-VIVO; MUTATIONS; APOPTOSIS; ONCOGENE; GENE	The c-Myc oncoprotein promotes proliferation and apoptosis, such that mutations that disable apoptotic programmes often cooperate with MYC during tumorigenesis. Here we report that two common mutant MYC alleles derived from human Burkitt's lymphoma uncouple proliferation from apoptosis and, as a result, are more effective than wild-type MYC at promoting B cell lymphomagenesis in mice. Mutant MYC proteins retain their ability to stimulate proliferation and activate p53, but are defective at promoting apoptosis due to a failure to induce the BH3-only protein Bim ( a member of the B cell lymphoma 2 (Bcl2) family) and effectively inhibit Bcl2. Disruption of apoptosis through enforced expression of Bcl2, or loss of either Bim or p53 function, enables wild-type MYC to produce lymphomas as efficiently as mutant MYC. These data show how parallel apoptotic pathways act together to suppress MYC-induced transformation, and how mutant MYC proteins, by selectively disabling a p53-independent pathway, enable tumour cells to evade p53 action during lymphomagenesis.	Cold Spring Harbor Lab, Howard Hughes Med Inst, Cold Spring Harbor, NY 11724 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; St Jude Children's Research Hospital	Lowe, SW (corresponding author), Cold Spring Harbor Lab, Howard Hughes Med Inst, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	lowe@cshl.org	Nilsson, Jonas/E-5346-2013	Nilsson, Jonas/0000-0003-0346-6837	NCI NIH HHS [P01 CA087497, P30 CA008748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748, P01CA087497] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALBERT T, 1994, ONCOGENE, V9, P759; Bemark M, 2000, ONCOGENE, V19, P3404, DOI 10.1038/sj.onc.1203686; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BHATIA KG, 1992, CANCER RES, V52, P4273; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; CLARK HM, 1994, CANCER RES, V54, P3383; Cole M D, 1986, Basic Life Sci, V38, P399; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Dang CV, 1999, MOL CELL BIOL, V19, P1; DAVIS M, 1984, NATURE, V308, P286, DOI 10.1038/308286a0; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FRYKBERG L, 1987, ONCOGENE, V1, P415; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Maclean KH, 2003, MOL CELL BIOL, V23, P7256, DOI 10.1128/MCB.23.20.7256-7270.2003; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SPENCER CA, 1991, ADV CANCER RES, V56, P1; WESTAWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P843, DOI 10.1073/pnas.81.3.843; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yu DN, 2002, ONCOGENE, V21, P1922, DOI 10.1038/sj.onc.1205244	30	340	368	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 11	2005	436	7052					807	811		10.1038/nature03845	http://dx.doi.org/10.1038/nature03845			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953XG	16094360	Green Accepted			2022-12-28	WOS:000231116500036
J	Ng, SK; van Hasselt, CA				Ng, SK; van Hasselt, CA			Images in clinical medicine - Patulous eustachian tube	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Prince Wales Hosp, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital	Ng, SK (corresponding author), Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.								0	0	0	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 11	2005	353	6					E5	E5		10.1056/NEJMicm040779	http://dx.doi.org/10.1056/NEJMicm040779			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	953ST	16093458				2022-12-28	WOS:000231101500013
J	Rosen, CJ				Rosen, CJ			Postmenopausal osteoporosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MINERAL DENSITY; RANDOMIZED CONTROLLED-TRIAL; VITAMIN-D DEFICIENCY; PARATHYROID-HORMONE; HIP FRACTURE; VERTEBRAL FRACTURES; ELDERLY-WOMEN; DOUBLE-BLIND; COMBINATION THERAPY; CLINICAL-TRIAL		St Joseph Hosp, Maine Ctr Osteoporosis Res & Educ, Bangor, ME 04401 USA		Rosen, CJ (corresponding author), St Joseph Hosp, Maine Ctr Osteoporosis Res & Educ, 900 Broadway,Bldg 2, Bangor, ME 04401 USA.	rofe@aol.com			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045433] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR45433, N01-AR-3-22687] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bahl S, 2003, OSTEOPOROSIS INT, V14, P884, DOI 10.1007/s00198-003-1492-2; Baroud G, 2003, EUR SPINE J, V12, P421, DOI 10.1007/s00586-002-0512-9; Bischoff-Ferrari HA, 2004, JAMA-J AM MED ASSOC, V291, P1999, DOI 10.1001/jama.291.16.1999; Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975; Black DM, 2005, NEW ENGL J MED, V353, P555, DOI 10.1056/NEJMoa050336; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; Chesnut C, 2001, ADV EXP MED BIOL, V496, P95; Chesnut CH, 2000, AM J MED, V109, P267, DOI 10.1016/S0002-9343(00)00490-3; Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325; Cosman F, 2005, NEW ENGL J MED, V353, P566, DOI 10.1056/NEJMoa050157; Cranney A, 2002, ENDOCR REV, V23, P570, DOI 10.1210/er.2001-9002; Cuddihy MT, 2002, ARCH INTERN MED, V162, P421, DOI 10.1001/archinte.162.4.421; Cummings SR, 1999, JAMA-J AM MED ASSOC, V282, P2124; Cummings SR, 2002, AM J MED, V112, P281, DOI 10.1016/S0002-9343(01)01124-X; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; Ensrud KE, 2004, J BONE MINER RES, V19, P1259, DOI 10.1359/JBMR.040326; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P2124; Ettinger B, 2004, OBSTET GYNECOL, V104, P443, DOI 10.1097/01.AOG.0000137833.43248.79; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725; Gabriel SE, 2002, OSTEOPOROSIS INT, V13, P323, DOI 10.1007/s001980200033; Gillespie WJ, 2002, ACTA ORTHOP SCAND, V73, P15, DOI 10.1080/000164702760379495; Greenspan SL, 2003, JAMA-J AM MED ASSOC, V289, P2525, DOI 10.1001/jama.289.19.2525; Greenspan SL, 2002, ANN INTERN MED, V137, P875, DOI 10.7326/0003-4819-137-11-200212030-00008; Guyatt GH, 2002, ENDOCRIN METAB CLIN, V31, P659, DOI 10.1016/S0889-8529(02)00024-5; Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344; HODGSON SF, 2004, ENDOCR PRACT, V10, P90; Hodgson Stephen F, 2003, Endocr Pract, V9, P544; Kelley GA, 2004, J WOMENS HEALTH, V13, P293, DOI 10.1089/154099904323016455; Klibanski A, 2001, JAMA-J AM MED ASSOC, V285, P785; LeBoff MS, 1999, JAMA-J AM MED ASSOC, V281, P1505, DOI 10.1001/jama.281.16.1505; Lindsay R, 2002, JAMA-J AM MED ASSOC, V287, P2668, DOI 10.1001/jama.287.20.2668; McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503; MCCLUNG MR, 2004, J BONE MINER RES, V19, P1072; Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436; National Osteoporosis Foundation, 2003, PHYS GUID PREV TREAT; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; *OFF SURG GEN, 2004, BON HLTH OST REP SUR, P436; PARKER MJ, 2001, COCHRANE DB SYST REV, V2, P1255; Pinilla TP, 1996, CALCIFIED TISSUE INT, V58, P231; Raisz LG, 2005, NEW ENGL J MED, V353, P164, DOI 10.1056/NEJMcp042092; Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219; RIGGS BL, 2003, NEW ENGL J MED, V348, P1192; Rittmaster RS, 2000, J CLIN ENDOCR METAB, V85, P2129, DOI 10.1210/jc.85.6.2129; Rosen CJ, 2005, J BONE MINER RES, V20, P141, DOI 10.1359/jbmr.2005.20.1.141; Rosen CJ, 2003, NEW ENGL J MED, V348, P1503, DOI 10.1056/NEJM200304103481521; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Shea B, 2002, ENDOCR REV, V23, P552, DOI 10.1210/er.2001-7002; Silverman SL, 2002, OSTEOPOROSIS INT, V13, P858, DOI 10.1007/s001980200118; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; Trivedi DP, 2003, BMJ-BRIT MED J, V326, P469, DOI 10.1136/bmj.326.7387.469; Watts NB, 2001, OSTEOPOROSIS INT, V12, P429, DOI 10.1007/s001980170086; Wells G, 2002, ENDOCR REV, V23, P529, DOI 10.1210/er.2001-5002	58	199	223	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 11	2005	353	6					595	603		10.1056/NEJMcp043801	http://dx.doi.org/10.1056/NEJMcp043801			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	953ST	16093468				2022-12-28	WOS:000231101500010
J	Osterberg, L; Blaschke, T				Osterberg, L; Blaschke, T			Drug therapy - Adherence to medication	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							AIDS CLINICAL-TRIALS; ANTIRETROVIRAL MEDICATION; TREATMENT NONADHERENCE; REPORTED ADHERENCE; PATIENT COMPLIANCE; PHARMACY RECORDS; STATIN THERAPY; HEART-FAILURE; SELF-REPORT; PREDICTORS		VA Palo Alto Hlth Care Syst, Div Gen Med, Palo Alto, CA 94304 USA; Stanford Univ, Med Ctr, Div Clin Pharmacol, Stanford, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Osterberg, L (corresponding author), VA Palo Alto Hlth Care Syst, Div Gen Med, 3801 Miranda Ave, Palo Alto, CA 94304 USA.	larso@stanford.edu		Blaschke, Terrence/0000-0001-5307-2620				Alcoba M, 2003, JAIDS-J ACQ IMM DEF, V33, P253, DOI 10.1097/00126334-200306010-00022; Ammassari A, 2002, JAIDS, V31, pS123, DOI 10.1097/00126334-200212153-00007; Balkrishnan R, 1998, CLIN THER, V20, P764, DOI 10.1016/S0149-2918(98)80139-2; Benner JS, 2002, JAMA-J AM MED ASSOC, V288, P455, DOI 10.1001/jama.288.4.455; BERG JS, 1993, ANN PHARMACOTHER, V27, pS1; Bhanji NH, 2004, EUR NEUROPSYCHOPHARM, V14, P87, DOI 10.1016/S0924-977X(03)00109-3; Black HR, 1999, AM J HYPERTENS, V12, p225S; Blaiss M, 2004, CLIN THER, V26, P1876, DOI 10.1016/j.clinthera.2004.11.003; Bouvy ML, 2003, J CARD FAIL, V9, P404, DOI 10.1054/S1071-9164(03)00130-1; Brackis-Cott Elizabeth, 2003, J Pediatr Health Care, V17, P252, DOI 10.1016/S0891-5245(02)88313-4; Burnier M, 2001, J HYPERTENS, V19, P335, DOI 10.1097/00004872-200102000-00022; Burnier M, 2000, BLOOD PRESS MONIT, V5, pS31, DOI 10.1097/00126097-200005001-00006; CANNER PL, 1980, NEW ENGL J MED, V303, P1038; Chesney M, 2003, AIDS PATIENT CARE ST, V17, P169, DOI 10.1089/108729103321619773; Christensen DB, 1997, MED CARE, V35, P1164, DOI 10.1097/00005650-199711000-00008; Claxton AJ, 2001, CLIN THER, V23, P1296, DOI 10.1016/S0149-2918(01)80109-0; Colom Francesc, 2000, Journal of Clinical Psychiatry, V61, P549; Cramer J, 2003, VALUE HEALTH, V6, P566, DOI 10.1046/j.1524-4733.2003.65269.x; Cramer J., 1991, PATIENT COMPLIANCE M, P387; CRAMER JA, 1990, ARCH INTERN MED, V150, P1509, DOI 10.1001/archinte.150.7.1509; Cramer JA, 1998, PSYCHIATR SERV, V49, P196, DOI 10.1176/ps.49.2.196; CRAMER JA, 1989, JAMA-J AM MED ASSOC, V262, P1472; CRAMER JA, 1995, NEUROLOGY, V45, pS25; CRAMER JA, 1989, JAMA-J AM MED ASSOC, V261, P3273, DOI 10.1001/jama.261.22.3273; Crespo-Fierro M, 1997, J Assoc Nurses AIDS Care, V8, P43, DOI 10.1016/S1055-3290(97)80012-X; DIMATTEO MR, 1993, HEALTH PSYCHOL, V12, P93, DOI 10.1037/0278-6133.12.2.93; Dunbar PJ, 2003, J AM MED INFORM ASSN, V10, P11, DOI 10.1197/jamia.M1047; EISEN SA, 1990, ARCH INTERN MED, V150, P1881, DOI 10.1001/archinte.150.9.1881; Elliott WJ, 2000, POSTGRAD MED, V107, P29, DOI 10.3810/pgm.2000.03.940; Ellis JJ, 2004, J GEN INTERN MED, V19, P638, DOI 10.1111/j.1525-1497.2004.30516.x; EPSTEIN LH, 1981, J APPL BEHAV ANAL, V14, P365, DOI 10.1901/jaba.1981.14-365; Farley J, 2003, JAIDS-J ACQ IMM DEF, V33, P211, DOI 10.1097/00126334-200306010-00016; Farris KB, 2004, CAN FAM PHYSICIAN, V50, P998; FEINSTEIN AR, 1990, ARCH INTERN MED, V150, P1377, DOI 10.1001/archinte.150.7.1377; Feldman R, 1998, CAN J PUBLIC HEALTH, V89, pI16, DOI 10.1007/BF03404494; FESTA RS, 1992, J PEDIATR-US, V120, P807, DOI 10.1016/S0022-3476(05)80256-2; FRIEDMAN IM, 1986, J ADOLESCENT HEALTH, V7, P12, DOI 10.1016/S0197-0070(86)80088-2; FRIEDMAN IM, 1987, J ADOLESCENT HEALTH, V8, P52, DOI 10.1016/0197-0070(87)90246-4; Fulmer T T, 1999, J Gerontol Nurs, V25, P6; GILLIS LS, 1987, S AFR MED J, V72, P602; Golin CE, 2002, J GEN INTERN MED, V17, P756, DOI 10.1046/j.1525-1497.2002.11214.x; Golin CE, 1996, DIABETES CARE, V19, P1153, DOI 10.2337/diacare.19.10.1153; GREENANFOWLER E, 1987, ARCH PHYS MED REHAB, V68, P846; GREENBERG RN, 1984, CLIN THER, V6, P592; Haynes R B, 2002, Cochrane Database Syst Rev, pCD000011; Haynes RB, 2002, JAMA-J AM MED ASSOC, V288, P2880, DOI 10.1001/jama.288.22.2880; HAYNES RB, 1980, HYPERTENSION, V2, P757, DOI 10.1161/01.HYP.2.6.757; Hoffman L, 2003, AM J MANAG CARE, V9, P70; HORWITZ RI, 1993, ARCH INTERN MED, V153, P1863, DOI 10.1001/archinte.153.16.1863; Ickovics JR, 1997, J CLIN EPIDEMIOL, V50, P385, DOI 10.1016/S0895-4356(97)00041-3; Ickovics JR, 2002, ANTIVIR THER, V7, P185; Ickovics JR, 2002, AIDS CARE, V14, P309, DOI 10.1080/09540120220123685; Jackevicius CA, 2002, JAMA-J AM MED ASSOC, V288, P462, DOI 10.1001/jama.288.4.462; JAY S, 1984, J ADOLESCENT HEALTH, V5, P124, DOI 10.1016/S0197-0070(84)80012-1; KASS MA, 1984, ARCH OPHTHALMOL-CHIC, V102, P1550; Kastrissios H, 1998, AIDS, V12, P2305, DOI 10.1097/00002030-199817000-00012; Lacro JP, 2002, J CLIN PSYCHIAT, V63, P892, DOI 10.4088/JCP.v63n1007; LaRosa J C, 2000, Curr Atheroscler Rep, V2, P1, DOI 10.1007/s11883-000-0086-0; Lau HS, 1997, J CLIN EPIDEMIOL, V50, P619, DOI 10.1016/S0895-4356(97)00040-1; Levy G, 2000, CLIN PHARMACOL THER, V68, P586, DOI 10.1067/mcp.2000.110976; Liu H, 2002, ANN INTERN MED, V136, P175, DOI 10.7326/0003-4819-134-10-200105150-00011; Liu HH, 2001, ANN INTERN MED, V134, P968, DOI 10.7326/0003-4819-134-10-200105150-00011; Loghmain-Adham M, 2003, AM J MANAG CARE, V9, P155; Love RC, 2002, AM J HEALTH-SYST PH, V59, pS10, DOI 10.1093/ajhp/59.suppl_8.S10; MAGRAB PR, 1977, J APPL BEHAV ANAL, V10, P573, DOI 10.1901/jaba.1977.10-573; Maro EE, 1997, E AFR MED J, V74, P539; McDonnell PJ, 2002, ANN PHARMACOTHER, V36, P1331, DOI 10.1345/aph.1A333; Michaud PA, 2004, ARCH DIS CHILD, V89, P943, DOI 10.1136/adc.2003.045377; Miller LG, 2002, J GEN INTERN MED, V17, P1, DOI 10.1046/j.1525-1497.2002.09004.x; Misdrahi D, 2002, ENCEPHALE, V28, P266; Mitchell P B, 1994, Aust Fam Physician, V23, P1771; Mitchell PB, 1994, AUST FAM PHYSICIAN, V23, P1776; Molassiotis A, 2003, AIDS CARE, V15, P125, DOI 10.1080/0954012021000039833; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; Mundt JC, 2001, DEPRESS ANXIETY, V13, P1, DOI 10.1002/1520-6394(2001)13:1<1::AID-DA1>3.0.CO;2-S; Murphy DA, 2003, ARCH PEDIAT ADOL MED, V157, P249, DOI 10.1001/archpedi.157.3.249; Murri R, 2004, J GEN INTERN MED, V19, P1104, DOI 10.1111/j.1525-1497.2004.30248.x; Nemeroff CB, 2003, J CLIN PSYCHIAT, V64, P25; NORELL SE, 1981, AM J OPHTHALMOL, V92, P727, DOI 10.1016/S0002-9394(14)74670-7; Nose M, 2003, BRIT J PSYCHIAT, V183, P197, DOI 10.1192/bjp.183.3.197; Ofman JJ, 2004, AM J MED, V117, P182, DOI 10.1016/j.amjmed.2004.03.018; Okuno J, 2001, EUR J CLIN PHARMACOL, V57, P589, DOI 10.1007/s002280100347; OSTERBERG LG, 2005, HYPERTENSION COMPANI, P848, DOI DOI 10.1016/B978-0-7216-0258-5.50131-9; Paes AHP, 1997, DIABETES CARE, V20, P1512, DOI 10.2337/diacare.20.10.1512; Paterson DL, 2002, JAIDS, V31, pS103, DOI 10.1097/00126334-200212153-00003; Patton K, 1997, AM J MANAG C, V3, P1693; Pekkala E, 2002, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD002831; Perkins DO, 2002, J CLIN PSYCHIAT, V63, P1121, DOI 10.4088/JCP.v63n1206; PULLAR T, 1989, CLIN PHARMACOL THER, V46, P163, DOI 10.1038/clpt.1989.121; Ran MS, 2003, SOC PSYCH PSYCH EPID, V38, P69, DOI 10.1007/s00127-003-0601-z; RAPOFF MA, 1984, ARCH PHYS MED REHAB, V65, P267; RAPOFF MA, 1989, ARTHRITIS CARE RES S, V2, P40; Rigsby MO, 2000, J GEN INTERN MED, V15, P841, DOI 10.1046/j.1525-1497.2000.00127.x; Rodgers P T, 1998, Manag Care Interface, V11, P67; RODGERS PT, 1998, MANAG CARE INTERFACE, V11, P75; Rosenheck R, 2000, J CLIN PSYCHIAT, V61, P382, DOI 10.4088/JCP.v61n0511; ROSS FM, 1991, SOC SCI MED, V32, P89, DOI 10.1016/0277-9536(91)90132-V; RUDD P, 1988, AM J HYPERTENS, V1, P309, DOI 10.1093/ajh/1.3.309; Safren SA, 2001, BEHAV RES THER, V39, P1151, DOI 10.1016/S0005-7967(00)00091-7; Schiff GD, 2003, AM J MED, V114, P625, DOI 10.1016/S0002-9343(03)00132-3; Schroeder K, 2004, ARCH INTERN MED, V164, P722, DOI 10.1001/archinte.164.7.722; Senst BL, 2001, AM J HEALTH-SYST PH, V58, P1126, DOI 10.1093/ajhp/58.12.1126; Sewitch MJ, 2003, AM J GASTROENTEROL, V98, P1535, DOI 10.1016/S0002-9270(03)00304-6; Shon KH, 2002, YONSEI MED J, V43, P579, DOI 10.3349/ymj.2002.43.5.579; Simoni Jane M, 2003, Top HIV Med, V11, P185; SPECTOR SL, 1986, J ALLERGY CLIN IMMUN, V77, P65, DOI 10.1016/0091-6749(86)90325-8; SPILKER B, 1991, PATIENT COMPLIANCE M, P37; Steiner JF, 2000, ANN INTERN MED, V132, P926, DOI 10.7326/0003-4819-132-11-200006060-00026; Steiner JF, 1997, J CLIN EPIDEMIOL, V50, P105, DOI 10.1016/S0895-4356(96)00268-5; STEPHENSON BJ, 1993, JAMA-J AM MED ASSOC, V269, P2779, DOI 10.1001/jama.269.21.2779; Stilley CS, 2004, ANN BEHAV MED, V27, P117, DOI 10.1207/s15324796abm2702_6; Stone VE, 2001, J ACQ IMMUN DEF SYND, V28, P124, DOI 10.1097/00042560-200110010-00003; Stuart B, 1999, HEALTH AFFAIR, V18, P201, DOI 10.1377/hlthaff.18.2.201; TEBBI CK, 1993, CANCER, V71, P3441, DOI 10.1002/1097-0142(19930515)71:10+<3441::AID-CNCR2820711751>3.0.CO;2-P; TEBBI CK, 1986, CANCER, V58, P1179, DOI 10.1002/1097-0142(19860901)58:5<1179::AID-CNCR2820580534>3.0.CO;2-E; Tucker CM, 2002, PEDIATR NEPHROL, V17, P251, DOI 10.1007/s00467-001-0806-x; Tuldra A, 2000, J ACQ IMMUN DEF SYND, V25, P221, DOI 10.1097/00126334-200011010-00003; Turner BJ, 2001, ANN INTERN MED, V134, P1004, DOI 10.7326/0003-4819-134-10-200105150-00015; Urquhart J, 2002, BRIT J CLIN PHARMACO, V54, P212, DOI 10.1046/j.1365-2125.2002.01629.x; Urquhart J, 1997, CLIN PHARMACOKINET, V32, P345, DOI 10.2165/00003088-199732050-00001; Van Servellen G, 2002, AIDS PATIENT CARE ST, V16, P269, DOI 10.1089/10872910260066705; Vergouwen A C M, 2002, Ned Tijdschr Geneeskd, V146, P204; Vrijens B, 1997, CONTROL CLIN TRIALS, V18, P187, DOI 10.1016/S0197-2456(96)00235-8; Waeber B, 1999, J HYPERTENS, V17, P1041, DOI 10.1097/00004872-199917070-00022; Wagner JH, 2001, J CLIN EPIDEMIOL, V54, pS91, DOI 10.1016/S0895-4356(01)00450-4; Walsh JC, 2002, AIDS, V16, P269, DOI 10.1097/00002030-200201250-00017; Weingarten SR, 2002, BRIT MED J, V325, P925, DOI 10.1136/bmj.325.7370.925; Wilson J, 2005, AM J MANAG CARE, V11, pSP27; World Health Organisation, 2003, ADHERENCE LONG TERM; Zyczynski T M, 2000, Curr Hypertens Rep, V2, P510, DOI 10.1007/s11906-996-0034-7; Zygmunt A, 2002, AM J PSYCHIAT, V159, P1653, DOI 10.1176/appi.ajp.159.10.1653	131	5444	5652	21	487	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 4	2005	353	5					487	497		10.1056/NEJMra050100	http://dx.doi.org/10.1056/NEJMra050100			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	951OB	16079372				2022-12-28	WOS:000230939000008
J	Pillai, RS; Bhattacharyya, SN; Artus, CG; Zoller, T; Cougot, N; Basyuk, E; Bertrand, E; Filipowicz, W				Pillai, RS; Bhattacharyya, SN; Artus, CG; Zoller, T; Cougot, N; Basyuk, E; Bertrand, E; Filipowicz, W			Inhibition of translational initiation by Let-7 microRNA in human cells	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; PROCESSING BODIES; MESSENGER-RNAS; PROTEIN-SYNTHESIS; EIF4E; MECHANISMS; EXPRESSION; SITES; DECAY	MicroRNAs (miRNAs) are similar to 21-nucteotide-long RNA molecules regulating gene expression in multicellular eukaryotes. In metazoa, miRNAs act by imperfectly base-pairing with the 3' untranslated region of target messenger RNAs (mRNAs) and repressing protein accumulation by an unknown mechanism. We demonstrate that endogenous let-7 microribonucleoproteins (miRNPs) or the tethering of Argonaute (Ago) proteins to reporter mRNAs in human cells inhibit translation initiation. M(7)G-cap-independent translation is not subject to repression, suggesting that miRNPs interfere with recognition of the cap. Repressed mRNAs, Ago proteins, and miRNAs were all found to accumulate in processing bodies. We propose that localization of mRNAs to these structures is a consequence of translational repression.	Friedrich Miescher Inst Biomed Res, CH-4002 Basel, Switzerland; Inst Genet Mol Montpellier, F-34000 Montpellier, France	Friedrich Miescher Institute for Biomedical Research; Universite de Montpellier	Filipowicz, W (corresponding author), Friedrich Miescher Inst Biomed Res, CH-4002 Basel, Switzerland.	Filipowi@fmi.ch	Cougot, Nicolas/K-8688-2012	Cougot, Nicolas/0000-0001-6614-8380; bertrand, edouard/0000-0002-9642-7994; Basyuk, Eugenia/0000-0001-9768-4557				Anderson P, 2002, J CELL SCI, V115, P3227; Andrei MA, 2005, RNA, V11, P717, DOI 10.1261/rna.2340405; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; CHANG J, 2004, RNA BIOL, V1, P2; Cho PF, 2005, CELL, V121, P411, DOI 10.1016/j.cell.2005.02.024; De Gregorio E, 2001, RNA, V7, P106, DOI 10.1017/S1355838201000577; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Jing Q, 2005, CELL, V120, P623, DOI 10.1016/j.cell.2004.12.038; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kolb FA, 2005, METHOD ENZYMOL, V392, P316, DOI 10.1016/S0076-6879(04)92019-8; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Liu JD, 2005, NAT CELL BIOL, V7, P719, DOI 10.1038/ncb1274; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; PILLAI R, UNPUB; Pillai RS, 2004, RNA, V10, P1518, DOI 10.1261/rna.7131604; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Seggerson K, 2002, DEV BIOL, V243, P215, DOI 10.1006/dbio.2001.0563; Sen GL, 2005, NAT CELL BIOL, V7, P633, DOI 10.1038/ncb1265; Seydoux G, 1999, DEVELOPMENT, V126, P3275; Sheth U, 2003, SCIENCE, V300, P805, DOI 10.1126/science.1082320; Teixeira D, 2005, RNA, V11, P371, DOI 10.1261/rna.7258505; Zeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100	25	1056	1124	0	72	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 2	2005	309	5740					1573	1576		10.1126/science.1115079	http://dx.doi.org/10.1126/science.1115079			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	962EY	16081698				2022-12-28	WOS:000231715000053
J	Palmieri, C; Fisher, RA; Sebire, NJ; Lindsay, I; Smith, JR; McCluggage, WG; Savage, P; Seckl, MJ				Palmieri, C; Fisher, RA; Sebire, NJ; Lindsay, I; Smith, JR; McCluggage, WG; Savage, P; Seckl, MJ			Placental site trophoblastic tumour arising from a partial hydatidiform mole	LANCET			English	Editorial Material							EPIDEMIOLOGY		Charing Cross Hosp, Dept Canc Med, London W6 8RF, England; Charing Cross Hosp, Imperial Coll London, Fac Med, London W6 8RF, England; Charing Cross Hosp, Dept Histopathol, London W6 8RF, England; Chelsea & Westminster Hosp, Dept Obstet & Gynaecol, London SW10 9NH, England; Royal Grp Hosp Trust, Dept Pathol, Belfast BT12 6BL, Antrim, North Ireland	Imperial College London; Imperial College London; Imperial College London; Imperial College London	Seckl, MJ (corresponding author), Charing Cross Hosp, Dept Canc Med, Fulham Palace Rd, London W6 8RF, England.	m.seckl@imperial.ac.uk	sebire, neil J/C-4960-2008	Sebire, Neil/0000-0001-5348-9063; Fisher, Rosemary/0000-0002-2721-8726; Savage, Philip/0000-0002-4792-6869				JACOBS PA, 1982, BRIT J OBSTET GYNAEC, V89, P258, DOI 10.1111/j.1471-0528.1982.tb04693.x; LAWLER SD, 1982, CANCER GENET CYTOGEN, V5, P309, DOI 10.1016/0165-4608(82)90096-6; Papadopoulos AJ, 2002, J REPROD MED, V47, P460; Seckl MJ, 2000, LANCET, V356, P36, DOI 10.1016/S0140-6736(00)02432-6; Steigrad SJ, 2003, BEST PRACT RES CL OB, V17, P837, DOI 10.1016/S1521-6934(03)00049-X	5	31	32	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 20	2005	366	9486					688	688		10.1016/S0140-6736(05)67143-7	http://dx.doi.org/10.1016/S0140-6736(05)67143-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958EB	16112308				2022-12-28	WOS:000231426400035
J	Brown, RS				Brown, RS			Hepatitis C and liver transplantation	NATURE			English	Review							INTERFERON-ALPHA-2B PLUS RIBAVIRIN; LIVING DONOR; MYCOPHENOLATE-MOFETIL; GRAFT-SURVIVAL; PEGYLATED INTERFERON-ALPHA-2B; PEGINTERFERON ALPHA-2A; 10-YEAR EXPERIENCE; NATURAL-HISTORY; POSITIVE GRAFTS; ACUTE REJECTION	Liver transplantation is a life-saving therapy to correct liver failure, portal hypertension and hepatocellular carcinoma arising from hepatitis C infection. But despite the successful use of living donors and improvements in immunosuppression and antiviral therapy, organ demand continues to outstrip supply and recurrent hepatitis C with accelerated progression to cirrhosis of the graft is a frequent cause of graft loss and the need for retransplantation. Appropriate selection of candidates and timing of transplantation, coupled with better pre- and post-transplant antiviral therapy, are needed to improve outcomes.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Surg, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Ctr Liver Dis & Transplantat, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Brown, RS (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 622 W 168th St, New York, NY 10032 USA.	rb464@columbia.edu						Abt PL, 2004, AM J TRANSPLANT, V4, P1302, DOI 10.1111/j.1600-6143.2004.00522.x; Ahmad J, 2001, LIVER TRANSPLANT, V7, P863, DOI 10.1053/jlts.2001.27869; Arenas JI, 2003, LIVER TRANSPLANT, V9, pS48, DOI 10.1053/jlts.2003.50252; Baltz Aaron C, 2003, Clin Liver Dis, V7, P651, DOI 10.1016/S1089-3261(03)00058-8; Berenguer M, 2000, HEPATOLOGY, V32, P852, DOI 10.1053/jhep.2000.17924; Berenguer M, 2002, LIVER TRANSPLANT, V8, pS14, DOI 10.1053/jlts.2002.35781; BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007; Brown RS, 2005, AM J TRANSPLANT, V5, P203, DOI 10.1111/j.1600-6143.2005.00769.x; Brown RS, 2003, NEW ENGL J MED, V348, P818, DOI 10.1056/NEJMsa021345; Cescon M, 2003, LIVER TRANSPLANT, V9, P1174, DOI 10.1053/jlts.2003.50234; Chalasani N, 2005, HEPATOLOGY, V41, P289, DOI 10.1002/hep.20560; Charlton M, 2004, LIVER TRANSPLANT, V10, P1120, DOI 10.1002/lt.20211; Charlton M, 1998, HEPATOLOGY, V28, P823, DOI 10.1002/hep.510280333; Charlton M, 1999, LIVER TRANSPLANT SUR, V5, pS107; Charlton Michael, 2003, Clin Liver Dis, V7, P585, DOI 10.1016/S1089-3261(03)00046-1; Crippin JS, 2002, LIVER TRANSPLANT, V8, P350, DOI 10.1053/jlts.2002.31748; Desai NM, 2004, TRANSPLANTATION, V77, P99, DOI 10.1097/01.TP.0000101009.91516.FC; Eason JD, 2003, TRANSPLANTATION, V75, P1396, DOI 10.1097/01.TP.0000062834.30922.FE; Everson Gregory T, 2004, Rev Gastroenterol Disord, V4 Suppl 1, pS31; Everson GT, 2003, LIVER TRANSPLANT, V9, pS90, DOI 10.1053/jlts.2003.50247; Everson GT, 2005, J HEPATOL, V42, P456, DOI 10.1016/j.jhep.2005.01.012; Freeman RB, 2003, LIVER TRANSPLANT, V9, pS54, DOI 10.1053/jlts.2003.50223; Gaglio PJ, 2003, LIVER TRANSPLANT, V9, P1028, DOI 10.1053/jlts.2003.50211; Gane E, 2002, LIVER TRANSPLANT, V8, pS28, DOI 10.1053/jlts.2002.35860; Garcia-Retortillo M, 2002, HEPATOLOGY, V35, P680, DOI 10.1053/jhep.2002.31773; Ghobrial RM, 2001, ANN SURG, V234, P384, DOI 10.1097/00000658-200109000-00012; Jain A, 2002, LIVER TRANSPLANT, V8, P40, DOI 10.1053/jlts.2002.29763; Lavezzo B, 2002, J HEPATOL, V37, P247, DOI 10.1016/S0168-8278(02)00109-5; Liu CL, 2003, LIVER TRANSPLANT, V9, P863, DOI 10.1053/jlts.2003.50163; Lucey M R, 1997, Liver Transpl Surg, V3, P628; Machicao VI, 2004, TRANSPLANTATION, V77, P84, DOI 10.1097/01.TP.0000095896.07048.BB; Marcos A, 2000, TRANSPLANTATION, V69, P1375, DOI 10.1097/00007890-200004150-00028; Merion RM, 2005, AM J TRANSPLANT, V5, P307, DOI 10.1111/j.1600-6143.2004.00703.x; Miller C, 2004, LIVER TRANSPLANT, V10, P1315, DOI 10.1002/lt.20227; Miller CM, 2001, ANN SURG, V234, P393; Nelson DR, 2001, LIVER TRANSPLANT, V7, P1064, DOI 10.1053/jlts.2001.29414; Olthoff KM, 2004, LIVER TRANSPLANT, V10, pA6, DOI 10.1002/lt.20247; Rodriguez-Luna H, 2004, TRANSPLANTATION, V77, P190, DOI 10.1097/01.TP.0000100481.14514.BB; Ross AS, 2004, CLIN TRANSPLANT, V18, P166, DOI 10.1046/j.1399-0012.2003.00145.x; Rudow DL, 2003, LIVER TRANSPLANT, V9, P254, DOI 10.1053/jlts.2003.50037; Russo MW, 2004, AM J TRANSPLANT, V4, P458, DOI 10.1111/j.1600-6143.2004.00387.x; Russo MW, 2004, LIVER TRANSPLANT, V10, P340, DOI 10.1002/lt.20090; Russo MW, 2004, AM J TRANSPLANT, V4, P427, DOI 10.1111/j.1600-6143.2004.00336.x; Saab S, 2003, LIVER TRANSPLANT, V9, P1053, DOI 10.1053/jlts.2003.50208; Saab S, 2003, AM J TRANSPLANT, V3, P1167, DOI 10.1034/j.1600-6143.2003.00189.x; Saab S, 2004, LIVER TRANSPLANT, V10, P859, DOI 10.1002/lt.20157; Samuel D, 2003, GASTROENTEROLOGY, V124, P642, DOI 10.1053/gast.2003.50095; Shiffman ML, 2004, GASTROENTEROLOGY, V126, P1015, DOI 10.1053/j.gastro.2004.01.014; Shiffman ML, 2004, LIVER TRANSPLANT, V10, P1248, DOI 10.1002/lt.20232; Stravitz RT, 2004, LIVER TRANSPLANT, V10, P850, DOI 10.1002/lt.20189; Terrault N A, 2000, Semin Gastrointest Dis, V11, P96; Toniutto P, 2005, J GASTROEN HEPATOL, V20, P577, DOI 10.1111/j.1440-1746.2005.03795.x; Trotter JF, 2000, LIVER TRANSPLANT, V6, P290, DOI 10.1053/lv.2000.6351; Wiesner R, 2001, LIVER TRANSPLANT, V7, P442, DOI 10.1053/jlts.2001.23356; Wiesner RH, 2003, LIVER TRANSPLANT, V9, pS1, DOI 10.1053/jlts.2003.50268; Zervos XA, 1998, TRANSPLANTATION, V65, P1044, DOI 10.1097/00007890-199804270-00006; Zhao Yi, 2004, Asian J Surg, V27, P114, DOI 10.1016/S1015-9584(09)60323-7	57	271	290	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 18	2005	436	7053					973	978		10.1038/nature04083	http://dx.doi.org/10.1038/nature04083			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955XQ	16107838				2022-12-28	WOS:000231263900040
J	Houghton, M; Abrignani, S				Houghton, M; Abrignani, S			Prospects for a vaccine against the hepatitis C virus	NATURE			English	Review							CELLULAR IMMUNE-RESPONSES; CD8(+) T-CELLS; VIRAL CLEARANCE; NEUTRALIZING ANTIBODY; HELPER-CELLS; INFECTION; CHIMPANZEES; PROTEIN; HCV; IMMUNIZATION	The recent discovery of natural immunity to the hepatitis C virus and vaccine efficacy in the chimpanzee challenge model has allowed optimism about the development of at least a partly effective vaccine against this heterogeneous pathogen that is responsible for much of the chronic liver disease around the world. The immune systems of some infected individuals can spontaneously clear the virus, whereas other people need treatment with antivirals that work partly by stimulating humoral and cellular immune responses. Therefore, therapeutic vaccine strategies are also being pursued to improve treatment outcome.	Chiron Corp, Emeryville, CA 94608 USA; INGM, Natl Inst Mol Genet, I-20122 Milan, Italy	Novartis; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR)	Houghton, M (corresponding author), Chiron Corp, 4560 Horton St, Emeryville, CA 94608 USA.	michael_houghton@chiron.com	Cheng, Yushao/E-6256-2011	Houghton, Michael/0000-0003-3762-6771; Abrignani, Sergio/0000-0002-0794-3285				Abel K, 2005, CLIN DIAGN LAB IMMUN, V12, P606, DOI 10.1128/CDLI.12.5.606-621.2005; Abraham JD, 2004, VACCINE, V22, P3917, DOI 10.1016/j.vaccine.2004.04.005; Alter HJ, 2000, SEMIN LIVER DIS, V20, P17, DOI 10.1055/s-2000-9505; Bartosch B, 2003, P NATL ACAD SCI USA, V100, P14199, DOI 10.1073/pnas.2335981100; Bassett SE, 2001, HEPATOLOGY, V33, P1479, DOI 10.1053/jhep.2001.24371; Baumert TF, 2000, HEPATOLOGY, V32, P610, DOI 10.1053/jhep.2000.9876; Brinster C, 2002, J GEN VIROL, V83, P369, DOI 10.1099/0022-1317-83-2-369; Catalucci D, 2005, J VIROL, V79, P6400, DOI 10.1128/JVI.79.10.6400-6409.2005; CHOO QL, 1994, P NATL ACAD SCI USA, V91, P1294, DOI 10.1073/pnas.91.4.1294; COATES S, 2005, P 11 INT S VIR HEP L, P118; Cooper S, 1999, IMMUNITY, V10, P439, DOI 10.1016/S1074-7613(00)80044-8; Cramp ME, 2000, GASTROENTEROLOGY, V118, P346, DOI 10.1016/S0016-5085(00)70217-4; Crotta S, 2002, J EXP MED, V195, P35, DOI 10.1084/jem.20011124; DIEPOLDER HM, 1995, LANCET, V346, P1006, DOI 10.1016/S0140-6736(95)91691-1; Erickson AL, 2001, IMMUNITY, V15, P883, DOI 10.1016/S1074-7613(01)00245-X; Farci P, 1996, P NATL ACAD SCI USA, V93, P15394, DOI 10.1073/pnas.93.26.15394; Farci P, 2000, SCIENCE, V288, P339, DOI 10.1126/science.288.5464.339; FARCI P, 1992, SCIENCE, V258, P135, DOI 10.1126/science.1279801; Forns X, 2000, HEPATOLOGY, V32, P618, DOI 10.1053/jhep.2000.9877; Foy E, 2005, P NATL ACAD SCI USA, V102, P2986, DOI 10.1073/pnas.0408707102; Franzusoff A, 2005, EXPERT OPIN BIOL TH, V5, P565, DOI 10.1517/14712598.5.4.565; Frese M, 2002, HEPATOLOGY, V35, P694, DOI 10.1053/jhep.2002.31770; Gerlach JT, 1999, GASTROENTEROLOGY, V117, P933, DOI 10.1016/S0016-5085(99)70353-7; Grakoui A, 2003, SCIENCE, V302, P659, DOI 10.1126/science.1088774; HOUGHTON M, 1997, VIRAL HEPATITIS LIVE, P656; Jeong SH, 2004, J VIROL, V78, P6995, DOI 10.1128/JVI.78.13.6995-7003.2004; KATO N, 1993, J VIROL, V67, P3923, DOI 10.1128/JVI.67.7.3923-3930.1993; Khakoo SI, 2004, SCIENCE, V305, P872, DOI 10.1126/science.1097670; Krahn MD, 2005, VACCINE, V23, P1549, DOI 10.1016/j.vaccine.2004.09.023; LAI ME, 1994, LANCET, V343, P388, DOI 10.1016/S0140-6736(94)91224-6; Lanford RE, 2004, J VIROL, V78, P1575, DOI 10.1128/JVI.78.3.1575-1581.2004; Lavillette D, 2005, J VIROL, V79, P6023, DOI 10.1128/JVI.79.10.6023-6034.2005; Lechner F, 2000, EUR J IMMUNOL, V30, P2479, DOI 10.1002/1521-4141(200009)30:9<2479::AID-IMMU2479>3.0.CO;2-B; Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499; Leroux-Roels G, 2004, VACCINE, V22, P3080, DOI 10.1016/j.vaccine.2004.02.002; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016; Logvinoff C, 2004, P NATL ACAD SCI USA, V101, P10149, DOI 10.1073/pnas.0403519101; McKeating JA, 2004, J VIROL, V78, P8496, DOI 10.1128/JVI.78.16.8496-8505.2004; Mehta SH, 2002, LANCET, V359, P1478, DOI 10.1016/S0140-6736(02)08435-0; Meunier JC, 2005, P NATL ACAD SCI USA, V102, P4560, DOI 10.1073/pnas.0501275102; Missale G, 1996, J CLIN INVEST, V98, P706, DOI 10.1172/JCI118842; Nelson DR, 1998, HEPATOLOGY, V28, P225, DOI 10.1002/hep.510280129; Nevens F, 2003, HEPATOLOGY, V38, P1289, DOI 10.1053/jhep.2003.50474; O'Hagan DT, 2004, VACCINE, V23, P672, DOI 10.1016/j.vaccine.2004.06.037; Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016; Pancholi P, 2003, J VIROL, V77, P382, DOI 10.1128/JVI.77.1.382-390.2003; Pearse MJ, 2005, ADV DRUG DELIVER REV, V57, P465, DOI 10.1016/j.addr.2004.09.006; Perri S, 2003, J VIROL, V77, P10394, DOI 10.1128/JVI.77.19.10394-10403.2003; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; Polakos NK, 2001, J IMMUNOL, V166, P3589, DOI 10.4049/jimmunol.166.5.3589; PRINCE AM, 1985, LANCET, V2, P1134; Puig M, 2004, VACCINE, V22, P991, DOI 10.1016/j.vaccine.2003.09.010; RALSTON R, 1993, J VIROL, V67, P6753, DOI 10.1128/JVI.67.11.6753-6761.1993; Rollier C, 2004, J VIROL, V78, P187, DOI 10.1128/JVI.78.1.187-196.2004; Rosa D, 1996, P NATL ACAD SCI USA, V93, P1759, DOI 10.1073/pnas.93.5.1759; Saadeh Sherif, 2004, Cleve Clin J Med, V71 Suppl 3, pS3; Seeff LB, 2002, HEPATOLOGY, V36, pS35, DOI 10.1053/jhep.2002.36806; Semmo N, 2005, HEPATOLOGY, V41, P1019, DOI 10.1002/hep.20669; Shoukry NH, 2003, J EXP MED, V197, P1645, DOI 10.1084/jem.20030239; Simmonds P, 2004, J GEN VIROL, V85, P3173, DOI 10.1099/vir.0.80401-0; Thimme R, 2001, J EXP MED, V194, P1395, DOI 10.1084/jem.194.10.1395; THOMSSEN R, 1992, MED MICROBIOL IMMUN, V181, P293, DOI 10.1007/BF00198849; Tsai SL, 1997, HEPATOLOGY, V25, P449; Tseng CTK, 2002, J EXP MED, V195, P43, DOI 10.1084/jem.20011145; Vrolijk JM, 2003, J INFECT DIS, V188, P1528, DOI 10.1086/379334; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Wedemeyer H, 2002, J IMMUNOL, V169, P3447, DOI 10.4049/jimmunol.169.6.3447; Weiner AJ, 2001, J VIROL, V75, P7142, DOI 10.1128/JVI.75.15.7142-7148.2001; WEINER AJ, 1992, P NATL ACAD SCI USA, V89, P3468, DOI 10.1073/pnas.89.8.3468; Wuest T, 2004, VACCINE, V22, P2717, DOI 10.1016/j.vaccine.2004.01.048; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102	72	246	283	0	23	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 18	2005	436	7053					961	966		10.1038/nature04081	http://dx.doi.org/10.1038/nature04081			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955XQ	16107836				2022-12-28	WOS:000231263900038
J	Lindenbach, BD; Rice, CM				Lindenbach, BD; Rice, CM			Unravelling hepatitis C virus replication from genome to function	NATURE			English	Review							NONSTRUCTURAL PROTEIN 5A; MAJOR PHOSPHORYLATION SITE; 3' NONTRANSLATED REGION; RNA REPLICATION; NS5A PROTEIN; IN-VIVO; EFFICIENT REPLICATION; MEMBRANE ASSOCIATION; UNTRANSLATED REGION; ION-CHANNEL	Since the discovery of the hepatitis C virus over 15 years ago, scientists have raced to develop diagnostics, study the virus and find new therapies. Yet virtually every attempt to dissect this pathogen has met with roadblocks that impeded progress. Its replication was restricted to humans or experimentally infected chimpanzees, and efficient growth of the virus in cell culture failed until very recently. Nevertheless hard-fought progress has been made and the first wave of antiviral drugs is entering clinical trials.	Rockefeller Univ, Ctr Study Hepatitis C, New York, NY 10021 USA	Rockefeller University	Rice, CM (corresponding author), Rockefeller Univ, Ctr Study Hepatitis C, 1230 York Ave, New York, NY 10021 USA.	ricec@rockefeller.edu						Appel N, 2005, J VIROL, V79, P3187, DOI 10.1128/JVI.79.5.3187-3194.2005; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Bartenschlager R, 2004, ADV VIRUS RES, V63, P71, DOI 10.1016/S0065-3527(04)63002-8; BARTENSCHLAGER R, 1994, J VIROL, V68, P5045, DOI 10.1128/JVI.68.8.5045-5055.1994; Bigger CB, 2004, J VIROL, V78, P13779, DOI 10.1128/JVI.78.24.13779-13792.2004; Bigger CB, 2001, J VIROL, V75, P7059, DOI 10.1128/JVI.75.15.7059-7066.2001; Blight KJ, 2002, J VIROL, V76, P13001, DOI 10.1128/JVI.76.24.13001-13014.2002; Blight KJ, 2003, J VIROL, V77, P3181, DOI 10.1128/JVI.77.5.3181-3190.2003; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Branch AD, 2005, SEMIN LIVER DIS, V25, P105, DOI 10.1055/s-2005-864786; Brass V, 2002, J BIOL CHEM, V277, P8130, DOI 10.1074/jbc.M111289200; Bressanelli S, 2002, J VIROL, V76, P3482, DOI 10.1128/JVI.76.7.3482-3492.2002; Bukh J, 2002, P NATL ACAD SCI USA, V99, P14416, DOI 10.1073/pnas.212532699; Bukh J, 2004, HEPATOLOGY, V39, P1469, DOI 10.1002/hep.20268; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Coito C, 2004, J VIROL, V78, P3502, DOI 10.1128/JVI.78.7.3502-3513.2004; Cormier EG, 2004, P NATL ACAD SCI USA, V101, P7270, DOI 10.1073/pnas.0402253101; Deforges S, 2004, J GEN VIROL, V85, P2515, DOI 10.1099/vir.0.80071-0; Egger D, 2002, J VIROL, V76, P5974, DOI 10.1128/JVI.76.12.5974-5984.2002; Einav S, 2004, J VIROL, V78, P11288, DOI 10.1128/JVI.78.20.11288-11295.2004; Evans MJ, 2004, P NATL ACAD SCI USA, V101, P13038, DOI 10.1073/pnas.0405152101; FAILLA C, 1994, J VIROL, V68, P3753, DOI 10.1128/JVI.68.6.3753-3760.1994; FEINSTONE SM, 1975, NEW ENGL J MED, V292, P767, DOI 10.1056/NEJM197504102921502; Forns X, 2000, P NATL ACAD SCI USA, V97, P13318, DOI 10.1073/pnas.230453597; Forton DM, 2004, J VIROL, V78, P5170, DOI 10.1128/JVI.78.10.5170-5183.2004; Frick DN, 2004, J BIOL CHEM, V279, P1269, DOI 10.1074/jbc.M310630200; Friebe P, 2005, J VIROL, V79, P380, DOI 10.1128/JVI.79.1.380-392.2005; Friebe P, 2002, J VIROL, V76, P5326, DOI 10.1128/JVI.76.11.5326-5338.2002; Friebe P, 2001, J VIROL, V75, P12047, DOI 10.1128/JVI.75.24.12047-12057.2001; Gao L, 2004, J VIROL, V78, P3480, DOI 10.1128/JVI.78.7.3480-3488.2004; Gosert R, 2003, J VIROL, V77, P5487, DOI 10.1128/JVI.77.9.5487-5492.2003; Griffin SDC, 2003, FEBS LETT, V535, P34, DOI 10.1016/S0014-5793(02)03851-6; He YP, 2002, VIRAL IMMUNOL, V15, P95, DOI 10.1089/088282402317340260; Hong Z, 2001, VIROLOGY, V285, P6, DOI 10.1006/viro.2001.0948; Hoofnagle JH, 2002, HEPATOLOGY, V36, pS21, DOI 10.1053/jhep.2002.36227; Ide Y, 1997, GENE, V201, P151, DOI 10.1016/S0378-1119(97)00440-X; Ji H, 2004, P NATL ACAD SCI USA, V101, P16990, DOI 10.1073/pnas.0407402101; Kapadia SB, 2005, P NATL ACAD SCI USA, V102, P2561, DOI 10.1073/pnas.0409834102; Kato T, 2003, GASTROENTEROLOGY, V125, P1808, DOI 10.1053/j.gastro.2003.09.023; Katze MG, 2000, VIROLOGY, V278, P501, DOI 10.1006/viro.2000.0662; Kim J, 1999, BIOCHEM BIOPH RES CO, V257, P777, DOI 10.1006/bbrc.1999.0460; Kim YK, 2002, BIOCHEM BIOPH RES CO, V290, P105, DOI 10.1006/bbrc.2001.6167; Kolykhalov AA, 1997, SCIENCE, V277, P570, DOI 10.1126/science.277.5325.570; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; Kolykhalov AA, 1996, J VIROL, V70, P3363, DOI 10.1128/JVI.70.6.3363-3371.1996; Lavillette D, 2005, HEPATOLOGY, V41, P265, DOI 10.1002/hep.20542; Levin MK, 2005, NAT STRUCT MOL BIOL, V12, P429, DOI 10.1038/nsmb920; LIN C, 1995, J VIROL, V69, P4373, DOI 10.1128/JVI.69.7.4373-4380.1995; Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016; LINDENBACH BD, 2001, FIELDS VIROLOGY, P991; Logvinoff C, 2004, P NATL ACAD SCI USA, V101, P10149, DOI 10.1073/pnas.0403519101; Lohmann V, 2003, J VIROL, V77, P3007, DOI 10.1128/JVI.77.5.3007-3019.2003; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Luo GX, 2003, J VIROL, V77, P3312, DOI 10.1128/JVI.77.5.3312-3318.2003; Macdonald A, 2004, J GEN VIROL, V85, P2485, DOI 10.1099/vir.0.80204-0; McKeating JA, 2004, J VIROL, V78, P8496, DOI 10.1128/JVI.78.16.8496-8505.2004; Meunier JC, 2005, P NATL ACAD SCI USA, V102, P4560, DOI 10.1073/pnas.0501275102; Miyanari Y, 2003, J BIOL CHEM, V278, P50301, DOI 10.1074/jbc.M305684200; Moradpour D, 2004, J VIROL, V78, P7400, DOI 10.1128/JVI.78.14.7400-7409.2004; Moradpour D, 1996, VIROLOGY, V222, P51, DOI 10.1006/viro.1996.0397; Neddermann P, 2004, J VIROL, V78, P13306, DOI 10.1128/JVI.78.23.13306-13314.2004; Neumann AU, 1998, SCIENCE, V282, P103, DOI 10.1126/science.282.5386.103; Otto GA, 2004, CELL, V119, P369, DOI 10.1016/j.cell.2004.09.038; Pang PS, 2002, EMBO J, V21, P1168, DOI 10.1093/emboj/21.5.1168; Pavlovic D, 2003, P NATL ACAD SCI USA, V100, P6104, DOI 10.1073/pnas.1031527100; Penin F, 2004, HEPATOLOGY, V39, P5, DOI 10.1002/hep.20032; Pietschmann T, 2002, J VIROL, V76, P4008, DOI 10.1128/JVI.76.8.4008-4021.2002; PIETSCHMANN T, 2004, P 11 INT S HEP C VIR; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; Reed KE, 1999, J BIOL CHEM, V274, P28011, DOI 10.1074/jbc.274.39.28011; Reed KE, 1997, J VIROL, V71, P7187, DOI 10.1128/JVI.71.10.7187-7197.1997; Reusken CBEM, 2003, J GEN VIROL, V84, P1761, DOI 10.1099/vir.0.19063-0; Sakai A, 2003, P NATL ACAD SCI USA, V100, P11646, DOI 10.1073/pnas.1834545100; Schmidt-Mende J, 2001, J BIOL CHEM, V276, P44052, DOI 10.1074/jbc.M103358200; Serebrov V, 2004, NATURE, V430, P476, DOI 10.1038/nature02704; Simmonds P, 2004, J GEN VIROL, V85, P3173, DOI 10.1099/vir.0.80401-0; Spahn CMT, 2001, SCIENCE, V291, P1959, DOI 10.1126/science.1058409; Su AI, 2002, P NATL ACAD SCI USA, V99, P15669, DOI 10.1073/pnas.202608199; Tai CL, 1996, J VIROL, V70, P8477, DOI 10.1128/JVI.70.12.8477-8484.1996; TANAKA T, 1995, BIOCHEM BIOPH RES CO, V215, P744, DOI 10.1006/bbrc.1995.2526; Tellinghuisen TL, 2005, NATURE, V435, P374, DOI 10.1038/nature03580; Tellinghuisen TL, 2004, J BIOL CHEM, V279, P48576, DOI 10.1074/jbc.M407787200; Tellinghuisen TL, 2002, CURR OPIN MICROBIOL, V5, P419, DOI 10.1016/S1369-5274(02)00341-7; Thimme R, 2002, P NATL ACAD SCI USA, V99, P15661, DOI 10.1073/pnas.202608299; van Dijk AA, 2004, J GEN VIROL, V85, P1077, DOI 10.1099/vir.0.19731-0; Voisset C, 2005, J BIOL CHEM, V280, P7793, DOI 10.1074/jbc.M411600200; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Wang CF, 2005, MOL CELL, V18, P425, DOI 10.1016/j.molcel.2005.04.004; Wang QM, 2002, J VIROL, V76, P3865, DOI 10.1128/JVI.76.8.3865-3872.2002; Wolk B, 2000, J VIROL, V74, P2293, DOI 10.1128/JVI.74.5.2293-2304.2000; Yanagi M, 1997, P NATL ACAD SCI USA, V94, P8738, DOI 10.1073/pnas.94.16.8738; Yanagi M, 1999, P NATL ACAD SCI USA, V96, P2291, DOI 10.1073/pnas.96.5.2291; Yang G, 2004, J VIROL, V78, P10202, DOI 10.1128/JVI.78.18.10202-10205.2004; Yasui K, 1998, J VIROL, V72, P6048, DOI 10.1128/JVI.72.7.6048-6055.1998; Ye J, 2003, P NATL ACAD SCI USA, V100, P15865, DOI 10.1073/pnas.2237238100; Yi MK, 2003, J VIROL, V77, P3557, DOI 10.1128/JVI.77.6.3557-3568.2003; You SY, 2004, J VIROL, V78, P1352, DOI 10.1128/JVI.78.3.1352-1366.2004; Zhang J, 2004, J VIROL, V78, P1448, DOI 10.1128/JVI.78.3.1448-1455.2004; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102	100	619	700	0	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 18	2005	436	7053					933	938		10.1038/nature04077	http://dx.doi.org/10.1038/nature04077			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955XQ	16107832	hybrid			2022-12-28	WOS:000231263900034
J	Ros, A; Eichhorn, R; Regtmeier, J; Duong, TT; Reimann, P; Anselmetti, D				Ros, A; Eichhorn, R; Regtmeier, J; Duong, TT; Reimann, P; Anselmetti, D			Brownian motion - Absolute negative particle mobility	NATURE			English	Editorial Material							RATCHET		Univ Bielefeld, D-33501 Bielefeld, Germany	University of Bielefeld	Ros, A (corresponding author), Univ Bielefeld, D-33501 Bielefeld, Germany.	alexandra.ros@physik.uni-bielefeld.de	Reimann, Peter/AAN-3909-2021; Anselmetti, Dario/F-1664-2011	Anselmetti, Dario/0000-0002-8720-4369				Bader JS, 1999, P NATL ACAD SCI USA, V96, P13165, DOI 10.1073/pnas.96.23.13165; Cleuren B, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.055101; Eichhorn R, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.190601; FAUCHEUX LP, 1995, J CHEM SOC FARADAY T, V91, P3163, DOI 10.1039/ft9959103163; Han J, 2000, SCIENCE, V288, P1026, DOI 10.1126/science.288.5468.1026; Huang LR, 2003, ANAL CHEM, V75, P6963, DOI 10.1021/ac0348524; KEAY BJ, 1995, PHYS REV LETT, V75, P4102, DOI 10.1103/PhysRevLett.75.4102; Marquet C, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.168301; ROUSSELET J, 1994, NATURE, V370, P446, DOI 10.1038/370446a0	9	94	94	3	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 18	2005	436	7053					928	928		10.1038/436928a	http://dx.doi.org/10.1038/436928a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955XQ	16107829	Bronze			2022-12-28	WOS:000231263900031
J	Zhou, FJ; Harpaz, R; Jumaan, AO; Winston, CA; Shefer, A				Zhou, FJ; Harpaz, R; Jumaan, AO; Winston, CA; Shefer, A			Impact of varicella vaccination on health care utilization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; HOSPITALIZATIONS; ZOSTER; IMMUNIZATION; MORTALITY; CHILDREN; DECLINE	Context Since varicella vaccine was first recommended for routine immunization in the United States in 1995, the incidence of disease has dropped substantially. However, national surveillance data are incomplete, and comprehensive data regarding outpatient as well as hospital utilization have not been reported. Objective To examine the impact of the varicella vaccination program on medical visits and associated expenditures. Design, Setting, and Patients Retrospective population-based study examining the trends in varicella health care utilization, based on data from the MarketScan databases, which include enrollees (children and adults) of more than 100 health insurance plans of approximately 40 large US employers, from 1994 to 2002. Main Outcome Measures Trends in rates of varicella-related hospitalizations and ambulatory visits and direct medical expenditures for hospitalizations and ambulatory visits, analyzed using 1994 and 1995 as the prevaccination baseline. Results From the prevaccination period to 2002, hospitalizations due to varicella declined by 88% (from 2.3 to 0.3 per 100000 population) and ambulatory visits declined by 59% (from 215 to 89 per 100000 population). Hospitalizations and ambulatory visits declined in all age groups, with the greatest declines among infants younger than 1 year. Total estimated direct medical expenditures for varicella hospitalizations and ambulatory visits declined by 74%, from an average of $84.9 million in 1994 and 1995 to $22.1 million in 2002. Conclusion Since the introduction of the varicella vaccination program, varicella hospitalizations, ambulatory visits, and their associated expenditures have declined dramatically among all age groups in the United States.	Ctr Dis Control & Prevent, Natl Immunizat Program, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Zhou, FJ (corresponding author), Ctr Dis Control & Prevent, Natl Immunizat Program, 1600 Clifton Rd NE,Mail Stop E-52, Atlanta, GA 30333 USA.	faz1@cdc.gov						[Anonymous], 1999, MMWR Recomm Rep, V48, P1; [Anonymous], 2001, MMWR-MORBID MORTAL W, V50, P637; Barker L, 2002, MMWR Morb Mortal Wkly Rep, V51, P664; Bramley J C, 2000, Commun Dis Public Health, V3, P282; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P884; Comm Infect Dis, 2000, PEDIATRICS, V105, P136; Davis MM, 2005, VACCINE, V23, P3053, DOI 10.1016/j.vaccine.2004.10.047; Davis MM, 2004, PEDIATRICS, V114, P786, DOI 10.1542/peds.2004-0012; Galil K, 2002, PEDIATR INFECT DIS J, V21, P931, DOI 10.1097/00006454-200210000-00009; GERSHON AA, 1999, VACCINES, P475; HALL CB, 1995, PEDIATRICS, V95, P791; HALLORAN ME, 1994, AM J EPIDEMIOL, V140, P81, DOI 10.1093/oxfordjournals.aje.a117238; Health, 2005, MED BENEFITS, V22, P12; Jumaan AO, 2005, J INFECT DIS, V191, P2002, DOI 10.1086/430325; Kann Laura, 1996, Morbidity and Mortality Weekly Report, V45, P1; Kuter B, 2004, PEDIATR INFECT DIS J, V23, P132, DOI 10.1097/01.inf.0000109287.97518.67; Lee BW, 1998, TROP MED INT HEALTH, V3, P886; Liu S C, 1998, J Microbiol Immunol Infect, V31, P217; *MEDSTAT GROUP, 2000, MARKETSCAN; Meyer PA, 2000, J INFECT DIS, V182, P383, DOI 10.1086/315714; Nguyen HQ, 2005, NEW ENGL J MED, V352, P450, DOI 10.1056/NEJMoa042271; Patel RA, 2004, J PEDIATR-US, V144, P68, DOI 10.1016/j.jpeds.2003.10.025; Ratner AJ, 2002, PEDIATR INFECT DIS J, V21, P927, DOI 10.1097/00006454-200210000-00008; Seward JF, 2002, JAMA-J AM MED ASSOC, V287, P606, DOI 10.1001/jama.287.5.606; *US CENS BUR, PROJ TOT RES POP 5 Y; *US CENS BUR, METR MICR STAT AR DE; *US CENS BUR, RES POP EST US AG SE; US Department of Labor. Bureau of Labor Statistics, CONS PRIC IND; Vazquez M, 2001, NEW ENGL J MED, V344, P955, DOI 10.1056/NEJM200103293441302; Wharton M, 1996, INFECT DIS CLIN N AM, V10, P571, DOI 10.1016/S0891-5520(05)70313-5; 2003, MMWR MORB MORTAL WKL, V52, P728; 1999, MMWR MORB MORTAL WKL, V48, P829; 2004, MMWR MORB MORTAL WKL, V53, P658; 1998, MMWR MORB MORTAL WKL, V47, P547; 2000, MMWR MORB MORTAL WKL, V49, P585	35	169	184	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	2005	294	7					797	802		10.1001/jama.294.7.797	http://dx.doi.org/10.1001/jama.294.7.797			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955LI	16106004	Bronze			2022-12-28	WOS:000231227000019
J	Lehrman, G; Hogue, IB; Palmer, S; Jennings, C; Spina, CA; Wiegand, A; Landay, AL; Coombs, RW; Richman, DD; Mellors, JW; Coffin, JM; Bosch, RJ; Margolis, DM				Lehrman, G; Hogue, IB; Palmer, S; Jennings, C; Spina, CA; Wiegand, A; Landay, AL; Coombs, RW; Richman, DD; Mellors, JW; Coffin, JM; Bosch, RJ; Margolis, DM			Depletion of latent HIV-1 infection in vivo: a proof-of-concept study	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; CD4(+) T-CELLS; LONG TERMINAL REPEAT; HUMAN-FACTORS YY1; CELLULAR RESERVOIRS; HIV-1-INFECTED PATIENTS; IMMUNE-ACTIVATION; VALPROIC ACID; TYPE-1 HIV-1	Background Persistent infection in resting CD4+ T cells prevents eradication of HIV-1. Since the chromatin remodeling enzyme histone deacetylase 1 (HDAC1) maintains latency of integrated HIV, we tested the ability of the HDAC inhibitor valproic acid to deplete persistent, latent infection in resting CD4+ T cells. Procedures We did a proof-of-concept study in four volunteers infected with HIV and on highly-active antiretroviral therapy (HAART). After intensifying the effect of HAART with subcutaneous enfuvirtide 90 mu g twice daily for 4-6 weeks to prevent the spread of HIV, we added oral valproic acid 500-750 mg twice daily to their treatment regimen for 3 months. We quantified latent infection of resting CD4+ T cells before and after augmented treatment by limiting-dilution culture of resting CD4+ T cells after ex-vivo activation. Findings The frequency of resting cell infection was stable before addition of enfuvirtide and valproic acid, but declined thereafter. This decline was significant in three of four patients (mean reduction 75%, range 68% to >84%). Patients had slight reactions to enfuvirtide at the injection site, but otherwise tolerated treatment well. Interpretation Combination therapy with an HDAC inhibitor and intensified HAART safely accelerates clearance of HIV from resting CD4+ T cells in vivo, suggesting a new and practical approach to eliminate HIV infection in this persistent reservoir. This finding, though not definitive, suggests that new approaches will allow the cure of HIV in the future.	Univ Texas, SW Med Ctr, Dept Med, Div Infect Dis, Dallas, TX 75390 USA; NCI, HIV Drug Resistance Program, NIH, Frederick, MD USA; Rush Presbyterian St Lukes Med Ctr, Dept Immunol Microbiol, Chicago, IL 60612 USA; Univ Calif San Diego, San Diego, CA 92103 USA; Vet Affairs Med Ctr, San Diego, CA 92161 USA; Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA USA; Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; N Texas Vet Hlth Care Syst, Dallas, TX USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Rush University; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Harvard T.H. Chan School of Public Health; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA North Texas Health Care System	Margolis, DM (corresponding author), Univ Texas, SW Med Ctr, Dept Med, Div Infect Dis, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	dmargo@med.unc.edu	Margolis, David M./Y-2468-2019	Margolis, David M./0000-0001-5714-0002; Hogue, Ian/0000-0002-1977-5573	DIVISION OF BASIC SCIENCES - NCI [Z01BC010526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R24AI106039, R01AI047745, U01AI043638, R01AI029164, N01AI085354, U01AI027670, P30AI027757, R21AI047745, R01AI045297, U01AI038858, R37AI029164, R01AI064074, R56AI047745, P30AI036214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049477] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-047745, R24 AI106039, N01-AI-85354, AI-043638, R01 AI064074, U01 AI-38858, AI-38858, AI-36214, N01AI85354, P30 AI027757, P30 AI036214, R56 AI047745, AI-27757, U01 AI043638, U01 AI038858, R37 AI029164, AI-27670, R21 AI047745, U01 AI027670, AI-29164, R01 AI-45297, R01 AI045297, R01 AI047745] Funding Source: Medline; NIDDK NIH HHS [DK-49477] Funding Source: Medline; PHS HHS [20XS190A] Funding Source: Medline	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Al-Harthi L, 2000, AIDS, V14, P761, DOI 10.1097/00002030-200005050-00001; Antoniou T, 2004, CLIN INFECT DIS, V38, pE38, DOI 10.1086/381760; Brooks DG, 2003, IMMUNITY, V19, P413, DOI 10.1016/S1074-7613(03)00236-X; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1999, NAT MED, V5, P651, DOI 10.1038/9498; Clotet B, 2004, AIDS, V18, P1137, DOI 10.1097/00002030-200405210-00007; Coombs RW, 1998, J INFECT DIS, V177, P320, DOI 10.1086/514213; Coull JJ, 2002, J VIROL, V76, P12349, DOI 10.1128/JVI.76.23.12349-12354.2002; Coull JJ, 2000, J VIROL, V74, P6790, DOI 10.1128/JVI.74.15.6790-6799.2000; Demonte D, 2004, BIOCHEM PHARMACOL, V68, P1231, DOI 10.1016/j.bcp.2004.05.040; Di Mascio M, 2003, J VIROL, V77, P2271, DOI 10.1128/JVI.77.3.2271-2275.2003; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Fraser C, 2000, AIDS, V14, P659, DOI 10.1097/00002030-200004140-00005; Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646; He GC, 2002, MOL CELL BIOL, V22, P2965, DOI 10.1128/MCB.22.9.2965-2973.2002; JENNINGS C, 10 C RETR OPP INF BO; Kulkosky J, 2002, J INFECT DIS, V186, P1403, DOI 10.1086/344357; Lehrman G, 2004, JAIDS-J ACQ IMM DEF, V36, P1103, DOI 10.1097/00126334-200408150-00015; LERTORA JJL, 1994, CLIN PHARMACOL THER, V56, P272, DOI 10.1038/clpt.1994.137; Macken C, 1999, J IMMUNOL METHODS, V222, P13, DOI 10.1016/S0022-1759(98)00133-1; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; MYERS LE, 1994, J CLIN MICROBIOL, V32, P732, DOI 10.1128/JCM.32.3.732-739.1994; Palmer S, 2003, J CLIN MICROBIOL, V41, P4531, DOI 10.1128/JCM.41.10.4531-4536.2003; Pierson T, 2000, ANNU REV IMMUNOL, V18, P665, DOI 10.1146/annurev.immunol.18.1.665; Pomerantz RJ, 2003, HIV CLIN TRIALS, V4, P137, DOI 10.1310/80JH-148K-NADQ-U927; Prins JM, 1999, AIDS, V13, P2405, DOI 10.1097/00002030-199912030-00012; Ramratnam B, 2004, JAIDS-J ACQ IMM DEF, V35, P33, DOI 10.1097/00126334-200401010-00004; Romerio F, 1997, J VIROL, V71, P9375, DOI 10.1128/JVI.71.12.9375-9382.1997; Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880; Stellbrink HJ, 2002, AIDS, V16, P1479, DOI 10.1097/00002030-200207260-00004; Strain MC, 2003, P NATL ACAD SCI USA, V100, P4819, DOI 10.1073/pnas.0736332100; Strain MC, 2005, J INFECT DIS, V191, P1410, DOI 10.1086/428777; Wang FX, 2005, J CLIN INVEST, V115, P128, DOI 10.1172/JCI200522574; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Ylisastigui L, 2004, J INFECT DIS, V190, P1429, DOI 10.1086/423822; Ylisastigui L, 2004, AIDS, V18, P1101, DOI 10.1097/00002030-200405210-00003	36	413	444	0	38	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 13	2005	366	9485					549	555		10.1016/S0140-6736(05)67098-5	http://dx.doi.org/10.1016/S0140-6736(05)67098-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955LL	16099290	Green Accepted			2022-12-28	WOS:000231227300026
J	Marchis, F; Descamps, P; Hestroffer, D; Berthier, J				Marchis, F; Descamps, P; Hestroffer, D; Berthier, J			Discovery of the triple asteroidal system 87 Sylvia	NATURE			English	Article							CATASTROPHIC COLLISIONS; SATELLITES; ORBIT	After decades of speculation(1), the existence of binary asteroids has been observationally confirmed(2,3), with examples in all minor planet populations(4). However, no triple systems have hitherto been discovered. Here we report the unambiguous detection of a triple asteroidal system in the main belt, composed of a 280-km primary ( 87 Sylvia) and two small moonlets orbiting at 710 and 1,360 km. We estimate their orbital elements and use them to refine the shape of the primary body. Both orbits are equatorial, circular and prograde, suggesting a common origin. Using the orbital information to estimate its mass and density, 87 Sylvia appears to have a rubble-pile structure with a porosity of 25 - 60 per cent. The system was most probably formed through the disruptive collision of a parent asteroid, with the new primary resulting from accretion of fragments, while the moonlets are formed from the debris, as has been predicted previously(5).	Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA; Observ Paris, Inst Mecan Celeste & Calculs Ephemerides, F-75014 Paris, France	University of California System; University of California Berkeley; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Sorbonne Universite	Marchis, F (corresponding author), Univ Calif Berkeley, Dept Astron, 601 Campbell Hall, Berkeley, CA 94720 USA.	fmarchis@berkeley.edu	Marchis, Franck/H-3971-2012	HESTROFFER, Daniel/0000-0003-0472-9459; Berthier, Jerome/0000-0003-1846-6485				Britt D. T., 2002, ASTEROIDS 3, VIII, P485; Brown M. E., 2001, 7588 IAU; Bus SJ, 2002, ICARUS, V158, P146, DOI 10.1006/icar.2002.6856; CHAPMAN CR, 1995, NATURE, V374, P783, DOI 10.1038/374783a0; CHAUVINEAU B, 1993, ICARUS, V105, P370, DOI 10.1006/icar.1993.1134; CLARK BE, 2004, ICARUS, V128, P3070; DESCAMPS P, 2005, B AM ASTRON SOC DIV, V95; Doressoundiram A, 1997, PLANET SPACE SCI, V45, P757, DOI 10.1016/S0032-0633(97)00037-8; Durda DD, 1996, ICARUS, V120, P212, DOI 10.1006/icar.1996.0046; Kaasalainen M, 2002, ICARUS, V159, P369, DOI 10.1006/icar.2002.6907; Marchis F, 2003, ICARUS, V165, P112, DOI 10.1016/S0019-1035(03)00195-7; MARCHIS F, IN PRESS ICARUS; MARCHIS F, 2004, B AM ASTRON SOC DIV, V36; MARGOT JL, 2001, B AM ASTRON SOC DIV, V33; Merline W.J., 2002, ASTEROIDS, VIII, P289; Merline WJ, 1999, NATURE, V401, P565, DOI 10.1038/44089; Michel P, 2001, SCIENCE, V294, P1696, DOI 10.1126/science.1065189; Petit JM, 1997, ICARUS, V130, P177, DOI 10.1006/icar.1997.5788; Scheeres DJ, 1999, CELEST MECH DYN ASTR, V73, P339, DOI 10.1023/A:1008384021964; STORRS A, 2001, 7590 IAU; Tedesco EF, 2002, ASTRON J, V123, P1056, DOI 10.1086/338320; [No title captured]	22	80	81	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 11	2005	436	7052					822	824		10.1038/nature04018	http://dx.doi.org/10.1038/nature04018			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953XG	16094362	Green Submitted			2022-12-28	WOS:000231116500039
J	Parsons, DW; Wang, TL; Samuels, Y; Bardelli, A; Cummins, JM; DeLong, L; Silliman, N; Ptak, J; Szabo, S; Willson, JKV; Markowitz, S; Kinzler, K; Vogelstein, B; Lengauer, C; Velculescu, VE				Parsons, DW; Wang, TL; Samuels, Y; Bardelli, A; Cummins, JM; DeLong, L; Silliman, N; Ptak, J; Szabo, S; Willson, JKV; Markowitz, S; Kinzler, K; Vogelstein, B; Lengauer, C; Velculescu, VE			Colorectal cancer - Mutations in a signalling pathway	NATURE			English	Editorial Material							GENE		Johns Hopkins Univ, Inst Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Inst Med, Howard Hughes Med Inst, Baltimore, MD 21231 USA; Univ Texas, SW Med Ctr, Harold C Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Howard Hughes Med Inst, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Ireland Canc Ctr, Cleveland, OH 44106 USA	Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Johns Hopkins University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Case Western Reserve University; Howard Hughes Medical Institute; University Hospitals of Cleveland; University Hospitals of Cleveland	Parsons, DW (corresponding author), Johns Hopkins Univ, Inst Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA.	velculescu@jhmi.edu	Velculescu, Victor/ABF-4846-2020; BARDELLI, Alberto/J-9721-2018	Velculescu, Victor/0000-0003-1195-438X; Parsons, Donald/0000-0002-8775-3501; BARDELLI, Alberto/0000-0003-1647-5070; Samuels, Yardena/0000-0002-3349-7266				Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Teng DHF, 1997, CANCER RES, V57, P4177; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang TL, 2002, P NATL ACAD SCI USA, V99, P16156, DOI 10.1073/pnas.202610899; Wells CM, 2002, J CELL SCI, V115, P3947, DOI 10.1242/jcs.00080	10	463	510	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 11	2005	436	7052					792	792		10.1038/436792a	http://dx.doi.org/10.1038/436792a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953XG	16094359	Bronze			2022-12-28	WOS:000231116500033
J	Ost, D; Tepper, J; Mihara, H; Lander, O; Heinzer, R; Fein, A				Ost, D; Tepper, J; Mihara, H; Lander, O; Heinzer, R; Fein, A			Duration of anticoagulation following venous thrombolembolism - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEEP-VEIN THROMBOSIS; INTENSITY WARFARIN THERAPY; ACUTE PULMONARY-EMBOLISM; 1ST EPISODE; CLINICAL-TRIALS; LONG-TERM; THROMBOEMBOLISM; PREVENTION; QUALITY; HETEROGENEITY	Context Patients with venous thromboembolism (VTE) are susceptible to recurrent events, but whether prolonging anticoagulation is warranted in patients with VTE remains controversial. Objective To review the available evidence and quantify the risks and benefits of extending the duration of anticoagulation in patients with VTE. Data Sources PubMed, EMBase Pharmacology, the Cochrane database, clinical trial Web sites, and a hand search of reference lists. Study Selection Included studies were randomized controlled trials with results published from 1969 through 2004 and evaluating the duration of anticoagulation in patients with VTE that measured recurrent VTE. Excluded studies were those enrolling only pure populations of high-risk patients. Two independent reviewers assessed each article for inclusion and exclusion criteria, with adjudication by a third reviewer in cases of disagreement. Fifteen of 67 studies were included in the analysis. Data Extraction Two independent reviewers performed data extraction using a standardized form, with adjudication by the remainder of the investigators in cases of disagreement. Data regarding recurrent VTE, major bleeding, person-time at risk, and study quality were extracted. Data Synthesis If patients in the long-term therapy group remained receiving anticoagulation, the risk of recurrent VTE with long- vs short-term therapy was reduced (weighted incidence rate, 0.020 vs 0.126 events/person-year; rate difference, -0.106 [95% confidence interval {Cl}, -0.145 to -0.067]; P<.001; pooled incidence rate ratio [IRR], 0.21 [95% Cl, 0.14 to 0.31]; P<.001). If anticoagulation in the long-term therapy group was discontinued, the risk reduction was less pronounced (weighted incidence rate, 0.052 vs 0.072 events/person-year; rate difference, -0.020 [95% Cl, -0.039 to -0.001]; P=.04; pooled IRR, 0.69 [95% Cl, 0.53 to 0.91]; P=.009). The risk of major bleeding with long- vs short-term therapy was similar (weighted incidence rate, 0.011 vs 0.006 events/person-year; rate difference, 0.005 [95% Cl, -0.002 to 0.011]; P=.14; pooled IRR, 1.80 [95% Cl, 0.72 to 4.51]; P=.21). Conclusions Patients who receive extended anticoagulation are protected from recurrent VTE while receiving long-term therapy. The clinical benefit is maintained after anticoagulation is discontinued, but the magnitude of the benefit is less pronounced.	N Shore Univ Hosp, Ctr Pulm & Crit Care Med, Manhasset, NY 11030 USA; Inst Clin Evaluat Sci, Toronto, ON, Canada; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA USA; NYU, Sch Med, New York, NY USA	Northwell Health; North Shore University Hospital; University of Toronto; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; New York University	Ost, D (corresponding author), N Shore Univ Hosp, Ctr Pulm & Crit Care Med, 300 Community Dr, Manhasset, NY 11030 USA.	dost@nshs.edu	Ost, David E./AAT-9505-2021	Ost, David E./0000-0001-6351-5552; Heinzer, Raphael/0000-0002-3215-7788				Agnelli G, 2003, ANN INTERN MED, V139, P19, DOI 10.7326/0003-4819-139-1-200307010-00008; Agnelli G, 2001, NEW ENGL J MED, V345, P165, DOI 10.1056/NEJM200107193450302; BELCARO G, 1993, ANGIOLOGY, V44, P328, DOI 10.1177/000331979304400410; BERLIN JA, 1995, AM J EPIDEMIOL, V142, P383, DOI 10.1093/oxfordjournals.aje.a117645; BULLER HR, 2004, CHEST, V126, pS104; Campbell IA, 2003, THORAX, V58, P470; COLDITZ GA, 1995, AM J EPIDEMIOL, V142, P371, DOI 10.1093/oxfordjournals.aje.a117644; FENNERTY A, 1988, BMJ-BRIT MED J, V297, P1285, DOI 10.1136/bmj.297.6659.1285; FENNERTY AG, 1987, CLIN LAB HAEMATOL, V9, P17; Goldhaber SZ, 1999, LANCET, V353, P1386, DOI 10.1016/S0140-6736(98)07534-5; HOLMGREN KAJ, 1985, ACTA MED SCAND, V218, P279; Huwiler-Muntener K, 2002, JAMA-J AM MED ASSOC, V287, P2801, DOI 10.1001/jama.287.21.2801; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Juni P, 1999, JAMA-J AM MED ASSOC, V282, P1054, DOI 10.1001/jama.282.11.1054; Kearon C, 2004, J THROMB HAEMOST, V2, P743, DOI 10.1046/j.1538-7836.2004.00698.x; Kearon C, 2003, NEW ENGL J MED, V349, P631, DOI 10.1056/NEJMoa035422; Kearon C, 1999, NEW ENGL J MED, V340, P901, DOI 10.1056/NEJM199903253401201; LEVINE MN, 1995, THROMB HAEMOSTASIS, V74, P606; Levine MN, 2004, CHEST, V126, p287S, DOI 10.1378/chest.126.3_suppl.287S; OSULLIVAN EF, 1972, MED J AUSTRALIA, V2, P1104, DOI 10.5694/j.1326-5377.1972.tb103752.x; Pinede L, 2001, CIRCULATION, V103, P2453; Pinede L, 2000, J INTERN MED, V247, P553, DOI 10.1046/j.1365-2796.2000.00631.x; Ridker PM, 2003, NEW ENGL J MED, V348, P1425, DOI 10.1056/NEJMoa035029; SCHULMAN S, 1985, ACTA MED SCAND, V217, P547; Schulman S, 1997, NEW ENGL J MED, V336, P393, DOI 10.1056/NEJM199702063360601; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; SUDLOW MF, 1992, LANCET, V340, P873; van Dongen CJJ, 2003, ARCH INTERN MED, V163, P1285, DOI 10.1001/archinte.163.11.1285	28	92	103	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	2005	294	6					706	715		10.1001/jama.294.6.706	http://dx.doi.org/10.1001/jama.294.6.706			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	953IA	16091573				2022-12-28	WOS:000231068600024
J	Dissanayake, C				Dissanayake, C			Global voices of science - Of stones and health: Medical geology in Sri Lanka	SCIENCE			English	Editorial Material									Univ Peradeniya, Peradeniya 20400, Sri Lanka	University of Peradeniya	Dissanayake, C (corresponding author), Univ Peradeniya, Peradeniya 20400, Sri Lanka.	cbdissa@hotmail.com							0	39	42	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 5	2005	309	5736					883	885		10.1126/science.1115174	http://dx.doi.org/10.1126/science.1115174			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953SS	16081722				2022-12-28	WOS:000231101400029
J	Kerfeld, CA; Sawaya, MR; Tanaka, S; Nguyen, CV; Phillips, M; Beeby, M; Yeates, TO				Kerfeld, CA; Sawaya, MR; Tanaka, S; Nguyen, CV; Phillips, M; Beeby, M; Yeates, TO			Protein structures forming the shell of primitive bacterial organelles	SCIENCE			English	Article							ANGSTROM RESOLUTION; CARBONIC-ANHYDRASE; CARBOXYSOME SHELL; POLYHEDRAL BODIES; VIRUS; PROKARYOTES; CYANOBACTERIA; HOMOLOGS	Bacterial microcompartments are primitive organelles composed entirely of protein subunits. Genomic sequence databases reveal the widespread occurrence of microcompartments across diverse microbes. The prototypical bacterial microcompartment is the carboxysome, a protein shell for sequestering carbon fixation reactions. We report three-dimensional crystal structures of multiple carboxysome shell proteins, revealing a hexameric unit as the basic microcompartment building block and showing how these hexamers assemble to form flat facets of the polyhedral shell. The structures suggest how molecular transport across the shell may be controlled and how structural variations might govern the assembly and architecture of these subcellular compartments.	Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, US DOE, Inst Genom & Proteom, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; United States Department of Energy (DOE); University of California System; University of California Los Angeles	Yeates, TO (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Box 951570, Los Angeles, CA 90095 USA.	yeates@mbi.ucla.edu	Beeby, Morgan/G-2768-2013	Beeby, Morgan/0000-0001-6413-9835; Yeates, Todd/0000-0001-5709-9839				Badger MR, 2002, FUNCT PLANT BIOL, V29, P161, DOI 10.1071/PP01213; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Cannon GC, 2002, FUNCT PLANT BIOL, V29, P175, DOI 10.1071/PP01200; Cannon GC, 2001, APPL ENVIRON MICROB, V67, P5351, DOI 10.1128/AEM.67.12.5351-5361.2001; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; CODD GA, 1984, BIOL REV, V59, P389, DOI 10.1111/j.1469-185X.1984.tb00710.x; Diprose JM, 2001, EMBO J, V20, P7229, DOI 10.1093/emboj/20.24.7229; GANTT E, 1969, J BACTERIOL, V97, P1486, DOI 10.1128/JB.97.3.1486-1493.1969; Gibrat JF, 1996, CURR OPIN STRUC BIOL, V6, P377, DOI 10.1016/S0959-440X(96)80058-3; HARRISON SC, 1995, CURR OPIN STRUC BIOL, V5, P157, DOI 10.1016/0959-440X(95)80070-0; Harrison SC, 2001, CURR OPIN STRUC BIOL, V11, P195, DOI 10.1016/S0959-440X(00)00189-5; Havemann GD, 2003, J BACTERIOL, V185, P5086, DOI 10.1128/JB.185.17.5086-5095.2003; HOGLE JM, 1987, SCI AM, V256, P42, DOI 10.1038/scientificamerican0387-42; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jensen TE, 1961, P IOWA ACAD SCI, V68, P89; Johnson JE, 1997, J MOL BIOL, V269, P665, DOI 10.1006/jmbi.1997.1068; Kofoid E, 1999, J BACTERIOL, V181, P5317, DOI 10.1128/JB.181.17.5317-5329.1999; Naitow H, 2002, NAT STRUCT BIOL, V9, P725, DOI 10.1038/nsb844; PRICE GD, 1992, PLANT PHYSIOL, V100, P784, DOI 10.1104/pp.100.2.784; PRICE GD, 1990, CAN J BOT, V69, P693; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; San Martin C, 2002, NAT STRUCT BIOL, V9, P756, DOI 10.1038/nsb837; Shively JM, 1998, CAN J BOT, V76, P906, DOI 10.1139/b98-088; SHIVELY JM, 1991, CAN J BOT, V69, P957, DOI 10.1139/b91-123; SHIVELY JM, 1973, SCIENCE, V182, P584, DOI 10.1126/science.182.4112.584; SHIVELY JM, 1970, J BACTERIOL, V96, P2138; So AKC, 2004, J BACTERIOL, V186, P623, DOI 10.1128/JB.186.3.623-630.2004; So AKC, 1998, PLANT MOL BIOL, V37, P205, DOI 10.1023/A:1005959200390; Stehle T, 1996, STRUCTURE, V4, P165, DOI 10.1016/S0969-2126(96)00020-2; Yuan P, 2003, NAT STRUCT BIOL, V10, P264, DOI 10.1038/nsb910	30	316	326	4	101	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 5	2005	309	5736					936	938		10.1126/science.1113397	http://dx.doi.org/10.1126/science.1113397			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953SS	16081736				2022-12-28	WOS:000231101400047
J	Seth, RB; Sun, LJ; Ea, CK; Chen, ZJJ				Seth, RB; Sun, LJ; Ea, CK; Chen, ZJJ			Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappa B and IRF3	CELL			English	Article							VIRAL-INFECTION; RNA HELICASE; VIRUS-INFECTION; IKK-EPSILON; RIG-I; PATHWAYS; APOPTOSIS; RESPONSES; MEMBRANE; BINDING	Viral infection triggers host innate immune responses through activation of the transcription factors NF-kappa B and IRF3, which coordinately regulate the expression of type-I interferons such as interferon-beta (IFN-beta). Herein, we report the identification of a novel protein termed MAVS (mitochondrial antiviral signaling), which mediates the activation of NF-kappa B and IRF3 in response to viral infection. Silencing of MAVS expression through RNA interference abolishes the activation of NF-kappa B and IRF3 by viruses, thereby permitting viral replication. Conversely, overexpression of MAVS induces the expression of IFN-beta through activation of NF-kappa B and IRF3, thus boosting antiviral immunity. Epistasis experiments show that MAVS is required for the phosphorylation of IRF3 and I kappa B and functions downstream of RIG-I, an intracellular receptor for viral RNA. MAVS contains an N-terminal CARD-like domain and a C-terminal transmembrane domain, both of which are essential for MAVS signaling. The transmembrane domain targets MAVS to the mitochondria, implicating a new role of mitochondria in innate immunity.	Univ Texas, SW Med Ctr, Dept Mol Biol, Howard Hughes Med Inst, Dallas, TX 75390 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chen, ZJJ (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, Howard Hughes Med Inst, Dallas, TX 75390 USA.	zhiiian.chen@utsouthwestern.edu	Chen, Zhijian/C-6039-2012; Sun, Lijun/ABD-4470-2021	Chen, Zhijian/0000-0002-8475-8251; 	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR019406] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060919] Funding Source: NIH RePORTER; NCRR NIH HHS [1-S10-RR19406] Funding Source: Medline; NIAID NIH HHS [R01-AI60919] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Andrejeva J, 2004, P NATL ACAD SCI USA, V101, P17264, DOI 10.1073/pnas.0407639101; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Balachandran S, 2004, NATURE, V432, P401, DOI 10.1038/nature03124; Crozat K, 2004, P NATL ACAD SCI USA, V101, P6835, DOI 10.1073/pnas.0401347101; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Gohda J, 2004, J IMMUNOL, V173, P2913, DOI 10.4049/jimmunol.173.5.2913; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; Hiscott J, 2003, ANN NY ACAD SCI, V1010, P237, DOI 10.1196/annals.1299.042; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; Kang DC, 2002, P NATL ACAD SCI USA, V99, P637, DOI 10.1073/pnas.022637199; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; Kim PK, 1999, J BIOL CHEM, V274, P36876, DOI 10.1074/jbc.274.52.36876; Kovacsovics M, 2002, CURR BIOL, V12, P838, DOI 10.1016/S0960-9822(02)00842-4; Maniatis T, 1998, COLD SPRING HARB SYM, V63, P609, DOI 10.1101/sqb.1998.63.609; Matsuda A, 2003, ONCOGENE, V22, P3307, DOI 10.1038/sj.onc.1206406; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Perry AK, 2004, J EXP MED, V199, P1651, DOI 10.1084/jem.20040528; Rehermann B, 2005, NAT REV IMMUNOL, V5, P215, DOI 10.1038/nri1573; Schwer B, 2004, J VIROL, V78, P7958, DOI 10.1128/JVI.78.15.7958-7968.2004; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Stumper R, 2005, J VIROL, V79, P2689, DOI 10.1128/JVI.79.5.2689-2699.2005; Sun LJ, 2004, CURR OPIN CELL BIOL, V16, P119, DOI 10.1016/j.ceb.2004.02.005; tenOever BR, 2004, J VIROL, V78, P10636, DOI 10.1128/JVI.78.19.10636-10649.2004; van Oers NSC, 2005, SCIENCE, V308, P65, DOI 10.1126/science.1110902; Wang XD, 2001, GENE DEV, V15, P2922; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Yoneyama M, 2002, J INTERF CYTOK RES, V22, P73, DOI 10.1089/107999002753452674	37	2355	2489	21	202	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 9	2005	122	5					669	682		10.1016/j.cell.2005.08.012	http://dx.doi.org/10.1016/j.cell.2005.08.012			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	963ZC	16125763	Bronze			2022-12-28	WOS:000231844300008
J	Shendure, J; Porreca, GJ; Reppas, NB; Lin, XX; McCutcheon, JP; Rosenbaum, AM; Wang, MD; Zhang, K; Mitra, RD; Church, GM				Shendure, J; Porreca, GJ; Reppas, NB; Lin, XX; McCutcheon, JP; Rosenbaum, AM; Wang, MD; Zhang, K; Mitra, RD; Church, GM			Accurate multiplex polony sequencing of an evolved bacterial genome	SCIENCE			English	Article							SINGLE DNA-MOLECULES; ESCHERICHIA-COLI; AMPLIFICATION; EVOLUTION	We describe a DNA sequencing technology in which a commonly available, inexpensive epifluorescence microscope is converted to rapid nonelectrophoretic DNA sequencing automation. We apply this technology to resequence an evolved strain of Escherichia coli at less than one error per million consensus bases. A cell-free, mate-paired library provided single DNA molecules that were amplified in parallel to 1-micrometer beads by emulsion polymerase chain reaction. Millions of beads were immobilized in a polyacrylamide gel and subjected to automated cycles of sequencing by ligation and four-color imaging. Cost per base was roughly one-ninth as much as that of conventional sequencing. Our protocols were implemented with off-the-shelf instrumentation and reagents.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Washington Univ, Dept Genet, St Louis, MO 63110 USA; Washington Univ, Howard Hughes Med Inst, St Louis, MO 63110 USA	Harvard University; Harvard Medical School; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Shendure, J (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.	shendure@alumni.princeton.edu; gregory_porreca@student.hms.harvard.edu	Zhang, Kun/ABE-6349-2020; Shendure, Jay/AAU-3684-2021	Zhang, Kun/0000-0002-7596-5224; McCutcheon, John/0000-0002-5489-6039; Mitra, Robi/0000-0002-2680-4264; Shendure, Jay/0000-0002-1516-1865; church, george/0000-0001-6232-9969				ADAMS CP, 1997, Patent No. 5641658; BARANY F, 1991, P NATL ACAD SCI USA, V88, P189, DOI 10.1073/pnas.88.1.189; Barker CS, 2004, J BACTERIOL, V186, P7529, DOI 10.1128/JB.186.22.7529-7537.2004; Braslavsky I, 2003, P NATL ACAD SCI USA, V100, P3960, DOI 10.1073/pnas.0230489100; Brenner S, 2000, NAT BIOTECHNOL, V18, P630, DOI 10.1038/76469; Collins FS, 2003, SCIENCE, V300, P286, DOI 10.1126/science.1084564; Dressman D, 2003, P NATL ACAD SCI USA, V100, P8817, DOI 10.1073/pnas.1133470100; Ghadessy FJ, 2001, P NATL ACAD SCI USA, V98, P4552, DOI 10.1073/pnas.071052198; Housby JN, 1998, NUCLEIC ACIDS RES, V26, P4259, DOI 10.1093/nar/26.18.4259; Leamon JH, 2003, ELECTROPHORESIS, V24, P3769, DOI 10.1002/elps.200305646; Levene MJ, 2003, SCIENCE, V299, P682, DOI 10.1126/science.1079700; Lizardi PM, 1998, NAT GENET, V19, P225, DOI 10.1038/898; MACEVICZ SC, 1998, Patent No. 5750341; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; Mitra RD, 2003, ANAL BIOCHEM, V320, P55, DOI 10.1016/S0003-2697(03)00291-4; Mitra RD, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.24.e34; Mucke M, 2001, J MOL BIOL, V312, P687, DOI 10.1006/jmbi.2001.4998; Nakano M, 2003, J BIOTECHNOL, V102, P117, DOI 10.1016/S0168-1656(03)00023-3; PLASTERK RHA, 1985, EMBO J, V4, P237, DOI 10.1002/j.1460-2075.1985.tb02341.x; REPPAS NB, UNPUB; Ronaghi M, 1996, ANAL BIOCHEM, V242, P84, DOI 10.1006/abio.1996.0432; SANGER F, 1977, NATURE, V265, P687, DOI 10.1038/265687a0; Seo TS, 2005, P NATL ACAD SCI USA, V102, P5926, DOI 10.1073/pnas.0501965102; Shendure J, 2004, NAT REV GENET, V5, P335, DOI 10.1038/nrg1325; SHORE D, 1983, J MOL BIOL, V170, P957, DOI 10.1016/S0022-2836(83)80198-3; Tawfik DS, 1998, NAT BIOTECHNOL, V16, P652, DOI 10.1038/nbt0798-652	26	865	1377	6	208	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 9	2005	309	5741					1728	1732		10.1126/science.1117389	http://dx.doi.org/10.1126/science.1117389			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	963WK	16081699				2022-12-28	WOS:000231836700046
J	Chochinov, HM				Chochinov, HM			Vicarious grief and response to global disasters	LANCET			English	Editorial Material							SEPTEMBER 11		Univ Manitoba, Dept Psychiat, CancerCare Manitoba, Manitoba Palliat Care Res Unit, Winnipeg, MB R3E 0V9, Canada	CancerCare Manitoba Foundation; University of Manitoba	Chochinov, HM (corresponding author), Univ Manitoba, Dept Psychiat, CancerCare Manitoba, Manitoba Palliat Care Res Unit, Winnipeg, MB R3E 0V9, Canada.	harvey.chochinov@cancercare.mb.ca		Chochinov, Harvey/0000-0003-2656-4704				*AAFRC TRUST PHIL, 2002, CHAR GIV REACH 212 B; Alagiri Priya, 2001, GLOBAL SPENDING HIV; *GLOB FUND FIGHT A, 2005, TUB MAL HIV AIDS TUB; NOLAN S, 2005, GLOBE MAIL      0111, pA1; Parkes, 2001, BEREAVEMENT STUDIES; RANDO T, 1997, DEATH QUEST MEANING, P257; RANDO T, 1994, DYING DEATH BEREAVEM, P253; RUBONIS AV, 1991, PSYCHOL BULL, V109, P384, DOI 10.1037/0033-2909.109.3.384; Schlenger WE, 2002, JAMA-J AM MED ASSOC, V288, P581, DOI 10.1001/jama.288.5.581; Schuster MA, 2001, NEW ENGL J MED, V345, P1507, DOI 10.1056/NEJM200111153452024; Silver RC, 2002, JAMA-J AM MED ASSOC, V288, P1235, DOI 10.1001/jama.288.10.1235; Wayment HA, 2004, PERS SOC PSYCHOL B, V30, P515, DOI 10.1177/0146167203261892; *WHO, 2005, GLOB TUB CONTR SURV; *WHO REG OFF SE AS, 2005, HIV AIDS FACTS FIG; World Health Organization, 2003, MAL IS AL WELL KILL	15	6	6	3	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 27	2005	366	9487					697	698		10.1016/S0140-6736(05)67154-1	http://dx.doi.org/10.1016/S0140-6736(05)67154-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958UV	16125572				2022-12-28	WOS:000231474600008
J	Fruhbeck, G				Fruhbeck, G			Does a NEAT difference in energy expenditure lead to obesity?	LANCET			English	Editorial Material							FAT		Univ Navarra, Univ Navarra Clin, Dept Endocrinol, Pamplona 31008, Spain; Univ Navarra, Univ Navarra Clin, Metab Res Lab, Pamplona 31008, Spain	University of Navarra; University of Navarra	Fruhbeck, G (corresponding author), Univ Navarra, Univ Navarra Clin, Dept Endocrinol, Pamplona 31008, Spain.	gfruhbeck@unav.es						Bjorntorp P, 2001, LANCET, V358, P1006, DOI 10.1016/S0140-6736(01)06110-4; Desapriya EBR, 2004, LANCET, V364, P1488, DOI 10.1016/S0140-6736(04)17270-X; Hill JO, 2003, SCIENCE, V299, P853, DOI 10.1126/science.1079857; Kotz CM, 2002, REGUL PEPTIDES, V104, P27, DOI 10.1016/S0167-0115(01)00346-9; Levine JA, 2005, SCIENCE, V307, P584, DOI 10.1126/science.1106561; Levine JA, 1999, J CLIN ENDOCR METAB, V84, P2751, DOI 10.1210/jc.84.8.2751; Levine James A., 1999, Science (Washington D C), V283, P212, DOI 10.1126/science.283.5399.212; PRENTICE AM, 1995, BRIT MED J, V311, P437, DOI 10.1136/bmj.311.7002.437; PRENTICE AM, 1999, REPORT BRIT NUTR FDN, P61; Wang C, 2005, CELL METAB, V1, P1, DOI 10.1016/j.cmet.2004.11.002	10	15	15	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 20	2005	366	9486					615	616		10.1016/S0140-6736(05)	http://dx.doi.org/10.1016/S0140-6736(05)			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958EB	16112286				2022-12-28	WOS:000231426400008
J	Taioli, E; Raimondi, S				Taioli, E; Raimondi, S			Genetic susceptibility to bladder cancer	LANCET			English	Editorial Material							S-TRANSFERASE M1; POOLED ANALYSIS; META-ANALYSES; SMOKING; POLYMORPHISMS; GSTM1; RISK		Fdn Policlin IRCCS, Mol & Genet Epidemiol Unit, I-20122 Milan, Italy		Taioli, E (corresponding author), Fdn Policlin IRCCS, Mol & Genet Epidemiol Unit, I-20122 Milan, Italy.	taioli@policlinico.mi.it	Raimondi, Sara/J-5236-2016	Raimondi, Sara/0000-0003-4673-9049				Benhamou S, 2002, CARCINOGENESIS, V23, P1343, DOI 10.1093/carcin/23.8.1343; Brennan P, 2000, INT J CANCER, V86, P289, DOI 10.1002/(SICI)1097-0215(20000415)86:2<289::AID-IJC21>3.0.CO;2-M; Engel LS, 2002, AM J EPIDEMIOL, V156, P95, DOI 10.1093/aje/kwf018; Garcia-Closas M, 2005, LANCET, V366, P649, DOI 10.1016/S0140-6736(05)67137-1; Hashibe M, 2003, CANCER EPIDEM BIOMAR, V12, P1509; Le Marchand LC, 2003, CANCER CAUSE CONTROL, V14, P339; Lee WJ, 2002, BIOMARKERS, V7, P230, DOI 10.1080/13547500210121882; Silverman DT, 1999, OX MED PUBL, P11; Smits KM, 2003, BIOMARKERS, V8, P299, DOI 10.1080/1354750031000121467; Vineis P, 2001, CANCER EPIDEM BIOMAR, V10, P1249; Vogl FD, 2004, CANCER EPIDEM BIOMAR, V13, P1473; 2005, INT COLLABORATIVE ST	12	10	10	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 20	2005	366	9486					610	612		10.1016/S0140-6736(05)67115-2	http://dx.doi.org/10.1016/S0140-6736(05)67115-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958EB	16112283				2022-12-28	WOS:000231426400005
J	de Villeneuve, VWA; Dullens, RPA; Aarts, DGAL; Groeneveld, E; Scherff, JH; Kegel, WK; Lekkerkerker, HNW				de Villeneuve, VWA; Dullens, RPA; Aarts, DGAL; Groeneveld, E; Scherff, JH; Kegel, WK; Lekkerkerker, HNW			Colloidal hard-sphere crystal growth frustrated by large spherical impurities	SCIENCE			English	Article							SURFACE-MORPHOLOGY; KDP CRYSTALS; KINETICS; NUCLEATION; MECHANISM; BIVALENT; PROTEIN; IONS	Impurities affect the nucleation, growth, and structure of crystals. Here we report the effect of large, spherical, polymethylmethacrylate impurities on the crystal growth of monodisperse, hard, polymethylmethacrylate colloids in a density- and optically matching apolar solvent mixture. Crystal growth, initiated at the bottom of the sample, was studied by imaging sequences of two-dimensional xy slices in the plane of the impurity's center with a laser scanning confocal microscope. Impurities form the center of grain boundaries, and a single fluid particle layer around the impurity persists in all cases. The growth rate sensitively depends on the impurity's size. Crystal growth is inhibited to a greater extent near smaller impurities, pointing to local crystal frustration induced by the curvature of the impurity.	Univ Utrecht, Debye Res Inst, Vant Hoff Lab, NL-3584 CH Utrecht, Netherlands	Utrecht University	Lekkerkerker, HNW (corresponding author), Univ Utrecht, Debye Res Inst, Vant Hoff Lab, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	h.n.w.lekkerkerker@chem.uu.nl	Kegel, Willem K/H-4084-2016					Auer S, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.015703; Auer S, 2001, NATURE, V413, P711, DOI 10.1038/35099513; Bosma G, 2002, J COLLOID INTERF SCI, V245, P292, DOI 10.1006/jcis.2001.7986; Cacciuto A, 2004, NATURE, V428, P404, DOI 10.1038/nature02397; Crocker JC, 1996, J COLLOID INTERF SCI, V179, P298, DOI 10.1006/jcis.1996.0217; Davis KJ, 2000, SCIENCE, V290, P1134, DOI 10.1126/science.290.5494.1134; DEHOOG EHA, 2001, THESIS U UTRECHT UTR; DIJKSTRA M, 2004, PHYS REV LETT, V93, P3303; Durbin SD, 1996, ANNU REV PHYS CHEM, V47, P171, DOI 10.1146/annurev.physchem.47.1.171; Eremina TA, 2005, J CRYST GROWTH, V273, P586, DOI 10.1016/j.jcrysgro.2004.09.068; Hurle DTJ, 2004, J CRYST GROWTH, V264, P550, DOI 10.1016/j.jcrysgro.2003.12.035; KERN R, 1992, J CRYST GROWTH, V116, P191, DOI 10.1016/0022-0248(92)90129-7; Kubota N, 2001, CRYST RES TECHNOL, V36, P749, DOI 10.1002/1521-4079(200110)36:8/10<749::AID-CRAT749>3.0.CO;2-#; Land TA, 1999, NATURE, V399, P442, DOI 10.1038/20886; MALKIN AJ, 1995, NAT STRUCT BIOL, V2, P956, DOI 10.1038/nsb1195-956; NELSON DR, 1982, PHILOS MAG A, V46, P105, DOI 10.1080/01418618208236211; NELSON DR, 2002, DEFECTS GEOMETRY CON, P68; Rak M, 2005, J CRYST GROWTH, V273, P577, DOI 10.1016/j.jcrysgro.2004.09.067; Schall P, 2004, SCIENCE, V305, P1944, DOI 10.1126/science.1102186	19	97	97	3	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 19	2005	309	5738					1231	1233		10.1126/science.1113207	http://dx.doi.org/10.1126/science.1113207			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	957TE	16109877	Green Submitted			2022-12-28	WOS:000231395400042
J	Kasper, DL; Sahani, D; Misdraji, J; Harris, NL; Ivers, L; McIntosh, K; Basgoz, N				Kasper, DL; Sahani, D; Misdraji, J; Harris, NL; Ivers, L; McIntosh, K; Basgoz, N			A man with prolonged fever and weight loss - Portal-vein thrombosis due to B-fragilis infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							YERSINIA-ENTEROCOLITICA; APPENDICITIS; PYLEPHLEBITIS; BACTERIOLOGY; THERAPY; DISEASE		Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Radiol, Boston, MA USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Kasper, DL (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.		Misdraji, Joseph/AGX-4779-2022; Ivers, Louise C/Q-4164-2018; Misdraji, Joseph/AAD-4588-2019	Ivers, Louise C/0000-0003-2314-9230; 				Arda IS, 2001, J PEDIATR SURG, V36, P1849, DOI 10.1053/jpsu.2001.28867; BENNION R S, 1990, Clinical Therapeutics, V12, P31; BENNION RS, 1991, AM SURGEON, V57, P766; BENNION RS, 1990, ANN SURG, V211, P165, DOI 10.1097/00000658-199002000-00008; BJORNSON HS, 1973, INFECT IMMUN, V8, P911, DOI 10.1128/IAI.8.6.911-918.1973; Blakelock Russell T, 2003, Semin Pediatr Surg, V12, P265, DOI 10.1053/j.sempedsurg.2003.08.008; BLASER MJ, 2005, HARRISONS PRINCIPLES, P907; BUTTERTON JR, 2005, HARRISONS PRINCIPLES, P754; CHANDLER ND, 1994, ARCH PEDIAT ADOL MED, V148, P527, DOI 10.1001/archpedi.1994.02170050085018; Choi YH, 2002, BIOCHEMISTRY-US, V41, P15144, DOI 10.1021/bi020491v; Dennis DT, 2005, HARRISONS PRINCIPLES, P921; Deutsch A, 1996, PEDIATR EMERG CARE, V12, P285, DOI 10.1097/00006565-199608000-00012; DIONISIO D, 1992, Recenti Progressi in Medicina, V83, P330; ELHAG KM, 1986, J MED MICROBIOL, V21, P245, DOI 10.1099/00222615-21-3-245; GESNER BM, 1961, J BACTERIOL, V81, P595, DOI 10.1128/JB.81.4.595-604.1961; GORBACH SL, 1974, NEW ENGL J MED, V290, P1289, DOI 10.1056/NEJM197406062902305; Hentges DJ, 1989, ANAEROBIC INFECT HUM, P37; HESELTINE PNR, 1983, J INFECT DIS, V148, P322, DOI 10.1093/infdis/148.2.322; Juric I, 2001, PEDIATR INT, V43, P152, DOI 10.1046/j.1442-200x.2001.01360.x; KNOBEL B, 1985, INFECTION, V13, P70, DOI 10.1007/BF01660417; LESSER CF, 2005, HARRISONS PRINCIPLES, P897; Martirosian G, 2001, Med Sci Monit, V7, P382; MOSDELL DM, 1994, AM J SURG, V167, P313, DOI 10.1016/0002-9610(94)90207-0; Naktin J, 1999, CLIN LAB MED, V19, P523; Perego P, 2003, SURG ENDOSC, V17, DOI 10.1007/s00464-002-4224-3; PIEPER R, 1982, ACTA CHIR SCAND, V148, P39; PIEPER R, 1979, SCAND J INFECT DIS, P92; PLEMMONS RM, 1995, CLIN INFECT DIS, V21, P1114, DOI 10.1093/clinids/21.5.1114; Puylaert JBCM, 1997, EUR RADIOL, V7, P3, DOI 10.1007/s003300050098; Rautio M, 2000, PEDIATR INFECT DIS J, V19, P1078, DOI 10.1097/00006454-200011000-00010; ROSENTHAL GA, 1989, INFECT IMMUN, V57, P338, DOI 10.1128/IAI.57.2.338-343.1989; SLOVIS TL, 1989, RADIOLOGY, V171, P823, DOI 10.1148/radiology.171.3.2655006; TZIANABOS AO, 1993, SCIENCE, V262, P416, DOI 10.1126/science.8211161; Vugia D., 2004, Morbidity and Mortality Weekly Report, V53, P340; WILSON SE, 1988, AM J SURG, V155, P61, DOI 10.1016/S0002-9610(88)80215-0	35	24	24	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 18	2005	353	7					713	722		10.1056/NEJMcpc059020	http://dx.doi.org/10.1056/NEJMcpc059020			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955UW	16107625				2022-12-28	WOS:000231254100011
J	Sarin, KY; Cheung, P; Gilison, D; Lee, E; Tennen, RI; Wang, E; Artandi, MK; Oro, AE; Artandi, SE				Sarin, KY; Cheung, P; Gilison, D; Lee, E; Tennen, RI; Wang, E; Artandi, MK; Oro, AE; Artandi, SE			Conditional telomerase induction causes proliferation of hair follicle stem cells	NATURE			English	Article							LABEL-RETAINING CELLS; SELF-RENEWAL; BONE-MARROW; MICE; SKIN; CYCLE; EXPRESSION; KERATINOCYTES; EPIDERMIS; CANCER	TERT, the protein component of telomerase(1,2), serves to maintain telomere function through the de novo addition of telomere repeats to chromosome ends, and is reactivated in 90% of human cancers. In normal tissues, TERT is expressed in stem cells and in progenitor cells(3), but its role in these compartments is not fully understood. Here we show that conditional transgenic induction of TERT in mouse skin epithelium causes a rapid transition from telogen ( the resting phase of the hair follicle cycle) to anagen ( the active phase), thereby facilitating robust hair growth. TERT overexpression promotes this developmental transition by causing proliferation of quiescent, multipotent stem cells in the hair follicle bulge region. This new function for TERT does not require the telomerase RNA component, which encodes the template for telomere addition, and therefore operates through a mechanism independent of its activity in synthesizing telomere repeats. These data indicate that, in addition to its established role in extending telomeres, TERT can promote proliferation of resting stem cells through a non-canonical pathway.	Stanford Univ, Sch Med, Dept Med, Div Hematol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Canc Biol Program, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Dermatol, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University	Artandi, SE (corresponding author), Stanford Univ, Sch Med, Dept Med, Div Hematol, Stanford, CA 94305 USA.	sartandi@stanford.edu		Oro, Anthony/0000-0002-6261-138X; Sarin, Kavita/0000-0001-5363-3053; Artandi, Maja/0000-0003-2342-6277	NCI NIH HHS [K08 CA082176, R55 CA109088] Funding Source: Medline; NIGMS NIH HHS [T32 GM007365] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA082176, R55CA109088] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alonso L, 2003, GENE DEV, V17, P1189, DOI 10.1101/gad.1086903; Artandi SE, 2002, P NATL ACAD SCI USA, V99, P8191, DOI 10.1073/pnas.112515399; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; Blasco MA, 2003, TRENDS CELL BIOL, V13, P289, DOI 10.1016/S0962-8924(03)00085-0; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Braun KM, 2003, DEVELOPMENT, V130, P5241, DOI 10.1242/dev.00703; Chang S, 2003, GENE DEV, V17, P88, DOI 10.1101/gad.1029903; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Forsyth NR, 2002, DIFFERENTIATION, V69, P188, DOI 10.1046/j.1432-0436.2002.690412.x; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; Morrison SJ, 1996, IMMUNITY, V5, P207, DOI 10.1016/S1074-7613(00)80316-7; Muller-Rover S, 2001, J INVEST DERMATOL, V117, P3, DOI 10.1046/j.0022-202x.2001.01377.x; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Ramirez RD, 1997, J INVEST DERMATOL, V108, P113, DOI 10.1111/1523-1747.ep12285654; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Sato N, 1999, J CLIN INVEST, V104, P855, DOI 10.1172/JCI7691; Sawamura D, 1999, J INVEST DERMATOL, V112, P828, DOI 10.1046/j.1523-1747.1999.00583.x; Smogorzewska A, 2004, ANNU REV BIOCHEM, V73, P177, DOI 10.1146/annurev.biochem.73.071403.160049; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; Trempus CS, 2003, J INVEST DERMATOL, V120, P501, DOI 10.1046/j.1523-1747.2003.12088.x; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Wright DE, 2001, BLOOD, V97, P2278, DOI 10.1182/blood.V97.8.2278; Yui J, 1998, BLOOD, V91, P3255, DOI 10.1182/blood.V91.9.3255.3255_3255_3262	30	329	356	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 18	2005	436	7053					1048	1052		10.1038/nature03836	http://dx.doi.org/10.1038/nature03836			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955XQ	16107853	Green Accepted			2022-12-28	WOS:000231263900057
J	Jefferson, T				Jefferson, T			Microbial challenge studies - a challenge worth accepting	LANCET			English	Editorial Material									Cochrane Vaccines Field, I-00061 Rome, Italy		Jefferson, T (corresponding author), Cochrane Vaccines Field, I-00061 Rome, Italy.	Toj1@aol.com						Academy of Medical Sciences, 2005, MICR CHALL STUD HUM; Thompson K.R., 1991, HARVARD HOSP ITS VOL; TYRRELL D, 1990, J ROY COLL PHYS LOND, V24, P137	3	7	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 13	2005	366	9485					531	533		10.1016/S0140-6736(05)67079-1	http://dx.doi.org/10.1016/S0140-6736(05)67079-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955LL	16099277	Bronze, Green Published			2022-12-28	WOS:000231227300009
J	Hong, JH; Hwang, ES; McManus, MT; Amsterdam, A; Tian, Y; Kalmukova, R; Mueller, E; Benjamin, T; Spiegelman, BM; Sharp, PA; Hopkins, N; Yaffe, MB				Hong, JH; Hwang, ES; McManus, MT; Amsterdam, A; Tian, Y; Kalmukova, R; Mueller, E; Benjamin, T; Spiegelman, BM; Sharp, PA; Hopkins, N; Yaffe, MB			TAZ, a transcriptional modulator of mesenchymal stem cell differentiation	SCIENCE			English	Article							MARROW STROMAL CELLS; OSTEOBLAST DIFFERENTIATION; BONE-MARROW; PPAR-GAMMA; ADIPOSE-TISSUE; ADIPOGENESIS; OSTEOPOROSIS; CBFA1; COACTIVATOR; PATHWAY	Mesenchymal stem cells (MSCs) are a pluripotent cell type that can differentiate into several distinct lineages. Two key transcription factors, Runx2 and peroxisome proliferator-activated receptor gamma (PPAR gamma), drive MSCs to differentiate into either osteoblasts or adipocytes, respectively. How these two transcription factors are regulated in order to specify these alternate cell fates remains a pivotal question. Here we report that a 14-3-3-binding protein, TAZ (transcriptional coactivator with PDZ-binding motif), coactivates Runx2-dependent gene transcription white repressing PPAR gamma-dependent gene transcription. By modulating TAZ expression in model cell lines, mouse embryonic fibroblasts, and primary MSCs in culture and in zebrafish in vivo, we observed alterations in osteogenic versus adipogenic potential. These results indicate that TAZ functions as a molecular rheostat that modulates MSC differentiation.	MIT, Ctr Canc Res, Dept Biol, Cambridge, MA 02139 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Yaffe, MB (corresponding author), MIT, Ctr Canc Res, Dept Biol, 77 Massachusetts Ave,E18-580, Cambridge, MA 02139 USA.	myaffe@mit.edu	Hong, Jeong-Ho/T-8099-2018; mcmanus, michael/AAB-1239-2020	Hong, Jeong-Ho/0000-0002-8235-9855; mcmanus, michael/0000-0003-3013-6569	NATIONAL CANCER INSTITUTE [P01CA042063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK075004, Z01DK075004] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM068762, R01GM060594] Funding Source: NIH RePORTER; NCI NIH HHS [CA042063] Funding Source: Medline; NIGMS NIH HHS [GM60594, GM68762] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; BURKHARDT R, 1987, BONE, V8, P157, DOI 10.1016/8756-3282(87)90015-9; Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471-4914(01)02016-0; Chang SCN, 2004, J SURG RES, V119, P85, DOI 10.1016/j.jss.2003.08.003; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; Cui CB, 2003, MOL CELL BIOL, V23, P1004, DOI 10.1128/MCB.23.3.1004-1013.2003; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756-3282(01)00415-X; Hong J.H., UNPUB; Kajkenova O, 1997, J BONE MINER RES, V12, P1772, DOI 10.1359/jbmr.1997.12.11.1772; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Kaplan FS, 2000, J BONE MINER RES, V15, P2084, DOI 10.1359/jbmr.2000.15.11.2084; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; MEUNIER P, 1971, CLIN ORTHOP RELAT R, V80, P147, DOI DOI 10.1097/00003086-197110000-00021; Nakashima K, 2003, TRENDS GENET, V19, P458, DOI 10.1016/S0168-9525(03)00176-8; Nuttall ME, 2000, BONE, V27, P177, DOI 10.1016/S8756-3282(00)00317-3; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; TIAN Y, UNPUB; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Verma S, 2002, J CLIN PATHOL, V55, P693, DOI 10.1136/jcp.55.9.693; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551	28	762	819	4	106	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 12	2005	309	5737					1074	1078		10.1126/science.1110955	http://dx.doi.org/10.1126/science.1110955			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955MN	16099986				2022-12-28	WOS:000231230100046
J	Gunsalus, KC; Ge, H; Schetter, AJ; Goldberg, DS; Han, JDJ; Hao, T; Berriz, GF; Bertin, N; Huang, J; Chuang, LS; Li, N; Mani, R; Hyman, AA; Sonnichsen, B; Echeverri, CJ; Roth, FP; Vidal, M; Piano, F				Gunsalus, KC; Ge, H; Schetter, AJ; Goldberg, DS; Han, JDJ; Hao, T; Berriz, GF; Bertin, N; Huang, J; Chuang, LS; Li, N; Mani, R; Hyman, AA; Sonnichsen, B; Echeverri, CJ; Roth, FP; Vidal, M; Piano, F			Predictive models of molecular machines involved in Caenorhabditis elegans early embryogenesis	NATURE			English	Article							C-ELEGANS; CENTROSOME DUPLICATION; MAPPING DATA; PROTEIN; CELL; INTERACTOME; CENTRIOLAR; NETWORK; MAP; TRANSCRIPTOME	Although numerous fundamental aspects of development have been uncovered through the study of individual genes and proteins, system-level models are still missing for most developmental processes. The first two cell divisions of Caenorhabditis elegans embryogenesis constitute an ideal test bed for a system-level approach. Early embryogenesis, including processes such as cell division and establishment of cellular polarity, is readily amenable to large-scale functional analysis. A first step toward a system-level understanding is to provide 'first-draft' models both of the molecular assemblies involved(1) and of the functional connections between them. Here we show that such models can be derived from an integrated gene/protein network generated from three different types of functional relationship(2): protein interaction(3), expression profiling similarity(4) and phenotypic profiling similarity(5), as estimated from detailed early embryonic RNA interference phenotypes systematically recorded for hundreds of early embryogenesis genes(6). The topology of the integrated network suggests that C. elegans early embryogenesis is achieved through coordination of a limited set of molecular machines. We assessed the overall predictive value of such molecular machine models by dynamic localization of ten previously uncharacterized proteins within the living embryo.	NYU, Dept Biol, Ctr Comparat Funct Genom, New York, NY 10003 USA; Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Cenix Biosci GmbH, D-01307 Dresden, Germany	New York University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Max Planck Society	Roth, FP (corresponding author), NYU, Dept Biol, Ctr Comparat Funct Genom, New York, NY 10003 USA.	fritz_roth@hms.harvard.edu; marc_vidal@dfci.harvard.edu; fp1@nyu.edu	Bertin, Nicolas/O-9602-2019; Chuang, Ling-shiang/GNH-1836-2022; Hyman, Tony/F-1923-2011; Hyman, Anthony A/B-3917-2017; Roth, Frederick P/H-6308-2011; Bertin, Nicolas/C-3025-2008	Chuang, Ling-shiang/0000-0001-5054-1305; Hyman, Anthony A/0000-0003-3664-154X; Bertin, Nicolas/0000-0002-9835-9606; Roth, Frederick/0000-0002-6628-649X				Alberts B, 1998, CELL, V92, P291, DOI 10.1016/S0092-8674(00)80922-8; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Baas AF, 2004, TRENDS CELL BIOL, V14, P312, DOI 10.1016/j.tcb.2004.04.001; Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2; Bader JS, 2004, NAT BIOTECHNOL, V22, P78, DOI 10.1038/nbt924; Begley TJ, 2002, MOL CANCER RES, V1, P103; Boulton SJ, 2002, SCIENCE, V295, P127, DOI 10.1126/science.1065986; Brajenovic M, 2004, J BIOL CHEM, V279, P12804, DOI 10.1074/jbc.M312171200; Cheeseman IM, 2004, GENE DEV, V18, P2255, DOI 10.1101/gad.1234104; Dammermann A, 2004, DEV CELL, V7, P815, DOI 10.1016/j.devcel.2004.10.015; Delattre M, 2004, NAT CELL BIOL, V6, P656, DOI 10.1038/ncb1146; Ge H, 2001, NAT GENET, V29, P482, DOI 10.1038/ng776; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Jansen R, 2003, SCIENCE, V302, P449, DOI 10.1126/science.1087361; Jansen R, 2002, GENOME RES, V12, P37, DOI 10.1101/gr.205602; Kim SK, 2001, SCIENCE, V293, P2087, DOI 10.1126/science.1061603; Kirkham M, 2003, CELL, V112, P575, DOI 10.1016/S0092-8674(03)00117-X; Kitagawa R, 2002, CURR BIOL, V12, P2118, DOI 10.1016/S0960-9822(02)01392-1; Lee I, 2004, SCIENCE, V306, P1555, DOI 10.1126/science.1099511; Leidel S, 2005, NAT CELL BIOL, V7, P115, DOI 10.1038/ncb1220; Leidel S, 2003, DEV CELL, V4, P431, DOI 10.1016/S1534-5807(03)00062-5; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Marcotte EM, 1999, NATURE, V402, P83, DOI 10.1038/47048; O'Connell KF, 2001, CELL, V105, P547, DOI 10.1016/S0092-8674(01)00338-5; Piano F, 2002, CURR BIOL, V12, P1959, DOI 10.1016/S0960-9822(02)01301-5; Schneider SQ, 2003, ANNU REV GENET, V37, P221, DOI 10.1146/annurev.genet.37.110801.142443; Schumacher JM, 1998, DEVELOPMENT, V125, P4391; Sonnichsen B, 2005, NATURE, V434, P462, DOI 10.1038/nature03353; Vidal M, 2001, CELL, V104, P333, DOI 10.1016/S0092-8674(01)00221-5; Walhout AJM, 2002, CURR BIOL, V12, P1952, DOI 10.1016/S0960-9822(02)01279-4	30	200	231	0	18	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 11	2005	436	7052					861	865		10.1038/nature03876	http://dx.doi.org/10.1038/nature03876			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953XG	16094371				2022-12-28	WOS:000231116500049
J	Posson, DJ; Ge, PH; Miller, C; Bezanilla, F; Selvin, PR				Posson, DJ; Ge, PH; Miller, C; Bezanilla, F; Selvin, PR			Small vertical movement of a K+ channel voltage sensor measured with luminescence energy transfer	NATURE			English	Article							POTASSIUM-CHANNEL; CHARYBDOTOXIN BLOCK; ELECTRIC-FIELD; GATING CHARGE; S4 SEGMENT; SHAKER; MECHANISM; PEPTIDE; PORE	Voltage-gated ion channels open and close in response to voltage changes across electrically excitable cell membranes(1). Voltage-gated potassium (Kv) channels are homotetramers with each subunit constructed from six transmembrane segments, S1 - S6 (ref. 2). The voltage-sensing domain ( segments S1 - S4) contains charged arginine residues on S4 that move across the membrane electric field(2,3), modulating channel open probability. Understanding the physical movements of this voltage sensor is of fundamental importance and is the subject of controversy. Recently, the crystal structure of the KvAP(4) channel motivated an unconventional 'paddle model' of S4 charge movement, indicating that the segments S3b and S4 might move as a unit through the lipid bilayer with a large ( 15-20-angstrom) transmembrane displacement(5). Here we show that the voltage-sensor segments do not undergo significant transmembrane translation. We tested the movement of these segments in functional Shaker K 1 channels by using luminescence resonance energy transfer to measure distances between the voltage sensors and a pore-bound scorpion toxin. Our results are consistent with a 2-angstrom vertical displacement of S4, not the large excursion predicted by the paddle model. This small movement supports an alternative model in which the protein shapes the electric field profile, focusing it across a narrow region of S4 ( ref. 6).	Univ Illinois, Dept Phys, Urbana, IL 61801 USA; Univ Illinois, Ctr Biophys, Urbana, IL 61801 USA; Brandeis Univ, Howard Hughes Med Inst, Dept Biochem, Waltham, MA 02454 USA; Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Anesthesiol, Los Angeles, CA 90095 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Brandeis University; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Selvin, PR (corresponding author), Univ Illinois, Dept Phys, 1110 W Green St, Urbana, IL 61801 USA.	selvin@uiuc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074770] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM030376, R37 GM030376, R01 GM074770] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; ARMSTRONG CM, 1973, NATURE, V242, P459, DOI 10.1038/242459a0; Asamoah OK, 2003, NEURON, V37, P85, DOI 10.1016/S0896-6273(02)01126-1; Baumgartner W, 1999, BIOPHYS J, V77, P1980, DOI 10.1016/S0006-3495(99)77039-6; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; Blaustein RO, 2000, NAT STRUCT BIOL, V7, P309; Cha A, 1999, NATURE, V402, P809, DOI 10.1038/45552; Clegg Robert M., 1995, Current Opinion in Biotechnology, V6, P103, DOI 10.1016/0958-1669(95)80016-6; Cuello LG, 2004, SCIENCE, V306, P491, DOI 10.1126/science.1101373; Eriksson MAL, 2002, BIOPHYS J, V83, P2595, DOI 10.1016/S0006-3495(02)75270-3; Glauner KS, 1999, NATURE, V402, P813, DOI 10.1038/45561; GOLDSTEIN SAN, 1993, BIOPHYS J, V65, P1613, DOI 10.1016/S0006-3495(93)81200-1; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; Hessa T, 2005, SCIENCE, V307, P1427, DOI 10.1126/science.1109176; Heyduk T, 2001, ANAL BIOCHEM, V289, P60, DOI 10.1006/abio.2000.4925; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Laine M, 2004, FEBS LETT, V564, P257, DOI 10.1016/S0014-5793(04)00273-X; Laine M, 2003, NEURON, V39, P467, DOI 10.1016/S0896-6273(03)00468-9; MACKINNON R, 1988, J GEN PHYSIOL, V91, P335, DOI 10.1085/jgp.91.3.335; Mannuzzu LM, 1996, SCIENCE, V271, P213, DOI 10.1126/science.271.5246.213; Reifenberger JG, 2003, J PHYS CHEM B, V107, P12862, DOI 10.1021/jp0357424; SELVIN PR, 1994, J AM CHEM SOC, V116, P6029, DOI 10.1021/ja00092a088; Selvin PR, 2002, ANNU REV BIOPH BIOM, V31, P275, DOI 10.1146/annurev.biophys.31.101101.140927; Selvin PR, 2000, NAT STRUCT BIOL, V7, P730, DOI 10.1038/78948; SHIMONY E, 1994, PROTEIN ENG, V7, P503, DOI 10.1093/protein/7.4.503; Starace DM, 2004, NATURE, V427, P548, DOI 10.1038/nature02270	28	158	161	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 11	2005	436	7052					848	851		10.1038/nature03819	http://dx.doi.org/10.1038/nature03819			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953XG	16094368	Green Accepted			2022-12-28	WOS:000231116500046
J	Shalowitz, DI; Miller, FG				Shalowitz, DI; Miller, FG			Disclosing individual results of clinical research - Implications of respect for participants	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CHILDRENS ONCOLOGY GROUP; IMPACT; ATTITUDES; TRIAL; RISK		NIH, Dept Clin Bioeth, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Miller, FG (corresponding author), NIH, Dept Clin Bioeth, Bldg 10,Room 1C118, Bethesda, MD 20892 USA.	fmiller@cc.nih.gov	Shalowitz, David/A-7432-2009; Shalowitz, David/AAS-9591-2021	Shalowitz, David/0000-0002-5189-4687				[Anonymous], 2002, INT ETH GUID BIOM RE; Banks T M, 2000, Sask Law Rev, V63, P539; Broadstock M, 2000, EUR J HUM GENET, V8, P731, DOI 10.1038/sj.ejhg.5200532; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V283, P2701, DOI 10.1001/jama.283.20.2701; Fanos JH, 2004, AM J MED GENET A, V129A, P248, DOI 10.1002/ajmg.a.30178; Fernandez Conrad V, 2003, IRB, V25, P12, DOI 10.2307/3564300; Fernandez CV, 2003, J PEDIAT HEMATOL ONC, V25, P704, DOI 10.1097/00043426-200309000-00006; Fernandez CV, 2003, CANCER-AM CANCER SOC, V97, P2904, DOI 10.1002/cncr.11391; Fuller BP, 1999, SCIENCE, V285, P1359, DOI 10.1126/science.285.5432.1359; hhs, 1979, BELM REP ETH PRINC G; Lawrence WF, 2001, CANCER EPIDEM BIOMAR, V10, P475; *NAT HEART LUNG BL, WORK GROUP REP GEN R; National Bioethics Advisory Commission, 1999, RES INV HUM BIOL MAT; National Institute of Health Executive Secretariat, PLAIN LANG IN; *OFF HUM RES PROT, PROT HUM SUBJ 2001; *OFF PROT RES RISK, 1993, PROT HUM RES SUBJ I; Partridge AH, 2005, LANCET, V365, P963, DOI 10.1016/S0140-6736(05)71085-0; Partridge AH, 2004, J NATL CANCER I, V96, P629, DOI 10.1093/jnci/djh096; Partridge AH, 2003, J NATL CANCER I, V95, P491, DOI 10.1093/jnci/95.6.491; Partridge AH, 2002, JAMA-J AM MED ASSOC, V288, P363, DOI 10.1001/jama.288.3.363; Schulz CJ, 2003, MED PEDIATR ONCOL, V41, P36, DOI 10.1002/mpo.10278; Smith CO, 2004, ARCH NEUROL-CHICAGO, V61, P875, DOI 10.1001/archneur.61.6.875; Steinbart EJ, 2001, ARCH NEUROL-CHICAGO, V58, P1828, DOI 10.1001/archneur.58.11.1828; van Dijk S, 2004, GENET TEST, V8, P235, DOI 10.1089/gte.2004.8.235; 2003, FED REG, V42, P493	25	202	202	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	2005	294	6					737	740		10.1001/jama.294.6.737	http://dx.doi.org/10.1001/jama.294.6.737			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	953IA	16091577				2022-12-28	WOS:000231068600028
J	Birn, AE				Birn, AE			Gates's grandest challenge: transcending technology as public health ideology	LANCET			English	Editorial Material							SOCIAL DIFFERENTIALS; MORTALITY; DECLINE; IMMUNIZATION; COUNTRIES; DISEASE; INFANT; POOR		Univ Toronto, Fac Med, Dept Publ Hlth Sci, Toronto, ON M5S 1A8, Canada	University of Toronto	Birn, AE (corresponding author), Univ Toronto, Fac Med, Dept Publ Hlth Sci, 1st Floor,McMurrich Bldg,12 Queens Pk Crescent W, Toronto, ON M5S 1A8, Canada.	ae.birn@utoronto.ca						ACKERNECHT EH, 1953, RUDOLF VIRCHOW, P127; Barr RG, 2001, AM J PUBLIC HEALTH, V91, P1487, DOI 10.2105/AJPH.91.9.1487; Beaglehole R., 2003, WORLD HLTH REPORT 20; Bhutta Z, 2003, BMJ-BRIT MED J, V327, P1000, DOI 10.1136/bmj.327.7422.1000; BIRN AE, 2004, IND U BLOOM HIST DEP; Brown P. J., 1998, Parassitologia (Rome), V40, P117; Bryce J, 2003, LANCET, V362, P159, DOI 10.1016/S0140-6736(03)13870-6; Burstrom B, 2003, INT J HEALTH SERV, V33, P723, DOI 10.2190/9GMR-TA8W-LA3B-5E2A; *CENTR INT AG, 2004, WORLD FACTB 2004; Corsini CA, 1997, DECLINE OF INFANT AND CHILD MORTALITY, pXIII; Deaton A, 2001, WORLD BANK RES OBSER, V16, P125, DOI 10.1093/wbro/16.2.125; Donnelly James S., 2001, GREAT IRISH POTATO F; Frenk J., 1989, Health Policy and Planning, V4, P29, DOI 10.1093/heapol/4.1.29; Global Forum for Health Research & World Health Organization, 2004, 1090 GLOB FOR HLTH R; Gloyd S, 2003, INT J HEALTH SERV, V33, P113, DOI 10.2190/25BV-JW2P-22CN-WNRR; Gomez-Dantes H., 2000, Parassitologia (Rome), V42, P69; Haines M. R, 2001, ANN DEMOGRAPHIE HIST, V101, P33, DOI DOI 10.3917/ADH.101.0033; Halstead S, 1985, GOOD HLTH LOW COST; Horton R, 2003, LANCET, V361, P712, DOI 10.1016/S0140-6736(03)12665-7; Humphreys M, 1996, ISIS, V87, P1, DOI 10.1086/357400; Jha P, 2002, SCIENCE, V295, P2036, DOI 10.1126/science.295.5562.2036; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Kawachi I, 2002, HLTH NATIONS; Kearns G., 1988, SOC HLTH POPULATION, P213; Krieger N, 1998, AM J PUBLIC HEALTH, V88, P1603, DOI 10.2105/AJPH.88.11.1603; Labonte R, 2003, BRIT MED J, V326, P722, DOI 10.1136/bmj.326.7392.722; MARMOT MG, 1994, DAEDALUS-US, V123, P197; MCKEOWN T, 1975, POP STUD-J DEMOG, V29, P391, DOI 10.2307/2173935; Muraskin W, 2004, AM J PUBLIC HEALTH, V94, P1922, DOI 10.2105/AJPH.94.11.1922; Navarro V, 2003, INT J HEALTH SERV, V33, P419, DOI 10.2190/R7GE-8DWK-YY6C-183U; Navarro V, 2001, SOC SCI MED, V52, P481, DOI 10.1016/S0277-9536(00)00197-0; NAVARRO V, 1981, IMPERIALISM HLTH MED, P15; Neufeld V, 2001, CAN MED ASSOC J, V164, P1158; Packard R. M., 1994, Parassitologia (Rome), V36, P197; Reddy S., 2003, NOT COUNT POOR; Riley J, 2001, RISING LIFE EXPECTAN; Sanders D, 2004, B WORLD HEALTH ORGAN, V82, P757; Schofield R, 1991, DECLINE MORTALITY EU; Sen A., 1983, POVERTY FAMINES ESSA; Szreter S, 1999, TROP MED INT HEALTH, V4, P146, DOI 10.1046/j.1365-3156.1999.00369.x; Szreter Simon, 1988, SOCIAL SCI MED, V1, P1, DOI DOI 10.1145/1073943.1073950; TOWNSEND P, 1987, J SOC POLICY, V16, P125, DOI 10.1017/S0047279400020341; Townsend P., 1993, INT ANAL POVERTY; Travis P, 2004, LANCET, V364, P900, DOI 10.1016/S0140-6736(04)16987-0; Varmus H, 2003, SCIENCE, V302, P398, DOI 10.1126/science.1091769; Wallace D., 2003, RETURN WHITE PLAGUE, P125; Wolleswinkel-van den Bosch JH, 2000, INT J EPIDEMIOL, V29, P1031, DOI 10.1093/ije/29.6.1031; WOODS RI, 1988, POPULATION STUDIES, P343; World Health Organization, 1995, WORLD HLTH REP 1995; Yamin Alicia Ely, 2003, BOSTON U INT LAW J, V21, P101; 2003, BMJ, V327, P1416	51	106	106	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 6	2005	366	9484					514	519		10.1016/S0140-6736(05)66479-3	http://dx.doi.org/10.1016/S0140-6736(05)66479-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	952RD	16084261				2022-12-28	WOS:000231022300034
J	Ihmels, J; Bergmann, S; Gerami-Nejad, M; Yanai, I; McClellan, M; Berman, J; Barkai, N				Ihmels, J; Bergmann, S; Gerami-Nejad, M; Yanai, I; McClellan, M; Berman, J; Barkai, N			Rewiring of the yeast transcriptional network through the evolution of motif usage	SCIENCE			English	Article							GENOME; DUPLICATION	Recent experiments revealed large-scale differences in the transcription programs of related species, yet little is known about the genetic basis underlying the evolution of gene expression and its contribution to phenotypic diversity. Here we describe a large-scale modulation of the yeast transcription program that is connected to the emergence of the capacity for rapid anaerobic growth. Genes coding for mitochondrial and cytoplasmic ribosomal proteins display a strongly correlated expression pattern in Candida, albicans, but this correlation is lost in the fermentative yeast Saccharomyces cerevisiae. We provide evidence that this change in gene expression is connected to the loss of a specific cis-regulatory element from dozens of genes following the apparent whole-genome duplication event. Our results shed new light on the genetic mechanisms underlying the large-scale evolution of transcriptional networks.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel; Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA	Weizmann Institute of Science; Weizmann Institute of Science; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Barkai, N (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	naama.barkai@weizmann.ac.il	Berman, Judith/AAS-5115-2021; Berman, Judith/ABA-8528-2021	Berman, Judith/0000-0002-8577-0084; Yanai, Itai/0000-0002-8438-2741; Bergmann, Sven/0000-0002-6785-9034	NIDCR NIH HHS [R01 DE/AI 14666] Funding Source: Medline; PHS HHS [A150562] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014666] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bergmann S, 2004, PLOS BIOL, V2, P85, DOI 10.1371/journal.pbio.0020009; Carroll SB, 2000, CELL, V101, P577, DOI 10.1016/S0092-8674(00)80868-5; Davidson E. H., 2001, DEV EVOLUTION; Dietrich FS, 2004, SCIENCE, V304, P304, DOI 10.1126/science.1095781; Gasch AP, 2004, PLOS BIOL, V2, P2202, DOI 10.1371/journal.pbio.0020398; Ihmels J, 2002, NAT GENET, V31, P370, DOI 10.1038/ng941; Kellis M, 2004, NATURE, V428, P617, DOI 10.1038/nature02424; KING MC, 1975, SCIENCE, V188, P107, DOI 10.1126/science.1090005; Piskur J, 2004, MOL MICROBIOL, V53, P381, DOI 10.1111/j.1365-2958.2004.04182.x; Schuller HJ, 2003, CURR GENET, V43, P139, DOI 10.1007/s00294-003-0381-8; Tanay A, 2005, P NATL ACAD SCI USA, V102, P7203, DOI 10.1073/pnas.0502521102; Tavazoie S, 1998, NAT BIOTECHNOL, V16, P566, DOI 10.1038/nbt0698-566; Wolfe K, 2004, CURR BIOL, V14, pR392, DOI 10.1016/j.cub.2004.05.015; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711	14	221	231	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 5	2005	309	5736					938	940		10.1126/science.1113833	http://dx.doi.org/10.1126/science.1113833			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953SS	16081737				2022-12-28	WOS:000231101400048
J	Burrows, DN; Romano, P; Falcone, A; Kobayashi, S; Zhang, B; Moretti, A; O'Brien, PT; Goad, MR; Campana, S; Page, KL; Angelini, L; Barthelmy, S; Beardmore, AP; Capalbi, M; Chincarini, G; Cummings, J; Cusumano, G; Fox, D; Giommi, P; Hill, JE; Kennea, JA; Krimm, H; Mangano, V; Marshall, F; Meszaros, P; Morris, DC; Nousek, JA; Osborne, JP; Pagani, C; Perri, M; Tagliaferri, G; Wells, AA; Woosley, S; Gehrels, N				Burrows, DN; Romano, P; Falcone, A; Kobayashi, S; Zhang, B; Moretti, A; O'Brien, PT; Goad, MR; Campana, S; Page, KL; Angelini, L; Barthelmy, S; Beardmore, AP; Capalbi, M; Chincarini, G; Cummings, J; Cusumano, G; Fox, D; Giommi, P; Hill, JE; Kennea, JA; Krimm, H; Mangano, V; Marshall, F; Meszaros, P; Morris, DC; Nousek, JA; Osborne, JP; Pagani, C; Perri, M; Tagliaferri, G; Wells, AA; Woosley, S; Gehrels, N			Bright X-ray flares in gamma-ray burst afterglows	SCIENCE			English	Article							EMISSION; SHOCKS	Gamma-ray burst (GRB) afterglows have provided important clues to the nature of these massive explosive events, providing direct information on the nearby environment and indirect information on the central engine that powers the burst. We report the discovery of two bright x-ray flares in GRB afterglows, including a giant flare comparable in total energy to the burst itself, each peaking minutes after the burst. These strong rapid x-ray flares imply that the central engines of the bursts have long periods of activity, with strong internal shocks continuing for hundreds of seconds after the gamma-ray emission has ended.	Penn State Univ, Dept Astron & Astrophys, Davey Lab 525, University Pk, PA 16802 USA; Osserv Astron Brera, INAF, I-23807 Merate, Italy; Penn State Univ, Ctr Gravitat Wave Phys, Davey Lab 104, University Pk, PA 16802 USA; Univ Nevada, Dept Phys, Las Vegas, NV 89154 USA; Univ Leicester, Dept Phys & Astron, Leicester LE1 7RH, Leics, England; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA; Agenzia Spaziale Italiana Sci Data Ctr, I-00044 Frascati, Italy; Univ Milano Bicocca, Dipartimento Fis, I-20126 Milan, Italy; INAF Ist Astrofis Spaziale & Fis Cosm, Sez Palermo, I-90146 Palermo, Italy; CALTECH, Dept Astron, Pasadena, CA 91125 USA; Univ Calif Santa Cruz, Dept Astron & Astrophys, Santa Cruz, CA 95064 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Istituto Nazionale Astrofisica (INAF); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Nevada System of Higher Education (NSHE); University of Nevada Las Vegas; University of Leicester; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Johns Hopkins University; Agenzia Spaziale Italiana (ASI); University of Milano-Bicocca; Istituto Nazionale Astrofisica (INAF); California Institute of Technology; University of California System; University of California Santa Cruz	Burrows, DN (corresponding author), Penn State Univ, Dept Astron & Astrophys, Davey Lab 525, University Pk, PA 16802 USA.	burrows@astro.psu.edu	Barthelmy, Scott D/D-2943-2012; Tagliaferri, Gianpiero/ABD-7556-2021; Campana, Sergio/AAL-6012-2020; Gehrels, Neil/D-2971-2012; Kennea, Jamie/AAF-2090-2019; giommi, paolo/L-1006-2018	Tagliaferri, Gianpiero/0000-0003-0121-0723; Campana, Sergio/0000-0001-6278-1576; Kennea, Jamie/0000-0002-6745-4790; Mangano, Vanessa/0000-0003-4262-8616; Cusumano, Giancarlo/0000-0002-8151-1990; giommi, paolo/0000-0002-2265-5003; Zhang, Bing/0000-0002-9725-2524; Meszaros, Peter/0000-0002-4132-1746; Beardmore, Andrew/0000-0001-5186-5950; Page, Kim/0000-0001-5624-2613; Goad, Michael/0000-0002-2908-7360; moretti, alberto/0000-0002-9770-0315; Fox, Derek/0000-0002-3714-672X; Perri, Matteo/0000-0003-3613-4409; O'Brien, Paul/0000-0002-5128-1899; Romano, Patrizia/0000-0003-0258-7469				BARTHELMY S, IN PRESS SPACE SCI R; Burrows DN, 2005, ASTROPHYS J, V622, pL85, DOI 10.1086/429666; BURROWS DN, IN PRESS SPACE SCI R; Campana S, 2005, ASTROPHYS J, V625, pL23, DOI 10.1086/430883; CUSUMANO G, UNPUB; Heise J, 2001, ESO ASTROPHY SYMP, P16, DOI 10.1007/10853853_4; Hjorth J, 2003, NATURE, V423, P847, DOI 10.1038/nature01750; HURLEY K, 1994, NATURE, V372, P652, DOI 10.1038/372652a0; IOKA K, IN PRESS ASTROPHYS J; KING A, IN PRESS ASTROPHYS J; Kobayashi S, 1997, ASTROPHYS J, V490, P92, DOI 10.1086/512791; KOBAYASHI S, IN PRESS ASTROPHYS J; Lazzati D, 2002, ASTRON ASTROPHYS, V396, pL5, DOI 10.1051/0004-6361:20021618; Lazzati D, 2001, MON NOT R ASTRON SOC, V325, pL19, DOI 10.1046/j.1365-8711.2001.04735.x; MacFadyen AI, 2001, ASTROPHYS J, V550, P410, DOI 10.1086/319698; MacFadyen AI, 1999, ASTROPHYS J, V524, P262, DOI 10.1086/307790; Meszaros P, 1997, ASTROPHYS J, V476, P232, DOI 10.1086/303625; Perna R, 2002, ASTROPHYS J, V580, P261, DOI 10.1086/343081; Piro L, 2005, ASTROPHYS J, V623, P314, DOI 10.1086/428377; Rees MJ, 1998, ASTROPHYS J, V496, pL1, DOI 10.1086/311244; Stanek KZ, 2003, ASTROPHYS J, V591, pL17, DOI 10.1086/376976; Tagliaferri G, 2005, NATURE, V436, P985, DOI 10.1038/nature03934; van Paradijs J, 2000, ANNU REV ASTRON ASTR, V38, P379, DOI 10.1146/annurev.astro.38.1.379; Watson D. K., UNPUB; Woods E, 1999, ASTROPHYS J, V523, P187, DOI 10.1086/307738; WOOSLEY SE, 1993, ASTROPHYS J, V405, P273, DOI 10.1086/172359; Zhang B, 2002, ASTROPHYS J, V581, P1236, DOI 10.1086/344338; Zhang Y, 2004, J ASIAN NAT PROD RES, V6, P19, DOI 10.1080/1028602031000119772	29	462	474	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 16	2005	309	5742					1833	1835		10.1126/science.1116168	http://dx.doi.org/10.1126/science.1116168			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	965ZN	16109845	Green Submitted			2022-12-28	WOS:000231989500042
J	Taylor, SJC; Candy, B; Bryar, RM; Ramsay, J; Vrijhoef, HJM; Esmond, G; Wedzicha, JA; Griffiths, CJ				Taylor, SJC; Candy, B; Bryar, RM; Ramsay, J; Vrijhoef, HJM; Esmond, G; Wedzicha, JA; Griffiths, CJ			Effectiveness of innovations in nurse led chronic disease management for patients with chronic obstructive pulmonary disease: systematic review of evidence	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED CLINICAL-TRIALS; RESPIRATORY HEALTH WORKER; HOME-CARE; PROGRAM; EFFICACY; QUALITY; COPD	Objective To determine the effectiveness of innovations in management of chronic disease involving nurses for patients with chronic obstructive pulmonary disease (COPD). Design Systematic review of randomised controlled trials. Data sources 24 electronic databases searched for English or Dutch language studies published between January 1980 and January 2005. Review methods Included studies described inpatient, outpatient, and community based interventions for chronic disease management that were led, coordinated, or delivered by nurses. Hospital at home and early discharge schemes for acute exacerbations of COPD were excluded. Results We identified nine relevant randomised controlled trials, most of which had some potential methodological flaws. All the interventions seemed to be variations on a case management model. The interventions described could be divided into brief (one month) and longer term (around a year) or more intensive interventions. Only two studies examined the effect of brief interventions; these found little evidence of any benefit. Meta-analysis of the long term interventions failed to detect any influence on mortality at 9-12 months' follow-up (Peto odds ratio 0.85, 95% confidence interval 0.58 to 1.26). There was evidence that the long term interventions had not improved patients' health related quality of life, psychological wellbeing, disability, or pulmonary function. The evidence on whether long term interventions reduced readmissions to hospital was equivocal, but the only study exclusively directed at patients on long term oxygen therapy reported a reduction in readmission. We identified several outcomes where little or no evidence was available; these included patients' satisfaction, self management skills, adherence with treatment recommendations, the likelihood of smoking cessation, and the effect of the interventions on carers. Conclusion There is little evidence to date to support the widespread implementation of nurse led management interventions for COPD, but the data are too sparse to exclude any clinically relevant benefit or harm arising from such interventions.	Barts & London Queen Marys Sch Med & Dent, Ctr Hlth Sci, London E1 2AT, England; City Univ London, St Bartholomew Sch Nursing & Midwifery, Publ Hlth & Primary Care Unit, London EC1A 7QN, England; Maastricht Univ, Dept Nursing Sci, Fac Hlth Sci, NL-6220 MD Maastricht, Netherlands; City Univ London, St Bartholomew Sch Nursing & Midwifery, Dept Adult Nursing, London E1 2EA, England; St Bartholomews Hosp, Barts & London Queen Marys Sch Med & Dent, Acad Unit Resp Med, London EC1A 7BE, England	University of London; Queen Mary University London; City University London; University of London; Queen Mary University London; Maastricht University; City University London; University of London; Queen Mary University London; University of London; Queen Mary University London	Taylor, SJC (corresponding author), Barts & London Queen Marys Sch Med & Dent, Ctr Hlth Sci, London E1 2AT, England.	s.j.c.taylor@qmul.ac.uk	Vrijhoef, Hubertus/AAR-2387-2020; TAYLOR, STEPHANIE/GYV-4768-2022	Vrijhoef, Hubertus/0000-0002-5539-4671; Taylor, Stephanie/0000-0001-7454-6354				BERGNER M, 1988, MED CARE, V26, P566, DOI 10.1097/00005650-198806000-00005; Bourbeau J, 2003, ARCH INTERN MED, V163, P585, DOI 10.1001/archinte.163.5.585; CANDY B, 2004, EVALUATING EFFECTIVE; Centre for Reviews Disseminations, 2001, 4 CRD; COCKCROFT A, 1987, BRIT MED J, V294, P225, DOI 10.1136/bmj.294.6566.225; DAMIANI M, 2002, MANAGING PRESSURE EM; *DEP HLTH, CHRON DISC MAN SELF; *DEP HLTH, LIB TAL HELP PRIM CA; Department of Health, INV GEN PRACT NEW GE; Department of Health, 2006, SUPP PEOPL LONG TERM; Department of Health, IMPR CHRON DIS MAN; Egan Elizabeth, 2002, Lippincotts Case Manag, V7, P170, DOI 10.1097/00129234-200209000-00002; Elphick HE, 2002, BMJ-BRIT MED J, V325, P381, DOI 10.1136/bmj.325.7360.381; ELPHICK HE, BMJ, V325, P381; Farrero E, 2001, CHEST, V119, P364, DOI 10.1378/chest.119.2.364; Feachem RGA, 2002, BMJ-BRIT MED J, V324, P135, DOI 10.1136/bmj.324.7330.135; HERMIZ O, 2003, BMJ-BRIT MED J, V325, P938; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; KANE RL, EVALUATION EVERCARE; Kara M, 2004, PATIENT EDUC COUNS, V55, P114, DOI 10.1016/j.pec.2003.08.006; Lacasse Y, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003793.pub2; LITTLEJOHNS P, 1991, THORAX, V46, P559, DOI 10.1136/thx.46.8.559; Monninkhof E, 2003, EUR RESPIR J, V22, P815, DOI 10.1183/09031936.03.00047003; Monninkhof E., 2002, COCHRANE DATABASE SY; MURRAY CJL, 2001, 36 GLOB PROGR EV HLT; *NAT HEART LUNG BL, 2003, GLOB STRAT DIAGN MAN; *OXF CTR EV BAS ME, LEV EV GRAD REC; Pauwels R, 2000, CHEST, V117, p332S, DOI 10.1378/chest.117.5_suppl_2.332S; Pearson MG, 1997, THORAX, V52, pS1; Ram FSF, 2004, BMJ-BRIT MED J, V329, P315, DOI 10.1136/bmj.38159.650347.55; Rea H, 2004, INTERN MED J, V34, P608, DOI 10.1111/j.1445-5994.2004.00672.x; *SECR STAT HLTH, 2001, EXP PAT NEW APPR CHR; Smith B., 2001, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD000994; Smith BJ, 1999, AUST NZ J MED, V29, P718, DOI 10.1111/j.1445-5994.1999.tb01621.x; Verhagen AP, 1998, J CLIN EPIDEMIOL, V51, P1235, DOI 10.1016/S0895-4356(98)00131-0; Walters JAE, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001288.pub3; Weingarten SR, 2002, BRIT MED J, V325, P925, DOI 10.1136/bmj.325.7370.925; World Health Organization, WORLD HLTH REP 1998	38	117	120	0	26	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 3	2005	331	7515					485	488		10.1136/bmj.38512.664167.8F	http://dx.doi.org/10.1136/bmj.38512.664167.8F			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	963RA	16093253	Green Published, Bronze			2022-12-28	WOS:000231820400015
J	Mackenzie, AP; Grigera, SA				Mackenzie, AP; Grigera, SA			A quantum critical route to field-induced superconductivity	SCIENCE			English	Editorial Material							FERROMAGNETISM		Univ St Andrews, Sch Phys & Astron, Scottish Univ Phys Alliance, St Andrews KY16 9SS, Fife, Scotland	University of St Andrews	Mackenzie, AP (corresponding author), Univ St Andrews, Sch Phys & Astron, Scottish Univ Phys Alliance, St Andrews KY16 9SS, Fife, Scotland.	apm9@st-and.ac.uk; sag2@st-and.ac.uk	Mackenzie, Andrew P/K-6742-2015; grigera, santiago a/A-4932-2010	Mackenzie, Andrew P/0000-0001-8000-4949; Grigera, Santiago/0000-0002-1343-5885	Engineering and Physical Sciences Research Council [EP/C511778/1] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Aoki D, 2001, NATURE, V413, P613, DOI 10.1038/35098048; Coleman P, 2005, NATURE, V433, P226, DOI 10.1038/nature03279; Grigera SA, 2004, SCIENCE, V306, P1154, DOI 10.1126/science.1104306; Grigera SA, 2001, SCIENCE, V294, P329, DOI 10.1126/science.1063539; Kim KH, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.206402; Levy F, 2005, SCIENCE, V309, P1343, DOI 10.1126/science.1115498; Mathur ND, 1998, NATURE, V394, P39, DOI 10.1038/27838; Saxena SS, 2000, NATURE, V406, P587, DOI 10.1038/35020500; Yuan HQ, 2003, SCIENCE, V302, P2104, DOI 10.1126/science.1091648	9	7	7	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 26	2005	309	5739					1330	1331		10.1126/science.1117436	http://dx.doi.org/10.1126/science.1117436			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TX	16123289				2022-12-28	WOS:000231543300030
J	Lu, R; Maduro, M; Li, F; Li, HW; Broitman-Maduro, G; Li, WX; Ding, SW				Lu, R; Maduro, M; Li, F; Li, HW; Broitman-Maduro, G; Li, WX; Ding, SW			Animal virus replication and RNAi-mediated antiviral silencing in Caenorhabditis elegans	NATURE			English	Article							C-ELEGANS; GENETIC INTERFERENCE; DISTINCT ROLES; SUPPRESSORS; PATHWAYS; PLANTS; INDUCTION; PROTEINS; POTENT	The worm Caenorhabditis elegans is a model system for studying many aspects of biology, including host responses to bacterial pathogens(1,2), but it is not known to support replication of any virus. Plants and insects encode multiple Dicer enzymes that recognize distinct precursors of small RNAs and may act cooperatively(3-7). However, it is not known whether the single Dicer of worms and mammals is able to initiate the small RNA-guided RNA interference (RNAi) antiviral immunity as occurs in plants(8) and insects(9). Here we show complete replication of the Flock house virus (FHV) bipartite, plus-strand RNA genome in C. elegans. We show that FHV replication in C. elegans triggers potent antiviral silencing that requires RDE-1, an Argonaute protein(10,11) essential for RNAi mediated by small interfering RNAs (siRNAs) but not by microRNAs. This immunity system is capable of rapid virus clearance in the absence of FHV B2 protein, which acts as a broad-spectrum RNAi inhibitor(9,12) upstream of rde-1 by targeting the siRNA precursor. This work establishes a C. elegans model for genetic studies of animal virus - host interactions and indicates that mammals might use a siRNA pathway as an antiviral response.	Univ Calif Riverside, Inst Integrat Genome Biol, Riverside, CA 92521 USA; Univ Calif Riverside, Dept Plant Pathol, Riverside, CA 92521 USA; Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA; Univ Calif Riverside, Grad Program Microbiol, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside; University of California System; University of California Riverside; University of California System; University of California Riverside	Ding, SW (corresponding author), Univ Calif Riverside, Inst Integrat Genome Biol, Riverside, CA 92521 USA.	dingsw@ucr.edu	Ding, Shou Wei/AAC-2533-2020	Broitman-Maduro, Gina/0000-0002-8059-8246; Ding, SW/0000-0002-4697-8413	NIAID NIH HHS [R01 AI052447] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052447] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ball LA, 1999, ADV VIRUS RES, V53, P229, DOI 10.1016/S0065-3527(08)60350-4; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; BRENNER S, 1974, GENETICS, V77, P71; Ding SW, 2004, VIRUS RES, V102, P109, DOI 10.1016/j.virusres.2004.01.021; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Grishok A, 2005, GENE DEV, V19, P683, DOI 10.1101/gad.1247705; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Lecellier CH, 2005, SCIENCE, V308, P557, DOI 10.1126/science.1108784; Lee WM, 2003, J VIROL, V77, P12819, DOI 10.1128/JVI.77.23.12819-12828.2003; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Li HW, 2002, SCIENCE, V296, P1319, DOI 10.1126/science.1070948; Li WX, 2004, P NATL ACAD SCI USA, V101, P1350, DOI 10.1073/pnas.0308308100; Li WX, 2001, CURR OPIN BIOTECH, V12, P150, DOI 10.1016/S0958-1669(00)00190-7; Maduro MF, 2001, MOL CELL, V7, P475, DOI 10.1016/S1097-2765(01)00195-2; Mahajan-Miklos S, 1999, CELL, V96, P47, DOI 10.1016/S0092-8674(00)80958-7; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Okamura K, 2004, GENE DEV, V18, P1655, DOI 10.1101/gad.1210204; Pfeffer S, 2004, SCIENCE, V304, P734, DOI 10.1126/science.1096781; Silhavy D, 2004, TRENDS PLANT SCI, V9, P76, DOI 10.1016/j.tplants.2003.12.010; Silhavy D, 2002, EMBO J, V21, P3070, DOI 10.1093/emboj/cdf312; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Tomari Y, 2005, GENE DEV, V19, P517, DOI 10.1101/gad.1284105; Vastenhouw NL, 2004, TRENDS GENET, V20, P314, DOI 10.1016/j.tig.2004.04.011; Voinnet O, 2005, NAT REV GENET, V6, P206, DOI 10.1038/nrg1555; Xie ZX, 2004, PLOS BIOL, V2, P642, DOI 10.1371/journal.pbio.0020104	28	313	325	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 18	2005	436	7053					1040	1043		10.1038/nature03870	http://dx.doi.org/10.1038/nature03870			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955XQ	16107851	Green Submitted, Green Accepted			2022-12-28	WOS:000231263900055
J	Wu, KY; Hengst, U; Cox, LJ; Macosko, EZ; Jeromin, A; Urquhart, ER; Jaffrey, SR				Wu, KY; Hengst, U; Cox, LJ; Macosko, EZ; Jeromin, A; Urquhart, ER; Jaffrey, SR			Local translation of RhoA regulates growth cone collapse	NATURE			English	Article							ACTIN MESSENGER-RNA; PROTEIN-SYNTHESIS; HIPPOCAMPAL-NEURONS; SYMPATHETIC NEURONS; SEMAPHORIN-III; LOCALIZATION; SEQUENCES; TRANSPORT; DEGRADATION; NEUROPILIN	Neuronal development requires highly coordinated regulation of the cytoskeleton within the developing axon. This dynamic regulation manifests itself in axonal branching, turning and pathfinding, presynaptic differentiation, and growth cone collapse and extension. Semaphorin 3A (Sema3A), a secreted guidance cue that primarily functions to repel axons from inappropriate targets, induces cytoskeletal rearrangements that result in growth cone collapse(1). These effects require intra-axonal messenger RNA translation. Here we show that transcripts for RhoA, a small guanosine triphosphatase ( GTPase) that regulates the actin cytoskeleton, are localized to developing axons and growth cones, and this localization is mediated by an axonal targeting element located in the RhoA 30 untranslated region (UTR). Sema3A induces intra-axonal translation of RhoA mRNA, and this local translation of RhoA is necessary and sufficient for Sema3A-mediated growth cone collapse. These studies indicate that local RhoA translation regulates the neuronal cytoskeleton and identify a new mechanism for the regulation of RhoA signalling.	Cornell Univ, Dept Pharmacol, Weill Med Coll, New York, NY 10021 USA; Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA	Cornell University; Baylor College of Medicine	Jaffrey, SR (corresponding author), Cornell Univ, Dept Pharmacol, Weill Med Coll, New York, NY 10021 USA.	srj2003@med.cornell.edu	Macosko, Evan/X-4664-2019; Hengst, Ulrich/L-1413-2014	Hengst, Ulrich/0000-0002-8061-2861; Jaffrey, Samie/0000-0003-3615-6958	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH066204] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS056306] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH066204] Funding Source: Medline; NINDS NIH HHS [R01 NS056306] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aakalu G, 2001, NEURON, V30, P489, DOI 10.1016/S0896-6273(01)00295-1; Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; Bassell GJ, 1998, J NEUROSCI, V18, P251; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Brittis PA, 2002, CELL, V110, P223, DOI 10.1016/S0092-8674(02)00813-9; Campbell DS, 2001, NEURON, V32, P1013, DOI 10.1016/S0896-6273(01)00551-7; Chen L, 2003, NEUROSCIENCE, V120, P1005, DOI 10.1016/S0306-4522(03)00406-8; Dontchev VD, 2002, J NEUROSCI, V22, P6659; Eng H, 1999, J NEUROSCI, V19, P1; Fiore R, 2003, FRONT BIOSCI-LANDMRK, V8, pS484, DOI 10.2741/1080; Gallo G, 2004, J NEUROBIOL, V58, P92, DOI 10.1002/neu.10282; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Jeromin A, 2003, J NEUROPHYSIOL, V90, P2741, DOI 10.1152/jn.00464.2003; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Kanai Y, 2004, NEURON, V43, P513, DOI 10.1016/j.neuron.2004.07.022; KISLAUSKIS EH, 1994, J CELL BIOL, V127, P441, DOI 10.1083/jcb.127.2.441; Kohrmann M, 1999, MOL BIOL CELL, V10, P2945, DOI 10.1091/mbc.10.9.2945; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Krichevsky AM, 2001, NEURON, V32, P683, DOI 10.1016/S0896-6273(01)00508-6; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; OlinkCoux M, 1996, J NEUROSCI, V16, P1346; Raju R, 1999, J VIROL, V73, P2410, DOI 10.1128/JVI.73.3.2410-2419.1999; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Steward O, 2003, NEURON, V40, P347, DOI 10.1016/S0896-6273(03)00635-4; Svenningsen AF, 2003, J NEUROSCI RES, V72, P565, DOI 10.1002/jnr.10610; Svitkin YV, 1998, J VIROL, V72, P5811, DOI 10.1128/JVI.72.7.5811-5819.1998; Tang SJ, 2001, NEURON, V32, P463, DOI 10.1016/S0896-6273(01)00493-7; TENNYSON VM, 1970, J CELL BIOL, V44, P62, DOI 10.1083/jcb.44.1.62; Tietjen I, 2003, NEURON, V38, P161, DOI 10.1016/S0896-6273(03)00229-0; Zheng JQ, 2001, J NEUROSCI, V21, P9291, DOI 10.1523/JNEUROSCI.21-23-09291.2001	30	327	334	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 18	2005	436	7053					1020	1024		10.1038/nature03885	http://dx.doi.org/10.1038/nature03885			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955XQ	16107849	Green Accepted			2022-12-28	WOS:000231263900051
J	Adger, WN; Hughes, TP; Folke, C; Carpenter, SR; Rockstrom, J				Adger, WN; Hughes, TP; Folke, C; Carpenter, SR; Rockstrom, J			Social-ecological resilience to coastal disasters	SCIENCE			English	Article							CLIMATE-CHANGE; VULNERABILITY; HURRICANES; RESISTANCE; CAPACITY	Social and ecological vulnerability to disasters and outcomes of any particular extreme event are influenced by buildup or erosion of resilience both before and after disasters occur. Resilient social-ecological. systems incorporate diverse mechanisms for living with, and learning from, change and unexpected shocks. Disaster management requires multilevel governance systems that can enhance the capacity to cope with uncertainty and surprise by mobilizing diverse sources of resilience.	Univ E Anglia, Sch Environm Sci, Tyndall Ctr Climate Change Res, Norwich NR4 7TJ, Norfolk, England; James Cook Univ N Queensland, Sch Marine Biol & Aquaculture, Ctr Coral Reef Biodivers, Townsville, Qld 4811, Australia; Stockholm Univ, Dept Syst Ecol, SE-10691 Stockholm, Sweden; Stockholm Univ, Ctr Transdisciplinary Environm Res, SE-10691 Stockholm, Sweden; Univ Wisconsin, Ctr Limnol, Madison, WI 53706 USA; Stockholm Environm Inst, SE-10314 Stockholm, Sweden	University of East Anglia; James Cook University; Stockholm University; Stockholm University; University of Wisconsin System; University of Wisconsin Madison; Stockholm Environment Institute	Adger, WN (corresponding author), Univ E Anglia, Sch Environm Sci, Tyndall Ctr Climate Change Res, Norwich NR4 7TJ, Norfolk, England.	n.adger@uea.ac.uk	Carpenter, Stephen/AAQ-6404-2020; Hughes, Terry P/L-4721-2013; Folke, Carl/Z-1545-2019; Adger, Neil/F-7676-2010	Hughes, Terry P/0000-0002-5257-5063; Adger, Neil/0000-0003-4244-2854; Rockstrom, Johan/0000-0001-8988-2983; Folke, Carl/0000-0002-4050-3281	Economic and Social Research Council [M545285002] Funding Source: researchfish	Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))		Adger W. N., 2003, NATURAL DISASTERS DE, P19; ADGER WN, IN PRESS GLOBAL ENV; Allen MR, 2004, NATURE, V432, P551, DOI 10.1038/432551a; Allison EH, 2004, FISH FISH, V5, P215, DOI 10.1111/j.1467-2679.2004.00153.x; [Anonymous], 2001, PANARCHY UNDERSTANDI; Bellwood DR, 2004, NATURE, V429, P827, DOI 10.1038/nature02691; Berkes F., 2003, NAVIGATING SOCIAL EC, V1, P30; Blaikie P., 1994, RISK NATURAL HAZARDS; Brown K, 1997, ENVIRON CONSERV, V24, P316, DOI 10.1017/S0376892997000428; Brown K., 2012, MAKING WAVES INTEGRA; Carpenter S, 2001, ECOSYSTEMS, V4, P765, DOI 10.1007/s10021-001-0045-9; Colding J., 2003, NAVIGATING SOCIAL EC, P163; Colwell RR, 1996, SCIENCE, V274, P2025, DOI 10.1126/science.274.5295.2025; Costanza R, 2000, BIOSCIENCE, V50, P149, DOI 10.1641/0006-3568(2000)050[0149:MOEP]2.3.CO;2; DAGER WN, 2001, LIVING ENV CHANGE SO; Dahdouh-Guebas F, 2005, CURR BIOL, V15, pR443, DOI 10.1016/j.cub.2005.06.008; Diamond J, 1999, GUNS GERMS STEEL; Dietz T, 2003, SCIENCE, V302, P1907, DOI 10.1126/science.1091015; Elmqvist T, 2003, FRONT ECOL ENVIRON, V1, P488, DOI 10.1890/1540-9295(2003)001[0488:RDECAR]2.0.CO;2; Folke C, 2002, AMBIO, V31, P437, DOI 10.1639/0044-7447(2002)031[0437:RASDBA]2.0.CO;2; Folke C, 2004, ANNU REV ECOL EVOL S, V35, P557, DOI 10.1146/annurev.ecolsys.35.021103.105711; FOLKE C, IN PRESS ANN REV ENV; Harvell CD, 1999, SCIENCE, V285, P1505, DOI 10.1126/science.285.5433.1505; Holling C.S., 1973, Annual Rev Ecol Syst, V4, P1, DOI 10.1146/annurev.es.04.110173.000245; Holt-Gimenez E, 2002, AGR ECOSYST ENVIRON, V93, P87, DOI 10.1016/S0167-8809(02)00006-3; Hughes TP, 2005, TRENDS ECOL EVOL, V20, P380, DOI 10.1016/j.tree.2005.03.022; Hughes TP, 2003, SCIENCE, V301, P929, DOI 10.1126/science.1085046; Huq S., 1999, VULNERABILITY ADAPTA; Ives AR, 1999, SCIENCE, V286, P542, DOI 10.1126/science.286.5439.542; Jansen K, 2003, DEV CHANGE, V34, P45, DOI 10.1111/1467-7660.00296; Liu PLF, 2005, SCIENCE, V308, P1595, DOI 10.1126/science.1110730; Lugo AE, 2000, AMBIO, V29, P106, DOI 10.1579/0044-7447-29.2.106; MCCLEAN RF, 2001, CLIMATE CHANGE 2001, P345; MILLER F, 2005, SUSTAINABLE DEV UPDA, V1, P2; Mirza MMQ, 2003, CLIM POLICY, V3, P233, DOI 10.1016/S1469-3062(03)00052-4; Nicholls RJ, 2004, GLOBAL ENVIRON CHANG, V14, P69, DOI 10.1016/j.gloenvcha.2003.10.007; Nystrom M, 2001, ECOSYSTEMS, V4, P406, DOI 10.1007/s10021-001-0019-y; O'Brien K, 2004, GLOBAL ENVIRON CHANG, V14, P303, DOI 10.1016/j.gloenvcha.2004.01.001; OKEEFE P, 1976, NATURE, V260, P566, DOI 10.1038/260566a0; Pielke RA, 2003, NAT HAZARDS REV, V4, P101, DOI 10.1061/(ASCE)1527-6988(2003)4:3(101); Sidle RC, 2004, QUATERN INT, V118, P181, DOI 10.1016/S1040-6182(03)00137-X; Small C, 2003, J COASTAL RES, V19, P584; Tompkins EL, 2004, ECOL SOC, V9; Tompkins EL, 2005, GLOBAL ENVIRON CHANG, V15, P139, DOI 10.1016/j.gloenvcha.2004.11.002; Trenberth K, 2005, SCIENCE, V308, P1753, DOI 10.1126/science.1112551; Turner BL, 2003, P NATL ACAD SCI USA, V100, P8074, DOI 10.1073/pnas.1231335100; WALKER B, 2004, ECOL SOC, V9, pU165	47	1446	1493	30	720	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 12	2005	309	5737					1036	1039		10.1126/science.1112122	http://dx.doi.org/10.1126/science.1112122			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	955MN	16099974				2022-12-28	WOS:000231230100034
J	Bader, MW; Sanowar, S; Daley, ME; Schneider, AR; Cho, US; Xu, WQ; Klevit, RE; Le Moual, H; Miller, S				Bader, MW; Sanowar, S; Daley, ME; Schneider, AR; Cho, US; Xu, WQ; Klevit, RE; Le Moual, H; Miller, S			Recognition of antimicrobial peptides by a bacterial sensor kinase	CELL			English	Article							2-COMPONENT REGULATORY SYSTEM; SALMONELLA-TYPHIMURIUM; LIPID-A; OUTER-MEMBRANE; VIRULENCE GENE; PMRA-PMRB; LOW PH; PROTEIN; RESISTANCE; SIGNAL	PhoQ is a membrane bound sensor kinase important for the pathogenesis of a number of Gram-negative bacterial species. PhoQ and its cognate response regulator PhoP constitute a signal-transduction cascade that controls inducible resistance to host antimicrobial peptides. We show that enzymatic activity of Salmonella typhimurium PhoQ is directly activated by antimicrobial peptides. A highly acidic surface of the PhoQ sensor domain participates in both divalentcation and antimicrobial-peptide binding as a first step in signal transduction across the bacterial membrane. Identification of PhoQ signaling mutants, binding studies with the PhoQ sensor domain, and structural analysis of this domain can be incorporated into a model in which antimicrobial peptides displace divalent cations from PhoQ metal binding sites to initiate signal transduction. Our findings reveal a molecular mechanism by which bacteria sense small innate immune molecules to initiate a transcriptional program that promotes bacterial virulence.	Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Genome Sci, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biol Struct, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada; McGill Univ, Fac Dent, Montreal, PQ H3A 2B4, Canada	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; McGill University; McGill University	Miller, S (corresponding author), Univ Washington, Sch Med, Dept Microbiol, 1959 NE Pacific St, Seattle, WA 98195 USA.	millersi@u.washington.edu	Klevit, Rachel/AAI-7038-2021	Klevit, Rachel/0000-0002-3476-969X; Xu, Wenqing/0000-0002-2884-3101; cho, uhn-soo/0000-0002-6992-2455	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030479] Funding Source: NIH RePORTER; NIAID NIH HHS [AI030479] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARANDA CMA, 1992, P NATL ACAD SCI USA, V89, P10079, DOI 10.1073/pnas.89.21.10079; ARTHUR M, 1992, J BACTERIOL, V174, P2582, DOI 10.1128/jb.174.8.2582-2591.1992; Bader MW, 2003, MOL MICROBIOL, V50, P219, DOI 10.1046/j.1365-2958.2003.03675.x; Bearson BL, 1998, J BACTERIOL, V180, P2409, DOI 10.1128/JB.180.9.2409-2417.1998; Castelli ME, 2000, J BIOL CHEM, V275, P22948, DOI 10.1074/jbc.M909335199; Christensen KA, 2002, J CELL SCI, V115, P599; Dathe M, 1999, BBA-BIOMEMBRANES, V1462, P71, DOI 10.1016/S0005-2736(99)00201-1; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Derzelle S, 2004, J BACTERIOL, V186, P1270, DOI 10.1128/JB.186.5.1270-1279.2004; Ernst RK, 1999, SCIENCE, V286, P1561, DOI 10.1126/science.286.5444.1561; FIELDS PI, 1989, SCIENCE, V243, P1059, DOI 10.1126/science.2646710; GALAN JE, 1989, MICROB PATHOGENESIS, V6, P433, DOI 10.1016/0882-4010(89)90085-5; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; GARCIADELPORTILLO F, 1992, MOL MICROBIOL, V6, P3289, DOI 10.1111/j.1365-2958.1992.tb02197.x; Georgellis D, 2001, SCIENCE, V292, P2314, DOI 10.1126/science.1059361; Gibbons HS, 2005, MOL MICROBIOL, V55, P425, DOI 10.1111/j.1365-2958.2004.04409.x; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; Grabenstein JP, 2004, INFECT IMMUN, V72, P4973, DOI 10.1128/IAI.72.9.4973-4984.2004; GROISMAN EA, 1989, P NATL ACAD SCI USA, V86, P7077, DOI 10.1073/pnas.86.18.7077; Gunn JS, 2000, INFECT IMMUN, V68, P6139, DOI 10.1128/IAI.68.11.6139-6146.2000; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; Hancock REW, 2000, TRENDS MICROBIOL, V8, P402, DOI 10.1016/S0966-842X(00)01823-0; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Hohmann EL, 1996, J INFECT DIS, V173, P1408, DOI 10.1093/infdis/173.6.1408; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kaspar S, 1999, MOL MICROBIOL, V33, P858, DOI 10.1046/j.1365-2958.1999.01536.x; Lee YW, 1995, P NATL ACAD SCI USA, V92, P12245, DOI 10.1073/pnas.92.26.12245; Lesley JA, 2001, J BIOL CHEM, V276, P30827, DOI 10.1074/jbc.M104262200; Llama-Palacios A, 2003, MOL MICROBIOL, V49, P347, DOI 10.1046/j.1365-2958.2003.03583.x; MAGNUSON R, 1994, CELL, V77, P207, DOI 10.1016/0092-8674(94)90313-1; McPhee JB, 2003, MOL MICROBIOL, V50, P205, DOI 10.1046/j.1365-2958.2003.03673.x; MEKALANOS JJ, 1992, J BACTERIOL, V174, P1; Miller MB, 2001, ANNU REV MICROBIOL, V55, P165, DOI 10.1146/annurev.micro.55.1.165; Miller SI, 2005, NAT REV MICROBIOL, V3, P36, DOI 10.1038/nrmicro1068; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; Montagne M, 2001, J BACTERIOL, V183, P1787, DOI 10.1128/JB.183.5.1787-1791.2001; Moss JE, 2000, CELL MICROBIOL, V2, P443, DOI 10.1046/j.1462-5822.2000.00065.x; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; PAPPENHEIMER AM, 1993, PROTEIN SCI, V2, P292; Peschel A, 2002, TRENDS MICROBIOL, V10, P179, DOI 10.1016/S0966-842X(02)02333-8; PIERS KL, 1994, MOL MICROBIOL, V12, P951, DOI 10.1111/j.1365-2958.1994.tb01083.x; POLLACK C, 1986, NATURE, V322, P834, DOI 10.1038/322834a0; Preston A, 2003, MOL MICROBIOL, V48, P725, DOI 10.1046/j.1365-2958.2003.03484.x; Rebeil R, 2004, MOL MICROBIOL, V52, P1363, DOI 10.1111/j.1365-2958.2004.04059.x; Robey M, 2001, INFECT IMMUN, V69, P4276, DOI 10.1128/IAI.69.7.4276-4286.2001; Rosenberger CM, 2004, P NATL ACAD SCI USA, V101, P2422, DOI 10.1073/pnas.0304455101; Salzman NH, 2003, NATURE, V422, P522, DOI 10.1038/nature01520; SAWYER JG, 1988, INFECT IMMUN, V56, P693, DOI 10.1128/IAI.56.3.693-698.1988; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; Waldburger CD, 1996, J BIOL CHEM, V271, P26630, DOI 10.1074/jbc.271.43.26630	51	414	432	8	61	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 12	2005	122	3					461	472		10.1016/j.cell.2005.05.030	http://dx.doi.org/10.1016/j.cell.2005.05.030			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	955UZ	16096064	Bronze			2022-12-28	WOS:000231254400016
J	Ding, S; Wu, XH; Li, G; Han, M; Zhuang, Y; Xu, T				Ding, S; Wu, XH; Li, G; Han, M; Zhuang, Y; Xu, T			Efficient transposition of the piggyBac resource (PB) transposon in mammalian cells and mice	CELL			English	Article							EMBRYONIC STEM-CELLS; MOUSE GERM-LINE; SLEEPING-BEAUTY; CHROMOSOMAL TRANSPOSITION; INSERTIONAL MUTAGENESIS; GENETIC-TRANSFORMATION; FUNCTIONAL-ANALYSIS; BACULOVIRUS GENOME; DROSOPHILA; VECTOR	Transposable elements have been routinely used for genetic manipulation in lower organisms, including generating transgenic animals and insertional mutagenesis. In contrast, the usage of transposons in mice and other vertebrate systems is still limited due to the lack of an efficient transposition system. We have tested the ability of piggyBac (PB), a DNA transposon from the cabbage looper moth Trichoplusia ni, to transpose in mammalian systems. We show that PB elements carrying multiple genes can efficiently transpose in human and mouse cell lines and also in mice. PB permits the expression of the marker genes it carried. During germline transposition, PB could excise precisely from original insertion sites and transpose into the mouse genome at diverse locations, preferably transcription units. These data provide a first and critical step toward a highly efficient transposon system for a variety of genetic manipulations including transgenesis and insertional mutagenesis in mice and other vertebrates.	Fudan Univ, Sch Life Sci, Inst Dev Biol & Mol Med, Shanghai 200433, Peoples R China; Univ Colorado, Dept MCDB, Howard Hughes Med Inst, Boulder, CO 80309 USA; Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Genet,Howard Hugh Med Inst, New Haven, CT 06536 USA	Fudan University; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; Duke University; Yale University	Wu, XH (corresponding author), Fudan Univ, Sch Life Sci, Inst Dev Biol & Mol Med, 220 Handan Rd, Shanghai 200433, Peoples R China.	xiaohui_wu@fudan.edu.cn; tian.xu@yale.edu	Li, Gang/H-5714-2015; Wilson, Matthew H/K-3193-2013	zhuang, yuan/0000-0002-2964-3654				Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; CARY LC, 1989, VIROLOGY, V172, P156, DOI 10.1016/0042-6822(89)90117-7; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; Drabek D, 2003, GENOMICS, V81, P108, DOI 10.1016/S0888-7543(02)00030-7; Dupuy AJ, 2001, GENESIS, V30, P82, DOI 10.1002/gene.1037; Fischer SEJ, 2001, P NATL ACAD SCI USA, V98, P6759, DOI 10.1073/pnas.121569298; FRASER MJ, 1995, VIROLOGY, V211, P397, DOI 10.1006/viro.1995.1422; Fraser MJ, 1996, INSECT MOL BIOL, V5, P141, DOI 10.1111/j.1365-2583.1996.tb00048.x; Gonzalez-Estevez C, 2003, P NATL ACAD SCI USA, V100, P14046, DOI 10.1073/pnas.2335980100; Handler AM, 2002, INSECT BIOCHEM MOLEC, V32, P1211, DOI 10.1016/S0965-1748(02)00084-X; HANDLER AM, 1993, ARCH INSECT BIOCHEM, V22, P373, DOI 10.1002/arch.940220306; Handler AM, 2001, INSECT BIOCHEM MOLEC, V31, P199, DOI 10.1016/S0965-1748(00)00119-3; Herron BJ, 2002, NAT GENET, V30, P185, DOI 10.1038/ng812; Horie K, 2003, MOL CELL BIOL, V23, P9189, DOI 10.1128/MCB.23.24.9189-9207.2003; Horie K, 2001, P NATL ACAD SCI USA, V98, P9191, DOI 10.1073/pnas.161071798; Horn C, 2003, GENETICS, V163, P647; Horn C, 2000, DEV GENES EVOL, V210, P630, DOI 10.1007/s004270000110; Hutchison CA, 1999, SCIENCE, V286, P2165, DOI 10.1126/science.286.5447.2165; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5; Izsvak Z, 2000, J MOL BIOL, V302, P93, DOI 10.1006/jmbi.2000.4047; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li X, 2005, INSECT MOL BIOL, V14, P17, DOI 10.1111/j.1365-2583.2004.00525.x; Lorenzen MD, 2003, INSECT MOL BIOL, V12, P433, DOI 10.1046/j.1365-2583.2003.00427.x; Luo GB, 1998, P NATL ACAD SCI USA, V95, P10769, DOI 10.1073/pnas.95.18.10769; MCCLINTOCK B, 1950, P NATL ACAD SCI USA, V36, P344, DOI 10.1073/pnas.36.6.344; Nagy A., 2003, MANIPULATING MOUSE E; Nguyen QT, 1998, SCIENCE, V279, P1725, DOI 10.1126/science.279.5357.1725; O'Gorman S, 1997, P NATL ACAD SCI USA, V94, P14602, DOI 10.1073/pnas.94.26.14602; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Robertson Hugh M., 2002, P1093; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; Sarkar A, 2003, MOL GENET GENOMICS, V270, P173, DOI 10.1007/s00438-003-0909-0; Sumitani M, 2003, INSECT BIOCHEM MOLEC, V33, P449, DOI 10.1016/S0965-1748(03)00009-2; Thibault ST, 2004, NAT GENET, V36, P283, DOI 10.1038/ng1314; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Vilen H, 2003, J VIROL, V77, P123, DOI 10.1128/JVI.77.1.123-134.2003; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Zagoraiou L, 2001, P NATL ACAD SCI USA, V98, P11474, DOI 10.1073/pnas.201392398	41	663	760	14	66	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 12	2005	122	3					473	483		10.1016/j.cell.2005.07.013	http://dx.doi.org/10.1016/j.cell.2005.07.013			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	955UZ	16096065	Bronze			2022-12-28	WOS:000231254400017
J	Nguyen, TH				Nguyen, TH			Microchallenges of chemical weapons proliferation	SCIENCE			English	Editorial Material									Lawrence Livermore Natl Lab, Ctr Global Secur Res & Chem & Mat Sci, Livermore, CA 94551 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Nguyen, TH (corresponding author), Lawrence Livermore Natl Lab, Ctr Global Secur Res & Chem & Mat Sci, Livermore, CA 94551 USA.	thnguyen@llnl.gov						Becker ED, 2002, PURE APPL CHEM, V74, pIV; HIEBERT M, 2002, FAR E EC REV     AUG, P13; Jahnisch K, 2004, ANGEW CHEM INT EDIT, V43, P406, DOI 10.1002/anie.200300577; Jensen KF, 2001, CHEM ENG SCI, V56, P293, DOI 10.1016/S0009-2509(00)00230-X; MOODIE M, 2001, BWC PROTOCOL CRITIQU, P17; *ORG PROH CHEM WEA, 2003, RC1DG2 ORG PROH CHEM; Parshall GW, 2002, PURE APPL CHEM, V74, P2259, DOI 10.1351/pac200274122259; Thayer AM, 2005, CHEM ENG NEWS, V83, P43, DOI 10.1021/cen-v083n022.p043; Zhang XN, 2004, ORG PROCESS RES DEV, V8, P455, DOI 10.1021/op034193x; 2002, IUPAC WORKSH IMP SCI	10	5	5	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 12	2005	309	5737					1021	1021		10.1126/science.1112445	http://dx.doi.org/10.1126/science.1112445			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955MN	16099966				2022-12-28	WOS:000231230100026
J	Black, DM; Bilezikian, JP; Ensrud, KE; Greenspan, SL; Palermo, L; Hue, T; Lang, TF; McGowan, JA; Rosen, CJ				Black, DM; Bilezikian, JP; Ensrud, KE; Greenspan, SL; Palermo, L; Hue, T; Lang, TF; McGowan, JA; Rosen, CJ		PaTH Study Investigators	One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MINERAL DENSITY; VERTEBRAL FRACTURES; POSTMENOPAUSAL WOMEN; RISK; MASS; TERIPARATIDE; TRIAL; REDUCTION; STRENGTH; THERAPY	BACKGROUND: Since the use of parathyroid hormone as a treatment for osteoporosis is limited to two years or less, the question of whether antiresorptive therapy should follow parathyroid hormone therapy is important. We previously reported results after the first year of this randomized trial comparing the use of full-length parathyroid hormone (1-84) alone, alendronate alone, or both combined. In the continuation of this trial, we asked whether antiresorptive therapy is required to maintain gains in bone mineral density after one year of therapy with parathyroid hormone (1-84). METHODS: In the data reported here, women who had received parathyroid hormone (1-84) monotherapy (100 microg daily) in year 1 were randomly reassigned to one additional year with either placebo (60 subjects) or alendronate (59 subjects). Subjects who had received combination therapy in year 1 received alendronate in year 2; those who had received alendronate monotherapy in year 1 continued with alendronate in year 2. Bone mineral density at the spine and hip was assessed with the use of dual-energy x-ray absorptiometry and quantitative computed tomography (CT). RESULTS: Over two years, alendronate therapy after parathyroid hormone therapy led to significant increases in bone mineral density in comparison with the results for placebo after parathyroid hormone therapy, a difference particularly evident for bone mineral density in trabecular bone at the spine on quantitative CT (an increase of 31 percent in the parathyroid hormone-alendronate group as compared with 14 percent in the parathyroid hormone-placebo group). During year 2, subjects receiving placebo lost substantial bone mineral density. CONCLUSIONS: After one year of parathyroid hormone (1-84), densitometric gains appear to be maintained or increased with alendronate but lost if parathyroid hormone is not followed by an antiresorptive agent. These results have clinical implications for therapeutic choices after the discontinuation of parathyroid hormone.	Univ Calif San Francisco, San Francisco Coordinating Ctr, Dept Epidemiol, San Francisco, CA 94105 USA; Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94105 USA; Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94105 USA; Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY USA; Minneapolis Vet Affairs Med Ctr, Dept Med, Minneapolis, MN USA; Minneapolis Vet Affairs Med Ctr, Dept Epidemiol, Minneapolis, MN USA; Univ Minnesota, Minneapolis, MN USA; Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA; NIAMSD, NIH, Bethesda, MD 20892 USA; St Joseph Hosp, Maine Ctr Osteoporosis Res, Bangor, ME USA	California Pacific Medical Center; California Pacific Medical Center Research Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Columbia University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Black, DM (corresponding author), Univ Calif San Francisco, San Francisco Coordinating Ctr, Dept Epidemiol, 74 New Montgomery St,Suite 600, San Francisco, CA 94105 USA.	dblack@psg.ucsf.edu	Lang, Thomas F/B-2685-2012	Lang, Thomas F/0000-0002-3720-8038; Ensrud, Kristine/0000-0002-9069-3036	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000056] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR000056] Funding Source: Medline; NIAMS NIH HHS [N01-AR-9-2245] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Crawford RP, 2003, BONE, V33, P744, DOI 10.1016/S8756-3282(03)00210-2; Cummings SR, 2002, AM J MED, V112, P281, DOI 10.1016/S0002-9343(01)01124-X; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117; Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725; Hochberg MC, 1999, ARTHRITIS RHEUM-US, V42, P1246, DOI 10.1002/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U; Kurland ES, 2004, OSTEOPOROSIS INT, V15, P992, DOI 10.1007/s00198-004-1636-z; Lane NE, 1998, J CLIN INVEST, V102, P1627, DOI 10.1172/JCI3914; Lang TF, 1999, J COMPUT ASSIST TOMO, V23, P130, DOI 10.1097/00004728-199901000-00027; Lindsay R, 2004, ARCH INTERN MED, V164, P2024, DOI 10.1001/archinte.164.18.2024; Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140-6736(97)02342-8; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; Rittmaster RS, 2000, J CLIN ENDOCR METAB, V85, P2129, DOI 10.1210/jc.85.6.2129; Samnegard E, 2001, BONE, V28, P414, DOI 10.1016/S8756-3282(01)00408-2	16	437	458	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 11	2005	353	6					555	565		10.1056/NEJMoa050336	http://dx.doi.org/10.1056/NEJMoa050336			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	953ST	16093464	Bronze			2022-12-28	WOS:000231101500006
J	Dumler, JS; Walker, DH				Dumler, JS; Walker, DH			Rocky mountain spotted-fever - Changing ecology and persisting virulence	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Johns Hopkins Univ, Sch Med, Dept Pathol, Div Med Microbiol, Baltimore, MD 21205 USA; Univ Texas, Med Branch, Dept Pathol, Galveston, TX 77550 USA	Johns Hopkins University; University of Texas System; University of Texas Medical Branch Galveston	Dumler, JS (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Div Med Microbiol, Baltimore, MD 21205 USA.								0	51	57	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 11	2005	353	6					551	553		10.1056/NEJMp058138	http://dx.doi.org/10.1056/NEJMp058138			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	953ST	16093463				2022-12-28	WOS:000231101500005
J	Nelson, LJ; Talbot, EA; Mwasekaga, MJ; Ngirubiu, PK; Mwansa, RA; Notha, M; Wells, CD				Nelson, LJ; Talbot, EA; Mwasekaga, MJ; Ngirubiu, PK; Mwansa, RA; Notha, M; Wells, CD			Antituberculosis drug resistance and anonymous HIV surveillance in tuberculosis patients in Botswana, 2002	LANCET			English	Article								Two surveys undertaken in Botswana in the 1990s have recorded low rates of antituberculosis drug resistance, despite a three-fold rise in tuberculosis since 1989. We under-took a third survey to determine both trends since 1995 and HIV prevalence in tuberculosis patients in Botswana. Sputum specimens were obtained from patients nationwide in 2002 who also underwent anonymous, rapid HIV testing by use of Oraquick. Of 2200 sputum smear-positive patients and 219 previously treated patients with suspected recurrent tuberculosis, 1457 (60%) were infected with HIV. Resistance to at least one drug in new patients rose from 16 (3.7%) isolates in 1995 to 123 (10.4%; p<0.0001) in 2002. interventions for tuberculosis control are urgently needed in Botswana to prevent further emergence of drug resistance.	BOTUSA Project, Gaborone, Botswana; Natl TB Reference Lab, Gaborone, Botswana; Minist Hlth, Botswana Natl TB Programme, Epidemiol Unit, Gaborone, Botswana		Nelson, LJ (corresponding author), CDC, Div TB Eliminat, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA.	LBN9@CDC.G0V						Kenyon TA, 1999, INT J TUBERC LUNG D, V3, P4; Sonnenberg P, 2001, LANCET, V358, P1687, DOI 10.1016/S0140-6736(01)06712-5; Talbot EA, 2004, CLIN INFECT DIS, V39, pE1, DOI 10.1086/421388; Talbot EA, 2003, INT J TUBERC LUNG D, V7, P710; Talbot EA, 2003, INT J TUBERC LUNG D, V7, P72; *WHO, 1996, WHOTB96216; World Health Organization, 2004, GUID HIV SURV TUB PA	7	34	38	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 6	2005	366	9484					488	490		10.1016/S0140-6736(05)67062-6	http://dx.doi.org/10.1016/S0140-6736(05)67062-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	952RD	16084258				2022-12-28	WOS:000231022300031
J	Brown, GK; Ten Have, T; Henriques, GR; Xie, SX; Hollander, JE; Beck, AT				Brown, GK; Ten Have, T; Henriques, GR; Xie, SX; Hollander, JE; Beck, AT			Cognitive therapy for the prevention of suicide attempts - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY-CARE; PSYCHIATRIC OUTPATIENTS; REGRESSION MODELS; RATING-SCALE; DEPRESSION; INTERVENTION; DISORDERS; HOPELESSNESS; SENSITIVITY; MANAGEMENT	Context Suicide attempts constitute a major risk factor for completed suicide, yet few interventions specifically designed to prevent suicide attempts have been evaluated. Objective To determine the effectiveness of a 10-session cognitive therapy intervention designed to prevent repeat suicide attempts in adults who recently attempted suicide. Design, Setting, and Participants Randomized controlled trial of adults (N=120) who attempted suicide and were evaluated at a hospital emergency department within 48 hours of the attempt. Potential participants (N = 350) were consecutively recruited from October 1999 to September 2002; 66 refused to participate and 164 were ineligible. Participants were followed up for 18 months. Intervention Cognitive therapy or enhanced usual care with, tracking and referral services. Main Outcome Measures Incidence of repeat suicide attempts and number of days until a repeat suicide attempt. Suicide ideation (dichotomized), hopelessness, and depression severity at 1, 3, 6, 12, and 18 months. Results From baseline to the 18-month assessment, 13 participants (24.1%) in the cognitive therapy group and 23 participants (41.6%) in the usual care group made at least1 subsequent suicide attempt (asymptotic z score, 1.97; P=.049). Using the Kaplan-Meier method, the estimated 18-month reattempt-free probability in the cognitive therapy group was 0.76 (95% confidence interval [CI], 0.62-0.85) and in the usual care group was 0.58 (95% Cl, 0.44-0.70). Participants in the cognitive therapy group had a significantly lower reattempt rate (Wald chi(2)(1)=3.9; P=.049) and were 50% less likely to reattempt suicide than participants in the usual care group (hazard ratio, 0.51; 95% Cl, 0.26-0.997). The severity of self-reported depression was significantly lower for the cognitive therapy group than for the usual care group at 6 months (P=.02),12 months(P=.009), and 18 months (P=.046). The cognitive therapy group reported significantly less hopelessness than the usual care group at 6 months (P=.045). There were no significant differences between groups based on rates of suicide ideation at any assessment point. Conclusion Cognitive therapy was effective in preventing suicide attempts for adults who recently attempted suicide.	Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA; Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA; Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; James Madison Univ, Dept Grad Psychol, Harrisonburg, VA 22807 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; James Madison University	Brown, GK (corresponding author), Univ Penn, Dept Psychiat, 3535 Market St,Room 2030, Philadelphia, PA 19104 USA.	gregbrow@mail.med.upenn.edu	Ulatan, Jeffrey/AAM-5560-2020	Ulatan, Jeffrey/0000-0002-3756-0568; Hollander, Judd/0000-0002-1318-2785	NIMH NIH HHS [R01 MH60915, R01 MH067805, P20 MH71905, P20 MH071905] Funding Source: Medline; ODCDC CDC HHS [R37 CCR316866] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P20MH071905, R01MH067805, R01MH060915] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); ODCDC CDC HHS; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Beck Aaron T., 1988, MANUAL BECK HOPELESS; Beck AT, 1997, BEHAV RES THER, V35, P1039, DOI 10.1016/S0005-7967(97)00073-9; BECK AT, 1975, JAMA-J AM MED ASSOC, V234, P1146, DOI 10.1001/jama.234.11.1146; Beck AT, 1996, PSYCHOL ASSESS; BECK AT, IN PRESS ARCH GEN PS; BECK RW, 1974, PSYCHOL REP, V34, P445, DOI 10.2466/pr0.1974.34.2.445; Berk MS, 2004, COGN BEHAV PRACT, V11, P265, DOI 10.1016/S1077-7229(04)80041-5; Brown GK, 2000, J CONSULT CLIN PSYCH, V68, P371, DOI 10.1037/0022-006X.68.3.371; Brown GK, 2002, COGNITIVE THERAPY TR; Bruce ML, 2004, JAMA-J AM MED ASSOC, V291, P1081, DOI 10.1001/jama.291.9.1081; [Centers for Disease Control and Prevention National Center for Injury Prevention and Control], WEBB INJ STAT QUER R; COX DR, 1972, J R STAT SOC B, V34, P187; Dahlsgaard KK, 1998, SUICIDE LIFE-THREAT, V28, P197; EDWARDS BC, 1984, BRIT J CLIN PSYCHOL, V23, P93, DOI 10.1111/j.2044-8260.1984.tb00632.x; FAWCETT J, 1990, AM J PSYCHIAT, V147, P1189; GOLDSTEIN RB, 1991, ARCH GEN PSYCHIAT, V48, P418; Guthrie E, 2001, BRIT MED J, V323, P135, DOI 10.1136/bmj.323.7305.135; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Harris EC, 1997, BRIT J PSYCHIAT, V170, P205, DOI 10.1192/bjp.170.3.205; HAWTON K, 2005, COCHRANE DATABASE SY; Henriques G, 2003, AM BEHAV SCI, V46, P1258, DOI 10.1177/0002764202250668; Hogan JW, 1996, BIOMETRICS, V52, P1002, DOI 10.2307/2533061; Hollander JE, 2002, ACAD EMERG MED, V9, P134, DOI 10.1111/j.1553-2712.2002.tb00230.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MCLEAVEY BC, 1994, SUICIDE LIFE-THREAT, V24, P382; Miliken G., 1984, ANAL MESSY DATA, VI; NORDSTROM P, 1995, ACTA PSYCHIAT SCAND, V92, P345, DOI 10.1111/j.1600-0447.1995.tb09595.x; OCarroll PW, 1996, SUICIDE LIFE-THREAT, V26, P237; Rudd M.D., 2001, TREATING SUICIDAL BE; SALKOVSKIS PM, 1990, BRIT J PSYCHIAT, V157, P871, DOI 10.1192/bjp.157.6.871; SCHOENFELD DA, 1983, BIOMETRICS, V39, P499, DOI 10.2307/2531021; SOSDJAN D, 2002, STUDY CASE MANAGEMEN; Spitzer RL, 1995, STRUCTURED CLIN INTE; Ten Have TR, 1998, BIOMETRICS, V54, P367; TERMANSEN PE, 1975, CAN PSYCHIAT ASSOC J, V20, P29, DOI 10.1177/070674377502000106; Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836; US Public Health Service, 2001, NAT STRAT SUIC PREV; VANHEERINGEN C, 1995, PSYCHOL MED, V25, P963, DOI 10.1017/S0033291700037454; Wells KB, 2000, JAMA-J AM MED ASSOC, V283, P212, DOI 10.1001/jama.283.2.212; WELU TC, 1977, SUICIDE LIFE-THREAT, V7, P17; Winer BJ., 1970, STAT PRINCIPLES EXPT, V2nd; YOUNG JE, 1980, MANUAL COGNITIVE THE; Young MA, 1996, J ABNORM PSYCHOL, V105, P155, DOI 10.1037/0021-843X.105.2.155	43	630	647	5	72	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	2005	294	5					563	570		10.1001/jama.294.5.563	http://dx.doi.org/10.1001/jama.294.5.563			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	951NN	16077050				2022-12-28	WOS:000230937500016
J	Vandenbroucke, JP				Vandenbroucke, JP			Homoeopathy and "the growth of truth"	LANCET			English	Editorial Material							PHARMACEUTICAL-INDUSTRY; MEDICINE; TRIALS		Leiden Univ, Med Ctr, Dept Clin Epidemiol, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Vandenbroucke, JP (corresponding author), Leiden Univ, Med Ctr, Dept Clin Epidemiol, NL-2300 RC Leiden, Netherlands.	j.p.vandenbroucke@lumc.nl	Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				[Anonymous], BR FOREIGN MED REV; Gould SJ, 2000, SCIENCE, V287, P253, DOI 10.1126/science.287.5451.253; Haack S., 1998, MANIFESTO PASSIONATE; Lexchin J, 2003, BMJ-BRIT MED J, V326, P1167, DOI 10.1136/bmj.326.7400.1167; Melander H, 2003, BMJ-BRIT MED J, V326, P1171, DOI 10.1136/bmj.326.7400.1171; Osler W, 1906, Br Med J, V2, P1077; Shang AJ, 2005, LANCET, V366, P726, DOI 10.1016/S0140-6736(05)67177-2; Topol EJ, 2005, JAMA-J AM MED ASSOC, V293, P366, DOI 10.1001/jama.293.3.366; Vandenbroucke JP, 1998, LANCET, V352, P2001, DOI 10.1016/S0140-6736(98)10208-8; Vandenbroucke JP, 1997, LANCET, V350, P824, DOI 10.1016/S0140-6736(97)22038-6; Vandenbroucke JP, 2001, ANN INTERN MED, V135, P507, DOI 10.7326/0003-4819-135-7-200110020-00010; Walton D, 1999, ONE SIDED ARGUMENTS	12	27	28	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 27	2005	366	9487					691	692		10.1016/S0140-6736(05)67151-6	http://dx.doi.org/10.1016/S0140-6736(05)67151-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958UV	16125568				2022-12-28	WOS:000231474600004
J	Schubeler, D; Turner, BM				Schubeler, D; Turner, BM			A new map for navigating the yeast epigenome	CELL			English	Editorial Material							GENOME-WIDE; HISTONE MODIFICATIONS	The posttranslational modification of histones by acetylation or methylation regulates chromatin structure and can determine how a DNA sequence is interpreted by, for example, the transcriptional machinery. In this issue of Cell, Pokholok and colleagues (2005) describe a new and reliable genome-wide microarray study of histone modifications and gene expression in yeast. Their epigenetic map can be used to guide further research on the epigenome.	Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; Univ Birmingham, Sch Med, Biomed Res Inst, Birmingham B15 2TT, W Midlands, England	Friedrich Miescher Institute for Biomedical Research; University of Birmingham	Schubeler, D (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.							Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Dion MF, 2005, P NATL ACAD SCI USA, V102, P5501, DOI 10.1073/pnas.0500136102; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; Lee CK, 2004, NAT GENET, V36, P900, DOI 10.1038/ng1400; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026; Reinke H, 2003, MOL CELL, V11, P1599, DOI 10.1016/S1097-2765(03)00186-2; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; van Leeuwen F, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-6-113; Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036	10	7	9	1	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 26	2005	122	4					489	492		10.1016/j.cell.2005.08.007	http://dx.doi.org/10.1016/j.cell.2005.08.007			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	959YI	16122415	Bronze			2022-12-28	WOS:000231555100002
J	Braun, S; Vogl, FD; Naume, B; Janni, W; Osborne, MP; Coombes, RC; Schlimok, G; Diel, IJ; Gerber, B; Gebauer, G; Pierga, JY; Marth, C; Oruzio, D; Wiedswang, G; Solomayer, EF; Kundt, G; Strobl, B; Fehm, T; Wong, GYC; Bliss, J; Vincent-Salomon, A; Pantel, K				Braun, S; Vogl, FD; Naume, B; Janni, W; Osborne, MP; Coombes, RC; Schlimok, G; Diel, IJ; Gerber, B; Gebauer, G; Pierga, JY; Marth, C; Oruzio, D; Wiedswang, G; Solomayer, EF; Kundt, G; Strobl, B; Fehm, T; Wong, GYC; Bliss, J; Vincent-Salomon, A; Pantel, K			A pooled analysis of bone marrow micrometastasis in breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DISSEMINATED TUMOR-CELLS; IMMUNOCYTOCHEMICAL DETECTION; EPITHELIAL-CELLS; PRIMARY SURGERY; LYMPH-NODES; METAANALYSIS; SURVIVAL; RELAPSE; TRIALS; TIME	Background: We assessed the prognostic significance of the presence of micrometastasis in the bone marrow at the time of diagnosis of breast cancer by means of a pooled analysis. Methods: We combined individual patient data from nine studies involving 4703 patients with stage I, II, or III breast cancer. We evaluated patient outcomes over a 10-year follow-up period (median, 5.2 years), using a multivariable piecewise Cox regression model. Results: Micrometastasis was detected in 30.6 percent of the patients. As compared with women without bone marrow micrometastasis, patients with bone marrow micrometastasis had larger tumors and tumors with a higher histologic grade and more often had lymph-node metastases and hormone receptor-negative tumors (P<0.001 for all variables). The presence of micrometastasis was a significant prognostic factor with respect to poor overall survival and breast-cancer-specific survival (univariate mortality ratios, 2.15 and 2.44, respectively; P<0.001 for both outcomes) and poor disease-free survival and distant-disease-free survival during the 10-year observation period (incidence-rate ratios, 2.13 and 2.33, respectively; P<0.001 for both outcomes). In the multivariable analysis, micrometastasis was an independent predictor of a poor outcome. In the univariate subgroup analysis, breast-cancer-specific survival among patients with micrometastasis was significantly shortened (P<0.001 for all comparisons) among those receiving adjuvant endocrine treatment (mortality ratio, 3.22) or cytotoxic therapy (mortality ratio, 2.32) and among patients who had tumors no larger than 2 cm in diameter without lymph-node metastasis and who did not receive systemic adjuvant therapy (mortality ratio, 3.65). Conclusions: The presence of micrometastasis in the bone marrow at the time of diagnosis of breast cancer is associated with a poor prognosis.	Innsbruck Med Univ, Dept Obstet & Gynecol, A-6020 Innsbruck, Austria; Gen Hosp, Dept Obstet & Gynecol, Merano, Italy; Norwegian Radium Hosp, Dept Oncol, Oslo, Norway; Univ Munich, Dept Obstet & Gynecol, Munich, Germany; Cornell Univ, New York Presbyterian Hosp, Dept Surg, New York, NY USA; Univ London Imperial Coll Sci Technol & Med, Div Med, London, England; Cent Hosp, Dept Hematol & Oncol, Augsburg, Germany; Univ Hosp, Dept Obstet & Gynecol, Heidelberg, Germany; Univ Hosp, Dept Obstet & Gynecol, Rostock, Germany; Univ Erlangen Nurnberg, Dept Obstet & Gynecol, Erlangen, Germany; Inst Curie, Dept Hematol & Oncol, Paris, France; Ullevaal Univ Hosp, Dept Surg, Oslo, Norway; Cornell Med Ctr, Strang Canc Prevent Ctr, New York, NY USA; Inst Canc Res, Sutton, Surrey, England; Eppendorf Univ, Inst Tumor Biol, Hamburg, Germany	Medical University of Innsbruck; University of Oslo; University of Munich; Cornell University; NewYork-Presbyterian Hospital; Imperial College London; Ruprecht Karls University Heidelberg; University of Rostock; University of Erlangen Nuremberg; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Oslo; Cornell University; University of London; Institute of Cancer Research - UK; University of Hamburg; University Medical Center Hamburg-Eppendorf	Braun, S (corresponding author), Innsbruck Med Univ, Dept Obstet & Gynecol, Anichstr 35, A-6020 Innsbruck, Austria.	stephan.braun@uklibk.ac.at		Bliss, Judith/0000-0001-7957-7424; Coombes, Raoul Charles/0000-0002-4811-1100; Fehm, Tanja/0000-0002-4926-0108				Braun S, 2005, J CLIN ONCOL, V23, P1623, DOI 10.1200/JCO.2005.10.073; Braun S, 2000, NEW ENGL J MED, V342, P525, DOI 10.1056/NEJM200002243420801; Braun S, 2001, J CLIN ONCOL, V19, P1468, DOI 10.1200/JCO.2001.19.5.1468; CLARKE MJ, 1994, BRIT MED J, V309, P1007, DOI 10.1136/bmj.309.6960.1007; Collett, 2003, MODELLING SURVIVAL D; COTE RJ, 1991, J CLIN ONCOL, V9, P1749, DOI 10.1200/JCO.1991.9.10.1749; COX DR, 1972, J R STAT SOC B, V34, P187; DerSimonian R, 1996, STAT MED, V15, P1237, DOI 10.1002/(SICI)1097-0258(19960630)15:12<1237::AID-SIM301>3.0.CO;2-N; Diel IJ, 1996, JNCI-J NATL CANCER I, V88, P1652, DOI 10.1093/jnci/88.22.1652; Fehm T, 2002, CLIN CANCER RES, V8, P2073; FISHER B, 1969, ARCH SURG-CHICAGO, V98, P347; Gangnus R, 2004, CLIN CANCER RES, V10, P3457, DOI 10.1158/1078-0432.CCR-03-0818; Gebauer G, 2001, J CLIN ONCOL, V19, P3669, DOI 10.1200/JCO.2001.19.16.3669; Gerber B, 2001, J CLIN ONCOL, V19, P960, DOI 10.1200/JCO.2001.19.4.960; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; HUNINK MGM, 1994, MED DECIS MAKING, V14, P59, DOI 10.1177/0272989X9401400108; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Klein CA, 2002, LANCET, V360, P683, DOI 10.1016/S0140-6736(02)09838-0; Mansi JL, 1999, LANCET, V354, P197, DOI 10.1016/S0140-6736(98)10175-7; OSBORNE MP, 1991, CANCER RES, V51, P2706; Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; Pierga JY, 2004, CLIN CANCER RES, V10, P1392, DOI 10.1158/1078-0432.CCR-0102-03; RAUN S, 2000, NEW ENGL J MED, V343, P308; Schmidt-Kittler O, 2003, P NATL ACAD SCI USA, V100, P7737, DOI 10.1073/pnas.1331931100; Wiedswang G, 2003, J CLIN ONCOL, V21, P3469, DOI 10.1200/JCO.2003.02.009; Woelfle U, 2003, CANCER RES, V63, P5679; Wong GYC, 2003, BREAST CANCER RES TR, V82, pS99	28	986	1023	6	38	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 25	2005	353	8					793	802		10.1056/NEJMoa050434	http://dx.doi.org/10.1056/NEJMoa050434			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	957YK	16120859				2022-12-28	WOS:000231409300008
J	Balduzzi, A; Valsecchi, MG; Uderzo, C; De Lorenzo, P; Klingebiel, T; Peters, C; Stary, J; Felice, MS; Magyarosy, E; Conter, V; Reiter, A; Messina, C; Gadner, H; Schroppe, M				Balduzzi, A; Valsecchi, MG; Uderzo, C; De Lorenzo, P; Klingebiel, T; Peters, C; Stary, J; Felice, MS; Magyarosy, E; Conter, V; Reiter, A; Messina, C; Gadner, H; Schroppe, M			Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study	LANCET			English	Article							BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; FOLLOW-UP; CHILDREN; EXPERIENCE; SURVIVAL; FEATURES; THERAPY; DONOR	Background The dismal prognosis of very-high-risk childhood acute lymphoblastic leukaemia could be improved by allogeneic haemopoietic cell transplantation. We compared this strategy with intensified chemotherapy protocols, with the aim to improve the outcome of children with very-high-risk acute lymphoblastic leukaemia in first complete remission. Methods A cooperative prospective study was set up in seven countries. Very-high-risk acute lymphoblastic leukaemia in first complete remission was defined by the presence of at least one of the following criteria: (1) failure to achieve complete remission after the first four-drug induction phase; (2) t(9;22) or t(4;11) clonal abnormalities; and (3) poor response to prednisone associated with T immunophenotype, white-blood-cell count of 100x10(9)/L or greater, or both. Children were allocated treatment by genetic chance, according to the availability of a compatible related donor, and assigned chemotherapy or haemopoietic-cell transplantation. The primary outcome was disease-free survival and analysis was by intention to treat. Findings Between April, 1995, and December, 2000, 357 children entered the study, of whom 280 were assigned chemotherapy and 77 related-donor haemopoietic-cell transplantation. 5-year disease-free survival was 40.6% (SE 3.1) in children allocated chemotherapy and 56.7% (5.7) in those assigned transplantation (hazard ratio 0.67 [95% CI 0.46-0.99]; p=0.02); 5-year survival was 50.1% (3.1) and 56.4% (5.9), respectively (0.73 [0.49-1.09]; p=0.12). Interpretation Children with very-high-risk acute lymphoblastic leukaemia benefit from related-donor haemopoietic-cell transplantation compared with chemotherapy. The gap between the two strategies increases as the risk profile of the patient worsens.	Univ Milano Bicocca, Osped San Gerardo, Pediat Clin, I-20052 Milan, Italy; Univ Milano Bicocca, Dipartimento Med Clin Prevenz & Biotecnol Sanit, Milan, Italy; Univ Frankfurt Klinikum, Klin Kinderheilkunde 3, D-6000 Frankfurt, Germany; St Anna Childrens Hosp, A-1090 Vienna, Austria; Univ Hosp Motol, Dept Paediat Haematol Oncol, Prague, Czech Republic; Hosp Pediat Prof Dr Juan P Garrahan, Buenos Aires, DF, Argentina; Semmelweis Univ, Paediat Clin, Dept 1, H-1085 Budapest, Hungary; Univ Giessen, Childrens Univ Hosp, Dept Paediat Haematol & Oncol, Giessen, Germany; Univ Padua, Clin Oncoematol, Padua, Italy; Univ Hosp Schleswig Holstein, Dept Paediat, Kiel, Germany	San Gerardo Hospital; University of Milano-Bicocca; University of Milano-Bicocca; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Saint Anna Children's Hospital; Motol University Hospital; Hospital de Pediatria Doctor Juan Garrahan; Semmelweis University; Justus Liebig University Giessen; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Padua; University of Kiel; Schleswig Holstein University Hospital	Balduzzi, A (corresponding author), Univ Milano Bicocca, Osped San Gerardo, Pediat Clin, Via Pergolesi 33, I-20052 Milan, Italy.	adriana.balduzzi@pediatriamonza.it	BALDUZZI, Adriana/AAC-1033-2019; Stary, Jan/AAB-9635-2020; Valsecchi, Maria Grazia/K-8891-2016	Valsecchi, Maria Grazia/0000-0001-5574-3504; Peters, Christina/0000-0003-0369-8515; Balduzzi, Adriana Cristina/0000-0002-5879-0610				Al-Kasim FA, 2002, BRIT J HAEMATOL, V116, P483, DOI 10.1046/j.0007-1048.2001.03282.x; Arico M, 2002, BLOOD, V100, P420, DOI 10.1182/blood.V100.2.420; Biondi A, 2000, LEUKEMIA, V14, P1939, DOI 10.1038/sj.leu.2401922; Bleakley M, 2002, BONE MARROW TRANSPL, V30, P1, DOI 10.1038/sj.bmt.1703601; BORDIGONI P, 1989, J CLIN ONCOL, V7, P747, DOI 10.1200/JCO.1989.7.6.747; CHESSELLS JM, 1992, LANCET, V340, P565, DOI 10.1016/0140-6736(92)92103-M; CHESSELLS JM, 1995, BRIT J HAEMATOL, V89, P364, DOI 10.1111/j.1365-2141.1995.tb03313.x; Conter V, 1998, HAEMATOLOGICA, V83, P791; GAYNON PS, 1993, J CLIN ONCOL, V11, P2234, DOI 10.1200/JCO.1993.11.11.2234; GRAY R, 1991, BONE MARROW TRANSPL, V7, P9; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Gupta V, 2004, BONE MARROW TRANSPL, V33, P397, DOI 10.1038/sj.bmt.1704368; LACHIN JM, 1986, BIOMETRICS, V42, P507, DOI 10.2307/2531201; Locatelli F, 2002, LEUKEMIA, V16, P2228, DOI 10.1038/sj.leu.2402690; MARUBINI E, 1995, ANAL SURVIVAL DATA C, P171; Nachman JB, 1998, NEW ENGL J MED, V338, P1663, DOI 10.1056/NEJM199806043382304; Pui CH, 2002, LANCET, V359, P1909, DOI 10.1016/S0140-6736(02)08782-2; Pui CH, 1998, NEW ENGL J MED, V339, P605, DOI 10.1056/NEJM199808273390907; Saarinen UM, 1996, BONE MARROW TRANSPL, V17, P357; Saarinen-Pihkala UM, 2001, J CLIN ONCOL, V19, P3406, DOI 10.1200/JCO.2001.19.14.3406; Schrappe M, 1998, BLOOD, V92, P2730; Schrappe M, 2000, BLOOD, V95, P3310; Sharathkumar A, 2004, BONE MARROW TRANSPL, V33, P39, DOI 10.1038/sj.bmt.1704319; Silverman LB, 2001, BLOOD, V97, P1211, DOI 10.1182/blood.V97.5.1211; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070; Suciu S, 2003, BLOOD, V102, P1232, DOI 10.1182/blood-2002-12-3714; Uckun FM, 1998, CANCER-AM CANCER SOC, V83, P2030, DOI 10.1002/(SICI)1097-0142(19981101)83:9<2030::AID-CNCR21>3.0.CO;2-Q; Uderzo C, 1997, BRIT J HAEMATOL, V96, P387, DOI 10.1046/j.1365-2141.1997.d01-2033.x; Valsecchi MG, 1996, ANN ONCOL, V7, P1005; Wheeler KA, 2000, BLOOD, V96, P2412; Woods WG, 2001, BLOOD, V97, P56, DOI 10.1182/blood.V97.1.56; Woolfrey AE, 2002, BLOOD, V99, P2002, DOI 10.1182/blood.V99.6.2002	32	132	140	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 20	2005	366	9486					635	642		10.1016/S0140-6736(05)66998-X	http://dx.doi.org/10.1016/S0140-6736(05)66998-X			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958EB	16112299				2022-12-28	WOS:000231426400026
J	Tena-Tamayo, C; Sotelo, J				Tena-Tamayo, C; Sotelo, J			Malpractice in Mexico: arbitration not litigation	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							MEDICAL MALPRACTICE; HEALTH-CARE; PHYSICIANS; CRISIS; ERROR		Natl Commiss Med Arbitrat, Mexico City 03020, DF, Mexico; Natl Inst Neurol & Neurosurg Mexico, Mexico City 14269, DF, Mexico		Tena-Tamayo, C (corresponding author), Natl Commiss Med Arbitrat, Mitla 250, Mexico City 03020, DF, Mexico.	ctena@conamed.gob.mx						Berger JE, 2000, PEDIATRICS, V106, P605; Cockburn J, 1997, BRIT MED J, V315, P520, DOI 10.1136/bmj.315.7107.520; Fraser JJ, 2001, PEDIATRICS, V107, P602, DOI 10.1542/peds.107.3.602; *JOINT EC COMM US, 2003, LIAB MED MALPR ISS E; JOURDAU S, 2000, LANCET, V356, P1268; KINNEY ED, 1995, J HEALTH POLIT POLIC, V20, P99, DOI 10.1215/03616878-20-1-99; LADIMER I, 1995, LEGAL MED, P25; Levinson W, 1997, JAMA-J AM MED ASSOC, V277, P553, DOI 10.1001/jama.277.7.553; Mello MM, 2003, NEW ENGL J MED, V348, P2281, DOI 10.1056/NEJMp030064; METZLOFF TB, 1997, SPEC LAW DIG HLTH CA, V215, P9; Mohr JC, 2000, JAMA-J AM MED ASSOC, V283, P1731, DOI 10.1001/jama.283.13.1731; Palmisano DJ, 2004, CIRCULATION, V109, P2933, DOI 10.1161/01.CIR.0000133602.21202.4B; PICKER BG, 1998, MEDIATION PRACTICE G; ROMANO M, 2003, MOD HEALTHCARE, V33, P26; Schmidt Mark D, 2003, Med Econ, V80, P71; Studdert DM, 2005, JAMA-J AM MED ASSOC, V293, P2609, DOI 10.1001/jama.293.21.2609; TENA C, 2003, REV MED IMSS, V41, P503; Tena Tamayo C., 2002, Revista Medica del Instituto Mexicano del Seguro Social, V40, P523; Tracy TF, 2003, ARCH SURG-CHICAGO, V138, P447, DOI 10.1001/archsurg.138.4.447; Walsh P, 2003, BRIT MED J, V326, P1333, DOI 10.1136/bmj.326.7402.1333; Weingart SN, 2000, BRIT MED J, V320, P774, DOI 10.1136/bmj.320.7237.774	21	12	14	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 20	2005	331	7514					448	451		10.1136/bmj.331.7514.448	http://dx.doi.org/10.1136/bmj.331.7514.448			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958WB	16110076	Green Published			2022-12-28	WOS:000231477800025
J	Juanes-Marcos, JC; Althorpe, SC; Wrede, E				Juanes-Marcos, JC; Althorpe, SC; Wrede, E			Theoretical study of geometric phase effects in the hydrogen-exchange reaction	SCIENCE			English	Article							POTENTIAL-ENERGY SURFACES; DIFFERENTIAL CROSS-SECTIONS; CONICAL INTERSECTIONS; POLYATOMIC-MOLECULES; CHEMICAL-REACTION; SCATTERING; RESONANCES; DYNAMICS; STATES	The crossing of two electronic potential surfaces (a conical intersection) should result in geometric phase effects even for molecular processes confined to the lower surface. However, recent quantum simulations of the hydrogen exchange reaction (H+H-2-> H-2+H) have predicted a cancellation in such effects when product distributions are integrated over all scattering angles. We used a simple topological argument to extract reaction paths with different senses from a nuclear wave function that encircles a conical intersection. In the hydrogen-exchange reaction, these senses correspond to paths that cross one or two transition states. These two sets of paths scatter their products into different regions of space, which causes the cancellation in geometric phase effects. The analysis should generalize to other direct reactions.	Univ Nottingham, Sch Chem, Nottingham NG7 2RD, England; Univ Durham, Dept Chem, Durham DH1 3LE, England	University of Nottingham; Durham University	Althorpe, SC (corresponding author), Univ Nottingham, Sch Chem, Univ Pk, Nottingham NG7 2RD, England.	stuart.althorpe@gmail.com	Wrede, Eckart/E-7366-2012	Wrede, Eckart/0000-0001-6773-8446				Althorpe SC, 2002, NATURE, V416, P67, DOI 10.1038/416067a; Applegate BE, 2003, CHEM SOC REV, V32, P38, DOI 10.1039/a910269h; BERRY MV, 1984, PROC R SOC LON SER-A, V392, P45, DOI 10.1098/rspa.1984.0023; Boothroyd AI, 1996, J CHEM PHYS, V104, P7139, DOI 10.1063/1.471430; Child M.S., 1996, MOL COLLISION THEORY; Child MS, 2002, ADV CHEM PHYS, V124, P1; Dobbyn AJ, 1999, PHYS CHEM CHEM PHYS, V1, P1115, DOI 10.1039/a809498e; Domcke W., 2003, CONICAL INTERSECTION; Fernandez-Alonso F, 2002, ANNU REV PHYS CHEM, V53, P67, DOI 10.1146/annurev.physchem.53.091001.094554; FEYNMAN RP, 1965, QUANTUM MECH PATH IN; Friedrich O, 2001, PHYS REV LETT, V86, P1183, DOI 10.1103/PhysRevLett.86.1183; Harich SA, 2002, NATURE, V419, P281, DOI 10.1038/nature01068; HERZBERG G, 1963, DISCUSS FARADAY SOC, P77, DOI 10.1039/df9633500077; Juanes-Marcos JC, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1924411; Juanes-Marcos JC, 2003, CHEM PHYS LETT, V381, P743, DOI 10.1016/j.cplett.2003.10.041; Kendrick B, 1997, J CHEM PHYS, V106, P3519, DOI 10.1063/1.473449; Kendrick BK, 2003, J PHYS CHEM A, V107, P6739, DOI 10.1021/jp021865x; Kendrick BK, 2000, J CHEM PHYS, V112, P5679, DOI 10.1063/1.481143; KUPPERMANN A, 1975, CHEM PHYS LETT, V32, P374, DOI 10.1016/0009-2614(75)85148-7; Kuppermann A, 2001, CHEM PHYS LETT, V349, P537, DOI 10.1016/S0009-2614(01)01210-6; Kuppermann A, 1996, DYNAMICS MOL CHEM RE, P411; LEPETIT B, 1990, CHEM PHYS LETT, V166, P581, DOI 10.1016/0009-2614(90)87154-J; LONGUETHIGGINS HC, 1975, P ROY SOC LOND A MAT, V344, P147, DOI 10.1098/rspa.1975.0095; Mahapatra S, 2001, J PHYS CHEM A, V105, P2321, DOI 10.1021/jp003784b; MEAD CA, 1979, J CHEM PHYS, V70, P2284, DOI 10.1063/1.437734; MEAD CA, 1992, REV MOD PHYS, V64, P51, DOI 10.1103/RevModPhys.64.51; MEAD CA, 1980, J CHEM PHYS, V72, P3839, DOI 10.1063/1.439600; Morandi G., 1984, European Journal of Physics, V5, P49, DOI 10.1088/0143-0807/5/1/011; Schulman L. S., 1981, TECHNIQUES APPL PATH; Stillwell J., 1993, CLASSICAL TOPOLOGY C; Varandas AJC, 2003, CHEM PHYS LETT, V367, P625, DOI 10.1016/S0009-2614(02)01780-3; Wrede E, 1997, J CHEM PHYS, V107, P786, DOI 10.1063/1.474378; Wrede E, 1999, J CHEM PHYS, V110, P9971, DOI 10.1063/1.478870	33	129	130	0	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 19	2005	309	5738					1227	1230		10.1126/science.1114890	http://dx.doi.org/10.1126/science.1114890			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	957TE	16109876				2022-12-28	WOS:000231395400041
J	Hancock, REW; McPhee, JB				Hancock, REW; McPhee, JB			Salmonella's sensor for host defense molecules	CELL			English	Editorial Material							ANTIMICROBIAL PEPTIDES; RESISTANCE; LPS		Univ British Columbia, Ctr Microbial dis & Immun Res, Vancouver, BC V6T 1Z4, Canada	University of British Columbia	Hancock, REW (corresponding author), Univ British Columbia, Ctr Microbial dis & Immun Res, Vancouver, BC V6T 1Z4, Canada.		McPhee, Joseph/AAG-5382-2019; Hancock, Robert E. W./E-1145-2013	Hancock, Robert E. W./0000-0001-5989-8503; McPhee, Joseph/0000-0002-6844-755X				Bader MW, 2005, CELL, V122, P461, DOI 10.1016/j.cell.2005.05.030; Bader MW, 2003, MOL MICROBIOL, V50, P219, DOI 10.1046/j.1365-2958.2003.03675.x; Bowdish DME, 2005, CURR PROTEIN PEPT SC, V6, P35, DOI 10.2174/1389203053027494; Bullen JJ, 2005, FEMS IMMUNOL MED MIC, V43, P325, DOI 10.1016/j.femsim.2004.11.010; Castelli ME, 2000, J BIOL CHEM, V275, P22948, DOI 10.1074/jbc.M909335199; Christensen KA, 2002, J CELL SCI, V115, P599; Gunn JS, 2001, J ENDOTOXIN RES, V7, P57, DOI 10.1177/09680519010070011001; Kawasaki K, 2004, J ENDOTOXIN RES, V10, P439, DOI 10.1179/096805104225006264; McPhee JB, 2003, MOL MICROBIOL, V50, P205, DOI 10.1046/j.1365-2958.2003.03673.x; Miller SI, 2005, NAT REV MICROBIOL, V3, P36, DOI 10.1038/nrmicro1068; Minagawa S, 2003, J BACTERIOL, V185, P3696, DOI 10.1128/JB.185.13.3696-3702.2003; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	12	14	15	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 12	2005	122	3					320	322		10.1016/j.cell.2005.07.023	http://dx.doi.org/10.1016/j.cell.2005.07.023			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	955UZ	16096052	Bronze			2022-12-28	WOS:000231254400003
J	Matsumoto, T; Wu, JZ; Kanamori, H; Katayose, Y; Fujisawa, M; Namiki, N; Mizuno, H; Yamamoto, K; Antonio, BA; Baba, T; Sakata, K; Nagamura, Y; Aoki, H; Arikawa, K; Arita, K; Bito, T; Chiden, Y; Fujitsuka, N; Fukunaka, R; Hamada, M; Harada, C; Hayashi, A; Hijishita, S; Honda, M; Hosokawa, S; Ichikawa, Y; Idonuma, A; Iijima, M; Ikeda, M; Ikeno, M; Ito, K; Ito, S; Ito, T; Ito, Y; Ito, Y; Iwabuchi, A; Kamiya, K; Karasawa, W; Kurita, K; Katagiri, S; Kikuta, A; Kobayashi, H; Kobayashi, N; Machita, K; Maehara, T; Masukawa, M; Mizubayashi, T; Mukai, Y; Nagasaki, H; Nagata, Y; Naito, S; Nakashima, M; Nakama, Y; Nakamichi, Y; Nakamura, M; Meguro, A; Negishi, M; Ohta, I; Ohta, T; Okamoto, M; Ono, N; Saji, S; Sakaguchi, M; Sakai, K; Shibata, M; Shimokawa, T; Song, JY; Takazaki, Y; Terasawa, K; Tsugane, M; Tsuji, K; Ueda, S; Waki, K; Yamagata, H; Yamamoto, M; Yamamoto, S; Yamane, H; Yoshiki, S; Yoshihara, R; Yukawa, K; Zhong, HS; Yano, M; Sasaki, T; Yuan, QP; Shu, OT; Liu, J; Jones, KM; Gansberger, K; Moffat, K; Hill, J; Bera, J; Fadrosh, D; Jin, SH; Johri, S; Kim, M; Overton, L; Reardon, M; Tsitrin, T; Vuong, H; Weaver, B; Ciecko, A; Tallon, L; Jackson, J; Pai, G; Van Aken, S; Utterback, T; Reidmuller, S; Feldblyum, T; Hsiao, J; Zismann, V; Iobst, S; de Vazeille, AR; Buell, CR; Ying, K; Li, Y; Lu, TT; Huang, YC; Zhao, Q; Feng, Q; Zhang, L; Zhu, JJ; Weng, QJ; Mu, J; Lu, YQ; Fan, DL; Liu, YL; Guan, JP; Zhang, YJ; Yu, SL; Liu, XH; Zhang, Y; Hong, GF; Han, B; Choisne, N; Demange, N; Orjeda, G; Samain, S; Cattolico, L; Pelletier, E; Couloux, A; Segurens, B; Wincker, P; D'Hont, A; Scarpelli, C; Weissenbach, J; Salanoubat, M; Quetier, F; Yu, Y; Kim, HR; Rambo, T; Currie, J; Collura, K; Luo, MZ; Yang, TJ; Ammiraju, JSS; Engler, F; Soderlund, C; Wing, RA; Palmer, LE; de la Bastide, M; Spiegel, L; Nascimento, L; Zutavern, T; O'Shaughnessy, A; Dike, S; Dedhia, N; Preston, R; Balija, V; McCombie, WR; Chow, TY; Chen, HH; Chung, MC; Chen, CS; Shaw, JF; Wu, HP; Hsiao, KJ; Chao, YT; Chu, MK; Cheng, CH; Hour, AL; Lee, PF; Lin, SJ; Lin, YC; Liou, JY; Liu, SM; Hsing, YI; Raghuvanshi, S; Mohanty, A; Bharti, AK; Gaur, A; Gupta, V; Kumar, D; Ravi, V; Vij, S; Kapur, A; Khurana, P; Khurana, P; Khurana, JP; Tyagi, AK; Gaikwad, K; Singh, A; Dalal, V; Srivastava, S; Dixit, A; Pal, AK; Ghazi, IA; Yadav, M; Pandit, A; Bhargava, A; Sureshbabu, K; Batra, K; Sharma, TR; Mohapatra, T; Singh, NK; Messing, J; Nelson, AB; Fuks, G; Kavchok, S; Keizer, G; Llaca, ELV; Song, RT; Tanyolac, B; Young, S; Il, KH; Hahn, JH; Sangsakoo, G; Vanavichit, A; de Mattos, LAT; Zimmer, PD; Malone, G; Dellagostin, O; de Oliveira, AC; Bevan, M; Bancroft, I; Minx, P; Cordum, H; Wilson, R; Cheng, ZK; Jin, WW; Jiang, JM; Leong, SA; Iwama, H; Gojobori, T; Itoh, T; Niimura, Y; Fujii, Y; Habara, T; Sakai, H; Sato, Y; Wilson, G; Kumar, K; McCouch, S; Juretic, N; Hoen, D; Wright, S; Bruskiewich, R; Bureau, T; Miyao, A; Hirochika, H; Nishikawa, T; Kadowaki, K; Sugiura, M				Matsumoto, T; Wu, JZ; Kanamori, H; Katayose, Y; Fujisawa, M; Namiki, N; Mizuno, H; Yamamoto, K; Antonio, BA; Baba, T; Sakata, K; Nagamura, Y; Aoki, H; Arikawa, K; Arita, K; Bito, T; Chiden, Y; Fujitsuka, N; Fukunaka, R; Hamada, M; Harada, C; Hayashi, A; Hijishita, S; Honda, M; Hosokawa, S; Ichikawa, Y; Idonuma, A; Iijima, M; Ikeda, M; Ikeno, M; Ito, K; Ito, S; Ito, T; Ito, Y; Ito, Y; Iwabuchi, A; Kamiya, K; Karasawa, W; Kurita, K; Katagiri, S; Kikuta, A; Kobayashi, H; Kobayashi, N; Machita, K; Maehara, T; Masukawa, M; Mizubayashi, T; Mukai, Y; Nagasaki, H; Nagata, Y; Naito, S; Nakashima, M; Nakama, Y; Nakamichi, Y; Nakamura, M; Meguro, A; Negishi, M; Ohta, I; Ohta, T; Okamoto, M; Ono, N; Saji, S; Sakaguchi, M; Sakai, K; Shibata, M; Shimokawa, T; Song, JY; Takazaki, Y; Terasawa, K; Tsugane, M; Tsuji, K; Ueda, S; Waki, K; Yamagata, H; Yamamoto, M; Yamamoto, S; Yamane, H; Yoshiki, S; Yoshihara, R; Yukawa, K; Zhong, HS; Yano, M; Sasaki, T; Yuan, QP; Shu, OT; Liu, J; Jones, KM; Gansberger, K; Moffat, K; Hill, J; Bera, J; Fadrosh, D; Jin, SH; Johri, S; Kim, M; Overton, L; Reardon, M; Tsitrin, T; Vuong, H; Weaver, B; Ciecko, A; Tallon, L; Jackson, J; Pai, G; Van Aken, S; Utterback, T; Reidmuller, S; Feldblyum, T; Hsiao, J; Zismann, V; Iobst, S; de Vazeille, AR; Buell, CR; Ying, K; Li, Y; Lu, TT; Huang, YC; Zhao, Q; Feng, Q; Zhang, L; Zhu, JJ; Weng, QJ; Mu, J; Lu, YQ; Fan, DL; Liu, YL; Guan, JP; Zhang, YJ; Yu, SL; Liu, XH; Zhang, Y; Hong, GF; Han, B; Choisne, N; Demange, N; Orjeda, G; Samain, S; Cattolico, L; Pelletier, E; Couloux, A; Segurens, B; Wincker, P; D'Hont, A; Scarpelli, C; Weissenbach, J; Salanoubat, M; Quetier, F; Yu, Y; Kim, HR; Rambo, T; Currie, J; Collura, K; Luo, MZ; Yang, TJ; Ammiraju, JSS; Engler, F; Soderlund, C; Wing, RA; Palmer, LE; de la Bastide, M; Spiegel, L; Nascimento, L; Zutavern, T; O'Shaughnessy, A; Dike, S; Dedhia, N; Preston, R; Balija, V; McCombie, WR; Chow, TY; Chen, HH; Chung, MC; Chen, CS; Shaw, JF; Wu, HP; Hsiao, KJ; Chao, YT; Chu, MK; Cheng, CH; Hour, AL; Lee, PF; Lin, SJ; Lin, YC; Liou, JY; Liu, SM; Hsing, YI; Raghuvanshi, S; Mohanty, A; Bharti, AK; Gaur, A; Gupta, V; Kumar, D; Ravi, V; Vij, S; Kapur, A; Khurana, P; Khurana, P; Khurana, JP; Tyagi, AK; Gaikwad, K; Singh, A; Dalal, V; Srivastava, S; Dixit, A; Pal, AK; Ghazi, IA; Yadav, M; Pandit, A; Bhargava, A; Sureshbabu, K; Batra, K; Sharma, TR; Mohapatra, T; Singh, NK; Messing, J; Nelson, AB; Fuks, G; Kavchok, S; Keizer, G; Llaca, ELV; Song, RT; Tanyolac, B; Young, S; Il, KH; Hahn, JH; Sangsakoo, G; Vanavichit, A; de Mattos, LAT; Zimmer, PD; Malone, G; Dellagostin, O; de Oliveira, AC; Bevan, M; Bancroft, I; Minx, P; Cordum, H; Wilson, R; Cheng, ZK; Jin, WW; Jiang, JM; Leong, SA; Iwama, H; Gojobori, T; Itoh, T; Niimura, Y; Fujii, Y; Habara, T; Sakai, H; Sato, Y; Wilson, G; Kumar, K; McCouch, S; Juretic, N; Hoen, D; Wright, S; Bruskiewich, R; Bureau, T; Miyao, A; Hirochika, H; Nishikawa, T; Kadowaki, K; Sugiura, M		Int Rice Genome Sequencing Project	The map-based sequence of the rice genome	NATURE			English	Article							ORYZA-SATIVA L.; ARABIDOPSIS-THALIANA; TRANSPOSABLE ELEMENTS; DRAFT SEQUENCE; JAPONICA RICE; GENES; ANNOTATION; CENTROMERE; MICRORNAS; INDICA	Rice, one of the world's most important food plants, has important syntenic relationships with the other cereal species and is a model plant for the grasses. Here we present a map-based, finished quality sequence that covers 95% of the 389 Mb genome, including virtually all of the euchromatin and two complete centromeres. A total of 37,544 non-transposable-element-related protein-coding genes were identified, of which 71% had a putative homologue in Arabidopsis. In a reciprocal analysis, 90% of the Arabidopsis proteins had a putative homologue in the predicted rice proteome. Twenty-nine per cent of the 37,544 predicted genes appear in clustered gene families. The number and classes of transposable elements found in the rice genome are consistent with the expansion of syntenic regions in the maize and sorghum genomes. We find evidence for widespread and recurrent gene transfer from the organelles to the nuclear chromosomes. The map-based sequence has proven useful for the identification of genes underlying agronomic traits. The additional single-nucleotide polymorphisms and simple sequence repeats identified in our study should accelerate improvements in rice production.	Natl Inst Agrobiol Sci, Inst Soc Techno Innovat Agr Forestry & Fisheries, Tsukuba, Ibaraki 3058602, Japan; Inst Genome Res, Rockville, MD 20850 USA; Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai 200233, Peoples R China; Ctr Natl Sequencage, INRA URGV, CNRS UMR 8030, F-91057 Evry, France; UMR PIA, Cirad Amis, F-34398 Montpellier 05, France; Univ Arizona, Dept Plant Sci, BIO5 Inst, Tucson, AZ 85721 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11723 USA; Acad Sinica, Inst Bot, Taipei 11529, Taiwan; Natl Cheng Kung Univ, Tainan 701, Taiwan; Natl Yang Ming Univ, Taipei 112, Taiwan; Univ Delhi, Dept Plant Mol Biol, New Delhi 110021, India; Indian Agr Res Inst, Natl Res Ctr Plant Biotechnol, New Delhi 110012, India; Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA; Natl Inst Agr Sci & Technol, RDA, Suwon 441707, South Korea; Kasetsart Univ, Rice Gene Unit, Nakron Pathom 73140, Thailand; Univ Fed Pelotas, Ctr Genom & Fitomelhoramento, BR-96001970 Pelotas, RS, Brazil; John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England; Washington Univ, Genome Sequencing Ctr, St Louis, MO 63108 USA; Univ Wisconsin, Dept Hort, Madison, WI 53706 USA; Univ Wisconsin, Dept Plant Pathol, Madison, WI 53706 USA; Natl Inst Genet, Ctr Informat Biol, Mishima, Shizuoka 4118540, Japan; Natl Inst Genet, DNA Data Bank Japan, Mishima, Shizuoka 4118540, Japan; Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Koto Ku, Tokyo 1350064, Japan; Natl Inst Agrobiol Sci, Tsukuba, Ibaraki 3058602, Japan; Natl Inst Adv Ind Sci & Technol, Inst Med Res, Bunkyo Ku, Tokyo 1138510, Japan; Japan Biol informat Consortium, Japan Biol Informat Res Ctr, Koto Ku, Tokyo 1350064, Japan; Cornell Univ, Dept Plant Breeding, Ithaca, NY 14850 USA; McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada; York Univ, Dept Biol, Toronto, ON M3J 1P3, Canada; Int Rice Res Inst, Biometr & Bioinformat Unit, Manila, Philippines; Nagoya City Univ, Grad Sch Nat Sci, Nagoya, Aichi 4678501, Japan; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	National Institute of Agrobiological Sciences - Japan; J. Craig Venter Institute; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); INRAE; UDICE-French Research Universities; Universite Paris Saclay; CEA; CIRAD; University of Arizona; Cold Spring Harbor Laboratory; Academia Sinica - Taiwan; National Cheng Kung University; National Yang Ming Chiao Tung University; University of Delhi; Indian Council of Agricultural Research (ICAR); ICAR - Indian Agricultural Research Institute; ICAR - National Institute For Plant Biotechnology (NIPB); Rutgers State University New Brunswick; Rural Development Administration (RDA), Republic of Korea; Kasetsart University; Universidade Federal de Pelotas; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Washington University (WUSTL); University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Agrobiological Sciences - Japan; National Institute of Advanced Industrial Science & Technology (AIST); Cornell University; McGill University; York University - Canada; CGIAR; International Rice Research Institute (IRRI); Nagoya City University; United States Department of Energy (DOE); Brookhaven National Laboratory	Sasaki, T (corresponding author), Natl Inst Agrobiol Sci, Inst Soc Techno Innovat Agr Forestry & Fisheries, 2-1-2 Kannondai, Tsukuba, Ibaraki 3058602, Japan.	tsasaki@nias.affrc.go.jp	TYAGI, AKHILESH KUMAR/D-2649-2009; Song, Rentao/A-6544-2012; Miyao, Akio/V-7306-2019; Wilson, Richard K./AAF-4139-2019; Jiang, Jiming/V-6060-2019; LIN, Yao-Cheng/B-4394-2008; Yang, Tae-Jin/AAT-5274-2020; Leong, Sally A/I-8550-2012; Jiang, Jiming/A-9614-2009; Song, Rentao/AAG-9107-2021; Oliveira, Antonio/K-5923-2019; Wing, Rod A/Z-2885-2019; Singh, Nouratan/N-9377-2017; Wright, Stephen I/C-3113-2008; Ravi, Vydianathan/B-2759-2009; Yano, Masahiro/AAC-5441-2019; Bancroft, Ian/AAH-3831-2020; Tanyolac, Bahattin/AAD-3762-2019; Dellagostin, Odir/C-2331-2009; Iobst, Stacey/AAJ-9564-2020; Reardon, Michael/ABF-8880-2021; DHONT, Angélique/AAL-8074-2021; Oliveira, Antonio/F-7508-2012; Quetier, Francis/J-7923-2017; Waki, Kazunori/T-6444-2019	Song, Rentao/0000-0003-1810-9875; Miyao, Akio/0000-0002-2822-2866; Wilson, Richard K./0000-0002-1992-1358; Jiang, Jiming/0000-0002-6435-6140; LIN, Yao-Cheng/0000-0002-9390-795X; Jiang, Jiming/0000-0002-6435-6140; Song, Rentao/0000-0003-1810-9875; Oliveira, Antonio/0000-0001-8835-8071; Wing, Rod A/0000-0001-6633-6226; Singh, Nouratan/0000-0002-8063-8375; Wright, Stephen I/0000-0001-9973-9697; Ravi, Vydianathan/0000-0003-0807-7697; Dellagostin, Odir/0000-0003-2803-4088; Oliveira, Antonio/0000-0001-8835-8071; Messing, Joachim/0000-0001-8260-2643; Quetier, Francis/0000-0003-4388-9287; Orjeda, Gisella/0000-0003-3013-5523; Itoh, Takeshi/0000-0002-6291-4233; Tsugane, Mika/0000-0002-7991-5224; Waki, Kazunori/0000-0001-7311-7208; Chao, Ya-Ting/0000-0002-4917-2183; Buell, C Robin/0000-0002-6727-4677; Cheng, Chia-Hsiung/0000-0003-0307-9650; Wu, Jianzhong/0000-0002-4033-852X; Gupta, Vikrant/0000-0002-3479-8749; Yuan, Qiaoping/0000-0002-5880-8702; Iobst, Stacey E./0000-0002-6954-2903				Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Barry GF, 2001, PLANT PHYSIOL, V125, P1164, DOI 10.1104/pp.125.3.1164; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Castelli V, 2004, GENOME RES, V14, P406, DOI 10.1101/gr.1515604; CAUSSE MA, 1994, GENETICS, V138, P1251; Chen MS, 2002, PLANT CELL, V14, P537, DOI 10.1105/tpc.010485; Cheng ZK, 2002, PLANT CELL, V14, P1691, DOI 10.1105/tpc.003079; Delcher AL, 1999, NUCLEIC ACIDS RES, V27, P2369, DOI 10.1093/nar/27.11.2369; Dong FG, 1998, P NATL ACAD SCI USA, V95, P8135, DOI 10.1073/pnas.95.14.8135; Eddy SR, 1998, BIOINFORMATICS, V14, P755, DOI 10.1093/bioinformatics/14.9.755; Feltus FA, 2004, GENOME RES, V14, P1812, DOI 10.1101/gr.2479404; Feng Q, 2002, NATURE, V420, P316, DOI 10.1038/nature01183; Goff SA, 2002, SCIENCE, V296, P92, DOI 10.1126/science.1068275; Guyot R, 2004, GENOME, V47, P610, DOI 10.1139/G04-016; Harushima Y, 1998, GENETICS, V148, P479; Hirochika H, 1996, P NATL ACAD SCI USA, V93, P7783, DOI 10.1073/pnas.93.15.7783; Juretic N, 2004, BIOINFORMATICS, V20, P155, DOI 10.1093/bioinformatics/bth019; KAMISUGI Y, 1994, MOL GEN GENET, V245, P133, DOI 10.1007/BF00283259; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kikuchi S, 2003, SCIENCE, V301, P376, DOI 10.1126/science.1081288; Lai JS, 2004, GENOME RES, V14, P1924, DOI 10.1101/gr.2701104; Mao L, 2000, GENOME RES, V10, P982, DOI 10.1101/gr.10.7.982; McCouch SR, 2002, DNA RES, V9, P257, DOI 10.1093/dnares/9.6.257; Messing J, 2004, P NATL ACAD SCI USA, V101, P14349, DOI 10.1073/pnas.0406163101; Miyao A, 2003, PLANT CELL, V15, P1771, DOI 10.1105/tpc.012559; MOORE G, 1995, CURR BIOL, V5, P737, DOI 10.1016/S0960-9822(95)00148-5; Nagaki K, 2004, NAT GENET, V36, P138, DOI 10.1038/ng1289; Ohmido N, 2000, MOL GEN GENET, V263, P388, DOI 10.1007/s004380051182; OONO K, 1980, CHROMOSOMA, V76, P85, DOI 10.1007/BF00292228; Paterson AH, 2004, P NATL ACAD SCI USA, V101, P9903, DOI 10.1073/pnas.0307901101; Peng S, 1999, CROP SCI, V39, P1552, DOI 10.2135/cropsci1999.3961552x; Peng SB, 2004, P NATL ACAD SCI USA, V101, P9971, DOI 10.1073/pnas.0403720101; Saji S, 2001, GENOME, V44, P32, DOI 10.1139/gen-44-1-32; Salse J, 2004, PLANT J, V38, P396, DOI 10.1111/j.1365-313X.2004.02058.x; Sasaki T, 2000, CURR OPIN PLANT BIOL, V3, P138, DOI 10.1016/S1369-5266(99)00047-3; Sasaki T, 2002, NATURE, V420, P312, DOI 10.1038/nature01184; Shen YJ, 2004, PLANT PHYSIOL, V135, P1198, DOI 10.1104/pp.103.038463; Shishido R, 2000, MOL GEN GENET, V263, P586, DOI 10.1007/s004380051205; Simillion C, 2004, GENOME RES, V14, P1095, DOI 10.1101/gr.2179004; Song R, 2002, GENOME RES, V12, P1549, DOI 10.1101/gr.268302; Turcotte K, 2001, PLANT J, V25, P169, DOI 10.1046/j.1365-313x.2001.00945.x; Wang JF, 2004, NUCLEIC ACIDS RES, V32, P1688, DOI 10.1093/nar/gkh332; Wang XJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r65; Wu JZ, 2004, PLANT CELL, V16, P967, DOI 10.1105/tpc.019273; Wu JZ, 2002, PLANT CELL, V14, P525, DOI 10.1105/tpc.010274; Yamamoto K, 1997, PLANT MOL BIOL, V35, P135, DOI 10.1023/A:1005735322577; Yu J, 2005, PLOS BIOL, V3, P266, DOI 10.1371/journal.pbio.0030038; Yu J, 2002, SCIENCE, V296, P79, DOI 10.1126/science.1068037; Yu YS, 2003, SCIENCE, V300, P1566, DOI 10.1126/science.1083523; Zhang Y, 2004, NUCLEIC ACIDS RES, V32, P2023, DOI 10.1093/nar/gkh521	50	2643	6716	35	665	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 11	2005	436	7052					793	800		10.1038/nature03895	http://dx.doi.org/10.1038/nature03895			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953XG	16100779	Bronze			2022-12-28	WOS:000231116500034
J	Phillips, LR; Milescu, M; Li-Smerin, YY; Mindell, JA; Kim, JI; Swartz, KJ				Phillips, LR; Milescu, M; Li-Smerin, YY; Mindell, JA; Kim, JI; Swartz, KJ			Voltage-sensor activation with a tarantula toxin as cargo	NATURE			English	Article							DEPENDENT K+ CHANNEL; POTASSIUM CHANNELS; GATING MODIFIER; SCORPION TOXIN; MOLECULAR DETERMINANTS; CHARGE MOVEMENT; SODIUM-CHANNELS; BINDING; HANATOXIN; FLUORESCENCE	The opening and closing of voltage-activated Na+, Ca2+ and K+ (Kv) channels underlies electrical and chemical signalling throughout biology, yet the structural basis of voltage sensing is unknown. Hanatoxin is a tarantula toxin that inhibits Kv channels by binding to voltage-sensor paddles(1-5), crucial helix-turn-helix motifs within the voltage-sensing domains that are composed of S3b and S4 helices(6). The active surface of the toxin is amphipathic(7,8), and related toxins have been shown to partition into membranes(9-12), raising the possibility that the toxin is concentrated in the membrane and interacts only weakly and transiently with the voltage sensors. Here we examine the kinetics and state dependence of the toxin - channel interaction and the physical location of the toxin in the membrane. We find that hanatoxin forms a strong and stable complex with the voltage sensors, far outlasting fluctuations of the voltage sensors between resting ( closed) conformations at negative voltages and activated ( open) conformations at positive voltages. Toxin affinity is reduced by voltage-sensor activation, explaining why the toxin stabilizes the resting conformation. We also find that when hanatoxin partitions into membranes it is localized to an interfacial region, with Trp 30 positioned about 8.5 angstrom from the centre of the bilayer. These results demonstrate that voltage-sensor paddles activate with a toxin as cargo, and suggest that the paddles traverse no more than the outer half of the bilayer during activation.	Natl Inst Neurol Disorders & Stroke, Mol Physiol & Biophys Sect, NIH, Bethesda, MD 20892 USA; Natl Inst Neurol Disorders & Stroke, Membrane Transport Biophys Unit, Porter Neurosci Res Ctr, NIH, Bethesda, MD 20892 USA; Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Gwangju Institute of Science & Technology (GIST)	Swartz, KJ (corresponding author), Natl Inst Neurol Disorders & Stroke, Mol Physiol & Biophys Sect, NIH, 35 Convent Dr,MSC 3701, Bethesda, MD 20892 USA.	swartzk@ninds.nih.gov	Mindell, Joseph/P-4461-2017	Mindell, Joseph/0000-0002-6952-8247	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002945] Funding Source: NIH RePORTER; Intramural NIH HHS [ZIA NS002945-13] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ABRAMS FS, 1992, BIOCHEMISTRY-US, V31, P5312, DOI 10.1021/bi00138a010; Ahern CA, 2004, J GEN PHYSIOL, V123, P205, DOI 10.1085/jgp.200308993; CATTERALL WA, 1979, J GEN PHYSIOL, V74, P375, DOI 10.1085/jgp.74.3.375; CATTERALL WA, 1977, J BIOL CHEM, V252, P8660; Cuello LG, 2004, SCIENCE, V306, P491, DOI 10.1126/science.1101373; Islas LD, 2001, J GEN PHYSIOL, V117, P69, DOI 10.1085/jgp.117.1.69; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jung HJ, 2005, BIOCHEMISTRY-US, V44, P6015, DOI 10.1021/bi0477034; Ladokhin AS, 2000, ANAL BIOCHEM, V285, P235, DOI 10.1006/abio.2000.4773; Ladokhin AS, 1999, BIOPHYS J, V76, P946, DOI 10.1016/S0006-3495(99)77258-9; Ladokhin AS, 1999, ANAL BIOCHEM, V276, P65, DOI 10.1006/abio.1999.4343; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; Lee HC, 2003, NEURON, V40, P527, DOI 10.1016/S0896-6273(03)00636-6; Lee SY, 2004, NATURE, V430, P232, DOI 10.1038/nature02632; Li-Smerin Y, 2001, J GEN PHYSIOL, V117, P205, DOI 10.1085/jgp.117.3.205; Li-Smerin Y, 2000, J GEN PHYSIOL, V115, P673, DOI 10.1085/jgp.115.6.673; McDonough SI, 1997, MOL PHARMACOL, V52, P1095, DOI 10.1124/mol.52.6.1095; MCINTOSH TJ, 1987, BIOCHEMISTRY-US, V26, P1783, DOI 10.1021/bi00380a042; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; Smith JJ, 2005, J BIOL CHEM, V280, P11127, DOI 10.1074/jbc.M412552200; Starace DM, 2004, NATURE, V427, P548, DOI 10.1038/nature02270; Suchyna TM, 2004, NATURE, V430, P235, DOI 10.1038/nature02743; Swartz KJ, 1997, NEURON, V18, P675, DOI 10.1016/S0896-6273(00)80307-4; Swartz KJ, 2004, NAT REV NEUROSCI, V5, P905, DOI 10.1038/nrn1559; SWARTZ KJ, 1995, NEURON, V15, P941, DOI 10.1016/0896-6273(95)90184-1; Swartz KJ, 1997, NEURON, V18, P665, DOI 10.1016/S0896-6273(00)80306-2; Takahashi H, 2000, J MOL BIOL, V297, P771, DOI 10.1006/jmbi.2000.3609; Wang JM, 2004, J GEN PHYSIOL, V123, P455, DOI 10.1085/jgp.200309005; Yang NB, 1996, NEURON, V16, P113, DOI 10.1016/S0896-6273(00)80028-8	30	160	166	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 11	2005	436	7052					857	860		10.1038/nature03873	http://dx.doi.org/10.1038/nature03873			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953XG	16094370				2022-12-28	WOS:000231116500048
J	Amant, F; Moerman, P; Neven, P; Timmerman, D; Van Limbergen, E; Vergote, I				Amant, F; Moerman, P; Neven, P; Timmerman, D; Van Limbergen, E; Vergote, I			Endometrial cancer	LANCET			English	Review							PAPILLARY-SEROUS-CARCINOMA; PHASE-III TRIAL; CLINICAL STAGE-I; HORMONE-REPLACEMENT THERAPY; GENE-EXPRESSION PROFILES; FACTOR-BINDING PROTEIN-1; ROUTINE FOLLOW-UP; POSTMENOPAUSAL WOMEN; RADIATION-THERAPY; BREAST-CANCER	Each year, endometrial cancer develops in about 142 000 women worldwide, and an estimated 42 000 women die from this cancer. The typical age-incidence curve for endometrial cancer shows that most cases are diagnosed after the menopause, with the highest incidence around the seventh decade of life. The appearance of symptoms early in the course explains why most women with endometrial cancer have early-stage disease at presentation. For all stages taken together, the overall 5-year survival is around 80%. There is a substantial prognostic difference between the histological types of endometrial cancers. The most common lesions (type 1) are typically hormone sensitive and low stage and have an excellent prognosis, whereas tumours of type 2 are high grade with a tendency to recur, even in early stage. The cornerstone of treatment for endometrial cancer is surgery, which not only is important for staging purposes but also enables appropriate tailoring of adjuvant treatment modalities that benefit high-risk patients only. We review current concepts about epidemiology, pathology, pathogenesis, risk factors and prevention, diagnosis, staging, prognostic factors, treatment, and follow-up of endometrial cancer.	Katholieke Univ Leuven, UZ Gasthuisberg, Dept Obstet & Gynaecol, Div Gynecol Oncol, Louvain, Belgium; Katholieke Univ Leuven, UZ Gasthuisberg, Multidisciplinary Breast Ctr, Louvain, Belgium; Katholieke Univ Leuven, UZ Gasthuisberg, Dept Histopathol, Louvain, Belgium; Katholieke Univ Leuven, UZ Gasthuisberg, Dept Radiat Oncol, Louvain, Belgium	KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven	Neven, P (corresponding author), UZKU Leuven, Div Gynecol Oncol, Dept Obstet & Gynaecol, Herestr 49, B-3000 Louvain, Belgium.	patrick.neven@uz.kuleuven.ac.be	Timmerman, Dirk/AAD-2363-2019; Creutzberg, Carien L/E-2253-2018; Amant, Frédéric/W-7436-2019; Georgiou, Ektoras/S-2419-2019	Timmerman, Dirk/0000-0002-3707-6645; Creutzberg, Carien L/0000-0002-7008-4321; Amant, Frédéric/0000-0002-5452-4905; 				AALDERS J, 1980, OBSTET GYNECOL, V56, P419; Aapro MS, 2003, ANN ONCOL, V14, P441, DOI 10.1093/annonc/mdg112; Abeler VM, 1996, CANCER, V78, P1740, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1740::AID-CNCR14>3.0.CO;2-Y; ABELER VM, 1991, CANCER, V67, P3093, DOI 10.1002/1097-0142(19910615)67:12<3093::AID-CNCR2820671226>3.0.CO;2-L; ABELER VM, 1991, CANCER, V68, P98, DOI 10.1002/1097-0142(19910701)68:1<98::AID-CNCR2820680120>3.0.CO;2-R; Adesanya OO, 1999, P NATL ACAD SCI USA, V96, P3287, DOI 10.1073/pnas.96.6.3287; Agboola OO, 1997, CAN MED ASSOC J, V157, P879; Alektiar KM, 2002, INT J RADIAT ONCOL, V54, P79, DOI 10.1016/S0360-3016(02)02913-9; AMBROS RA, 1995, HUM PATHOL, V26, P1260, DOI 10.1016/0046-8177(95)90203-1; Anderson GL, 2003, JAMA-J AM MED ASSOC, V290, P1739, DOI 10.1001/jama.290.13.1739; Anderson KE, 2001, CANCER EPIDEM BIOMAR, V10, P611; Arko D, 2000, J ULTRAS MED, V19, P639; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; Ayabe T, 1997, ENDOCR J, V44, P419, DOI 10.1507/endocrj.44.419; Bahamondes L, 2003, ACTA OBSTET GYN SCAN, V82, P580; Bandera EV, 2003, NUTR CANCER, V45, P24, DOI 10.1207/S15327914NC4501_3; BARAKAT RR, 2004, P 35 ANN M SOC GYN O, V78; BARRETT RJ, 1993, AM J CLIN ONCOL-CANC, V16, P494, DOI 10.1097/00000421-199312000-00007; BENEDETTIPANICI P, 1998, INT J GYNECOL CANCER, V8, P1837; Beral V, 2005, LANCET, V365, P1543, DOI 10.1016/S0140-6736(05)66455-0; Berliere M, 2000, EUR J CANCER, V36, pS35; Bernstein L, 1999, J NATL CANCER I, V91, P1654, DOI 10.1093/jnci/91.19.1654; BERTELLI G, 2004, BREAST CANC RES T S1, V88; BOKHMAN JV, 1983, GYNECOL ONCOL, V15, P10, DOI 10.1016/0090-8258(83)90111-7; BORONOW RC, 1984, OBSTET GYNECOL, V63, P825; Brinkmann D, 2004, JNCI-J NATL CANCER I, V96, P1441, DOI 10.1093/jnci/djh272; Bristow RE, 2000, GYNECOL ONCOL, V78, P85, DOI 10.1006/gyno.2000.5843; Bristow RE, 2001, GYNECOL ONCOL, V81, P92, DOI 10.1006/gyno.2000.6110; BURKE TW, 1993, GYNECOL ONCOL, V51, P397, DOI 10.1006/gyno.1993.1310; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Carcangiu ML, 1997, AM J SURG PATHOL, V21, P1507, DOI 10.1097/00000478-199712000-00015; CARCANGIU ML, 1992, GYNECOL ONCOL, V47, P298, DOI 10.1016/0090-8258(92)90130-B; Chi DS, 1997, GYNECOL ONCOL, V67, P56, DOI 10.1006/gyno.1997.4838; Chubak J, 2004, CANCER EPIDEM BIOMAR, V13, P1296; Cirisano FD, 1999, GYNECOL ONCOL, V74, P385, DOI 10.1006/gyno.1999.5505; Clark TJ, 2004, CURR OPIN OBSTET GYN, V16, P305, DOI 10.1097/01.gco.0000136491.26463.c2; Clark TJ, 2002, BJOG-INT J OBSTET GY, V109, P313, DOI 10.1016/S1470-0328(02)01088-1; Clark TJ, 2002, JAMA-J AM MED ASSOC, V288, P1610, DOI 10.1001/jama.288.13.1610; Clark TJ, 2001, ACTA OBSTET GYN SCAN, V80, P784; Clement PB, 2002, ADV ANAT PATHOL, V9, P145, DOI 10.1097/00125480-200205000-00001; Cohen I, 2004, GYNECOL ONCOL, V94, P256, DOI 10.1016/j.ygyno.2004.03.048; Cohn DE, 2002, GYNECOL ONCOL, V87, P243, DOI 10.1006/gyno.2002.6825; Colbert LH, 2003, CANCER CAUSE CONTROL, V14, P559, DOI 10.1023/A:1024866827775; Cragun JM, 2005, J CLIN ONCOL, V23, P3668, DOI 10.1200/JCO.2005.04.144; Crawford SC, 2002, BRIT J CANCER, V86, P1837, DOI 10.1038/sj.bjc.6600358; CREASMAN WT, 1987, CANCER, V60, P2035, DOI 10.1002/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO;2-8; Creasman WT, 2004, GYNECOL ONCOL, V95, P593, DOI 10.1016/j.ygyno.2004.08.019; CREASMAN WT, 1989, GYNECOL ONCOL, V35, P129, DOI 10.1016/0090-8258(89)90028-0; Creutzberg CL, 2004, J CLIN ONCOL, V22, P1234, DOI 10.1200/JCO.2004.08.159; Creutzberg CL, 2000, LANCET, V355, P1404, DOI 10.1016/S0140-6736(00)02139-5; Creutzberg CL, 2003, GYNECOL ONCOL, V89, P201, DOI 10.1016/S0090-8258(03)00126-4; Cuzick J, 2003, LANCET, V361, P296, DOI 10.1016/S0140-6736(03)12342-2; Darvishian T, 2004, AM J SURG PATHOL, V28, P1568, DOI 10.1097/00000478-200412000-00004; de Kroon CD, 2003, BJOG-INT J OBSTET GY, V110, P938, DOI 10.1016/S1470-0328(03)02472-8; de Vries CS, 2005, DRUG SAFETY, V28, P241, DOI 10.2165/00002018-200528030-00005; Deligeoroglou E, 2003, ANN NY ACAD SCI, V997, P199, DOI 10.1196/annals.1290.023; DESPIERRE E, IN PRESS INT J GYNEC; Dijkhuizen FPHLJ, 2000, CANCER, V89, P1765, DOI 10.1002/1097-0142(20001015)89:8<1765::AID-CNCR17>3.0.CO;2-F; Dijkhuizen FPHLJ, 2003, MATURITAS, V45, P275, DOI 10.1016/S0378-5122(03)00152-X; Dotters DJ, 2000, AM J OBSTET GYNECOL, V182, P1328, DOI 10.1067/mob.2000.106251; EIFEL P, 1982, CANCER-AM CANCER SOC, V50, P163, DOI 10.1002/1097-0142(19820701)50:1<163::AID-CNCR2820500131>3.0.CO;2-K; Einhorn N, 2003, ACTA ONCOL, V42, P557, DOI 10.1080/02841860310014417; ENOMOTO T, 1991, CANCER RES, V51, P5308; FELDMAN S, 1995, GYNECOL ONCOL, V56, P376, DOI 10.1006/gyno.1995.1066; Fleming GF, 2004, J CLIN ONCOL, V22, P2159, DOI 10.1200/JCO.2004.07.184; Franchi M, 2000, GYNECOL ONCOL, V76, P357, DOI 10.1006/gyno.1999.5694; Furberg AS, 2003, INT J CANCER, V104, P669, DOI 10.1002/ijc.10974; GAL D, 1992, CANCER, V69, P200, DOI 10.1002/1097-0142(19920101)69:1<200::AID-CNCR2820690132>3.0.CO;2-D; Garcia F, 2003, J REPROD MED, V48, P882; Gardner FJE, 2000, LANCET, V356, P1711, DOI 10.1016/S0140-6736(00)03204-9; Gehrig PA, 2004, GYNECOL ONCOL, V94, P208, DOI 10.1016/j.ygyno.2004.04.009; Geisler JP, 1999, GYNECOL ONCOL, V74, P465, DOI 10.1006/gyno.1999.5513; Gerber B, 2001, EUR J CANCER, V37, P64, DOI 10.1016/S0959-8049(00)00356-7; Gielen SCJP, 2005, J SOC GYNECOL INVEST, V12, P58, DOI 10.1016/j.jsgi.2004.08.003; Ginsburg ES, 1996, JAMA-J AM MED ASSOC, V276, P1747, DOI 10.1001/jama.276.21.1747; GOFF BA, 1994, GYNECOL ONCOL, V52, P237, DOI 10.1006/gyno.1994.1038; Goodman MT, 1997, AM J EPIDEMIOL, V146, P294, DOI 10.1093/oxfordjournals.aje.a009270; GREDMARK T, 1995, BRIT J OBSTET GYNAEC, V102, P133, DOI 10.1111/j.1471-0528.1995.tb09066.x; GREEN JB, 1990, OBSTET GYNECOL, V75, P696; GRIGSBY PW, 1992, INT J RADIAT ONCOL, V22, P905, DOI 10.1016/0360-3016(92)90786-H; Gruber SB, 1996, CANCER EPIDEM BIOMAR, V5, P411; Gu M, 2001, ACTA CYTOL, V45, P555, DOI 10.1159/000327864; Gupta JK, 2002, ACTA OBSTET GYN SCAN, V81, P799, DOI 10.1034/j.1600-0412.2001.810902.x; Haiman CA, 2001, CANCER RES, V61, P3955; Hardiman P, 2003, LANCET, V361, P1810, DOI 10.1016/S0140-6736(03)13409-5; HAROUNY VR, 1988, OBSTET GYNECOL, V72, P394; Harvey E B, 1985, Natl Cancer Inst Monogr, V68, P99; Hemminki K, 2004, EUR J CANCER, V40, P90, DOI 10.1016/S0959-8049(03)00627-0; HENDRICKSON M, 1982, AM J SURG PATHOL, V6, P93, DOI 10.1097/00000478-198203000-00002; Hill HA, 1996, OBSTET GYNECOL, V88, P919; Hinkula M, 2002, INT J CANCER, V98, P912, DOI 10.1002/ijc.10267; Horn-Ross PL, 2003, J NATL CANCER I, V95, P1158, DOI 10.1093/jnci/djg015; Horowitz NS, 2004, GYNECOL ONCOL, V95, P546, DOI 10.1016/j.ygyno.2004.08.009; Hoskins PJ, 2001, J CLIN ONCOL, V19, P4048, DOI 10.1200/JCO.2001.19.20.4048; Hubacher D, 2002, OBSTET GYNECOL SURV, V57, P120, DOI 10.1097/00006254-200202000-00024; Huh WK, 2003, GYNECOL ONCOL, V91, P470, DOI 10.1016/j.ygyno.2003.08.027; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jolly EE, 2003, MENOPAUSE, V10, P337, DOI 10.1097/01.GME.0000058772.59606.2A; Kaaks R, 2002, CANCER EPIDEM BIOMAR, V11, P1531; Keys HM, 2004, GYNECOL ONCOL, V92, P744, DOI 10.1016/j.ygyno.2003.11.048; KILGORE LC, 1995, GYNECOL ONCOL, V56, P29, DOI 10.1006/gyno.1995.1005; Kim YB, 1997, CANCER, V79, P320, DOI 10.1002/(SICI)1097-0142(19970115)79:2<320::AID-CNCR15>3.0.CO;2-2; Kinkel K, 1999, RADIOLOGY, V212, P711, DOI 10.1148/radiology.212.3.r99au29711; Kjaer SK, 2004, INT J EPIDEMIOL, V33, P596, DOI 10.1093/ije/dyh046; Klip H, 2000, CANCER CAUSE CONTROL, V11, P319, DOI 10.1023/A:1008921211309; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; KOSARY CL, 1994, SEMIN SURG ONCOL, V10, P31, DOI 10.1002/ssu.2980100107; Kucera E, 2000, GYNECOL OBSTET INVES, V49, P62, DOI 10.1159/000010215; Lacey JV, 2004, CANCER EPIDEM BIOMAR, V13, P607; LAMBRECHTS S, IN PRESS INT J GYNEC; Langer RD, 1997, NEW ENGL J MED, V337, P1792, DOI 10.1056/NEJM199712183372502; Lax SF, 2000, CANCER-AM CANCER SOC, V88, P814, DOI 10.1002/(SICI)1097-0142(20000215)88:4<814::AID-CNCR12>3.3.CO;2-L; Lax SF, 2000, AM J SURG PATHOL, V24, P1201, DOI 10.1097/00000478-200009000-00002; Lentz SS, 1996, J CLIN ONCOL, V14, P357, DOI 10.1200/JCO.1996.14.2.357; LESKO SM, 1985, NEW ENGL J MED, V313, P593, DOI 10.1056/NEJM198509053131001; LEVENBACK C, 1992, GYNECOL ONCOL, V46, P317, DOI 10.1016/0090-8258(92)90224-7; Lindauer J, 2003, GYNECOL ONCOL, V91, P547, DOI 10.1016/j.ygyno.2003.08.003; LONG HJ, 1988, J NATL CANCER I, V80, P276, DOI 10.1093/jnci/80.4.276; Lu KH, 2005, OBSTET GYNECOL, V105, P569, DOI 10.1097/01.AOG.0000154885.44002.ae; Luoto R, 2004, BRIT J CANCER, V90, P1756, DOI 10.1038/sj.bjc.6601763; LYNCH HT, 1966, ARCH INTERN MED, V117, P206, DOI 10.1001/archinte.117.2.206; Madison T, 2004, AM J PUBLIC HEALTH, V94, P2104, DOI 10.2105/AJPH.94.12.2104; Manolitsas TP, 2001, CANCER, V91, P1437, DOI 10.1002/1097-0142(20010415)91:8<1437::AID-CNCR1150>3.0.CO;2-P; Mariani A, 2004, GYNECOL ONCOL, V95, P120, DOI 10.1016/j.ygyno.2004.06.042; Mariani A, 2000, AM J OBSTET GYNECOL, V182, P1506, DOI 10.1067/mob.2000.107335; McTiernan A, 2004, CANCER RES, V64, P2923, DOI 10.1158/0008-5472.CAN-03-3393; Memarzadeh S, 2002, INT J GYNECOL CANCER, V12, P454, DOI 10.1046/j.1525-1438.2002.01149.x; Morales L, 2005, ANN ONCOL, V16, P70, DOI 10.1093/annonc/mdi021; Moreno-Bueno G, 2003, CANCER RES, V63, P5697; Morice P, 2001, EUR J CANCER, V37, P985, DOI 10.1016/S0959-8049(01)00066-1; MORROW CP, 1991, GYNECOL ONCOL, V40, P55, DOI 10.1016/0090-8258(91)90086-K; MORROW CP, 1990, GYNECOL ONCOL, V36, P166, DOI 10.1016/0090-8258(90)90166-I; Mutter GL, 2000, J CLIN ENDOCR METAB, V85, P2334, DOI 10.1210/jc.85.6.2334; Mutter GL, 2001, GYNECOL ONCOL, V83, P177, DOI 10.1006/gyno.2001.6352; Mutter GL, 2000, JNCI-J NATL CANCER I, V92, P924, DOI 10.1093/jnci/92.11.924; *NCI, 2002, SURV EP END RES PROG; Neven P, 2000, DRUG SAFETY, V22, P1, DOI 10.2165/00002018-200022010-00001; Neven P, 1998, LANCET, V351, P155, DOI 10.1016/S0140-6736(05)78216-7; Neven P, 1998, LANCET, V351, P36, DOI 10.1016/S0140-6736(05)78091-0; Obermair A, 2000, INT J GYNECOL CANCER, V10, P275, DOI 10.1046/j.1525-1438.2000.010004275.x; OKAMOTO A, 1991, CANCER RES, V51, P5632; Parkin DM, 1999, CA-CANCER J CLIN, V49, P33, DOI 10.3322/canjclin.49.1.33; Parslov M, 2000, AM J OBSTET GYNECOL, V182, P23, DOI 10.1016/S0002-9378(00)70486-8; PASMANTIER MW, 1985, CANCER TREAT REP, V69, P539; Pearcey RG, 2000, RADIOTHER ONCOL, V56, P17, DOI 10.1016/S0167-8140(00)00171-7; Pocard M, 2003, LANCET ONCOL, V4, P637, DOI 10.1016/S1470-2045(03)01224-5; Podratz KC, 2003, GYNECOL ONCOL, V91, P461, DOI 10.1016/j.ygyno.2003.10.031; POETTER R, 2002, GEC ESTRO HDB BRACHY, P365; Pothuri B, 2003, OBSTET GYNECOL, V101, P941, DOI 10.1016/S0029-7844(03)00234-5; Potischman N, 1996, J NATL CANCER I, V88, P1127, DOI 10.1093/jnci/88.16.1127; Prat J, 2004, HUM PATHOL, V35, P649, DOI 10.1016/j.humpath.2004.02.007; RAMIREZGONZALEZ CE, 1987, OBSTET GYNECOL, V70, P212; Ramondetta L, 2001, GYNECOL ONCOL, V82, P156, DOI 10.1006/gyno.2001.6211; RANDALL ME, 2003, P AN M AM SOC CLIN, V22, P2; Revel A, 2004, OBSTET GYNECOL SURV, V59, P280, DOI 10.1097/01.OGX.0000120173.09136.4A; Risinger JI, 2003, CANCER RES, V63, P6; Risinger JI, 1997, CANCER RES, V57, P4736; Robertson G, 2003, MED J AUSTRALIA, V178, P657, DOI 10.5694/j.1326-5377.2003.tb05400.x; Ronnett B, 2002, BLAUSTEINS PATHOLOGY, P501; ROSENBERG P, 1993, GYNECOL ONCOL, V48, P32, DOI 10.1006/gyno.1993.1006; Sagae S, 2005, J CLIN ONCOL, V23, p455S; Santin AD, 2003, GYNECOL ONCOL, V88, P263, DOI 10.1016/S0090-8258(02)00094-X; Schneider A, 2004, GYNECOL ONCOL, V94, P861, DOI 10.1016/j.ygyno.2004.06.009; Schouten LJ, 2004, JNCI-J NATL CANCER I, V96, P1635, DOI 10.1093/jnci/djh291; SELTZER V, 1984, GYNECOL ONCOL, V19, P308, DOI 10.1016/0090-8258(84)90197-5; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Slomovitz BM, 2004, OBSTET GYNECOL, V104, P255, DOI 10.1097/01.AOG.0000131620.67911.03; Slomovitz BM, 2003, GYNECOL ONCOL, V91, P463, DOI 10.1016/j.ygyno.2003.08.018; Smid-Koopman E, 2000, BRIT J CANCER, V83, P246; Smith RA, 2003, CA-CANCER J CLIN, V53, P27, DOI 10.3322/canjclin.53.1.27; Smith-Bindman R, 1998, JAMA-J AM MED ASSOC, V280, P1510, DOI 10.1001/jama.280.17.1510; Sonoda Y, 2001, GYNECOL ONCOL, V80, P378, DOI 10.1006/gyno.2000.6079; Soslow RA, 2000, AM J SURG PATHOL, V24, P726, DOI 10.1097/00000478-200005000-00012; Stefansson IM, 2004, HISTOPATHOLOGY, V44, P472, DOI 10.1111/j.1365-2559.2004.01882.x; SuvantoLuukkonen E, 1995, MATURITAS, V22, P255, DOI 10.1016/0378-5122(95)00935-E; Thigpen JT, 2004, J CLIN ONCOL, V22, P3902, DOI 10.1200/JCO.2004.02.088; Timmerman D, 2003, ULTRASOUND OBST GYN, V22, P166, DOI 10.1002/uog.203; TIMMERMAN D, 2003, INT J GYNECOL CAN S1, V13, pS26; Trimbos JB, 2003, JNCI-J NATL CANCER I, V95, P113, DOI 10.1093/jnci/95.2.113; TROPE C, 1984, AM J OBSTET GYNECOL, V149, P379, DOI 10.1016/0002-9378(84)90147-9; ULBRIGHT TM, 1985, HUM PATHOL, V16, P28, DOI 10.1016/S0046-8177(85)80210-0; Umar A, 2004, NAT REV CANCER, V4, P153, DOI 10.1038/nrc1278; Unfer V, 2004, FERTIL STERIL, V82, P145, DOI 10.1016/j.fertnstert.2003.11.041; Van den Bosch T, 2003, AM J OBSTET GYNECOL, V188, P1249, DOI 10.1067/mob.2003.272; Van Gorp T, 2002, MATURITAS, V42, P93, DOI 10.1016/S0378-5122(02)00031-2; VANDENBOSCH T, 1995, OBSTET GYNECOL, V85, P349, DOI 10.1016/0029-7844(94)00421-9; VANEYCKEN E, 2000, KANK VLAAND; VERGOTE I, 1989, CANCER, V64, P1011, DOI 10.1002/1097-0142(19890901)64:5<1011::AID-CNCR2820640507>3.0.CO;2-7; Vergote I, 2002, GYNECOL ONCOL, V84, P537, DOI 10.1006/gyno.2001.6422; Viswanathan AN, 2005, INT J CANCER, V114, P996, DOI 10.1002/ijc.20821; Weiderpass E, 2000, CANCER CAUSE CONTROL, V11, P185, DOI 10.1023/A:1008946825313; Wheeler DT, 2000, AM J SURG PATHOL, V24, P797, DOI 10.1097/00000478-200006000-00004; Whitney CW, 2004, GYNECOL ONCOL, V92, P4, DOI 10.1016/j.ygyno.2003.09.018; Xu WH, 2004, BMJ-BRIT MED J, V328, P1285, DOI 10.1136/bmj.38093.646215.AE; Yu CKH, 2005, BJOG-INT J OBSTET GY, V112, P115, DOI 10.1111/j.1471-0528.2004.00335.x; Zaino RJ, 1998, AM J SURG PATHOL, V22, P1379, DOI 10.1097/00000478-199811000-00008; ZAINO RJ, 1995, CANCER-AM CANCER SOC, V75, P81, DOI 10.1002/1097-0142(19950101)75:1<81::AID-CNCR2820750114>3.0.CO;2-F; ZAINO RJ, 1988, SEMIN DIAGN PATHOL, V5, P154; Zanotti KM, 1999, GYNECOL ONCOL, V74, P272, DOI 10.1006/gyno.1999.5444; Zeleniuch-Jacquotte A, 2001, BRIT J CANCER, V84, P975, DOI 10.1054/bjoc.2001.1704; Zheng WX, 2004, GYNECOL ONCOL, V92, P1008, DOI 10.1016/j.ygyno.2003.11.026	201	1161	1212	7	118	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 6	2005	366	9484					491	505		10.1016/S0140-6736(05)67063-8	http://dx.doi.org/10.1016/S0140-6736(05)67063-8			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	952RD	16084259	Green Accepted			2022-12-28	WOS:000231022300032
J	Campisi, J				Campisi, J			Cancer - Suppressing cancer: The importance of being senescent	SCIENCE			English	Editorial Material							FIBROBLASTS; GROWTH; CELLS		Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Buck Inst Age Res, Novato, CA 94945 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Buck Institute for Research on Aging	Campisi, J (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, 1 Cyclotron Rd, Berkeley, CA 94720 USA.	jcampisi@lbl.gov						Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890	8	197	214	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 5	2005	309	5736					886	887		10.1126/science.1116801	http://dx.doi.org/10.1126/science.1116801			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953SS	16081723				2022-12-28	WOS:000231101400030
J	Bain, BJ				Bain, BJ			Current concepts: Diagnosis from the blood smear	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							AUTOMATED PLATELET COUNT; HEMOGLOBIN-C DISEASE; ANEMIA; FILM		St Marys Hosp, Dept Haematol, London W2 1NY, England	Imperial College London	Bain, BJ (corresponding author), St Marys Hosp, Dept Haematol, Praed St, London W2 1NY, England.	b.bain@imperial.ac.uk						Abramson N, 2004, BLOOD, V103, P367, DOI 10.1182/blood-2003-10-3576; Arnold JA, 1999, BRIT J HAEMATOL, V104, P1; BAIN BJ, 1993, BRIT J HAEMATOL, V83, P516, DOI 10.1111/j.1365-2141.1993.tb04679.x; Bain BJ, 1999, BRIT J HAEMATOL, V104, P647, DOI 10.1046/j.1365-2141.1999.01330.x; DIGGS LW, 1965, BLOOD-J HEMATOL, V25, P218, DOI 10.1182/blood.V25.2.218.218; Kakkar N, 2004, J CLIN PATHOL, V57, P1096, DOI 10.1136/jcp.2004.016758; Latif S, 2003, AM J CLIN PATHOL, V120, P882, DOI 10.1309/H2K6#59LYFE63GPB; Lesesve JF, 2004, AM J CLIN PATHOL, V121, P739, DOI 10.1309/MY7077989KWDYP88; Luethi U, 2004, BLOOD, V103, P486, DOI 10.1182/blood-2003-05-1615; Marks PW, 2004, NEW ENGL J MED, V351, P1333, DOI 10.1056/NEJMcpc040921; Shattil SJ, 2003, BLOOD, V101, P2453, DOI 10.1182/blood-2003-01-0140; van der Meer W, 2003, J CLIN PATHOL, V56, P772, DOI 10.1136/jcp.56.10.772	12	195	213	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 4	2005	353	5					498	507		10.1056/NEJMra043442	http://dx.doi.org/10.1056/NEJMra043442			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	951OB	16079373				2022-12-28	WOS:000230939000009
J	Gulati, M; Black, HR; Shaw, LJ; Arnsdorf, MF; Merz, CNB; Lauer, MS; Marwick, TH; Pandey, DK; Wicklund, RH; Thisted, RA				Gulati, M; Black, HR; Shaw, LJ; Arnsdorf, MF; Merz, CNB; Lauer, MS; Marwick, TH; Pandey, DK; Wicklund, RH; Thisted, RA			The prognostic value of a nomogram for exercise capacity in women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREDICTING FUNCTIONAL-CAPACITY; CORONARY-ARTERY-DISEASE; MAXIMAL OXYGEN INTAKE; METABOLIC EQUIVALENTS; PHYSICAL-FITNESS; HEALTHY-MEN; FOLLOW-UP; MORTALITY; DEATH; AGE	BACKGROUND: Recent studies have demonstrated that exercise capacity is an independent predictor of mortality in women. Normative values of exercise capacity for age in women have not been well established. Our objectives were to construct a nomogram to permit determination of predicted exercise capacity for age in women and to assess the predictive value of the nomogram with respect to survival. METHODS: A total of 5721 asymptomatic women underwent a symptom-limited, maximal stress test. Exercise capacity was measured in metabolic equivalents (MET). Linear regression was used to estimate the mean MET achieved for age. A nomogram was established to allow the percentage of predicted exercise capacity to be estimated on the basis of age and the exercise capacity achieved. The nomogram was then used to determine the percentage of predicted exercise capacity for both the original cohort and a referral population of 4471 women with cardiovascular symptoms who underwent a symptom-limited stress test. Survival data were obtained for both cohorts, and Cox survival analysis was used to estimate the rates of death from any cause and from cardiac causes in each group. RESULTS: The linear regression equation for predicted exercise capacity (in MET) on the basis of age in the cohort of asymptomatic women was as follows: predicted MET = 14.7 - (0.13 x age). The risk of death among asymptomatic women whose exercise capacity was less than 85 percent of the predicted value for age was twice that among women whose exercise capacity was at least 85 percent of the age-predicted value (P<0.001). Results were similar in the cohort of symptomatic women. CONCLUSIONS: We have established a nomogram for predicted exercise capacity on the basis of age that is predictive of survival among both asymptomatic and symptomatic women. These findings could be incorporated into the interpretation of exercise stress tests, providing additional prognostic information for risk stratification.	Rush Univ, Med Ctr, Dept Prevent Med, Chicago, IL 60612 USA; Cedars Sinai Med Ctr, Cedars Sinai Res Inst, Dept Med, Div Cardiol, Los Angeles, CA 90048 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA; Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA; Princess Alexandra Hosp, Dept Med, Brisbane, Qld 4102, Australia; Univ Illinois, Dept Neurol, Chicago, IL USA; St James Hosp & Hlth Ctr, Div Cardiol, Chicago, IL USA	Rush University; Cedars Sinai Medical Center; University of Chicago; University of Chicago; Cleveland Clinic Foundation; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gulati, M (corresponding author), Northwestern Univ, Bluhm Cardiovasc Inst, 201 E Huron St, Chicago, IL 60611 USA.	mgulati@nmff.org	Lauer, Michael S/L-9656-2013; Thisted, Ronald A/B-1985-2008; Marwick, Thomas H/C-7261-2013; Gulati, Martha/AAB-7722-2022	Lauer, Michael S/0000-0002-9217-8177; Marwick, Thomas H/0000-0001-9065-0899; Pandey, Dilip/0000-0001-7242-3182				BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; BRUCE RA, 1971, ANN CLIN RES, V3, P323; BRUCE RA, 1973, AM HEART J, V85, P546, DOI 10.1016/0002-8703(73)90502-4; DEHN MM, 1972, J APPL PHYSIOL, V33, P805, DOI 10.1152/jappl.1972.33.6.805; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; FOSTER C, 1984, AM HEART J, V107, P1229, DOI 10.1016/0002-8703(84)90282-5; FROELICHER VF, 1974, AEROSPACE MED, V45, P310; Gulati M, 2003, CIRCULATION, V108, P1554, DOI 10.1161/01.CIR.0000091080.57509.E9; JETTE M, 1990, CLIN CARDIOL, V13, P555, DOI 10.1002/clc.4960130809; Marwick TH, 2001, CIRCULATION, V103, P2566; Marwick TH, 1999, AM J MED, V106, P172, DOI 10.1016/S0002-9343(98)00388-X; Mora S, 2003, JAMA-J AM MED ASSOC, V290, P1600, DOI 10.1001/jama.290.12.1600; MORRIS CK, 1993, J AM COLL CARDIOL, V22, P175, DOI 10.1016/0735-1097(93)90832-L; MYERS J, 1991, J AM COLL CARDIOL, V17, P1334, DOI 10.1016/S0735-1097(10)80144-5; ROBERTS JM, 1984, AM HEART J, V108, P1454, DOI 10.1016/0002-8703(84)90692-6; Shaw LJ, 2005, J AM COLL CARDIOL, V45, P1494, DOI 10.1016/j.jacc.2005.01.036; SULLIVAN M, 1984, AM HEART J, V107, P486, DOI 10.1016/0002-8703(84)90090-5; Wei M, 1999, JAMA-J AM MED ASSOC, V282, P1547, DOI 10.1001/jama.282.16.1547; WOLTHUIS RA, 1977, CIRCULATION, V55, P153, DOI 10.1161/01.CIR.55.1.153	19	285	290	1	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 4	2005	353	5					468	475		10.1056/NEJMoa044154	http://dx.doi.org/10.1056/NEJMoa044154			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	951OB	16079370				2022-12-28	WOS:000230939000006
J	Tezcan, FA; Kaiser, JT; Mustafi, D; Walton, MY; Howard, JB; Rees, DC				Tezcan, FA; Kaiser, JT; Mustafi, D; Walton, MY; Howard, JB; Rees, DC			Nitrogenase complexes: Multiple docking sites for a nucleotide switch protein	SCIENCE			English	Article							AZOTOBACTER-VINELANDII; ELECTRON-TRANSFER; SIGNAL-TRANSDUCTION; TRANSITION-STATE; CROSS-LINKING; IRON PROTEIN; MECHANISM; INHIBITION; INSIGHTS	Adenosine triphosphate (ATP) hydrolysis in the nitrogenase complex controls the cycle of association and dissociation between the electron donor adenosine triphosphatase (ATPase) (Fe-protein) and its target catalytic protein (MoFe-protein), driving the reduction of dinitrogen into ammonia. Crystal structures in different nucleotide states have been determined that identify conformational changes in the nitrogenase complex during ATP turnover. These structures reveal distinct and mutually exclusive interaction sites on the MoFe-protein surface that are selectively populated, depending on the Fe-protein nucleotide state. A consequence of these different docking geometries is that the distance between redox cofactors, a critical determinant of the intermolecular electron transfer rate, is coupled to the nucleotide state. More generally, stabilization of distinct docking geometries by different nucleotide states, as seen for nitrogenase, could enable nucleotide hydrolysis to drive the relative motion of protein partners in molecular motors and other systems.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; Univ Minnesota, Dept Biochem, Minneapolis, MN 55455 USA	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute; University of Minnesota System; University of Minnesota Twin Cities	Rees, DC (corresponding author), CALTECH, Div Chem & Chem Engn, Mail Code 114-96, Pasadena, CA 91125 USA.	dcrees@caltech.edu		Mustafi, Debarshi/0000-0002-9164-7488				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; Bustamante C, 2001, ACCOUNTS CHEM RES, V34, P412, DOI 10.1021/ar0001719; Chiu HJ, 2001, BIOCHEMISTRY-US, V40, P641, DOI 10.1021/bi001645e; DEITS TL, 1990, J BIOL CHEM, V265, P3859; Duyvis MG, 1996, FEBS LETT, V380, P233, DOI 10.1016/0014-5793(96)00019-1; Gabdoulline RR, 2002, CURR OPIN STRUC BIOL, V12, P204, DOI 10.1016/S0959-440X(02)00311-1; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; Gray HB, 2003, Q REV BIOPHYS, V36, P341, DOI 10.1017/S0033583503003913; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; HOWARD JB, 1994, ANNU REV BIOCHEM, V63, P235, DOI 10.1146/annurev.bi.63.070194.001315; Igarashi RY, 2003, CRIT REV BIOCHEM MOL, V38, P351, DOI 10.1080/10409230390242380; Jacobs D, 1995, ARCH BIOCHEM BIOPHYS, V324, P317, DOI 10.1006/abbi.1995.0044; Jang SB, 2000, BIOCHEMISTRY-US, V39, P14745, DOI 10.1021/bi001705g; Lanzilotta WN, 1996, BIOCHEMISTRY-US, V35, P7188, DOI 10.1021/bi9603985; Leys D, 2003, NAT STRUCT BIOL, V10, P219, DOI 10.1038/nsb894; Miyashita O, 2004, P NATL ACAD SCI USA, V101, P16174, DOI 10.1073/pnas.0405745101; NELSON P, 2004, BIOL PHYS ENERGY LIF; Page CC, 2003, CURR OPIN CHEM BIOL, V7, P551, DOI 10.1016/j.cbpa.2003.08.005; Rees DC, 2000, CURR OPIN CHEM BIOL, V4, P559, DOI 10.1016/S1367-5931(00)00132-0; Renner KA, 1996, BIOCHEMISTRY-US, V35, P5353, DOI 10.1021/bi960441o; Schindelin N, 1997, NATURE, V387, P370, DOI 10.1038/387370a0; Schlessman JL, 1998, J MOL BIOL, V280, P669, DOI 10.1006/jmbi.1998.1898; Schliwa M, 2003, NATURE, V422, P759, DOI 10.1038/nature01601; Schmid B, 2002, BIOCHEMISTRY-US, V41, P15557, DOI 10.1021/bi026642b; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Thorneley R. N. F., 1985, MOLYBDENUM ENZYMES, P221; van Amsterdam IMC, 2002, NAT STRUCT BIOL, V9, P48, DOI 10.1038/nsb736; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WILLING A, 1990, J BIOL CHEM, V265, P6596; WILLING AH, 1989, J BIOL CHEM, V264, P8499	32	167	169	3	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 26	2005	309	5739					1377	1380		10.1126/science.1115653	http://dx.doi.org/10.1126/science.1115653			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TX	16123301				2022-12-28	WOS:000231543300045
J	Costa-Mattioli, M; Gobert, D; Harding, H; Herdy, B; Azzi, M; Bruno, M; Bidinosti, M; Ben Mamou, C; Marcinkiewicz, E; Yoshida, M; Imataka, H; Cuello, AC; Seidah, N; Sossin, W; Lacaille, JC; Ron, D; Nader, K; Sonenberg, N				Costa-Mattioli, M; Gobert, D; Harding, H; Herdy, B; Azzi, M; Bruno, M; Bidinosti, M; Ben Mamou, C; Marcinkiewicz, E; Yoshida, M; Imataka, H; Cuello, AC; Seidah, N; Sossin, W; Lacaille, JC; Ron, D; Nader, K; Sonenberg, N			Translational control of hippocampal synaptic plasticity and memory by the eIF2 alpha kinase GCN2	NATURE			English	Article							LONG-TERM POTENTIATION; MAMMALIAN HOMOLOG; GENE-EXPRESSION; CA1 REGION; STORAGE; NEUROSCIENCE; ENHANCEMENT; DEGRADATION; INDUCTION	Studies on various forms of synaptic plasticity have shown a link between messenger RNA translation, learning and memory. Like memory, synaptic plasticity includes an early phase that depends on modification of pre-existing proteins, and a late phase that requires transcription and synthesis of new proteins(1,2). Activation of postsynaptic targets seems to trigger the transcription of plasticity-related genes. The new mRNAs are either translated in the soma or transported to synapses before translation. GCN2, a key protein kinase, regulates the initiation of translation. Here we report a unique feature of hippocampal slices from GCN2(-/-) mice: in CA1, a single 100-Hz train induces a strong and sustained long-termpotentiation ( late LTP or L-LTP), which is dependent on transcription and translation. In contrast, stimulation that elicits L-LTP in wild-type slices, such as four 100-Hz trains or forskolin, fails to evoke L-LTP in GCN2(-/-) slices. This aberrant synaptic plasticity is mirrored in the behaviour of GCN2(-/-) mice in the Morris water maze: after weak training, their spatial memory is enhanced, but it is impaired after more intense training. Activated GCN2 stimulates mRNA translation of ATF4, an antagonist of cyclic-AMP-response-element-binding protein ( CREB). Thus, in the hippocampus of GCN2(-/-) mice, the expression of ATF4 is reduced and CREB activity is increased. Our study provides genetic, physiological, behavioural and molecular evidence that GCN2 regulates synaptic plasticity, as well as learning and memory, through modulation of the ATF4/CREB pathway.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Psychol, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3G 1Y6, Canada; Univ Montreal, Ctr Rech Sci Neurol, Dept Physiol, Montreal, PQ H3C 3J7, Canada; NYU, Sch Med, Dept Med, Skirball Inst, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ H2W 1R7, Canada; RIKEN, Genom Sci Ctr, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan	McGill University; McGill University; McGill University; McGill University; McGill University; Universite de Montreal; New York University; New York University; New York University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; RIKEN	Sonenberg, N (corresponding author), McGill Univ, Dept Biochem, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.	nahum.sonenberg@mcgill.ca	Cuello, A. Claudio/N-8211-2015; Marcinkiewicz, Edyta/N-4203-2018; Seidah, Nabil/I-3596-2013	Marcinkiewicz, Edyta/0000-0002-2229-4084; Seidah, Nabil/0000-0001-6503-9342; Harding, Heather P/0000-0002-7359-7974; Ron, David/0000-0002-3014-5636; Cuello, Claudio/0000-0003-2143-2745	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008681] Funding Source: NIH RePORTER; NIDDK NIH HHS [R37 DK047119, R01 DK047119] Funding Source: Medline; NIEHS NIH HHS [R01 ES008681] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abel T, 1998, SCIENCE, V279, P338, DOI 10.1126/science.279.5349.338; Barco A, 2002, CELL, V108, P689, DOI 10.1016/S0092-8674(02)00657-8; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x; Chan J, 2004, RNA, V10, P528, DOI 10.1261/rna.5200204; Chen A, 2003, NEURON, V39, P655, DOI 10.1016/S0896-6273(03)00501-4; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; HUANG YY, 1995, P NATL ACAD SCI USA, V92, P2446, DOI 10.1073/pnas.92.7.2446; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kelleher RJ, 2004, CELL, V116, P467, DOI 10.1016/S0092-8674(04)00115-1; Lapointe V, 2004, J PHYSIOL-LONDON, V555, P125, DOI 10.1113/jphysiol.2003.053603; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Malleret G, 2001, CELL, V104, P675, DOI 10.1016/S0092-8674(01)00264-1; Mathews MB, 2000, COLD SPRING HARBOR M, V39, P1; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Palmer MJ, 1997, NEUROPHARMACOLOGY, V36, P1517, DOI 10.1016/S0028-3908(97)00181-0; Santoyo J, 1997, J BIOL CHEM, V272, P12544, DOI 10.1074/jbc.272.19.12544; Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896-6273(04)00182-5; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Seidah NG, 2003, P NATL ACAD SCI USA, V100, P928, DOI 10.1073/pnas.0335507100; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; Sonenberg N, 2003, CURR OPIN STRUC BIOL, V13, P56, DOI 10.1016/S0959-440X(03)00009-5; Sood R, 2000, GENETICS, V154, P787; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9	30	290	311	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 25	2005	436	7054					1166	1170		10.1038/nature03897	http://dx.doi.org/10.1038/nature03897			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	958AK	16121183	Green Accepted, Green Published			2022-12-28	WOS:000231416600048
J	Lee, SJ; Ralston, HJP; Drey, EA; Partridge, JC; Rosen, MA				Lee, SJ; Ralston, HJP; Drey, EA; Partridge, JC; Rosen, MA			Fetal pain - A systematic multidisciplinary review of the evidence	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							LEGAL-ABORTION MORTALITY; VELOCITY WAVE-FORMS; PRETERM INFANTS; INVASIVE PROCEDURES; STRESS-RESPONSE; NEWBORN-INFANTS; UNITED-STATES; HUMAN BRAIN; HUMAN FETUS; ANESTHESIA	Context Proposed federal legislation would require physicians to inform women seeking abortions at 20 or more weeks after fertilization that the fetus feels pain and to offer anesthesia administered directly to the fetus. This article examines whether a fetus feels pain and if so, whether safe and effective techniques exist for providing direct fetal anesthesia or analgesia in the context of therapeutic procedures or abortion. Evidence Acquisition Systematic search of PubMed for English-language articles focusing on human studies related to fetal pain, anesthesia, and analgesia. included articles studied fetuses of less than 30 weeks' gestational age or specifically addressed fetal pain perception or nociception. Articles were reviewed for additional references. The search was performed without date limitations and was current as of June 6, 2005. Evidence Synthesis Pain perception requires conscious recognition or awareness of a noxious stimulus. Neither withdrawal reflexes nor hormonal stress responses to invasive procedures prove the existence of fetal pain, because they can be elicited by nonpainful stimuli and occur without conscious cortical processing. Fetal awareness of noxious stimuli requires functional thalamocortical connections. Thalamocortical fibers begin appearing between 23 to 30 weeks' gestational age, while electroencephalography suggests the capacity for functional pain perception in preterm neonates probably does not exist before 29 or 30 weeks. For fetal surgery, women may receive general anesthesia and/or analgesics intended for placental transfer, and parenteral opioids may be administered to the fetus under direct or sonographic visualization. In these circumstances, administration of anesthesia and analgesia serves purposes unrelated to reduction of fetal pain, including inhibition of fetal movement, prevention of fetal hormonal stress responses, and induction of uterine atony. Conclusions Evidence regarding the capacity for fetal pain is limited but indicates that fetal perception of pain is unlikely before the third trimester. Little or no evidence addresses the effectiveness of direct fetal anesthetic or analgesic techniques. Similarly, limited or no data exist on the safety of such techniques for pregnant women in the context of abortion. Anesthetic techniques currently used during fetal surgery are not directly applicable to abortion procedures.	Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, WM Keck Fdn Integrat Neurosci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Rosen, MA (corresponding author), Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, 513 Parnassus Ave, San Francisco, CA 94143 USA.	rosenm@anesthesia.ucsf.edu						ANAND KJS, 1992, NEW ENGL J MED, V326, P1, DOI 10.1056/NEJM199201023260101; ANAND KJS, 1987, LANCET, V1, P62; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; ANDREWS K, 1994, PAIN, V56, P95, DOI 10.1016/0304-3959(94)90154-6; ASHWAL S, 1990, PEDIATR NEUROL, V6, P233, DOI 10.1016/0887-8994(90)90113-F; ATRASH HK, 1987, AM J OBSTET GYNECOL, V156, P605, DOI 10.1016/0002-9378(87)90061-5; ATRASH HK, 1988, AM J OBSTET GYNECOL, V158, P420, DOI 10.1016/0002-9378(88)90169-X; Barbas H, 2000, BRAIN RES BULL, V52, P319, DOI 10.1016/S0361-9230(99)00245-2; Bartlett LA, 2004, OBSTET GYNECOL, V103, P729, DOI 10.1097/01.AOG.0000116260.81570.60; Benatar D, 2001, BIOETHICS, V15, P57, DOI 10.1111/1467-8519.00212; Burgess JA, 1996, BIOETHICS, V10, P1, DOI 10.1111/j.1467-8519.1996.tb00100.x; Carrasco GA, 2003, EUR J PHARMACOL, V463, P235, DOI 10.1016/S0014-2999(03)01285-8; Cauldwell Charles B, 2002, Anesthesiol Clin North Am, V20, P211, DOI 10.1016/S0889-8537(03)00062-2; Clancy RR, 2003, CURRENT PRACTICE CLI, P160; Clyburn PA, 2004, ANAESTHESIA, V59, P1157, DOI 10.1111/j.1365-2044.2004.04060.x; Craig K. D., 2001, HDB PAIN ASSESSMENT, P153; CRAIG KD, 1993, PAIN, V52, P287, DOI 10.1016/0304-3959(93)90162-I; CRAIG KD, 1994, J PEDIATR PSYCHOL, V19, P305, DOI 10.1093/jpepsy/19.3.305; Derbyshire SWG, 1999, BIOETHICS, V13, P1, DOI 10.1111/1467-8519.00129; Derbyshire SWG, 2001, BIOETHICS, V15, P77, DOI 10.1111/1467-8519.00213; Fisch B. J., 1999, FISCH SPEHLMANNS EEG; Fisk NM, 2001, ANESTHESIOLOGY, V95, P828, DOI 10.1097/00000542-200110000-00008; Fitzgerald M, 2003, PAIN INFANTS CHILDRE, V2nd, P19; Franck LS, 1997, J PAIN SYMPTOM MANAG, V14, P343, DOI 10.1016/S0885-3924(97)00222-4; Gaiser RR, 1999, SEMIN PERINATOL, V23, P507, DOI 10.1016/S0146-0005(99)80029-9; GERDIN E, 1990, J PERINAT MED, V18, P305, DOI 10.1515/jpme.1990.18.4.305; GIANNAKOULOPOULOS X, 1994, LANCET, V344, P77, DOI 10.1016/S0140-6736(94)91279-3; Giannakoulopoulos X, 1999, PEDIATR RES, V45, P494, DOI 10.1203/00006450-199904010-00007; Glover V, 1999, BRIT J OBSTET GYNAEC, V106, P881, DOI 10.1111/j.1471-0528.1999.tb08424.x; Goubet N, 2001, J DEV BEHAV PEDIATR, V22, P418, DOI 10.1097/00004703-200112000-00009; GREGORY GA, 1983, ANESTH ANALG, V62, P9; Hadjistavropoulos HD, 1997, PAIN, V73, P319, DOI 10.1016/S0304-3959(97)00113-9; HARAM K, 1980, BRIT J OBSTET GYNAEC, V87, P506, DOI 10.1111/j.1471-0528.1980.tb04587.x; Henshaw K, 2003, PERSPECT SEX REPRO H, V35, P16; Hevner RF, 2000, J NEUROPATH EXP NEUR, V59, P385, DOI 10.1093/jnen/59.5.385; HRBEK A, 1973, ELECTROEN CLIN NEURO, V34, P225, DOI 10.1016/0013-4694(73)90249-6; Humphery T, 1964, PROGR BRAIN RES, V4, P93, DOI [10.1016/s0079-6123(08)61273-x, DOI 10.1016/S0079-6123(08)61273-X, 10.1016/S0079-6123]; *INT ASS STUD PAIN, 2004, IASP PAIN TERM; Jauniaux E, 1996, HUM REPROD, V11, P889; Johnston CC, 1996, DEV MED CHILD NEUROL, V38, P438; JOHNSTON CC, 1995, PAIN, V61, P471, DOI 10.1016/0304-3959(94)00213-X; Johnston CC, 1996, PEDIATRICS, V98, P925; KLIMACH VJ, 1988, DEV MED CHILD NEUROL, V30, P208; KONSTANTINIDOU AD, 1995, J COMP NEUROL, V354, P1, DOI 10.1002/cne.903540102; KOSTOVIC I, 1995, INT J PSYCHOPHYSIOL, V19, P85, DOI 10.1016/0167-8760(94)00081-O; Kostovic I, 2002, ANAT RECORD, V267, P1, DOI 10.1002/ar.10069; KOSTOVIC I, 1984, J NEUROSCI, V4, P25; KOSTOVIC I, 1983, J COMP NEUROL, V219, P431, DOI 10.1002/cne.902190405; KOSTOVIC I, 1990, J COMP NEUROL, V297, P441, DOI 10.1002/cne.902970309; KRMPOTICNEMANIC J, 1983, ACTA ANAT, V116, P69; LEHMANN KA, 1991, ACTA ANAESTH SCAND, V35, P221, DOI 10.1111/j.1399-6576.1991.tb03277.x; Lindh V, 1997, EARLY HUM DEV, V48, P131, DOI 10.1016/S0378-3782(96)01851-8; LOFTUS JR, 1995, ANESTHESIOLOGY, V83, P300, DOI 10.1097/00000542-199508000-00010; Missant C, 2004, Acta Anaesthesiol Belg, V55, P239; MRZLJAK L, 1988, J COMP NEUROL, V271, P355, DOI 10.1002/cne.902710306; Munnur U, 2004, CRIT CARE CLIN, V20, P617, DOI 10.1016/j.ccc.2004.05.011; Myers Laura B, 2004, Best Pract Res Clin Anaesthesiol, V18, P231, DOI 10.1016/j.bpa.2004.01.001; Myers LB, 2002, PAEDIATR ANAESTH, V12, P569, DOI 10.1046/j.1460-9592.2002.00840.x; Oberlander TF, 2002, PEDIATRICS, V110, P570, DOI 10.1542/peds.110.3.570; OKADO N, 1984, CLIN DEV MED, V94, P31; Pilon M, 1996, BRAIN INJURY, V10, P421, DOI 10.1080/026990596124287; POKELA ML, 1994, PEDIATRICS, V93, P379; Porter FL, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.1.e13; RADUNOVIC N, 1993, AM J PERINAT, V10, P112, DOI 10.1055/s-2007-994640; RAYBURN W, 1989, AM J OBSTET GYNECOL, V161, P202, DOI 10.1016/0002-9378(89)90266-4; ROSEN MA, 1991, SEMIN PERINATOL, V15, P410; Rosen MA, 2001, YONSEI MED J, V42, P669, DOI 10.3349/ymj.2001.42.6.669; ROSEN MA, 1984, UNBORN PATIENT PRENA, P417; *ROYAL COLL OBST G, 2004, CONF ENQ MAT CHILD H; SCHENK VWD, 1968, BRAIN, V91, P497, DOI 10.1093/brain/91.3.497; SCHER MS, 1999, ELECTROENCEPHALOGRAP, P896; Schnitzler A, 2000, J CLIN NEUROPHYSIOL, V17, P592, DOI 10.1097/00004691-200011000-00005; SCHULZE S, 1988, SURGERY, V103, P321; Schwarz Uwe, 2003, Semin Pediatr Surg, V12, P196, DOI 10.1016/S1055-8586(03)00025-8; SEEDS JW, 1986, AM J OBSTET GYNECOL, V155, P818, DOI 10.1016/S0002-9378(86)80028-X; Sharbrough F. W., 1999, ELECTROENCEPHALOGRAP, P215; Smith RP, 2000, EUR J OBSTET GYN R B, V92, P161, DOI 10.1016/S0301-2115(00)00441-3; Strauss Lilo T., 2004, Morbidity and Mortality Weekly Report, V53, P1; Strigo IA, 2003, J NEUROPHYSIOL, V89, P3294, DOI 10.1152/jn.01048.2002; Strumper D, 2003, ANESTHESIOLOGY, V98, P1400, DOI 10.1097/00000542-200306000-00015; Taddio A, 1997, LANCET, V349, P599, DOI 10.1016/S0140-6736(96)10316-0; Taylor A, 2000, LANCET, V355, P120, DOI 10.1016/S0140-6736(99)02549-0; Teixeira JMA, 1999, AM J OBSTET GYNECOL, V181, P1018, DOI 10.1016/S0002-9378(99)70340-6; TORRES F, 1985, J CLIN NEUROPHYSIOL, V2, P89, DOI 10.1097/00004691-198504000-00001; Ulfig N, 2000, HISTOL HISTOPATHOL, V15, P771, DOI 10.14670/HH-15.771; Van De Velde M, 2005, ANESTH ANALG, V101, P251, DOI 10.1213/01.ANE.0000156566.62182.AB; VOGT BA, 1979, SCIENCE, V204, P205, DOI 10.1126/science.107587; Waxman SG, 1996, PROG BRAIN RES, V107, P595; White Michelle C, 2004, Best Pract Res Clin Anaesthesiol, V18, P205, DOI 10.1016/j.bpa.2003.12.011; WILLIAMS RH, 2003, WILLIAMS TXB ENDOCRI; WLADIMIROFF JW, 1987, OBSTET GYNECOL, V69, P705; WOO JSK, 1987, OBSTET GYNECOL, V70, P613; Xia Chuanxiong, 2002, J Huazhong Univ Sci Technolog Med Sci, V22, P84	93	212	223	0	43	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 24	2005	294	8					947	954		10.1001/jama.294.8.947	http://dx.doi.org/10.1001/jama.294.8.947			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	957JM	16118385	Bronze			2022-12-28	WOS:000231366100025
J	Bijl, M; van den Brink, RBA				Bijl, M; van den Brink, RBA			Four artificial heart valves	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Albert Schweitzer Ziekenhuis, NL-3300 AH Dordrecht, Netherlands; Acad Med Ctr, NL-1100 DE Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Bijl, M (corresponding author), Albert Schweitzer Ziekenhuis, NL-3300 AH Dordrecht, Netherlands.								0	2	2	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 18	2005	353	7					712	712		10.1056/NEJMicm040922	http://dx.doi.org/10.1056/NEJMicm040922			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955UW	16107624	Green Published			2022-12-28	WOS:000231254100009
J	Gostin, LO				Gostin, LO			Medical marijuana, American federalism, and the Supreme Court	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Georgetown Law Ctr, Washington, DC 20001 USA	Georgetown University	Gostin, LO (corresponding author), Georgetown Law Ctr, 600 New Jersey Law Ctr NW, Washington, DC 20001 USA.	gostin@georgetown.edu						GREENHOUSE L, 2005, NY TIMES        0710, P3; Institute of Medicine, 1999, MAR MED ASS SCI BAS; ISIKOFF M, 1988, WASHINGTON POST 0907; Kassirer JP, 1997, NEW ENGL J MED, V336, P366, DOI 10.1056/NEJM199701303360509; MADISON J, 1968, FEDERALIST PAPERS, P292; SATEL S, 2005, NY TIMES        0608, P3; Steinbrook R, 2004, NEW ENGL J MED, V351, P1380, DOI 10.1056/NEJMp048222; 2001, FED REG 20038, V66	8	10	10	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	2005	294	7					842	844		10.1001/jama.294.7.842	http://dx.doi.org/10.1001/jama.294.7.842			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955LI	16106011				2022-12-28	WOS:000231227000026
J	Higashi, T; Shekelle, PG; Adams, JL; Kamberg, CJ; Roth, CP; Solomon, DH; Reuben, DB; Chiang, L; MacLean, CH; Chang, JT; Young, RT; Saliba, DM; Wenger, NS				Higashi, T; Shekelle, PG; Adams, JL; Kamberg, CJ; Roth, CP; Solomon, DH; Reuben, DB; Chiang, L; MacLean, CH; Chang, JT; Young, RT; Saliba, DM; Wenger, NS			Quality of care is associated with survival in vulnerable older patients	ANNALS OF INTERNAL MEDICINE			English	Article							MEDICAL-CARE; HEALTH-CARE; MORTALITY; ELDERS	Background: Although assessment of the quality of medical care often relies on measures of process of care, the linkage between performance of these process measures during usual clinical care and subsequent patient outcomes is unclear. Objective: To examine the link between the quality of care that patients received and their survival. Design: Observational cohort study. Setting: Two managed care organizations. Patients: Community-dwelling high-risk patients 65 years of age or older who were continuously enrolled in the managed care organizations from 1 July 1998 to 31 July 1999. Measurements: Quality of care received by patients (as measured by a set of quality indicators covering 22 clinical conditions) and their survival over the following 3 years. Results: The 372 vulnerable older patients were eligible for a mean of 21 quality indicators (range, 8 to 54) and received, on average, 53% of the care processes prescribed in quality indicators (range, 27% to 88%). Eighty-six (23%) persons died during the 3-year follow-up. There was a graded positive relationship between quality score and 3-year survival. After adjustment for sex, health status, and health service use, quality score was not associated with mortality for the first 500 days, but a higher quality score was associated with lower mortality after 500 days (hazard ratio, 0.64 [95% Cl, 0.49 to 0.84] for a 10% higher quality score). Limitations: The observational design limits causal inference regarding the effect of quality of care on survival. Conclusions: Better performance on process quality measures is strongly associated with better survival among community-dwelling vulnerable older adults.	RAND Corp, 1700 Main St, Santa Monica, CA 90407 USA; Univ Calif Los Angeles, Los Angeles, CA USA; Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA	RAND Corporation; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Wenger, NS (corresponding author), RAND Corp, Santa Monica, CA 90407 USA.		Adams, John/ABE-6170-2021; Chang, John T./L-7840-2019					[Anonymous], 2001, ANN INTERN MED, V135, P653, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00004; Brook RH, 1996, NEW ENGL J MED, V335, P966, DOI 10.1056/NEJM199609263351311; Hanlon JT, 2002, MED CARE, V40, P166, DOI 10.1097/00005650-200202000-00011; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; *HLTH CAR FIN ADM, 1986, HCFA PUBL; Institute of Medicine, 2001, CROSS QUAL CHASM; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P3611, DOI 10.1001/jama.260.24.3611; Jencks SF, 2000, JAMA-J AM MED ASSOC, V284, P1670, DOI 10.1001/jama.284.13.1670; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1953, DOI 10.1001/jama.264.15.1953; KATZMAN R, 1983, AM J PSYCHIAT, V140, P734; Lilford R, 2004, LANCET, V363, P1147, DOI 10.1016/S0140-6736(04)15901-1; MANT J, 1995, BMJ-BRIT MED J, V311, P793, DOI 10.1136/bmj.311.7008.793; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; *NAT COMM QUAL ASS, 2004, HEDIS 2004 SUMM TABL; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; Saliba D, 2001, J AM GERIATR SOC, V49, P1691, DOI 10.1046/j.1532-5415.2001.49281.x; Schuster MA, 1998, MILBANK Q, V76, P517, DOI 10.1111/1468-0009.00105; Sloss EM, 2000, J AM GERIATR SOC, V48, P363, DOI 10.1111/j.1532-5415.2000.tb04691.x; Solomon DH, 2003, J AM GERIATR SOC, V51, P902, DOI 10.1046/j.1365-2389.2003.513331.x; THOMAS JW, 1993, INQUIRY-J HEALTH CAR, V30, P6; Wenger NS, 2003, ANN INTERN MED, V139, P740, DOI 10.7326/0003-4819-139-9-200311040-00008; Wenger NS, 2001, ANN INTERN MED, V135, P642, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00002	23	165	168	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 16	2005	143	4					274	281		10.7326/0003-4819-143-4-200508160-00008	http://dx.doi.org/10.7326/0003-4819-143-4-200508160-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	955PA	16103471				2022-12-28	WOS:000231237100004
J	Ogilvie, D; Gruer, L; Haw, S				Ogilvie, D; Gruer, L; Haw, S			Young people's access to tobacco, alcohol, and other drugs	BMJ-BRITISH MEDICAL JOURNAL			English	Review							YOUTH ACCESS; SUBSTANCE-ABUSE; PRICE; HEROIN; AVAILABILITY; SMOKING; POLICY; INTERVENTIONS; PREVENTION; REDUCTION		Univ Glasgow, MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland; NHS Hlth Scotland, Glasgow G3 7LS, Lanark, Scotland; NHS Hlth Scotland, Edinburgh EH10 4SG, Midlothian, Scotland	MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNIT; University of Glasgow	Ogilvie, D (corresponding author), Univ Glasgow, MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland.	d.ogilvie@msoc.mrc.gla.ac.uk	Ogilvie, David/B-2444-2012	Ogilvie, David/0000-0002-0270-4672				*AC MED SCI, 2004, CALL TIM NAT DRINK H; *ASH SCOTL, 2001, TOB TAX SMUGGL SCOTL; Aust R, 2002, PREVALENCE DRUG USE; Babor TF, 2003, ALCOHOL NO ORDINARY; BOREHAM R, 2001, SMOKING DRINKING DRU; BOREHAM R, 2002, DRUG USE SMOKING DRI; BOREHAM R, 2004, SMOKING DRINKING DRU; BRADSHAW P, 2003, UNDERAGE DRINKING IL; Bucke T., 2002, POLICE J, V75, P15; Caulkins JP, 2001, AM J PUBLIC HEALTH, V91, P1446, DOI 10.2105/AJPH.91.9.1446; Caulkins JP, 1998, J DRUG ISSUES, V28, P593, DOI 10.1177/002204269802800302; Chaloupka F., 2000, TOBACCO CONTROL DEV; Coope S., 2004, REDUCING IMPACT LOCA; Croghan E, 2003, TOB CONTROL, V12, P67, DOI 10.1136/tc.12.1.67; CROME IB, 2004, YOUNG PEOPLE SUBSTAN; CURRIE C, 2004, SCOTTISH SCH ADOLESC; CURRIE C, 2003, SCOTTISH SCH ADOLESC; Day C, 2003, ADDICTION, V98, P93, DOI 10.1046/j.1360-0443.2003.00266.x; DiFranza JR, 2000, TOB CONTROL, V9, P120, DOI 10.1136/tc.9.2.120; ESMAIL A, 1992, BRIT MED J, V305, P692, DOI 10.1136/bmj.305.6855.692; *EUR MON CTR DRUGS, 2003, STAT DRUGS PROBL EUR; *EUR OP RES GROUP, 2002, ATT OP YOUNG PEOPL E; FIELDSMITH M, 2004, 17 ST GEORG HOSP MED; Forman RF, 2003, JAMA-J AM MED ASSOC, V290, P889, DOI 10.1001/jama.290.7.889; Forster JL, 1998, ANNU REV PUBL HEALTH, V19, P203, DOI 10.1146/annurev.publhealth.19.1.203; Guindon GE, 2002, TOB CONTROL, V11, P35, DOI 10.1136/tc.11.1.35; Halpern JH, 2001, AM J PSYCHIAT, V158, P481, DOI 10.1176/appi.ajp.158.3.481; Hayward B., 2003, YOUNG PEOPLE ICT 200; HIBELL B, 2004, 2003 ESPAD REP ALC O; Higgins K, 2004, J SOC ISSUES, V60, P485, DOI 10.1111/j.0022-4537.2004.00368.x; *HM CUST EXC, 2002, MEAS IND TAX LOSS; *HM CUST EXC, 2003, MEAS TACKL IND TAX L; Hopkins DP, 2001, AM J PREV MED, V20, P16, DOI 10.1016/S0749-3797(00)00297-X; *HOUS COMM NO IR A, 2003, ILL DRUGS TRAD DRUG; *IND DRUG MON UN, DRUG PRIC; Jha P., 1999, CURBING EPIDEMIC GOV; Joossens L, 2000, BRIT MED J, V321, P947, DOI 10.1136/bmj.321.7266.947; Joossens L, 1999, SMUGGLING CROSS BORD; KETELAARS T, 2002, REPORT EMCDDA REITOX; Lantz PM, 2000, TOB CONTROL, V9, P47, DOI 10.1136/tc.9.1.47; Levy DT, 2002, DRUG-EDUC PREV POLIC, V9, P285, DOI 10.1080/09687630210129538; LUDBROOK A, 2001, EFFECTIVE COST EFFEC; Lupton R., 2002, ROCK HARD PLACE DRUG; MacCoun R, 2001, BRIT J PSYCHIAT, V178, P123, DOI 10.1192/bjp.178.2.123; MAKELA P, 2002, EFFECTS NORDIC ALCOH; Marmot MG, 2004, BRIT MED J, V328, P906, DOI 10.1136/bmj.328.7445.906; MAY T, 2000, SERVING IMPACT LAW L; McArdle P, 2004, ARCH DIS CHILD, V89, P701, DOI 10.1136/adc.2003.040584; McKeganey N, 2004, DRUG-EDUC PREV POLIC, V11, P315, DOI 10.1080/09687630410001687888; MCMULLAN S, 2003, EXPERIENCE DRUG MISU; Moller L., 2002, EFFECTS NORDIC ALCOH; MOSKOWITZ JM, 1989, J STUD ALCOHOL, V50, P54, DOI 10.15288/jsa.1989.50.54; *NAT CTR ADD SUBST, 2004, YOUV GOT DRUGS PRESC; *NAT CTR SOC RES, 2004, DRUG US SMOK DRINK Y; *NAT DRUG INT CTR, 2000, NAT DRUG THREAT ASS; National Criminal Intelligence Service, 2003, UK THREAT ASS THREAT; National Drug Intelligence Centre, 2002, INF B DRUGS YOUTH IN; *OFF NAT STAT, 2004, SOC TRENDS, V34; *OFF NAT STAT, 2004, CONS PRIC IND MAY 20; Prime Minister's Strategy Unit, 2003, STRAT UN ALC HARM RE; PUDNEY S, 2002, ROAD RUIN SEQUENCES; Rehn N, 2001, ALCOHOL EUROPEAN REG; Reinarman C, 2004, AM J PUBLIC HEALTH, V94, P836, DOI 10.2105/AJPH.94.5.836; Room R, 2005, LANCET, V365, P519, DOI 10.1016/S0140-6736(05)70276-2; *SECR HLTH HUM SER, 2000, 10 US DEP HHS US C A; SEWEL K, 2002, INT ALCOHOL POLICIES; Shults RA, 2001, AM J PREV MED, V21, P66, DOI 10.1016/S0749-3797(01)00381-6; SMART RG, 1977, J STUD ALCOHOL, V38, P1313, DOI 10.15288/jsa.1977.38.1313; Smith D.J., 2001, EDINBURGH STUDY YOUT; Smithson M, 2004, ADDICTION, V99, P340, DOI 10.1046/j.1360-0443.2003.00603.x; STEAD LF, 2005, COCHRANE DB SYST REV, V25; Stolzenberg L, 2003, J CRIM JUST, V31, P185, DOI 10.1016/S0047-2352(02)00224-6; TAURAS JA, 2001, EFFECTS PRICE ACCESS; Topp L, 2003, DRUG ALCOHOL DEPEN, V70, P275, DOI 10.1016/S0376-8716(03)00013-9; TOWNSEND J, 1994, BMJ-BRIT MED J, V309, P923, DOI 10.1136/bmj.309.6959.923; Townsend J, 1996, BRIT MED BULL, V52, P132, DOI 10.1093/oxfordjournals.bmb.a011521; Turner KM, 2004, HEALTH PROMOT INT, V19, P428, DOI 10.1093/heapro/dah404; US Department of Health and Human Services, 2000, RED TOB US REP SURG; Viner R, 2005, BRIT MED J, V330, P527, DOI 10.1136/bmj.330.7490.527; Wagenaar AC, 2002, J STUD ALCOHOL, P206, DOI 10.15288/jsas.2002.s14.206; Weatherburn D, 2003, ADDICTION, V98, P83, DOI 10.1046/j.1360-0443.2003.00248.x; WEST P, 2002, REV YOUNG PEOPL HLTH; Williams J, 2004, HEALTH ECON, V13, P123, DOI 10.1002/hec.796; Wood E, 2003, CAN MED ASSOC J, V168, P165; WOOLLERY T, 2000, TOBACCO CONTROL DEV; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20; [No title captured]	87	26	28	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 13	2005	331	7513					393	396E		10.1136/bmj.331.7513.393	http://dx.doi.org/10.1136/bmj.331.7513.393			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	956SK	16096309	Green Accepted, Green Published			2022-12-28	WOS:000231319900020
J	Rai, VK; Jackson, TL; Thiemens, MH				Rai, VK; Jackson, TL; Thiemens, MH			Photochemical mass-independent sulfur isotopes in achondritic meteorites	SCIENCE			English	Article							SOLAR NEBULA; OXYGEN; CHONDRITES; ATMOSPHERE; CHEMISTRY; FRACTIONATION; EXPLOSION; ENSTATITE; ABUNDANCE; COMPONENT	Sulfides from four achondrite meteorite groups are enriched in S-33 (up to 0.040 per mil) as compared with primitive chondrites and terrestrial standards. Stellar nucleosynthesis and cosmic ray spallation are ruled out as causes of the anomaly, but photochemical reactions in the early solar nebula could produce the isotopic composition. The large S-33 excess present in oldhamite from the Norton County aubrite (0.161 per mil) suggests that refractory sulfide minerals condensed from a nebular gas with an enhanced carbon-oxygen ratio, but otherwise solar composition is the carrier. The presence of a mass-independent sulfur effect in meteorites argues for a similar process that could account for oxygen isotopic anomalies observed in refractory inclusions in primitive chondrites.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Rai, VK (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.	rai@chem.ucsd.edu		Rai, Vinai K/0000-0003-4838-7630				Chin YN, 1996, ASTRON ASTROPHYS, V305, P960; CLAYTON RN, 1973, SCIENCE, V182, P485, DOI 10.1126/science.182.4111.485; Colman JJ, 1996, SCIENCE, V273, P774, DOI 10.1126/science.273.5276.774; Cooper GW, 1997, SCIENCE, V277, P1072, DOI 10.1126/science.277.5329.1072; Farquhar J, 2000, SCIENCE, V289, P756, DOI 10.1126/science.289.5480.756; Farquhar J, 2000, GEOCHIM COSMOCHIM AC, V64, P1819, DOI 10.1016/S0016-7037(00)00356-2; Farquhar J, 2000, NATURE, V404, P50, DOI 10.1038/35003517; Farquhar J, 1998, SCIENCE, V280, P1580, DOI 10.1126/science.280.5369.1580; Farquhar J, 2002, SCIENCE, V298, P2369, DOI 10.1126/science.1078617; Farquhar J, 2001, J GEOPHYS RES-PLANET, V106, P32829, DOI 10.1029/2000JE001437; GAO X, 1993, GEOCHIM COSMOCHIM AC, V57, P3159, DOI 10.1016/0016-7037(93)90300-L; GAO X, 1993, GEOCHIM COSMOCHIM AC, V57, P3171, DOI 10.1016/0016-7037(93)90301-C; Gao X., 1991, GEOCHIM COSMOCHIM AC, V55, P2671, DOI DOI 10.1016/0016-7037(91)90381-E; Gao YQ, 2001, SCIENCE, V293, P259, DOI 10.1126/science.1058528; Krot A. N., 2000, Protostars and planets 4, P1019; LARIMER JW, 1979, GEOCHIM COSMOCHIM AC, V43, P1455, DOI 10.1016/0016-7037(79)90140-6; LODDERS K, 1993, EARTH PLANET SC LETT, V117, P125, DOI 10.1016/0012-821X(93)90122-P; Mauersberger R, 2004, ASTRON ASTROPHYS, V426, P219, DOI 10.1051/0004-6361:20040451; Miller MF, 2002, P NATL ACAD SCI USA, V99, P10988, DOI 10.1073/pnas.172378499; Nakano H, 2003, ASTROPHYS J, V592, P1252, DOI 10.1086/375856; Nittler LR, 2003, GEOCHIM COSMOCHIM AC, V67, P4961, DOI 10.1016/S0016-7037(03)00485-X; Pasek MA, 2005, ICARUS, V175, P1, DOI 10.1016/j.icarus.2004.10.012; Ramdohr P., 1972, Meteoritics, V7, P565, DOI 10.1111/j.1945-5100.1972.tb00138.x; REES CE, 1977, GEOCHIM COSMOCHIM AC, V41, P1679, DOI 10.1016/0016-7037(77)90177-6; Shu FH, 1997, SCIENCE, V277, P1475, DOI 10.1126/science.277.5331.1475; THIEMENS MH, 1983, SCIENCE, V219, P1073, DOI 10.1126/science.219.4588.1073; Thiemens MH, 1999, SCIENCE, V283, P341, DOI 10.1126/science.283.5400.341; Thiemens MH, 2001, ACCOUNTS CHEM RES, V34, P645, DOI 10.1021/ar960224f; Thiemens MH, 2003, TREATISE GEOCHEMISTR, V4, P159; WOOSLEY SE, 1995, ASTROPHYS J SUPPL S, V101, P181, DOI 10.1086/192237; Woosley SE, 2002, REV MOD PHYS, V74, P1015, DOI 10.1103/RevModPhys.74.1015	33	51	52	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 12	2005	309	5737					1062	1065		10.1126/science.1112954	http://dx.doi.org/10.1126/science.1112954			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955MN	16099982				2022-12-28	WOS:000231230100042
J	Sundkvist, D; Krasnoselskikh, V; Shukla, PK; Vaivads, A; Andre, M; Buchert, S; Reme, H				Sundkvist, D; Krasnoselskikh, V; Shukla, PK; Vaivads, A; Andre, M; Buchert, S; Reme, H			In situ multi-satellite detection of coherent vortices as a manifestation of Alfvenic turbulence	NATURE			English	Article							MAGNETOSPHERE; IONOSPHERE; WAVES	Turbulence in fluids(1) and plasmas(2-5) is a ubiquitous phenomenon driven by a variety of sources - currents, sheared flows, gradients in density and temperature, and so on. Turbulence involves fluctuations of physical properties on many different scales, which interact nonlinearly to produce self-organized structures in the form of vortices(2-5). Vortex motion in fluids and magnetized plasmas is typically governed by nonlinear equations(2-5), examples of which include the Navier - Stokes equation(1,2), the Charney - Hasegawa - Mima equations(2-5) and their numerous generalizations(6-9). These nonlinear equations admit solutions(2-5) in the form of different types of vortices that are frequently observed in a variety of contexts: in atmospheres, in oceans and planetary systems(2,4), in the heliosphere(10,11), in the Earth's ionosphere and magnetosphere(12-17), and in laboratory plasma experiments(18). Here we report the discovery by the Cluster satellites(19) of a distinct class of vortex motion - short-scale drift-kinetic Alfven (DKA) vortices(8,9) - in the Earth's magnetospheric cusp region. As is the case for the larger Kelvin - Helmholtz vortices observed previously(17), these dynamic structures should provide a channel for transporting plasma particles and energy through the magnetospheric boundary layers.	CNRS, Lab Phys & Chim Environm, F-45071 Orleans, France; Swedish Inst Space Phys, SE-75121 Uppsala, Sweden; Ruhr Univ Bochum, Inst Theoret Phys 4, D-44780 Bochum, Germany; Ctr Etud Spatiale Rayonnements, F-31029 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); Ruhr University Bochum	Sundkvist, D (corresponding author), CNRS, Lab Phys & Chim Environm, F-45071 Orleans, France.	davids@irfu.se	Vaivads, Andris/H-8169-2013; Shukla, Padma Kant/E-9077-2011	Vaivads, Andris/0000-0003-1654-841X; Buchert, Stephan/0000-0003-2158-6074; Krasnoselskikh, Vladimir/0000-0002-6809-6219				BURLAGA LF, 1990, J GEOPHYS RES-SPACE, V95, P4333, DOI 10.1029/JA095iA04p04333; CHMYREV VM, 1991, PLANET SPACE SCI, V39, P1025, DOI 10.1016/0032-0633(91)90108-M; CHMYREV VM, 1988, PHYS SCRIPTA, V38, P841, DOI 10.1088/0031-8949/38/6/016; Escoubet CP, 1997, SPACE SCI REV, V79, P11, DOI 10.1023/A:1004923124586; Frisch U., 1995, LEGACY AN KOLMOGOROV; Hasegawa H, 2004, NATURE, V430, P755, DOI 10.1038/nature02799; HONES EW, 1981, J GEOPHYS RES-SPACE, V86, P814, DOI 10.1029/JA086iA02p00814; Horton W, 1999, REV MOD PHYS, V71, P735, DOI 10.1103/RevModPhys.71.735; Horton W, 1994, CHAOS, V4, P226; LIU JX, 1986, J PLASMA PHYS, V36, P1, DOI 10.1017/S0022377800011557; Petviashvili V I, 1992, SOLITARY WAVES PLASM; PETVIASHVILI VI, 1985, JETP LETT+, V42, P54; Pokhotelov OA, 1996, PLASMA PHYS REP, V22, P852; SAMSON JC, 1980, GEOPHYS J ROY ASTR S, V61, P115, DOI 10.1111/j.1365-246X.1980.tb04308.x; Savin SP, 2001, JETP LETT+, V74, P547, DOI 10.1134/1.1450288; SHUKLA PK, 1985, PHYS LETT A, V109, P322, DOI 10.1016/0375-9601(85)90183-5; SHUKLA PK, 1986, PHYS REV A, V34, P3478, DOI 10.1103/PhysRevA.34.3478; Spolaore M, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.215003; Stasiewicz K, 2000, SPACE SCI REV, V92, P423, DOI 10.1023/A:1005207202143; Sundkvist D, 2005, ANN GEOPHYS-GERMANY, V23, P983, DOI 10.5194/angeo-23-983-2005; VOLOKITIN AS, 1989, PLANET SPACE SCI, V37, P761, DOI 10.1016/0032-0633(89)90127-X; Weiland J., 2000, PLAS PHYS S; Zhou Y, 2004, REV MOD PHYS, V76, P1015, DOI 10.1103/RevModPhys.76.1015	23	116	116	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 11	2005	436	7052					825	828		10.1038/nature03931	http://dx.doi.org/10.1038/nature03931			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953XG	16094363				2022-12-28	WOS:000231116500040
J	Holloway, RG; Benesch, CG; Burgin, WS; Zentner, JB				Holloway, RG; Benesch, CG; Burgin, WS; Zentner, JB			Prognosis and decision making in severe stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE-UNIT; OF-LIFE CARE; REQUIRING MECHANICAL VENTILATION; HEMISPHERIC ISCHEMIC-STROKE; LOCKED-IN SYNDROME; INTRACEREBRAL HEMORRHAGE; TREATMENT PREFERENCES; PALLIATIVE CARE; SERIOUSLY ILL; SUSTAINING TREATMENTS	Context An increasing number of deaths following severe stroke are due to terminal extubations. Variation in withdrawal-of-care practices suggests the possibility of unnecessary prolongation of suffering or of unwanted deaths. Objectives To review the available evidence on prognosis in mechanically ventilated stroke patients and to provide an overall framework to optimize decision making for clinicians, patients, and families. Data Sources Search of MEDLINE from 1980 through March 2005 for English-language articles addressing prognosis in mechanically ventilated stroke patients. From 689 articles identified, we selected 17 for further review. We also identified factors that influence, and decision-making biases that may result, in overuse or underuse of life-sustaining therapies, with a particular emphasis on mechanical ventilation. Evidence Synthesis Overall mortality among mechanically ventilated stroke patients is high, with a 30-day death rate approximating 58% (range in literature, 46%-75%). Although data are limited, among survivors as many as one third may have no or only slight disability, yet many others have severe disability. One can further refine prognosis according to knowledge of stroke syndromes, early patient characteristics, use of clinical prediction rules, and the need for continuing interventions. Factors influencing preferences for life-sustaining treatments include the severity and pattern of future clinical deficits, the probability of these deficits, and the burdens of treatments. Decision-making biases that may affect with drawal-of-treatment decisions include erroneous prognostic estimates, inappropriate methods of communicating evidence, misunderstanding patient values and expectations, and failing to appreciate the extent to which patients can physically and psychologically adapt. Conclusions Although prognosis among mechanically ventilated stroke patients is generally poor, a minority do survive without severe disability. Prognosis can be assessed according to clinical presentation and patient characteristics. There is an urgent need to better understand the marked variation in the care of these patients and to reliably measure and improve the patient-centeredness of such decisions.	Univ Rochester, Sch Med, Dept Neurol, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Dept Community & Prevent Med, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Dept Imaging Sci, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Ctr Palliat Care & Clin Eth, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester	Holloway, RG (corresponding author), Univ Rochester, Sch Med, Dept Neurol, 601 Elmwood Ave,Box 673, Rochester, NY 14642 USA.	robert_holloway@urmc.rochester.edu		Burgin, William/0000-0001-5376-8302				Adams HP, 2003, STROKE, V34, P1056, DOI 10.1161/01.STR.0000064841.47697.22; AINSLIE N, 1994, ARCH INTERN MED, V154, P2225, DOI 10.1001/archinte.154.19.2225; Appelros P, 2003, STROKE, V34, P122, DOI 10.1161/01.STR.0000047852.05842.3C; Ariesen MJ, 2005, J NEUROL NEUROSUR PS, V76, P839, DOI 10.1136/jnnp.2004.048223; Back AL, 2005, JAMA-J AM MED ASSOC, V293, P1374, DOI 10.1001/jama.293.11.1374; Becker KJ, 2001, NEUROLOGY, V56, P766, DOI 10.1212/WNL.56.6.766; Berrouschot J, 2000, CRIT CARE MED, V28, P2956, DOI 10.1097/00003246-200008000-00045; Bestue M, 1999, NEUROLOGY, V52, P1922; BONITA R, 1988, STROKE, V19, P1497, DOI 10.1161/01.STR.19.12.1497; Booth CM, 2004, JAMA-J AM MED ASSOC, V291, P870, DOI 10.1001/jama.291.7.870; Broderick JP, 1999, STROKE, V30, P905, DOI 10.1161/01.STR.30.4.905; BURTIN P, 1994, INTENS CARE MED, V20, P32, DOI 10.1007/BF02425052; Bushnell CD, 1999, NEUROLOGY, V52, P1374, DOI 10.1212/WNL.52.7.1374; Carlet J, 2004, INTENS CARE MED, V30, P770, DOI 10.1007/s00134-004-2241-5; *CDC NCHS, 2001, TECHN APP VIT STAT U; CHRISTAKIS NA, 1995, AM J PUBLIC HEALTH, V85, P367, DOI 10.2105/AJPH.85.3.367; Clarke J, 2005, LANCET, V365, P764, DOI 10.1016/S0140-6736(05)17983-5; Cook D, 2003, NEW ENGL J MED, V349, P1123, DOI 10.1056/NEJMoa030083; Coppola KM, 1999, DEATH STUD, V23, P617, DOI 10.1080/074811899200803; Counsell C, 2001, CEREBROVASC DIS, V12, P159, DOI 10.1159/000047699; Curtis JR, 2005, AM J RESP CRIT CARE, V171, P844, DOI 10.1164/rccm.200409-1267OC; Damschroder LJ, 2005, SOC SCI MED, V61, P267, DOI 10.1016/j.socscimed.2004.11.060; Dennis MS, 2003, CEREBROVASC DIS, V16, P9, DOI 10.1159/000069935; Diamond PT, 2003, DISABIL REHABIL, V25, P689, DOI 10.1080/0963828031000090470; Diringer MN, 2001, CRIT CARE MED, V29, P1792, DOI 10.1097/00003246-200109000-00023; Ditto PH, 1996, HEALTH PSYCHOL, V15, P332, DOI 10.1037/0278-6133.15.5.332; Doble JE, 2003, J HEAD TRAUMA REHAB, V18, P435, DOI 10.1097/00001199-200309000-00005; ElAd B, 1996, NEUROLOGY, V47, P657, DOI 10.1212/WNL.47.3.657; Elkins JS, 2003, STROKE, V34, P2109, DOI 10.1161/01.STR.0000085829.60324.DE; *EPEC TEAM, 1999, ED PHYS END OF LIF C; Epstein RM, 2004, JAMA-J AM MED ASSOC, V291, P2359, DOI 10.1001/jama.291.19.2359; Fanshawe M, 2002, ANAESTH INTENS CARE, V30, P628, DOI 10.1177/0310057X0203000515; Foerch C, 2004, J NEUROL NEUROSUR PS, V75, P988, DOI 10.1136/jnnp.2003.021014; Frankel MR, 2000, NEUROLOGY, V55, P952, DOI 10.1212/WNL.55.7.952; Frick S, 2003, CRIT CARE MED, V31, P456, DOI 10.1097/01.CCM.0000049945.69373.7C; Fried TR, 2003, ARCH INTERN MED, V163, P2073, DOI 10.1001/archinte.163.17.2073; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; Goodlin SJ, 1999, JAMA-J AM MED ASSOC, V282, P2333, DOI 10.1001/jama.282.24.2333; Grant MD, 1998, JAMA-J AM MED ASSOC, V279, P1973, DOI 10.1001/jama.279.24.1973; GROTTA J, 1995, NEUROLOGY, V45, P640, DOI 10.1212/WNL.45.4.640; Gujjar AR, 1998, NEUROLOGY, V51, P447, DOI 10.1212/WNL.51.2.447; Hallenbeck J, 2005, JAMA-J AM MED ASSOC, V293, P2265, DOI 10.1001/jama.293.18.2265; Hamel Mary Beth, 1995, JAMA (Journal of the American Medical Association), V273, P1842, DOI 10.1001/jama.273.23.1842; Hankey GJ, 2003, CEREBROVASC DIS, V16, P14, DOI 10.1159/000069936; Hanson LC, 1996, ARCH INTERN MED, V156, P785, DOI 10.1001/archinte.156.7.785; Heinsius T, 1998, NEUROLOGY, V50, P341, DOI 10.1212/WNL.50.2.341; Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891; Hinkka H, 2002, J MED ETHICS, V28, P109, DOI 10.1136/jme.28.2.109; Institute of Medicine, 2001, CROSSING QUALITY CHA; JENNETT B, 1975, LANCET, V1, P480; Jorgensen HS, 1999, STROKE, V30, P2008, DOI 10.1161/01.STR.30.10.2008; Karlawish JHT, 1999, ANN INTERN MED, V130, P835, DOI 10.7326/0003-4819-130-10-199905180-00018; Lamont EB, 2003, JAMA-J AM MED ASSOC, V290, P98, DOI 10.1001/jama.290.1.98; Leker RR, 2000, J NEUROL SCI, V176, P83, DOI 10.1016/S0022-510X(00)00316-6; Lessire H, 1996, INTENS CARE MED, V22, P174, DOI 10.1007/BF01720727; Magi E, 2000, Minerva Med, V91, P99; MAHONEY F I, 1965, Md State Med J, V14, P61; MALENKA DJ, 1993, J GEN INTERN MED, V8, P543, DOI 10.1007/BF02599636; Mayer SA, 2000, STROKE, V31, P2346, DOI 10.1161/01.STR.31.10.2346; Mayor SA, 1999, NEUROLOGY, V52, P1602, DOI 10.1212/WNL.52.8.1602; MAZUR DJ, 1993, J AM GERIATR SOC, V41, P223, DOI 10.1111/j.1532-5415.1993.tb06696.x; Mebane EW, 1999, J AM GERIATR SOC, V47, P579, DOI 10.1111/j.1532-5415.1999.tb02573.x; Meisel A, 2000, JAMA-J AM MED ASSOC, V284, P2495, DOI 10.1001/jama.284.19.2495; Morrison RS, 2004, NEW ENGL J MED, V350, P2582, DOI 10.1056/NEJMcp035232; Navarrete-Navarro P, 2003, INTENS CARE MED, V29, P1237, DOI 10.1007/s00134-003-1755-6; Norero E, 2004, REV MED CHILE, V132, P11; *ORG PROC TRANSPL, DAT REP 2003; Patrick DL, 1997, ANN INTERN MED, V127, P509, DOI 10.7326/0003-4819-127-7-199710010-00002; Pearlman R A, 2000, J Palliat Med, V3, P37, DOI 10.1089/jpm.2000.3.37; Post PN, 2001, STROKE, V32, P1425, DOI 10.1161/01.STR.32.6.1425; Prendergast TJ, 1998, AM J RESP CRIT CARE, V158, P1163, DOI 10.1164/ajrccm.158.4.9801108; Prendergast TJ, 2002, JAMA-J AM MED ASSOC, V288, P2732, DOI 10.1001/jama.288.21.2732; Rabinstein AA, 2004, CEREBROVASC DIS, V18, P325, DOI 10.1159/000080771; Rabow MW, 2004, JAMA-J AM MED ASSOC, V291, P483, DOI 10.1001/jama.291.4.483; REDELMEIER DA, 1993, JAMA-J AM MED ASSOC, V270, P72, DOI 10.1001/jama.270.1.72; Roch A, 2003, CRIT CARE MED, V31, P2651, DOI 10.1097/01.CCM.0000094222.57803.B4; Rocker G, 2004, CRIT CARE MED, V32, P1149, DOI 10.1097/01.CCM.0000126402.51524.52; Santoli F, 2001, INTENS CARE MED, V27, P1141, DOI 10.1007/s001340100998; Schapira MM, 2001, MED DECIS MAKING, V21, P459, DOI 10.1177/02729890122062811; SCHIELKE E, 2005, J NEUROL         JUN; Sepucha KR, 2004, HLTH AFF S; Sheehy E, 2003, NEW ENGL J MED, V349, P667, DOI 10.1056/NEJMsa021271; Smith E, 2005, BMJ-BRIT MED J, V330, P406, DOI 10.1136/bmj.330.7488.406; Steiner T, 1997, STROKE, V28, P711, DOI 10.1161/01.STR.28.4.711; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709; Weimar C, 2002, J NEUROL, V249, P888, DOI 10.1007/s00415-002-0755-8; Weissman DE, 2004, JAMA-J AM MED ASSOC, V292, P1738, DOI 10.1001/jama.292.14.1738; Wennberg JE, 2004, BMJ-BRIT MED J, V328, P607, DOI 10.1136/bmj.328.7440.607; Wijdicks EFM, 1997, NEUROLOGY, V49, P1342, DOI 10.1212/WNL.49.5.1342; Wijdicks EFM, 1997, MAYO CLIN PROC, V72, P210, DOI 10.4065/72.3.210; Wijdicks EFM, 1996, STROKE, V27, P1301, DOI 10.1161/01.STR.27.8.1301; WUNSCH H, 2005, INTENSIVE CARE MED	92	94	95	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	2005	294	6					725	733						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	953IA	16091575				2022-12-28	WOS:000231068600026
J	Anderson, EW				Anderson, EW			ABC of conflict and disaster - Approaches to conflict resolution	BRITISH MEDICAL JOURNAL			English	Review									Univ Durham, Durham DH1 3HP, England	Durham University	Anderson, EW (corresponding author), Univ Durham, Durham DH1 3HP, England.							DOEL M, 1999, ESSENTIAL GROUPWORKE; Horwath J., 1999, EFFECTIVE STAFF TRAI; MERRILLS JG, 1993, INT DISPUTE SETTLEME	3	2	2	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	AUG 6	2005	331	7512					344	346		10.1136/bmj.331.7512.344	http://dx.doi.org/10.1136/bmj.331.7512.344			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955WZ	16081450	Green Published			2022-12-28	WOS:000231259800028
J	Howell, A				Howell, A			Adjuvant aromatase inhibitors for breast cancer	LANCET			English	Editorial Material							TAMOXIFEN; TRIAL		Christie Hosp NHS Trust, CRUK Dept Med Oncol, Manchester M20 4BX, Lancs, England	Christie NHS Foundation Trust; Christie Hospital	Howell, A (corresponding author), Christie Hosp NHS Trust, CRUK Dept Med Oncol, Manchester M20 4BX, Lancs, England.	maria.parker@christie-tr.nwest.nhs.uk		Howell, Anthony/0000-0002-6233-719X				Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Boccardo F, 2005, J CLIN ONCOL, V23, P5138, DOI 10.1200/JCO.2005.04.120; Coombes RC, 2004, BREAST CANCER RES TR, V88, pS7; CUZICK J, IN PRESS BR J CANC; GOSS P, 2004, P AN M AM SOC CLIN, V22, P847; Howell A, 2005, LANCET, V365, P60, DOI 10.1016/s0140-6736(04)17666-6; Jakesz R, 2005, J CLIN ONCOL, V23, p10S; Jakesz R, 2005, LANCET, V366, P455, DOI 10.1016/S0140-6736(05)67059-6; Jelovac D, 2005, CANCER RES, V65, P5439, DOI 10.1158/0008-5472.CAN-04-2782; OSBORNE CK, 2005, STEROID BIOCH M 0711, DOI DOI 10.1016/J.JSBMB.2005.04.021; Punglia RS, 2005, J CLIN ONCOL, V23, P5178, DOI 10.1200/JCO.2005.02.964; Sabnis GJ, 2005, CANCER RES, V65, P3903, DOI 10.1158/0008-5472.CAN-04-4092; SANTEN RJ, 2005, STEROID BIOCH M 0714, DOI DOI 10.1016/J.JSBMB2005.04.025; Thurlimann BJ, 2005, J CLIN ONCOL, V23, p6S	14	19	19	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 6	2005	366	9484					431	433		10.1016/S0140-6736(05)67036-5	http://dx.doi.org/10.1016/S0140-6736(05)67036-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	952RD	16084234				2022-12-28	WOS:000231022300005
J	Cohen, MH; d'Adesky, AC; Anastos, K				Cohen, MH; d'Adesky, AC; Anastos, K			Women in Rwanda - Another world is possible	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							GENDER-BASED VIOLENCE; HIV/AIDS		Cook Cty Bur Hlth Serv, CORE, Ctr Prevent Care & Res Infect Dis, Chicago, IL 60612 USA; Stroger Hosp, Dept Med, Chicago, IL USA; Rush Med Coll, Chicago, IL 60612 USA; Albert Einstein Coll Med, Bronx, NY 10467 USA; Womens Equ Access Care & Treatment HIV Initiat W, San Francisco, CA USA	John H Stroger Junior Hospital Cook County; Rush University; Yeshiva University; Albert Einstein College of Medicine	Cohen, MH (corresponding author), Cook Cty Bur Hlth Serv, CORE, Ctr Prevent Care & Res Infect Dis, 2020 W Harrison, Chicago, IL 60612 USA.	mcohen@corecenter.org			NIAID NIH HHS [U01-AI-35004] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035004] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		African Rights, 2004, RWAND BROK BOD TORN; Amowitz LL, 2002, JAMA-J AM MED ASSOC, V287, P513, DOI 10.1001/jama.287.4.513; [Anonymous], 2004, 2004 REP GLOB AIDS E; Barkan SE, 1998, EPIDEMIOLOGY, V9, P117, DOI 10.1097/00001648-199803000-00004; Castro A, 2005, AM J PUBLIC HEALTH, V95, P53, DOI 10.2105/AJPH.2003.028563; DADESKY A, 2003, POZ MAGAZINE     SEP; Donovan P, 2002, LANCET, V360, pS17, DOI 10.1016/S0140-6736(02)11804-6; Dunkle KL, 2004, LANCET, V363, P1415, DOI 10.1016/S0140-6736(04)16098-4; Germain A, 2004, LANCET, V363, P65, DOI 10.1016/S0140-6736(03)15173-2; HRW, 2005, NO PROT RAP SEX VIOL; *HUM RIGHTS WATCH, 2004, LEAV NON TELL STOR G; *HUM RIGHTS WATCH, 2004, RWAND RAP SURV FIND; Human Rights Watch/Africa, 1996, SHATT LIV SEX VIOL R; Jefferson, 2004, WAR PEACE SEXUAL VIO; *JOINT UN PROGR HI, 2005, AIDS AFR 3 SCEN 2025; Martin SL, 2004, LANCET, V363, P1410, DOI 10.1016/S0140-6736(04)16133-3; Parker RG, 2000, AIDS, V14, pS22, DOI 10.1097/00002030-200006001-00004; Pham PN, 2004, JAMA-J AM MED ASSOC, V292, P602, DOI 10.1001/jama.292.5.602; WAAL A, 2003, GLOBAL HLTH CHALLENG, P125; WARD J, 2002, NOT ADDRESSING GENDE; Watts C, 2002, LANCET, V359, P1232, DOI 10.1016/S0140-6736(02)08221-1	21	18	18	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	2005	294	5					613	615		10.1001/jama.294.5.613	http://dx.doi.org/10.1001/jama.294.5.613			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	951NN	16077056				2022-12-28	WOS:000230937500022
J	Baron, RJ; Fabens, EL; Schiffman, M; Wolf, E				Baron, RJ; Fabens, EL; Schiffman, M; Wolf, E			Electronic health records: Just around the corner? Or over the cliff?	ANNALS OF INTERNAL MEDICINE			English	Article								We recently implemented a full-featured electronic health record in our independent, 4-internist, community-based practice of general internal medicine. We encountered various challenges, some unexpected, in moving from paper to computer. This article describes the effects that use of electronic health records has had on our finances, work flow, and office environment. Its financial impact is not clearly positive; work flows were substantially disrupted; and the quality of the office environment initially deteriorated greatly for staff, physicians, and patients. That said, none of us would go back to paper health records, and all of us find that the technology helps us to better meet patient expectations, expedites many tedious work processes (such as prescription writing and creation of chart notes), and creates new ways in which we can improve the health of our patients. Five broad issues must be addressed to promote successful implementation of electronic health records in a small office: financing; interoperability, standardization, and connectivity of clinical information systems; help with redesign of work flow; technical support and training; and help with change management. We hope that sharing our experience can better prepare others who plan to implement electronic health records and inform policymakers on the strategies needed for success in the small practice environment.	Greenhouse Internists, Philadelphia, PA 19119 USA		Baron, RJ (corresponding author), Greenhouse Internists, PC,345 E Mt Airy Ave, Philadelphia, PA 19119 USA.	rbaron@greenhouseinternists.com	Schiffman, Mark/B-9766-2015; Greiver, Michelle/N-8764-2015; Tao, Youyou/D-2367-2014	Greiver, Michelle/0000-0001-8957-0285; 				AGOSTINO RB, NHLBI NATL CHOLESTER; *AM COLL PHYS, 2003, ACP REV SUMM 1 2 NOV; [Anonymous], 2001, CROSSING QUALITY CHA, DOI DOI 10.17226/10027; CHIN T, 2004, AM MED NEWS     0201, P9; CORRIGAN JM, 2002, FOSTERING RAPID ADV; *MARKL FDN RW JOHN, CONN HLTH FIN LEG OR; MILLER RH, ELECT MED RECORDS LE; The Center for Information Technology Leadership, 2005, VAL HEALTHC INF EXCH	8	105	106	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 2	2005	143	3					222	226		10.7326/0003-4819-143-3-200508020-00008	http://dx.doi.org/10.7326/0003-4819-143-3-200508020-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	951TM	16061920				2022-12-28	WOS:000230953900007
J	Johnson, S; Nolan, F; Pilling, S; Sandor, A; Hoult, J; McKenzie, N; White, IR; Thompson, M; Bebbington, P				Johnson, S; Nolan, F; Pilling, S; Sandor, A; Hoult, J; McKenzie, N; White, IR; Thompson, M; Bebbington, P			Randomised controlled trial of acute mental health care by a crisis resolution team: the north Islington crisis study	BRITISH MEDICAL JOURNAL			English	Article							HOME TREATMENT	Objective To evaluate the effectiveness of a crisis resolution team. Design Randomised controlled trial. Participants 260 residents of the inner London Borough of Islington who were experiencing crises severe enough for hospital admission to be considered. Interventions Acute care including a 24 hour crisis resolution team (experimental group), compared with standard care from inpatient services and community mental health teams (control group). Main outcome measures Hospital admission and patients' satisfaction. Results Patients in the experimental group were less likely to be admitted to hospital in the eight weeks after the crisis (odds ratio 0.19, 95% confidence interval 0.11 to 0.32), though compulsory admission was not significantly reduced. A difference of 1.6 points in the mean score on the client satisfaction questionnaire (CSQ-8) was not quite significant (P = 0.07), although it became so after adjustment for baseline characteristics (P = 0.002). Conclusion Crisis resolution teams can reduce hospital admissions in mental health crises. They may also increase patients' satisfaction, but this was an equivocal finding.	UCL, Royal Free & Univ Coll Med Sch, Dept Mental Hlth Sci, London W1W 7EY, England; Camden & Islington Menatl Hlth & Social Care Trus, London NW1 0PE, England; UCL, CORE British Psychol Psychol, Subdept Clin Hlth Psychol, London WC1E 7HB, England; Cent & NW London Mental Hlth NHS Trust, London W2 6LA, England; MRC, Biostat Unit, Cambridge CB2 2SR, England; Univ Surrey, Dept Clin Psychol, Surrey GU2 7XH, England	University of London; University College London; University of London; University College London; MRC Biostatistics Unit; University of Surrey	Johnson, S (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Dept Mental Hlth Sci, London W1W 7EY, England.	sjohnson@ucl.ac.uk	Johnson, Sonia/A-5220-2008; Johnson, Sonia/ABF-1457-2020; Bebbington, Paul Ernest/C-1939-2008; Nolan, Fiona/U-3558-2018	Johnson, Sonia/0000-0002-2219-1384; Johnson, Sonia/0000-0002-2219-1384; Bebbington, Paul Ernest/0000-0002-6030-7456; Nolan, Fiona/0000-0002-6633-341X				Attkisson C C, 1982, Eval Program Plann, V5, P233, DOI 10.1016/0149-7189(82)90074-X; Britton A, 1999, J Health Serv Res Policy, V4, P112; COHEN BMZ, 2001, ACUTE MENTAL HLTH CA; *DEP HLTH, 2000, NHS PLAN; Department of Health, 2001, MENT HLTH POL IMPL G; HOULT J, 1983, AUST NZ J PSYCHIAT, V17, P160, DOI 10.3109/00048678309160000; Johnson S, 2005, BRIT J PSYCHIAT, V187, P68, DOI 10.1192/bjp.187.1.68; Johnson S, 2001, ACTA PSYCHIAT SCAND, V104, P47, DOI 10.1034/j.1600-0447.2001.1040s2047.x; Johnson S, 2004, PSYCHIATRY, V3, P22; Johnson S., 1997, LONDONS MENTAL HLTH; LUKOFF D, 1986, SCHIZOPHRENIA BULL, V12, P578, DOI 10.1093/schbul/12.4.578; MARKS I, 1994, BRIT J PSYCHIAT, V65, P179; PARKER G, 1991, ACTA PSYCHIAT SCAND, V83, P145, DOI 10.1111/j.1600-0447.1991.tb07381.x; Pelosi AJ, 2000, BRIT MED J, V320, P308; Priebe S, 1999, INT J SOC PSYCHIATR, V45, P7, DOI 10.1177/002076409904500102; RAMSAY R, 1997, LONDONS MENTAL HLTH; REYNOLDS I, 1990, MED J AUSTRALIA, V152, P646, DOI 10.5694/j.1326-5377.1990.tb125421.x; Slade M, 2000, SOC PSYCH PSYCH EPID, V35, P78; Smyth MG, 2000, BRIT MED J, V320, P305, DOI 10.1136/bmj.320.7230.305; STEIN LI, 1980, ARCH GEN PSYCHIAT, V37, P392; Wing JK, 1998, BRIT J PSYCHIAT, V172, P11, DOI 10.1192/bjp.172.1.11	21	160	164	0	22	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 17	2005	331	7517					599	602		10.1136/bmj.38519.678148.8F	http://dx.doi.org/10.1136/bmj.38519.678148.8F			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	967EK	16103032	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000232074100014
J	Cardone, L; Hirayamna, J; Giordano, F; Tarnaru, T; Palvimo, JJ; Sassone-Corsi, P				Cardone, L; Hirayamna, J; Giordano, F; Tarnaru, T; Palvimo, JJ; Sassone-Corsi, P			Circadian clock control by SUMOylation of BMAL1	SCIENCE			English	Article							SUMO-1 MODIFICATION; GENE-EXPRESSION; UBIQUITIN; TRANSCRIPTION; DIMERIZATION; MECHANISMS; PACEMAKER; PROTEIN; CRY2	The molecular machinery that governs circadian rhythmicity is based on clock proteins organized in regulatory feedback loops. Although posttranstational modification of clock proteins is likely to finely control their circadian functions, only limited information is available to date. Here, we show that BMAL1, an essential transcription factor component of-the clock mechanism, is SUMOylated on a highly conserved lysine residue (Lys(259)) in vivo. BMAL1 shows a circadian pattern of SUMOylation that parallels its activation in the mouse liver. SUMOylation of BMAL1 requires and is induced by CLOCK, the heterodimerization partner of BMAL1. Ectopic expression of a SUMO-deficient BMAL1 demonstrates that SUMOylation plays an important role in BMAL1 circadian expression and clock rhythmicity. This reveals an additional level of regulation within the core mechanism of the circadian clock.	Inst Genet & Biol Mol & Cellulaire, F-67404 Strasbourg, France; Toho Univ, Sch Med, Dept Physiol, Ohta Ku, Tokyo 1438540, Japan; Univ Helsinki, Biomedicum Helsinki, Inst Biomed, FIN-00014 Helsinki, Finland	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Helsinki	Sassone-Corsi, P (corresponding author), Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries, F-67404 Strasbourg, France.	paolosc@igbmc.u-strasbg.fr	Sassone-Corsi, Paolo/H-6182-2011	Cardone, Luca/0000-0001-8184-2856; Palvimo, Jorma/0000-0003-2373-0578; Hirayama, Jun/0000-0002-8485-3320				Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; Bailey D, 2004, J BIOL CHEM, V279, P692, DOI 10.1074/jbc.M306195200; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Bunger MK, 2000, CELL, V103, P1009, DOI 10.1016/S0092-8674(00)00205-1; Cermakian N, 2001, EMBO J, V20, P3967, DOI 10.1093/emboj/20.15.3967; Cermakian N, 2000, NAT REV MOL CELL BIO, V1, P59, DOI 10.1038/35036078; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Gill G, 2003, CURR OPIN GENET DEV, V13, P108, DOI 10.1016/S0959-437X(03)00021-2; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Kondratov RV, 2003, GENE DEV, V17, P1921, DOI 10.1101/gad.1099503; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Lowrey PL, 2000, ANNU REV GENET, V34, P533, DOI 10.1146/annurev.genet.34.1.533; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Okamura H, 2004, J BIOL RHYTHM, V19, P388, DOI 10.1177/0748730404269169; Salinas S, 2004, J CELL BIOL, V165, P767, DOI 10.1083/jcb.200310136; Schibler U, 2002, CELL, V111, P919, DOI 10.1016/S0092-8674(02)01225-4; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Suzuki T, 1999, J BIOL CHEM, V274, P31131, DOI 10.1074/jbc.274.44.31131; Tamaru T, 2003, GENES CELLS, V8, P973, DOI 10.1046/j.1365-2443.2003.00686.x; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576	29	233	241	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 26	2005	309	5739					1390	1394		10.1126/science.1110689	http://dx.doi.org/10.1126/science.1110689			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TX	16109848				2022-12-28	WOS:000231543300049
J	Baker, J; Bizzarro, M; Wittig, N; Connelly, J; Haack, H				Baker, J; Bizzarro, M; Wittig, N; Connelly, J; Haack, H			Early planetesimal melting from an age of 4.5662 Gyr for differentiated meteorites	NATURE			English	Article							SOLAR-SYSTEM; ISOTOPE SYSTEMATICS; CHONDRULES; DORBIGNY; ABUNDANCES; TIMESCALES; SEARCH; TIME	Long- and short-lived radioactive isotopes and their daughter products in meteorites are chronometers that can test models for Solar System formation(1,2). Differentiated meteorites come from parent bodies that were once molten and separated into metal cores and silicate mantles. Mineral ages for these meteorites, however, are typically younger than age constraints for planetesimal differentiation(3-5). Such young ages indicate that the energy required to melt their parent bodies could not have come from the most likely heat source(6) - radioactive decay of short-lived nuclides (Al-26 and Fe-60) injected from a nearby supernova - because these would have largely decayed by the time of melting. Here we report an age of 4.5662 +/- 0.0001 billion years ( based on Pb - Pb dating) for basaltic angrites, which is only 1Myr younger than the currently accepted minimum age of the Solar System(7) and corresponds to a time when Al-26 and Fe-60 decay could have triggered planetesimal melting. Small Mg-26 excesses in bulk angrite samples confirm that Al-26 decay contributed to the melting of their parent body. These results indicate that the accretion of differentiated planetesimals pre-dated that of undifferentiated planetesimals, and reveals the minimum Solar System age to be 4.5695 +/- 0.0002 billion years.	Victoria Univ Wellington, Sch Earth Sci, Wellington, New Zealand; Inst Geol, DK-1350 Copenhagen, Denmark; Geol Museum, DK-1350 Copenhagen, Denmark; Univ Texas, Dept Geol Sci, Austin, TX 78712 USA	Victoria University Wellington; University of Texas System; University of Texas Austin	Baker, J (corresponding author), Victoria Univ Wellington, Sch Earth Sci, POB 600, Wellington, New Zealand.	joel.baker@vuw.ac.nz	Bizzarro, Martin/M-7474-2019; Haack, Henning/A-4807-2013; Bizzarro, Martin/I-8701-2012; Baker, Joel/A-3477-2008; Connelly, James/O-7996-2015	Bizzarro, Martin/0000-0001-9966-2124; Haack, Henning/0000-0002-4618-3178; Bizzarro, Martin/0000-0001-9966-2124; Baker, Joel/0000-0001-6371-5060; Wittig Brooks, Nadine/0000-0002-0008-5441				Amelin Y, 2002, SCIENCE, V297, P1678, DOI 10.1126/science.1073950; AMELIN Y, 2004, GEOCHIM COSMOCHIM AC, V68; Baker J, 2004, CHEM GEOL, V211, P275, DOI 10.1016/j.chemgeo.2004.06.030; Bizzarro M, 2004, NATURE, V431, P275, DOI 10.1038/nature02882; Gilmour JD, 2001, PHILOS T R SOC A, V359, P2037, DOI 10.1098/rsta.2001.0895; Glavin DP, 2004, METEORIT PLANET SCI, V39, P693, DOI 10.1111/j.1945-5100.2004.tb00112.x; Halliday AN, 2001, EARTH PLANET SC LETT, V192, P545, DOI 10.1016/S0012-821X(01)00479-4; JAGOUTZ E, 2003, 66 ANN MET SOC M; KITA NT, 2004, WORKSH CONDR PROT DI; Kleine T, 2004, GEOCHIM COSMOCHIM AC, V68, P2935, DOI 10.1016/j.gca.2004.01.009; KLEINE T, 2004, EOS S, V85; Kurat G, 2004, GEOCHIM COSMOCHIM AC, V68, P1901, DOI 10.1016/j.gca.2003.10.016; LaTourrette T, 1998, EARTH PLANET SC LETT, V158, P91, DOI 10.1016/S0012-821X(98)00048-X; LISSAUER JJ, 1987, ICARUS, V69, P249, DOI 10.1016/0019-1035(87)90104-7; Lugmair GW, 1998, GEOCHIM COSMOCHIM AC, V62, P2863, DOI 10.1016/S0016-7037(98)00189-6; LUGMAIR GW, 1992, GEOCHIM COSMOCHIM AC, V56, P1673, DOI 10.1016/0016-7037(92)90234-A; Lugmair GW, 2001, METEORIT PLANET SCI, V36, P1017, DOI 10.1111/j.1945-5100.2001.tb01941.x; Mittlefehldt DW, 2005, TREATISE GEOCHEM, V1, P291; Mittlefehldt DW, 2002, METEORIT PLANET SCI, V37, P345, DOI 10.1111/j.1945-5100.2002.tb00821.x; Nyquist L, 2001, METEORIT PLANET SCI, V36, P911, DOI 10.1111/j.1945-5100.2001.tb01930.x; NYQUIST LE, 2003, LUN PLAN SCI C, V34; Stirling CH, 2005, GEOCHIM COSMOCHIM AC, V69, P1059, DOI 10.1016/j.gca.2004.06.034; TATSUMOTO M, 1973, SCIENCE, V180, P1279, DOI 10.1126/science.180.4092.1279; UREY HC, 1955, P NATL ACAD SCI USA, V41, P127, DOI 10.1073/pnas.41.3.127; WASSERBURG GJ, 1987, EARTH PLANET SC LETT, V86, P129, DOI 10.1016/0012-821X(87)90219-6; Yin QZ, 2002, NATURE, V418, P949, DOI 10.1038/nature00995; Young ED, 2005, SCIENCE, V308, P223, DOI 10.1126/science.1108140	27	189	193	5	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 25	2005	436	7054					1127	1131		10.1038/nature03882	http://dx.doi.org/10.1038/nature03882			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	958AK	16121173				2022-12-28	WOS:000231416600038
J	Gehi, A; Haas, D; Fuster, V				Gehi, A; Haas, D; Fuster, V			Primary prophylaxis with the implantable cardioverter-defibrillator - The need for improved risk stratification	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SUDDEN-DEATH; VALIDATION; THERAPY; TRIAL		CUNY Mt Sinai Sch Med, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Gehi, A (corresponding author), Mt Sinai Med Ctr, 1 Gustave L Levy Pl,Box 1030, New York, NY 10029 USA.	anil.gehi@msnyuhealth.org	Fuster, Valentin/H-4319-2015	Fuster, Valentin/0000-0002-9043-9986				Antman EM, 2000, JAMA-J AM MED ASSOC, V284, P835, DOI 10.1001/jama.284.7.835; Bailey JJ, 2001, J AM COLL CARDIOL, V38, P1902, DOI 10.1016/S0735-1097(01)01667-9; Bardy GH, 2005, NEW ENGL J MED, V352, P225, DOI 10.1056/NEJMoa043399; Bloomfield DM, 2004, CIRCULATION, V110, P1885, DOI 10.1161/01.CIR.0000143160.14610.53; Buxton AE, 1999, NEW ENGL J MED, V341, P1882, DOI 10.1056/NEJM199912163412503; Buxton Alfred E, 2003, Card Electrophysiol Rev, V7, P434, DOI 10.1023/B:CEPR.0000023159.96742.d2; Connolly SJ, 2000, CIRCULATION, V101, P1297, DOI 10.1161/01.CIR.101.11.1297; Desai Akshay S., 2004, Curr Treat Options Cardiovasc Med, V6, P3, DOI 10.1007/s11936-004-0010-y; Essebag Vidal, 2003, Card Electrophysiol Rev, V7, P43, DOI 10.1023/A:1023639006565; Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864; Gerin W, 2002, BLOOD PRESS MONIT, V7, P313, DOI 10.1097/00126097-200212000-00004; Gregoratos Gabriel, 2002, Circulation, V106, P2145, DOI 10.1161/01.CIR.0000035996.46455.09; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Huikuri HV, 2001, NEW ENGL J MED, V345, P1473, DOI 10.1056/NEJMra000650; Jouven X, 2005, NEW ENGL J MED, V352, P1951, DOI 10.1056/NEJMoa043012; Kuck KH, 2000, CIRCULATION, V102, P748, DOI 10.1161/01.CIR.102.7.748; La Rovere MT, 2001, CIRCULATION, V103, P2072; Makikallio TH, 2002, CIRCULATION, V105, pE69, DOI 10.1161/hc1202.106048; Malm S, 2004, J AM COLL CARDIOL, V44, P1030, DOI 10.1016/j.jacc.2004.05.068; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; McClellan MB, 2005, NEW ENGL J MED, V352, P222, DOI 10.1056/NEJMp048354; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; Otterstad JE, 1997, EUR HEART J, V18, P507; Sheldon R, 2001, CIRCULATION, V104, P1622, DOI 10.1161/hc3901.096720; Steinbrook R, 2005, NEW ENGL J MED, V353, P221, DOI 10.1056/NEJMp058158; Tapanainen JM, 2004, J AM COLL CARDIOL, V43, P757, DOI 10.1016/j.jacc.2003.09.048	26	27	28	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 24	2005	294	8					958	960		10.1001/jama.294.8.958	http://dx.doi.org/10.1001/jama.294.8.958			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	957JM	16118387				2022-12-28	WOS:000231366100027
J	Wingert, RA; Galloway, JL; Barut, B; Foott, H; Fraenkel, P; Axe, JL; Weber, GJ; Dooley, K; Davidson, AJ; Schmidt, B; Paw, BH; Shaw, GC; Kingsley, P; Palis, J; Schubert, H; Chen, O; Kaplan, J; Zon, LI				Wingert, RA; Galloway, JL; Barut, B; Foott, H; Fraenkel, P; Axe, JL; Weber, GJ; Dooley, K; Davidson, AJ; Schmidt, B; Paw, BH; Shaw, GC; Kingsley, P; Palis, J; Schubert, H; Chen, O; Kaplan, J; Zon, LI		Tubingen 2000 Screen Consortium	Deficiency of glutaredoxin 5 reveals Fe-S clusters are required for vertebrate haem synthesis	NATURE			English	Article							IRON-SULFUR CLUSTERS; LINKED SIDEROBLASTIC ANEMIA; GENE; PROTEIN; GRX5; MUTATION; ATAXIA; YEAST; ABC7; TRANSPORTER	Iron is required to produce haem and iron - sulphur ( Fe - S) clusters, processes thought to occur independently(1,2). Here we show that the hypochromic anaemia in shiraz ( sir) zebrafish mutants is caused by deficiency of glutaredoxin 5 (grx5), a gene required in yeast for Fe - S cluster assembly. We found that grx5 was expressed in erythroid cells of zebrafish and mice. Zebrafish grx5 rescued the assembly of Delta grx5 yeast Fe - S, showing that the biochemical function of grx5 is evolutionarily conserved. In contrast to yeast, vertebrates use iron regulatory protein 1 (IRP1) to sense intracellular iron and regulate mRNA stability or the translation of iron metabolism genes(1,2). We found that loss of Fe - S cluster assembly in sir animals activated IRP1 and blocked haem biosynthesis catalysed by aminolaevulinate synthase 2 (ALAS2). Overexpression of ALAS2 RNA without the 50 iron response element that binds IRP1 rescued sir embryos, whereas overexpression of ALAS2 including the iron response element did not. Further, antisense knockdown of IRP1 restored sir embryo haemoglobin synthesis. These findings uncover a connection between haem biosynthesis and Fe - S clusters, indicating that haemoglobin production in the differentiating red cell is regulated through Fe - S cluster assembly.	Harvard Univ, Sch Med, Childrens Hosp, Stem Cell Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol, Boston, MA 02115 USA; Univ Rochester, Dept Pediat, Med Ctr, Rochester, NY 14642 USA; Univ Utah, Dept Pathol, Sch Med, Salt Lake City, UT 84132 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Rochester; Utah System of Higher Education; University of Utah	Zon, LI (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Stem Cell Program, Boston, MA 02115 USA.	zon@enders.tch.harvard.edu	Wingert, Rebecca A/ABE-2786-2020	Wingert, Rebecca A/0000-0003-3133-7549; Fraenkel, Paula/0000-0001-8894-0117; Maderspacher, Florian/0000-0003-4324-8455; Paw, Barry/0000-0002-0492-1419; Dahm, Ralf/0000-0001-5203-8578; Palis, James/0000-0001-7324-1049				Allikmets R, 1999, HUM MOL GENET, V8, P743, DOI 10.1093/hmg/8.5.743; Alves R, 2004, PROTEINS, V57, P481, DOI 10.1002/prot.20228; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Bekri S, 2000, BLOOD, V96, P3256; Belli G, 2002, J BIOL CHEM, V277, P37590, DOI 10.1074/jbc.M201688200; Brownlie A, 1998, NAT GENET, V20, P244, DOI 10.1038/3049; Chen OS, 2002, P NATL ACAD SCI USA, V99, P16922, DOI 10.1073/pnas.232392299; Dernbach E, 2004, BLOOD, V104, P3591, DOI 10.1182/blood-2003-12-4103; Fernandes AP, 2004, ANTIOXID REDOX SIGN, V6, P63, DOI 10.1089/152308604771978354; Gross U, 2000, J INHERIT METAB DIS, V23, P641, DOI 10.1023/A:1005645624262; Henderson ER, 1996, J BIOL CHEM, V271, P4900; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; JAFFREY SR, 1993, NUCLEIC ACIDS RES, V21, P4627, DOI 10.1093/nar/21.19.4627; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Land T, 1998, MOL CELL, V2, P807, DOI 10.1016/S1097-2765(00)80295-6; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Maguire A, 2001, BRIT J HAEMATOL, V115, P910, DOI 10.1046/j.1365-2141.2001.03015.x; Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7; Muhlenhoff U, 2003, EMBO J, V22, P4815, DOI 10.1093/emboj/cdg446; Nakajima O, 1999, EMBO J, V18, P6282, DOI 10.1093/emboj/18.22.6282; Napier I, 2005, BLOOD, V105, P1867, DOI 10.1182/blood-2004-10-3856; PALIS J, 1995, MOL REPROD DEV, V42, P19, DOI 10.1002/mrd.1080420104; Ransom DG, 1996, DEVELOPMENT, V123, P311; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; Tamarit J, 2003, J BIOL CHEM, V278, P25745, DOI 10.1074/jbc.M303477200; Tong WH, 2000, EMBO J, V19, P5692, DOI 10.1093/emboj/19.21.5692; Vilella F, 2004, COMP FUNCT GENOM, V5, P328, DOI 10.1002/cfg.406; Wingert RA, 2004, DEVELOPMENT, V131, P6225, DOI 10.1242/dev.01540	30	293	309	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 18	2005	436	7053					1035	1039		10.1038/nature03887	http://dx.doi.org/10.1038/nature03887			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955XQ	16110529				2022-12-28	WOS:000231263900054
J	Zhang, ZH; Wang, SY; Li, Q; Yao, SL; Zeng, BX; Ziegelstein, RC; Hu, QH				Zhang, ZH; Wang, SY; Li, Q; Yao, SL; Zeng, BX; Ziegelstein, RC; Hu, QH			Capillary leak syndrome in children with C4A-deficiency undergoing cardiac surgery with cardiopulmonary bypass: a double-blind, randomised controlled study	LANCET			English	Article							TUMOR-NECROSIS-FACTOR; OPEN-HEART OPERATIONS; ACUTE LUNG INJURY; COMPLEMENT ACTIVATION; FACTOR-ALPHA; MICROVASCULAR PERMEABILITY; PEDIATRIC-PATIENTS; ENDOTHELIAL-CELLS; AORTIC-SURGERY; INTERLEUKIN-8	Background Capillary leak syndrome is a life-threatening complication after cardiopulmonary bypass (CPB), with an incidence of about 4-37% in children worldwide. On the basis of previous results, we undertook a randomised controlled study to investigate the priming with plasma rich in the C4A isotype of complement component 4 on the incidence of capillary leak syndrome in children with C4A deficiency. Methods In a hospital in Wuhan, China, we randomly assigned 116 neonates, infants, and children lacking complement component C4A to receive C4A-free or C4A-rich plasma priming (n=58 each, 20 mL/kg). The primary outcome was capillary leak syndrome, identified as an increased transvascular escape rate of Evans blue dye from plasma. Concentrations of activated complement components C4 and C3, inflammatory mediators interleukin 6, interleukin 8, tumour necrosis factor (TNF) alpha, plasma protein, and PaO2/F1O2 ratios (ratio of the partial arterial pressure of oxygen to the fractional concentration of oxygen in inspired air) were measured before and 4 h after CPB. Analysis was by intention to treat. Findings Three (5%) patients given C4A-rich plasma priming had capillary leak syndrome compared with 56 (97%) given C4A-free plasma (p<0.0001). At 4 h after CPB, activated C4, interleukin 6, interleukin 8, and TNF alpha concentrations were higher, whereas PaO2/F1O2 ratios and plasma protein concentrations were significantly lower in the C4A-free group than changes in the C4A-rich group. Activated C3 rose equally in both groups. Activated C4 significantly correlated with interleukin 6, interleukin 8, and TNF alpha concentrations; PaO2/F1O2 ratios; and the escape rate of Evans blue dye at 4 h after CPB. Two patients in the C4A-free group died of respiratory and renal failure on day 3 after CPB. Interpretation In paediatric patients with C4A deficiency, C4A-rich plasma priming reduces the incidence of CPB-related capillary leak syndrome by blocking the activated C4 increase and attenuating the systemic inflammatory response after CPB.	Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Anaesthesiol, Wuhan 430074, Peoples R China; Huazhong Univ Sci & Technol, Tongjii Med Coll, Minist Hlth China, Key Lab Pulm Dis, Wuhan 430074, Peoples R China; Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21224 USA	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Johns Hopkins University	Hu, QH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21224 USA.	qinghuaa@jhmi.edu						AWDEH ZL, 1980, P NATL ACAD SCI-BIOL, V77, P3576, DOI 10.1073/pnas.77.6.3576; BALLMER PE, 1994, METABOLISM, V43, P697, DOI 10.1016/0026-0495(94)90117-1; BIFFL WL, 1995, J TRAUMA, V39, P98, DOI 10.1097/00005373-199507000-00013; Blanchong CA, 2001, INT IMMUNOPHARMACOL, V1, P365, DOI 10.1016/S1567-5769(01)00019-4; Bocsi J, 2002, CRIT CARE, V6, P226, DOI 10.1186/cc1494; CHENOWETH DE, 1981, NEW ENGL J MED, V304, P497, DOI 10.1056/NEJM198102263040901; Cremer J, 1996, ANN THORAC SURG, V61, P1714, DOI 10.1016/0003-4975(96)00055-0; DAUBER IM, 1993, CIRCULATION, V88, P726, DOI 10.1161/01.CIR.88.2.726; Dodds AW, 1996, NATURE, V379, P177, DOI 10.1038/379177a0; DUBINETT SM, 1994, CELL IMMUNOL, V157, P170, DOI 10.1006/cimm.1994.1214; Eising GP, 2000, THORAC CARDIOV SURG, V48, P86; ELGEBALY SA, 1994, ANN THORAC SURG, V57, P391, DOI 10.1016/0003-4975(94)91003-0; ELLIOTT MJ, 1993, ANN THORAC SURG, V56, P1518, DOI 10.1016/0003-4975(93)90744-3; FINN A, 1993, J THORAC CARDIOV SUR, V105, P234, DOI 10.1016/S0022-5223(19)33806-1; FOREMAN KE, 1994, J CLIN INVEST, V94, P1147, DOI 10.1172/JCI117430; FREEDMAN FB, 1969, AM J PHYSIOL, V216, P675, DOI 10.1152/ajplegacy.1969.216.3.675; Guo YL, 1999, AM J PHYSIOL-RENAL, V276, pF390, DOI 10.1152/ajprenal.1999.276.3.F390; KIRKLIN JK, 1986, ANN THORAC SURG, V41, P193, DOI 10.1016/S0003-4975(10)62668-9; KIRKLIN JK, 1991, ANN THORAC SURG, V51, P529, DOI 10.1016/0003-4975(91)90302-7; Kohl J, 2001, MOL IMMUNOL, V38, P175, DOI 10.1016/S0161-5890(01)00041-4; LAW SKA, 1984, EMBO J, V3, P1819, DOI 10.1002/j.1460-2075.1984.tb02052.x; LEVY JH, 1993, CAN J ANAESTH, V40, P1009, DOI 10.1007/BF03009469; Li Y, 2001, MICROVASC RES, V61, P253, DOI 10.1006/mvre.2001.2304; LINDERKAMP O, 1977, EUR J PEDIATR, V125, P135, DOI 10.1007/BF00489986; Loubser PG, 1997, J CARDIOVASC PHARM, V29, P23, DOI 10.1097/00005344-199701000-00004; MARUO N, 1992, ENDOCRINOLOGY, V131, P710, DOI 10.1210/en.131.2.710; MATIS LA, 1995, NAT MED, V1, P839, DOI 10.1038/nm0895-839; MILLS AN, 1991, J THORAC CARDIOV SUR, V101, P909; PLOTZ FB, 1993, J THORAC CARDIOV SUR, V105, P823; Raijmakers PGHM, 1997, THORAX, V52, P866, DOI 10.1136/thx.52.10.866; RAIJMAKERS PGHM, 1995, AM J RESP CRIT CARE, V151, P698; Seghaye MC, 1996, J THORAC CARDIOV SUR, V112, P687, DOI 10.1016/S0022-5223(96)70053-3; Shastri KA, 1997, J THORAC CARDIOV SUR, V114, P482, DOI 10.1016/S0022-5223(97)70197-1; Stiller B, 2001, INTENS CARE MED, V27, P193, DOI 10.1007/s001340000704; Takabayashi T, 1996, J IMMUNOL, V156, P3455; Tassani P, 2002, J THORAC CARDIOV SUR, V123, P735, DOI 10.1067/mtc.2002.120348; TEELUCKSINGH S, 1990, Q J MED, V75, P515; TONZ M, 1995, CHEST, V108, P1551, DOI 10.1378/chest.108.6.1551; Zhang SH, 2004, ANESTHESIOLOGY, V100, P1387, DOI 10.1097/00000542-200406000-00009	39	23	27	1	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 13	2005	366	9485					556	562		10.1016/S0140-6736(05)67099-7	http://dx.doi.org/10.1016/S0140-6736(05)67099-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955LL	16099291				2022-12-28	WOS:000231227300027
J	Denis, MM; Tolley, ND; Bunting, M; Schwertz, H; Jiang, HM; Lindemann, S; Yost, CC; Rubner, FJ; Albertine, KH; Swoboda, KJ; Fratto, CM; Tolley, E; Kraiss, LW; McIntyre, TM; Zimmerman, GA; Weyrich, AS				Denis, MM; Tolley, ND; Bunting, M; Schwertz, H; Jiang, HM; Lindemann, S; Yost, CC; Rubner, FJ; Albertine, KH; Swoboda, KJ; Fratto, CM; Tolley, E; Kraiss, LW; McIntyre, TM; Zimmerman, GA; Weyrich, AS			Escaping the nuclear confines: Signal-dependent Pre-mRNA splicing in anucleate platelets	CELL			English	Article							GENE-EXPRESSION; PROTEIN; U1; RIBONUCLEOPROTEIN; TRANSLATION; PARTICLES; BIRTH	Platelets are specialized hemostatic cells that circulate in the blood as anucleate cytoplasts. We report that platelets unexpectedly possess a functional spliceosome, a complex that processes pre-mRNAs in the nuclei of other cell types. Spliceosome components are present in the cytoplasm of human megakaryocytes and in proplatelets that extend from megakaryocytes. Primary human platelets also contain essential spliceosome factors including small nuclear RNAs, splicing proteins, and endogenous pre-mRNAs. In response to integrin engagement and surface receptor activation, platelets precisely excise introns from interleukin-1 beta pre-mRNA, yielding a mature message that is translated into protein. Signal-dependent splicing is a novel function of platelets that demonstrates remarkable specialization in the regulatory repertoire of this anucleate cell. While this mechanism may be unique to platelets, it also suggests previously unrecognized diversity regarding the functional roles of the spliceosome in eukaryotic cells.	Univ Utah, Eccles Inst Human Genet, Salt Lake City, UT 84112 USA; Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA; Univ Utah, Dept Neurol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pediat, Salt Lake City, UT 84112 USA; Univ Utah, Dept Surg, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Weyrich, AS (corresponding author), Univ Utah, Eccles Inst Human Genet, Salt Lake City, UT 84112 USA.	andy.weyrich@hmbg.utah.edu	Lindemann, Stephan/AAH-3888-2020; Schwertz, Hansjorg/Q-3305-2019	Albertine, Kurt/0000-0001-8497-0861; Swoboda, Kathryn/0000-0002-4593-6342; Weyrich, Andrew/0000-0001-9622-4647; Yost, Christian/0000-0002-1258-3595	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD054599] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025764] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075507, R01HL066277, R37HL044525, R01HL044513, R01HL044525, R01HL062875] Funding Source: NIH RePORTER; NCRR NIH HHS [UL1 RR025764] Funding Source: Medline; NHLBI NIH HHS [HL-44513, HL-44525, R01 HL044513, R01 HL062875, R01 HL044525, R01 HL075507, R01 HL066277, HL-66277, HL-62875, HL-75507, R37 HL044525] Funding Source: Medline; NICHD NIH HHS [R01 HD054599] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Albertine KH, 1999, AM J RESP CRIT CARE, V159, P945, DOI 10.1164/ajrccm.159.3.9804027; Bahou WF, 2004, SEMIN THROMB HEMOST, V30, P473, DOI 10.1055/s-2004-833482; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Blencowe BJ, 1998, GENE DEV, V12, P996, DOI 10.1101/gad.12.7.996; Brogren H, 2004, BLOOD, V104, P3943, DOI 10.1182/blood-2004-04-1439; Graveley BR, 2001, RNA, V7, P806, DOI 10.1017/S1355838201010317; Hartwig J, 2003, J THROMB HAEMOST, V1, P1580, DOI 10.1046/j.1538-7836.2003.00331.x; Hastings ML, 2001, CURR OPIN CELL BIOL, V13, P302, DOI 10.1016/S0955-0674(00)00212-X; Hato T., 2002, PLATELETS, P105; Italiano JE, 2003, J THROMB HAEMOST, V1, P1174, DOI 10.1046/j.1538-7836.2003.00290.x; Italiano JE, 1999, J CELL BIOL, V147, P1299, DOI 10.1083/jcb.147.6.1299; JARROUS N, 1994, J BIOL CHEM, V269, P23141; Kochetov AV, 1998, FEBS LETT, V440, P351, DOI 10.1016/S0014-5793(98)01482-3; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KRAINER AR, 1988, NUCLEIC ACIDS RES, V16, P9415, DOI 10.1093/nar/16.20.9415; Lindemann S, 2001, J BIOL CHEM, V276, P33947, DOI 10.1074/jbc.M104281200; Lindemann S, 2001, J CELL BIOL, V154, P485, DOI 10.1083/jcb.200105058; Lindemann SW, 2004, P NATL ACAD SCI USA, V101, P7076, DOI 10.1073/pnas.0401901101; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; Martin KC, 2004, CURR OPIN NEUROBIOL, V14, P305, DOI 10.1016/j.conb.2004.05.009; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; Mayeda A, 1999, METH MOL B, V118, P309; MCEVER RP, 1990, BLOOD CELLS, V16, P73; McRedmond JP, 2004, MOL CELL PROTEOMICS, V3, P133, DOI 10.1074/mcp.M300063-MCP200; Pellizzoni L, 2002, SCIENCE, V298, P1775, DOI 10.1126/science.1074962; Ravid K, 2002, J CELL PHYSIOL, V190, P7, DOI 10.1002/jcp.10035; Reed R, 2001, NAT CELL BIOL, V3, pE201, DOI 10.1038/ncb0901-e201; ROMAC JMJ, 1994, MOL CELL BIOL, V14, P4662, DOI 10.1128/MCB.14.7.4662; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; Weyrich AS, 1996, J CLIN INVEST, V97, P1525, DOI 10.1172/JCI118575; Weyrich AS, 1998, P NATL ACAD SCI USA, V95, P5556, DOI 10.1073/pnas.95.10.5556; Weyrich AS, 2004, SEMIN THROMB HEMOST, V30, P491, DOI 10.1055/s-2004-833484; Weyrich AS, 2003, J THROMB HAEMOST, V1, P1897, DOI 10.1046/j.1538-7836.2003.00304.x; Will CL, 2001, CURR OPIN CELL BIOL, V13, P290, DOI 10.1016/S0955-0674(00)00211-8; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Xie JY, 2001, NATURE, V410, P936, DOI 10.1038/35073593; Yong JS, 2002, EMBO J, V21, P1188, DOI 10.1093/emboj/21.5.1188; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031; Zhou ZL, 2002, P NATL ACAD SCI USA, V99, P12203, DOI 10.1073/pnas.182427099	40	460	481	0	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 12	2005	122	3					379	391		10.1016/j.cell.2005.06.015	http://dx.doi.org/10.1016/j.cell.2005.06.015			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	955UZ	16096058	Bronze, Green Accepted			2022-12-28	WOS:000231254400010
J	Livio, M; Rees, MJ				Livio, M; Rees, MJ			Anthropic reasoning	SCIENCE			English	Editorial Material							COSMOLOGICAL CONSTANT; SUPERNOVAE		Space Telescope Sci Inst, Baltimore, MD 21218 USA; Univ Cambridge, Inst Astron, Cambridge CB3 0HA, England	Space Telescope Science Institute; University of Cambridge	Livio, M (corresponding author), Space Telescope Sci Inst, 3700 San Martin Dr, Baltimore, MD 21218 USA.	mlivio@stsci.edu; mjr36@cam.ac.uk						Garriga J, 2000, PHYS REV D, V61, DOI 10.1103/PhysRevD.61.023503; Kachru S, 2003, PHYS REV D, V68, DOI 10.1103/PhysRevD.68.046005; Perlmutter S, 1999, ASTROPHYS J, V517, P565, DOI 10.1086/307221; Riess AG, 1998, ASTRON J, V116, P1009, DOI 10.1086/300499; Spergel DN, 2003, ASTROPHYS J SUPPL S, V148, P175, DOI 10.1086/377226; Steinhardt P. J., 1983, Very Early Universe. Proceedings of the Nuffield Workshop, P251; Tegmark M, 1998, ASTROPHYS J, V499, P526, DOI 10.1086/305673; TEGMARK M, 2005, J COSMOL ASTROP 0404; VILENKIN A, 1983, PHYS REV D, V27, P2848, DOI 10.1103/PhysRevD.27.2848; WEINBERG S, 1987, PHYS REV LETT, V59, P2607, DOI 10.1103/PhysRevLett.59.2607	11	28	28	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 12	2005	309	5737					1022	1023		10.1126/science.1111446	http://dx.doi.org/10.1126/science.1111446			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955MN	16099967				2022-12-28	WOS:000231230100027
J	Ly, TY; Fowler, RA				Ly, TY; Fowler, RA			Images in clinical medicine - Chylothorax and chyloperitoneum	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Toronto, Toronto, ON MN4 3M5, Canada	University of Toronto	Ly, TY (corresponding author), Univ Toronto, Toronto, ON MN4 3M5, Canada.								0	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 11	2005	353	6					616	616		10.1056/NEJMicm040707	http://dx.doi.org/10.1056/NEJMicm040707			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	953ST	16093470				2022-12-28	WOS:000231101500012
J	Muller, P; Kuttenkeuler, D; Gesellchen, V; Zeidler, MP; Boutros, M				Muller, P; Kuttenkeuler, D; Gesellchen, V; Zeidler, MP; Boutros, M			Identification of JAK/STAT signalling components by genome-wide RNA interference	NATURE			English	Article							DROSOPHILA; PATHWAY; GENE; EXPRESSION; PROTEIN; KINASE; CELLS; TRANSCRIPTION; TRANSDUCTION; ACTIVATION	Signalling pathways mediating the transduction of information between cells are essential for development, cellular differentiation and homeostasis(1). Their dysregulation is also frequently associated with human malignancies. The Janus tyrosine kinase/ signal transducer and activator of transcription (JAK/STAT) pathway represents one such signalling cascade whose evolutionarily conserved roles include cell proliferation and haematopoiesis(2). Here we describe a systematic genome-wide survey for genes required for JAK/STAT pathway activity. Analysis of 20,026 RNA interference (RNAi)-induced phenotypes in cultured Drosophila melanogaster haemocyte-like cells identified interacting genes encoding 4 known and 86 previously uncharacterized proteins. Subsequently, cell-based epistasis experiments were used to classify these proteins on the basis of their interaction with known components of the signalling cascade. In addition to multiple human disease gene homologues, we have found the tyrosine phosphatase Ptp61F and the Drosophila homologue of BRWD3, a bromo-domain-containing protein disrupted in leukaemia(3). Moreover, in vivo analysis demonstrates that disrupted dBRWD3 and overexpressed Ptp61F function as suppressors of leukaemia-like blood cell tumours. This screen represents a comprehensive identification of novel loci required for JAK/STAT signalling and provides molecular insights into an important pathway relevant for human cancer. Human homologues of identified pathway modifiers may constitute targets for therapeutic interventions.	German Canc Res Ctr, D-69120 Heidelberg, Germany; Max Planck Inst Biophys Chem, Dept Mol Dev Biol, D-37077 Gottingen, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Max Planck Society	Zeidler, MP (corresponding author), German Canc Res Ctr, Neuenheimer Feld 580, D-69120 Heidelberg, Germany.	mzeidle@gwdg.de; m.boutros@dkfz.de	Boutros, Michael/C-3566-2008; Müller, Patrick/C-8096-2014; Zeidler, Martin/E-6209-2010	Boutros, Michael/0000-0002-9458-817X; Müller, Patrick/0000-0002-0702-6209; Zeidler, Martin/0000-0003-2942-1135				Bach EA, 2003, GENETICS, V165, P1149; Betz A, 2001, P NATL ACAD SCI USA, V98, P9563, DOI 10.1073/pnas.171302098; BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; Boutros M, 2002, DEV CELL, V3, P711, DOI 10.1016/S1534-5807(02)00325-8; Boutros M, 2004, SCIENCE, V303, P832, DOI 10.1126/science.1091266; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Brown S, 2001, CURR BIOL, V11, P1700, DOI 10.1016/S0960-9822(01)00524-3; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Hannon GJ, 2004, NATURE, V431, P371, DOI 10.1038/nature02870; Harrison DA, 1998, GENE DEV, V12, P3252, DOI 10.1101/gad.12.20.3252; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; Hombria JCG, 2002, CURR BIOL, V12, pR569, DOI 10.1016/S0960-9822(02)01057-6; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Kalla C, 2005, GENE CHROMOSOME CANC, V42, P128, DOI 10.1002/gcc.20131; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Karsten P, 2002, MECH DEVELOP, V117, P343, DOI 10.1016/S0925-4773(02)00216-2; Kittler R, 2004, NATURE, V432, P1036, DOI 10.1038/nature03159; Kwon FJ, 2000, J BIOL CHEM, V275, P19824, DOI 10.1074/jbc.M001114200; Lagueux M, 2000, P NATL ACAD SCI USA, V97, P11427, DOI 10.1073/pnas.97.21.11427; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; MCLAUGHLIN S, 1993, J BIOL CHEM, V268, P6839; Meister M, 2003, CELL MICROBIOL, V5, P573, DOI 10.1046/j.1462-5822.2003.00302.x; Mesilaty-Gross S, 1999, GENE, V231, P173, DOI 10.1016/S0378-1119(99)00053-0; Mukherjee T, 2005, ONCOGENE, V24, P2503, DOI 10.1038/sj.onc.1208487; O'Shea JJ, 2004, NAT REV DRUG DISCOV, V3, P555, DOI 10.1038/nrd1441; Sefton L, 2000, NATURE, V405, P970, DOI 10.1038/35016119; Spradling AC, 1999, GENETICS, V153, P135; Yan RQ, 1996, P NATL ACAD SCI USA, V93, P5842, DOI 10.1073/pnas.93.12.5842; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8	30	225	235	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 11	2005	436	7052					871	875		10.1038/nature03869	http://dx.doi.org/10.1038/nature03869			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953XG	16094372	Green Published			2022-12-28	WOS:000231116500051
J	Ryan, PD; Kopans, DB; Sgroi, DC				Ryan, PD; Kopans, DB; Sgroi, DC			Case records of the Massachusetts General Hospital: Case 24-2005: A 58-year-old woman with early-stage estrogen-receptor-positive breast cancer - Invasive ductal carcinoma, T2N0, positive for estrogen receptor and progesterone receptor, negative for HER2/neu amplification.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							20-YEAR FOLLOW-UP; POSTMENOPAUSAL WOMEN; RANDOMIZED-TRIAL; EXPRESSION PROFILES; TAMOXIFEN THERAPY; ADJUVANT THERAPY; PREDICTION; MASTECTOMY; SIGNATURE; CONSENSUS		Massachusetts Gen Hosp, Dept Hematol & Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University	Ryan, PD (corresponding author), Massachusetts Gen Hosp, Dept Hematol & Oncol, Boston, MA 02114 USA.		Sgroi, Dennis/AAV-2487-2021					Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Baum M, 2003, Cancer, V98, P1802; Chang JC, 2003, LANCET, V362, P362, DOI 10.1016/S0140-6736(03)14023-8; Coombes RC, 2004, NEW ENGL J MED, V351, P2461; Coombes RC, 2004, NEW ENGL J MED, V350, P1081, DOI 10.1056/NEJMoa040331; Eifel P, 2001, JNCI-J NATL CANCER I, V93, P979; Fisher B, 2002, NEW ENGL J MED, V347, P1233, DOI 10.1056/NEJMoa022152; Goldhirsch A, 2003, J CLIN ONCOL, V21, P3357, DOI 10.1200/JCO.2003.04.576; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Goss PE, 2003, NEW ENGL J MED, V349, P1793, DOI 10.1056/NEJMoa032312; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Olivotto IA, 2005, J CLIN ONCOL, V23, P2716, DOI 10.1200/JCO.2005.06.178; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Sgroi DC, 2004, CANCER CELL, V6, P445, DOI 10.1016/j.ccr.2004.11.001; Sgroi DC, 1999, CANCER RES, V59, P5656; SGROI DC, 2004, J CLIN ONCOL S, V22, pS14; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Veronesi U, 2003, NEW ENGL J MED, V349, P546, DOI 10.1056/NEJMoa012782; Veronesi U, 2002, NEW ENGL J MED, V347, P1227, DOI 10.1056/NEJMoa020989; Winer EP, 2005, J CLIN ONCOL, V23, P619, DOI 10.1200/JCO.2005.09.121	25	2	2	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 11	2005	353	6					617	622		10.1056/NEJMcpc059018	http://dx.doi.org/10.1056/NEJMcpc059018			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	953ST	16093471				2022-12-28	WOS:000231101500014
J	Winch, PJ; Alam, MA; Akther, A; Afroz, D; Ali, NA; Ellis, AA; Baqui, AH; Darmstadt, GL; El Arifeen, S; Seraji, MHR				Winch, PJ; Alam, MA; Akther, A; Afroz, D; Ali, NA; Ellis, AA; Baqui, AH; Darmstadt, GL; El Arifeen, S; Seraji, MHR		Bangladesh PROJAHNMO Study Grp	Local understandings of vulnerability and protection during the neonatal period in Sylhet district, Bangladesh: a qualitative study	LANCET			English	Article							CARE-SEEKING; POPULAR THERAPEUTICS; CHILDHOOD DEATHS; RURAL BANGLADESH; PRETERM INFANTS; NEWBORN BABIES; SKIN BARRIER; HEALTH; INDIA; WOMEN	Background Understanding of local knowledge and practices relating to the newborn period, as locally defined, is needed in the development of interventions to reduce neonatal mortality. We describe the organisation of the neonatal period in Sylhet District, Bangladesh, the perceived threats to the well-being of neonates, and the ways in which families seek to protect them. Methods We did 39 in-depth, unstructured, qualitative interviews with mothers, fathers, and grandmothers of neonates, and traditional birth attendants. Data on neonatal knowledge and practices were also obtained from a household survey of 6050 women who had recently given birth. Findings Interviewees defined the neonatal period as the first 40 days of life (chollish din). Confinement of the mother and baby is most strongly observed before the noai ceremony on day 7 or 9, and involves restriction of movement outside the home, sleeping where the birth took place rather than in the mother's bedroom, and sleeping on a mat on the floor. Newborns are seen as vulnerable to cold air, cold food or drinks (either directly or indirectly through the mother), and to malevolent spirits or evil eye. Bathing, skin care, confinement, and dietary practices all aim to reduce exposure to cold, but some of these practices might increase the risk of hypothermia. Interpretation Although fatalism and cultural acceptance of high mortality have been cited as reasons for high levels of neonatal mortality, Sylheti families seek to protect newborns in several ways. These actions reflect a set of assumptions about the newborn period that differ from those of neonatal health specialists, and have implications for the design of interventions for neonatal care.	Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Social & Behav Intervent Program, Baltimore, MD 21205 USA; Project Adv Hlth Newborns & Mothers, Sylhet, Bangladesh; ICDDR B, Ctr Hlth & Populat Res, Dhaka, Bangladesh; Save Children USA, Saving Newborn Lives, Washington, DC USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; International Centre for Diarrhoeal Disease Research (ICDDR); Save the Children	Winch, PJ (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Social & Behav Intervent Program, Room E5030,615 N Wolfe St, Baltimore, MD 21205 USA.	pwinch@jhsph.edu	Darmstadt, Gary/AAU-7488-2020	Darmstadt, Gary/0000-0002-7522-5824; Arifeen, Shams/0000-0002-5372-5932; Alam, Neeloy Ashraful/0000-0001-7034-1095				Afsana K, 2000, DISCOURSING BIRTHING; Ahmed S, 2001, J TROP PEDIATRICS, V47, P98, DOI 10.1093/tropej/47.2.98; Bang AT, 1999, LANCET, V354, P1955, DOI 10.1016/S0140-6736(99)03046-9; BANG AT, 1994, B WORLD HEALTH ORGAN, V72, P897; Baqui AH, 1998, B WORLD HEALTH ORGAN, V76, P161; Baqui AH, 2001, ACTA PAEDIATR, V90, P682, DOI 10.1080/080352501750258775; Bell Catherine, 1997, RITUAL PERSPECTIVES; BERLAND J, 2000, CULTURE CREATION PRO, P157; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Carter A. T., 1982, CONCEPTS PERSON KINS, P118, DOI [10.1525/aa.1984.86.4.02a00190, DOI 10.1525/AA.1984.86.4.02A00190]; Cecil R., 1996, ANTHR PREGNANCY LOSS; COMAROFF J, 1977, MED ENCOUNTERS EXPER, P115; Cosminsky Sheila, 1994, ETHNOGRAPHY FERTILIT, P195; Darmstadt GL, 2005, LANCET, V365, P1039, DOI 10.1016/S0140-6736(05)74228-8; Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6; Darmstadt GL, 2004, PEDIATR INFECT DIS J, V23, P719, DOI 10.1097/01.inf.0000133047.50836.6f; Darmstadt GL, 2002, ACTA PAEDIATR, V91, P546, DOI 10.1080/080352502753711678; Davis-Floyd Robbie, 1997, CHILDBIRTH AUTHORITA; de Souza ACT, 2000, SOC SCI MED, V51, P1675, DOI 10.1016/S0277-9536(00)00100-3; De Zoysa I, 1998, SOC SCI MED, V47, P2101, DOI 10.1016/S0277-9536(98)00275-5; DeLoache Judy, 2000, WORLD BABIES IMAGINE; Dundes L., 2003, MANNER BORN BIRTH RI; Fikree FF, 2005, SOC SCI MED, V60, P911, DOI 10.1016/j.socscimed.2004.06.034; Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.2307/3088292; Gennep Arnold van, 1960, RITES PASSAGE; GIDEON TEC, 1962, AM ANTHROPOL, V64, P1220; GOODBURN EA, 1995, STUD FAMILY PLANN, V26, P22, DOI 10.2307/2138048; Gottlieb Alma, 2004, AFTERLIFE IS WE COME; HART DV, 1965, SE ASIAN BIRTH CUSTO; Jeffery Patricia, 1993, KNOWLEDGE POWER PRAC, P7; Jeffery PM, 1985, CONTAMINATING STATES; JEFFERY PM, 1989, LABOUR PAINS LAOUR P; Kay Margarita Artschwager, 1982, ANTHR HUMAN BIRTH; KITZINGER S, 1994, ETHNOGRAPHY FERTILIT, P171; Knippenberg R, 2005, LANCET, V365, P1087, DOI 10.1016/S0140-6736(05)74233-1; LADERMAN C, 1987, SOC SCI MED, V25, P357, DOI 10.1016/0277-9536(87)90274-7; Laderman Carol, 1983, WIVES MIDWIVES CHILD; LAMBERT H, 1992, SOC SCI MED, V34, P1069, DOI 10.1016/0277-9536(92)90280-4; Lambert H, 1996, LANCET, V348, P1706, DOI 10.1016/S0140-6736(96)07135-8; Lambert Helen, 2000, CULTURES RELATEDNESS, P73; LANCHET T, 1984, WOMEN POLLUTION MARG; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Lawn JE, 2004, LANCET, V364, P399, DOI 10.1016/S0140-6736(04)16783-4; LAYNE L.L., 2003, MOTHERHOOD LOST; MacCormack C.P., 1994, ETHNOGRAPHY FERTILIT; Mahon-Daly P, 2002, HEALTH PLACE, V8, P61, DOI 10.1016/S1353-8292(01)00026-0; MANDERSON L, 1981, SOC SCI MED-MED ANTH, V15, P509, DOI 10.1016/0160-7987(81)90025-9; Marsh David R, 2002, J Perinatol, V22, P572, DOI 10.1038/sj.jp.7210793; MCCLAIN CS, 1975, ANTHR Q, V40, P38; McGilvray Dennis B., 1994, ETHNOGRAPHY FERTILIT, P15; Niang C.I., 2004, FORMATIVE RES PERINE; NICHTER M, 1983, HUM ORGAN, V42, P235, DOI 10.17730/humo.42.3.43081445235366lk; NICHTER M, 1987, SOC SCI MED, V25, P377, DOI 10.1016/0277-9536(87)90276-0; REISSLAND N, 1987, SOC SCI MED, V25, P231, DOI 10.1016/0277-9536(87)90226-7; REISSLAND N, 1988, SOC SCI MED, V27, P461, DOI 10.1016/0277-9536(88)90369-3; Rice PL, 2000, MIDWIFERY, V16, P22, DOI 10.1054/midw.1999.0180; Rice PL, 2000, EARLY HUM DEV, V57, P189, DOI 10.1016/S0378-3782(99)00062-6; RICE PL, 1994, MED J AUSTRALIA, V160, P577, DOI 10.5694/j.1326-5377.1994.tb138351.x; Romney A. Kimball, 1963, 6 CULTURES STUDIES C, P541; Sesia PM, 1996, MED ANTHROPOL Q, V10, P121, DOI 10.1525/maq.1996.10.2.02a00020; Subbarayappa BV, 1997, LANCET, V350, P1841, DOI 10.1016/S0140-6736(97)04223-2; SUTRISNA B, 1993, LANCET, V342, P787, DOI 10.1016/0140-6736(93)91545-W; THOMPSON C, 1985, SOC SCI MED, V21, P701, DOI 10.1016/0277-9536(85)90210-2; Turner Victor, 1969, RITUAL PROCESS; VanHollen C, 2003, BIRTH ON THE THRESHOLD: CHILDBIRTH AND MODERNITY IN SOUTH INDIA, P1	65	136	136	0	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 6	2005	366	9484					478	485		10.1016/S0140-6736(05)66836-5	http://dx.doi.org/10.1016/S0140-6736(05)66836-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	952RD	16084256				2022-12-28	WOS:000231022300029
J	Niessing, J; Ebisch, B; Schmidt, KE; Niessing, M; Singer, W; Galuske, RAW				Niessing, J; Ebisch, B; Schmidt, KE; Niessing, M; Singer, W; Galuske, RAW			Hemodynamic signals correlate tightly with synchronized gamma oscillations	SCIENCE			English	Article							OPTICAL INTRINSIC SIGNALS; VISUAL-CORTEX; NEURONAL-ACTIVITY; MODULATION; ATTENTION; FMRI; MECHANISMS; PATHWAYS; PATTERNS; AROUSAL	Functional imaging methods monitor neural activity by measuring hemodynamic signals. These are more closely related to local field potentials (LFPs) than to action potentials. We simultaneously recorded electrical and hemodynamic responses in the cat visual cortex. Increasing stimulus strength enhanced spiking activity, high-frequency LFP oscillations, and hemodynamic responses. With constant stimulus intensity, the hemodynamic response fluctuated; these fluctuations were only loosely related to action potential frequency but tightly correlated to the power of LFP oscillations in the gamma range. These oscillations increase with the synchrony of synaptic events, which suggests a close correlation between hemodynamic responses and neuronal synchronization.	Max Planck Inst Brain Res, D-60528 Frankfurt, Germany; Tech Univ Darmstadt, Dept Biol, D-64238 Darmstadt, Germany	Max Planck Society; Technical University of Darmstadt	Galuske, RAW (corresponding author), Max Planck Inst Brain Res, D-60528 Frankfurt, Germany.	gatuske@mpih-frankfurt.mpg.de	Singer, Wolf/D-6874-2012; anand, amit/A-7222-2009					Arthurs OJ, 2002, TRENDS NEUROSCI, V25, P27, DOI 10.1016/S0166-2236(00)01995-0; Attwell D, 2001, J CEREBR BLOOD F MET, V21, P1133, DOI 10.1097/00004647-200110000-00001; Azouz R, 1999, J NEUROSCI, V19, P2209; Boynton GM, 1996, J NEUROSCI, V16, P4207, DOI 10.1523/jneurosci.16-13-04207.1996; Cauli B, 2004, J NEUROSCI, V24, P8940, DOI 10.1523/JNEUROSCI.3065-04.2004; Engel AK, 2001, NAT REV NEUROSCI, V2, P704, DOI 10.1038/35094565; Fries P, 2001, SCIENCE, V291, P1560, DOI 10.1126/science.1055465; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; Herculano-Houzel S, 1999, J NEUROSCI, V19, P3992; Kastner S, 1999, NEURON, V22, P751, DOI 10.1016/S0896-6273(00)80734-5; Kayser C, 2004, CEREB CORTEX, V14, P881, DOI 10.1093/cercor/bhh047; Kosslyn SM, 2001, NAT REV NEUROSCI, V2, P635, DOI 10.1038/35090055; Lauritzen M, 2005, NAT REV NEUROSCI, V6, P77, DOI 10.1038/nrn1589; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Mathiesen C, 1998, J PHYSIOL-LONDON, V512, P555, DOI 10.1111/j.1469-7793.1998.555be.x; McCormick DA, 1997, ANNU REV NEUROSCI, V20, P185, DOI 10.1146/annurev.neuro.20.1.185; MITZDORF U, 1978, EXP BRAIN RES, V33, P371; Muller MM, 2000, INT J PSYCHOPHYSIOL, V38, P283, DOI 10.1016/s0167-8760(00)00171-9; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; Pouratian N, 2002, MAGN RESON MED, V47, P766, DOI 10.1002/mrm.10096; Rees G, 2000, NAT NEUROSCI, V3, P716, DOI 10.1038/76673; Rodriguez R, 2004, J NEUROSCI, V24, P10369, DOI 10.1523/JNEUROSCI.1839-04.2004; Schmidt KE, 2004, J NEUROPHYSIOL, V91, P1661, DOI 10.1152/jn.00878.2003; Sheth S, 2003, NEUROIMAGE, V19, P884, DOI 10.1016/S1053-8119(03)00086-7; Smith AJ, 2002, P NATL ACAD SCI USA, V99, P10765, DOI 10.1073/pnas.132272199; Steriade M, 1996, SCIENCE, V272, P225, DOI 10.1126/science.272.5259.225; Tallon-Baudry C, 2003, J PHYSIOL-PARIS, V97, P355, DOI 10.1016/j.jphysparis.2003.09.009; Traub RD, 1996, NATURE, V383, P621, DOI 10.1038/383621a0; VALTSCHANOFF JG, 1993, NEUROSCI LETT, V157, P157, DOI 10.1016/0304-3940(93)90726-2; Volgushev M, 1998, NEUROSCIENCE, V83, P15, DOI 10.1016/S0306-4522(97)00380-1; Williams BR, 2003, RRD CANCER, V5, P101	31	599	611	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 5	2005	309	5736					948	951		10.1126/science.1110948	http://dx.doi.org/10.1126/science.1110948			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953SS	16081740				2022-12-28	WOS:000231101400051
J	Lavender, T; Kingdon, C; Hart, A; Gyte, G; Gabbay, M; Neilson, JP				Lavender, T; Kingdon, C; Hart, A; Gyte, G; Gabbay, M; Neilson, JP			Could a randomised trial answer the controversy relating to elective caesarean section? National survey of consultant obstetricians and heads of midwifery	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Cent Lancashire, Dept Midwifery Studies, Preston PR1 2HE, Lancs, England; Univ Cent Lancashire, Lancashire Sch Hlth & Post Grad Med, Preston PR1 2HE, Lancs, England; Univ Liverpool, Liverpool Womens Hosp, Cochrane Pregnancy & Childbirth Grp, Liverpool L8 7SS, Merseyside, England; Univ Liverpool, Liverpool L69 3GB, Merseyside, England; Univ Liverpool, Liverpool Womens Hosp, Sch Reprod & Dev Med, Liverpool L8 7SS, Merseyside, England	University of Central Lancashire; University of Central Lancashire; University of Liverpool; University of Liverpool; University of Liverpool	Lavender, T (corresponding author), Univ Cent Lancashire, Dept Midwifery Studies, Preston PR1 2HE, Lancs, England.	tinalav@yahoo.co.uk	Lavender, Tina/B-1211-2011	Lavender, Tina/0000-0003-1473-4956; Gabbay, Mark/0000-0002-0126-8485; Kingdon, Carol/0000-0002-5958-9257				Ecker JL, 2004, AM J OBSTET GYNECOL, V190, P314, DOI 10.1016/S0002-9378(03)00869-X; Minkoff H, 2003, NEW ENGL J MED, V348, P946, DOI 10.1056/NEJMsb022734; National Collaborating Centre for Women's and Children's Health, 2004, CAES SECT CLIN GUID; Weijer C, 2000, BMJ-BRIT MED J, V321, P756, DOI 10.1136/bmj.321.7263.756	4	33	33	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 3	2005	331	7515					490	491		10.1136/bmj.38560.572639.3A	http://dx.doi.org/10.1136/bmj.38560.572639.3A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	963RA	16115829	Green Published, Bronze			2022-12-28	WOS:000231820400017
J	McManus, RJ; Mant, J; Roalfe, A; Oakes, RA; Bryan, S; Pattison, HM; Hobbs, FDR				McManus, RJ; Mant, J; Roalfe, A; Oakes, RA; Bryan, S; Pattison, HM; Hobbs, FDR			Targets and self monitoring in hypertension: randomised controlled trial and cost effectiveness analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; ANTIHYPERTENSIVE DRUGS; WORKING PARTY; PATIENT; QUESTIONNAIRE; PREVENTION; GUIDELINES; MANAGEMENT; CARE	Objectives To assess whether blood pressure control in primary care could be improved with the use of patient held targets and self monitoring in a practice setting, and to assess the impact of these on health behaviours, anxiety, prescribed antihypertensive drugs, patients' preferences, and costs. Design Randomised controlled trial. Setting Eight general practices in south Birmingham. Participants 441 people receiving treatment in primary care for hypertension but not controlled below the target of < 140/85 mm Hg. Interventions Patients in the intervention group received treatment targets along with facilities to measure their own blood pressure at their general practice; they were also asked to visit their general practitioner or practice nurse if their blood pressure was repeatedly above the target level. Patients in the control group received usual care (blood pressure monitoring by their practice). Main outcome measures Primary outcome: change in systolic blood pressure at six months and one year in both intervention and control groups. Secondary outcomes: change in health behaviours, anxiety, prescribed antihypertensive drugs, patients' preferences of method of blood pressure monitoring, and costs. Results 400 (91%) patients attended follow up at one year. Systolic blood pressure in the intervention group had significantly reduced after six months (mean difference 4.3 mm Hg (95% confidence interval 0.8 turn Hg to 7.9 min Hg)) but not after one year (mean difference 2.7 mm Hg (-1.2 mm Hg to 6.6 mm Hg)). No overall difference was found in diastolic blood pressure, anxiety, health behaviours, or number of prescribed drugs. Patients who self monitored lost more weight than controls (as evidenced by a drop in body mass index), rated self monitoring above monitoring by a doctor or nurse, and consulted less often. Overall, self monitoring did not cost significantly more than usual care (251 pound ($437; 364) pound (95% confidence interval 233 pound to 275) pound versus 240 pound (217 pound to 263) pound. Conclusions Practice based self monitoring resulted in small but significant improvements of blood pressure at six months, which were not sustained after a year. Self monitoring was well received by patients, anxiety did not increase, and there was no appreciable additional cost. Practice based self monitoring is feasible and results in blood pressure control that is similar to that in usual care.	Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Hlth Econ Fac, Hlth Serv Management Ctr, Birmingham B15 2RT, W Midlands, England; Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England	University of Birmingham; University of Birmingham; Aston University	McManus, RJ (corresponding author), Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England.	r.j.mcmanus@bham.ac.uk	Pattison, Helen/D-2702-2009	Pattison, Helen/0000-0002-9483-4342; hobbs, richard/0000-0001-7976-7172; Mant, Jonathan/0000-0002-9531-0268				Cappuccio FP, 2004, BMJ-BRIT MED J, V329, P145, DOI 10.1136/bmj.38121.684410.AE; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; *DEP HLTH, NAT REF COSTS 2002; El Assaad MA, 2003, BLOOD PRESS MONIT, V8, P127, DOI 10.1097/00126097-200306000-00006; GODIN G, 1985, Canadian Journal of Applied Sport Sciences, V10, P141; Hamilton W, 2003, J PUBLIC HEALTH MED, V25, P125, DOI 10.1093/pubmed/fdg027; HM Treasury, 2003, GREEN BOOK APPR EV C; Hollis S, 1999, BRIT MED J, V319, P670, DOI 10.1136/bmj.319.7211.670; *JOINT FORM COMM, 2001, BRIT NAT FORM 42; JONES JK, 1995, BMJ-BRIT MED J, V311, P293, DOI 10.1136/bmj.311.7000.293; Kernick DP, 2000, BRIT J GEN PRACT, V50, P401; Little P, 2002, BRIT MED J, V325, P258, DOI 10.1136/bmj.325.7358.258; Little P, 2002, BMJ-BRIT MED J, V325, P254, DOI 10.1136/bmj.325.7358.254; Little P, 1999, J EPIDEMIOL COMMUN H, V53, P165, DOI 10.1136/jech.53.3.165; Mant J, 2000, J PUBLIC HEALTH MED, V22, P198, DOI 10.1093/pubmed/22.2.198; Marshall T, 2002, BMJ-BRIT MED J, V325, P197, DOI 10.1136/bmj.325.7357.197; MARTEAU TM, 1992, BRIT J CLIN PSYCHOL, V31, P301, DOI 10.1111/j.2044-8260.1992.tb00997.x; Mathers CD, 2003, GLOBAL BURDEN DIS 20; Montgomery AA, 2003, J HYPERTENS, V21, P1753, DOI 10.1097/00004872-200309000-00026; NETTEN A, UNIT COSTS HLTH SOCI; Ogden J, 2002, PATIENT EDUC COUNS, V47, P223, DOI 10.1016/S0738-3991(01)00200-2; Phillips LS, 2001, ANN INTERN MED, V135, P825, DOI 10.7326/0003-4819-135-9-200111060-00012; Psaty BN, 2003, JAMA-J AM MED ASSOC, V289, P2534, DOI 10.1001/jama.289.19.2534; Ramsay LE, 1999, J HUM HYPERTENS, V13, P569, DOI 10.1038/sj.jhh.1000917; Schulz KF, 2002, LANCET, V359, P515, DOI 10.1016/S0140-6736(02)07683-3; SOGHIKIAN K, 1992, MED CARE, V30, P855, DOI 10.1097/00005650-199209000-00009; Steel N, 2000, BRIT MED J, V320, P1446, DOI 10.1136/bmj.320.7247.1446; Townsend PP., 1988, HLTH DEPRIVATION INE; Williams B, 2004, J HUM HYPERTENS, V18, P139, DOI 10.1038/sj.jhh.1001683; Wolf-Maier K, 2004, HYPERTENSION, V43, P10, DOI 10.1161/01.HYP.0000103630.72812.10	30	99	101	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 3	2005	331	7515					493	496A		10.1136/bmj.38558.393669.E0	http://dx.doi.org/10.1136/bmj.38558.393669.E0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	963RA	16115830	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000231820400019
J	Kyzer, S; Zhang, JW; Landick, R				Kyzer, S; Zhang, JW; Landick, R			Inhibition of RNA polymerase by streptolydigin: No cycling allowed	CELL			English	Editorial Material							II ELONGATION COMPLEX; STRUCTURAL BASIS; TRANSCRIPTION; MECHANISM	Bacterial RNA polymerase is a common target for many antibiotics. In two recent papers in Cell and Molecular Cell, Tuske et al. (2005) and Temiakov et al. (2005) describe a structural basis for inhibition of bacterial RNA polymerase by the antibiotic streptolydigin. Streptolydigin may prevent distortion of a "bridge" alpha helix postulated to occur during the nucleotide addition cycle of RNA polymerase or may block a small movement of the bridge helix that helps load nucleotide triphosphates into the active site.	Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Kyzer, S (corresponding author), Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA.		Zhang, Jinwei/AAU-9195-2020; Zhang, Jinwei/D-8953-2012	Zhang, Jinwei/0000-0002-2114-173X; 				Bar-Nahum G, 2005, CELL, V120, P183, DOI 10.1016/j.cell.2004.11.045; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Gong XQ, 2005, MOL CELL, V18, P461, DOI 10.1016/j.molcel.2005.04.011; Kettenberger H, 2004, MOL CELL, V16, P955, DOI 10.1016/j.molcel.2004.11.040; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; MCCLURE WR, 1980, J BIOL CHEM, V255, P1610; Sosunov V, 2003, EMBO J, V22, P2234, DOI 10.1093/emboj/cdg193; Temiakov D, 2005, MOL CELL, V19, P655, DOI 10.1016/j.molcel.2005.07.020; Tuske S, 2005, CELL, V122, P541, DOI 10.1016/j.cell.2005.07.017; Westover KD, 2004, CELL, V119, P481, DOI 10.1016/j.cell.2004.10.016	10	7	8	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 26	2005	122	4					494	496		10.1016/j.cell.2005.08.008	http://dx.doi.org/10.1016/j.cell.2005.08.008			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	959YI	16122417	Bronze			2022-12-28	WOS:000231555100004
J	Rowsell, JLC; Spencer, EC; Eckert, J; Howard, JAK; Yaghi, OM				Rowsell, JLC; Spencer, EC; Eckert, J; Howard, JAK; Yaghi, OM			Gas adsorption sites in a large-pore metal-organic framework	SCIENCE			English	Article							X-RAY-DIFFRACTION; NEUTRON-SCATTERING; HYDROGEN; MOLECULES; METHANE; DESIGN; DIFFUSIVITY; INCLUSION; SORPTION; ZEOLITE	The primary adsorption sites for Ar and N-2 within metal-organic framework-5, a cubic structure composed of Zn4O(CO2)(6) units and phenylene links defining large pores 12 and 15 angstroms in diameter, have been identified by single-crystal x-ray diffraction. Refinement of data collected between 293 and 30 kelvin revealed a total of eight symmetry-independent adsorption sites. Five of these are sites on the zinc oxide unit and the organic link; the remaining three sites form a second layer in the pores. The structural integrity and high symmetry of the framework are retained throughout, with-negligible changes resulting from gas adsorption.	Univ Michigan, Dept Chem, Mat Design & Discovery Grp, Ann Arbor, MI 48109 USA; Univ Durham, Dept Chem, Durham DH1 3LE, England; Univ Calif Santa Barbara, Mat Res Lab, Santa Barbara, CA 93106 USA; Los Alamos Natl Lab, Los Alamos Neutron Sci Ctr 12, Los Alamos, NM 87545 USA	University of Michigan System; University of Michigan; Durham University; University of California System; University of California Santa Barbara; United States Department of Energy (DOE); Los Alamos National Laboratory	Yaghi, OM (corresponding author), Univ Michigan, Dept Chem, Mat Design & Discovery Grp, 930 N Univ Ave, Ann Arbor, MI 48109 USA.	oyaghi@umich.edu	Yaghi, Omar M/C-6749-2013; Howard, Judith A K/H-7113-2012	Yaghi, Omar/0000-0002-5611-3325				Anderson CR, 1999, J CHEM PHYS, V111, P7599, DOI 10.1063/1.480104; Atwood JL, 2002, SCIENCE, V296, P2367, DOI 10.1126/science.1072252; BARRETT CS, 1964, J CHEM PHYS, V41, P1078, DOI 10.1063/1.1726009; Chae HK, 2004, NATURE, V427, P523, DOI 10.1038/nature02311; DELARA EC, 1992, ZEOLITES, V12, P256; Dybtsev DN, 2004, J AM CHEM SOC, V126, P32, DOI 10.1021/ja038678c; ECKERT J, 1979, PHYS REV LETT, V43, P1329, DOI 10.1103/PhysRevLett.43.1329; Eddaoudi M, 2002, SCIENCE, V295, P469, DOI 10.1126/science.1067208; Evans J. S. O., 1999, DALTON T, P3317; Ferey G, 2004, ANGEW CHEM INT EDIT, V43, P6296, DOI 10.1002/anie.200460592; Ferey G, 2003, CHEM COMMUN, P2976, DOI 10.1039/b308903g; Goeta AE, 2004, CHEM SOC REV, V33, P490, DOI 10.1039/b312763j; KAHN R, 1989, J CHEM PHYS, V91, P5097, DOI 10.1063/1.457601; Kitagawa S, 2004, ANGEW CHEM INT EDIT, V43, P2334, DOI 10.1002/anie.200300610; Kitaura R, 2002, SCIENCE, V298, P2358, DOI 10.1126/science.1078481; Kubota Y, 2005, ANGEW CHEM INT EDIT, V44, P920, DOI 10.1002/anie.200461895; Li H, 1999, NATURE, V402, P276, DOI 10.1038/46248; MacKinnon JA, 2001, J CHEM PHYS, V114, P10137, DOI 10.1063/1.1352733; Noro S, 2000, ANGEW CHEM INT EDIT, V39, P2082; NOWAK R, 1988, J CHEM PHYS, V89, P1309, DOI 10.1063/1.455182; Rosi NL, 2003, SCIENCE, V300, P1127, DOI 10.1126/science.1083440; Rowsell JLC, 2004, J AM CHEM SOC, V126, P5666, DOI 10.1021/ja049408c; SCHUCH AF, 1970, J CHEM PHYS, V52, P6000, DOI 10.1063/1.1672899; Seki K, 2002, J PHYS CHEM B, V106, P1380, DOI 10.1021/jp0130416; SLOAN ED, 1998, CLATHRATE HYDRATES N, pCH2; Takamizawa S, 2003, ANGEW CHEM INT EDIT, V42, P4331, DOI 10.1002/anie.200351368; Trabelsi M, 1997, SURF SCI, V377, P38, DOI 10.1016/S0039-6028(96)01324-6; WEBER T, 1990, J CHEM PHYS, V92, P90, DOI 10.1063/1.458394; Yaghi OM, 2003, NATURE, V423, P705, DOI 10.1038/nature01650; Zecchina A, 1996, CHEM SOC REV, V25, P187, DOI 10.1039/cs9962500187	30	791	826	15	429	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 26	2005	309	5739					1350	1354		10.1126/science.1113247	http://dx.doi.org/10.1126/science.1113247			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TX	16123294				2022-12-28	WOS:000231543300037
J	Crespo-Hernandez, CE; Cohen, B; Kohler, B				Crespo-Hernandez, CE; Cohen, B; Kohler, B			Base stacking controls excited-state dynamics in A-T DNA	NATURE			English	Article							THYMINE DIMER FORMATION; ELECTRON-TRANSFER; CROSS-LINKING; ADENINE; FLUORESCENCE; RESONANCE; POLYNUCLEOTIDES; LUMINESCENCE; SPECTROSCOPY; TEMPERATURE	Solar ultraviolet light creates excited electronic states in DNA that can decay to mutagenic photoproducts. This vulnerability is compensated for in all organisms by enzymatic repair of photodamaged DNA. As repair is energetically costly, DNA is intrinsically photostable. Single bases eliminate electronic energy non-radiatively on a subpicosecond timescale(1), but base stacking and base pairing mediate the decay of excess electronic energy in the double helix in poorly understood ways. In the past, considerable attention has been paid to excited base pairs(2). Recent reports have suggested that light-triggered motion of a proton in one of the hydrogen bonds of an isolated base pair initiates non-radiative decay to the electronic ground state(3,4). Here we show that vertical base stacking, and not base pairing, determines the fate of excited singlet electronic states in single- and double-stranded oligonucleotides composed of adenine ( A) and thymine ( T) bases. Intrastrand excimer states with lifetimes of 50 - 150 ps are formed in high yields whenever A is stacked with itself or with T. Excimers limit excitation energy to one strand at a time in the B-form double helix, enabling repair using the undamaged strand as a template.	Ohio State Univ, Dept Chem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Kohler, B (corresponding author), Ohio State Univ, Dept Chem, 100 W 18th Ave, Columbus, OH 43210 USA.	kohler@chemistry.ohio-state.edu	Kohler, Bern/A-1728-2011; Cohen, Boiko/C-4381-2008; Crespo-Hernández, Carlos E./A-9915-2008	Kohler, Bern/0000-0001-5353-1655; Cohen, Boiko/0000-0002-5400-4678; Crespo-Hernández, Carlos E./0000-0002-3594-0890	NIGMS NIH HHS [R01 GM064563-04, R01 GM064563] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064563] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abo-Riziq A, 2005, P NATL ACAD SCI USA, V102, P20, DOI 10.1073/pnas.0408574102; AZUMI T, 1964, J CHEM PHYS, V41, P3839, DOI 10.1063/1.1725823; Cadet J, 1990, PHOTOCHEMISTRY NUCL, P1; CANTOR CR, 1970, BIOPOLYMERS, V9, P1059, DOI 10.1002/bip.1970.360090909; Crespo-Hernandez CE, 2004, CHEM REV, V104, P1977, DOI 10.1021/cr0206770; Crespo-Hernandez CE, 2004, J PHYS CHEM B, V108, P11182, DOI 10.1021/jp0496046; Cukier RI, 1998, ANNU REV PHYS CHEM, V49, P337, DOI 10.1146/annurev.physchem.49.1.337; DANILOV VI, 1994, PHOTOCHEM PHOTOBIOL, V59, P125, DOI 10.1111/j.1751-1097.1994.tb05010.x; DEWEY TG, 1979, BIOCHEMISTRY-US, V18, P5757, DOI 10.1021/bi00593a002; DOUHAL A, 1995, NATURE, V378, P260, DOI 10.1038/378260a0; Douki T, 2003, NUCLEIC ACIDS RES, V31, P3134, DOI 10.1093/nar/gkg408; EISINGER J, 1966, P NATL ACAD SCI USA, V55, P1015, DOI 10.1073/pnas.55.5.1015; GLISIN VR, 1967, BIOCHIM BIOPHYS ACTA, V142, P314, DOI 10.1016/0005-2787(67)90614-4; HOSSZU JL, 1967, BIOCHEM BIOPH RES CO, V29, P327, DOI 10.1016/0006-291X(67)90457-3; Kelley SO, 1999, SCIENCE, V283, P375, DOI 10.1126/science.283.5400.375; KYPR J, 1994, J BIOMOL STRUCT DYN, V11, P1225, DOI 10.1080/07391102.1994.10508065; LAMOLA AA, 1968, P NATL ACAD SCI USA, V59, P46, DOI 10.1073/pnas.59.1.46; Lewis FD, 2002, J AM CHEM SOC, V124, P4568, DOI 10.1021/ja0177859; LOWDIN PO, 1963, REV MOD PHYS, V35, P724, DOI 10.1103/RevModPhys.35.724; Marguet S, 2005, J AM CHEM SOC, V127, P5780, DOI 10.1021/ja050648h; Markovitsi D, 2003, CHEMPHYSCHEM, V4, P303, DOI 10.1002/cphc.200390050; Ostrowski T, 2003, J ORG CHEM, V68, P6502, DOI 10.1021/jo030086p; Pecourt JML, 2001, J AM CHEM SOC, V123, P10370, DOI 10.1021/ja0161453; Plutzer C, 2003, PHYS CHEM CHEM PHYS, V5, P1158, DOI 10.1039/b212338i; RAHN RO, 1976, NUCLEIC ACIDS RES, V3, P879, DOI 10.1093/nar/3.4.879; RAHN RO, 1966, J CHEM PHYS, V45, P2947, DOI 10.1063/1.1728050; Samoylova E, 2005, J AM CHEM SOC, V127, P1782, DOI 10.1021/ja044369q; Schultz T, 2004, SCIENCE, V306, P1765, DOI 10.1126/science.1104038; VIGNY P, 1973, CR ACAD SCI D NAT, V277, P1941	29	381	382	2	150	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 25	2005	436	7054					1141	1144		10.1038/nature03933	http://dx.doi.org/10.1038/nature03933			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	958AK	16121177				2022-12-28	WOS:000231416600042
J	Haring, M; Vestergaard, G; Rachel, R; Chen, LM; Garrett, RA; Prangishvili, D				Haring, M; Vestergaard, G; Rachel, R; Chen, LM; Garrett, RA; Prangishvili, D			Virology: Independent virus development outside a host	NATURE			English	Editorial Material									Inst Pasteur, Mol Biol Gene Extremophiles Unit, F-75724 Paris, France; Univ Regensburg, D-93053 Regensburg, Germany; Univ Copenhagen, Inst Mol Biol & Physiol, Danish Archaea Ctr, DK-1307 Copenhagen, Denmark	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Regensburg; University of Copenhagen	Haring, M (corresponding author), Inst Pasteur, Mol Biol Gene Extremophiles Unit, F-75724 Paris, France.	prangish@pasteur.fr	Garrett, Roger A/M-2450-2014	Garrett, Roger A/0000-0001-8452-9099; Vestergaard, Gisle/0000-0003-2541-4974				ACKERMANN HW, 2000, 7 INT COMM TAX VIR, P111; Ausmees N, 2003, CELL, V115, P705, DOI 10.1016/S0092-8674(03)00935-8; Herrmann H, 2000, CURR OPIN CELL BIOL, V12, P79, DOI 10.1016/S0955-0674(99)00060-5; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Pettit SC, 2004, J VIROL, V78, P8477, DOI 10.1128/JVI.78.16.8477-8485.2004; Prangishvili D, 2001, TRENDS MICROBIOL, V9, P39, DOI 10.1016/S0966-842X(00)01910-7; Strelkov SV, 2003, BIOESSAYS, V25, P243, DOI 10.1002/bies.10246; Swanstrom R., 1997, P263; van Regenmortel MHV, 2000, VIRUS TAXONOMY, P3	9	109	193	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 25	2005	436	7054					1101	1102		10.1038/4361101a	http://dx.doi.org/10.1038/4361101a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	958AK	16121167				2022-12-28	WOS:000231416600031
J	Hoffman, LR; D'Argenio, DA; MacCoss, MJ; Zhang, ZY; Jones, RA; Miller, SI				Hoffman, LR; D'Argenio, DA; MacCoss, MJ; Zhang, ZY; Jones, RA; Miller, SI			Aminoglycoside antibiotics induce bacterial biofilm formation	NATURE			English	Article							PSEUDOMONAS-AERUGINOSA BIOFILMS; CYCLIC DIGUANYLIC ACID; GENE-EXPRESSION; CYSTIC-FIBROSIS; CELLULOSE SYNTHESIS; TWITCHING MOTILITY; EAL DOMAIN; DI-GMP; RESISTANCE; TOBRAMYCIN	Biofilms are adherent aggregates of bacterial cells that form on biotic and abiotic surfaces, including human tissues. Biofilms resist antibiotic treatment and contribute to bacterial persistence in chronic infections(1,2). Hence, the elucidation of the mechanisms by which biofilms are formed may assist in the treatment of chronic infections, such as Pseudomonas aeruginosa in the airways of patients with cystic fibrosis(2). Here we show that subinhibitory concentrations of aminoglycoside antibiotics induce biofilm formation in P. aeruginosa and Escherichia coli. In P. aeruginosa, a gene, which we designated aminoglycoside response regulator (arr), was essential for this induction and contributed to biofilm-specific aminoglycoside resistance. The arr gene is predicted to encode an inner-membrane phosphodiesterase whose substrate is cyclic di-guanosine monophosphate (c-di-GMP) - a bacterial second messenger that regulates cell surface adhesiveness(3). We found that membranes from arr mutants had diminished c-di-GMP phosphodiesterase activity, and P. aeruginosa cells with a mutation changing a predicted catalytic residue of Arr were defective in their biofilm response to tobramycin. Furthermore, tobramycin-inducible biofilm formation was inhibited by exogenous GTP, which is known to inhibit c-di-GMP phosphodiesterase activity(4). Our results demonstrate that biofilm formation can be a specific, defensive reaction to the presence of antibiotics, and indicate that the molecular basis of this response includes alterations in the level of c-di-GMP.	Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; Rutgers State Univ, Dept Chem, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Biol Chem, Piscataway, NJ 08854 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Miller, SI (corresponding author), Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.	millersi@u.washington.edu	Hoffman, Lucas/AAX-1853-2021; Jones, Roger A./GRY-0637-2022	Jones, Roger A./0000-0002-6835-6615	NIAID NIH HHS [K08 AI066251] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI066251] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMIKAM D, 1989, J BACTERIOL, V171, P6649, DOI 10.1128/jb.171.12.6649-6655.1989; Bader MW, 2003, MOL MICROBIOL, V50, P219, DOI 10.1046/j.1365-2958.2003.03675.x; Bagge N, 2004, ANTIMICROB AGENTS CH, V48, P1175, DOI 10.1128/AAC.48.4.1175-1187.2004; Barclay ML, 1996, J ANTIMICROB CHEMOTH, V37, P1155, DOI 10.1093/jac/37.6.1155; Bergey DH, 1984, BERGEYS MANUAL SYSTE; Bobrov AG, 2005, FEMS MICROBIOL LETT, V247, P123, DOI 10.1016/j.femsle.2005.04.036; Chiang P, 2003, J BACTERIOL, V185, P2374, DOI 10.1128/JB.185.7.2374-2378.2003; D'Argenio DA, 2004, MICROBIOL-SGM, V150, P2497, DOI 10.1099/mic.0.27099-0; Drenkard E, 2002, NATURE, V416, P740, DOI 10.1038/416740a; Galperin MY, 2001, FEMS MICROBIOL LETT, V203, P11, DOI 10.1111/j.1574-6968.2001.tb10814.x; Goh EB, 2002, P NATL ACAD SCI USA, V99, P17025, DOI 10.1073/pnas.252607699; He JX, 2004, P NATL ACAD SCI USA, V101, P2530, DOI 10.1073/pnas.0304622101; Hisert KB, 2005, MOL MICROBIOL, V56, P1234, DOI 10.1111/j.1365-2958.2005.04632.x; Huang BX, 2003, J BACTERIOL, V185, P7068, DOI 10.1128/JB.185.24.7068-7076.2003; Jacobs MA, 2003, P NATL ACAD SCI USA, V100, P14339, DOI 10.1073/pnas.2036282100; Moskowitz SM, 2004, J CLIN MICROBIOL, V42, P1915, DOI 10.1128/JCM.42.5.1915-1922.2004; MUKHOPADHYAY S, 1994, RESP MED, V88, P203, DOI 10.1016/S0954-6111(05)80348-8; O'Toole GA, 1998, MOL MICROBIOL, V30, P295, DOI 10.1046/j.1365-2958.1998.01062.x; Paul R, 2004, GENE DEV, V18, P715, DOI 10.1101/gad.289504; Rachid S, 2000, ANTIMICROB AGENTS CH, V44, P3357, DOI 10.1128/AAC.44.12.3357-3363.2000; Ramsey BW, 1999, NEW ENGL J MED, V340, P23, DOI 10.1056/NEJM199901073400104; Rosenfeld M, 2001, PEDIATR PULM, V32, P356, DOI 10.1002/ppul.1144; ROSS P, 1990, J BIOL CHEM, V265, P18933; Simm R, 2004, MOL MICROBIOL, V53, P1123, DOI 10.1111/j.1365-2958.2004.04206.x; Taylor P., 1985, PHARM BASIS THERAPEU, V7th, P215; Whiteley M, 2001, NATURE, V413, P860, DOI 10.1038/35101627; Wolfgang MC, 2003, P NATL ACAD SCI USA, V100, P8484, DOI 10.1073/pnas.0832438100	28	871	935	11	289	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 25	2005	436	7054					1171	1175		10.1038/nature03912	http://dx.doi.org/10.1038/nature03912			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	958AK	16121184				2022-12-28	WOS:000231416600049
J	Jessop, PG; Heldebrant, DJ; Li, XW; Eckert, CA; Liotta, CL				Jessop, PG; Heldebrant, DJ; Li, XW; Eckert, CA; Liotta, CL			Green chemistry - Reversible nonpolar-to-polar solvent	NATURE			English	Editorial Material							CARBON-DIOXIDE		Queens Univ, Dept Chem, Kingston, ON K7L 3N6, Canada; Georgia Inst Technol, Sch Chem, Atlanta, GA 30332 USA; Georgia Inst Technol, Sch Chem Engn, Atlanta, GA 30332 USA	Queens University - Canada; University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology	Jessop, PG (corresponding author), Queens Univ, Dept Chem, Kingston, ON K7L 3N6, Canada.	jessop@chem.queensu.ca	Jessop, Philip/AAB-5265-2020	Jessop, Philip/0000-0002-5323-5095				Heldebrant DJ, 2005, J ORG CHEM, V70, P5335, DOI 10.1021/jo0503759; JESSOP PG, 1999, CHEM SYNTHESIS USING; Munshi P, 2002, J AM CHEM SOC, V124, P7963, DOI 10.1021/ja0167856; Perez ER, 2004, J ORG CHEM, V69, P8005, DOI 10.1021/jo049243q; SUBRAMANIAM B., 2002, CARBON DIOXIDE CONVE, P364	5	709	754	10	441	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 25	2005	436	7054					1102	1102		10.1038/4361102a	http://dx.doi.org/10.1038/4361102a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	958AK	16121169	Bronze			2022-12-28	WOS:000231416600032
J	Chan, AT; Giovannucci, EL; Meyerhardt, JA; Schernhammer, ES; Curhan, GC; Fuchs, CS				Chan, AT; Giovannucci, EL; Meyerhardt, JA; Schernhammer, ES; Curhan, GC; Fuchs, CS			Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-DOSE ASPIRIN; NF-KAPPA-B; COLON-CANCER; CYCLOOXYGENASE-2 EXPRESSION; PRIMARY PREVENTION; RANDOMIZED-TRIAL; ANALGESIC USE; REDUCED RISK; ADENOMA; CELECOXIB	Context Randomized trials of short-term aspirin use for prevention of recurrent colorectal adenoma have provided compelling evidence of a causal relationship between aspirin and colorectal neoplasia. However, data on long-term risk of colorectal cancer according to dose, timing, or duration of therapy with aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) remain limited. Objective To examine the influence of aspirin and NSAIDs in prevention of colorectal cancer. Design, Setting, and Participants Prospective cohort study of 82 911 women enrolled in the Nurses' Health Study providing data on medication use biennially since 1980 and followed up through June 1, 2000. Main Outcome Measure Incident colorectal cancer. Results Over a 20-year period, we documented 962 cases of colorectal cancer. Among women who regularly used aspirin (>= 2 standard [325-mg] tablets per week), the multivariate relative risk (RR) for colorectal cancer was 0.77 (95% confidence interval [01, 0.67-0.88) compared with nonregular users. However, significant risk reduction was not observed until more than 10 years of use (P <=.001 for trend). The benefit appeared related to dose: compared with women who reported no use, the multivariate RRs for cancer were 1.10 (95% Cl, 0.92-1.31) for women who used 0.5 to 1.5 standard aspirin tablets per week, 0.89 (95% Cl, 0.73-1.10) for 2 to 5 aspirin per week, 0.78 (95% Cl, 0.62-0.97) for 6 to 14 aspirin per week, and 0.68 (95% Cl, 0.49-0.95) for more than 14 aspirin per week (P<.001 for trend). Notably, women who used more than 14 aspirin per week for longer than 10 years in the past had a multivariate RR for cancer of 0.47 (95 % Cl, 0.31-0.71). A similar dose-response relationship was found for nonaspirin NSAIDs (P=.007 for trend). The incidence of reported major gastrointestinal bleeding events per 1000 person-years also appeared to be dose-related: 0.77 among women who denied any aspirin use; 1.07 for 0.5 to 1.5 standard aspirin tablets per week; 1.07 for 2 to 5 aspirin per week; 1.40 for 6 to 14 aspirin per week; and 1.57 for more than 14 aspirin per week. Conclusions Regular, long-term aspirin use reduces risk of colorectal cancer. Non-aspirin NSAIDs appear to have a similar effect. However, a significant benefit of aspirin is not apparent until more than a decade of use, with maximal risk reduction at doses greater than 14 tablets per week. These results suggest that optimal chemoprevention for colorectal cancer requires long-term use of aspirin doses substantially higher than those recommended for prevention of cardiovascular disease, but the dose-related risk of gastrointestinal bleeding must also be considered.	Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; Dana Farber Harvard Canc Ctr, Canc Epidemiol Program, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute	Chan, AT (corresponding author), Massachusetts Gen Hosp, Gastrointestinal Unit, 55 Fruit St,GRJ 722, Boston, MA 02114 USA.	achan@partners.org	Schernhammer, Eva S/L-7898-2018; Chan, Andrew T/P-8293-2014	Schernhammer, Eva S/0000-0002-4337-9415; Chan, Andrew T/0000-0001-7284-6767	NATIONAL CANCER INSTITUTE [K07CA107412, P01CA087969, P01CA055075] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Awtry EH, 2000, CIRCULATION, V101, P1206, DOI 10.1161/01.CIR.101.10.1206; Baron JA, 2003, NEW ENGL J MED, V348, P891, DOI 10.1056/NEJMoa021735; BARON JA, 1909, NEW ENGL J MED, V340, P101; Benamouzig R, 2003, GASTROENTEROLOGY, V125, P328, DOI 10.1016/S0016-5085(03)00887-4; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Chan AT, 2004, CLIN GASTROENTEROL H, V2, P704, DOI 10.1016/S1542-3565(04)00294-0; Chan AT, 2004, ANN INTERN MED, V140, P157, DOI 10.7326/0003-4819-140-3-200402030-00006; Chan AT, 2005, JNCI-J NATL CANCER I, V97, P457, DOI 10.1093/jnci/dji066; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Chlebowski RT, 2004, NEW ENGL J MED, V350, P991, DOI 10.1056/NEJMoa032071; Collet JP, 1999, BRIT J CANCER, V81, P62, DOI 10.1038/sj.bjc.6690651; Coogan PF, 2000, CANCER CAUSE CONTROL, V11, P249, DOI 10.1023/A:1008931708716; Cook NR, 2005, JAMA-J AM MED ASSOC, V294, P47, DOI 10.1001/jama.294.1.47; Curhan GC, 2004, ARCH INTERN MED, V164, P1519, DOI 10.1001/archinte.164.14.1519; Curhan GC, 2002, ARCH INTERN MED, V162, P2204, DOI 10.1001/archinte.162.19.2204; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; EIDE TJ, 1986, INT J CANCER, V38, P173, DOI 10.1002/ijc.2910380205; FARRELL B, 1991, J NEUROL NEUROSUR PS, V54, P1044, DOI 10.1136/jnnp.54.12.1044; Friedman GD, 1998, PHARMACOEPIDEM DR S, V7, P99, DOI 10.1002/(SICI)1099-1557(199803/04)7:2<99::AID-PDS320>3.0.CO;2-0; GANN PH, 1993, JNCI-J NATL CANCER I, V85, P1220, DOI 10.1093/jnci/85.15.1220; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; GIOVANNUCCI E, 1994, ANN INTERN MED, V121, P241, DOI 10.7326/0003-4819-121-4-199408150-00001; Greene FL, 2002, AJCC CANC STAGING HD; Grodstein F, 1998, ANN INTERN MED, V128, P705, DOI 10.7326/0003-4819-128-9-199805010-00001; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hu FB, 1999, AM J EPIDEMIOL, V149, P531, DOI 10.1093/oxfordjournals.aje.a009849; Iso H, 1999, STROKE, V30, P1764, DOI 10.1161/01.STR.30.9.1764; Jessup JM, 1996, CANCER-AM CANCER SOC, V78, P918; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Kune GA, 2007, INT J EPIDEMIOL, V36, P951, DOI 10.1093/ije/dym193; Langman MJS, 2000, BRIT MED J, V320, P1642, DOI 10.1136/bmj.320.7250.1642; LaVecchia C, 1997, BRIT J CANCER, V76, P675, DOI 10.1038/bjc.1997.444; MANSON JE, 1991, JAMA-J AM MED ASSOC, V266, P521, DOI 10.1001/jama.266.4.521; MULLER AD, 1994, DIGEST DIS SCI, V39, P2480, DOI 10.1007/BF02087670; MUSCAT JE, 1994, CANCER-AM CANCER SOC, V74, P1847, DOI 10.1002/1097-0142(19941001)74:7<1847::AID-CNCR2820740704>3.0.CO;2-#; O'Connell JB, 2004, JNCI-J NATL CANCER I, V96, P1420, DOI 10.1093/jnci/djh275; Patrono C, 2001, CHEST, V119, p39S, DOI 10.1378/chest.119.1_suppl.39S; Peleg II, 1996, DIGEST DIS SCI, V41, P1319, DOI 10.1007/BF02088554; PELEG II, 1994, ARCH INTERN MED, V154, P394, DOI 10.1001/archinte.154.4.394; Rahme E, 2003, GASTROENTEROLOGY, V125, P404, DOI 10.1016/S0016-5085(03)00880-1; Reeves MJ, 1996, CANCER EPIDEM BIOMAR, V5, P955; RODERICK PJ, 1993, BRIT J CLIN PHARMACO, V35, P219, DOI 10.1111/j.1365-2125.1993.tb05689.x; Rodriguez LAG, 2000, EPIDEMIOLOGY, V11, P376, DOI 10.1097/00001648-200007000-00003; Rodriguez LAG, 2001, EPIDEMIOLOGY, V12, P88, DOI 10.1097/00001648-200101000-00015; ROSENBERG L, 1991, J NATL CANCER I, V83, P355, DOI 10.1093/jnci/83.5.355; Rosenberg L, 1998, CANCER-AM CANCER SOC, V82, P2326, DOI 10.1002/(SICI)1097-0142(19980615)82:12<2326::AID-CNCR5>3.0.CO;2-Q; Ruffin MT, 1997, JNCI-J NATL CANCER I, V89, P1152, DOI 10.1093/jnci/89.15.1152; Sandler RS, 2003, NEW ENGL J MED, V348, P883, DOI 10.1056/NEJMoa021633; SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138, DOI 10.1097/00001648-199403000-00003; Sheehan KM, 1999, JAMA-J AM MED ASSOC, V282, P1254, DOI 10.1001/jama.282.13.1254; Shureiqi I, 2000, CANCER RES, V60, P6846; Smalley W, 1999, ARCH INTERN MED, V159, P161, DOI 10.1001/archinte.159.2.161; Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405; Sorensen HT, 2003, BRIT J CANCER, V88, P1687, DOI 10.1038/sj.bjc.6600945; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; SUH O, 1993, CANCER-AM CANCER SOC, V72, P1171, DOI 10.1002/1097-0142(19930815)72:4<1171::AID-CNCR2820720407>3.0.CO;2-D; Tangrea JA, 2003, CANCER CAUSE CONTROL, V14, P403, DOI 10.1023/A:1024990617158; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; THUN MJ, 1993, CANCER RES, V53, P1322; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; VANGIJN J, 1991, NEW ENGL J MED, V325, P1261, DOI 10.1056/NEJM199110313251801; WEIL J, 1995, BMJ-BRIT MED J, V310, P827, DOI 10.1136/bmj.310.6983.827; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307	66	359	377	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 24	2005	294	8					914	923		10.1001/jama.294.8.914	http://dx.doi.org/10.1001/jama.294.8.914			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	957JM	16118381	Green Accepted, Bronze			2022-12-28	WOS:000231366100021
J	Garcia-Closas, M; Malats, N; Silverman, D; Dosemeci, M; Kogevinas, M; Hein, DW; Tardon, A; Serra, C; Carrato, A; Garcia-Closas, R; Lloreta, J; Castano-Vinyals, G; Yeager, M; Welch, R; Chanock, S; Chatterjee, N; Wacholder, S; Samanic, C; Tora, M; Fernandez, F; Real, FX; Rothman, N				Garcia-Closas, M; Malats, N; Silverman, D; Dosemeci, M; Kogevinas, M; Hein, DW; Tardon, A; Serra, C; Carrato, A; Garcia-Closas, R; Lloreta, J; Castano-Vinyals, G; Yeager, M; Welch, R; Chanock, S; Chatterjee, N; Wacholder, S; Samanic, C; Tora, M; Fernandez, F; Real, FX; Rothman, N			NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses	LANCET			English	Article							GLUTATHIONE-S-TRANSFERASE; N-ACETYLTRANSFERASE 2; GENETIC POLYMORPHISMS; CIGARETTE-SMOKING; AROMATIC-AMINES; POOLED ANALYSIS; M1; SUSCEPTIBILITY; ASSOCIATION; T1	Background Many reported associations between common genetic polymorphisms and complex diseases have not been confirmed in subsequent studies. An exception could be the association between NAT2 slow acetylation, GSTM1 null genotype, and bladder-cancer risk. However, current evidence is based on meta-analyses of relatively small studies (range 23-374 cases) with some evidence of publication bias and study heterogeneity. Associations between polymorphisms in other NAT and GST genes and bladder-cancer risk have been inconsistent. Methods We investigated polymorphisms in NAT2, GSTM1, NAT1, GSTT1, GSTM3, and GSTP1 in 1150 patients with transitional-cell carcinoma of the urinary bladder and 1149 controls in Spain; all the participants were white. We also carried out meta-analyses of NAT2, GSTM1, and bladder cancer that included more than twice as many cases as in previous reports. Findings In our study, the odds ratios for bladder cancer for individuals with deletion of one or two copies of the GSTM1 gene were 1.2 (95% CI 0.8-1.7)and 1.9 (1.4-2.7) respectively (p for trend <0.0001). Compared with NAT2 rapid or intermediate acetylators, NAT2 slow acetylators had an increased overall risk of bladder cancer (1.4 [1.2-1.7]) that was stronger for cigarette smokers than for never smokers (p for interaction 0.008). No significant associations were found with the other polymorphisms. Meta-analyses showed that the overall association for NAT2 was robust (p<0.0001), and case-only meta-analyses provided support for an interaction between NAT2 and king (p for interaction 0.009). The overall association for GSTM1 was also robust (p<0.0001) and was not smoking modified by smoking status (p=0.86). Interpretation The GSTM1 null genotype increases the overall risk of bladder cancer, and the NAT2 slow-acetylator genotype increases risk particularly among cigarette smokers. These findings provide compelling evidence for the role of common polymorphisms in the aetiology of cancer. Relevance to practice Although the relative risks are modest, these polymorphisms could account for up to 31% of bladder cancers because of their high prevalence.	NCI, Div Canc Epidemiol & Genet, Dept Hlth & Human Serv, Bethesda, MD 20892 USA; NCI, Core Genotype Facil, Ctr Adv Technol, Dept Hlth & Human Serv, Bethesda, MD 20892 USA; Inst Municipal Invest Med, E-08003 Barcelona, Spain; Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA; Univ Louisville, Sch Med, James Graham Brown Canc Ctr, Louisville, KY 40292 USA; Univ Oviedo, Oviedo, Spain; Consorci Hosp Parc Tauli, Sabadell, Spain; Univ Pompeu Fabra, Barcelona, Spain; Hosp Gen Elche, Elche, Spain; Hosp Univ Canarias, Unidad Invest, San Cristobal la Laguna, Spain; Univ Autonoma Barcelona, Hosp Mar, IMAS, Dept Pathol, Barcelona, Spain	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Louisville; University of Louisville; University of Oviedo; Autonomous University of Barcelona; Parc Tauli Hospital Universitari; Pompeu Fabra University; Universidad de la Laguna; Autonomous University of Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar	Garcia-Closas, M (corresponding author), NCI, Hormonal & Reprod Epidemiol Branch, Div Canc Epidemiol & Genet, NIH, 6120 Execut Blvd,Room 7076,MSC 7234, Rockville, MD 20852 USA.	montse@nih.gov	Castaño-Vinyals, Gemma/H-7021-2017; Lloreta-Trull, Josep/GRR-9682-2022; Garcia-Closas, Montserrat/AAZ-6930-2021; Yeager, Meredith/AAA-5322-2020; Kogevinas, Manolis/C-3918-2017; Arribas, Francisco X Real/H-5275-2015; Castaño-Vinyals, Gemma/N-3885-2019; Lloreta-Trull, Josep/AAZ-1229-2020; TARDON, ADONINA/B-6563-2014; Hein, David W/A-9707-2008; Garcia-Closas, Montserrat/F-3871-2015; Serra, C/E-6879-2014; Lloreta, J/I-2112-2014; Malats, Nuria/H-7041-2015	Castaño-Vinyals, Gemma/0000-0003-4468-1816; Garcia-Closas, Montserrat/0000-0003-1033-2650; Kogevinas, Manolis/0000-0002-9605-0461; Arribas, Francisco X Real/0000-0001-9501-498X; Castaño-Vinyals, Gemma/0000-0003-4468-1816; TARDON, ADONINA/0000-0001-5150-1209; Garcia-Closas, Montserrat/0000-0003-1033-2650; Serra, C/0000-0001-8337-8356; Lloreta, J/0000-0003-1644-9470; CARRATO, ALFREDO/0000-0001-7749-8140; Malats, Nuria/0000-0003-2538-3784; Hein, David/0000-0003-3261-9775	NATIONAL CANCER INSTITUTE [Z01CP010121, R01CA034627, Z01SC010083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK036120] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA034627, CA34627, N02CP11015] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aktas D, 2001, CANCER GENET CYTOGEN, V125, P1, DOI 10.1016/S0165-4608(00)00307-1; AliOsman F, 1997, J BIOL CHEM, V272, P10004; *AR N AC NOM COMM, AR N AC NAT NOM; BARTSCH H, 1993, EUR J CANCER, V29A, P1199, DOI 10.1016/S0959-8049(05)80315-6; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Brockmoller J, 1996, CANCER RES, V56, P3915; Cascorbi I, 2001, CANCER RES, V61, P5051; CHATTERJEE N, IN PRESS BIOMETRIKA; Colhoun HM, 2003, LANCET, V361, P865, DOI 10.1016/S0140-6736(03)12715-8; Deitz AC, 2004, CANCER EPIDEM BIOMAR, V13, P1543; dErrico A, 1996, BIOMARKERS, V1, P149, DOI 10.3109/13547509609079352; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Engel LS, 2002, AM J EPIDEMIOL, V156, P95, DOI 10.1093/aje/kwf018; Epstein JI, 1998, AM J SURG PATHOL, V22, P1435, DOI 10.1097/00000478-199812000-00001; ERRICO A, 1999, IARC SCI PUBL, V148, P323; Garte S, 2001, CANCER EPIDEM BIOMAR, V10, P1239; Georgiou I, 2000, EUR UROL, V37, P660, DOI 10.1159/000020234; Giannakopoulos X, 2002, ANTICANCER RES, V22, P3801; Green J, 2000, BRIT J CANCER, V83, P412, DOI 10.1054/bjoc.2000.1265; Gu J, 2005, MUTAT RES-GEN TOX EN, V581, P97, DOI 10.1016/j.mrgentox.2004.11.012; HANSSEN HP, 1985, EUR UROL, V11, P263; Harries LW, 1997, CARCINOGENESIS, V18, P641, DOI 10.1093/carcin/18.4.641; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Hayes JD, 2000, PHARMACOLOGY, V61, P154, DOI 10.1159/000028396; Hein DW, 2002, MUTAT RES-FUND MOL M, V506, P65, DOI 10.1016/S0027-5107(02)00153-7; Hein DW, 2000, PHARMACOGENETICS, V10, P291, DOI 10.1097/00008571-200006000-00002; HOSMER DW, 1992, EPIDEMIOLOGY, V3, P452, DOI 10.1097/00001648-199209000-00012; Hsieh FI, 1999, BRIT J CANCER, V81, P537, DOI 10.1038/sj.bjc.6690727; Hung RJ, 2004, INT J CANCER, V110, P598, DOI 10.1002/ijc.20157; Inatomi H, 1999, INT J UROL, V6, P446, DOI 10.1046/j.1442-2042.1999.00096.x; Jaskula-Sztul Renata, 2001, Journal of Applied Genetics, V42, P223; Jeong HJ, 2003, CANCER LETT, V202, P193, DOI 10.1016/j.canlet.2003.09.007; Johns LE, 2000, ENVIRON MOL MUTAGEN, V36, P221, DOI 10.1002/1098-2280(2000)36:3<221::AID-EM5>3.0.CO;2-Q; Johns LE, 2000, MUTAGENESIS, V15, P399, DOI 10.1093/mutage/15.5.399; KAISARY A, 1987, CANCER RES, V47, P5488; Karagas MR, 2005, CANCER LETT, V219, P63, DOI 10.1016/j.canlet.2004.10.006; Katoh T, 1998, CANCER LETT, V132, P147, DOI 10.1016/S0304-3835(98)00183-9; Kim WJ, 2000, J UROLOGY, V164, P209, DOI 10.1016/S0022-5347(05)67496-4; Kim WJ, 2002, UROLOGY, V60, P913, DOI 10.1016/S0090-4295(02)01892-7; Laird N M, 1990, Int J Technol Assess Health Care, V6, P5; Lee SJ, 2002, CANCER LETT, V177, P173, DOI 10.1016/S0304-3835(01)00820-5; Ma QW, 2002, BIOMED ENVIRON SCI, V15, P253; Marcus PM, 2000, CANCER EPIDEM BIOMAR, V9, P461; Marcus PM, 2000, PHARMACOGENETICS, V10, P115, DOI 10.1097/00008571-200003000-00003; MITTAL RD, 2004, CLIN UROL, V30, P279; Moore LE, 2004, CANCER LETT, V211, P199, DOI 10.1016/j.canlet.2004.04.011; Okkels H, 1997, CANCER EPIDEM BIOMAR, V6, P225; PARKER BR, 2004, NUCLEIC ACIDS RES, V3, pD528; Sanyal S, 2004, CARCINOGENESIS, V25, P729, DOI 10.1093/carcin/bgh058; Schnakenberg E, 2000, CYTOGENET CELL GENET, V91, P234, DOI 10.1159/000056851; SILVERMAN DT, IN PRESS CANC EPIDEM; Smits KM, 2004, INT J CANCER, V110, P266, DOI 10.1002/ijc.20114; Srivastava DSL, 2004, ARCH TOXICOL, V78, P430, DOI 10.1007/s00204-004-0559-y; Steinhoff C, 2000, ARCH TOXICOL, V74, P521, DOI 10.1007/s002040000161; Taylor JA, 1998, CANCER RES, V58, P3603; THOMPSON WD, 1991, J CLIN EPIDEMIOL, V44, P221, DOI 10.1016/0895-4356(91)90033-6; Toruner GA, 2001, ARCH TOXICOL, V75, P459, DOI 10.1007/s002040100268; Tsukino H, 2004, EUR J CANCER PREV, V13, P509, DOI 10.1097/00008469-200412000-00008; Umbach DM, 1997, STAT MED, V16, P1731, DOI 10.1002/(SICI)1097-0258(19970815)16:15<1731::AID-SIM595>3.0.CO;2-S; Vineis P, 1997, CANCER CAUSE CONTROL, V8, P346, DOI 10.1023/A:1018453104303; Vineis P, 2001, CANCER EPIDEM BIOMAR, V10, P1249	61	467	481	1	54	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 20	2005	366	9486					649	659		10.1016/S0140-6736(05)67137-1	http://dx.doi.org/10.1016/S0140-6736(05)67137-1			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958EB	16112301	Green Accepted			2022-12-28	WOS:000231426400028
J	Anfinrud, P; Schotte, F				Anfinrud, P; Schotte, F			X-ray fingerprinting of chemical intermediates in solution	SCIENCE			English	Editorial Material							CRYSTALLOGRAPHY; PROTEIN; TIME; DIFFRACTION; MYOGLOBIN		NIH, Chem Phys Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Anfinrud, P (corresponding author), NIH, Chem Phys Lab, Bldg 10, Bethesda, MD 20892 USA.	anfinrud@nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK029031, ZIADK029031] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABERG T, 1997, CONCEPTUAL DESIGN RE; Brunori M, 2004, J STRUCT BIOL, V147, P223, DOI 10.1016/j.jsb.2004.04.008; Chen S, 2005, P NATL ACAD SCI USA, V102, P8854, DOI 10.1073/pnas.0504022102; Cho A, 2002, SCIENCE, V296, P1008, DOI 10.1126/science.296.5570.1008; CORNACCHIA M, 1998, SLACR512 LCLS STANF; Davidsson J, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.245503; Ihee H, 2005, P NATL ACAD SCI USA, V102, P7145, DOI 10.1073/pnas.0409035102; Ihee H, 2005, SCIENCE, V309, P1223, DOI [10.1126/science.1114782, 10.1126/scheme.1114782]; Ihee H, 2001, SCIENCE, V291, P458, DOI 10.1126/science.291.5503.458; KIM KJ, 2005, WORKSH GEN US SHORT; Rousse A, 2001, NATURE, V410, P65, DOI 10.1038/35065045; Schotte F, 2004, J STRUCT BIOL, V147, P235, DOI 10.1016/j.jsb.2004.06.009; Schotte F, 2003, SCIENCE, V300, P1944, DOI 10.1126/science.1078797; Siwick BJ, 2003, SCIENCE, V302, P1382, DOI 10.1126/science.1090052; Srajer V, 1996, SCIENCE, V274, P1726, DOI 10.1126/science.274.5293.1726; Wulff M, 2003, FARADAY DISCUSS, V122, P13, DOI 10.1039/b202740m	16	5	6	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 19	2005	309	5738					1192	1193		10.1126/science.1117325	http://dx.doi.org/10.1126/science.1117325			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	957TE	16109869				2022-12-28	WOS:000231395400029
J	Huang, JB; Wu, S; Barrera, J; Matthews, K; Pan, DJ				Huang, JB; Wu, S; Barrera, J; Matthews, K; Pan, DJ			The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila homolog of YAP	CELL			English	Article							YES-ASSOCIATED PROTEIN; MYOTONIC-DYSTROPHY KINASE; TUMOR-SUPPRESSOR; PROMOTES APOPTOSIS; CYCLE EXIT; GROWTH; SALVADOR; ENCODES; FAMILY; DOMAIN	Coordination between cell proliferation and cell death is essential to maintain homeostasis in multicellular organisms. In Drosophila, these two processes are regulated by a pathway involving the Ste20-like kinase Hippo (Hpo) and the NDR family kinase Warts (Wts; also called Lats). Hpo phosphorylates and activates Wts, which in turn, through unknown mechanisms, negatively regulates the transcription of cell-cycle and cell-death regulators such as cycE and diap1. Here we identify Yorkie (Yki), the Drosophila ortholog of the mammalian transcriptional coactivator yes-associated protein (YAP), as a missing link between Wts and transcriptional regulation. Yki is required for normal tissue growth and diapl transcription and is phosphorylated and inactivated by Wts. Overexpression of yki phenocopies loss-of-function mutations of hpo or wts, including elevated transcription of cycE and diapl, increased proliferation, defective apoptosis, and tissue overgrowth. Thus, Yki Is a critical target of the Wts/Lats protein kinase and a potential oncogene.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Pan, DJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.	djpan@jhmi.edu		Wu, Shian/0000-0003-4990-6594				Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Chan EH, 2005, ONCOGENE, V24, P2076, DOI 10.1038/sj.onc.1208445; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Gong WJ, 2003, P NATL ACAD SCI USA, V100, P2556, DOI 10.1073/pnas.0535280100; Guertin DA, 2000, EMBO J, V19, P1803, DOI 10.1093/emboj/19.8.1803; Hafen E, 2003, CURR TOP MICROBIOL, V279, P153; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Hay BA, 2003, DEV CELL, V5, P361, DOI 10.1016/S1534-5807(03)00270-3; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hipfner DR, 2004, NAT REV MOL CELL BIO, V5, P805, DOI 10.1038/nrm1491; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Jia JH, 2003, GENE DEV, V17, P2514, DOI 10.1101/gad.1134003; Jones L, 2000, DEVELOPMENT, V127, P4619; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kango-Singh M, 2002, DEVELOPMENT, V129, P5719, DOI 10.1242/dev.00168; Lai ZC, 2005, CELL, V120, P675, DOI 10.1016/j.cell.2004.12.036; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; Mah AS, 2001, P NATL ACAD SCI USA, V98, P7325, DOI 10.1073/pnas.141098998; Newsome TP, 2000, DEVELOPMENT, V127, P851; Pan DJ, 2004, TRENDS CELL BIOL, V14, P78, DOI 10.1016/j.tcb.2003.12.006; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Pignoni F, 1997, DEVELOPMENT, V124, P271; Ryoo HD, 2003, NAT CELL BIOL, V5, P853, DOI 10.1038/ncb1003-853; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; SUDOL M, 1994, ONCOGENE, V9, P2145; Tamaskovic R, 2003, FEBS LETT, V546, P73, DOI 10.1016/S0014-5793(03)00474-5; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Verde F, 1998, P NATL ACAD SCI USA, V95, P7526, DOI 10.1073/pnas.95.13.7526; Wolff Tanya, 1993, P1277; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; XU TA, 1995, DEVELOPMENT, V121, P1053; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yang XL, 2004, NAT CELL BIOL, V6, P609, DOI 10.1038/ncb1140	39	1297	1350	6	140	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 12	2005	122	3					421	434		10.1016/j.cell.2005.06.007	http://dx.doi.org/10.1016/j.cell.2005.06.007			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	955UZ	16096061	Bronze			2022-12-28	WOS:000231254400013
J	Kritchevsky, SB; Nicklas, BJ; Visser, M; Simonsick, EM; Newman, AB; Harris, TB; Lange, EM; Penninx, BW; Goodpaster, BH; Satterfield, S; Colbert, LH; Rubin, SM; Pahor, M				Kritchevsky, SB; Nicklas, BJ; Visser, M; Simonsick, EM; Newman, AB; Harris, TB; Lange, EM; Penninx, BW; Goodpaster, BH; Satterfield, S; Colbert, LH; Rubin, SM; Pahor, M			Angiotensin-converting enzyme insertion/deletion genotype, exercise, and physical decline	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN SKELETAL-MUSCLE; ACE GENE; OLDER PERSONS; DELETION POLYMORPHISM; I/D POLYMORPHISM; BODY-COMPOSITION; BLOOD-PRESSURE; I ALLELE; PERFORMANCE; STRENGTH	Context Physical performance in response to exercise appears to be influenced by the angiotensin-converting enzyme (ACE) insertion (I)/deletion (D) genotype in young adults, but whether this relationship could help explain variation in older individuals' response to exercise has not been well studied. Objective To determine whether the ACE genotype interacts with significant physical activity to affect the incidence of mobility limitation in well-functioning older adults. Design, Setting, and Participants The Health Aging and Body Composition (Health ABC) Cohort Study, conducted in the metropolitan areas of Memphis, Tenn, and Pittsburgh, Pa. A total of 3075 well-functioning community-dwelling adults aged 70 through 79 years were enrolled from 1997 to 1998 and had a mean of 4.1 years of follow-up. Main Outcome Measure Incident mobility limitation defined as the report of difficulty walking a quarter of a mile (0.4 km) or walking up 10 steps on 2 consecutive semiannual interviews (n=1204). Results Physically active participants (those reporting expending >= 1000 kcal/wk in exercise, walking, and stair climbing) were less likely to develop mobility limitation regardless of genotype. However, activity level interacted significantly with the ACE genotype (P=.002). In the inactive group, the ACE genotype was not associated with limitation (P=.46). In the active group, those with the II genotype were more likely to develop mobility limitation after adjusting for potential confounders compared with those with ID/DD genotypes (adjusted rate ratio, 1.45, 95% confidence interval, 1.08-1.94). The gene association was especially strong among participants reporting weightlifting. Exploration of possible physiological correlates revealed that among active participants, those with the II genotype had higher percentage of body fat (P=.02) and more intermuscular thigh fat (P=.02) but had similar quadriceps strength as those with ID/DD. Conclusions Among older individuals who exercised, those with the ACE DD or ID genotypes were less likely to develop mobility limitation than those with the II genotype. Regardless of genotype, individuals who exercised were less likely to develop mobility limitation than those who did not exercise.	Wake Forest Univ, Bowman Gray Sch Med,Sticht Ctr Aging, Dept Internal Med, Sect Gerontol & Geriatr Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genom, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA; Vrije Univ Amsterdam, Dept Psychiat, Amsterdam, Netherlands; Vrije Univ Amsterdam, Inst Hlth Sci, Amsterdam, Netherlands; NIA, Gerontol Res Ctr, Baltimore, MD 21224 USA; Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA USA; NIA, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA; Univ Tennessee, Dept Prevent Med, Memphis, TN USA; Univ Wisconsin, Dept Kinesiol, Madison, WI USA; Univ Calif San Francisco, Prevent Sci Grp, San Francisco, CA 94143 USA; Univ Florida, Dept Aging & Geriatr Res, Gainesville, FL USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Tennessee System; University of Tennessee Health Science Center; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California San Francisco; State University System of Florida; University of Florida	Kritchevsky, SB (corresponding author), Wake Forest Univ, Bowman Gray Sch Med,Sticht Ctr Aging, Dept Internal Med, Sect Gerontol & Geriatr Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	skritche@wfubmc.edu	Nicklas, Barbara/AAA-2781-2020; Visser, Marjolein/AAP-3224-2020; Penninx, Brenda WJH/S-7627-2017; Newman, Anne B./C-6408-2013; Simonsick, Eleanor/W-6864-2019	Penninx, Brenda WJH/0000-0001-7779-9672; Newman, Anne B./0000-0002-0106-1150; Visser, Marjolein/0000-0002-5136-298X; Kritchevsky, Stephen/0000-0003-3336-6781	NIA NIH HHS [N01-AG-6-2103, P30 AG-021332, N01-AG-6-2106, N01-AG-6-2101, R01 AG-18702] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [N01AG062101, N01AG062106, R01AG018702, Z01AG007390, N01AG062103, P30AG021332] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ades PA, 1996, ANN INTERN MED, V124, P568, DOI 10.7326/0003-4819-124-6-199603150-00005; AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; An P, 2003, INT J SPORTS MED, V24, P492; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Bean JF, 2003, J GERONTOL A-BIOL, V58, P728; Blais C, 1999, J APPL PHYSIOL, V87, P1197, DOI 10.1152/jappl.1999.87.3.1197; Boppart MD, 1999, J APPL PHYSIOL, V87, P1668, DOI 10.1152/jappl.1999.87.5.1668; Bouchard C, 2001, MED SCI SPORT EXER, V33, pS446, DOI 10.1097/00005768-200106001-00013; Broadwin J, 2001, J AM GERIATR SOC, V49, P1641, DOI 10.1111/j.1532-5415.2001.49273.x; Carter CS, 2004, J GERONTOL A-BIOL, V59, P416; Clark DO, 1996, AM J PUBLIC HEALTH, V86, P57, DOI 10.2105/AJPH.86.1.57; Coates D, 2003, INT J BIOCHEM CELL B, V35, P769, DOI 10.1016/S1357-2725(02)00309-6; Cress ME, 1999, J GERONTOL A-BIOL, V54, pM242, DOI 10.1093/gerona/54.5.M242; Di Bari M, 2004, J AM GERIATR SOC, V52, P961, DOI 10.1111/j.1532-5415.2004.52265.x; Ding JZ, 2004, AM J HYPERTENS, V17, P971, DOI 10.1016/j.amjhyper.2004.05.001; Foldvari M, 2000, J GERONTOL A-BIOL, V55, pM192, DOI 10.1093/gerona/55.4.M192; Folland J, 2000, EXP PHYSIOL, V85, P575, DOI 10.1017/S0958067000020571; Frederiksen H, 2003, AGING CLIN EXP RES, V15, P284; Frederiksen H, 2003, SCAND J MED SCI SPOR, V13, P9, DOI 10.1034/j.1600-0838.2003.20219.x; Frederiksen H, 2003, ANN EPIDEMIOL, V13, P57, DOI 10.1016/S1047-2797(02)00254-5; Gayagay G, 1998, HUM GENET, V103, P48, DOI 10.1007/s004390050781; Goodpaster BH, 2004, PEDIATR DIABETES, V5, P219, DOI 10.1111/j.1399-543X.2004.00071.x; Goodpaster BH, 2001, J APPL PHYSIOL, V90, P2157, DOI 10.1152/jappl.2001.90.6.2157; Gordon SE, 2001, AM J PHYSIOL-ENDOC M, V280, pE150, DOI 10.1152/ajpendo.2001.280.1.E150; Hirvensalo M, 2000, J AM GERIATR SOC, V48, P493, DOI 10.1111/j.1532-5415.2000.tb04994.x; Jones A, 2002, EXERC SPORT SCI REV, V30, P184, DOI 10.1097/00003677-200210000-00008; KNOWLER WC, 1988, AM J HUM GENET, V43, P520; Kohlstedt K, 2004, CIRC RES, V94, P60, DOI 10.1161/01.RES.0000107195.13573.E4; LEE IM, 1992, AM J EPIDEMIOL, V135, P915, DOI 10.1093/oxfordjournals.aje.a116387; LEXELL J, 1988, J NEUROL SCI, V84, P275, DOI 10.1016/0022-510X(88)90132-3; Martinez E, 2000, J HUM HYPERTENS, V14, P131, DOI 10.1038/sj.jhh.1000958; MILLER B, 1993, ANAL EPIDEMIOLOGIC S, V27, P41; Montgomery HE, 1997, CIRCULATION, V96, P741; Myerson S, 1999, J APPL PHYSIOL, V87, P1313, DOI 10.1152/jappl.1999.87.4.1313; Myerson SG, 2001, CIRCULATION, V103, P226; Nagi SZ, 1991, DISABILITY AM NATL A, P309, DOI DOI 10.17226/1579; NAKAI K, 1994, CIRCULATION, V90, P2199, DOI 10.1161/01.CIR.90.5.2199; Nazarov IB, 2001, EUR J HUM GENET, V9, P797, DOI 10.1038/sj.ejhg.5200711; Newman AB, 2003, J GERONTOL A-BIOL, V58, P715; Onder G, 2002, LANCET, V359, P926, DOI 10.1016/S0140-6736(02)08024-8; Penninx BWJH, 2001, ARCH INTERN MED, V161, P2309, DOI 10.1001/archinte.161.19.2309; Perusse L, 2003, MED SCI SPORT EXER, V35, P1248, DOI 10.1249/01.MSS.0000078938.84161.22; Rantanen T, 1997, J AM GERIATR SOC, V45, P1439, DOI 10.1111/j.1532-5415.1997.tb03193.x; RENELAND R, 1994, SCAND J CLIN LAB INV, V54, P105, DOI 10.3109/00365519409086516; Resnick HE, 2001, J CLIN EPIDEMIOL, V54, P869, DOI 10.1016/S0895-4356(01)00359-6; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; Singh MAF, 2002, J GERONTOL A-BIOL, V57, pM262, DOI 10.1093/gerona/57.5.M262; STEBBINS CL, 1990, J APPL PHYSIOL, V69, P1225, DOI 10.1152/jappl.1990.69.4.1225; Strazzullo P, 2003, ANN INTERN MED, V138, P17, DOI 10.7326/0003-4819-138-1-200301070-00007; Stuck AE, 1999, SOC SCI MED, V48, P445, DOI 10.1016/S0277-9536(98)00370-0; Suehiro T, 2004, HUM GENET, V115, P91, DOI 10.1007/s00439-004-1136-4; Thomis MAI, 1998, MED SCI SPORT EXER, V30, P724, DOI 10.1097/00005768-199805000-00013; van Loon LJC, 2004, J APPL PHYSIOL, V97, P1170, DOI 10.1152/japplphysiol.00368.2004; Visser M, 2005, J GERONTOL A-BIOL, V60, P324, DOI 10.1093/gerona/60.3.324; Visser M, 2005, J AM GERIATR SOC, V53, P762, DOI 10.1111/j.1532-5415.2005.53257.x; Visser M, 1998, J GERONTOL A-BIOL, V53, pM214, DOI 10.1093/gerona/53A.3.M214; Visser M, 2002, J AM GERIATR SOC, V50, P897, DOI 10.1046/j.1532-5415.2002.50217.x; WASHBURN RA, 1991, J CLIN EPIDEMIOL, V44, P1319, DOI 10.1016/0895-4356(91)90093-O; Williams AG, 2000, NATURE, V403, P614, DOI 10.1038/35001141; Wu SC, 1999, J AM GERIATR SOC, V47, P1082, DOI 10.1111/j.1532-5415.1999.tb05231.x; Zamboni M, 1999, J AM GERIATR SOC, V47, P1403, DOI 10.1111/j.1532-5415.1999.tb01557.x; Zhang B, 2003, CLIN GENET, V63, P139, DOI 10.1034/j.1399-0004.2003.00029.x	62	75	77	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	2005	294	6					691	698		10.1001/jama.294.6.691	http://dx.doi.org/10.1001/jama.294.6.691			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	953IA	16091571	Bronze			2022-12-28	WOS:000231068600022
J	Aaron, SD; Vandemheen, KL; Ferris, W; Fergusson, D; Tullis, E; Haase, D; Berthiaume, Y; Brown, N; Wilcox, P; Yazghatlian, V; Bye, P; Bell, S; Chan, F; Rose, B; Jeanneret, A; Stephenson, A; Noseworthy, M; Freitag, A; Paterson, N; Doucette, S; Harbour, C; Ruel, M; MacDonald, N				Aaron, SD; Vandemheen, KL; Ferris, W; Fergusson, D; Tullis, E; Haase, D; Berthiaume, Y; Brown, N; Wilcox, P; Yazghatlian, V; Bye, P; Bell, S; Chan, F; Rose, B; Jeanneret, A; Stephenson, A; Noseworthy, M; Freitag, A; Paterson, N; Doucette, S; Harbour, C; Ruel, M; MacDonald, N			Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial	LANCET			English	Article							PSEUDOMONAS-AERUGINOSA; STENOTROPHOMONAS-MALTOPHILIA; PULMONARY EXACERBATION; AZITHROMYCIN; RESISTANCE	Background We did a randomised, double-blind, controlled clinical trial to prospectively assess whether use of combination antibiotic susceptibility testing improved clinical outcomes in patients with acute pulmonary exacerbations of cystic fibrosis who were infected with multiresistant bacteria. Methods 251 patients with cystic fibrosis who were chronically infected with multiresistant gram negative bacteria gave sputum at 3-month intervals for conventional culture and sensitivity tests and for combination antibiotic susceptibility tests using multiple combination bactericidal antibiotic testing (MCBT). Patients who developed an exacerbation of pulmonary disease were randomised to receive a 14-day course of any two blinded intravenous antibiotics chosen on the basis of either results from conventional sputum culture and sensitivity testing or the result of MCBT. The primary outcome was time from randomisation until the patient's next pulmonary exacerbation. Analysis was by intention-to-treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN60187870. Findings 132 patients had a pulmonary exacerbation and were randomised during the 4.5-year study period. The time to next pulmonary exacerbation was not prolonged in the MCBT-treated group (hazard ratio 0.86 in favour of the conventionally-treated group, 95% Cl 0.60-1.23, p=0.40). There was no difference between the groups in treatment failure rate. After 14 days of intravenous antibiotic therapy, changes in lung function, dyspnoea, and sputum bacterial density were similar in both groups. Interpretation Antibiotic therapy directed by combination antibiotic susceptibility testing did not result in better clinical and bacteriological outcomes compared with therapy directed by standard culture and sensitivity techniques. The non-bactericidal effects of antibiotic therapy might play an important part in determining improvement in patients with cystic fibrosis pulmonary exacerbations.	Univ Ottawa, Ottawa Hlth Res Inst, Ottawa, ON, Canada; Childrens Hosp Eastern Ontario, Ottawa, ON K1H 8L1, Canada; St Michaels Hosp, Toronto, ON M5B 1W8, Canada; Dalhousie Univ, Halifax, NS, Canada; Univ Montreal, Montreal, PQ, Canada; Univ Alberta, Edmonton, AB, Canada; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; Royal Prince Alfred Hosp, Sydney, NSW, Australia; Prince Charles Hosp, Brisbane, Qld 4032, Australia; Univ Sydney, Sydney, NSW 2006, Australia; McMaster Univ, Hamilton, ON, Canada; Mem Univ Newfoundland, St John, NF, Canada; Univ Western Ontario, London, ON, Canada; Univ Laval, Ste Foy, PQ G1K 7P4, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Children's Hospital of Eastern Ontario; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Dalhousie University; Universite de Montreal; University of Alberta; University of British Columbia; University of Sydney; Prince Charles Hospital; University of Sydney; McMaster University; Memorial University Newfoundland; Western University (University of Western Ontario); Laval University	Aaron, SD (corresponding author), Ottawa Hosp, Div Resp Med, Gen Campus,Room 1812F,501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.	saaron@ottawahospital.on.ca	Bell, Scott C/A-7241-2011; Bell, Scott/AAJ-4298-2020; Berthiaume, Yves/K-7588-2012	Bell, Scott C/0000-0001-8651-7139; Bell, Scott/0000-0001-8651-7139; Fergusson, Dean/0000-0002-3389-2485; Aaron, Shawn/0000-0002-4762-3542				Aaron SD, 2004, AM J RESP CRIT CARE, V169, P811, DOI 10.1164/rccm.200309-1306OC; Aaron SD, 2002, J CLIN MICROBIOL, V40, P4172, DOI 10.1128/JCM.40.11.4172-4179.2002; Aaron SD, 2000, AM J RESP CRIT CARE, V161, P1206, DOI 10.1164/ajrccm.161.4.9907147; Chernish RN, 2003, CURR OPIN PULM MED, V9, P509, DOI 10.1097/00063198-200311000-00011; Costerton W, 2003, J CLIN INVEST, V112, P1466, DOI 10.1172/JCI200320365; *CYST FIBR FDN, 1994, MICR INF DIS CYST FI, V5, P1; Deeks JJ, 1999, ANN ONCOL, V10, P761, DOI 10.1023/A:1008359805260; Drenkard E, 2002, NATURE, V416, P740, DOI 10.1038/416740a; ELPHICK HE, 2001, COCHRANE DATABASE SY, V1; Equi A, 2002, LANCET, V360, P978, DOI 10.1016/S0140-6736(02)11081-6; Ferris W, 1997, ICAAC P, V1, pE147; Goossens H, 2005, LANCET, V365, P579, DOI 10.1016/S0140-6736(05)17907-0; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; Lang BJ, 2000, AM J RESP CRIT CARE, V162, P2241, DOI 10.1164/ajrccm.162.6.2005018; LECHTZIN N, IN PRESS RESPIRATION; Lijmer JG, 1999, JAMA-J AM MED ASSOC, V282, P1061, DOI 10.1001/jama.282.11.1061; MAHLER DA, 1984, CHEST, V85, P751, DOI 10.1378/chest.85.6.751; Moskowitz SM, 2004, J CLIN MICROBIOL, V42, P1915, DOI 10.1128/JCM.42.5.1915-1922.2004; Perrier A, 2005, NEW ENGL J MED, V352, P1760, DOI 10.1056/NEJMoa042905; REGELMANN WE, 1990, AM REV RESPIR DIS, V141, P914, DOI 10.1164/ajrccm/141.4_Pt_1.914; Rosenfeld M, 2001, J PEDIATR-US, V139, P359, DOI 10.1067/mpd.2001.117288; Saiman L, 1996, CLIN INFECT DIS, V23, P532, DOI 10.1093/clinids/23.3.532; Saiman L, 2003, JAMA-J AM MED ASSOC, V290, P1749, DOI 10.1001/jama.290.13.1749; Saiman L, 2002, ANTIMICROB AGENTS CH, V46, P1105, DOI 10.1128/AAC.46.4.1105-1107.2002; San Gabriel P, 2004, ANTIMICROB AGENTS CH, V48, P168, DOI 10.1128/AAC.48.1.168-171.2004; Singh PK, 2000, NATURE, V407, P762, DOI 10.1038/35037627; Smith AL, 1999, J PEDIATR-US, V134, P413, DOI 10.1016/S0022-3476(99)70197-6; Smith AL, 2003, CHEST, V123, P1495, DOI 10.1378/chest.123.5.1495; Wenzel RP, 2000, NEW ENGL J MED, V343, P1961, DOI 10.1056/NEJM200012283432610	29	175	179	1	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 6	2005	366	9484					463	471		10.1016/S0140-6736(05)67060-2	http://dx.doi.org/10.1016/S0140-6736(05)67060-2			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	952RD	16084254				2022-12-28	WOS:000231022300027
J	Stewart, ML; Krishna, S; Burchmore, RJS; Brun, R; de Koning, HP; Boykin, DW; Tidwell, RR; Hall, JE; Barrett, MP				Stewart, ML; Krishna, S; Burchmore, RJS; Brun, R; de Koning, HP; Boykin, DW; Tidwell, RR; Hall, JE; Barrett, MP			Detection of arsenical drug resistance in Trypanosoma brucei with a simple fluorescence test	LANCET			English	Article								The resurgence of human African trypanosomiasis (HAT), coupled with an increased incidence of drug resistance, is of concern. We report a quick, simple, and sensitive test for identification of parasites resistant to melarsoprol, the main drug used to treat late stage HAT. Resistant parasites are defective in a plasma membrane transporter responsible for drug uptake. The same transporter carries the fluorescent diamidine DB99 (2,5-bis-(4-amidinophenyl)-3,4-dimethylfuran) into trypanosomes. The two DNA-containing structures in the trypanosome the nucleus and the kinetoplast-begin to fluoresce within 1 min of introduction of DB99, unless drug resistant.	Univ London St Georges Hosp, Sch Med, Dept Cellular & Mol Med Infect Dis, London SW17 0RE, England; Georgia State Univ, Dept Chem, Atlanta, GA 30303 USA; Univ N Carolina, Sch Pharm, Div Med Chem & Nat Prod, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC USA; Swiss Trop Inst, CH-4002 Basel, Switzerland	St Georges University London; University System of Georgia; Georgia State University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Basel; Swiss Tropical & Public Health Institute	Barrett, MP (corresponding author), Univ Glasgow, Div Infect & Immun, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland.	m.barrett@bio.gla.ac.uk	Burchmore, Richard/A-1896-2011	Burchmore, Richard/0000-0003-1663-9004; Krishna, Sanjeev/0000-0003-0066-0634; De Koning, Harry/0000-0002-9963-1827; Barrett, Mike/0000-0001-9447-3519	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Barrett MP, 2003, LANCET, V362, P1469, DOI 10.1016/S0140-6736(03)14694-6; Brun R, 2001, TROP MED INT HEALTH, V6, P906, DOI 10.1046/j.1365-3156.2001.00775.x; CARTER NS, 1993, NATURE, V361, P173, DOI 10.1038/361173a0; Matovu E, 2003, EUKARYOT CELL, V2, P1003, DOI 10.1128/EC.2.5.1003-1008.2003; Scott AG, 1996, ACTA TROP, V60, P251, DOI 10.1016/0001-706X(96)00131-3	5	39	40	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 6	2005	366	9484					486	487		10.1016/S0140-6736(05)66793-1	http://dx.doi.org/10.1016/S0140-6736(05)66793-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	952RD	16084257				2022-12-28	WOS:000231022300030
J	Li, CR; Zhang, XN; Cao, ZX				Li, CR; Zhang, XN; Cao, ZX			Triangular and Fibonacci number patterns driven by stress on core/shell microstructures	SCIENCE			English	Article							THIN-FILMS; SILICON; GROWTH	Fibonacci number patterns and triangular patterns with intrinsic defects occur frequently on nonplanar surfaces in nature, particularly in plants. By controlling the geometry and the stress upon cooling, these patterns can be reproduced on the surface of microstructures about 10 micrometers in diameter. Spherules of the Ag core/SiO(x) shell structure, possessing markedly uniform size and shape, self-assembled into the Fibonacci number patterns (5 by 8 and 13 by 21) or the triangular pattern, depending on the geometry of the primary supporting surface. Under proper geometrical constraints, the patterns developed through self-assembly in order to minimize the total strain energy. This demonstrates that highly ordered microstructures can be prepared simultaneously across large areas by stress engineering.	Chinese Acad Sci, Inst Phys, Beijing 100080, Peoples R China	Chinese Academy of Sciences; Institute of Physics, CAS	Cao, ZX (corresponding author), Chinese Acad Sci, Inst Phys, POB 603, Beijing 100080, Peoples R China.	zxcao@aphy.iphy.ac.cn						Adelung R, 2004, NAT MATER, V3, P375, DOI 10.1038/nmat1128; Adler I, 1997, ANN BOT-LONDON, V80, P231, DOI 10.1006/anbo.1997.0422; Aggarwal S, 2000, SCIENCE, V287, P2235, DOI 10.1126/science.287.5461.2235; Altschuler EL, 1997, PHYS REV LETT, V78, P2681, DOI 10.1103/PhysRevLett.78.2681; Bowden N, 1998, NATURE, V393, P146, DOI 10.1038/30193; Bowick M, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.185502; Chen X, 2004, SCRIPTA MATER, V50, P797, DOI 10.1016/j.scriptamat.2003.11.035; Cromwell P. R., 1997, POLYHEDRA; Hanbucken M., 2001, STRESS STRAIN EPITAX; Hill JP, 2004, SCIENCE, V304, P1481, DOI 10.1126/science.1097789; Kaye G.W.C., 1993, TABLES PHYS CHEM CON, V15th ed.; Lee H, 2001, APPL PHYS LETT, V78, P105, DOI 10.1063/1.1336554; Su PY, 2004, APPL PHYS LETT, V84, P3480, DOI 10.1063/1.1737797; Timoshenko SP, 1961, THEORY ELASTIC STABI; Vlasov YA, 2001, NATURE, V414, P289, DOI 10.1038/35104529; Weyl H., 1952, SYMMETRY; Yin YD, 2004, SCIENCE, V304, P711, DOI 10.1126/science.1096566; Zhang XN, 2004, MATER LETT, V58, P1917, DOI 10.1016/j.matlet.2003.11.027	18	89	96	4	127	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 5	2005	309	5736					909	911		10.1126/science.1113412	http://dx.doi.org/10.1126/science.1113412			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953SS	16081729				2022-12-28	WOS:000231101400038
J	Lee, BC; Kim, MK; Jang, G; Oh, HJ; Yuda, F; Kim, HJ; Shamim, MH; Kim, JJ; Kang, SK; Schatten, G; Hwang, WS				Lee, BC; Kim, MK; Jang, G; Oh, HJ; Yuda, F; Kim, HJ; Shamim, MH; Kim, JJ; Kang, SK; Schatten, G; Hwang, WS			Dogs cloned from adult somatic cells	NATURE			English	Editorial Material							DISEASE		Seoul Natl Univ, Coll Vet Med, Dept Theriogenol & Biotechnol, Seoul 151742, South Korea; Univ Pittsburgh, Sch Med, Magee Womens Res Inst, Pittsburgh Dev Ctr,Dept Obstet Gynecol Reprod Sci, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Magee Womens Res Inst, Pittsburgh Dev Ctr,Dept Cell Biol Physiol, Pittsburgh, PA 15213 USA	Seoul National University (SNU); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute	Lee, BC (corresponding author), Seoul Natl Univ, Coll Vet Med, Dept Theriogenol & Biotechnol, Seoul 151742, South Korea.	hwangws@snu.ac.kr	Schatten, Gerald/B-3253-2009; Fibrianto, Yuda Heru/GOV-3784-2022	Schatten, Gerald/0000-0001-5206-7782; Fibrianto, Yuda Heru/0000-0002-5886-6697				Galli C, 2003, NATURE, V424, P635, DOI 10.1038/424635a; Lohi H, 2005, SCIENCE, V307, P81, DOI 10.1126/science.1102832; Modiano JF, 2005, CANCER RES, V65, P5654, DOI 10.1158/0008-5472.CAN-04-4613; Ostrander EA, 1997, AM J HUM GENET, V61, P475, DOI 10.1086/515522; Shin T, 2002, NATURE, V415, P859, DOI 10.1038/nature723; Sutter NB, 2004, NAT REV GENET, V5, P900, DOI 10.1038/nrg1492; Westhusin ME, 2001, J REP FER S, P287; Woods GL, 2003, SCIENCE, V301, P1063, DOI 10.1126/science.1086743; Zhou Q, 2003, SCIENCE, V302, P1179, DOI 10.1126/science.1088313	9	328	374	1	115	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 4	2005	436	7051					641	641		10.1038/436641a	http://dx.doi.org/10.1038/436641a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	951XA	16079832				2022-12-28	WOS:000230964500029
J	Wang, H; Nussbaum-Wagler, T; Li, BL; Zhao, Q; Vigouroux, Y; Faller, M; Bomblies, K; Lukens, L; Doebley, JF				Wang, H; Nussbaum-Wagler, T; Li, BL; Zhao, Q; Vigouroux, Y; Faller, M; Bomblies, K; Lukens, L; Doebley, JF			The origin of the naked grains of maize	NATURE			English	Article							MOLECULAR EVOLUTION; FRUIT SIZE; GENE; DOMESTICATION; SELECTION; TEOSINTE; LOCUS	The most critical step in maize (Zea mays ssp. mays) domestication was the liberation of the kernel from the hardened, protective casing that envelops the kernel in the maize progenitor, teosinte(1). This evolutionary step exposed the kernel on the surface of the ear, such that it could readily be used by humans as a food source. Here we show that this key event in maize domestication is controlled by a single gene ( teosinte glume architecture or tga1), belonging to the SBP-domain family(2) of transcriptional regulators. The factor controlling the phenotypic difference between maize and teosinte maps to a 1-kilobase region, within which maize and teosinte show only seven fixed differences in their DNA sequences. One of these differences encodes a non-conservative amino acid substitution and may affect protein function, and the other six differences potentially affect gene regulation. Molecular evolution analyses show that this region was the target of selection during maize domestication. Our results demonstrate that modest genetic changes in single genes can induce dramatic changes in phenotype during domestication and evolution.	Univ Wisconsin, Genet Lab, Madison, WI 53706 USA; DuPont Crop Genet, Wilmington, DE 19880 USA; Univ Guelph, Dept Plant Agr, Guelph, ON N1G 2W1, Canada	University of Wisconsin System; University of Wisconsin Madison; DuPont; University of Guelph	Doebley, JF (corresponding author), Univ Wisconsin, Genet Lab, Madison, WI 53706 USA.	jdoebley@wisc.edu	vigouroux, Yves/A-9056-2011	vigouroux, Yves/0000-0002-8361-6040; Lukens, Lewis/0000-0003-3963-2008; Bomblies, Kirsten/0000-0002-2434-3863	NIGMS NIH HHS [R01 GM058816] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058816] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1861, ORIGIN SPECIES MEANS; Beadle GW, 1939, J HERED, V30, P245, DOI 10.1093/oxfordjournals.jhered.a104728; Clark RM, 2004, P NATL ACAD SCI USA, V101, P700, DOI 10.1073/pnas.2237049100; Cong B, 2002, P NATL ACAD SCI USA, V99, P13606, DOI 10.1073/pnas.172520999; Doebley J, 2004, ANNU REV GENET, V38, P37, DOI 10.1146/annurev.genet.38.072902.092425; Doebley J, 1997, NATURE, V386, P485, DOI 10.1038/386485a0; DOEBLEY J, 1993, GENETICS, V134, P559; DORWEILER J, 1993, SCIENCE, V262, P233, DOI 10.1126/science.262.5131.233; Dorweiler JE, 1997, AM J BOT, V84, P1313, DOI 10.2307/2446130; GOTTLIEB LD, 1984, AM NAT, V123, P681, DOI 10.1086/284231; HUDSON RR, 1987, GENETICS, V116, P153; Jackson DP., 1992, MOL PLANT PATHOLOGY, P163; Kim Y, 2002, GENETICS, V160, P765; Klein J, 1996, MOL GEN GENET, V250, P7, DOI 10.1007/BF02191820; LANDE R, 1983, HEREDITY, V50, P47, DOI 10.1038/hdy.1983.6; Mangelsdorf PC, 1938, P NATL ACAD SCI USA, V24, P303, DOI 10.1073/pnas.24.8.303; Nesbitt TC, 2002, GENETICS, V162, P365; Przeworski M, 2003, GENETICS, V164, P1667; Purugganan MD, 2000, GENETICS, V155, P855; Rozas J, 1999, BIOINFORMATICS, V15, P174, DOI 10.1093/bioinformatics/15.2.174; SMITH JM, 1981, NATURE, V289, P13, DOI 10.1038/289013a0; TAJIMA F, 1989, GENETICS, V123, P585; Tenaillon MI, 2004, MOL BIOL EVOL, V21, P1214, DOI 10.1093/molbev/msh102; White SE, 1999, GENETICS, V153, P1455; WILKES HG, 1967, TEOSINTE CLOSET RELA	25	392	446	7	160	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 4	2005	436	7051					714	719		10.1038/nature03863	http://dx.doi.org/10.1038/nature03863			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	951XA	16079849	Green Accepted			2022-12-28	WOS:000230964500047
J	Rubin, GJ; Brewin, CR; Greenberg, N; Simpson, J; Wessely, S				Rubin, GJ; Brewin, CR; Greenberg, N; Simpson, J; Wessely, S			Psychological and behavioural reactions to the bombings in London on 7 July 2005: cross sectional survey of a representative sample of Londoners.	BRITISH MEDICAL JOURNAL			English	Article							STRESS-DISORDER; SEPTEMBER 11; ATTACKS	Objectives To assess the impact of the bombings in London on 7 July on stress levels and travel intentions in London's population. Design A cross sectional telephone survey using random digit dialling was conducted to contact a representative sample of adults. Respondents were asked to participate in an interview enquiring about current levels of stress and travel intentions. Setting Inter views took place between 18 and 20 July. Participants 1010 participants (10% of the eligible people we contacted) completed the interviews. Main outcome measures Main outcomes were presence of substantial stress, measured by using an identical tool to that used to assess the emotional impact of I I September 2001 in the US population, and intention to travel less on tubes, trains, and buses, or into central London, once the transport network had returned to normal. Results 31% of Londoners reported substantial stress and 32% reported an intention to travel less. Among other things, having difficulty contacting friends or family by mobile phone (odds ratio 1.7,95% confidence interval 1.1 to 2.7), having thought you could have been injured or killed (3.8, 2.4 to 6.2), and being Muslim (4.0, 2.5 to 6.6) were associated with a greater presence of substantial stress, whereas being white (0.3,0.2 to 0.4) and having previous experience of terrorism (0.6, 0.5 to 0.9) were associated with reduced stress. Only 12 participants (1%) felt that they needed professional help to deal with their emotional response to the attacks. Conclusions Although the psychological needs of those intimately caught up in the attacks will require further assessment, we found no evidence of a widespread desire for professional counselling. The attacks have inflicted disproportionately high levels of distress among non-white and Muslim Londoners.	Kings Coll London, Inst Psychiat, Dept Psychol Med, Weston Educ Ctr, London SE5 9RJ, England; UCL, Subdept Clin Hlth Psychol, London WC1E 6BT, England; Hlth Protect Agcy, Ctr Emergency Preparedness & Response, Salisbury SP4 0JG, Wilts, England	University of London; King's College London; University of London; University College London; Health Protection Agency	Rubin, GJ (corresponding author), Kings Coll London, Inst Psychiat, Dept Psychol Med, Weston Educ Ctr, PO62, London SE5 9RJ, England.	g.rubin@iop.kcl.ac.uk	Brewin, Chris R/C-4566-2008; Wessely, Simon C/A-8713-2008	Brewin, Chris R/0000-0002-7462-4460; greenberg, neil/0000-0003-4550-2971; Wessely, Simon Charles/0000-0002-6743-9929				Apolone G, 2002, NEW ENGL J MED, V346, P1495; Bleich A, 2003, JAMA-J AM MED ASSOC, V290, P612, DOI 10.1001/jama.290.5.612; Greenberg N., 2003, J MENTAL HLTH, V12, P565, DOI [10.1080/09638230310001627928, DOI 10.1080/09638230310001627928]; Grieger TA, 2003, PSYCHIAT SERV, V54, P1383, DOI 10.1176/appi.ps.54.10.1383; HM Government, PREP EM WHAT YOU NEE; MELTZER H, 1995, PREVALENCE PSYCHIAT; *MORI, US SURV MAN DEC; North CS, 1999, JAMA-J AM MED ASSOC, V282, P755, DOI 10.1001/jama.282.8.755; Pfefferbaum B, 1999, AM J PSYCHIAT, V156, P1069; Rose S, 2003, PSYCHOTHER PSYCHOSOM, V72, P176, DOI 10.1159/000070781; Schlenger WE, 2002, JAMA-J AM MED ASSOC, V288, P581, DOI 10.1001/jama.288.5.581; Schuster MA, 2001, NEW ENGL J MED, V345, P1507, DOI 10.1056/NEJM200111153452024; Silver RC, 2002, JAMA-J AM MED ASSOC, V288, P1235, DOI 10.1001/jama.288.10.1235; Weich S, 2004, PSYCHOL MED, V34, P1543, DOI 10.1017/S0033291704002715; Wessely S., 2005, J MENTAL HLTH, V14, P106, DOI [10.1080/09638230500048099, DOI 10.1080/09638230500048099, 10.1080/09638230500048099.]; 2005, ECONOMIST       0709, P9	16	178	178	1	21	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 17	2005	331	7517					606	611		10.1136/bmj.38583.728484.3A	http://dx.doi.org/10.1136/bmj.38583.728484.3A			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	967EK	16126821	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000232074100016
J	Handschin, C; Lin, JD; Rhee, J; Peyer, AK; Chin, S; Wu, PH; Meyer, UA; Spiegelman, BM				Handschin, C; Lin, JD; Rhee, J; Peyer, AK; Chin, S; Wu, PH; Meyer, UA; Spiegelman, BM			Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1 alpha	CELL			English	Article							SYNTHASE GENE-EXPRESSION; DELTA-AMINOLEVULINATE SYNTHASE; FORKHEAD TRANSCRIPTION FACTOR; ACUTE INTERMITTENT PORPHYRIA; ACTIVATED PROTEIN-KINASE; 5-AMINOLEVULINATE SYNTHASE; COACTIVATOR PGC-1; ACID SYNTHASE; MITOCHONDRIAL BIOGENESIS; RAT HEPATOCYTES	Inducible hepatic porphyrias are inherited genetic disorders of enzymes of heme biosynthesis. The main clinical manifestations are acute attacks of neuropsychiatric symptoms frequently precipitated by drugs, hormones, or fasting, associated with increased urinary excretion of delta-aminolevulinic acid (ALA). Acute attacks are treated by heme infusion and glucose administration, but the mechanisms underlying the precipitating effects of fasting and the beneficial effects of glucose are unknown. We show that the rate-limiting enzyme in hepatic heme biosynthesis, 5-amino-levulinate synthase (ALAS-1), is regulated by the peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1 alpha). Elevation of PGC-1 alpha in mice via adenoviral vectors increases the levels of heme precursors in vivo as observed in acute attacks. The induction of ALAS-1 by fasting is lost in liver-specific PGC-1 alpha knockout animals, as is the ability of porphyrogenic drugs to dysregulate heme biosynthesis. These data show that PGC-1 alpha links nutritional status to heme biosynthesis and acute hepatic porphyria.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Basel, Biozentrum, Div Pharmacol & Neurobiol, CH-4056 Basel, Switzerland	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; University of Basel	Spiegelman, BM (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.	bruce_spiegelman@dfci.harvard.edu	Handschin, Christoph/E-6886-2015; Rhee, James/V-9973-2019; Wu, Pei-Hsuan/AAL-1704-2020	Handschin, Christoph/0000-0003-0603-1097; Wu, Pei-Hsuan/0000-0002-6690-0744	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054477, K01DK065584, R01DK061562, R01DK060837, R56DK054477] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54477, DK61562, R01DK060837, 1K01DK065584] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BONKOVSKY HL, 1992, BIOCHEM PHARMACOL, V43, P2359, DOI 10.1016/0006-2952(92)90314-9; BRAIDOTTI G, 1993, J BIOL CHEM, V268, P1109; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CANEPA ET, 1984, BIOCHIM BIOPHYS ACTA, V804, P8, DOI 10.1016/0167-4889(84)90092-2; DAVIS JR, 1967, ARCH ENVIRON HEALTH, V15, P53, DOI 10.1080/00039896.1967.10664873; DEMATTEIS F, 1973, ENZYME, V16, P266, DOI 10.1159/000459390; DEMATTEIS F, 1973, BIOCHEM J, V134, P717, DOI 10.1042/bj1340717; Elder GH, 1997, LANCET, V349, P1613, DOI 10.1016/S0140-6736(96)09070-8; Elder GH, 1998, CLIN DERMATOL, V16, P225, DOI 10.1016/S0738-081X(97)00202-2; Fraser DJ, 2003, J BIOL CHEM, V278, P39392, DOI 10.1074/jbc.M306148200; Fraser DJ, 2002, J BIOL CHEM, V277, P34717, DOI 10.1074/jbc.M204699200; GIGER U, 1981, J BIOL CHEM, V256, P1182; Handschin C, 2003, P NATL ACAD SCI USA, V100, P7111, DOI 10.1073/pnas.1232352100; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; IniguezLluhi JA, 1997, J BIOL CHEM, V272, P4149, DOI 10.1074/jbc.272.7.4149; KAPPAS A, 1995, PORPHYRIAS; Kawaguchi T, 2002, J BIOL CHEM, V277, P3829, DOI 10.1074/jbc.M107895200; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Lindberg RLP, 1996, NAT GENET, V12, P195, DOI 10.1038/ng0296-195; Lindberg RLP, 1999, J CLIN INVEST, V103, P1127, DOI 10.1172/JCI5986; LOFTUS LS, 1991, BRIT MED J, V303, P1589, DOI 10.1136/bmj.303.6817.1589; MACALPINE I, 1968, BMJ-BRIT MED J, V1, P7, DOI 10.1136/bmj.1.5583.7; MACALPINE I, 1966, BMJ-BRIT MED J, V5479, P65; MAY BK, 1995, PROG NUCLEIC ACID RE, V51, P1, DOI 10.1016/S0079-6603(08)60875-2; Mendez M, 1999, GEN PHARMACOL, V32, P259, DOI 10.1016/S0306-3623(98)00202-X; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Pierach C A, 1999, Sudhoffs Arch, V83, P50; Podvinec M, 2004, P NATL ACAD SCI USA, V101, P9127, DOI 10.1073/pnas.0401845101; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; ROBERT TL, 1994, NUTRITION, V10, P551; Scassa ME, 2004, J BIOL CHEM, V279, P28082, DOI 10.1074/jbc.M401792200; Scassa ME, 2001, EXP CELL RES, V271, P201, DOI 10.1006/excr.2001.5386; Scassa ME, 1998, EXP CELL RES, V244, P460, DOI 10.1006/excr.1998.4206; Thadani H, 2000, BMJ-BRIT MED J, V320, P1647, DOI 10.1136/bmj.320.7250.1647; Thunell S, 2000, SCAND J CLIN LAB INV, V60, P509, DOI 10.1080/003655100448310; Varone CL, 1999, ARCH BIOCHEM BIOPHYS, V372, P261, DOI 10.1006/abbi.1999.1470; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yamashita H, 2001, P NATL ACAD SCI USA, V98, P9116, DOI 10.1073/pnas.161284298; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	43	256	266	2	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 26	2005	122	4					505	515		10.1016/j.cell.2005.06.040	http://dx.doi.org/10.1016/j.cell.2005.06.040			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	959YI	16122419	Green Published, Green Accepted, Bronze			2022-12-28	WOS:000231555100007
J	Havlir, DV; Hammer, SM				Havlir, DV; Hammer, SM			Patients versus patients? Antiretroviral therapy in India	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Calif San Francisco, San Francisco, CA 94143 USA; San Francisco Gen Hosp, HIV AIDS Div, San Francisco, CA 94110 USA; Columbia Univ, Coll Phys & Surg, New York, NY 10027 USA; Columbia Univ, Med Ctr, New York Presbyterian Hosp, New York, NY USA	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; Columbia University; Columbia University; NewYork-Presbyterian Hospital	Havlir, DV (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.								0	11	12	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 25	2005	353	8					749	751		10.1056/NEJMp058106	http://dx.doi.org/10.1056/NEJMp058106			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	957YK	16120852				2022-12-28	WOS:000231409300001
J	Watanabe, D; Suzuma, K; Matsui, S; Kurimoto, M; Kiryu, J; Kita, M; Suzuma, I; Ohashi, H; Ojima, T; Murakami, T; Kobayashi, T; Masuda, S; Nagao, M; Yoshimura, N; Takagi, H				Watanabe, D; Suzuma, K; Matsui, S; Kurimoto, M; Kiryu, J; Kita, M; Suzuma, I; Ohashi, H; Ojima, T; Murakami, T; Kobayashi, T; Masuda, S; Nagao, M; Yoshimura, N; Takagi, H			Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; DEPENDENT PRODUCTION; RECEPTOR; CELLS; NEOVASCULARIZATION; INHIBITION; PROTECTS; THERAPY; BINDING; SITE	Background: Although vascular endothelial growth factor (VEGF) is a primary mediator of retinal angiogenesis, VEGF inhibition alone is insufficient to prevent retinal neovascularization. Hence, it is postulated that there are other potent ischemia-induced angiogenic factors. Erythropoietin possesses angiogenic activity, but its potential role in ocular angiogenesis is not established. Methods: We measured both erythropoietin and VEGF levels in the vitreous fluid of 144 patients with the use of radioimmunoassay and enzyme-linked immunosorbent assay. Vitreous proliferative potential was measured according to the growth of retinal endothelial cells in vitro and with soluble erythropoietin receptor. In addition, a murine model of ischemia-induced retinal neovascularization was used to evaluate erythropoietin expression and regulation in vivo. Results: The median vitreous erythropoietin level in 73 patients with proliferative diabetic retinopathy was significantly higher than that in 71 patients without diabetes (464.0 vs. 36.5 mIU per milliliter, P<0.001). The median VEGF level in patients with retinopathy was also significantly higher than that in patients without diabetes (345.0 vs. 3.9 pg per milliliter, P<0.001). Multivariate logistic-regression analyses indicated that erythropoietin and VEGF were independently associated with proliferative diabetic retinopathy and that erythropoietin was more strongly associated with the presence of proliferative diabetic retinopathy than was VEGF. Erythropoietin and VEGF gene-expression levels are up-regulated in the murine ischemic retina, and the blockade of erythropoietin inhibits retinal neovascularization in vivo and endothelial-cell proliferation in the vitreous of patients with diabetic retinopathy in vitro. Conclusions: Our data suggest that erythropoietin is a potent ischemia-induced angiogenic factor that acts independently of VEGF during retinal angiogenesis in proliferative diabetic retinopathy.	Hyogo Kenritsu Amagasaki Hosp, Dept Ophthalmol, Amagasaki, Hyogo 6600828, Japan; Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan; Kyoto Univ, Grad Sch Publ Hlth, Dept Pharmacoepidmeiol, Kyoto, Japan; Kyoto Univ, Grad Sch Biostudies, Lab Biosignals & Response, Kyoto, Japan; Otsu Red Cross Hosp, Dept Ophthalmol, Otsu, Shiga, Japan	Kyoto University; Kyoto University; Kyoto University	Takagi, H (corresponding author), Hyogo Kenritsu Amagasaki Hosp, Dept Ophthalmol, Higashidaimotsu Cho 1-1-1, Amagasaki, Hyogo 6600828, Japan.	hitoshi@kuhp.kyoto-u.ac.jp	KOBAYASHI, Toshihiro/M-2087-2013	KOBAYASHI, Toshihiro/0000-0002-7650-1763; Murakami, Tomoaki/0000-0002-0314-8807				AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; ANAGNOSTOU A, 1990, P NATL ACAD SCI USA, V87, P5978, DOI 10.1073/pnas.87.15.5978; ANAGNOSTOU A, 1994, P NATL ACAD SCI USA, V91, P3974, DOI 10.1073/pnas.91.9.3974; Ashley RA, 2002, PEDIATR RES, V51, P472, DOI 10.1203/00006450-200204000-00012; Bainbridge JWB, 2002, GENE THER, V9, P320, DOI 10.1038/sj.gt.3301680; BARANY E, 1955, ACTA PHYSIOL SCAND, V34, P99, DOI 10.1111/j.1748-1716.1955.tb01229.x; Becerra SP, 2002, NEW ENGL J MED, V347, P1968, DOI 10.1056/NEJMcibr022629; Bianchi R, 2004, P NATL ACAD SCI USA, V101, P823, DOI 10.1073/pnas.0307823100; CARLINI RG, 1995, KIDNEY INT, V47, P740, DOI 10.1038/ki.1995.113; Chow J, 2001, DEV BRAIN RES, V130, P123, DOI 10.1016/S0165-3806(01)00220-6; Davis MD, 1998, INVEST OPHTH VIS SCI, V39, P233; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; FRIEDMAN EA, 1995, AM J KIDNEY DIS, V26, P202, DOI 10.1016/0272-6386(95)90175-2; Fuste B, 2002, THROMB HAEMOSTASIS, V88, P678; Glaspy J, 2004, ONCOLOGY-BASEL, V67, P5, DOI 10.1159/000080705; Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723; Hamma-Kourbali Y, 2001, J BIOL CHEM, V276, P39748, DOI 10.1074/jbc.M101117200; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399; KING GL, 1985, J CLIN INVEST, V75, P1028, DOI 10.1172/JCI111764; Kobayashi T, 2002, BIOCHEM BIOPH RES CO, V296, P145, DOI 10.1016/S0006-291X(02)00832-X; KRANTZ SB, 1991, BLOOD, V77, P419; Kuriyama S, 1997, NEPHRON, V77, P176, DOI 10.1159/000190270; Lipton SA, 2004, NEW ENGL J MED, V350, P2516, DOI 10.1056/NEJMcibr041121; MASUDA S, 1994, J BIOL CHEM, V269, P19488; MASUDA S, 1993, J BIOL CHEM, V268, P11208; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; NAGAO M, 1992, BIOCHEM BIOPH RES CO, V188, P888, DOI 10.1016/0006-291X(92)91139-H; PURCELL EF, 1954, AMA ARCH OPHTHALMOL, V51, P1; Ribatti D, 1999, BLOOD, V93, P2627, DOI 10.1182/blood.V93.8.2627.408k21_2627_2636; RONDON IJ, 1991, J BIOL CHEM, V266, P16594; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Sinclair SH, 2003, AM J OPHTHALMOL, V135, P740, DOI 10.1016/S0002-9394(02)02149-9; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Suzuma I, 2002, J BIOL CHEM, V277, P1047, DOI 10.1074/jbc.M105336200; Yamaji R, 1996, EUR J BIOCHEM, V239, P494, DOI 10.1111/j.1432-1033.1996.0494u.x; Yasuda Y, 2001, BRIT J CANCER, V84, P836, DOI 10.1054/bjoc.2000.1666; Yasuda Y, 1998, J BIOL CHEM, V273, P25381, DOI 10.1074/jbc.273.39.25381; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223	40	354	396	1	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 25	2005	353	8					782	792		10.1056/NEJMoa041773	http://dx.doi.org/10.1056/NEJMoa041773			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	957YK	16120858				2022-12-28	WOS:000231409300007
J	Patchell, RA; Tibbs, PA; Regine, WF; Payne, R; Saris, S; Kryscio, RJ; Mohiuddin, M; Young, B				Patchell, RA; Tibbs, PA; Regine, WF; Payne, R; Saris, S; Kryscio, RJ; Mohiuddin, M; Young, B			Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial	LANCET			English	Article							VERTEBRAL BODY RESECTION; EPIDURAL METASTASES; MANAGEMENT; DISEASE; TUMORS; STABILIZATION; RADIOTHERAPY; GUIDELINES; DIAGNOSIS	Background The standard treatment for spinal cord compression caused by metastatic cancer is corticosteroids and radiotherapy. The role of surgery has not been established. We assessed the efficacy of direct decompressive surgery. Methods In this randomised, multi-institutional, non-blinded trial, we randomly assigned patients with spinal cord compression caused by metastatic cancer to either surgery followed by radiotherapy (n=50) or radiotherapy alone (n=51). Radiotherapy for both treatment groups was given in ten 3 Gy fractions. The primary endpoint was the ability to walk. Secondary endpoints were urinary continence, muscle strength and functional status, the need for corticosteroids and opioid analgesics, and survival time. All analyses were by intention to treat. Findings After an interim analysis the study was stopped because the criterion of a predetermined early stopping rule was met. Thus, 123 patients were assessed for eligibility before the study closed and 101 were randomised. Significantly more patients in the surgery group (42/50, 84%) than in the radiotherapy group (29/51, 57%) were able to walk after treatment (odds ratio 6.2 [95% CI 2.0-19.8] p=0.001). Patients treated with surgery also retained the ability to walk significantly longer than did those with radiotherapy alone (median 122 days vs 13 days, p=0.003). 32 patients entered the study unable to walk; significantly more patients in the surgery group regained the ability to walk than patients in the radiation group (10/16 [62%] vs 3/16 [19%], p=0.01). The need for corticosteroids and opioid analgesics was significantly reduced in the surgical group. Interpretation Direct decompressive surgery plus postoperative radiotherapy is superior to treatment with radiotherapy alone for patients with spinal cord compression caused by metastatic cancer.	Univ Kentucky, Med Ctr, Dept Surg Neurosurg, Div Neurosurg, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Neurol, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Stat, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Radiat Med, Lexington, KY 40536 USA; Univ Maryland, Sch Med, Dept Radiat Oncol, Baltimore, MD 21201 USA; Duke Univ, Med Ctr, Duke Inst Care End Life, Durham, NC USA; Rhode Isl Hosp, Dept Neurosurg, Providence, RI USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; University System of Maryland; University of Maryland Baltimore; Duke University; Lifespan Health Rhode Island; Rhode Island Hospital	Patchell, RA (corresponding author), Univ Kentucky, Med Ctr, Dept Surg Neurosurg, Div Neurosurg, 800 Rose St, Lexington, KY 40536 USA.	rpatchell@aol.com			NCI NIH HHS [R01 CA55256] Funding Source: Medline; NINDS NIH HHS [K24 NS502180] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055256] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		American Spinal Injury Association, 1984, STAND NEUR CLASS SPI; BLACK P, 1979, NEUROSURGERY, V5, P726, DOI 10.1227/00006123-197912000-00016; BYRNE TN, 1992, NEW ENGL J MED, V327, P614; Byrne TN., 2000, DIS SPINE SPINAL COR, P166; COX DR, 1972, J R STAT SOC B, V34, P187; CYBULSKI GR, 1989, NEUROSURGERY, V25, P240, DOI 10.1227/00006123-198908000-00014; FINDLAY GFG, 1984, J NEUROL NEUROSUR PS, V47, P761, DOI 10.1136/jnnp.47.8.761; Frankel H L, 1969, Paraplegia, V7, P179; GILBERT RW, 1978, ANN NEUROL, V3, P40, DOI 10.1002/ana.410030107; GREENBERG HS, 1980, ANN NEUROL, V8, P361, DOI 10.1002/ana.410080404; HARRINGTON KD, 1984, J NEUROSURG, V61, P107, DOI 10.3171/jns.1984.61.1.0107; Klimo P, 2005, NEURO-ONCOLOGY, V7, P64, DOI 10.1215/S1152851704000262; Loblaw DA, 2005, J CLIN ONCOL, V23, P2028, DOI 10.1200/JCO.2005.00.067; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; OVERBY MC, 1985, J NEUROSURG, V62, P344, DOI 10.3171/jns.1985.62.3.0344; Piantadosi S, 1997, CLIN TRIALS METHODOL, P248; Posner J, 1995, NEUROLOGIC COMPLICAT, P111; RODRIGUEZ M, 1980, MAYO CLIN PROC, V55, P442; SIEGAL T, 1985, J BONE JOINT SURG AM, V67A, P375, DOI 10.2106/00004623-198567030-00004; SIEGAL T, 1982, ANN NEUROL, V11, P28, DOI 10.1002/ana.410110106; SORENSEN PS, 1990, CANCER, V65, P1502, DOI 10.1002/1097-0142(19900401)65:7<1502::AID-CNCR2820650709>3.0.CO;2-D; SUNDARESAN N, 1984, CANCER, V53, P1393, DOI 10.1002/1097-0142(19840315)53:6<1393::AID-CNCR2820530629>3.0.CO;2-0; YOUNG RF, 1980, J NEUROSURG, V53, P741, DOI 10.3171/jns.1980.53.6.0741	23	1377	1432	2	44	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 20	2005	366	9486					643	648		10.1016/S0140-6736(05)66954-1	http://dx.doi.org/10.1016/S0140-6736(05)66954-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958EB	16112300				2022-12-28	WOS:000231426400027
J	Aoki, SK; Pamma, R; Hernday, AD; Bickham, JE; Braaten, BA; Low, DA				Aoki, SK; Pamma, R; Hernday, AD; Bickham, JE; Braaten, BA; Low, DA			Contact-dependent inhibition of growth in Escherichia coli	SCIENCE			English	Article							PAP; BACTERIA; SEQUENCE; ROLES	Bacteria have developed mechanisms to communicate and compete with each other for Limited environmental resources. We found that certain Escherichia coli, including uropathogenic strains, contained. a bacterial growth-inhibition system that uses direct cell-to-cell contact. Inhibition was conditional, dependent upon the growth state of the inhibitory cell and the pili expression state of the target cell. Both a large cell-surface protein designated Contact-dependent inhibitor A (CdiA) and two-partner secretion family member CdiB were required for growth inhibition. The CdiAB system may function to regulate the growth of specific cells within a differentiated bacterial population.	Univ Calif Santa Barbara, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Low, DA (corresponding author), Univ Calif Santa Barbara, Santa Barbara, CA 93106 USA.	low@lifesci.ucsb.edu			NIAID NIH HHS [AI23348] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023348, R21AI023348] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AOKI S, UNPUB; Blomfield IC, 2001, ADV MICROB PHYSIOL, V45, P1, DOI 10.1016/S0065-2911(01)45001-6; Boulos L, 1999, J MICROBIOL METH, V37, P77, DOI 10.1016/S0167-7012(99)00048-2; Dobrindt U, 2002, INFECT IMMUN, V70, P6365, DOI 10.1128/IAI.70.11.6365-6372.2002; Henke JM, 2004, TRENDS CELL BIOL, V14, P648, DOI 10.1016/j.tcb.2004.09.012; Hernday AD, 2003, MOL CELL, V12, P947, DOI 10.1016/S1097-2765(03)00383-6; Jelsbak L, 2000, CURR OPIN MICROBIOL, V3, P637, DOI 10.1016/S1369-5274(00)00153-3; JOHANSON I, 1992, INFECT IMMUN, V60, P3416, DOI 10.1128/IAI.60.8.3416-3422.1992; Justice SS, 2004, P NATL ACAD SCI USA, V101, P1333, DOI 10.1073/pnas.0308125100; KNAPP S, 1986, J BACTERIOL, V168, P22, DOI 10.1128/jb.168.1.22-30.1986; LOW D, 1987, MOL MICROBIOL, V1, P335, DOI 10.1111/j.1365-2958.1987.tb01940.x; Lyon GJ, 2004, PEPTIDES, V25, P1389, DOI 10.1016/j.peptides.2003.11.026; RenauldMongenie G, 1996, J BACTERIOL, V178, P1053, DOI 10.1128/jb.178.4.1053-1060.1996; SCHMOLL T, 1990, MICROB PATHOGENESIS, V9, P331, DOI 10.1016/0882-4010(90)90067-Z; SPANGLER R, 1985, J BACTERIOL, V163, P167, DOI 10.1128/JB.163.1.167-173.1985; Welch R, 2001, P NATL ACAD SCI USA, V98, P14907, DOI 10.1073/pnas.261574598; Welch RA, 2002, P NATL ACAD SCI USA, V99, P17020, DOI 10.1073/pnas.252529799	17	295	305	4	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 19	2005	309	5738					1245	1248		10.1126/science.1115109	http://dx.doi.org/10.1126/science.1115109			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	957TE	16109881				2022-12-28	WOS:000231395400047
J	Kim, KA; Kakitani, M; Zhao, JS; Oshima, T; Tang, T; Binnerts, M; Liu, Y; Boyle, B; Park, E; Emtage, P; Funk, WD; Tomizuka, K				Kim, KA; Kakitani, M; Zhao, JS; Oshima, T; Tang, T; Binnerts, M; Liu, Y; Boyle, B; Park, E; Emtage, P; Funk, WD; Tomizuka, K			Mitogenic influence of human R-spondin1 on the intestinal epithelium	SCIENCE			English	Article							IN-VIVO; COLORECTAL-CANCER; CELLS; PROLIFERATION; RECEPTOR; CHEMOTHERAPY; EXPRESSION; MORTALITY; CATENIN; INJURY	Several described growth factors influence the proliferation and regeneration of the intestinal epithelium. Using a transgenic mouse model, we identified a human gene, R-spondin1, with potent and specific proliferative effects on intestinal crypt cells. Human R-spondin1 (hRSpo1) is a thrombospondin domain-containing protein expressed in enteroendocrine cells as well, as in epithelial cells in various tissues. Upon injection into mice, the protein induced rapid onset of crypt cell proliferation involving beta-catenin stabilization, possibly by a process that is distinct from the canonical Wnt-mediated signaling pathway. The protein also displayed efficacy in a model of chemotherapy-induced intestinal mucositis and may have therapeutic application in gastrointestinal diseases.	Nuvelo Inc, Sunnyvale, CA 94085 USA; Kirin Brewery Co Ltd, Div Pharmaceut, Pharmaceut Res Labs, Takasaki, Gumma 3701295, Japan	Kirin Brewery Company Limited	Funk, WD (corresponding author), Nuvelo Inc, 675 Almanor Ave, Sunnyvale, CA 94085 USA.	wfunk@nuvelo.com; ktomizuka@kirin.co.jp						Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Beck PL, 2003, AM J PATHOL, V162, P597, DOI 10.1016/S0002-9440(10)63853-9; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bjerknes M, 2001, P NATL ACAD SCI USA, V98, P12497, DOI 10.1073/pnas.211278098; Boushey RP, 2001, CANCER RES, V61, P687; Farrell CL, 1998, CANCER RES, V58, P933; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; HOUSLEY RM, 1994, J CLIN INVEST, V94, P1764, DOI 10.1172/JCI117524; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kakitani M, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni083; Kamata T, 2004, BBA-GENE STRUCT EXPR, V1676, P51, DOI 10.1016/j.bbaexp.2003.10.009; Kazanskaya O, 2004, DEV CELL, V7, P525, DOI 10.1016/j.devcel.2004.07.019; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; LOGAN CY, 2004, ANN REV CELL DEV BIO; Munroe DG, 1999, P NATL ACAD SCI USA, V96, P1569, DOI 10.1073/pnas.96.4.1569; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; POTTEN CS, 1995, GUT, V36, P864, DOI 10.1136/gut.36.6.864; Sandborn WJ, 2002, GASTROENTEROLOGY, V122, P1592, DOI 10.1053/gast.2002.33426; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Walsh NA, 2003, ENDOCRINOLOGY, V144, P4385, DOI 10.1210/en.2003-0309	22	414	456	2	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 19	2005	309	5738					1256	1259		10.1126/science.1112521	http://dx.doi.org/10.1126/science.1112521			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	957TE	16109882				2022-12-28	WOS:000231395400051
J	Feld, JJ; Hoofnagle, JH				Feld, JJ; Hoofnagle, JH			Mechanism of action of interferon and ribavirin in treatment of hepatitis C	NATURE			English	Review							NONSTRUCTURAL 5A PROTEIN; INDUCED ANTIVIRAL RESPONSE; VIRUS-INFECTION; GENE-EXPRESSION; ALPHA-INTERFERON; PEGINTERFERON ALPHA-2A; MICROARRAY ANALYSIS; INITIAL TREATMENT; RNA REPLICATION; PLUS RIBAVIRIN	Since the identification of the hepatitis C virus, great strides have been made in the development of an antiviral therapy. As a crucial mediator of the innate antiviral immune response, interferon-alpha (IFN-alpha) was a natural choice for treatment. Whereas treatment with IFN-alpha alone achieved only modest success, the addition of the broad-spectrum antiviral agent ribavirin greatly improved responses. However, half of the infected individuals with chronic disease do not achieve sustained clearance of hepatitis C virus. To optimize current therapeutic strategies and to develop new therapies, a better understanding of the mechanism of action of IFN and ribavirin will be essential.	NIDDKD, Liver Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hoofnagle, JH (corresponding author), NIDDKD, Liver Dis Branch, NIH, Bldg 31,Room 9A27,31 Ctr Dr, Bethesda, MD 20892 USA.	Hoofnagle@extra.niddk.nih.gov	Feld, Jordan/AAH-5628-2020; Yang, Chen/G-1379-2010	Feld, Jordan/0000-0003-2640-2211; 				Abe K, 2005, VIRUS RES, V107, P73, DOI 10.1016/j.virusres.2004.06.013; Basu A, 2001, VIROLOGY, V288, P379, DOI 10.1006/viro.2001.1100; Bekisz J, 2004, GROWTH FACTORS, V22, P243, DOI 10.1080/08977190400000833; Bigger CB, 2004, J VIROL, V78, P13779, DOI 10.1128/JVI.78.24.13779-13792.2004; Bigger CB, 2001, J VIROL, V75, P7059, DOI 10.1128/JVI.75.15.7059-7066.2001; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Blindenbacher A, 2003, GASTROENTEROLOGY, V124, P1465, DOI 10.1016/S0016-5085(03)00290-7; Chen LM, 2005, GASTROENTEROLOGY, V128, P1437, DOI 10.1053/j.gastro.2005.01.059; Contreras AM, 2002, J VIROL, V76, P8505, DOI 10.1128/JVI.76.17.8505-8517.2002; Cramp ME, 2000, GASTROENTEROLOGY, V118, P346, DOI 10.1016/S0016-5085(00)70217-4; Crotty S, 2000, NAT MED, V6, P1375, DOI 10.1038/82191; Crotty S, 2001, P NATL ACAD SCI USA, V98, P6895, DOI 10.1073/pnas.111085598; de Veer MJ, 2001, J LEUKOCYTE BIOL, V69, P912; Di Bisceglie AM, 2002, HEPATOLOGY, V36, pS121, DOI 10.1053/jhep.2002.36228; DIBISCEGLIE AM, 1995, ANN INTERN MED, V123, P897, DOI 10.7326/0003-4819-123-12-199512150-00001; Dixit NM, 2004, NATURE, V432, P922, DOI 10.1038/nature03153; Enomoto N, 1996, NEW ENGL J MED, V334, P77, DOI 10.1056/NEJM199601113340203; Fiedler MA, 1996, J VIROL, V70, P9079, DOI 10.1128/JVI.70.12.9079-9082.1996; Foy E, 2005, P NATL ACAD SCI USA, V102, P2986, DOI 10.1073/pnas.0408707102; Foy E, 2003, SCIENCE, V300, P1145, DOI 10.1126/science.1082604; Frese M, 2002, HEPATOLOGY, V35, P694, DOI 10.1053/jhep.2002.31770; Frese M, 2001, J GEN VIROL, V82, P723, DOI 10.1099/0022-1317-82-4-723; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; Gale M, 1998, MOL CELL BIOL, V18, P5208, DOI 10.1128/MCB.18.9.5208; Gale M, 2003, HEPATOLOGY, V37, P975, DOI 10.1053/jhep.2003.50201; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; GILMOUR KC, 1995, GENE EXPRESSION, V5, P1; Girard S, 2002, VIROLOGY, V295, P272, DOI 10.1006/viro.2002.1373; Glue P, 2000, CLIN PHARMACOL THER, V68, P556, DOI 10.1067/mcp.2000.110973; Guo JT, 2001, J VIROL, V75, P8516, DOI 10.1128/JVI.75.18.8516-8523.2001; Guo JT, 2004, VIROLOGY, V325, P71, DOI 10.1016/j.virol.2004.04.031; Hadziyannis SJ, 2004, ANN INTERN MED, V140, P346, DOI 10.7326/0003-4819-140-5-200403020-00010; Heathcote EJ, 2000, NEW ENGL J MED, V343, P1673, DOI 10.1056/NEJM200012073432302; Heim MH, 1999, J VIROL, V73, P8469, DOI 10.1128/JVI.73.10.8469-8475.1999; Herion D, 1997, HEPATOLOGY, V25, P769, DOI 10.1002/hep.510250346; Honda M, 2005, GASTROENTEROLOGY, V128, P449, DOI 10.1053/j.gastro.2004.11.064; HOOFNAGLE JH, 1986, NEW ENGL J MED, V315, P1575, DOI 10.1056/NEJM198612183152503; Hoofnagle JH, 1996, J VIRAL HEPATITIS, V3, P247, DOI 10.1111/j.1365-2893.1996.tb00050.x; Jaeckel E, 2001, NEW ENGL J MED, V345, P1452, DOI 10.1056/NEJMoa011232; Ji XH, 2003, HEPATOLOGY, V37, P610, DOI 10.1053/jhep.2003.50105; Kamal SM, 2004, HEPATOLOGY, V39, P1721, DOI 10.1002/hep.20266; Kamal SM, 2002, GASTROENTEROLOGY, V123, P1070, DOI 10.1053/gast.2002.36045; Katze MG, 2002, NAT REV IMMUNOL, V2, P675, DOI 10.1038/nri888; Khabar KSA, 1997, J EXP MED, V186, P1077, DOI 10.1084/jem.186.7.1077; Lanford RE, 2003, J VIROL, V77, P1092, DOI 10.1128/JVI.77.2.1092-1104.2003; Lanford RE, 2001, J VIROL, V75, P8074, DOI 10.1128/JVI.75.17.8074-8081.2001; Lau DTY, 1998, HEPATOLOGY, V28, P1121, DOI 10.1002/hep.510280430; Lau JYN, 1996, ANN INTERN MED, V124, P868, DOI 10.7326/0003-4819-124-10-199605150-00002; Lau JYN, 2002, HEPATOLOGY, V35, P1002, DOI 10.1053/jhep.2002.32672; Layden JE, 2002, HEPATOLOGY, V35, P967, DOI 10.1053/jhep.2002.32711; Layden-Almer JE, 2003, HEPATOLOGY, V37, P1343, DOI 10.1053/jhep.2003.50217; Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499; Lindahl K, 2005, HEPATOLOGY, V41, P275, DOI 10.1002/hep.20563; Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016; Lindsay KL, 2001, HEPATOLOGY, V34, P395, DOI 10.1053/jhep.2001.26371; Lutchman A, 2004, HEPATOLOGY, V40, p385A; Maag D, 2001, J BIOL CHEM, V276, P46094, DOI 10.1074/jbc.C100349200; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Marcellin P, 1997, ANN INTERN MED, V127, P875, DOI 10.7326/0003-4819-127-10-199711150-00003; McHutchison JG, 1999, SEMIN LIVER DIS, V19, P57; Muir AJ, 2004, NEW ENGL J MED, V350, P2265, DOI 10.1056/NEJMoa032502; Neumann AU, 1998, SCIENCE, V282, P103, DOI 10.1126/science.282.5386.103; Pavio N, 2002, J VIROL, V76, P1265, DOI 10.1128/JVI.76.3.1265-1272.2002; Pawlotsky JM, 2004, GASTROENTEROLOGY, V126, P703, DOI 10.1053/j.gastro.2003.12.002; Polyak SJ, 2001, J VIROL, V75, P6095, DOI 10.1128/JVI.75.13.6095-6106.2001; Polyak SJ, 2001, J VIROL, V75, P6209, DOI 10.1128/JVI.75.13.6209-6211.2001; Rahman F, 2004, HEPATOLOGY, V40, P87, DOI 10.1002/hep.20253; Reesink HW, 2005, GASTROENTEROLOGY, V128, pA697; Rehermann B, 2005, NAT REV IMMUNOL, V5, P215, DOI 10.1038/nri1573; Robek MD, 2005, J VIROL, V79, P3851, DOI 10.1128/JVI.79.6.3851-3854.2005; Rodriguez-Torres M, 2005, GASTROENTEROLOGY, V128, pA695; Santantonio T, 2005, J HEPATOL, V42, P329, DOI 10.1016/j.jhep.2004.11.021; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Shiffman ML, 2002, HEPATOLOGY, V36, pS128, DOI 10.1053/jhep.2002.36816; Soza A, 2005, J HEPATOL, V43, P67, DOI 10.1016/j.jhep.2005.02.023; Strader DB, 2002, HEPATOLOGY, V36, pS226, DOI 10.1053/jhep.2002.36991; Stumper R, 2005, J VIROL, V79, P2689, DOI 10.1128/JVI.79.5.2689-2699.2005; Su AI, 2002, P NATL ACAD SCI USA, V99, P15669, DOI 10.1073/pnas.202608199; Tam RC, 1999, J HEPATOL, V30, P376, DOI 10.1016/S0168-8278(99)80093-2; Taylor DR, 1999, SCIENCE, V285, P107, DOI 10.1126/science.285.5424.107; Taylor DR, 2000, J MOL MED, V78, P182, DOI 10.1007/s001090000100; Thomson M, 2003, J VIROL, V77, P862, DOI 10.1128/JVI.77.2.862-870.2003; Tilg H, 1997, GASTROENTEROLOGY, V112, P1017, DOI 10.1053/gast.1997.v112.pm9041265; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Wang CF, 2003, J VIROL, V77, P3898, DOI 10.1128/JVI.77.7.3898-3912.2003; Young KC, 2003, HEPATOLOGY, V38, P869, DOI 10.1053/jhep.2003.50445; Zeuzem S, 2000, NEW ENGL J MED, V343, P1666, DOI 10.1056/NEJM200012073432301; Zhang YH, 2003, J VIROL, V77, P5933, DOI 10.1128/JVI.77.10.5933-5947.2003; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102; Zhou SF, 2003, VIROLOGY, V310, P333, DOI 10.1016/S0042-6822(03)00152-1; Zhu HZ, 2003, HEPATOLOGY, V37, P1180, DOI 10.1053/jhep.2003.50184	91	757	809	2	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 18	2005	436	7053					967	972		10.1038/nature04082	http://dx.doi.org/10.1038/nature04082			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955XQ	16107837				2022-12-28	WOS:000231263900039
J	Trivedi, AN; Zaslavsky, AM; Schneider, EC; Ayanian, JZ				Trivedi, AN; Zaslavsky, AM; Schneider, EC; Ayanian, JZ			Trends in the quality of care and racial disparities in Medicare managed care	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-CARE; ETHNIC DISPARITIES; MYOCARDIAL-INFARCTION; BENEFICIARIES; ADULTS; INSURANCE; ENROLLEES; PROGRAMS; THERAPY; IMPACT	Background: Since 1997, all managed-care plans administered by Medicare have reported on quality-of-care measures from the Health Plan Employer Data and Information Set (HEDIS). Studies of early data found that blacks received care that was of lower quality than that received by whites. In this study, we assessed changes over time in the overall quality of care and in the magnitude of racial disparities in nine measures of clinical performance. Methods: In order to compare the quality of care for elderly white and black beneficiaries enrolled in Medicare managed-care plans who were eligible for at least one of nine HEDIS measures, we analyzed 1.8 million individual-level observations from 183 health plans from 1997 to 2003. For each measure, we assessed whether the magnitude of the racial disparity had changed over time with the use of multivariable models that adjusted for the age, sex, health plan, Medicaid eligibility, and socioeconomic position of beneficiaries on the basis of their area of residence. Results: During the seven-year study period, clinical performance improved on all measures for both white enrollees and black enrollees (P<0.001). The gap between white beneficiaries and black beneficiaries narrowed for seven HEDIS measures (P<0.01). However, racial disparities did not decrease for glucose control among patients with diabetes (increasing from 4 percent to 7 percent, P<0.001) or for cholesterol control among patients with cardiovascular disorders (increasing from 14 percent to 17 percent; change not significant, P=0.72). Conclusions: The measured quality of care for elderly Medicare beneficiaries in managed-care plans improved substantially from 1997 to 2003. Racial disparities declined for most, but not all, HEDIS measures we studied. Future research should examine factors that contributed to the narrowing of racial disparities on some measures and focus on interventions to eliminate persistent disparities in the quality of care.	Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Gen Med & Primary Care, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Ayanian, JZ (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.	ayanian@hcp.med.harvard.edu		Schneider, Eric/0000-0002-1132-5084	AHRQ HHS [P01-HS10803] Funding Source: Medline; PHS HHS [5 T32 HP11001-15] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P01HS010803] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Arday SL, 2000, HEALTH CARE FINANC R, V21, P107; Ayanian JZ, 1999, MED CARE, V37, P1260, DOI 10.1097/00005650-199912000-00009; Ayanian JZ, 2002, ARCH INTERN MED, V162, P1013, DOI 10.1001/archinte.162.9.1013; Bach PB, 2004, NEW ENGL J MED, V351, P575, DOI 10.1056/NEJMsa040609; Baker LC, 2004, INT J QUAL HEALTH C, V16, P19, DOI 10.1093/intqhc/mzh003; Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; Bradley EH, 2004, JAMA-J AM MED ASSOC, V292, P1563, DOI 10.1001/jama.292.13.1563; DeLaet DE, 2002, J GEN INTERN MED, V17, P451, DOI 10.1046/j.1525-1497.2002.10512.x; Federman AD, 2001, JAMA-J AM MED ASSOC, V286, P1732, DOI 10.1001/jama.286.14.1732; Fiscella K, 2000, JAMA-J AM MED ASSOC, V283, P2579, DOI 10.1001/jama.283.19.2579; Grimshaw J, 2003, QUAL SAF HEALTH CARE, V12, P298, DOI 10.1136/qhc.12.4.298; Hassett P, 2005, HEALTH AFFAIR, V24, P417, DOI 10.1377/hlthaff.24.2.417; *HLTH CAR FIN ADM, HEDIS301998 HLTH CAR; *I MED, 2001, CROSS EQ CHASM NEW H; Institute of Medicine Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care, 2003, UNEQUAL TREATMENT CO, DOI DOI 10.17226/12875; Jencks SF, 2003, JAMA-J AM MED ASSOC, V289, P305, DOI 10.1001/jama.289.3.305; Jencks SF, 2000, JAMA-J AM MED ASSOC, V284, P1670, DOI 10.1001/jama.284.13.1670; Jencks SF, 2002, JAMA-J AM MED ASSOC, V289, P2649; Jha AK, 2003, NEW ENGL J MED, V348, P2218, DOI 10.1056/NEJMsa021899; Kiefe CI, 2001, JAMA-J AM MED ASSOC, V285, P2871, DOI 10.1001/jama.285.22.2871; Lied TR, 2001, HEALTH CARE FINANC R, V23, P149; McCormick D, 2002, JAMA-J AM MED ASSOC, V288, P1484, DOI 10.1001/jama.288.12.1484; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Persell SD, 2005, J GEN INTERN MED, V20, P123, DOI 10.1111/j.1525-1497.2005.40155.x; Persell SD, 2004, PREV MED, V39, P746, DOI 10.1016/j.ypmed.2004.02.045; *RW JOHNS FDN, COLL RAC ETHN DAT HL; Schneider EC, 2001, JAMA-J AM MED ASSOC, V286, P1455, DOI 10.1001/jama.286.12.1455; Schneider EC, 2002, JAMA-J AM MED ASSOC, V287, P1288, DOI 10.1001/jama.287.10.1288; Sehgal AR, 2003, JAMA-J AM MED ASSOC, V289, P996, DOI 10.1001/jama.289.8.996; Ver Ploeg M., 2004, ELIMINATING HLTH DIS; Virnig BA, 2002, HEALTH AFFAIR, V21, P224, DOI 10.1377/hlthaff.21.6.224; Weiner M, 2003, ANN INTERN MED, V139, P430, DOI 10.7326/0003-4819-139-5_Part_2-200309021-00010; Weingarten SR, 2002, BRIT MED J, V325, P925, DOI 10.1136/bmj.325.7370.925; Zaslavsky AM, 2005, MED CARE, V43, P303, DOI 10.1097/01.mlr.0000159975.43573.8d; Zaslavsky AM, 2000, MED CARE, V38, P981, DOI 10.1097/00005650-200010000-00002	35	298	299	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 18	2005	353	7					692	700		10.1056/NEJMsa051207	http://dx.doi.org/10.1056/NEJMsa051207			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	955UW	16107622				2022-12-28	WOS:000231254100007
J	Wilkins, C; Dishongh, R; Moore, SC; Whitt, MA; Chow, M; Machaca, K				Wilkins, C; Dishongh, R; Moore, SC; Whitt, MA; Chow, M; Machaca, K			RNA interference is an antiviral defence mechanism in Caenorhabditis elegans	NATURE			English	Article							C-ELEGANS; VESICULAR STOMATITIS; FUNCTIONAL-ANALYSIS; VIRAL SUPPRESSORS; VIRUS; REPLICATION; INFLUENZA; SYSTEM; CELLS; PROTEINS	RNA interference (RNAi) is an evolutionarily conserved sequence-specific post-transcriptional gene silencing mechanism that is well defined genetically in Caenorhabditis elegans(1-4). RNAi has been postulated to function as an adaptive antiviral immune mechanism in the worm, but there is no experimental evidence for this. Part of the limitation is that there are no known natural viral pathogens of C. elegans. Here we describe an infection model in C. elegans using the mammalian pathogen vesicular stomatitis virus (VSV) to study the role of RNAi in antiviral immunity. VSV infection is potentiated in cells derived from RNAi-defective worm mutants (rde-1; rde-4), leading to the production of infectious progeny virus, and is inhibited in mutants with an enhanced RNAi response (rrf-3; eri-1). Because the RNAi response occurs in the absence of exogenously added VSV small interfering RNAs, these results show that RNAi is activated during VSV infection and that RNAi is a genuine antiviral immune defence mechanism in the worm.	Univ Arkansas Med Sci, Dept Microbiol & Immunol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72205 USA; Harding Univ, Dept Biol, Searcy, AR 72149 USA; Univ Tennessee, Dept Mol Sci, Hlth Sci Ctr, Memphis, TN 38163 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Tennessee System; University of Tennessee Health Science Center	Chow, M (corresponding author), Univ Arkansas Med Sci, Dept Microbiol & Immunol, Little Rock, AR 72205 USA.	chowmarie@uams.edu; kamachaca@uams.edu	Machaca, Khaled/AAF-3579-2019; Abrams, William R/A-5782-2008	Machaca, Khaled/0000-0001-6215-2411; Wilkins, Courtney/0000-0003-4001-7686				Adelman ZN, 2002, J VIROL, V76, P12925, DOI 10.1128/JVI.76.24.12925-12933.2002; Bennasser Y, 2005, IMMUNITY, V22, P607, DOI 10.1016/j.immuni.2005.03.010; Boritz E, 1999, J VIROL, V73, P6937, DOI 10.1128/JVI.73.8.6937-6945.1999; Christensen M, 2002, NEURON, V33, P503, DOI 10.1016/S0896-6273(02)00591-3; Denli AM, 2003, TRENDS BIOCHEM SCI, V28, P196, DOI 10.1016/S0968-0004(03)00058-6; Ge Q, 2003, P NATL ACAD SCI USA, V100, P2718, DOI 10.1073/pnas.0437841100; Gitlin L, 2002, NATURE, V418, P430, DOI 10.1038/nature00873; Grishok A, 2002, ADV GENET, V46, P339; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hu WY, 2002, CURR BIOL, V12, P1301, DOI 10.1016/S0960-9822(02)00975-2; Kennedy S, 2004, NATURE, V427, P645, DOI 10.1038/nature02302; Letchworth GJ, 1999, VET J, V157, P239, DOI 10.1053/tvjl.1998.0303; Li HW, 2002, SCIENCE, V296, P1319, DOI 10.1126/science.1070948; Li WX, 2004, P NATL ACAD SCI USA, V101, P1350, DOI 10.1073/pnas.0308308100; Li WX, 2001, CURR OPIN BIOTECH, V12, P150, DOI 10.1016/S0958-1669(00)00190-7; Roberts A, 1998, J VIROL, V72, P4704, DOI 10.1128/JVI.72.6.4704-4711.1998; ROSE JK, 2004, FIELDS VIROLOGY, P1221; Roth BM, 2004, VIRUS RES, V102, P97, DOI 10.1016/j.virusres.2004.01.020; Schnell MJ, 1996, P NATL ACAD SCI USA, V93, P11359, DOI 10.1073/pnas.93.21.11359; Simmer F, 2002, CURR BIOL, V12, P1317, DOI 10.1016/S0960-9822(02)01041-2; STILLMAN EA, 1995, J VIROL, V69, P2946, DOI 10.1128/JVI.69.5.2946-2953.1995; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Tabara H, 2002, CELL, V109, P861, DOI 10.1016/S0092-8674(02)00793-6; Takada A, 1997, P NATL ACAD SCI USA, V94, P14764, DOI 10.1073/pnas.94.26.14764; Tijsterman M, 2004, CELL, V117, P1, DOI 10.1016/S0092-8674(04)00293-4; Tijsterman M, 2004, CURR BIOL, V14, P111, DOI 10.1016/j.cub.2003.12.029; Vance V, 2001, SCIENCE, V292, P2277, DOI 10.1126/science.1061334; Voinnet O, 2001, TRENDS GENET, V17, P449, DOI 10.1016/S0168-9525(01)02367-8	28	243	267	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 18	2005	436	7053					1044	1047		10.1038/nature03957	http://dx.doi.org/10.1038/nature03957			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955XQ	16107852				2022-12-28	WOS:000231263900056
J	Bachofner, A; Poeppel, TD; Scherer, A				Bachofner, A; Poeppel, TD; Scherer, A			A tumour masquerade	LANCET			English	Editorial Material							SPLENOSIS		Univ Dusseldorf, Dept Nucl Med, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Scherer, A (corresponding author), Univ Dusseldorf, Dept Nucl Med, Moorenstr 5, D-40225 Dusseldorf, Germany.	scherera@uni-duesseldorf.de	Scherer, Axel/ABF-5147-2021					ARMAS RR, 1985, SEMIN NUCL MED, V15, P260, DOI 10.1016/S0001-2998(85)80004-0; Lin WC, 2003, AM J ROENTGENOL, V180, P493, DOI 10.2214/ajr.180.2.1800493; Sikov WM, 2000, AM J HEMATOL, V65, P56, DOI 10.1002/1096-8652(200009)65:1<56::AID-AJH10>3.3.CO;2-T; ZWAS ST, 1986, EUR J NUCL MED, V12, P125	4	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 13	2005	366	9485					606	606		10.1016/S0140-6736(05)67104-8	http://dx.doi.org/10.1016/S0140-6736(05)67104-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955LL	16099298				2022-12-28	WOS:000231227300034
J	Boule, JB; Vega, LR; Zakian, VA				Boule, JB; Vega, LR; Zakian, VA			The yeast Pif1p helicase removes telomerase from telomeric DNA	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; NUCLEOPROTEIN FILAMENTS; CHROMOSOME ENDS; IN-VIVO; ELONGATION; IDENTIFICATION; DISRUPTION; SUBFAMILY; COMPLEX	Telomeres are the physical ends of eukaryotic chromosomes. Genetic studies have established that the baker's yeast Pif1p DNA helicase is a negative regulator of telomerase, the specialized reverse transcriptase that maintains telomeric DNA, but the biochemical basis for this inhibition was unknown. Here we show that in vitro, Pif1p reduces the processivity of telomerase and releases telomerase from telomeric oligonucleotides. The released telomerase is enzymatically active because it is able to lengthen a challenger oligonucleotide. In vivo, overexpression of Pif1p reduces telomerase association with telomeres, whereas depleting cells of Pif1p increases the levels of telomere-bound Est1p, a telomerase subunit that is present on the telomere when telomerase is active. We propose that Pif1p helicase activity limits telomerase action both in vivo and in vitro by displacing active telomerase from DNA ends.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Zakian, VA (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	vzakian@molbio.princeton.edu	Boulé, Jean-Baptiste/M-8200-2017; Vega, Leticia/AAF-4981-2021	Boulé, Jean-Baptiste/0000-0002-0994-5831; Vega, Leticia/0000-0001-7605-1048				Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; Bessler JB, 2001, TRENDS CELL BIOL, V11, P60, DOI 10.1016/S0962-8924(00)01877-8; Burgers PMJ, 1999, METHODS, V18, P349, DOI 10.1006/meth.1999.0796; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; Collins K, 1999, ANNU REV BIOCHEM, V68, P187, DOI 10.1146/annurev.biochem.68.1.187; COLLINS K, 1993, GENE DEV, V7, P1364, DOI 10.1101/gad.7.7b.1364; Diede SJ, 1999, CELL, V99, P723, DOI 10.1016/S0092-8674(00)81670-0; Fisher TS, 2004, NAT STRUCT MOL BIOL, V11, P1198, DOI 10.1038/nsmb854; Forstemann K, 2001, MOL CELL BIOL, V21, P7277, DOI 10.1128/MCB.21.21.7277-7286.2001; GREIDER CW, 1991, MOL CELL BIOL, V11, P4572, DOI 10.1128/MCB.11.9.4572; Haering CH, 2000, P NATL ACAD SCI USA, V97, P6367, DOI 10.1073/pnas.130187397; Hammond PW, 1997, MOL CELL BIOL, V17, P296, DOI 10.1128/MCB.17.1.296; Jankowsky E, 2001, SCIENCE, V291, P121, DOI 10.1126/science.291.5501.121; Krejci L, 2003, NATURE, V423, P305, DOI 10.1038/nature01577; LAHAYE A, 1991, EMBO J, V10, P997, DOI 10.1002/j.1460-2075.1991.tb08034.x; Lue NF, 2004, BIOESSAYS, V26, P955, DOI 10.1002/bies.20093; Mangahas JL, 2001, MOL BIOL CELL, V12, P4078, DOI 10.1091/mbc.12.12.4078; MANTELL LL, 1994, EMBO J, V13, P3211, DOI 10.1002/j.1460-2075.1994.tb06620.x; Marcand S, 2000, CURR BIOL, V10, P487, DOI 10.1016/S0960-9822(00)00450-4; Monson EK, 1997, PEZ FDN SYM, V8, P97; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Myung K, 2001, NATURE, V411, P1073, DOI 10.1038/35082608; Peng Y, 2001, MOL CELL, V7, P1201, DOI 10.1016/S1097-2765(01)00268-4; Prescott J, 1997, GENE DEV, V11, P2790, DOI 10.1101/gad.11.21.2790; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; Schramke V, 2004, NAT GENET, V36, P46, DOI 10.1038/ng1284; SCHULZ VP, 1994, CELL, V76, P145, DOI 10.1016/0092-8674(94)90179-1; Shiratori A, 1999, YEAST, V15, P219, DOI 10.1002/(SICI)1097-0061(199902)15:3<219::AID-YEA349>3.3.CO;2-V; SIKORSKI RS, 1989, GENETICS, V122, P19; Singh SM, 2002, EUKARYOT CELL, V1, P967, DOI 10.1128/EC.1.6.967-977.2002; Taggart AKP, 2002, SCIENCE, V297, P1023, DOI 10.1126/science.1074968; Teixeira MT, 2004, CELL, V117, P323, DOI 10.1016/S0092-8674(04)00334-4; Tsukamoto Y, 2001, CURR BIOL, V11, P1328, DOI 10.1016/S0960-9822(01)00372-4; Veaute X, 2005, EMBO J, V24, P180, DOI 10.1038/sj.emboj.7600485; Veaute X, 2003, NATURE, V423, P309, DOI 10.1038/nature01585; Zhou JQ, 2000, SCIENCE, V289, P771, DOI 10.1126/science.289.5480.771; Zhou JQ, 2002, MOL BIOL CELL, V13, P2180, DOI 10.1091/mbc.02-02-0021	37	187	193	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 3	2005	438	7064					57	61		10.1038/nature04091	http://dx.doi.org/10.1038/nature04091			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979XS	16121131				2022-12-28	WOS:000232979000039
J	Torres-Larios, A; Swinger, KK; Krasilnikov, AS; Pan, T; Mondragon, A				Torres-Larios, A; Swinger, KK; Krasilnikov, AS; Pan, T; Mondragon, A			Crystal structure of the RNA component of bacterial ribonuclease P	NATURE			English	Article							PHOTOAFFINITY CROSS-LINKING; MAGNESIUM-IONS; RIBONUCLEOPROTEIN ENZYME; CATALYTIC SUBUNIT; ESCHERICHIA-COLI; SUBSTRATE; RIBOZYME; RECOGNITION; BINDING; DOMAIN	Transfer RNA ( tRNA) is produced as a precursor molecule that needs to be processed at its 30 and 50 ends. Ribonuclease P is the sole endonuclease responsible for processing the 50 end of tRNA by cleaving the precursor and leading to tRNA maturation. It was one of the first catalytic RNA molecules identified(1) and consists of a single RNA component in all organisms and only one protein component in bacteria. It is a true multi- turnover ribozyme and one of only two ribozymes ( the other being the ribosome) that are conserved in all kingdoms of life. Here we show the crystal structure at 3.85 angstrom resolution of the RNA component of Thermotoga maritima ribonuclease P. The entire RNA catalytic component is revealed, as well as the arrangement of the two structural domains. The structure shows the general architecture of the RNA molecule, the inter- and intra- domain interactions, the location of the universally conserved regions, the regions involved in pre- tRNA recognition and the location of the active site. A model with bound tRNA is in agreement with all existing data and suggests the general basis for RNA - RNA recognition by this ribozyme.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	Northwestern University; University of Chicago	Mondragon, A (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.	a-mondragon@northwestern.edu		Torres-Larios, Alfredo/0000-0002-0702-350X				Beebe JA, 1996, BIOCHEMISTRY-US, V35, P10493, DOI 10.1021/bi960870m; Brown JW, 1996, P NATL ACAD SCI USA, V93, P3001, DOI 10.1073/pnas.93.7.3001; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen JL, 1997, RNA, V3, P557; Christian EL, 2002, EMBO J, V21, P2253, DOI 10.1093/emboj/21.9.2253; Christian EL, 2002, METHODS, V28, P307, DOI 10.1016/S1046-2023(02)00238-4; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; GUERRIERTAKADA C, 1992, P NATL ACAD SCI USA, V89, P1266, DOI 10.1073/pnas.89.4.1266; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; Harris ME, 1997, RNA, V3, P561; HARRIS ME, 1994, EMBO J, V13, P3953, DOI 10.1002/j.1460-2075.1994.tb06711.x; KIRSEBOM LA, 1994, EMBO J, V13, P4870, DOI 10.1002/j.1460-2075.1994.tb06814.x; Krasilnikov AS, 2004, SCIENCE, V306, P104, DOI 10.1126/science.1101489; Krasilnikov AS, 2003, NATURE, V421, P760, DOI 10.1038/nature01386; Kurz JC, 2000, CURR OPIN CHEM BIOL, V4, P553, DOI 10.1016/S1367-5931(00)00131-9; LAGRANDEUR TE, 1994, EMBO J, V13, P3945, DOI 10.1002/j.1460-2075.1994.tb06710.x; Loria A, 1997, BIOCHEMISTRY-US, V36, P6317, DOI 10.1021/bi970115o; Loria A, 1996, RNA, V2, P551; Massire C, 1998, J MOL BIOL, V279, P773, DOI 10.1006/jmbi.1998.1797; Massire C, 1997, RNA, V3, P553; MCCLAIN WH, 1987, SCIENCE, V238, P527, DOI 10.1126/science.2443980; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Odell L, 1998, NUCLEIC ACIDS RES, V26, P3717, DOI 10.1093/nar/26.16.3717; Pannucci JA, 1999, P NATL ACAD SCI USA, V96, P7803, DOI 10.1073/pnas.96.14.7803; PERREAULT JP, 1993, J MOL BIOL, V230, P750, DOI 10.1006/jmbi.1993.1197; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; Siegel RW, 1996, RNA, V2, P452; SMITH D, 1993, BIOCHEMISTRY-US, V32, P5273, DOI 10.1021/bi00071a001; Tsai HY, 2003, J MOL BIOL, V325, P661, DOI 10.1016/S0022-2836(02)01267-6; Zahler NH, 2003, RNA, V9, P734, DOI 10.1261/rna.5220703	30	179	185	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 22	2005	437	7058					584	587		10.1038/nature04074	http://dx.doi.org/10.1038/nature04074			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	966FF	16113684				2022-12-28	WOS:000232004800057
J	Ellaway, A; Macintyre, S; Bonnefoy, X				Ellaway, A; Macintyre, S; Bonnefoy, X			Graffiti, greenery, and obesity in adults: secondary analysis of European cross sectional survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Glasgow, MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland; WHO European Ctr Environm & Hlth, D-53113 Bonn, Germany	MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNIT; University of Glasgow	Ellaway, A (corresponding author), Univ Glasgow, MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland.	anne@msoc.mrc.gla.ac.uk	Ellaway, Anne/A-3065-2009; Macintyre, Sally/P-6246-2014	Ellaway, Anne/0000-0002-2117-4451				Ball K, 2001, PREV MED, V33, P434, DOI 10.1006/pmed.2001.0912; Bonnefoy XR, 2003, AM J PUBLIC HEALTH, V93, P1559, DOI 10.2105/AJPH.93.9.1559; Ellaway A, 1997, INT J OBESITY, V21, P304, DOI 10.1038/sj.ijo.0800405; Must A, 1999, JAMA-J AM MED ASSOC, V282, P1523, DOI 10.1001/jama.282.16.1523; Sundquist J, 1999, INT J EPIDEMIOL, V28, P841, DOI 10.1093/ije/28.5.841	5	244	247	1	30	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 17	2005	331	7517					611	612		10.1136/bmj.38575.664549.F7	http://dx.doi.org/10.1136/bmj.38575.664549.F7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	967EK	16113034	Green Published, Green Accepted, Bronze			2022-12-28	WOS:000232074100017
J	Ferguson, NM; Cummings, DAT; Cauchemez, S; Fraser, C; Riley, S; Meeyai, A; Iamsirithaworn, S; Burke, DS				Ferguson, NM; Cummings, DAT; Cauchemez, S; Fraser, C; Riley, S; Meeyai, A; Iamsirithaworn, S; Burke, DS			Strategies for containing an emerging influenza pandemic in Southeast Asia	NATURE			English	Article							VIRUS INFECTIONS; ANTIVIRAL DRUG; TRANSMISSION; OSELTAMIVIR; HOUSEHOLD; RISK; RESISTANT; EPIDEMIC; OUTBREAK; DISEASES	Highly pathogenic H5N1 influenza A viruses are now endemic in avian populations in Southeast Asia, and human cases continue to accumulate. Although currently incapable of sustained human-to-human transmission, H5N1 represents a serious pandemic threat owing to the risk of a mutation or reassortment generating a virus with increased transmissibility. Identifying public health interventions that might be able to halt a pandemic in its earliest stages is therefore a priority. Here we use a simulation model of influenza transmission in Southeast Asia to evaluate the potential effectiveness of targeted mass prophylactic use of antiviral drugs as a containment strategy. Other interventions aimed at reducing population contact rates are also examined as reinforcements to an antiviral-based containment policy. We show that elimination of a nascent pandemic may be feasible using a combination of geographically targeted prophylaxis and social distancing measures, if the basic reproduction number of the new virus is below 1.8. We predict that a stockpile of 3 million courses of antiviral drugs should be sufficient for elimination. Policy effectiveness depends critically on how quickly clinical cases are diagnosed and the speed with which antiviral drugs can be distributed.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Infect Dis Epidemiol, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Inst Math Sci, London SW7 2PG, England; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; INSERM, U707, F-75571 Paris, France; Univ Hong Kong, Dept Community Med, Hong Kong, Hong Kong, Peoples R China; Minist Publ Hlth, Dept Dis Control, Bur Epidemiol, Nonthaburi 11000, Thailand	Imperial College London; Imperial College London; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Hong Kong; Ministry of Public Health - Thailand	Ferguson, NM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Infect Dis Epidemiol, St Marys Campus,Norfolk Pl, London W2 1PG, England.	neil.ferguson@imperial.ac.uk	Fraser, Christophe/A-8109-2008; Riley, Steven/C-4384-2009; Ferguson, Neil/B-8578-2008	Fraser, Christophe/0000-0003-2399-9657; Ferguson, Neil/0000-0002-1154-8093; Riley, Steven/0000-0001-7904-4804; /0000-0002-5704-8094				Abbott A, 2004, NATURE, V427, P472, DOI 10.1038/427472a; ANDERSON R M, 1991; Axtell RL, 2001, SCIENCE, V293, P1818, DOI 10.1126/science.1062081; Brooks MJ, 2004, CURR OPIN PULM MED, V10, P197, DOI 10.1097/00063198-200405000-00009; Carrat F, 2002, ARCH INTERN MED, V162, P1842, DOI 10.1001/archinte.162.16.1842; Cauchemez S, 2004, STAT MED, V23, P3469, DOI 10.1002/sim.1912; CHAMRATRITHIRON.A, 1995, NATL MIGRATION SURVE; Coombes R, 2005, BRIT MED J, V330, P495, DOI 10.1136/bmj.330.7490.495; ELVEBACK LR, 1976, AM J EPIDEMIOL, V103, P152, DOI 10.1093/oxfordjournals.aje.a112213; Ferguson NM, 2004, SCIENCE, V304, P968, DOI 10.1126/science.1096898; Ferguson NM, 2003, J ANTIMICROB CHEMOTH, V51, P977, DOI 10.1093/jac/dkg136; FLAHAULT A, 1988, STAT MED, V7, P1147, DOI 10.1002/sim.4780071107; Fleming DM, 1999, EUR J EPIDEMIOL, V15, P467, DOI 10.1023/A:1007525402861; FOX JP, 1982, AM J EPIDEMIOL, V116, P212, DOI 10.1093/oxfordjournals.aje.a113407; Fraser C, 2004, P NATL ACAD SCI USA, V101, P6146, DOI 10.1073/pnas.0307506101; Hayden FG, 1999, JAMA-J AM MED ASSOC, V282, P1240, DOI 10.1001/jama.282.13.1240; Hayden FG, 1998, J CLIN INVEST, V101, P643, DOI 10.1172/JCI1355; Herlocher ML, 2004, J INFECT DIS, V190, P1627, DOI 10.1086/424572; Heymann A, 2004, PEDIATR INFECT DIS J, V23, P675, DOI 10.1097/01.inf.0000128778.54105.06; Leneva IA, 2000, ANTIVIR RES, V48, P101, DOI 10.1016/S0166-3542(00)00123-6; LONGINI IM, 1988, AM J EPIDEMIOL, V128, P845, DOI 10.1093/oxfordjournals.aje.a115038; Longini IM, 2004, AM J EPIDEMIOL, V159, P623, DOI 10.1093/aje/kwh092; Mills CE, 2004, NATURE, V432, P904, DOI 10.1038/nature03063; *MIN LAB THAIL, 2003, YB LAB STAT; MOSER MR, 1979, AM J EPIDEMIOL, V110, P1; *NAT STAT OFF THAI, 1999, NAT MIGR SURV; *NAT STAT OFF THAI, 2000, POP CENS 2000; *OAKR NAT LAB, 2003, LANDSC GLOB POP DAT; Principi N, 2004, ARCH DIS CHILD, V89, P1002, DOI 10.1136/adc.2003.045401; Riley S, 2003, SCIENCE, V300, P1961, DOI 10.1126/science.1086478; SPICER CC, 1984, J HYG-CAMBRIDGE, V93, P105, DOI 10.1017/S0022172400060988; Stohr K, 2004, SCIENCE, V306, P2195, DOI 10.1126/science.1108165; Viboud C, 2004, BRIT J GEN PRACT, V54, P684; *WHO, 2005, WHO INT CONS INFL A; World Health Organization, 2005, AV INFL ASS PAND THR; YANG Y, 2004, 0409 EM U DEP BIOST	36	1269	1315	5	265	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 8	2005	437	7056					209	214		10.1038/nature04017	http://dx.doi.org/10.1038/nature04017			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	961YE	16079797	Green Submitted, Bronze			2022-12-28	WOS:000231696900046
J	Drummond, AER; Pearson, B; Lincoln, NB; Berman, P				Drummond, AER; Pearson, B; Lincoln, NB; Berman, P			Ten year follow-up of a randomised controlled trial of care in a stroke rehabilitation unit	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Queens Med Ctr, Div Ageing & Rehabil, Nottingham NG7 2UH, England; Derbyshire Royal Infirm, Derby DE1 2QY, England; Univ Nottingham, Inst Work Hlth & Org, Nottingham NG7 2RQ, England; City Hosp, Nottingham NG5 1PB, England	University of Nottingham; University of Nottingham; University of Nottingham	Drummond, AER (corresponding author), Queens Med Ctr, Div Ageing & Rehabil, Nottingham NG7 2UH, England.	Avril.Drummond@nottingham.ac.uk	Lincoln, Nadina B/B-9149-2009	Drummond, Avril/0000-0003-1220-8354				Collin C, 1988, Int Disabil Stud, V10, P61; Indredavik B, 1999, STROKE, V30, P1524, DOI 10.1161/01.STR.30.8.1524; Juby LC, 1996, CEREBROVASC DIS, V6, P106, DOI 10.1159/000108005; Lincoln NB, 2000, BMJ-BRIT MED J, V320, P549, DOI 10.1136/bmj.320.7234.549; *STROK UN TRIAL CO, 1997, BMJ-BRIT MED J, V814, P1151	5	27	28	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 3	2005	331	7515					491	492		10.1136/bmj.38537.679479.E0	http://dx.doi.org/10.1136/bmj.38537.679479.E0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	963RA	16093255	Bronze, Green Published			2022-12-28	WOS:000231820400018
J	Sherwood, SC; Lanzante, JR; Meyer, CL				Sherwood, SC; Lanzante, JR; Meyer, CL			Radiosonde daytime biases and late-20th century warming	SCIENCE			English	Article							TEMPERATURE TRENDS; RADIATION; DATASETS; CARDS	The temperature difference between adjacent 0000 and 1200 UTC weather balloon (radiosonde) reports shows a pervasive tendency toward cooler daytime compared to nighttime observations since the 1970s, especially at tropical stations. Several characteristics of this trend indicate that it is an artifact of systematic reductions over time in the uncorrected error due to daytime solar heating of the instrument and should be absent from accurate climate records. Although other problems may exist, this effect alone is of sufficient magnitude to reconcile radiosonde tropospheric temperature trends and surface trends during the late 20th century.	Yale Univ, Dept Geol & Geophys, New Haven, CT 06520 USA; Princeton Univ, NOAA, Geophys Fluid Dynam Lab, Princeton, NJ 08542 USA	Yale University; National Oceanic Atmospheric Admin (NOAA) - USA; Princeton University	Sherwood, SC (corresponding author), Yale Univ, Dept Geol & Geophys, POB 6666, New Haven, CT 06520 USA.	ssherwood@alum.mit.edu	Sherwood, Steven/B-5673-2008; Lanzante, John R./G-7643-2019	Sherwood, Steven/0000-0001-7420-8216; Lanzante, John R./0000-0002-1736-7170				Angell JK, 2003, J CLIMATE, V16, P2288, DOI 10.1175/2763.1; Chapman S., 1970, ATMOSPHERIC TIDES, V1970th ed.; Christy JR, 2003, J ATMOS OCEAN TECH, V20, P613, DOI 10.1175/1520-0426(2003)20<613:EEOVOM>2.0.CO;2; Dai A, 1999, J CLIMATE, V12, P2451, DOI [10.1175/1520-0442(1999)012<2451:EOCSMP>2.0.CO;2, 10.1175/1520-0442(1999)012&lt;2451:EOCSMP&gt;2.0.CO;2]; Douglass DH, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020212; Durre I, 2002, J CLIMATE, V15, P1335, DOI 10.1175/1520-0442(2002)015<1335:EOTEOT>2.0.CO;2; Easterling DR, 1997, SCIENCE, V277, P364, DOI 10.1126/science.277.5324.364; ESKRIDGE RE, 1995, B AM METEOROL SOC, V76, P1759, DOI 10.1175/1520-0477(1995)076<1759:ACARDS>2.0.CO;2; Free M, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD005481; Free M, 2002, B AM METEOROL SOC, V83, P891, DOI 10.1175/1520-0477(2002)083<0891:CCRDCW>2.3.CO;2; Gaffen DJ, 1999, J CLIMATE, V12, P811, DOI 10.1175/1520-0442(1999)012<0811:CATOUS>2.0.CO;2; Gaffen DJ, 2000, SCIENCE, V287, P1242, DOI 10.1126/science.287.5456.1242; Haimberger L, 2005, ERA 40 PROJECT REPOR, V23; KRISHNAIAH P.R., 1988, HDB STAT, V7; Lanzante JR, 2003, J CLIMATE, V16, P241, DOI 10.1175/1520-0442(2003)016<0241:THOMRT>2.0.CO;2; LIOU KN, 1975, J ATMOS SCI, V32, P2166, DOI 10.1175/1520-0469(1975)032<2166:OTTOSR>2.0.CO;2; LUERS JK, 1995, J APPL METEOROL, V34, P1241, DOI 10.1175/1520-0450(1995)034<1241:TCFTVA>2.0.CO;2; PARKER DE, 1995, INT J CLIMATOL, V15, P473, DOI 10.1002/joc.3370150502; Parker DE, 1997, GEOPHYS RES LETT, V24, P1499, DOI 10.1029/97GL01186; Randel WJ, 1999, SCIENCE, V285, P1689, DOI 10.1126/science.285.5434.1689; RANDEL WJ, UNPUB; Riehl Herbert, 1954, TROPICAL METEOROLOGY; Santer BD, 2005, SCIENCE, V309, P1551, DOI 10.1126/science.1114867; SASAMORI T, 1966, J ATMOS SCI, V23, P543; Seidel DJ, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD005526; Seidel DJ, 2004, J CLIMATE, V17, P2225, DOI 10.1175/1520-0442(2004)017<2225:UISOLC>2.0.CO;2; Sherwood SC, 2000, GEOPHYS RES LETT, V27, P3525, DOI 10.1029/2000GL011424; THORNE PW, IN PRESS J GEOPHYS R	28	111	113	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 2	2005	309	5740					1556	1559		10.1126/science.1115640	http://dx.doi.org/10.1126/science.1115640			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	962EY	16099950				2022-12-28	WOS:000231715000048
J	Levy, F; Sheikin, I; Grenier, B; Huxley, AD				Levy, F; Sheikin, I; Grenier, B; Huxley, AD			Magnetic field-induced superconductivity in the ferromagnet URhGe	SCIENCE			English	Article							2-DIMENSIONAL ORGANIC CONDUCTOR; COEXISTENCE	In several metals, including URhGe, superconductivity has recently been observed to appear and coexist with ferromagnetism at temperatures well below that at which the ferromagnetic state forms. However, the material characteristics leading to such a state of coexistence have not yet been fully elucidated. We report that in URhGe there is a magnetic transition where the direction of the spin axis changes when a magnetic field of 12 testa is applied parallel to the crystal b axis. We also report that a second pocket of superconductivity occurs at low temperature for a range of fields enveloping this magnetic transition, well above the field of 2 testa at which superconductivity is first destroyed. Our findings strongly suggest that excitations in which the spins rotate stimulate superconductivity in the neighborhood of a quantum phase transition under high magnetic field.	CEA, Dept Rech Fondamentale Mat Condensee, Serv Phys Stat Magnet & Supraconduct, F-38054 Grenoble, France; CNRS, Grenoble High Magnet Field Lab, F-38042 Grenoble, France	CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS)	Huxley, AD (corresponding author), CEA, Dept Rech Fondamentale Mat Condensee, Serv Phys Stat Magnet & Supraconduct, F-38054 Grenoble, France.	huxley@cea.fr	Lévy-Bertrand, Florence/G-8734-2012	Sheikin, Ilya/0000-0002-3704-1848				Aoki D, 2001, NATURE, V413, P613, DOI 10.1038/35098048; Custers J, 2003, NATURE, V424, P524, DOI 10.1038/nature01774; FAY D, 1980, PHYS REV B, V22, P3173, DOI 10.1103/PhysRevB.22.3173; Grigera SA, 2004, SCIENCE, V306, P1154, DOI 10.1126/science.1104306; Hardy F, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.247006; Harrison N, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.096402; JACCARINO V, 1962, PHYS REV LETT, V9, P290, DOI 10.1103/PhysRevLett.9.290; Kirkpatrick TR, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.127003; Konoike T, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.094514; LIFSHITZ EM, 1991, STAT PHYS 2, V9; Lonzarich G. G., 1997, ELECTRON; Mathur ND, 1998, NATURE, V394, P39, DOI 10.1038/27838; MEUL HW, 1984, PHYS REV LETT, V53, P497, DOI 10.1103/PhysRevLett.53.497; Mineev VP, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.134504; Pfleiderer C, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.147005; Prokes K., UNPUB; Roussev R, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.140504; Saxena SS, 2000, NATURE, V406, P587, DOI 10.1038/35020500; Sheikin I, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.220503; Uji S, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.104525; Uji S, 2001, NATURE, V410, P908, DOI 10.1038/35073531	21	234	238	4	72	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 26	2005	309	5739					1343	1346		10.1126/science.1115498	http://dx.doi.org/10.1126/science.1115498			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TX	16123293				2022-12-28	WOS:000231543300035
J	Bell, T; Newman, JA; Silverman, BW; Turner, SL; Lilley, AK				Bell, T; Newman, JA; Silverman, BW; Turner, SL; Lilley, AK			The contribution of species richness and composition to bacterial services	NATURE			English	Article							MICROBIAL COMMUNITY STRUCTURE; TERRESTRIAL ECOSYSTEM; CURRENT KNOWLEDGE; BIODIVERSITY; DIVERSITY; SOIL; PRODUCTIVITY; ECOLOGY	Bacterial communities provide important services. They break down pollutants, municipal waste and ingested food, and they are the primary means by which organic matter is recycled to plants and other autotrophs. However, the processes that determine the rate at which these services are supplied are only starting to be identified. Biodiversity influences the way in which ecosystems function(1), but the form of the relationship between bacterial biodiversity and functioning remains poorly understood. Here we describe a manipulative experiment that measured how biodiversity affects the functioning of communities containing up to 72 bacterial species constructed from a collection of naturally occurring culturable bacteria. The experimental design allowed us to manipulate large numbers of bacterial species selected at random from those that were culturable. We demonstrate that there is a decelerating relationship between community respiration and increasing bacterial diversity. We also show that both synergistic interactions among bacterial species and the composition of the bacterial community are important in determining the level of ecosystem functioning.	NERC, Ctr Ecol & Hydrol, Mol Microbial Ecol Grp, Oxford OX1 3SR, England; Univ Oxford, Dept Zool, Oxford OX1 3PS, England; St Peters Coll, Oxford, England; Univ Guelph, Dept Environm Biol, Guelph, ON N1G 2W1, Canada	UK Centre for Ecology & Hydrology (UKCEH); UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); University of Oxford; University of Oxford; University of Guelph	Lilley, AK (corresponding author), NERC, Ctr Ecol & Hydrol, Mol Microbial Ecol Grp, Mansfield Rd, Oxford OX1 3SR, England.	akl@ceh.ac.uk	Turner, Sarah/K-4683-2012; Newman, Jonathan/A-5932-2008; Silverman, Bernard W/K-6417-2012	Turner, Sarah/0000-0002-8937-6922; Newman, Jonathan/0000-0003-3155-4084; Silverman, Bernard W/0000-0002-4059-2376; Bell, Thomas/0000-0002-2615-3932				Bell T, 2005, SCIENCE, V308, P1884, DOI 10.1126/science.1111318; Cardinale BJ, 2002, NATURE, V415, P426, DOI 10.1038/415426a; Cavigelli MA, 2001, SOIL BIOL BIOCHEM, V33, P297, DOI 10.1016/S0038-0717(00)00141-3; Cavigelli MA, 2000, ECOLOGY, V81, P1402; Cohan FM, 2002, ANNU REV MICROBIOL, V56, P457, DOI 10.1146/annurev.micro.56.012302.160634; Curtis TP, 2003, ENVIRON SCI TECHNOL, V37, p64A, DOI 10.1021/es0323493; Emmerson MC, 2001, NATURE, V411, P73, DOI 10.1038/35075055; Fierer N, 2003, MICROB ECOL, V45, P63, DOI 10.1007/s00248-002-1007-2; Franklin RB, 2001, APPL ENVIRON MICROB, V67, P702, DOI 10.1128/AEM.67.2.702-712.2001; Garland JL, 1999, FEMS MICROBIOL ECOL, V30, P333, DOI 10.1111/j.1574-6941.1999.tb00661.x; Griffiths BS, 2001, SOIL BIOL BIOCHEM, V33, P1713, DOI 10.1016/S0038-0717(01)00094-3; Griffiths BS, 2004, MICROB ECOL, V47, P104, DOI 10.1007/s00248-002-2043-7; Hector A, 1999, SCIENCE, V286, P1123, DOI 10.1126/science.286.5442.1123; Hooper DU, 2005, ECOL MONOGR, V75, P3, DOI 10.1890/04-0922; Horz HP, 2004, P NATL ACAD SCI USA, V101, P15136, DOI 10.1073/pnas.0406616101; Huston MA, 1997, OECOLOGIA, V110, P449, DOI 10.1007/s004420050180; KITCHING RL, 1971, J ANIM ECOL, V40, P281, DOI 10.2307/3247; Loreau M, 2001, NATURE, V412, P72, DOI 10.1038/35083573; Loreau M, 2001, SCIENCE, V294, P804, DOI 10.1126/science.1064088; McGradySteed J, 1997, NATURE, V390, P162, DOI 10.1038/36561; Naeem S, 2000, NATURE, V403, P762, DOI 10.1038/35001568; Rappe MS, 2003, ANNU REV MICROBIOL, V57, P369, DOI 10.1146/annurev.micro.57.030502.090759; SASSER M, 2001, 101 MIDI INC; Schimel JP, 1998, GLOBAL CHANGE BIOL, V4, P745, DOI 10.1046/j.1365-2486.1998.00195.x; THOMPSON IP, 1993, FEMS MICROBIOL ECOL, V102, P75, DOI 10.1016/0378-1097(93)90002-J; Tilman D, 2001, SCIENCE, V294, P843, DOI 10.1126/science.1060391; van der Heijden MGA, 1998, NATURE, V396, P69, DOI 10.1038/23932; Yin B, 2000, APPL ENVIRON MICROB, V66, P4361, DOI 10.1128/AEM.66.10.4361-4365.2000; Zengler K, 2002, P NATL ACAD SCI USA, V99, P15681, DOI 10.1073/pnas.252630999; Zibilske LM., 1994, METHODS SOIL ANAL 2, P835	30	623	678	15	462	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 25	2005	436	7054					1157	1160		10.1038/nature03891	http://dx.doi.org/10.1038/nature03891			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	958AK	16121181				2022-12-28	WOS:000231416600046
J	Alard, O; Luguet, A; Pearson, NJ; Griffin, WL; Lorand, JP; Gannoun, A; Burton, KW; O'Reilly, SY				Alard, O; Luguet, A; Pearson, NJ; Griffin, WL; Lorand, JP; Gannoun, A; Burton, KW; O'Reilly, SY			In situ Os isotopes in abyssal peridotites bridge the isotopic gap between MORBs and their source mantle	NATURE			English	Article							SIDEROPHILE ELEMENT GEOCHEMISTRY; MIDOCEAN RIDGE; MARK AREA; OSMIUM; SYSTEMATICS; HETEROGENEITY; SIGNATURE; SULFIDES; BASALTS; RATIOS	Abyssal peridotites are assumed to represent the mantle residue of mid-ocean-ridge basalts ( MORBs). However, the osmium isotopic compositions of abyssal peridotites and MORB do not appear to be in equilibrium(1-8), raising questions about the cogenetic relationship between those two reservoirs. However, the cause of this isotopic mismatch is mainly due to a drastic filtering of the data based on the possibility of osmium contamination by sea water(5). Here we present a detailed study of magmatic sulphides ( the main carrier of osmium) in abyssal peridotites and show that the Os-187/Os-188 ratio of these sulphides is of primary mantle origin and can reach radiogenic values suggesting equilibrium with MORB. Thus, the effect of sea water on the osmium systematics of abyssal peridotites has been overestimated and consequently there is no true osmium isotopic gap between MORBs and abyssal peridotites.	Macquarie Univ, GEMOC ARC Natl Key Ctr, Sch Earth & Planetary Sci, N Ryde, NSW 2109, Australia; Open Univ, Dept Earth Sci, Milton Keynes MK7 6AA, Bucks, England; Univ Montpellier 2, Lab Tectonophys, ISTEEM,CNRS, UMR5560, F-34095 Montpellier, France; Museum Natl Hist Nat, Lab Mineral Meteorites Manteau, FREE 2456, CNRS, F-75005 Paris, France; Carnegie Inst Sci, Dept Terr Magnetism, Washington, DC 20015 USA	Macquarie University; Open University - UK; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); Universite de Montpellier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); Carnegie Institution for Science	Alard, O (corresponding author), Macquarie Univ, GEMOC ARC Natl Key Ctr, Sch Earth & Planetary Sci, N Ryde, NSW 2109, Australia.	o.alard@open.ac.uk	GAU, geochemist/H-1985-2016; ALARD, Olivier/R-7755-2016; ALARD, Olivier/AAV-8846-2020; ALARD, Olivier/A-7128-2008; Griffin, W.L./F-7713-2011; O'Reilly, Suzanne Y/A-1315-2008	ALARD, Olivier/0000-0002-0832-6625; ALARD, Olivier/0000-0002-0832-6625; Griffin, W.L./0000-0002-0980-2566; O'Reilly, Suzanne Y/0000-0002-3883-5498; luguet, ambre/0000-0002-4899-8776; Burton, Kevin/0000-0002-3381-7004				Alard O, 2000, NATURE, V407, P891, DOI 10.1038/35038049; Alard O, 2002, EARTH PLANET SC LETT, V203, P651, DOI 10.1016/S0012-821X(02)00799-9; Ballhaus C, 2001, J PETROL, V42, P1911, DOI 10.1093/petrology/42.10.1911; Bockrath C, 2004, SCIENCE, V305, P1951, DOI 10.1126/science.1100160; Brandon AD, 2000, EARTH PLANET SC LETT, V177, P319, DOI 10.1016/S0012-821X(00)00044-3; Burton KW, 1999, EARTH PLANET SC LETT, V172, P311, DOI 10.1016/S0012-821X(99)00207-1; CRAIG JR, 1989, EC GEOL MONOGR GEOLO, P343; ESPERANCA S, 1999, LUNAR PLANETARY I CO, V971; Gannoun A, 2004, GEOCHIM COSMOCHIM AC, V68, pA703; Gannoun A, 2004, SCIENCE, V303, P70, DOI 10.1126/science.1090266; Hirschmann MM, 1996, CONTRIB MINERAL PETR, V124, P185, DOI 10.1007/s004100050184; HOFMANN AW, 2004, TREATISE GEOCHEMISTR, P61, DOI DOI 10.1016/B978-0-08-095975-7.00203-5; Levasseur S, 1998, SCIENCE, V282, P272, DOI 10.1126/science.282.5387.272; Lorand JP, 2001, GEOCHIM COSMOCHIM AC, V65, P2789, DOI 10.1016/S0016-7037(01)00627-5; Luguet A, 2001, EARTH PLANET SC LETT, V189, P285, DOI 10.1016/S0012-821X(01)00357-0; Luguet A, 2004, CHEM GEOL, V208, P175, DOI 10.1016/j.chemgeo.2004.04.011; Luguet A, 2003, GEOCHIM COSMOCHIM AC, V67, P1553, DOI 10.1016/S0016-7037(02)01133-X; Luguet A, 1999, CR ACAD SCI II A, V329, P637, DOI 10.1016/S1251-8050(00)87640-5; MARTIN CE, 1991, GEOCHIM COSMOCHIM AC, V55, P1421, DOI 10.1016/0016-7037(91)90318-Y; MCDONOUGH WF, 1995, CHEM GEOL, V120, P223, DOI 10.1016/0009-2541(94)00140-4; Meisel T, 1996, NATURE, V383, P517, DOI 10.1038/383517a0; Pearson NJ, 2002, GEOCHIM COSMOCHIM AC, V66, P1037, DOI 10.1016/S0016-7037(01)00823-7; Rehkamper M, 1999, EARTH PLANET SC LETT, V172, P65, DOI 10.1016/S0012-821X(99)00193-4; ROYBARMAN M, 1994, GEOCHIM COSMOCHIM AC, V58, P5043, DOI 10.1016/0016-7037(94)90230-5; Schiano P, 1997, EARTH PLANET SC LETT, V150, P363, DOI 10.1016/S0012-821X(97)00098-8; Seyler M, 2004, GEOLOGY, V32, P301, DOI 10.1130/G20191.1; Seyler M, 2001, GEOLOGY, V29, P155, DOI 10.1130/0091-7613(2001)029<0155:CMRIEM>2.0.CO;2; SNOW JE, 1995, EARTH PLANET SC LETT, V133, P411, DOI 10.1016/0012-821X(95)00099-X; SNOW JE, 1994, NATURE, V371, P57, DOI 10.1038/371057a0; Snow JE, 2000, EARTH PLANET SC LETT, V175, P119, DOI 10.1016/S0012-821X(99)00280-0; Standish JJ, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2001GC000161	31	182	194	1	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 18	2005	436	7053					1005	1008		10.1038/nature03902	http://dx.doi.org/10.1038/nature03902			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955XQ	16107845				2022-12-28	WOS:000231263900047
J	Morrison, J				Morrison, J			Early practical experience and the social responsiveness of clinical education: systematic review - Commentary: The challenges of systematic reviews of educational research	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Glasgow, Glasgow G12 9LX, Lanark, Scotland	University of Glasgow	Morrison, J (corresponding author), Univ Glasgow, Glasgow G12 9LX, Lanark, Scotland.	jmm4y@clinmed.gla.ac.uk						*BEME GROUP, 2000, MED TEACH, V22, P242; Harden RM, 2000, MED TEACH, V22, P117; Littlewood S, 2005, BMJ-BRIT MED J, V331, P387, DOI 10.1136/bmj.331.7513.387; Norman GR, 2000, MED EDUC, V34, P721, DOI 10.1046/j.1365-2923.2000.00749.x	4	8	9	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 13	2005	331	7513					391	391		10.1136/bmj.331.7513.391	http://dx.doi.org/10.1136/bmj.331.7513.391			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	956SK	16096307	Green Published			2022-12-28	WOS:000231319900018
J	Thingstad, TF; Krom, MD; Mantoura, RFC; Flaten, GAF; Groom, S; Herut, B; Kress, N; Law, CS; Pasternak, A; Pitta, P; Psarra, S; Rassoulzadegan, F; Tanaka, T; Tselepides, A; Wassmann, P; Woodward, EMS; Riser, CW; Zodiatis, G; Zohary, T				Thingstad, TF; Krom, MD; Mantoura, RFC; Flaten, GAF; Groom, S; Herut, B; Kress, N; Law, CS; Pasternak, A; Pitta, P; Psarra, S; Rassoulzadegan, F; Tanaka, T; Tselepides, A; Wassmann, P; Woodward, EMS; Riser, CW; Zodiatis, G; Zohary, T			Nature of phosphorus limitation in the ultraoligotrophic eastern Mediterranean	SCIENCE			English	Article							NITROGEN-FIXATION; ATLANTIC-OCEAN; NORTH-ATLANTIC; SEA; STOICHIOMETRY; CYANOBACTERIUM; SYNECHOCOCCUS; PRODUCTIVITY; COMPETITION; NUTRIENTS	Phosphate addition to surface waters of the ultraoligotrophic, phosphorus-starved eastern Mediterranean in a Lagrangian experiment caused unexpected ecosystem responses. The system exhibited a decline in chlorophyll and an increase in bacterial production and copepod egg abundance. Although nitrogen and phosphorus colimitation hindered phytoplankton growth, phosphorous may have been transferred through the microbial food web to copepods via two, not mutually exclusive, pathways: (i) bypass of the phytoplankton compartment by phosphorus uptake in heterotrophic bacteria and (ii) tunnelling, whereby phosphate luxury consumption rapidly shifts the stoichiometric composition of copepod prey. Copepods may thus be coupled to lower trophic levels through interactions not usually considered.	Univ Bergen, Dept Biol, Bergen, Norway; Univ Leeds, Sch Earth & Environm Sci, Leeds, W Yorkshire, England; Univ Leeds, Earth & Biosphere Inst, Leeds, W Yorkshire, England; Plymouth Marine Lab, Plymouth, Devon, England; IAEA, Marine Environm Lab, Monaco, Monaco; Israel Oceanog & Limnol Res, Natl Inst Oceanog, Haifa, Israel; Natl Inst Water & Atmospher Res, Wellington, New Zealand; Univ Tromso, Norwegian Coll Fishery Sci, Tromso, Norway; Hellen Ctr Marine Res, Iraklion, Crete, Greece; Stn Zool, Villefranche Sur Mer, France; Univ Cyprus, Oceanog Ctr, Nicosia, Cyprus; IOLR, Kinneret Limnol Lab, Tiberias, Israel	University of Bergen; University of Leeds; University of Leeds; Plymouth Marine Laboratory; Israel Oceanographic & Limnological Research Institute; National Institute of Water & Atmospheric Research (NIWA) - New Zealand; UiT The Arctic University of Tromso; Hellenic Centre for Marine Research; UDICE-French Research Universities; Sorbonne Universite; University of Cyprus	Thingstad, TF (corresponding author), Univ Bergen, Dept Biol, Bergen, Norway.	frede.thingstad@bio.uib.no	Tselepides, Anastasios/AAO-3965-2021; Tanaka, Tsuneo/G-3751-2011; Pasternak, Anna F/E-6121-2014; Krom, Michael D/I-5076-2012; Groom, Steve/A-1355-2012; Rassoulzadegan, Fereidoun/A-2650-2012; Woodward, Ernest M S/D-5755-2016; Thingstad, Tron Frede/B-2254-2008	Pasternak, Anna F/0000-0003-0317-5861; Krom, Michael D/0000-0003-3386-9215; Woodward, Ernest M S/0000-0002-7187-6689; Thingstad, Tron Frede/0000-0002-5593-819X; Pitta, Paraskevi/0000-0003-3557-0575; Tselepides, Anastasios/0000-0002-7880-9091; Law, Cliff/0000-0002-7669-2475; Herut, Barak/0000-0002-7093-8753				Ammerman J.W., 2003, EOS T AM GEOPHYS UN, V84, P165, DOI [10.1029/2003-o180001, DOI 10.1029/2003EO180001, 10.1029/2003EO180001]; Andersen T, 2004, ECOL LETT, V7, P884, DOI 10.1111/j.1461-0248.2004.00646.x; Bertilsson S, 2003, LIMNOL OCEANOGR, V48, P1721, DOI 10.4319/lo.2003.48.5.1721; Bethoux JP, 2002, DEEP-SEA RES PT II, V49, P2007, DOI 10.1016/S0967-0645(02)00024-3; BONIN DJ, 1989, AQUAT SCI, V51, P129, DOI 10.1007/BF00879299; Ducobu H, 1998, J PHYCOL, V34, P467, DOI 10.1046/j.1529-8817.1998.340467.x; Jeffrey SW, 1999, MAR ECOL PROG SER, V189, P35, DOI 10.3354/meps189035; Jickells T, 2002, GLOB CHANGE IGBP SER, P93; Karl DM, 2001, DEEP-SEA RES PT II, V48, P1529, DOI 10.1016/S0967-0645(00)00152-1; Kress N, 2001, DEEP-SEA RES PT I, V48, P2347, DOI 10.1016/S0967-0637(01)00022-X; KROM MD, 1991, LIMNOL OCEANOGR, V36, P424, DOI 10.4319/lo.1991.36.3.0424; Mills MM, 2004, NATURE, V429, P292, DOI 10.1038/nature02550; Moutin T, 2002, LIMNOL OCEANOGR, V47, P1562, DOI 10.4319/lo.2002.47.5.1562; Redfield A. C, 1963, SEA, P26, DOI DOI 10.1016/J.ORGGEOCHEM.2014.06.002; Sanudo-Wilhelmy SA, 2004, NATURE, V432, P897, DOI 10.1038/nature03125; Sanudo-Wilhelmy SA, 2001, NATURE, V411, P66, DOI 10.1038/35075041; Struck U, 2001, GEOCHIM COSMOCHIM AC, V65, P3249, DOI 10.1016/S0016-7037(01)00668-8; Sundareshwar PV, 2003, SCIENCE, V299, P563, DOI 10.1126/science.1079100; Thingstad TF, 2005, LIMNOL OCEANOGR-METH, V3, P94, DOI 10.4319/lom.2005.3.94; Thingstad TF, 1999, PROG OCEANOGR, V44, P271, DOI 10.1016/S0079-6611(99)00029-4; Vadstein O, 1998, AQUAT MICROB ECOL, V14, P119, DOI 10.3354/ame014119; Van Wambeke F, 2002, MICROB ECOL, V43, P119, DOI 10.1007/s00248-001-0038-4; Wu JF, 2000, SCIENCE, V289, P759, DOI 10.1126/science.289.5480.759; Zohary T, 1998, LIMNOL OCEANOGR, V43, P387, DOI 10.4319/lo.1998.43.3.0387	24	366	379	9	168	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 12	2005	309	5737					1068	1071		10.1126/science.1112632	http://dx.doi.org/10.1126/science.1112632			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955MN	16099984				2022-12-28	WOS:000231230100044
J	Demma, LJ; Traeger, MS; Nicholson, WL; Paddock, CD; Blau, DM; Eremeeva, ME; Dasch, GA; Levin, ML; Singleton, JJ; Zaki, SR; Cheek, JE; Swerdlow, DL; McQuiston, JH				Demma, LJ; Traeger, MS; Nicholson, WL; Paddock, CD; Blau, DM; Eremeeva, ME; Dasch, GA; Levin, ML; Singleton, JJ; Zaki, SR; Cheek, JE; Swerdlow, DL; McQuiston, JH			Rocky mountain spotted fever from an unexpected tick vector in Arizona	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BROWN DOG TICK; RHIPICEPHALUS-SANGUINEUS ACARI; RICKETTSIA-RICKETTSII; HUMAN PARASITISM; INFECTED TICKS; SUSCEPTIBILITY; PREVALENCE; ANTIBODIES; HUMANS; DNA	BACKGROUND: Rocky Mountain spotted fever is a life-threatening, tick-borne disease caused by Rickettsia rickettsii. This disease is rarely reported in Arizona, and the principal vectors, Dermacentor species ticks, are uncommon in the state. From 2002 through 2004, a focus of Rocky Mountain spotted fever was investigated in rural eastern Arizona. METHODS: We obtained blood and tissue specimens from patients with suspected Rocky Mountain spotted fever and ticks from patients' homesites. Serologic, molecular, immunohistochemical, and culture assays were performed to identify the causative agent. On the basis of specific laboratory criteria, patients were classified as having confirmed or probable Rocky Mountain spotted fever infection. RESULTS: A total of 16 patients with Rocky Mountain spotted fever infection (11 with confirmed and 5 with probable infection) were identified. Of these patients, 13 (81 percent) were children 12 years of age or younger, 15 (94 percent) were hospitalized, and 2 (12 percent) died. Dense populations of Rhipicephalus sanguineus ticks were found on dogs and in the yards of patients' homesites. All patients with confirmed Rocky Mountain spotted fever had contact with tick-infested dogs, and four had a reported history of tick bite preceding the illness. R. rickettsii DNA was detected in nonengorged R. sanguineus ticks collected at one home, and R. rickettsii isolates were cultured from these ticks. CONCLUSIONS: This investigation documents the presence of Rocky Mountain spotted fever in eastern Arizona, with common brown dog ticks (R. sanguineus) implicated as a vector of R. rickettsii. The broad distribution of this common tick raises concern about its potential to transmit R. rickettsii in other settings.	Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div Viral & Rickettsial Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA 30333 USA; Indian Hlth Serv, Whiteriver Serv Unit, Whiteriver, AZ USA; Indian Hlth Serv, Natl Epidemiol Program, Albuquerque, NM USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Demma, LJ (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div Viral & Rickettsial Dis, 1600 Clifton Rd,MS D63, Atlanta, GA 30333 USA.	ldemma@cdc.gov		Dasch, Gregory/0000-0001-6090-1810				Badger LF, 1933, PUBLIC HEALTH REP, V48, P791, DOI 10.2307/4580839; Bustamante M. E., 1947, REV INST SALUBRIDAD Y ENFERM TROP, V8, P139; Bustamante M. E., 1946, REV INST SALUBRIDAD Y ENFERM TROP, V7, P39; CARPENTER TL, 1990, J MED ENTOMOL, V27, P1065, DOI 10.1093/jmedent/27.6.1065; Cooley R. A, 1938, NATL I HLTH B, V171, P1; DALTON MJ, 1995, AM J TROP MED HYG, V52, P405, DOI 10.4269/ajtmh.1995.52.405; Dasch G. A., 1992, The Prokaryotes. A handbook on the biology of bacteria: ecophysiology, isolation, identification, applications. Volume III.., P2407; Elchos BN, 2003, J AM VET MED ASSOC, V223, P1450, DOI 10.2460/javma.2003.223.1450; ELLIOTT LB, 1990, ANN NY ACAD SCI, V590, P221, DOI 10.1111/j.1749-6632.1990.tb42223.x; Eremeeva ME, 2003, J CLIN MICROBIOL, V41, P5466, DOI 10.1128/JCM.41.12.5466-5472.2003; Eremeeva ME, 2003, ANN NY ACAD SCI, V990, P717, DOI 10.1111/j.1749-6632.2003.tb07449.x; EREMEEVA ME, 2001, MOL MED MICROBIOLOGY, P2175; Felz MW, 1996, J PARASITOL, V82, P505, DOI 10.2307/3284095; FOX MT, 1985, VET REC, V116, P661, DOI 10.1136/vr.116.25.661; GODDARD J, 1989, J MED ENTOMOL, V26, P628, DOI 10.1093/jmedent/26.6.628; GORDON JC, 1984, AM J TROP MED HYG, V33, P1026, DOI 10.4269/ajtmh.1984.33.1026; Harrison BA, 1997, J VECTOR ECOL, V22, P6; KEENAN KP, 1977, J INFECT DIS, V135, P911, DOI 10.1093/infdis/135.6.911; LORD CC, 2001, U FLORIDA PUBLICATIO; MAGNARELLI LA, 1982, AM J VET RES, V43, P656; Mannelli A, 2003, PREV VET MED, V60, P13, DOI 10.1016/S0167-5877(03)00079-5; NORMENT BR, 1984, AM J VET RES, V45, P1706; Paddock CD, 1999, J INFECT DIS, V179, P1469, DOI 10.1086/314776; Paddock CD, 2002, AM J TROP MED HYG, V66, P197, DOI 10.4269/ajtmh.2002.66.197; PARKER R. R., 1933, AMER JOUR TROP MED, V13, P341; PHILIP RN, 1976, J CLIN MICROBIOL, V3, P51; RAOULT D, 1993, AM J TROP MED HYG, V48, P249, DOI 10.4269/ajtmh.1993.48.249; Raoult D, 1997, CLIN MICROBIOL REV, V10, P694, DOI 10.1128/CMR.10.4.694; Roux V, 1996, J CLIN MICROBIOL, V34, P2058, DOI 10.1128/JCM.34.9.2058-2065.1996; Schriefer Martin E., 1994, P314; SEXTON DJ, 1976, AM J EPIDEMIOL, V103, P192, DOI 10.1093/oxfordjournals.aje.a112217; Treadwell TA, 2000, AM J TROP MED HYG, V63, P21, DOI 10.4269/ajtmh.2000.63.21; TZIANABOS T, 1989, J CLIN MICROBIOL, V27, P2866, DOI 10.1128/JCM.27.12.2866-2868.1989; Uspensky I, 2002, INT J MED MICROBIOL, V291, P156, DOI 10.1016/S1438-4221(02)80030-3	34	278	300	0	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 11	2005	353	6					587	594		10.1056/NEJMoa050043	http://dx.doi.org/10.1056/NEJMoa050043			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	953ST	16093467				2022-12-28	WOS:000231101500009
J	Sirocko, F; Seelos, K; Schaber, K; Rein, B; Dreher, F; Diehl, M; Lehne, R; Jager, K; Krbetschek, M; Degering, D				Sirocko, F; Seelos, K; Schaber, K; Rein, B; Dreher, F; Diehl, M; Lehne, R; Jager, K; Krbetschek, M; Degering, D			A late Eemian aridity pulse in central Europe during the last glacial inception	NATURE			English	Article							NORTH-ATLANTIC; CIRCULATION CHANGES; CLIMATE; TEMPERATURE; LONG; SEA	Investigating the processes that led to the end of the last interglacial period is relevant for understanding how our ongoing interglacial will end, which has been a matter of much debate ( see, for example, refs 1,2). A recent ice core from Greenland demonstrates climate cooling from 122,000 years ago(3) driven by orbitally controlled insolation, with glacial inception at 118,000 years ago(4-8). Here we present an annually resolved, layer-counted record of varve thickness, quartz grain size and pollen assemblages from a maar lake in the Eifel ( Germany), which documents a late Eemian aridity pulse lasting 468 years with dust storms, aridity, bushfire and a decline of thermophilous trees at the time of glacial inception. We interpret the decrease in both precipitation and temperature as an indication of a close link of this extreme climate event to a sudden southward shift of the position of the North Atlantic drift, the ocean current that brings warm surface waters to the northern European region. The late Eemian aridity pulse occurred at a 65 degrees N July insolation of 416 W m(-2), close to today's value of 428 W m(-2) ( ref. 9), and may therefore be relevant for the interpretation of present-day climate variability.	Johannes Gutenberg Univ Mainz, Inst Geosci, D-55099 Mainz, Germany; Saxon Acad Sci Leipzig, D-09596 Freiberg, Germany	Johannes Gutenberg University of Mainz	Sirocko, F (corresponding author), Johannes Gutenberg Univ Mainz, Inst Geosci, D-55099 Mainz, Germany.	sirocko@uni-mainz.de						Allen JRM, 1999, NATURE, V400, P740, DOI 10.1038/23432; Andersen KK, 2004, NATURE, V431, P147, DOI 10.1038/nature02805; BERGER A, 1991, QUATERNARY SCI REV, V10, P297, DOI 10.1016/0277-3791(91)90033-Q; Berger A, 2002, SCIENCE, V297, P1287, DOI 10.1126/science.1076120; Bjorck S, 2000, QUATERNARY SCI REV, V19, P509, DOI 10.1016/S0277-3791(99)00025-6; BOND GC, 1995, SCIENCE, V267, P1005, DOI 10.1126/science.267.5200.1005; Calov R, 2005, CLIM DYNAM, V24, P545, DOI 10.1007/s00382-005-0007-6; Chapman MR, 1999, GEOLOGY, V27, P795, DOI 10.1130/0091-7613(1999)027<0795:GIVFNA>2.3.CO;2; de Beaulieu J.L., 1992, VEG HIST ARCHAEOBOT, V1, P233, DOI DOI 10.1007/BF00189500; Erfurt G, 2003, NUCL INSTRUM METH B, V207, P487, DOI 10.1016/S0168-583X(03)01121-2; Holzkamper S, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL019112; Khodri M, 2001, NATURE, V410, P570, DOI 10.1038/35069044; Kuhl N, 2003, VEG HIST ARCHAEOBOT, V12, P205, DOI 10.1007/s00334-003-0019-2; Kukla G, 1997, QUATERNARY SCI REV, V16, P605, DOI 10.1016/S0277-3791(96)00114-X; KUKLA GJ, 1992, START GLACIAL; Lambeck K, 2001, SCIENCE, V292, P679, DOI 10.1126/science.1059549; Larsen CPS, 1998, QUATERNARY SCI REV, V17, P711, DOI 10.1016/S0277-3791(97)00043-7; Lehman SJ, 2002, QUATERNARY SCI REV, V21, P1917, DOI 10.1016/S0277-3791(02)00078-1; MCMANUS JF, 1994, NATURE, V371, P326, DOI 10.1038/371326a0; Menke B., 1984, GEOLOGISCHE JB SER, V76, P3; Muller H., 1974, GEOL JB, V21, P149; Muller UC, 2004, GEOLOGY, V32, P1009, DOI 10.1130/G20901.1; Sanchezgoni MF, 2002, CLIM DYNAM, V19, P95, DOI 10.1007/s00382-001-0212-x; Seelos K, 2005, SEDIMENTOLOGY, V52, P669, DOI 10.1111/j.1365-3091.2005.00715.x; THOUVENY N, 1994, NATURE, V371, P503, DOI 10.1038/371503a0; van Kreveld S, 2000, PALEOCEANOGRAPHY, V15, P425, DOI 10.1029/1999PA000464; VANDENBOGAARD P, 1989, NATURE, V342, P523, DOI 10.1038/342523a0; Voelker AHL, 2002, QUATERNARY SCI REV, V21, P1185, DOI 10.1016/S0277-3791(01)00139-1; WOILLARD G, 1979, NATURE, V281, P558, DOI 10.1038/281558a0	29	123	124	2	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 11	2005	436	7052					833	836		10.1038/nature03905	http://dx.doi.org/10.1038/nature03905			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953XG	16094365				2022-12-28	WOS:000231116500042
J	Hendy, J; Reeves, BC; Fulop, N; Hutchings, A; Masseria, C				Hendy, J; Reeves, BC; Fulop, N; Hutchings, A; Masseria, C			Challenges to implementing the national programme for information technology (NPfIT): a qualitative study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE; SYSTEMS	Objectives To describe the context for implementing the national programme for information technology (NPfIT) in England, actual and perceived barriers, and opportunities to facilitate implementation. Design Case studies and in depth interviews, with themes identified using a framework developed from grounded theory. Setting Four acute NHS trusts in England. Participants Senior trust managers and clinicians, including chief executives, directors of information technology, medical directors, and directors of nursing. Results The trusts varied in their circumstances, which may affect their ability to implement the NPfIT The process of implementation has been suboptimal, leading to reports of low morale by the NHS staff responsible for implementation. The overall timetable is unrealistic, and trusts are uncertain about their implementation schedules. Short term benefits alone are unlikely to persuade NHS staff to adopt the national programme enthusiastically, and some may experience a loss of electronic functionality in the short term. Conclusions: The sociocultural challenges to implementing the NPfIT are as daunting as the technical and logistical ones. Senior NHS staff feel these have been neglected. We recommend that national programme managers prioritise strategies to improve communication with, and to gain the cooperation of, front line staff.	Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Hendy, J (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1E 7HT, England.	jane.hendy@lshtm.ac.uk		Fulop, Naomi/0000-0001-5306-6140; Hutchings, Andrew/0000-0003-0215-9923				Ash JS, 2001, J AM MED INFORM ASSN, P22; Ash JS, 2003, J AM MED INFORM ASSN, V10, P229, DOI 10.1197/jamia.M1204; Berg M, 2001, INT J MED INFORM, V64, P143, DOI 10.1016/S1386-5056(01)00200-3; *COMM HLTH IMPR, PERF RAT OV SUMM RES; *COMPTR AUD GEN, 2004, NHS ENGL SUMM ACC 20; Cross M, 2005, BRIT MED J, V330, P276, DOI 10.1136/bmj.330.7486.276; DARBYSHIRE P, 2001, NURSE RES, V8, P4; *DEP HLTH, 2002, DEL 21ST CENT IT SUP; *DEP HLTH, 2002, IMPR EXP REF NEX 3 Y; Department of Health, 2002, IMPR EXP REF NEXT 3; DYKE P, 2003, PUBLIC FINANCE   SEP, P24; Dykstra R, 2002, AMIA 2002 SYMPOSIUM, PROCEEDINGS, P230; FULOP N, 2002, BMJ-BRIT MED J, P325; Fulop N., 2002, BMJ-BRIT MED J, V325, P1, DOI [10.1136/bmj.325.7358.246, DOI 10.1136/BMJ.325.7358.246]; Glaser B.G., 1965, AWARENESS DYING; GOSLING P, 2004, PUBLIC FINANCE   JUL, P22; Harper RHR, 1997, BRIT J ANAESTH, V78, P762, DOI 10.1093/bja/78.6.762; Heathfield H, 1998, BRIT MED J, V316, P1959, DOI 10.1136/bmj.316.7149.1959; HERBERT M, 1998, MEDINFO, V9, P849; Herbst K, 1999, J PUBLIC HEALTH MED, V21, P305, DOI 10.1093/pubmed/21.3.305; HOEKSMA J, 2002, HLTH SERVICES J, V579, P74; HOEKSMA J, 2002, HLTH SERVICES J, V5797, P4; JONES AJ, 2003, USE ELECT PATIENT RE, P1; McNulty T, 2002, REENGINEERING HLTH C; MILES MB, 1979, ADMIN SCI QUART, V24, P590, DOI 10.2307/2392365; Moorman PW, 1999, METHOD INFORM MED, V38, P294; *NAT AUD OFF, 2005, DEP HLTH PAT CHOIC P; *NAT PROGR INF TEC, 2005, NHS CAR REC SERV IND; *NHS CONF, 2003, NAT PROGR IT INT R G; NHS Executive, 1998, INF HLTH INF STRAT M; *NHS NAT PROGR INF, 2004, MAK IT HAPP INF NAT; *PARL OFF SCI TECH, 2004, 214 PARL OFF SCI TEC; Pettigrew A. M., 1987, MANAGEMENT STRATEGIC; Southon G, 1999, INT J MED INFORM, V55, P33, DOI 10.1016/S1386-5056(99)00018-0; Timmons S, 2003, METHOD INFORM MED, V42, P471; TIMMONS S, 2000, METHOD INFORM MED, V42, P471; *UK NAT AUD OFF PU, WORK PROGR DEP HLTH; Wanless, 2002, SECURING OUR FUTURE; Wyatt J.F., 1998, RETHINKING IT HLTH, P100; 2003, E HLTH INSIDER	40	101	101	1	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 6	2005	331	7512					331	334B		10.1136/bmj.331.7512.331	http://dx.doi.org/10.1136/bmj.331.7512.331			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955WZ	16081447	Green Submitted, Green Accepted, Bronze, Green Published			2022-12-28	WOS:000231259800022
J	Kaduszkiewicz, H; Zimmermann, T; Beck-Bornholdt, HP; van den Bussche, H				Kaduszkiewicz, H; Zimmermann, T; Beck-Bornholdt, HP; van den Bussche, H			Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; NEUROPSYCHIATRIC INVENTORY; GLOBAL FUNCTION; DONEPEZIL; EFFICACY; RIVASTIGMINE; GALANTAMINE; SAFETY; AD	Objectives Pharmacological treatment of Alzheimer's disease focuses on correcting the cholinergic deficiency in the central nervous system with cholinesterase inhibitors. Three cholinesterase inhibitors are currently recommended: donepezil, rivastigmine, and galantamine. This review assessed the scientific evidence for the recommendation of these agents. Data sources The terms "donepezil", "rivastigmine", and "galantamine", limited by "randomized-controlled-trials" were searched in Medline (1989-November 2004), Embase (1989-November 2004), and the Cochrane Database of Systematic Reviews without restriction for language. Study selection All published, double blind, randomised controlled trials examining efficacy on the basis of clinical outcomes, in which treatment with donepezil, rivastigmine, or galantamine was compared with placebo in patients with Alzheimer's disease, were included. Each study was assessed independently, following a predefined checklist of criteria of methodological quality. Results 22 trials met the inclusion criteria. Follow-up ranged from six weeks to three years. 12 of 14 studies measuring the cognitive outcome by means of the 70 point Alzheimer's disease assessment scale-cognitive subscale showed differences ranging from 1.5 points to 3.9 points in favour of the respective cholinesterase inhibitors. Benefits were also reported from all 12 trials that used the clinician's interview based impression of change scale with input from caregivers. Methodological assessment of all studies found considerable flaws-for example, multiple testing without correction for multiplicity or exclusion of patients after randomisation. Conclusion Because of flawed methods and small clinical benefits, the scientific basis for recommendations of cholinesterase inhibitors for the treatment of Alzheimer's disease is questionable.	Univ Med Ctr Hamburg Eppendorf, Ctr Psychosocial Med, Dept Primary Med Care, D-20246 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Kaduszkiewicz, H (corresponding author), Univ Med Ctr Hamburg Eppendorf, Ctr Psychosocial Med, Dept Primary Med Care, Martinistr 52, D-20246 Hamburg, Germany.	kaduszki@uke.uni-hamburg.de						Agid Y, 1998, CURR THER RES CLIN E, V59, P837, DOI 10.1016/S0011-393X(98)85048-0; Bentham P, 2004, LANCET, V363, P2105; Birks J, 2006, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001190.pub2, 10.1002/14651858.CD001190.pub3]; Birks JS, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001191.pub3; Brane G, 2001, DEMENT GERIATR COGN, V12, P1, DOI 10.1159/000051230; Burns A, 1999, DEMENT GERIATR COGN, V10, P237, DOI 10.1159/000017126; COREYBLOOM J, 1998, INT J GERIATR PSYCHO, V1, P55; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; DEJONG R, 1989, CLIN THER, V11, P545; Doody RS, 2001, NEUROLOGY, V56, P1154, DOI 10.1212/WNL.56.9.1154; *FDA, 1989, PER CENTR NERV SYST, P227; Feldman H, 2001, NEUROLOGY, V57, P613, DOI 10.1212/WNL.57.4.613; FLORACK C, 2002, OFFIZIELLES MITTEILU, P1; Forette F, 1999, EUR J NEUROL, V6, P423, DOI 10.1046/j.1468-1331.1999.640423.x; FRITZE J, 2005, PSYCHONEUROENDOCRINO, V31, P46; Greenberg SM, 2000, ARCH NEUROL-CHICAGO, V57, P94, DOI 10.1001/archneur.57.1.94; GUY W, 1976, ECDEU ASSESSMENT MAN, P207; Holmes C, 2004, NEUROLOGY, V63, P214, DOI 10.1212/01.WNL.0000129990.32253.7B; Homma A, 2000, DEMENT GERIATR COGN, V11, P299, DOI 10.1159/000017259; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Moher D, 2001, ANN INTERN MED, V134, P657, DOI 10.7326/0003-4819-134-8-200104170-00011; Mohs RC, 2001, NEUROLOGY, V57, P481, DOI 10.1212/WNL.57.3.481; *NICE, 2001, GUID US DON RIV GAL; Olin J.T., 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001747; Potkin SG, 2001, INT J NEUROPSYCHOPH, V4, P223, DOI 10.1017/S1461145701002528; Raskind MA, 2000, NEUROLOGY, V54, P2261, DOI 10.1212/WNL.54.12.2261; REISBERG B, 1994, CIBIC PLUS INTERVIEW; Ritchie CW, 2004, AM J GERIAT PSYCHIAT, V12, P358, DOI 10.1176/appi.ajgp.12.4.358; Rockwood K, 2001, J NEUROL NEUROSUR PS, V71, P589, DOI 10.1136/jnnp.71.5.589; Rogers SL, 1998, NEUROLOGY, V50, P136, DOI 10.1212/WNL.50.1.136; Rogers SL, 1998, ARCH INTERN MED, V158, P1021, DOI 10.1001/archinte.158.9.1021; Rogers SL, 1996, DEMENTIA, V7, P293, DOI 10.1159/000106895; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; Rosler M, 1999, BMJ-BRIT MED J, V318, P633, DOI 10.1136/bmj.318.7184.633; Tariot PN, 2000, NEUROLOGY, V54, P2269, DOI 10.1212/WNL.54.12.2269; Tariot PN, 2001, J AM GERIATR SOC, V49, P1590, DOI 10.1046/j.1532-5415.2001.t01-1-49266.x; Whitehead A, 2004, INT J GERIATR PSYCH, V19, P624, DOI 10.1002/gps.1133; Wilcock GK, 2000, BRIT MED J, V321, P1; Wilkinson D, 2001, INT J GERIATR PSYCH, V16, P852, DOI 10.1002/gps.409; Winblad B, 2001, NEUROLOGY, V57, P489, DOI 10.1212/WNL.57.3.489; Wood S, 2000, AM J GERIAT PSYCHIAT, V8, P75, DOI 10.1097/00019442-200002000-00010; Woodford N, 2001, Lancet Infect Dis, V1, P9, DOI 10.1016/S1473-3099(01)00015-9	42	361	382	0	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 6	2005	331	7512					321	323		10.1136/bmj.331.7512.321	http://dx.doi.org/10.1136/bmj.331.7512.321			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955WZ	16081444	Green Published, Bronze			2022-12-28	WOS:000231259800015
J	Kohn, D; Murrell, G; Parker, J; Whitehorn, M				Kohn, D; Murrell, G; Parker, J; Whitehorn, M			What Henslow taught Darwin	NATURE			English	Article									Drew Univ, Dept Hist, Madison, NJ 07940 USA; Univ Cambridge, Dept Plant Sci, Herbarium, Cambridge CB2 3EA, England; Univ Cambridge, Bot Gardens, Cambridge CB2 1JF, England; Univ Oxford Worcester Coll, Informat & Learning Serv, Worcester WR2 6AJ, England	Drew University; University of Cambridge; University of Cambridge; University of Oxford	Kohn, D (corresponding author), Drew Univ, Dept Hist, Madison, NJ 07940 USA.							Barlow N, 1963, B BRIT MUS NAT HIST, V2, P203; BURKHARDT FB, 1993, CORRES C DARWIN, V8, P191; Darwin C, 1877, EFFECTS CROSS SELF F; Darwin CH., 1962, J P LINNEAN SOC BOT, V6, P77; DARWIN CR, BEAGLE, pA13; DARWIN CR, EXPT BOOK, P53; DARWIN CR, 1845, J RES, P393; de Candolle A.P., 1832, PHYSL VEGETALE; Hauy R.J., 1801, TRAITE MINERALOGIE; Henslow J. S, 1830, MAGAZINE NATURAL HIS, V3, P406; HENSLOW JS, 1826, COMMUNICATION   0925; HENSLOW JS, 1835, PRINCIPLES DESCRIPTI, P305; HENSLOW JS, 1833, SKETCH COURSE LECT B, P7; HENSLOW JS, 1836, MAG ZOOL BOT, V1, P116; Hooker JD, 1851, T LINN SOC LOND, V20, P235; HOOKER JD, 1851, T LINNEAN SOC, V20, P163; KEYNES RD, 2000, C DARWINS ZOOLOGY NO, P298; LYELL C, 1832, PRINCIPLES GEOLOGY, V2; SMITH JE, 1790, ENGLISH BOT, V1, P4; SMITH JE, 1799, ENGLISH BOT, V8, P513; SULLOWAY F J, 1982, Journal of the History of Biology, V15, P1, DOI 10.1007/BF00132004; Sulloway F.J., 1982, Journal of the History of Biology, V15, P325, DOI 10.1007/BF00133143	22	25	29	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 4	2005	436	7051					643	645		10.1038/436643a	http://dx.doi.org/10.1038/436643a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	951XA	16079834				2022-12-28	WOS:000230964500031
J	Kravchenko, JE; Rogozin, IB; Koonin, EV; Chumakov, PM				Kravchenko, JE; Rogozin, IB; Koonin, EV; Chumakov, PM			Transcription of mammalian messenger RNAs by a nuclear RNA polymerase of mitochondrial origin	NATURE			English	Article							DNA; CELLS; MTDNA; TOOL; SEQUENCES; ALIGNMENT; PATTERNS; B1	Transcription of eukaryotic genes is performed by three nuclear RNA polymerases, of which RNA polymerase II is thought to be solely responsible for the synthesis of messenger RNAs1. Here we show that transcription of some mRNAs in humans and rodents is mediated by a previously unknown single-polypeptide nuclear RNA polymerase (spRNAP-IV). spRNAP-IV is expressed from an alternative transcript of the mitochondrial RNA polymerase gene (POLRMT). The spRNAP-IV lacks 262 amino-terminal amino acids of mitochondrial RNA polymerase, including the mitochondrial-targeting signal, and localizes to the nucleus. Transcription by spRNAP-IV is resistant to the RNA polymease II inhibitor alpha-amanitin but is sensitive to short interfering RNA specific for the POLRMT gene. The promoters for spRNAP-IV differ substantially from those used by RNA polymerase II, do not respond to transcriptional enhancers and contain a common functional sequence motif.	Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; VA Engelhardt Mol Biol Inst, Moscow 119991, Russia; Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA	Cleveland Clinic Foundation; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Chumakov, PM (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	chumakp@ccf.org		Rogozin, Igor/0000-0003-0802-4851; Chumakov, Peter/0000-0002-8078-2908	NCI NIH HHS [R01 CA104903] Funding Source: Medline; NIA NIH HHS [R01 AG025278, R01 AG025278-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104903] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG025278] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569; Falkenberg M, 2002, NAT GENET, V31, P289, DOI 10.1038/ng909; Gabaldon T, 2003, SCIENCE, V301, P609, DOI 10.1126/science.1085463; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gray MW, 1998, TRENDS MICROBIOL, V6, P1, DOI 10.1016/S0966-842X(97)01182-7; Grundy WN, 1996, COMPUT APPL BIOSCI, V12, P303; HARLOW E, 1999, USING ANTIBODIES LAB, P276; Herr AJ, 2005, SCIENCE, V308, P118, DOI 10.1126/science.1106910; Hertz GZ, 1999, BIOINFORMATICS, V15, P563, DOI 10.1093/bioinformatics/15.7.563; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Keich U, 2002, BIOINFORMATICS, V18, P1382, DOI 10.1093/bioinformatics/18.10.1382; Kel AE, 2003, NUCLEIC ACIDS RES, V31, P3576, DOI 10.1093/nar/gkg585; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; KING MP, 1988, CELL, V52, P811, DOI 10.1016/0092-8674(88)90423-0; Kurland CG, 2000, MICROBIOL MOL BIOL R, V64, P786, DOI 10.1128/MMBR.64.4.786-820.2000; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; LEWIN B, 2004, GENES, V8, P597; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; McCulloch V, 2003, MOL CELL BIOL, V23, P5816, DOI 10.1128/MCB.23.16.5816-5824.2003; Onodera Y, 2005, CELL, V120, P613, DOI 10.1016/j.cell.2005.02.007; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Pfeifer A, 2002, P NATL ACAD SCI USA, V99, P2140, DOI 10.1073/pnas.251682798; Rantanen A, 2001, MAMM GENOME, V12, P787, DOI 10.1007/s00335-001-2052-8; SCHULER GD, 1990, PROTEIN-STRUCT FUNCT, V9, P180; Seidel-Rogol BL, 2002, NUCLEIC ACIDS RES, V30, P1929, DOI 10.1093/nar/30.9.1929; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; TARONI F, 1991, J BIOL CHEM, V266, P13267; Tiranti V, 1997, HUM MOL GENET, V6, P615, DOI 10.1093/hmg/6.4.615	30	44	48	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 4	2005	436	7051					735	739		10.1038/nature03848	http://dx.doi.org/10.1038/nature03848			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	951XA	16079853	Green Accepted			2022-12-28	WOS:000230964500051
J	Sheffield, JVL; Larson, EB				Sheffield, JVL; Larson, EB			Update in general internal medicine	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CONJUGATED EQUINE ESTROGENS; HEALTH INITIATIVE MEMORY; POSTMENOPAUSAL WOMEN; RISK		Ctr Htlh Studies, Grp Htlh Cooperat, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA		Larson, EB (corresponding author), Ctr Htlh Studies, Grp Htlh Cooperat, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.							Dansinger ML, 2005, JAMA-J AM MED ASSOC, V293, P43, DOI 10.1001/jama.293.1.43; Espeland MA, 2004, JAMA-J AM MED ASSOC, V291, P2959, DOI 10.1001/jama.291.24.2959; Furberg CD, 2005, CIRCULATION, V111, P249, DOI 10.1161/01.CIR.0000155081.76164.17; Graham DJ, 2005, LANCET, V365, P475, DOI 10.1016/S0140-6736(05)17864-7; Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947	6	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 2	2005	143	3					212	221		10.7326/0003-4819-143-3-200508020-00007	http://dx.doi.org/10.7326/0003-4819-143-3-200508020-00007			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	951TM	16061919				2022-12-28	WOS:000230953900006
J	Oransky, I				Oransky, I			David Tyrrell - Obituary	LANCET			English	Biographical-Item												ivan-oransky@erols.com						TYRRELL D, PUBLICATION LIST	1	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 18	2005	365	9477					2084	2084		10.1016/S0140-6736(05)66722-0	http://dx.doi.org/10.1016/S0140-6736(05)66722-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	936LZ	16121448				2022-12-28	WOS:000229858800014
J	Kussell, E; Leibler, S				Kussell, E; Leibler, S			Phenotypic diversity, population growth, and information in fluctuating environments	SCIENCE			English	Article							BACTERIAL PERSISTENCE; CANDIDA-ALBICANS; PHASE VARIATION; STRATEGIES; MECHANISM; SURVIVAL; LOCI; GENE	Organisms in fluctuating environments must constantly adapt their behavior to survive. In clonal populations; this may be achieved through sensing followed by response or through the generation of diversity by stochastic phenotype switching. Here we show that stochastic switching can be favored over sensing when the environment changes infrequently. The optimal switching rates then mimic the statistics of environmental changes. We derive a relation between the long-term growth rate of the organism,and the information available about its fluctuating environment.	Rockefeller Univ, Lab Living Matter, New York, NY 10021 USA; Rockefeller Univ, Ctr Studies Phys & Biol, New York, NY 10021 USA	Rockefeller University; Rockefeller University	Kussell, E (corresponding author), Rockefeller Univ, Lab Living Matter, 1230 York Ave,Box 34, New York, NY 10021 USA.	kussele@rockefeller.edu	chen, qi/C-8585-2011					Balaban NQ, 2004, SCIENCE, V305, P1622, DOI 10.1126/science.1099390; Bayliss CD, 2001, J CLIN INVEST, V107, P657, DOI 10.1172/JCI12557; Bonifield HR, 2003, J BACTERIOL, V185, P3567, DOI 10.1128/JB.185.12.3567-3574.2003; Bourret RB, 2002, J BIOL CHEM, V277, P9625, DOI 10.1074/jbc.R100066200; Cohen J.E., 1979, STOCH PROC APPL, V9, P245, DOI [10.1016/0304-4149(79)90046-2, DOI 10.1016/0304-4149(79)90046-2]; Cover TM., 2006, ELEMENTS INFORM THEO, DOI [10.1002/047174882X, DOI 10.1002/047174882X]; CRISTANTI A, 1993, PRODUCTS RANDOM MATR; DEMETRIUS L, 1983, J STAT PHYS, V30, P709, DOI 10.1007/BF01009685; Grafen A, 1999, P ROY SOC B-BIOL SCI, V266, P799, DOI 10.1098/rspb.1999.0708; HACCOU P, 1995, THEOR POPUL BIOL, V47, P212, DOI 10.1006/tpbi.1995.1009; Kearns DB, 2004, MOL MICROBIOL, V52, P357, DOI 10.1111/j.1365-2958.2004.03996.x; Kussell E, 2005, GENETICS, V169, P1807, DOI 10.1534/genetics.104.035352; Lachke SA, 2002, MICROBIOL-SGM, V148, P2661, DOI 10.1099/00221287-148-9-2661; Lachmann M, 1996, J THEOR BIOL, V181, P1, DOI 10.1006/jtbi.1996.0109; LEWONTIN RC, 1969, P NATL ACAD SCI USA, V62, P1056, DOI 10.1073/pnas.62.4.1056; Michel P, 2004, CR MATH, V338, P697, DOI 10.1016/j.crma.2004.03.006; MOXON ER, 1994, CURR BIOL, V4, P24, DOI 10.1016/S0960-9822(00)00005-1; Perez-Martin J, 1999, EMBO J, V18, P2580, DOI 10.1093/emboj/18.9.2580; Robson AJ, 1999, J THEOR BIOL, V197, P541, DOI 10.1006/jtbi.1998.0894; SASAKI A, 1995, EVOLUTION, V49, P337, DOI 10.1111/j.1558-5646.1995.tb02246.x; Seger J., 1987, Oxford Surveys in Evolutionary Biology, V4, P182; SOLL DR, 1988, DEV GENET, V9, P615, DOI 10.1002/dvg.1020090438; Thattai M, 2004, GENETICS, V167, P523, DOI 10.1534/genetics.167.1.523; van der Woude MW, 2004, CLIN MICROBIOL REV, V17, P581, DOI 10.1128/CMR.17.3.581-611.2004; Vilar JMG, 2003, J CELL BIOL, V161, P471, DOI 10.1083/jcb.200301125; Wolf DM, 2005, J THEOR BIOL, V234, P227, DOI 10.1016/j.jtbi.2004.11.020	26	894	914	2	126	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 23	2005	309	5743					2075	2078		10.1126/science.1114383	http://dx.doi.org/10.1126/science.1114383			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968SF	16123265				2022-12-28	WOS:000232181900057
J	Getz, L; Sigurdsson, JA; Hetlevik, I; Kirkengen, AL; Romundstad, S; Holmen, J				Getz, L; Sigurdsson, JA; Hetlevik, I; Kirkengen, AL; Romundstad, S; Holmen, J			Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: modelling study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							JOINT TASK-FORCE; CLINICAL-PRACTICE; CORONARY RISK; PRIMARY PREVENTION; PUBLIC-HEALTH; SOCIETIES; BARRIERS; MATTER; TRIAL; HEART	Objective To estimate the high risk group for cardiovascular disease in a well defined Norwegian population according to European guidelines and the systematic coronary risk evaluation system. Design Modelling study. Setting Nord-Trondelag health study 1995-7 (HUNT 2), Nor-way. Participants 5548 participants of the Nord-Trondelag health study 1995-7, aged 40, 50, 55, 60, and 65. Main outcome measures Distribution of risk categories for cardiovascular disease, with emphasis on the high risk group. Main results At age 40,22.5% (95% confidence interval 19.3% to 25.7%) of women and 85.9% (83.2% to 88.6%) of men were at high risk of cardiovascular disease. Corresponding numbers at age 50 were 39.5% (35.9% to 43.1%) and 88.7% (86.3% to 91.0%) and at age 65 were 84.0% (80.6% to 87.4%) and 91.6% (88.6% to 94.1%). At age 40, one out of 10 women and no men would be classified at low risk for cardiovascular disease. Conclusion Implementation of the 2003 European guidelines on prevention of cardiovascular disease in clinical practice would classify most adult Norwegians at high risk for fatal cardiovascular disease.	Landspitali Univ Hosp, Off Human Resources, IS-101 Reykjavik, Iceland; Norwegian Univ Sci & Technol, Dept Publ Hlth & Gen Pratice, N-7489 Trondheim, Norway; Univ Iceland, Dept Family Med, IS-107 Reykjavik, Iceland; Norwegian Univ Sci & Technol, HUNT Res Ctr, Fac Med, Dept Publ Hlth & Gen Practice, N-7650 Verdal, Norway	Landspitali National University Hospital; Norwegian University of Science & Technology (NTNU); University of Iceland; Norwegian University of Science & Technology (NTNU)	Getz, L (corresponding author), Landspitali Univ Hosp, Off Human Resources, IS-101 Reykjavik, Iceland.	linngetz@med.is		Sigurdsson, Johann Agust/0000-0002-5646-6411				Brindle P, 2003, BMJ-BRIT MED J, V327, P1267, DOI 10.1136/bmj.327.7426.1267; Callahan D, 2002, AM J PUBLIC HEALTH, V92, P169, DOI 10.2105/AJPH.92.2.169; Conroy RM, 2003, EUR HEART J, V24, P987, DOI 10.1016/S0195-668X(03)00114-3; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; De Backer G, 2003, EUR J CARDIOV PREV R, V10, pS1, DOI 10.1097/01.hjr.0000087913.96265.e2; De Backer G, 2003, EUR HEART J, V24, P1601, DOI 10.1016/S0195-668X(03)00347-6; Getz L, 2005, SCAND J PRIM HEALTH, V23, P65, DOI 10.1080/02813430510018518; Getz L, 2004, SCAND J PRIM HEALTH, V22, P202, DOI 10.1080/02813430410006693; Getz L, 2003, SCAND J PRIM HEALTH, V21, P3, DOI 10.1080/02813430310000483; Hetlevik I., 1999, THESIS NORWEGIAN U S; Holmen JM K., 2003, NORSK EPIDEMIOLOGI, V13, P19, DOI [10.5324/nje.v13i1.305, DOI 10.1093/eurheartj/eht019]; Marshall T, 2002, BMJ-BRIT MED J, V325, P197, DOI 10.1136/bmj.325.7357.197; Marteau TM, 2002, BRIT MED J, V325, P78, DOI 10.1136/bmj.325.7355.78; Midthjell K, 1999, DIABETES CARE, V22, P1813, DOI 10.2337/diacare.22.11.1813; OTTERSTAD JE, NEW EUROPEAN GUIDELI; PEDERSEN TR, 1994, LANCET, V344, P1383; Phillips LS, 2001, ANN INTERN MED, V135, P825, DOI 10.7326/0003-4819-135-9-200111060-00012; Reynolds TM, 2004, CURR MED RES OPIN, V20, P811, DOI 10.1185/030079904125003647; Shekelle PG, 1999, BRIT MED J, V318, P593, DOI 10.1136/bmj.318.7183.593; Tunstall-Pedoe H., 2003, MONICA MONOGRAPH MUL; van Steenkiste B, 2004, PATIENT EDUC COUNS, V55, P301, DOI 10.1016/j.pec.2003.11.005; van Steenkiste B, 2004, SCAND J PRIM HEALTH, V22, P32, DOI 10.1080/02813430310004489; *WHO, EUR HLTH ALL; *WHO, COR HLTH IND NORW; World Health Organization, COR HLTH IND; World Health Organization, EUR HLTH ALL DAT; Yarnall KSH, 2003, AM J PUBLIC HEALTH, V93, P635, DOI 10.2105/AJPH.93.4.635	27	67	68	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 10	2005	331	7516					551	554A		10.1136/bmj.38555.648623.8F	http://dx.doi.org/10.1136/bmj.38555.648623.8F			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	965GX	16103030	Green Published, Bronze			2022-12-28	WOS:000231939700018
J	Shang, AJ; Huwiler-Muntener, K; Nartey, L; Juni, P; Dorig, S; Sterne, JA; Pewsner, D; Egger, M				Shang, AJ; Huwiler-Muntener, K; Nartey, L; Juni, P; Dorig, S; Sterne, JA; Pewsner, D; Egger, M			Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy	LANCET			English	Article							RANDOMIZED-TRIALS; METHODOLOGICAL QUALITY; SYSTEMATIC REVIEWS; HEALTH-CARE; METAANALYSIS; BIAS; HETEROGENEITY; COMPLEMENTARY; PUBLICATION; MEDICINE	Background Homoeopathy is widely used, but specific effects of homoeopathic remedies seem implausible. Bias in the conduct and reporting of trials is a possible explanation for positive findings of trials of both homoeopathy and conventional medicine. We analysed trials of homoeopathy and conventional medicine and estimated treatment effects in trials least likely to be affected by bias. Methods Placebo-controlled trials of homoeopathy were identified by a comprehensive literature search, which covered 19 electronic databases, reference lists of relevant papers, and contacts with experts. Trials in conventional medicine matched to homoeopathy trials for disorder and type of outcome were randomly selected from the Cochrane Controlled Trials Register (issue 1, 2003). Data were extracted in duplicate and outcomes coded so that odds ratios below 1 indicated benefit. Trials described as double-blind, with adequate randomisation, were assumed to be of higher methodological quality. Bias effects were examined in funnel plots and meta-regression models. Findings 110 homoeopathy trials and 110 matched conventional-medicine trials were analysed. The median study size was 65 participants (range ten to 1573). 21 homoeopathy trials (19%) and nine (8%) conventional-medicine trials were of higher quality. In both groups, smaller trials and those of lower quality showed more beneficial treatment effects than larger and higher-quality trials. When the analysis was restricted to large trials of higher quality, the odds ratio was 0.88 (95% CI 0.65-1.19) for homoeopathy (eight trials) and 0.58 (0.39-0.85) for conventional medicine (six trials). Interpretation Biases are present in placebo-controlled trials of both homoeopathy and conventional medicine. When account was taken for these biases in the analysis, there was weak evidence for a specific effect of homoeopathic remedies, but strong evidence for specific effects of conventional interventions. This finding is compatible with the notion that the clinical effects of homoeopathy are placebo effects.	Univ Bern, Dept Social & Prevent Med, Bern, Switzerland; Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Bristol, Avon, England; Univ Zurich, Dept Pharmacol, Zurich, Switzerland; MediX Gen Practice Network, Practice Bruckfeld, Bern, Switzerland	University of Bern; University of Bristol; University of Zurich	Egger, M (corresponding author), Univ Bern, Dept Social & Prevent Med, Bern, Switzerland.	egger@ispm.unibe.ch	Sterne, Jonathan/Z-3106-2019; Juni, Peter/Q-8700-2016	Sterne, Jonathan/0000-0001-8496-6053; Juni, Peter/0000-0002-5985-0670; Egger, Matthias/0000-0001-7462-5132				ALTMAN DG, 1995, BRIT MED J, V311, P485, DOI 10.1136/bmj.311.7003.485; Di Blasi Z, 2001, LANCET, V357, P757, DOI 10.1016/S0140-6736(00)04169-6; Dickersin K, 2002, EVAL HEALTH PROF, V25, P38, DOI 10.1177/0163278702025001004; Egger M, 1998, BMJ-BRIT MED J, V316, P61, DOI 10.1136/bmj.316.7124.61; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ernst E, 2000, BMJ-BRIT MED J, V321, P1133, DOI 10.1136/bmj.321.7269.1133; GOTZSCHE PC, 1993, LANCET, V341, P1533; HASSELBLAD V, 1995, PSYCHOL BULL, V117, P167, DOI 10.1037/0033-2909.117.1.167; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V285, P437, DOI 10.1001/jama.285.4.437; Jonas W., 1996, HEALING HOMEOPATHY; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Kaptchuk TJ, 1998, ANN INTERN MED, V129, P1061, DOI 10.7326/0003-4819-129-12-199812150-00011; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; KLEIJNEN J, 1994, LANCET, V344, P1347, DOI 10.1016/S0140-6736(94)90699-8; Linde K, 2001, INT J EPIDEMIOL, V30, P526, DOI 10.1093/ije/30.3.526; Linde K, 1999, J CLIN EPIDEMIOL, V52, P631, DOI 10.1016/S0895-4356(99)00048-7; Linde K, 1997, LANCET, V350, P834, DOI 10.1016/S0140-6736(97)02293-9; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Morrison B, 2000, PERFUSION, V13, P132; Rennie D, 1999, JAMA-J AM MED ASSOC, V282, P1766, DOI 10.1001/jama.282.18.1766; Schulte J, 1999, Br Homeopath J, V88, P155, DOI 10.1054/homp.1999.0317; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Schulz KF, 1996, LANCET, V348, P596, DOI 10.1016/S0140-6736(96)01201-9; SKRABANEK P, 1986, LANCET, V2, P1107; Sterne JAC, 2000, J CLIN EPIDEMIOL, V53, P1119, DOI 10.1016/S0895-4356(00)00242-0; Sterne JAC, 2001, BMJ-BRIT MED J, V323, P101, DOI 10.1136/bmj.323.7304.101; Sterne JAC, 2001, J CLIN EPIDEMIOL, V54, P1046, DOI 10.1016/S0895-4356(01)00377-8; Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V; Vandenbroucke JP, 1997, LANCET, V350, P824, DOI 10.1016/S0140-6736(97)22038-6; Vickers A, 1999, BRIT MED J, V319, P1115, DOI 10.1136/bmj.319.7217.1115	31	485	523	5	150	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 27	2005	366	9487					726	732		10.1016/S0140-6736(05)67177-2	http://dx.doi.org/10.1016/S0140-6736(05)67177-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958UV	16125589				2022-12-28	WOS:000231474600028
J	Kamer, I; Sarig, R; Zaltsman, Y; Niv, H; Oberkovitz, G; Regev, L; Haimovich, G; Lerenthal, Y; Marcellus, RC; Gross, A				Kamer, I; Sarig, R; Zaltsman, Y; Niv, H; Oberkovitz, G; Regev, L; Haimovich, G; Lerenthal, Y; Marcellus, RC; Gross, A			Proapoptotic BID is an ATM effector in the DNA-damage response	CELL			English	Article							NORMAL HUMAN FIBROBLASTS; APOPTOSIS; MITOCHONDRIA; RADIATION; PROTEINS; ARREST; PHASE	The "BH3-only" proapoptotic BCL-2 family members are sentinels of intracellular damage. Here, we demonstrated that the BH3-only BID protein partially localizes to the nucleus in healthy cells, is important for apoptosis induced by DNA damage, and is phosphorylated following induction of double-strand breaks in DNA. We also found that BID phosphorylation is mediated by the ATM kinase and occurs in mouse BID on two ATM consensus sites. Interestingly, BID-/- cells failed to accumulate in the S phase of the cell cycle following treatment with the topoisomerase 11 poison etoposide; reintroducing wildtype BID restored accumulation. In contrast, introducing a nonphosphorylatable BID mutant did not restore accumulation in the S phase and resulted in an increase in cellular sensitivity to etoposide-induced apoptosis. These results implicate BID as an ATM effector and raise the possibility that proapoptotic BID may also play a prosurvival role important for S phase arrest.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Human Genet, IL-69978 Tel Aviv, Israel; Geminx Biotechnol Inc, Montreal, PQ H2W 2M9, Canada	Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine	Gross, A (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.	atan.gross@weizmann.ac.il	Haimovich, Gal/H-3316-2019; Gross, Atan/ABC-2640-2020	Haimovich, Gal/0000-0002-3360-5108; 				Baus F, 2003, EMBO J, V22, P3992, DOI 10.1093/emboj/cdg387; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Elkon R, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-5-r43; Iliakis G, 2003, ONCOGENE, V22, P5834, DOI 10.1038/sj.onc.1206682; Kaina B, 2003, BIOCHEM PHARMACOL, V66, P1547, DOI 10.1016/S0006-2952(03)00510-0; Kamijo T, 1999, CANCER RES, V59, P2464; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Sarig R, 2003, J BIOL CHEM, V278, P10707, DOI 10.1074/jbc.M210296200; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Tripathi AK, 2003, LEUKEMIA RES, V27, P899, DOI 10.1016/S0145-2126(03)00025-0; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zhao YG, 2001, J BIOL CHEM, V276, P27432, DOI 10.1074/jbc.M102465200; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022	18	178	184	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 26	2005	122	4					593	603		10.1016/j.cell.2005.06.014	http://dx.doi.org/10.1016/j.cell.2005.06.014			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	959YI	16122426	Bronze			2022-12-28	WOS:000231555100014
J	Park, JY; Ogletree, DF; Salmeron, M; Ribeiro, RA; Canfield, PC; Jenks, CJ; Thiel, PA				Park, JY; Ogletree, DF; Salmeron, M; Ribeiro, RA; Canfield, PC; Jenks, CJ; Thiel, PA			High frictional anisotropy of periodic and aperiodic directions on a quasicrystal surface	SCIENCE			English	Article							OXIDATION	Strong friction anisotropy is found when the twofold surface of an atomically clean aluminum-nickel-cobalt quasicrystal slides against a thiol-passivated titanium-nitride tip. Friction along the aperiodic direction is one-eighth as much as that along the periodic direction. This anisotropy, which is about three times as large as the highest value observed in anisotropic crystalline surfaces, disappears after the surface is oxidized in air. These results reveal a strong connection between interface atomic structure and the mechanisms by which energy is dissipated, which likely include electronic or phononic contributions, or both.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA; Iowa State Univ, Ames Lab, Ames, IA 50011 USA; Iowa State Univ, Dept Chem, Ames, IA 50011 USA; Iowa State Univ, Dept Phys & Astron, Ames, IA 50011 USA; Iowa State Univ, Dept Mat Sci & Engn, Ames, IA 50011 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Iowa State University; United States Department of Energy (DOE); Ames National Laboratory; Iowa State University; Iowa State University; Iowa State University	Salmeron, M (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA.	mbsalmeron@lbl.gov	Canfield, Paul/H-2698-2014; Park, Jeong Young/A-2999-2008; Jenks, Cynthia/ABC-6507-2020; Ribeiro, Raquel/B-9041-2012	Park, Jeong Young/0000-0002-8132-3076; Ribeiro, Raquel/0000-0001-6075-1701; Thiel, Patricia/0000-0003-4195-0216				BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; Carpick RW, 1997, CHEM REV, V97, P1163, DOI 10.1021/cr960068q; Chang SL, 1996, J NON-CRYST SOLIDS, V195, P95, DOI 10.1016/0022-3093(95)00537-4; DIANLIN Z, 1991, PHYS REV LETT, V66, P2778; Dienwiebel M, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.126101; Dubois JM, 2004, J NON-CRYST SOLIDS, V334, P475, DOI 10.1016/j.jnoncrysol.2003.12.027; DUBOIS JM, 1991, J MATER SCI LETT, V10, P537, DOI 10.1007/BF00726930; Dugain F, 1999, EUR PHYS J B, V7, P513, DOI 10.1007/s100510050640; Hafner J, 1996, PHYS REV LETT, V76, P2738, DOI 10.1103/PhysRevLett.76.2738; HIRANO M, 1991, PHYS REV LETT, V67, P2642, DOI 10.1103/PhysRevLett.67.2642; JANOT C, 1992, MONOGRAPHS PHYS CHEM, V48; Kishida M, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.094208; Ko JS, 1999, SURF SCI, V423, P243, DOI 10.1016/S0039-6028(98)00911-X; Liley M, 1998, SCIENCE, V280, P273, DOI 10.1126/science.280.5361.273; Mancinelli C, 2003, J MATER RES, V18, P1447, DOI 10.1557/JMR.2003.0199; MARTIN S, 1991, PHYS REV LETT, V67, P719, DOI 10.1103/PhysRevLett.67.719; OGLETREE DF, UNPUB; Park JY, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.144203; Park JY, 2004, TRIBOL LETT, V17, P629, DOI 10.1023/B:TRIL.0000044513.85505.60; Persson B. N. J., 1998, SLIDING FRICTION PHY; Pinhero PJ, 1999, PHILOS MAG B, V79, P91, DOI 10.1080/13642819908206784; SHECHTMAN D, 1984, PHYS REV LETT, V53, P1951, DOI 10.1103/PhysRevLett.53.1951; Singer I.L., 1998, QUASICRYSTALS, P769; Steurer W, 2004, Z KRISTALLOGR, V219, P391, DOI 10.1524/zkri.219.7.391.35643; van Erp TS, 1999, PHYS REV B, V60, P6522, DOI 10.1103/PhysRevB.60.6522; Vanossi A, 2001, PHYS REV E, V63, DOI 10.1103/PhysRevE.63.017203	26	159	161	2	91	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 26	2005	309	5739					1354	1356		10.1126/science.1113239	http://dx.doi.org/10.1126/science.1113239			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TX	16123295				2022-12-28	WOS:000231543300038
J	Clary, DC				Clary, DC			Geometric phase in chemical reactions	SCIENCE			English	Editorial Material							DIFFERENTIAL CROSS-SECTIONS; HYDROGEN-EXCHANGE REACTION; CONICAL INTERSECTIONS; REACTION DYNAMICS; ENERGY		Univ Oxford, Dept Phys & Theoret Chem, Oxford OX1 3QZ, England	University of Oxford	Clary, DC (corresponding author), Univ Oxford, Dept Phys & Theoret Chem, S Parks Rd, Oxford OX1 3QZ, England.	david.clary@chem.ox.ac.uk	Clary, David C/AAC-3903-2019	Clary, David C/0000-0003-4439-741X				Althorpe SC, 2003, ANNU REV PHYS CHEM, V54, P493, DOI 10.1146/annurev.physchem.54.011002.103750; Althorpe SC, 2002, NATURE, V416, P67, DOI 10.1038/416067a; Applegate BE, 2003, CHEM SOC REV, V32, P38, DOI 10.1039/a910269h; Bell R, 1980, TUNNEL EFFECT CHEM; BERRY MV, 1984, PROC R SOC LON SER-A, V392, P45, DOI 10.1098/rspa.1984.0023; Dobbyn AJ, 1999, PHYS CHEM CHEM PHYS, V1, P1115, DOI 10.1039/a809498e; HERZBERG G, 1963, DISCUSS FARADAY SOC, P77, DOI 10.1039/df9633500077; Juanes-Marcos JC, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1924411; Juanes-Marcos JC, 2005, SCIENCE, V309, P1227, DOI 10.1126/science.1114890; Kendrick BK, 2003, J PHYS CHEM A, V107, P6739, DOI 10.1021/jp021865x; LEPETIT B, 1990, CHEM PHYS LETT, V166, P581, DOI 10.1016/0009-2614(90)87154-J; MEAD CA, 1979, J CHEM PHYS, V70, P2284, DOI 10.1063/1.437734; Wrede E, 1999, J CHEM PHYS, V110, P9971, DOI 10.1063/1.478870	14	12	12	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 19	2005	309	5738					1195	1196		10.1126/science.1117201	http://dx.doi.org/10.1126/science.1117201			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	957TE	16109871				2022-12-28	WOS:000231395400031
J	Glatter, KA; Chiamvimonvat, N; Viitasalo, M; Wang, Q; Tuteja, D				Glatter, KA; Chiamvimonvat, N; Viitasalo, M; Wang, Q; Tuteja, D			Risk stratification in Brugada syndrome	LANCET			English	Editorial Material							ST-SEGMENT-ELEVATION; SUDDEN CARDIAC DEATH; BUNDLE-BRANCH BLOCK; INDIVIDUALS		Univ Calif Davis, Dept Cardiol, Sacramento, CA 95817 USA; Univ Helsinki Hosp, Dept Cardiol, Helsinki, Finland; Cleveland Clin Fdn, Ctr Cardiovasc Genet, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Mol Cardiol Cardiol, Cleveland, OH 44195 USA	University of California System; University of California Davis; University of Helsinki; Helsinki University Central Hospital; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Glatter, KA (corresponding author), Univ Calif Davis, Dept Cardiol, Sacramento, CA 95817 USA.	kaglatter@ucdavis.edu			NHLBI NIH HHS [R01 HL066251] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066251] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antzelevitch C, 2005, CIRCULATION, V111, P659, DOI 10.1161/01.CIR.0000152479.54298.51; Belhassen B, 2004, CIRCULATION, V110, P1731, DOI 10.1161/01.CIR.0000143159.30585.90; Brugada J, 2003, CIRCULATION, V108, P3092, DOI 10.1161/01.CIR.0000104568.13957.4F; BRUGADA P, 1992, J AM COLL CARDIOL, V20, P1391, DOI 10.1016/0735-1097(92)90253-J; Chen QY, 1998, NATURE, V392, P293, DOI 10.1038/32675; Eckardt L, 2005, CIRCULATION, V111, P257, DOI 10.1161/01.CIR.0000153267.21278.8D; Glatter KA, 2004, AM J CARDIOL, V93, P1320, DOI 10.1016/j.amjcard.2004.02.023; Priori SG, 2000, CIRCULATION, V102, P2509, DOI 10.1161/01.CIR.102.20.2509; Priori SG, 2002, CIRCULATION, V105, P1342, DOI 10.1161/hc1102.105288; Veerakul G, 2000, Cardiol Rev, V8, P90, DOI 10.1097/00045415-200008020-00005; Wang Q, 1996, GENOMICS, V34, P9, DOI 10.1006/geno.1996.0236	11	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 13	2005	366	9485					530	531		10.1016/S0140-6736(05)67078-X	http://dx.doi.org/10.1016/S0140-6736(05)67078-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955LL	16099276	Green Accepted			2022-12-28	WOS:000231227300008
J	Seale, C; Kirk, D; Tobin, M; Burton, P; Grundy, R; Pritchard-Jones, K; Dixon-Woods, M				Seale, C; Kirk, D; Tobin, M; Burton, P; Grundy, R; Pritchard-Jones, K; Dixon-Woods, M			Effect of media portrayals of removal of children's tissue on UK tumour bank	BRITISH MEDICAL JOURNAL			English	Editorial Material							ALDER-HEY AFFAIR; PERFORMANCE		Brunel Univ, Sch Social Sci & Law, Uxbridge UB8 3PH, Middx, England; Univ Leicester, Dept Hlth Sci, Leicester LE1 6TP, Leics, England; Univ Nottingham, Queens Med Ctr, Childrens Brain Tumour Res Ctr, Nottingham NG7 2UH, England; Royal Marsden Hosp, Childrens Dept, Sutton SM2 5PT, Surrey, England; Inst Canc Res, Sutton SM2 5PT, Surrey, England	Brunel University; University of Leicester; University of Nottingham; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Seale, C (corresponding author), Brunel Univ, Sch Social Sci & Law, Uxbridge UB8 3PH, Middx, England.	clive.seale@brunel.ac.uk	Pritchard-Jones, Kathy/F-4286-2014	Pritchard-Jones, Kathy/0000-0002-2384-9475; Dixon-Woods, Mary/0000-0002-5915-0041; Tobin, Martin/0000-0002-3596-7874	Economic and Social Research Council [RES-151-25-0026] Funding Source: researchfish	Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))		[Anonymous], 2001, ROYAL LIVERPOOL CHIL; Bauchner H, 2001, BMJ-BRIT MED J, V322, P309, DOI 10.1136/bmj.322.7282.309; Burton JL, 2003, J CLIN PATHOL, V56, P537, DOI 10.1136/jcp.56.7.537; Burton JL, 2001, J CLIN PATHOL, V54, P820, DOI 10.1136/jcp.54.11.820; Burton P, 1998, STAT MED, V17, P1261, DOI 10.1002/(SICI)1097-0258(19980615)17:11<1261::AID-SIM846>3.0.CO;2-Z; *COI COMM, 2003, RES EV TOPL PUBL OP; Dixon-Woods M, 2003, SOCIOL HEALTH ILL, V25, P143, DOI 10.1111/1467-9566.00329; English V, 2003, J MED ETHICS, V29, P147, DOI 10.1136/jme.29.3.147; Galea G, 2003, LANCET, V362, P932, DOI 10.1016/S0140-6736(03)14397-8; Kennedy I, 2001, INQUIRY MANAGEMENT C; Kitzinger J, 2000, MEDIA CULT SOC, V22, P61, DOI 10.1177/016344300022001004; Lull J., 1997, MEDIA SCANDALS MORAL; MATSANZ R, 2002, TRANSPLANT P, V35, P987; Seale C., 2002, MEDIA HLTH, DOI 10.4135/9781446216286	14	13	13	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	AUG 13	2005	331	7513					401	403		10.1136/bmj.331.7513.401	http://dx.doi.org/10.1136/bmj.331.7513.401			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	956SK	16096311	Green Published, Green Submitted			2022-12-28	WOS:000231319900022
J	Abe, M; Kobayashi, Y; Yamamoto, S; Daimon, Y; Yamaguchi, A; Ikeda, Y; Ichinoki, H; Notaguchi, M; Goto, K; Araki, T				Abe, M; Kobayashi, Y; Yamamoto, S; Daimon, Y; Yamaguchi, A; Ikeda, Y; Ichinoki, H; Notaguchi, M; Goto, K; Araki, T			FD, a bZIP protein mediating signals from the floral pathway integrator FT at the shoot apex	SCIENCE			English	Article							FLOWERING-TIME GENES; ARABIDOPSIS; CONSTANS; ACTIVATION; ROLES; APETALA1; IDENTITY; LEAFY; RICE	FLOWERING LOCUS T (FT) is a conserved promoter of flowering that acts downstream of various regulatory pathways, including one that mediates photoperiodic induction through CONSTANS (CO), and is expressed in the vasculature of cotyledons and leaves. A bZIP transcription factor, FD, preferentially expressed in the shoot apex is required for FT to promote flowering. FD and FT are interdependent partners through protein interaction and act at the shoot apex to promote floral transition and to initiate floral development through transcriptional activation of a floral meristem identity gene, APETALA1 (AP1). FT may represent a long-distance signal in flowering.	Kyoto Univ, Grad Sch Sci, Dept Bot, Sakyo Ku, Kyoto 6068502, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi 3320012, Japan; Res Inst Biol Sci Okayama, Okayama 7161241, Japan; Natl Inst Genet, Adjunct Div Appl Genet, Mishima, Shizuoka 4118540, Japan	Kyoto University; Japan Science & Technology Agency (JST); Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Araki, T (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Bot, Sakyo Ku, Kyoto 6068502, Japan.	taraqui@cosmos.bot.kyoto-u.ac.jp	Araki, Takashi/G-1760-2013; Abe, Mitsutomo/AAX-4110-2021; Notaguchi, Michitaka/GVS-9676-2022; Abe, Mitsutomo/Y-6065-2019; Notaguchi, Michitaka/AAL-8676-2021	Araki, Takashi/0000-0002-3616-1493; Abe, Mitsutomo/0000-0002-8423-1716; Ikeda, Yoko/0000-0002-3150-8902				An HL, 2004, DEVELOPMENT, V131, P3615, DOI 10.1242/dev.01231; CHAILAKHYAN MK, 1937, DOKL AKAD NAUK SSSR, V16, P227; Ferrandiz C, 2000, DEVELOPMENT, V127, P725; Hayama R, 2003, NATURE, V422, P719, DOI 10.1038/nature01549; Hempel FD, 1997, DEVELOPMENT, V124, P3845; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Jakoby M, 2002, TRENDS PLANT SCI, V7, P106, DOI 10.1016/S1360-1385(01)02223-3; Kardailsky I, 1999, SCIENCE, V286, P1962, DOI 10.1126/science.286.5446.1962; Kobayashi Y, 1999, SCIENCE, V286, P1960, DOI 10.1126/science.286.5446.1960; Kojima S, 2002, PLANT CELL PHYSIOL, V43, P1096, DOI 10.1093/pcp/pcf156; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; Lee H, 2000, GENE DEV, V14, P2366, DOI 10.1101/gad.813600; Liljegren SJ, 1999, PLANT CELL, V11, P1007, DOI 10.1105/tpc.11.6.1007; Nilsson O, 1998, GENETICS, V150, P403; Onouchi H, 2000, PLANT CELL, V12, P885, DOI 10.1105/tpc.12.6.885; Ratcliffe OJ, 1999, DEVELOPMENT, V126, P1109; RuizGarcia L, 1997, PLANT CELL, V9, P1921, DOI 10.1105/tpc.9.11.1921; Samach A, 2000, SCIENCE, V288, P1613, DOI 10.1126/science.288.5471.1613; Simpson GG, 2002, SCIENCE, V296, P285, DOI 10.1126/science.296.5566.285; Suarez-Lopez P, 2001, NATURE, V410, P1116, DOI 10.1038/35074138; Takada S, 2003, PLANT CELL, V15, P2856, DOI 10.1105/tpc.016345; Yamaguchi A, 2005, PLANT CELL PHYSIOL, V46, P1175, DOI 10.1093/pcp/pci151; Yanovsky MJ, 2002, NATURE, V419, P308, DOI 10.1038/nature00996; ZEEVAART JAD, 1976, ANNU REV PLANT PHYS, V27, P321, DOI 10.1146/annurev.pp.27.060176.001541	24	1061	1240	25	334	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 12	2005	309	5737					1052	1056		10.1126/science.1115983	http://dx.doi.org/10.1126/science.1115983			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955MN	16099979				2022-12-28	WOS:000231230100039
J	Redhead, J; Ward, P; Batrick, N				Redhead, J; Ward, P; Batrick, N			The London attacks - Response - Prehospital and hospital care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									St Marys Hosp, Dept Accid & Emergency, London, England	Imperial College London	Redhead, J (corresponding author), St Marys Hosp, Dept Accid & Emergency, London, England.								0	20	20	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 11	2005	353	6					546	547		10.1056/NEJMp058178	http://dx.doi.org/10.1056/NEJMp058178			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	953ST	16093461				2022-12-28	WOS:000231101500003
J	Benitah, SA; Frye, M; Glogauer, M; Watt, FM				Benitah, SA; Frye, M; Glogauer, M; Watt, FM			Stem cell depletion through epidermal deletion of Rac1	SCIENCE			English	Article							LABEL-RETAINING CELLS; MOUSE EPIDERMIS; MYC ACTIVATION; RHO-GTPASES; DIFFERENTIATION; PROLIFERATION	Mammalian epidermis is maintained by self-renewal of stem cells, but the underlying mechanisms are unknown. Deletion of Rac1, a Rho guanosine triphosphatase, in adult mouse epidermis stimulated stem cells to divide and undergo terminal differentiation, leading to failure to maintain the interfollicular epidermis, hair follicles, and sebaceous glands. Rac1 exerts its effects in the epidermis by negatively regulating c-Myc through p21-activated kinase 2 (PAK2) phosphorylation. We conclude that a pleiotropic regulator of cell adhesion and the cytoskeleton plays a critical role in controlling exit from the stem cell niche and propose that Rac and Myc represent a global stem cell regulatory axis.	Canc Res UK London Res Inst, Keratinocyte Lab, London WC2A 3PX, England; Univ Toronto, Fac Dent, Toronto, ON M5S 1A8, Canada	Cancer Research UK; University of Toronto	Watt, FM (corresponding author), Canc Res UK London Res Inst, Keratinocyte Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	fiona.watt@cancer.org.uk	Aznar-Benitah, Salvador/F-4761-2016; Watt, Fiona/AHB-0226-2022; Glogauer, Michael/D-2504-2011	Aznar-Benitah, Salvador/0000-0002-9059-5049; Watt, Fiona/0000-0001-9151-5154; Frye, Michaela/0000-0002-5636-6840; Glogauer, Michael/0000-0002-6248-5977				Arnold I, 2001, CURR BIOL, V11, P558, DOI 10.1016/S0960-9822(01)00154-3; Benitah SA, 2004, BBA-REV CANCER, V1705, P121, DOI 10.1016/j.bbcan.2004.10.002; BENITAH SA, UNPUB; Braun KM, 2003, DEVELOPMENT, V130, P5241, DOI 10.1242/dev.00703; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Frye M, 2003, DEVELOPMENT, V130, P2793, DOI 10.1242/dev.00462; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Glogauer M, 2003, J IMMUNOL, V170, P5652, DOI 10.4049/jimmunol.170.11.5652; Gu Y, 2003, SCIENCE, V302, P445, DOI 10.1126/science.1088485; Hong KU, 2004, AM J PATHOL, V164, P577, DOI 10.1016/S0002-9440(10)63147-1; Huang ZD, 2004, MOL CELL BIOL, V24, P1582, DOI 10.1128/MCB.24.4.1582-1594.2004; Legg J, 2003, DEVELOPMENT, V130, P6049, DOI 10.1242/dev.00837; Morris RJ, 1999, J INVEST DERMATOL, V112, P470, DOI 10.1046/j.1523-1747.1999.00537.x; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; Murphy MJ, 2005, TRENDS CELL BIOL, V15, P128, DOI 10.1016/j.tcb.2005.01.008; Owens DM, 2003, NAT REV CANCER, V3, P444, DOI 10.1038/nrc1096; Stappenbeck TS, 2000, DEVELOPMENT, V127, P2629; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Waikel RL, 2001, NAT GENET, V28, P165, DOI 10.1038/88889; Walmsley MJ, 2003, SCIENCE, V302, P459, DOI 10.1126/science.1089709; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399	21	213	220	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 5	2005	309	5736					933	935		10.1126/science.1113579	http://dx.doi.org/10.1126/science.1113579			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953SS	16081735				2022-12-28	WOS:000231101400046
J	Wang, DW; Mitchell, DA; Teague, WJ; Jarosz, E; Hulbert, MS				Wang, DW; Mitchell, DA; Teague, WJ; Jarosz, E; Hulbert, MS			Extreme waves under Hurricane Ivan	SCIENCE			English	Article									USN, Res Lab, Stennis Space Ctr, MS 39529 USA	United States Department of Defense; United States Navy; Naval Research Laboratory	Wang, DW (corresponding author), USN, Res Lab, Stennis Space Ctr, MS 39529 USA.	dwang@nrlssc.navy.mil						*ATL OC MET LAB HU, HURR IV 2004; BEA RG, 1974, P 6 OFFSH TECHN C HO, P791; Hsu SA, 2000, J COASTAL RES, V16, P823; Tucker M.J., 1991, WAVES OCEAN ENG MEAS; *USA CORPS ENG COA, 1984, SHOR PROT MAN, V1; YOUNG IR, 1988, J WATERW PORT C-ASCE, V114, P637, DOI 10.1061/(ASCE)0733-950X(1988)114:5(637)	6	99	100	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 5	2005	309	5736					896	896		10.1126/science.1112509	http://dx.doi.org/10.1126/science.1112509			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953SS	16081728				2022-12-28	WOS:000231101400035
J	Koelle, K; Rodo, X; Pascual, M; Yunus, M; Mostafa, G				Koelle, K; Rodo, X; Pascual, M; Yunus, M; Mostafa, G			Refractory periods and climate forcing in cholera dynamics	NATURE			English	Article							RURAL BANGLADESH; ENDEMIC CHOLERA; VARIABILITY; ENSO	Outbreaks of many infectious diseases, including cholera, malaria and dengue, vary over characteristic periods longer than 1 year(1,2). Evidence that climate variability drives these interannual cycles has been highly controversial, chiefly because it is difficult to isolate the contribution of environmental forcing while taking into account nonlinear epidemiological dynamics generated by mechanisms such as host immunity(2-4). Here we show that a critical interplay of environmental forcing, specifically climate variability, and temporary immunity explains the interannual disease cycles present in a four-decade cholera time series from Matlab, Bangladesh. We reconstruct the transmission rate, the key epidemiological parameter affected by extrinsic forcing, over time for the predominant strain ( El Tor) with a nonlinear population model that permits a contributing effect of intrinsic immunity. Transmission shows clear interannual variability with a strong correspondence to climate patterns at long periods ( over 7 years, for monsoon rains and Brahmaputra river discharge) and at shorter periods ( under 7 years, for flood extent in Bangladesh, sea surface temperatures in the Bay of Bengal and the El Nino Southern Oscillation). The importance of the interplay between extrinsic and intrinsic factors in determining disease dynamics is illustrated during refractory periods, when population susceptibility levels are low as the result of immunity and the size of cholera outbreaks only weakly reflects climate forcing.	Univ Michigan, Dept Ecol & Evolutionary Biol, Ann Arbor, MI 48109 USA; Univ Barcelona, ICREA, E-08028 Barcelona, Spain; Univ Barcelona, Climat Res Lab, E-08028 Barcelona, Spain; Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh	University of Michigan System; University of Michigan; ICREA; University of Barcelona; University of Barcelona; International Centre for Diarrhoeal Disease Research (ICDDR)	Pascual, M (corresponding author), Univ Michigan, Dept Ecol & Evolutionary Biol, 2045 Kraus Nat Sci Bldg,830 N Univ Ave, Ann Arbor, MI 48109 USA.	pascual@umich.edu	Rodó, Xavier/F-7663-2017	Rodó, Xavier/0000-0003-4843-6180	ICREA Funding Source: Custom	ICREA(ICREA)		ANDERSON R M, 1991; Bouma MJ, 2001, HYDROBIOLOGIA, V460, P147, DOI 10.1023/A:1013165215074; CLEMENS JD, 1991, LANCET, V337, P883, DOI 10.1016/0140-6736(91)90207-6; De Jong M., 1995, EPIDEMIC MODELS THEI, P84; Dixon PA, 1999, SCIENCE, V283, P1528, DOI 10.1126/science.283.5407.1528; Elsner J., 1996, SINGULAR SPECTRUM AN; GLASS RI, 1982, AM J EPIDEMIOL, V116, P959, DOI 10.1093/oxfordjournals.aje.a113498; Glass Roger I., 1992, P129; Hastie T., 1990, GEN ADDITIVE MODELS; Hay SI, 2000, P NATL ACAD SCI USA, V97, P9335, DOI 10.1073/pnas.97.16.9335; KAPLAN D, 1995, TXT APPL MATH, P342; KAWAMURA R, 1998, J MET SOC JPN, P76; Koelle K, 2004, AM NAT, V163, P901, DOI 10.1086/420798; Lau NC, 2004, J CLIMATE, V17, P245, DOI 10.1175/1520-0442(2004)017<0245:CGSOAV>2.0.CO;2; Lau NC, 2000, J CLIMATE, V13, P4287, DOI 10.1175/1520-0442(2000)013<4287:IOEOTV>2.0.CO;2; Levine Myron M., 1992, P285; LUI WM, 1987, J MATH BIOL, V25, P359; Parthasarathy B, 1995, RR065 IITM; Pascual M, 2000, SCIENCE, V289, P1766, DOI 10.1126/science.289.5485.1766; Pascual M, 2002, MICROBES INFECT, V4, P237, DOI 10.1016/S1286-4579(01)01533-7; Rodo X, 2002, P NATL ACAD SCI USA, V99, P12901, DOI 10.1073/pnas.182203999; Rogers DJ, 2002, NATURE, V415, P710, DOI 10.1038/415710a; SCHWARTZ IB, 1992, J MATH BIOL, V30, P473, DOI 10.1007/BF00160532; SHUKLA J, 1994, P INT C MONS VAR PRE, P567; SIDDIQUE AK, 1991, LANCET, V337, P1125, DOI 10.1016/0140-6736(91)92789-5; Taubes G, 1997, SCIENCE, V278, P1004, DOI 10.1126/science.278.5340.1004; WALDOR MK, 1994, P NATL ACAD SCI USA, V91, P11388, DOI 10.1073/pnas.91.24.11388; Webster P.J., 2002, METEOROLOGY MILLENNI, V83, P198, DOI DOI 10.1016/S0074-6142(02)80168-1; WOODWARD WE, 1972, AM J EPIDEMIOL, V96, P342, DOI 10.1093/oxfordjournals.aje.a121465; Zhou G, 2004, P NATL ACAD SCI USA, V101, P2375, DOI 10.1073/pnas.0308714100	30	273	280	1	76	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 4	2005	436	7051					696	700		10.1038/nature03820	http://dx.doi.org/10.1038/nature03820			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	951XA	16079845	Green Published			2022-12-28	WOS:000230964500043
J	Ozima, M; Seki, K; Terada, N; Miura, YN; Podosek, FA; Shinagawa, H				Ozima, M; Seki, K; Terada, N; Miura, YN; Podosek, FA; Shinagawa, H			Terrestrial nitrogen and noble gases in lunar soils	NATURE			English	Article							ARCHEAN GEOMAGNETIC-FIELD; SOLAR; SAMPLES; VENUS; IONS; BARBERTON; ISOTOPES; EARTH	The nitrogen in lunar soils is correlated to the surface and therefore clearly implanted from outside. The straightforward interpretation is that the nitrogen is implanted by the solar wind, but this explanation has difficulties accounting for both the abundance of nitrogen and a variation of the order of 30 per cent in the N-15/N-14 ratio. Here we propose that most of the nitrogen and some of the other volatile elements in lunar soils may actually have come from the Earth's atmosphere rather than the solar wind. We infer that this hypothesis is quantitatively reasonable if the escape of atmospheric gases, and implantation into lunar soil grains, occurred at a time when the Earth had essentially no geomagnetic field. Thus, evidence preserved in lunar soils might be useful in constraining when the geomagnetic field first appeared. This hypothesis could be tested by examination of lunar farside soils, which should lack the terrestrial component.	Univ Tokyo, Grad Sch Earth & Planetary Sci, Tokyo 1130033, Japan; Washington Univ, Dept Earth & Planetary Sci, St Louis, MO 63130 USA; ETH Zentrum, Inst Isotope Geol & Mineral Resources, CH-8092 Zurich, Switzerland; Univ Tokyo, Earthquake Res Inst, Tokyo 1130033, Japan; Nagoya Univ, Solar Terr Environm Lab, Aichi 4428507, Japan	University of Tokyo; Washington University (WUSTL); Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Tokyo; Nagoya University	Ozima, M (corresponding author), Univ Tokyo, Grad Sch Earth & Planetary Sci, Tokyo 1130033, Japan.	EZZ03651@nifty.ne.jp	Naoki, Terada/AAC-6868-2019	Naoki, Terada/0000-0001-5685-9736; Seki, Kanako/0000-0001-5557-9062				Abe M, 2001, J GEODETIC SOC JAPAN, V47, P514, DOI [10.11366/sokuchi1954.47.514, DOI 10.11366/SOKUCHI1954.47.514]; ABE Y, 1993, LITHOS, V30, P223, DOI 10.1016/0024-4937(93)90037-D; BERNATOWICZ T, 1978, P LUNAR PLANET SCI C, V8, P2763; Bilitza D, 2001, RADIO SCI, V36, P261, DOI 10.1029/2000RS002432; Bills BG, 1999, GEOPHYS RES LETT, V26, P3045, DOI 10.1029/1999GL008348; BOCHSLER P, 1994, ADV SPACE RES, V14, P161, DOI 10.1016/0273-1177(94)90022-1; Busemann H, 2000, METEORIT PLANET SCI, V35, P949, DOI 10.1111/j.1945-5100.2000.tb01485.x; Dalrymple GB, 1996, J GEOPHYS RES-PLANET, V101, P26069, DOI 10.1029/96JE02806; Eugster O, 2001, METEORIT PLANET SCI, V36, P1097, DOI 10.1111/j.1945-5100.2001.tb01947.x; GEISS J, 1982, GEOCHIM COSMOCHIM AC, V46, P529, DOI 10.1016/0016-7037(82)90156-9; GEISS J, 1973, P 13 INT COSM RAY C, P3375; GREBOWSKY JM, 1993, J GEOPHYS RES-PLANET, V98, P9055, DOI 10.1029/93JE00300; HALE CJ, 1984, GEOPHYS RES LETT, V11, P97, DOI 10.1029/GL011i002p00097; Hamano Y., 1978, TERRESTRIAL RARE GAS, P155; Hashizume K, 2000, SCIENCE, V290, P1142, DOI 10.1126/science.290.5494.1142; Hashizume K, 2002, EARTH PLANET SC LETT, V202, P201, DOI 10.1016/S0012-821X(02)00781-1; Heber VS, 2003, ASTROPHYS J, V597, P602, DOI 10.1086/378402; KASPRZAK WT, 1991, J GEOPHYS RES-SPACE, V96, P11175, DOI 10.1029/91JA00677; KERRIDGE JF, 1993, REV GEOPHYS, V31, P423, DOI 10.1029/93RG01953; KERRIDGE JF, 1975, SCIENCE, V188, P162, DOI 10.1126/science.188.4184.162; Mall U, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013957; MEGRUE GH, 1973, J GEOPHYS RES, V78, P3216, DOI 10.1029/JB078i017p03216; Murray C. D., 1999, SOLAR SYSTEM DYNAMIC; Ozima M, 2004, ICARUS, V170, P17, DOI 10.1016/j.icarus.2004.02.007; Ozima M., 2022, NOBLE GAS GEOCHEMIST; Picone JM, 2000, PHYS CHEM EARTH PT C, V25, P537, DOI 10.1016/S1464-1917(00)00072-6; RICHARDS PG, 1994, J GEOPHYS RES-SPACE, V99, P8981, DOI 10.1029/94JA00518; Seki K, 2001, SCIENCE, V291, P1939, DOI 10.1126/science.1058913; Shizgal BD, 1996, REV GEOPHYS, V34, P483, DOI 10.1029/96RG02213; Wieler R, 1999, EARTH PLANET SC LETT, V167, P47, DOI 10.1016/S0012-821X(99)00012-6; WIELER R, 2002, REV MINERAOLOGY GEOC, V47; Yoshihara A, 2004, PRECAMBRIAN RES, V131, P111, DOI 10.1016/j.precamres.2004.01.003	33	72	73	3	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 4	2005	436	7051					655	659		10.1038/nature03929	http://dx.doi.org/10.1038/nature03929			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	951XA	16079836				2022-12-28	WOS:000230964500033
J	Steinbrook, R				Steinbrook, R			Public solicitation of organ donors	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		BURDICK JF, 2004, COMMUNICATION   1029; Delmonico FL, 2004, NEW ENGL J MED, V350, P1812, DOI 10.1056/NEJMp038228	2	36	37	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 4	2005	353	5					441	444		10.1056/NEJMp058151	http://dx.doi.org/10.1056/NEJMp058151			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	951OB	16079365				2022-12-28	WOS:000230939000001
J	West, RA; Brown, ME; Salinas, SV; Bouchez, AH; Roe, HG				West, RA; Brown, ME; Salinas, SV; Bouchez, AH; Roe, HG			No oceans on Titan from the absence of a near-infrared specular reflection	NATURE			English	Article							OPTICAL-CONSTANTS; ATMOSPHERE; LIQUID; MODEL	With its substantial atmosphere of nitrogen, hydrocarbons and nitriles, Saturn's moon Titan is a unique planetary satellite. Photochemical processing of the gaseous constituents produces an extended haze that obscures the surface. Soon after the Voyager fly-bys in 1980 and 1981 photochemical models(1-3) led to the conclusion that there should be enough liquid methane/ethane/ nitrogen to cover the surface to a depth of several hundred metres. Recent Earth-based radar echoes imply that surface liquid may be present at a significant fraction of the locations sampled(4). Here we present ground-based observations ( at near-infrared wavelengths) and calculations showing that there is no evidence thus far for surface liquid(5). Combined with the specular signatures from radar observations, we infer mechanisms that produce very flat solid surfaces, involving a substance that was liquid in the past but is not in liquid form at the locations we studied.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; Natl Univ Singapore, Ctr Remote Imaging Sensing & Proc, Singapore 119260, Singapore; WM Keck Observ, Kamuela, HI 96743 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); California Institute of Technology; National University of Singapore	West, RA (corresponding author), CALTECH, Jet Prop Lab, MS 169-237,4800 Oak Grove Dr, Pasadena, CA 91109 USA.	Robert.A.West@jpl.nasa.gov		Brown, Michael E./0000-0002-8255-0545; Salinas, Santo V./0000-0001-7455-5939				BOUCHEZ AH, 2004, B AM ASTRON SOC, V36, P1696; Brown ME, 2002, NATURE, V420, P795, DOI 10.1038/nature01302; Brown RH, 2004, SPACE SCI REV, V115, P111, DOI 10.1007/s11214-004-1453-x; Campbell DB, 2003, SCIENCE, V302, P431, DOI 10.1126/science.1088969; DEUZE JL, 1989, J QUANT SPECTROSC RA, V41, P483, DOI 10.1016/0022-4073(89)90118-0; EVANS KF, 1991, J QUANT SPECTROSC RA, V46, P413, DOI 10.1016/0022-4073(91)90043-P; FLASAR FM, 1983, SCIENCE, V221, P55, DOI 10.1126/science.221.4605.55; GIBBARD SG, 2004, GEOPHYS RES LETT, V32, DOI UNSP L17S02; Grieger B, 2003, PLANET SPACE SCI, V51, P147, DOI 10.1016/S0032-0633(02)00142-3; KHARE BN, 1984, ICARUS, V60, P127, DOI 10.1016/0019-1035(84)90142-8; LEMMON MT, 1994, THESIS ARIZONA U; LUNINE JI, 1983, SCIENCE, V222, P1229, DOI 10.1126/science.222.4629.1229; MARTONCHIK JV, 1994, APPL OPTICS, V33, P8306, DOI 10.1364/AO.33.008306; Porco CC, 2005, NATURE, V434, P159, DOI 10.1038/nature03436; WEST RA, 1991, ICARUS, V90, P330, DOI 10.1016/0019-1035(91)90113-8; Wizinowich P, 2000, P SOC PHOTO-OPT INS, V4007, P2, DOI 10.1117/12.390368; YUNG YL, 1984, ASTROPHYS J SUPPL S, V55, P465, DOI 10.1086/190963	17	51	52	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 4	2005	436	7051					670	672		10.1038/nature03824	http://dx.doi.org/10.1038/nature03824			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	951XA	16079839				2022-12-28	WOS:000230964500036
J	Porter, M; Haslam, N				Porter, M; Haslam, N			Predisplacement and postdisplacement factors associated with mental health of refugees and internally displaced persons - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							POSTTRAUMATIC-STRESS-DISORDER; CROSS-CULTURAL INSTRUMENT; LATIN-AMERICAN REFUGEES; PSYCHOLOGICAL RESPONSES; POLITICAL VIOLENCE; PROLONGED STRESS; WAR; CHILDREN; PSYCHOPATHOLOGY; TRAUMA	Context The global refugee crisis requires that researchers, policyrnakers, and clinicians comprehend the magnitude of the psychological consequences of forced displacement and the factors that moderate them. To date, no empirical synthesis of research on these issues has been undertaken. Objective To meta-analytically establish the extent of compromised mental health among refugees (including internally displaced persons, asylum seekers,and stateless persons) using a worldwide study sample. Potential moderators of mental health outcomes were examined, including enduring contextual variables (eg, postdisplacement accommodation and economic opportunity) and refugee characteristics. Data Sources Published studies (1959-2002) were obtained using broad searches of computerized databases (PsycINFO and PILOTS), manual searches of reference lists, and interviews with prominent authors. Study Selection Studies were selected if they investigated a refugee group and at least 1 nonrefugee comparison group and reported 1 or more quantitative group comparison on measures of psychopathology. Fifty-six reports met inclusion criteria (4.4% of identified reports), yielding 59 independent comparisons and including 67 294 participants (22 221 refugees and 45 073 nonrefugees). Data Extraction Data on study and report characteristics, study participant characteristics, and statistical outcomes were extracted using a coding manual and subjected to blind recoding, which indicated high reliability. Methodological quality information was coded to assess potential sources of bias. Data Synthesis Effect size estimates for the refugee-nonrefugee comparisons were averaged across psychopathology measures within studies and weighted by sample size. The weighted mean effect size was 0.41 (SD, 0.02; range, -1.36 to 2.91 [SE, 0.01]), indicating that refugees had moderately poorer outcomes. Postdisplacement conditions moderated mental health outcomes. Worse outcomes were observed for refugees living in institutional accommodation, experiencing restricted economic opportunity, displaced internally within their own country, repatriated to a country they ugees w o were had previously fled, or whose initiating conflict was unresolved. Re older, more educated, and female and who had higher predisplacement socioeconomic status and rural residence also had worse outcomes. Methodological differences between studies affected effect sizes. Conclusions The sociopolitical context of the refugee experience is associated with refugee mental health. Humanitarian efforts that improve these conditions are likely to have positive impacts.	Columbia Presbyterian Med Ctr, Dept Pediat Psychiat, New York, NY 10032 USA; Univ Melbourne, Melbourne, Vic, Australia	Columbia University; NewYork-Presbyterian Hospital; University of Melbourne	Porter, M (corresponding author), Columbia Presbyterian Med Ctr, Dept Pediat Psychiat, 622 W 165th St,6th Floor N, New York, NY 10032 USA.	mattporteremail@yahoo.com	Haslam, Nick/D-9026-2011	Haslam, Nick/0000-0002-1913-2340				Achenbach T.M., 1991, MANUAL CHILD BEHAV C, DOI DOI 10.1023/A; ADAMS PL, 1980, CHILD PSYCHIAT HUM D, V10, P135, DOI 10.1007/BF01433626; Ahmad A, 2000, EUR CHILD ADOLES PSY, V9, P285, DOI 10.1007/s007870070032; ALEISSA YA, 1995, SOC SCI MED, V41, P1033, DOI 10.1016/0277-9536(94)00414-O; Allden K, 1996, AM J PUBLIC HEALTH, V86, P1561, DOI 10.2105/AJPH.86.11.1561; BAUER M, 1994, PSYCHIAT RES, V51, P61, DOI 10.1016/0165-1781(94)90047-7; Bayard-Burfield L, 2001, J EPIDEMIOL COMMUN H, V55, P657, DOI 10.1136/jech.55.9.657; Beck A.T., 1987, BECK DEPRESSION INVE; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BEISER M, 1987, CULT MED PSYCHIAT, V11, P437, DOI 10.1007/BF00048493; BOOTHBY N, 1991, CHILDREN MOZAMBIQUE; BRACKEN PJ, 1995, SOC SCI MED, V40, P1073, DOI 10.1016/0277-9536(94)00181-R; BRODY E, 1994, AMIDST PERIL PAIN ME, P57; BROWN G. W., 1989, LIFE EVENTS ILLNESS, P3; CARBALLO M, 1996, HLTH SOCIAL STATUS D; Cardozo BL, 2000, JAMA-J AM MED ASSOC, V284, P569, DOI 10.1001/jama.284.5.569; CERVANTES RC, 1989, HOSP COMMUNITY PSYCH, V40, P615; Chung RCY, 1998, J NERV MENT DIS, V186, P112, DOI 10.1097/00005053-199802000-00007; Clark S, 1996, PSYCHOL REP, V79, P819, DOI 10.2466/pr0.1996.79.3.819; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; CONRAD M, 1989, J CONSULT CLIN PSYCH, V57, P663, DOI 10.1037/0022-006X.57.5.663; Cooper H, 1994, HDB RES SYNTHESIS, P439; Cooper H. M., 1998, SYNTHESIZING RES GUI, V3rd; de Jong JTVM, 2001, JAMA-J AM MED ASSOC, V286, P555, DOI 10.1001/jama.286.5.555; DEGIROLAMO G, 1996, ETHNOCULTURAL ASPECT; *DEP VET AFF, PILOTS DAT EL IND TR; Dohrenwend B. P., 1969, SOCIAL STATUS PSYCHO; DUBE KC, 1968, SOC PSYCHIATR, V3, P139, DOI 10.1007/BF00577944; DUNNIGAN T, 1993, J CROSS CULT PSYCHOL, V24, P344, DOI 10.1177/0022022193243005; EISENBRUCH M, 1991, SOC SCI MED, V33, P673, DOI 10.1016/0277-9536(91)90021-4; EITINGER L, 1959, J MENT SCI, V105, P326, DOI 10.1192/bjp.105.439.326; ELHABIR E, 1994, AUST NZ J PSYCHIAT, V28, P100; Elvik R, 1998, ACCIDENT ANAL PREV, V30, P255, DOI 10.1016/S0001-4575(97)00076-6; FAZEL MK, 1988, J SCI STUD RELIG, V27, P229, DOI 10.2307/1386717; Folnegovic-Smalc Vera, 1997, Croatian Medical Journal, V38, P273; FREEDY JR, 1992, J TRAUMA STRESS, V5, P441, DOI 10.1002/jts.2490050308; GARBARINO J, 1991, NO PLACE BE CHILD GR; GARCIAPELTONIEM.R, 1991, DHHS PUBLICATION, P24; Glass G.V., 1976, ED RES, V5, P3, DOI [DOI 10.3102/0013189X005010003, 10.2307/1174772ISSN0536-1036]; GOENJIAN AK, 1994, ACTA PSYCHIAT SCAND, V90, P214, DOI 10.1111/j.1600-0447.1994.tb01580.x; GREEN BL, 1991, J AM ACAD CHILD PSY, V30, P945, DOI 10.1097/00004583-199111000-00012; GREEN BL, 1990, AM J ORTHOPSYCHIAT, V60, P43, DOI 10.1037/h0079168; GREEN BL, 1997, STRESS HLTH SERIES M, V7, P283; Hedges L.V., 1985, STAT METHODS METAANA, DOI [10.1016/C2009-0-03396-0, DOI 10.1016/C2009-0-03396-0]; HEDGES LV, 1980, UNBIASED ESTIMATION, P25; Herceg Marko, 1996, Croatian Medical Journal, V37, P111; HIGGINBOTHAM N, 1988, SOC SCI MED, V27, P553, DOI 10.1016/0277-9536(88)90379-6; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hjern A, 1998, SCAND J SOC MED, V26, P18, DOI 10.1177/14034948980260010701; Hollifield M, 2002, JAMA-J AM MED ASSOC, V288, P611, DOI 10.1001/jama.288.5.611; HOURANI LL, 1986, SOC SCI MED, V23, P269, DOI 10.1016/0277-9536(86)90347-3; Howard M, 2000, J AM ACAD CHILD PSY, V39, P368, DOI 10.1097/00004583-200003000-00020; HUERTA F, 1978, GERONTOLOGIST, V18, P541, DOI 10.1093/geront/18.6.541; HUFFCUTT AI, 1995, J APPL PSYCHOL, V80, P327, DOI 10.1037/0021-9010.80.2.327; JABLENSKY A, 1994, AMIDST PERIL PAIN ME, P327; JENSEN SB, 1989, ACTA PSYCHIAT SCAND, V80, P125, DOI 10.1111/j.1600-0447.1989.tb01313.x; KINZIE DJ, 1993, INT HDB TRAUMATIC ST, P311; KINZIE JD, 1986, J AM ACAD CHILD PSY, V25, P370, DOI 10.1016/S0002-7138(09)60259-4; KLIMIDIS S, 1994, COMPR PSYCHIAT, V35, P393, DOI 10.1016/0010-440X(94)90281-X; Kocijan-Hercigonja D, 1998, NORD J PSYCHIAT, V52, P45, DOI 10.1080/080394898422562; KocijanHercigonja D, 1996, NORD J PSYCHIAT, V50, P451, DOI 10.3109/08039489609082513; KocijanHercigonja D, 1996, J PSYCHIATR RES, V30, P391, DOI 10.1016/0022-3956(96)00011-8; KONDIC L, 1992, PSYCHOL BEITR, V34, P179; Kulka R.A., 1990, TRAUMA VIETNAM WAR G; KUTEROVAC G, 1994, BRIT J MED PSYCHOL, V67, P363, DOI 10.1111/j.2044-8341.1994.tb01804.x; Laor N, 1996, ARCH GEN PSYCHIAT, V53, P416, DOI 10.1001/archpsyc.1996.01830050052008; Lipsey M, 2001, APPL SOCIAL RES METH, V49; Locke CJ, 1996, ARCH PEDIAT ADOL MED, V150, P822, DOI 10.1001/archpedi.1996.02170330048008; Loughry M, 2001, CHILD ABUSE NEGLECT, V25, P249, DOI 10.1016/S0145-2134(00)00240-4; Macksoud MS, 1996, CHILD DEV, V67, P70, DOI 10.1111/j.1467-8624.1996.tb01720.x; Marsella A.J., 1996, ETHNOCULTURAL ASPECT; MARSELLA AJ, 1994, AMIDST PERIL PAIN ME, P341, DOI DOI 10.1037/10147-018; MARTIN SF, 1994, AMIDST PERIL PAIN ME, P69, DOI DOI 10.1037/10147-002; MCCLOSKEY LA, 1995, J COMMUNITY PSYCHOL, V23, P95, DOI 10.1002/1520-6629(199504)23:2<95::AID-JCOP2290230202>3.0.CO;2-A; MOLLICA RF, 1992, J NERV MENT DIS, V180, P111, DOI 10.1097/00005053-199202000-00008; Mollica RF, 2002, J NERV MENT DIS, V190, P158, DOI 10.1097/00005053-200203000-00004; Myers K M, 1987, Int J Soc Psychiatry, V33, P56, DOI 10.1177/002076408703300109; *NORW REF COUNC, 2005, INT DISPL GLOB OV TR; Onwumere J., 2002, PSYCHOL HEALTH MED, V7, P61, DOI DOI 10.1080/13548500120101568; Paardekooper B, 1999, J CHILD PSYCHOL PSYC, V40, P529, DOI 10.1017/S002196309900390X; PERNICE R, 1994, INT J SOC PSYCHIATR, V40, P177, DOI 10.1177/002076409404000303; Porter M, 2001, J TRAUMA STRESS, V14, P817, DOI 10.1023/A:1013054524810; PUNAMAKI RL, 1990, J PEACE RES, V27, P75, DOI 10.1177/0022343390027001007; PYNOOS RS, 1987, ARCH GEN PSYCHIAT, V44, P1057; QUTA S, 1993, DERASAT NAFSEYAH, V3, P1; RANGARAJ A, 1998, REFUGEES TRAUMA EXIL, P41; RASANEN E, 1989, ACTA PSYCHIAT SCAND, V80, P280, DOI 10.1111/j.1600-0447.1989.tb01338.x; Rasekh Z, 1998, JAMA-J AM MED ASSOC, V280, P449, DOI 10.1001/jama.280.5.449; Reeler A. P., 1994, Central African Journal of Medicine, V40, P309; Riolli L, 2002, J APPL SOC PSYCHOL, V32, P1604, DOI 10.1111/j.1559-1816.2002.tb02765.x; ROGLIC G, 1993, BEHAV MED, V19, P53, DOI 10.1080/08964289.1993.9937565; Roncevic-Grzeta I, 2001, MIL MED, V166, P530; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; Rousseau C, 2000, CAN J PSYCHIAT, V45, P905, DOI 10.1177/070674370004501005; RUBONIS AV, 1991, PSYCHOL BULL, V109, P384, DOI 10.1037/0033-2909.109.3.384; Sabioncello A, 2000, PSYCHOSOM MED, V62, P502, DOI 10.1097/00006842-200007000-00008; Silove D, 1998, ACTA PSYCHIAT SCAND, V97, P175, DOI 10.1111/j.1600-0447.1998.tb09984.x; Silove D, 2000, CURR OPIN PSYCHIATR, V13, P231, DOI 10.1097/00001504-200003000-00016; SMITHER R, 1979, J CROSS CULT PSYCHOL, V10, P469, DOI 10.1177/0022022179104006; Song FJ, 2002, INT J EPIDEMIOL, V31, P88, DOI 10.1093/ije/31.1.88; Summerfield D, 1996, J NERV MENT DIS, V184, P375, DOI 10.1097/00005053-199606000-00008; Sundelin-Wahlsten V, 2001, ACTA PAEDIATR, V90, P563, DOI 10.1080/080352501750197728; Sundquist J, 1996, SOC PSYCH PSYCH EPID, V31, P21; SUNDQUIST J, 1993, ACTA PSYCHIAT SCAND, V87, P208, DOI 10.1111/j.1600-0447.1993.tb03357.x; SUNDQUIST J, 1994, SOC PSYCH PSYCH EPID, V29, P20; SURTEES PG, 1986, J AFFECT DISORDERS, V10, P37, DOI 10.1016/0165-0327(86)90047-9; SURTEES PG, 1989, LIFE EVENTS ILLNESS, P160; Thulesius H, 1999, J TRAUMA STRESS, V12, P167, DOI 10.1023/A:1024758718971; Tousignant M, 1999, J AM ACAD CHILD PSY, V38, P1426, DOI 10.1097/00004583-199911000-00018; *UN HIGH COMM REF, 2004, STAT YB 2003 TRENDS; *UN HIGH COMM REF, 2005, 2004 GLOB REP; *UN REL WORKS AG P, 2005, ANN REP DE HLTH 2004; VANWILLIGEN LHM, 1995, TROP GEOGR MED, V47, P118; VONBUCHWALD U, 1994, AMIDST PERIL PAIN ME, P229; Weisaeth L., 1993, INT HDB TRAUMATIC ST, P69, DOI [DOI 10.1007/978-1-4615-2820-3, 10.1007/978-1-4615-2820-3_6, DOI 10.1007/978-1-4615-2820-3_6]; WILKINSON CB, 1983, AM J PSYCHIAT, V140, P1134; WONGRIEGER D, 1987, J CROSS CULT PSYCHOL, V18, P345, DOI 10.1177/0022002187018003005; Young MY, 1997, INT J PSYCHOL, V32, P289, DOI 10.1080/002075997400665; ZIVCIC I, 1993, J AM ACAD CHILD PSY, V32, P709, DOI 10.1097/00004583-199307000-00002	119	961	970	2	132	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	2005	294	5					602	612		10.1001/jama.294.5.602	http://dx.doi.org/10.1001/jama.294.5.602			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	951NN	16077055				2022-12-28	WOS:000230937500021
J	Lechler, T; Fuchs, E				Lechler, T; Fuchs, E			Asymmetric cell divisions promote stratification and differentiation of mammalian skin	NATURE			English	Article							C-ELEGANS; EPIDERMAL MORPHOGENESIS; CONDITIONAL ABLATION; DROSOPHILA; NUMA; INTEGRIN; BETA-1-INTEGRIN; HEMIDESMOSOMES; PROLIFERATION; LOCALIZATION	The epidermis is a stratified squamous epithelium forming the barrier that excludes harmful microbes and retains body fluids. To perform these functions, proliferative basal cells in the innermost layer periodically detach from an underlying basement membrane of extracellular matrix, move outward and eventually die. Once suprabasal, cells stop dividing and enter a differentiation programme to form the barrier(1). The mechanism of stratification is poorly understood. Although studies in vitro have led to the view that stratification occurs through the delamination and subsequent movement of epidermal cells(2-4), most culture conditions favour keratinocytes that lack the polarity and cuboidal morphology of basal keratinocytes in tissue. These features could be important in considering an alternative mechanism, that stratification occurs through asymmetric cell divisions in which the mitotic spindle orients perpendicularly to the basement membrane(5-7). Here we show that basal epidermal cells use their polarity to divide asymmetrically, generating a committed suprabasal cell and a proliferative basal cell. We further demonstrate that integrins and cadherins are essential for the apical localization of atypical protein kinase C, the Par3 - LGN - Inscuteable complex and NuMA - dynactin to align the spindle.	Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	Fuchs, E (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA.	fuchslb@rockefeller.edu	Fuchs, Elaine/G-1565-2016		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027883] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR027883-28] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Betschinger J, 2004, CURR BIOL, V14, pR674, DOI 10.1016/j.cub.2004.08.017; Brakebusch C, 2000, EMBO J, V19, P3990, DOI 10.1093/emboj/19.15.3990; Cowan CR, 2004, ANNU REV CELL DEV BI, V20, P427, DOI 10.1146/annurev.cellbio.19.111301.113823; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; Du QS, 2004, CELL, V119, P503, DOI 10.1016/j.cell.2004.10.028; Du QS, 2001, NAT CELL BIOL, V3, P1069, DOI 10.1038/ncb1201-1069; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; Grill SW, 2003, SCIENCE, V301, P518, DOI 10.1126/science.1086560; Kaushik R, 2003, MOL BIOL CELL, V14, P3144, DOI 10.1091/mbc.E03-04-0212; Kisurina-Evgenieva O, 2004, J CELL SCI, V117, P6391, DOI 10.1242/jcs.01568; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Lu BW, 2001, NATURE, V409, P522, DOI 10.1038/35054077; Mariotti A, 2001, J CELL BIOL, V155, P447, DOI 10.1083/jcb.200105017; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Parmentier ML, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-14-j0003.2000; PRICE CM, 1986, EXP CELL RES, V166, P95; Raghavan S, 2000, J CELL BIOL, V150, P1149, DOI 10.1083/jcb.150.5.1149; Roegiers F, 2004, CURR OPIN CELL BIOL, V16, P195, DOI 10.1016/j.ceb.2004.02.010; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; Srinivasan DG, 2003, GENE DEV, V17, P1225, DOI 10.1101/gad.1081203; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Vaezi A, 2002, DEV CELL, V3, P367, DOI 10.1016/S1534-5807(02)00259-9; vanderNeut R, 1996, NAT GENET, V13, P366, DOI 10.1038/ng0796-366; Vasioukhin V, 2001, NAT CELL BIOL, V3, P1076, DOI 10.1038/ncb1201-1076; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; WATT FM, 1984, J CELL BIOL, V98, P16, DOI 10.1083/jcb.98.1.16; WATT FM, 1982, NATURE, V295, P434, DOI 10.1038/295434a0; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5	31	732	752	1	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 8	2005	437	7056					275	280		10.1038/nature03922	http://dx.doi.org/10.1038/nature03922			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	961YE	16094321	Green Accepted			2022-12-28	WOS:000231696900060
J	Myer, L; Morroni, C; El-Sadr, WM				Myer, L; Morroni, C; El-Sadr, WM			Reproductive decisions in HIV-infected individuals	LANCET			English	Editorial Material							POSITIVE WOMEN; MEN; PREGNANCY		Univ Cape Town, Sch Publ Hlth & Family Med, Infect Dis Epidemiol Unit, ZA-7925 Cape Town, South Africa; Univ Cape Town, Sch Publ Hlth & Family Med, Womens Hlth Res Unit, ZA-7700 Rondebosch, South Africa; Columbia Univ, Mailman Sch Publ Hlth, Int Ctr AIDS Programs, New York, NY USA	University of Cape Town; University of Cape Town; Columbia University	Myer, L (corresponding author), Univ Cape Town, Sch Publ Hlth & Family Med, Infect Dis Epidemiol Unit, ZA-7925 Cape Town, South Africa.	lmyer@cormack.uct.ac.za		Morroni, Chelsea/0000-0002-2026-6039				Chen JL, 2001, FAM PLANN PERSPECT, V33, P144, DOI 10.2307/2673717; Dickinson BD, 2001, OBSTET GYNECOL, V98, P853, DOI 10.1016/S0029-7844(01)01532-0; Dyer SJ, 2002, HUM REPROD, V17, P1663, DOI 10.1093/humrep/17.6.1663; Feldman R, 2003, REPROD HEALTH MATTER, V11, P162, DOI 10.1016/S0968-8080(03)02284-5; Kirshenbaum SB, 2004, PERSPECT SEX REPRO H, V36, P106, DOI 10.1111/j.1931-2393.2004.tb00198.x; Myer L, 2005, REPROD HEALTH MATTER, V13, P136, DOI 10.1016/S0968-8080(05)25185-6; Nebie Y, 2001, J ACQ IMMUN DEF SYND, V28, P367, DOI 10.1097/00126334-200112010-00010; Paiva V, 2003, REPROD HEALTH MATTER, V11, P91, DOI 10.1016/S0968-8080(03)02293-6; Rossi AD, 2005, CONTRACEPTION, V71, P45, DOI 10.1016/j.contraception.2004.07.001; Saada M, 2000, AIDS, V14, P2355, DOI 10.1097/00002030-200010200-00017; Shelton JD, 2004, LANCET, V364, P1916, DOI 10.1016/S0140-6736(04)17489-8; VanDevanter N, 1999, AIDS CARE, V11, P181, DOI 10.1080/09540129948072; Watts DH, 2002, NEW ENGL J MED, V346, P1879, DOI 10.1056/NEJMra013338; *WHO, 2004, MED EL CONTR US	14	27	29	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 27	2005	366	9487					698	700		10.1016/S0140-6736(05)67155-3	http://dx.doi.org/10.1016/S0140-6736(05)67155-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958UV	16125573				2022-12-28	WOS:000231474600009
J	Wagner, JE; Thompson, JS; Carter, SL; Kernan, NA				Wagner, JE; Thompson, JS; Carter, SL; Kernan, NA		Unrelated Donor Marrow Transplanta	Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial	LANCET			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; COMPETING RISKS; TRANSPLANTATION; LYMPHOCYTES; PREVENTION; PROGRAM	Background Graft-versus-host disease (GVHD) reduces the efficacy of unrelated donor bone marrow transplantation in patients with lymphohaemopoietic malignancy. A multi-centre, randomised trial was undertaken to determine the effects of ex-vivo T-cell depletion versus methotrexate and cyclosporine immunosuppression on 3-year disease-free survival. Methods Between Mar 1, 1995, and Oct 31, 2000, 405 patients with lymphohaemopoietic malignancy, from 15 participating centres, were randomly assigned to undergo transplantation with either T-cell depleted marrow and cyclosporine A (TCD arm; n=201) or methotrexate and cyclosporine A after transplantation of T-replete marrow (M/C arm; n=204). The primary outcome was 3-year disease-free survival and was analysed by intention to treat. Findings Five patients died before transplantation. Seven in the TCD arm received T-replete grafts. Disease-free survival at 3 years was 27% (95% CI 21-33) and 34% (27-40) in recipients of TCD and M/C, respectively (p=0.16). TCD was associated with significantly more rapid neutrophil recovery (15 days vs 20 days, p<0.0001), less grade III-IV acute GVHD (18% vs 37%, p<0.0001), reduced grade III-IV toxicities (19% vs 29%, p=0.017), reduced duration of initial hospitalisation, but higher risk of chronic myelogenous leukaemia relapse (20% vs 7%, p=0.009) and cytomegalovirus infection (28% vs 17%, p=0.023) than was M/C. Interpretation Disease-free survival at 3 years did not differ between TCD and M/C groups. Relapse and opportunistic infection are important obstacles to successful unrelated donor bone marrow transplantation, irrespective of the method of GVHD prophylaxis used.	Univ Minnesota, Sch Med, Blood & Marrow Transplantat Program, Minneapolis, MN 55455 USA; Univ Kentucky, Lexington, KY USA; EMMES Corp, Rockville, MD USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Kentucky; Emmes Corporation; Memorial Sloan Kettering Cancer Center	Wagner, JE (corresponding author), Univ Minnesota, Sch Med, Blood & Marrow Transplantat Program, Mayo Mail Code 366 UMHC, Minneapolis, MN 55455 USA.	wagne002@umn.edu		Kernan, Nancy/0000-0003-1417-1823	DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB047094, N01HB047097, N01HB047098, N01HB047095] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HB-47098, N01-HB-47097, N01-HB-47095, N01-HB-47094] Funding Source: Medline	DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEARMAN SI, 1988, J CLIN ONCOL, V6, P1562, DOI 10.1200/JCO.1988.6.10.1562; BEATTY PG, 1993, BLOOD, V81, P249; Confer D L, 1997, Curr Opin Hematol, V4, P408; COX DR, 1972, J R STAT SOC B, V34, P187; de Lima M, 2001, Rev Clin Exp Hematol, V5, P100, DOI 10.1046/j.1468-0734.2001.00035.x; DEWITTE T, 1986, BLOOD, V67, P1302; *EUR GROUP BLOODMA, TRANSPL ACT SURV 200; Ferrara J L, 1999, Biol Blood Marrow Transplant, V5, P347, DOI 10.1016/S1083-8791(99)70011-X; FILIPOVICH AH, 1982, LANCET, V1, P1266; GOLDMAN JM, 1988, ANN INTERN MED, V108, P806, DOI 10.7326/0003-4819-108-6-806; Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O; HANSEN JA, 1980, NEW ENGL J MED, V303, P565, DOI 10.1056/NEJM198009043031007; Hongeng S, 1997, LANCET, V350, P767, DOI 10.1016/S0140-6736(97)03098-5; HOROWITZ MM, 2003, THOMAS HEMATOPOIETIC, P9; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kawanishi Y, 1997, BONE MARROW TRANSPL, V19, P1069, DOI 10.1038/sj.bmt.1700807; KERNAN NA, 1993, NEW ENGL J MED, V328, P593, DOI 10.1056/NEJM199303043280901; Lin DY, 1997, STAT MED, V16, P901, DOI 10.1002/(SICI)1097-0258(19970430)16:8<901::AID-SIM543>3.0.CO;2-M; Madrigal JA, 1997, IMMUNOL REV, V157, P153, DOI 10.1111/j.1600-065X.1997.tb00980.x; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MCGLAVE P, 1993, BLOOD, V81, P543; OCHS L, 1995, BLOOD, V86, P3979, DOI 10.1182/blood.V86.10.3979.bloodjournal86103979; OREILLY RJ, 1992, SEMIN HEMATOL, V29, P20; Parkman R, 1997, IMMUNOL REV, V157, P73, DOI 10.1111/j.1600-065X.1997.tb00975.x; Pearson K, 1900, PHILOS MAG, V50, P157, DOI 10.1080/14786440009463897; PETERSDORF EW, 1995, BLOOD, V86, P1606, DOI 10.1182/blood.V86.4.1606.bloodjournal8641606; PETERSDORF EW, 2003, THOMAS HEMATOPOIET C, P1132; Ringden O DH, 1996, GRAFT VS HOST DIS, P525; Rowlings PA, 1997, BRIT J HAEMATOL, V97, P855, DOI 10.1046/j.1365-2141.1997.1112925.x; Sierra J, 1997, BLOOD, V89, P4226, DOI 10.1182/blood.V89.11.4226; Snedecor GW, 1980, STAT METHODS, V7th; SOIFFER RJ, 1992, J CLIN ONCOL, V10, P1191, DOI 10.1200/JCO.1992.10.7.1191; Sposto R, 1997, STAT MED, V16, P695, DOI 10.1002/(SICI)1097-0258(19970330)16:6<695::AID-SIM436>3.0.CO;2-C; WAGNER JE, 1992, J CLIN ONCOL, V10, P779, DOI 10.1200/JCO.1992.10.5.779; WAGNER JE, 1990, BLOOD, V75, P1370; Weisdorf DJ, 2003, BIOL BLOOD MARROW TR, V9, P512, DOI 10.1016/S1083-8791(03)00162-9	36	171	178	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 27	2005	366	9487					733	741		10.1016/S0140-6736(05)66996-6	http://dx.doi.org/10.1016/S0140-6736(05)66996-6			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958UV	16125590				2022-12-28	WOS:000231474600029
J	Bagga, S; Bracht, J; Hunter, S; Massirer, K; Holtz, J; Eachus, R; Pasquinelli, AE				Bagga, S; Bracht, J; Hunter, S; Massirer, K; Holtz, J; Eachus, R; Pasquinelli, AE			Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation	CELL			English	Article							HETEROCHRONIC GENE LIN-14; NEGATIVE POSTTRANSCRIPTIONAL REGULATION; MICRORNA-DIRECTED CLEAVAGE; UTR SEQUENCE MOTIF; CAENORHABDITIS-ELEGANS; C-ELEGANS; DEVELOPMENTAL SWITCH; K-BOX; EXPRESSION; COMPLEX	MicroRNAs (miRNAs) are similar to 22 nucleotide RNAs that negatively regulate the expression of protein-coding genes. In a present model of miRNA function in animals, miRNAs that form imperfect duplexes with their targets inhibit protein expression without affecting mRNA levels. Here, we report that in C. elegans, regulation by the let-7miRNA results in degradation of its lin-41 target mRNA, despite the fact that its 3'UTR regulatory sequences can only partially base-pair with the miRNA. Furthermore, lin-14 and lin-28 are targets of the lin-4 miRNA, and we show that the mRNA levels for these protein-coding genes significantly decrease in response to lin-4 expression. This study reveals that mRNAs containing partial miRNA complementary sites can be targeted for degradation in vivo, raising the possibility that regulation at the level of mRNA stability may be more common than previously appreciated for the miRNA pathway.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Pasquinelli, AE (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.	apasquin@ucsd.edu	Massirer, Katlin Brauer/C-8321-2016	Massirer, Katlin Brauer/0000-0001-6390-2560	NIAID NIH HHS [5P30 AI36214] Funding Source: Medline; NIGMS NIH HHS [GM071654-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071654] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBROS V, 1989, CELL, V57, P49, DOI 10.1016/0092-8674(89)90171-2; ARASU P, 1991, GENE DEV, V5, P1825, DOI 10.1101/gad.5.10.1825; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bracht J, 2004, RNA, V10, P1586, DOI 10.1261/rna.7122604; Chu DS, 2002, GENE DEV, V16, P796, DOI 10.1101/gad.972702; Cullen BR, 2004, MOL CELL, V16, P861, DOI 10.1016/j.molcel.2004.12.002; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Dugas DV, 2004, CURR OPIN PLANT BIOL, V7, P512, DOI 10.1016/j.pbi.2004.07.011; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Grishok A, 2005, GENE DEV, V19, P683, DOI 10.1101/gad.1247705; Ha I, 1996, GENE DEV, V10, P3041, DOI 10.1101/gad.10.23.3041; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Jing Q, 2005, CELL, V120, P623, DOI 10.1016/j.cell.2004.12.038; Johnson SM, 2003, DEV BIOL, V259, P364, DOI 10.1016/S0012-1606(03)00202-1; Jones-Rhoades MW, 2004, MOL CELL, V14, P787, DOI 10.1016/j.molcel.2004.05.027; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kasschau KD, 2003, DEV CELL, V4, P205, DOI 10.1016/S1534-5807(03)00025-X; Kim J, 2004, P NATL ACAD SCI USA, V101, P360, DOI 10.1073/pnas.2333854100; Lai EC, 1997, DEVELOPMENT, V124, P4847; Lai EC, 1998, DEVELOPMENT, V125, P4077; Lai EC, 2005, GENE DEV, V19, P1067, DOI 10.1101/gad.1291905; Lai EC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-115; Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865; Lai WS, 1999, MOL CELL BIOL, V19, P4311; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Liu JD, 2005, NAT CELL BIOL, V7, P719, DOI 10.1038/ncb1274; Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311; Mansfield JH, 2004, NAT GENET, V36, P1079, DOI 10.1038/ng1421; Martinez J, 2004, GENE DEV, V18, P975, DOI 10.1101/gad.1187904; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Mello CC, 2004, NATURE, V431, P338, DOI 10.1038/nature02872; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; Nelson PT, 2004, RNA, V10, P387, DOI 10.1261/rna.5181104; Newbury S, 2004, RNA, V10, P59, DOI 10.1261/rna.2195504; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Orban TI, 2005, RNA, V11, P459, DOI 10.1261/rna.7231505; Page MF, 1999, MOL CELL BIOL, V19, P5943; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; Pasquinelli AE, 2002, ANNU REV CELL DEV BI, V18, P495, DOI 10.1146/annurev.cellbio.18.012502.105832; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Pasquinelli AE, 2003, EVOL DEV, V5, P372, DOI 10.1046/j.1525-142X.2003.03044.x; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Reinhart BJ, 2001, GENETICS, V157, P199; RUVKUN G, 1989, NATURE, V338, P313, DOI 10.1038/338313a0; Sandoval J, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh091; Seggerson K, 2002, DEV BIOL, V243, P215, DOI 10.1006/dbio.2001.0563; Sen GL, 2005, NAT CELL BIOL, V7, P633, DOI 10.1038/ncb1265; Shen BZ, 2004, SCIENCE, V306, P997, DOI 10.1126/science.1103521; Simmer F, 2002, CURR BIOL, V12, P1317, DOI 10.1016/S0960-9822(02)01041-2; Slack FJ, 2000, MOL CELL, V5, P659, DOI 10.1016/S1097-2765(00)80245-2; Souret FF, 2004, MOL CELL, V15, P173, DOI 10.1016/j.molcel.2004.06.006; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Tang GL, 2003, GENE DEV, V17, P49, DOI 10.1101/gad.1048103; Vella MC, 2004, CHEM BIOL, V11, P1619, DOI 10.1016/j.chembiol.2004.09.010; Vella MC, 2004, GENE DEV, V18, P132, DOI 10.1101/gad.1165404; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; WIGHTMAN B, 1991, GENE DEV, V5, P1813, DOI 10.1101/gad.5.10.1813; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434; Zeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100; Zeng Y, 2002, MOL CELL, V9, P1327, DOI 10.1016/S1097-2765(02)00541-5	62	1068	1152	5	88	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 26	2005	122	4					553	563		10.1016/j.cell.2005.07.031	http://dx.doi.org/10.1016/j.cell.2005.07.031			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	959YI	16122423	Bronze			2022-12-28	WOS:000231555100011
J	Bannister, AJ; Kouzarides, T				Bannister, AJ; Kouzarides, T			Reversing histone methylation	NATURE			English	Article							ARGININE METHYLATION; CHROMATIN; HETEROCHROMATIN; COMPLEX; METHYLTRANSFERASES; TRIMETHYLATION; DEMETHYLATION; ACETYLATION; RECRUITMENT; DOMAINS	Histones package DNA, and post-translational modifications of histones can regulate access to DNA. Until recently, histone methylation - unlike all other histone modifications - was considered a permanent mark. The discovery of enzymes that reverse the methylation of lysines and arginines challenges our current thinking on the unique nature of histone methylation, and substantially increases the complexity of histone modification pathways.	Gurdon Inst, Cambridge CB2 1QN, England; Dept Pathol, Cambridge CB2 1QN, England		Kouzarides, T (corresponding author), Gurdon Inst, Tennis Court Rd, Cambridge CB2 1QN, England.	tk106@mole.bio.cam.ac.uk		Kouzarides, Tony/0000-0002-8918-4162; Bannister, Andrew/0000-0002-6312-4436				Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; BOISVERT FM, 2005, SCI STKE; Cuthbert GL, 2004, CELL, V118, P545, DOI 10.1016/j.cell.2004.08.020; Elgin SCR, 2003, CURR BIOL, V13, pR895, DOI 10.1016/j.cub.2003.11.006; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Freitag M, 2005, CURR OPIN GENET DEV, V15, P191, DOI 10.1016/j.gde.2005.02.003; Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Kohlmaier A, 2004, PLOS BIOL, V2, P991, DOI 10.1371/journal.pbio.0020171; Lee DY, 2005, ENDOCR REV, V26, P147, DOI 10.1210/er.2004-0008; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Martens JHA, 2005, EMBO J, V24, P800, DOI 10.1038/sj.emboj.7600545; Maurer-Stroh S, 2003, TRENDS BIOCHEM SCI, V28, P69, DOI 10.1016/S0968-0004(03)00004-5; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; METZGER E, NATURE; PAIK WK, 1973, BIOCHEM BIOPH RES CO, V51, P781, DOI 10.1016/0006-291X(73)91383-1; Pal-Bhadra M, 2004, SCIENCE, V303, P669, DOI 10.1126/science.1092653; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Rougeulle C, 2004, MOL CELL BIOL, V24, P5475, DOI 10.1128/MCB.24.12.5475-5484.2004; Sanders SL, 2004, CELL, V119, P603, DOI 10.1016/j.cell.2004.11.009; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; Verdel A, 2004, SCIENCE, V303, P672, DOI 10.1126/science.1093686; Vossenaar ER, 2003, BIOESSAYS, V25, P1106, DOI 10.1002/bies.10357; Wang Y, 2004, SCIENCE, V306, P279, DOI 10.1126/science.1101400; White SA, 2004, NAT CELL BIOL, V6, P696, DOI 10.1038/ncb0804-696; Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036	36	354	374	9	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 25	2005	436	7054					1103	1106		10.1038/nature04048	http://dx.doi.org/10.1038/nature04048			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	958AK	16121170				2022-12-28	WOS:000231416600034
J	Weylandt, KH; Kang, JX				Weylandt, KH; Kang, JX			Rethinking lipid mediators	LANCET			English	Editorial Material							POLYUNSATURATED FATTY-ACIDS; ANTI-INFLAMMATION; IMMUNE-RESPONSES; RESOLVIN E1; RECEPTOR; PROSTAGLANDINS; EXPRESSION; ASPIRIN; BRAIN; CELLS		Charite Univ Hosp, Dept Gastroenterol & Hepatol, D-13353 Berlin, Germany; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med, Charlestown, MA USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Harvard University; Massachusetts General Hospital	Weylandt, KH (corresponding author), Charite Univ Hosp, Dept Gastroenterol & Hepatol, Campus Virchow, D-13353 Berlin, Germany.	karsten.weylandt@charite.de						Arita M, 2005, P NATL ACAD SCI USA, V102, P7671, DOI 10.1073/pnas.0409271102; Arita M, 2005, J EXP MED, V201, P713, DOI 10.1084/jem.20042031; Bagga D, 2003, P NATL ACAD SCI USA, V100, P1751, DOI 10.1073/pnas.0334211100; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; Kang JX, 1996, P NATL ACAD SCI USA, V93, P3542, DOI 10.1073/pnas.93.8.3542; Langenbach R, 1999, ANN NY ACAD SCI, V889, P52, DOI 10.1111/j.1749-6632.1999.tb08723.x; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; McMahon B, 2004, AM J PHYSIOL-RENAL, V286, pF189, DOI 10.1152/ajprenal.00224.2003; MONCADA S, 1973, NATURE, V246, P217, DOI 10.1038/246217a0; Narumiya S, 2001, J CLIN INVEST, V108, P25, DOI 10.1172/JCI200113455; Peters-Golden M, 2005, J IMMUNOL, V174, P589, DOI 10.4049/jimmunol.174.2.589; ROTH GJ, 1975, P NATL ACAD SCI USA, V72, P3073, DOI 10.1073/pnas.72.8.3073; Serhan CN, 2005, PHARMACOL THERAPEUT, V105, P7, DOI 10.1016/j.pharmthera.2004.09.002; Serhan CN, 2001, J CLIN INVEST, V107, P1481, DOI 10.1172/JCI13375; Simopoulos AP, 2002, BIOMED PHARMACOTHER, V56, P365, DOI 10.1016/S0753-3322(02)00253-6; Tilley SL, 2001, J CLIN INVEST, V108, P15, DOI 10.1172/JCI200113416; Warner TD, 2004, FASEB J, V18, P790, DOI 10.1096/fj.03-0645rev; Yang PY, 2004, J LIPID RES, V45, P1030, DOI 10.1194/jlr.M300455-JLR200; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	19	45	51	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 20	2005	366	9486					618	620		10.1016/S0140-6736(05)67119-X	http://dx.doi.org/10.1016/S0140-6736(05)67119-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958EB	16112288				2022-12-28	WOS:000231426400010
J	Nee, S; Colegrave, N; West, SA; Grafen, A				Nee, S; Colegrave, N; West, SA; Grafen, A			The illusion of invariant quantities in life histories	SCIENCE			English	Article							BODY-SIZE; SEX-CHANGE; TRADE-OFF; REPRODUCTION; EVOLUTION; GROWTH; AGE; ANIMALS; MODELS; FISHES	Life-history theory attempts to provide evolutionary explanations for variations in the ways in which animal species live their lives. Recent analyses have suggested that the dimensionless ratios of several key life-history parameters are the same for different species, even across distant taxa. However, we show here that previous analyses may have given a false picture and created an illusion of invariants, which do not necessarily exist; essentially, this is because life-history variables have been regressed against themselves. The following question arises from our analysis: How do we identify an invariant?	Univ Edinburgh, Sch Biol Sci, Inst Evolutionary Biol, Edinburgh EH9 3JT, Midlothian, Scotland; Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Edinburgh; University of Oxford	Nee, S (corresponding author), Univ Edinburgh, Sch Biol Sci, Inst Evolutionary Biol, W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.	sean.nee@ed.ac.uk	Colegrave, Nick/F-3916-2010; West, Stuart A/M-3608-2014	West, Stuart A/0000-0003-2152-3153; Grafen, Alan/0000-0002-1843-6457				Allsop DJ, 2003, J EVOLUTION BIOL, V16, P921, DOI 10.1046/j.1420-9101.2003.00590.x; Allsop DJ, 2003, NATURE, V425, P783, DOI 10.1038/425783a; Beddington JR, 2005, PHILOS T R SOC B, V360, P163, DOI 10.1098/rstb.2004.1582; Buston PM, 2004, NATURE, V428, DOI 10.1038/nature02512; Charnov EL, 2000, EVOL ECOL RES, V2, P1067; Charnov EL, 1997, NATURE, V387, P393, DOI 10.1038/387393a0; Charnov EL, 2002, EVOL ECOL RES, V4, P749; Charnov EL, 2001, P NATL ACAD SCI USA, V98, P9460, DOI 10.1073/pnas.161294498; Charnov Eric L., 1993, P1; Cipriani R, 2005, J EVOLUTION BIOL, V18, P1613, DOI 10.1111/j.1420-9101.2005.00949.x; Clobert J, 1998, J EVOLUTION BIOL, V11, P329; Economo EP, 2005, ECOL LETT, V8, P353, DOI 10.1111/j.1461-0248.2005.00737.x; Gardner A, 2005, AM NAT, V165, P551, DOI 10.1086/429526; Gemmill AW, 1999, J EVOLUTION BIOL, V12, P1148, DOI 10.1046/j.1420-9101.1999.00117.x; Hawkes K, 2004, NATURE, V428, P128, DOI 10.1038/428128a; He JX, 2001, ECOLOGY, V82, P784, DOI 10.1890/0012-9658(2001)082[0784:AASAFR]2.0.CO;2; Heino M, 1999, J EVOLUTION BIOL, V12, P423; Jensen AL, 1996, CAN J FISH AQUAT SCI, V53, P820, DOI 10.1139/cjfas-53-4-820; Jones KE, 2001, EVOL ECOL RES, V3, P465; Kozlowski J, 1997, AM NAT, V149, P352; KOZLOWSKI J, 1996, P ROY SOC LOND B BIO, V263, P556; Lester NP, 2004, P ROY SOC B-BIOL SCI, V271, P1625, DOI 10.1098/rspb.2004.2778; Mangel M, 1996, EVOL ECOL, V10, P249, DOI 10.1007/BF01237683; MILES DB, 1994, ECOLOGY, V75, P2143; Moller AP, 2002, OECOLOGIA, V132, P492, DOI 10.1007/s00442-002-0952-2; Morand S, 1996, FUNCT ECOL, V10, P210, DOI 10.2307/2389845; PURVIS A, 1995, J ZOOL, V237, P259, DOI 10.1111/j.1469-7998.1995.tb02762.x; Ricklefs RE, 2000, CONDOR, V102, P9, DOI 10.1650/0010-5422(2000)102[0009:DDEOAT]2.0.CO;2; Roff Derek, 2002, pi; SMITH JM, 1993, Q REV BIOL, V68, P557; Stearns S.C., 1992, pi; West GB, 2004, PHYS TODAY, V57, P36, DOI 10.1063/1.1809090; Willemsen RE, 1999, J ZOOL, V248, P379, DOI 10.1111/j.1469-7998.1999.tb01037.x; Williams EH, 2003, CAN J FISH AQUAT SCI, V60, P710, DOI 10.1139/F03-059	34	71	73	3	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 19	2005	309	5738					1236	1239		10.1126/science.1114488	http://dx.doi.org/10.1126/science.1114488			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	957TE	16109879				2022-12-28	WOS:000231395400044
J	Gawande, A				Gawande, A			Naked	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Gawande, A (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.			Gawande, Atul/0000-0002-1824-9176				*AD HOC COMM PHYS, 1996, REP SEX BOUND ISS; Dehlendorf CE, 1998, JAMA-J AM MED ASSOC, V279, P1883, DOI 10.1001/jama.279.23.1883; Enbom JA, 1997, AM J OBSTET GYNECOL, V176, P1340, DOI 10.1016/S0002-9378(97)70355-7; *GEN MED COUNC STA, 2000, INT EX; Royal College of Obstetricians and Gynaecologists, 2002, GYN EX GUID SPEC PRA	5	6	6	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 18	2005	353	7					645	648		10.1056/NEJMp058120	http://dx.doi.org/10.1056/NEJMp058120			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955UW	16107618				2022-12-28	WOS:000231254100001
J	Artsimovitch, I; Vassylyeva, MN; Svetlov, D; Svetlov, V; Perederina, A; Igarashi, N; Matsugaki, N; Wakatsuki, S; Tahirov, TH; Vassylyev, DG				Artsimovitch, I; Vassylyeva, MN; Svetlov, D; Svetlov, V; Perederina, A; Igarashi, N; Matsugaki, N; Wakatsuki, S; Tahirov, TH; Vassylyev, DG			Allosteric modulation of the RNA polymerase catalytic reaction is an essential component of transcription control by rifamycins	CELL			English	Article							RIFAMPICIN-RESISTANCE MUTATIONS; ELECTRON-DENSITY MAPS; COLI RPOB GENE; ESCHERICHIA-COLI; MYCOBACTERIUM-TUBERCULOSIS; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; BETA-SUBUNIT; INHIBITION; DNA	Rifamycins, the clinically important antibiotics, target bacterial RNA polymerase (RNAP). A proposed mechanism in which rifamycins sterically block the extension of nascent RNA beyond three nucleotides does not alone explain why certain RNAP mutations confer resistance to some but not other rifamycins. Here we show that unlike rifampicin and rifapentin, and contradictory to the steric model, rifabutin inhibits formation of the first and second phosphodiester bonds. We report 2.5 angstrom resolution structures of rifabutin and rifapentin complexed with the Thermus thermophilus RNAP holoenzyme. The structures reveal functionally important distinct interactions of antibiotics with the initiation sigma factor. Strikingly, both complexes lack the catalytic Mg2+ ion observed in the apo-holoenzyme, whereas an increase in Mg2+ concentration confers resistance to rifamycins. We propose that a rifamycin-induced signal is transmitted over 19 angstrom to the RNAP active site to slow down catalysis. Based on structural predictions, we designed enzyme substitutions that apparently interrupt this allosteric signal.	RIKEN, Harima Inst, Struct & Mol Biol Lab, Sayo, Hyogo 6795148, Japan; Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; RIKEN, Harima Inst, High Throughput Factory, Sayo, Hyogo 6795148, Japan; High Energy Accelerator Res Org, KEK, Inst Mat Struct Sci, Photon Factory,Struct Biol Res Ctr, Tsukuba, Ibaraki 3050801, Japan; Univ Alabama, Sch Med, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama, Sch Dent, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA	RIKEN; University System of Ohio; Ohio State University; RIKEN; High Energy Accelerator Research Organization (KEK); University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Vassylyev, DG (corresponding author), RIKEN, Harima Inst, Struct & Mol Biol Lab, Spring 8,1-1-1 Kouto,Mikazuki Cho, Sayo, Hyogo 6795148, Japan.	dmitry@uab.edu	Vassylyev, Dmitry/A-9005-2008; Artsimovitch, Irina/L-3467-2019	Svetlov, Dmitri/0000-0002-2094-3183; Tahirov, Tahir/0000-0002-1238-0069; Igarashi, Noriyuki/0000-0003-2617-3690; Matsugaki, Naohiro/0000-0001-9640-1949; Wakatsuki, Soichi/0000-0001-5896-7968	NIAID NIH HHS [AI64819, R21 AI064819-01] Funding Source: Medline; NIGMS NIH HHS [R01 GM067153-02, GM67153, R01 GM074252-01, GM74252] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI064819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074252, R01GM067153] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN CR, 1994, P NATL ACAD SCI USA, V91, P3784, DOI 10.1073/pnas.91.9.3784; Artsimovitch I, 2004, CELL, V117, P299, DOI 10.1016/S0092-8674(04)00401-5; Artsimovitch I, 2003, J BIOL CHEM, V278, P12344, DOI 10.1074/jbc.M211214200; Bacchi A, 1998, J MED CHEM, V41, P2319, DOI 10.1021/jm970791o; BARH W, 1976, RNA POLYMERASE, P369; BOYD DH, 1974, MOL GEN GENET, V130, P315, DOI 10.1007/BF00333870; BRUFANI M, 1982, MOL PHARMACOL, V21, P394; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campbell EA, 2001, CELL, V104, P901, DOI 10.1016/S0092-8674(01)00286-0; Campbell EA, 2005, EMBO J, V24, P674, DOI 10.1038/sj.emboj.7600499; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Floss HG, 2005, CHEM REV, V105, P621, DOI 10.1021/cr030112j; GILL S, 1990, J MOL BIOL, V220, P307; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAWAI M, 1976, MOL GEN GENET, V143, P233, DOI 10.1007/BF00269399; KERRICHSANTO RE, 1974, EUR J BIOCHEM, V43, P521, DOI 10.1111/j.1432-1033.1974.tb03439.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Maggi N, 1965, Antimicrob Agents Chemother (Bethesda), V5, P765; Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258; MCCLURE WR, 1978, J BIOL CHEM, V253, P8949; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MUSTAEV A, 1994, P NATL ACAD SCI USA, V91, P12036, DOI 10.1073/pnas.91.25.12036; Nickels BE, 2004, CELL, V118, P281, DOI 10.1016/j.cell.2004.07.021; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OVCHINNIKOV YA, 1983, MOL GEN GENET, V190, P344, DOI 10.1007/BF00330662; ROMERO E, 1973, NATURE-NEW BIOL, V246, P225, DOI 10.1038/newbio246225a0; Sarubbi E, 2004, EUR J BIOCHEM, V271, P3146, DOI 10.1111/j.1432-1033.2004.04244.x; SCHULZ W, 1981, NUCLEIC ACIDS RES, V9, P6889, DOI 10.1093/nar/9.24.6889; SEVERINOV K, 1993, J BIOL CHEM, V268, P14820; SEVERINOV K, 1994, MOL GEN GENET, V244, P120, DOI 10.1007/BF00283512; SIPPEL AE, 1970, EUR J BIOCHEM, V16, P152, DOI 10.1111/j.1432-1033.1970.tb01066.x; STENDER W, 1975, EUR J BIOCHEM, V56, P129, DOI 10.1111/j.1432-1033.1975.tb02215.x; TELENTI A, 1993, LANCET, V341, P647, DOI 10.1016/0140-6736(93)90417-F; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; Vassylyeva MN, 2002, ACTA CRYSTALLOGR D, V58, P1497, DOI 10.1107/S0907444902011770; Wang ZM, 1997, NAT STRUCT BIOL, V4, P519, DOI 10.1038/nsb0797-519; Wegrzyn A, 1998, FEBS LETT, V440, P172, DOI 10.1016/S0014-5793(98)01449-5; WEHRLI W, 1969, BIOCHIM BIOPHYS ACTA, V182, P24, DOI 10.1016/0005-2787(69)90516-4; Wichelhaus TA, 2001, J ANTIMICROB CHEMOTH, V47, P153, DOI 10.1093/jac/47.2.153; Williams DL, 1998, ANTIMICROB AGENTS CH, V42, P1853, DOI 10.1128/AAC.42.7.1853; YIN H, 1995, SCIENCE, V270, P1653, DOI 10.1126/science.270.5242.1653; Zenkin N, 2004, P NATL ACAD SCI USA, V101, P4396, DOI 10.1073/pnas.0400886101	44	131	138	1	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 12	2005	122	3					351	363		10.1016/j.cell.2005.07.014	http://dx.doi.org/10.1016/j.cell.2005.07.014			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	955UZ	16096056	Bronze			2022-12-28	WOS:000231254400008
J	Wilks, M				Wilks, M			A stain on medical ethics	LANCET			English	Editorial Material							DOCTORS		BMA House, London WC1H 9JP, England		Wilks, M (corresponding author), BMA House, Tavistock Sq, London WC1H 9JP, England.	mwilks@bma.org.uk						*AM PSYCH ASS, 2005, REP AM PSYCH ASS PRE; *AM PSYCH ASS, 2005, STAT PSYCH PRACT GUA; *ASS SECR DEF HLTH, 2005, MED PROGR PRINC PROC; Bloche MG, 2005, NEW ENGL J MED, V353, P6, DOI 10.1056/NEJMp058145; Bloche MG, 2005, NEW ENGL J MED, V352, P3, DOI 10.1056/NEJMp048346; *BRIT MED ASS, 1992, MED BETR, P43; Bush George W., 2002, COMMUNICATION 0207; *DEP DEF, 2004, FIN REP IND PAN REV; GONZALEZ AR, 2002, COMMUNICATION   0801; International Dual Loyalty Working Group, 2002, DUAL LOYALT HUM RIGH; LEE BJ, 2005, WASHINGTON POST 0701; Lewis Neil A, 2004, N Y Times Web, pA14; LIFTON R, 1986, NAZI DOCTORS PSYCHOL; Lifton RJ, 2004, NEW ENGL J MED, V351, P415, DOI 10.1056/NEJMp048065; MAYER J, 2005, NEW YORKER      0711, P61; Physicians for Human Rights, 2005, BREAK THEM SYST US P; Slevin Peter, 2004, Washington Post, pA13	17	23	23	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 6	2005	366	9484					429	431		10.1016/S0140-6736(05)67035-3	http://dx.doi.org/10.1016/S0140-6736(05)67035-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	952RD	16084233				2022-12-28	WOS:000231022300004
J	Kurosu, H; Yamamoto, M; Clark, JD; Pastor, JV; Nandi, A; Gurnani, P; McGuinness, OP; Chikuda, H; Yamaguchi, M; Kawaguchi, H; Shimomura, I; Takayama, Y; Herz, J; Kahn, CR; Rosenblatt, KP; Kuro-o, M				Kurosu, H; Yamamoto, M; Clark, JD; Pastor, JV; Nandi, A; Gurnani, P; McGuinness, OP; Chikuda, H; Yamaguchi, M; Kawaguchi, H; Shimomura, I; Takayama, Y; Herz, J; Kahn, CR; Rosenblatt, KP; Kuro-o, M			Suppression of aging in mice by the hormone Klotho	SCIENCE			English	Article							INSULIN-RECEPTOR; LIFE-SPAN; FUNCTIONAL VARIANT; BONE-DENSITY; GENE; ASSOCIATION; LONGEVITY; MUTANT; POLYMORPHISMS; GLUCOSE	A defect in Klotho gene expression in mice accelerates the degeneration of multiple age-sensitive traits. Here, we show that overexpression of Klotho in mice extends life span. Klotho protein functions as a circulating hormone that binds to a cell-surface receptor and represses intracellular signals of insulin and insulin-like growth factor 1 (IGF1), an evolutionarily conserved mechanism for extending life span. Alleviation of aging-like phenotypes in Klotho-deficient mice was observed by perturbing insulin and IGF1 signaling, suggesting that Klotho-mediated inhibition of insulin and IGF1 signaling contributes to its anti-aging properties. Klotho protein may function as an anti-aging hormone in mammals.	Univ Texas, SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr Dallas, Dept Mol Genet, Dallas, TX 75390 USA; Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Univ Tokyo, Dept Sensory & Motor Syst Med, Bunkyo Ku, Tokyo 1138655, Japan; Osaka Univ, Dept Internal Med & Mol Sci, Suita, Osaka 5650871, Japan; Harvard Univ, Sch Med, Joslin Diabet Ctr, Dept Med,Res Div, Boston, MA 02215 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Vanderbilt University; University of Tokyo; Osaka University; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Kuro-o, M (corresponding author), Univ Texas, SW Med Ctr Dallas, Dept Pathol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	makoto.kuro-o@utsouthwestern.edu	Takayama, Yoshiharu/E-3662-2010; Kahn, Ronald/AAY-2435-2021; Takayama, Yoshiharu/M-8826-2019	Takayama, Yoshiharu/0000-0003-4532-7114; Kahn, Ronald/0000-0002-7583-9228; Takayama, Yoshiharu/0000-0003-4532-7114	NHLBI NIH HHS [R37 HL063762] Funding Source: Medline; NIA NIH HHS [R01 AG025326-03, R01 AG019712, R01AG19712, R01 AG019712-05, R01AG25326, R01 AG025326] Funding Source: Medline; NIDDK NIH HHS [U24 DK059637] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL063762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U24DK059637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG025326, R01AG019712] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Arking DE, 2005, CIRC RES, V96, P412, DOI 10.1161/01.RES.0000157171.04054.30; Arking DE, 2003, AM J HUM GENET, V72, P1154, DOI 10.1086/375035; Arking DE, 2002, P NATL ACAD SCI USA, V99, P856, DOI 10.1073/pnas.022484299; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; GRABNITZ F, 1991, EUR J BIOCHEM, V200, P301, DOI 10.1111/j.1432-1033.1991.tb16186.x; Halseth AE, 1999, AM J PHYSIOL-ENDOC M, V276, pE70, DOI 10.1152/ajpendo.1999.276.1.E70; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Imura A, 2004, FEBS LETT, V565, P143, DOI 10.1016/j.febslet.2004.03.090; Kawano KI, 2002, J BONE MINER RES, V17, P1744, DOI 10.1359/jbmr.2002.17.10.1744; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; MILLER RA, 2001, SCI AGING KNOWLEDGE, pVP6; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Ogata N, 2002, BONE, V31, P37, DOI 10.1016/S8756-3282(02)00786-X; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Takahashi Y, 2000, P NATL ACAD SCI USA, V97, P12407, DOI 10.1073/pnas.210382097; Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; Utsugi T, 2000, METABOLISM, V49, P1118, DOI 10.1053/meta.2000.8606; WEINDRUCH R, 1986, J NUTR, V116, P641, DOI 10.1093/jn/116.4.641; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x; Yamada Y, 2005, J MOL MED, V83, P50, DOI 10.1007/s00109-004-0578-4	27	1280	1368	2	136	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 16	2005	309	5742					1829	1833		10.1126/science.1112766	http://dx.doi.org/10.1126/science.1112766			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	965ZN	16123266	Green Accepted			2022-12-28	WOS:000231989500041
J	Bhan, MK; Bahl, R; Bhatnagar, S				Bhan, MK; Bahl, R; Bhatnagar, S			Typhoid and paratyphoid fever	LANCET			English	Review							ENTERICA-SEROVAR-TYPHI; RESISTANT SALMONELLA-TYPHI; VI-CAPSULAR POLYSACCHARIDE; CONTROLLED FIELD TRIAL; INTESTINAL EPITHELIAL-CELLS; RANDOMIZED CONTROLLED-TRIAL; HIGH-DOSE DEXAMETHASONE; IMMATURE BEAGLE DOGS; MULTIDRUG-RESISTANT; BONE-MARROW	Typhoid fever is estimated to have caused 21.6 million illnesses and 216 500 deaths globally in 2000, affecting all ages. There is also one case of paratyphoid fever for every four of typhoid. The global emergence of multidrug-resistant strains and of strains with reduced susceptibility to fluoroquinolones is of great concern. We discuss the occurrence of poor clinical response to fluoroquinolones despite disc sensitivity. Developments are being made in our understanding of the molecular pathogenesis, and genomic and proteomic studies reveal the possibility of new targets for diagnosis and treatment. Further, we review guidelines for use of diagnostic tests and for selection of antimicrobials in varying clinical situations. The importance of safe water, sanitation, and immunisation in the presence of increasing antibiotic resistance is paramount. Routine immunisation of school-age children with Vi or Ty21a vaccine is recommended for countries endemic for typhoid. Vi vaccine should be used for 2-5 year-old children in highly endemic settings.	All India Inst Med Sci, New Delhi 110029, India	All India Institute of Medical Sciences (AIIMS) New Delhi	Bhan, MK (corresponding author), All India Inst Med Sci, New Delhi 110029, India.	mkbhan@dbt.nic.in		bhatnagar, shinjini/0000-0003-1703-5296				Abdel Fadeel M, 2004, AM J TROP MED HYG, V70, P323, DOI 10.4269/ajtmh.2004.70.323; ACHARYA IL, 1987, NEW ENGL J MED, V317, P1101, DOI 10.1056/NEJM198710293171801; Ackers ML, 2000, JAMA-J AM MED ASSOC, V283, P2668, DOI 10.1001/jama.283.20.2668; Akinyemi KO, 2000, Z NATURFORSCH C, V55, P489; Albaqali A, 2003, AM J KIDNEY DIS, V41, P709, DOI 10.1053/ajkd.2003.50135; Asna SMZH, 2003, JPN J INFECT DIS, V56, P32; Bahl R, 2004, J HEALTH POPUL NUTR, V22, P304; Bahrmand AR, 1997, SCAND J INFECT DIS, V29, P265, DOI 10.3109/00365549709019040; Balasubramanian S, 2003, ANN TROP PAEDIATR, V23, P223; Battikhi MNG, 2003, MICROBIOLOGICA, V26, P363; Begier EM, 2004, CLIN INFECT DIS, V38, P771, DOI 10.1086/381548; Bethell DB, 1996, ARCH DIS CHILD, V74, P44, DOI 10.1136/adc.74.1.44; Beuzon CR, 2000, EMBO J, V19, P3235, DOI 10.1093/emboj/19.13.3235; Bhan MK, 2002, J INFECT DIS, V186, P1857, DOI 10.1086/345762; Bhutta ZA, 1999, AM J TROP MED HYG, V61, P654, DOI 10.4269/ajtmh.1999.61.654; BHUTTA ZA, 1991, REV INFECT DIS, V13, P832; Bhutta ZA, 2000, ANTIMICROB AGENTS CH, V44, P450, DOI 10.1128/AAC.44.2.450-452.2000; BLACK RE, 1990, VACCINE, V8, P81, DOI 10.1016/0264-410X(90)90183-M; BLACK RE, 1985, B WORLD HEALTH ORGAN, V63, P899; Boddicker JD, 2004, INFECT IMMUN, V72, P2002, DOI 10.1128/IAI.72.4.2002-2013.2004; Brown JC, 1996, J ANTIMICROB CHEMOTH, V37, P891, DOI 10.1093/jac/37.5.891; BURKHARDT JE, 1990, VET PATHOL, V27, P162, DOI 10.1177/030098589002700303; Butler T, 1999, J ANTIMICROB CHEMOTH, V44, P243, DOI 10.1093/jac/44.2.243; BUTLER T, 1991, REV INFECT DIS, V13, P85; Cao X T, 1999, Pediatr Infect Dis J, V18, P245; Chandel DS, 2000, EMERG INFECT DIS, V6, P420, DOI 10.3201/eid0604.000420; Chaudhry Rama, 2003, Trop Gastroenterol, V24, P198; Chen LM, 1999, J EXP MED, V189, P1479, DOI 10.1084/jem.189.9.1479; Chinh NT, 2000, ANTIMICROB AGENTS CH, V44, P1855, DOI 10.1128/AAC.44.7.1855-1859.2000; Chiu CH, 2002, NEW ENGL J MED, V346, P413, DOI 10.1056/NEJMoa012261; Chiu CH, 1999, LANCET, V354, P2001, DOI 10.1016/S0140-6736(05)76779-9; Cho JC, 1999, FEMS MICROBIOL LETT, V170, P257, DOI 10.1111/j.1574-6968.1999.tb13382.x; Connerton P, 2000, J CLIN MICROBIOL, V38, P895, DOI 10.1128/JCM.38.2.895-897.2000; COOVADIA YM, 1992, Q J MED, V82, P91; Crump JA, 2004, B WORLD HEALTH ORGAN, V82, P346; Dharmana E, 2002, EUR J IMMUNOGENET, V29, P297, DOI 10.1046/j.1365-2370.2002.00318.x; Doherty CP, 2000, ANN TROP PAEDIATR, V20, P297, DOI 10.1080/02724936.2000.11748151; Dunstan SJ, 2001, J INFECT DIS, V183, P261, DOI 10.1086/317940; DUTTA P, 1993, ANTIMICROB AGENTS CH, V37, P1197, DOI 10.1128/AAC.37.5.1197; Dutta P, 2001, INDIAN J MED RES, V113, P210; EDELMAN R, 1986, REV INFECT DIS, V8, P329; Elsarnagawy D, 1978, Arch Inst Pasteur Alger, V53, P282; ELSHERBINI A, 1992, J TROP PEDIATRICS, V38, P331, DOI 10.1093/tropej/38.6.331; Engels EA, 1998, BRIT MED J, V316, P110, DOI 10.1136/bmj.316.7125.110; FAROOQUI BJ, 1991, J CLIN PATHOL, V44, P258, DOI 10.1136/jcp.44.3.258; Faucher JF, 2002, CLIN INFECT DIS, V35, P1147, DOI 10.1086/342908; FERRECCIO C, 1988, J INFECT DIS, V157, P1235, DOI 10.1093/infdis/157.6.1235; Frenck RW, 2000, CLIN INFECT DIS, V31, P1134, DOI 10.1086/317450; Frenck RW, 2004, CLIN INFECT DIS, V38, P951, DOI 10.1086/382359; Galan JE, 2000, P NATL ACAD SCI USA, V97, P8754, DOI 10.1073/pnas.97.16.8754; Galan JE, 2001, ANNU REV CELL DEV BI, V17, P53, DOI 10.1146/annurev.cellbio.17.1.53; Gasem MH, 2003, ANTIMICROB AGENTS CH, V47, P1727, DOI 10.1128/AAC.47.5.1727-1731.2003; Gasem MH, 2002, J MED MICROBIOL, V51, P173, DOI 10.1099/0022-1317-51-2-173; Gasem MH, 2001, TROP MED INT HEALTH, V6, P484, DOI 10.1046/j.1365-3156.2001.00734.x; GASEM MH, 1995, TROP GEOGR MED, V47, P164; Gendrel D, 2003, LANCET INFECT DIS, V3, P537, DOI 10.1016/S1473-3099(03)00736-9; GILMAN RH, 1975, LANCET, V1, P1211; Girgis NI, 1999, ANTIMICROB AGENTS CH, V43, P1441, DOI 10.1128/AAC.43.6.1441; GOH K T, 1981, Southeast Asian Journal of Tropical Medicine and Public Health, V12, P55; GOTUZZO E, 1987, J CLIN MICROBIOL, V25, P1779, DOI 10.1128/JCM.25.9.1779-1781.1987; GOTUZZO E, 1994, ANTIMICROB AGENTS CH, V38, P558, DOI 10.1128/AAC.38.3.558; GOTUZZO E, 1988, J INFECT DIS, V157, P1221, DOI 10.1093/infdis/157.6.1221; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Harish BN, 2004, J MED MICROBIOL, V53, P819, DOI 10.1099/jmm.0.05451-0; Hatta M, 2002, AM J TROP MED HYG, V66, P416, DOI 10.4269/ajtmh.2002.66.416; Hermans PWM, 1996, J CLIN MICROBIOL, V34, P1373, DOI 10.1128/JCM.34.6.1373-1379.1996; Hernandez LD, 2004, SCIENCE, V304, P1805, DOI 10.1126/science.1098188; Hirose K, 2002, J CLIN MICROBIOL, V40, P633, DOI 10.1128/JCM.40.02.633-636.2002; Hoa NTT, 1998, T ROY SOC TROP MED H, V92, P503, DOI 10.1016/S0035-9203(98)90891-4; HOFFMAN SL, 1984, NEW ENGL J MED, V310, P82, DOI 10.1056/NEJM198401123100203; HOFFMAN SL, 1986, AM J TROP MED HYG, V35, P836, DOI 10.4269/ajtmh.1986.35.836; HORNICK RB, 1970, NEW ENGL J MED, V283, P739, DOI 10.1056/NEJM197010012831406; HORNICK RB, 1970, NEW ENGL J MED, V283, P686, DOI 10.1056/NEJM197009242831306; Hosoglu S, 2004, AM J EPIDEMIOL, V160, P46, DOI 10.1093/aje/kwh172; House D, 2001, J CLIN MICROBIOL, V39, P1002, DOI 10.1128/JCM.39.3.1002-1007.2001; House D, 2001, CURR OPIN INFECT DIS, V14, P573, DOI 10.1097/00001432-200110000-00011; JEGATHESAN M, 1983, J HYG-CAMBRIDGE, V90, P91, DOI 10.1017/S0022172400063889; JESUDASAN MV, 1990, LANCET, V336, P252, DOI 10.1016/0140-6736(90)91783-7; Jesudason M, 2002, INDIAN J MED RES, V116, P70; Jong EC, 2002, J TRAVEL MED, V9, P66, DOI 10.2310/7060.2002.21955; Kariuki S, 2004, J CLIN MICROBIOL, V42, P1477, DOI 10.1128/JCM.42.4.1477-1482.2004; Kariuki S, 2000, EMERG INFECT DIS, V6, P649, DOI 10.3201/eid0606.000616; KARMAKER S, 1991, J MED MICROBIOL, V34, P149, DOI 10.1099/00222615-34-3-149; Keddy KH, 1999, VACCINE, V17, P110, DOI 10.1016/S0264-410X(98)00160-1; Kidgell C, 2002, INFECT GENET EVOL, V2, P39, DOI 10.1016/S1567-1348(02)00089-8; Klugman KP, 1996, VACCINE, V14, P435, DOI 10.1016/0264-410X(95)00186-5; KLUGMAN KP, 1987, LANCET, V2, P1165; Konadu EY, 2000, INFECT IMMUN, V68, P1529, DOI 10.1128/IAI.68.3.1529-1534.2000; Kops SK, 1996, MICROBIOL IMMUNOL, V40, P799, DOI 10.1111/j.1348-0421.1996.tb01145.x; LANATA CF, 1983, LANCET, V2, P441; LANG R, 1992, SCAND J INFECT DIS, V24, P793, DOI 10.3109/00365549209062466; Lanh MN, 2003, NEW ENGL J MED, V349, P1390, DOI 10.1056/NEJM200310023491423; Le TAH, 2004, J CLIN MICROBIOL, V42, P3094, DOI 10.1128/JCM.42.7.3094-3099.2004; Lee JH, 2004, DIGEST LIVER DIS, V36, P141, DOI 10.1016/j.dld.2003.10.013; Lee WS, 2000, ANN TROP PAEDIATR, V20, P125, DOI 10.1080/02724936.2000.11748121; LEVINE MM, 1987, LANCET, V1, P1049; LEVINE MM, 1990, LANCET, V336, P891; LEVINE MM, 1982, J INFECT DIS, V146, P724, DOI 10.1093/infdis/146.6.724; Levine MM, 1999, VACCINE, V17, pS22, DOI 10.1016/S0264-410X(99)00231-5; Lin FYC, 2000, AM J TROP MED HYG, V62, P644, DOI 10.4269/ajtmh.2000.62.644; Lin FYC, 2001, NEW ENGL J MED, V344, P1263, DOI 10.1056/NEJM200104263441701; Loebermann M, 2004, CLIN THER, V26, P1084, DOI 10.1016/S0149-2918(04)90180-4; Luby SP, 1998, EPIDEMIOL INFECT, V120, P129, DOI 10.1017/S0950268897008558; Luxemburger C, 2001, T ROY SOC TROP MED H, V95, P19, DOI 10.1016/S0035-9203(01)90318-9; Lyczak JB, 2002, INFECT IMMUN, V70, P6416, DOI 10.1128/IAI.70.11.6416-6423.2002; Lyczak JB, 2001, CELL MICROBIOL, V3, P763, DOI 10.1046/j.1462-5822.2001.00154.x; Mandal S., 2003, Indian Journal of Experimental Biology, V41, P360; Mandal S, 2004, Indian J Med Sci, V58, P16; Mandal S, 2003, JPN J INFECT DIS, V56, P156; McClelland M, 2004, NAT GENET, V36, P1268, DOI 10.1038/ng1470; Mehta G, 2001, EUR J CLIN MICROBIOL, V20, P760, DOI 10.1007/s100960100603; Memon IA, 1997, SOUTHERN MED J, V90, P1204, DOI 10.1097/00007611-199712000-00008; Mermin JH, 1999, J INFECT DIS, V179, P1416, DOI 10.1086/314766; Merrell DS, 2004, NATURE, V430, P250, DOI 10.1038/nature02760; Mert A, 2004, INTERNAL MED, V43, P436, DOI 10.2169/internalmedicine.43.436; Metzger WG, 2004, VACCINE, V22, P2273, DOI 10.1016/j.vaccine.2003.11.020; Mills-Robertson F, 2002, FEMS MICROBIOL LETT, V215, P249, DOI [10.1016/S0378-1097(02)00967-9, 10.1111/j.1574-6968.2002.tb11398.x]; Mirza S, 2000, J CLIN MICROBIOL, V38, P1449, DOI 10.1128/JCM.38.4.1449-1452.2000; Mirza SH, 1996, J MED MICROBIOL, V44, P317, DOI 10.1099/00222615-44-5-317; Mohanty S, 2003, Indian J Med Sci, V57, P199; Monack DM, 2004, J EXP MED, V199, P231, DOI 10.1084/jem.20031319; MORRIS JG, 1984, AM J TROP MED HYG, V33, P1198, DOI 10.4269/ajtmh.1984.33.1198; Murdoch DA, 1998, LANCET, V351, P339, DOI 10.1016/S0140-6736(05)78338-0; Nakaya H, 2003, EMERG INFECT DIS, V9, P255; NCCLS, 2004, M100S14 NCCLS; NISHIO T, 1981, ZBL BAKT MIK HYG B, V172, P415; Olopoenia LA, 2000, POSTGRAD MED J, V76, P80, DOI 10.1136/pmj.76.892.80; Olsen SJ, 2004, J CLIN MICROBIOL, V42, P1885, DOI 10.1128/JCM.42.5.1885-1889.2004; Olsen SJ, 2003, EPIDEMIOL INFECT, V130, P13, DOI 10.1017/S0950268802007598; Osler W., 1912, PRINCIPLES PRACTICE, V8th, P1; PANG T, 1983, J CLIN PATHOL, V36, P471, DOI 10.1136/jcp.36.4.471; Panhotra BR, 2004, SAUDI MED J, V25, P1509; Panigrahi D, 1996, TROP MED INT HEALTH, V1, P439, DOI 10.1046/j.1365-3156.1996.d01-80.x; Parkhill J, 2001, NATURE, V413, P848, DOI 10.1038/35101607; Parry CM, 1999, J CLIN MICROBIOL, V37, P2882, DOI 10.1128/JCM.37.9.2882-2886.1999; Parry CM, 2002, NEW ENGL J MED, V347, P1770, DOI 10.1056/NEJMra020201; Parry CM, 2004, T ROY SOC TROP MED H, V98, P413, DOI 10.1016/j.trstmh.2003.10.014; Pier GB, 1998, NATURE, V393, P79, DOI 10.1038/30006; PRADHAN KM, 1995, ACTA PAEDIATR, V84, P555, DOI 10.1111/j.1651-2227.1995.tb13694.x; Proell S, 2002, J TRAVEL MED, V9, P122, DOI 10.2310/7060.2002.23845; PUNJABI NH, 1988, PEDIATR INFECT DIS J, V7, P598, DOI 10.1097/00006454-198808000-00002; Rahman M, 2002, EPIDEMIOL INFECT, V129, P29, DOI 10.1017/S0950268802007203; Rajagopal A, 2002, Trop Gastroenterol, V23, P181; Reller ME, 2003, CLIN INFECT DIS, V37, P141, DOI 10.1086/375590; Renuka K, 2004, MICROB DRUG RESIST, V10, P146, DOI 10.1089/1076629041310028; ROGERSON SJ, 1991, T ROY SOC TROP MED H, V85, P113, DOI 10.1016/0035-9203(91)90180-7; ROWE B, 1990, LANCET, V336, P1065, DOI 10.1016/0140-6736(90)92532-M; Rowe B, 1997, CLIN INFECT DIS, V24, pS106, DOI 10.1093/clinids/24.Supplement_1.S106; RUBIN FA, 1990, J CLIN MICROBIOL, V28, P825, DOI 10.1128/JCM.28.4.825-827.1990; RYAN CA, 1989, REV INFECT DIS, V11, P1; Saha SK, 1999, PEDIATR INFECT DIS J, V18, P387, DOI 10.1097/00006454-199904000-00018; Saha SK, 2001, PEDIATR INFECT DIS J, V20, P521, DOI 10.1097/00006454-200105000-00010; Salazar-Gonzalez RM, 2004, IMMUNOL LETT, V93, P115, DOI 10.1016/j.imlet.2004.01.010; SCHAAD UB, 1995, PEDIATR INFECT DIS J, V14, P1, DOI 10.1097/00006454-199501000-00001; Sherburne CK, 2000, NUCLEIC ACIDS RES, V28, P2177, DOI 10.1093/nar/28.10.2177; Shetty AK, 1999, J TROP PEDIATRICS, V45, P287, DOI 10.1093/tropej/45.5.287; Shlim, 1995, J Travel Med, V2, P165, DOI 10.1111/j.1708-8305.1995.tb00645.x; SIMANJUNTAK CH, 1991, LANCET, V338, P1055, DOI 10.1016/0140-6736(91)91910-M; Singh M, 1999, MICROBIOL IMMUNOL, V43, P535, DOI 10.1111/j.1348-0421.1999.tb02439.x; Sinha A, 1999, LANCET, V354, P734, DOI 10.1016/S0140-6736(98)09001-1; Slinger R, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-36; SMITH MD, 1994, ANTIMICROB AGENTS CH, V38, P1716, DOI 10.1128/AAC.38.8.1716; Snyder GE, 2004, AM J EMERG MED, V22, P138, DOI 10.1016/S0735-6757(03)00019-6; Sood S, 1999, EMERG INFECT DIS, V5, P483, DOI 10.3201/eid0503.990329; Sood S, 1999, LANCET, V353, P1241, DOI 10.1016/S0140-6736(99)00637-6; Stahlmann R, 2000, ARCH TOXICOL, V73, P564, DOI 10.1007/s002040050009; Steinberg EB, 2004, CLIN INFECT DIS, V39, P186, DOI 10.1086/421945; Swaddiwudhipong Witaya, 2001, Journal of the Medical Association of Thailand, V84, P1513; Tacket CO, 2004, J INFECT DIS, V190, P565, DOI 10.1086/421469; Tankhiwale SS, 2003, INDIAN J MED RES, V117, P10; Tatli MM, 2003, INT J ANTIMICROB AG, V21, P350, DOI 10.1016/S0924-8579(02)00388-6; TAYLOR DE, 1985, ANTIMICROB AGENTS CH, V28, P452, DOI 10.1128/AAC.28.3.452; THISYAKORN U, 1987, AM J DIS CHILD, V141, P862, DOI 10.1001/archpedi.1987.04460080048025; Thong KL, 1996, J CLIN MICROBIOL, V34, P1029, DOI 10.1128/JCM.34.4.1029-1033.1996; Thong KL, 2000, Int J Infect Dis, V4, P194, DOI 10.1016/S1201-9712(00)90108-5; Threlfall EJ, 1999, LANCET, V353, P1590, DOI 10.1016/S0140-6736(99)01001-6; Threlfall EJ, 2003, INT J ANTIMICROB AG, V22, P487, DOI 10.1016/S0924-8579(03)00262-0; Threlfall EJ, 2001, J ANTIMICROB CHEMOTH, V48, P740, DOI 10.1093/jac/48.5.740; VALLENAS C, 1985, PEDIATR INFECT DIS J, V4, P496, DOI 10.1097/00006454-198509000-00011; VANBASTEN JP, 1994, TROP GEOGR MED, V46, P336; Vazquez-Torres A, 2004, J IMMUNOL, V172, P6202, DOI 10.4049/jimmunol.172.10.6202; VIDAL S, 1995, J EXP MED, V182, P655, DOI 10.1084/jem.182.3.655; Vinh H, 2004, PEDIATR INFECT DIS J, V23, P226, DOI 10.1097/01.inf.0000114905.87426.c2; Vinh H, 1996, ANTIMICROB AGENTS CH, V40, P958, DOI 10.1128/AAC.40.4.958; Vollaard AM, 2004, JAMA-J AM MED ASSOC, V291, P2607, DOI 10.1001/jama.291.21.2607; WAHDAN MH, 1982, J INFECT DIS, V145, P292, DOI 10.1093/infdis/145.3.292; Wain J, 2002, LANCET INFECT DIS, V2, P163, DOI 10.1016/S1473-3099(02)00225-6; Wain J, 1999, J CLIN MICROBIOL, V37, P2466, DOI 10.1128/JCM.37.8.2466-2472.1999; Wain J, 1998, J CLIN MICROBIOL, V36, P1683, DOI 10.1128/JCM.36.6.1683-1687.1998; Wain J, 1997, CLIN INFECT DIS, V25, P1404, DOI 10.1086/516128; Wain J, 2001, J CLIN MICROBIOL, V39, P1571, DOI 10.1128/JCM.39.4.1571-1576.2001; Wait DA, 2001, WATER SCI TECHNOL, V43, P139, DOI 10.2166/wst.2001.0725; Walker RA, 2003, INT J ANTIMICROB AG, V22, P622, DOI 10.1016/j.ijantimicag.2003.05.005; WALLACE MR, 1993, EUR J CLIN MICROBIOL, V12, P907, DOI 10.1007/BF01992163; WANG F, 1989, J ANTIMICROB CHEMOTH, V23, P785, DOI 10.1093/jac/23.5.785; Waterman SR, 2003, CELL MICROBIOL, V5, P501, DOI 10.1046/j.1462-5822.2003.00294.x; WATSON JP, 1992, TROP DOCT, V22, P172, DOI 10.1177/004947559202200412; Weinstein DL, 1998, INFECT IMMUN, V66, P2310, DOI 10.1128/IAI.66.5.2310-2318.1998; White NJ, 1996, LANCET, V348, P547, DOI 10.1016/S0140-6736(05)64703-4; WOODWARD TE, 1948, ANN INTERN MED, V29, P131, DOI 10.7326/0003-4819-29-1-131; World Health Organization (WHO), 2003, WHOVB0307; Yang HH, 2001, J INFECT DIS, V183, P1775, DOI 10.1086/320729; Yang HH, 2001, B WORLD HEALTH ORGAN, V79, P625; YEW FS, 1991, J TROP MED HYG, V94, P352; Yoo S, 2004, J KOREAN MED SCI, V19, P15, DOI 10.3346/jkms.2004.19.1.15	205	338	360	0	44	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 27	2005	366	9487					749	762		10.1016/S0140-6736(05)67181-4	http://dx.doi.org/10.1016/S0140-6736(05)67181-4			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958UV	16125594				2022-12-28	WOS:000231474600033
J	Honjo, T				Honjo, T			In search of the best grant system	SCIENCE			English	Article									Japan Soc Promot Sci, Res Ctr Sci Syst, Tokyo, Japan; Kyoto Univ, Kyoto, Japan	Japan Society for the Promotion of Science; Kyoto University	Honjo, T (corresponding author), Japan Soc Promot Sci, Res Ctr Sci Syst, Tokyo, Japan.	honjo@mfour.med.kyoto-u.ac.jp	Honjo, Tasuku/N-4470-2016					*JAP I SCI TECHN, 74 JAP I SCI TECHN	1	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 26	2005	309	5739					1329	1329		10.1126/science.1115377	http://dx.doi.org/10.1126/science.1115377			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TX	16123288				2022-12-28	WOS:000231543300029
J	Bowen, DG; Walker, CM				Bowen, DG; Walker, CM			Adaptive immune responses in acute and chronic hepatitis C virus infection	NATURE			English	Review							CD8(+) T-CELLS; IN-VITRO PROLIFERATION; DENDRITIC CELLS; LYMPHOCYTE RESPONSE; PERIPHERAL-BLOOD; INTRAHEPATIC EXPRESSION; NEUTRALIZING ANTIBODY; QUANTITATIVE-ANALYSIS; ESCAPE MUTATIONS; VIRAL CLEARANCE	The hepatitis C virus (HCV) persists in the majority of infected individuals and is a significant cause of human illness and death globally. Recent studies have yielded important insights into immunity to HCV, in particular revealing the central role of T cells in viral control and clearance. Other key features of adaptive immune responses remain obscure, including mechanisms by which T cells control HCV replication, the role of antibodies in conferring protection and how cellular and humoral immunity are subverted in persistent infection.	Columbus Childrens Res Inst, Ctr Vaccines & Immun, Columbus, OH 43205 USA; Ohio State Univ, Coll Med & Publ Hlth, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University	Walker, CM (corresponding author), Columbus Childrens Res Inst, Ctr Vaccines & Immun, Columbus, OH 43205 USA.	walkerc@pediatrics.ohio-state.edu		Bowen, David/0000-0002-7965-5581				ABE K, 1992, HEPATOLOGY, V15, P690, DOI 10.1002/hep.1840150423; Abrignani S, 1997, SEMIN LIVER DIS, V17, P319, DOI 10.1055/s-2007-1007208; Accapezzato D, 2004, J CLIN INVEST, V113, P963, DOI [10.1172/JCI200420415, 10.1172/JCI200420515]; Accapezzato D, 2004, EUR J IMMUNOL, V34, P438, DOI 10.1002/eji.200324540; ALTER HJ, 1995, J VIRAL HEPATITIS, V2, P121, DOI 10.1111/j.1365-2893.1995.tb00017.x; Altfeld M, 2005, J VIROL, V79, P5000, DOI 10.1128/JVI.79.8.5000-5005.2005; Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379; Auffermann-Gratzinger S, 2001, BLOOD, V97, P3171, DOI 10.1182/blood.V97.10.3171; Bain C, 2001, GASTROENTEROLOGY, V120, P512, DOI 10.1053/gast.2001.21212; Bartosch B, 2003, P NATL ACAD SCI USA, V100, P14199, DOI 10.1073/pnas.2335981100; Bassett SE, 2001, HEPATOLOGY, V33, P1479, DOI 10.1053/jhep.2001.24371; BEACH MJ, 1992, J MED VIROL, V36, P226, DOI 10.1002/jmv.1890360314; Bertolino P, 2002, IMMUNOL CELL BIOL, V80, P84, DOI 10.1046/j.0818-9641.2001.01048.x; Boettler T, 2005, J VIROL, V79, P7860, DOI 10.1128/JVI.79.12.7860-7867.2005; Bowen DG, 2005, J EXP MED, V201, P1709, DOI 10.1084/jem.20050808; Bowen DG, 2005, J HEPATOL, V42, P408, DOI 10.1016/j.jhep.2004.12.013; BUKH J, 1995, SEMIN LIVER DIS, V15, P41, DOI 10.1055/s-2007-1007262; Cabrera R, 2004, HEPATOLOGY, V40, P1062, DOI 10.1002/hep.20454; Chang KM, 1997, J CLIN INVEST, V100, P2376, DOI 10.1172/JCI119778; Cooper S, 1999, IMMUNITY, V10, P439, DOI 10.1016/S1074-7613(00)80044-8; Cox AL, 2005, J EXP MED, V201, P1741, DOI 10.1084/jem.20050121; Crotta S, 2002, J EXP MED, V195, P35, DOI 10.1084/jem.20011124; Day CL, 2003, J CLIN INVEST, V112, P831, DOI 10.1172/JCI200318509; Day CL, 2002, J VIROL, V76, P12584, DOI 10.1128/JVI.76.24.12584-12595.2002; DIEPOLDER HM, 1995, LANCET, V346, P1006, DOI 10.1016/S0140-6736(95)91691-1; Erickson AL, 2001, IMMUNITY, V15, P883, DOI 10.1016/S1074-7613(01)00245-X; Farci P, 2000, SCIENCE, V288, P339, DOI 10.1126/science.288.5464.339; FARCI P, 1994, P NATL ACAD SCI USA, V91, P7792, DOI 10.1073/pnas.91.16.7792; FARCI P, 1992, SCIENCE, V258, P135, DOI 10.1126/science.1279801; Frasca L, 1999, J IMMUNOL, V163, P650; Freeman AJ, 2003, J HEPATOL, V38, P349, DOI 10.1016/S0168-8278(02)00424-5; Frese M, 2002, HEPATOLOGY, V35, P694, DOI 10.1053/jhep.2002.31770; Friedrich TC, 2004, NAT MED, V10, P275, DOI 10.1038/nm998; Gerlach JT, 1999, GASTROENTEROLOGY, V117, P933, DOI 10.1016/S0016-5085(99)70353-7; Grakoui A, 2003, SCIENCE, V302, P659, DOI 10.1126/science.1088774; Gruener NH, 2001, J VIROL, V75, P5550, DOI 10.1128/JVI.75.12.5550-5558.2001; Hahn YS, 2003, CURR OPIN IMMUNOL, V15, P443, DOI 10.1016/S0952-7915(03)00076-1; He XS, 1999, P NATL ACAD SCI USA, V96, P5692, DOI 10.1073/pnas.96.10.5692; Jinushi M, 2004, J IMMUNOL, V173, P6072, DOI 10.4049/jimmunol.173.10.6072; Kanto T, 1999, J IMMUNOL, V162, P5584; Khakoo SI, 2004, SCIENCE, V305, P872, DOI 10.1126/science.1097670; Khanolkar A, 2004, J IMMUNOL, V172, P2834, DOI 10.4049/jimmunol.172.5.2834; Kimura Y, 2005, J VIROL, V79, P4870, DOI 10.1128/JVI.79.8.4870-4876.2005; KOZIEL MJ, 1995, J CLIN INVEST, V96, P2311, DOI 10.1172/JCI118287; KOZIEL MJ, 1993, J VIROL, V67, P7522, DOI 10.1128/JVI.67.12.7522-7532.1993; KOZIEL MJ, 1992, J IMMUNOL, V149, P3339; Kurokohchi K, 2003, J CLIN IMMUNOL, V23, P518, DOI 10.1023/B:JOCI.0000010428.98823.02; LAI ME, 1994, LANCET, V343, P388, DOI 10.1016/S0140-6736(94)91224-6; Lanford RE, 2003, J VIROL, V77, P1092, DOI 10.1128/JVI.77.2.1092-1104.2003; Lanford RE, 2004, J VIROL, V78, P1575, DOI 10.1128/JVI.78.3.1575-1581.2004; Larsson M, 2004, J VIROL, V78, P6151, DOI 10.1128/JVI.78.12.6151-6161.2004; Lauer GM, 2002, J VIROL, V76, P6104, DOI 10.1128/JVI.76.12.6104-6113.2002; Lauer GM, 2004, GASTROENTEROLOGY, V127, P924, DOI 10.1053/j.gastro.2004.06.015; Lechner F, 2000, EUR J IMMUNOL, V30, P2479, DOI 10.1002/1521-4141(200009)30:9<2479::AID-IMMU2479>3.0.CO;2-B; Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499; Leslie A, 2005, J EXP MED, V201, P891, DOI 10.1084/jem.20041455; Leslie AJ, 2004, NAT MED, V10, P282, DOI 10.1038/nm992; Logvinoff C, 2004, P NATL ACAD SCI USA, V101, P10149, DOI 10.1073/pnas.0403519101; Lucas M, 2004, J IMMUNOL, V172, P1744, DOI 10.4049/jimmunol.172.3.1744; MacDonald AJ, 2002, J INFECT DIS, V185, P720, DOI 10.1086/339340; Major ME, 2002, J VIROL, V76, P6586, DOI 10.1128/JVI.76.13.6586-6595.2002; McGuinness PH, 2000, GUT, V46, P260, DOI 10.1136/gut.46.2.260; Mehta SH, 2002, LANCET, V359, P1478, DOI 10.1016/S0140-6736(02)08435-0; Meunier JC, 2005, P NATL ACAD SCI USA, V102, P4560, DOI 10.1073/pnas.0501275102; Meyer-Olson D, 2004, J EXP MED, V200, P307, DOI 10.1084/jem.20040638; Missale G, 1996, J CLIN INVEST, V98, P706, DOI 10.1172/JCI118842; Moore CB, 2002, SCIENCE, V296, P1439, DOI 10.1126/science.1069660; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; Napoli J, 1996, HEPATOLOGY, V24, P759; NEGRO F, 1992, P NATL ACAD SCI USA, V89, P2247, DOI 10.1073/pnas.89.6.2247; Nelson DR, 1997, J IMMUNOL, V158, P1473; NOURIARIA KT, 1995, J PATHOL, V175, P77, DOI 10.1002/path.1711750112; Pawlotsky JM, 1999, J HEPATOL, V31, P71, DOI 10.1016/S0168-8278(99)80378-X; Pearlman BL, 2004, AM J MED, V117, P344, DOI 10.1016/j.amjmed.2004.03.024; Penna A, 2002, HEPATOLOGY, V35, P1225, DOI 10.1053/jhep.2002.33153; Piccioli D, 2005, J HEPATOL, V42, P61, DOI 10.1016/j.jhep.2004.09.014; Post JJ, 2004, J INFECT DIS, V189, P1846, DOI 10.1086/383279; Ray SC, 2005, J EXP MED, V201, P1753, DOI 10.1084/jem.20050122; Rehermann B, 1996, J CLIN INVEST, V98, P1432, DOI 10.1172/JCI118931; Rosen HR, 2002, HEPATOLOGY, V35, P190, DOI 10.1053/jhep.2002.30293; Rushbrook SM, 2005, J VIROL, V79, P7852, DOI 10.1128/JVI.79.12.7852-7859.2005; Semmo N, 2005, HEPATOLOGY, V41, P1019, DOI 10.1002/hep.20669; Shoukry NH, 2004, ANNU REV MICROBIOL, V58, P391, DOI 10.1146/annurev.micro.58.030603.123836; Shoukry NH, 2004, J IMMUNOL, V172, P483, DOI 10.4049/jimmunol.172.1.483; Shoukry NH, 2003, J EXP MED, V197, P1645, DOI 10.1084/jem.20030239; Sugimoto K, 2003, HEPATOLOGY, V38, P1437, DOI 10.1016/j.hep.2003.09.026; Takaki A, 2000, NAT MED, V6, P578, DOI 10.1038/75063; Tester I, 2005, J EXP MED, V201, P1725, DOI 10.1084/jem.20042284; Thimme R, 2002, P NATL ACAD SCI USA, V99, P15661, DOI 10.1073/pnas.202608299; Thimme R, 2001, J EXP MED, V194, P1395, DOI 10.1084/jem.194.10.1395; Timm J, 2004, J EXP MED, V200, P1593, DOI 10.1084/jem.20041006; Tseng CTK, 2002, J EXP MED, V195, P43, DOI 10.1084/jem.20011145; Ulsenheimer A, 2003, HEPATOLOGY, V37, P1189, DOI 10.1053/jhep.2003.50194; Urbani S, 2002, J VIROL, V76, P12423, DOI 10.1128/JVI.76.24.12423-12434.2002; Urbani S, 2005, J EXP MED, V201, P675, DOI 10.1084/jem.20041058; Wang H, 1999, J IMMUNOL, V162, P4177; Wang JH, 2003, HUM IMMUNOL, V64, P662, DOI 10.1016/S0198-8859(03)00070-3; Wedemeyer H, 2002, J IMMUNOL, V169, P3447, DOI 10.4049/jimmunol.169.6.3447; Wong DKH, 1998, J IMMUNOL, V160, P1479; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205	100	590	630	0	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 18	2005	436	7053					946	952		10.1038/nature04079	http://dx.doi.org/10.1038/nature04079			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955XQ	16107834				2022-12-28	WOS:000231263900036
J	De Francesco, R; Migliaccio, G				De Francesco, R; Migliaccio, G			Challenges and successes in developing new therapies for hepatitis C	NATURE			English	Review							DEPENDENT RNA-POLYMERASE; VIRUS SERINE-PROTEASE; SMALL INTERFERING RNAS; TOLL-LIKE RECEPTORS; PEPTIDE-BASED INHIBITORS; IN-VITRO RESISTANCE; CRYSTAL-STRUCTURE; NS3 PROTEASE; HCVNS5B POLYMERASE; THIOPHENE-2-CARBOXYLIC ACIDS	Hepatitis C virus (HCV) will continue to be a serious global health threat for many years to come because of the chronic nature of the infection, its high prevalence and the significant morbidity of the resulting disease. Recently, a small number of molecules have produced encouraging results in proof-of-concept clinical trials. At the same time, preclinical evidence is accumulating that development of resistance will eventually limit the efficacy of new drugs. Thus, combinations of multiple agents will be required to treat chronic HCV infection.	Ist Ric Biol Mol P Angeletti, I-00040 Pomezia, Italy	Merck & Company	De Francesco, R (corresponding author), Ist Ric Biol Mol P Angeletti, Via Pontina Km 30-600, I-00040 Pomezia, Italy.	raffaele_defrancesco@merck.com	De Francesco, Raffaele/J-6003-2012	De Francesco, Raffaele/0000-0001-8754-5123; Migliaccio, Giovanni/0000-0001-8951-9957				AFDAL N, 2005, ENHANCED ANTIVIRAL E; AFDHAL N, FINAL PHASE 1 2 TRIA; Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; *AN PHARM, 2004, AN PHARM ANN SEL ANA; Beaulieu Pierre L, 2004, Curr Opin Investig Drugs, V5, P838; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Biswal BK, 2005, J BIOL CHEM, V280, P18202, DOI 10.1074/jbc.M413410200; Boehme KW, 2004, J VIROL, V78, P7867, DOI 10.1128/JVI.78.15.7867-7873.2004; Braasch DA, 2004, BIOORG MED CHEM LETT, V14, P1139, DOI 10.1016/j.bmcl.2003.12.074; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Brownell Isaac, 2003, Dermatol Online J, V9, P13; Carroll S, 2004, ANTIVIR RES, V62, pA83; Chan L, 2004, BIOORG MED CHEM LETT, V14, P793, DOI 10.1016/j.bmcl.2003.10.067; Chan L, 2004, BIOORG MED CHEM LETT, V14, P797, DOI 10.1016/j.bmcl.2003.10.068; Chen SH, 2005, LETT DRUG DES DISCOV, V2, P118, DOI 10.2174/1570180053175115; Cheng J, 2002, IEEE T WIREL COMMUN, V1, P3, DOI 10.1109/7693.975440; Dhanak D, 2002, J BIOL CHEM, V277, P38322, DOI 10.1074/jbc.M205566200; DIMARCO S, 2005, J BIOL CHEM     0613; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Foster GR, 2004, SEMIN LIVER DIS, V24, P97, DOI 10.1055/s-2004-832934; Goudreau N, 2004, J MED CHEM, V47, P123, DOI 10.1021/jm0303002; Gu BH, 2003, J BIOL CHEM, V278, P16602, DOI 10.1074/jbc.M210891200; Hahn YS, 2003, CURR OPIN IMMUNOL, V15, P443, DOI 10.1016/S0952-7915(03)00076-1; HAN J, 2004, 11 INT S HEP C VIR R; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hashimoto H., 2001, Patent Application, Patent No. [WO01/47883, 0147883]; Hinrichsen H, 2004, GASTROENTEROLOGY, V127, P1347, DOI 10.1053/j.gastro.2004.08.002; Horsmans Y, 2004, HEPATOLOGY, V40, p282A; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Kapadia SB, 2003, P NATL ACAD SCI USA, V100, P2014, DOI 10.1073/pnas.252783999; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; Kronke J, 2004, J VIROL, V78, P3436, DOI 10.1128/JVI.78.7.3436-3446.2004; Lamarre D, 2003, NATURE, V426, P186, DOI 10.1038/nature02099; LaPlante SR, 2004, ANGEW CHEM INT EDIT, V43, P4306, DOI 10.1002/anie.200460326; Lee J, 2003, P NATL ACAD SCI USA, V100, P6646, DOI 10.1073/pnas.0631696100; Lemon Stanley M, 2005, Hepatology, V41, P671, DOI 10.1002/hep.20610; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Lin C, 2004, J BIOL CHEM, V279, P17508, DOI 10.1074/jbc.M313020200; Lin C, 2004, HEPATOLOGY, V40, p404A; Llinas-Brunet M, 2000, BIOORG MED CHEM LETT, V10, P2267, DOI 10.1016/S0960-894X(00)00465-0; Llinas-Brunet M, 1998, BIOORG MED CHEM LETT, V8, P1713, DOI 10.1016/S0960-894X(98)00299-6; Love RA, 1996, CELL, V87, P331, DOI 10.1016/S0092-8674(00)81350-1; Love RA, 2003, J VIROL, V77, P7575, DOI 10.1128/JVI.77.13.7575-7581.2003; LU H, 2005, Patent No. 2005000308; Lu LJ, 2004, ANTIMICROB AGENTS CH, V48, P2260, DOI 10.1128/AAC.48.6.2260-2266.2004; Ludmerer SW, 2005, ANTIMICROB AGENTS CH, V49, P2059, DOI 10.1128/AAC.49.5.2059-2069.2005; Manoharan M, 2004, CURR OPIN CHEM BIOL, V8, P570, DOI 10.1016/j.cbpa.2004.10.007; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; McKenna K, 2005, J VIROL, V79, P17, DOI 10.1128/JVI.79.1.17-27.2005; Migliaccio G, 2003, J BIOL CHEM, V278, P49164, DOI 10.1074/jbc.M305041200; Nguyen TT, 2003, ANTIMICROB AGENTS CH, V47, P3525, DOI 10.1128/AAC.47.11.3525-3530.2003; O'Neill LAJ, 2004, TRENDS IMMUNOL, V25, P687, DOI 10.1016/j.it.2004.10.005; Olsen DB, 2004, ANTIMICROB AGENTS CH, V48, P3944, DOI 10.1128/AAC.48.10.3944-3953.2004; Randall G, 2003, P NATL ACAD SCI USA, V100, P235, DOI 10.1073/pnas.0235524100; Reiser M, 2005, HEPATOLOGY, V41, P832, DOI 10.1002/hep.20612; Schetter C, 2004, CURR OPIN DRUG DISC, V7, P204; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; STANDRING DN, 2004, NM283 POTENT ANTIVIR; Steinkuhler C, 1998, BIOCHEMISTRY-US, V37, P8899, DOI 10.1021/bi980313v; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Thibeault D, 2004, J VIROL, V78, P7352, DOI 10.1128/JVI.78.14.7352-7359.2004; Tomei L, 2004, J VIROL, V78, P938, DOI 10.1128/JVI.78.2.938-946.2004; Tomei L, 2003, J VIROL, V77, P13225, DOI 10.1128/JVI.77.24.13225-13231.2003; Tomei Licia, 2005, Antiviral Chemistry & Chemotherapy, V16, P225; Trozzi C, 2003, J VIROL, V77, P3669, DOI 10.1128/JVI.77.6.3669-3679.2003; Tsantrizos YS, 2003, ANGEW CHEM INT EDIT, V42, P1355, DOI 10.1002/anie.200390347; Urbani A, 1997, J BIOL CHEM, V272, P9204; *VERT PHARM, 2005, VERT PHARM REP OR HE; *VIROPHARMA, 2005, VIROPHARMA ANN DAT H; Wang MT, 2003, J BIOL CHEM, V278, P9489, DOI 10.1074/jbc.M209397200; Wasley A, 2000, SEMIN LIVER DIS, V20, P1, DOI 10.1055/s-2000-9506; Wilson JA, 2005, J VIROL, V79, P7050, DOI 10.1128/JVI.79.11.7050-7058.2005; Wilson JA, 2003, P NATL ACAD SCI USA, V100, P2783, DOI 10.1073/pnas.252758799; Yan YW, 1998, PROTEIN SCI, V7, P837; Yokota T, 2003, EMBO REP, V4, P602, DOI 10.1038/sj.embor.embor840; Zender L, 2003, P NATL ACAD SCI USA, V100, P7797, DOI 10.1073/pnas.1330920100; 2005, COLEY REPORTS RESULT; 2004, POOR BIOAVAILABILITY	78	363	421	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 18	2005	436	7053					953	960		10.1038/nature04080	http://dx.doi.org/10.1038/nature04080			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955XQ	16107835				2022-12-28	WOS:000231263900037
J	Mayo, GL; Tolentino, MJ				Mayo, GL; Tolentino, MJ			Central serous chorioretinopathy in pregnancy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Kaiser Permanente, Riverside, CA 92505 USA; Ctr Retina & Macular Dis, Winter Haven, FL 33880 USA	Kaiser Permanente	Mayo, GL (corresponding author), Kaiser Permanente, Riverside, CA 92505 USA.								0	5	5	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 18	2005	353	7					E6	E6		10.1056/NEJMicm040678	http://dx.doi.org/10.1056/NEJMicm040678			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955UW	16107617				2022-12-28	WOS:000231254100010
J	Martin, RE; Hislop, TG; Grams, GD; Moravan, V; Calam, B				Martin, RE; Hislop, TG; Grams, GD; Moravan, V; Calam, B			Beware of multiple names in database linkage research: prevalence of aliases in female prison population	BRITISH MEDICAL JOURNAL			English	Article							CRIMINAL ALIAS		Univ British Columbia, Dept Family Practice, Vancouver, BC V6T 1Z3, Canada; British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada	University of British Columbia; British Columbia Cancer Agency	Martin, RE (corresponding author), Univ British Columbia, Dept Family Practice, Mather Bldg,5804 Fairview Crescent, Vancouver, BC V6T 1Z3, Canada.	ruth.martin@familymed.ubc.ca						BOSHIER R, 1977, AUST NZ J CRIMINOL, V10, P17, DOI 10.1177/000486587701000105; HARRY B, 1986, J FORENSIC SCI, V31, P1023; Martin RE, 2004, CAN J PUBLIC HEALTH, V95, P285, DOI 10.1007/BF03405133; Rendleman N, 1998, WESTERN J MED, V169, P318; Vollm Birgit, 2002, Crim Behav Ment Health, V12, P269, DOI 10.1002/cbm.505	5	4	4	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	AUG 6	2005	331	7512					335	336		10.1136/bmj.331.7512.335	http://dx.doi.org/10.1136/bmj.331.7512.335			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955WZ	16081448	Green Published, Bronze			2022-12-28	WOS:000231259800023
J	MacMillan, HL; Wathen, CN				MacMillan, HL; Wathen, CN			Family violence research - Lessons learned and where from here?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INTIMATE PARTNER VIOLENCE; PREVENTIVE HEALTH-CARE; SERVICES TASK-FORCE; DOMESTIC VIOLENCE; RECOMMENDATION STATEMENT; RANDOMIZED-TRIAL; HOME VISITATION; CHILD-ABUSE; WOMEN; INTERVENTIONS		McMaster Univ, Dept Psychiat & Behav Neurosci, Offord Ctr Child Studies, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Pediat, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University	MacMillan, HL (corresponding author), McMaster Univ, Dept Psychiat & Behav Neurosci, Offord Ctr Child Studies, Patterson Bldg,Chedoke Site,Hamilton Hlth Sci,1200, Hamilton, ON L8N 3Z5, Canada.	macmilnh@mcmaster.ca	MacMillan, Harriet/B-4530-2016	MacMillan, Harriet/0000-0002-1223-706X				Aldarondo E, 1996, J CONSULT CLIN PSYCH, V64, P1010, DOI 10.1037/0022-006X.64.5.1010; *AM COLL OBST GYN, 1995, ACOG TECHN B, V209; *AM MED ASS, 2000, POL STAT FAM INT PAR; Babcock JC, 2004, CLIN PSYCHOL REV, V23, P1023, DOI 10.1016/j.cpr.2002.07.001; Berg AO, 2004, ANN INTERN MED, V140, P382, DOI 10.7326/0003-4819-140-5-200403020-00021; Campbell JC, 1999, J INTERPERS VIOLENCE, V14, P21, DOI 10.1177/088626099014001002; Cole TB, 2000, JAMA-J AM MED ASSOC, V284, P551, DOI 10.1001/jama.284.5.551; Dienemann J, 2003, JOGNN-J OBST GYN NEO, V32, P594, DOI 10.1177/0884217503256943; Duggan A, 2004, CHILD ABUSE NEGLECT, V28, P597, DOI 10.1016/j.chiabu.2003.08.007; Duggan AK, 1999, FUTURE CHILD, V9, P66, DOI 10.2307/1602722; Dunford FW, 2000, J CONSULT CLIN PSYCH, V68, P468, DOI 10.1037//0022-006X.68.3.468; Ferris LE, 2004, BRIT MED J, V328, P595, DOI 10.1136/bmj.328.7440.595; Gelles RJ, 2000, AM J PREV MED, V19, P298, DOI 10.1016/S0749-3797(00)00245-2; Holt VL, 2002, JAMA-J AM MED ASSOC, V288, P589, DOI 10.1001/jama.288.5.589; Landenburger K, 1989, Issues Ment Health Nurs, V10, P209, DOI 10.3109/01612848909140846; MacMillan HL, 2000, CAN MED ASSOC J, V163, P1451; MacMillan HL, 2005, LANCET, V365, P1786, DOI 10.1016/S0140-6736(05)66388-X; Nelson HD, 2004, ANN INTERN MED, V140, P387, DOI 10.7326/0003-4819-140-5-200403020-00015; Nygren P, 2004, ANN FAM MED, V2, P161, DOI 10.1370/afm.113; Olds David L, 2002, Prev Sci, V3, P153, DOI 10.1023/A:1019990432161; OLDS DL, 1986, PEDIATRICS, V78, P65; Pears KC, 2001, CHILD ABUSE NEGLECT, V25, P1439, DOI 10.1016/S0145-2134(01)00286-1; Ramsay J, 2002, BRIT MED J, V325, P314, DOI 10.1136/bmj.325.7359.314; ROSENBAUM A, 1988, J FAMILY VIOLENCE, V3, P91; Sullivan CM, 1999, J CONSULT CLIN PSYCH, V67, P43, DOI 10.1037/0022-006X.67.1.43; U. S. Department of Health and Human Services & U. S. Advisory Board on Child Abuse and Neglect, 1991, CREAT CAR COMM BLUEP; Wathen CN, 2003, CAN MED ASSOC J, V169, P582; Wathen CN, 2003, JAMA-J AM MED ASSOC, V289, P589, DOI 10.1001/jama.289.5.589	28	18	18	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	2005	294	5					618	620		10.1001/jama.294.5.618	http://dx.doi.org/10.1001/jama.294.5.618			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	951NN	16077058				2022-12-28	WOS:000230937500024
J	Caudron, M; Bunt, G; Bastiaens, P; Karsenti, E				Caudron, M; Bunt, G; Bastiaens, P; Karsenti, E			Spatial coordination of spindle assembly by chromosome-mediated signaling gradients	SCIENCE			English	Article							XENOPUS EGG EXTRACTS; GTP-BOUND RAN; MITOTIC-SPINDLE; SELF-ORGANIZATION; MICROTUBULES; TRANSPORT; CHROMATIN; PROTEIN; CELLS; TPX2	During cell division, chromosomes are distributed to daughter cells by the mitotic spindle. This system requires spatial cues to reproducibly self-organize. We report that such cues are provided by chromosome-mediated interaction gradients between the small guanosine triphosphatase (GTPase) Ran and importin-beta. This produces activity gradients that determine the spatial distribution of microtubule nucleation and stabilization around chromosomes and that are essential for the self-organization of microtubules into a bipolar spindle.	European Mol Biol Lab, Cell Biol & Biophys Dept, D-69117 Heidelberg, Germany; Max Planck Inst Expt Med, D-37075 Gottingen, Germany	European Molecular Biology Laboratory (EMBL); Max Planck Society	Bastiaens, P (corresponding author), European Mol Biol Lab, Cell Biol & Biophys Dept, D-69117 Heidelberg, Germany.	bastiaen@embl-heidelberg.de; karsenti@embl-heidetberg.de		Caudron-Herger, Maiwen/0000-0002-7030-8153				Bischoff FR, 1997, FEBS LETT, V419, P249, DOI 10.1016/S0014-5793(97)01467-1; Carazo-Salas RE, 2003, CURR BIOL, V13, P1728, DOI 10.1016/j.cub.2003.09.006; Carazo-Salas RE, 1999, NATURE, V400, P178, DOI 10.1038/22133; Dogterom M, 1996, J CELL BIOL, V133, P125, DOI 10.1083/jcb.133.1.125; Floer M, 1997, J BIOL CHEM, V272, P19538, DOI 10.1074/jbc.272.31.19538; Floer M, 1996, J BIOL CHEM, V271, P5313, DOI 10.1074/jbc.271.10.5313; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gruss OJ, 2002, NAT CELL BIOL, V4, P871, DOI 10.1038/ncb870; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Hyman AA, 1996, CELL, V84, P401, DOI 10.1016/S0092-8674(00)81285-4; Kalab P, 1999, CURR BIOL, V9, P481, DOI 10.1016/S0960-9822(99)80213-9; Kalab P, 2002, SCIENCE, V295, P2452, DOI 10.1126/science.1068798; Karsenti E, 2001, SCIENCE, V294, P543, DOI 10.1126/science.1063488; Karsenti E., 1984, J CELL BIOL, V99, P47; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; Li HY, 2004, CELL CYCLE, V3, P993; Matthies HJG, 1996, J CELL BIOL, V134, P455, DOI 10.1083/jcb.134.2.455; Nedelec F, 2003, CURR OPIN CELL BIOL, V15, P118, DOI 10.1016/S0955-0674(02)00014-5; Smirnova EA, 1998, CELL MOTIL CYTOSKEL, V40, P22, DOI 10.1002/(SICI)1097-0169(1998)40:1<22::AID-CM3>3.0.CO;2-H; STEFFEN W, 1986, J CELL BIOL, V102, P1679, DOI 10.1083/jcb.102.5.1679; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359; Wittmann T, 2000, J CELL BIOL, V149, P1405, DOI 10.1083/jcb.149.7.1405; Wollman R, 2005, CURR BIOL, V15, P828, DOI 10.1016/j.cub.2005.03.019; Wouters FS, 2001, TRENDS CELL BIOL, V11, P203, DOI 10.1016/S0962-8924(01)01982-1	25	223	226	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 26	2005	309	5739					1373	1376		10.1126/science.1115964	http://dx.doi.org/10.1126/science.1115964			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TX	16123300				2022-12-28	WOS:000231543300044
J	Clark, MA; Fisher, C; Judson, I; Thomas, JM				Clark, MA; Fisher, C; Judson, I; Thomas, JM			Medical progress: Soft-tissue sarcomas in adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GASTROINTESTINAL STROMAL TUMORS; MAGNETIC-RESONANCE-SPECTROSCOPY; ENDOTHELIAL GROWTH-FACTOR; LYMPH-NODE METASTASIS; PROGNOSTIC-FACTORS; RADIATION-THERAPY; PHASE-II; INTENSIVE CHEMOTHERAPY; SYNOVIAL SARCOMA; EWINGS FAMILY		Royal Marsden Hosp Natl Hlth Serv Fdn Trust, Sarcoma Unit, London, England	Royal Marsden NHS Foundation Trust	Clark, MA (corresponding author), Middlemore Hosp, Dept Gen Surg, POB 93311 Otahuhu, Auckland, New Zealand.	sarcoma@mac.com						Alektiar KM, 2000, INT J RADIAT ONCOL, V47, P157, DOI 10.1016/S0360-3016(99)00546-5; ALVEGARD TA, 1989, J CLIN ONCOL, V7, P1845, DOI 10.1200/JCO.1989.7.12.1845; Arndt CAS, 1999, NEW ENGL J MED, V341, P342, DOI 10.1056/NEJM199907293410507; Ballo MT, 2004, INT J RADIAT ONCOL, V58, P1461, DOI 10.1016/j.ijrobp.2003.09.079; Bar-Shalom R, 2003, J NUCL MED, V44, P1200; Bastiaannet E, 2004, CANCER TREAT REV, V30, P83, DOI 10.1016/j.ctrv.2003.07.004; Behranwala KA, 2004, ANN SURG ONCOL, V11, P714, DOI 10.1245/ASO.2004.04.027; BICKELS J, 2002, CLIN ORTHOP RELAT R, V399, P201; Billingsley KG, 1999, ANN SURG, V229, P602, DOI 10.1097/00000658-199905000-00002; BOWDEN L, 1958, SURGERY, V44, P963; BRADY MS, 1992, ARCH SURG-CHICAGO, V127, P1379; Burkill GJC, 2003, RADIOLOGY, V226, P527, DOI 10.1148/radiol.2262011880; Clark MA, 2003, SURG LAPARO ENDO PER, V13, P290, DOI 10.1097/00129689-200308000-00015; Clark MA, 2003, LANCET ONCOL, V4, P335, DOI 10.1016/S1470-2045(03)01113-6; Clasby R, 1997, BRIT J SURG, V84, P1692, DOI 10.1002/bjs.1800841213; D'Incalci A, 2003, EXPERT OPIN INV DRUG, V12, P1843; DEMAS BE, 1988, AM J ROENTGENOL, V150, P615, DOI 10.2214/ajr.150.3.615; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Eggermont AMM, 2003, LANCET ONCOL, V4, P429, DOI 10.1016/S1470-2045(03)01141-0; Eiling S, 2002, BRIT J DERMATOL, V147, P150, DOI 10.1046/j.1365-2133.2002.04726.x; Fata F, 1999, CANCER-AM CANCER SOC, V86, P2034, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2034::AID-CNCR21>3.0.CO;2-P; Fletcher CDM, 2002, HUM PATHOL, V33, P459, DOI 10.1053/hupa.2002.123545; Fletcher CDM., 2002, PATHOLOGY GENETICS T, V5; FONG YM, 1993, ANN SURG, V217, P72, DOI 10.1097/00000658-199301000-00012; Frustaci S, 2001, J CLIN ONCOL, V19, P1238, DOI 10.1200/JCO.2001.19.5.1238; Gerrand CH, 2001, J BONE JOINT SURG BR, V83B, P1149, DOI 10.1302/0301-620X.83B8.12028; Greene FL, 2002, AJCC CANC STAGING MA, DOI DOI 10.1007/978-1-4757-3656-4; Guillou L, 1997, J CLIN ONCOL, V15, P350, DOI 10.1200/JCO.1997.15.1.350; GUSTERSON B, 1985, INT J CANCER, V36, P689; Hayes AJ, 2004, BRIT J SURG, V91, P242, DOI 10.1002/bjs.4398; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190; Hensley ML, 2002, J CLIN ONCOL, V20, P2824, DOI 10.1200/JCO.2002.11.050; Heslin MJ, 1997, ANN SURG ONCOL, V4, P425, DOI 10.1007/BF02305557; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hoeber I, 2001, ANN SURG ONCOL, V8, P80, DOI 10.1007/s10434-001-0080-y; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Janjan N, 2002, AM J CLIN ONCOL-CANC, V25, P9, DOI 10.1097/00000421-200202000-00002; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Judson I, 2001, EUR J CANCER, V37, P870, DOI 10.1016/S0959-8049(01)00050-8; KARPEH MS, 1995, BRIT J CANCER, V72, P986, DOI 10.1038/bjc.1995.447; Kattan MW, 2002, J CLIN ONCOL, V20, P791, DOI 10.1200/JCO.2002.20.3.791; Kindblom LG, 1998, AM J PATHOL, V152, P1259; Kolb EA, 2003, J CLIN ONCOL, V21, P3423, DOI 10.1200/JCO.2003.10.033; KRUZELOCK RP, 1995, HEMATOL ONCOL CLIN N, V9, P513, DOI 10.1016/S0889-8588(18)30082-0; Ladanyi M, 2002, CANCER RES, V62, P135; Langstein HN, 1999, SEMIN SURG ONCOL, V17, P52, DOI 10.1002/(SICI)1098-2388(199907/08)17:1<52::AID-SSU7>3.0.CO;2-I; Lee YF, 2003, BRIT J CANCER, V88, P510, DOI 10.1038/sj.bjc.6600766; Levi F, 1999, EUR J CANCER, V35, P1711, DOI 10.1016/S0959-8049(99)00179-3; LICHTER AS, 1995, NEW ENGL J MED, V332, P371, DOI 10.1056/NEJM199502093320607; Maki RG, 2002, INT J CANCER, V100, P623, DOI 10.1002/ijc.10535; Mankin HJ, 1996, J BONE JOINT SURG AM, V78A, P656, DOI 10.2106/00004623-199605000-00004; Mccarter Martin D, 2002, Surg Oncol Clin N Am, V11, P11, DOI 10.1016/S1055-3207(03)00073-5; MCCLAIN KL, 1995, NEW ENGL J MED, V332, P12, DOI 10.1056/NEJM199501053320103; Merimsky O, 2001, ONCOLOGY-BASEL, V60, P55, DOI 10.1159/000055297; Merimsky O, 1997, ACTA ONCOL, V36, P151, DOI 10.3109/02841869709109223; Nielsen TO, 2003, AM J PATHOL, V163, P1449, DOI 10.1016/S0002-9440(10)63502-X; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; O'Sullivan B, 2002, LANCET, V359, P2235, DOI 10.1016/S0140-6736(02)09292-9; O'Sullivan Brian, 2003, Curr Oncol Rep, V5, P274, DOI 10.1007/s11912-003-0066-y; Oberlin O, 2001, BRIT J CANCER, V85, P1646, DOI 10.1054/bjoc.2001.2150; Patel SR, 1998, AM J CLIN ONCOL-CANC, V21, P317, DOI 10.1097/00000421-199806000-00025; Pisters PWT, 1996, J CLIN ONCOL, V14, P1679, DOI 10.1200/JCO.1996.14.5.1679; Pitcher M E, 1994, Eur J Surg Oncol, V20, P441; Ramanathan RC, 1999, ANN SURG ONCOL, V6, P57, DOI 10.1007/s10434-999-0057-9; Ray-Coquard I, 2004, ANN ONCOL, V15, P307, DOI 10.1093/annonc/mdh058; ROSENBERG SA, 1982, ANN SURG, V196, P305, DOI 10.1097/00000658-198209000-00009; Rossi CR, 2004, CANCER-AM CANCER SOC, V100, P1943, DOI 10.1002/cncr.20192; Rydholm A, 1997, ACTA ORTHOP SCAND, V68, P4, DOI 10.1080/17453674.1997.11744695; Rydholm A, 1998, BMJ-BRIT MED J, V317, P93, DOI 10.1136/bmj.317.7151.93; Sanders T G, 2001, Cancer Control, V8, P221; Schuck A, 2003, INT J RADIAT ONCOL, V55, P168, DOI 10.1016/S0360-3016(02)03797-5; Schwartz DL, 2001, INT J RADIAT ONCOL, V50, P449, DOI 10.1016/S0360-3016(00)01586-8; Segal NH, 2003, AM J PATHOL, V163, P691, DOI 10.1016/S0002-9440(10)63696-6; Shimizu A, 1999, CANCER RES, V59, P3719; Sijens PE, 1995, NMR BIOMED, V8, P215, DOI 10.1002/nbm.1940080506; SINDELAR W, 1993, ARCH SURG-CHICAGO, V128, P402; Singer S, 2003, ANN SURG, V238, P358, DOI 10.1097/01.sla.0000086542.11899.38; Somer EJR, 2003, EUR J NUCL MED MOL I, V30, P54, DOI 10.1007/s00259-002-0994-z; Stojadinovic A, 2002, J CLIN ONCOL, V20, P4344, DOI 10.1200/JCO.2002.07.154; Strander H, 2003, ACTA ONCOL, V42, P516, DOI 10.1080/02841860310014732; STRATTON MR, 1990, ONCOGENE, V5, P1297; Strauss SJ, 2003, J CLIN ONCOL, V21, P2974, DOI 10.1200/JCO.2003.04.106; STRONG LC, 1992, AM J EPIDEMIOL, V135, P190, DOI 10.1093/oxfordjournals.aje.a116271; Temple Larissa K F, 2002, Semin Thorac Cardiovasc Surg, V14, P35, DOI 10.1053/stcs.2002.31892; TEPPER JE, 1985, CANCER-AM CANCER SOC, V56, P475, DOI 10.1002/1097-0142(19850801)56:3<475::AID-CNCR2820560311>3.0.CO;2-S; Tierney JF, 1997, LANCET, V350, P1647; Trovik CS, 1998, CYTOPATHOLOGY, V9, P320, DOI 10.1046/j.1365-2303.1998.00102.x; Vaidya SJ, 2003, EUR J CANCER, V39, P728, DOI 10.1016/S0959-8049(02)00728-1; van Dalen T, 2004, ANN SURG ONCOL, V11, P483, DOI 10.1245/ASO.2004.09.005; Van Glabbeke M, 1999, J CLIN ONCOL, V17, P150, DOI 10.1200/JCO.1999.17.1.150; van Oosterom AT, 2002, EUR J CANCER, V38, P2397, DOI 10.1016/S0959-8049(02)00491-4; van Oosterom AT, 2001, LANCET, V358, P1421, DOI 10.1016/S0140-6736(01)06535-7; VERWEIJ J, 2003, P AN M AM SOC CLIN, V22, P814; Weitz J, 2003, J CLIN ONCOL, V21, P2719, DOI 10.1200/JCO.2003.02.026; Whooley BP, 2000, ANN SURG ONCOL, V7, P9, DOI 10.1007/s10434-000-0009-x; Wong FL, 1997, JAMA-J AM MED ASSOC, V278, P1262, DOI 10.1001/jama.278.15.1262; Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491; Yovine A, 2004, J CLIN ONCOL, V22, P890, DOI 10.1200/JCO.2004.05.210; Zahm SH, 1997, SEMIN ONCOL, V24, P504	100	615	665	3	39	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 18	2005	353	7					701	711		10.1056/NEJMra041866	http://dx.doi.org/10.1056/NEJMra041866			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955UW	16107623				2022-12-28	WOS:000231254100008
J	Krot, AN; Amelin, Y; Cassen, P; Meibom, A				Krot, AN; Amelin, Y; Cassen, P; Meibom, A			Young chondrules in CB chondrites from a giant impact in the early Solar System	NATURE			English	Article							ZONED METAL GRAINS; BENCUBBIN; NEBULA; ORIGIN; ACCRETION; GUJBA	Chondrules, which are the major constituent of chondritic meteorites, are believed to have formed during brief, localized, repetitive melting of dust ( probably caused by shock waves(1,2)) in the protoplanetary disk around the early Sun. The ages of primitive chondrules(3-6) in chondritic meteorites indicate that their formation started shortly after that of the calcium-aluminium-rich inclusions (4,567.2 +/- 0.7 Myr ago) and lasted for about 3 Myr, which is consistent with the dissipation timescale for protoplanetary disks around young solar-mass stars(7). Here we report the Pb-207-Pb-206 ages of chondrules in the metal-rich CB (Bencubbin-like) carbonaceous chondrites Gujba (4,562.7 +/- 0.5 Myr) and Hammadah al Hamra 237 (4,562.8 +/- 0.9 Myr), which formed during a single-stage, highly energetic event(8-11). Both the relatively young ages and the single-stage formation of the CB chondrules are inconsistent with formation during a nebular shock wave(2). We conclude that chondrules and metal grains in the CB chondrites formed from a vapour-melt plume produced by a giant impact between planetary embryos after dust in the protoplanetary disk had largely dissipated. These findings therefore provide evidence for planet-sized objects in the earliest asteroid belt, as required by current numerical simulations of planet formation in the inner Solar System(12).	Univ Hawaii Manoa, Hawaii Inst Geophys & Planetol, Sch Ocean & Earth Sci & Technol, Honolulu, HI 96822 USA; Geol Survey Canada, Ottawa, ON K1A 0E8, Canada; Univ Toronto, Dept Geol, Toronto, ON, Canada; SETI Inst, Mountain View, CA 94043 USA; Museum Natl Hist Nat, Lab Etud Mat Extraterr, USM 0205, F-75005 Paris, France	University of Hawaii System; University of Hawaii Manoa; Natural Resources Canada; Lands & Minerals Sector - Natural Resources Canada; Geological Survey of Canada; University of Toronto; Museum National d'Histoire Naturelle (MNHN)	Krot, AN (corresponding author), Univ Hawaii Manoa, Hawaii Inst Geophys & Planetol, Sch Ocean & Earth Sci & Technol, 2525 Correa Rd, Honolulu, HI 96822 USA.	sasha@higp.hawaii.edu		Meibom, Anders/0000-0002-4542-2819				Alexander CMO, 2004, METEORIT PLANET SCI, V39, pA13; Amelin Y, 2002, SCIENCE, V297, P1678, DOI 10.1126/science.1073950; Bizzarro M, 2004, NATURE, V431, P275, DOI 10.1038/nature02882; BOSS AP, 1993, ICARUS, V106, P168, DOI 10.1006/icar.1993.1164; BOSS AP, IN PRESS CHONDRITES; Campbell AJ, 2001, GEOCHIM COSMOCHIM AC, V65, P163, DOI 10.1016/S0016-7037(00)00526-3; Campbell AJ, 2002, GEOCHIM COSMOCHIM AC, V66, P647, DOI 10.1016/S0016-7037(01)00794-3; Canup RM, 2004, ICARUS, V168, P433, DOI 10.1016/j.icarus.2003.09.028; Chambers JE, 2002, METEORIT PLANET SCI, V37, P1523, DOI 10.1111/j.1945-5100.2002.tb00808.x; Chambers JE, 2001, METEORIT PLANET SCI, V36, P381, DOI 10.1111/j.1945-5100.2001.tb01881.x; Desch SJ, 2002, METEORIT PLANET SCI, V37, P183, DOI 10.1111/j.1945-5100.2002.tb01104.x; HARTMANN L, IN PRESS CHONDRITES; Jones R. H., 2000, Protostars and planets 4, P927; KITA N, IN PRESS CHONDRITES; KLEINE T, UNPUB GEOCHIM COSMOC; KLEINE T, 2005, LUNAR PLANET SCI, V36, P1940; Krot AN, 2001, SCIENCE, V291, P1776, DOI 10.1126/science.291.5509.1776; Krot AN, 2004, METEORIT PLANET SCI, V39, pA56; McKeegan KD, 2005, TREATISE GEOCHEM, V1, P431; Meibom A, 2000, SCIENCE, V288, P839, DOI 10.1126/science.288.5467.839; MELOSH HJ, 2004, WORKSH CHONDR PROT D, P125; NAKAMOTO T, IN PRESS CHONDRITES; Petaev MI, 2001, METEORIT PLANET SCI, V36, P93, DOI 10.1111/j.1945-5100.2001.tb01812.x; Rubin AE, 2003, GEOCHIM COSMOCHIM AC, V67, P3283, DOI 10.1016/S0016-7037(00)00098-X; SCOTT ERD, 2003, TREATISE GEOCHEMISTR, V1, P327; Weidenschilling SJ, 1998, SCIENCE, V279, P681, DOI 10.1126/science.279.5351.681; Weisberg MK, 2001, METEORIT PLANET SCI, V36, P401, DOI 10.1111/j.1945-5100.2001.tb01882.x; Wood JA, 1996, METORIT PLANET SCI, V31, P641, DOI 10.1111/j.1945-5100.1996.tb02037.x; WOOD JA, 1984, EARTH PLANET SC LETT, V70, P11, DOI 10.1016/0012-821X(84)90205-X	30	247	247	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 18	2005	436	7053					989	992		10.1038/nature03830	http://dx.doi.org/10.1038/nature03830			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955XQ	16107841				2022-12-28	WOS:000231263900043
J	Okie, S				Okie, S			Medical marijuana and the Supreme Court	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Abrams DI, 2003, ANN INTERN MED, V139, P258, DOI 10.7326/0003-4819-139-4-200308190-00008; BINZ S, 2005, SAN FRANCISCO C 0624, pB4; Joy JE, 1999, MARIJUANA MED ASSESS	3	16	16	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 18	2005	353	7					648	651		10.1056/NEJMp058165	http://dx.doi.org/10.1056/NEJMp058165			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955UW	16107619				2022-12-28	WOS:000231254100002
J	Williams, S; Bottle, A; Aylin, P				Williams, S; Bottle, A; Aylin, P			Dr Foster's case notes - Length of hospital stay and subsequent emergency readmission	BRITISH MEDICAL JOURNAL			English	Article									Univ London Imperial Coll Sci Technol & Med, Dr Foster Unit, London SW7 2AZ, England	Imperial College London	Williams, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dr Foster Unit, London SW7 2AZ, England.		Aylin, Paul/A-1073-2014	Bottle, Alex/0000-0001-9978-2011; Aylin, Paul/0000-0003-4589-1743					0	10	10	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	AUG 13	2005	331	7513					371	+		10.1136/bmj.331.7513.371	http://dx.doi.org/10.1136/bmj.331.7513.371			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	956SK	16096303	Green Published			2022-12-28	WOS:000231319900011
J	Baldini, G; Cannone, F; Chirico, G				Baldini, G; Cannone, F; Chirico, G			Pre-unfolding resonant oscillations of single green fluorescent protein molecules	SCIENCE			English	Article							GEL SILICA GLASS; ENERGY-TRANSFER; DYNAMICS; FLUCTUATIONS; SPECTROSCOPY; LANDSCAPES; MICROSCOPY; KINETICS; STATES; LIGHT	Fluorescence spectroscopy of a green fluorescent protein mutant at single-molecule resolution has revealed a remarkable oscillatory behavior that can also be driven by applied fields. We show that immediately before unfolding, several periodic oscillations among the chemical substates of the protein chromophore occur. We also show that applied alternating electric or acoustic fields, when tuned to the protein characteristic frequencies, give rise to strong resonance effects.	Univ Milano Bicocca, INFM, CNR, I-20126 Milan, Italy; Univ Milano Bicocca, Dept Phys, Lab Adv Biospectroscopy, I-20126 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Milano-Bicocca; University of Milano-Bicocca	Baldini, G (corresponding author), Univ Milano Bicocca, Dept Phys, Lab Adv Biospectroscopy, I-20126 Milan, Italy.	baldini@mib.infn.it		CHIRICO, Giuseppe/0000-0001-6578-6460				Abbruzzetti S, 2005, J AM CHEM SOC, V127, P626, DOI 10.1021/ja045400r; Badjic JD, 1999, CHEM MATER, V11, P3671, DOI 10.1021/cm990507c; BENAVRAHAM D, 1993, PHYS REV B, V47, P14559, DOI 10.1103/PhysRevB.47.14559; BETTATI S, 2004, ENCY NANOSCIENCE NAN, V9, P81; Campanini B, 2005, PROTEIN SCI, V14, P1125, DOI 10.1110/ps.041190805; Cannone F, 2004, MICROSC RES TECHNIQ, V65, P186, DOI 10.1002/jemt.20125; Chattoraj M, 1996, P NATL ACAD SCI USA, V93, P8362, DOI 10.1073/pnas.93.16.8362; Chirico G, 2002, PROTEIN SCI, V11, P1152, DOI 10.1110/ps.4490102; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Creemers TMH, 2000, P NATL ACAD SCI USA, V97, P2974, DOI 10.1073/pnas.050365997; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; Deniz AA, 2000, P NATL ACAD SCI USA, V97, P5179, DOI 10.1073/pnas.090104997; Dickson RM, 1997, NATURE, V388, P355, DOI 10.1038/41048; Edman L, 1996, P NATL ACAD SCI USA, V93, P6710, DOI 10.1073/pnas.93.13.6710; Edman L, 2000, P NATL ACAD SCI USA, V97, P8266, DOI 10.1073/pnas.130589397; Eggers DK, 2001, J MOL BIOL, V314, P911, DOI 10.1006/jmbi.2001.5166; Eggers DK, 2001, PROTEIN SCI, V10, P250, DOI 10.1110/ps.36201; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; FRAUENFELDER H, 1988, ANNU REV BIOPHYS BIO, V17, P451; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; Garcia-Parajo MF, 2000, P NATL ACAD SCI USA, V97, P7237, DOI 10.1073/pnas.97.13.7237; Ha TJ, 1999, P NATL ACAD SCI USA, V96, P893, DOI 10.1073/pnas.96.3.893; Haupts U, 1998, P NATL ACAD SCI USA, V95, P13573, DOI 10.1073/pnas.95.23.13573; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; Lim MH, 1998, P NATL ACAD SCI USA, V95, P15315, DOI 10.1073/pnas.95.26.15315; Liphardt J, 2001, SCIENCE, V292, P733, DOI 10.1126/science.1058498; Lipman EA, 2003, SCIENCE, V301, P1233, DOI 10.1126/science.1085399; Lu HP, 1998, SCIENCE, V282, P1877, DOI 10.1126/science.282.5395.1877; Moerner WE, 2003, REV SCI INSTRUM, V74, P3597, DOI 10.1063/1.1589587; Rao CV, 2002, NATURE, V420, P231, DOI 10.1038/nature01258; Scharnagl C, 1999, BIOPHYS J, V77, P1839, DOI 10.1016/S0006-3495(99)77028-1; Shen CY, 1997, J AM CHEM SOC, V119, P1304, DOI 10.1021/ja961867t; Silvano D, 2002, MICROSC RES TECHNIQ, V59, P536, DOI 10.1002/jemt.10235; Talaga DS, 2000, P NATL ACAD SCI USA, V97, P13021, DOI 10.1073/pnas.97.24.13021; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Viappiani C, 2004, P NATL ACAD SCI USA, V101, P14414, DOI 10.1073/pnas.0405987101; Vlad MO, 2002, P NATL ACAD SCI USA, V99, P12548, DOI 10.1073/pnas.192439099; Weber W, 1999, P NATL ACAD SCI USA, V96, P6177, DOI 10.1073/pnas.96.11.6177; Xie XS, 1998, ANNU REV PHYS CHEM, V49, P441, DOI 10.1146/annurev.physchem.49.1.441; Xie Z, 2004, P NATL ACAD SCI USA, V101, P534, DOI 10.1073/pnas.2636333100; Zimmer M, 2002, CHEM REV, V102, P759, DOI 10.1021/cr010142r; [No title captured]	42	51	51	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 12	2005	309	5737					1096	1100		10.1126/science.1115001	http://dx.doi.org/10.1126/science.1115001			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955MN	16099991				2022-12-28	WOS:000231230100052
J	Mclaughlin, AC; Sher, F; Attfield, JP				Mclaughlin, AC; Sher, F; Attfield, JP			RETRACTED: Negative lattice expansion from the superconductivity-antiferromagnetism crossover in ruthenium copper oxides (Retracted Article. See vol 437, pg 1057, 2005)	NATURE			English	Article; Retracted Publication							COEXISTENCE; TRANSITION	The mechanism of high-transition-temperature (high-T-c) superconductivity in doped copper oxides is an enduring problem. Antiferromagnetism is established as the competing order(1,2), but the relationship between the two states in the intervening 'pseudogap' regime has become a central puzzle(3). The role of the crystal lattice, which is important in conventional superconductors, also remains unclear. Here we report an anomalous increase of the distance between copper oxide planes on cooling, which results in negative thermal volume expansion, for layered ruthenium copper oxides(4,5) that have been doped to the boundary of antiferromagnetism and superconductivity. We propose that a crossover between these states is driven by spin ordering in the ruthenium oxide layers, revealing a novel mechanism for negative lattice expansion in solids. The differences in volume and lattice strain between the distinct superconducting and antiferromagnetic states can account for the phase segregation phenomena found extensively in low-doped copper oxides, and show that Cooper pair formation is coupled to the lattice. Unusually large variations of resistivity with magnetic field are found in these ruthenium copper oxides at low temperatures through coupling between the ordered Ru and Cu spins.	Univ Edinburgh, Ctr Sci Extreme Condit, Edinburgh EH9 3JZ, Midlothian, Scotland; Univ Aberdeen, Dept Chem, Aberdeen AB24 3UE, Scotland; Univ Edinburgh, Sch Chem, Edinburgh EH9 3JZ, Midlothian, Scotland; Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; PIEAS, Dept Chem & Mat Engn, Nilore, Islamabad, Pakistan	University of Edinburgh; University of Aberdeen; University of Edinburgh; University of Cambridge; Pakistan Institute of Engineering & Applied Science	Attfield, JP (corresponding author), Univ Edinburgh, Ctr Sci Extreme Condit, Kings Bldg,Mayfield Rd, Edinburgh EH9 3JZ, Midlothian, Scotland.	j.p.attfield@ed.ac.uk	Sher, Falak/S-8860-2019; sher, Falak/G-3412-2015	Sher, Falak/0000-0003-3868-157X; Mclaughlin, Abbie/0000-0001-9960-723X				Ahn KH, 2004, NATURE, V428, P401, DOI 10.1038/nature02364; Ando Y, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.247003; Arvanitidis J, 2003, NATURE, V425, P599, DOI 10.1038/nature01994; Awana VPS, 2002, PHYSICA C, V378, P249, DOI 10.1016/S0921-4534(02)01422-3; Bernhard C, 1999, PHYS REV B, V59, P14099, DOI 10.1103/PhysRevB.59.14099; Chen XH, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.064506; Chmaissem O, 2000, PHYS REV B, V61, P6401, DOI 10.1103/PhysRevB.61.6401; Cuk T, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.117003; Felner I, 1997, PHYS REV B, V55, pR3374, DOI 10.1103/PhysRevB.55.R3374; Hinkov V, 2004, NATURE, V430, P650, DOI 10.1038/nature02774; Kang HJ, 2003, NATURE, V423, P522, DOI 10.1038/nature01641; Kiyama T, 1996, PHYS REV B, V54, pR756, DOI 10.1103/PhysRevB.54.R756; Kobayashi KL, 1998, NATURE, V395, P677, DOI 10.1038/27167; Lavrov AN, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.227003; Lynn JW, 2000, PHYS REV B, V61, P14964, DOI 10.1103/PhysRevB.61.R14964; Matsukawa M, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.132402; McCrone JE, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.064514; Mclaughlin AC, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.014503; McLaughlin AC, 1999, PHYS REV B, V60, P7512, DOI 10.1103/PhysRevB.60.7512; McLaughlin AC, 2000, INT J INORG MATER, V2, P95, DOI 10.1016/S1466-6049(99)00070-7; Noce C., 2002, RUTHENATE RUTHENO CU; Orenstein J, 2000, SCIENCE, V288, P468, DOI 10.1126/science.288.5465.468; Rao CNR, 1998, COLOSSAL MAGNETORESISTANCE, CHARGE ORDERING AND RELATED PROPERTIES OF MANGANESE OXIDES, P1; Shi L, 2003, PHYSICA C, V399, P69, DOI 10.1016/S0921-4534(03)01295-4; Sleight A, 2003, NATURE, V425, P674, DOI 10.1038/425674a; Tokura Y., 2000, COLOSSAL MAGNETORESI; van Schilfgaarde M, 1999, NATURE, V400, P46, DOI 10.1038/21848; Yanase Y, 1999, J PHYS SOC JPN, V68, P2999, DOI 10.1143/JPSJ.68.2999	30	37	37	0	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 11	2005	436	7052					829	832		10.1038/nature03828	http://dx.doi.org/10.1038/nature03828			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953XG	16094364				2022-12-28	WOS:000231116500041
J	Christenson, LJ; Borrowman, TA; Vachon, CM; Tollefson, MM; Otley, CC; Weaver, AL; Roenigk, RK				Christenson, LJ; Borrowman, TA; Vachon, CM; Tollefson, MM; Otley, CC; Weaver, AL; Roenigk, RK			Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NONMELANOMA SKIN-CANCER; INCIDENCE RATES; UNITED-STATES; TRENDS; ADULTS; MINNESOTA; AUSTRALIA; ROCHESTER; AGE; ASSOCIATION	Context The incidence of nonmelanoma skin cancer is increasing rapidly among elderly persons, but little is known about its incidence in the population younger than 40 years. Objectives To estimate the sex- and age-specific incidences of basal cell carcinoma and squamous cell carcinoma in persons younger than 40 years in Olmsted County, Minnesota, and to evaluate change in incidence over time; to describe the clinical presentation, rate of recurrence and metastasis, and histologic characteristics of these tumors in this population-based sample. Design Population-based retrospective incidence case review. Setting Residents of Olmsted County, Minnesota, a population with comprehensive medical records captured through the Rochester Epidemiology Project. Participants Patients younger than 40 years with basal cell carcinoma or squamous cell carcinoma diagnosed between 1976 and 2003. Main Outcome Measures Incident basal cell carcinomas and squamous cell carcinomas and change in incidence of these tumors over time. Results During the study period, 451 incident basal cell carcinomas were diagnosed in 417 patients and 70 incident squamous cell carcinomas were diagnosed in 68 patients. Of these tumors, 328 were histologically confirmed basal cell carcinomas and 51 were histologically confirmed squamous coil carcinomas. Overall, the age-adjusted incidence of basal cell carcinoma per 100000 persons was 25.9 (95% confidence interval [CI], 22.6-29.2) for women and 20.9 (95% Cl, 17.8-23.9) for men. The incidence of basal cell carcinoma increased significantly during the study period among women (P<.001) but not men (P=.19). Nodular basal cell carcinoma was the most common histologic subtype; 43.0% of tumors were solely nodular basal cell carcinoma and 11.0% had a mixed composition, including the nodular subtype. The incidence of squamous cell carcinoma was similar in men and women, with an average age- and sex-adjusted incidence per 100000 persons of 3.9 (95% Cl, 3.0-4.8); the incidence of squamous cell carcinoma increased significantly over the study period among both women (P=.01) and men (P=.04). Conclusions This population-based study demonstrated an increase in the incidence of nonmelanoma skin cancer among young women and men residing in Olmsted County, Minnesota. There was a disproportionate increase in basal cell carcinoma in young women. This increase may lead to an exponential increase in the overall occurrence of nonmelanoma skin cancers over time as this population ages, which emphasizes the need to focus on skin cancer prevention in young adults.	Mayo Clin & Mayo Fdn, Dept Dermatol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Epidemiol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Biostat, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Christenson, LJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Dermatol, 200 1st St SW, Rochester, MN 55905 USA.							*AM CANC SOC, CANC FACTS FIG 2001; AUBRY F, 1985, CANCER-AM CANCER SOC, V55, P907, DOI 10.1002/1097-0142(19850215)55:4<907::AID-CNCR2820550433>3.0.CO;2-5; Bastiaens MT, 1998, J INVEST DERMATOL, V110, P880, DOI 10.1046/j.1523-1747.1998.00217.x; BETTI R, 1995, INT J DERMATOL, V34, P174, DOI 10.1111/j.1365-4362.1995.tb01561.x; Boyd AS, 2002, J AM ACAD DERMATOL, V46, P706, DOI 10.1067/mjd.2002.120467; Buettner PG, 1998, INT J CANCER, V78, P587, DOI 10.1002/(SICI)1097-0215(19981123)78:5<587::AID-IJC10>3.0.CO;2-E; Chen JG, 2001, DERMATOL SURG, V27, P1035, DOI 10.1046/j.1524-4725.2001.01004.x; CHUANG TY, 1990, J AM ACAD DERMATOL, V22, P413, DOI 10.1016/0190-9622(90)70056-N; CHUANG TY, 1990, ARCH DERMATOL, V126, P185, DOI 10.1001/archderm.126.2.185; COEBERGH JWW, 1991, BRIT J DERMATOL, V125, P353, DOI 10.1111/j.1365-2133.1991.tb14171.x; COX NH, 1992, BRIT J DERMATOL, V127, P26, DOI 10.1111/j.1365-2133.1992.tb14820.x; EMMETT AJJ, 1990, AUST NZ J SURG, V60, P855, DOI 10.1111/j.1445-2197.1990.tb07489.x; GALLAGHER RP, 1990, J AM ACAD DERMATOL, V23, P413, DOI 10.1016/0190-9622(90)70234-9; Gray DT, 1997, ARCH DERMATOL, V133, P735, DOI 10.1001/archderm.133.6.735; GREEN A, 1988, J AM ACAD DERMATOL, V19, P1045, DOI 10.1016/S0190-9622(88)70270-4; Green A, 1996, AM J EPIDEMIOL, V144, P1034, DOI 10.1093/oxfordjournals.aje.a008875; GRODSTEIN F, 1995, J NATL CANCER I, V87, P1061, DOI 10.1093/jnci/87.14.1061; Hannuksela-Svahn A, 1999, ARCH DERMATOL, V135, P781, DOI 10.1001/archderm.135.7.781; Harris RB, 2001, J AM ACAD DERMATOL, V45, P528, DOI 10.1067/mjd.2001.114742; Holme SA, 2000, BRIT J DERMATOL, V143, P1224, DOI 10.1046/j.1365-2133.2000.03892.x; Karagas MR, 1999, INT J CANCER, V81, P555, DOI 10.1002/(SICI)1097-0215(19990517)81:4<555::AID-IJC9>3.0.CO;2-R; Kikuchi A, 1996, ARCH DERMATOL, V132, P320, DOI 10.1001/archderm.132.3.320; KOPF A W, 1979, Journal of Dermatology (Tokyo), V6, P267; LEFFELL DJ, 1991, ARCH DERMATOL, V127, P1663, DOI 10.1001/archderm.127.11.1663; MARKS R, 1993, INT J CANCER, V53, P585, DOI 10.1002/ijc.2910530410; Matta JL, 2003, J AM ACAD DERMATOL, V49, P433, DOI 10.1067/S0190-9622(03)00918-6; McCullagh P, 1983, GENERALIZED LINEAR M, P127; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; OLIPHANT JA, 1994, AM J PUBLIC HEALTH, V84, P476, DOI 10.2105/AJPH.84.3.476; Pearce MS, 2003, MELANOMA RES, V13, P421, DOI 10.1097/00008390-200308000-00013; Robinson JK, 1997, J AM ACAD DERMATOL, V37, P179, DOI 10.1016/S0190-9622(97)80122-3; Roudier-Pujol C, 1999, DERMATOLOGY, V199, P119, DOI 10.1159/000018217; Scotto J., 1983, NIH PUBLICATION, V83-2433; Scrivener Y, 2002, BRIT J DERMATOL, V147, P41, DOI 10.1046/j.1365-2133.2002.04804.x; SEXTON M, 1990, J AM ACAD DERMATOL, V23, P1118, DOI 10.1016/0190-9622(90)70344-H; Staples M, 1998, INT J CANCER, V78, P144, DOI 10.1002/(SICI)1097-0215(19981005)78:2<144::AID-IJC3>3.0.CO;2-Z; Weedon D., 2002, SKIN PATHOLOGY, P765	38	389	410	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	2005	294	6					681	690		10.1001/jama.294.6.681	http://dx.doi.org/10.1001/jama.294.6.681			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	953IA	16091570	Bronze			2022-12-28	WOS:000231068600021
J	Jakesz, R; Jonat, W; Gnant, M; Mittlboeck, M; Greil, R; Tausch, C; Hilfrich, J; Kwasny, W; Menzel, C; Samonigg, H; Seifert, M; Gademann, G; Kaufmann, M				Jakesz, R; Jonat, W; Gnant, M; Mittlboeck, M; Greil, R; Tausch, C; Hilfrich, J; Kwasny, W; Menzel, C; Samonigg, H; Seifert, M; Gademann, G; Kaufmann, M		ABCSG; GABG	Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial	LANCET			English	Article							RANDOMIZED-TRIAL; THERAPY; AROMATIZATION; EXEMESTANE; LETROZOLE	Background Tamoxifen has been the standard adjuvant treatment for postmenopausal women with hormone-responsive early breast cancer for more than 20 years. However, the third-generation aromatase inhibitor anastrozole has proven efficacy and tolerability benefits compared with tamoxifen when used as initial adjuvant therapy. We investigate whether women who have received a period of adjuvant tamoxifen would benefit from being switched to anastrozole. Methods We present a combined analysis of data from two prospective, multicentre, randomised, open-label trials with nearly identical inclusion criteria. Postmenopausal women with hormone-sensitive early breast cancer who had completed 2 years' adjuvant oral tamoxifen (20 or 30 mg daily) were randomised to receive 1 mg oral anastrozole (n=1618) or 20 or 30 mg tamoxifen (n=1606) daily for the remainder of their adjuvant therapy. The primary endpoint was event-free survival, with an event defined as local or distant metastasis, or contralateral breast cancer. Analysis was by intention to treat. Findings 3224 patients were included in analyses. At a median follow-up of 28 months, we noted a 40% decrease in the risk for an event in the anastrozole group as compared with the tamoxifen group (67 events with anastrozole vs 110 with tamoxifen, hazard ratio 0.60, 95% CI 0.44-0.81, p=0.0009). Both study treatments were well tolerated. There were significantly more fractures (p=0.015) and significantly fewer thromboses (p=0.034) in patients treated with anastrozole than in those on tamoxifen. Interpretation These data lend support to a switch from tamoxifen to anastrozole in patients who have completed 2 years' adjuvant tamoxifen.	Vienna Med Univ, Vienna Gen Hosp, ABCSG, A-1090 Vienna, Austria; Goethe Univ Frankfurt, German Adjuvant Breast Canc Grp, D-6000 Frankfurt, Germany	Medical University of Vienna; Goethe University Frankfurt	Jakesz, R (corresponding author), Vienna Med Univ, Vienna Gen Hosp, ABCSG, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	raimund.jakesz@meduniwien.ac.at	Jonat, Walter/E-3024-2010; Greil, Richard F/C-7673-2017; Gnant, Michael/AAN-7054-2020	Greil, Richard F/0000-0002-4462-3694; Gnant, Michael/0000-0003-1002-2118; Mittlboeck, Martina/0000-0003-1097-4047				Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Anderson WF, 2002, BREAST CANCER RES TR, V76, P27, DOI 10.1023/A:1020299707510; Baum M, 2002, LANCET, V359, P2131; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; Boccardo F, 2005, J CLIN ONCOL, V23, P5138, DOI 10.1200/JCO.2005.04.120; Clarke R, 2001, PHARMACOL REV, V53, P25; Coleman RE, 2004, BREAST CANCER RES TR, V88, pS35; Coombes RC, 2004, NEW ENGL J MED, V350, P1081, DOI 10.1056/NEJMoa040331; COX DR, 1972, J R STAT SOC B, V34, P187; *EARL BREAST CANC, 2004, COCHR LIB; Ferlay J, 2004, GLOBOCAN 2002 CANC I; Fisher B, 1996, JNCI-J NATL CANCER I, V88, P1529, DOI 10.1093/jnci/88.21.1529; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; Geisler J, 1998, CLIN CANCER RES, V4, P2089; Geisler J, 2002, J CLIN ONCOL, V20, P751, DOI 10.1200/JCO.2002.20.3.751; Goldhirsch A, 2003, J CLIN ONCOL, V21, P3357, DOI 10.1200/JCO.2003.04.576; Goss Paul, 2002, Cancer Control, V9, P2; Goss PE, 2003, NEW ENGL J MED, V349, P1793, DOI 10.1056/NEJMoa032312; Howell A, 2005, LANCET, V365, P60, DOI 10.1016/s0140-6736(04)17666-6; JAIYESIMI IA, 1995, J CLIN ONCOL, V13, P513, DOI 10.1200/JCO.1995.13.2.513; Jakesz R, 2005, J CLIN ONCOL, V23, p10S; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LONNING PE, 2005, J CLIN ONCOL    0627, DOI DOI 10.1200/JC3.2005.07.097; Lundin J, 2001, J CLIN ONCOL, V19, P28, DOI 10.1200/JCO.2001.19.1.28; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Morandi P, 2004, BREAST CANCER RES TR, V88, pS165; Peto R, 1996, J NATL CANCER I, V88, P1791, DOI 10.1093/jnci/88.24.1791; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Saphner T, 1996, J CLIN ONCOL, V14, P2738, DOI 10.1200/JCO.1996.14.10.2738; Winer EP, 2005, J CLIN ONCOL, V23, P619, DOI 10.1200/JCO.2005.09.121	31	673	695	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 6	2005	366	9484					455	462		10.1016/S0140-6736(05)67059-6	http://dx.doi.org/10.1016/S0140-6736(05)67059-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	952RD	16084253				2022-12-28	WOS:000231022300026
J	Szlufarska, I; Nakano, A; Vashishta, P				Szlufarska, I; Nakano, A; Vashishta, P			A crossover in the mechanical response of nanocrystalline ceramics	SCIENCE			English	Article							MATERIALS SCIENCE; GRAIN-BOUNDARIES; SILICON-CARBIDE; NANOINDENTATION; DEFORMATION; TOUGHNESS; DISLOCATIONS; SIMULATIONS; PLASTICITY; STRENGTH	Multimillion-atom molecular dynamics simulation of indentation of nanocrystalline silicon carbide reveals unusual deformation mechanisms in brittle nanophase materials, resulting from the coexistence of brittle grains and soft amorphous grain boundary phases. Simulations predict a crossover from intergranular continuous deformation to intragrain discrete deformation at a critical indentation depth. The crossover arises from the interplay between cooperative grain sliding, grain rotations, and intergranular dislocation formation similar to stick-slip behavior. The crossover is also manifested in switching from deformation dominated by indentation-induced crystallization to deformation dominated by disordering, leading to amorphization. This interplay between deformation mechanisms is critical for the design of ceramics with superior mechanical properties.	Univ Wisconsin, Dept Mat Sci & Engn, Madison, WI 53706 USA; Univ So Calif, Dept Chem Engn & Mat Sci, Los Angeles, CA 90089 USA	University of Wisconsin System; University of Wisconsin Madison; University of Southern California	Szlufarska, I (corresponding author), Univ Wisconsin, Dept Mat Sci & Engn, 1509 Univ Ave, Madison, WI 53706 USA.	izabela@engr.wisc.edu	Szlufarska, Izabela/AFY-3304-2022					Blumenau AT, 2002, J PHYS-CONDENS MAT, V14, P12741, DOI 10.1088/0953-8984/14/48/311; Chen D, 2000, J AM CERAM SOC, V83, P2079, DOI 10.1111/j.1151-2916.2000.tb01515.x; Chen D, 2000, ACTA MATER, V48, P4599, DOI 10.1016/S1359-6454(00)00246-9; Chen MW, 2003, SCIENCE, V300, P1275, DOI 10.1126/science.1083727; CLAPP P, 2001, NANOSTRUCT MATER, pCH6; Feichtinger D, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.024113; Gerberich WW, 1999, ACTA MATER, V47, P4115, DOI 10.1016/S1359-6454(99)00270-0; Gouldstone A, 2000, ACTA MATER, V48, P2277, DOI 10.1016/S1359-6454(00)00009-4; Guicciardi S, 2004, J AM CERAM SOC, V87, P2101, DOI 10.1111/j.1151-2916.2004.tb06366.x; Hahn H, 1995, NANOSTRUCT MATER, V6, P191, DOI 10.1016/0965-9773(95)00042-9; Hasnaoui A, 2004, ACTA MATER, V52, P2251, DOI 10.1016/j.actamat.2004.01.018; Hasnaoui A, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.184112; Heitjans P, 2003, J PHYS-CONDENS MAT, V15, pR1257, DOI 10.1088/0953-8984/15/30/202; Keblinski P, 1997, ACTA MATER, V45, P987, DOI 10.1016/S1359-6454(96)00236-4; Keblinski P, 1996, PHYS REV LETT, V77, P2965, DOI 10.1103/PhysRevLett.77.2965; Knapp JA, 2004, J MATER RES, V19, P218, DOI 10.1557/jmr.2004.19.1.218; Li J, 2002, CMES-COMP MODEL ENG, V3, P219; Li J, 2002, NATURE, V418, P307, DOI 10.1038/nature00865; Liao F, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1920434; Madar R, 2004, NATURE, V430, P974, DOI 10.1038/430974a; Minor AM, 2001, APPL PHYS LETT, V79, P1625, DOI 10.1063/1.1400768; NIX WD, 1989, METALL TRANS A, V20, P2217, DOI 10.1007/BF02666659; Ohyanagi M, 2004, SCRIPTA MATER, V50, P111, DOI 10.1016/j.scriptamat.2003.09.027; OLIVER WC, 1992, J MATER RES, V7, P1564, DOI 10.1557/JMR.1992.1564; Ovid'ko IA, 2002, SCIENCE, V295, P2386, DOI 10.1126/science.1071064; PETHICA JB, 1983, PHILOS MAG A, V48, P593, DOI 10.1080/01418618308234914; Rino JP, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.045207; Schiotz J, 1999, PHYS REV B, V60, P11971, DOI 10.1103/PhysRevB.60.11971; Schiotz J, 1998, NATURE, V391, P561, DOI 10.1038/35328; Shan ZW, 2004, SCIENCE, V305, P654, DOI 10.1126/science.1098741; SIEGEL RW, 1996, NANOMATERIALS SYNTHE, P201; Szlufarska I, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1849843; Szlufarska I, 2004, APPL PHYS LETT, V85, P378, DOI 10.1063/1.1774252; Van Swygenhoven H, 2002, SCIENCE, V296, P66; Vetter WM, 2004, J CRYST GROWTH, V260, P201, DOI 10.1016/j.jcrysgro.2003.08.043; Wolf D, 2005, ACTA MATER, V53, P1, DOI 10.1016/j.actamat.2004.08.045; Yip S, 1998, NATURE, V391, P532, DOI 10.1038/35254; Zhang S, 2003, SURF COAT TECH, V167, P113, DOI 10.1016/S0257-8972(02)00903-9; Zhao YS, 2004, APPL PHYS LETT, V84, P1356, DOI 10.1063/1.1650556	39	206	213	11	151	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 5	2005	309	5736					911	914		10.1126/science.1114411	http://dx.doi.org/10.1126/science.1114411			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953SS	16081730				2022-12-28	WOS:000231101400039
J	Cook, PJ; Ludwig, J; Braga, AA				Cook, PJ; Ludwig, J; Braga, AA			Criminal records of homicide offenders	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FIREARM INJURIES; VIOLENCE; RISK	Context Homicide prevention strategies can be either targeted toward high-risk groups or addressed to the population at large. One high-risk group of particular interest is adults with a criminal record. But the prevalence of a criminal record among homicide offenders has not been reliably quantified, nor has the prevalence of criminal record in the general population. Objective To determine what portion of the homicide problem would be addressed by interventions linked to arrest or conviction. Design, Setting, and Participants A case-control analysis was performed using a comprehensive data set of all arrests and felony convictions in Illinois for 1990-2001. Cases were defined as Illinois residents aged 18 to 64 years who were arrested for homicide in 2001. Controls were all other Illinois residents aged 18 to 64 years in 2001. Illinois criminal and juvenile record information for cases and controls was compiled for 1990-2000. Five definitions of previous record were considered (arrest, arrest for a violent crime, 5 or more arrests with at least 1 for a violent crime, felony conviction, and violent-felony conviction), each measured for 1990-2000 and for 1996-2000. Main Outcome Measure The population-attributable risk: the portion of homicide offenses that would be eliminated by a hypothetical intervention that reduced the offending risk of individuals with a record to the offending risk of those who lack a record. Results For 1990-2000, 42.6% of 884 cases had at least 1 felony conviction compared with 3.9% of nearly 7.9 million controls, for a population-attributable risk of 40.3% (95% Cl, 37.0%-43.8%); among cases, 71.6% had experienced any arrest from 1990-2000 compared with 18.2% of controls, for a population-attributable risk of 65.3% (95% Cl, 61.6%-68.8%). For 1996-2000, the population-attributable risk among individuals with a felony conviction or any arrest was 31.0% (95% Cl, 27.9%-34.2%) and 58.5% (95% Cl, 54.9%-62.1%), respectively. Conclusions Interventions after arrestor conviction, such as supervised release, imprisonment, correctional programs, or bans on firearm possession, are targeted toward a group that has relatively high incidence of lethal violence, but they leave a large portion of the problem untouched.	Duke Univ, Sanford Inst Publ Policy, Dept Publ Policy Studies, Durham, NC 27708 USA; Georgetown Univ, Washington, DC USA; Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA	Duke University; Georgetown University; Harvard University	Cook, PJ (corresponding author), Duke Univ, Sanford Inst Publ Policy, Dept Publ Policy Studies, Durham, NC 27708 USA.	pcook@duke.edu		Cook, Philip/0000-0001-5094-9052				Braga AA, 2003, J QUANT CRIMINOL, V19, P33, DOI 10.1023/A:1022566628159; BRAGA AA, 1999, HOMICIDE STUDIES, V0003; *BUR JUST STAT, 2002, SOURC CRIM JUST STAT; Campbell JC, 2003, AM J PUBLIC HEALTH, V93, P1089, DOI 10.2105/AJPH.93.7.1089; *CDCP, 2005, WISQARS INJ MORT REP; *CHAP HALL CTR CHI, 2003, ILL STAT POL ARR DAT; CHRISTOFFEL KK, 1991, PEDIATRICS, V88, P294; CONKLIN B, 1981, PUBLIC AFF REP, V22, P1; DOWD MD, 1994, PEDIATRICS, V94, P867; Hawkins G., 1997, CRIME IS NOT PROBLEM; Kates D. B., 1995, TENN LAW REV, V62, P513; Kennedy D., 1996, FIRE GUN BUY BACKS E, P141; Kleck Gary, 1983, LAW POLY Q, V5, P280; Lane Roger, 1997, MURDER AM HIST; LANGFORD L, 1998, HOMICIDE STUDIES, V0002; LEUNG HM, 1981, BIOMETRICS, V37, P293, DOI 10.2307/2530418; McGarrell E. F., 2003, POLICING GANGS YOUTH, P77; MERCY JA, 1989, AM J PUBLIC HEALTH, V79, P595, DOI 10.2105/AJPH.79.5.595; Myers WC., 1998, HOMICIDE STUD, V2, P160, DOI [10.1177/1088767998002002004, DOI 10.1177/1088767998002002004]; Spitzer RobertJ., 2015, POLITICS GUN CONTROL; STRAUS M, 1986, B NY ACAD MED, V62, P4446; Tita, 2003, POLICING GANGS YOUTH, P102; *US BUR CENS, 2000, PUBL US MICR SAMPL C; *US BUR CENS, 2001, AM COMM SURV 2001; Vernick JS, 2003, EVALUATING GUN POLIC, P345; WEBSTER DW, 1991, ISSUES SCI TECHNOL, V7, P73; Wolfgang M. E., 1958, PATTERNS CRIMINAL HO	27	60	61	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	2005	294	5					598	601		10.1001/jama.294.5.598	http://dx.doi.org/10.1001/jama.294.5.598			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	951NN	16077054	Bronze			2022-12-28	WOS:000230937500020
J	St Clair, D; Xu, MQ; Wang, P; Yu, YQ; Fang, YR; Zhang, F; Zheng, XY; Gu, NF; Feng, GY; Sham, P; He, L				St Clair, D; Xu, MQ; Wang, P; Yu, YQ; Fang, YR; Zhang, F; Zheng, XY; Gu, NF; Feng, GY; Sham, P; He, L			Rates of adult schizophrenia following prenatal exposure to the Chinese famine of 1959-1961	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OBSTETRIC COMPLICATIONS; EARLY-ONSET; INFLUENZA; RISK; HYPOTHESIS; DISORDERS; STRESS	Context Schizophrenia is a common major mental disorder. Intrauterine nutritional deficiency may increase the risk of schizophrenia. The main evidence comes from studies of the 1944-1945 Dutch Hunger Winter when a sharp and time-limited decline in food intake occurred. The most exposed cohort conceived during the famine showed a 2-fold increased risk of schizophrenia. Objective To determine whether those who endured a massive 1959-1961 famine in China experienced similar results. Design, Setting, and Participants The risk of schizophrenia was examined in the Wuhu region of Anhui, one of the most affected provinces. Rates were compared among those born before, during, and after the famine years. Wuhu and its surrounding 6 counties are served by a single psychiatric hospital. All psychiatric case records for the years 1971 through 2001 were examined, and clinical and sociodemographic information on patients with schizophrenia was extracted by researchers who were blinded to the nature of exposure. Data on number of births and deaths in the famine years were available, and cumulative mortality was estimated from later demographic surveys. Main Outcome Measures Evidence of famine was verified, and unadjusted and, mortality-adjusted relative risks of schizophrenia were calculated. Results The birth rates (per 1000) in Anhui decreased approximately 80% during the famine years from 28.28 in 1958 and 20.97 in 1959 to 8.61 in 1960 and 11.06 in 1961. Among births that occurred during the famine years, the adjusted risk of developing schizophrenia in later life increased significantly, from 0.84% in 1959 to 2.15% in 1960 and 1.81% in 1961. The mortality-adjusted relative risk was 2.30 (95% confidence interval, 1.99-2.65) for those born in 1960 and 1.93 (95% confidence interval, 1.68-2.23) for those born in 1961. Conclusion Our findings replicate the Dutch data for a separate racial group and show that prenatal exposure to famine increases risk of schizophrenia in later life.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Shanghai 200031, Peoples R China; Shanghai Jiao Tong Univ, Shanghai 200030, Peoples R China; Fourth Peoples Hosp, Wuhu, Anhui, Peoples R China; Second Peoples Hosp, Huang Shan, Anhui, Peoples R China; Peking Univ, Inst Populat Res, Beijing 100871, Peoples R China; Shanghai Inst Mental Hlth, Shanghai, Peoples R China; Univ Hong Kong, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China; Shanghai Jiao Tong Univ, NHGG, Shanghai 200030, Peoples R China; Univ Aberdeen, Dept Mental Hlth, Aberdeen AB9 1FX, Scotland; Inst Psychiat, Div Psychol Med, London, England	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Peking University; University of Hong Kong; Shanghai Jiao Tong University; University of Aberdeen; University of London; King's College London	St Clair, D (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, 294 Taiyuan Rd, Shanghai 200031, Peoples R China.	d.stclair@abdn.ac.uk; helin@nhgg.org	St Clair, David/AAN-2412-2021					American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; *ANH PROV BUR STAT, 1991, ANH STAT YB 1991; [Anonymous], 1992, INT CLASS DIS; Brown AS, 2004, ARCH GEN PSYCHIAT, V61, P774, DOI 10.1001/archpsyc.61.8.774; Cannon M, 2002, AM J PSYCHIAT, V159, P1080, DOI 10.1176/appi.ajp.159.7.1080; Cannon M, 2003, EPIDEMIOLOGY SCHIZOP, P74; Chang Jung., 1991, WILD SWANS 3 DAUGHTE; Chen C. H., 1998, CHINESE J PSYCHIAT, V31, P72; Cotter D, 2002, BRIT J PSYCHIAT, V181, P363, DOI 10.1192/bjp.181.5.363; Goldner EM, 2002, CAN J PSYCHIAT, V47, P833, DOI 10.1177/070674370204700904; Gottesman I.I., 1991, SCHIZOPHRENIA GENESI; Hultman CM, 1999, BRIT MED J, V318, P421, DOI 10.1136/bmj.318.7181.421; Jablensky A, 2000, EUR ARCH PSY CLIN N, V250, P274, DOI 10.1007/s004060070002; LIXIN W, 1993, AGR REFORMS ANHUI TR; McGrath JJ, 2003, ANN MED, V35, P86, DOI 10.1080/07853890310010005; MCGUFFIN P, 2002, PSYCHIAT GENETICS GE; MEDNICK SA, 1988, ARCH GEN PSYCHIAT, V45, P189, DOI 10.1001/archpsyc.1988.01800260109013; Mortensen PB, 1999, NEW ENGL J MED, V340, P603, DOI 10.1056/NEJM199902253400803; MURRAY RM, 1987, BRIT MED J, V295, P681, DOI 10.1136/bmj.295.6600.681; Neugebauer R, 1999, JAMA-J AM MED ASSOC, V282, P455, DOI 10.1001/jama.282.5.455; OCALLAGHAN E, 1992, BRIT MED J, V305, P1256, DOI 10.1136/bmj.305.6864.1256; Rosenberg SM, 2004, NATURE, V430, P625, DOI 10.1038/430625a; Rutherford SL, 2003, NAT REV GENET, V4, P263, DOI 10.1038/nrg1041; Schwahn B, 2001, Am J Pharmacogenomics, V1, P189, DOI 10.2165/00129785-200101030-00004; SHAM PC, 1992, BRIT J PSYCHIAT, V160, P461, DOI 10.1192/bjp.160.4.461; Smil V, 1999, BMJ-BRIT MED J, V319, P1619, DOI 10.1136/bmj.319.7225.1619; *STAT STAT BUR, 1988, COMP MAT POP CENS ST; Susser E, 1998, AM J EPIDEMIOL, V147, P213; Susser E, 1996, ARCH GEN PSYCHIAT, V53, P25; SUSSER ES, 1992, ARCH GEN PSYCHIAT, V49, P983; van Os J, 1998, BRIT J PSYCHIAT, V172, P324, DOI 10.1192/bjp.172.4.324; Verdoux H, 1997, AM J PSYCHIAT, V154, P1220; Waddington CH, 1942, NATURE, V150, P563, DOI 10.1038/150563a0; ZHENG Y, 1987, CHINESE POPULATION A	34	480	493	2	49	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	2005	294	5					557	562		10.1001/jama.294.5.557	http://dx.doi.org/10.1001/jama.294.5.557			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	951NN	16077049	Bronze			2022-12-28	WOS:000230937500015
J	Puhan, MA; Steurer, J; Bachmann, LM; ter Riet, G				Puhan, MA; Steurer, J; Bachmann, LM; ter Riet, G			A randomized trial of ways to describe test accuracy: The effect on physicians' post-test probability estimates	ANNALS OF INTERNAL MEDICINE			English	Article							DIAGNOSTIC-TEST; VARIABILITY; SPECIFICITY; SENSITIVITY	Background: some people believe that likelihood ratios provide diagnostic information that is more useful than sensitivity and specificity estimates. Objective: To assess how physicians' estimates about probability of illness are affected by the presentation of a diagnostic test's value as an estimate of sensitivity and specificity versus a likelihood ratio or an inexact numerical graphic. Design: Random assignment of vignettes with different presentation formats of diagnostic test accuracy. Setting: Auditorium at a continuing medical education conference. Participants: 183 physicians. Intervention: After estimating probabilities of 6 common illnesses described in patient vignettes, physicians reviewed pertinent test results presented in 1 of 3 formats. Measurements: Physicians' probability estimates of illness before and after receiving test information, and post-test probability estimates based on the Bayes theorem. Results: Absolute percentage point differences between the physicians' estimated and the Bayes-based post-test probabilities varied from -7 to 31, from -7 to 28, and from 1 to 29 for the sensitivity and specificity, likelihood ratio, and graphical groups, respectively. Mean differences of probability estimates between the sensitivity and specificity and the likelihood ratio groups were small for all vignettes (-2 to 3 percentage points; summary mean z value across the 6 vignettes, 0.04 [95% CI, -0.14 to 0.21]). Limitations: The small pool of participants (who were potentially selected) and the limited number of vignettes prevented a more detailed analysis of relationships between the interpreted strength of diagnostic evidence and estimations of illness probability. Conclusions: These findings suggest that presenting diagnostic test accuracy with likelihood ratios does not affect some physicians' estimates of illness probability compared with presenting diagnostic test results as sensitivity and specificity.	Univ Hosp Zurich, Horten Ctr, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital	Puhan, MA (corresponding author), Univ Hosp Zurich, Horten Ctr, Postfach Nord, CH-8091 Zurich, Switzerland.	milo.puhan@evimed.ch	Bachmann, Lucas M/C-9686-2011; Puhan, Milo/ABE-6298-2020; Riet, Gerben ter/A-6943-2011	Puhan, Milo/0000-0003-4721-1879; Riet, Gerben ter/0000-0002-2231-7637				Bachmann LM, 2003, ACTA OBSTET GYN SCAN, V82, P564, DOI 10.1034/j.1600-0412.2003.00176.x; Bachmann LM, 2003, BRIT MED J, V326, P393; Davie AP, 1996, BRIT MED J, V312, P222; Ginsberg JS, 1998, ANN INTERN MED, V129, P1006, DOI 10.7326/0003-4819-129-12-199812150-00003; Goehring C, 2004, STAT MED, V23, P125, DOI 10.1002/sim.1591; Hoffrage U, 2000, SCIENCE, V290, P2261, DOI 10.1126/science.290.5500.2261; HUNINK MG, 2001, DECISION MAKING HLTH, P128; Irwig L, 2002, BRIT MED J, V324, P669, DOI 10.1136/bmj.324.7338.669; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; Jaeschke R, 2002, USERS GUIDES MED LIT, P121; LEDLEY RS, 1959, SCIENCE, V130, P9, DOI 10.1126/science.130.3366.9; Miettinen OS, 2001, CAN MED ASSOC J, V165, P781; Moons KGM, 2004, CLIN CHEM, V50, P473, DOI 10.1373/clinchem.2003.024752; Moons KGM, 1997, EPIDEMIOLOGY, V8, P12, DOI 10.1097/00001648-199701000-00002; Puhan MA, 2004, ANN INTERN MED, V141, P578, DOI 10.7326/0003-4819-141-7-200410050-00028; Reid MC, 1998, AM J MED, V104, P374, DOI 10.1016/S0002-9343(98)00054-0; Schouten HJA, 2000, J CLIN EPIDEMIOL, V53, P1137, DOI 10.1016/S0895-4356(00)00238-9; SOX HC, 1988, MED DECIS MAKING, P67; Steurer J, 2002, BRIT MED J, V324, P824, DOI 10.1136/bmj.324.7341.824; Weinstein MC, 1980, CLIN DECISION ANAL, P75	20	44	45	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 2	2005	143	3					184	189		10.7326/0003-4819-143-3-200508020-00004	http://dx.doi.org/10.7326/0003-4819-143-3-200508020-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	951TM	16061916				2022-12-28	WOS:000230953900003
J	Padma, TV				Padma, TV			Strong bonds	NATURE			English	Editorial Material																			0	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 28	2005	436	7050					494	494						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	949LE	16089008				2022-12-28	WOS:000230788800048
J	Whiten, A; Horner, V; de Waal, FBM				Whiten, A; Horner, V; de Waal, FBM			Conformity to cultural norms of tool use in chimpanzees	NATURE			English	Article							CAPTIVE CHIMPANZEES; TRANSMISSION; INFORMATION; EVOLUTION	Rich circumstantial evidence suggests that the extensive behavioural diversity recorded in wild great apes reflects a complexity of cultural variation unmatched by species other than our own(1-12). However, the capacity for cultural transmission assumed by this interpretation has remained difficult to test rigorously in the field, where the scope for controlled experimentation is limited(13-16). Here we show that experimentally introduced technologies will spread within different ape communities. Unobserved by group mates, we first trained a high-ranking female from each of two groups of captive chimpanzees to adopt one of two different tool-use techniques for obtaining food from the same 'Pan-pipe' apparatus, then re-introduced each female to her respective group. All but two of 32 chimpanzees mastered the new technique under the influence of their local expert, whereas none did so in a third population lacking an expert. Most chimpanzees adopted the method seeded in their group, and these traditions continued to diverge over time. A subset of chimpanzees that discovered the alternative method nevertheless went on to match the predominant approach of their companions, showing a conformity bias that is regarded as a hallmark of human culture(11).	Univ St Andrews, Sch Psychol, Ctr Social Learning & Cognit Evolut, St Andrews KY16 9JP, Fife, Scotland; Emory Univ, Yerkes Natl Primate Res Ctr, Field Stn, Atlanta, GA 30322 USA	University of St Andrews; Emory University	Whiten, A (corresponding author), Univ St Andrews, Sch Psychol, Ctr Social Learning & Cognit Evolut, St Andrews KY16 9JP, Fife, Scotland.	a.whiten@st-and.ac.uk		Whiten, Andrew/0000-0003-2426-5890	Biotechnology and Biological Sciences Research Council [S16447] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ASCH SE, 1956, PSYCHOL MONOGR, V70, P1, DOI 10.1037/h0093718; Biro D, 2003, ANIM COGN, V6, P213, DOI 10.1007/s10071-003-0183-x; BRUNER JS, 1972, AM PSYCHOL, V27, P687, DOI 10.1037/h0033144; Call Josep, 1996, P371; de Waal F., 2001, APE SUSHI MASTER CUL; Fragaszy D.M., 2003, BIOL TRADITIONS MODE; Galef Bennett G. Jr, 2003, P159, DOI 10.1017/CBO9780511584022.007; Henrich J, 2003, EVOL ANTHROPOL, V12, P123, DOI 10.1002/evan.10110; Huffman MA, 2004, PRIMATES, V45, P113, DOI 10.1007/s10329-003-0065-5; JACOBS RC, 1961, J ABNORM SOC PSYCH, V62, P649, DOI 10.1037/h0044182; Kendal RL, 2004, BEHAV ECOL, V15, P269, DOI 10.1093/beheco/arh008; LALAND KN, 1990, ANIM LEARN BEHAV, V18, P246, DOI 10.3758/BF03205282; Laland KN, 2003, EVOL ANTHROPOL, V12, P150, DOI 10.1002/evan.10111; Lefebvre Louis, 2000, P311; Lonsdorf EV, 2004, NATURE, V428, P715, DOI 10.1038/428715a; Matsuzawa T, 2001, PRIMATE ORIGINS OF HUMAN COGNITION AND BEHAVIOR, P557; Matsuzawa Tetsuro, 1994, P351; McGrew William, 2004, CULTURED CHIMPANZEE; MENZEL EW, 1972, FOLIA PRIMATOL, V17, P161; Rendell L, 2001, BEHAV BRAIN SCI, V24, P309, DOI 10.1017/S0140525X0100396X; RICHERSON PJ, 2005, NOT GENES CULTURE TR; Sherif M., 1936, PSYCHOL SOCIAL NORMS; Tomasello Michael, 1999, CULTURAL ORIGINS HUM; Tonooka R, 1997, JPN PSYCHOL RES, V39, P253, DOI 10.1111/1468-5884.00058; van Schaik CP, 2003, SCIENCE, V299, P102, DOI 10.1126/science.1078004; Whiten A, 2001, BEHAVIOUR, V138, P1481, DOI 10.1163/156853901317367717; Whiten A, 2003, EVOL ANTHROPOL, V12, P92, DOI 10.1002/evan.10107; Whiten A, 2004, LEARN BEHAV, V32, P36; Whiten A, 2005, NATURE, V437, P52, DOI 10.1038/nature04023; Whiten A, 1999, NATURE, V399, P682, DOI 10.1038/21415	30	443	456	4	217	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 29	2005	437	7059					737	740		10.1038/nature04047	http://dx.doi.org/10.1038/nature04047			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	968JD	16113685				2022-12-28	WOS:000232157900053
J	Kioy, D; Mattock, N				Kioy, D; Mattock, N			Control of sleeping sickness - time to integrate approaches	LANCET			English	Editorial Material									WHO, Special Programme Res & Training Trop Dis, World Bank, UNDP,UNICEF, CH-1211 Geneva, Switzerland	The World Bank; World Health Organization	Kioy, D (corresponding author), WHO, Special Programme Res & Training Trop Dis, World Bank, UNDP,UNICEF, CH-1211 Geneva, Switzerland.	kioyd@who.int						Donelson JE, 2003, ACTA TROP, V85, P391, DOI 10.1016/S0001-706X(02)00237-1; Enyaru JCK, 1999, ANN TROP MED PARASIT, V93, P817, DOI 10.1080/00034989957817; Fevre EM, 2005, LANCET, V366, P745, DOI 10.1016/S0140-6736(05)67179-6; Fevre EM, 2001, LANCET, V358, P625, DOI 10.1016/S0140-6736(01)05778-6; *ICPTV, 2003, NEWSL INT CONTR PATH; KUZOE FAS, 2005, TDRIDETRY051; SERAP A, 2005, TRENDS PARASITOL, V21, P107; *WHO REG OFF E MED, 2003, EMRC507 WHO REG OFF	8	6	6	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 27	2005	366	9487					695	696		10.1016/S0140-6736(05)67153-X	http://dx.doi.org/10.1016/S0140-6736(05)67153-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958UV	16125571				2022-12-28	WOS:000231474600007
J	Clarke, PR				Clarke, PR			Gradient signal orchestrates the mitotic spindle	SCIENCE			English	Editorial Material							MICROTUBULES; MECHANISMS; CAPTURE		Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland	University of Dundee	Clarke, PR (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland.	paul.clarke@cancer.org.uk	Clarke, Paul/B-1684-2009; Clarke, Paul R./AAA-6803-2020	Clarke, Paul/0000-0003-3525-2622; 	Biotechnology and Biological Sciences Research Council [BB/C007778/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Arnaoutov A, 2005, NAT CELL BIOL, V7, P626, DOI 10.1038/ncb1263; Brown GC, 1999, FEBS LETT, V457, P452, DOI 10.1016/S0014-5793(99)01058-3; Caudron M, 2005, SCIENCE, V309, P1373, DOI 10.1126/science.1115964; Gorlich D, 2003, EMBO J, V22, P1088, DOI 10.1093/emboj/cdg113; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Kalab P, 2002, SCIENCE, V295, P2452, DOI 10.1126/science.1068798; KARSENTI E, 1984, J CELL BIOL, V99, pS47, DOI 10.1083/jcb.99.1.47s; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; Kloc M, 2002, CELL, V108, P533, DOI 10.1016/S0092-8674(02)00651-7; Niethammer P, 2004, SCIENCE, V303, P1862, DOI 10.1126/science.1094108; Osterfield M, 2003, CELL, V113, P425, DOI 10.1016/S0092-8674(03)00359-3; Tanaka K, 2005, NATURE, V434, P987, DOI 10.1038/nature03483; Wollman R, 2005, CURR BIOL, V15, P828, DOI 10.1016/j.cub.2005.03.019	13	16	16	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 26	2005	309	5739					1334	1335		10.1126/science.1117842	http://dx.doi.org/10.1126/science.1117842			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TX	16123292				2022-12-28	WOS:000231543300033
J	Cowan, CA; Atienza, J; Melton, DA; Eggan, K				Cowan, CA; Atienza, J; Melton, DA; Eggan, K			Nuclear reprogramming of somatic cells after fusion with human embryonic stem cells	SCIENCE			English	Article							HUMAN TERATOCARCINOMA CELLS; HUMAN BLASTOCYSTS; GENE-EXPRESSION; LINES; DIFFERENTIATION; PLURIPOTENCY; CLONING; NANOG	We have explored the use of embryonic stem cells as an alternative to oocytes for reprogramming human somatic nuclei. Human embryonic stem (hES) cells were fused with human fibroblasts, resulting in hybrid cells that maintain a stable tetraploid DNA content and have morphology, growth rate, and antigen expression patterns characteristic of hES cells. Differentiation of hybrid cells in vitro and in vivo yielded cell types from each embryonic germ layer. Analysis of genome-wide transcriptional activity, reporter gene activation, allele-specific gene expression, and DNA methylation showed that the somatic genome was reprogrammed to an embryonic state. These results establish that hES cells can reprogram the transcriptional state of somatic nuclei and provide a system for investigating the underlying mechanisms.	Harvard Univ, Howard Hughes Med Inst, Harvard Stem Cell Inst, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University; Howard Hughes Medical Institute	Eggan, K (corresponding author), Harvard Univ, Howard Hughes Med Inst, Harvard Stem Cell Inst, Dept Mol & Cellular Biol, 7 Divin Ave, Cambridge, MA 02138 USA.	Eggan@mcb.harvard.edu	Eggan, Kevin/P-7119-2018; Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				Abeyta MJ, 2004, HUM MOL GENET, V13, P601, DOI 10.1093/hmg/ddh068; ANDREWS PW, 1984, HYBRIDOMA, V3, P347, DOI 10.1089/hyb.1984.3.347; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; Bhattacharya B, 2004, BLOOD, V103, P2956, DOI 10.1182/blood-2003-09-3314; Brivanlou AH, 2003, SCIENCE, V300, P913, DOI 10.1126/science.1082940; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Cowan CA, 2004, NEW ENGL J MED, V350, P1353, DOI 10.1056/NEJMsr040330; Daley GQ, 2002, CURR OPIN GENET DEV, V12, P607, DOI 10.1016/S0959-437X(02)00346-5; Deb-Rinker P, 2005, J BIOL CHEM, V280, P6257, DOI 10.1074/jbc.C400479200; Do JT, 2004, STEM CELLS, V22, P941, DOI 10.1634/stemcells.22-6-941; EASTER SS, 1993, J NEUROSCI, V13, P285; Eiges R, 2001, CURR BIOL, V11, P514, DOI 10.1016/S0960-9822(01)00144-0; Gurdon JB, 2003, P NATL ACAD SCI USA, V100, P11819, DOI 10.1073/pnas.1834207100; Hochedlinger K, 2002, NATURE, V415, P1035, DOI 10.1038/nature718; Hochedlinger K, 2003, NEW ENGL J MED, V349, P275, DOI 10.1056/NEJMra035397; Hwang WS, 2005, SCIENCE, V308, P1777, DOI 10.1126/science.1112286; Itskovitz-Eldor J, 2000, MOL MED, V6, P88, DOI 10.1007/BF03401776; KANNAGI R, 1983, EMBO J, V2, P2355, DOI 10.1002/j.1460-2075.1983.tb01746.x; MACDONALD DJ, 1978, CLIN CHIM ACTA, V87, P367, DOI 10.1016/0009-8981(78)90180-8; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Richards M, 2004, STEM CELLS, V22, P51, DOI 10.1634/stemcells.22-1-51; Rideout WM, 2001, SCIENCE, V293, P1093, DOI 10.1126/science.1063206; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; SHEVINSKY LH, 1982, CELL, V30, P697, DOI 10.1016/0092-8674(82)90274-4; Tada M, 2001, CURR BIOL, V11, P1553, DOI 10.1016/S0960-9822(01)00459-6; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Zaehres H, 2005, STEM CELLS, V23, P299, DOI 10.1634/stemcells.2004-0252	28	662	770	1	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 26	2005	309	5739					1369	1373		10.1126/science.1116447	http://dx.doi.org/10.1126/science.1116447			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TX	16123299				2022-12-28	WOS:000231543300043
J	Pokholok, DK; Harbison, CT; Levine, S; Cole, M; Hannett, NM; Lee, TI; Bell, GW; Walker, K; Rolfe, PA; Herbolsheimer, E; Zeitlinger, J; Lewitter, F; Gifford, DK; Young, RA				Pokholok, DK; Harbison, CT; Levine, S; Cole, M; Hannett, NM; Lee, TI; Bell, GW; Walker, K; Rolfe, PA; Herbolsheimer, E; Zeitlinger, J; Lewitter, F; Gifford, DK; Young, RA			Genome-wide map of nucleosorne acetylation and methylation in yeast	CELL			English	Article							RNA-POLYMERASE-II; GLOBAL HISTONE ACETYLATION; DNA-BINDING PROTEINS; SACCHAROMYCES-CEREVISIAE; ACTIVE GENES; IN-VIVO; GCN4 PROTEIN; TRANSCRIPTIONAL ELONGATION; TARGETED RECRUITMENT; EUKARYOTIC GENOME	Eukaryotic genomes are packaged into nucleosomes whose position and chemical modification state can profoundly influence regulation of gene expression. We profiled nucleosome modifications across the yeast genome using chromatin immunoprecipitation coupled with DNA microarrays to produce high-resolution genome-wide maps of histone acetylation and methylation. These maps take into account changes in nucleosome occupancy at actively transcribed genes and, in doing so, revise previous assessments of the modifications associated with gene expression. Both acetylation and methylation of histones are associated with transcriptional activity, but the former occurs predominantly at the beginning of genes, whereas the latter can occur throughout transcribed regions. Most notably, specific methylation events are associated with the beginning, middle, and end of actively transcribed genes. These maps provide the foundation for further understanding the roles of chromatin in gene expression and genome maintenance.	Nine Cambridge Ctr, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Young, RA (corresponding author), Nine Cambridge Ctr, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.	young@wi.mit.edu	Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Levine, Stuart/0000-0001-7363-562X	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002668] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069676] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG002668] Funding Source: Medline; NIGMS NIH HHS [GM069676] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; Bannister AJ, 2005, J BIOL CHEM, V280, P17732, DOI 10.1074/jbc.M500796200; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Bernstein BE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r62; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Bhaumik SR, 2001, GENE DEV, V15, P1935, DOI 10.1101/gad.911401; Boeger H, 2003, MOL CELL, V11, P1587, DOI 10.1016/S1097-2765(03)00231-4; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Deckert J, 2001, MOL CELL BIOL, V21, P2726, DOI 10.1128/MCB.21.8.2726-2735.2001; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Gregory PD, 1999, EMBO J, V18, P6407, DOI 10.1093/emboj/18.22.6407; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; Humphrey EL, 2004, CHEM BIOL, V11, P295, DOI 10.1016/j.chembiol.2004.03.001; Kireeva ML, 2002, MOL CELL, V9, P541, DOI 10.1016/S1097-2765(02)00472-0; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; Kurdistani SK, 2002, NAT GENET, V31, P248, DOI 10.1038/ng907; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; Lee CK, 2004, NAT GENET, V36, P900, DOI 10.1038/ng1400; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Nagy PL, 2003, P NATL ACAD SCI USA, V100, P6364, DOI 10.1073/pnas.1131966100; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Natarajan K, 2001, MOL CELL BIOL, V21, P4347, DOI 10.1128/MCB.21.13.4347-4368.2001; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Ng HH, 2003, P NATL ACAD SCI USA, V100, P1820, DOI 10.1073/pnas.0437846100; Ng HH, 2002, GENE DEV, V16, P806, DOI 10.1101/gad.978902; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Reid JL, 2000, MOL CELL, V6, P1297, DOI 10.1016/S1097-2765(00)00128-3; Reinke H, 2003, MOL CELL, V11, P1599, DOI 10.1016/S1097-2765(03)00186-2; Reinke H, 2001, MOL CELL, V7, P529, DOI 10.1016/S1097-2765(01)00200-3; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Robert F, 2004, MOL CELL, V16, P199, DOI 10.1016/j.molcel.2004.09.021; Robyr D, 2002, CELL, V109, P437, DOI 10.1016/S0092-8674(02)00746-8; Roh TY, 2004, NAT BIOTECHNOL, V22, P1013, DOI 10.1038/nbt990; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Suka N, 2002, NAT GENET, V32, P378, DOI 10.1038/ng1017; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Xiao TJ, 2003, GENE DEV, V17, P654, DOI 10.1101/gad.1055503; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155	59	1053	1079	0	48	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 26	2005	122	4					517	527		10.1016/j.cell.2005.06.026	http://dx.doi.org/10.1016/j.cell.2005.06.026			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	959YI	16122420	Bronze			2022-12-28	WOS:000231555100008
J	Kumar, J; Wierzbicki, AS				Kumar, J; Wierzbicki, AS			Images in clinical medicine: Lipemia retinalis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									St Thomas Hosp, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust	Kumar, J (corresponding author), St Thomas Hosp, London SE1 7EH, England.		Wierzbicki, Anthony/AAP-1735-2020	Wierzbicki, Anthony/0000-0003-2756-372X					0	8	8	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 25	2005	353	8					823	823		10.1056/NEJMicm040437	http://dx.doi.org/10.1056/NEJMicm040437			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	957YK	16120862				2022-12-28	WOS:000231409300011
J	Annema, JT; Versteegh, MI; Veselic, M; Welker, L; Mauad, T; Sont, JK; Willems, LNA; Rabe, KF				Annema, JT; Versteegh, MI; Veselic, M; Welker, L; Mauad, T; Sont, JK; Willems, LNA; Rabe, KF			Endoscopic ultrasound added to mediastinoscopy for preoperative staging of patients with lung cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSITRON-EMISSION-TOMOGRAPHY; COMPUTED-TOMOGRAPHY; EUS; MANAGEMENT; LESIONS; TRIAL	Context Up to 40% of thoracotomies performed for non-small cell lung cancer are unnecessary, predominantly due to inaccurate preoperative detection of lymph node metastases and mediastinal tumor invasion (T4). Mediastinoscopy and the novel, minimally invasive technique of transesophageal ultrasound-guided fine-needle aspiration (EUS-FNA) target different mediastinal lymph node stations. In addition, EUS can identify tumor invasion in neighboring organs if tumors are located adjacent to the esophagus. Objective To investigate the additional value of EUS-FNA to mediastinoscopy in the preoperative staging of patients with non-small cell lung cancer. Design, Setting, and Patients Prospective, nonrandomized multicenter trial performed in 1 referral and 5 general hospitals in the Netherlands. During a 3-year period (2000-2003), 107 consecutive patients with potential resectable non-small cell lung cancer underwent preoperative staging by both EUS-FNA and mediastinoscopy. Patients underwent thoracotomy with tumor resection if mediastinoscopy was negative. Surgical-pathological staging was compared with preoperative findings and the added benefit of the combined strategy was assessed. Intervention The EUS-FNA examination was performed as an additional staging test to mediastinoscopy in all patients. Main Outcome Measure Detection of mediastinal tumor invasion (T4) and lymph node metastases (N2/N3) comparing the combined staging by both EUS-FNA and mediastinoscopy with staging by mediastinoscopy alone. Results The combination of EUS-FNA and mediastinoscopy identified more patients with tumor invasion or lymph node metastases (36%; 95% confidence interval [CI], 27%-46%) compared with either mediastinoscopy alone (20%; 95% Cl, 13%-29%) or EUS-FNA (28%; 95% Cl, 19%-38%) alone. This indicated that 16% of thoracotomies could have been avoided by using EUS-FNA in addition to mediastinoscopy. However, 2% of the EUS-FNA findings were false-positive. Conclusion These preliminary findings suggest that EUS-FNA, when added to mediastinoscopy, improves the preoperative staging of lung cancer due to the complementary reach of EUS-FNA in detecting mediastinal lymph node metastases and the ability to assess mediastinal tumor invasion.	Leiden Univ, Med Ctr, Dept Pulmonol C3 P, Div Pulm Med, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Div Cardiothorac Surg, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Div Pathol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Div Med Decis Making, NL-2300 RC Leiden, Netherlands; Krankenhaus Grosshansdorf, Div Pulm Med, Grosshansdorf, Germany	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Grosshansdorf Hospital	Annema, JT (corresponding author), Leiden Univ, Med Ctr, Dept Pulmonol C3 P, Div Pulm Med, Albinusdreef 2,POB 9600, NL-2300 RC Leiden, Netherlands.	j.t.annema@lumc.nl	Mauad, Thais/G-1254-2012; Sont, Jacob K/J-8071-2015; Rabe, Klaus F./AAW-6296-2021	Mauad, Thais/0000-0002-3354-1466; Sont, Jacob K/0000-0002-5840-0651; Rabe, Klaus F./0000-0002-7020-1401				Annema JT, 2004, LUNG CANCER, V44, P53, DOI 10.1016/j.lungcan.2003.10.013; COUGHLIN M, 1985, ANN THORAC SURG, V40, P556, DOI 10.1016/S0003-4975(10)60348-7; Detterbeck FC, 2003, CHEST, V123, p167S, DOI 10.1378/chest.123.1_suppl.167S; Fritscher-Ravens A, 2003, AM J RESP CRIT CARE, V168, P1293, DOI 10.1164/rccm.200301-050OC; Hammoud ZT, 1999, J THORAC CARDIOV SUR, V118, P894, DOI 10.1016/S0022-5223(99)70059-0; Herder GJM, 2002, THORAX, V57, P11, DOI 10.1136/thorax.57.1.11; Kramer H, 2003, ANN SURG, V238, P180, DOI 10.1097/01.SLA.0000081086.37779.1a; Lardinois D, 2003, NEW ENGL J MED, V348, P2500, DOI 10.1056/NEJMoa022136; Larsen SS, 2002, THORAX, V57, P98, DOI 10.1136/thorax.57.2.98; Mountain CF, 1997, CHEST, V111, P1718, DOI 10.1378/chest.111.6.1718; Pfister DG, 2004, J CLIN ONCOL, V22, P330, DOI 10.1200/JCO.2004.09.053; Pieterman RM, 2000, NEW ENGL J MED, V343, P254, DOI 10.1056/NEJM200007273430404; Spira A, 2004, NEW ENGL J MED, V350, P379, DOI 10.1056/NEJMra035536; Spiro SG, 2002, AM J RESP CRIT CARE, V166, P1166, DOI 10.1164/rccm.200202-070SO; Toloza EM, 2003, CHEST, V123, p157S, DOI 10.1378/chest.123.1_suppl.157S; Toloza EM, 2003, CHEST, V123, p137S, DOI 10.1378/chest.123.1_suppl.137S; van Tinteren H, 2002, LANCET, V359, P1388, DOI 10.1016/S0140-6736(02)08352-6; Varadarajulu S, 2004, GASTROINTEST ENDOSC, V59, P345, DOI 10.1016/S0016-5107(03)02541-0; VENUTA F, 1992, EUR J CARDIO-THORAC, V6, P238, DOI 10.1016/1010-7940(92)90104-6; Wallace MB, 2001, GASTROINTEST ENDOSC, V54, P441, DOI 10.1067/mge.2001.117764	20	133	138	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 24	2005	294	8					931	936		10.1001/jama.294.8.931	http://dx.doi.org/10.1001/jama.294.8.931			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	957JM	16118383	Bronze			2022-12-28	WOS:000231366100023
J	Loevinsohn, B; Harding, A				Loevinsohn, B; Harding, A			Buying results? Contracting for health service delivery in developing countries	LANCET			English	Article							PUBLIC-PRIVATE PARTNERSHIP; MIDDLE-INCOME COUNTRIES; CARE	To achieve the health-related Millennium Development Goals, the delivery of health services will need to improve. Contracting with non-state entities, including non-governmental organisations (NGOs), has been proposed as a means for improving health care delivery, and the global experience with such contracts is reviewed here. The ten investigated examples indicate that contracting for the delivery of primary care can be very effective and that improvements can be rapid. These results were achieved in various settings and services. Many of the anticipated difficulties with contracting were either not observed in practice or did not compromise contracting's effectiveness. Seven of the nine cases with sufficient experience (greater than 3 years' elapsed experience) have been sustained and expanded. Provision of a package of basic services by contractors costs between roughly US$3 and US$6 per head per year in low-income countries. Contracting for health service delivery should be expanded and future efforts must include rigorous evaluations.	World Bank, Washington, DC 20433 USA	The World Bank	Loevinsohn, B (corresponding author), World Bank, 1818 H St NW,Mailstop MC11-1106, Washington, DC 20433 USA.	bloevinsohn@worldbank.org						Abramson W.B., 1999, PARTNERSHIPS PUBLIC; BHUSHAN J, 2002, ERD POLICY BRIEF SER, V6; Chakraborty S, 2000, HEALTH POLICY PLANN, V15, P400, DOI 10.1093/heapol/15.4.400; Domberger S., 1999, CONTRACTING ORG STRA; EICHLER R, CONTRACTING PUBLIC S; ENGLAND R, CONTRACTING PERFORMA; FRICKCARDELLE AJ, 2003, HLTH CARE REFORM CEN; HARDING A, 2003, INNOVATIONS HLTH SER; Hebrang Andrija, 2002, Lijec Vjesn, V124, P239; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Karim R, 2003, BANGLADESH INTEGRATE; Koppel A, 2003, SOC SCI MED, V56, P2461, DOI 10.1016/S0277-9536(02)00280-0; La Forgia G, 2004, CONTRACTING BASIC HL; Lavadenz F, 2001, Rev Panam Salud Publica, V9, P182, DOI 10.1590/S1020-49892001000300008; LOEVINSOHN B, WORLD BANK I FLA DEC; Mahmud H., 2002, MIDTERM HLTH FACILIT; Marek T, 1999, HEALTH POLICY PLANN, V14, P382, DOI 10.1093/heapol/14.4.382; Mills A, 1998, HEALTH POLICY PLANN, V13, P32, DOI 10.1093/heapol/13.1.32; Murthy KJR, 2001, INT J TUBERC LUNG D, V5, P354; NAKWANI N, 1997, J ECON, V77, P87; Palmer N, 2000, B WORLD HEALTH ORGAN, V78, P821; Pfeiffer J, 2003, SOC SCI MED, V56, P725, DOI 10.1016/S0277-9536(02)00068-0; Savas E. S, 2000, PRIVATIZATION PUBLIC; Schwartz JB, 2004, B WORLD HEALTH ORGAN, V82, P661; SCHWARTZ JB, REDUCING INEQUITY PR; SLACK K, 2001, PUBLICATION INT AM D; Soderlund N., 2003, NEW PUBLIC PRIVATE M; Sorensen RJ, 2003, HEALTH POLICY, V66, P73, DOI 10.1016/S0168-8510(03)00026-5; TAYLOR R, 2003, PRIVATE PARTICIPATIO, pCH3; Turshen M., 1999, PRIVATIZING HLTH SER; World Bank, 2004, WORLD DEV REP MAK SE	31	185	186	0	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 20	2005	366	9486					676	681		10.1016/S0140-6736(05)67140-1	http://dx.doi.org/10.1016/S0140-6736(05)67140-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	958EB	16112305				2022-12-28	WOS:000231426400032
J	Man, WN; Megens, M; Steinhardt, PJ; Chaikin, PM				Man, WN; Megens, M; Steinhardt, PJ; Chaikin, PM			Experimental measurement of the photonic properties of icosahedral quasicrystals	NATURE			English	Article							TRANSMISSION; GAP	Quasicrystalline structures may have optical bandgap properties-frequency ranges in which the propagation of light is forbidden-that make them well-suited to the scientific and technological applications for which photonic crystals(1-3) are normally considered(4). Such quasicrystals can be constructed from two or more types of dielectric material arranged in a quasiperiodic pattern whose rotational symmetry is forbidden for periodic crystals (such as five-fold symmetry in the plane and icosahedral symmetry in three dimensions). Because quasicrystals have higher point group symmetry than ordinary crystals, their gap centre frequencies are closer and the gaps widths are more uniform-optimal conditions for forming a complete bandgap that is more closely spherically symmetric. Although previous studies have focused on one-dimensional and two-dimensional quasicrystals(4-7,) where exact (one-dimensional) or approximate (two-dimensional) band structures can be calculated numerically, analogous calculations for the three-dimensional case are computationally challenging and have not yet been performed. Here we circumvent the computational problem by doing an experiment. Using stereolithography, we construct a photonic quasicrystal with centimetre-scale cells and perform microwave transmission measurements. We show that three-dimensional icosahedral quasicrystals exhibit sizeable stop gaps and, despite their quasi-periodicity, yield uncomplicated spectra that allow us to experimentally determine the faces of their effective Brillouin zones. Our studies confirm that they are excellent candidates for photonic bandgap materials.	Princeton Univ, Dept Phys, Princeton, NJ 08544 USA; Princeton Univ, Princeton Inst Sci & technol Mat, Princeton, NJ 08544 USA; Philips Res Labs, NL-5656 AA Eindhoven, Netherlands; NYU, Dept Phys, New York, NY 10003 USA; NYU, Ctr Soft Condensed Matter Res, New York, NY 10003 USA	Princeton University; Princeton University; Philips; Philips Research; New York University; New York University	Steinhardt, PJ (corresponding author), Princeton Univ, Dept Phys, Princeton, NJ 08544 USA.	steinh@princeton.edu		Steinhardt, Paul/0000-0003-3488-1603				Chan YS, 1998, PHYS REV LETT, V80, P956, DOI 10.1103/PhysRevLett.80.956; Cheng SSM, 1999, PHYS REV B, V59, P4091, DOI 10.1103/PhysRevB.59.4091; Dal Negro L, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.055501; Foresi JS, 1997, NATURE, V390, P143, DOI 10.1038/36514; FUJIWARA T, 1999, QUASICRYSTALS STATE, P361; Joannopoulos J. D., 1995, PHOTONIC CRYSTALS; Johnson SG, 2001, OPT EXPRESS, V8, P173, DOI 10.1364/OE.8.000173; Kaliteevski MA, 2001, J PHYS-CONDENS MAT, V13, P10459, DOI 10.1088/0953-8984/13/46/314; LEVINE D, 1984, PHYS REV LETT, V53, P2477, DOI 10.1103/PhysRevLett.53.2477; PIERCE FS, 1993, PHYS REV LETT, V70, P3919, DOI 10.1103/PhysRevLett.70.3919; Steinhardt P. J., 1987, PHYS QUASICRYSTALS; YABLONOVITCH E, 1987, PHYS REV LETT, V58, P2059, DOI 10.1103/PhysRevLett.58.2059; ZENG XC, 1988, PHYS REV B, V38, P10970, DOI 10.1103/PhysRevB.38.10970; [No title captured]	14	205	215	5	78	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 18	2005	436	7053					993	996		10.1038/nature03977	http://dx.doi.org/10.1038/nature03977			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955XQ	16107842				2022-12-28	WOS:000231263900044
J	Sachs, BP; Delbanco				Sachs, BP; Delbanco			A 38-year-old woman with fetal loss and hysterectomy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PHYSICIANS; TERM; CARE		Beth Israel Deaconess Med Ctr, Dept Obstet & Gynecol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Fac Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Sachs, BP (corresponding author), Beth Israel Deaconess Med Ctr, Dept Obstet & Gynecol, 330 Brookline Ave, Boston, MA 02215 USA.	bsachs@bidmc.harvard.edu						*AG HEALTHC RES QU, CHOOS PERF MEAS; *AM COLL OBST GYN, 1999, ACOG PRACT B, V94; *AM COLL OBST GYN, 2004, 2005 COMP SEL PUBL; *AM COLL OBST GYN, 2004, ACOGS RED AL OBGYN C; [Anonymous], 2001, CROSSING QUALITY CHA, DOI DOI 10.17226/10027; Blendon RJ, 2002, NEW ENGL J MED, V347, P1933, DOI 10.1056/NEJMsa022151; Ellrodt G, 1997, JAMA-J AM MED ASSOC, V278, P1687, DOI 10.1001/jama.278.20.1687; Foley ME, 2005, AM J OBSTET GYNECOL, V192, P102, DOI 10.1016/j.ajog.2004.06.102; Gallagher TH, 2003, JAMA-J AM MED ASSOC, V289, P1001, DOI 10.1001/jama.289.8.1001; Grimshaw JM, 2004, HEALTH TECHNOL ASSES, V8, P1, DOI 10.3310/hta8060; Hamilton ME, 2004, SYNAPSE, V53, P1, DOI 10.1002/syn.20028; Hamman WR, 2004, QUAL SAF HEALTH CARE, V13, pI72, DOI 10.1136/qshc.2004.009910; Helmreich RL, 1999, INT J AVIAT PSYCHOL, V9, P19, DOI 10.1207/s15327108ijap0901_2; Howell W.C., 1998, MAKING DECISIONS STR, P415; *JOINT COMM ACCR H, 2002, OV PREGN REL COND PR; KOHN LT, 1999, ERR HUMAN BUILDING S; Landrigan CP, 2004, NEW ENGL J MED, V351, P1838, DOI 10.1056/NEJMoa041406; Leonard M, 2004, QUAL SAF HEALTH CARE, V13, pI85, DOI 10.1136/qshc.2004.010033; McIntyre R.M., 1995, TEAM EFFECTIVENESS D, V16, P9, DOI DOI 10.1111/J.1475-6773.2006.00566.X; Moorman DW, 2005, AM J SURG, V189, P253, DOI 10.1016/j.amjsurg.2004.11.027; Ofir K, 2004, AM J OBSTET GYNECOL, V191, P425, DOI 10.1016/j.ajog.2004.01.026; Parer JT, 1997, AM J OBSTET GYNECOL, V177, P1385; PARER JT, 1996, HDB FETAL HEART RATE, P181; Pomposelli JJ, 1997, J VASC SURG, V25, P1007, DOI 10.1016/S0741-5214(97)70124-1; Richardson BS, 2005, AM J OBSTET GYNECOL, V192, P219, DOI 10.1016/j.ajog.2004.06.034; THACKER SB, COCHRANE DATABASE SY; *US DEP DEF MIL HL, TRICARE YOUR MIL HLT; Vincent C, 2003, NEW ENGL J MED, V348, P1051, DOI 10.1056/NEJMhpr020760; Waterstone M, 2001, BMJ-BRIT MED J, V322, P1089, DOI 10.1136/bmj.322.7294.1089; Williams JG, 2004, POSTGRAD MED J, V80, P415, DOI 10.1136/pgmj.2003.015974; Wright MC, 2004, QUAL SAF HEALTH CARE, V13, pI65, DOI 10.1136/qshc.2004.009951	31	30	30	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	2005	294	7					833	840		10.1001/jama.294.7.833	http://dx.doi.org/10.1001/jama.294.7.833			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955LI	16106009				2022-12-28	WOS:000231227000024
J	Ship, AN				Ship, AN			A 43-year-old woman with end-stage renal disease, 2 years 6 months later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Chertow GM, 2004, JAMA-J AM MED ASSOC, V291, P1252, DOI 10.1001/jama.291.10.1252	1	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	2005	294	7					841	841		10.1001/jama.294.7.841	http://dx.doi.org/10.1001/jama.294.7.841			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955LI	16106010				2022-12-28	WOS:000231227000025
J	Hill, N; Moor, G; Cameron, MM; Butlin, A; Preston, S; Williamson, MS; Bass, C				Hill, N; Moor, G; Cameron, MM; Butlin, A; Preston, S; Williamson, MS; Bass, C			Single blind, randomised, comparative study of the Bug Buster kit and over the counter pediculicide treatments against head lice in the United Kingdom	BRITISH MEDICAL JOURNAL			English	Article							RESISTANCE; PERMETHRIN; MALATHION; TRIAL	Objective To compare the effectiveness of the Bug Buster kit regimen with a single treatment of over the counter pediculicides for eliminating head lice. Design Single blind, multicentre, randomised, comparative clinical study. Setting Four counties in England and one county in Scotland. Participants 133 young people aged 2-15 years with head louse infestation; 56 were allocated to the Bug Buster kit and 70 to pediculicide treatment. Interventions Home use of proprietary pediculicides (organophosphate or pyrethroid) or the Bug Buster kit. Main outcome measure Presence of head lice 2-4 days after end of treatment: day 5 for the pediculicides and day 15 for the Bug Buster kit. Results The cure rate using the Bug Buster kit was significantly greater than that for the pediculicides (57% v 13%; relative risk 4.4,95% confidence interval 2.3 to 8.5). Number needed to treat for the Bug Buster kit compared with the pediculicides was 2.26. Conclusion The Bug Buster kit was the most effective over the counter treatment for head louse infestation in the community when compared with pediculicides.	Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England; Rothamsted Res, Biol Chem Div, Harpenden AL5 2JQ, Herts, England	University of London; London School of Hygiene & Tropical Medicine; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	Hill, N (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.	nigel.hill@lshtm.ac.uk		Cameron, Mary/0000-0001-5693-082X; Bass, Chris/0000-0002-2590-1492				[Anonymous], COCHRANE DATABASE SY; Bingham P, 2000, PUBLIC HEALTH, V114, P265, DOI 10.1016/S0033-3506(00)00342-5; *BRIT MED ASS, 2004, BRIT NAT FORM, P589; Burgess I., 1990, Pharmaceutical Journal, V245, P159; Burgess I., 1991, Pharmaceutical Journal, V247, P630; BURGESS IF, 1995, BRIT MED J, V311, P752, DOI 10.1136/bmj.311.7007.752; Downs AMR, 2002, BRIT J DERMATOL, V146, P88, DOI 10.1046/j.1365-2133.2002.04473.x; Downs AMR, 1999, BRIT J DERMATOL, V141, P508, DOI 10.1046/j.1365-2133.1999.03046.x; Figueroa J. L., 1998, PRIMARY HLTH CARE GU, V98, p[1, 3]; Figueroa JI, 2000, CURR OPIN INFECT DIS, V13, P135, DOI 10.1097/00001432-200004000-00007; GRATSIANSKII NA, 1997, KARDIOLOGIYA, V1, P8; IBARRA J, 2005, NURSE PRESCRIBING, V3, P810; Lee SH, 2000, PESTIC BIOCHEM PHYS, V66, P130, DOI 10.1006/pest.1999.2460; Nash B, 2003, BRIT MED J, V326, P1256, DOI 10.1136/bmj.326.7401.1256; PURCELL S, 1998, CHEM DRUG, V250, P14; Roberts RJ, 2000, LANCET, V356, P540, DOI 10.1016/S0140-6736(00)02578-2; Vander Stichele RH, 2002, J ROY SOC MED, V95, P348, DOI 10.1258/jrsm.95.7.348; VANDERSTICHELE RH, 1995, BMJ-BRIT MED J, V311, P604, DOI 10.1136/bmj.311.7005.604	18	47	50	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	AUG 13	2005	331	7513					384	386A		10.1136/bmj.38537.468623.E0	http://dx.doi.org/10.1136/bmj.38537.468623.E0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	956SK	16085658	Green Published, Green Accepted			2022-12-28	WOS:000231319900016
J	Hocht, S; Hinkelbein, W				Hocht, S; Hinkelbein, W			Postoperative radiotherapy for prostate cancer	LANCET			English	Editorial Material							RADICAL PROSTATECTOMY; RANDOMIZED-TRIAL		Charite Univ Med Berlin, Klin Radioonkol & Strahlentherapie, D-12200 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Hocht, S (corresponding author), Charite Univ Med Berlin, Klin Radioonkol & Strahlentherapie, Campus Benjamin Franklin, D-12200 Berlin, Germany.	stefan.hoecht@charite.de						Bill-Axelson A, 2005, NEW ENGL J MED, V352, P1977, DOI 10.1056/NEJMoa043739; Blute ML, 2001, J UROLOGY, V165, P119, DOI 10.1097/00005392-200101000-00030; Bolla M, 2005, LANCET, V366, P572, DOI 10.1016/S0140-6736(05)67101-2; Bolla M, 2002, LANCET, V360, P103, DOI 10.1016/S0140-6736(02)09408-4; Cooperberg MR, 2004, J CLIN ONCOL, V22, P2141, DOI 10.1200/JCO.2004.10.062; Davis BJ, 2003, CURR OPIN UROL, V13, P117, DOI 10.1097/00042307-200303000-00006; Dearnaley DP, 1999, LANCET, V353, P267, DOI 10.1016/S0140-6736(98)05180-0; Potosky AL, 2004, J NATL CANCER I, V96, P1358, DOI 10.1093/jnci/djh259; Schostak M, 2004, WORLD J UROL, V22, P441, DOI 10.1007/s00345-004-0447-3; Stephenson AJ, 2004, JAMA-J AM MED ASSOC, V291, P1325, DOI 10.1001/jama.291.11.1325; Vicini FA, 2002, CANCER-AM CANCER SOC, V95, P2126, DOI 10.1002/cncr.10919; WIEGEL T, 2005, P ASCO, P4513	12	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 13	2005	366	9485					524	525		10.1016/S0140-6736(05)67075-4	http://dx.doi.org/10.1016/S0140-6736(05)67075-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955LL	16099273				2022-12-28	WOS:000231227300005
J	De Strooper, B				De Strooper, B			Nicastrin: Gatekeeper of the gamma-secretase complex	CELL			English	Editorial Material							TRANSMEMBRANE DOMAIN; ALZHEIMERS-DISEASE; PRESENILIN; APH-1		Ctr Human Genet, B-3000 Louvain, Belgium; Katholieke Univ Leuven, B-3000 Louvain, Belgium	KU Leuven	De Strooper, B (corresponding author), Ctr Human Genet, VIB4, B-3000 Louvain, Belgium.		de+Strooper, Bart/Z-1638-2019; De Strooper, Bart/F-6507-2012	De Strooper, Bart/0000-0001-5455-5819				Annaert W, 2002, ANNU REV CELL DEV BI, V18, P25, DOI 10.1146/annurev.cellbio.18.020402.142302; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Capell A, 2003, J BIOL CHEM, V278, P52519, DOI 10.1074/jbc.C300435200; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Morais VA, 2003, J BIOL CHEM, V278, P43284, DOI 10.1074/jbc.M305685200; Schenk D, 2000, NATURE, V407, P34, DOI 10.1038/35024194; Shah S, 2005, CELL, V122, P435, DOI 10.1016/j.cell.2005.05.022; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	11	33	34	0	1	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 12	2005	122	3					318	320		10.1016/j.cell.2005.07.021	http://dx.doi.org/10.1016/j.cell.2005.07.021			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	955UZ	16096051	Bronze			2022-12-28	WOS:000231254400002
J	Fuyuno, I				Fuyuno, I			Ancient foil maker wraps up mobile-phone market	NATURE			English	News Item																			0	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 11	2005	436	7052					775	775		10.1038/436775a	http://dx.doi.org/10.1038/436775a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953XG	16094341	Bronze			2022-12-28	WOS:000231116500016
J	Shulman, AI; Mangelsdorf, DJ				Shulman, AI; Mangelsdorf, DJ			Mechanisms of disease: Retinoid X receptor heterodimers in the metabolic syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PHOSPHOLIPID TRANSFER PROTEIN; PEROXISOME-PROLIFERATOR; ACTIVATED RECEPTOR; PPAR-GAMMA; GENE-EXPRESSION; NUCLEAR RECEPTOR; INSULIN-RESISTANCE; FATTY-ACIDS; BILE-ACIDS; LXR-ALPHA		Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Pharmacol, Dallas, TX 75390 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mangelsdorf, DJ (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Pharmacol, 6001 Forest Pk Rd, Dallas, TX 75390 USA.	mango@utsouthwestern.edu		Mangelsdorf, David/0000-0002-4355-0796	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U19DK062434] Funding Source: NIH RePORTER; NIDDK NIH HHS [U19DK62434] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akiyama TE, 2001, J BIOL CHEM, V276, P39088, DOI 10.1074/jbc.M107073200; Altshuler D, 2000, NAT GENET, V26, P76, DOI 10.1038/79216; Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; Aubert J, 1997, BIOCHEM BIOPH RES CO, V238, P606, DOI 10.1006/bbrc.1997.7348; Barak Y, 2002, P NATL ACAD SCI USA, V99, P303, DOI 10.1073/pnas.012610299; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Bosse Y, 2003, OBES RES, V11, P809, DOI 10.1038/oby.2003.112; Cao GQ, 2002, J BIOL CHEM, V277, P39561, DOI 10.1074/jbc.M207187200; Chawla A, 2003, P NATL ACAD SCI USA, V100, P1268, DOI 10.1073/pnas.0337331100; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Finck BN, 2002, J CLIN INVEST, V109, P121, DOI 10.1172/JCI200214080; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Forrest D, 2000, THYROID, V10, P41, DOI 10.1089/thy.2000.10.41; Fourcade S, 2001, EUR J BIOCHEM, V268, P3490, DOI 10.1046/j.1432-1327.2001.02249.x; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; Greschik I, 2003, CURR TOP MED CHEM, V3, P1573, DOI 10.2174/1568026033451736; Grover GJ, 2003, P NATL ACAD SCI USA, V100, P10067, DOI 10.1073/pnas.1633737100; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Grundy SM, 2004, CIRCULATION, V109, P433, DOI 10.1161/01.CIR.0000111245.75752.C6; Guan HP, 2002, NAT MED, V8, P1122, DOI 10.1038/nm780; Gurnell M, 2003, J CLIN ENDOCR METAB, V88, P2412, DOI 10.1210/jc.2003-030435; He WM, 2003, P NATL ACAD SCI USA, V100, P15712, DOI 10.1073/pnas.2536828100; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Hevener AL, 2003, NAT MED, V9, P1491, DOI 10.1038/nm956; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; Kaneko E, 2003, J BIOL CHEM, V278, P36091, DOI 10.1074/jbc.M304153200; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757; Kok T, 2003, J BIOL CHEM, V278, P41930, DOI 10.1074/jbc.M306309200; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Lakka HM, 2002, JAMA-J AM MED ASSOC, V288, P2709, DOI 10.1001/jama.288.21.2709; Lambert G, 2003, J BIOL CHEM, V278, P2563, DOI 10.1074/jbc.M209525200; Lee CH, 2003, ENDOCRINOLOGY, V144, P2201, DOI 10.1210/en.2003-0288; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; McDonnell DP, 1999, TRENDS ENDOCRIN MET, V10, P301, DOI 10.1016/S1043-2760(99)00177-0; Moschetta A, 2004, NAT MED, V10, P1352, DOI 10.1038/nm1138; Muoio DM, 2002, J BIOL CHEM, V277, P26089, DOI 10.1074/jbc.M203997200; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Pasternak RC, 2002, CIRCULATION, V106, P1024, DOI 10.1161/01.CIR.0000032466.44170.44; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2002, NAT MED, V8, P1243, DOI 10.1038/nm1102-1243; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Ribon V, 1998, P NATL ACAD SCI USA, V95, P14751, DOI 10.1073/pnas.95.25.14751; Rizvi NA, 1998, CLIN CANCER RES, V4, P1437; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Sfeir Z, 1997, PROSTAG LEUKOTR ESS, V57, P17, DOI 10.1016/S0952-3278(97)90487-7; Shulman AI, 2004, CELL, V116, P417, DOI 10.1016/S0092-8674(04)00119-9; Tangirala RK, 2002, P NATL ACAD SCI USA, V99, P11896, DOI 10.1073/pnas.182199799; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; TONTONOZ P, 1995, CELL, V80, P957; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Wan YJY, 2000, MOL CELL BIOL, V20, P4436, DOI 10.1128/MCB.20.12.4436-4444.2000; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Watanabe M, 2004, J CLIN INVEST, V113, P1408, DOI 10.1172/JCI200421025; Watts GF, 1999, CURR OPIN LIPIDOL, V10, P561, DOI 10.1097/00041433-199912000-00011; Way JM, 2001, ENDOCRINOLOGY, V142, P1269, DOI 10.1210/en.142.3.1269; Wolfrum C, 2001, P NATL ACAD SCI USA, V98, P2323, DOI 10.1073/pnas.051619898; YOUNG PW, 1995, DIABETES, V44, P1087, DOI 10.2337/diabetes.44.9.1087; Zhang Y, 2001, J BIOL CHEM, V276, P43018, DOI 10.1074/jbc.M107823200	93	301	314	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 11	2005	353	6					604	615		10.1056/NEJMra043590	http://dx.doi.org/10.1056/NEJMra043590			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	953ST	16093469				2022-12-28	WOS:000231101500011
J	Coombs, NJ; Taylor, R; Wilcken, N; Boyages, J				Coombs, NJ; Taylor, R; Wilcken, N; Boyages, J			Hormone replacement therapy and breast cancer: estimate of risk	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							HEALTHY POSTMENOPAUSAL WOMEN; RANDOMIZED CONTROLLED-TRIAL; ESTROGEN PLUS PROGESTIN; POPULATION		Univ Sydney, Westmead Hosp, New S Wales Breast Canc Inst, Westmead, NSW 2145, Australia; Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney	Boyages, J (corresponding author), Univ Sydney, Westmead Hosp, New S Wales Breast Canc Inst, Westmead, NSW 2145, Australia.	johnb@bci.org.au	Boyages, John/GSE-6200-2022	Boyages, John/0000-0003-3208-3966				Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Andersson K, 1996, LANCET, V348, P1521, DOI 10.1016/S0140-6736(05)65943-0; Armitage P., 2001, STAT METHODS MED RES; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Beral V, 2002, LANCET, V360, P942, DOI 10.1016/S0140-6736(02)11032-4; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Brett KM, 1997, AM J EPIDEMIOL, V145, P536; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; COOMBS NJ, IN PRESS AUST FAM PH; CORNFIELD J, 1957, AM J PUBLIC HEALTH N, V47, P601, DOI 10.2105/AJPH.47.5.601; Day N E, 1992, IARC Sci Publ, P862; Haas JS, 2004, ANN INTERN MED, V140, P184, DOI 10.7326/0003-4819-140-3-200402030-00009; ISAACS AJ, 1995, BRIT MED J, V311, P1399, DOI 10.1136/bmj.311.7017.1399; MacLennan AH, 2002, CLIMACTERIC, V5, P351, DOI 10.1080/713605314; MACLENNAN AH, 1995, MED J AUSTRALIA, V162, P420, DOI 10.5694/j.1326-5377.1995.tb139971.x; MACLENNAN AH, 1993, MATURITAS, V16, P173; McNagny SE, 1997, ANN INTERN MED, V127, P1093, DOI 10.7326/0003-4819-127-12-199712150-00007; Olesen C, 1999, BRIT J CLIN PHARMACO, V47, P323, DOI 10.1046/j.1365-2125.1999.00879.x; Pedersen AT, 1997, LANCET, V350, P1277, DOI 10.1016/S0140-6736(97)06005-4; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; Shapiro S, 2004, CLIMACTERIC, V7, P3, DOI 10.1080/13697130310001651418; Taylor R, 2000, AUST NZ J SURG, V70, P725, DOI 10.1046/j.1440-1622.2000.01936.x; TAYLOR R, 1993, AUST J PUBLIC HEALTH, V17, P358; Taylor R, 2001, J MED SCREEN, V8, P73, DOI 10.1136/jms.8.2.73; Taylor R, 1993, TOB CONTROL, V2, P18	27	10	11	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 6	2005	331	7512					347	349		10.1136/bmj.331.7512.347	http://dx.doi.org/10.1136/bmj.331.7512.347			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955WZ	16081451	Green Submitted, Green Published			2022-12-28	WOS:000231259800029
J	Gordon, MD; Dionne, MS; Schneider, DS; Nusse, R				Gordon, MD; Dionne, MS; Schneider, DS; Nusse, R			WntD is a feedback inhibitor of Dorsal/NF-kappa B in Drosophila development and immunity	NATURE			English	Article							SIGNALING PATHWAY; NUCLEAR IMPORT; TOLL; HOST; ACTIVATION; PROTEIN; EMBRYO; GENE; MELANOGASTER; MORPHOGEN	Regulating the nuclear factor-kappa B (NF-kappa B) family of transcription factors is of critical importance to animals, with consequences of misregulation that include cancer, chronic inflammatory diseases and developmental defects(1). Studies in Drosophila melanogaster have proved fruitful in determining the signals used to control NF-kappa B proteins, beginning with the discovery that the Toll/NF-kappa B pathway, in addition to patterning the dorsal - ventral axis of the fly embryo, defines a major component of the innate immune response in both Drosophila and mammals(2,3). Here, we characterize the Drosophila wntD (Wnt inhibitor of Dorsal) gene. We show that WntD acts as a feedback inhibitor of the NF-kappa B homologue Dorsal during both embryonic patterning and the innate immune response to infection. wntD expression is under the control of Toll/Dorsal signalling, and increased levels of WntD block Dorsal nuclear accumulation, even in the absence of the I kappa B homologue Cactus. The WntD signal is independent of the common Wnt signalling component Armadillo (beta-catenin). By engineering a gene knockout, we show that wntD loss-of-function mutants have immune defects and exhibit increased levels of Toll/Dorsal signalling. Furthermore, the wntD mutant phenotype is suppressed by loss of zygotic dorsal. These results describe the first secreted feedback antagonist of Toll signalling, and demonstrate a novel Wnt activity in the fly.	Stanford Univ, Sch Med, Beckman Ctr, Howard Hughes Med Inst,Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University	Nusse, R (corresponding author), Stanford Univ, Sch Med, Beckman Ctr, Howard Hughes Med Inst,Dept Dev Biol, Stanford, CA 94305 USA.	rnusse@stanford.edu	Gordon, Michael D/H-9586-2012; Dionne, Marc/J-2572-2013	Gordon, Michael D/0000-0002-5440-986X; Dionne, Marc/0000-0002-8283-1750	NIAID NIH HHS [R01 AI053080] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060388] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELVIN MP, 1995, GENE DEV, V9, P783, DOI 10.1101/gad.9.7.783; Bettencourt R, 2004, J CELL BIOCHEM, V92, P849, DOI 10.1002/jcb.20123; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; Brandt SM, 2004, PLOS BIOL, V2, P2067, DOI 10.1371/journal.pbio.0020418; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; De Gregorio E, 2002, EMBO J, V21, P2568, DOI 10.1093/emboj/21.11.2568; Dionne MS, 2003, INFECT IMMUN, V71, P3540, DOI 10.1128/IAI.71.6.3540-3550.2003; Drier EA, 2000, CURR BIOL, V10, P23, DOI 10.1016/S0960-9822(99)00267-5; Ganguly A, 2005, DEVELOPMENT, V132, P3419, DOI 10.1242/dev.01903; GILLESPIE SKH, 1994, MOL CELL BIOL, V14, P3559, DOI 10.1128/MCB.14.6.3559; Green C, 2000, GENETICS, V156, P1117; Gross I, 1996, NUCLEIC ACIDS RES, V24, P1238, DOI 10.1093/nar/24.7.1238; Hamada F, 1999, SCIENCE, V283, P1739, DOI 10.1126/science.283.5408.1739; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hedengren M, 1999, MOL CELL, V4, P827, DOI 10.1016/S1097-2765(00)80392-5; Lemaitre B, 2004, NAT REV IMMUNOL, V4, P521, DOI 10.1038/nri1390; LEMAITRE B, 1995, EMBO J, V14, P536, DOI 10.1002/j.1460-2075.1995.tb07029.x; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LEMAITRE B, 1995, P NATL ACAD SCI USA, V92, P9465, DOI 10.1073/pnas.92.21.9465; Llimargas M, 2001, P NATL ACAD SCI USA, V98, P14487, DOI 10.1073/pnas.251304398; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Mansfield BE, 2003, CELL MICROBIOL, V5, P901, DOI 10.1046/j.1462-5822.2003.00329.x; Meng XJ, 1999, GENE DEV, V13, P792, DOI 10.1101/gad.13.7.792; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; Rorth P, 1998, MECH DEVELOP, V78, P113, DOI 10.1016/S0925-4773(98)00157-9; RUSCH J, 1994, GENE DEV, V8, P1247, DOI 10.1101/gad.8.11.1247; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; Stathopoulos A, 2002, CELL, V111, P687, DOI 10.1016/S0092-8674(02)01087-5; Zambon RA, 2005, P NATL ACAD SCI USA, V102, P7257, DOI 10.1073/pnas.0409181102; Zettervall CJ, 2004, P NATL ACAD SCI USA, V101, P14192, DOI 10.1073/pnas.0403789101	30	123	134	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 29	2005	437	7059					746	749		10.1038/nature04073	http://dx.doi.org/10.1038/nature04073			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968JD	16107793	Green Accepted			2022-12-28	WOS:000232157900055
J	Jones, M; Onslow, M; Packman, A; Williams, S; Ormond, T; Schwarz, I; Gebski, V				Jones, M; Onslow, M; Packman, A; Williams, S; Ormond, T; Schwarz, I; Gebski, V			Randomised controlled trial of the Lidcombe programme of early stuttering intervention	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RECOVERY; CHILDREN; IMPACT	Objectives To evaluate the efficacy of the Lidcombe programme of early Stuttering intervention by comparison to a control group. Design A pragmatic, open plan, parallel group, randomised controlled trial with blinded outcome assessment. Setting Two public speech clinics in New Zealand. Participants Stuttering preschool children who presented to the speech clinics for treatment. Inclusion criteria were age 3-6 years and frequency of stuttering of at least 2% syllables stuttered. Exclusion criteria were onset of stuttering during the six months before recruitment and treatment for stuttering during the previous 12 months. 54 participants were randomised: 29 to the Lidcombe programme arm and 25 to the control arm. 12 of the participants were girls. Intervention Lidcombe programme of early stuttering intervention. Main outcome measures Frequency of stuttering was measured as the proportion of syllables stuttered, from audiotaped recordings of participants' conversational speech outside the clinic. Parents in both arms of the trial collected speech samples in three different speaking situations before randomisation and at three, six, and nine months after randomisation. Results Analysis showed a highly significant difference (P = 0.003) at nine months after randomisation. The mean proportion of syllables stuttered at nine months after randomisation was 1.50% (SD 1.4) for the treatment arm and 3.9% (SD 3.5) for the control arm, giving an effect size of 2.3% of syllables stuttered (95% confidence interval 0.8 to 3.9). This effect size was more than double the minimum clinically worthwhile difference specified in the trial protocol. Conclusions The results provide evidence from a randomised controlled trial to support early intervention for stuttering. The Lidcombe programme is an efficacious treatment for stuttering in children of preschool age.	Univ Sydney, Stuttering Res Ctr, Lidcombe, NSW 2141, Australia; Univ Queensland, Princess Alexandra Hosp, Queensland Clin Trials Ctr, Woolloongabba, Qld 4102, Australia; Stuttering Treatment & Res Trust, Auckland 1001, New Zealand; Univ Canterbury, Dept Commun Disorders, Christchurch 8020, New Zealand; Univ Tennessee, Dept Speech Pathol & Audiol, Knoxville, TN 37996 USA; Univ Sydney, Clin Trials Ctr, Natl Hlth & Med Res Council, Camperdown, NSW 2050, Australia	University of Sydney; University of Queensland; University of Canterbury; University of Tennessee System; University of Tennessee Knoxville; University of Sydney	Onslow, M (corresponding author), Univ Sydney, Stuttering Res Ctr, Lidcombe, NSW 2141, Australia.	m.onslow@fhs.usyd.edu.au	; Jones, Mark/I-2720-2016	Packman, Ann/0000-0001-7378-326X; Jones, Mark/0000-0001-6858-9710; Onslow, Mark/0000-0003-2629-2390				Bloodstein O., 1995, HDB STUTTERING; Bonelli P, 2000, CLIN LINGUIST PHONET, V14, P427; CRAIG AR, 1991, J SPEECH HEAR RES, V34, P279, DOI 10.1044/jshr.3402.279; Davis S, 2002, J CHILD PSYCHOL PSYC, V43, P939, DOI 10.1111/1469-7610.00093; Harris V, 2002, J FLUENCY DISORD, V27, P203, DOI 10.1016/S0094-730X(02)00127-4; Hayhow R, 2002, J FLUENCY DISORD, V27, P1, DOI 10.1016/S0094-730X(01)00102-4; Jones M, 2000, J SPEECH LANG HEAR R, V43, P1440, DOI 10.1044/jslhr.4306.1440; King W, 2004, AFR AM REV, V38, P165, DOI 10.2307/1512246; Lincoln M, 1996, AM J SPEECH-LANG PAT, V5, P73, DOI [10.1044/1058-0360.0502.73, DOI 10.1044/1058-0360.0502.73]; Lincoln M., 1997, AM J SPEECH-LANG PAT, V6, P77, DOI [10.1044/1058-0360.0602.77, DOI 10.1044/1058-0360.0602.77]; Lincoln M., 1997, AM J SPEECH-LANG PAT, V6, P51, DOI [10.1044/1058-0360.0601.51, DOI 10.1044/1058-0360.0601.51]; ONSLOW M, 1994, J SPEECH HEAR RES, V37, P1244, DOI 10.1044/jshr.3706.1244; ONSLOW M, 1990, J SPEECH HEAR DISORD, V55, P405, DOI 10.1044/jshd.5503.405; Onslow M, 2003, LIDCOMBE PROGRAM EAR; ONSLOW M, 1999, HDB EARLY STUTTERING; ONSLOW M, 1996, BEHAV MANAGEMENT STU; ROSEMAN B, 1998, EASY DOES IT FLUENCY; SIGNORINI DF, 1993, STAT MED, V12, P2343, DOI 10.1002/sim.4780122410; VAIRI E, 1999, J SPEECH LANG HEAR R, V42, P1097; Woods S, 2002, INT J LANG COMM DIS, V37, P31, DOI 10.1080/13682820110096670; Yairi E, 1996, J COMMUN DISORD, V29, P51, DOI 10.1016/0021-9924(95)00051-8; Yairi E, 1999, J SPEECH LANG HEAR R, V42, P1097, DOI 10.1044/jslhr.4205.1097	22	138	140	0	43	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 24	2005	331	7518					659	661		10.1136/bmj.38520.451840.E0	http://dx.doi.org/10.1136/bmj.38520.451840.E0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970HH	16096286	Bronze, Green Published			2022-12-28	WOS:000232295400015
J	Fevre, EM; Picozzi, K; Fyfe, J; Waiswa, C; Odiit, M; Coleman, PG; Welburn, SC				Fevre, EM; Picozzi, K; Fyfe, J; Waiswa, C; Odiit, M; Coleman, PG; Welburn, SC			A burgeoning epidemic of sleeping sickness in Uganda	LANCET			English	Article								The epidemic of Trypanosoma brucei rhodesiense sleeping sickness in eastern Uganda, which began in 1998 as a result of movements of the livestock reservoir of the parasite, has continued to spread. An additional 133 000 people have been put at risk of infection in Kaberamaido, another newly affected district. The few resources committed to control interventions in Soroti district have failed to contain the epidemic. The high prevalence of the parasite in cattle presents a significant risk for transmission to human beings and further spread of this neglected zoonotic disease. Targeted interventions are urgently needed to control epidemics and reduce the high mortality resulting from sleeping sickness.	Univ Edinburgh, Royal Dick Sch Vet Studies, Ctr Trop Vet Med, Roslin EH25 9RG, Midlothian, Scotland; Makerere Univ, Fac Vet Med, Kampala, Uganda; Minist Hlth Uganda, Kampala, Uganda; London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Dis Control & Vector Biol Unit, London WC1, England	University of Edinburgh; Makerere University; University of London; London School of Hygiene & Tropical Medicine	Fevre, EM (corresponding author), Univ Edinburgh, Royal Dick Sch Vet Studies, Ctr Trop Vet Med, Roslin EH25 9RG, Midlothian, Scotland.	Eric.Fevre@ed.ac.uk		Welburn, Susan/0000-0002-9903-7086; Fevre, Eric/0000-0001-8931-4986				Fevre EM, 2001, LANCET, V358, P625, DOI 10.1016/S0140-6736(01)05778-6; Hutchinson OC, 2003, LANCET INFECT DIS, V3, P42, DOI 10.1016/S1473-3099(03)00488-2; Nathan N, 2004, LANCET, V363, P1402, DOI 10.1016/S0140-6736(04)16070-4; ODIIT M, IN PRESS TROP MED IN; Welburn SC, 2001, LANCET, V358, P2017, DOI 10.1016/S0140-6736(01)07096-9	5	72	72	1	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 27	2005	366	9487					745	747		10.1016/S0140-6736(05)67179-6	http://dx.doi.org/10.1016/S0140-6736(05)67179-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958UV	16125592				2022-12-28	WOS:000231474600031
J	Curtis, TP; Sloan, WT				Curtis, TP; Sloan, WT			Exploring microbial diversity - A vast below	SCIENCE			English	Editorial Material							BACTERIAL DIVERSITY; TAXA; DNA		Univ Newcastle Upon Tyne, Sch Civil Engn & Geosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ Glasgow, Dept Civil Engn, Glasgow G12 8LT, Lanark, Scotland	Newcastle University - UK; University of Glasgow	Curtis, TP (corresponding author), Univ Newcastle Upon Tyne, Sch Civil Engn & Geosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	tom.curtis@ncl.ac.uk; sloan@civil.gla.ac.uk	sloan, William/A-2430-2009	Sloan, William T/0000-0002-9450-7384; Curtis, Thomas/0000-0002-9009-1748	Engineering and Physical Sciences Research Council [GR/S59543/01, GR/S67128/01] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Bell T, 2005, SCIENCE, V308, P1884, DOI 10.1126/science.1111318; Curtis TP, 2002, P NATL ACAD SCI USA, V99, P10494, DOI 10.1073/pnas.142680199; Dunbar J, 2002, APPL ENVIRON MICROB, V68, P3035, DOI 10.1128/AEM.68.6.3035-3045.2002; Dykhuizen DE, 1998, ANTON LEEUW INT J G, V73, P25, DOI 10.1023/A:1000665216662; Gans J, 2005, SCIENCE, V309, P1387, DOI 10.1126/science.1112665; Green JL, 2004, NATURE, V432, P747, DOI 10.1038/nature03034; Hagstrom A, 2002, APPL ENVIRON MICROB, V68, P3628, DOI 10.1128/AEM.68.7.3628-3633.2002; Harte J, 2003, NATURE, V424, P1006, DOI 10.1038/4241006a; Horner-Devine MC, 2004, NATURE, V432, P750, DOI 10.1038/nature03073; Lunn M, 2004, ENVIRON MICROBIOL, V6, P1081, DOI 10.1111/j.1462-2920.2004.00641.x; MAC ARTHUR ROBERT H., 1967; MAY RM, 1974, ECOLOGY EVOLUTION CO, P81; TORSVIK V, 1990, APPL ENVIRON MICROB, V56, P782, DOI 10.1128/AEM.56.3.782-787.1990; van der Gast CJ, 2005, ENVIRON MICROBIOL, V7, P1220, DOI 10.1111/j.1462-2920.2005.00802.x; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; WILSON EO, 1993, DIVERSITY LIFE	16	121	133	2	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 26	2005	309	5739					1331	1333		10.1126/science.1118176	http://dx.doi.org/10.1126/science.1118176			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TX	16123290				2022-12-28	WOS:000231543300031
J	Korner, C; Asshoff, R; Bignucolo, O; Hattenschwiler, S; Keel, SG; Pelaez-Riedl, S; Pepin, S; Siegwolf, RTW; Zotz, G				Korner, C; Asshoff, R; Bignucolo, O; Hattenschwiler, S; Keel, SG; Pelaez-Riedl, S; Pepin, S; Siegwolf, RTW; Zotz, G			Carbon flux and growth in mature deciduous forest trees exposed to elevated CO2	SCIENCE			English	Article							ATMOSPHERIC CO2; DOWN-REGULATION; ENRICHMENT; SOIL; RESPONSES; ECOSYSTEMS; LEAF; PHOTOSYNTHESIS; DIOXIDE; CANOPY	Whether rising atmospheric carbon dioxide (CO) concentrations will cause forests to grow faster and store more carbon is an open question. Using free air CO2 release in combination with a canopy crane, we found an immediate and sustained enhancement of carbon flux through 35-meter-tall temperate forest trees when exposed to elevated CO2 However, there was no overall stimulation in stem growth and leaf titter production after 4 years. Photosynthetic capacity was not reduced, leaf chemistry changes were minor, and tree species differed in their responses. Although growing vigorously, these trees did not accrete more biomass carbon in stems in response to elevated CO2, thus challenging projections of growth responses derived from tests with smaller trees.	Univ Basel, Inst Bot, CH-4056 Basel, Switzerland; CNRS, CEFE, Ctr Funct Ecol & Evolut, F-34293 Montpellier, France; Paul Scherrer Inst, Lab Atmospher Chem, CH-5232 Villigen, Switzerland; Univ Laval, Fac Sci Agr & Alimentat, Quebec City, PQ G1K 7P4, Canada	University of Basel; UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Institut Agro; Montpellier SupAgro; CIRAD; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Universite Paul-Valery; Universite de Montpellier; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; Laval University	Korner, C (corresponding author), Univ Basel, Inst Bot, Schonbeinstr 6, CH-4056 Basel, Switzerland.	ch.koerner@unibas.ch	Gutierrez, Emilia/O-7568-2014; Körner, Christian/B-6592-2014; Siegwolf, Rolf Theodor Walter/GLT-9297-2022; Siegwolf, Rolf TW/D-4121-2009; Zotz, Gerhard/Q-5365-2018; Keel, Sonja G./AAE-4495-2019; Bignucolo, Olivier/AAP-2975-2021	Gutierrez, Emilia/0000-0002-6085-5700; Körner, Christian/0000-0001-7768-7638; Siegwolf, Rolf Theodor Walter/0000-0002-0249-0651; Siegwolf, Rolf TW/0000-0002-0249-0651; Zotz, Gerhard/0000-0002-6823-2268; Keel, Sonja G./0000-0002-2645-273X; Bignucolo, Olivier/0000-0003-4735-049X; Pepin, Steeve/0000-0002-2003-5687				Blaschke L, 2001, PLANT BIOLOGY, V3, P288, DOI 10.1055/s-2001-15203; Canadell Josep G., 2002, Trends in Ecology and Evolution, V17, P156, DOI 10.1016/S0169-5347(02)02451-5; CHEVILLAT VS, IN PRESS BASIC APPL; Egli P, 2001, OIKOS, V92, P279, DOI 10.1034/j.1600-0706.2001.920210.x; Gaudinski JB, 2001, OECOLOGIA, V129, P420, DOI 10.1007/s004420100746; Gielen B, 2003, GLOBAL CHANGE BIOL, V9, P1022, DOI 10.1046/j.1365-2486.2003.00644.x; Hamilton JG, 2002, OECOLOGIA, V131, P250, DOI 10.1007/s00442-002-0884-x; Handa IT, 2005, ECOLOGY, V86, P1288, DOI 10.1890/04-0711; Hattenschwiler S, 1998, OECOLOGIA, V113, P104, DOI 10.1007/s004420050358; Herrick JD, 2001, PLANT CELL ENVIRON, V24, P53, DOI 10.1046/j.1365-3040.2001.00652.x; Hoch G, 2003, PLANT CELL ENVIRON, V26, P1067, DOI 10.1046/j.0016-8025.2003.01032.x; Isebrands JG, 2001, ENVIRON POLLUT, V115, P359, DOI 10.1016/S0269-7491(01)00227-5; Jarvis PG, 1998, EUROPEAN FORESTS GLO; King JS, 2004, GLOBAL CHANGE BIOL, V10, P1027, DOI 10.1111/j.1529-8817.2003.00789.x; Korner C, 2003, J ECOL, V91, P4, DOI 10.1046/j.1365-2745.2003.00742.x; Korner C, 2001, ECOLOGY: ACHIEVEMENT AND CHALLENGE, P227; KORNER C, 1992, SCIENCE, V257, P1672, DOI 10.1126/science.257.5077.1672; Korner C, 2000, ECOL APPL, V10, P1590, DOI 10.2307/2641226; Leuzinger S, 2005, TREE PHYSIOL, V25, P641, DOI 10.1093/treephys/25.6.641; Loya WM, 2003, NATURE, V425, P705, DOI 10.1038/nature02047; Matamala R, 2003, SCIENCE, V302, P1385, DOI 10.1126/science.1089543; Norby RJ, 2004, P NATL ACAD SCI USA, V101, P9689, DOI 10.1073/pnas.0403491101; Norby RJ, 2003, OECOLOGIA, V136, P574, DOI 10.1007/s00442-003-1296-2; Norby RJ, 2001, NEW PHYTOL, V150, P215, DOI 10.1046/j.1469-8137.2001.00118.x; Oren R, 2001, NATURE, V411, P469, DOI 10.1038/35078064; Pepin S, 2002, OECOLOGIA, V133, P1, DOI 10.1007/s00442-002-1008-3; Sholtis JD, 2004, NEW PHYTOL, V162, P343, DOI 10.1111/j.1469-8137.2004.01028.x; Steinmann KTW, 2004, OECOLOGIA, V141, P489, DOI 10.1007/s00442-004-1674-4; Tangley L, 2001, SCIENCE, V292, P36, DOI 10.1126/science.292.5514.36; Zak DR, 2000, NEW PHYTOL, V147, P201, DOI 10.1046/j.1469-8137.2000.00687.x; Zotz G, 2005, PLANT BIOLOGY, V7, P369, DOI 10.1055/s-2005-837635	31	405	424	6	224	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 26	2005	309	5739					1360	1362		10.1126/science.1113977	http://dx.doi.org/10.1126/science.1113977			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TX	16123297				2022-12-28	WOS:000231543300040
J	Li, DS				Li, DS			PGC-1 alpha: Looking behind the sweet treat for porphyria	CELL			English	Editorial Material							5-AMINOLEVULINATE SYNTHASE; GENE; IDENTIFICATION	Porphyrias are a group of genetic disorders caused by mutations in enzymes of the heme biosynthesis pathway. Acute attacks of porphyria, reputedly the disease that incapacitated the British sovereign King George III (see this Cell cover), are precipitated by fasting and are treated by infusing heme or glucose, although the underlying molecular mechanisms remain unclear. In this issue of Cell, Handschin et al. (2005) reveal that a transcriptional coactivator called PGC-1 alpha is a key player in both induction of porphyria by fasting and amelioration of the symptoms by glucose treatment.	Cell Press, Cambridge, MA 02138 USA		Li, DS (corresponding author), Cell Press, 1100 Massachusetts Ave, Cambridge, MA 02138 USA.							Anderson KE, 2005, ANN INTERN MED, V142, P439, DOI 10.7326/0003-4819-142-6-200503150-00010; BRAIDOTTI G, 1993, J BIOL CHEM, V268, P1109; Giono LE, 2001, BIOCHEM J, V353, P307, DOI 10.1042/0264-6021:3530307; HANDSCHIN C, 2005, CELL, P122; Kauppinen R, 2005, LANCET, V365, P241; Lindberg RLP, 1996, NAT GENET, V12, P195, DOI 10.1038/ng0296-195; Podvinec M, 2004, P NATL ACAD SCI USA, V101, P9127, DOI 10.1073/pnas.0401845101; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Scassa ME, 2004, J BIOL CHEM, V279, P28082, DOI 10.1074/jbc.M401792200	10	8	8	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 26	2005	122	4					487	489		10.1016/j.cell.2005.08.010	http://dx.doi.org/10.1016/j.cell.2005.08.010			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	959YI	16122414	Bronze			2022-12-28	WOS:000231555100001
J	Stubbs, J; Simpson, KM; Triglia, T; Plouffe, D; Tonkin, CJ; Duraisingh, MT; Maier, AG; Winzeler, EA; Cowman, AF				Stubbs, J; Simpson, KM; Triglia, T; Plouffe, D; Tonkin, CJ; Duraisingh, MT; Maier, AG; Winzeler, EA; Cowman, AF			Molecular mechanism for switching of P-falciparum invasion pathways into human erythrocytes	SCIENCE			English	Article							PHENOTYPIC VARIATION; MEROZOITE PROTEINS; MALARIA; VIVAX; RECEPTOR; EXPRESSION; DEFINES; HOMOLOG; COMPLEX	The malaria parasite, Plasmodium falciparum, exploits multiple ligand-receptor interactions, called invasion pathways, to invade the host erythrocyte. Strains of P. falciparum vary in their dependency on sialated red cell receptors for invasion. We show that switching from sialic acid-dependent to -independent invasion is reversible and depends on parasite ligand use. Expression of P. falciparum reticulocyte-binding like homolog 4 (PfRh4) correlates with sialic acid-independent invasion, and PfRh4 is essential for switching invasion pathways. Differential activation of PfRh4 represents a previously unknown mechanism to switch invasion pathways and provides P. falciparum with exquisite adaptability in the face of erythrocyte receptor polymorphisms and host immune responses.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Univ Melbourne, Cooperat Res Ctr Vaccine Technol, Parkville, Vic 3010, Australia; Univ Melbourne, Dept Med Biol, Parkville, Vic 3010, Australia; Scripps Res Inst, La Jolla, CA 92037 USA; Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA	Walter & Eliza Hall Institute; University of Melbourne; University of Melbourne; Scripps Research Institute; Novartis	Cowman, AF (corresponding author), Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.	cowman@wehi.edu.au	Maier, Alex G/A-6499-2009; Tonkin, Christopher/K-6534-2019; Cowman, Alan F/C-7642-2013; Winzeler, Elizabeth/AAP-6752-2020	Maier, Alex G/0000-0001-7369-1058; Tonkin, Christopher/0000-0002-7036-6222; Cowman, Alan F/0000-0001-5145-9004; Winzeler, Elizabeth/0000-0002-4049-2113	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Barnwell John W., 1998, P93; Baum J, 2003, INFECT IMMUN, V71, P1856, DOI 10.1128/IAI.71.4.1856-1863.2003; BUSHELL GR, 1988, MOL BIOCHEM PARASIT, V28, P105, DOI 10.1016/0166-6851(88)90057-6; Cowman AF, 2000, FEBS LETT, V476, P84, DOI 10.1016/S0014-5793(00)01703-8; DOLAN SA, 1990, J CLIN INVEST, V86, P618, DOI 10.1172/JCI114753; Duraisingh MT, 2003, P NATL ACAD SCI USA, V100, P4796, DOI 10.1073/pnas.0730883100; Duraisingh MT, 2003, EMBO J, V22, P1047, DOI 10.1093/emboj/cdg096; GALINSKI MR, 1992, CELL, V69, P1213, DOI 10.1016/0092-8674(92)90642-P; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gilberger TW, 2003, J BIOL CHEM, V278, P14480, DOI 10.1074/jbc.M211446200; Kaneko O, 2002, MOL BIOCHEM PARASIT, V121, P275, DOI 10.1016/S0166-6851(02)00042-7; Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025; OKOYE VCN, 1985, SCIENCE, V227, P169, DOI 10.1126/science.3880920; Preiser PR, 1999, NATURE, V398, P618, DOI 10.1038/19309; Rayner JC, 2001, J EXP MED, V194, P1571, DOI 10.1084/jem.194.11.1571; Rayner JC, 2000, P NATL ACAD SCI USA, V97, P9648, DOI 10.1073/pnas.160469097; Reed MB, 2000, P NATL ACAD SCI USA, V97, P7509, DOI 10.1073/pnas.97.13.7509; Triglia T, 2001, MOL BIOCHEM PARASIT, V116, P55, DOI 10.1016/S0166-6851(01)00303-6	18	211	215	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 26	2005	309	5739					1384	1387		10.1126/science.1115257	http://dx.doi.org/10.1126/science.1115257			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TX	16123303				2022-12-28	WOS:000231543300047
J	Magrath, I				Magrath, I			Role of the global civil society	LANCET			English	Editorial Material									Inst Pasteur, INCTR, B-1180 Brussels, Belgium		Magrath, I (corresponding author), Inst Pasteur, INCTR, B-1180 Brussels, Belgium.	imagrath@inctr.be						Boland R G, 1982, Bull Pan Am Health Organ, V16, P233; Brugha R, 1998, HEALTH POLICY PLANN, V13, P107, DOI 10.1093/heapol/13.2.107; DEEN T, 2005, GLOB POL FOR JUN 3; LAURENT P, 2002, TRANSNATIONALES ASS, V54, P9; Loevinsohn B, 2005, LANCET, V366, P676, DOI 10.1016/S0140-6736(05)67140-1; PAUL JA, 2000, GLOB POL FOR JUN; United Nations, 2000, MILL DECL; Willets P., 1996, CONSCIENCE WORLD INF; World Bank, 2004, WORLD DEV REP 2004 M, DOI [10.1596/0-8213-5468-x, DOI 10.1596/0-8213-5468-X]	9	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 20	2005	366	9486					613	615		10.1016/S0140-6736(05)67117-6	http://dx.doi.org/10.1016/S0140-6736(05)67117-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958EB	16112285				2022-12-28	WOS:000231426400007
J	de Jong, G				de Jong, G			Is invariance across animal species just an illusion?	SCIENCE			English	Editorial Material							SEX-CHANGE; SIZE; TEMPERATURE; GROWTH		Univ Utrecht, Evolutionary Populat Biol Grp, NL-3584 CH Utrecht, Netherlands	Utrecht University	de Jong, G (corresponding author), Univ Utrecht, Evolutionary Populat Biol Grp, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	g.dejong@bio.uu.nl	de Jong, Gerdien/J-6569-2012					Allsop DJ, 2003, NATURE, V425, P783, DOI 10.1038/425783a; BURSTON PM, 2004, NATURE, V428; Buston P, 2003, NATURE, V424, P145, DOI 10.1038/424145a; Charnov EL, 2000, EVOL ECOL RES, V2, P1067; Charnov Eric L., 1993, P1; CIPRIANI R, 2005, J EVOL BIOL; Clarke A, 2004, FUNCT ECOL, V18, P252, DOI 10.1111/j.0269-8463.2004.00842.x; Gardner A, 2005, AM NAT, V165, P551, DOI 10.1086/429526; Gillooly JF, 2001, SCIENCE, V293, P2248, DOI 10.1126/science.1061967; Kozlowski J, 2004, FUNCT ECOL, V18, P283, DOI 10.1111/j.0269-8463.2004.00830.x; Kozlowski J, 1996, P ROY SOC B-BIOL SCI, V263, P559, DOI 10.1098/rspb.1996.0084; Nee S, 2005, SCIENCE, V309, P1236, DOI 10.1126/science.1114488; Rodgers EW, 2005, BIOL BULL-US, V208, P120, DOI 10.2307/3593120; West GB, 2004, PHYS TODAY, V57, P36, DOI 10.1063/1.1809090; West GB, 2002, P NATL ACAD SCI USA, V99, P2473, DOI 10.1073/pnas.012579799	15	9	11	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 19	2005	309	5738					1193	1195		10.1126/science.1117591	http://dx.doi.org/10.1126/science.1117591			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	957TE	16109870	Green Submitted			2022-12-28	WOS:000231395400030
J	Bolla, M; van Poppel, H; Collette, L; van Cangh, P; Vekemans, K; Da Pozzo, L; de Reijke, TM; Verbaeys, A; Bosset, JF; van Velthoven, R; Marechal, JM; Scalliet, P; Haustermans, K; Pierart, M				Bolla, M; van Poppel, H; Collette, L; van Cangh, P; Vekemans, K; Da Pozzo, L; de Reijke, TM; Verbaeys, A; Bosset, JF; van Velthoven, R; Marechal, JM; Scalliet, P; Haustermans, K; Pierart, M		European Organization Res Treatmen	Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)	LANCET			English	Article							ADJUVANT RADIATION-THERAPY; ANTIGEN LEVELS; CANCER; ADENOCARCINOMA; IRRADIATION; CARCINOMA; FAILURE; PSA	Background Local failure after prostatectomy can arise in patients with cancer extending beyond the capsule. We did a randomised controlled trial to compare radical prostatectomy followed by immediate external irradiation with prostatectomy alone for patients with positive surgical margin or pT3 prostate cancer. Methods After undergoing radical retropubic prostatectomy, 503 patients were randomly assigned to a wait-and-see policy, and 502 to immediate postoperative radiotherapy (60 Gy conventional irradiation delivered over 6 weeks). Eligible patients had pN0M0 tumours and one or more pathological risk factors: capsule perforation, positive surgical margins, invasion of seminal vesicles. Our revised primary endpoint was biochemical progression-free survival. Analysis was by intention to treat. Findings The median age was 65 years (IQR 61-69). After a median follow-up of 5 years, biochemical progression-free survival was significantly improved in the irradiated group (74.0%, 98% CI 68.7-79.3 vs 52.6%, 46.6-58.5; p<0.0001). Clinical progression-free survival was also significantly improved (p=0.0009). The cumulative rate of locoregional failure was significantly lower in the irradiated group (p<0.0001). Grade 2 or 3 late effects were significantly more frequent in the postoperative irradiation group (p=0.0005), but severe toxic toxicity (grade 3 or higher) were rare, with a 5-year rate of 2.6% in the wait-and-see group and 4.2% in the postoperative irradiation group (p=0.0726). Interpretation Immediate external irradiation after radical prostatectomy improves biochemical progression-free survival and local control in patients with positive surgical margins or pT3 prostate cancer who are at high risk of progression. Further follow-up is needed to assess the effect on overall survival.	CHU A Michallon, Dept Radiat Oncol, Grenoble, France; Univ Ziekenhuis Gasthuisberg, Dept Urol, Brussels, Belgium; Univ Ziekenhuis Gasthuisberg, Dept Radiat Oncol, Brussels, Belgium; European Org Res & Treatment Canc Data Ctr, Brussels, Belgium; Hop St Luc, Dept Urol, Brussels, Belgium; Hop St Luc, Dept Radiat Oncol, Brussels, Belgium; Virga Jesse Zienkenhuis, Dept Urol, Hasselt, Belgium; Univ Milan, Osped San Raffaele, Dept Urol, I-20127 Milan, Italy; Univ Amsterdam, Acad Med Ctr, Dept Urol, NL-1105 AZ Amsterdam, Netherlands; State Univ Ghent Hosp, Dept Urol, B-9000 Ghent, Belgium; Hop Jean Minjoz, Dept Radiat Oncol, F-25030 Besancon, France; Inst Jules Bordet, Dept Urol, B-1000 Brussels, Belgium; Hop Edouard Herriot, Dept Urol, Lyon, France	CHU Grenoble Alpes; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; European Organisation for Research & Treatment of Cancer; University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Amsterdam; Academic Medical Center Amsterdam; Ghent University; Ghent University Hospital; Universite de Franche-Comte; CHU Besancon; Institut Jules Bordet; CHU Lyon	Bolla, M (corresponding author), Univ Hosp, Dept Radiotherapy, BP 217, F-38043 Grenoble, France.	MBolla@chu-grenoble.fr	Haustermans, Karin/AAB-5912-2021	Haustermans, Karin/0000-0003-0364-682X; Collette, Laurence/0000-0003-2518-7281; Da Pozzo, Luigi Filippo/0000-0002-7051-6980	NATIONAL CANCER INSTITUTE [S15CA048821, S15CA048834] Funding Source: NIH RePORTER; NCI NIH HHS [5U10-CA488-34, 5U10 CA488-21] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1978, 29 ICRU; ANSCHER MS, 1995, INT J RADIAT ONCOL, V33, P37, DOI 10.1016/0360-3016(95)00038-Z; Aus G, 2002, BJU INT, V90, P561, DOI 10.1046/j.1464-410X.2002.02982.x; Blute ML, 1997, UROLOGY, V50, P733, DOI 10.1016/S0090-4295(97)00450-0; Bolla M, 2004, P AN M AM SOC CLIN, V23, P382; Catton C, 2001, RADIOTHER ONCOL, V59, P51, DOI 10.1016/S0167-8140(01)00302-4; Choo R, 2002, INT J RADIAT ONCOL, V53, P269, DOI 10.1016/S0360-3016(02)02730-X; Davis JB, 2002, RADIOTHER ONCOL, V64, P65, DOI 10.1016/S0167-8140(02)00143-3; Elias S, 1997, AM J CLIN ONCOL-CANC, V20, P120, DOI 10.1097/00000421-199704000-00002; Forman JD, 1997, J UROLOGY, V158, P1436, DOI 10.1016/S0022-5347(01)64235-6; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Kupelian PA, 1997, INT J RADIAT ONCOL, V37, P1043, DOI 10.1016/S0360-3016(96)00590-1; LANGE PH, 1990, J UROLOGY, V144, P927, DOI 10.1016/S0022-5347(17)39624-6; Lennernas B, 2003, SCAND J UROL NEPHROL, V37, P10, DOI 10.1080/00365590310008613; MCCARTHY JF, 1994, J UROLOGY, V151, P1575, DOI 10.1016/S0022-5347(17)35305-3; Morris MM, 1997, INT J RADIAT ONCOL, V38, P731, DOI 10.1016/S0360-3016(97)00080-1; *NIH CONS DEV PAN, 1988, NCI MON, V7, P3; Nudell DM, 1999, UROLOGY, V54, P1049, DOI 10.1016/S0090-4295(99)00299-X; Perez C A, 2000, Radiology, V215 Suppl, P1419; Pollack A, 2000, J CLIN ONCOL, V18, P3904, DOI 10.1200/JCO.2000.18.23.3904; RAY GR, 1975, J UROLOGY, V114, P98, DOI 10.1016/S0022-5347(17)66953-2; Schild SE, 1996, INT J RADIAT ONCOL, V34, P535, DOI 10.1016/0360-3016(95)02161-2; Spiessl B, 1989, TNM ATLAS ILLUSTRATE; Valicenti RK, 1999, INT J RADIAT ONCOL, V45, P53, DOI 10.1016/S0360-3016(99)00169-8; VanCangh PJ, 1998, J UROLOGY, V159, P164, DOI 10.1016/S0022-5347(01)64044-8; VANUYTSEL L, 2000, ADJUVANT RADIOTHERAP, P377; Vargas C, 2005, INT J RADIAT ONCOL, V61, P714, DOI 10.1016/j.ijrobp.2004.06.018; WHO, 1979, WHO HDB REP RES CANC; Zelefsky MJ, 1997, INT J RADIAT ONCOL, V39, P327, DOI 10.1016/S0360-3016(97)00056-4; ZIETMAN AL, 1993, UROLOGY, V42, P292, DOI 10.1016/0090-4295(93)90618-K; ZINCKE H, 1994, J UROLOGY, V152, P1850, DOI 10.1016/S0022-5347(17)32399-6	31	943	957	0	26	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 13	2005	366	9485					572	578		10.1016/S0140-6736(05)67101-2	http://dx.doi.org/10.1016/S0140-6736(05)67101-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955LL	16099293				2022-12-28	WOS:000231227300029
J	Rabe, KF; Bateman, ED; O'Donnell, D; Witte, S; Bredenbroker, D; Bethke, TD				Rabe, KF; Bateman, ED; O'Donnell, D; Witte, S; Bredenbroker, D; Bethke, TD			Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial	LANCET			English	Article							AIR-FLOW LIMITATION; PHOSPHODIESTERASE-4 INHIBITOR; HEALTH-STATUS; BURDEN; ASTHMA; FLUTICASONE; CILOMILAST; TIOTROPIUM; MORTALITY; EFFICACY	Background Chronic-obstructive pulmonary disease (COPD) is characterised by progressive airflow limitation associated with chronic inflammation. There are few treatment options for the disease. This study assessed the efficacy and safety of roflumilast, a phosphodiesterase-4 inhibitor, in patients with moderate to severe COPD. Methods This phase III, multicentre, double-blind, randomised, placebo-controlled study was undertaken in an outpatient setting. 1411 patients with COPD were randomly assigned roflumilast 250 mu g (n=576), roflumilast 500 mu g (n=555), or placebo (n=280) given orally once daily for 24 weeks. Primary outcomes were postbronchodilator FEV1 and health-related quality of life. Secondary outcomes included other lung function parameters and COPD exacerbations. Analyses were by intention to treat. Findings 1157 (82%) patients completed the study; 32 (11%) withdrew from the placebo group, 100 (17%) from the roflumilast 250 mu g group, and 124 (22%) from the roflumilast 500 mu g group. Postbronchodilator FEV1 at the end of treatment significantly improved with roflumilast 250 mu g (by 74 mL [SD 18]) and roflumilast 500 mu g (by 97 mL [18]) compared with placebo (p<0.0001). Improvement in health-related quality of life was greater with roflumilast 250 mu g (-3.4 units [0.6]) and roflumilast 500 mu g (-3.5 units [0.6]) than with placebo (-1.8 units [0.8]), although the differences between treatment groups were not significant. The mean numbers of exacerbations per patient were 1.13 (2.37), 1.03 (2.33), and 0.75 (1.89) with placebo, roflumilast 250 mu g, and roflumilast 500 mu g, respectively. Most adverse events were mild to moderate in intensity and resolved during the study. Interpretation Roflumilast is a promising candidate for anti-inflammatory COPD treatment because it improved lung function and reduced exacerbations compared with placebo. Long-term studies are needed to fully assess the effect on health-related quality of life.	Leiden Univ, Med Ctr, Dept Pulmonol, NL-2333 ZA Leiden, Netherlands; Univ Cape Town, ZA-7925 Cape Town, South Africa; Kingston Gen Hosp, Kingston, ON K7L 2V7, Canada; ALTANA Pharma AG, Constance, Germany	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Cape Town; Queens University - Canada; Altana	Rabe, KF (corresponding author), Leiden Univ, Med Ctr, Dept Pulmonol, C3P,Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.	k.f.rabe@lumc.nl	Rabe, Klaus F./AAW-6296-2021	Rabe, Klaus F./0000-0002-7020-1401				[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Barnes PJ, 2003, EUR RESPIR J, V22, P672, DOI 10.1183/09031936.03.00040703; Barnette M S, 1999, Prog Drug Res, V53, P193; Bundschuh DS, 2001, J PHARMACOL EXP THER, V297, P280; Burge PS, 2000, BMJ-BRIT MED J, V320, P1297, DOI 10.1136/bmj.320.7245.1297; Calverley P, 2003, LANCET, V361, P449, DOI 10.1016/S0140-6736(03)12459-2; Calverley PM, 2003, EUR RESPIR J, V22, P912, DOI 10.1183/09031936.03.00027003; Calverley PMA, 2003, LANCET, V362, P1053, DOI 10.1016/S0140-6736(03)14416-9; Casaburi R, 2002, EUR RESPIR J, V19, P217, DOI 10.1183/09031936.02.00269802; Compton CH, 2001, LANCET, V358, P265, DOI 10.1016/S0140-6736(01)05481-2; *CPMP, 1999, CPMPEWP56298 EUR AG; Donohue JF, 2002, CHEST, V122, P47, DOI 10.1378/chest.122.1.47; Engelstaetter R., 2005, ANN ALLERG ASTHMA IM, V94, P169; *GLOB IN CHRON OBS, 2004, GLOB STRAT DIAGN MAN; Global Initiative for Chronic Obstructive Lung Disease, 2001, NHLBI WHO WORKSH REP; Grootendorst DC, 2003, PULM PHARMACOL THER, V16, P115, DOI 10.1016/S1094-5539(02)00172-4; Halbert RJ, 2003, CHEST, V123, P1684, DOI 10.1378/chest.123.5.1684; Hansen EF, 2001, AM J RESP CRIT CARE, V163, P690, DOI 10.1164/ajrccm.163.3.2006120; Hatzelmann A, 2001, J PHARMACOL EXP THER, V297, P267; Hogg JC, 2004, LANCET, V364, P709, DOI 10.1016/S0140-6736(04)16900-6; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; Kumar RK, 2003, J PHARMACOL EXP THER, V307, P349, DOI 10.1124/jpet.103.053819; Lipworth BJ, 2005, LANCET, V365, P167, DOI 10.1016/S0140-6736(05)17708-3; Muise ES, 2002, BIOCHEM PHARMACOL, V63, P1527, DOI 10.1016/S0006-2952(02)00903-6; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; O'Donnell DE, 1999, AM J RESP CRIT CARE, V160, P542, DOI 10.1164/ajrccm.160.2.9901038; ODONNELL DE, 1994, CHEST, V106, P904, DOI 10.1378/chest.106.3.904; Pauwels RA, 2004, LANCET, V364, P613, DOI 10.1016/S0140-6736(04)16855-4; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Swanney MP, 2000, AM J RESP CRIT CARE, V162, P917, DOI 10.1164/ajrccm.162.3.9907115; Szafranski W, 2003, EUR RESPIR J, V21, P74, DOI 10.1183/09031936.03.00031402; Timmer W, 2002, J CLIN PHARMACOL, V42, P297, DOI 10.1177/00912700222011328; Viegi G, 2001, RESPIRATION, V68, P4, DOI 10.1159/000050456	33	351	372	0	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 13	2005	366	9485					563	571		10.1016/S0140-6736(05)67100-0	http://dx.doi.org/10.1016/S0140-6736(05)67100-0			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955LL	16099292				2022-12-28	WOS:000231227300028
J	Bestor, TH				Bestor, TH			Transposons reanimated in mice	CELL			English	Editorial Material							SLEEPING-BEAUTY; RETROTRANSPOSITION; CELLS		Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA	Columbia University	Bestor, TH (corresponding author), Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA.							Bestor TH, 2003, TRENDS GENET, V19, P185, DOI 10.1016/S0168-9525(03)00049-0; DING S, 2005, IN PRESS CELL; Dupuy AJ, 2005, NATURE, V436, P221, DOI 10.1038/nature03691; Han JS, 2004, NATURE, V429, P314, DOI 10.1038/nature02535; HITOTSUMACHI S, 1985, P NATL ACAD SCI USA, V82, P6619, DOI 10.1073/pnas.82.19.6619; Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; Ostertag EM, 2002, NAT GENET, V32, P655, DOI 10.1038/ng1022	8	50	60	2	6	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 12	2005	122	3					322	325		10.1016/j.cell.2005.07.024	http://dx.doi.org/10.1016/j.cell.2005.07.024			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	955UZ	16096053	Bronze			2022-12-28	WOS:000231254400004
J	Mills, E				Mills, E			Insurance in a climate of change	SCIENCE			English	Article							EXTREMES; FLUCTUATIONS; TRAGEDY; IMPACTS; WEATHER; COMMONS; HEALTH; RISK	Catastrophe insurance provides peace of mind and financial security. Climate change can have adverse impacts on insurance affordability and availability, potentially slowing the growth of the industry and shifting more of the burden to governments and individuals. Most forms of insurance are vulnerable, including property, liability, health, and life. It is incumbent on insurers, their regulators, and the policy community to develop a better grasp of the physical and business risks. Insurers are well positioned to participate in public-private initiatives to monitor loss trends, improve catastrophe modeling, address the causes of climate change, and prepare for and adapt to the impacts.	Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Mills, E (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, MS 90-4000, Berkeley, CA 94720 USA.	emills@lbl.gov						*ALL GROUP WORLD W, 2005, CLIM CHANG FIN SECT; All Industry Research Advisory Council, 1986, CAT LOSS INS SYST WO; Allen MR, 2004, NATURE, V432, P551, DOI 10.1038/432551a; ALLEY RB, 2003, SCIENCE, V10, P1126; *AM RE, 2005, ANN REV N AM CAT 200; *ASS BRIT INS, 2005, FIN RISKS CLIM CHANG; Association of British Insurers, 2004, CHANG CLIM INS; Changnon SA, 1996, CLIMATIC CHANGE, V32, P411, DOI 10.1007/BF00140354; Changnon SA, 2000, B AM METEOROL SOC, V81, P437, DOI 10.1175/1520-0477(2000)081<0437:HFETIL>2.3.CO;2; Changnon SD, 2003, B AM METEOROL SOC, V84, P1231, DOI 10.1175/BAMS-84-9-1231; Easterling DR, 2000, SCIENCE, V289, P2068, DOI 10.1126/science.289.5487.2068; Epstein PR, 1999, SCIENCE, V285, P347, DOI 10.1126/science.285.5426.347; Fried JS, 2004, CLIMATIC CHANGE, V64, P169, DOI 10.1023/B:CLIM.0000024667.89579.ed; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; Hardin G, 1998, SCIENCE, V280, P682, DOI 10.1126/science.280.5364.682; Karl TR, 2003, SCIENCE, V302, P1719, DOI 10.1126/science.1090228; Kunkel KE, 1999, B AM METEOROL SOC, V80, P1077, DOI 10.1175/1520-0477(1999)080<1077:TFIWAC>2.0.CO;2; KUNREUTHER H, 2005, INSURANCE COPING GLO; LACOMMARE K, 2004, 55718 LAWR BERK NAT; LINNEROOTHBAYER J, 2003, UNFCCC UN NAT FRAM C; MENZINGER I, 2002, FLOODS ARE INSURABLE; Millan EJ, 2002, J PROTEIN CHEM, V21, P1, DOI 10.1023/A:1014174630063; Mills E, 2003, ENERG POLICY, V31, P1257, DOI 10.1016/S0301-4215(02)00186-6; MILLS E, 2004, 52220 LAWR BERK NAT; MILLS E, 1996, J SOC INSUR RES  FAL, P21; MILLS E, IN PRESS MITIGATION; *MUN RE GEOSC RES, 2000, TOP 2000 NAT CAT CUR; *MUN RE MUN REINS, 1973, FLOOD IN; *MUNCH RUCKV GES, 2005, WEATH CAT CLIM CHANG; *N AM EL REL COUNC, ANN DIST REP 1992 20; Nelson FE, 2001, NATURE, V410, P889, DOI 10.1038/35073746; Nutter F. W., 1996, J SOC INSUR RES  FAL, P15; Reeve N, 1999, Q J ROY METEOR SOC, V125, P893, DOI 10.1002/qj.49712555507; Schar C, 2004, NATURE, V427, P332, DOI 10.1038/nature02300; Schwartz P., 2003, ABRUPT CLIMATE CHANG; *SWISS RE CTR GLOB, 2004, CLIM CHANG FUT EX RO; *SWISS RE SWISS RE, 2002, OPP RISKS CLIM CHANG; UNEP, 2002, CLIM CHANG FIN SERV; *US GOV ACC OFF, 2005, GAO05199; Vellinga P.V, 2001, CLIMATE CHANGE 2001; WHO, 2003, CLIM CHANG HUM HLTH; ZHANG K, 2005, CLIMATIC CHANGE, V64, P41	42	223	225	3	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 12	2005	309	5737					1040	1044		10.1126/science.1112121	http://dx.doi.org/10.1126/science.1112121			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955MN	16099975				2022-12-28	WOS:000231230100035
J	Banin, A				Banin, A			Planetary science - The enigma of the Martian soil	SCIENCE			English	Editorial Material							X-RAY SPECTROMETER; MERIDIANI-PLANUM; GUSEV CRATER; MOSSBAUER SPECTROMETER; CHEMICAL-COMPOSITION; MICROBIAL LIFE; ATACAMA DESERT; MARS; ROCKS; MINERALOGY		Hebrew Univ Jerusalem, Dept Soil & Water Sci, IL-76100 Rehovot, Israel; SETI Inst, Mountain View, CA 94043 USA	Hebrew University of Jerusalem	Banin, A (corresponding author), Hebrew Univ Jerusalem, Dept Soil & Water Sci, IL-76100 Rehovot, Israel.	amos.banin@huji.ac.il						Banin A, 1997, J GEOPHYS RES-PLANET, V102, P13341, DOI 10.1029/97JE01160; BANIN A., 2000, MARS, P594; Benner SA, 2000, P NATL ACAD SCI USA, V97, P2425, DOI 10.1073/pnas.040539497; Biemann K., 1977, Journal of Geophysical Research, V82, P4641, DOI 10.1029/JS082i028p04641; BURNS RG, 1990, J GEOPHYS RES-SOLID, V95, P14415, DOI 10.1029/JB095iB09p14415; CLARK BC, 1982, J GEOPHYS RES, V87, P59, DOI 10.1029/JB087iB12p10059; Gellert R, 2004, SCIENCE, V305, P829, DOI 10.1126/science.1099913; Klingelhofer G, 2004, SCIENCE, V306, P1740, DOI 10.1126/science.1104653; Levin G. V., 1977, Journal of Geophysical Research, V82, P4663, DOI 10.1029/JS082i028p04663; Maier RM, 2004, SCIENCE, V306, P1289; Morris RV, 2004, SCIENCE, V305, P833, DOI 10.1126/science.1100020; Navarro-Gonzalez R, 2003, SCIENCE, V302, P1018, DOI 10.1126/science.1089143; Rieder R, 1997, SCIENCE, V278, P1771, DOI 10.1126/science.278.5344.1771; Rieder R, 2004, SCIENCE, V306, P1746, DOI 10.1126/science.1104358; Squyres SW, 2004, SCIENCE, V305, P794, DOI 10.1126/science.3050794; Squyres SW, 2004, SCIENCE, V306, P1698, DOI 10.1126/science.1106171; Squyres SW, 2004, SCIENCE, V306, P1709, DOI 10.1126/science.1104559; Tosca NJ, 2004, J GEOPHYS RES-PLANET, V109, DOI 10.1029/2003JE002218; Toulmin P.  III, 1977, Journal of Geophysical Research, V82, P4625, DOI 10.1029/JS082i028p04625	19	14	13	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 5	2005	309	5736					888	890		10.1126/science.1112794	http://dx.doi.org/10.1126/science.1112794			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953SS	16081725				2022-12-28	WOS:000231101400032
J	VanderVen, BC; Harder, JD; Crick, DC; Belisle, JT				VanderVen, BC; Harder, JD; Crick, DC; Belisle, JT			Export-mediated assembly of mycobacterial glycoproteins parallels eukaryotic pathways	SCIENCE			English	Article							ESCHERICHIA-COLI; O-MANNOSYLATION; TUBERCULOSIS; GLYCOSYLATION; ANTIGEN; BIOSYNTHESIS; SECRETION; RESPONSES; MEMBRANE; PROTEINS	Protein O-mannosylation is an essential and evolutionarily conserved post-translational modification among eukaryotes. This form of protein modification is also described in Mycobacterium tuberculosis; however, the mechanism of mannoprotein assembly remains unclear. Evaluation of differentially translocated chimeric proteins and mass spectrometry to monitor glycosylation demonstrated that specific translocation processes were required for protein O-mannosylation in M. tuberculosis. Additionally, Rv1002c, a M. tuberculosis membrane protein homolog of eukaryotic protein mannosyltransferases, was shown to catalyze the initial step of protein mannosylation. Thus, the-process of protein mannosylation is conserved between M. tuberculosis and eukaryotic organisms.	Colorado State Univ, Dept Microbiol Immunol & Pathol, Mycobacteria Res Labs, Ft Collins, CO 80523 USA	Colorado State University	Belisle, JT (corresponding author), Colorado State Univ, Dept Microbiol Immunol & Pathol, Mycobacteria Res Labs, Ft Collins, CO 80523 USA.	jbelisle@colostate.edu	Crick, Dean/H-8251-2017; Belisle, John/B-8944-2017	Crick, Dean/0000-0001-9281-7058; Belisle, John/0000-0002-2539-2798	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044042] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI-44042] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSEN P, 1991, INFECT IMMUN, V59, P1905, DOI 10.1128/IAI.59.6.1905-1910.1991; Belisle JT, 1997, SCIENCE, V276, P1420, DOI 10.1126/science.276.5317.1420; Bensing BA, 2004, J BACTERIOL, V186, P638, DOI 10.1128/JB.186.3.638-645.2004; Braunstein M, 2003, MOL MICROBIOL, V48, P453, DOI 10.1046/j.1365-2958.2003.03438.x; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Cooper HN, 2002, GLYCOBIOLOGY, V12, P427, DOI 10.1093/glycob/cwf051; Danese PN, 1998, ANNU REV GENET, V32, P59, DOI 10.1146/annurev.genet.32.1.59; Dobos KM, 1996, J BACTERIOL, V178, P2498, DOI 10.1128/jb.178.9.2498-2506.1996; Ecker M, 2003, EMBO REP, V4, P628, DOI 10.1038/sj.embor.embor864; ESPITIA C, 1989, CLIN EXP IMMUNOL, V77, P378; GARBE T, 1993, INFECT IMMUN, V61, P260, DOI 10.1128/IAI.61.1.260-267.1993; Girrbach V, 2000, J BIOL CHEM, V275, P19288, DOI 10.1074/jbc.M001771200; Horn C, 1999, J BIOL CHEM, V274, P32023, DOI 10.1074/jbc.274.45.32023; Hsu T, 2003, P NATL ACAD SCI USA, V100, P12420, DOI 10.1073/pnas.1635213100; Josenhans C, 2002, FEMS MICROBIOL LETT, V210, P165, DOI 10.1016/S0378-1097(02)00638-9; Michell SL, 2003, J BIOL CHEM, V278, P16423, DOI 10.1074/jbc.M207959200; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Romain F, 1999, INFECT IMMUN, V67, P5567, DOI 10.1128/IAI.67.11.5567-5572.1999; Ronning DR, 2000, NAT STRUCT BIOL, V7, P141; Schmidt MA, 2003, TRENDS MICROBIOL, V11, P554, DOI 10.1016/j.tim.2003.10.004; Stanley SA, 2003, P NATL ACAD SCI USA, V100, P13001, DOI 10.1073/pnas.2235593100; Strahl-Bolsinger S, 1999, BBA-GEN SUBJECTS, V1426, P297, DOI 10.1016/S0304-4165(98)00131-7; Upreti RK, 2003, PROTEOMICS, V3, P363, DOI 10.1002/pmic.200390052; Wacker M, 2002, SCIENCE, V298, P1790, DOI 10.1126/science.298.5599.1790; Willer T, 2003, CURR OPIN STRUC BIOL, V13, P621, DOI 10.1016/j.sbi.2003.09.003	25	108	117	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 5	2005	309	5736					941	943		10.1126/science.1114347	http://dx.doi.org/10.1126/science.1114347			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953SS	16081738				2022-12-28	WOS:000231101400049
J	Busch, MP; Caglioti, S; Robertson, EF; McAuley, JD; Tobler, LH; Kamel, H; Linnen, JM; Shyamala, V; Tomasulo, P; Kleinman, SH				Busch, MP; Caglioti, S; Robertson, EF; McAuley, JD; Tobler, LH; Kamel, H; Linnen, JM; Shyamala, V; Tomasulo, P; Kleinman, SH			Screening the blood supply for west nile virus RNA by nucleic acid amplification testing	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; UNITED-STATES; HEPATITIS-C; TRANSFUSION; INFECTIONS; TRANSMISSION; DONORS	BACKGROUND: The use of nucleic acid amplification tests of ``minipools'' of 16 samples to screen blood donors for West Nile virus RNA began in July 2003. We report the yield and characteristics of positive donations and the incremental yield and safety of nucleic acid amplification tests of individual donations. METHODS: Reactive minipools were analyzed to identify the individual reactive donations. For the regions with the highest yield on minipool testing, retrospective nucleic acid amplification testing was performed on individual donations that were negative on minipool testing. Reactive donations were confirmed by alternative nucleic acid amplification tests and IgM and IgG tests, and donors were followed to document seroconversion. RESULTS: From July 1 through October 31, 2003, 677,603 donations were prospectively screened for West Nile virus by minipool testing, yielding 183 confirmed viremic donations (0.027 percent, or 1 in 3703 donations). Retrospective individual testing of 23,088 donations from high-prevalence regions that were negative on minipool testing yielded 30 additional units with a low level of viremia, with 14 additional viremic units detected by prospective testing of individual donations late in the 2003 transmission season. Of all the viremic units detected, 5 percent were detected only by individual testing and were negative for IgM antibody, 29 percent were detected by individual testing after IgM seroconversion, and 66 percent were detected by minipool testing. West Nile virus infection was confirmed in both recipients of IgM-negative units that were reactive on individual testing, whereas neither recipient of antibody-positive blood components that were reactive on individual testing was infected. In 2004, prospective testing of individual donations in regions that yielded donations that were reactive on minipool testing resulted in a 32 percent incremental yield of units with a low level of viremia that would have been missed by minipool testing. CONCLUSIONS: Although nucleic acid amplification testing of minipools of blood donations prevented hundreds of cases of West Nile virus infection in 2003, it failed to detect units with a low level of viremia, some of which were antibody-negative and infectious. These data support the use of targeted nucleic acid amplification testing of individual donations in high-prevalence regions, a strategy that was implemented successfully in 2004.	Blood Syst Res Inst, San Francisco, CA USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Blood Syst Labs, Tempe, AZ USA; Blood Syst, Scottsdale, AZ USA; Gen Probe, San Diego, CA USA; Chiron Corp, Emeryville, CA USA; Univ British Columbia, Victoria, BC, Canada	Vitalant; Vitalant Research Institute; University of California System; University of California San Francisco; Novartis; University of British Columbia	Busch, MP (corresponding author), Blood Syst Res Inst, San Francisco, CA USA.				NCPDCID CDC HHS [R01-CI-000214] Funding Source: Medline; NATIONAL CENTER FOR INFECTIOUS DISEASES (NCID) [R01CI000214] Funding Source: NIH RePORTER	NCPDCID CDC HHS; NATIONAL CENTER FOR INFECTIOUS DISEASES (NCID)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)		Busch MP, 2005, TRANSFUSION, V45, P492, DOI 10.1111/j.0041-1132.2005.04382.x; Busch MP, 2005, TRANSFUSION, V45, P254, DOI 10.1111/j.1537-2995.2004.04215.x; Custer B, 2004, TRANSFUSION, V44, P1547, DOI 10.1111/j.0041-1132.2004.04227.x; Diamond MS, 2003, J EXP MED, V198, P1853, DOI 10.1084/jem.20031223; Dodd RY, 2003, NEW ENGL J MED, V349, P1205, DOI 10.1056/NEJMp038138; Epstein JS, 2005, TRANSFUSION, V45, P460, DOI 10.1111/j.0041-1132.2005.45041.x; *FOOD DRUG ADM CTR, 2002, WORKSH DEV DON SCREE; Giachetti C, 2002, J CLIN MICROBIOL, V40, P2408, DOI 10.1128/JCM.40.7.2408-2419.2002; Hollinger FB, 2003, TRANSFUSION, V43, P992, DOI 10.1046/j.1537-2995.2003.00501.x; Kleinman S, 2005, TRANSFUSION, V45, P469, DOI 10.1111/j.0041-1132.2005.04315.x; KRUGMAN S, 1959, NEW ENGL J MED, V261, P729, DOI 10.1056/NEJM195910082611501; Marshall DA, 2004, VOX SANG, V86, P28, DOI 10.1111/j.0042-9007.2004.00379.x; Pealer LN, 2003, NEW ENGL J MED, V349, P1236, DOI 10.1056/NEJMoa030969; Petersen LR, 2003, JAMA-J AM MED ASSOC, V290, P524, DOI 10.1001/jama.290.4.524; Prince HE, 2003, CLIN DIAGN LAB IMMUN, V10, P764, DOI 10.1128/CDLI.10.5.764-768.2003; Ratterree MS, 2004, J INFECT DIS, V189, P669, DOI 10.1086/381461; SOUTHAM CM, 1954, AM J TROP MED HYG, V3, P19, DOI 10.4269/ajtmh.1954.3.19; Stramer SL, 2004, NEW ENGL J MED, V351, P760, DOI 10.1056/NEJMoa040085; TURNBULL BW, 1976, J R STAT SOC B, V38, P290; 2003, MMWR MORB MORTAL WKL, V52, P942; 2003, MMWR MORB MORTAL WKL, V52, P916; 2004, MMWR MORB MORTAL WKL, V53, P281; 2002, MMWR MORB MORTAL WKL, V51, P1129	23	152	155	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 4	2005	353	5					460	467		10.1056/NEJMoa044029	http://dx.doi.org/10.1056/NEJMoa044029			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	951OB	16079369	Bronze			2022-12-28	WOS:000230939000005
J	Dadosh, T; Gordin, Y; Krahne, R; Khivrich, I; Mahalu, D; Frydman, V; Sperling, J; Yacoby, A; Bar-Joseph, I				Dadosh, T; Gordin, Y; Krahne, R; Khivrich, I; Mahalu, D; Frydman, V; Sperling, J; Yacoby, A; Bar-Joseph, I			Measurement of the conductance of single conjugated molecules	NATURE			English	Article							NANOPARTICLES; FABRICATION; TRANSISTOR; TRANSPORT; DEVICES	Electrical conduction through molecules depends critically on the delocalization of the molecular electronic orbitals and their connection to the metallic contacts. Thiolated (-SH) conjugated organic molecules are therefore considered good candidates for molecular conductors(1,2): in such molecules, the orbitals are delocalized throughout the molecular backbone, with substantial weight on the sulphur - metal bonds(1-4). However, their relatively small size, typically similar to 1 nm, calls for innovative approaches to realize a functioning single-molecule device(5-11). Here we report an approach for contacting a single molecule, and use it to study the effect of localizing groups within a conjugated molecule on the electrical conduction. Our method is based on synthesizing a dimer structure, consisting of two colloidal gold particles connected by a dithiolated short organic molecule(12,13), and electrostatically trapping it between two metal electrodes. We study the electrical conduction through three short organic molecules: 4,4' - biphenyldithiol (BPD), a fully conjugated molecule; bis( 4-mercaptophenyl)- ether (BPE)(14), in which the conjugation is broken at the centre by an oxygen atom; and 1,4-benzenedimethanethiol (BDMT), in which the conjugation is broken near the contacts by a methylene group. We find that the oxygen in BPE and the methylene groups in BDMT both suppress the electrical conduction relative to that in BPD.	Weizmann Inst Sci, Dept Condensed Matter Phys, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel; CNR INFM, Natl Nanotechnol Lab, I-73100 Lecce, Italy	Weizmann Institute of Science; Weizmann Institute of Science; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR)	Bar-Joseph, I (corresponding author), Weizmann Inst Sci, Dept Condensed Matter Phys, IL-76100 Rehovot, Israel.	hbar@wisemail.weizmann.ac.il	FRYDMAN, VERONICA/K-1770-2012	Krahne, Roman/0000-0003-0066-7019				Amlani I, 2002, APPL PHYS LETT, V80, P2761, DOI 10.1063/1.1469655; BARON AL, 1970, MAKROMOLEKUL CHEM, V140, P83; Bezryadin A, 1997, APPL PHYS LETT, V71, P1273, DOI 10.1063/1.119871; Brousseau LC, 1999, ADV MATER, V11, P447, DOI 10.1002/(SICI)1521-4095(199904)11:6<447::AID-ADMA447>3.0.CO;2-I; Cui XD, 2001, SCIENCE, V294, P571, DOI 10.1126/science.1064354; Grabar KC, 1996, LANGMUIR, V12, P2353, DOI 10.1021/la950561h; Grabert H., 1992, NATO ASI SER B, V294; Handley D. A., 1989, COLLOIDAL GOLD PRINC, V1, P13; Hazani M, 2004, CHEM PHYS LETT, V391, P389, DOI 10.1016/j.cplett.2004.05.042; Joachim C, 2000, NATURE, V408, P541, DOI 10.1038/35046000; Krahne R, 2002, APPL PHYS LETT, V81, P730, DOI 10.1063/1.1495080; Lee JO, 2003, NANO LETT, V3, P113, DOI 10.1021/nl025882+; Liang WJ, 2002, NATURE, V417, P725, DOI 10.1038/nature00790; Nitzan A, 2003, SCIENCE, V300, P1384, DOI 10.1126/science.1081572; Park H, 1999, APPL PHYS LETT, V75, P301, DOI 10.1063/1.124354; Park H, 2000, NATURE, V407, P57, DOI 10.1038/35024031; Park J, 2002, NATURE, V417, P722, DOI 10.1038/nature00791; Peng XG, 1997, ANGEW CHEM INT EDIT, V36, P145, DOI 10.1002/anie.199701451; Reed MA, 1997, SCIENCE, V278, P252, DOI 10.1126/science.278.5336.252; Reichert J, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.176804; Remacle F, 2004, CHEM PHYS LETT, V383, P537, DOI 10.1016/j.cplett.2003.11.072; Ron H, 1998, LANGMUIR, V14, P1116, DOI 10.1021/la970785v; Smit RHM, 2002, NATURE, V419, P906, DOI 10.1038/nature01103; Weisbecker CS, 1996, LANGMUIR, V12, P3763, DOI 10.1021/la950776r; Xiao XY, 2004, NANO LETT, V4, P267, DOI 10.1021/nl035000m; Xu HX, 1999, PHYS REV LETT, V83, P4357, DOI 10.1103/PhysRevLett.83.4357; Xue YQ, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.115406; Zhu T, 2003, LANGMUIR, V19, P9518, DOI 10.1021/la035157u	28	381	401	3	106	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 4	2005	436	7051					677	680		10.1038/nature03898	http://dx.doi.org/10.1038/nature03898			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	951XA	16079841				2022-12-28	WOS:000230964500038
J	Oransky, I				Oransky, I			Jeanne Petrek - Obituary	LANCET			English	Biographical-Item												ivan-oransky@erols.com							0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 28	2005	365	9474					1844	1844		10.1016/S0140-6736(05)66606-8	http://dx.doi.org/10.1016/S0140-6736(05)66606-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	931JK	16118904				2022-12-28	WOS:000229481400013
J	Rogan, WJ; Chen, AM				Rogan, WJ; Chen, AM			Health risks and benefits of bis(4-chlorophenyl)-1,1,1-trichloroethane (DDT)	LANCET			English	Review							NON-HODGKINS-LYMPHOMA; BREAST-CANCER RISK; SERUM ORGANOCHLORINE RESIDUES; AFRICAN-AMERICAN FARMERS; VECTOR-CONTROL WORKERS; POLYCHLORINATED-BIPHENYLS; MALARIA CONTROL; DICHLORODIPHENYL DICHLOROETHENE; ENVIRONMENTAL EXPOSURE; PANCREATIC-CANCER	DDT (bis[4-chlorophenyl]-1,1,1-trichloroethane) is a persistent insecticide that was used worldwide from the mid-1940s until its ban in the USA and other countries in the 1970s. When a global ban on DDT was proposed in 2001, several countries in sub-Saharan Africa claimed that DDT was still needed as a cheap and effective means for vector control. Although DDT is generally not toxic to human beings and was banned mainly for ecological reasons, subsequent research has shown that exposure to DDT at amounts that would be needed in malaria control might cause preterm birth and early weaning, abrogating the benefit of reducing infant mortality from malaria. Historically, DDT has had mixed success in Africa; only the countries that are able to find and devote substantial resources towards malaria control have made major advances. DDT might be useful in controlling malaria, but the evidence of its adverse effects on human health needs appropriate research on whether it achieves a favourable balance of risk versus benefit.	US Natl Inst Environm Hlth Sci, Epidemiol Branch, Res Triangle Pk, NC 27709 USA		Rogan, WJ (corresponding author), US Natl Inst Environm Hlth Sci, Epidemiol Branch, POB 12233, Res Triangle Pk, NC 27709 USA.	rogan@niehs.nih.gov	Rogan, Walter/I-6034-2012	Rogan, Walter/0000-0002-9302-0160; Chen, Aimin/0000-0001-9713-6438	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES043002, ZIAES043002] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akkina JE, 2004, J TOXICOL ENV HEAL A, V67, P1407, DOI 10.1080/15287390490483845; Andersen HR, 1999, ENVIRON HEALTH PERSP, V107, P89, DOI 10.2307/3434476; [Anonymous], 1991, IARC MONOGR EVAL CAR, V53; ATSDR, 2017, TOXICOLOGICAL PROFIL; Attaran A, 2000, BRIT MED J, V321, P1403, DOI 10.1136/bmj.321.7273.1403; Ayotte P, 2001, EPIDEMIOLOGY, V12, P366, DOI 10.1097/00001648-200105000-00022; BANERJEE BD, 1987, B ENVIRON CONTAM TOX, V39, P827, DOI 10.1007/BF01855862; BANERJEE BD, 1987, B ENVIRON CONTAM TOX, V39, P822, DOI 10.1007/BF01855861; Baris D, 1998, OCCUP ENVIRON MED, V55, P522, DOI 10.1136/oem.55.8.522; Beard J, 2003, ENVIRON HEALTH PERSP, V111, P724, DOI 10.1289/ehp.5885; BERCOVICI B, 1983, ENVIRON RES, V30, P169, DOI 10.1016/0013-9351(83)90176-7; Berkowitz GS, 1996, ARCH ENVIRON CON TOX, V30, P139, DOI 10.1007/BF00211340; Bhatia R, 2005, ENVIRON HEALTH PERSP, V113, P220, DOI 10.1289/ehp.7382; Bilrha H, 2003, ENVIRON HEALTH PERSP, V111, P1952, DOI 10.1289/ehp.6433; Bjerregaard P, 2000, SCI TOTAL ENVIRON, V245, P195, DOI 10.1016/S0048-9697(99)00444-1; BOUWMAN H, 1990, B WORLD HEALTH ORGAN, V68, P761; BOUWMAN H, 1991, J TOXICOL ENV HEALTH, V33, P141, DOI 10.1080/15287399109531514; BRUCECHWATT LJ, 1984, B WORLD HEALTH ORGAN, V62, P19; Calle EE, 2002, CA-CANCER J CLIN, V52, P301, DOI 10.3322/canjclin.52.5.301; CANTOR KP, 1992, CANCER RES, V52, P2447; Charlier C, 2004, CLIN CHEM LAB MED, V42, P222, DOI 10.1515/CCLM.2004.040; Charlier C, 2003, OCCUP ENVIRON MED, V60, P348, DOI 10.1136/oem.60.5.348; Chen A, 2003, EMERG INFECT DIS, V9, P960; Cocco P, 2005, ENVIRON RES, V98, P120, DOI 10.1016/j.envres.2004.09.007; Cocco P, 2004, J ENDOCRINOL, V182, P391, DOI 10.1677/joe.0.1820391; Cocco P, 1997, ARCH ENVIRON HEALTH, V52, P299, DOI 10.1080/00039899709602202; Cocco P, 2000, ENVIRON HEALTH PERSP, V108, P1, DOI 10.2307/3454288; Cocco P, 1998, ONCOLOGY-BASEL, V55, P334, DOI 10.1159/000011872; Cohn BA, 2003, LANCET, V361, P2205, DOI 10.1016/S0140-6736(03)13776-2; Cooper GS, 2005, EPIDEMIOLOGY, V16, P191, DOI 10.1097/01.ede.0000152913.12393.86; Cooper GS, 2004, ENVIRON HEALTH PERSP, V112, P1080, DOI 10.1289/ehp.6892; Cooper GS, 2002, EPIDEMIOLOGY, V13, P729, DOI 10.1097/00001648-200211000-00021; Curtis CF, 2000, PARASITOL TODAY, V16, P119, DOI 10.1016/S0169-4758(99)01605-1; Dalvie MA, 2004, ENVIRON RES, V96, P9, DOI 10.1016/j.envres.2003.09.003; Dalvie MA, 2004, ENVIRON RES, V96, P1, DOI 10.1016/j.envres.2003.09.002; de Joode BV, 2001, LANCET, V357, P1014, DOI 10.1016/S0140-6736(00)04249-5; Demers A, 2000, CANCER EPIDEM BIOMAR, V9, P161; *DEP ENV, BANN NON PEST UK; Dewailly E, 2000, ENVIRON HEALTH PERSP, V108, P205, DOI 10.2307/3454435; Dorner G, 2002, NEUROENDOCRINOL LETT, V23, P427; FABRO S, 1984, AM J OBSTET GYNECOL, V148, P929, DOI 10.1016/0002-9378(84)90535-0; Flores-Luevano S, 2003, SALUD PUBLICA MEXICO, V45, P431, DOI 10.1590/S0036-36342003000600002; Freyberger A, 2004, TOXICOLOGY, V195, P113, DOI 10.1016/j.tox.2003.09.008; Fryzek JP, 1997, INT J CANCER, V72, P62, DOI 10.1002/(SICI)1097-0215(19970703)72:1&lt;62::AID-IJC9&gt;3.0.CO;2-2; Gammon MD, 2002, CANCER EPIDEM BIOMAR, V11, P686; GARABRANT DH, 1992, J NATL CANCER I, V84, P764, DOI 10.1093/jnci/84.10.764; Gerhard I, 1998, ENVIRON HEALTH PERSP, V106, P675, DOI 10.2307/3434097; GIGLIOLI G, 1972, B WORLD HEALTH ORGAN, V46, P181; GLADEN BC, 1995, AM J PUBLIC HEALTH, V85, P504, DOI 10.2105/AJPH.85.4.504; Gladen BC, 2004, ENVIRON HEALTH PERSP, V112, P1761, DOI 10.1289/ehp.7287; Gladen BC, 2000, J PEDIATR-US, V136, P490, DOI 10.1016/S0022-3476(00)90012-X; Gladen BC, 2003, ANN EPIDEMIOL, V13, P151, DOI 10.1016/S1047-2797(02)00268-5; GLADEN BC, 1988, J PEDIATR-US, V113, P991, DOI 10.1016/S0022-3476(88)80569-9; GLADEN BC, 1991, J PEDIATR-US, V119, P58, DOI 10.1016/S0022-3476(05)81039-X; Greenwood B, 2002, NATURE, V415, P670, DOI 10.1038/415670a; Guttes S, 1998, ARCH ENVIRON CON TOX, V35, P140, DOI 10.1007/s002449900361; Hagmar L, 2001, ARCH ENVIRON HEALTH, V56, P138, DOI 10.1080/00039890109604065; Hardell L, 2004, GYNECOL ONCOL, V95, P706, DOI 10.1016/j.ygyno.2004.08.022; Hargreaves K, 2003, MED VET ENTOMOL, V17, P417, DOI 10.1111/j.1365-2915.2003.00460.x; Hauser R, 2003, HUM REPROD, V18, P2525, DOI 10.1093/humrep/deg508; Hauser R, 2003, ENVIRON HEALTH PERSP, V111, P1505, DOI 10.1289/ehp.6175; Helzlsouer KJ, 1999, CANCER EPIDEM BIOMAR, V8, P525; Hoppin JA, 2000, CANCER EPIDEM BIOMAR, V9, P199; Hosie S, 2000, EUR J PEDIATR SURG, V10, P304, DOI 10.1055/s-2008-1072381; Hougard JM, 2002, TRENDS PARASITOL, V18, P283, DOI 10.1016/S1471-4922(02)02291-2; Howsam M, 2004, ENVIRON HEALTH PERSP, V112, P1460, DOI 10.1289/ehp.7143; Hunter DJ, 1997, NEW ENGL J MED, V337, P1253, DOI 10.1056/NEJM199710303371801; Jaga Kushik, 2003, Int J Occup Med Environ Health, V16, P7; Karmaus W, 2002, J PEDIATR-US, V140, P33, DOI 10.1067/mpd.2002.120764; Karmaus Wilfried, 2004, Environ Health, V3, P1, DOI 10.1186/1476-069X-3-1; KELCE WR, 1995, NATURE, V375, P581, DOI 10.1038/375581a0; Korrick SA, 2001, ANN EPIDEMIOL, V11, P491, DOI 10.1016/S1047-2797(01)00239-3; Kremsner PG, 2004, LANCET, V364, P285, DOI 10.1016/S0140-6736(04)16680-4; Krstevska-Konstantinova M, 2001, HUM REPROD, V16, P1020, DOI 10.1093/humrep/16.5.1020; Laden F, 2001, JNCI-J NATL CANCER I, V93, P768, DOI 10.1093/jnci/93.10.768; LENGELER C, 2003, REDUCING MALARIAS BU; LEONI V, 1989, ECOTOX ENVIRON SAFE, V17, P1, DOI 10.1016/0147-6513(89)90002-X; LI HC, 1995, J BIOCHEM TOXICOL, V10, P51; LINES JD, 1991, MED VET ENTOMOL, V5, P261, DOI 10.1111/j.1365-2915.1991.tb00550.x; Longnecker MP, 2005, ENVIRON RES, V97, P127, DOI 10.1016/S0013-9351(03)00108-7; Longnecker MP, 2002, AM J EPIDEMIOL, V155, P313, DOI 10.1093/aje/155.4.313; Longnecker MP, 2001, LANCET, V358, P110, DOI 10.1016/S0140-6736(01)05329-6; Lopez-Cervantes M, 2004, ENVIRON HEALTH PERSP, V112, P207, DOI [10.1289/ehp.6492, 10.1289/ehp.112-1241830]; Mabaso MLH, 2004, TROP MED INT HEALTH, V9, P846, DOI 10.1111/j.1365-3156.2004.01263.x; *MARA, DISTR END MAL; Martin SA, 2002, EPIDEMIOLOGY, V13, P454, DOI 10.1097/00001648-200207000-00014; McDuffie HH, 2001, CANCER EPIDEM BIOMAR, V10, P1155; Molineaux L, 1997, ANN TROP MED PARASIT, V91, P811, DOI 10.1080/00034989760572; Nanni O, 1998, CANCER CAUSE CONTROL, V9, P277, DOI 10.1023/A:1008821119851; *NAT CANC I, 1978, CARC TECHN REP SER, V131; OLEARY JA, 1970, AM J OBSTET GYNECOL, V108, P1291, DOI 10.1016/0002-9378(70)90109-2; Pavuk M, 2003, J EXPO ANAL ENV EPID, V13, P267, DOI 10.1038/sj.jea.7500277; *POPS EL NETW, DDT MAL ANSW COMM QU; Porta M, 1999, LANCET, V354, P2125, DOI 10.1016/S0140-6736(99)04232-4; Quintana PJE, 2004, ENVIRON HEALTH PERSP, V112, P854, DOI 10.1289/ehp.6726; RATCLIFF.DA, 1967, NATURE, V215, P208, DOI 10.1038/215208a0; Ribas-Fito N, 2003, PEDIATRICS, V111, pE580, DOI 10.1542/peds.111.5.e580; Rignell-Hydbom A, 2004, HUM REPROD, V19, P2066, DOI 10.1093/humrep/deh362; RIGNELLHYDBOM A, 2005, ENV HLTH PERSPECT, V113, P1; Ritchie JM, 2003, J OCCUP ENVIRON MED, V45, P692, DOI 10.1097/01.jom.0000071510.96740.0b; RiveroRodriguez L, 1997, ENVIRON HEALTH PERSP, V105, P98, DOI 10.2307/3433069; Roberts DR, 2000, LANCET, V356, P330, DOI 10.1016/S0140-6736(00)02516-2; Rogan W J, 1991, Ann Epidemiol, V1, P407, DOI 10.1016/1047-2797(91)90010-A; ROGAN WJ, 1987, AM J PUBLIC HEALTH, V77, P1294, DOI 10.2105/AJPH.77.10.1294; ROGAN WJ, 1986, J PEDIATR-US, V109, P335, DOI 10.1016/S0022-3476(86)80397-3; Romieu I, 2000, AM J EPIDEMIOL, V152, P363, DOI 10.1093/aje/152.4.363; Rothman N, 1997, LANCET, V350, P240, DOI 10.1016/S0140-6736(97)02088-6; Ruxin J, 2005, LANCET, V365, P618, DOI 10.1016/S0140-6736(05)70806-0; Salazar-Garcia F, 2004, ENVIRON HEALTH PERSP, V112, P542, DOI 10.1289/ehp.6759; SAXENA MC, 1981, J ANAL TOXICOL, V5, P6, DOI 10.1093/jat/5.1.6; Schantz SL, 2001, ENVIRON HEALTH PERSP, V109, P605, DOI 10.2307/3455035; Schantz SL, 1999, ENVIRON RES, V80, pS46, DOI 10.1006/enrs.1998.3904; Sharp B, 2002, TROP MED INT HEALTH, V7, P732, DOI 10.1046/j.1365-3156.2002.00928.x; Siddiqui MKJ, 2003, INT ARCH OCC ENV HEA, V76, P75, DOI 10.1007/s00420-002-0393-6; Sierra-Santoyo A, 2000, TOXICOL SCI, V54, P81, DOI 10.1093/toxsci/54.1.81; Slebos RJC, 2000, CANCER EPIDEM BIOMAR, V9, P1223; Smith AG, 2001, HDB PESTICIDE TOXICO, P1305; Smith D, 1999, INT J EPIDEMIOL, V28, P179, DOI 10.1093/ije/28.2.179; Snedeker SM, 2001, ENVIRON HEALTH PERSP, V109, P35, DOI [10.2307/3434845, 10.2307/3434918]; Snow RW, 1999, PARASITOL TODAY, V15, P99, DOI 10.1016/S0169-4758(99)01395-2; Snow RW, 1999, B WORLD HEALTH ORGAN, V77, P624; Steketee RW, 2001, AM J TROP MED HYG, V64, P28, DOI 10.4269/ajtmh.2001.64.28; Sturgeon SR, 1998, CANCER CAUSE CONTROL, V9, P417, DOI 10.1023/A:1008823802393; Sugiura-Ogasawara M, 2003, AM J REPROD IMMUNOL, V50, P485, DOI 10.1046/j.8755-8920.2003.00106.x; Takayama S, 1999, J CANCER RES CLIN, V125, P219, DOI 10.1007/s004320050266; Torres-Arreola L, 2003, ANN EPIDEMIOL, V13, P158, DOI 10.1016/S1047-2797(02)00424-6; Trigg PI, 1998, B WORLD HEALTH ORGAN, V76, P11; Turusov V, 2002, ENVIRON HEALTH PERSP, V110, P125, DOI 10.1289/ehp.02110125; United Nations Environmental Programme, STOCKH CONV PERS ORG; *US DEP HHS, NAT TOX PROGR REP CA; vantVeer P, 1997, BMJ-BRIT MED J, V315, P81, DOI 10.1136/bmj.315.7100.81; Vasiliu O, 2004, HUM REPROD, V19, P1506, DOI 10.1093/humrep/deh292; Vine MF, 2001, AM J EPIDEMIOL, V153, P53, DOI 10.1093/aje/153.1.53; Waliszewski SM, 2001, ARCH ENVIRON CON TOX, V40, P432, DOI 10.1007/s002440010194; WASSERMANN M, 1982, ENVIRON RES, V28, P106, DOI 10.1016/0013-9351(82)90158-X; Weiderpass E, 2000, CANCER EPIDEM BIOMAR, V9, P487; Weisskopf MG, 2005, ENVIRON RES, V97, P149, DOI 10.1016/j.envres.2004.01.014; *WHO, WHOHTMRBM2004; *WHO, 1979, WHO ENV HLTH CRIT, V9; Windham GC, 2005, EPIDEMIOLOGY, V16, P182, DOI 10.1097/01.ede.0000152527.24339.17; Wolff MS, 2000, CANCER EPIDEM BIOMAR, V9, P271; WOLFF MS, 1993, JNCI-J NATL CANCER I, V85, P648, DOI 10.1093/jnci/85.8.648; WOODS JS, 1987, J NATL CANCER I, V78, P899; Yanez L, 2004, ENVIRON RES, V94, P18, DOI 10.1016/S0013-9351(03)00047-1; Yanez L, 2002, ENVIRON RES, V88, P174, DOI 10.1006/enrs.2002.4333; You L, 2001, MOL CELL ENDOCRINOL, V178, P207, DOI 10.1016/S0303-7207(01)00445-2; Zheng TZ, 1999, AM J EPIDEMIOL, V150, P453, DOI 10.1093/oxfordjournals.aje.a010033; Zheng TZ, 2000, CANCER EPIDEM BIOMAR, V9, P167	148	207	220	6	89	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 27	2005	366	9487					763	773		10.1016/S0140-6736(05)67182-6	http://dx.doi.org/10.1016/S0140-6736(05)67182-6			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958UV	16125595	Green Submitted			2022-12-28	WOS:000231474600034
J	Ray, PS; Fox, PL				Ray, PS; Fox, PL			Equality of the sexes: Found in translation	CELL			English	Editorial Material							MSL-2 MESSENGER-RNA; DOSAGE COMPENSATION; POLY(A) TAIL; DROSOPHILA; LETHAL	Male fruit flies (and humans) have half the number of X chromosomes that females have, yet the expression of X-linked proteins in males is the same because of a sex-specific compensatory mechanism. In this issue of Cell, Beckmann et al. (2005) report that a unique two-stage translation silencing mechanism thwarts synthesis of a male-specific transcription activator in female flies, ensuring that gene dosage compensation occurs only in males.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Ray, PS (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA.		Ray, Partho Sarothi/H-3020-2019	Ray, Partho Sarothi/0000-0002-8795-3060				Bashaw GJ, 1997, CELL, V89, P789, DOI 10.1016/S0092-8674(00)80262-7; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Gebauer F, 2003, MOL CELL, V11, P1397, DOI 10.1016/S1097-2765(03)00176-X; Gebauer F, 1999, EMBO J, V18, P6146, DOI 10.1093/emboj/18.21.6146; Kelley RL, 1997, NATURE, V387, P195, DOI 10.1038/387195a0; Mazumder B, 2001, MOL CELL BIOL, V21, P6440, DOI 10.1128/MCB.21.19.6440-6449.2001; Mazumder B, 2003, TRENDS BIOCHEM SCI, V28, P91, DOI 10.1016/S0968-0004(03)00002-1; Meller VH, 2002, ADV GENET, V46, P1; MULLER HJ, 1948, HARVEY LECT, V43, P165	9	0	0	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 26	2005	122	4					492	493		10.1016/j.cell.2005.08.005	http://dx.doi.org/10.1016/j.cell.2005.08.005			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	959YI	16122416	Bronze			2022-12-28	WOS:000231555100003
J	Nedimovic, MR; Carbotte, SM; Harding, AJ; Detrick, RS; Canales, JP; Diebold, JB; Kent, GM; Tischer, M; Babcock, JM				Nedimovic, MR; Carbotte, SM; Harding, AJ; Detrick, RS; Canales, JP; Diebold, JB; Kent, GM; Tischer, M; Babcock, JM			Frozen magma lenses below the oceanic crust	NATURE			English	Article							MOHO TRANSITION ZONE; MANTLE TRANSITION; SPREADING CENTER; OMAN; OPHIOLITE; BENEATH; ORIGIN; MELT; BAY	The Earth's oceanic crust crystallizes from magmatic systems generated at mid-ocean ridges. Whereas a single magma body residing within the mid-crust is thought to be responsible for the generation of the upper oceanic crust, it remains unclear if the lower crust is formed from the same magma body, or if it mainly crystallizes from magma lenses located at the base of the crust(1-3). Thermal modelling(4-6), tomography(7), compliance(8) and wide-angle seismic studies(9), supported by geological evidence(3,10-18), suggest the presence of gabbroic-melt accumulations within the Moho transition zone in the vicinity of fast- to intermediate-spreading centres. Until now, however, no reflection images have been obtained of such a structure within the Moho transition zone. Here we show images of groups of Moho transition zone reflection events that resulted from the analysis of similar to 1,500 km of multichannel seismic data collected across the intermediate-spreading-rate(19) Juan de Fuca ridge. From our observations we suggest that gabbro lenses and melt accumulations embedded within dunite or residual mantle peridotite are the most probable cause for the observed reflectivity, thus providing support for the hypothesis that the crust is generated from multiple magma bodies.	Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA; Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA	Columbia University; University of California System; University of California San Diego; Scripps Institution of Oceanography; Woods Hole Oceanographic Institution	Nedimovic, MR (corresponding author), Columbia Univ, Lamont Doherty Earth Observ, 61 Route 9W,POB 1000, Palisades, NY 10964 USA.	mladen@ldeo.columbia.edu	Nedimovic, Mladen/Q-6865-2019; Nedimovic, Mladen/B-8459-2009	Nedimovic, Mladen/0000-0003-0327-5192; Babcock, Jeffrey/0000-0001-5308-8673; Canales, Juan Pablo/0000-0003-3066-7888				Amri I, 1996, EARTH PLANET SC LETT, V139, P177, DOI 10.1016/0012-821X(95)00233-3; BENN K, 1988, TECTONOPHYSICS, V151, P75, DOI 10.1016/0040-1951(88)90241-7; Boudier F, 1996, EARTH PLANET SC LETT, V144, P239, DOI 10.1016/0012-821X(96)00167-7; BOUDIER F, 1995, J PETROL, V36, P777, DOI 10.1093/petrology/36.3.777; BROCHER TM, 1985, GEOLOGY, V13, P62, DOI 10.1130/0091-7613(1985)13<62:SSOTOM>2.0.CO;2; Carlson R.L, 2001, HDB ELASTIC PROPERTI, P377; Ceuleneer G, 1996, NATURE, V379, P149, DOI 10.1038/379149a0; Cherkaoui ASM, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2001GC000215; COLLINS JA, 1986, J GEOPHYS RES-SOLID, V91, P2520, DOI 10.1029/JB091iB12p12520; Crawford WC, 2002, EARTH PLANET SC LETT, V203, P117, DOI 10.1016/S0012-821X(02)00831-2; Dunn RA, 2001, SCIENCE, V291, P1955, DOI 10.1126/science.1057683; GARMANY J, 1989, NATURE, V340, P628, DOI 10.1038/340628a0; Garrido CJ, 2001, GEOCHEM GEOPHY GEOSY, V2, DOI 10.1029/2000GC000136; Godard M, 2000, EARTH PLANET SC LETT, V180, P133, DOI 10.1016/S0012-821X(00)00149-7; HEY R, 1980, J GEOPHYS RES, V85, P3647, DOI 10.1029/JB085iB07p03647; HEY RN, 1986, J GEOPHYS RES-SOLID, V91, P3369, DOI 10.1029/JB091iB03p03369; Jousselin D, 2000, MAR GEOPHYS RES, V21, P229, DOI 10.1023/A:1026733019682; KARSON JA, 1984, J GEOPHYS RES, V89, P6126, DOI 10.1029/JB089iB07p06126; Kelemen PB, 1998, GEOPH MONOG SERIES, V106, P267; Korenaga J, 1997, J GEOPHYS RES-SOL EA, V102, P27729, DOI 10.1029/97JB02604; MACIENNAN J, 2004, GEOCHEM GEOPHY GEOSY, V5, pQF25; Nicolas A, 2000, MAR GEOPHYS RES, V21, P147, DOI 10.1023/A:1026769727917; PHIPPSMORGAN J, 1993, J GEOPHYS RES, V98, P6283; SINTON JM, 1992, J GEOPHYS RES-SOL EA, V97, P197, DOI 10.1029/91JB02508; WILSON DS, 1993, J GEOPHYS RES-SOL EA, V98, P16053, DOI 10.1029/93JB01227	25	73	74	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 25	2005	436	7054					1149	1152		10.1038/nature03944	http://dx.doi.org/10.1038/nature03944			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	958AK	16121179	Green Submitted			2022-12-28	WOS:000231416600044
J	Neale, MJ; Pan, J; Keeney, S				Neale, MJ; Pan, J; Keeney, S			Endonucleolytic processing of covalent protein-linked DNA double-strand breaks	NATURE			English	Article							MEIOTIC CHROMOSOME SYNAPSIS; TOPOISOMERASE-II; SACCHAROMYCES-CEREVISIAE; YEAST MEIOSIS; RECOMBINATION; REPAIR; SPO11; COMPLEX; MOUSE; GENE	DNA double-strand breaks (DSBs) with protein covalently attached to 50 strand termini are formed by Spo11 to initiate meiotic recombination(1,2). The Spo11 protein must be removed for the DSB to be repaired, but the mechanism for removal is unclear(3). Here we show that meiotic DSBs in budding yeast are processed by endonucleolytic cleavage that releases Spo11 attached to an oligonucleotide with a free 3'-OH. Two discrete Spo11-oligonucleotide complexes were found in equal amounts, differing with respect to the length of the bound DNA. We propose that these forms arise from different spacings of strand cleavages flanking the DSB, with every DSB processed asymmetrically. Thus, the ends of a single DSB may be biochemically distinct at or before the initial processing step - much earlier than previously thought. SPO11- oligonucleotide complexes were identified in extracts of mouse testis, indicating that this mechanism is evolutionarily conserved. Oligonucleotide - topoisomerase II complexes were also present in extracts of vegetative yeast, although not subject to the same genetic control as for generating Spo11 - oligonucleotide complexes. Our findings suggest a general mechanism for repair of protein-linked DSBs.	Cornell Univ, Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University	Keeney, S (corresponding author), Cornell Univ, Mem Sloan Kettering Canc Ctr, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.	keeneys@mskcc.org	Keeney, Scott/GVR-8515-2022	Keeney, Scott/0000-0002-1283-6417; Neale, Matthew/0000-0002-6453-1877	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD040916] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058673] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD040916] Funding Source: Medline; NIGMS NIH HHS [R01 GM058673] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; BARCHI M, IN PRESS MOL CELL BI; Baudat F, 2000, MOL CELL, V6, P989, DOI 10.1016/S1097-2765(00)00098-8; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; Connelly JC, 2003, DNA REPAIR, V2, P795, DOI 10.1016/S1568-7864(03)00063-6; Connelly JC, 2004, MOL CELL, V13, P307, DOI 10.1016/S1097-2765(04)00056-5; Diaz RL, 2002, MOL CELL BIOL, V22, P1106, DOI 10.1128/MCB.22.4.1106-1115.2002; Fortune JM, 2000, PROG NUCLEIC ACID RE, V64, P221, DOI 10.1016/S0079-6603(00)64006-0; Henderson KA, 2004, P NATL ACAD SCI USA, V101, P4519, DOI 10.1073/pnas.0400843101; Hunter N, 2001, CELL, V106, P59, DOI 10.1016/S0092-8674(01)00430-5; Johnson RE, 1998, CURR GENET, V34, P21, DOI 10.1007/s002940050362; Keeney S, 1999, GENOMICS, V61, P170, DOI 10.1006/geno.1999.5956; Keeney S, 2001, CURR TOP DEV BIOL, V52, P1, DOI 10.1016/S0070-2153(01)52008-6; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; LIU JH, 1995, EMBO J, V14, P4599, DOI 10.1002/j.1460-2075.1995.tb00139.x; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; NITISS JL, 1992, CANCER RES, V52, P4467; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Pittman DL, 1998, MOL CELL, V1, P697, DOI 10.1016/S1097-2765(00)80069-6; Pouliot JJ, 1999, SCIENCE, V286, P552, DOI 10.1126/science.286.5439.552; Romanienko PJ, 2000, MOL CELL, V6, P975, DOI 10.1016/S1097-2765(00)00097-6; Romanienko PJ, 1999, GENOMICS, V61, P156, DOI 10.1006/geno.1999.5955; SCHWACHA A, 1994, CELL, V76, P51, DOI 10.1016/0092-8674(94)90172-4; Shinohara M, 2000, P NATL ACAD SCI USA, V97, P10814, DOI 10.1073/pnas.97.20.10814; Stohr BA, 2001, GENETICS, V158, P19; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Walker JV, 2002, CANCER INVEST, V20, P570, DOI 10.1081/CNV-120002156	29	418	431	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 18	2005	436	7053					1053	1057		10.1038/nature03872	http://dx.doi.org/10.1038/nature03872			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955XQ	16107854	Green Accepted			2022-12-28	WOS:000231263900058
J	Rothberg, MB; Celestin, C; Fiore, LD; Lawler, E; Cook, JR				Rothberg, MB; Celestin, C; Fiore, LD; Lawler, E; Cook, JR			Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: Meta-analysis with estimates of risk and benefit	ANNALS OF INTERNAL MEDICINE			English	Article							ORAL ANTICOAGULANT-THERAPY; ST-SEGMENT ELEVATION; ARTERY-DISEASE; ANTITHROMBOTIC THERAPY; SECONDARY PREVENTION; UNSTABLE ANGINA; MORTALITY; DEATH; TRIAL; INDEX	Background: After the acute coronary syndrome, adding warfarin to standard aspirin therapy decreases myocardial infarction and stroke but increases major bleeding. Purpose: To quantify the risks and benefits of warfarin therapy after the acute coronary syndrome. Data Sources: MEDLINE from 1990 to October 2004. Additional data were obtained from study authors. Clinical risk factors were used to classify hypothetical patients into cardiovascular and bleeding risk groups on the basis of published data. Study Selection: Randomized trials comparing intensive warfarin therapy (international normalized ratio > 2.0) plus aspirin with aspirin alone after the acute coronary syndrome. Data Extraction: Two reviewers independently selected studies and extracted data on study design; quality; and clinical outcomes, including myocardial infarction, stroke, revascularization, death, and major and minor bleeding. Rate ratios for outcomes were calculated and pooled by using the method of DerSimonian and Laird. Data Synthesis: Ten trials involving a total of 5938 patients (11 334 patient-years) met the study criteria. Compared with aspirin alone, warfarin plus aspirin was associated with a decrease in the annual rate of myocardial infarction (0.022 vs. 0.041; rate ratio, 0.56 [95% CI, 0.46 to 0.69]), ischemic stroke (0.004 vs. 0.008; rate ratio, 0.46 [CI, 0.27 to 0.77]), and revascularization (0.115 vs. 0.135; rate ratio, 0.80 [CI, 0.67 to 0.95]). Warfarin was associated with an increase in major bleeding (0.015 vs. 0.006; rate ratio, 2.5 [CI, 1.7 to 3.7]). Mortality did not differ. Limitations: Two large studies provided most of the data. Studies did not include coronary stenting, and results should not be applied to patients with stents. Relative risk reductions may not be consistent across risk groups. Conclusions: For patients with the acute coronary syndrome who are at low or intermediate risk for bleeding, the cardiovascular benefits of warfarin outweigh the bleeding risks.	Baystate Med Ctr, Div Gen Med & Geriatr, Springfield, MA 01199 USA; Tufts Univ, Sch Med, Massachussets Vet Epidemiol Res & Informat Ctr, Vet Affairs Boston Healthcare Syst, Boston, MA USA	Baystate Medical Center; Tufts University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Rothberg, MB (corresponding author), Baystate Med Ctr, Div Gen Med & Geriatr, 759 Chestnut St, Springfield, MA 01199 USA.	Michael.Rothberg@bhs.org						*AM HEART ASS, 2004, HEART DIS STROK STAT; Anand SS, 1999, JAMA-J AM MED ASSOC, V282, P2058, DOI 10.1001/jama.282.21.2058; Anand SS, 1998, CIRCULATION, V98, P1064, DOI 10.1161/01.CIR.98.11.1064; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Bertrand ME, 1998, CIRCULATION, V98, P1597, DOI 10.1161/01.CIR.98.16.1597; Beyth RJ, 1998, AM J MED, V105, P91, DOI 10.1016/S0002-9343(98)00198-3; Brouwer MA, 2002, CIRCULATION, V106, P659, DOI 10.1161/01.CIR.0000024408.81821.32; Budaj A, 2002, CIRCULATION, V106, P1622, DOI 10.1161/01.CIR.0000029926.71825.E2; Cleland JGF, 2004, AM HEART J, V148, P157, DOI 10.1016/j.ahj.2004.03.010; COHEN M, 1994, CIRCULATION, V89, P81, DOI 10.1161/01.CIR.89.1.81; COHEN M, 1990, AM J CARDIOL, V66, P1287, DOI 10.1016/0002-9149(90)91155-Y; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Eagle KA, 2004, JAMA-J AM MED ASSOC, V291, P2727, DOI 10.1001/jama.291.22.2727; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fiore LD, 2002, CIRCULATION, V105, P557, DOI 10.1161/hc0502.103329; Fuster V, 1997, LANCET, V350, P389; Gaspoz J, 2002, NEW ENGL J MED, V346, P1800, DOI 10.1056/NEJM200206063462309; GITTER MJ, 1995, MAYO CLIN PROC, V70, P725, DOI 10.4065/70.8.725; Go AS, 1999, ANN INTERN MED, V131, P927, DOI 10.7326/0003-4819-131-12-199912210-00004; Hoey John, 2002, CMAJ, V167, P1036; Hurlen M, 2002, NEW ENGL J MED, V347, P969, DOI 10.1056/NEJMoa020496; Huynh T, 2001, CIRCULATION, V103, P3069, DOI 10.1161/01.CIR.103.25.3069; Hylek EM, 2003, NEW ENGL J MED, V349, P1019, DOI 10.1056/NEJMoa022913; Kaplan RC, 2002, J CLIN EPIDEMIOL, V55, P654, DOI 10.1016/S0895-4356(02)00405-5; KORNOWSKI R, 1995, CARDIOLOGY, V86, P163, DOI 10.1159/000176864; KORNOWSKI R, 1993, AM J CARDIOL, V72, P883, DOI 10.1016/0002-9149(93)91100-V; Kuijer PMM, 1999, ARCH INTERN MED, V159, P457, DOI 10.1001/archinte.159.5.457; LANDEFELD CS, 1989, AM J MED, V87, P144; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Leon MB, 1998, NEW ENGL J MED, V339, P1665, DOI 10.1056/NEJM199812033392303; Marchioli R, 2001, EUR HEART J, V22, P2085, DOI 10.1053/euhj.2000.2544; Marshall T, 2003, BMJ-BRIT MED J, V327, P1264, DOI 10.1136/bmj.327.7426.1264; McMahan DA, 1998, J GEN INTERN MED, V13, P311, DOI 10.1046/j.1525-1497.1998.00096.x; Meade TW, 1998, LANCET, V351, P233; MERLINI PA, 1994, CIRCULATION, V90, P61, DOI 10.1161/01.CIR.90.1.61; MOSS AJ, 1990, NEW ENGL J MED, V322, P743, DOI 10.1056/NEJM199003153221107; Palareti G, 1996, LANCET, V348, P423, DOI 10.1016/S0140-6736(96)01109-9; PEDERSEN TR, 1994, LANCET, V344, P1383; Pullicino P, 2003, NEW ENGL J MED, V348, P256; Rudnicka AR, 2003, ARCH INTERN MED, V163, P1454, DOI 10.1001/archinte.163.12.1454; Ryan TJ, 1999, CIRCULATION, V100, P1016, DOI 10.1161/01.CIR.100.9.1016; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; SMITH P, 2002, PATHOPHYSIOL HAEMO T, V32, pS76; Stafford RS, 1996, ARCH INTERN MED, V156, P2537, DOI 10.1001/archinte.156.22.2537; Topol Eric J, 2003, ACP J Club, V138, P34; van Es RF, 2002, LANCET, V360, P109, DOI 10.1016/S0140-6736(02)09409-6; vanderMeer FJM, 1996, THROMB HAEMOSTASIS, V76, P12; WALLENTIN LC, 1991, J AM COLL CARDIOL, V18, P1587, DOI 10.1016/0735-1097(91)90489-V; Wells PS, 2003, ARCH INTERN MED, V163, P917, DOI 10.1001/archinte.163.8.917; Williams MJA, 1997, J AM COLL CARDIOL, V30, P364, DOI 10.1016/S0735-1097(97)00153-8; Wiviott SD, 2004, J AM COLL CARDIOL, V44, P783, DOI 10.1016/j.jacc.2004.05.045; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; Yusuf S, 2005, JAMA-J AM MED ASSOC, V293, P427; Yusuf S, 2001, NEW ENGL J MED, V345, P494; Yusuf S, 2001, J AM COLL CARDIOL, V37, P475; Yusuf S, 2000, NEW ENGL J MED, V342, P145; Zibaeenezhad MJ, 2004, ANGIOLOGY, V55, P17, DOI 10.1177/000331970405500103	59	251	262	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 16	2005	143	4					241	250		10.7326/0003-4819-143-4-200508160-00005	http://dx.doi.org/10.7326/0003-4819-143-4-200508160-00005			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955PA	16103468				2022-12-28	WOS:000231237100001
J	Gosden, C; Gardener, D				Gosden, C; Gardener, D			ABC of conflict and disaster - Weapons of mass destruction - threats and responses	BRITISH MEDICAL JOURNAL			English	Review									Univ Liverpool, Royal Liverpool Univ Hosp, Dept Pathol, Liverpool L69 3BX, Merseyside, England	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Gosden, C (corresponding author), Univ Liverpool, Royal Liverpool Univ Hosp, Dept Pathol, Liverpool L69 3BX, Merseyside, England.							Centers for Disease Control and Prevention, EM PREP RESP; DWYER A, 2003, JANES CHEMBIO HDB; Ellison D., 2000, HDB CHEM BIOL WARFAR; *NAT GUID CLEAR, GUID BIOT; World Health Organization, 2004, PUBL HLTH RESP BIOL	5	14	14	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	AUG 13	2005	331	7513					397	400		10.1136/bmj.331.7513.397	http://dx.doi.org/10.1136/bmj.331.7513.397			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	956SK	16096310	Green Published			2022-12-28	WOS:000231319900021
J	Wessely, S				Wessely, S			The London attacks - Aftermath - Victimhood and resilience	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Kings Ctr Mil Hlth Res, London, England	University of London; King's College London	Wessely, S (corresponding author), Kings Coll London, Inst Psychiat, London, England.		Wessely, Simon C/A-8713-2008	Wessely, Simon Charles/0000-0002-6743-9929				Gillespie K, 2002, BEHAV RES THER, V40, P345, DOI 10.1016/S0005-7967(02)00004-9; Jones E, 2004, SOC HIST MED, V17, P463, DOI 10.1093/shm/17.3.463; RITCHIE C, 2005, 9 11 MENTAL HLTH WAK; SHALEV A, 2005, DISASTERS MENTAL HLT; van Emmerik AAP, 2002, LANCET, V360, P766, DOI 10.1016/S0140-6736(02)09897-5	5	42	44	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 11	2005	353	6					548	550		10.1056/NEJMp058180	http://dx.doi.org/10.1056/NEJMp058180			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	953ST	16093462				2022-12-28	WOS:000231101500004
J	Halpern, SD				Halpern, SD			HIV testing without consent in critically ill patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							AMERICANS		Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Bioeth, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Halpern, SD (corresponding author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Med, 115 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.	shalpern@cceb.med.upenn.edu						Akinola NO, 2004, CLIN INFECT DIS, V39, P579, DOI 10.1086/422722; Aldrich J, 2000, ARCH INTERN MED, V160, P715, DOI 10.1001/archinte.160.5.715; *AM MED ASS, H 20 920 HIV TEST; Annas GJ, 1998, NEW ENGL J MED, V339, P1255, DOI 10.1056/NEJM199810223391723; BAYER R, 1991, NEW ENGL J MED, V324, P1500, DOI 10.1056/NEJM199105233242111; BAYER R, 2000, AIDS DOCTORS VOICES, P156; BEAUCHAMP TL, 1994, RESPECT AUTONOMY PRI, P120; Bernard GR, 2004, AM J RESP CRIT CARE, V170, P1375, DOI 10.1164/rccm.200406-726ST; Bogart LM, 2005, JAIDS-J ACQ IMM DEF, V38, P213, DOI 10.1097/00126334-200502010-00014; Burris Scott, 1994, John Marshall Law Rev, V27, P251; Domingo P, 1997, LANCET, V349, P1554, DOI 10.1016/S0140-6736(05)62136-8; Dyer G, 2000, BRIT MED J, V320, P135; ELLEMENT J, 1996, BOSTON GLOBE CI 0601, P13; *GEN MED COUNC, 1997, SER COMM DIS; Luce JM, 2003, CRIT CARE MED, V31, pS153, DOI 10.1097/01.CCM.0000054901.80339.01; MARKS HM, 1997, PROGR EXPT SCI THERA, P229; PAUKER SG, 1980, NEW ENGL J MED, V302, P1109, DOI 10.1056/NEJM198005153022003; Sommerville A, 2002, BRIT MED J, V325, P1226; *TUL LAW SCH, 2004, LAW SEXUALITY REV LE, V13, P5; TURNOCK BJ, 1989, JAMA-J AM MED ASSOC, V261, P3415, DOI 10.1001/jama.261.23.3415	20	15	16	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	2005	294	6					734	737		10.1001/jama.294.6.734	http://dx.doi.org/10.1001/jama.294.6.734			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	953IA	16091576				2022-12-28	WOS:000231068600027
J	Maitland, K; Nadel, S; Pollard, AJ; Williams, TN; Newton, CRJC; Levin, M				Maitland, K; Nadel, S; Pollard, AJ; Williams, TN; Newton, CRJC; Levin, M			Management of severe malaria in children: proposed guidelines for the United Kingdom	BRITISH MEDICAL JOURNAL			English	Review							CHILDHOOD CEREBRAL MALARIA; PLASMODIUM-FALCIPARUM MALARIA; KENYAN CHILDREN; AFRICAN CHILDREN; INTRACRANIAL-PRESSURE; ACIDOSIS		Kenya Govt Med Res Ctr, Wellcome Trust Programme, Ctr Geog Med Res Coast, Kilifi, Kenya; St Marys Hosp, Dept Paediat, London W2 1NY, England; Univ Oxford, John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England; Univ Sussex, Brighton & Sussex Med Sch, Brighton BN1 9PS, E Sussex, England	Kenya Medical Research Institute; Imperial College London; University of Oxford; University of Brighton; University of Sussex	Maitland, K (corresponding author), Kenya Govt Med Res Ctr, Wellcome Trust Programme, Ctr Geog Med Res Coast, POB 230, Kilifi, Kenya.	kmaitland@kilifi.mimcom.net	Newton, Charles RJC/B-7578-2014; Newton, Charles/V-7872-2019	Newton, Charles RJC/0000-0002-6999-5507; Newton, Charles/0000-0002-6999-5507; Levin, Michael/0000-0003-2767-6919; Maitland, Kathryn/0000-0002-0007-0645				*AM HEART ASS, 1997, PED ADV LIF SUPP 199; [Anonymous], 2000, T R SOC TROP MED S1, V94, pS1; BONDI FS, 1992, T ROY SOC TROP MED H, V86, P17, DOI 10.1016/0035-9203(92)90420-H; BRADLEY D, 2003, ILLNESS ENGLAND WALE, P48; Carter JA, 2003, BRAIN INJURY, V17, P217, DOI 10.1080/0269905021000038447; Crawley J, 1996, QJM-INT J MED, V89, P591; Crawley J, 2000, LANCET, V355, P701, DOI 10.1016/S0140-6736(99)07148-2; English M, 1996, AM J TROP MED HYG, V55, P521, DOI 10.4269/ajtmh.1996.55.521; Harbour R, 2001, BRIT MED J, V323, P334, DOI 10.1136/bmj.323.7308.334; Jelinek T, 2002, CLIN INFECT DIS, V34, P572, DOI 10.1086/338235; Ladhani S, 2003, PEDIATR INFECT DIS J, V22, P814, DOI 10.1097/01.inf.0000086401.13592.79; Maitland K, 2005, CLIN INFECT DIS, V40, P538, DOI 10.1086/427505; Maitland K, 2005, CLIN INFECT DIS, V40, P9, DOI 10.1086/426022; Maitland K, 2005, TRENDS PARASITOL, V21, P11, DOI 10.1016/j.pt.2004.10.010; Maitland K, 2003, QJM-INT J MED, V96, P427, DOI 10.1093/qjmed/hcg077; Maitland Kathryn, 2004, Pediatr Crit Care Med, V5, P81, DOI 10.1097/01.PCC.0000102398.91277.08; Maitland Kathryn, 2003, Pediatr Crit Care Med, V4, P426, DOI 10.1097/01.PCC.0000090293.32810.4E; Moody A H, 2002, Br J Biomed Sci, V59, P228; Muentener P, 1999, B WORLD HEALTH ORGAN, V77, P560; Newton CRJC, 1998, AM J TROP MED HYG, V58, P673, DOI 10.4269/ajtmh.1998.58.673; NEWTON CRJC, 1991, LANCET, V337, P573, DOI 10.1016/0140-6736(91)91638-B; Newton CRJC, 1997, T ROY SOC TROP MED H, V91, P161, DOI 10.1016/S0035-9203(97)90207-8; Newton CRJC, 1997, ARCH DIS CHILD, V76, P219, DOI 10.1136/adc.76.3.219; Palmer CJ, 2003, J CLIN MICROBIOL, V41, P5178, DOI 10.1128/JCM.41.11.5178-5182.2003; Pamba A, 2004, ARCH DIS CHILD, V89, P950, DOI 10.1136/adc.2003.032516; POSNER E, 2001, ADV PAED LIFE SUPPOR; Riddle MS, 2002, CLIN INFECT DIS, V34, P1192, DOI 10.1086/339810; SNOW R, 2003, 11 NIH FOG INT CTR, P1; Stoppacher R, 2003, J FORENSIC SCI, V48, P404; Taylor TE, 2004, NAT MED, V10, P143, DOI 10.1038/nm986; WALKER O, 1992, T ROY SOC TROP MED H, V86, P491, DOI 10.1016/0035-9203(92)90082-N; WALLER D, 1991, T ROY SOC TROP MED H, V85, P362, DOI 10.1016/0035-9203(91)90291-6; WHITE NJ, 1987, LANCET, V1, P708; White VA, 2001, T ROY SOC TROP MED H, V95, P618, DOI 10.1016/S0035-9203(01)90097-5	34	36	36	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	AUG 6	2005	331	7512					337	343		10.1136/bmj.331.7512.337	http://dx.doi.org/10.1136/bmj.331.7512.337			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955WZ	16081449	Green Published, Green Submitted			2022-12-28	WOS:000231259800024
J	Lam, TKT; Gutierrez-Juarez, R; Pocai, A; Rossetti, L				Lam, TKT; Gutierrez-Juarez, R; Pocai, A; Rossetti, L			Regulation of blood glucose by hypothalamic pyruvate metabolism	SCIENCE			English	Article							FOOD-INTAKE; MITOCHONDRIAL DYSFUNCTION; LACTATE-DEHYDROGENASE; LEPTIN RECEPTOR; ARCUATE NUCLEUS; BRAIN; RATS; HYPERGLYCEMIA; NEURONS; OBESITY	The brain keenly depends on glucose for energy, and mammalians have redundant systems to control glucose production. An increase in circulating glucose inhibits glucose production in the liver, but this negative feedback is impaired in type 2 diabetes. Here we report that a primary increase in hypothalamic glucose levels lowers blood glucose through inhibition of glucose production in rats. The effect of glucose requires its conversion to lactate followed by stimulation of pyruvate metabolism, which leads to activation of adenosine triphosphate (ATP)-sensitive potassium channels. Thus, interventions designed to enhance the hypothalamic sensing of glucose may improve glucose homeostasis in diabetes.	Yeshiva Univ Albert Einstein Coll Med, Dept Med, Ctr Diabet Res, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Ctr Diabet Res, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Rossetti, L (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Med, Ctr Diabet Res, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	rossetti@aecom.yu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020541, R01DK045024, R29DK045024, R37DK048321, R01DK048321] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG023475, P01AG021654] Funding Source: NIH RePORTER; NIA NIH HHS [T32-AG023475, AG 21654] Funding Source: Medline; NIDDK NIH HHS [DK 20541, DK 45024, DK 48321] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bittar PG, 1996, J CEREBR BLOOD F MET, V16, P1079, DOI 10.1097/00004647-199611000-00001; Borg MA, 1997, J CLIN INVEST, V99, P361, DOI 10.1172/JCI119165; Brooks GA, 1999, P NATL ACAD SCI USA, V96, P1129, DOI 10.1073/pnas.96.3.1129; Cohen P, 2001, J CLIN INVEST, V108, P1113, DOI 10.1172/JCI200113914; Coppari R, 2005, CELL METAB, V1, P63, DOI 10.1016/j.cmet.2004.12.004; Cryer PE, 2003, DIABETES CARE, V26, P1902, DOI 10.2337/diacare.26.6.1902; DAVIS JD, 1981, SCIENCE, V212, P81, DOI 10.1126/science.7193909; Flier JS, 2004, CELL, V116, P337, DOI 10.1016/S0092-8674(03)01081-X; GUTIERREZJUAREZ.R, UNPUB; Itoh Y, 2003, P NATL ACAD SCI USA, V100, P4879, DOI 10.1073/pnas.0831078100; Kasischke KA, 2004, SCIENCE, V305, P99, DOI 10.1126/science.1096485; Lam TKT, 2005, NAT MED, V11, P320, DOI 10.1038/nm1201; Levin BE, 2004, DIABETES, V53, P2521, DOI 10.2337/diabetes.53.10.2521; Lowell BB, 2005, SCIENCE, V307, P384, DOI 10.1126/science.1104343; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; MAHER F, 1994, FASEB J, V8, P1003, DOI 10.1096/fasebj.8.13.7926364; Mevorach M, 1998, J CLIN INVEST, V102, P744, DOI 10.1172/JCI2720; Morton GJ, 2003, ENDOCRINOLOGY, V144, P2016, DOI 10.1210/en.2002-0115; Obici S, 2003, NAT MED, V9, P756, DOI 10.1038/nm873; Obici S, 2002, NAT MED, V8, P1376, DOI 10.1038/nm798; Pellerin L, 2004, SCIENCE, V305, P50, DOI 10.1126/science.1100428; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314; Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889; Pocai A, 2005, NATURE, V434, P1026, DOI 10.1038/nature03439; ROSSETTI L, 1987, J CLIN INVEST, V80, P1037, DOI 10.1172/JCI113157; ROSSETTI L, 1993, J CLIN INVEST, V92, P1126, DOI 10.1172/JCI116681; SACCA L, 1978, J CLIN ENDOCR METAB, V47, P1160, DOI 10.1210/jcem-47-5-1160; Schwartz MW, 2005, SCIENCE, V307, P375, DOI 10.1126/science.1104344; Taylor SI, 1999, CELL, V97, P9, DOI 10.1016/S0092-8674(00)80709-6; THOMPSON DA, 1977, SCIENCE, V198, P1065, DOI 10.1126/science.929188; WOODS SC, 1978, SCIENCE, V202, P1209, DOI 10.1126/science.725595	32	257	269	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 5	2005	309	5736					943	947		10.1126/science.1112085	http://dx.doi.org/10.1126/science.1112085			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953SS	16081739				2022-12-28	WOS:000231101400050
J	Saks, MJ; Koehler, JJ				Saks, MJ; Koehler, JJ			The coming paradigm shift in forensic identification science	SCIENCE			English	Review								Converging legal and scientific forces are pushing the traditional forensic identification sciences toward fundamental change. The assumption of discernible uniqueness that resides at the core of these fields is weakened by evidence of errors in proficiency testing and in actual cases. Changes in the law pertaining to the admissibility of expert evidence in court, together with the emergence of DNA typing as a model for a scientifically defensible approach to questions of shared identity, are driving the older forensic sciences toward a new scientific paradigm.	Arizona State Univ, Coll Law, Tempe, AZ 85287 USA; Univ Texas, McCombs Sch Business, Austin, TX 78712 USA	Arizona State University; Arizona State University-Tempe; University of Texas System; University of Texas Austin	Saks, MJ (corresponding author), Arizona State Univ, Coll Law, Tempe, AZ 85287 USA.	saks@asu.edu; koehler@mail.utexas.edu						COLE S, IN PRESS J CRIM LAW; *COLL TEST SERV IN, 1993, FOR TEST PROGR LAT P; *COMM DNA TECHN FO, 1992, DNA TECHN FOR SCI; Cooley C. M., 2004, STAN L POLY REV, V15, P381; Epstein R, 2002, SOUTH CALIF LAW REV, V75, P605; Faigman D. L., 2002, MODERN SCI EVIDENCE; FISHER D, 1995, HARD EVIDENCE; Furton KG, 1999, J FORENSIC SCI, V44, P128; Giannelli P. C., 1997, VIRGINIA J SOCIAL PO, V439, P439; Giannelli PC, 2003, ISSUES SCI TECHNOL, V20, P55; Grieve David L., 1996, J FORENSIC IDENTIFIC, V46, P524; HEATH D, 2004, SEATTLE TIMES   0521; Houck MM, 2002, J FORENSIC SCI, V47, P964; KAHNEMAN D, 1973, PSYCHOL REV, V80, P237, DOI 10.1037/h0034747; Koehler J.J., 1995, JURIMETRICS J LAW SC, V35, P201; Koehler J. J., 1997, JURIMETRICS J, V37, P425; Koehler JJ, 1996, BEHAV BRAIN SCI, V19, P1, DOI 10.1017/S0140525X00041157; Kuhn T. S., 1996, STRUCTURE SCI REVOLU; LANDER ES, 1994, NATURE, V371, P735, DOI 10.1038/371735a0; LEWONTIN RC, 1991, SCIENCE, V254, P1745, DOI 10.1126/science.1845040; MOENSSENS AA, 1993, J CRIM LAW CRIM, V84, P1, DOI 10.2307/1143885; *NAT RES COUNC, 2004, FOR AN WEIGH BULL LE; OSTERBURG JW, 1969, J CRIM LAW CRIMINOL, V60, P97, DOI 10.2307/1141742; Peterson J, 1984, FORENSIC EVIDENCE PO; PETERSON J, 1986, FORENSIC SCI COURTS; Pretty IA, 2001, SCI JUSTICE, V41, P85, DOI 10.1016/S1355-0306(01)71859-X; ROEDER K, 1994, STAT SCI, V9, P263; Saks MJ, 1998, HASTINGS LAW J, V49, P1069; Saks MJ, 2003, SCI JUSTICE, V43, P77, DOI 10.1016/S1355-0306(03)71747-X; Saks MJ, 1991, CARDOZO L REV, V13, P361; Scheck B., 2000, ACTUAL INNOCENCE; STONEY DA, 1991, J FORENSIC SCI SOC, V31, P197, DOI 10.1016/S0015-7368(91)73138-1; *TECHN WORK GROUP, 1991, CRIME LAB DIGEST, V18, P44	33	359	364	2	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 5	2005	309	5736					892	895		10.1126/science.1111565	http://dx.doi.org/10.1126/science.1111565			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	953SS	16081727				2022-12-28	WOS:000231101400034
J	Vigolo, B; Coulon, C; Maugey, M; Zakri, C; Poulin, P				Vigolo, B; Coulon, C; Maugey, M; Zakri, C; Poulin, P			An experimental approach to the percolation of sticky nanotubes	SCIENCE			English	Article							CARBON NANOTUBES; STATISTICAL-THEORY; FIBERS; MACROMOLECULES; CONNECTEDNESS; CONDUCTIVITY; TRANSITION; BEHAVIOR; PHASE	Percolation is a statistical concept that describes the formation of an infinite cluster of connected particles or pathways. Lowering the percolation threshold is a critical issue to achieve light and low-cost conductive composites made of an insulating matrix loaded with conductive particles. This has interest for applications where charge dissipation and electrical conductivity are sought in films, coatings, paints, or composite materials. One route to decreasing the loading required for percolation is to use rod-like particles. Theoretical predictions indicate that this may also be achieved by altering the interaction potential between the particles. Although percolation may not always respond monotonicalty to interactions, the use of adhesive rods can be expected to be an ideal combination. By using a system made of carbon nanotubes in an aqueous Surfactant solution, we find that very small attraction can markedly lower the percolation threshold. The strength of this effect can thereby have direct technological interest and explain the large variability of experimental results in the literature dealing with the electrical behavior of composites loaded with conducting rods.	CNRS, Ctr Rech Paul Pascal, F-33600 Pessac, France	Centre de Recherche Paul Pascal; Centre National de la Recherche Scientifique (CNRS)	Poulin, P (corresponding author), CNRS, Ctr Rech Paul Pascal, Ave Schweitzer, F-33600 Pessac, France.	poulin@crpp-bordeaux.cnrs.fr	Zakri, Cecile/K-2116-2013; Vigolo, Brigitte/F-4870-2016	Vigolo, Brigitte/0000-0002-1463-0121; Poulin, Philippe/0000-0001-7748-8671				Badaire S, 2004, LANGMUIR, V20, P10367, DOI 10.1021/la049096r; BALBERG I, 1984, PHYS REV LETT, V52, P1465, DOI 10.1103/PhysRevLett.52.1465; Barrau S, 2003, MACROMOLECULES, V36, P5187, DOI 10.1021/ma021263b; BIBETTE J, 1992, PHYS REV LETT, V69, P981, DOI 10.1103/PhysRevLett.69.981; Bonard JM, 1997, ADV MATER, V9, P827, DOI 10.1002/adma.19970091014; Breuer O, 2004, POLYM COMPOSITE, V25, P630, DOI 10.1002/pc.20058; BUG ALR, 1985, PHYS REV LETT, V55, P1896, DOI 10.1103/PhysRevLett.55.1896; CARMONA F, 1984, SOLID STATE COMMUN, V51, P255, DOI 10.1016/0038-1098(84)91008-1; CHIEW YC, 1983, J PHYS A-MATH GEN, V16, P2599, DOI 10.1088/0305-4470/16/11/026; CLERC JP, 1983, ANN PHYS-PARIS, V8, P5; Coleman JN, 1998, PHYS REV B, V58, pR7492, DOI 10.1103/PhysRevB.58.R7492; CONIGLIO A, 1977, J PHYS A-MATH GEN, V10, P1123, DOI 10.1088/0305-4470/10/7/011; Curran SA, 1998, ADV MATER, V10, P1091, DOI 10.1002/(SICI)1521-4095(199810)10:14<1091::AID-ADMA1091>3.0.CO;2-L; GROSBERG AY, 1981, ADV POLYM SCI, V41, P53; HILL TL, 1955, J CHEM PHYS, V23, P617, DOI 10.1063/1.1742067; Hough LA, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.168102; Islam MF, 2003, NANO LETT, V3, P269, DOI 10.1021/nl025924u; Nikolaev P, 1999, CHEM PHYS LETT, V313, P91, DOI 10.1016/S0009-2614(99)01029-5; Potschke P, 2003, POLYMER, V44, P5023, DOI 10.1016/S0032-3861(03)00451-8; Rahmani A, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.184202; SAFRAN SA, 1985, PHYS REV A, V32, P506, DOI 10.1103/PhysRevA.32.506; Sandler J, 1999, POLYMER, V40, P5967, DOI 10.1016/S0032-3861(99)00166-4; Shaffer MSP, 1999, ADV MATER, V11, P937, DOI 10.1002/(SICI)1521-4095(199908)11:11<937::AID-ADMA937>3.0.CO;2-9; STROUD D, 1982, PHYS REV B, V25, P2061, DOI 10.1103/PhysRevB.25.2061; VANDERSCHOOT P, 1992, J CHEM PHYS, V97, P515, DOI 10.1063/1.463599; Vigolo B, 2000, SCIENCE, V290, P1331, DOI 10.1126/science.290.5495.1331; VINCHES C, 1994, J PHYS II, V4, P1165, DOI 10.1051/jp2:1994193; Wang XL, 2003, J CHEM PHYS, V118, P10787, DOI 10.1063/1.1575201	28	223	227	1	105	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 5	2005	309	5736					920	923		10.1126/science.1112835	http://dx.doi.org/10.1126/science.1112835			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953SS	16081733				2022-12-28	WOS:000231101400042
J	Stramer, SL; Fang, CT; Foster, GA; Wagner, AG; Brodsky, JP; Dodd, RY				Stramer, SL; Fang, CT; Foster, GA; Wagner, AG; Brodsky, JP; Dodd, RY			West Nile virus among blood donors in the United States, 2003 and 2004	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNOGLOBULIN-M; ESTIMATED RISK; NEW-YORK; TRANSFUSION; TRANSMISSION; ENCEPHALITIS; INFECTIONS; EPIDEMIC; ANTIBODY	BACKGROUND: West Nile virus first appeared in the United States in 1999 and has since spread throughout the contiguous states, resulting in thousands of cases of disease. By 2002, it was clear that the virus could be transmitted by blood transfusion, and by the middle of 2003, essentially all blood donations were being tested for West Nile virus RNA with the use of investigational nucleic acid amplification tests; testing was performed on individual samples or on ``minipools'' of up to 16 donations. METHODS: We analyzed data from the West Nile virus testing program of the American Red Cross for 2003 and 2004 to identify geographic and temporal trends. In areas with a high incidence of infection, individual donations were tested to increase the sensitivity of testing. Donors with reactive results participated in follow-up studies to confirm the original reactivity and to assess the natural history of infection. RESULTS: Routine testing in 2003 and 2004 identified 540 donations that were positive for West Nile virus RNA, of which 362 (67 percent) were IgM-antibody-negative and most likely infectious. Of the 540 positive donations, 148 (27 percent) were detectable only by testing of individual donations, but only 15 of the 148 (10 percent) were negative for IgM antibody. The overall frequencies of RNA-positive donations during the epidemic periods were 1.49 per 10,000 donations in 2003 and 0.44 per 10,000 in 2004. In 2004, 52 percent of the positive donations were from donors in four counties in southern California. CONCLUSIONS: Rapid implementation of a nucleic acid amplification test led to the prospective identification of 519 donors who were positive for West Nile virus RNA and the removal of more than 1000 potentially infectious related components from the blood supply of the Red Cross. No cases of transfusion-transmitted infection were confirmed among recipients of the tested blood.	Amer Red Cross, Gaithersburg, MD 20877 USA; Amer Red Cross, Rockville, MD USA; Qual Analyt, Riverwoods, IL USA	American Red Cross; American Red Cross	Stramer, SL (corresponding author), Amer Red Cross, 9315 Gaither Rd, Gaithersburg, MD 20877 USA.	stramers@usa.redcross.org						[Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P833; Biggerstaff BJ, 2003, TRANSFUSION, V43, P1007, DOI 10.1046/j.1537-2995.2003.00480.x; Biggerstaff BJ, 2002, TRANSFUSION, V42, P1019, DOI 10.1046/j.1537-2995.2002.00167.x; BUSCH MP, VIREMIA ANTIBODY STU; Custer B, 2004, TRANSFUSION, V44, P1547, DOI 10.1111/j.0041-1132.2004.04227.x; de Oliveira AM, 2004, TRANSFUSION, V44, P1695, DOI 10.1111/j.0041-1132.2004.04130.x; *DEP HLTH HUM SERV, 2005, GUID IND REV REC ASS; *DEP HLTH HUM SERV, 2003, GUID IND REV REC ASS; *DEP HLTH HUM SERV, 2002, GUID IND REC ASS DON; Dodd RY, 2003, NEW ENGL J MED, V349, P1205, DOI 10.1056/NEJMp038138; Iwamoto M, 2003, NEW ENGL J MED, V348, P2196, DOI 10.1056/NEJMoa022987; Mostashari F, 2001, LANCET, V358, P261, DOI 10.1016/S0140-6736(01)05480-0; ORTON S, IN PRESS TRANSFUSION; Pealer LN, 2003, NEW ENGL J MED, V349, P1236, DOI 10.1056/NEJMoa030969; Petersen LR, 2004, NEW ENGL J MED, V351, P2257, DOI 10.1056/NEJMp048261; Prince HE, 2003, CLIN DIAGN LAB IMMUN, V10, P764, DOI 10.1128/CDLI.10.5.764-768.2003; Roehrig JT, 2003, EMERG INFECT DIS, V9, P376, DOI 10.3201/eid0903.020531; SAZAMA K, 2004, AABB B, V403, P1; SMITHBURN K. C, 1940, AMER JOUR TROP MED, V20, P471; Stramer SL, 2004, NEW ENGL J MED, V351, P760, DOI 10.1056/NEJMoa040085; STRAMER SL, 2005, 6 NAT C W NIL VIR US; STRAMER SL, 2003, TRANSFUSION S2A, V43; STRAMER SL, 2003, TRANSFUSION S3A, V43; 1999, MMWR MORB MORTAL WKL, V48, P845; 2003, MMWR MORB MORTAL WKL, V52, P769; 2004, MMWR MORB MORTAL WKL, V53, P281; 2005, 2003 2004 W NIL VIR; 2004, MMWR MORB MORTAL WKL, V53, P842	28	160	162	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 4	2005	353	5					451	459		10.1056/NEJMoa044333	http://dx.doi.org/10.1056/NEJMoa044333			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	951OB	16079368				2022-12-28	WOS:000230939000004
J	Jeffcoate, W				Jeffcoate, W			Care and despair in the UK National Health Service	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Jeffcoate, W (corresponding author), The Lancet, London NW1 7BY, England.							CARVEL J, 2005, GUARDIAN        0707, P13; DAVIS J., 2005, GUARDIAN        0627, P18; HEWITT P, 2005, GUARDIAN        0702, P20; Pollock AM, 2004, NHS PLC PRIVATISATIO; RUSSELL J, 2005, GUARDIAN        0430, P23; Taylor C, 2005, LANCET, V366, P742, DOI 10.1016/S0140-6736(05)67178-4	6	2	3	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 27	2005	366	9487					694	695		10.1016/S0140-6736(05)67152-8	http://dx.doi.org/10.1016/S0140-6736(05)67152-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	958UV	16125570				2022-12-28	WOS:000231474600006
J	Handelsman, J; Cantor, N; Carnes, M; Denton, D; Fine, E; Grosz, B; Hinshaw, V; Marrett, C; Rosser, S; Shalala, D; Sheridan, J				Handelsman, J; Cantor, N; Carnes, M; Denton, D; Fine, E; Grosz, B; Hinshaw, V; Marrett, C; Rosser, S; Shalala, D; Sheridan, J			More women in science	SCIENCE			English	Editorial Material							FEMALE		Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA; Univ Wisconsin, Dept Plant Pathol, Madison, WI 53706 USA; Univ Wisconsin, Women Sci & Engn Leadership Inst, Madison, WI USA; Syracuse Univ, Syracuse, NY 13244 USA; Univ Wisconsin, Dept Med, Madison, WI USA; Univ Wisconsin, Ctr Womens Hlth Res, Madison, WI USA; Univ Calif Santa Cruz, Santa Cruz, CA 95064 USA; Harvard Univ, Cambridge, MA 02138 USA; Univ Calif Davis, Davis, CA 95616 USA; Georgia Inst Technol, Ivan Allen Coll Liberal Arts, Atlanta, GA 30332 USA; Univ Miami, Coral Gables, FL 33124 USA	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Syracuse University; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Santa Cruz; Harvard University; University of California System; University of California Davis; University System of Georgia; Georgia Institute of Technology; University of Miami	Handelsman, J (corresponding author), Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA.	joh@plantpath.wisc.edu						[Anonymous], 1985, ADV GROUP PROCESSES; Dovidio JF, 2000, PSYCHOL SCI, V11, P315, DOI 10.1111/1467-9280.00262; Fox MF, 2003, EQUAL RITES, UNEQUAL OUTCOMES: WOMEN IN AMERICAN RESEARCH UNIVERSITIES, P91; Goldin C, 2000, AM ECON REV, V90, P715, DOI 10.1257/aer.90.4.715; MARTELL RF, 1991, J APPL SOC PSYCHOL, V21, P23; McLeod PL, 1996, SMALL GR RES, V27, P248, DOI 10.1177/1046496496272003; Milem JF., 2003, COMPELLING INTEREST, P126, DOI [10.1515/9780804764537-009, DOI 10.1515/9780804764537-009]; Miner-Rubino K, 2004, J OCCUP HEALTH PSYCH, V9, P107, DOI 10.1037/1076-8998.9.2.107; Nelson Donna J., 2004, NELSON DIVERSITY SUR; Park SM, 1996, J HIGH EDUC, V67, P46, DOI 10.2307/2943903; Rosser S., 2004, SCI GLASS CEILING AC; SEYMOUR E, 1997, TALKING LEAVING UNDE; SPELKE ES, 2005, SEX DIFFERENCES INTR; Trix F, 2003, DISCOURSE SOC, V14, P191, DOI 10.1177/0957926503014002277; Valian V., 1999, WHY SO SLOW ADV WOME, V1 1st; Wenneras C, 1997, NATURE, V387, P341, DOI 10.1038/387341a0	16	133	134	0	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 19	2005	309	5738					1190	1191		10.1126/science.1113252	http://dx.doi.org/10.1126/science.1113252			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	957TE	16109868				2022-12-28	WOS:000231395400028
J	Windecker, S; Remondino, A; Eberli, FR; Juni, P; Raber, L; Wenaweser, P; Togni, M; Billinger, M; Tuller, D; Seiler, C; Roffi, M; Corti, R; Sutsch, G; Maier, W; Luscher, T; Hess, OM; Egger, M; Meier, B				Windecker, S; Remondino, A; Eberli, FR; Juni, P; Raber, L; Wenaweser, P; Togni, M; Billinger, M; Tuller, D; Seiler, C; Roffi, M; Corti, R; Sutsch, G; Maier, W; Luscher, T; Hess, OM; Egger, M; Meier, B			Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIERARCHICAL BAYESIAN METAANALYSIS; RANDOMIZED CONTROLLED-TRIAL; BALLOON ANGIOPLASTY; ARTERY-DISEASE; CLINICAL-TRIALS; SLOW-RELEASE; DOUBLE-BLIND; RESTENOSIS; LESIONS; IMPLANTATION	Background: Sirolimus-eluting stents and paclitaxel-eluting stents, as compared with bare-metal stents, reduce the risk of restenosis. It is unclear whether there are differences in safety and efficacy between the two types of drug-eluting stents. Methods: We conducted a randomized, controlled, single-blind trial comparing sirolimus-eluting stents with paclitaxel-eluting stents in 1012 patients undergoing percutaneous coronary intervention. The primary end point was a composite of major adverse cardiac events (death from cardiac causes, myocardial infarction, and ischemia-driven revascularization of the target lesion) by nine months. Follow-up angiography was completed in 540 of 1012 patients (53.4 percent). Results: The two groups had similar baseline clinical and angiographic characteristics. The rate of major adverse cardiac events at nine months was 6.2 percent in the sirolimus-stent group and 10.8 percent in the paclitaxel-stent group (hazard ratio, 0.56; 95 percent confidence interval, 0.36 to 0.86; P=0.009). The difference was driven by a lower rate of target-lesion revascularization in the sirolimus-stent group than in the paclitaxel-stent group (4.8 percent vs. 8.3 percent; hazard ratio, 0.56; 95 percent confidence interval, 0.34 to 0.93; P=0.03). Rates of death from cardiac causes were 0.6 percent in the sirolimus-stent group and 1.6 percent in the paclitaxel-stent group (P=0.15); the rates of myocardial infarction were 2.8 percent and 3.5 percent, respectively (P=0.49); and the rates of angiographic restenosis were 6.6 percent and 11.7 percent, respectively (P=0.02). Conclusions: As compared with paclitaxel-eluting stents, the use of sirolimus-eluting stents results in fewer major adverse cardiac events, primarily by decreasing the rates of clinical and angiographic restenosis.	Univ Hosp Bern, Dept Cardiol, CH-3010 Bern, Switzerland; Univ Hosp Bern, Dept Social & Prevent Med, CH-3010 Bern, Switzerland; Univ Hosp Bern, Dept Cardiol, CH-3010 Bern, Switzerland; Univ Bristol, MRC, Hlth Serv Res Collaborat, Bristol, Avon, England	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; University of Bristol	Windecker, S (corresponding author), Univ Hosp Bern, Dept Cardiol, CH-3010 Bern, Switzerland.	stephan.windecker@insel.ch	Juni, Peter/Q-8700-2016; Wenaweser, Peter/AAN-7009-2021	Juni, Peter/0000-0002-5985-0670; Egger, Matthias/0000-0001-7462-5132				Al Suwaidi J, 2000, JAMA-J AM MED ASSOC, V284, P1828, DOI 10.1001/jama.284.14.1828; Ardissino D, 2004, JAMA-J AM MED ASSOC, V292, P2727, DOI 10.1001/jama.292.22.2727; Brophy JM, 2003, ANN INTERN MED, V138, P777, DOI 10.7326/0003-4819-138-10-200305200-00005; Colombo A, 2003, CIRCULATION, V108, P788, DOI 10.1161/01.CIR.0000086926.62288.A6; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Gershlick A, 2004, CIRCULATION, V109, P487, DOI 10.1161/01.CIR.0000109694.58299.A0; Goy JJ, 2005, J AM COLL CARDIOL, V45, P308, DOI 10.1016/j.jacc.2004.10.062; Grube E, 2003, CIRCULATION, V107, P38, DOI 10.1161/01.CIR.0000047700.58683.A1; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Kastrati A, 2005, JAMA-J AM MED ASSOC, V293, P165, DOI 10.1001/jama.293.2.165; Kimura T, 1996, NEW ENGL J MED, V334, P561, DOI 10.1056/NEJM199602293340903; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; Moses JW, 2003, NEW ENGL J MED, V349, P1315, DOI 10.1056/NEJMoa035071; Park SJ, 2003, NEW ENGL J MED, V348, P1537, DOI 10.1056/NEJMoa021007; Schampaert E, 2004, J AM COLL CARDIOL, V43, P1110, DOI 10.1016/j.jacc.2004.01.024; Schofer J, 2003, LANCET, V362, P1093, DOI 10.1016/S0140-6736(03)14462-5; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201; Stone GW, 2004, NEW ENGL J MED, V350, P221, DOI 10.1056/NEJMoa032441; Togni M, 2004, CIRCULATION, V110, P135, DOI 10.1161/01.CIR.0000134956.96543.4F; Wenaweser P, 2005, EUR HEART J, V26, P1180, DOI 10.1093/eurheartj/ehi135	22	447	480	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 18	2005	353	7					653	662		10.1056/NEJMoa051175	http://dx.doi.org/10.1056/NEJMoa051175			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955UW	16105989				2022-12-28	WOS:000231254100003
J	Potter, JD				Potter, JD			Vegetables, fruit, and cancer	LANCET			English	Editorial Material							IOWA-WOMENS-HEALTH; LUNG-CANCER; COLON-CANCER; BREAST-CANCER; VITAMIN-C; PROSPECTIVE COHORT; GASTRIC-CANCER; DIETARY FIBER; FOLLOW-UP; RISK		Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Potter, JD (corresponding author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA.	jpotter@fhcrc.org		Potter, John/0000-0001-5439-1500				Collins FS, 2004, NATURE, V429, P475, DOI 10.1038/nature02628; Feskanich D, 2000, JNCI-J NATL CANCER I, V92, P1812, DOI 10.1093/jnci/92.22.1812; Flood A, 2002, AM J CLIN NUTR, V75, P936, DOI 10.1093/ajcn/75.5.936; FRASER GE, 1991, AM J EPIDEMIOL, V133, P683, DOI 10.1093/oxfordjournals.aje.a115943; GIOVANNUCCI E, 1994, ANN MED, V26, P443, DOI 10.3109/07853899409148367; Giovannucci E, 1998, CANCER RES, V58, P442; GIOVANNUCCI E, 1994, CANCER RES, V54, P2390; Holmes MD, 1999, JAMA-J AM MED ASSOC, V281, P914, DOI 10.1001/jama.281.10.914; Hung HC, 2004, JNCI-J NATL CANCER I, V96, P1577, DOI 10.1093/jnci/djh296; HUNTER DJ, 1993, NEW ENGL J MED, V329, P234, DOI 10.1056/NEJM199307223290403; Joshipura KJ, 1999, JAMA-J AM MED ASSOC, V282, P1233, DOI 10.1001/jama.282.13.1233; Joshipura KJ, 2001, ANN INTERN MED, V134, P1106, DOI 10.7326/0003-4819-134-12-200106190-00010; KATO I, 1992, JPN J CANCER RES, V83, P568, DOI 10.1111/j.1349-7006.1992.tb00127.x; Kobayashi M, 2002, INT J CANCER, V102, P39, DOI 10.1002/ijc.10659; KROMHOUT D, 1987, AM J CLIN NUTR, V45, P1361, DOI 10.1093/ajcn/45.5.1361; KVALE G, 1983, INT J CANCER, V31, P397, DOI 10.1002/ijc.2910310402; Liu Y, 2004, CANCER CAUSE CONTROL, V15, P349, DOI 10.1023/B:CACO.0000027507.22124.20; Michaud DS, 1999, JNCI-J NATL CANCER I, V91, P605, DOI 10.1093/jnci/91.7.605; Michels KB, 2000, JNCI-J NATL CANCER I, V92, P1740, DOI 10.1093/jnci/92.21.1740; Miller AB, 2004, INT J CANCER, V108, P269, DOI 10.1002/ijc.11559; NOMURA AMY, 1995, JPN J CANCER RES, V86, P916, DOI 10.1111/j.1349-7006.1995.tb03001.x; POTTER JD, 1995, CANCER EPIDEM BIOMAR, V4, P319; Potter JD, 2004, CANCER EPIDEM BIOMAR, V13, P895; ROHAN TE, 1993, CANCER CAUSE CONTROL, V4, P29, DOI 10.1007/BF00051711; SHIBATA A, 1992, BRIT J CANCER, V66, P673, DOI 10.1038/bjc.1992.336; Slattery ML, 2000, J NATL CANCER I, V92, P1831, DOI 10.1093/jnci/92.22.1831; Smith-Warner SA, 2001, INT J CANCER, V92, P767, DOI 10.1002/1097-0215(20010601)92:5&lt;767::AID-IJC1247&gt;3.0.CO;2-0; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P325, DOI 10.1007/BF00051672; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P427, DOI 10.1007/BF00054304; STEINMETZ KA, 1994, AM J EPIDEMIOL, V139, P1; STEINMETZ KA, 1993, CANCER RES, V53, P536; Terry P, 2001, JNCI-J NATL CANCER I, V93, P525, DOI 10.1093/jnci/93.7.525; THUN MJ, 1992, JNCI-J NATL CANCER I, V84, P1491, DOI 10.1093/jnci/84.19.1491; Voorrips LE, 2000, AM J EPIDEMIOL, V152, P1081, DOI 10.1093/aje/152.11.1081; WANG LD, 1985, CHINESE MED J-PEKING, V98, P206; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; [World Cancer Research Fund American Institute for Cancer Research], 1997, FOOD NUTR PREV CANC; Zhang SM, 1999, JNCI-J NATL CANCER I, V91, P547, DOI 10.1093/jnci/91.6.547; Zhang SMM, 2000, CANCER EPIDEM BIOMAR, V9, P477	40	47	51	4	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 13	2005	366	9485					527	530		10.1016/S0140-6736(05)67077-8	http://dx.doi.org/10.1016/S0140-6736(05)67077-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955LL	16099275				2022-12-28	WOS:000231227300007
J	Allenby, B; Fink, J				Allenby, B; Fink, J			Toward inherently secure and resilient societies	SCIENCE			English	Article								Recent years have seen a number of challenges to social stability and order, ranging from terrorist attacks and natural disasters to epidemics such as AIDS and SARS. Such challenges have generated specific policy responses, such as enhanced security at transportation hubs and planned deployment of a global tsunami detection network. However, the range of challenges and the practical impossibility of adequately addressing each in turn argue for adoption of a more comprehensive systems perspective. This should be based on the principle of enhancing social and economic resiliency as well as meeting security and emergency response needs and, to the extent possible, developing and implementing dual-use technologies that offer societal benefits even if anticipated disasters never occur.	Arizona State Univ, Dept Civil & Environm Engn, Tempe, AZ 85287 USA; Arizona State Univ, Off Vice President Res & Econ Affairs, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe	Allenby, B (corresponding author), Arizona State Univ, Dept Civil & Environm Engn, Tempe, AZ 85287 USA.	brad.allenby@asu.edu	Fink, Jonathan/AAF-7526-2020	Fink, Jonathan/0000-0003-2272-9751				*AARP, 2002, STAY CURV AARP WORK; ALLENBY B, 2003, IMPLEMENTING KNOWLED; ALLENBY BR, 2005, ENV QUAL MANAGE, V8, P3; Amin M., 2004, DIGITAL INFRASTRUCTU, P116; *AT T BEST PRACT, 2005, NETW CONT OV; Barabasi A. L., 2002, FORMULA UNIVERSAL LA; Castells M., 2000, RISE NETWORK SOC; Conference Board, 2002, VOIC EXP MAT WORK FU; Drucker P. F., 2002, MANAGING NEXT SOC; Edvinsson L., 1997, INTELLECTUAL CAPITAL; FINK J, AM GEOPHYSICAL UNION, V56, P413; Gartner Group, 2000, R110910 GARTN GROUP; MOSS M, 2004, DIGITAL INFRASTRUCTU, P141; *NAT RES COUNC, 1994, INF TECHN SERV SOC; National Research Council, 2003, CIT TRANSF; ROITZ J, COMMUNICATION; ROITZ J, 2005, LESSONS LEARNED NETW; US The White House, 2003, NAT STRAT SEC CYB; Vale L. J., 2005, RESILIENT CITY; ZIMMERMAN R, 2004, DIGITAL INFRASTRUCTU; 2005, ECONOMIST       0625, P57	21	204	213	7	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 12	2005	309	5737					1034	1036		10.1126/science.1111534	http://dx.doi.org/10.1126/science.1111534			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955MN	16099973				2022-12-28	WOS:000231230100033
J	Kung, C				Kung, C			A possible unifying principle for mechanosensation	NATURE			English	Review							POLYCYSTIC KIDNEY-DISEASE; TOUCH RECEPTOR NEURONS; ESCHERICHIA-COLI; ION-CHANNEL; LARGE-CONDUCTANCE; CATION CHANNEL; TRP CHANNELS; LATERAL PRESSURES; GATING MECHANISM; MICE LACKING	Of Aristotle's five senses, we know that sight, smell and much of taste are initiated by ligands binding to G-protein-coupled receptors; however, the mechanical sensations of touch and hearing remain without a clear understanding of their molecular basis. Recently, the relevant force-transducing molecules - the mechanosensitive ion channels - have been identified. Such channel proteins purified from bacteria sense forces from the lipid bilayer in the absence of other proteins. Recent evidence has shown that lipids are also intimately involved in opening and closing the mechanosensitive channels of fungal, plant and animal species.	Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA; Univ Wisconsin, Dept Genet, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Kung, C (corresponding author), Univ Wisconsin, Mol Biol Lab, 1525 Linden Dr, Madison, WI 53706 USA.	ckung@wisc.edu						APOSTLE HG, 1981, ARISTOTLES SOUL ANIM, P42; Bandell M, 2004, NEURON, V41, P849, DOI 10.1016/S0896-6273(04)00150-3; Barr MM, 1999, NATURE, V401, P386, DOI 10.1038/43916; Bass RB, 2002, SCIENCE, V298, P1582, DOI 10.1126/science.1077945; BERRIER C, 1992, EUR J BIOCHEM, V206, P559, DOI 10.1111/j.1432-1033.1992.tb16960.x; Bianchi L, 2004, NAT NEUROSCI, V7, P1337, DOI 10.1038/nn1347; Birder LA, 2002, NAT NEUROSCI, V5, P856, DOI 10.1038/nn902; Blount P, 2003, NEURON, V37, P731, DOI 10.1016/S0896-6273(03)00122-3; Blount P, 1996, EMBO J, V15, P4798, DOI 10.1002/j.1460-2075.1996.tb00860.x; BRITTEN RJ, 1962, BACTERIOL REV, V26, P292, DOI 10.1128/MMBR.26.3.292-335.1962; Cantor RS, 1997, J PHYS CHEM B, V101, P1723, DOI 10.1021/jp963911x; Cantor RS, 1998, TOXICOL LETT, V101, P451, DOI 10.1016/S0378-4274(98)00220-3; Cantor RS, 1999, CHEM PHYS LIPIDS, V101, P45, DOI 10.1016/S0009-3084(99)00054-7; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Chelur DS, 2002, NATURE, V420, P669, DOI 10.1038/nature01205; Chemin J, 2005, EMBO J, V24, P44, DOI 10.1038/sj.emboj.7600494; Chemin J, 2005, J BIOL CHEM, V280, P4415, DOI 10.1074/jbc.M408246200; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Colbert HA, 1997, J NEUROSCI, V17, P8259; Corey DP, 2004, NATURE, V432, P723, DOI 10.1038/nature03066; Corey DP, 2004, NATURE, V428, P901, DOI 10.1038/428901a; Corey DP, 2003, NEURON, V39, P585, DOI 10.1016/S0896-6273(03)00505-1; DELCOUR AH, 1989, BIOPHYS J, V56, P631, DOI 10.1016/S0006-3495(89)82710-9; Denis V, 2002, J CELL BIOL, V156, P29, DOI 10.1083/jcb.200111004; Di Palma F, 2002, P NATL ACAD SCI USA, V99, P14994, DOI 10.1073/pnas.222425399; Emtage L, 2004, NEURON, V44, P795, DOI 10.1016/j.neuron.2004.11.010; Erler I, 2004, J BIOL CHEM, V279, P34456, DOI 10.1074/jbc.M404778200; Ermakov YA, 2001, BIOPHYS J, V80, P1851, DOI 10.1016/S0006-3495(01)76155-3; Ernstrom GG, 2002, ANNU REV GENET, V36, P411, DOI 10.1146/annurev.genet.36.061802.101708; Gao X, 2003, J BIOL CHEM, V278, P27129, DOI 10.1074/jbc.M302517200; Gong ZF, 2004, J NEUROSCI, V24, P9059, DOI 10.1523/JNEUROSCI.1645-04.2004; Goodman MB, 2003, ANNU REV PHYSIOL, V65, P429, DOI 10.1146/annurev.physiol.65.092101.142659; Goodman MB, 2002, NATURE, V415, P1039, DOI 10.1038/4151039a; GUHARAY F, 1984, J PHYSIOL-LONDON, V352, P685, DOI 10.1113/jphysiol.1984.sp015317; Gullingsrud J, 2003, BIOPHYS J, V85, P2087, DOI 10.1016/S0006-3495(03)74637-2; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; Hamill OP, 1996, PHARMACOL REV, V48, P231; Hirono M, 2004, NEURON, V44, P309, DOI 10.1016/j.neuron.2004.09.020; Howard J, 2004, CURR BIOL, V14, pR224, DOI 10.1016/j.cub.2004.02.050; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Jordt SE, 2004, NATURE, V427, P260, DOI 10.1038/nature02282; Kahn-Kirby AH, 2004, CELL, V119, P889, DOI 10.1016/j.cell.2004.11.005; Kim J, 2003, NATURE, V424, P81, DOI 10.1038/nature01733; KUNG C, 1990, P145; Kung C., 1990, EVOLUTION 1 NERVOUS, P203; Levina N, 1999, EMBO J, V18, P1730, DOI 10.1093/emboj/18.7.1730; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Liedtke W, 2003, P NATL ACAD SCI USA, V100, P14531, DOI 10.1073/pnas.2235619100; Lindahl E, 2000, J CHEM PHYS, V113, P3882, DOI 10.1063/1.1287423; Lundbaek JA, 1997, BIOCHEMISTRY-US, V36, P5695, DOI 10.1021/bi9619841; Maingret F, 2000, J BIOL CHEM, V275, P10128, DOI 10.1074/jbc.275.14.10128; Maroto R, 2005, NAT CELL BIOL, V7, P179, DOI 10.1038/ncb1218; MARTINAC B, 1990, NATURE, V348, P261, DOI 10.1038/348261a0; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; MARTINI B, 1992, Acta Ophthalmologica Supplementum, P3; Maurer JA, 2003, J BIOL CHEM, V278, P21076, DOI 10.1074/jbc.M302892200; MINKE B, 1975, NATURE, V258, P84, DOI 10.1038/258084a0; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 1998, CURR OPIN NEUROBIOL, V8, P389, DOI 10.1016/S0959-4388(98)80066-4; MORRIS CE, 1991, SCIENCE, V251, P1246, DOI 10.1126/science.1706535; O'Hagan R, 2005, NAT NEUROSCI, V8, P43, DOI 10.1038/nn1362; Ou XR, 1998, P NATL ACAD SCI USA, V95, P11471, DOI 10.1073/pnas.95.19.11471; Palmer CP, 2001, P NATL ACAD SCI USA, V98, P7801, DOI 10.1073/pnas.141036198; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; Patel AJ, 2001, ANESTHESIOLOGY, V95, P1013, DOI 10.1097/00000542-200110000-00034; Patel AJ, 2001, CURR OPIN CELL BIOL, V13, P422, DOI 10.1016/S0955-0674(00)00231-3; Perozo E, 2002, NAT STRUCT BIOL, V9, P696, DOI 10.1038/nsb827; Perozo E, 2002, NATURE, V418, P942, DOI 10.1038/nature00992; SHEETZ MP, 1974, P NATL ACAD SCI USA, V71, P4457, DOI 10.1073/pnas.71.11.4457; Sidi S, 2003, SCIENCE, V301, P96, DOI 10.1126/science.1084370; Siemens J, 2004, NATURE, V428, P950, DOI 10.1038/nature02483; Sollner C, 2004, NATURE, V428, P955, DOI 10.1038/nature02484; Story GM, 2003, CELL, V112, P819, DOI 10.1016/S0092-8674(03)00158-2; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Suchyna TM, 2004, NATURE, V430, P235, DOI 10.1038/nature02743; Suchyna TM, 2001, J GEN PHYSIOL, V117, P371; Sukharev S, 2001, NATURE, V409, P720, DOI 10.1038/35055559; SUKHAREV S, 2004, SCI STKE, DOI DOI 10.1126/STKE.2332004EG7; Sukharev Sergei I., 1994, Methods (Orlando), V6, P51, DOI 10.1006/meth.1994.1007; SUKHAREV SI, 1993, BIOPHYS J, V65, P177, DOI 10.1016/S0006-3495(93)81044-0; Sukharev SI, 1999, J GEN PHYSIOL, V113, P525, DOI 10.1085/jgp.113.4.525; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; Suzuki M, 2003, J BIOL CHEM, V278, P22664, DOI 10.1074/jbc.M302561200; Tobin DM, 2002, NEURON, V35, P307, DOI 10.1016/S0896-6273(02)00757-2; Tracey WD, 2003, CELL, V113, P261, DOI 10.1016/S0092-8674(03)00272-1; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Voets T, 2004, NATURE, V430, P748, DOI 10.1038/nature02732; Vriens J, 2004, P NATL ACAD SCI USA, V101, P396, DOI 10.1073/pnas.0303329101; Walker RG, 2000, SCIENCE, V287, P2229, DOI 10.1126/science.287.5461.2229; Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807; Wiggins P, 2004, P NATL ACAD SCI USA, V101, P4071, DOI 10.1073/pnas.0307804101; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333; Zhang SF, 2004, CURR BIOL, V14, P1888, DOI 10.1016/j.cub.2004.10.030; Zhang Y, 2000, J PHYSIOL-LONDON, V523, P117, DOI 10.1111/j.1469-7793.2000.t01-1-00117.x; Zhang Y, 2000, J PHYSIOL-LONDON, V523, P101, DOI 10.1111/j.1469-7793.2000.00101.x; Zhou XL, 2005, EUR BIOPHYS J BIOPHY, V34, P413, DOI 10.1007/s00249-005-0465-0; Zhou XL, 2003, P NATL ACAD SCI USA, V100, P7105, DOI 10.1073/pnas.1230540100	100	457	481	1	138	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 4	2005	436	7051					647	654		10.1038/nature03896	http://dx.doi.org/10.1038/nature03896			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	951XA	16079835				2022-12-28	WOS:000230964500032
J	Michaloglou, C; Vredeveld, LCW; Soengas, MS; Denoyelle, C; Kuilman, T; van der Horst, CMAM; Majoor, DM; Shay, JW; Mooi, WJ; Peeper, DS				Michaloglou, C; Vredeveld, LCW; Soengas, MS; Denoyelle, C; Kuilman, T; van der Horst, CMAM; Majoor, DM; Shay, JW; Mooi, WJ; Peeper, DS			BRAF(E600)-associated senescence-like cell cycle arrest of human naevi	NATURE			English	Article							MALIGNANT-MELANOMA; TUMOR SUPPRESSION; BRAF MUTATIONS; CANCER; P53; P16; TRANSFORMATION; ONCOGENE; GENES	Most normal mammalian cells have a finite lifespan(1), thought to constitute a protective mechanism against unlimited proliferation(2-4). This phenomenon, called senescence, is driven by telomere attrition, which triggers the induction of tumour suppressors including p16(INK4a) (ref. 5). In cultured cells, senescence can be elicited prematurely by oncogenes(6); however, whether such oncogene-induced senescence represents a physiological process has long been debated. Human naevi ( moles) are benign tumours of melanocytes that frequently harbour oncogenic mutations ( predominantly V600E, where valine is substituted for glutamic acid) in BRAF(7), a protein kinase and downstream effector of Ras. Nonetheless, naevi typically remain in a growth-arrested state for decades and only rarely progress into malignancy (melanoma)(8-10). This raises the question of whether naevi undergo BRAF(V600E)- induced senescence. Here we show that sustained BRAF(V600E) expression in human melanocytes induces cell cycle arrest, which is accompanied by the induction of both p16(INK4a) and senescence- associated acidic beta-galactosidase (SA-beta-Gal) activity, a commonly used senescence marker. Validating these results in vivo, congenital naevi are invariably positive for SA-beta-Gal, demonstrating the presence of this classical senescence-associated marker in a largely growth-arrested, neoplastic human lesion. In growth-arrested melanocytes, both in vitro and in situ, we observed a marked mosaic induction of p16(INK4a), suggesting that factors other than p16(INK4a) contribute to protection against BRAF(V600E)- driven proliferation. Naevi do not appear to suffer from telomere attrition, arguing in favour of an active oncogene-driven senescence process, rather than a loss of replicative potential. Thus, both in vitro and in vivo, BRAF(V600E)-expressing melanocytes display classical hallmarks of senescence, suggesting that oncogene-induced senescence represents a genuine protective physiological process.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Pathol, NL-1066 CX Amsterdam, Netherlands; Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Amsterdam, Acad Med Ctr, Dept Plast Reconstruct & Hand Surg, NL-1100 AZ Amsterdam, Netherlands; Univ Texas, SW Med Ctr, Dept Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Harold Simmons Canc Ctr, Dallas, TX 75390 USA; Free Univ Amsterdam, Med Ctr, Dept Pathol, NL-1081 HV Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Amsterdam; Academic Medical Center Amsterdam; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Vrije Universiteit Amsterdam	Peeper, DS (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	wj.mooi@vumc.nl; d.peeper@nki.nl	Soengas, Maria S/H-6455-2015; Shay, Jerry W/F-7878-2011; Peeper, Daniel/AAA-2430-2020; DENOYELLE, Christophe CD/K-6205-2015	Soengas, Maria S/0000-0003-0612-6299; DENOYELLE, Christophe CD/0000-0001-7153-8826; Kuilman, Thomas/0000-0001-6724-6767				Bandyopadhyay D, 2001, EXP GERONTOL, V36, P1265, DOI 10.1016/S0531-5565(01)00098-5; Bastian BC, 2003, ONCOGENE, V22, P3081, DOI 10.1038/sj.onc.1206463; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Bennett DC, 2003, ONCOGENE, V22, P3063, DOI 10.1038/sj.onc.1206446; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Chin L, 1998, GENE DEV, V12, P3467, DOI 10.1101/gad.12.22.3467; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Hingorani SR, 2003, CANCER RES, V63, P5198; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KUWATA T, 1993, VIRCHOWS ARCH A, V423, P359, DOI 10.1007/BF01607148; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Mathon NE, 2001, NAT REV CANCER, V1, P203, DOI 10.1038/35106045; Miracco C, 2002, BRIT J DERMATOL, V146, P399, DOI 10.1046/j.1365-2133.2002.04600.x; MOOI WJ, 1992, BIOPSY PATHOLOGY MEL, P56; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Peeper DS, 2002, NAT CELL BIOL, V4, P148, DOI 10.1038/ncb742; PEEPER DS, 2002, HISTOPATHOLOGY, V41, pS139; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Robinson WA, 1998, MELANOMA RES, V8, P499, DOI 10.1097/00008390-199812000-00004; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharpless NE, 2003, ONCOGENE, V22, P3092, DOI 10.1038/sj.onc.1206461; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; Wang YL, 1996, BRIT J DERMATOL, V134, P269; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	30	1592	1641	4	130	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 4	2005	436	7051					720	724		10.1038/nature03890	http://dx.doi.org/10.1038/nature03890			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	951XA	16079850	Green Published			2022-12-28	WOS:000230964500048
J	Oransky, I				Oransky, I			Joseph Bogen - Obituary	LANCET			English	Biographical-Item												ivan-oransky@erols.com							0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 4	2005	365	9475					1922	1922		10.1016/S0140-6736(05)66649-4	http://dx.doi.org/10.1016/S0140-6736(05)66649-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932XJ	16121410				2022-12-28	WOS:000229587800017
J	Lee, MG; Wynder, C; Cooch, N; Shiekhattar, R				Lee, MG; Wynder, C; Cooch, N; Shiekhattar, R			An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation	NATURE			English	Article							SANT DOMAIN; GENE-EXPRESSION; NEURONAL GENES; N-COR; COMPLEX; COMPONENT; OXIDASE; REPRESSION; SMRT; SNF	We have previously described a multiprotein complex termed the BHC or BRAF - HDAC complex, which is required for the repression of neuronal-specific genes(1). We have shown that the BHC complex is recruited by a neuronal silencer, REST (RE1-silencing transcription factor), and mediates the repression of REST-responsive genes1. BHC is a multiprotein complex consisting of two enzymatic activities: a histone deacetylase (HDAC1 or 2) and a recently described histone demethylase (BHC110, also known as LSD1 or AOF2)(1-3). Here we show that BHC110-containing complexes show a nearly fivefold increase in demethylation of histone H3 lysine 4 (H3K4) compared to recombinant BHC110. Furthermore, recombinant BHC110 is unable to demethylate H3K4 on nucleosomes, but BHC110-containing complexes readily demethylate nucleosomes. In vitro reconstitution of the BHC complex using recombinant subunits reveals an essential role for the REST corepressor CoREST, not only in stimulating demethylation on core histones but also promoting demethylation of nucleosomal substrates. We find that nucleosomal demethylation is the result of CoREST enhancing the association between BHC110 and nucleosomes. Depletion of CoREST in in vivo cell culture results in de-repression of REST-responsive gene expression and increased methylation of H3K4. Together, these results highlight an essential role for CoREST in demethylation of H3K4 both in vitro and in vivo.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	The Wistar Institute	Shiekhattar, R (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	shiekhattar@wistar.org						Aasland R, 1996, TRENDS BIOCHEM SCI, V21, P87, DOI 10.1016/S0968-0004(96)30009-1; Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3; Barak O, 2003, EMBO J, V22, P6089, DOI 10.1093/emboj/cdg582; Battaglioli E, 2002, J BIOL CHEM, V277, P41038, DOI 10.1074/jbc.M205691200; Binda C, 1999, STRUCTURE, V7, P265, DOI 10.1016/S0969-2126(99)80037-9; Binda C, 2003, P NATL ACAD SCI USA, V100, P9750, DOI 10.1073/pnas.1633804100; Boyer LA, 2002, MOL CELL, V10, P935, DOI 10.1016/S1097-2765(02)00634-2; Dallman JE, 2004, J NEUROSCI, V24, P7186, DOI 10.1523/JNEUROSCI.0238-04.2004; Ding ZH, 2003, MOL CELL BIOL, V23, P250, DOI 10.1128/MCB.23.1.250-258.2003; Dong YS, 2003, MOL CELL, V12, P1087, DOI 10.1016/S1097-2765(03)00424-6; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Grimes JA, 2000, J BIOL CHEM, V275, P9461, DOI 10.1074/jbc.275.13.9461; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599; Hakimi MA, 2003, J BIOL CHEM, V278, P7234, DOI 10.1074/jbc.M208992200; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Sterner DE, 2002, J BIOL CHEM, V277, P8178, DOI 10.1074/jbc.M108601200; Yamagoe S, 2003, MOL CELL BIOL, V23, P1025, DOI 10.1128/MCB.23.3.1025-1033.2003; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454; Yu JJ, 2003, EMBO J, V22, P3403, DOI 10.1093/emboj/cdg326	23	578	616	3	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 15	2005	437	7057					432	435		10.1038/nature04021	http://dx.doi.org/10.1038/nature04021			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	964AS	16079794				2022-12-28	WOS:000231849100058
J	Taylor, C; Graham, J; Potts, HW; Richards, MA; Ramirez, AJ				Taylor, C; Graham, J; Potts, HW; Richards, MA; Ramirez, AJ			Changes in mental health of UK hospital consultants since the mid-1990s	LANCET			English	Article							NHS	We assessed changes in the mental health of UK hospital consultants from five specialties, on the basis of surveys done in 1994 (880 participants) and 2002 (1308 participants). The proportion of consultants with psychiatric morbidity rose from 27% (235) in 1994 to 32% (414) in 2002. The prevalence of emotional exhaustion increased from 32% (284) in 1994 to 41% (526) in 2002. Multivariate analyses showed that increased job stress without a comparable increase in job satisfaction accounted for the decline in mental health, which was especially marked in clinical and surgical oncologists. Action is needed to improve the working lives of consultants.	Kings Coll London, Inst Psychiat, Canc Res UK London Psychosocial Grp, London SE1 7EH, England; UCL, Ctr Hlth Informat & Multiprofess Educ, London, England	University of London; King's College London; University of London; University College London	Ramirez, AJ (corresponding author), Kings Coll London, Inst Psychiat, Canc Res UK London Psychosocial Grp, St Thomas Campus, London SE1 7EH, England.	amanda-jane.ramirez@kcl.ac.uk	Potts, Henry WW/B-9597-2008	Potts, Henry WW/0000-0002-6200-8804				Aasland OG, 2001, SOC SCI MED, V52, P259, DOI 10.1016/S0277-9536(00)00226-4; *DEP HLTH, 1994, MED DENT WORKF CENS; Goldberg D.P., 1988, USERS GUIDE GEN HLTH; Maslach C, 2016, MASLACH BURNOUT INVE; Pattani S, 2001, BRIT MED J, V322, P208, DOI 10.1136/bmj.322.7280.208; Ramirez AJ, 1996, LANCET, V347, P724, DOI 10.1016/S0140-6736(96)90077-X; *U ESS, 1994, BRIT HOUS PAN SURV; Wall TD, 1997, BRIT J PSYCHIAT, V171, P519, DOI 10.1192/bjp.171.6.519	8	124	127	1	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 27	2005	366	9487					742	744		10.1016/S0140-6736(05)67178-4	http://dx.doi.org/10.1016/S0140-6736(05)67178-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	958UV	16125591				2022-12-28	WOS:000231474600030
J	Beckmann, K; Grskovic, M; Gebauer, F; Hentze, MW				Beckmann, K; Grskovic, M; Gebauer, F; Hentze, MW			A dual inhibitory mechanism restricts msl-2 mRNA translation for dosage compensation in Drosophila	CELL			English	Article							SEX-LETHAL; BINDING-PROTEIN; INITIATION-FACTORS; RIBOSOMAL-SUBUNIT; IN-VITRO; OSKAR; GENE; LOCALIZATION; RECRUITMENT; COMPLEX	Drosophila MSL-2 is the limiting component of the dosage compensation complex. Female flies must inhibit msl-2 mRNA translation for survival, and this inhibition is mediated by Sex-lethal (SXL) binding to sites in both the 5' and the 3' untranslated regions (UTRs). Here, we uncover the mechanism by which SXL achieves tight control of translation initiation. SXL binding to the 3'UTR regulatory region inhibits the recruitment of 43S ribosomal preinitiation complexes to the mRNA. Ribosomal complexes escaping this block and binding to the 5' end of the mRNA are challenged by SXL bound to the 5'UTR, which interferes with scanning to the downstream initiation codon of the mRNA. This failsafe mechanism thus forms the molecular basis of a critical step in dosage compensation. The results also elucidate a two step principle of translational control via multiple regulatory sites within an mRNA.	European Mol Biol Lab, Gene Express Unit, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Hentze, MW (corresponding author), European Mol Biol Lab, Gene Express Unit, Meyerhofstr 1, D-69117 Heidelberg, Germany.	hentze@embl.de	Grskovic, Marica/AAJ-4080-2021; Hentze, Matthias W/V-3980-2017; Gebauer, Fatima/E-7725-2015	Hentze, Matthias W/0000-0002-4023-7876; Gebauer, Fatima/0000-0001-7563-0013				ANTHONY DD, 1992, J BIOL CHEM, V267, P1554; BASHAW GJ, 1995, DEVELOPMENT, V121, P3245; Bashaw GJ, 1997, CELL, V89, P789, DOI 10.1016/S0092-8674(00)80262-7; Braat AK, 2004, DEV CELL, V7, P125, DOI 10.1016/j.devcel.2004.06.009; Castagnetti S, 2000, DEVELOPMENT, V127, P1063; Clark IE, 2000, CURR BIOL, V10, P1311, DOI 10.1016/S0960-9822(00)00754-5; Deshpande G, 1996, MOL CELL BIOL, V16, P5036; Dong ZH, 1999, GENE, V237, P421, DOI 10.1016/S0378-1119(99)00303-0; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; Ferrandon D, 1997, EMBO J, V16, P1751, DOI 10.1093/emboj/16.7.1751; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; Forrest KM, 2004, DEVELOPMENT, V131, P5849, DOI 10.1242/dev.01460; Gaba A, 2001, EMBO J, V20, P6453, DOI 10.1093/emboj/20.22.6453; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Gebauer F, 2003, MOL CELL, V11, P1397, DOI 10.1016/S1097-2765(03)00176-X; Gebauer F, 1999, EMBO J, V18, P6146, DOI 10.1093/emboj/18.21.6146; Gebauer F, 1998, RNA, V4, P142; Gilfillan GD, 2004, FEBS LETT, V567, P8, DOI 10.1016/j.febslet.2004.03.110; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; Grskovic M, 2003, EMBO J, V22, P5571, DOI 10.1093/emboj/cdg539; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; KELLEY RL, 1995, CELL, V81, P867, DOI 10.1016/0092-8674(95)90007-1; Kelley RL, 1997, NATURE, V387, P195, DOI 10.1038/387195a0; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KIMHA J, 1995, CELL, V81, P403, DOI 10.1016/0092-8674(95)90393-3; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kuersten S, 2003, NAT REV GENET, V4, P626, DOI 10.1038/nrg1125; Mathews MB, 2000, COLD SPRING HARBOR M, V39, P1; Meise M, 1998, DEVELOPMENT, V125, P1487; Muckenthaler M, 1998, MOL CELL, V2, P383, DOI 10.1016/S1097-2765(00)80282-8; Nakamura A, 2004, DEV CELL, V6, P69, DOI 10.1016/S1534-5807(03)00400-3; Nelson MR, 2004, EMBO J, V23, P150, DOI 10.1038/sj.emboj.7600026; Ostareck DH, 2001, CELL, V104, P281, DOI 10.1016/S0092-8674(01)00212-4; Paraskeva E, 1999, MOL CELL BIOL, V19, P807; Pestova TV, 2000, NATURE, V403, P332, DOI 10.1038/35002118; Pestova TV, 1998, NATURE, V394, P854, DOI 10.1038/29703; PESTOVA TV, 2000, RIBOSOMAL SUBUNIT JO, P425; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; RONGO C, 1995, DEVELOPMENT, V121, P2737; Sakashita E, 1996, J BIOCHEM, V120, P1028; Samuels M, 1998, NUCLEIC ACIDS RES, V26, P2625, DOI 10.1093/nar/26.11.2625; SAMUELS ME, 1994, MOL CELL BIOL, V14, P4975, DOI 10.1128/MCB.14.7.4975; Sonenberg N, 2003, CURR OPIN STRUC BIOL, V13, P56, DOI 10.1016/S0959-440X(03)00009-5; STRIPECKE R, 1994, MOL CELL BIOL, V14, P5898, DOI 10.1128/MCB.14.9.5898; Wang JW, 1997, J BIOL CHEM, V272, P22227, DOI 10.1074/jbc.272.35.22227; Wickens M, 2000, COLD SPRING HARBOR M, V39, P295; Wilhelm JE, 2003, J CELL BIOL, V163, P1197, DOI 10.1083/jcb.200309088; Wilkie GS, 2003, TRENDS BIOCHEM SCI, V28, P182, DOI 10.1016/S0968-0004(03)00051-3; ZHOU SB, 1995, EMBO J, V14, P2884, DOI 10.1002/j.1460-2075.1995.tb07288.x	52	73	75	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 26	2005	122	4					529	540		10.1016/j.cell.2005.06.011	http://dx.doi.org/10.1016/j.cell.2005.06.011			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	959YI	16122421	hybrid			2022-12-28	WOS:000231555100009
J	Raghoebarsing, AA; Smolders, AJP; Schmid, MC; Rijpstra, WIC; Wolters-Arts, M; Derksen, J; Jetten, MSM; Schouten, S; Damste, JSS; Lamers, LPM; Roelofs, JGM; den Camp, HJMO; Strous, M				Raghoebarsing, AA; Smolders, AJP; Schmid, MC; Rijpstra, WIC; Wolters-Arts, M; Derksen, J; Jetten, MSM; Schouten, S; Damste, JSS; Lamers, LPM; Roelofs, JGM; den Camp, HJMO; Strous, M			Methanotrophic symbionts provide carbon for photosynthesis in peat bogs	NATURE			English	Article							ACIDOPHILIC BACTERIUM; MICROBIAL-POPULATIONS; BIOMARKER RECORD; GEN. NOV.; LIPIDS; GROUNDWATER; SPHAGNUM	Wetlands are the largest natural source of atmospheric methane(1), the second most important greenhouse gas(2). Methane flux to the atmosphere depends strongly on the climate(3); however, by far the largest part of the methane formed in wetland ecosystems is recycled and does not reach the atmosphere(4,5). The biogeochemical controls on the efficient oxidation of methane are still poorly understood. Here we show that submerged Sphagnum mosses, the dominant plants in some of these habitats, consume methane through symbiosis with partly endophytic methanotrophic bacteria, leading to highly effective in situ methane recycling. Molecular probes revealed the presence of the bacteria in the hyaline cells of the plant and on stem leaves. Incubation with C-13-methane showed rapid in situ oxidation by these bacteria to carbon dioxide, which was subsequently fixed by Sphagnum, as shown by incorporation of C-13-methane into plant sterols. In this way, methane acts as a significant ( 10 - 15%) carbon source for Sphagnum. The symbiosis explains both the efficient recycling of methane and the high organic carbon burial in these wetland ecosystems.	Radboud Univ Nijmegen, Dept Aquat Ecol & Environm Biol, NL-6525 ED Nijmegen, Netherlands; Radboud Univ Nijmegen, Dept Microbiol, NL-6525 ED Nijmegen, Netherlands; Radboud Univ Nijmegen, Dept Plant Cell Biol, NL-6525 ED Nijmegen, Netherlands; Netherlands Inst Sea Res, Dept Marine Biogeochem & Toxicol, NL-1790 AB Den Burg, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Utrecht University; Royal Netherlands Institute for Sea Research (NIOZ)	Smolders, AJP (corresponding author), Radboud Univ Nijmegen, Dept Aquat Ecol & Environm Biol, Toernooiveld 1, NL-6525 ED Nijmegen, Netherlands.	a.smolders@science.ru.nl; damste@nioz.nl	Camp, Huub J.M. Op den/F-5114-2011; Jetten, Mike/B-8834-2011; Schmid, Markus C/D-2669-2012; Smolders, Alfons J.P./H-2583-2012; Roelofs, Jan GM/C-1243-2011; Strous, Marc/B-4064-2017; Lamers, Leon P.M./A-8718-2012; Damste, Jaap S Sinninghe/F-6128-2011	Camp, Huub J.M. Op den/0000-0003-1990-9030; Jetten, Mike/0000-0002-4691-7039; Strous, Marc/0000-0001-9600-3828; Lamers, Leon P.M./0000-0003-3769-2154; Damste, Jaap S Sinninghe/0000-0002-8683-1854				AMANN RI, 1990, APPL ENVIRON MICROB, V56, P1919, DOI 10.1128/AEM.56.6.1919-1925.1990; Daims H, 1999, SYST APPL MICROBIOL, V22, P434, DOI 10.1016/S0723-2020(99)80053-8; Damste JSS, 2004, ORG GEOCHEM, V35, P561, DOI 10.1016/j.orrgeochem.2004.01.013; Dedysh SN, 1998, SCIENCE, V282, P281, DOI 10.1126/science.282.5387.281; Dedysh SN, 2002, INT J SYST EVOL MICR, V52, P251, DOI 10.1099/00207713-52-1-251; Dedysh SN, 2000, INT J SYST EVOL MICR, V50, P955, DOI 10.1099/00207713-50-3-955; Hein R, 1997, GLOBAL BIOGEOCHEM CY, V11, P43, DOI 10.1029/96GB03043; Jahnke LL, 1999, GEOCHIM COSMOCHIM AC, V63, P79, DOI 10.1016/S0016-7037(98)00270-1; Juretschko S, 1998, APPL ENVIRON MICROB, V64, P3042; KEELEY JE, 1992, PLANT CELL ENVIRON, V15, P1021, DOI 10.1111/j.1365-3040.1992.tb01653.x; Lamers LPM, 1999, J ECOL, V87, P639, DOI 10.1046/j.1365-2745.1999.00380.x; Lomans BP, 2001, APPL ENVIRON MICROB, V67, P1044, DOI 10.1128/AEM.67.3.1044-1051.2001; Ludwig W, 2004, NUCLEIC ACIDS RES, V32, P1363, DOI 10.1093/nar/gkh293; Marguillier S, 1997, MAR ECOL PROG SER, V151, P115, DOI 10.3354/meps151115; POST WM, 1982, NATURE, V298, P156, DOI 10.1038/298156a0; RODHE H, 1990, SCIENCE, V248, P1217, DOI 10.1126/science.248.4960.1217; ROHMER M, 1992, BIOLOGICAL MARKERS IN SEDIMENTS AND PETROLEUM, P1; RYDIN H, 1989, PROC R SOC SER B-BIO, V237, P63, DOI 10.1098/rspb.1989.0037; Schouten S, 1998, GEOCHIM COSMOCHIM AC, V62, P1397, DOI 10.1016/S0016-7037(98)00076-3; Smith LC, 2004, SCIENCE, V303, P353, DOI 10.1126/science.1090553; Smolders AJP, 2003, WETL ECOL MANAG, V11, P403, DOI 10.1023/B:WETL.0000007195.25180.94; Smolders AJP, 2002, J APPL ECOL, V39, P391, DOI 10.1046/j.1365-2664.2002.00724.x; Wolters-Arts M, 2002, PLANT CELL ENVIRON, V25, P513, DOI 10.1046/j.1365-3040.2002.00827.x; YAO R, 1992, J BACTERIOL, V174, P4683, DOI 10.1128/JB.174.14.4683-4688.1992	24	299	323	3	227	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 25	2005	436	7054					1153	1156		10.1038/nature03802	http://dx.doi.org/10.1038/nature03802			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	958AK	16121180	Green Published			2022-12-28	WOS:000231416600045
J	Woodhead, JL; Zhao, FQ; Craig, R; Egelman, EH; Alamo, L; Padron, R				Woodhead, JL; Zhao, FQ; Craig, R; Egelman, EH; Alamo, L; Padron, R			Atomic model of a myosin filament in the relaxed state	NATURE			English	Article							SMOOTH-MUSCLE MYOSIN; PHOSPHORYLATION-DEPENDENT REGULATION; THICK FILAMENTS; HEAVY-MEROMYOSIN; IMAGE-RECONSTRUCTION; STRUCTURAL-CHANGES; TARANTULA MUSCLE; SKELETAL-MUSCLE; HEADS; ARRANGEMENT	Contraction of muscle involves the cyclic interaction of myosin heads on the thick filaments with actin subunits in the thin filaments(1). Muscles relax when this interaction is blocked by molecular switches on either or both filaments(2). Insight into the relaxed ( switched OFF) structure of myosin has come from electron microscopic studies of smooth muscle myosin molecules, which are regulated by phosphorylation. These studies suggest that the OFF state is achieved by an asymmetric, intramolecular interaction between the actin-binding region of one head and the converter region of the other, switching both heads off(3). Although this is a plausible model for relaxation based on isolated myosin molecules, it does not reveal whether this structure is present in native myosin filaments. Here we analyse the structure of a phosphorylation-regulated striated muscle thick filament using cryo-electron microscopy. Three-dimensional reconstruction and atomic fitting studies suggest that the 'interacting-head' structure is also present in the filament, and that it may underlie the relaxed state of thick filaments in both smooth and myosin-regulated striated muscles over a wide range of species.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Inst Venezolano Invest Cient, Dept Biol Estructural, Caracas 1020A, Venezuela	University of Massachusetts System; University of Massachusetts Worcester; University of Virginia; Venezuelan Institute Science Research	Craig, R (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA.	Roger.Craig@umassmed.edu	Egelman, Edward H/A-2488-2009; Padron, Raul/E-5975-2010	Padron, Raul/0000-0002-1412-2450; Egelman, Edward/0000-0003-4844-5212	NIAMS NIH HHS [R01 AR034711] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR034711] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Burgess S, 2002, BIOPHYS J, V82, p356A; Burgess SA, 1997, J CELL BIOL, V139, P675, DOI 10.1083/jcb.139.3.675; CRAIG R, 1987, J CELL BIOL, V105, P1319, DOI 10.1083/jcb.105.3.1319; Craig R., 2004, MYOLOGY, V3, P129; CROWTHER RA, 1985, J MOL BIOL, V184, P429, DOI 10.1016/0022-2836(85)90292-X; Eakins F, 2002, J STRUCT BIOL, V137, P154, DOI 10.1006/jsbi.2002.4453; Egelman EH, 2000, ULTRAMICROSCOPY, V85, P225, DOI 10.1016/S0304-3991(00)00062-0; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; Hidalgo C, 2001, BIOPHYS J, V81, P2817, DOI 10.1016/S0006-3495(01)75923-1; HUXLEY HE, 1967, J MOL BIOL, V30, P383, DOI 10.1016/S0022-2836(67)80046-9; Jung HS, 2004, BIOPHYS J, V86, p403A; LEHMAN W, 1975, J GEN PHYSIOL, V66, P1, DOI 10.1085/jgp.66.1.1; Levine RJC, 1996, BIOPHYS J, V71, P898, DOI 10.1016/S0006-3495(96)79293-7; Liu J, 2003, J MOL BIOL, V329, P963, DOI 10.1016/S0022-2836(03)00516-3; Offer G, 2000, J MOL BIOL, V298, P239, DOI 10.1006/jmbi.2000.3664; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Rovner AS, 1998, J BIOL CHEM, V273, P27939, DOI 10.1074/jbc.273.43.27939; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; SELLERS JR, 1981, J BIOL CHEM, V256, P9274; Stafford WF, 2001, J MOL BIOL, V307, P137, DOI 10.1006/jmbi.2000.4490; STEWART M, 1985, J CELL BIOL, V101, P402, DOI 10.1083/jcb.101.2.402; STEWART M, 1986, J MOL BIOL, V192, P831, DOI 10.1016/0022-2836(86)90032-X; SUZUKI H, 1985, J BIOL CHEM, V260, P4810; Trybus KM, 1998, J BIOL CHEM, V273, P18423, DOI 10.1074/jbc.273.29.18423; Trybus KM, 1997, P NATL ACAD SCI USA, V94, P48, DOI 10.1073/pnas.94.1.48; VIBERT P, 1992, J MOL BIOL, V223, P661, DOI 10.1016/0022-2836(92)90982-P; Wendt T, 2001, P NATL ACAD SCI USA, V98, P4361, DOI 10.1073/pnas.071051098; WRAY JS, 1975, NATURE, V257, P561, DOI 10.1038/257561a0; WRAY JS, 1979, NATURE, V277, P37, DOI 10.1038/277037a0	30	221	223	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 25	2005	436	7054					1195	1199		10.1038/nature03920	http://dx.doi.org/10.1038/nature03920			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	958AK	16121187				2022-12-28	WOS:000231416600054
J	Bamshad, M				Bamshad, M			Genetic influences on health - Does race matter?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TYROSINE-PHOSPHATASE PTPN22; ETHNIC-DIFFERENCES; RACIAL-DIFFERENCES; AFRICAN-AMERICAN; Y-CHROMOSOME; DISEASE; ASSOCIATION; POPULATION; POLYMORPHISM; ADMIXTURE	Race is frequently used by clinicians and biomedical researchers to make inferences about an individual's ancestry and to predict whether an individual carries specific genetic risk factors that influence health. The extent to which race is useful for making such predictions depends on how well race corresponds with genetic inferences of ancestry, how frequently common diseases in different racial groups are influenced by the same vs different gene variants, and whether such variants have the same effects in different racial groups. New studies of human genetic variation show that while genetic ancestry is highly correlated with geographic ancestry, its correlation with race is modest. Therefore, while data on the correspondence of race, ancestry, and health-related traits are still limited, particularly in minority populations, geographic ancestry and explicit genetic information are alternatives to race that appear to be more accurate predictors of genetic risk factors that influence health. Making accurate ancestry inferences is crucial because common diseases and drug responses are sometimes influenced by gene variants that vary in frequency or differ altogether among racial groups. Thus, operationalizing alternatives to race for clinicians will be an important step toward providing more personalized health care.	Univ Utah, Eccles Inst Human Genet, Dept Pediat, Salt Lake City, UT 84112 USA; Univ Utah, Eccles Inst Human Genet, Dept Human Genet, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Bamshad, M (corresponding author), Univ Utah, Eccles Inst Human Genet, Dept Pediat, Salt Lake City, UT 84112 USA.	mike@genetics.utah.edu			NCRR NIH HHS [RR00064] Funding Source: Medline; NIAID NIH HHS [AI46326, U54 AI065357, U54 AI065357-01, AI65357] Funding Source: Medline; NICHD NIH HHS [HD48895] Funding Source: Medline; ODCDC CDC HHS [U50/CCU822097] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD048895] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI046326, R37AI046326, R01AI046326, U54AI065357] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); ODCDC CDC HHS; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abe-Sandes K, 2004, HUM BIOL, V76, P77, DOI 10.1353/hub.2004.0014; Ackerman MJ, 2003, MAYO CLIN PROC, V78, P1479, DOI 10.4065/78.12.1479; Badano JL, 2002, NAT REV GENET, V3, P779, DOI 10.1038/nrg910; Bamshad M, 2003, NAT REV GENET, V4, P99, DOI 10.1038/nrg999; Bamshad M, 2004, NAT REV GENET, V5, P598, DOI 10.1038/nrg1401; Bamshad MJ, 2003, SCI AM, V289, P78, DOI 10.1038/scientificamerican1203-78; Bamshad MJ, 2003, AM J HUM GENET, V72, P578, DOI 10.1086/368061; Basehore MJ, 2004, J ALLERGY CLIN IMMUN, V114, P80, DOI 10.1016/j.jaci.2004.05.035; Begovich AB, 2004, AM J HUM GENET, V75, P330, DOI 10.1086/422827; Bradley EH, 2004, JAMA-J AM MED ASSOC, V292, P1563, DOI 10.1001/jama.292.13.1563; Burchard EG, 2003, NEW ENGL J MED, V348, P1170, DOI 10.1056/NEJMsb025007; Carlson CS, 2003, NAT GENET, V33, P518, DOI 10.1038/ng1128; Cho MK, 2004, NAT GENET, V36, pS8, DOI 10.1038/ng1594; Cohen J, 2005, NAT GENET, V37, P328, DOI 10.1038/ng0305-328c; Cooper RS, 2003, NEW ENGL J MED, V348, P1166, DOI 10.1056/NEJMsb022863; Cooper RS, 2001, INT J EPIDEMIOL, V30, pS48, DOI 10.1093/ije/30.suppl_1.S48; Edwards AWF, 2003, BIOESSAYS, V25, P798, DOI 10.1002/bies.10315; Ezenwaka C, 2005, J ENDOCRINOL, V185, P439, DOI 10.1677/joe.1.06117; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041; Fay JC, 2002, NATURE, V415, P1024, DOI 10.1038/4151024a; Fernandez JR, 2003, OBES RES, V11, P904, DOI 10.1038/oby.2003.124; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Frodsham AJ, 2004, HUM MOL GENET, V13, pR187, DOI 10.1093/hmg/ddh225; Frudakis T, 2003, J FORENSIC SCI, V48, P771; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gonzalez E, 2005, SCIENCE, V307, P1434, DOI 10.1126/science.1101160; Gonzalez E, 1999, P NATL ACAD SCI USA, V96, P12004, DOI 10.1073/pnas.96.21.12004; Gonzalez E, 2001, P NATL ACAD SCI USA, V98, P5199, DOI 10.1073/pnas.091056898; Gower BA, 2003, DIABETES, V52, P1047, DOI 10.2337/diabetes.52.4.1047; Gregersen PK, 2005, IMMUNOL REV, V204, P74, DOI 10.1111/j.0105-2896.2005.00243.x; Haga SB, 2003, SCIENCE, V301, P466, DOI 10.1126/science.1087004; Harding RM, 2004, CURR OPIN GENET DEV, V14, P667, DOI 10.1016/j.gde.2004.08.010; Harpending H, 2000, ANNU REV GENOM HUM G, V1, P361, DOI 10.1146/annurev.genom.1.1.361; Hinds DA, 2005, SCIENCE, V307, P1072, DOI 10.1126/science.1105436; *I MED, 2003, UN TREATM CONFR RAC; Ioannidis JPA, 2004, NAT GENET, V36, P1312, DOI 10.1038/ng1474; Jorde LB, 2000, AM J HUM GENET, V66, P979, DOI 10.1086/302825; Kittles RA, 2003, ANNU REV GENOM HUM G, V4, P33, DOI 10.1146/annurev.genom.4.070802.110356; Knight JC, 1999, NAT GENET, V22, P145, DOI 10.1038/9649; Kruglyak L, 2001, NAT GENET, V27, P234, DOI 10.1038/85776; Kugathasan S, 2005, INFLAMM BOWEL DIS, V11, P631, DOI 10.1097/01.MIB.0000171279.05471.21; Kyogoku C, 2004, AM J HUM GENET, V75, P504, DOI 10.1086/423790; LI WH, 1991, GENETICS, V129, P513; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; Martin MP, 1998, SCIENCE, V282, P1907, DOI 10.1126/science.282.5395.1907; MILLER LH, 1975, SCIENCE, V189, P561, DOI 10.1126/science.1145213; Mori M, 2005, J HUM GENET, V50, P264, DOI 10.1007/s10038-005-0246-8; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Oppenheimer GM, 2001, AM J PUBLIC HEALTH, V91, P1049, DOI 10.2105/AJPH.91.7.1049; OSBORNE NG, 1992, JAMA-J AM MED ASSOC, V267, P275, DOI 10.1001/jama.267.2.275; Pang CP, 2002, HUM MUTAT, V19, P189, DOI 10.1002/humu.10053; Pritchard JK, 2002, HUM MOL GENET, V11, P2417, DOI 10.1093/hmg/11.20.2417; Ptak SE, 2002, TRENDS GENET, V18, P559, DOI 10.1016/S0168-9525(02)02781-6; Reiner AP, 2005, AM J HUM GENET, V76, P463, DOI 10.1086/428654; Riedel MJ, 2005, HUM GENET, V116, P133, DOI 10.1007/s00439-004-1216-5; Risch N., 2002, GENOME BIOL, V3, pcomm, DOI [10.1186/gb-2002-3-7-comment2007, 10.1186/GB-2002-3-7-COMMENT2007]; Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311; Rosenberg NA, 2003, AM J HUM GENET, V73, P1402, DOI 10.1086/380416; Rosskopf D, 2002, PHARMACOGENETICS, V12, P209, DOI 10.1097/00008571-200204000-00005; Sankar P, 2004, JAMA-J AM MED ASSOC, V291, P2985, DOI 10.1001/jama.291.24.2985; Satta Y, 2004, MOL ECOL, V13, P877, DOI 10.1046/j.1365-294X.2003.02069.x; Sehgal AR, 2004, HYPERTENSION, V43, P566, DOI 10.1161/01.HYP.0000118019.28487.9c; Sethi AA, 2003, ARTERIOSCL THROM VAS, V23, P1269, DOI 10.1161/01.ATV.0000079007.40884.5C; Shriver Mark D., 2005, Human Genomics, V2, P81; Shriver MD, 2003, HUM GENET, V112, P387, DOI 10.1007/s00439-002-0896-y; Siffert W, 1999, J AM SOC NEPHROL, V10, P1921; Tang H, 2005, AM J HUM GENET, V76, P268, DOI 10.1086/427888; Tate SK, 2004, NAT GENET, V36, pS34, DOI 10.1038/ng1437; Thomas PD, 2004, P NATL ACAD SCI USA, V101, P15398, DOI 10.1073/pnas.0404380101; Tishkoff SA, 2002, NAT REV GENET, V3, P611, DOI 10.1038/nrg865; *US CENS, 2000, GEN DEM CHAR DP 1; Watkins WS, 2003, GENOME RES, V13, P1607, DOI 10.1101/gr.894603; Wilson JF, 2001, NAT GENET, V29, P265, DOI 10.1038/ng761; Xie HG, 2001, ANNU REV PHARMACOL, V41, P815, DOI 10.1146/annurev.pharmtox.41.1.815; Yen CJ, 1997, BIOCHEM BIOPH RES CO, V241, P270, DOI 10.1006/bbrc.1997.7798; Yu N, 2002, GENETICS, V161, P269; Zhang JH, 2003, AM J HUM GENET, V73, P1073, DOI 10.1086/379154; Zhu XF, 2005, NAT GENET, V37, P177, DOI 10.1038/ng1510	78	109	109	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 24	2005	294	8					937	946		10.1001/jama.294.8.937	http://dx.doi.org/10.1001/jama.294.8.937			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	957JM	16118384				2022-12-28	WOS:000231366100024
J	Collins, ED; Kleber, HD; Whittington, RA; Heitler, NE				Collins, ED; Kleber, HD; Whittington, RA; Heitler, NE			Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RAPID OPIATE DETOXIFICATION; ULTRARAPID OPIOID DETOXIFICATION; GENERAL-ANESTHESIA; FOLLOW-UP; INPATIENT DETOXIFICATION; WITHDRAWAL SYMPTOMS; SYSTEMATIC REVIEWS; ADDICTED PATIENTS; DEEP SEDATION; MAINTENANCE	Context Rapid opioid detoxification with opioid antagonist induction using general anesthesia has emerged as an expensive, potentially dangerous, unproven approach to treat opioid dependence. Objective To determine how anesthesia-assisted detoxification with rapid antagonist induction for heroin dependence compared with 2 alternative detoxification and antagonist induction methods. Design, Setting, and Patients A total of 106 treatment-seeking heroin-dependent patients, aged 21 through 50 years, were randomly assigned to 1 of 3 inpatient withdrawal treatments over 72 hours followed by 12 weeks of outpatient naltrexone maintenance with relapse prevention psychotherapy. This randomized trial was conducted between 2000 and 2003 at Columbia University Medical Center's Clinical Research Center. Outpatient treatment occurred at the Columbia University research service for substance use disorders. Patients were included if they had an American Society of Anesthesiologists physical status of I or 11, were without major comorbid psychiatric illness, and were not dependent on other drugs or alcohol. Interventions Anesthesia-assisted rapid opioid detoxification with naltrexone induction, buprenorphine-assisted rapid opioid detoxification with naltrexone induction, and clonidine-assisted opioid detoxification with delayed naltrexone induction. Main Outcome Measures Withdrawal severity scores on objective and subjective scales; proportions of patients receiving naltrexone, completing inpatient detoxification, and retained in treatment; proportion of opioid-positive urine specimens. Results Mean withdrawal severities were comparable across the 3 treatments. Compared with clonidine-assisted detoxification, the anesthesia- and buprenorphine-assisted detoxification interventions had significantly greater rates of naltrexone induction (94% anesthesia, 97% buprenorphine, and 21 % clonidine), but the groups did not differ in rates of completion of inpatient detoxification. Treatment retention over 12 weeks was not significantly different among groups with 7 of 35 (20%) retained in the anesthesia-assisted group, 9 of 37 (24%) in the buprenorphine-assisted group, and 3 of 34 (9%) in the clonidine-assisted group. Induction with 50 mg of naltrexone significantly reduced the risk of dropping out (odds ratio, 0.28; 95% confidence interval, 0.15-0.51). There were no significant group differences in proportions of opioid-positive urine specimens. The anesthesia procedure was associated with 3 potentially life-threatening adverse events. Conclusion These data do not support the use of general anesthesia for heroin detoxification and rapid opioid antagonist induction.	Columbia Univ, Coll Phys & Surg, Div Subst Abuse, Dept Psychiat, New York, NY 10032 USA; New York State Psychiat Inst & Hosp, Div Subst Abuse, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Anesthesiol, New York, NY 10032 USA	Columbia University; New York State Psychiatry Institute; Columbia University	Collins, ED (corresponding author), Columbia Univ, Coll Phys & Surg, Div Subst Abuse, Dept Psychiat, 1051 Riverside Dr,Unit 120, New York, NY 10032 USA.	edc3@columbia.edu			NCRR NIH HHS [M01-RR-00645] Funding Source: Medline; NIDA NIH HHS [DA-00317, DA-12644, DA-14284] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA012644, K05DA014284] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Albanese AP, 2000, J ADDICT DIS, V19, P11, DOI 10.1300/J069v19n02_02; Ali R, 2003, DRUG ALCOHOL REV, V22, P425, DOI 10.1080/09595230310001613949; Amato L, 2005, J SUBST ABUSE TREAT, V28, P321, DOI 10.1016/j.jsat.2005.02.007; Amato L, 2004, DRUG ALCOHOL DEPEN, V73, P219, DOI 10.1016/j.drugalcdep.2003.11.002; Bartter T, 1996, AM J DRUG ALCOHOL AB, V22, P489, DOI 10.3109/00952999609001675; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Bell JR, 1999, MED J AUSTRALIA, V171, P26, DOI 10.5694/j.1326-5377.1999.tb123493.x; Berger VW, 1999, CONTROL CLIN TRIALS, V20, P319, DOI 10.1016/S0197-2456(99)00014-8; Brewer C, 1999, HOSP MED, V60, P70; BREWER C, 1988, BRIT J PSYCHIAT, V153, P340, DOI 10.1192/bjp.153.3.340; Brewer C, 1997, ADDICT BIOL, V2, P291, DOI 10.1080/13556219772589; BREWER C, 1997, BR J INTENS CARE, P138; Carnwath T, 1998, DRUG ALCOHOL DEPEN, V50, P251, DOI 10.1016/S0376-8716(98)00040-4; Carreno JE, 2002, ADDICT BIOL, V7, P243, DOI 10.1080/135562102200120479; CARROLL KM, 1991, AM J DRUG ALCOHOL AB, V17, P249, DOI 10.3109/00952999109027550; Comer SD, 2001, PSYCHOPHARMACOLOGY, V154, P28, DOI 10.1007/s002130000623; Cucchia AT, 1998, DRUG ALCOHOL DEPEN, V52, P243, DOI 10.1016/S0376-8716(98)00100-8; Elman I, 2001, DRUG ALCOHOL DEPEN, V61, P163, DOI 10.1016/S0376-8716(00)00139-3; Gold CG, 1999, ANESTHESIOLOGY, V91, P1639, DOI 10.1097/00000542-199912000-00015; Golden SA, 2004, J ADDICT DIS, V23, P65, DOI 10.1300/J069v23n01_06; GONZALEZ JP, 1988, DRUGS, V35, P192, DOI 10.2165/00003495-198835030-00002; GOSSOP M, 1986, BRIT MED J, V293, P103, DOI 10.1136/bmj.293.6539.103; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hamilton RJ, 2002, ACAD EMERG MED, V9, P63, DOI 10.1111/j.1553-2712.2002.tb01169.x; HANDELSMAN L, 1987, AM J DRUG ALCOHOL AB, V13, P293, DOI 10.3109/00952998709001515; Heatherton B, 2000, J ADDICT DIS, V19, P109, DOI 10.1300/J069v19n02_09; Hensel M, 2000, BRIT J ANAESTH, V84, P236, DOI 10.1093/oxfordjournals.bja.a013408; Hoffman WE, 1998, J NEUROSURG ANESTH, V10, P205; Hoffman WE, 1998, J CLIN ANESTH, V10, P372, DOI 10.1016/S0952-8180(98)00047-6; Justins D, 1998, HOSP MED, V59, P180; Kaye AD, 2003, CAN J ANAESTH, V50, P663, DOI 10.1007/BF03018708; KELMAN HARVEY, 1964, MINN MED, V47, P525; Kienbaum P, 1998, ANESTHESIOLOGY, V88, P1154, DOI 10.1097/00000542-199805000-00004; Kienbaum P, 2000, CRIT CARE MED, V28, P969, DOI 10.1097/00003246-200004000-00010; KLEBER HD, 1982, J CLIN PSYCHIAT, V43, P30; KLEBER HD, 1985, ARCH GEN PSYCHIAT, V42, P391; Kleber HD, 1998, ADDICTION, V93, P1629; Kolb L, 1938, AM J PSYCHIAT, V94, P759, DOI 10.1176/ajp.94.4.759; Krabbe PFM, 2003, ADDICT BIOL, V8, P351, DOI 10.1080/13556210310001602275; Lawental E, 2000, J SUBST ABUSE, V11, P173, DOI 10.1016/S0899-3289(00)00019-5; Liu J, 1997, ANESTH ANALG, V84, P185, DOI 10.1097/00000539-199701000-00033; LOIMER N, 1990, BRIT J PSYCHIAT, V157, P748, DOI 10.1192/bjp.157.5.748; McGregor C, 2002, DRUG ALCOHOL DEPEN, V68, P5, DOI 10.1016/S0376-8716(02)00077-7; MCLELLAN AT, 1992, J SUBST ABUSE TREAT, V9, P199, DOI 10.1016/0740-5472(92)90062-S; METZGER DS, 1993, J ACQ IMMUN DEF SYND, V6, P1049; NEWMAN MK, 1941, ARCH PHYSL THER, V22, P161; O'Connor PG, 1998, JAMA-J AM MED ASSOC, V279, P229, DOI 10.1001/jama.279.3.229; OBRIEN CP, 2004, TXB SUBSTANCE ABUSE; OConnor PG, 1997, ANN INTERN MED, V127, P526, DOI 10.7326/0003-4819-127-7-199710010-00004; Office of National Drug Control Policy, 2004, NAT DRUG CONTR STRAT; PEACHEY JE, 1988, BRIT J ADDICT, V83, P193; Pfab R, 1999, J TOXICOL-CLIN TOXIC, V37, P43, DOI 10.1081/CLT-100102407; PRESSLICH O, 1989, J TOXICOL-CLIN TOXIC, V27, P263, DOI 10.3109/15563658908994422; Rabinowitz J, 1998, PSYCHIATR SERV, V49, P831, DOI 10.1176/ps.49.6.831; Rabinowitz J, 2002, AM J ADDICTION, V11, P52, DOI 10.1080/10550490252801639; Rabinowitz J, 1997, DRUG ALCOHOL DEPEN, V47, P77, DOI 10.1016/S0376-8716(97)00073-2; Rothenberg JL, 2002, J SUBST ABUSE TREAT, V23, P351, DOI 10.1016/S0740-5472(02)00301-X; SAN L, 1995, AM J PSYCHIAT, V152, P956; Shreeram SS, 2001, AM J PSYCHIAT, V158, P970, DOI 10.1176/appi.ajp.158.6.970; Simon DL, 1997, J ADDICT DIS, V16, P103, DOI 10.1300/J069v16n01_07; Spanagel R, 1998, DRUG ALCOHOL DEPEN, V52, P251, DOI 10.1016/S0376-8716(98)00106-9; Spanagel R, 1999, LANCET, V354, P2017, DOI 10.1016/S0140-6736(99)90248-9; Stephenson J, 1997, JAMA-J AM MED ASSOC, V277, P363, DOI 10.1001/jama.277.5.363; Strang J, 1997, BRIT MED J, V315, P1249, DOI 10.1136/bmj.315.7118.1249; *SUBST AB MENT HLT, 2004, NAT SURV SUBST AB TR; Tillim SJ, 1942, AM J PSYCHIAT, V99, P84, DOI 10.1176/ajp.99.1.84; Tornay CB, 2003, DRUG ALCOHOL DEPEN, V69, P283, DOI 10.1016/S0376-8716(02)00326-5; Tretter F, 1998, ADDICTION, V93, P269, DOI 10.1046/j.1360-0443.1998.93226910.x; Umbricht A, 1999, DRUG ALCOHOL DEPEN, V56, P181, DOI 10.1016/S0376-8716(99)00033-2; WANG RIH, 1974, CLIN PHARMACOL THER, V16, P653; Whittington RA, 2000, ANESTHESIOLOGY, V93, P1363, DOI 10.1097/00000542-200011000-00039	71	90	91	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 24	2005	294	8					903	913		10.1001/jama.294.8.903	http://dx.doi.org/10.1001/jama.294.8.903			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	957JM	16118380	Bronze			2022-12-28	WOS:000231366100020
J	Manning, MR; Lowe, DC; Moss, RC; Bodeker, GE; Allan, W				Manning, MR; Lowe, DC; Moss, RC; Bodeker, GE; Allan, W			Short-term variations in the oxidizing power of the atmosphere	NATURE			English	Article							COSMOGENIC (CO)-C-14; TROPOSPHERIC OH; C-14 PRODUCTION; CO; ABUNDANCE; CYCLE; CH4	The hydroxyl radical is the predominant atmospheric oxidant(1), responsible for removing a wide range of trace gases, including greenhouse gases, from the atmosphere. Determination of trends and variability in hydroxyl radical concentrations(2,3) is critical to understanding whether the 'cleansing' properties of the atmosphere are changing. The variability in hydroxyl radical concentrations on annual to monthly timescales, however, is difficult to quantify. Here we show records of carbon monoxide containing radiocarbon ((CO)-C-14), which is oxidized by hydroxyl radicals(4,5), from clean-air sites at Baring Head, New Zealand, and Scott Base, Antarctica, spanning 13 years. Using a model study, we correct for known variations in production of (CO)-C-14 (refs 6, 7), allowing us to exploit this species as a diagnostic for short term changes in hydroxyl radical concentrations. We find no significant long-term trend in hydroxyl radical concentrations but provide evidence for recurring short-term variations of around ten per cent persisting for a few months. We also find decreases in hydroxyl radical concentrations of up to 20 per cent, apparently triggered by the eruption of Mt Pinatubo in 1991 and by the occurrence of extensive fires in Indonesia in 1997.	IPCC Working Grp Support Unit 1, Boulder, CO 80305 USA; Natl Inst Water & Atmospher Res, Wellington 6003, New Zealand	National Institute of Water & Atmospheric Research (NIWA) - New Zealand	Manning, MR (corresponding author), IPCC Working Grp Support Unit 1, Boulder, CO 80305 USA.	Martin.Manning@noaa.gov	Bodeker, Greg E/A-8870-2008	Bodeker, Greg E/0000-0003-1094-5852				Allen DR, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017117; Bergamaschi P, 2000, J GEOPHYS RES-ATMOS, V105, P1909, DOI 10.1029/1999JD900818; Bergamaschi P, 2001, J GEOPHYS RES-ATMOS, V106, P7993, DOI 10.1029/2000JD900576; BRENNINKMEIJER CAM, 1992, NATURE, V356, P50, DOI 10.1038/356050a0; Brenninkmeijer CAM, 1995, J GEOPHYS RES-ATMOS, V100, P26163, DOI 10.1029/95JD02528; BRENNINKMEIJER CAM, 1993, J GEOPHYS RES-ATMOS, V98, P10595, DOI 10.1029/93JD00587; Dlugokencky EJ, 1996, GEOPHYS RES LETT, V23, P2761, DOI 10.1029/96GL02638; Forster PMF, 2001, J GEOPHYS RES-ATMOS, V106, P12241, DOI 10.1029/2000JD900813; Jockel P, 1999, J GEOPHYS RES-ATMOS, V104, P11733, DOI 10.1029/1999JD900061; Jockel P, 2003, ATMOS CHEM PHYS, V3, P999; Jockel P, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001324; Jockel P, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001104; Kalnay E, 1996, B AM METEOROL SOC, V77, P437, DOI 10.1175/1520-0477(1996)077<0437:TNYRP>2.0.CO;2; Krol M, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002423; LEVY H, 1971, SCIENCE, V173, P141, DOI 10.1126/science.173.3992.141; Lowe DC, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL014719; Lowe DC, 2002, RADIOCARBON, V44, P149, DOI 10.1017/S0033822200064754; MAK JE, 1994, J GEOPHYS RES-ATMOS, V99, P22915, DOI 10.1029/94JD01931; Masarik J, 1999, J GEOPHYS RES-ATMOS, V104, P12099, DOI 10.1029/1998JD200091; Matsueda H, 1999, GEOPHYS RES LETT, V26, P2413, DOI 10.1029/1999GL900089; Novelli PC, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD003031; Prinn RG, 2001, SCIENCE, V292, P1882, DOI 10.1126/science.1058673; Quay P, 2000, J GEOPHYS RES-ATMOS, V105, P15147, DOI 10.1029/2000JD900122; Santer BD, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002258; SCHAUFFLER SM, 1994, J GEOPHYS RES-ATMOS, V99, P25747, DOI 10.1029/94JD02223; Spivakovsky CM, 2000, J GEOPHYS RES-ATMOS, V105, P8931, DOI 10.1029/1999JD901006; Thompson DWJ, 2002, SCIENCE, V296, P895, DOI 10.1126/science.1069270; VOLZ A, 1981, J GEOPHYS RES-OCEANS, V86, P5163, DOI 10.1029/JC086iC06p05163; WEINSTOCK B, 1972, SCIENCE, V176, P290, DOI 10.1126/science.176.4032.290; Wooster MJ, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2000GB001357	30	59	61	1	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 18	2005	436	7053					1001	1004		10.1038/nature03900	http://dx.doi.org/10.1038/nature03900			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955XQ	16107844				2022-12-28	WOS:000231263900046
J	Mukamel, R; Gelbard, H; Arieli, A; Hasson, U; Fried, I; Malach, R				Mukamel, R; Gelbard, H; Arieli, A; Hasson, U; Fried, I; Malach, R			Coupling between neuronal firing, field potentials, and fMR1 in human auditory cortex	SCIENCE			English	Article							BOLD HEMODYNAMIC-RESPONSES; CEREBRAL-BLOOD-FLOW; SYNAPTIC ACTIVITY; BRAIN; SPIKES; SIGNAL; SYNCHRONIZATION	Functional magnetic resonance imaging (fMRI) is an important tool. for investigating human brain function, but the relationship between the hemodynamicatly based fMRI signals in the human brain and the underlying neuronal activity is unclear. We recorded single unit activity and local field potentials in auditory cortex of two neurosurgical patients and compared them with the fMRI signals of 11 healthy subjects during presentation of an identical movie segment. The predicted fMRI signals derived from single units and the measured fMRI signals from auditory cortex showed a highly significant correlation (r = 0.7S, P <10(-47)). Thus, fMRI signals can provide a reliable measure of the firing rate of human cortical neurons.	Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA; NYU, Ctr Neural Sci, New York, NY 10003 USA; Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Tel Aviv Univ, Tel Aviv Med Ctr, Funct Neurosurg Unit, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; New York University; Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	Malach, R (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Los Angeles, CA 90095 USA.	ifried@mednet.ucla.edu; rafi.malach@weizmann.ac.il	Mukamel, Roy/AAV-2900-2021; Galbard-Sagiv, Hagar/J-8482-2014; Jovicich, Jorge/D-2293-2010	Mukamel, Roy/0000-0001-9359-8950; Galbard-Sagiv, Hagar/0000-0003-0379-3854; Gelbard, Harris/0000-0001-5095-7976; Hasson, Uri/0000-0002-3599-7168				Aguirre GK, 1998, NEUROIMAGE, V8, P360, DOI 10.1006/nimg.1998.0369; Ances BM, 2004, J CEREBR BLOOD F MET, V24, P1, DOI 10.1097/01.WCB.0000103920.96801.12; Attwell D, 2002, TRENDS NEUROSCI, V25, P621, DOI 10.1016/S0166-2236(02)02264-6; Belin P, 2000, NATURE, V403, P309, DOI 10.1038/35002078; Boynton GM, 1996, J NEUROSCI, V16, P4207, DOI 10.1523/jneurosci.16-13-04207.1996; Caesar K, 2003, P NATL ACAD SCI USA, V100, P16000, DOI 10.1073/pnas.2635195100; Dale AM, 1997, HUM BRAIN MAPP, V5, P329, DOI 10.1002/(SICI)1097-0193(1997)5:5<329::AID-HBM1>3.0.CO;2-5; Giraud AL, 2000, J NEUROPHYSIOL, V84, P1588, DOI 10.1152/jn.2000.84.3.1588; GOEBEL R, 1996, NEUROIMAGE, V3, P604; Handwerker DA, 2004, NEUROIMAGE, V21, P1639, DOI 10.1016/j.neuroimage.2003.11.029; Hasson U, 2004, SCIENCE, V303, P1634, DOI 10.1126/science.1089506; Haxby JV, 2001, SCIENCE, V293, P2425, DOI 10.1126/science.1063736; Heeger DJ, 2000, NAT NEUROSCI, V3, P631, DOI 10.1038/76572; Iadecola C, 2004, NAT REV NEUROSCI, V5, P347, DOI 10.1038/nrn1387; Laufs H, 2003, P NATL ACAD SCI USA, V100, P11053, DOI 10.1073/pnas.1831638100; Lerner Y, 2002, CEREB CORTEX, V12, P163, DOI 10.1093/cercor/12.2.163; Levy I, 2004, CURR BIOL, V14, P996, DOI 10.1016/j.cub.2004.05.045; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Logothetis NK, 2004, ANNU REV PHYSIOL, V66, P735, DOI 10.1146/annurev.physiol.66.082602.092845; Mathiesen C, 1998, J PHYSIOL-LONDON, V512, P555, DOI 10.1111/j.1469-7793.1998.555be.x; Moosmann M, 2003, NEUROIMAGE, V20, P145, DOI 10.1016/S1053-8119(03)00344-6; Rees G, 2000, NAT NEUROSCI, V3, P716, DOI 10.1038/76673; Sewards TV, 1999, INT J PSYCHOPHYSIOL, V32, P35, DOI 10.1016/S0167-8760(98)00062-2; Siegel M, 2003, J NEUROSCI, V23, P4251; Talairach J., 1988, COPLANAR STEREOTAXIC; Yacoub E, 2001, MAGN RESON MED, V45, P184, DOI 10.1002/1522-2594(200102)45:2<184::AID-MRM1024>3.0.CO;2-C	26	689	695	6	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 5	2005	309	5736					951	954		10.1126/science.1110913	http://dx.doi.org/10.1126/science.1110913			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953SS	16081741				2022-12-28	WOS:000231101400052
J	Pascual, G; Fong, AL; Ogawa, S; Gamliel, A; Li, AC; Perissi, V; Rose, DW; Willson, TM; Rosenfeld, MG; Glass, CK				Pascual, G; Fong, AL; Ogawa, S; Gamliel, A; Li, AC; Perissi, V; Rose, DW; Willson, TM; Rosenfeld, MG; Glass, CK			A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma	NATURE			English	Article							ACTIVATED RECEPTOR-GAMMA; OXIDE SYNTHASE GENE; MACROPHAGE ACTIVATION; TRANSCRIPTION FACTORS; COREPRESSOR COMPLEX; ANDROGEN-RECEPTOR; NUCLEAR RECEPTORS; CO-REPRESSOR; PROTEINS; LIGAND	Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) has essential roles in adipogenesis and glucose homeostasis, and is a molecular target of insulin-sensitizing drugs(1-3). Although the ability of PPAR-gamma agonists to antagonize inflammatory responses by transrepression of nuclear factor kappa B (NF-kappa B) target genes is linked to antidiabetic(4) and antiatherogenic actions(5), the mechanisms remain poorly understood. Here we report the identification of a molecular pathway by which PPAR-gamma represses the transcriptional activation of inflammatory response genes in mouse macrophages. The initial step of this pathway involves ligand-dependent SUMOylation of the PPAR-gamma ligand-binding domain, which targets PPAR-gamma to nuclear receptor corepressor (NCoR)-histone deacetylase-3 (HDAC3) complexes on inflammatory gene promoters. This in turn prevents recruitment of the ubiquitylation/19S proteosome machinery that normally mediates the signal-dependent removal of corepressor complexes required for gene activation. As a result, NCoR complexes are not cleared from the promoter and target genes are maintained in a repressed state. This mechanism provides an explanation for how an agonist-bound nuclear receptor can be converted from an activator of transcription to a promoter-specific repressor of NF-kappa B target genes that regulate immunity and homeostasis.	Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA; GlaxoSmithKline Inc, Res Triangle Pk, NC 27709 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; GlaxoSmithKline	Glass, CK (corresponding author), Univ Calif San Diego, Dept Cellular & Mol Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	cglass@ucsd.edu	feinstein, doug/M-9414-2019; Glass, Christopher/AAI-3933-2021	Glass, Christopher/0000-0003-4344-3592; Perissi, Valentina/0000-0002-3716-0003	NATIONAL CANCER INSTITUTE [R01CA052599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK091183, R37DK039949] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA052599] Funding Source: Medline; NIDDK NIH HHS [R01 DK091183, R37 DK039949] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Glass CK, 2000, GENE DEV, V14, P121; Guenther MG, 2000, GENE DEV, V14, P1048; Haffner SM, 2002, CIRCULATION, V106, P679, DOI 10.1161/01.CIR.0000025403.20953.23; Hoberg JE, 2004, MOL CELL, V16, P245, DOI 10.1016/j.molcel.2004.10.010; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Janne OA, 2000, BIOCHEM SOC T, V28, P401, DOI 10.1042/0300-5127:0280401; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Li M, 2000, MOL CELL BIOL, V20, P4699, DOI 10.1128/MCB.20.13.4699-4707.2000; Ling Y, 2004, NUCLEIC ACIDS RES, V32, P598, DOI 10.1093/nar/gkh195; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; Oberfield JL, 1999, P NATL ACAD SCI USA, V96, P6102, DOI 10.1073/pnas.96.11.6102; Ogawa S, 2004, P NATL ACAD SCI USA, V101, P14461, DOI 10.1073/pnas.0405786101; Ohshima T, 2004, J BIOL CHEM, V279, P29551, DOI 10.1074/jbc.M403866200; Pascual-Le Tallec L, 2003, MOL ENDOCRINOL, V17, P2529, DOI 10.1210/me.2003-0299; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Willson TM, 2001, ANNU REV BIOCHEM, V70, P341, DOI 10.1146/annurev.biochem.70.1.341; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9	30	976	1022	2	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 29	2005	437	7059					759	763		10.1038/nature03988	http://dx.doi.org/10.1038/nature03988			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968JD	16127449	Green Accepted			2022-12-28	WOS:000232157900058
J	Trauth, MH; Maslin, MA; Deino, A; Strecker, MR				Trauth, MH; Maslin, MA; Deino, A; Strecker, MR			Late Cenozoic moisture history of East Africa	SCIENCE			English	Article							ENVIRONMENTAL-CHANGE; CLIMATE-CHANGE; PLEISTOCENE; EVOLUTION	Lake sediments in 10 Ethiopian, Kenyan, and Tanzanian rift basins suggest that there were three humid periods at 2.7 to 2.5 million years ago (Ma), 1.9 to 1.7 Ma, and 1,1 to 0.9 Ma, superimposed on the longer-term aridification of East Africa. These humid periods correlate with increased aridity in northwest and northeast Africa and with substantial global climate transitions. These episodes could have had important impacts on the speciation and dispersal of mammals and hominins, because a number of key events, such as the origin of the genus Homo and the evolution of the species Homo erectus, took place in this region during that time.	Univ Potsdam, Inst Geowissensch, D-14415 Potsdam, Germany; Berkeley Geochronol Ctr, Berkeley, CA 94709 USA; UCL, Dept Geog, Environm Change Res Ctr, London WC1E 6BT, England	University of Potsdam; Berkeley Geochronolgy Center; University of London; University College London	Trauth, MH (corresponding author), Univ Potsdam, Inst Geowissensch, POB 601553, D-14415 Potsdam, Germany.		Trauth, Martin H/A-6293-2008	Trauth, Martin H/0000-0001-5164-7267; Maslin, Mark/0000-0001-9957-3463				ASHLEY GM, 2002, SEPM SPECIAL PUBLICA, V73, P107, DOI DOI 10.2110/PEC.02.73.0107; BAKER BH, 1988, J GEOL SOC LONDON, V145, P107, DOI 10.1144/gsjgs.145.1.0107; Barker PA, 2004, DEV PALEOENVIRON RES, V6, P117; Behrensmeyer A. K., 2002, SEPM SPECIAL PUBLICA, V73, P97; BERGER WH, 1994, GEOPHYS MONOGR SER, V85, P295, DOI DOI 10.1029/GM085P0295; BROWN FH, 1991, KOOBI FORA RES PROJE, V3, P1; Butzer K.W., 1969, QUATERNARIA, V11, P15; CLEMENS S, 1991, NATURE, V353, P720, DOI 10.1038/353720a0; Clement AC, 2004, CLIM DYNAM, V22, P327, DOI 10.1007/s00382-003-0375-8; Deino AL, 2002, J HUM EVOL, V42, P185, DOI 10.1006/jhev.2001.0517; DeMenocal PB, 2004, EARTH PLANET SC LETT, V220, P3, DOI 10.1016/S0012-821X(04)00003-2; Dupont LM, 2001, GEOLOGY, V29, P195, DOI 10.1130/0091-7613(2001)029<0195:MPECIT>2.0.CO;2; Ebinger CJ, 1998, NATURE, V395, P788, DOI 10.1038/27417; Ebinger CJ, 2000, GEOL SOC AM BULL, V112, P163, DOI 10.1130/0016-7606(2000)112<163:RDMAPL>2.0.CO;2; EVERNDEN JG, 1965, CURR ANTHROPOL, V6, P177; Feibel C.S., 1991, P321; Foster A, 1997, J GEOL SOC LONDON, V154, P689, DOI 10.1144/gsjgs.154.4.0689; GASSE F, 1990, AAPG MEMOIR, V50, P1; Haug GH, 1998, NATURE, V393, P673, DOI 10.1038/31447; HILL A, 2003, ANN M GEOL SOC AM SE; HILLAIREMARCEL C, 1986, QUATERNARY RES, V25, P312, DOI 10.1016/0033-5894(86)90004-9; KUTZBACH JE, 1985, NATURE, V317, P130, DOI 10.1038/317130a0; LAPORTE LF, 1983, S AFR J SCI, V79, P96; Levin NE, 2004, EARTH PLANET SC LETT, V219, P93, DOI 10.1016/S0012-821X(03)00707-6; Potts R, 1998, YEARB PHYS ANTHROPOL, V41, P93; Potts R, 1999, J HUM EVOL, V37, P747, DOI 10.1006/jhev.1999.0344; PRODEHL C, 1991, NATURE, V354, P223, DOI 10.1038/354223a0; Ravelo AC, 2004, NATURE, V429, P263, DOI 10.1038/nature02567; STURCHIO NC, 1993, NATURE, V362, P233, DOI 10.1038/362233a0; Tiercelin JJ, 2002, ADV GLOB CHANGE RES, V12, P3; Trauth MH, 2003, EARTH PLANET SC LETT, V206, P297, DOI 10.1016/S0012-821X(02)01105-6; WILLIAMS LAJ, 1983, P REGIONAL SEMINAR G, P61; WILLIAMS MAJ, 1979, NATURE, V282, P29, DOI 10.1038/282029a0; WoldeGabriel G, 2000, GEOL S AM S, P83	34	262	274	0	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 23	2005	309	5743					2051	2053		10.1126/science.1112964	http://dx.doi.org/10.1126/science.1112964			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	968SF	16109847				2022-12-28	WOS:000232181900049
J	Brown, ET; Molnar, P; Bourles, DL				Brown, ET; Molnar, P; Bourles, DL			Comment on "Slip-rate measurements on the Karakorum Fault may imply secular variations in fault motion"	SCIENCE			English	Editorial Material							GLACIATION; MONSOON		Univ Minnesota, Large Lakes Observ, Duluth, MN 55812 USA; Univ Minnesota, Dept Geol Sci, Duluth, MN 55812 USA; Univ Colorado, Cooperat Inst Res Environm Sci, Boulder, CO 80309 USA; Univ Colorado, Dept Geol Sci, Boulder, CO 80309 USA; Univ Aix Marseille 3, F-13545 Aix En Provence, France; CNRS, Unite Mixte Rech, Ctr Europeen Rech & Enseignement Geosci Environm, F-13545 Aix En Provence, France	University of Minnesota System; University of Minnesota Duluth; University of Minnesota System; University of Minnesota Duluth; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Brown, ET (corresponding author), Univ Minnesota, Large Lakes Observ, Duluth, MN 55812 USA.	etbrown@d.umn.edu		Brown, Erik T/0000-0001-7154-2729				Benn DI, 1998, J GEOL SOC LONDON, V155, P353, DOI 10.1144/gsjgs.155.2.0353; Brown ET, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2000JB000100; Chevalier ML, 2005, SCIENCE, V307, P411, DOI 10.1126/science.1105466; Finkel RC, 2003, GEOLOGY, V31, P561, DOI 10.1130/0091-7613(2003)031<0561:BDOMEM>2.0.CO;2; GOSSE JC, 1995, SCIENCE, V268, P1329, DOI 10.1126/science.268.5215.1329; HALLET B, 1994, SCIENCE, V265, P937, DOI 10.1126/science.265.5174.937; IMBRIE J, 1984, MILANKOVITCH CLIMA 1, P269; Jade S, 2004, GEOL SOC AM BULL, V116, P1385, DOI 10.1130/B25357.1; Owen LA, 2003, GEOL SOC AM BULL, V115, P1356, DOI 10.1130/B25314.1; Putkonen J, 2003, QUATERNARY RES, V59, P255, DOI 10.1016/S0033-5894(03)00006-1; Van der Woerd J, 1998, GEOLOGY, V26, P695, DOI 10.1130/0091-7613(1998)026<0695:HLSRDB>2.3.CO;2; Wright TJ, 2004, SCIENCE, V305, P236, DOI 10.1126/science.1096388	12	42	42	3	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 26	2005	309	5739								10.1126/science.1112508	http://dx.doi.org/10.1126/science.1112508			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TX	16123287				2022-12-28	WOS:000231543300025
J	Peng, GY; Guo, Z; Kiniwa, Y; Voo, KS; Peng, WY; Fu, TH; Wang, DY; Li, YC; Wang, HY; Wang, RF				Peng, GY; Guo, Z; Kiniwa, Y; Voo, KS; Peng, WY; Fu, TH; Wang, DY; Li, YC; Wang, HY; Wang, RF			Toll-like, receptor 8-mediated reversal of CD4(+) regulatory T cell function	SCIENCE			English	Article							SINGLE-STRANDED RNA; RECOGNITION; TLR7	CD4(+) regulatory T (Treg) cells have a profound ability to suppress host immune responses, yet little is understood about how these cells are regulated. We describe a mechanism [inking Toll-like receptor (TLR) 8 signaling to the control of Treg cell function, in which synthetic and natural ligands for human TLR8 can reverse Treg cell function. This effect was independent of dendritic cells but required functional TLR8-MYD88-IRAK4 signaling in Treg cells. Adoptive transfer of TLR8 ligand-stimulated Treg cells into tumor-bearing mice enhanced antitumor immunity. These results suggest that TLR8 signaling could play a critical role in controlling immune responses to cancer and other diseases.	Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Wang, RF (corresponding author), Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA.	Rongfuw@bcm.tmc.edu			NCI NIH HHS [P50 CA093459, P50CA58204, R01CA90327, R01CA101795, P01CA94237] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090327, P01CA094237, R01CA101795, P50CA058204, P50CA093459] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; Crozat K, 2004, P NATL ACAD SCI USA, V101, P6835, DOI 10.1073/pnas.0401347101; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Hartmann G, 2003, EUR J IMMUNOL, V33, P1633, DOI 10.1002/eji.200323813; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jurk M, 2002, NAT IMMUNOL, V3, P499, DOI 10.1038/ni0602-499; Klinman DM, 2004, NAT REV IMMUNOL, V4, P248, DOI 10.1038/nri1329; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Powrie F, 2003, SCIENCE, V299, P1030, DOI 10.1126/science.1082031; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Ulevitch RJ, 2004, NAT REV IMMUNOL, V4, P512, DOI 10.1038/nri1396; Wang HY, 2005, J IMMUNOL, V174, P2661, DOI 10.4049/jimmunol.174.5.2661; Wang HY, 2004, IMMUNITY, V20, P107, DOI 10.1016/S1074-7613(03)00359-5; WANG RF, 1995, J EXP MED, V181, P799, DOI 10.1084/jem.181.2.799; Woo EY, 2001, CANCER RES, V61, P4766	25	606	679	3	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 26	2005	309	5739					1380	1384		10.1126/science.1113401	http://dx.doi.org/10.1126/science.1113401			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TX	16123302				2022-12-28	WOS:000231543300046
J	Zheng, JR; Kwak, K; Asbury, J; Chen, X; Piletic, IR; Fayer, MD				Zheng, JR; Kwak, K; Asbury, J; Chen, X; Piletic, IR; Fayer, MD			Ultrafast dynamics of solute-solvent complexation observed at thermal equilibrium in real time	SCIENCE			English	Article							AROMATIC RINGS; SPECTROSCOPY; WATER	In general, the formation and dissociation of solute-solvent complexes have been too rapid to measure without disturbing the thermal equilibrium. We were able to do so with the use of two-dimensional infrared vibrational echo spectroscopy, an ultrafast vibrational analog of two-dimensional nuclear magnetic resonance spectroscopy. The equilibrium dynamics of phenol complexation to benzene in a benzene-carbon tetrachloride solvent mixture were measured in real time by the appearance of off-diagonal peaks in the two-dimensional vibrational echo spectrum of the phenol hydroxyl stretch. The dissociation time constant tau(d) for the phenol-benzene complex was 8 picoseconds. Adding two electron-donating methyl groups to the benzene nearly tripled the value of tau(d) and stabilized the complex, whereas bromobenzene, with an electron-withdrawing bromo group, formed a slightly weaker complex with a slightly lower,tau(d). The spectroscopic method holds promise for studying a wide variety of other fast chemical exchange processes.	Stanford Univ, Dept Chem, Stanford, CA 94305 USA	Stanford University	Fayer, MD (corresponding author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.	fayer@stanford.edu	Asbury, John B./AAJ-5642-2020; Zheng, Junrong/I-5171-2014; Kwak, Kyungwon/D-8046-2015; Piletic, Ivan/AHD-0354-2022	Asbury, John B./0000-0002-3641-7276; Zheng, Junrong/0000-0001-7419-5494; 				Asbury JB, 2004, J CHEM PHYS, V121, P12431, DOI 10.1063/1.1818107; Asbury JB, 2004, J LUMIN, V107, P271, DOI 10.1016/j.jlumin.2003.12.035; Asbury JB, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.237402; Demirdoven N, 2001, J PHYS CHEM A, V105, P8025, DOI 10.1021/jp011215d; Fujii A, 2002, J PHYS CHEM A, V106, P8554, DOI 10.1021/jp0208992; Golonzka O, 2001, PHYS REV LETT, V86, P2154, DOI 10.1103/PhysRevLett.86.2154; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Kim YS, 2005, J PHYS CHEM B, V109, P6884, DOI 10.1021/jp0449511; KNEE JL, 1987, J CHEM PHYS, V87, P115, DOI 10.1063/1.453608; MEIER BH, 1979, J AM CHEM SOC, V101, P6441, DOI 10.1021/ja00515a053; Meyer EA, 2003, ANGEW CHEM INT EDIT, V42, P1210, DOI 10.1002/anie.200390319; Mukamel S, 2000, ANNU REV PHYS CHEM, V51, P691, DOI 10.1146/annurev.physchem.51.1.691; Mukamel S., 1995, PRINCIPLES NONLINEAR, V1st; Palmer AG, 2004, CHEM REV, V104, P3623, DOI 10.1021/cr030413t; PERUTZ MF, 1993, PHILOS T R SOC A, V345, P105, DOI 10.1098/rsta.1993.0122; PIMENTEL GC, 1971, ANNU REV PHYS CHEM, V22, P347, DOI 10.1146/annurev.pc.22.100171.002023; Reichardt C., 2003, SOLVENTS SOLVENT EFF, V3rd; Schneider H.-J., 2000, PRINCIPLES METHODS S; Tan HS, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1883605; THROOP GJ, 1965, J CHEM PHYS, V42, P2408, DOI 10.1063/1.1696308; Vinogradov S.N., 1971, HYDROGEN BONDING	21	371	375	2	138	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 26	2005	309	5739					1338	1343		10.1126/science.1116213	http://dx.doi.org/10.1126/science.1116213			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TX	16081697				2022-12-28	WOS:000231543300034
J	Ikeda, N; Ohsumi, H; Ohwada, K; Ishii, K; Inami, T; Kakurai, K; Murakami, Y; Yoshii, K; Mori, S; Horibe, Y; Kito, H				Ikeda, N; Ohsumi, H; Ohwada, K; Ishii, K; Inami, T; Kakurai, K; Murakami, Y; Yoshii, K; Mori, S; Horibe, Y; Kito, H			Ferroelectricity from iron valence ordering in the charge-frustrated system LuFe2O4	NATURE			English	Article								Ferroelectric materials are widely used in modern electric devices such as memory elements, filtering devices and high-performance insulators. Ferroelectric crystals have a spontaneous electric polarization arising from the coherent arrangement of electric dipoles(1) ( specifically, a polar displacement of anions and cations). First-principles calculations(2,3) and electron density analysis(4) of ferroelectric materials have revealed that the covalent bond between the anions and cations, or the orbital hybridization of electrons on both ions, plays a key role in establishing the dipolar arrangement. However, an alternative model - electronic ferroelectricity(5) - has been proposed in which the electric dipole depends on electron correlations, rather than the covalency. This would offer the attractive possibility of ferroelectric materials that could be controlled by the charge, spin and orbital degrees of freedom of the electron. Here we report experimental evidence for ferroelectricity arising from electron correlations in the triangular mixed valence oxide, LuFe2O4. Using resonant X-ray scattering measurements, we determine the ordering of the Fe2+ and Fe3+ ions. They form a superstructure that supports an electric polarization consisting of distributed electrons of polar symmetry. The polar ordering arises from the repulsive property of electrons - electron correlations - acting on a frustrated geometry.	SPring8, Japan Synchrotron Radiat Res Inst, Mikazuki, Hyogo 6795198, Japan; Japan Atom Energy Res Inst, SPring8, Synchrotron Radiat Res Ctr, Mikazuki, Hyogo 6795148, Japan; Japan Atom Energy Res Inst, Ibaraki 3191195, Japan; Tohoku Univ, Dept Phys, Sendai, Miyagi 9808578, Japan; Osaka Prefecture Univ, Dept Phys Sci, Osaka 5998531, Japan; Natl Inst Adv Ind Sci & Technol, Tsukuba, Ibaraki 3058561, Japan	Japan Synchrotron Radiation Research Institute; Japan Atomic Energy Agency; Japan Synchrotron Radiation Research Institute; Japan Atomic Energy Agency; Tohoku University; Osaka Metropolitan University; National Institute of Advanced Industrial Science & Technology (AIST)	Ikeda, N (corresponding author), SPring8, Japan Synchrotron Radiat Res Inst, Mikazuki, Hyogo 6795198, Japan.	ikedan@spring8.or.jp	Kito, Hijiri/L-6292-2018; Ishii, Kenji/G-3453-2017; Ohsumi, Hiroyuki/H-2550-2013; 吉井, 賢資/AAH-4272-2019; IKEDA, Naoshi/B-2587-2011	Kito, Hijiri/0000-0001-5655-8933; Ishii, Kenji/0000-0002-6465-8202; Yoshii, Kenji/0000-0001-9346-5875; Murakami, youichi/0000-0003-4507-4209; Ohsumi, Hiroyuki/0000-0002-6418-8984				Blume, 1994, RESONANT ANOMALOUS X; COHEN RE, 1992, NATURE, V358, P136, DOI 10.1038/358136a0; FUNAHASHI S, 1984, J PHYS SOC JPN, V53, P2688, DOI 10.1143/JPSJ.53.2688; Hill NA, 2000, J PHYS CHEM B, V104, P6694, DOI [10.1021/jp000114x, 10.1021/jpc00114x]; IKEDA N, 1994, J PHYS SOC JPN, V63, P4556, DOI 10.1143/JPSJ.63.4556; Ikeda N, 2000, J PHYS SOC JPN, V69, P1526, DOI 10.1143/JPSJ.69.1526; Kimizuka N., 1990, HDB PHYS CHEM RARE E, V13, P283; KITTEL C, 1995, INTRO SOLID STATE PH; Kuroiwa Y, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.217601; MEKATA M, 1978, J PHYS SOC JPN, V44, P806, DOI 10.1143/JPSJ.44.806; Murakami Y, 1998, PHYS REV LETT, V80, P1932, DOI 10.1103/PhysRevLett.80.1932; Portengen T, 1996, PHYS REV B, V54, P17452, DOI 10.1103/PhysRevB.54.17452; SAGHISZABO G, 2001, PHYS REV LETT, V87; SASAKI S, 1995, REV SCI INSTRUM, V66, P1573, DOI 10.1063/1.1145911; TANAKA M, 1984, J PHYS SOC JPN, V53, P760, DOI 10.1143/JPSJ.53.760; Yamada Y, 1997, J PHYS SOC JPN, V66, P3733, DOI 10.1143/JPSJ.66.3733	16	792	816	6	346	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 25	2005	436	7054					1136	1138		10.1038/nature04039	http://dx.doi.org/10.1038/nature04039			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	958AK	16121175				2022-12-28	WOS:000231416600040
J	Watanabe, N; Wang, YH; Lee, HK; Ito, T; Wang, YH; Cao, W; Liu, YJ				Watanabe, N; Wang, YH; Lee, HK; Ito, T; Wang, YH; Cao, W; Liu, YJ			Hassall's corpuscles instruct dendritic cells to induce CD4(+)CD25(+) regulatory T cells in human thymus	NATURE			English	Article							EPITHELIAL-CELLS; HUMAN THYMOCYTES; GROWTH-FACTOR; GUINEA-PIG; IN-VITRO; SELECTION; EXPRESSION; SELF; PEPTIDE; DIFFERENTIATION	Hassall's corpuscles - first described in the human thymus over 150 years ago(1) - are groups of epithelial cells within the thymic medulla. The physical nature of these structures differs between mammalian species(2). Although Hassall's corpuscles have been proposed to act in both the removal of apoptotic thymocytes(3,4) and the maturation of developing thymocytes(5) within the thymus, the function of Hassall's corpuscles has remained an enigma. Here we report that human Hassall's corpuscles express thymic stromal lymphopoietin ( TSLP). Human TSLP activates thymic CD11c-positive dendritic cells to express high levels of CD80 and CD86. These TSLP-conditioned dendritic cells are then able to induce the proliferation and differentiation of CD4(+) CD8(-) CD25(-) thymic T cells into CD4(+) CD25(+) FOXP3(+) (forkhead box P3) regulatory T cells. This induction depends on peptide - major histocompatibility complex class II interactions, and the presence of CD80 and CD86, as well as interleukin 2. Immunohistochemistry studies reveal that CD25(+) CTLA4(+) (cytotoxic T-lymphocyte-associated protein 4) regulatory T cells associate in the thymic medulla with activated or mature dendritic cells and TSLP-expressing Hassall's corpuscles. These findings suggest that Hassall's corpuscles have a critical role in dendritic-cell-mediated secondary positive selection of medium-to-high affinity self-reactive T cells, leading to the generation of CD4(+) CD25(+) regulatory T cells within the thymus.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77054 USA; Univ Texas, MD Anderson Canc Ctr, Ctr Canc Immunol Res, Houston, TX 77054 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Liu, YJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, 7455 Fannin St, Houston, TX 77054 USA.	yjliu@mdanderson.org	Lee, Heung Kyu/C-2073-2011	Lee, Heung Kyu/0000-0002-3977-1510; Cao, Wei/0000-0002-8952-9159				Annunziato F, 2000, J IMMUNOL, V165, P238, DOI 10.4049/jimmunol.165.1.238; Apostolou I, 2002, NAT IMMUNOL, V3, P756, DOI 10.1038/ni816; Bender J, 1999, J EXP MED, V190, P367, DOI 10.1084/jem.190.3.367; Bendriss-Vermare N, 2001, J CLIN INVEST, V107, P835, DOI 10.1172/JCI11734; BLAU JN, 1967, IMMUNOLOGY, V12, P363; BLAU JN, 1965, NATURE, V208, P564, DOI 10.1038/208564a0; Ernst B, 1999, IMMUNITY, V11, P173, DOI 10.1016/S1074-7613(00)80092-8; Farr AG, 2002, IMMUNOL REV, V189, P20, DOI 10.1034/j.1600-065X.2002.18903.x; Fontenot JD, 2004, SEMIN IMMUNOL, V16, P73, DOI 10.1016/j.smim.2003.12.002; FRIEND SL, 1994, EXP HEMATOL, V22, P321; Hassall AH., 1885, INHALATION TREATMENT; HE W, 1995, J IMMUNOL, V154, P3726; Hsieh CS, 2004, IMMUNITY, V21, P267, DOI 10.1016/j.immuni.2004.07.009; Jordan MS, 2001, NAT IMMUNOL, V2, P301, DOI 10.1038/86302; Klein L, 2000, CURR OPIN IMMUNOL, V12, P179, DOI 10.1016/S0952-7915(99)00069-2; LE PT, 1991, J EXP MED, V174, P1147, DOI 10.1084/jem.174.5.1147; Leonard WJ, 2002, NAT IMMUNOL, V3, P605, DOI 10.1038/ni0702-605; Malek TR, 2002, IMMUNITY, V17, P167, DOI 10.1016/S1074-7613(02)00367-9; Nishio H, 2001, ACTA HISTOCHEM, V103, P89, DOI 10.1078/0065-1281-00581; Romagnani P, 1998, BLOOD, V91, P3323, DOI 10.1182/blood.V91.9.3323.3323_3323_3332; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; SENELAR R, 1976, BIOMEDICINE, V24, P112; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Stephens LA, 2001, EUR J IMMUNOL, V31, P1247, DOI 10.1002/1521-4141(200104)31:4<1247::AID-IMMU1247>3.0.CO;2-M; Tai XG, 2005, NAT IMMUNOL, V6, P152, DOI 10.1038/ni1160; Tarbell KV, 2004, J EXP MED, V199, P1467, DOI 10.1084/jem.20040180; Von Boehmer H, 2004, ADV IMMUNOL, V84, P201, DOI 10.1016/S0065-2776(04)84006-9; Watanabe N, 2004, NAT IMMUNOL, V5, P426, DOI 10.1038/ni1048; Zaitseva M, 2002, J IMMUNOL, V168, P2609, DOI 10.4049/jimmunol.168.6.2609	30	546	605	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 25	2005	436	7054					1181	1185		10.1038/nature03886	http://dx.doi.org/10.1038/nature03886			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	958AK	16121185				2022-12-28	WOS:000231416600051
J	Brouwer, WBF; Niessen, LW; Postma, MJ; Rutten, FFH				Brouwer, WBF; Niessen, LW; Postma, MJ; Rutten, FFH			Need for differential discounting of costs and health effects in cost effectiveness analyses	BRITISH MEDICAL JOURNAL			English	Editorial Material							BLOOD-PRESSURE; ENGLAND		Erasmus MC, Inst Med Technol Assessment, NL-3000 DR Rotterdam, Netherlands; Univ Groningen, Inst Drug Explorat, Groningen, Netherlands	Erasmus University Rotterdam; Erasmus MC; University of Groningen	Brouwer, WBF (corresponding author), Erasmus MC, Inst Med Technol Assessment, POB 1738, NL-3000 DR Rotterdam, Netherlands.	wbrouwer@erasmusmc.nl	Niessen, Louis/F-6254-2015	Niessen, Louis/0000-0002-8639-5191; Postma, Maarten/0000-0002-6306-3653; Brouwer, Werner/0000-0002-0476-8397				BROUWER WBF, 2000, J HEALTH SERV RES PO, V5, P1; BROUWER WBF, 2005, LEVEL DISCOUNT RATES; Cairns J., 2001, EC EVALUATION HLTH C; Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275; Drummond MF, 2015, METHODS EC EVALUATIO; Gold MR, 1996, COST EFFECTIVENESS H; Gravelle H, 2001, HEALTH ECON, V10, P587, DOI 10.1002/hec.618; Gray A, 2002, BRIT MED J, V325, P860, DOI 10.1136/bmj.325.7369.860; *HER MAJ TREAS, 2004, GREEN BOOK; KEELER EB, 1983, MANAGE SCI, V29, P300, DOI 10.1287/mnsc.29.3.300; NICE, 2004, GUID METH TECHN APPR; Parsonage M, 1992, Health Econ, V1, P71, DOI 10.1002/hec.4730010110; Pigou AC, 1932, EC WELFARE, V4th; Rawlins MD, 2004, BRIT MED J, V329, P224, DOI 10.1136/bmj.329.7459.224; Smith DH, 2001, INT J TECHNOL ASSESS, V17, P236, DOI 10.1017/S0266462300105094; Stearne MR, 1998, BMJ-BRIT MED J, V317, P720; Torgerson DJ, 1999, BRIT MED J, V319, P914, DOI 10.1136/bmj.319.7214.914; Trotter CL, 2002, BRIT MED J, V324, P809, DOI 10.1136/bmj.324.7341.809; Van Hout BA, 1998, HEALTH ECON, V7, P581, DOI 10.1002/(SICI)1099-1050(1998110)7:7<581::AID-HEC380>3.0.CO;2-U; Walker A, 2003, BRIT MED J, V327, P1316, DOI 10.1136/bmj.327.7427.1316; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304	21	152	155	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	AUG 20	2005	331	7514					446	448		10.1136/bmj.331.7514.446	http://dx.doi.org/10.1136/bmj.331.7514.446			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	958WB	16110075	Green Published, Green Submitted			2022-12-28	WOS:000231477800024
J	Huntley, JS				Huntley, JS			Benefits of experience - missing the perf	LANCET			English	Editorial Material									Musculoskeletal Res Unit, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh	Huntley, JS (corresponding author), Musculoskeletal Res Unit, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	jimhuntley@doctors.org.uk		Huntley, James/0000-0003-1826-4007					0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 20	2005	366	9486					687	687		10.1016/S0140-6736(05)67142-5	http://dx.doi.org/10.1016/S0140-6736(05)67142-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958EB	16112307				2022-12-28	WOS:000231426400034
J	Dibra, A; Kastrati, A; Mehilli, J; Pache, J; Schuhlen, H; von Beckerath, N; Ulm, K; Wessely, R; Dirschinger, J; Schomig, A				Dibra, A; Kastrati, A; Mehilli, J; Pache, J; Schuhlen, H; von Beckerath, N; Ulm, K; Wessely, R; Dirschinger, J; Schomig, A		ISAR-DIABETES Study Investigators	Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BALLOON-EXPANDABLE STENT; SURROGATE END-POINTS; CORONARY REVASCULARIZATION; CLINICAL-TRIALS; MELLITUS; ANGIOPLASTY; ATHEROSCLEROSIS; OUTCOMES; CARDIOLOGY; ABCIXIMAB	Background: Drug-eluting stents are highly effective in reducing the rate of in-stent restenosis. It is not known whether there are differences in the effectiveness of currently approved drug-eluting stents in the high-risk subgroup of patients with diabetes mellitus. Methods: We enrolled 250 patients with diabetes and coronary artery disease: 125 were randomly assigned to receive paclitaxel-eluting stents, and 125 to receive sirolimus-eluting stents. The primary end point was in-segment late luminal loss. Secondary end points were angiographic restenosis (defined as in-segment stenosis of at least 50 percent at follow-up angiography) and the need for revascularization of the target lesion during a nine-month follow-up period. The study was designed to show noninferiority of the paclitaxel stent as compared with the sirolimus stent, defined as a difference in the extent of in-segment late luminal loss of no more than 0.16 mm. Results: The extent of in-segment late luminal loss was 0.24 mm (95 percent confidence interval, 0.09 to 0.39) greater in the paclitaxel-stent group than in the sirolimus-stent group (P=0.002). In-segment restenosis was identified on follow-up angiography in 16.5 percent of the patients in the paclitaxel-stent group and 6.9 percent of the patients in the sirolimus-stent group (P=0.03). Target-lesion revascularization was performed in 12.0 percent of the patients in the paclitaxel-stent group and 6.4 percent of the patients in the sirolimus-stent group (P=0.13). Conclusions: In patients with diabetes mellitus and coronary artery disease, use of the sirolimus-eluting stent is associated with a decrease in the extent of late luminal loss, as compared with use of the paclitaxel-eluting stent, suggesting a reduced risk of restenosis.	Deutsch Herzzentrum Munich, D-80636 Munich, Germany; Tech Univ, Med Klin Rechts Isar 1, Munich, Germany; Tech Univ, Inst Med Stat & Epidemiol, Munich, Germany	German Heart Centre Munich; Technical University of Munich; Technical University of Munich	Kastrati, A (corresponding author), Deutsch Herzzentrum Munich, Lazarettstr 36, D-80636 Munich, Germany.	kastrati@dhm.mhn.de	, Kastrati/Y-2389-2019; Mehilli, Julinda/F-2629-2016	Schuhlen, Helmut/0000-0001-8630-4264				Abizaid A, 1998, J AM COLL CARDIOL, V32, P584, DOI 10.1016/S0735-1097(98)00286-1; [Anonymous], 1985, World Health Organ Tech Rep Ser, V727, P1; Bauters C, 1997, PROG CARDIOVASC DIS, V40, P107, DOI 10.1016/S0033-0620(97)80003-5; CARROZZA JP, 1993, ANN INTERN MED, V118, P344, DOI 10.7326/0003-4819-118-5-199303010-00004; Chow S, 1992, DESIGN ANAL BIOAVAIL; Colombo A, 2003, CIRCULATION, V108, P788, DOI 10.1161/01.CIR.0000086926.62288.A6; D'Agostino RB, 2003, STAT MED, V22, P169, DOI 10.1002/sim.1425; Elezi S, 1998, J AM COLL CARDIOL, V32, P1866, DOI 10.1016/S0735-1097(98)00467-7; ELLIS SG, 1990, CIRCULATION, V82, P1193, DOI 10.1161/01.CIR.82.4.1193; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; Frye RL, 2003, CIRCULATION, V107, P1837, DOI 10.1161/01.CIR.0000066419.24566.28; Goraya TY, 2002, J AM COLL CARDIOL, V40, P946, DOI 10.1016/S0735-1097(02)02065-X; Grundy SM, 2001, CIRCULATION, V104, P491, DOI 10.1161/01.CIR.104.4.491; Hermiller JB, 2005, J AM COLL CARDIOL, V45, P1172, DOI 10.1016/j.jacc.2004.10.075; Hurst RT, 2003, ANN INTERN MED, V139, P824, DOI 10.7326/0003-4819-139-10-200311180-00010; Kastrati A, 2004, NEW ENGL J MED, V350, P232, DOI 10.1056/NEJMoa031859; Kastrati A, 2005, JAMA-J AM MED ASSOC, V293, P165, DOI 10.1001/jama.293.2.165; Kuntz RE, 1999, CIRCULATION, V99, P847, DOI 10.1161/01.CIR.99.7.847; Leon MB, 2003, AM HEART J, V146, DOI 10.1016/j.ahj.2003.09.004; Luscher TF, 2003, CIRCULATION, V108, P1655, DOI 10.1161/01.CIR.0000089189.70578.E2; Mak KH, 2003, EUR HEART J, V24, P1087, DOI 10.1016/S0195-668X(03)00111-8; Mauri L, 2005, CIRCULATION, V111, P321, DOI 10.1161/01.CIR.0000153356.72810.97; Mehilli J, 2004, CIRCULATION, V110, P3627, DOI 10.1161/01.CIR.0000148956.93631.4D; Mehran R, 1999, CIRCULATION, V100, P1872, DOI 10.1161/01.CIR.100.18.1872; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; Moses JW, 2003, NEW ENGL J MED, V349, P1315, DOI 10.1056/NEJMoa035071; Moussa I, 2004, CIRCULATION, V109, P2273, DOI 10.1161/01.CIR.0000129767.45513.71; O'Brien RG., APPL ANAL VARIANCE B, V1993, P297; Popma JJ, 2004, CIRCULATION, V110, P3773, DOI 10.1161/01.CIR.0000150331.14687.4B; Psaty BM, 1999, JAMA-J AM MED ASSOC, V282, P786, DOI 10.1001/jama.282.8.786; Regar E, 2002, CIRCULATION, V106, P1949, DOI 10.1161/01.CIR.0000034045.36219.12; Sousa JE, 2003, CIRCULATION, V107, P2383, DOI 10.1161/01.CIR.0000069331.67148.2F; Sousa JE, 2003, CIRCULATION, V107, P2274, DOI 10.1161/01.CIR.0000069330.41022.90; Stone GW, 2004, NEW ENGL J MED, V350, P221, DOI 10.1056/NEJMoa032441; Topol EJ, 1998, LANCET, V352, P87, DOI 10.1016/S0140-6736(98)85010-1; REALITY LAST REALITY	36	412	446	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 18	2005	353	7					663	670		10.1056/NEJMoa044372	http://dx.doi.org/10.1056/NEJMoa044372			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955UW	16105990	Bronze			2022-12-28	WOS:000231254100004
J	Keegan, M; Konig, F; McClelland, R; Bruck, W; Morales, Y; Bitsch, A; Panitch, H; Lassmann, H; Weinshenker, B; Rodriguez, M; Parisi, J; Lucchinetti, CF				Keegan, M; Konig, F; McClelland, R; Bruck, W; Morales, Y; Bitsch, A; Panitch, H; Lassmann, H; Weinshenker, B; Rodriguez, M; Parisi, J; Lucchinetti, CF			Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange	LANCET			English	Article							DEMYELINATING DISEASE; ANTIBODIES	Early, active multiple sclerosis lesions show four immunopathological patterns of demyelination. Although these patterns differ between patients, multiple active lesions from a given patient have an identical pattern, which suggests pathogenic heterogeneity. Therapeutic plasma exchange (TPE) has been successfully used to treat fulminant demyelinating attacks unresponsive to steroids. We postulated that patients with pattern II would be more likely to improve after TPE than those with other patterns since pattern II lesions are distinguished by prominent immunoglobulin deposition and complement activation. We retrospectively studied 19 patients treated with TPE for an attack of fulminant CNS inflammatory demyelinating disease. All patients with pattern II (n=10), but none with pattern I (n=3) or pattern III (n=6), achieved moderate to substantial functional neurological improvement after TPE (p<0.0001). Patients with multiple sclerosis with pattern II pathology are more likely to respond favourably to TPE than are patients with patterns I or III.	Mayo Clin Coll Med, Dept Neurol, Rochester, MN 55905 USA; Mayo Clin Coll Med, Dept Hlth Sci Res, Rochester, MN 55905 USA; Mayo Clin Coll Med, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Mayo Clin Coll Med, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin Coll Med, Mayo Grad Sch, Rochester, MN 55905 USA; Inst Neuropathol, Gottingen, Germany; Ruppiner Kliniken GmbH, Neuruppin, Germany; Univ Vermont, Burlington, VT USA; Univ Vienna, Brain Res Inst, Vienna, Austria	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Ruppiner Kliniken GmbH; University of Vermont; University of Vienna	Lucchinetti, CF (corresponding author), Mayo Clin Coll Med, Dept Neurol, Rochester, MN 55905 USA.	lucchinetti.claudia@mayo.edu	Weinshenker, Brian G/ABH-6146-2020; Lassmann, Hans/Z-2269-2019	Weinshenker, Brian G/0000-0001-5806-6203; Lassmann, Hans/0000-0001-8617-5052; Odia, Yazmin/0000-0003-3602-3899; Rodriguez, Moses/0000-0001-6328-6497				Berger T, 2003, NEW ENGL J MED, V349, P139, DOI 10.1056/NEJMoa022328; Cross AH, 2001, J NEUROIMMUNOL, V112, P1, DOI 10.1016/S0165-5728(00)00409-4; Keegan M, 2002, NEUROLOGY, V58, P143, DOI 10.1212/WNL.58.1.143; Lennon VA, 2004, LANCET, V364, P2106, DOI 10.1016/S0140-6736(04)17551-X; Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q; PITTOCK SJ, IN PRESS J NEUROL NE; WEINSHENKER B, 2001, MULTIPLE SCLEROSIS T, P267; Weinshenker BG, 1999, ANN NEUROL, V46, P878, DOI 10.1002/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q	8	304	316	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 13	2005	366	9485					579	582		10.1016/S0140-6736(05)67102-4	http://dx.doi.org/10.1016/S0140-6736(05)67102-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955LL	16099294				2022-12-28	WOS:000231227300030
J	Takeda, K; Yanagida, M				Takeda, K; Yanagida, M			Regulation of nuclear proteasome by Rhp6/Ubc2 through ubiquitination and destruction of the sensor and anchor Cut8	CELL			English	Article							REPAIR GENE RAD6; FISSION YEAST; DNA-REPAIR; SCHIZOSACCHAROMYCES-POMBE; CONJUGATING ENZYME; 26S PROTEASOME; SACCHAROMYCES-CEREVISIAE; COMPLEX-FORMATION; MITOSIS; PROTEIN	While proteasome is central to the degradation of cellular ubiquitinated proteins, the control of its nuclear function is barely understood. Here we show that the fission yeast ubiquitin-conjugating Rhp6/Ubc2/Rad6 and ligating enzymes Ubr1 are responsible for nuclear enrichment of proteasome through the function of Cut8, a nuclear envelope protein. Cut8 is an Rhp6 substrate that physically interacts with and tethers proteasome. Nonubiquitinatable K-all-R Cut8 weakly interacts with proteasome and fails to enrich nuclear proteasome. Consistently, the nuclear enrichment of proteasome also falls in rhp6 and ubr1 null mutants. Further, cut8 null and cut8 K-all-R mutants are hypersensitive to DNA damage, probably due to the paucity of nuclear proteasome. Thus, Rhp6 enhances the retention of nuclear proteasome through regulating Cut8. The short-lived nature of Cut8 is crucial for feedback enrichment of the proteasome within the nucleus. This is likely to be a conserved mechanism as we describe a Cut8 homolog in flies.	Kyoto Univ, Grad Sch Biostudies, Dept Gene Mechanisms, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University; Kyoto University	Yanagida, M (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Gene Mechanisms, Sakyo Ku, Kyoto 6068501, Japan.	yanagida@kozo.lif.kyoto-u.ac.jp						ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; Du FY, 2002, P NATL ACAD SCI USA, V99, P14110, DOI 10.1073/pnas.172527399; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; Gordon C, 1996, J BIOL CHEM, V271, P5704, DOI 10.1074/jbc.271.10.5704; Goshima G, 2003, J CELL BIOL, V162, P1003, DOI 10.1083/jcb.200303022; Gutz H., 1974, HDB GENETICS, V1, P395; Hershko A, 1999, PHILOS T R SOC B, V354, P1571, DOI 10.1098/rstb.1999.0500; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Kao CF, 2004, GENE DEV, V18, P184, DOI 10.1101/gad.1149604; Kitamura K, 2001, DEV CELL, V1, P389, DOI 10.1016/S1534-5807(01)00037-5; KOKEN MHM, 1991, P NATL ACAD SCI USA, V88, P8865, DOI 10.1073/pnas.88.20.8865; Kominami K, 1998, GENES CELLS, V3, P721, DOI 10.1046/j.1365-2443.1998.00225.x; Krogan NJ, 2004, MOL CELL, V16, P1027, DOI 10.1016/j.molcel.2004.11.033; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; Mitchison JM, 1970, METHOD CELL PHYSIOL, V4, P131; Nabeshima K, 1997, METHOD ENZYMOL, V283, P459; Nielsen IS, 2002, EUKARYOT CELL, V1, P613, DOI 10.1128/EC1.4.613-625.2002; Osaka F, 1997, MOL CELL BIOL, V17, P3388, DOI 10.1128/MCB.17.6.3388; PAL JK, 1994, INT J DEV BIOL, V38, P525; PRAKASH L, 1989, GENOME, V31, P597, DOI 10.1139/g89-111; REYNOLDS P, 1990, EMBO J, V9, P1423, DOI 10.1002/j.1460-2075.1990.tb08258.x; Roest HP, 1996, CELL, V86, P799, DOI 10.1016/S0092-8674(00)80154-3; Rowley R, 1999, GENETICS, V152, P61; SAMEJIMA I, 1994, MOL CELL BIOL, V14, P6361, DOI 10.1128/MCB.14.9.6361; Seino H, 2003, MOL CELL BIOL, V23, P3497, DOI 10.1128/MCB.23.10.3497-3505.2003; Shekhar MPV, 2002, CANCER RES, V62, P2115; Singh J, 1998, MOL CELL BIOL, V18, P5511, DOI 10.1128/MCB.18.9.5511; Tamai KK, 2002, J CELL SCI, V115, P1847; TANAKA K, 1989, J CELL PHYSIOL, V139, P34, DOI 10.1002/jcp.1041390107; Tatebe H, 2000, CURR BIOL, V10, P1329, DOI 10.1016/S0960-9822(00)00773-9; Wilkinson CRM, 1998, EMBO J, V17, P6465, DOI 10.1093/emboj/17.22.6465; Xie YM, 2000, P NATL ACAD SCI USA, V97, P2497, DOI 10.1073/pnas.060025497; Xin H, 2000, NUCLEIC ACIDS RES, V28, P2847, DOI 10.1093/nar/28.14.2847; Yamano H, 2004, J BIOL CHEM, V279, P18974, DOI 10.1074/jbc.M311060200; Yamashita YM, 1996, NATURE, V384, P276, DOI 10.1038/384276a0; Yen HCS, 2003, CELL, V112, P207, DOI 10.1016/S0092-8674(03)00043-6	43	66	68	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 12	2005	122	3					393	405		10.1016/j.cell.2005.05.023	http://dx.doi.org/10.1016/j.cell.2005.05.023			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	955UZ	16096059	Bronze			2022-12-28	WOS:000231254400011
J	Ryan, J; Montgomery, H				Ryan, J; Montgomery, H			The London attacks - preparedness - Terrorism and the medical response	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									UCL, London WC1E 6BT, England; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; UCL Hosp, London, England	University of London; University College London; Uniformed Services University of the Health Sciences - USA; University College London Hospitals NHS Foundation Trust; University of London; University College London	Ryan, J (corresponding author), UCL, London WC1E 6BT, England.		Montgomery, Hugh/L-1229-2019; Montgomery, Hugh/C-2592-2008	Montgomery, Hugh/0000-0001-8797-5019				Chaloner E, 2005, BRIT MED J, V331, P119, DOI 10.1136/bmj.331.7509.119; Gutierrez de Ceballos J Peral, 2005, Crit Care Med, V33, pS107, DOI 10.1097/01.CCM.0000151072.17826.72; Kluger Y, 2004, Scand J Surg, V93, P11	3	37	38	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 11	2005	353	6					543	545		10.1056/NEJMp058177	http://dx.doi.org/10.1056/NEJMp058177			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	953ST	16093460	Bronze			2022-12-28	WOS:000231101500002
J	McManus, IC				McManus, IC			Sir James Paget's research into medical education	LANCET			English	Editorial Material							STUDENTS		UCL, Dept Psychol, London WC1E 6BT, England	University of London; University College London	McManus, IC (corresponding author), UCL, Dept Psychol, Gower St, London WC1E 6BT, England.	i.mcmanus@ucl.ac.uk		McManus, Ian/0000-0003-3510-4814				Arulampalam W, 2004, MED EDUC, V38, P492, DOI 10.1046/j.1365-2929.2004.01815.x; Bauer AW, 2005, MED BIBL INF, V5, P16; Becker Howard, 1961, BOYS WHITE STUDENT C; Bliss Michael, 2007, WILLIAM OSLER LIFE M; Bonner T., 1995, BECOMING PHYS MED ED; Brody H, 2000, LANCET, V356, P64, DOI 10.1016/S0140-6736(00)02442-9; CALLENDER GW, 1864, PRESENT SYSTEM MED E; Corner EM, 1929, LANCET, V2, P951; CORNER EM, 1920, ST THOMASS HOSP GAZE, V27, P288; Critchley M, 1998, JH JACKSON FATHER EN; DOBSON J, 1949, J BONE JOINT SURG BR, V31, P127, DOI 10.1302/0301-620X.31B1.127; Eliot G., 1965, MIDDLEMARCH; Flexner A, 1925, MED ED COMP STUDY; Galton F, 1889, NATURAL INHERITANCE, P1; GRAVES R, 1957, HANGED MY SAINTLY BI; Hamarneh Sami K., 1970, HIST MED ED, P39; HARRIS AD, 1948, LANCET, V2, P317; Hodgkin T, 1828, ESSAY MED ED; HUTCHINSON H, 1946, LIFE LETT J HUTCHINS; Kinnell HG, 2000, BRIT MED J, V321, P1594, DOI 10.1136/bmj.321.7276.1594; LITTLE EG, 1929, LANCET, V2, P907; McGuire C, 1999, MED EDUC, V33, P312; McManus IC, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-29; Mcmanus IC, 1996, BRIT MED J, V313, P173, DOI 10.1136/bmj.313.7050.173a; Mendel G., 1866, VERHAND NATURF VER B, V4, P3, DOI DOI 10.5962/BHL.TITLE.61004; Merton R, 1957, STUDENT PHYS; Miller J F, 1969, Transplant Rev, V1, P3; Nutton Vivian, 1995, HIST MED ED BRITAIN; Osler W, 1932, AEQUANIMITAS; PAGET J, 1902, SELECTED ESSAYS ADDR, P381; PAGET J, 1869, BARTHOLOMEWS HOSP RE, V5, P238; PAGET J, 1871, LANCET, V1, P735; PAGET J, 1871, LANCET, V1, P774; PAGET J, 2003, MEMOIRS LETT J PAGET; PAGET J, 1879, BARTHOLOMEWS HOSP RE, V15, P41; PAROSKI MW, 1985, NEUROLOGY, V35, P448, DOI 10.1212/WNL.35.3.448; PETERSON MJ, 1984, B HIST MED, V58, P457; PETERSON MJ, 1814, JAMES 1 BARONET; POWER D, 1833, THOMAS 1 BARONAT; Rothman KJ, 1996, LANCET, V347, P37, DOI 10.1016/S0140-6736(96)91562-7; SHAW AB, 1980, PRACTITIONER, V224, P1323; Simpson MA., 1972, MED ED CRITICAL APPR; Thornton J L, 1957, Ann R Coll Surg Engl, V21, P199; THORNTON JL, 1957, MED STUDENTS BARTHOL; TURNER SM, 1860, LANCET, V1, P382; Waddington K, 2002, SOC HIST MED, V15, P45, DOI 10.1093/shm/15.1.45; WADDINGTON K, 2003, MED ED ST BARTHOLOME, P1123; WELCH WH, 1924, MED SCI GERMAN U STU; White H., 1974, ROYAL HOSP SAINT BAR, P205; 2005, LANCET, V1, P593; 1869, MED TIMES GAZETTE, V2, P645; 1869, LANCET, V2, P653; 1946, BMJ, V2, P375; 1948, LANCET, V2, P333; 1909, BMJ, V2, P1101; 1847, TIMES LONDON    0512, P7; 1843, LANCET, V40, P487; 2003, DERBY EVENING T 1106	58	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 6	2005	366	9484					506	513		10.1016/S0140-6736(05)67064-X	http://dx.doi.org/10.1016/S0140-6736(05)67064-X			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	952RD	16084260				2022-12-28	WOS:000231022300033
J	Chen, ZB; Trotman, LC; Shaffer, D; Lin, HK; Dotan, ZA; Niki, M; Koutcher, JA; Scher, HI; Ludwig, T; Gerald, W; Cordon-Cardo, C; Pandolfi, PP				Chen, ZB; Trotman, LC; Shaffer, D; Lin, HK; Dotan, ZA; Niki, M; Koutcher, JA; Scher, HI; Ludwig, T; Gerald, W; Cordon-Cardo, C; Pandolfi, PP			Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis	NATURE			English	Article							PROSTATE-CANCER; P53; CELLS; PATHWAY; REGION; MDM2	Cellular senescence has been theorized to oppose neoplastic transformation triggered by activation of oncogenic pathways in vitro(1-3), but the relevance of senescence in vivo has not been established. The PTEN and p53 tumour suppressors are among the most commonly inactivated or mutated genes in human cancer including prostate cancer(4,5). Although they are functionally distinct, reciprocal cooperation has been proposed, as PTEN is thought to regulate p53 stability, and p53 to enhance PTEN transcription(6-10). Here we show that conditional inactivation of Trp53 in the mouse prostate fails to produce a tumour phenotype, whereas complete Pten inactivation in the prostate triggers non-lethal invasive prostate cancer after long latency. Strikingly, combined inactivation of Pten and Trp53 elicits invasive prostate cancer as early as 2 weeks after puberty and is invariably lethal by 7 months of age. Importantly, acute Pten inactivation induces growth arrest through the p53-dependent cellular senescence pathway both in vitro and in vivo, which can be fully rescued by combined loss of Trp53. Furthermore, we detected evidence of cellular senescence in specimens from early-stage human prostate cancer. Our results demonstrate the relevance of cellular senescence in restricting tumorigenesis in vivo and support a model for cooperative tumour suppression in which p53 is an essential failsafe protein of Pten-deficient tumours.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Canc Biol & Genet Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Pathol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Radiol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Med Phys, New York, NY 10021 USA; Columbia Univ, Inst Canc Genet, Dept Anat & Cell Biol, New York, NY 10032 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Columbia University	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Canc Biol & Genet Program, 1275 York Ave, New York, NY 10021 USA.	p-pandolfi@ski.mskcc.org	Ludwig, Thomas/Q-6484-2016	Ludwig, Thomas/0000-0003-3461-2585; Dotan, Zohar/0000-0002-9005-2992	NCI NIH HHS [P50 CA092629, R01 CA137050] Funding Source: Medline; NIMHD NIH HHS [R01 MD004038] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA137050, P50CA092629] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [R01MD004038] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))		Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Feilotter HE, 1998, ONCOGENE, V16, P1743, DOI 10.1038/sj.onc.1200205; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Hermans KG, 2004, GENE CHROMOSOME CANC, V39, P171, DOI 10.1002/gcc.10311; Jonkers J, 2002, NAT REV CANCER, V2, P251, DOI 10.1038/nrc777; Levi F, 2004, PROSTATE, V60, P46, DOI 10.1002/pros.20058; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Maeda T, 2005, NATURE, V433, P278, DOI 10.1038/nature03203; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Miyauchi H, 2004, EMBO J, V23, P212, DOI 10.1038/sj.emboj.7600045; Muller M, 2000, Prostate Cancer Prostatic Dis, V3, pS32, DOI 10.1038/sj.pcan.4500457; Navone NM, 1999, J UROLOGY, V161, P304, DOI 10.1016/S0022-5347(01)62136-0; Qian JQ, 2002, MODERN PATHOL, V15, P35, DOI 10.1038/modpathol.3880487; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Stewart Sherri L., 2004, Morbidity and Mortality Weekly Report, V53, P1; Suzuki H, 1998, CANCER RES, V58, P204; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Trotman LC, 2003, CANCER CELL, V3, P97, DOI 10.1016/S1535-6108(03)00022-9; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	30	1473	1527	2	108	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 4	2005	436	7051					725	730		10.1038/nature03918	http://dx.doi.org/10.1038/nature03918			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	951XA	16079851	Green Accepted			2022-12-28	WOS:000230964500049
J	Collado, M; Gil, J; Efeyan, A; Guerra, C; Schuhmacher, AJ; Barradas, M; Benguria, A; Zaballos, A; Flores, JM; Barbacid, M; Beach, D; Serrano, M				Collado, M; Gil, J; Efeyan, A; Guerra, C; Schuhmacher, AJ; Barradas, M; Benguria, A; Zaballos, A; Flores, JM; Barbacid, M; Beach, D; Serrano, M			Tumour biology - Senescence in premalignant tumours	NATURE			English	Editorial Material							RAS; P53		CNIO, Spanish Natl Canc Ctr, Madrid 28029, Spain; Univ London Imperial Coll Sci Technol & Med, MRC, Ctr Clin Sci, London W12 0NN, England; CSIC, CNB, Spanish Natl Ctr Biotechnol, E-28049 Madrid, Spain; Univ Complutense, Dept Anim Surg & Med, E-28040 Madrid, Spain; Inst Cell & Mol Sci, Ctr Cutaneous Res, London E1 2AT, England	Centro Nacional de Investigaciones Oncologicas (CNIO); Imperial College London; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Complutense University of Madrid; University of London; Queen Mary University London	Collado, M (corresponding author), CNIO, Spanish Natl Canc Ctr, Madrid 28029, Spain.	mserrano@cnio.es	J. Schuhmacher, Alberto/F-4028-2016; Zaballos, Ángel/O-2853-2015; Collado, Manuel/K-8140-2014; Efeyan, Alejo/J-8197-2016; Schuhmacher, Alberto J./R-6765-2019; Benguria, Alberto/M-9911-2014; Serrano, Manuel/H-2634-2015; Guerra, Carmen/K-5852-2014; Gil, Jesus/C-7739-2012	Collado, Manuel/0000-0002-0330-0880; Efeyan, Alejo/0000-0002-3806-6799; Schuhmacher, Alberto J./0000-0002-0136-1049; Benguria, Alberto/0000-0002-5536-566X; Serrano, Manuel/0000-0001-7177-9312; Gil, Jesus/0000-0002-4303-6260; Zaballos, Angel/0000-0002-7555-5815; Flores, Juana M/0000-0002-7995-4426; Guerra, Carmen/0000-0002-3891-046X				DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6	7	1117	1154	1	105	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 4	2005	436	7051					642	642		10.1038/436642a	http://dx.doi.org/10.1038/436642a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	951XA	16079833	Bronze			2022-12-28	WOS:000230964500030
J	Basoglu, M; Livanou, M; Crnobaric, C; Franciskovic, T; Suljic, E; Duric, D; Vranesic, M				Basoglu, M; Livanou, M; Crnobaric, C; Franciskovic, T; Suljic, E; Duric, D; Vranesic, M			Psychiatric and cognitive effects of war in former Yugoslavia - Association of lack of redress for trauma and posttraumatic stress reactions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EARTHQUAKE SURVIVORS; BEHAVIORAL TREATMENT; SINGLE-SESSION; DISORDER; TORTURE; TURKEY; RECONCILIATION; EVENTS; FEMALE; TRIAL	Context Although impunity for those responsible for trauma is widely thought to be associated with psychological problems in survivors of political violence, no study has yet investigated this issue. Objective To examine the mental health and cognitive effects of war trauma and how appraisal of redress for trauma and beliefs about justice, safety, other people, war cause, and religion relate to posttraumatic stress responses in war survivors. Design, Setting, and Participants A cross-sectional survey conducted between March 2000 and July 2002 with a population-based sample of 1358 war survivors who had experienced at least 1 war-related stressor (combat, torture, internal displacement, refugee experience, siege, and/or aerial bombardment) from 4 sites in former Yugoslavia, accessed through linkage sampling. Control groups at 2 study sites were matched with survivors on sex, age, and education. Main Outcome Measures Semi-structured Interview for Survivors of War, Redress for Trauma Survivors Questionnaire, Emotions and Beliefs After War questionnaire, Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Results The mean (SD) age was 39 (12) years, 806 (59%) were men, and 339 (25%) had high school or higher level of education. Participants reported experiencing a mean of 12.6 war-related events, with 292 (22%) and 451 (33%) having current and lifetime posttraumatic stress disorder (PTSD), respectively, and 129 (10%) with current major depression. A total of 1074 (79%) of the survivors reported a sense of injustice in relation to perceived lack of redress for trauma. Perceived impunity for those held responsible for trauma was only one of the factors associated with sense of injustice. Relative to controls, survivors had stronger emotional responses to impunity, greater fear and loss of control over life, less belief in benevolence of people, greater loss of meaning in war cause, stronger faith in God, and higher rates of PTSD and depression. Fear and loss of control over life were associated with PTSD and depression (odds ratio [OR], 2.91; 95% Cl, 2.27-3.74 and OR, 2.30; 95% Cl, 1.75-3.03, respectively), and emotional responses to impunity showed a relatively weaker association with PTSD (OR, 1.53; 95% Cl, 1.16-2.02) and depression (OR, 1.39; 95% Cl, 1.02-1.91). Appraisal of redress for trauma was not associated with PTSD or depression. Conclusions PTSD and depression in war survivors appear to be independent of sense of injustice arising from perceived lack of redress for trauma. Fear of threat to safety and loss of control over life appeared to be the most important mediating factors in PTSD and depression. These findings may have important implications for reconciliation efforts in postwar countries and effective interventions for traumatized war survivors.	Univ London Kings Coll, Inst Psychiat, Trauma Studies Unit, London SE5 8AF, England; Clin Hosp Zvezdara, Dept Psychiat, Belgrade, Serbia Monteneg; Univ Rijeka, Sch Med, Psychiat Clin, Psychotrauma Ctr, Rijeka, Croatia; Univ Sarajevo, Psychiat Clin, Sarajevo 71000, Bosnia & Herceg; Inst Phys Med & Rehabil Dr Miroslav Zotovic, Banja Luka, Republ Srpska, Bosnia & Herceg	University of London; King's College London; University of Rijeka; University of Sarajevo	Basoglu, M (corresponding author), Univ London Kings Coll, Inst Psychiat, Trauma Studies Unit, Box PO91,DeCrespigny Pk, London SE5 8AF, England.	spjumeb@iop.kcl.ac.uk	Livanou, Maria/AAH-6958-2019; Basoglu, Metin/A-1394-2008; Franciskovic, Tanja/R-8177-2018	Livanou, Maria/0000-0002-1373-4404; Franciskovic, Tanja/0000-0003-4106-9461				Basoglu M, 1997, PSYCHOL MED, V27, P1421, DOI 10.1017/S0033291797005679; BASOGLU M, 1994, JAMA-J AM MED ASSOC, V272, P357, DOI 10.1001/jama.272.5.357; Basoglu M, 2005, J TRAUMA STRESS, V18, P1, DOI 10.1002/jts.20011; BASOGLU M, 1993, JAMA-J AM MED ASSOC, V270, P606, DOI 10.1001/jama.270.5.606; BASOGLU M, 1994, AM J PSYCHIAT, V151, P76; Basoglu M, 2004, J TRAUMA STRESS, V17, P133, DOI 10.1023/B:JOTS.0000022619.31615.e8; Basoglu M, 2003, PSYCHOL MED, V33, P647, DOI 10.1017/S0033291703007360; Basoglu M, 2003, AM J PSYCHIAT, V160, P788, DOI 10.1176/appi.ajp.160.4.788; Basoglu M., 1992, TORTURE ITS CONSEQUE, P182; Basoglu M., 2001, MENTAL HLTH CONSEQUE, P35, DOI DOI 10.1007/978-1-4615-1295-0; BASOGLU M, 1996, J ANXIETY DISORD, V18, P357; BASOGLU M, 1996, TORTURE, V6, P61; Basoglu M., 1992, TORTURE ITS CONSEQUE, P1; Biro M., 2004, MY NEIGHBOR MY ENEMY, P183, DOI [10.1017/CBO9780511720352, DOI 10.1017/CBO9780511720352, DOI 10.1017/CBO9780511720352.013]; Carmichael K., 1996, TORTURE, V6, P7; Carmil D., 1991, J TRAUMA STRESS, V4, P393, DOI [10.1002/jts.2490040307, DOI 10.1002/JTS.2490040307]; DANIELI Y, 1996, INT RESPONSE TRAUMAT, P1; de Jong JTVM, 2001, JAMA-J AM MED ASSOC, V286, P555, DOI 10.1001/jama.286.5.555; ENGDAHL B, 2001, MENTAL HLTH CONSEQUE, P133; Fairbank J. A., 2001, MENTAL HLTH CONSEQUE, P121; First M. D., 1996, USERS GUIDE STRUCTUR; Fletcher L., 2004, MY NEIGHBOR MY ENEMY, P29; Foa EB, 2004, J CONSULT CLIN PSYCH, V72, P879, DOI 10.1037/0022-006X.72.5.879; Frank O, 1994, J OFF STAT, V10, P53; Gordon N., 1994, TORTURE, V4, P111; HAMBER B, 1995, SLEEPING DOGS LIE PS; HAYNER PB, 1994, HUM RIGHTS QUART, V16, P597, DOI 10.2307/762562; Herman Judith Lewis, 1997, TRAUMA RECOVERY AFTE, P189; JANOFFBULMAN R, 1992, SHATTERED ASSUMPTION, P70; Kaminer D, 2001, BRIT J PSYCHIAT, V178, P373, DOI 10.1192/bjp.178.4.373; King LA, 1998, J PERS SOC PSYCHOL, V74, P420, DOI 10.1037/0022-3514.74.2.420; KINZIE DJ, 2001, MENTAL HLTH CONSEQUE, P111; Lagos Dario, 1994, TORTURE, V4, P13; LERNER MJ, 1978, PSYCHOL BULL, V85, P1030, DOI 10.1037/0033-2909.85.5.1030; LIFTON RJ, 1976, PSYCHIATRY, V39, P1; Livanou M, 2002, PSYCHOL MED, V32, P157, DOI 10.1017/S0033291701004767; LOPES, 2000, JAMA, V284, P569; NEUMANN E, 1991, 3 INT C HLTH POL REP; Pham PN, 2004, JAMA-J AM MED ASSOC, V292, P602, DOI 10.1001/jama.292.5.602; ROHTARRIAZA N, 1995, IMPUNITY HUMAN RIGHT, P13; SALCIOGLU E, 2004, THESIS U LONDON; SILOVE D, 2001, MENTAL HLTH CONSEQUE, P159; Stover Eric., 2004, MY NEIGHBOR MY ENEMY, P104, DOI DOI 10.1177/1077801210382860; WATTERS JK, 1989, SOC PROBL, V36, P416, DOI 10.1525/sp.1989.36.4.03a00070	44	171	177	0	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	2005	294	5					580	590		10.1001/jama.294.5.580	http://dx.doi.org/10.1001/jama.294.5.580			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	951NN	16077052	Bronze			2022-12-28	WOS:000230937500018
J	Hampel, H; Abraham, NS; El-Serag, HB				Hampel, H; Abraham, NS; El-Serag, HB			Meta-analysis: Obesity and the risk for gastroesophageal reflux disease and its complications	ANNALS OF INTERNAL MEDICINE			English	Review							LOWER ESOPHAGEAL SPHINCTER; BODY-MASS INDEX; Y GASTRIC BYPASS; HELICOBACTER-PYLORI; BARRETTS-ESOPHAGUS; EROSIVE ESOPHAGITIS; HIATAL-HERNIA; UNITED-STATES; ADENOCARCINOMA; SYMPTOMS	Background: The association of body mass index and gastroesophageal reflux disease (GERD), including its complications (esophagitis, Barrett esophagus, and esophageal adenocarcinoma), is unclear. Purpose: To conduct a systematic review and meta-analysis to estimate the magnitude and determinants of an association between obesity and GERD symptoms, erosive esophagitis, Barrett esophagus, and adenocarcinoma of the esophagus and of the gastric cardia. Data Sources: MEDLINE search between 1966 and October 2004 for published full studies. Study Selection: Studies that provided risk estimates and met criteria on defining exposure and reporting outcomes and sample size. Data Extraction: Two investigators independently performed standardized search and data abstraction. Unadjusted and adjusted odds ratios for individual outcomes were obtained or calculated for each study and were pooled by using a random-effects model. Data Synthesis: Nine studies examined the association of body mass index (BMI) with GERD symptoms. Six of these studies found statistically significant associations. Six of 7 studies found significant associations of BMI with erosive esophagitis, 6 of 7 found significant associations with esophageal adenocarcinoma, and 4 of 6 found significant associations with gastric cardia adenocarcinoma. In data from 8 studies, there was a trend toward a dose-response relationship with an increase in the pooled adjusted odds ratios for GERD symptoms of 1.43 (95% CI, 1.158 to 1.774) for BMI of 25 kg/m(2) to 30 kg/m(2) and 1.94 (CI, 1.468 to 2.566) for BMI greater than 30 kg/m(2). Similarly, the pooled adjusted odds ratios for esophageal adenocarcinoma for BMI of 25 kg/m(2) to 30 kg/m(2) and BMI greater than 30 kg/m(2) were 1.52 (CI, 1.147 to 2.009) and 2.78 (CI, 1.850 to 4.164), respectively. Limitations: Heterogeneity in the findings was present, although it was mostly in the magnitude of statistically significant positive associations. No studies in this review examined the association between Barrett esophagus and obesity. Conclusion: Obesity is associated with a statistically significant increase in the risk for GERD symptoms, erosive esophagitis, and esophageal adenocarcinoma. The risk for these disorders seems to progressively increase with increasing weight.	Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA	Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Michael E DeBakey VA Medical Center	Hampel, H (corresponding author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.	hasheme@bcm.tmc.edu						ANDERSEN LI, 1991, J INTERN MED, V230, P5, DOI 10.1111/j.1365-2796.1991.tb00399.x; BACKMAN L, 1983, ACTA CHIR SCAND, V149, P193; Barak N, 2002, Obes Rev, V3, P9, DOI 10.1046/j.1467-789X.2002.00049.x; BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/oxfordjournals.aje.a115704; BERLIN JA, 1993, EPIDEMIOLOGY, V4, P218, DOI 10.1097/00001648-199305000-00005; Blot WJ, 1999, SEMIN ONCOL, V26, P2; BROWN LM, 1995, J NATL CANCER I, V87, P104, DOI 10.1093/jnci/87.2.104; Bujanda L, 2000, AM J GASTROENTEROL, V95, P3374, DOI 10.1111/j.1572-0241.2000.03347.x; Caygill CPJ, 2002, AM J GASTROENTEROL, V97, P1328, DOI 10.1111/j.1572-0241.2002.05768.x; Chak A, 2002, GUT, V51, P323, DOI 10.1136/gut.51.3.323; Chang CS, 1997, AM J GASTROENTEROL, V92, P668; Cheng KK, 2000, BRIT J CANCER, V83, P127; Chow WH, 1998, JNCI-J NATL CANCER I, V90, P150, DOI 10.1093/jnci/90.2.150; Devesa SS, 1998, CANCER, V83, P2049, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2; Diaz-Rubio M, 2004, ALIMENT PHARM THER, V19, P95, DOI 10.1046/j.1365-2036.2003.01769.x; El-Serag HB, 1998, GUT, V43, P327, DOI 10.1136/gut.43.3.327; El-Serag HB, 2002, SCAND J GASTROENTERO, V37, P899, DOI 10.1080/003655202760230847; El-Serag HB, 2002, GUT, V50, P368, DOI 10.1136/gut.50.3.368; El-Serag HB, 2002, GASTROENTEROL CLIN N, V31, P421, DOI 10.1016/S0889-8553(02)00016-X; Fisher BL, 1999, DIGEST DIS SCI, V44, P2290, DOI 10.1023/A:1026617106755; Fraser-Moodie CA, 1999, SCAND J GASTROENTERO, V34, P337, DOI 10.1080/003655299750026326; Frezza EE, 2002, SURG ENDOSC, V16, P1027, DOI 10.1007/s00464-001-8313-5; Furukawa N, 1999, J GASTROENTEROL, V34, P441, DOI 10.1007/s005350050293; Gerson LB, 2002, GASTROENTEROLOGY, V123, P461, DOI 10.1053/gast.2002.34748; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; HAGEN J, 1987, INT SURG, V72, P1; Ji BT, 1997, CANCER EPIDEM BIOMAR, V6, P481; Jones KB, 1998, OBES SURG, V8, P35, DOI 10.1381/096089298765555024; Kahrilas PJ, 1999, YALE J BIOL MED, V72, P101; KITCHIN LI, 1991, ARCH INTERN MED, V151, P448, DOI 10.1001/archinte.151.3.448; Kjellin A, 1996, SCAND J GASTROENTERO, V31, P1047, DOI 10.3109/00365529609036885; Labenz J, 2004, AM J GASTROENTEROL, V99, P1652, DOI 10.1111/j.1572-0241.2004.30390.x; Lagergren J, 2000, Lakartidningen, V97, P1950; Lagergren J, 1999, ANN INTERN MED, V130, P883, DOI 10.7326/0003-4819-130-11-199906010-00003; Lagergren J, 2000, GUT, V47, P26, DOI 10.1136/gut.47.1.26; Lagergren J, 2000, ANN INTERN MED, V133, P165, DOI 10.7326/0003-4819-133-3-200008010-00007; Locke GR, 1999, AM J MED, V106, P642, DOI 10.1016/S0002-9343(99)00121-7; MADDOX A, 1989, SCAND J GASTROENTERO, V24, P593, DOI 10.3109/00365528909093095; MERCER CD, 1985, AM J SURG, V149, P177, DOI 10.1016/S0002-9610(85)80029-5; MERCER CD, 1987, J MED, V18, P135; Murray L, 2003, INT J EPIDEMIOL, V32, P645, DOI 10.1093/ije/dyg108; Nandurkar S, 2004, ALIMENT PHARM THER, V20, P497, DOI 10.1111/j.1365-2036.2004.02156.x; Nilsson M, 2003, JAMA-J AM MED ASSOC, V290, P66, DOI 10.1001/jama.290.1.66; Nilsson M, 2002, SCAND J GASTROENTERO, V37, P626, DOI 10.1080/00365520212502; OBRIEN TF, 1980, J CLIN GASTROENTEROL, V2, P145, DOI 10.1097/00004836-198006000-00007; Oliveria SA, 1999, ARCH INTERN MED, V159, P1592, DOI 10.1001/archinte.159.14.1592; Orlando RC, 2001, AM J MED, V111, P174, DOI 10.1016/S0002-9343(01)00828-2; Pandolfino JE, 2000, EUR J GASTROEN HEPAT, V12, P837, DOI 10.1097/00042737-200012080-00002; Polednak AP, 2003, CANCER DETECT PREV, V27, P415, DOI 10.1016/j.cdp.2003.09.002; Raghunath A, 2003, BMJ-BRIT MED J, V326, P737, DOI 10.1136/bmj.326.7392.737; Ruhl CE, 1999, ANN EPIDEMIOL, V9, P424, DOI 10.1016/S1047-2797(99)00020-4; Sharma P, 2003, ALIMENT PHARM THER, V17, P297, DOI 10.1046/j.1365-2036.2003.01428.x; Stanghellini V, 1999, SCAND J GASTROENTERO, V34, P20, DOI 10.1080/003655299750025237; STENELARSEN G, 1988, SCAND J GASTROENTERO, V23, P427, DOI 10.3109/00365528809093890; Terry P, 2000, NUTR CANCER, V38, P186, DOI 10.1207/S15327914NC382_7; VAUGHAN TL, 1995, CANCER EPIDEM BIOMAR, V4, P85; Wajed SA, 2001, ARCH SURG-CHICAGO, V136, P1014, DOI 10.1001/archsurg.136.9.1014; Wei Jeffrey T, 2003, Semin Gastrointest Dis, V14, P112; Wilson LJ, 1999, AM J GASTROENTEROL, V94, P2840, DOI 10.1111/j.1572-0241.1999.01426.x; Wu AH, 2001, CANCER CAUSE CONTROL, V12, P721, DOI 10.1023/A:1011290704728; Wu AH, 2003, CANCER, V98, P940, DOI 10.1002/cncr.11568; ZACCHI P, 1991, DIGEST DIS SCI, V36, P1473, DOI 10.1007/BF01296818; Zhang J, 2003, WORLD J GASTROENTERO, V9, P2658; Zhang ZF, 1996, CANCER EPIDEM BIOMAR, V5, P761	64	779	847	1	36	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 2	2005	143	3					199	211		10.7326/0003-4819-143-3-200508020-00006	http://dx.doi.org/10.7326/0003-4819-143-3-200508020-00006			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	951TM	16061918				2022-12-28	WOS:000230953900005
J	Guan, JS; Xu, ZZ; Gao, H; He, SQ; Ma, GQ; Sun, T; Wang, LH; Zhang, ZN; Lena, I; Kitchen, I; Elde, R; Zimmer, A; He, C; Pei, G; Bao, L; Zhang, X				Guan, JS; Xu, ZZ; Gao, H; He, SQ; Ma, GQ; Sun, T; Wang, LH; Zhang, ZN; Lena, I; Kitchen, I; Elde, R; Zimmer, A; He, C; Pei, G; Bao, L; Zhang, X			Interaction with vesicle luminal protachykinin regulates surface expression of delta-opioid receptors and opioid analgesia	CELL			English	Article							SECRETORY GRANULE BIOGENESIS; PROTEIN-COUPLED RECEPTOR; ROOT GANGLION NEURONS; RAT SPINAL-CORD; SUBSTANCE-P; PHYSICAL-DEPENDENCE; MU; SELECTIVITY; MORPHINE; CLONING	Opioid and tachykinin systems are involved in modulation of pain transmission in the spinal cord. Regulation of surface opioid receptors on nociceptive afferents is critical for opioid analgesia. Plasma-membrane insertion of delta-opioid receptors (DORs) is induced by stimulus-triggered exocytosis of DOR-containing large dense-core vesicles (LDCVs), but how DORs become sorted into the regulated secretory pathway is unknown. Here we report that direct interaction between protachykinin and DOR is responsible for sorting of DORs into LDCVs, allowing stimulus-induced surface insertion of DORs and DOR-mediated spinal analgesia. This interaction is mediated by the substance P domain of protachykinin and the third luminal domain of DOR. Furthermore, deletion of the preprotachykinin A gene reduced stimulus-induced surface insertion of DORs and abolished DOR-mediated spinal analgesia and morphine tolerance. Thus, protachylkinin is essential for modulation of the sensitivity of nociceptive afferents to opioids, and the opioid and tachykinin systems are directly linked by protachykinin/DOR interaction.	Chinese Acad Sci, Inst Neurosci, Key Lab Neurobiol, Shanghai 200031, Peoples R China; Chinese Acad Sci, Mol Cell Biol Lab, Inst Biochem & Cell Biol, SIBS, Shanghai 200031, Peoples R China; Chinese Acad Sci, Grad Sch, Shanghai 200031, Peoples R China; Univ Bonn, Dept Psychiat, D-53105 Bonn, Germany; Univ Minnesota, Dept Cell Biol & Neuroanat, St Paul, MN 55108 USA; Univ Surrey, Sch Biomed & Mol Sci, Pharmacol Grp, Guildford GU2 7XH, Surrey, England	Chinese Academy of Sciences; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; University of Bonn; University of Minnesota System; University of Minnesota Twin Cities; University of Surrey	Zhang, X (corresponding author), Chinese Acad Sci, Inst Neurosci, Key Lab Neurobiol, Shanghai 200031, Peoples R China.	xu.zhang@ion.ac.cn	Léna, Isabelle/O-7956-2016; Zimmer, Andreas/B-8357-2009	Léna, Isabelle/0000-0002-1708-8497; Xu, Zhen-Zhong/0000-0001-6578-211X; Guan, Ji-Song/0000-0001-5219-0289				Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; Bao L, 2003, NEURON, V37, P121, DOI 10.1016/S0896-6273(02)01103-0; BESSE D, 1992, BRAIN RES, V578, P115, DOI 10.1016/0006-8993(92)90237-4; Bilsky EJ, 2000, J PHARMACOL EXP THER, V293, P151; Cao YQ, 1998, NATURE, V392, P390, DOI 10.1038/32897; CHENG PY, 1995, J NEUROSCI, V15, P5976; CHIWAKATA C, 1991, ENDOCRINOLOGY, V128, P2441, DOI 10.1210/endo-128-5-2441; COOL DR, 1995, J BIOL CHEM, V270, P8723, DOI 10.1074/jbc.270.15.8723; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; Decaillot FM, 2003, NAT STRUCT BIOL, V10, P629, DOI 10.1038/nsb950; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; ERSPAMER V, 1989, P NATL ACAD SCI USA, V86, P5188, DOI 10.1073/pnas.86.13.5188; EVA C, 1990, FEBS LETT, V271, P81, DOI 10.1016/0014-5793(90)80377-U; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FIELDS HL, 1980, NATURE, V284, P351, DOI 10.1038/284351a0; Gomes I, 2004, P NATL ACAD SCI USA, V101, P5135, DOI 10.1073/pnas.0307601101; Gorr SU, 2001, MOL CELL ENDOCRINOL, V172, P1, DOI 10.1016/S0303-7207(00)00342-7; HELKE CJ, 1990, FASEB J, V4, P1606, DOI 10.1096/fasebj.4.6.1969374; HOKFELT T, 1975, SCIENCE, V190, P889, DOI 10.1126/science.242075; HYLDEN JLK, 1980, EUR J PHARMACOL, V67, P313, DOI 10.1016/0014-2999(80)90515-4; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; Kim T, 2001, CELL, V106, P499, DOI 10.1016/S0092-8674(01)00459-7; Kitchen I, 1997, BRAIN RES, V778, P73, DOI 10.1016/S0006-8993(97)00988-8; Labuz D, 1998, NEUROPEPTIDES, V32, P511, DOI 10.1016/S0143-4179(98)90079-8; MANTYH PW, 1995, SCIENCE, V268, P1629, DOI 10.1126/science.7539937; Meng F, 1996, EUR J PHARMACOL, V311, P285, DOI 10.1016/0014-2999(96)00431-1; NAWA H, 1983, NATURE, V306, P32, DOI 10.1038/306032a0; Nitsche JF, 2002, J NEUROSCI, V22, P10906; Pepin MC, 1997, J BIOL CHEM, V272, P9260; Rupniak NMJ, 1999, TRENDS PHARMACOL SCI, V20, P485, DOI 10.1016/S0165-6147(99)01396-6; Schiller PW, 1999, J MED CHEM, V42, P3520, DOI 10.1021/jm980724+; SMITH RE, 1966, J CELL BIOL, V31, P319, DOI 10.1083/jcb.31.2.319; THOMPSON RC, 1993, NEURON, V11, P903, DOI 10.1016/0896-6273(93)90120-G; Tooze SA, 2001, TRENDS CELL BIOL, V11, P116, DOI 10.1016/S0962-8924(00)01907-3; Varga EV, 1996, MOL PHARMACOL, V50, P1619; Wang WW, 1995, P NATL ACAD SCI USA, V92, P12436, DOI 10.1073/pnas.92.26.12436; WILSON PR, 1978, EUR J PHARMACOL, V51, P323, DOI 10.1016/0014-2999(78)90423-5; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; Zhang X, 1998, NEUROSCIENCE, V82, P223; ZHANG X, 1995, J COMP NEUROL, V352, P481, DOI 10.1002/cne.903520402; Zhang X, 1998, NEUROSCIENCE, V82, P1225; Zhu YX, 1999, NEURON, V24, P243, DOI 10.1016/S0896-6273(00)80836-3; Zimmer A, 1998, P NATL ACAD SCI USA, V95, P2630, DOI 10.1073/pnas.95.5.2630	44	126	139	0	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 26	2005	122	4					619	631		10.1016/j.cell.2005.06.010	http://dx.doi.org/10.1016/j.cell.2005.06.010			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	959YI	16122428	Bronze			2022-12-28	WOS:000231555100016
J	Bauer, A; Westkamper, F; Grimme, S; Bach, T				Bauer, A; Westkamper, F; Grimme, S; Bach, T			Catalytic enantioselective reactions driven by photoinduced electron transfer	NATURE			English	Article							CYCLIZATION REACTIONS; CONFIGURATION	Photoinduced electron transfer is an essential step in the conversion of solar energy into chemical energy in photosystems I and II (ref. 1), and is also frequently used by chemists to build complex molecules from simple precursors(2). During this process, light absorption generates molecules in excited electronic states that are susceptible to accepting or donating electrons. But although the excited states are straightforward to generate, their short lifetimes makes it challenging to control electron transfer and subsequent product formation - particularly if enantiopure products are desired. Control strategies developed so far use hydrogen bonding, to embed photochemical substrates in chiral environments(3) and to render photochemical reactions enantioselective through the use of rigid chiral complexing agents(4). To go beyond such stoichiometric chiral information transmission, catalytic turnover is required(5). Here we present a catalytic photoinduced electron transfer reaction that proceeds with considerable turnover and high enantioselectivity. By using an electron accepting chiral organocatalyst that enforces a chiral environment on the substrate through hydrogen bonding, we obtain the product in significant enantiomeric excess ( up to 70%) and in yields reaching 64%. This performance suggests that photochemical routes to chiral compounds may find use in general asymmetric synthesis.	Tech Univ Munich, Lehrstuhl Organ Chem 1, D-85747 Garching, Germany; Univ Munster, Inst Organ Chem, D-48149 Munster, Germany	Technical University of Munich; University of Munster	Bach, T (corresponding author), Tech Univ Munich, Lehrstuhl Organ Chem 1, Lichtenbergstr 4, D-85747 Garching, Germany.	thorsten.bach@ch.tum.de	Bauer, Andreas C/B-3104-2011; Grimme, Stefan/B-2873-2010; Bach, Thorsten/M-2850-2014	Bauer, Andreas C/0000-0002-0263-6171; Bach, Thorsten/0000-0002-1342-0202				Aechtner T, 2004, ANGEW CHEM INT EDIT, V43, P5849, DOI 10.1002/anie.200461222; Asaoka S, 2003, J AM CHEM SOC, V125, P3008, DOI 10.1021/ja028680o; Bach T, 2002, J AM CHEM SOC, V124, P7982, DOI 10.1021/ja0122288; Bach T, 2002, CHEM-EUR J, V8, P2464, DOI 10.1002/1521-3765(20020603)8:11<2464::AID-CHEM2464>3.0.CO;2-S; Bergmann H, 2004, J ORG CHEM, V69, P970, DOI 10.1021/jo0354847; Bertrand S, 2000, EUR J ORG CHEM, V2000, P2227; Diedrich C, 2003, J PHYS CHEM A, V107, P2524, DOI 10.1021/jp0275802; GROSCH B, 2004, HDB ORGANIC PHOTOCHE; Hoffmann R, 1999, J AM CHEM SOC, V121, P10702, DOI 10.1021/ja991315l; JEON YT, 1991, J AM CHEM SOC, V113, P8847, DOI 10.1021/ja00023a038; Nelson N, 2004, NAT REV MOL CELL BIO, V5, P971, DOI 10.1038/nrm1525; NOYORI R, 2004, MOL SUPRAMOLECULAR P, V11, P129; Polavarapu PL, 2002, CHIRALITY, V14, P768, DOI 10.1002/chir.10145; Schimoldt P., 2003, MOL SUPRAMOLECULAR P, V9, P185	14	362	363	6	133	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 25	2005	436	7054					1139	1140		10.1038/nature03955	http://dx.doi.org/10.1038/nature03955			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	958AK	16121176				2022-12-28	WOS:000231416600041
J	Ullrich, C; Wu, A; Armsby, C; Rieber, S; Wingerter, S; Brugnara, C; Shapiro, D; Bernstein, H				Ullrich, C; Wu, A; Armsby, C; Rieber, S; Wingerter, S; Brugnara, C; Shapiro, D; Bernstein, H			Screening healthy infants for iron deficiency using reticulocyte hemoglobin content	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THALASSEMIA TRAIT; LABORATORY TESTS; CLINICAL UTILITY; UNITED-STATES; RET-Y; DIAGNOSIS; ANEMIA; INDEXES; ERYTHROPOIESIS; THERAPY	Context Current clinical practice relies on hemoglobin to detect iron deficiency, which misses infants not yet anemic and places them at higher risk for neurocognitive impairment. Reticulocyte hemoglobin content (CHr) has never been compared with hemoglobin for screening healthy infants. Objectives To evaluate CHr for detecting iron deficiency without anemia in healthy 9- to 12-month-old infants and to compare CHr with hemoglobin in screening for iron deficiency in this population. A secondary objective was to explore the association between CHr and subsequent development of anemia. Design, Setting, and Patients A prospective observational cohort study of 202 healthy 9- to 12-month-old infants from an urban, hospital-based, primary care clinic in Boston, Mass, who were screened for iron deficiency between June 2000 and April 2003, and followed up for a median of 5.6 months. Main Outcome Measures Iron deficiency (transferrin saturation <10%) and anemia (hemoglobin < 11 g/dL). Results Of 202 infants enrolled, 23 (11.4%) had iron deficiency and 6 (3%) had iron deficiency and anemia. Iron-deficient and non-iron-deficient infants had significantly different values for all measured hematological and biochemical markers for iron deficiency. Optimal CHr cutoff for detecting iron deficiency was 27.5 pg (sensitivity, 83% and specificity, 72%); a hemoglobin level of less than 11 g/dL resulted in a sensitivity of 26% and a specificity of 95%. Reticulocyte hemoglobin content was more accurate overall than hemoglobin was for detecting iron deficiency (area under the receiver operating characteristic curve, 0.85 vs 0.73; P=.007). A CHr of less than 27.5 pg without anemia at initial screening was associated with subsequent anemia when screened again in the second year of life (risk ratio, 9.1; 95% confidence interval, 1.04-78.9; P=.01). Conclusions A CHr of less than 27.5 pg is a more accurate hematological indicator of iron deficiency compared with hemoglobin of less than 11 g/dL in these healthy 9- to 12-month-old infants. Further studies are warranted to determine whether CHr should be the preferred screening tool in the early detection of iron deficiency in infants.	Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Childrens Hosp, Dept Med, Boston, MA 02115 USA; Childrens Hosp, Dept Anesthesia, Boston, MA 02115 USA; Childrens Hosp, Dept Infect Dis & Emergency Med, Boston, MA 02115 USA; Childrens Hosp, Dept Lab Med & Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Yale University; Harvard University; Harvard T.H. Chan School of Public Health	Ullrich, C (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA.	christina.ullrich@childrens.harvard.edu	Wu, Ann/AAY-4293-2020; Brugnara, Carlo/A-8041-2010	Wu, Ann/0000-0003-0599-9063; Brugnara, Carlo/0000-0001-8192-8713				[Anonymous], 1998, MMWR MORB MORTAL WKL, V47, P1; Bothwell T.H., 1979, IRON METABOLISM MAN; Brugnara C, 1999, JAMA-J AM MED ASSOC, V281, P2225, DOI 10.1001/jama.281.23.2225; Brugnara C, 2003, CLIN CHEM, V49, P1573, DOI 10.1373/49.10.1573; BRUGNARA C, 1994, BLOOD, V83, P3100, DOI 10.1182/blood.V83.10.3100.3100; Brugnara C, 1998, INT J CLIN LAB RES, V28, P1, DOI 10.1007/s005990050011; BURNS ER, 1990, AM J CLIN PATHOL, V93, P240, DOI 10.1093/ajcp/93.2.240; Buttarello M, 2004, AM J CLIN PATHOL, V121, P489, DOI 10.1309/W65295DTUWK7U1HH; Centers for Disease Control and Prevention (CDC), 2002, MMWR MORB MORTAL WKL, V51, P897; DALLMAN PR, 1981, J PEDIATR-US, V99, P376, DOI 10.1016/S0022-3476(81)80321-6; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; DONOFRIO G, 1992, ARCH PATHOL LAB MED, V116, P84; DONOFRIO G, 1995, BLOOD, V85, P818, DOI 10.1182/blood.V85.3.818.bloodjournal853818; FAIRBANKS VF, 1991, HOSP PRACT, V26, P17; Franck S, 2004, CLIN CHEM, V50, P1240, DOI 10.1373/clinchem.2004.030254; GARN SM, 1981, AM J CLIN NUTR, V34, P1645, DOI 10.1093/ajcn/34.9.1645; Goodnough LT, 2000, BLOOD, V96, P823, DOI 10.1182/blood.V96.3.823.015k49_823_833; HALLBERG L, 1993, BRIT J HAEMATOL, V85, P787, DOI 10.1111/j.1365-2141.1993.tb03225.x; Halterman JS, 2001, PEDIATRICS, V107, P1381, DOI 10.1542/peds.107.6.1381; Hastka J, 1996, CLIN CHEM, V42, P718; Kazal LA, 1996, J FAM PRACTICE, V42, P237; Kleinman RE, 2004, PEDIAT NUTR HDB; Lafferty JD, 1996, AM J CLIN PATHOL, V106, P201; Looker AC, 1997, JAMA-J AM MED ASSOC, V277, P973, DOI 10.1001/jama.277.12.973; LOZOFF B, 1982, J PEDIATR-US, V101, P948, DOI 10.1016/S0022-3476(82)80016-4; Lozoff B, 2004, PEDIATR RES, V55, p23A; Lozoff B, 2003, PEDIATRICS, V112, P846; LOZOFF B, 1987, PEDIATRICS, V79, P981; LOZOFF B, 1991, NEW ENGL J MED, V325, P687, DOI 10.1056/NEJM199109053251004; Lozoff B, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.4.e51; Major A, 1997, BRIT J HAEMATOL, V98, P292, DOI 10.1046/j.1365-2141.1997.2123031.x; Mast AE, 2002, BLOOD, V99, P1489, DOI 10.1182/blood.V99.4.1489; MENTZER WC, 1973, LANCET, V1, P882; OSKI FA, 1983, PEDIATRICS, V71, P877; PERRY GS, 1992, J NUTR, V122, P1417, DOI 10.1093/jn/122.7.1417; REED WW, 1991, ARCH INTERN MED, V151, P501, DOI 10.1001/archinte.151.3.501; SCHIFMAN RB, 1982, JAMA-J AM MED ASSOC, V248, P2012, DOI 10.1001/jama.248.16.2012; Thomas C, 2002, CLIN CHEM, V48, P1066; US Department of Health and Human Services, 2010, HLTH PEOPL 2010, V2; WALTER T, 1983, J PEDIATR-US, V102, P519, DOI 10.1016/S0022-3476(83)80177-2; WALTER T, 1989, PEDIATRICS, V84, P7	41	123	133	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 24	2005	294	8					924	930		10.1001/jama.294.8.924	http://dx.doi.org/10.1001/jama.294.8.924			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	957JM	16118382	Bronze			2022-12-28	WOS:000231366100022
J	Kennedy, C; McCann, D; Campbell, MJ; Kimm, L; Thornton, R				Kennedy, C; McCann, D; Campbell, MJ; Kimm, L; Thornton, R			Universal newborn screening for permanent childhood hearing impairment: an 8-year follow-up of a controlled trial	LANCET			English	Article							IDENTIFICATION	An 8-year follow-up study of the birth cohort of babies enrolled in the Wessex controlled trial of universal newborn screening (UNS) for permanent childhood hearing impairment (PCHI) was undertaken to establish whether UNS would increase the proportion of all true cases of PCHI in children aged 7-9 years who are referred early. The proportion referred before 6 months of age increased from 11 of 35 (31%) children with true PCHI born during periods without UNS to 23 of 31 (74%) born during periods with UNS (difference 43%, 95% CI 19-60). UNS leads to early referral of PCHI.	Univ Southampton, Dept Child Hlth, Southampton, Hants, England; Univ Sheffield, Inst Primary Care & Gen Practice, Sheffield, S Yorkshire, England; MRC, Inst Hearing Res, Southampton, Hants, England	University of Southampton; University of Sheffield	Kennedy, C (corresponding author), Southampton Gen Hosp, Dept Paediat Neurol, Mailpoint 21, Southampton SO16 6YD, Hants, England.	crk1@soton.ac.uk	Campbell, Michael J/I-4253-2014	Campbell, Michael J/0000-0003-3529-2739	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BESS FH, 1994, PEDIATRICS, V94, P959; Dalzell L, 2000, EAR HEARING, V21, P118, DOI 10.1097/00003446-200004000-00006; Davis A, 1997, HEALTH TECHNOL ASSES, V1, P1; Harris S, 2001, OXFORD ART J, V24, P89; Kennedy C, 2000, LANCET, V356, P1903, DOI 10.1016/S0140-6736(00)03267-0; Kennedy CR, 1998, LANCET, V352, P1957; *OFF NAT STAT, 2003, REF POP MOB FIG HAMP; Thompson DC, 2001, JAMA-J AM MED ASSOC, V286, P2000, DOI 10.1001/jama.286.16.2000; Yoshinaga-Itano C, 1998, PEDIATRICS, V102, P1161, DOI 10.1542/peds.102.5.1161	9	109	122	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 20	2005	366	9486					660	662		10.1016/S0140-6736(05)67138-3	http://dx.doi.org/10.1016/S0140-6736(05)67138-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958EB	16112302				2022-12-28	WOS:000231426400029
J	Wani, M; Nga, E; Navaratnasingham, R				Wani, M; Nga, E; Navaratnasingham, R			Evidence based case report - Should a patient with primary intracerebral haemorrhage receive antiplatelet or anticoagulant therapy?	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CEREBRAL AMYLOID ANGIOPATHY; ACUTE ISCHEMIC-STROKE; ATRIAL-FIBRILLATION; INTRACRANIAL HEMORRHAGE; RISK; PREVENTION; ASPIRIN; HEPARIN		Morriston Hosp, Dept Stroke Med, Swansea SA6 6NL, W Glam, Wales	Morriston Hospital	Wani, M (corresponding author), Morriston Hosp, Dept Stroke Med, Swansea SA6 6NL, W Glam, Wales.	mushtaq.wani@swansea-tr.wales.nhs.uk						Albers GW, 2005, JAMA-J AM MED ASSOC, V293, P690; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Bailey RD, 2001, NEUROLOGY, V56, P773, DOI 10.1212/WNL.56.6.773; Berge E, 2000, LANCET, V355, P1205, DOI 10.1016/S0140-6736(00)02085-7; Bertram M, 2000, J NEUROL, V247, P209, DOI 10.1007/s004150050565; Bungard TJ, 2000, ARCH INTERN MED, V160, P41, DOI 10.1001/archinte.160.1.41; COUNSELL C, 1995, CEREBROVASC DIS, V5, P26, DOI 10.1159/000107814; Eckman MH, 2003, STROKE, V34, P1710, DOI 10.1161/01.STR.0000078311.18928.16; HART RG, 1995, STROKE, V26, P1471, DOI 10.1161/01.STR.26.8.1471; He J, 1998, JAMA-J AM MED ASSOC, V280, P1930, DOI 10.1001/jama.280.22.1930; Keir SL, 2002, CEREBROVASC DIS, V14, P197, DOI 10.1159/000065661; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; MacMahon S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5; MCBRIDE R, 1994, LANCET, V343, P687; McCarron MO, 2000, ANN NY ACAD SCI, V903, P176, DOI 10.1111/j.1749-6632.2000.tb06366.x; Rodgers A, 1998, LANCET, V352, P1801; Saxena R, 2001, STROKE, V32, P2333, DOI 10.1161/hs1001.097093; Senior K, 2002, LANCET, V359, P769, DOI 10.1016/S0140-6736(02)07911-4; Stollberger C, 2003, EUR NEUROL, V50, P127, DOI 10.1159/000073052; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557; Vermeer SE, 2002, NEUROLOGY, V59, P205, DOI 10.1212/WNL.59.2.205; VINTERS HV, 1987, STROKE, V18, P311, DOI 10.1161/01.STR.18.2.311; WOLF PA, 1978, NEUROLOGY, V28, P973, DOI 10.1212/WNL.28.10.973	24	18	18	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 20	2005	331	7514					439	442		10.1136/bmj.331.7514.439	http://dx.doi.org/10.1136/bmj.331.7514.439			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958WB	16110073	Green Published			2022-12-28	WOS:000231477800019
J	Giovannoni, SJ; Tripp, HJ; Givan, S; Podar, M; Vergin, KL; Baptista, D; Bibbs, L; Eads, J; Richardson, TH; Noordewier, M; Rappe, MS; Short, JM; Carrington, JC; Mathur, EJ				Giovannoni, SJ; Tripp, HJ; Givan, S; Podar, M; Vergin, KL; Baptista, D; Bibbs, L; Eads, J; Richardson, TH; Noordewier, M; Rappe, MS; Short, JM; Carrington, JC; Mathur, EJ			Genome streamlining in a cosmopolitan oceanic bacterium	SCIENCE			English	Article							DISSOLVED ORGANIC-CARBON; RIBOSOMAL-RNA OPERON; SARGASSO SEA; SEQUENCE; EVOLUTION; KINETICS; AFFINITY; CLADE; COPY; FLUX	The SAR11 clade consists of very small, heterotrophic marine alpha-proteobacteria that are found throughout the oceans, where they account for about 25% of all microbial cells. Pelagibacter ubique, the first cultured member of this clade, has the smallest genome and encodes the smallest number of predicted open reading frames known for a free-living microorganism. In contrast to parasitic bacteria and archaea with small genomes, P. ubique has complete biosynthetic pathways for all 20 amino acids and all but a few cofactors. P. ubique has no pseudogenes, introns, transposons, extrachromosomat elements, or inteins; few paralogs; and the shortest intergenic spacers yet observed for any cell.	Oregon State Univ, Dept Microbiol, Corvallis, OR 97331 USA; Oregon State Univ, Ctr Gene Res & Biotechnol, Corvallis, OR 97331 USA; Diversa Corp, San Diego, CA 92121 USA; Univ Hawaii, Sch Ocean & Earth Sci & Technol, Hawaii Inst Marine Biol, Kaneohe, HI 96744 USA	Oregon State University; Oregon State University; University of Hawaii System	Giovannoni, SJ (corresponding author), Oregon State Univ, Dept Microbiol, Corvallis, OR 97331 USA.	steve.giovannoni@oregonstate.edu	Podar, Mircea/B-7299-2012; Carrington, James C/A-4656-2012; Short, Jay/GQY-7343-2022	Podar, Mircea/0000-0003-2776-0205; Carrington, James C/0000-0003-3572-129X; Givan, Scott/0000-0002-0630-8589				Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; Azam F, 1998, SCIENCE, V280, P694, DOI 10.1126/science.280.5364.694; Button DK, 2004, APPL ENVIRON MICROB, V70, P5511, DOI 10.1128/AEM.70.9.5511-5521.2004; BUTTON DK, 1991, APPL ENVIRON MICROB, V57, P2033, DOI 10.1128/AEM.57.7.2033-2038.1991; CARLSON CA, 1994, NATURE, V371, P405, DOI 10.1038/371405a0; Dandekar T, 1999, BIOCHEM J, V343, P115, DOI 10.1042/0264-6021:3430115; Dufresne A, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-2-r14; Elsen S, 2004, MICROBIOL MOL BIOL R, V68, P263, DOI 10.1128/MMBR.68.2.263-279.2004; GIOVANNONI SJ, IN PRESS NATURE; Hansell DA, 1998, GLOBAL BIOGEOCHEM CY, V12, P443, DOI 10.1029/98GB01928; Hansell DA, 2001, DEEP-SEA RES PT II, V48, P1649, DOI 10.1016/S0967-0645(00)00153-3; Kimura M., 1983, NEUTRAL THEORY MOL E; Klappenbach JA, 2000, APPL ENVIRON MICROB, V66, P1328, DOI 10.1128/AEM.66.4.1328-1333.2000; Lanoil BD, 1996, GENOME RES, V6, P1160, DOI 10.1101/gr.6.12.1160; Malmstrom RR, 2004, APPL ENVIRON MICROB, V70, P4129, DOI 10.1128/AEM.70.7.4129-4135.2004; MelendezHevia E, 1997, EUR J BIOCHEM, V244, P527, DOI 10.1111/j.1432-1033.1997.t01-1-00527.x; Mira A, 2001, TRENDS GENET, V17, P589, DOI 10.1016/S0168-9525(01)02447-7; Moran MA, 2004, NATURE, V432, P910, DOI 10.1038/nature03170; Morris RM, 2002, NATURE, V420, P806, DOI 10.1038/nature01240; Myllykallio H, 2002, SCIENCE, V297, P105, DOI 10.1126/science.1072113; Myllykallio H, 2003, TRENDS MICROBIOL, V11, P220, DOI 10.1016/S0966-842X(03)00101-X; Rappe MS, 2002, NATURE, V418, P630, DOI 10.1038/nature00917; REEVES RE, 1968, J BIOL CHEM, V243, P5486; Rocap G, 2003, NATURE, V424, P1042, DOI 10.1038/nature01947; Ronimus Ron S., 2003, Archaea, V1, P199, DOI 10.1155/2003/162593; Ruby EG, 2005, P NATL ACAD SCI USA, V102, P3004, DOI 10.1073/pnas.0409900102; Strehl B, 1999, FEMS MICROBIOL LETT, V181, P261, DOI 10.1016/S0378-1097(99)00548-0; Ussery DW, 2004, MICROBIOL-SGM, V150, P749, DOI 10.1099/mic.0.27103-0; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857	29	769	1023	3	161	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 19	2005	309	5738					1242	1245		10.1126/science.1114057	http://dx.doi.org/10.1126/science.1114057			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	957TE	16109880				2022-12-28	WOS:000231395400046
J	Zhang, M; Fang, SL; Zakhidov, AA; Lee, SB; Aliev, AE; Williams, CD; Atkinson, KR; Baughman, RH				Zhang, M; Fang, SL; Zakhidov, AA; Lee, SB; Aliev, AE; Williams, CD; Atkinson, KR; Baughman, RH			Strong, transparent, multifunctional, carbon nanotube sheets	SCIENCE			English	Article							FILMS; FIBERS; PERMITTIVITY; ORIENTATION; TECHNOLOGY; COMPOSITES; DEPOSITION; NOISE; YARNS	Individual carbon nanotubes are like minute bits of string, and many trillions of these invisible strings must be assembled to make useful macroscopic articles. We demonstrated such assembly at rates above 7 meters per minute by cooperatively rotating carbon nanotubes in vertically oriented nanotube arrays (forests) and made 5-centimeter-wide, meter-long transparent sheets. These self-supporting nanotube sheets are initially formed as a highly anisotropic electronically conducting aerogel that can be densified into strong sheets that are as thin as 50 nanometers. The measured gravimetric strength of orthogonally oriented sheet arrays exceeds that of sheets of high-strength steel. These nanotube sheets have been used in laboratory demonstrations for the microwave bonding of plastics and for making transparent, highly elastomeric electrodes; planar sources of polarized broad-band radiation; conducting appliques; and flexible organic light-emitting diodes.	Univ Texas, Nanotech Inst, Richardson, TX 75083 USA; Commonwealth Sci & Ind Res Org Text & Fibre Techn, Belmont, Vic 3216, Australia	University of Texas System; University of Texas Dallas; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Baughman, RH (corresponding author), Univ Texas, Nanotech Inst, Richardson, TX 75083 USA.	ray.baughman@utdallas.edu	Atkinson, Ken R/B-9931-2008; Baughman, Ray/A-8628-2018; Han, Jinhua/F-9464-2010; Aliev, Ali/R-3034-2019	Baughman, Ray/0000-0001-5845-5137; Aliev, Ali/0000-0003-0034-9707; Zakhidov, Anvar/0000-0003-3983-2229				Ago H, 1999, ADV MATER, V11, P1281, DOI 10.1002/(SICI)1521-4095(199910)11:15<1281::AID-ADMA1281>3.0.CO;2-6; Coleman JN, 2003, APPL PHYS LETT, V82, P1682, DOI 10.1063/1.1559421; Collins PG, 2000, APPL PHYS LETT, V76, P894, DOI 10.1063/1.125621; Dalton AB, 2003, NATURE, V423, P703, DOI 10.1038/423703a; DEHEER WA, 1995, SCIENCE, V268, P845, DOI 10.1126/science.268.5212.845; Edwards DL, 2004, HIGH PERFORM POLYM, V16, P277, DOI 10.1177/0954008304044106; Endo M, 2005, NATURE, V433, P476, DOI 10.1038/433476a; EPSTEIN AJ, 1995, SYNTHETIC MET, V69, P179, DOI 10.1016/0379-6779(94)02410-Z; Ericson LM, 2004, SCIENCE, V305, P1447, DOI 10.1126/science.1101398; Fischer JE, 2003, J APPL PHYS, V93, P2157, DOI 10.1063/1.1536733; Hata K, 2004, SCIENCE, V306, P1362, DOI 10.1126/science.1104962; Hu L, 2004, NANO LETT, V4, P2513, DOI 10.1021/nl048435y; Jiang KL, 2002, NATURE, V419, P801, DOI 10.1038/419801a; Kim Y, 2003, JPN J APPL PHYS 1, V42, P7629, DOI 10.1143/JJAP.42.7629; Kozlov ME, 2005, ADV MATER, V17, P614, DOI 10.1002/adma.200401130; Lee K, 2004, NANO LETT, V4, P911, DOI 10.1021/nl0496522; Li P, 2003, APPL PHYS LETT, V82, P1763, DOI 10.1063/1.1558900; Li YL, 2004, SCIENCE, V304, P276, DOI 10.1126/science.1094982; Ouacha H, 2002, APPL PHYS LETT, V80, P1055, DOI 10.1063/1.1447313; Pelrine R, 2000, SCIENCE, V287, P836, DOI 10.1126/science.287.5454.836; Rinzler AG, 1998, APPL PHYS A-MATER, V67, P29, DOI 10.1007/s003390050734; Romero DB, 1996, ADV MATER, V8, P899, DOI 10.1002/adma.19960081105; Roschier L, 2001, APPL PHYS LETT, V78, P3295, DOI 10.1063/1.1362281; Sreekumar TV, 2003, CHEM MATER, V15, P175, DOI 10.1021/cm020367y; Vigolo B, 2002, APPL PHYS LETT, V81, P1210, DOI 10.1063/1.1497706; Watts PCP, 2003, ADV MATER, V15, P600, DOI 10.1002/adma.200304485; Whitehead KS, 2000, APPL PHYS LETT, V76, P2946, DOI 10.1063/1.126525; Wu JH, 2004, APPL PHYS LETT, V84, P4956, DOI 10.1063/1.1762693; Wu ZC, 2004, SCIENCE, V305, P1273, DOI 10.1126/science.1101243; Zhang M, 2004, SCIENCE, V306, P1358, DOI 10.1126/science.1104276	30	1415	1545	32	1033	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 19	2005	309	5738					1215	1219		10.1126/science.1115311	http://dx.doi.org/10.1126/science.1115311			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	957TE	16109875				2022-12-28	WOS:000231395400038
J	Di Toro, G; Nielsen, S; Pennacchioni, G				Di Toro, G; Nielsen, S; Pennacchioni, G			Earthquake rupture dynamics frozen in exhumed ancient faults	NATURE			English	Article							PSEUDOTACHYLYTE; PROPAGATION; STRESS; SLIP	Most of our knowledge about co-seismic rupture propagation is derived from inversion and interpretation of strong-ground-motion seismograms(1-3), laboratory experiments on rock(4,5) and rock-analogue material(6), or inferred from theoretical and numerical elastodynamic models(7-9). However, additional information on dynamic rupture processes can be provided by direct observation of faults exhumed at the Earth's surface(10). Pseudotachylytes (solidified friction-induced melts(11,12)) are the most certain fault-rock indicator of seismicity on ancient faults(13). Here we show how the asymmetry in distribution and the orientation of pseudotachylyte-filled secondary fractures around an exhumed fault can be used to reconstruct the earthquake rupture directivity, rupture velocity and fracture energy, by comparison with the theoretical dynamic stress field computed around propagating fractures. In particular, the studied natural network of pseudotachylytes is consistent with a dominant propagation direction during repeated seismic events and subsonic rupture propagation close to the Rayleigh wave velocity.	Univ Padua, Dipartimento Geol Paleontol & Geofis, I-35137 Padua, Italy; Ist Nazl Geofis & Vulcanol, I-00143 Rome, Italy	University of Padua; Istituto Nazionale Geofisica e Vulcanologia (INGV)	Nielsen, S (corresponding author), Univ Padua, Dipartimento Geol Paleontol & Geofis, I-35137 Padua, Italy.	snielsen@na.infn.it	Nielsen, Stefan B/F-6210-2011; pennacchioni, giorgio/L-9471-2019	Nielsen, Stefan B/0000-0002-9214-2932; pennacchioni, giorgio/0000-0002-5956-5327				Allen JL, 2005, TECTONOPHYSICS, V402, P37, DOI 10.1016/j.tecto.2004.10.017; Andrews DJ, 2005, J GEOPHYS RES-SOL EA, V110, DOI 10.1029/2004JB003191; ARCHULETA RJ, 1984, J GEOPHYS RES, V89, P4559, DOI 10.1029/JB089iB06p04559; Ben-Zion Y, 1998, B SEISMOL SOC AM, V88, P1085; BROBERG KB, 1989, INT J FRACTURE, V39, P1, DOI 10.1007/BF00047435; BURRIDGE R, 1979, J GEOPHYS RES, V84, P2210, DOI 10.1029/JB084iB05p02210; Chester FM, 2000, J GEOPHYS RES-SOL EA, V105, P23421, DOI 10.1029/2000JB900241; COX SJD, 1988, J GEOPHYS RES-SOLID, V93, P3307, DOI 10.1029/JB093iB04p03307; Dalguer LA, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB001738; Di Toro G, 2005, TECTONOPHYSICS, V402, P55, DOI 10.1016/j.tecto.2004.12.036; Di Toro G, 2005, TECTONOPHYSICS, V402, P3, DOI 10.1016/j.tecto.2004.10.014; FREUND LB, 1979, J GEOPHYS RES, V84, P2199, DOI 10.1029/JB084iB05p02199; HEATON TH, 1990, PHYS EARTH PLANET IN, V64, P1, DOI 10.1016/0031-9201(90)90002-F; IDA Y, 1973, J GEOPHYS RES, V78, P3418, DOI 10.1029/JB078i017p03418; Kame N, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB002189; LAQUECHE H, 1986, INT J ROCK MECH MIN, V23, P347, DOI 10.1016/0148-9062(86)90002-1; LI VC, 1989, FRACTURE MECH ROCKS, P351; MCKENZIE D, 1972, GEOPHYS J ROY ASTR S, V29, P65, DOI 10.1111/j.1365-246X.1972.tb06152.x; Peyrat S, 2001, J GEOPHYS RES-SOL EA, V106, P26467, DOI 10.1029/2001JB000205; Poliakov ANB, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000572; Rice JR, 2005, B SEISMOL SOC AM, V95, P109, DOI 10.1785/0120030166; Rosakis AJ, 1999, SCIENCE, V284, P1337, DOI 10.1126/science.284.5418.1337; RZHEVSKY Y, 1971, PHYS ROCKS; SCHMID SM, 1989, GEOL SOC LOND SPEC P, V45, P153, DOI DOI 10.1144/GSL.SP.1989.045.01.08; SIBSON RH, 1975, GEOPHYS J ROY ASTR S, V43, P775, DOI 10.1111/j.1365-246X.1975.tb06195.x; SIBSON RH, 1989, J STRUCT GEOL, V11, P1, DOI 10.1016/0191-8141(89)90032-1; Snoke A.W., 1998, FAULT RELATED ROCKS; Spera F. J., 2000, ENCY VOLCANOES, P171; SWANSON MT, 1992, TECTONOPHYSICS, V204, P223, DOI 10.1016/0040-1951(92)90309-T; Wilson B, 2005, NATURE, V434, P749, DOI 10.1038/nature03433	30	121	121	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 18	2005	436	7053					1009	1012		10.1038/nature03910	http://dx.doi.org/10.1038/nature03910			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955XQ	16107846				2022-12-28	WOS:000231263900048
J	Gale, M; Foy, EM				Gale, M; Foy, EM			Evasion of intracellular host defence by hepatitis C virus	NATURE			English	Review							INTERFERON REGULATORY FACTOR-3; NONSTRUCTURAL PROTEIN 5A; TOLL-LIKE RECEPTORS; GENE-EXPRESSION; RNA REPLICATION; INHIBITS INTERFERON; ANTIVIRAL ACTIVITY; CORE PROTEIN; KINASE PKR; KAPPA-B	Viral infection of mammalian cells rapidly triggers intracellular signalling events leading to interferon alpha/beta production and a cellular antiviral state. This 'host response' is our first line of immune defence against infection as it imposes several barriers to viral replication and spread. Hepatitis C virus (HCV) evades the host response through a complex combination of processes that include signalling interference, effector modulation and continual viral genetic variation. These evasion strategies support persistent infection and the spread of HCV. Defining the molecular mechanisms by which HCV regulates the host response is of crucial importance and may reveal targets for novel therapeutic strategies.	Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gale, M (corresponding author), Univ Texas, SW Med Ctr, Dept Microbiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	michael.gale@utsouthwestern.edu		Gale, Michael/0000-0002-6332-7436				Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; Andrejeva J, 2004, P NATL ACAD SCI USA, V101, P17264, DOI 10.1073/pnas.0407639101; Appel N, 2005, J VIROL, V79, P3187, DOI 10.1128/JVI.79.5.3187-3194.2005; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; Au WC, 2001, VIROLOGY, V280, P273, DOI 10.1006/viro.2000.0782; Barnes BJ, 2001, J BIOL CHEM, V276, P23382, DOI 10.1074/jbc.M101216200; Barth H, 2005, BLOOD, V105, P3605, DOI 10.1182/blood-2004-05-1952; Bigger CB, 2004, J VIROL, V78, P13779, DOI 10.1128/JVI.78.24.13779-13792.2004; Bigger CB, 2001, J VIROL, V75, P7059, DOI 10.1128/JVI.75.15.7059-7066.2001; Blight KJ, 2002, J VIROL, V76, P13001, DOI 10.1128/JVI.76.24.13001-13014.2002; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Blindenbacher A, 2003, GASTROENTEROLOGY, V124, P1465, DOI 10.1016/S0016-5085(03)00290-7; Bode JG, 2003, FASEB J, V17, P488, DOI 10.1096/fj.02-0664fje; Breiman A, 2005, J VIROL, V79, P3969, DOI 10.1128/JVI.79.7.3969-3978.2005; Colonna M, 2004, NAT IMMUNOL, V5, P1219, DOI 10.1038/ni1141; Cook DN, 2004, NAT IMMUNOL, V5, P975, DOI 10.1038/ni1116; De Francesco R, 2000, CURR TOP MICROBIOL, V242, P149; Delhem N, 2001, ONCOGENE, V20, P5836, DOI 10.1038/sj.onc.1204744; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Duguay D, 2002, CANCER RES, V62, P5148; Duong FHT, 2004, GASTROENTEROLOGY, V126, P263, DOI 10.1053/j.gastro.2003.10.076; Enomoto N, 1996, NEW ENGL J MED, V334, P77, DOI 10.1056/NEJM199601113340203; Farci P, 2000, SCIENCE, V288, P339, DOI 10.1126/science.288.5464.339; Farci P, 2001, Clin Liver Dis, V5, P895, DOI 10.1016/S1089-3261(05)70200-2; Farci P, 2002, P NATL ACAD SCI USA, V99, P3081, DOI 10.1073/pnas.052712599; Ferreon JC, 2005, J BIOL CHEM, V280, P20483, DOI 10.1074/jbc.M500422200; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Foy E, 2005, P NATL ACAD SCI USA, V102, P2986, DOI 10.1073/pnas.0408707102; Foy E, 2003, SCIENCE, V300, P1145, DOI 10.1126/science.1082604; Fredericksen B, 2002, VIRAL IMMUNOL, V15, P29, DOI 10.1089/088282402317340215; Frese M, 2002, HEPATOLOGY, V35, P694, DOI 10.1053/jhep.2002.31770; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; Gale M, 1998, MOL CELL BIOL, V18, P5208, DOI 10.1128/MCB.18.9.5208; Geiss GK, 2003, J VIROL, V77, P6367, DOI 10.1128/JVI.77.11.6367-6375.2003; Gimenez-Barcons M, 2005, J INTERF CYTOK RES, V25, P152, DOI 10.1089/jir.2005.25.152; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; Guo JT, 2001, J VIROL, V75, P8516, DOI 10.1128/JVI.75.18.8516-8523.2001; Han JQ, 2004, J INTERF CYTOK RES, V24, P664, DOI 10.1089/jir.2004.24.664; Han JQ, 2002, RNA, V8, P512, DOI 10.1017/S1355838202020617; Heim MH, 1999, J VIROL, V73, P8469, DOI 10.1128/JVI.73.10.8469-8475.1999; Heylbroeck C, 2000, J VIROL, V74, P3781, DOI 10.1128/JVI.74.8.3781-3792.2000; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Kanazawa N, 2004, J VIROL, V78, P9713, DOI 10.1128/JVI.78.18.9713-9720.2004; Katze MG, 2002, NAT REV IMMUNOL, V2, P675, DOI 10.1038/nri888; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; Khabar KSA, 1997, J EXP MED, V186, P1077, DOI 10.1084/jem.186.7.1077; Li K, 2005, J BIOL CHEM, V280, P16739, DOI 10.1074/jbc.M414139200; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; Liang TJ, 2004, GASTROENTEROLOGY, V127, pS62, DOI 10.1053/j.gastro.2004.09.017; LIDENBACH BD, 2005, SCIENCE, V309, P623; Lin RT, 1999, MOL CELL BIOL, V19, P959; Macdonald A, 2004, J GEN VIROL, V85, P2485, DOI 10.1099/vir.0.80204-0; Malmgaard L, 2004, J INTERF CYTOK RES, V24, P439, DOI 10.1089/1079990041689665; McCormick CJ, 2004, J GEN VIROL, V85, P429, DOI 10.1099/vir.0.19676-0; McHutchison JG, 2004, AM J MANAG CARE, V10, pS21; McHutchison JG, 2002, HEPATOLOGY, V36, pS245, DOI 10.1053/jhep.2002.36795; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Mihm S, 2004, LAB INVEST, V84, P1148, DOI 10.1038/labinvest.3700135; Noguchi T, 2001, MICROBIOL IMMUNOL, V45, P829, DOI 10.1111/j.1348-0421.2001.tb01322.x; Pascu M, 2004, GUT, V53, P1345, DOI 10.1136/gut.2003.031336; Pflugheber J, 2002, P NATL ACAD SCI USA, V99, P4650, DOI 10.1073/pnas.062055699; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Polyak SJ, 2001, J VIROL, V75, P6095, DOI 10.1128/JVI.75.13.6095-6106.2001; Polyak SJ, 2001, J VIROL, V75, P6209, DOI 10.1128/JVI.75.13.6209-6211.2001; Prabhu R, 2004, EXP MOL PATHOL, V76, P242, DOI 10.1016/j.yexmp.2004.01.004; Reed KE, 1998, CURR STUD HEMATOL BL, P1; Richmond A, 2002, NAT REV IMMUNOL, V2, P664, DOI 10.1038/nri887; Sarcar B, 2004, VIROLOGY, V322, P51, DOI 10.1016/j.virol.2004.01.008; Schinkel J, 2004, ANTIVIR THER, V9, P275; Schulz O, 2005, NATURE, V433, P887, DOI 10.1038/nature03326; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Shimazaki T, 2002, HEPATOLOGY, V35, P199, DOI 10.1053/jhep.2002.30202; Shoukry NH, 2004, ANNU REV MICROBIOL, V58, P391, DOI 10.1146/annurev.micro.58.030603.123836; Smith MW, 2003, HEPATOLOGY, V38, P1458, DOI [10.1016/jhep.2003.09.024, 10.1053/jhep.2003.09024]; Stumper R, 2005, J VIROL, V79, P2689, DOI 10.1128/JVI.79.5.2689-2699.2005; Su AI, 2002, P NATL ACAD SCI USA, V99, P15669, DOI 10.1073/pnas.202608199; Sumpter R, 2004, J VIROL, V78, P11591, DOI 10.1128/JVI.78.21.11591-11604.2004; Taguchi T, 2004, J GEN VIROL, V85, P959, DOI 10.1099/vir.0.19513-0; Tai DI, 2000, HEPATOLOGY, V31, P656, DOI 10.1002/hep.510310316; Tanaka Y, 2000, VIROLOGY, V270, P229, DOI 10.1006/viro.2000.0252; Taylor DR, 1999, SCIENCE, V285, P107, DOI 10.1126/science.285.5424.107; Tuplin A, 2002, RNA, V8, P824, DOI 10.1017/S1355838202554066; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Walker CM, 1997, SPRINGER SEMIN IMMUN, V19, P85, DOI 10.1007/BF00945027; Wang CF, 2003, J VIROL, V77, P3898, DOI 10.1128/JVI.77.7.3898-3912.2003; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102; Zhu HZ, 2003, J VIROL, V77, P5493, DOI 10.1128/JVI.77.9.5493-5498.2003; Zhu HZ, 2003, HEPATOLOGY, V37, P1180, DOI 10.1053/jhep.2003.50184	94	495	529	1	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 18	2005	436	7053					939	945		10.1038/nature04078	http://dx.doi.org/10.1038/nature04078			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955XQ	16107833				2022-12-28	WOS:000231263900035
J	Orme, CDL; Davies, RG; Burgess, M; Eigenbrod, F; Pickup, N; Olson, VA; Webster, AJ; Ding, TS; Rasmussen, PC; Ridgely, RS; Stattersfield, AJ; Bennett, PM; Blackburn, TM; Gaston, KJ; Owens, IPF				Orme, CDL; Davies, RG; Burgess, M; Eigenbrod, F; Pickup, N; Olson, VA; Webster, AJ; Ding, TS; Rasmussen, PC; Ridgely, RS; Stattersfield, AJ; Bennett, PM; Blackburn, TM; Gaston, KJ; Owens, IPF			Global hotspots of species richness are not congruent with endemism or threat	NATURE			English	Article							INDICATOR TAXA; CONSERVATION; RARITY; BIODIVERSITY; PATTERNS; COMPLEMENTARITY; COINCIDENCE; DIVERSITY	Biodiversity hotspots have a prominent role in conservation biology(1-9), but it remains controversial to what extent different types of hotspot are congruent(4,10-14). Previous studies were unable to provide a general answer because they used a single biodiversity index, were geographically restricted, compared areas of unequal size or did not quantitatively compare hotspot types(1-10,12-22). Here we use a new global database on the breeding distribution of all known extant bird species to test for congruence across three types of hotspot. We demonstrate that hotspots of species richness, threat and endemism do not show the same geographical distribution. Only 2.5% of hotspot areas are common to all three aspects of diversity, with over 80% of hotspots being idiosyncratic. More generally, there is a surprisingly low overall congruence of biodiversity indices, with any one index explaining less than 24% of variation in the other indices. These results suggest that, even within a single taxonomic class, different mechanisms are responsible for the origin and maintenance of different aspects of diversity. Consequently, the different types of hotspots also vary greatly in their utility as conservation tools.	Univ London Imperial Coll Sci Technol & Med, Div Biol, Ascot SL5 7PY, Berks, England; Univ London Imperial Coll Sci Technol & Med, NERC, Ctr Populat Biol, Ascot SL5 7PY, Berks, England; Univ Sheffield, Biodivers & Macroecol Grp, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England; Zool Soc London, Inst Zool, London NW1 4RY, England; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Natl Taiwan Univ, Sch Forestry & Resource Conservat, Taipei 106, Taiwan; Michigan State Univ Museum, E Lansing, MI 48824 USA; Michigan State Univ, Dept Zool, E Lansing, MI 48824 USA; Acad Nat Sci Philadelphia, Philadelphia, PA 19103 USA; Birdlife Int, Cambridge CB3 0NA, England	Imperial College London; Imperial College London; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); University of Sheffield; Zoological Society of London; University of Birmingham; National Taiwan University; Michigan State University; Michigan State University; Drexel University; BirdLife International	Owens, IPF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Biol, Silwood Pk, Ascot SL5 7PY, Berks, England.	i.owens@imperial.ac.uk	Burgess, Malcolm D/B-5793-2014; Owens, Ian PF/F-1392-2010; Davies, Richard/H-7447-2019; Blackburn, Tim/AAC-3144-2019; DING, Tzung-Su/AAG-7712-2019; Blackburn, Tim M/A-7685-2011	Burgess, Malcolm D/0000-0003-1288-1231; Blackburn, Tim/0000-0003-0152-2663; Owens, Ian/0000-0001-6080-3321; DING, Tzung-Su/0000-0002-1102-3879; Eigenbrod, Felix/0000-0001-8982-824X	Natural Environment Research Council [NER/O/S/2001/01230] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Baillie J. E. M., 2004, 2004 IUCN RED LIST T; Berg A, 1996, BIODIVERS CONSERV, V5, P101, DOI 10.1007/BF00056294; Bibby C.J., 1992, PUTTING BIODIVERSITY; BirdLife International, 2000, THREAT BIRDS WORLD; Bonn A, 2002, ECOL LETT, V5, P733, DOI 10.1046/j.1461-0248.2002.00376.x; Brooks T, 2001, BIOSCIENCE, V51, P613, DOI 10.1641/0006-3568(2001)051[0613:TABFCI]2.0.CO;2; Dobson AP, 1997, SCIENCE, V275, P550, DOI 10.1126/science.275.5299.550; Gaston KJ, 1996, P ROY SOC B-BIOL SCI, V263, P235, DOI 10.1098/rspb.1996.0037; Howard PC, 1998, NATURE, V394, P472, DOI 10.1038/28843; Jetz W, 2004, ECOL LETT, V7, P1180, DOI 10.1111/j.1461-0248.2004.00678.x; Jetz W, 2002, SCIENCE, V297, P1548, DOI 10.1126/science.1072779; Lawton JH, 1998, NATURE, V391, P72, DOI 10.1038/34166; Lennon JJ, 2004, ECOL LETT, V7, P81, DOI 10.1046/j.1461-0248.2004.00548.x; Mittermeier R. A., 1999, CHELONIAN CONSERV BI; Mittermeier Russell A., 2004, P1; Myers N, 2000, NATURE, V403, P853, DOI 10.1038/35002501; Myers N, 1988, Environmentalist, V8, P187, DOI 10.1007/BF02240252; Myers N, 1990, Environmentalist, V10, P243, DOI 10.1007/BF02239720; Olson DM, 2001, BIOSCIENCE, V51, P933, DOI 10.1641/0006-3568(2001)051[0933:TEOTWA]2.0.CO;2; PRENDERGAST JR, 1993, NATURE, V365, P335, DOI 10.1038/365335a0; PRESSEY RL, 1993, TRENDS ECOL EVOL, V8, P124, DOI 10.1016/0169-5347(93)90023-I; Rahbek C, 2001, P NATL ACAD SCI USA, V98, P4534, DOI 10.1073/pnas.071034898; Sibley CG, 1990, DISTRIBUTION TAXONOM; Stattersfield A.J., 1998, ENDEMIC BIRD AREAS W, V115, P1089, DOI 10.2307/4089533; THOMAS CD, 1985, BIOL CONSERV, V33, P95, DOI 10.1016/0006-3207(85)90098-9; Virolainen KM, 2000, P ROY SOC B-BIOL SCI, V267, P1143, DOI 10.1098/rspb.2000.1120; Williams P, 1996, CONSERV BIOL, V10, P155, DOI 10.1046/j.1523-1739.1996.10010155.x	27	802	863	5	363	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 18	2005	436	7053					1016	1019		10.1038/nature03850	http://dx.doi.org/10.1038/nature03850			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955XQ	16107848				2022-12-28	WOS:000231263900050
J	Wendler, D; Belsky, L; Thompson, KM; Emanuel, EJ				Wendler, D; Belsky, L; Thompson, KM; Emanuel, EJ			Quantifying the federal minimal risk standard - Implications for pediatric research without a prospect of direct benefit	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHILDREN; EXPERIMENTATION; VENIPUNCTURE; HEALTH; BIASES	United States federal regulations allow institutional review boards (IRBs) to approve pediatric research that does not offer participants a "prospect of direct" benefit only when, the risks are minimal or a "minor" increase over minimal. The federal regulations define minimal risks based on the risks "ordinarily encountered in daily life or during routine physical or psychological examinations or tests." In the absence of empirical data, IRB members may assume they are familiar with the risks of daily life and with the risks of routine examinations and tests and rely on their own intuitive judgment to make these assessments. Yet intuitive judgment of risk is subject to systematic errors, highlighting the need for empirical data to guide IRB review and approval of pediatric research. Current data reveal that car trips pose the highest risk of mortality ordinarily encountered by healthy children. On average, these risks are approximately 0.06 per million for children aged 14 years and younger, and approximately 0.4 per million for children aged 15 through 19 years. Riskier, but still ordinary, car trips pose an approximately 0.6 per million chance of death for children aged 14 years and younger and an approximately 4 per million chance of,death for children aged 15 through 19 years. Participation in sports represents the upper end of the range of morbidity risks for healthy children. For every million instances of playing basketball, approximately 1900 individuals will sustain injuries, including 180 broken bones and 58 permanent disabilities. These findings suggest IRBs are implementing the federal minimal risk standard too cautiously in many cases. These data also raise the question of whether the federal minimal risk standard may sometimes fail to provide sufficient protection for children, prompting the need to consider alternative standards.	NIH, Dept Clin Bioeth, NIH Clin Ctr, Bethesda, MD 20892 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Kids Risk Project, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Wendler, D (corresponding author), NIH, Dept Clin Bioeth, NIH Clin Ctr, Bldg 10,Room 1C118, Bethesda, MD 20892 USA.	dwendler@nih.gov		Thompson, Kimberly/0000-0002-0849-9147				Ackerman T F, 1994, J Pediatr Oncol Nurs, V11, P134, DOI 10.1177/104345429401100310; Ackerman Terrence F, 1980, Bioethics Q, V2, P94, DOI 10.1007/BF00915263; *AM AC PED, BRIGHT FUT TOOLS RES; *AM RED CROSS, YOUTH SERV; *AM SPORTS DAT, 2002, COMPR STUD SPORT INJ; BARTHOLOME W, 1977, RES INVOLVING CHILDR, V3, P1; Caldwell PHY, 2004, LANCET, V364, P803, DOI 10.1016/S0140-6736(04)16942-0; Council for International Organizations of Medical Sciences WHO, 2002, INT ETH GUID BIOM RE; GALENA HJ, 1992, J FAM PRACTICE, V34, P582; *HAB HUM, CAMP CHAPT YOUTH PRO; *I MED, 2004, ETH COND CLIN RES IN; JANOFSKY J, 1981, J PEDIATR-US, V98, P842, DOI 10.1016/S0022-3476(81)80865-7; Kauffman R E, 2000, Paediatr Drugs, V2, P411, DOI 10.2165/00128072-200002060-00001; Koocher G.P., 1994, CHILDREN RES SUBJECT, P47; Kopelman LM, 2004, J MED PHILOS, V29, P351, DOI 10.1080/03605310490500545; KOPELMAN LM, 1989, CHILDREN HLTH CARE M, P89; McCarthy AM, 2001, ARCH PEDIAT ADOL MED, V155, P1197; MCCORMICK RA, 1974, PERSPECT BIOL MED, V18, P2; MCCORMICK RA, 1976, HASTINGS CENT REP, V6, P41, DOI 10.2307/3561148; *NAT HIGHW TRAFF S, TRAFF SAF FACTS 2002; *NAT HIGHW TRAFF S, TRAFF SAF FACTS 2003; *NAT HUM RES PROT, CHILD WORK GROUP REP; Nicholson RH, 1986, MED RES CHILDREN ETH; RAMSEY P, 1977, HASTINGS CENT REP, V7, P40, DOI 10.2307/3561857; RAMSEY P, 1976, HASTINGS CENT REP, V6, P21, DOI 10.2307/3560383; Resnik DB, 2005, J MED ETHICS, V31, P35, DOI 10.1136/jme.2004.010470; Roberts R, 2003, JAMA-J AM MED ASSOC, V290, P905, DOI 10.1001/jama.290.7.905; Sandman P.M., 1993, RESPONDING COMMUNITY; Shah S, 2004, JAMA-J AM MED ASSOC, V291, P476, DOI 10.1001/jama.291.4.476; SLOVIC P, 1987, SCIENCE, V236, P280, DOI 10.1126/science.3563507; Trouern-Trend JJ, 1999, TRANSFUSION, V39, P316, DOI 10.1046/j.1537-2995.1999.39399219291.x; TURKELTAUB PC, 1989, J ALLERGY CLIN IMMUN, V84, P886, DOI 10.1016/0091-6749(89)90384-9; TVERSKY A, 1981, SCIENCE, V211, P453, DOI 10.1126/science.7455683; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; Varni JW, 2003, AMBUL PEDIATR, V3, P329, DOI 10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2; WEINSTEIN ND, 1989, SCIENCE, V246, P1232, DOI 10.1126/science.2686031; 2002, FED REG, V67, P211	37	86	86	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	2005	294	7					826	832		10.1001/jama.294.7.826	http://dx.doi.org/10.1001/jama.294.7.826			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	955LI	16106008				2022-12-28	WOS:000231227000023
J	Bower, M; Gazzard, B; Mandalia, S; Newsom-Davis, T; Thirlwell, C; Dhillon, T; Young, AM; Powles, T; Gaya, A; Nelson, M; Stebbing, J				Bower, M; Gazzard, B; Mandalia, S; Newsom-Davis, T; Thirlwell, C; Dhillon, T; Young, AM; Powles, T; Gaya, A; Nelson, M; Stebbing, J			A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CYCLOPHOSPHAMIDE; SURVIVAL; CHEMOTHERAPY; VINCRISTINE; DOXORUBICIN; IMPACT; COMBINATION; INHIBITORS; SARCOMA	Background: The established international Prognostic index for lymphomas has not included patients with systemic AIDS-related non-Hodgkin lymphoma. Objective: To establish the most appropriate prognostic index for use in patients with systemic AIDS-related non-Hodgkin lymphoma. Design: A prospective study involving univariate and multivariable analyses of patients with AIDS-related non-Hodgkin lymphoma whose data were used to examine standard and new criteria for survival after diagnosis. Setting: The Chelsea and Westminster cohort of HIV-1-infected persons. Patients: 9621 HIV-positive patients, 111 in whom AIDS-related non-Hodgkin lymphoma was treated after 1996, in the era of highly active antiretroviral therapy (HAART). Intervention: Cox proportional hazards regression analysis to determine the prognostic significance of multiple clinicopathologic variables. Results: Survival of patients with AIDS-related non-Hodgkin lymphoma has increased in the HAART era (log-rank chi-square, 9.23; P = 0.002). Univariate analyses using the established International Prognostic Index factors of age, tumor stage, lactate dehydrogenase level, Eastern Cooperative Oncology Group performance status, and number of extranodal sites were confirmed to be significant variables. Regression modeling for patients in whom disease was diagnosed after 1996 revealed only 2 independent predictors of death: International Prognostic Index risk group and CD4 cell count. These predictors yielded 4 internally validated risk strata with predicted 1-year survival rates of 82%, 47%, 20%, and 15% (P < 0.001). Prognostic risk scores in the highest quartile yielded a likelihood ratio for death of 7.90 (hazard ratio, 1.0), whereas a prognostic score less than 1.0 yielded a likelihood ratio of 0.23 (hazard ratio, 0.15 [95% Cl, 0.06 to 0.33]). Limitations: The sample was small, and different HAART regimens were used. Conclusions: For patients with AIDS-related non-Hodgkin lymphoma that was diagnosed in the era of HAART, application of the International Prognostic Index remains useful. The addition of CD4 cell count provides further independent prognostic information. Patients who present with AIDS-related non-Hodgkin lymphoma and a low CD4 cell count have a poor prognosis; this information can be used to guide therapeutic options.	Chelsea & Westminster Hosp, London SW10 9NH, England	Imperial College London	Bower, M (corresponding author), Chelsea & Westminster Hosp, 369 Fulham Rd, London SW10 9NH, England.	m.bower@imperial.ac.uk; j.stebbing@imperial.ac.uk		Stebbing, Justin/0000-0002-1117-6947; Bower, Mark/0000-0002-4077-6351				Appleby P, 2000, JNCI-J NATL CANCER I, V92, P1823, DOI 10.1093/jnci/92.22.1823; Benzel J E, 1968, Del Med J, V40, P78; Bower M, 2004, BLOOD, V104, P2943, DOI 10.1182/blood-2004-05-1747; Cortes J, 2002, CANCER, V94, P1492, DOI 10.1002/cncr.10365; Efron B, 1996, P NATL ACAD SCI USA, V93, P13429, DOI 10.1073/pnas.93.23.13429; Efron B, 1993, INTRO BOOTSTRAP, DOI DOI 10.1111/1467-9639.00050; Efron B., 1986, STAT SCI, V1, P54, DOI [10.1214/ss/1177013815, DOI 10.1214/SS/1177013815]; Gabarre J, 2004, HAEMATOLOGICA, V89, P1100; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; Jacobson LP, 1999, J ACQ IMMUN DEF SYND, V21, pS34; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; LITTLE R, 1999, P AN M AM SOC CLIN, V18, pA10; Little RF, 2003, BLOOD, V101, P4653, DOI 10.1182/blood-2002-11-3589; Lossos IS, 2004, NEW ENGL J MED, V350, P1828, DOI 10.1056/NEJMoa032520; Matthews GV, 2000, BLOOD, V96, P2730; Mocroft A, 2000, LANCET, V356, P291, DOI 10.1016/S0140-6736(00)02504-6; Murdaca G, 2002, AIDS, V16, P304, DOI 10.1097/00002030-200201250-00029; Navarro JT, 1998, HAEMATOLOGICA, V83, P508; Navarro JT, 2001, BRIT J HAEMATOL, V112, P909, DOI 10.1046/j.1365-2141.2001.02656.x; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Ratner L, 2001, J CLIN ONCOL, V19, P2171, DOI 10.1200/JCO.2001.19.8.2171; ROSENBERG SA, 1977, CANCER TREAT REP, V61, P1023; Rossi G, 1999, CANCER-AM CANCER SOC, V86, P2391, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2391::AID-CNCR29>3.0.CO;2-0; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; Sparano JA, 2004, J CLIN ONCOL, V22, P1491, DOI 10.1200/JCO.2004.08.195; Stebbing J, 2004, J CLIN ONCOL, V22, P2177, DOI 10.1200/JCO.2004.11.097; Stebbing J, 2004, CANCER TREAT REV, V30, P249, DOI 10.1016/j.ctrv.2003.12.004; Stebbing J, 2004, INT J CANCER, V108, P473, DOI 10.1002/ijc.11601; Stebbing J, 2003, LANCET ONCOL, V4, P438, DOI 10.1016/S1470-2045(03)01142-2; Stebbing J, 2003, J ANTIMICROB CHEMOTH, V51, P1095, DOI 10.1093/jac/dkg199; Steyerberg EW, 2001, MED DECIS MAKING, V21, P45, DOI 10.1177/0272989X0102100106; Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9; THIRLWELL C, 2002, 6 INT C DRUG THER HI, P94; Vaccher E, 2001, CANCER-AM CANCER SOC, V91, P155, DOI 10.1002/1097-0142(20010101)91:1<155::AID-CNCR20>3.0.CO;2-B; Yeni PG, 2004, JAMA-J AM MED ASSOC, V292, P251, DOI 10.1001/jama.292.2.251	38	88	93	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 16	2005	143	4					265	273		10.7326/0003-4819-143-4-200508160-00007	http://dx.doi.org/10.7326/0003-4819-143-4-200508160-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955PA	16103470				2022-12-28	WOS:000231237100003
J	Costello, A; Osrin, D				Costello, A; Osrin, D			The case for a new Global Fund for maternal, neonatal, and child survival	LANCET			English	Editorial Material							INTEGRATED MANAGEMENT; ILLNESS IMCI; HEALTH; COUNTRIES; CALL		UCL, Inst Child Hlth, Int Perinatal Care Unit, London WC1N 1EH, England	University of London; University College London	Costello, A (corresponding author), UCL, Inst Child Hlth, Int Perinatal Care Unit, London WC1N 1EH, England.	a.costello@ich.ucl.ac.uk		Osrin, David/0000-0001-9691-9684				Brugha R, 2002, LANCET, V359, P435, DOI 10.1016/S0140-6736(02)07607-9; Claeson M, 2003, LANCET, V362, P323, DOI 10.1016/S0140-6736(03)13977-3; *DEV ASS COMM SECR, 2000, REC TRENDS OFF DEV A; Devarajan S., 2002, PROSPECTS COSTS APRI; *DFID, STAT INT DEV; El Arifeen S, 2004, LANCET, V364, P1595, DOI 10.1016/S0140-6736(04)17312-1; Garner P, 2000, BMJ-BRIT MED J, V321, P129, DOI 10.1136/bmj.321.7254.129; Haines A, 2004, BMJ-BRIT MED J, V329, P394, DOI 10.1136/bmj.329.7462.394; HANCOCK G, 1991, LORDS POVERTY POWER; Horton R, 2004, LANCET, V364, P2071, DOI 10.1016/S0140-6736(04)17560-0; Levine Ruth, 2004, MILLIONS SAVED PROVE; Manandhar DS, 2004, LANCET, V364, P970, DOI 10.1016/S0140-6736(04)17021-9; Martines J, 2005, LANCET, V365, P1189, DOI 10.1016/S0140-6736(05)71882-1; Morris SS, 2004, LANCET, V364, P2030, DOI 10.1016/S0140-6736(04)17515-6; SACHS J, 2001, REPORT COMMISSION MA; Sachs JD, 2004, B WORLD HEALTH ORGAN, V82, P947; Schellenberg JRMA, 2004, LANCET, V364, P1583, DOI 10.1016/S0140-6736(04)17311-X; UNDP, HUM DEV REP 2004 CUL; *UNFPA, UN POP FUND ANN REP; *UNICEF, ANN REP 2003; *USAID, FISC YEAR 2003 PERF; Whitehead M, 2001, LANCET, V358, P833, DOI 10.1016/S0140-6736(01)05975-X; *WHO, PROP PROGR BUDG 2004	23	24	24	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 13	2005	366	9485					603	605		10.1016/S0140-6736(05)66703-7	http://dx.doi.org/10.1016/S0140-6736(05)66703-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955LL	16099297				2022-12-28	WOS:000231227300033
J	Farquhar, CM				Farquhar, CM			Ectopic pregnancy	LANCET			English	Review							HUMAN CHORIONIC-GONADOTROPIN; DOSE SYSTEMIC METHOTREXATE; SINGLE SERUM PROGESTERONE; IN-VITRO FERTILIZATION; RANDOMIZED-TRIAL; TRANSVAGINAL SONOGRAPHY; LAPAROSCOPIC SURGERY; TUBAL PREGNANCY; RISK-FACTORS; EXPECTANT MANAGEMENT	Ectopic pregnancy is an important cause of morbidity and mortality worldwide. Use of transvaginal. ultrasonography and quantitative measurement of the beta subunit of human chorionic gonadotropin (beta-hCG) has led to a reduction in the need for diagnostic laparoscopy. Furthermore, with earlier diagnosis, medical therapy with methotrexate can be offered and surgery avoided in some women, though the best regimen remains unclear. in the surgical management of ectopic pregnancy, the benefits of salpingectomy over salpingostomy are uncertain. Although there have been advances in the management of ectopic pregnancy there are still questions to be answered.	Univ Auckland, Natl Womens Hlth Auckland City Hosp, Dept Obstet & Gynaecol, Auckland 1, New Zealand	Auckland City Hospital; University of Auckland	Farquhar, CM (corresponding author), Univ Auckland, Natl Womens Hlth Auckland City Hosp, Dept Obstet & Gynaecol, Private Bag 92019, Auckland 1, New Zealand.	c.farquhar@auckland.ac.nz		Farquhar, Cynthia/0000-0002-3685-3553				Ankum WM, 1996, FERTIL STERIL, V65, P1093, DOI 10.1016/S0015-0282(16)58320-4; ANKUM WM, 1993, HUM REPROD, V8, P1301, DOI 10.1093/oxfordjournals.humrep.a138246; Atri M, 2003, J CLIN ULTRASOUND, V31, P1, DOI 10.1002/jcu.10131; Bakken Inger Johanne, 2003, Tidsskr Nor Laegeforen, V123, P3016; Banerjee S, 2001, BRIT J OBSTET GYNAEC, V108, P158, DOI 10.1111/j.1471-0528.2001.00031.x; Bangsgaard N, 2003, BJOG-INT J OBSTET GY, V110, P765, DOI 10.1111/j.1471-0528.2003.02253.x; Barnhart KT, 2004, OBSTET GYNECOL, V104, P50, DOI 10.1097/01.AOG.0000128174.48843.12; Barnhart KT, 2003, OBSTET GYNECOL, V101, P778, DOI 10.1016/S0029-7844(02)03158-7; Barnhart KT, 1999, OBSTET GYNECOL, V94, P583, DOI 10.1016/S0029-7844(99)00347-6; Bernoux A, 2000, HUM REPROD, V15, P1173, DOI 10.1093/humrep/15.5.1173; Bouyer J, 2003, AM J EPIDEMIOL, V157, P185, DOI 10.1093/aje/kwf190; Bouyer J, 2000, FERTIL STERIL, V74, P899, DOI 10.1016/S0015-0282(00)01605-8; BRAUNSTEIN GD, 1976, AM J OBSTET GYNECOL, V126, P678, DOI 10.1016/0002-9378(76)90518-4; BROWN DL, 1994, J ULTRAS MED, V13, P259, DOI 10.7863/jum.1994.13.4.259; BUSTER JE, 1995, CURR OPIN OBSTET GYN, V7, P168, DOI 10.1097/00001703-199506000-00003; Buster JE, 1999, CLIN OBSTET GYNECOL, V42, P23, DOI 10.1097/00003081-199903000-00006; Clausen I, 1996, ACTA OBSTET GYN SCAN, V75, P8, DOI 10.3109/00016349609033276; COLLINS JA, 1995, FERTIL STERIL, V64, P22, DOI 10.1016/s0015-0282(16)57650-x; Condous G, 2003, ULTRASOUND OBST GYN, V21, P504, DOI 10.1002/uog.106; Coste J, 1996, CONTRACEPT FERTIL S, V24, P135; CREININ MD, 1993, FERTIL STERIL, V60, P963; Dart R, 1999, ACAD EMERG MED, V6, P1024, DOI 10.1111/j.1553-2712.1999.tb01187.x; Egger M, 1998, BRIT MED J, V316, P1776, DOI 10.1136/bmj.316.7147.1776; Elson J, 2004, ULTRASOUND OBST GYN, V23, P552, DOI 10.1002/uog.1061; Fernandez H, 2004, HUM REPROD UPDATE, V10, P503, DOI 10.1093/humupd/dmh043; Fernandez H, 1998, HUM REPROD, V13, P3239, DOI 10.1093/humrep/13.11.3239; Furlong LA, 2002, J REPROD MED, V47, P881; Gazvani MR, 1998, HUM REPROD, V13, P1987, DOI 10.1093/humrep/13.7.1987; Goyaux N, 2003, ACTA OBSTET GYN SCAN, V82, P305, DOI 10.1034/j.1600-0412.2003.00175.x; Graczykowski JW, 1997, OBSTET GYNECOL, V89, P118, DOI 10.1016/S0029-7844(96)00370-5; GRAY DT, 1995, LANCET, V345, P1139, DOI 10.1016/S0140-6736(95)90977-X; Hajenius PJ, 1997, LANCET, V350, P774, DOI 10.1016/S0140-6736(97)05487-1; HAJENIUS PJ, 2000, COCHRANE DATABASE SY, V1; Hillis SD, 1997, AM J OBSTET GYNECOL, V176, P103, DOI 10.1016/S0002-9378(97)80020-8; Isaacs JD, 1996, OBSTET GYNECOL, V88, P694, DOI 10.1016/0029-7844(96)00252-9; Izquierdo LA, 2003, J CLIN ULTRASOUND, V31, P484, DOI 10.1002/jcu.10201; JobSpira N, 1996, HUM REPROD, V11, P99; Jurkovic D, 2003, ULTRASOUND OBST GYN, V21, P220, DOI 10.1002/uog.56; KADAR N, 1990, FERTIL STERIL, V54, P783; KADAR N, 1993, FERTIL STERIL, V60, P409; KADAR N, 1994, FERTIL STERIL, V61, P1016; Kamwendo F, 2000, SEX TRANSM INFECT, V76, P28, DOI 10.1136/sti.76.1.28; Kaplan BC, 1996, ANN EMERG MED, V28, P10, DOI 10.1016/S0196-0644(96)70131-2; Klauser CK, 2005, OBSTET GYNECOL, V105, p64S; LAVIE O, 1993, AM J OBSTET GYNECOL, V169, P1149, DOI 10.1016/0002-9378(93)90272-K; Lipscomb GH, 1999, NEW ENGL J MED, V341, P1974, DOI 10.1056/NEJM199912233412604; Ludwig M, 1999, EUR J OBSTET GYN R B, V87, P91, DOI 10.1016/S0301-2115(99)00079-2; Lundorff P, 1991, ACTA OBSTET GYN SCAN, V70, P343, DOI 10.3109/00016349109007885; Maymon R, 2004, HUM REPROD, V19, P278, DOI 10.1093/humrep/deh060; Maymon R, 1996, HUM REPROD UPDATE, V2, P541, DOI 10.1093/humupd/2.6.541; McCord ML, 1996, FERTIL STERIL, V66, P513, DOI 10.1016/S0015-0282(16)58560-4; Mehta TS, 1997, RADIOLOGY, V205, P569, DOI 10.1148/radiology.205.2.9356647; Mol BWJ, 1999, FERTIL STERIL, V72, P643, DOI 10.1016/S0015-0282(99)00328-3; Mol BWJ, 1997, BRIT J OBSTET GYNAEC, V104, P834, DOI 10.1111/j.1471-0528.1997.tb12029.x; Mol BWJ, 1998, HUM REPROD, V13, P1804, DOI 10.1093/humrep/13.7.1804; Mol BWJ, 1999, AM J OBSTET GYNECOL, V181, P945, DOI 10.1016/S0002-9378(99)70330-3; Mol BWJ, 1998, FERTIL STERIL, V70, P972, DOI 10.1016/S0015-0282(98)00278-7; Mol BWJ, 1995, CONTRACEPTION, V52, P337, DOI 10.1016/0010-7824(95)00221-9; Mol BWJ, 2002, ACTA OBSTET GYN SCAN, V81, P661, DOI 10.1034/j.1600-0412.2002.810713.x; Mol BWJ, 1998, HUM REPROD, V13, P3220, DOI 10.1093/humrep/13.11.3220; Morlock RJ, 2000, OBSTET GYNECOL, V95, P407, DOI 10.1016/S0029-7844(99)00548-7; MURPHY AA, 1992, FERTIL STERIL, V57, P1180; Nazac A, 2003, ULTRASOUND OBST GYN, V21, P181, DOI 10.1002/uog.9; *NCHS, 1994, ADV REP FIN MORT STA; Ness RB, 1998, AM J OBSTET GYNECOL, V179, P697, DOI 10.1016/S0002-9378(98)70067-5; Nieuwkerk PT, 1998, FERTIL STERIL, V70, P511, DOI 10.1016/S0015-0282(98)00212-X; OFILIYEBOVI D, 2003, ULTRASOUND OBSTET S1, V22, P5; ORY SJ, 1992, JAMA-J AM MED ASSOC, V267, P534, DOI 10.1001/jama.267.4.534; Parker J, 1997, AUST NZ J OBSTET GYN, V37, P115, DOI 10.1111/j.1479-828X.1997.tb02232.x; Perdu M, 1998, AM J OBSTET GYNECOL, V179, P640, DOI 10.1016/S0002-9378(98)70057-2; Peterson HB, 1997, NEW ENGL J MED, V336, P762, DOI 10.1056/NEJM199703133361104; Pisarska MD, 1998, LANCET, V351, P1115, DOI 10.1016/S0140-6736(97)11476-3; PITTAWAY DE, 1985, AM J OBSTET GYNECOL, V152, P299, DOI 10.1016/S0002-9378(85)80215-5; Potter MB, 2003, AM J OBSTET GYNECOL, V188, P1192, DOI 10.1067/mob.2003.310; *RCOG, 2001, WHY MOTH DIE 1997 19; RIZK B, 1991, AM J OBSTET GYNECOL, V164, P161, DOI 10.1016/0002-9378(91)90648-B; Robson SJ, 1996, AUST NZ J OBSTET GYN, V36, P182, DOI 10.1111/j.1479-828X.1996.tb03282.x; Rojansky N, 1996, J ASSIST REPROD GEN, V13, P594, DOI 10.1007/BF02066615; Rozenberg P, 2003, HUM REPROD, V18, P1802, DOI 10.1093/humrep/deg344; Saraiya M, 1999, AM J EPIDEMIOL, V149, P1025; Saraj AJ, 1998, OBSTET GYNECOL, V92, P989, DOI 10.1016/S0029-7844(98)00324-X; Seifer DB, 1997, FERTIL STERIL, V68, P402, DOI 10.1016/S0015-0282(97)00271-9; Seow KM, 2004, ULTRASOUND OBST GYN, V23, P247, DOI 10.1002/uog.974; SHULMAN A, 1994, J ASSIST REPROD GEN, V11, P111, DOI 10.1007/BF02332087; SILVA PD, 1993, OBSTET GYNECOL, V81, P710; Skjeldestad FE, 1998, OBSTET GYNECOL, V91, P129, DOI 10.1016/S0029-7844(97)00603-0; Sowter MC, 2001, BRIT J OBSTET GYNAEC, V108, P192, DOI 10.1111/j.1471-0528.2001.00038.x; Sowter MC, 2001, BRIT J OBSTET GYNAEC, V108, P204, DOI 10.1111/j.1471-0528.2001.00037.x; STOVALL TG, 1992, FERTIL STERIL, V57, P456; STOVALL TG, 1992, HUM REPROD, V7, P723, DOI 10.1093/oxfordjournals.humrep.a137725; Strandell A, 1999, FERTIL STERIL, V71, P282, DOI 10.1016/S0015-0282(98)00441-5; Tay JI, 2000, BRIT MED J, V320, P916, DOI 10.1136/bmj.320.7239.916; Thorburn J, 1995, Lakartidningen, V92, P4701; THORNTON KL, 1991, OBSTET GYN CLIN N AM, V18, P95; TROUT S, 1995, FERTIL STERIL, V64, P866, DOI 10.1016/S0015-0282(16)57869-8; Tulandi T, 1999, CLIN OBSTET GYNECOL, V42, P31, DOI 10.1097/00003081-199903000-00007; Tulandi T, 2000, CURR OPIN OBSTET GYN, V12, P289, DOI 10.1097/00001703-200008000-00004; VERMESH M, 1992, FERTIL STERIL, V57, P682; Vial Y, 2000, ULTRASOUND OBST GYN, V16, P592, DOI 10.1046/j.1469-0705.2000.00300-2.x; WASHINGTON AE, 1993, OBSTET GYNECOL, V81, P287; WECKSTEIN LN, 1985, OBSTET GYNECOL, V65, P393; WESTROM L, 1992, SEX TRANSM DIS, V19, P185, DOI 10.1097/00007435-199207000-00001; Wieringa-de Waard M, 2002, HUM REPROD, V17, P2445, DOI 10.1093/humrep/17.9.2445; XIONG X, 1995, CONTRACEPTION, V52, P23, DOI 10.1016/0010-7824(95)00120-Y; Yao M, 1996, HUM REPROD, V11, P2762; Yao ML, 1997, FERTIL STERIL, V67, P421, DOI 10.1016/S0015-0282(97)80064-7; Yeh JM, 2003, SEX TRANSM DIS, V30, P369, DOI 10.1097/00007435-200305000-00001; Zane Suzanne B, 2002, Matern Child Health J, V6, P227, DOI 10.1023/A:1021106032198; Zullo F, 1996, EUR J OBSTET GYN R B, V70, P213, DOI 10.1016/S0301-2115(95)02573-1; 1995, MMWR MORB MORTAL WKL, V44, P46; 2003, HEALTHCARE COST UTIL	111	320	350	0	49	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 13	2005	366	9485					583	591		10.1016/S0140-6736(05)67103-6	http://dx.doi.org/10.1016/S0140-6736(05)67103-6			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955LL	16099295				2022-12-28	WOS:000231227300031
J	Opdenakker, G				Opdenakker, G			Immunohistopathology to guide multiple sclerosis treatment	LANCET			English	Editorial Material							PLASMA-EXCHANGE		Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium	KU Leuven	Opdenakker, G (corresponding author), Katholieke Univ Leuven, Rega Inst Med Res, Minderbroedersstr 10, B-3000 Louvain, Belgium.	ghislain.opdenakker@rega.kuleuven.ac.be	Opdenakker, Ghislain/V-8562-2019; Opdenakker, Ghislain/Q-3130-2017	Opdenakker, Ghislain/0000-0003-1714-2294; Opdenakker, Ghislain/0000-0003-1714-2294	Multiple Sclerosis Society [651] Funding Source: Medline	Multiple Sclerosis Society(National Multiple Sclerosis Society)		Buntinx M, 2002, CRIT REV IMMUNOL, V22, P391; Corboy John R., 2003, Curr Treat Options Neurol, V5, P35, DOI 10.1007/s11940-003-0021-0; Hohlfeid R, 2004, P NATL ACAD SCI USA, V101, P14599, DOI 10.1073/pnas.0404874101; Keegan M, 2005, LANCET, V366, P579, DOI 10.1016/S0140-6736(05)67102-4; Lassmann H, 2001, TRENDS MOL MED, V7, P115, DOI 10.1016/S1471-4914(00)01909-2; MUNARI L, 2004, COCHRANE DB SYST REV, V1; Opdenakker G, 2003, LANCET NEUROL, V2, P747, DOI 10.1016/S1474-4422(03)00587-8; Opdenakker G, 2003, TRENDS IMMUNOL, V24, P94, DOI 10.1016/S1471-4906(02)00037-6; OPDENAKKER G, 1994, IMMUNOL TODAY, V15, P103, DOI 10.1016/0167-5699(94)90151-1; Paemen L, 1994, Eur J Neurol, V1, P55, DOI 10.1111/j.1468-1331.1994.tb00051.x; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; Vamvakas EC, 1995, J CLIN APHERESIS, V10, P163, DOI 10.1002/jca.2920100402	12	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 13	2005	366	9485					526	527		10.1016/S0140-6736(05)67076-6	http://dx.doi.org/10.1016/S0140-6736(05)67076-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955LL	16099274				2022-12-28	WOS:000231227300006
J	Garcia, KC; Adams, EJ				Garcia, KC; Adams, EJ			How the T cell receptor sees antigen - A structural view	CELL			English	Review							PEPTIDE-MHC; RECOGNITION; REPERTOIRE	Structures of many of the cell surface receptor-ligand complexes mediating the interactions between T cells and target cells have been determined in the past ten years. While snapshots of T cell receptors bound to their peptide-MHC ligands appear to have defined a general interaction or "docking" solution, many of the most fundamental structural questions in antigen re cognition lack detailed answers and thus pose exciting experimental challenges for the future.	Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Biol Struct, Howard Hughes Med Inst, Stanford, CA 94305 USA	Stanford University; Howard Hughes Medical Institute; Stanford University	Garcia, KC (corresponding author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA.	kcgarcia@stanford.edu			NIAID NIH HHS [AI48540] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048540] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams EJ, 2005, SCIENCE, V308, P227, DOI 10.1126/science.1106885; BLACKMAN M, 1986, CELL, V47, P349, DOI 10.1016/0092-8674(86)90591-X; Borg NA, 2005, NAT IMMUNOL, V6, P171, DOI 10.1038/ni1155; Buslepp J, 2003, IMMUNITY, V19, P595, DOI 10.1016/S1074-7613(03)00269-3; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; Hahn M, 2005, NAT IMMUNOL, V6, P490, DOI 10.1038/ni1187; Hennecke J, 2001, CELL, V104, P1, DOI 10.1016/S0092-8674(01)00185-4; Housset D, 2003, TRENDS IMMUNOL, V24, P429, DOI 10.1016/S1471-4906(03)00180-7; JERNE N K, 1971, European Journal of Immunology, V1, P1, DOI 10.1002/eji.1830010102; Manning TC, 1998, IMMUNITY, V8, P413, DOI 10.1016/S1074-7613(00)80547-6; Maynard J, 2005, IMMUNITY, V22, P81, DOI 10.1016/j.immuni.2004.11.015; Reinherz EL, 1999, SCIENCE, V286, P1913, DOI 10.1126/science.286.5446.1913; Reiser JB, 2003, NAT IMMUNOL, V4, P241, DOI 10.1038/ni891; Rudolph MG, 2002, ANNU REV BIOPH BIOM, V31, P121, DOI 10.1146/annurev.biophys.31.082901.134423; Wu LC, 2002, NATURE, V418, P552, DOI 10.1038/nature00920; Zerrahn J, 1997, CELL, V88, P627, DOI 10.1016/S0092-8674(00)81905-4	16	112	117	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 12	2005	122	3					333	336		10.1016/j.cell.2005.07.015	http://dx.doi.org/10.1016/j.cell.2005.07.015			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	955UZ	16096054	Bronze			2022-12-28	WOS:000231254400006
J	Harvey, SL; Charlet, A; Haas, W; Gygi, SP; Kellogg, DR				Harvey, SL; Charlet, A; Haas, W; Gygi, SP; Kellogg, DR			Cdk1-dependent regulation of the mitotic inhibitor Wee1	CELL			English	Article							CDC28 PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; MORPHOGENESIS CHECKPOINT; FISSION YEAST; CELL-SIZE; BUDDING YEAST; SCHIZOSACCHAROMYCES-POMBE; TYROSINE PHOSPHORYLATION; NEGATIVE REGULATION; SYSTEMATIC IDENTIFICATION	The Wee1 kinase phosphorylates and inhibits cyclin-dependent kinase 1 (Cdk1), thereby delaying entry into mitosis until appropriate conditions have been met. An understanding of the mechanisms that regulate Wee1 should provide new insight into how cells make the decision to enter mitosis. We report here that Swe1, the budding-yeast homolog of Wee1, is directly regulated by Cdk1. Phosphorylation of Swe1 by Cdk1 activates Swe1 and is required for formation of a stable Swe1-Cdk1 complex that maintains Cdk1 in the inhibited state. Dephosphorylation of Cdk1 leads to further phosphorylation of Swe1 and release of Cdk1. Thus, Cdk1 both positively and negatively regulates its own inhibitor. Regulation of the Swe1-Cdk1 complex is likely to play a critical role in controlling the transition into mitosis.	Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	University of California System; University of California Santa Cruz; Harvard University; Harvard Medical School	Kellogg, DR (corresponding author), Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA.	kellogg@darwin.ucsc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053959] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM53959] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ballif BA, 2004, MOL CELL PROTEOMICS, V3, P1093, DOI 10.1074/mcp.M400085-MCP200; Bishop AC, 2000, NATURE, V407, P395, DOI 10.1038/35030148; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; Breeding CS, 1998, MOL BIOL CELL, V9, P3399, DOI 10.1091/mbc.9.12.3399; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; FANTES P, 1977, EXP CELL RES, V107, P377, DOI 10.1016/0014-4827(77)90359-7; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; Harvey SL, 2003, CURR BIOL, V13, P264, DOI 10.1016/S0960-9822(03)00049-6; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Jorgensen P, 2002, SCIENCE, V297, P395, DOI 10.1126/science.1070850; Kanoh J, 1998, MOL BIOL CELL, V9, P3321, DOI 10.1091/mbc.9.12.3321; Kellogg DR, 2003, J CELL SCI, V116, P4883, DOI 10.1242/jcs.00908; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; Lew DJ, 2003, CURR OPIN CELL BIOL, V15, P648, DOI 10.1016/j.ceb.2003.09.001; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; McMillan JN, 1999, MOL CELL BIOL, V19, P5981; McMillan JN, 1999, MOL CELL BIOL, V19, P6929; McMillan JN, 1998, J CELL BIOL, V142, P1487, DOI 10.1083/jcb.142.6.1487; Mortensen EM, 2002, MOL BIOL CELL, V13, P2091, DOI 10.1091/mbc.01-10-0500; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Peng JM, 2001, J MASS SPECTROM, V36, P1083, DOI 10.1002/jms.229; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; Rudner AD, 2000, J CELL BIOL, V149, P1361, DOI 10.1083/jcb.149.7.1361; Rupes I, 2002, TRENDS GENET, V18, P479, DOI 10.1016/S0168-9525(02)02745-2; Rupes I, 2001, MOL BIOL CELL, V12, P3892, DOI 10.1091/mbc.12.12.3892; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Sakchaisri K, 2004, P NATL ACAD SCI USA, V101, P4124, DOI 10.1073/pnas.0400641101; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shulewitz MJ, 1999, MOL CELL BIOL, V19, P7123; Sia RAL, 1998, EMBO J, V17, P6678, DOI 10.1093/emboj/17.22.6678; Sreenivasan A, 1999, MOL CELL BIOL, V19, P7983; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; Takeda DY, 2001, J BIOL CHEM, V276, P1993, DOI 10.1074/jbc.M005719200; TANG ZH, 1993, EMBO J, V12, P3427, DOI 10.1002/j.1460-2075.1993.tb06017.x; Tjandra H, 1998, CURR BIOL, V8, P991, DOI 10.1016/S0960-9822(07)00419-8; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795; YOUNG PG, 1987, J CELL SCI, V88, P295	51	156	160	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 12	2005	122	3					407	420		10.1016/j.cell.2005.05.029	http://dx.doi.org/10.1016/j.cell.2005.05.029			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	955UZ	16096060	Bronze			2022-12-28	WOS:000231254400012
J	Li, XL; Manley, JL				Li, XL; Manley, JL			Inactivation of the SR protein splicing factor ASF/SF2 results in genomic instability	CELL			English	Article							RNA-POLYMERASE-II; R-LOOP FORMATION; MESSENGER-RNA; COUPLING TRANSCRIPTION; SITE SELECTION; DNA; COMPLEX; BINDING; PHOSPHORYLATION; STABILITY	SR proteins constitute a family of pre-mRNA splicing factors now thought to play several roles in mRNA metabolism in metazoan cells. Here we provide evidence that a prototypical SR protein, ASF/SF2, is unexpectedly required for maintenance of genomic stability. We first show that in vivo depletion of ASF/SF2 results in a hypermutation phenotype likely due to DNA rearrangements, reflected in the rapid appearance of DNA double-strand breaks and high-molecular-weight DNA fragments. Analysis of DNA from ASF/ SF2-depleted cells revealed that the nontemplate strand of a transcribed gene was single stranded due to formation of an RNA:DNA hybrid, R loop structure. Stable overexpression of RNase H suppressed the DNA-fragmentation and hypermutation phenotypes. Indicative of a direct role, ASF/SF2 prevented R loop formation in a reconstituted in vitro transcription reaction. Our results support a model by which recruitment of ASF/SF2 to nascent transcripts by RNA polymerase 11 prevents formation of mutagenic R loop structures.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Manley, JL (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	jlm2@columbia.edu		Manley, James/0000-0002-8341-1459; Li, Xialu/0000-0002-5631-6245	NIGMS NIH HHS [R37 GM48259] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM048259] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aguilera A, 2002, EMBO J, V21, P195, DOI 10.1093/emboj/21.3.195; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; BROWN DG, 1993, J BIOL CHEM, V268, P3037; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Chen Z, 2000, MOL CELL BIOL, V20, P5064, DOI 10.1128/MCB.20.14.5064-5076.2000; Chen Z, 2003, MOL CELL BIOL, V23, P7350, DOI 10.1128/MCB.23.20.7350-7362.2003; Daneholt B, 2001, P NATL ACAD SCI USA, V98, P7012, DOI 10.1073/pnas.111145498; Daneholt B, 2001, CHROMOSOMA, V110, P173, DOI 10.1007/s004120000127; DROLET M, 1995, P NATL ACAD SCI USA, V92, P3526, DOI 10.1073/pnas.92.8.3526; Drolet M, 2003, FRONT BIOSCI, V8, pD210, DOI 10.2741/970; Duquette ML, 2004, GENE DEV, V18, P1618, DOI 10.1101/gad.1200804; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; Gall JG, 1999, MOL BIOL CELL, V10, P4385, DOI 10.1091/mbc.10.12.4385; Gallardo M, 2003, J BIOL CHEM, V278, P24225, DOI 10.1074/jbc.M302900200; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; Hacker S, 2004, J BIOL CHEM, V279, P5049, DOI 10.1074/jbc.C300522200; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; Hirose Y, 2000, GENE DEV, V14, P1415; Huang YQ, 2003, MOL CELL, V11, P837, DOI 10.1016/S1097-2765(03)00089-3; Huertas P, 2003, MOL CELL, V12, P711, DOI 10.1016/j.molcel.2003.08.010; Hurt E, 2004, P NATL ACAD SCI USA, V101, P1858, DOI 10.1073/pnas.0308663100; Johnson VL, 2000, J CELL SCI, V113, P2941; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; Lemaire R, 2002, GENE DEV, V16, P594, DOI 10.1101/gad.939502; LIBER HL, 1982, MUTAT RES, V94, P467, DOI 10.1016/0027-5107(82)90308-6; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Longman D, 2000, EMBO J, V19, P1625, DOI 10.1093/emboj/19.7.1625; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Masse E, 1999, J BIOL CHEM, V274, P16659, DOI 10.1074/jbc.274.23.16659; Millhouse S, 2005, MOL CELL BIOL, V25, P533, DOI 10.1128/MCB.25.2.533-544.2005; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Papavasiliou FN, 2000, NATURE, V408, P216, DOI 10.1038/35041599; REABAN ME, 1994, J BIOL CHEM, V269, P21850; Reed R, 2003, CURR OPIN CELL BIOL, V15, P326, DOI 10.1016/S0955-0674(03)00048-6; Rehwinkel J, 2004, NAT STRUCT MOL BIOL, V11, P558, DOI 10.1038/nsmb759; RING HJ, 1994, MOL CELL BIOL, V14, P7499, DOI 10.1128/MCB.14.11.7499; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rondon AG, 2003, J BIOL CHEM, V278, P39037, DOI 10.1074/jbc.M305718200; Sakahira H, 1999, CURR BIOL, V9, P543, DOI 10.1016/S0960-9822(99)80240-1; Sanford J R, 2003, Prog Mol Subcell Biol, V31, P33; Sanford JR, 2004, GENE DEV, V18, P755, DOI 10.1101/gad.286404; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; SUGIMOTO N, 1995, BIOCHEMISTRY-US, V34, P11211, DOI 10.1021/bi00035a029; Tacke R, 1999, CURR OPIN CELL BIOL, V11, P358, DOI 10.1016/S0955-0674(99)80050-7; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; Takagaki Y, 1998, MOL CELL, V2, P761, DOI 10.1016/S1097-2765(00)80291-9; Wang J, 1996, GENE DEV, V10, P2588, DOI 10.1101/gad.10.20.2588; Wang J, 1998, GENE DEV, V12, P2222, DOI 10.1101/gad.12.14.2222; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Xu XD, 2005, CELL, V120, P59, DOI 10.1016/j.cell.2004.11.036; Yu KF, 2003, NAT IMMUNOL, V4, P442, DOI 10.1038/ni919; Zimmer C, 2001, RNA, V7, P1628	57	515	527	3	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 12	2005	122	3					365	378		10.1016/j.cell.2005.06.008	http://dx.doi.org/10.1016/j.cell.2005.06.008			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	955UZ	16096057	Bronze			2022-12-28	WOS:000231254400009
J	Shah, S; Lee, SF; Tabuchi, K; Hao, YH; Yu, C; LaPlant, Q; Ball, H; Dann, CE; Sudhof, T; Yu, G				Shah, S; Lee, SF; Tabuchi, K; Hao, YH; Yu, C; LaPlant, Q; Ball, H; Dann, CE; Sudhof, T; Yu, G			Nicastrin functions as a gamma-secretase-substrate receptor	CELL			English	Article							AMYLOID PRECURSOR PROTEIN; SIGNAL PEPTIDE PEPTIDASE; INTRAMEMBRANE PROTEOLYSIS; TRANSMEMBRANE DOMAIN; CHEMICAL LIGATION; BINDING-SITE; ACTIVE-SITE; PRESENILIN; CLEAVAGE; COMPLEX	gamma-secretase catalyzes the intramembrane cleavage of amyloid precursor protein (APP) and Notch after their extracellular domains are shed by site-specific proteolysis. Nicastrin is an essential glycoprotein component of the gamma-secretase complex but has no known function. We now show that the ectodomain of nicastrin binds the new amino terminus that is generated upon proteolysis of the extracellular APP and Notch domains, thereby recruiting the APP and Notch substrates into the gamma-secretase complex. Chemicalor anti body-mediated blocking of the free amino terminus, addition of purified nicastrin ectodomain, or mutations in the ectodomain markedly reduce the binding and cleavage of substrate by gamma-secretase. These results indicate that nicastrin is a receptor for the amino-terminal stubs that are generated by ectodomain shedding of type I transmembrane proteins. Our data are consistent with a model where nicastrin presents these substrates toy-secretase and thereby facilitates their cleavage via intramembrane proteolysis.	Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yu, G (corresponding author), Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75390 USA.	gang.yu@utsouthwestern.edu	Dann, Charles E/C-2747-2018		NIA NIH HHS [R01 AG023104] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG023104] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chen FS, 2001, NAT CELL BIOL, V3, P751, DOI 10.1038/35087069; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; Dawson PE, 2000, ANNU REV BIOCHEM, V69, P923, DOI 10.1146/annurev.biochem.69.1.923; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Fagan R, 2001, TRENDS BIOCHEM SCI, V26, P213, DOI 10.1016/S0968-0004(01)01789-3; Farmery MR, 2003, J BIOL CHEM, V278, P24277, DOI 10.1074/jbc.M211992200; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Kornilova AY, 2005, P NATL ACAD SCI USA, V102, P3230, DOI 10.1073/pnas.0407640102; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Lee SF, 2004, J BIOL CHEM, V279, P4144, DOI 10.1074/jbc.M309745200; Lemberg MK, 2002, MOL CELL, V10, P735, DOI 10.1016/S1097-2765(02)00655-X; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Luciani N, 1998, BIOCHEMISTRY-US, V37, P686, DOI 10.1021/bi971705p; Marchler-Bauer A, 2005, NUCLEIC ACIDS RES, V33, pD192, DOI 10.1093/nar/gki069; Shirotani K, 2004, J NEUROCHEM, V89, P1520, DOI 10.1111/j.1471-4159.2004.02447.x; Spector S, 2003, PROTEIN EXPRES PURIF, V32, P317, DOI 10.1016/j.pep.2003.08.004; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Thompson MW, 2003, ARCH BIOCHEM BIOPHYS, V413, P236, DOI 10.1016/S0003-9861(03)00123-1; Urban S, 2003, MOL CELL, V11, P1425, DOI 10.1016/S1097-2765(03)00181-3; Urban S, 2001, CELL, V107, P173, DOI 10.1016/S0092-8674(01)00525-6; Vazeux G, 1998, BIOCHEM J, V334, P407, DOI 10.1042/bj3340407; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 2000, P NATL ACAD SCI USA, V97, P9299, DOI 10.1073/pnas.97.16.9299; Ye J, 2000, P NATL ACAD SCI USA, V97, P5123, DOI 10.1073/pnas.97.10.5123; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	32	372	391	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 12	2005	122	3					435	447		10.1016/j.cell.2005.05.022	http://dx.doi.org/10.1016/j.cell.2005.05.022			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	955UZ	16096062	Bronze			2022-12-28	WOS:000231254400014
J	Shiono, M; Matsugaki, N; Takeda, K				Shiono, M; Matsugaki, N; Takeda, K			Structure of the blue cornflower pigment - Packaging red-rose anthocyanin as part of a 'superpigment' in another flower turns it brilliant blue.	NATURE			English	Editorial Material							SUPRAMOLECULAR PIGMENT; COLOR DEVELOPMENT; CENTAUREA-CYANUS; PROTOCYANIN		Kyushu Univ, Grad Sch Sci, Dept Phys, Fukuoka 8128581, Japan; High Energy Accelerator Res Org, Photon Factory, Tsukuba, Ibaraki 3050801, Japan; Tokyo Gakugei Univ, Dept Biol, Tokyo 1848501, Japan	Kyushu University; High Energy Accelerator Research Organization (KEK); Tokyo Gakugei University	Shiono, M (corresponding author), Kyushu Univ, Grad Sch Sci, Dept Phys, Hakozaki 6-10-1, Fukuoka 8128581, Japan.	takedks@ss.iij4u.or.jp		Matsugaki, Naohiro/0000-0001-9640-1949				BAYER E, 1958, CHEM BER-RECL, V91, P1115, DOI 10.1002/cber.19580910539; Bayer E., 1966, ANGEW CHEM, V78, P834; Brouillard R., 1994, FLAVONOIDS ADV RES 1, P565; Hayashi A, 1997, SCRIPTA MATER, V37, P393, DOI 10.1016/S1359-6462(97)00129-2; KONDO T, 1994, ANGEW CHEM INT EDIT, V33, P978, DOI 10.1002/anie.199409781; KONDO T, 1992, NATURE, V358, P515, DOI 10.1038/358515a0; Kondo T, 1998, TETRAHEDRON LETT, V39, P8307, DOI 10.1016/S0040-4039(98)01858-9; Robinson GM, 1931, BIOCHEM J, V25, P1687, DOI 10.1042/bj0251687; SAITO N, 1961, P JPN ACAD, V37, P485, DOI 10.2183/pjab1945.37.485; Shibata K, 1919, J AM CHEM SOC, V41, P208, DOI 10.1021/ja01459a008; Takeda K, 2005, PHYTOCHEMISTRY, V66, P1607, DOI 10.1016/j.phytochem.2005.04.002; Willstatter R, 1913, LIEBIGS ANN CHEM, V401, P189; Willstatter R, 1915, LIEBIGS ANN CHEM, V408, P147	13	114	123	7	81	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 11	2005	436	7052					791	791		10.1038/436791a	http://dx.doi.org/10.1038/436791a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953XG	16094358				2022-12-28	WOS:000231116500032
J	Pas, MFWT; Claes, F; Buscher, P				Pas, MFWT; Claes, F; Buscher, P			Fast, simple, and low-cost test for drug-resistant pathogens	LANCET			English	Editorial Material							AFRICAN TRYPANOSOMES		Univ Wageningen & Res Ctr, Anim Sci Grp, ID Lelystad, Div Anim Resource Dev,Anim Genom Grp, NL-8200 AB Lelystad, Netherlands; Inst Trop Med Prince Leopold, Dept Parasitol, B-2000 Antwerp, Belgium	Animal Sciences Group of Wageningen UR; Wageningen University & Research; Institute of Tropical Medicine (ITM)	Pas, MFWT (corresponding author), Univ Wageningen & Res Ctr, Anim Sci Grp, ID Lelystad, Div Anim Resource Dev,Anim Genom Grp, NL-8200 AB Lelystad, Netherlands.	Marinus.tepas@wur.nl	Büscher, Philippe/B-9956-2012	Büscher, Philippe/0000-0002-1926-7472				Agbo EC, 2003, TRENDS MICROBIOL, V11, P322, DOI 10.1016/S0966-842X(03)00151-3; Agbo EC, 2003, CHROMOSOMA, V111, P518, DOI 10.1007/s00412-002-0228-y; Agbo EC, 2003, INFECT GENET EVOL, V3, P165, DOI 10.1016/S1567-1348(03)00071-6; Agbo EEC, 2002, PARASITOLOGY, V124, P349, DOI 10.1017/S003118200100138X; Anene BM, 2001, VET PARASITOL, V96, P83, DOI 10.1016/S0304-4017(00)00427-1; MAJIWA P, 2000, ICPTV NEWSLETTERS; Matovu E, 2003, EUKARYOT CELL, V2, P1003, DOI 10.1128/EC.2.5.1003-1008.2003; Matovu E, 2001, MOL BIOCHEM PARASIT, V117, P73, DOI 10.1016/S0166-6851(01)00332-2; Shabbits J A, 2001, Expert Rev Anticancer Ther, V1, P585, DOI 10.1586/14737140.1.4.585; Stewart ML, 2005, LANCET, V366, P486, DOI 10.1016/S0140-6736(05)66793-1; *WELLC TRUST SANG, 2004, TRYP BRUC GEN PROJ	11	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 6	2005	366	9484					437	438		10.1016/S0140-6736(05)66833-X	http://dx.doi.org/10.1016/S0140-6736(05)66833-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	952RD	16084237				2022-12-28	WOS:000231022300008
J	Simini, B				Simini, B			Pulmonary artery catheters in intensive care	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; CRITICALLY ILL PATIENTS; HEART; RISK		Osped Gen Prov, Serv Sanit Nazl, Reg Toscano, I-55100 Lucca, Italy		Simini, B (corresponding author), Osped Gen Prov, Serv Sanit Nazl, Reg Toscano, I-55100 Lucca, Italy.	bruno.simini@virgilio.it						Angus D, 2001, BRIT MED J, V322, P446, DOI 10.1136/bmj.322.7284.446; Bertolini G, 2003, ANAESTHESIA, V58, P199; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; DEXTER L, 1947, J CLIN INVEST, V26, P547, DOI 10.1172/JCI101839; Harvey S, 2005, LANCET, V366, P472, DOI 10.1016/S0140-6736(05)67061-4; MIMOZ O, 1994, CRIT CARE MED, V22, P573, DOI 10.1097/00003246-199404000-00011; Richard C, 2003, JAMA-J AM MED ASSOC, V290, P2713, DOI 10.1001/jama.290.20.2713; Sandham JD, 2003, NEW ENGL J MED, V348, P5, DOI 10.1056/NEJMoa021108; Soni N, 1996, BMJ-BRIT MED J, V313, P763; SWAN HJC, 1970, NEW ENGL J MED, V283, P447, DOI 10.1056/NEJM197008272830902; Wilson J, 1999, BRIT MED J, V318, P1099, DOI 10.1136/bmj.318.7191.1099; ZION MM, 1990, CHEST, V98, P1331, DOI 10.1378/chest.98.6.1331	12	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 6	2005	366	9484					435	436		10.1016/S0140-6736(05)67038-9	http://dx.doi.org/10.1016/S0140-6736(05)67038-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	952RD	16084236				2022-12-28	WOS:000231022300007
J	de Anda, FC; Pollarolo, G; Da Silva, JS; Camoletto, PG; Feiguin, F; Dotti, CG				de Anda, FC; Pollarolo, G; Da Silva, JS; Camoletto, PG; Feiguin, F; Dotti, CG			Centrosome localization determines neuronal polarity	NATURE			English	Article							HIPPOCAMPAL-NEURONS; ESTABLISHMENT	Neuronal polarization occurs shortly after mitosis. In neurons differentiating in vitro, axon formation follows the segregation of growth-promoting activities to only one of the multiple neurites that form after mitosis(1,2). It is unresolved whether such spatial restriction makes use of an intrinsic program, like during C. elegans embryo polarization(3), or is extrinsic and cue-mediated, as in migratory cells(4). Here we show that in hippocampal neurons in vitro, the axon consistently arises from the neurite that develops first after mitosis. Centrosomes, the Golgi apparatus and endosomes cluster together close to the area where the first neurite will form, which is in turn opposite from the plane of the last mitotic division. We show that the polarized activities of these organelles are necessary and sufficient for neuronal polarization: ( 1) polarized microtubule polymerization and membrane transport precedes first neurite formation, ( 2) neurons with more than one centrosome sprout more than one axon and ( 3) suppression of centrosome-mediated functions precludes polarization. We conclude that asymmetric centrosome-mediated dynamics in the early post-mitotic stage instruct neuronal polarity, implying that pre-mitotic mechanisms with a role in division orientation may in turn participate in this event.	Univ Turin, Cavalieri Ottolenghi Sci Inst, I-10043 Turin, Italy; Catholic Univ Louvain, Dept Human Genet, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium	University of Turin; Universite Catholique Louvain	Feiguin, F (corresponding author), Univ Turin, Cavalieri Ottolenghi Sci Inst, I-10043 Turin, Italy.	fabian.feiguin@unito.it; carlos.dotti@unito.it	Dotti, Carlos G/I-5533-2015; de Anda, Froylan Calderon/AAQ-4811-2021; Feiguin, Fabian/ABC-2514-2020	Dotti, Carlos G/0000-0003-4052-1719; Pollarolo, Giulia/0000-0002-7140-8981; Calderon de Anda, Froylan/0000-0003-2743-7774				Bradke F, 1999, SCIENCE, V283, P1931, DOI 10.1126/science.283.5409.1931; Carney GE, 1997, P NATL ACAD SCI USA, V94, P12024, DOI 10.1073/pnas.94.22.12024; Cowan CR, 2004, NATURE, V431, P92, DOI 10.1038/nature02825; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; Da Silva JS, 2005, NAT NEUROSCI, V8, P606, DOI 10.1038/nn1442; Da Silva JS, 2002, NAT REV NEUROSCI, V3, P694, DOI 10.1038/nrn918; de Hoop MJ, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 1, P154; DOTTI CG, 1988, J NEUROSCI, V8, P1454; DOTTI CG, 1991, J CELL SCI, P75; Eda M, 2001, J CELL SCI, V114, P3273; Feiguin F, 1998, CURR TOP DEV BIOL, V36, P279; GOSLIN K, 1989, J CELL BIOL, V108, P1507, DOI 10.1083/jcb.108.4.1507; Grill SW, 2003, SCIENCE, V301, P518, DOI 10.1126/science.1086560; Horton AC, 2003, NEURON, V40, P277, DOI 10.1016/S0896-6273(03)00629-9; HOULISTON E, 1989, J CELL BIOL, V108, P543, DOI 10.1083/jcb.108.2.543; Megraw TL, 2002, J CELL SCI, V115, P4707, DOI 10.1242/jcs.00134; Nishimura T, 2004, NAT CELL BIOL, V6, P328, DOI 10.1038/ncb1118; PIPERNO G, 1985, J CELL BIOL, V101, P2085, DOI 10.1083/jcb.101.6.2085; Schwamborn JC, 2004, NAT NEUROSCI, V7, P923, DOI 10.1038/nn1295; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Shi SH, 2004, CURR BIOL, V14, P2025, DOI 10.1016/j.cub.2004.11.009; SINGER SJ, 1986, ANNU REV CELL BIOL, V2, P337, DOI 10.1146/annurev.cb.02.110186.002005; Surrey T, 1998, P NATL ACAD SCI USA, V95, P4293, DOI 10.1073/pnas.95.8.4293; Sydor AM, 1996, J CELL BIOL, V134, P1197, DOI 10.1083/jcb.134.5.1197; Ueda M, 1997, P NATL ACAD SCI USA, V94, P9674, DOI 10.1073/pnas.94.18.9674; WU CF, 1990, J NEUROBIOL, V21, P499, DOI 10.1002/neu.480210310; WU CF, 1983, J NEUROSCI, V3, P1888; Yoshimura T, 2005, CELL, V120, P137, DOI 10.1016/j.cell.2004.11.012	28	243	247	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 4	2005	436	7051					704	708		10.1038/nature03811	http://dx.doi.org/10.1038/nature03811			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	951XA	16079847				2022-12-28	WOS:000230964500045
J	Ingelfinger, JR				Ingelfinger, JR			Risks and benefits to the living donor	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							KIDNEY DONORS											Abecassis M, 2000, JAMA-J AM MED ASSOC, V284, P2919; Delmonico FL, 2005, TRANSPLANTATION, V79, pS53; Fehrman-Ekholm I, 2000, TRANSPLANTATION, V69, P2067, DOI 10.1097/00007890-200005270-00016; Fehrman-Ekholm I, 2001, TRANSPLANTATION, V72, P444, DOI 10.1097/00007890-200108150-00015; Matas AJ, 2003, AM J TRANSPLANT, V3, P830, DOI 10.1034/j.1600-6143.2003.00126.x	5	42	48	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 4	2005	353	5					447	449		10.1056/NEJMp058156	http://dx.doi.org/10.1056/NEJMp058156			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	951OB	16079367				2022-12-28	WOS:000230939000003
J	Kim, KM; Kopelman, RI				Kim, KM; Kopelman, RI			Medical mystery - Abdominal pain	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Tufts Univ, Sch Med, Boston, MA 02111 USA; Tufts New England Med Ctr, Boston, MA 02111 USA	Tufts University; Tufts Medical Center	Kim, KM (corresponding author), Tufts Univ, Sch Med, Boston, MA 02111 USA.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 4	2005	353	5					508	508		10.1056/NEJMicm040183	http://dx.doi.org/10.1056/NEJMicm040183			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	951OB	16079374				2022-12-28	WOS:000230939000010
J	Wibberley, CAJ; Shimamoto, T				Wibberley, CAJ; Shimamoto, T			Earthquake slip weakening and asperities explained by thermal pressurization	NATURE			English	Article							FAULT GOUGE; GAS-PERMEABILITY; FLUID PRESSURE; DISTANCE; PSEUDOTACHYLYTE; NUCLEATION; FRICTION; ZONES; TIME	An earthquake occurs when a fault weakens during the early portion of its slip at a faster rate than the release of tectonic stress driving the fault motion(1,2). This slip weakening occurs over a critical distance, D-c. Understanding the controls on D-c in nature is severely limited, however, because the physical mechanism of weakening is unconstrained. Conventional friction experiments, typically conducted at slow slip rates and small displacements, have obtained Dc values that are orders of magnitude lower than values estimated from modelling seismological data for natural earthquakes(3-6). Here we present data on fluid transport properties of slip zone rocks and on the slip zone width in the centre of the Median Tectonic Line fault zone, Japan. We show that the discrepancy between laboratory and seismological results can be resolved if thermal pressurization of the pore fluid(7-10) is the slip-weakening mechanism. Our analysis indicates that a planar fault segment with an impermeable and narrow slip zone will become very unstable during slip and is likely to be the site of a seismic asperity.	Univ Nice Sophia Antipolis, CNRS, F-06560 Valbonne, France; Kyoto Univ, Grad Sch Sci, Div Earth & Planetary Sci, Kyoto 6068502, Japan	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Kyoto University	Wibberley, CAJ (corresponding author), Univ Nice Sophia Antipolis, CNRS, 250 Rue A Einstein, F-06560 Valbonne, France.	wibbs@geoazur.unice.fr						AKI K, 1984, J GEOPHYS RES, V89, P5867, DOI 10.1029/JB089iB07p05867; Andrews DJ, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2002JB001942; BLANPIED ML, 1998, FAULT RELATED ROCKS, P72; Di Toro G, 2004, NATURE, V427, P436, DOI 10.1038/nature02249; DIETERICH JH, 1978, PURE APPL GEOPHYS, V116, P790, DOI 10.1007/BF00876539; DIETERICH JH, 1981, GEOPHYS MONOGR SER, V24, P103, DOI DOI 10.1029/GM024P0103; Faulkner DR, 1998, GEOL SOC SPEC PUBL, V147, P147, DOI 10.1144/GSL.SP.1998.147.01.10; Fukuchi T, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB002007; Fukuyama E, 2003, B SEISMOL SOC AM, V93, P1835, DOI 10.1785/0120020184; Hirose T, 2003, J STRUCT GEOL, V25, P1569, DOI 10.1016/S0191-8141(03)00009-9; IDA Y, 1972, J GEOPHYS RES, V77, P3796, DOI 10.1029/JB077i020p03796; Ide S, 1997, J GEOPHYS RES-SOL EA, V102, P27379, DOI 10.1029/97JB02675; Jaeger J. C., 1979, FUNDAMENTALS ROCK ME; Kanamori H., 1981, M EWING SERIES, V4, P1, DOI DOI 10.1029/ME004P0001; LACHENBRUCH AH, 1980, J GEOPHYS RES, V85, P6097, DOI 10.1029/JB085iB11p06097; MARONE C, 1993, NATURE, V362, P618, DOI 10.1038/362618a0; MASE CW, 1987, J GEOPHYS RES-SOLID, V92, P6249, DOI 10.1029/JB092iB07p06249; Mikumo T, 2003, B SEISMOL SOC AM, V93, P264, DOI 10.1785/0120020082; OHNAKA M, 1992, TECTONOPHYSICS, V211, P149, DOI 10.1016/0040-1951(92)90057-D; Ohnaka M, 1999, J GEOPHYS RES-SOL EA, V104, P817, DOI 10.1029/1998JB900007; SCHOLZ CH, 1988, NATURE, V336, P761, DOI 10.1038/336761a0; SIBSON RH, 1975, GEOPHYS J ROY ASTR S, V43, P775, DOI 10.1111/j.1365-246X.1975.tb06195.x; SIBSON RH, 1973, NATURE-PHYS SCI, V243, P66, DOI 10.1038/physci243066a0; Sibson RH, 2003, B SEISMOL SOC AM, V93, P1169, DOI 10.1785/0120020061; SUWA K, 1997, J GEOL SOC JPN, V103, P35; Tsutsumi A, 2004, TECTONOPHYSICS, V379, P93, DOI 10.1016/j.tecto.2003.10.007; Uehara S, 2004, TECTONOPHYSICS, V378, P183, DOI 10.1016/j.tecto.2003.09.007; Wibberley CAJ, 2002, EARTH PLANETS SPACE, V54, P1153, DOI 10.1186/BF03353317; Wibberley CAJ, 2003, J STRUCT GEOL, V25, P59, DOI 10.1016/S0191-8141(02)00014-7; WIBBERLEY CAJ, 2004, GEOPHYS RES ABSTR, V6	30	251	265	3	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 4	2005	436	7051					689	692		10.1038/nature03901	http://dx.doi.org/10.1038/nature03901			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	951XA	16079843				2022-12-28	WOS:000230964500041
J	Berkley, J; Mwangi, I; Griffiths, K; Ahmed, I; Mithwani, S; English, M; Newton, C; Maitland, K				Berkley, J; Mwangi, I; Griffiths, K; Ahmed, I; Mithwani, S; English, M; Newton, C; Maitland, K			Assessment of severe malnutrition among hospitalized children in rural Kenya - Comparison of weight for height and mid upper arm circumference	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROTEIN-ENERGY MALNUTRITION; DEVELOPING-COUNTRIES; MALNOURISHED CHILDREN; AFRICAN CHILDREN; MANAGEMENT; MORTALITY; DEATH; ANTHROPOMETRY; INDICATORS; DIARRHEA	Context Severe malnutrition has a high mortality rate among hospitalized children in sub-Saharan Africa. However, reports suggest that malnutrition is often poorly assessed. The World Health Organization recommends using weight for height, but this method is problematic and often not undertaken in practice. Mid Upper arm circumference (MUAC) and the clinical sign "visible severe wasting" are simple and inexpensive methods but have not been evaluated in this setting. Objectives To evaluate MUAC and visible severe wasting as predictors of inpatient mortality at a district hospital in sub-Saharan Africa and to compare these with weight-for-height z score (WHZ). Design, Setting, and Participants Cohort study with data collected at admission and at discharge or death. Predictive values for inpatient death were determined using the area under receiver operating characteristic curves. Participants were children aged 12 to 59 months admitted to a district hospital in rural Kenya between April 1, 1999, and July 31, 2002. Main Outcome Measure MUAC, WHZ, and visible severe wasting as predictors of inpatient death. Results Overall, 4.4% (359) of children included in the study died while in the hospital. Sixteen percent (1282/8190) of admitted children had severe wasting (WHZ <= -3) (n=756), kwashiorkor (n=778), or both. The areas under the receiver operating characteristic curves for predicting inpatient death did not significantly differ (MUAC: 0.75 [95% confidence interval, 0.72-0.78]; WHZ: 0.74 [95% confidence interval, 0.71-0.77]) (P=39). Although sensitivity and specificity for subsequent inpatient death were 46% and 91%, respectively, for MUAC less than or equal to 11.5 cm, 42% and 92% for WHZ less than or equal to -3, and 47% and 93% for visible severe wasting, the 3 indices identified different sets of children and were independently associated with mortality. Clinical features of malnutrition were significantly more common among children with MUAC less than or equal to 11.5 cm than among those with WHZ less than or equal to -3. Conclusions MUAC is a practical screening tool that performs at least as well as WHZ in predicting subsequent inpatient mortality among severely malnourished children hospitalized in rural Kenya. Visible severe wasting is also a potentially useful sign at this level, providing appropriate training has been given.	Kenya Med Inst Ctr Geog Med Res Coast, Kilifi, Kenya; Univ Oxford, Ctr Clin Vaccinol & Trop Med, Oxford, England; Univ Oxford, Dept Paediat, Oxford, England; Inst Child Hlth, London, England; Univ London Imperial Coll Sci & Technol, Dept Paediat, London, England	University of Oxford; University of Oxford; University of London; University College London; Imperial College London	Berkley, J (corresponding author), Kenya Med Inst Ctr Geog Med Res Coast, POB 230, Kilifi, Kenya.	jberkley@kilifi.mimcom.net	Newton, Charles/C-6222-2009; Newton, Charles RJC/B-7578-2014; Newton, Charles/V-7872-2019	Newton, Charles RJC/0000-0002-6999-5507; Newton, Charles/0000-0002-6999-5507; Berkley, James/0000-0002-1236-849X; Maitland, Kathryn/0000-0002-0007-0645; English, Michael/0000-0002-7427-0826	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ahmed T, 1999, LANCET, V353, P1919, DOI 10.1016/S0140-6736(98)07499-6; Ashworth A, 2004, LANCET, V363, P1110, DOI 10.1016/S0140-6736(04)15894-7; BAKER JP, 1982, NEW ENGL J MED, V306, P969, DOI 10.1056/NEJM198204223061606; Berkley JA, 2003, BRIT MED J, V326, P361, DOI 10.1136/bmj.326.7385.361; Bern C, 1997, B WORLD HEALTH ORGAN, V75, P87; BERN C, 1995, LANCET, V345, P631, DOI 10.1016/S0140-6736(95)90527-8; Bhan MK, 2003, BMJ-BRIT MED J, V326, P146, DOI 10.1136/bmj.326.7381.146; BRIEND A, 1986, BRIT MED J, V293, P373, DOI 10.1136/bmj.293.6543.373; Collins S, 1996, JAMA-J AM MED ASSOC, V276, P391, DOI 10.1001/jama.276.5.391; English M, 2004, LANCET, V363, P1948, DOI 10.1016/S0140-6736(04)16408-8; *GOV KEN, 2000, AIDS KEN; Hamer C, 2004, ARCH DIS CHILD, V89, P181, DOI 10.1136/adc.2002.022715; Lee LA, 1995, B WORLD HEALTH ORGAN, V73, P779; Maitland K, 2003, QJM-INT J MED, V96, P427, DOI 10.1093/qjmed/hcg077; *OXF CTR EV BAS ME, LIK RAT; PELLETIER DL, 1994, J NUTR, V124, pS2047; Rice AL, 2000, B WORLD HEALTH ORGAN, V78, P1207; ROSS DA, 1990, INT J EPIDEMIOL, V19, P636, DOI 10.1093/ije/19.3.636; Schellenberg D, 1999, AM J TROP MED HYG, V61, P431, DOI 10.4269/ajtmh.1999.61.431; Schofield C, 1996, B WORLD HEALTH ORGAN, V74, P223; VELLA V, 1993, AM J PUBLIC HEALTH, V83, P1616, DOI 10.2105/AJPH.83.11.1616; World Health Organization, 2000, MAN CHILD SER INF SE	22	121	124	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	2005	294	5					591	597		10.1001/jama.294.5.591	http://dx.doi.org/10.1001/jama.294.5.591			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	951NN	16077053	Bronze			2022-12-28	WOS:000230937500019
J	Klekociuk, AR; Brown, PG; Pack, DW; ReVelle, DO; Edwards, WN; Spalding, RE; Tagliaferri, E; Yoo, BB; Zagari, J				Klekociuk, AR; Brown, PG; Pack, DW; ReVelle, DO; Edwards, WN; Spalding, RE; Tagliaferri, E; Yoo, BB; Zagari, J			Meteoritic dust from the atmospheric disintegration of a large meteoroid	NATURE			English	Article							STRATOSPHERIC CLOUDS; LIDAR MEASUREMENTS; PARTICLES; VALIDATION; ANTARCTICA; DATABASE; MIDDLE; EARTH	Much of the mass of most meteoroids entering the Earth's atmosphere is consumed in the process of ablation. Larger meteoroids (> 10 cm), which in some cases reach the ground as meteorites, typically have survival fractions near 1 - 25 per cent of their initial mass(1). The fate of the remaining ablated material is unclear, but theory suggests that much of it should recondense through coagulation as nanometre-sized particles(2). No direct measurements of such meteoric 'smoke' have hitherto been made(3). Here we report the disintegration of one of the largest meteoroids to have entered the Earth's atmosphere during the past decade, and show that the dominant contribution to the mass of the residual atmospheric aerosol was in the form of micrometre-sized particles. This result is contrary to the usual view that most of the material in large meteoroids is efficiently converted to particles of much smaller size through ablation(4). Assuming that our observations are of a typical event, we suggest that large meteoroids provide the dominant source of micrometre-sized meteoritic dust at the Earth's surface over long timescales.	Australian Antarctic Div, Kingston, Tas 7050, Australia; Univ Western Ontario, Dept Phys & Astron, London, ON N6A 3K7, Canada; Aerosp Corp, El Segundo, CA 90245 USA; Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Sandia Natl Labs, Albuquerque, NM 87185 USA	Australian Antarctic Division; Western University (University of Western Ontario); Aerospace Corporation - USA; United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Sandia National Laboratories	Klekociuk, AR (corresponding author), Australian Antarctic Div, Channel Highway, Kingston, Tas 7050, Australia.	andrew.klekociuk@aad.gov.au	Klekociuk, Andrew/A-4498-2015; Brown, Peter/C-8763-2018	Klekociuk, Andrew/0000-0003-3335-0034; Brown, Peter/0000-0001-6130-7039				ADACHI H, 2001, APPL OPTICS, V36, P6578; Artemieva NA, 2001, J GEOPHYS RES-PLANET, V106, P3297, DOI 10.1029/2000JE001264; Britt DT, 2003, METEORIT PLANET SCI, V38, P1161, DOI 10.1111/j.1945-5100.2003.tb00305.x; Brown P, 2002, NATURE, V420, P294, DOI 10.1038/nature01238; CEPLECHA Z, 1993, ASTRON ASTROPHYS, V279, P615; Ceplecha Z, 1998, SPACE SCI REV, V84, P327, DOI 10.1023/A:1005069928850; EDWARDS WN, IN PRESS EARTH MOON; Fetzer E, 2003, IEEE T GEOSCI REMOTE, V41, P418, DOI 10.1109/TGRS.2002.808293; Fisher AA, 2000, PLANET SPACE SCI, V48, P911, DOI 10.1016/S0032-0633(00)00056-8; Gerding M, 2003, ANN GEOPHYS-GERMANY, V21, P1057, DOI 10.5194/angeo-21-1057-2003; Gobbi GP, 1998, J GEOPHYS RES-ATMOS, V103, P10859, DOI 10.1029/98JD00280; HUNTEN DM, 1980, J ATMOS SCI, V37, P1342, DOI 10.1175/1520-0469(1980)037<1342:SADPOM>2.0.CO;2; Jager C, 2003, J QUANT SPECTROSC RA, V79, P765, DOI 10.1016/S0022-4073(02)00301-1; Jenniskens P, 2004, ADV SPACE RES-SERIES, V33, P1444, DOI 10.1016/j.asr.2003.05.001; Karner DB, 2003, GEOCHIM COSMOCHIM AC, V67, P751, DOI 10.1016/S0016-7037(02)01145-6; Klekociuk AR, 2003, ADV SPACE RES, V32, P771, DOI 10.1016/S0273-1177(03)00421-6; Lal D, 2002, ASTROPHYS J, V576, P1090, DOI 10.1086/341797; Lazzarin M, 1997, ASTRON ASTROPHYS, V327, P388; MISHCHENKO MI, 1995, OPT LETT, V20, P1356, DOI 10.1364/OL.20.001356; Mishchenko MI, 1998, J QUANT SPECTROSC RA, V60, P309, DOI 10.1016/S0022-4073(98)00008-9; Morris GA, 2000, J GEOPHYS RES-ATMOS, V105, P17875, DOI 10.1029/1999JD901118; Penner JE, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P289; ReVelle D. O., 2002, ESA, P127; ROTHMAN LS, 1992, J QUANT SPECTROSC RA, V48, P469, DOI 10.1016/0022-4073(92)90115-K; Santacesaria V, 2001, TELLUS B, V53, P306, DOI 10.1034/j.1600-0889.2001.01155.x; SWINBANK R, 1994, MON WEATHER REV, V122, P686, DOI 10.1175/1520-0493(1994)122<0686:ASTDAS>2.0.CO;2; TOON OB, 1981, ANNU REV EARTH PL SC, V9, P19, DOI 10.1146/annurev.ea.09.050181.000315	27	59	62	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 25	2005	436	7054					1132	1135		10.1038/nature03881	http://dx.doi.org/10.1038/nature03881			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	958AK	16121174				2022-12-28	WOS:000231416600039
J	Michael, HA; Mulligan, AE; Harvey, CF				Michael, HA; Mulligan, AE; Harvey, CF			Seasonal oscillations in water exchange between aquifers and the coastal ocean	NATURE			English	Article							SUBMARINE GROUNDWATER DISCHARGE; SALT WATER; INPUTS; NUTRIENT; FLORIDA; RADIUM; FLUXES; ZONE; SEA	Ground water of both terrestrial and marine origin flows into coastal surface waters as submarine groundwater discharge, and constitutes an important source of nutrients, contaminants and trace elements to the coastal ocean(1-5). Large saline discharges have been observed by direct measurements(3,6-10) and inferred from geochemical tracers(11-13), but sufficient seawater inflow has not been observed to balance this outflow. Geochemical tracers also suggest a time lag between changes in submarine groundwater discharge rates(12,14) and the seasonal oscillations of inland recharge that drive groundwater flow towards the coast. Here we use measurements of hydraulic gradients and offshore fluxes taken at Waquoit Bay, Massachusetts, together with a modelling study of a generalized coastal groundwater system to show that a shift in the freshwater - saltwater interface - controlled by seasonal changes in water table elevation - can explain large saline discharges that lag inland recharge cycles. We find that sea water is drawn into aquifers as the freshwater - saltwater interface moves landward during winter, and discharges back into coastal waters as the interface moves seaward in summer. Our results demonstrate the connection between the seasonal hydrologic cycle inland and the saline groundwater system in coastal aquifers, and suggest a potentially important seasonality in the chemical loading of coastal waters.	MIT, Dept Civil & Environm Engn, Cambridge, MA 02139 USA; Woods Hole Oceanog Inst, Marine Policy Ctr, Woods Hole, MA 02543 USA	Massachusetts Institute of Technology (MIT); Woods Hole Oceanographic Institution	Harvey, CF (corresponding author), MIT, Dept Civil & Environm Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	charvey@mit.edu	Michael, Holly A/F-8447-2010; harvey, charles F/A-8601-2012	Michael, Holly A/0000-0003-1107-7698; harvey, charles F/0000-0002-7759-4447				[Anonymous], INTERACTIVE GRAPHICS; Bear J, 1999, SEAWATER INTRUSION C; Burnett WC, 2003, BIOGEOCHEMISTRY, V66, P3, DOI 10.1023/B:BIOG.0000006066.21240.53; Changnon SA, 1988, J CLIMATE, V1, P1239, DOI 10.1175/1520-0442(1988)001<1239:RBPASG>2.0.CO;2; COOPER HH, 1959, J GEOPHYS RES, V64, P461, DOI 10.1029/JZ064i004p00461; Crotwell AM, 2003, AQUAT GEOCHEM, V9, P191, DOI 10.1023/B:AQUA.0000022954.89019.c9; Eltahir EAB, 1999, WATER RESOUR RES, V35, P1199, DOI 10.1029/1998WR900071; JOHANNES RE, 1980, MAR ECOL PROG SER, V3, P365, DOI 10.3354/meps003365; Kelly RP, 2002, LIMNOL OCEANOGR, V47, P1796, DOI 10.4319/lo.2002.47.6.1796; Kim G, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018378; KOHOUT FA, 1960, J GEOPHYS RES, V65, P2133, DOI 10.1029/JZ065i007p02133; LEE DR, 1977, LIMNOL OCEANOGR, V22, P140, DOI 10.4319/lo.1977.22.1.0140; Li L, 1999, WATER RESOUR RES, V35, P3253, DOI 10.1029/1999WR900189; Michael HA, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016000; Moore WS, 1996, NATURE, V380, P612, DOI 10.1038/380612a0; Moore WS, 1996, NATURE, V382, P122, DOI 10.1038/382122a0; Moore WS, 1997, EARTH PLANET SC LETT, V150, P141, DOI 10.1016/S0012-821X(97)00083-6; Moore WS, 1999, MAR CHEM, V65, P111, DOI 10.1016/S0304-4203(99)00014-6; PAYNE R, FALMOUTH MONTHLY CLI; Robinson M, 1998, GROUND WATER MONIT R, V18, P83, DOI 10.1111/j.1745-6592.1998.tb00605.x; SIMMONS GM, 1992, MAR ECOL PROG SER, V84, P173, DOI 10.3354/meps084173; Slomp CP, 2004, J HYDROL, V295, P64, DOI 10.1016/j.jhydrol.2004.02.018; Smith L, 2003, BIOGEOCHEMISTRY, V66, P95, DOI 10.1023/B:BIOG.0000006108.80520.c9; Taniguchi M, 2005, GROUND WATER, V43, P336, DOI 10.1111/j.1745-6584.2005.0027.x; Tapley BD, 2004, SCIENCE, V305, P503, DOI 10.1126/science.1099192; VALIELA I, 1990, BIOGEOCHEMISTRY, V10, P177	26	385	395	9	157	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 25	2005	436	7054					1145	1148		10.1038/nature03935	http://dx.doi.org/10.1038/nature03935			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	958AK	16121178				2022-12-28	WOS:000231416600043
J	Ortuno, FJ; Heras, I				Ortuno, FJ; Heras, I			Images in clinical medicine: Coagulase-negative staphylococcus within neutrophils in acute leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Hosp Morales Meseguer, E-30008 Murcia, Spain		Ortuno, FJ (corresponding author), Hosp Morales Meseguer, E-30008 Murcia, Spain.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 25	2005	353	8					E7	E7		10.1056/NEJMicm041018	http://dx.doi.org/10.1056/NEJMicm041018			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	957YK	16120851				2022-12-28	WOS:000231409300012
J	Zhang, J; Gilles, JM; Barnhart, K; Creinin, MD; Westhoff, C; Frederick, MM				Zhang, J; Gilles, JM; Barnhart, K; Creinin, MD; Westhoff, C; Frederick, MM		NICHD Management Early Pregnancy F	A comparison of medical management with misoprostol and surgical management for early pregnancy failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EXPECTANT MANAGEMENT; ENDOMETRIAL THICKNESS; MISCARRIAGE; ABORTION; ULTRASOUND; CURETTAGE; TRIAL	Background: Misoprostol is increasingly used to treat women who have a failed pregnancy in the first trimester. We assessed the efficacy, safety, and acceptability of this treatment in a large, randomized trial. Methods: A total of 652 women with a first-trimester pregnancy failure (anembryonic gestation, embryonic or fetal death, or incomplete or inevitable spontaneous abortion) were randomly assigned to receive 800 microg of misoprostol vaginally or to undergo vacuum aspiration (standard of care) in a 3:1 ratio. The misoprostol group received treatment on day 1, a second dose on day 3 if expulsion was incomplete, and vacuum aspiration on day 8 if expulsion was still incomplete. Surgical treatment (for the misoprostol group) or repeated aspiration (for the vacuum-aspiration group) within 30 days after the initial treatment constituted treatment failure. Results: Of the 491 women assigned to receive misoprostol, 71 percent had complete expulsion by day 3 and 84 percent by day 8 (95 percent confidence interval, 81 to 87 percent). Treatment failed in 16 percent of the misoprostol group and 3 percent of the surgical group (absolute difference, 12 percent; 95 percent confidence interval, 9 to 16 percent) by day 30. Hemorrhage or endometritis requiring hospitalization was rare (1 percent or less in each group), with no significant differences between the groups. In the misoprostol group, 78 percent of the women stated that they would use misoprostol again if the need arose and 83 percent stated that they would recommend it to others. Conclusions: Treatment of early pregnancy failure with 800 microg of misoprostol vaginally is a safe and acceptable approach, with a success rate of approximately 84 percent.	NICHD, Epidemiol Branch, NIH, Bethesda, MD 20892 USA; Univ Miami, Miami, FL 33152 USA; Univ Penn, Philadelphia, PA 19104 USA; Columbia Univ, New York, NY USA; Clin Trials & Surveys Corp, Baltimore, MD USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Miami; University of Pennsylvania; Columbia University	Zhang, J (corresponding author), NICHD, Epidemiol Branch, NIH, Bldg 6100,Rm 7B03, Bethesda, MD 20892 USA.	zhangj@mail.nih.gov	Creinin, Mitchell/AAH-3488-2020	Creinin, Mitchell/0000-0001-5967-8180; Nansel, Tonja/0000-0002-8298-7595	NCRR NIH HHS [M01 RR000056] Funding Source: Medline; NICHD NIH HHS [N01-HD-3322, N01-HD-3325, N01-HD-3324, N01-HD-3323, N01-HD-1-3321] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008724, N01HD013321] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000056] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Alberman E, 1992, SPONTANEOUS ABORTION, P19; Ballagh SA, 1998, AM J OBSTET GYNECOL, V179, P1279, DOI 10.1016/S0002-9378(98)70147-4; Creinin MD, 2004, INT J GYNECOL OBSTET, V86, P22, DOI 10.1016/j.ijgo.2004.02.004; Creinin MD, 2001, OBSTET GYNECOL SURV, V56, P105, DOI 10.1097/00006254-200102000-00024; *CYT SOFTW CORP, 2000, STATXACT 4 WIND US M, P428; Fox JL, 2004, ASM NEWS, V70, P261; GOLDSTEIN SR, 1992, OBSTET GYNECOL, V80, P670; Graziosi GCM, 2004, HUM REPROD, V19, P1894, DOI 10.1093/humrep/deh344; Grimes D A, 1979, Obstet Gynecol Surv, V34, P177, DOI 10.1097/00006254-197903000-00001; Harwood B, 2001, CONTRACEPTION, V63, P255, DOI 10.1016/S0010-7824(01)00205-0; Hertig AT, 1944, NEW ENGL J MED, V230, P797; Honkanen H, 2004, BJOG-INT J OBSTET GY, V111, P715, DOI 10.1111/j.1471-0528.2004.00153.x; Jurkovic D, 1998, BRIT J OBSTET GYNAEC, V105, P670, DOI 10.1111/j.1471-0528.1998.tb10184.x; Luise C, 2002, ULTRASOUND OBST GYN, V19, P580, DOI 10.1046/j.1469-0705.2002.00662.x; Luise C, 2002, BMJ-BRIT MED J, V324, P873, DOI 10.1136/bmj.324.7342.873; MACROW P, 1993, BRIT MED J, V306, P876, DOI 10.1136/bmj.306.6882.876; MAKUCH R, 1978, CANCER TREAT REP, V62, P1037; Newhall Elizabeth Pirruccello, 2000, American Journal of Obstetrics and Gynecology, V183, pS44; NYBERG DA, 1987, J ULTRAS MED, V6, P23; Pang MW, 2001, HUM REPROD, V16, P2283, DOI 10.1093/humrep/16.11.2283; REVILL SI, 1976, ANAESTHESIA, V31, P1191, DOI 10.1111/j.1365-2044.1976.tb11971.x; Rowling SE, 1997, RADIOLOGY, V203, P211, DOI 10.1148/radiology.203.1.9122395; Tang OS, 2003, HUM REPROD, V18, P176, DOI 10.1093/humrep/deg013	23	180	185	1	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 25	2005	353	8					761	769		10.1056/NEJMoa044064	http://dx.doi.org/10.1056/NEJMoa044064			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	957YK	16120856				2022-12-28	WOS:000231409300005
J	Lenders, JWM; Eisenhofer, G; Mannelli, M; Pacak, K				Lenders, JWM; Eisenhofer, G; Mannelli, M; Pacak, K			Phaeochromocytoma	LANCET			English	Review							ENDOCRINE NEOPLASIA TYPE-2; HIPPEL-LINDAU-DISEASE; POSITRON-EMISSION-TOMOGRAPHY; ADRENAL-SPARING SURGERY; LAPAROSCOPIC ADRENALECTOMY; MALIGNANT PHEOCHROMOCYTOMA; HEREDITARY PHEOCHROMOCYTOMA; PLASMA METANEPHRINES; CHROMOGRANIN-A; EXTRAADRENAL PHEOCHROMOCYTOMA	Phaeochromocytomas are rare neuroendocrine tumours with a highly variable clinical presentation but most commonly presenting with episodes of headaches, sweating, palpitations, and hypertension. The serious and potentially lethal cardiovascular complications of these tumours are due to the potent effects of secreted catecholamines. Biochemical testing for phaeochromocytoma is indicated not only in symptomatic patients, but also in patients with adrenal incidentalomas or identified genetic predispositions (eg, multiple endocrine neoplasia type 2, von Hippel-Lindau syndrome, neurofibromatosis type 1, and mutations of the succinate dehydrogenase genes). Imaging techniques such as CT or MRI and functional ligands such as I-123-MIBG are used to localise biochemically proven tumours. After the use of appropriate preoperative treatment to block the effects of secreted catecholamines, laparoscopic tumour removal is the preferred procedure. If removal of phaeochromocytoma is timely, prognosis is excellent. However, prognosis is poor in patients with metastases, which especially occur in patients with large, extra-adrenal tumours.	Radboud Univ Nijmegen Med Ctr, Dept Internal Med, Div Gen Internal Med, NL-6525 GA Nijmegen, Netherlands; Univ Florence, Dept Clin Pathophysiol, I-50121 Florence, Italy; NICHHD, Reprod Biol & Med Branch, NIH, Bethesda, MD 20892 USA; Natl Inst Neurol Disorders & Stroke, Clin Neurocardiol Sect, NIH, Bethesda, MD USA	Radboud University Nijmegen; University of Florence; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Lenders, JWM (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Internal Med, Div Gen Internal Med, NL-6525 GA Nijmegen, Netherlands.	j.lenders@aig.umcn.nl	Lenders, J.W.M./L-4487-2015; Eisenhofer, Graeme/AAU-9829-2021	Lenders, J.W.M./0000-0002-7658-4466; Eisenhofer, Graeme/0000-0002-8601-9903; Mannelli, Massimo/0000-0002-8001-9857	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008735] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002979] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams S, 2001, CANCER-AM CANCER SOC, V92, P263, DOI 10.1002/1097-0142(20010715)92:2<263::AID-CNCR1318>3.0.CO;2-Z; Amar L, 2005, J CLIN ENDOCR METAB, V90, P2110, DOI 10.1210/jc.2004-1398; ANDERSON GH, 1994, J HYPERTENS, V12, P609, DOI 10.1097/00004872-199405000-00015; Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282; Augoustides JG, 2004, ANESTHESIOLOGY, V101, P1022, DOI 10.1097/00000542-200410000-00031; AVERBUCH SD, 1988, ANN INTERN MED, V109, P267, DOI 10.7326/0003-4819-109-4-267; Baghai M, 2002, ARCH SURG-CHICAGO, V137, P682, DOI 10.1001/archsurg.137.6.682; Baguet JP, 2004, EUR J ENDOCRINOL, V150, P681, DOI 10.1530/eje.0.1500681; Bauters C, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.6.e75; Baysal BE, 2004, AM J MED GENET C, V129C, P85, DOI 10.1002/ajmg.c.30018; Baysal BE, 2002, J MED GENET, V39, P178, DOI 10.1136/jmg.39.3.178; BERGLAND BE, 1989, AM J EMERG MED, V7, P44, DOI 10.1016/0735-6757(89)90084-3; Bernini GP, 2001, BRIT J CANCER, V84, P636, DOI 10.1054/bjoc.2000.1659; BOOMSMA F, 1995, CLIN CHIM ACTA, V239, P57, DOI 10.1016/0009-8981(95)06100-R; Brandi ML, 2001, J CLIN ENDOCR METAB, V86, P5658, DOI 10.1210/jc.86.12.5658; Brauckhoff M, 2004, SURG TODAY, V34, P251, DOI 10.1007/s00595-003-2690-4; BRAVO EL, 1981, NEW ENGL J MED, V305, P623, DOI 10.1056/NEJM198109103051107; Bravo EL, 2003, ENDOCR REV, V24, P539, DOI 10.1210/er.2002-0013; Brouwers FM, 2003, REV ENDOCR METAB DIS, V4, P121, DOI 10.1023/A:1022981801344; Brunt LM, 2002, ANN SURG, V235, P713, DOI 10.1097/00000658-200205000-00014; Bryant J, 2003, J NATL CANCER I, V95, P1196, DOI 10.1093/jnci/djg024; CANALE MP, 1994, J CLIN ENDOCR METAB, V78, P1139, DOI 10.1210/jc.78.5.1139; Cheah WK, 2002, WORLD J SURG, V26, P1048, DOI 10.1007/s00268-002-6669-x; CHOYKE PL, 1995, RADIOLOGY, V194, P629, DOI 10.1148/radiology.194.3.7862955; Coupland RE., 1965, NATURAL HIST CHROMAF; Davidson DF, 2002, ANN CLIN BIOCHEM, V39, P557, DOI 10.1258/000456302760413333; Eisenhofer G, 2004, ENDOCR-RELAT CANCER, V11, P423, DOI 10.1677/erc.1.00829; Eisenhofer G, 2005, J CLIN ENDOCR METAB, V90, P2068, DOI 10.1210/jc.2004-2025; Eisenhofer G, 2004, PHARMACOL REV, V56, P331, DOI 10.1124/pr.56.3.1; Eisenhofer G, 2003, J CLIN ENDOCR METAB, V88, P2656, DOI 10.1210/jc.2002-030005; Eisenhofer G, 1999, NEW ENGL J MED, V340, P1872, DOI 10.1056/NEJM199906173402404; Eisenhofer G, 1998, J CLIN ENDOCR METAB, V83, P2175, DOI 10.1210/jc.83.6.2175; Eisenhofer G, 2001, J CLIN ENDOCR METAB, V86, P1999, DOI 10.1210/jc.86.5.1999; Elder EE, 2003, EUR J SURG ONCOL, V29, P278, DOI 10.1053/ejso.2002.1413; Erickson D, 2001, J CLIN ENDOCR METAB, V86, P5210, DOI 10.1210/jc.86.11.5210; Favier J, 2005, HORM RES, V63, P171, DOI 10.1159/000084685; FernandezCruz L, 1996, WORLD J SURG, V20, P762, DOI 10.1007/s002689900116; Furuta N, 1999, INT J UROL, V6, P119, DOI 10.1046/j.1442-2042.1999.06310.x; Gardet V, 2001, J HYPERTENS, V19, P1029, DOI 10.1097/00004872-200106000-00006; GERLO EAM, 1994, CLIN CHEM, V40, P250; Gill IS, 2001, J UROLOGY, V166, P429, DOI 10.1016/S0022-5347(05)65958-7; Gimenez-Roqueplo AP, 2003, CANCER RES, V63, P5615; Henry JF, 2000, WORLD J SURG, V24, P1342, DOI 10.1007/s002680010222; Hes FJ, 2003, J CLIN ENDOCR METAB, V88, P969, DOI 10.1210/jc.2002-021466; Hoegerle S, 2002, RADIOLOGY, V222, P507, DOI 10.1148/radiol.2222010622; Hwang JJ, 2004, J UROLOGY, V171, P72, DOI 10.1097/01.ju.0000102081.46348.a4; Ilias I, 2004, J CLIN ENDOCR METAB, V89, P479, DOI 10.1210/jc.2003-031091; Ilias I, 2003, J CLIN ENDOCR METAB, V88, P4083, DOI 10.1210/jc.2003-030235; Janetschek G, 1998, J UROLOGY, V160, P330, DOI 10.1016/S0022-5347(01)62886-6; Januszewicz W, 2001, BLOOD PRESSURE, V10, P212, DOI 10.1080/08037050152669729; Jaroszewski DE, 2003, MAYO CLIN PROC, V78, P1501, DOI 10.4065/78.12.1501; Kaltsas G, 2001, J CLIN ENDOCR METAB, V86, P895, DOI 10.1210/jc.86.2.895; Kaltsas GA, 2004, FRONT HORM RES, V31, P61; Kebebew E, 1998, Surg Oncol Clin N Am, V7, P765; Khorram-Manesh A, 2004, EJSO, V30, P556, DOI 10.1016/j.ejso.2004.03.006; Kinney MAO, 2002, J CARDIOTHOR VASC AN, V16, P359, DOI 10.1053/jcan.2002.124150; Kinney MAO, 2000, ANESTH ANALG, V91, P1118, DOI 10.1097/00000539-200011000-00013; Kobayashi T, 2005, J SURG ONCOL, V90, P31, DOI 10.1002/jso.20234; Kocak S, 2002, INT SURG, V87, P191; La Batide-Alanore A, 2003, J HYPERTENS, V21, P1703, DOI 10.1097/00004872-200309000-00020; Lebuffe G, 2005, ANAESTHESIA, V60, P439, DOI 10.1111/j.1365-2044.2005.04156.x; Lehnert H, 2004, FRONT HORM RES, V31, P155; LENDERS JWM, 1993, CLIN CHEM, V39, P97; Lenders JWM, 2002, JAMA-J AM MED ASSOC, V287, P1427, DOI 10.1001/jama.287.11.1427; Liao WB, 2000, AM J EMERG MED, V18, P622, DOI 10.1053/ajem.2000.7341; Lo CY, 2000, AM J SURG, V179, P212, DOI 10.1016/S0002-9610(00)00296-8; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Maher ER, 2002, HUM MOL GENET, V11, P2347, DOI 10.1093/hmg/11.20.2347; MANGER WM, 1996, CLIN EXPT PHEOCHROMO; Mannelli M, 1999, EUR J ENDOCRINOL, V141, P619, DOI 10.1530/eje.0.1410619; Mansmann G, 2004, ENDOCR REV, V25, P309, DOI 10.1210/er.2002-0031; Mantero F, 2000, J CLIN ENDOCR METAB, V85, P637, DOI 10.1210/jc.85.2.637; Mayo-Smith WW, 2004, RADIOLOGY, V231, P225, DOI 10.1148/radiol.2311031007; McNeil AR, 2000, AUST NZ J MED, V30, P648, DOI 10.1111/j.1445-5994.2000.tb04358.x; Miskulin J, 2003, SURGERY, V134, P918, DOI 10.1016/S0039-6060(03)00416-1; MODIGLIANI E, 1995, J INTERN MED, V238, P363, DOI 10.1111/j.1365-2796.1995.tb01211.x; Mukherjee JJ, 1997, RADIOLOGY, V202, P227, DOI 10.1148/radiology.202.1.8988215; NEUMANN HPH, 1993, NEW ENGL J MED, V329, P1531, DOI 10.1056/NEJM199311183292103; Neumann HPH, 1999, BRIT J SURG, V86, P94, DOI 10.1046/j.1365-2168.1999.00974.x; Neumann HPH, 1999, J CLIN ENDOCR METAB, V84, P2608, DOI 10.1210/jc.84.8.2608; Neumann HPH, 2002, NEW ENGL J MED, V346, P1459, DOI 10.1056/NEJMoa020152; Neumann HPH, 2004, JAMA-J AM MED ASSOC, V292, P943, DOI 10.1001/jama.292.8.943; Niemann U, 2002, EUR J SURG, V168, P716, DOI 10.1080/00000000000000009; Olson SW, 2004, ANN INTERN MED, V140, P850, DOI 10.7326/0003-4819-140-10-200405180-00033; Omura M, 2004, HYPERTENS RES, V27, P193, DOI 10.1291/hypres.27.193; ORiordain DS, 1996, WORLD J SURG, V20, P916, DOI 10.1007/s002689900139; Pacak K, 2001, HYPERTENSION, V38, P6, DOI 10.1161/01.HYP.38.1.6; Pacak K, 2004, ENDOCR REV, V25, P568, DOI 10.1210/er.2003-0032; Pacak K, 2001, ANN INTERN MED, V134, P315, DOI 10.7326/0003-4819-134-4-200102200-00016; PACAK K, 2001, PROGR DIAGNOSIS TREA, P379; Peaston RT, 2004, ANN CLIN BIOCHEM, V41, P17, DOI 10.1258/000456304322664663; PERRY RR, 1990, ANN SURG, V212, P621, DOI 10.1097/00000658-199011000-00010; PLATTS JK, 1995, J ROY COLL PHYS LOND, V29, P299; Plouin PF, 1997, HYPERTENSION, V29, P1133, DOI 10.1161/01.HYP.29.5.1133; Plouin PF, 2001, J CLIN ENDOCR METAB, V86, P1480, DOI 10.1210/jc.86.4.1480; PLOUIN PF, 1981, NOUV PRESSE MED, V10, P869; PROYE C, 1986, SURGERY, V100, P1154; Prys-Roberts C, 2000, BRIT J ANAESTH, V85, P44, DOI 10.1093/bja/85.1.44; Prys-Roberts C, 2002, WORLD J SURG, V26, P1037, DOI 10.1007/s00268-002-6667-z; QUEZADO ZN, 1992, CRIT CARE MED, V20, P549, DOI 10.1097/00003246-199204000-00022; Raber W, 2000, ARCH INTERN MED, V160, P2957, DOI 10.1001/archinte.160.19.2957; Rao FW, 2000, HYPERTENSION, V36, P1045, DOI 10.1161/01.HYP.36.6.1045; Richard S, 1994, Adv Nephrol Necker Hosp, V23, P1; ROIZEN MF, 1987, ANESTHESIOL CLIN N A, V5, P269; Rose B, 2003, CANCER, V98, P239, DOI 10.1002/cncr.11518; Sahdev A, 2005, EUR RADIOL, V15, P85, DOI 10.1007/s00330-004-2412-3; Sawka AM, 2003, J CLIN ENDOCR METAB, V88, P553, DOI 10.1210/jc.2002-021251; Schurmeyer TH, 1997, EUR J CLIN INVEST, V27, P189, DOI 10.1046/j.1365-2362.1997.850646.x; SHAPIRO B, 1985, J NUCL MED, V26, P576; Shapiro B, 2001, TRENDS ENDOCRIN MET, V12, P469, DOI 10.1016/S1043-2760(01)00492-1; SHEPS SG, 1988, ENDOCRIN METAB CLIN, V17, P397, DOI 10.1016/S0889-8529(18)30426-2; Shulkin BL, 1999, RADIOLOGY, V212, P35, DOI 10.1148/radiology.212.1.r99jl3035; SINCLAIR AM, 1987, ARCH INTERN MED, V147, P1289, DOI 10.1001/archinte.147.7.1289; Sisson JC, 2002, ANN NY ACAD SCI, V970, P54, DOI 10.1111/j.1749-6632.2002.tb04412.x; SJOERDSMA A, 1966, ANN INTERN MED, V65, P1302, DOI 10.7326/0003-4819-65-6-1302; SOLANKI KK, 1992, NUCL MED COMMUN, V13, P513, DOI 10.1097/00006231-199207000-00006; Sprung J, 2000, UROLOGY, V55, P339, DOI 10.1016/S0090-4295(99)00466-5; Steinsapir J, 1997, ARCH INTERN MED, V157, P901, DOI 10.1001/archinte.157.8.901; Tauzin-Fin P, 2004, BRIT J ANAESTH, V92, P512, DOI 10.1093/bja/aeh083; Tauzin-Fin P, 1999, ANAESTH INTENS CARE, V27, P646, DOI 10.1177/0310057X9902700615; Trampal C, 2004, RADIOLOGY, V230, P423, DOI 10.1148/radiol.2302021678; Ulchaker JC, 1999, J UROLOGY, V161, P764, DOI 10.1016/S0022-5347(01)61762-2; van der Harst E, 2002, EUR J ENDOCRINOL, V147, P85, DOI 10.1530/eje.0.1470085; van der Harst E, 2001, J CLIN ENDOCR METAB, V86, P685, DOI 10.1210/jc.86.2.685; Vargas HI, 1997, UROLOGY, V49, P673, DOI 10.1016/S0090-4295(97)00083-6; Walther MM, 2000, J UROLOGY, V164, P14, DOI 10.1016/S0022-5347(05)67438-1; Walther MM, 1999, J UROLOGY, V162, P659, DOI 10.1097/00005392-199909010-00004; Walz MK, 2004, SURG CLIN N AM, V84, P743, DOI 10.1016/j.suc.2004.01.003; Walz MK, 2002, WORLD J SURG, V26, P1005, DOI 10.1007/s00268-002-6632-x; WERBEL SS, 1995, MED CLIN N AM, V79, P131, DOI 10.1016/S0025-7125(16)30088-8; WHALEN RK, 1992, J UROLOGY, V147, P1, DOI 10.1016/S0022-5347(17)37119-7; Witteles RM, 2000, ANESTH ANALG, V91, P302, DOI 10.1097/00000539-200008000-00011; Yip L, 2004, J AM COLL SURGEONS, V198, P525, DOI 10.1016/j.jamcollsurg.2003.12.001	133	1099	1169	1	86	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 20	2005	366	9486					665	675		10.1016/S0140-6736(05)67139-5	http://dx.doi.org/10.1016/S0140-6736(05)67139-5			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958EB	16112304				2022-12-28	WOS:000231426400031
J	Coles, HJ; Pivnenko, MN				Coles, HJ; Pivnenko, MN			Liquid crystal 'blue phases' with a wide temperature range	NATURE			English	Article								Liquid crystal 'blue phases' are highly fluid self-assembled three-dimensional cubic defect structures that exist over narrow temperature ranges in highly chiral liquid crystals(1). The characteristic period of these defects is of the order of the wavelength of visible light, and they give rise to vivid specular reflections(2) that are controllable with external fields(3-8). Blue phases may be considered as examples of tuneable photonic crystals(9) with many potential applications. The disadvantage of these materials, as predicted theoretically and proved experimentally(1), is that they have limited thermal stability: they exist over a small temperature range (0.5-2 degrees C) between isotropic and chiral nematic (N*) thermotropic phases, which limits their practical applicability. Here we report a generic family of liquid crystals that demonstrate an unusually broad body-centred cubic phase (BPI*) from 60 degrees C down to 16 degrees C. We prove this with optical texture analysis, selective reflection spectroscopy, Kossel diagrams and differential scanning calorimetry, and show, using a simple polarizer-free electro-optic cell, that the reflected colour is switched reversibly in applied electric fields over a wide colour range in typically 10 ms. We propose that the unusual behaviour of these blue phase materials is due to their dimeric molecular structure and their very high flexoelectric coefficients. This in turn sets out new theoretical challenges and potentially opens up new photonic applications.	Univ Cambridge, Ctr Mol Mat Photon & Elect, Dept Engn, Cambridge CB2 1PZ, England	University of Cambridge	Coles, HJ (corresponding author), Univ Cambridge, Ctr Mol Mat Photon & Elect, Dept Engn, Trumpington St, Cambridge CB2 1PZ, England.	hjc37@cam.ac.uk	Pivnenko, Mike/AAR-7933-2021					Bohley C, 2003, P SOC PHOTO-OPT INS, V5184, P202, DOI 10.1117/12.503554; Cao WY, 2002, NAT MATER, V1, P111, DOI 10.1038/nmat727; COLES HJ, 1989, MOL CRYST LIQ CRYST, V167, P213, DOI 10.1080/00268948908037178; COLES HJ, UNPUB J APPL PHYS; COLES HJ, 2001, Patent No. 2356629; Crooker PP, 2001, PART ORDER, P186; DMITRIENKO VE, 1989, LIQ CRYST, V5, P847, DOI 10.1080/02678298908026390; Etchegoin P, 2000, PHYS REV E, V62, P1435, DOI 10.1103/PhysRevE.62.1435; GERBER PR, 1985, MOL CRYST LIQ CRYST, V116, P197, DOI 10.1080/00268948508074573; GLEESON H, 1985, MOL CRYST LIQ CRYST, V129, P37, DOI 10.1080/15421408408084164; Heppke G., 1991, J PHYS, V50, P2291; Hisakado Y, 2005, ADV MATER, V17, P96, DOI 10.1002/adma.200400639; Kikuchi H, 2002, NAT MATER, V1, P64, DOI 10.1038/nmat712; Kitzerow HS, 1991, MOL CRYST LIQ CRYST, V202, P51, DOI 10.1080/00268949108035659; KITZEROW HS, 1993, LIQ CRYST, V14, P911, DOI 10.1080/02678299308027768; PARRY O, 1999, Patent No. 2329636; PATEL JS, 1987, PHYS REV LETT, V58, P1538, DOI 10.1103/PhysRevLett.58.1538; Pieranski P, 2001, PART ORDER, P28; STEGEMEYER H, 1986, LIQ CRYST, V1, P3, DOI 10.1080/02678298608086486; Wu S. T., 2002, REFLECTIVE LIQUID CR	20	522	537	5	283	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 18	2005	436	7053					997	1000		10.1038/nature03932	http://dx.doi.org/10.1038/nature03932			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955XQ	16107843				2022-12-28	WOS:000231263900045
J	Packer, C; Ikanda, D; Kissui, B; Kushnir, H				Packer, C; Ikanda, D; Kissui, B; Kushnir, H			Lion attacks on humans in Tanzania - Understanding the timing and distribution of attacks on rural communities will help to prevent them.	NATURE			English	Editorial Material							HUMAN-CARNIVORE CONFLICT; PANTHERA-LEO; LIVESTOCK; PREDATION		Univ Minnesota, Dept Ecol Evolut & Behav, St Paul, MN 55108 USA; Tanzania Wildlife Res Inst, Arusha, Tanzania	University of Minnesota System; University of Minnesota Twin Cities	Packer, C (corresponding author), Univ Minnesota, Dept Ecol Evolut & Behav, St Paul, MN 55108 USA.	packer@cbs.umn.edu						Bauer H, 2004, ORYX, V38, P26, DOI 10.1017/S0030605304000055; CARDONNET P, 2002, CONSERVATION AFRICAN; Kellert SR, 1996, CONSERV BIOL, V10, P977, DOI 10.1046/j.1523-1739.1996.10040977.x; KERBISPETERHANS JC, 2002, E AFRIC NAT HIST, V90, P1; Loe J, 2004, AMBIO, V33, P283, DOI 10.1639/0044-7447(2004)033[0283:LCAHSA]2.0.CO;2; NICHOLSON B, 2001, LAST OLD AFRICA; Ogada MO, 2003, CONSERV BIOL, V17, P1521, DOI 10.1111/j.1523-1739.2003.00061.x; Patterson BD, 2004, BIOL CONSERV, V119, P507, DOI 10.1016/j.biocon.2004.01.013; RUSHBY GG, 1965, NO MORE TUSKER; *TRAFFIC, 1998, FOOD THOUGHT UT WILD; Treves A, 2004, CONSERV BIOL, V18, P114, DOI 10.1111/j.1523-1739.2004.00189.x; Treves A, 2003, CONSERV BIOL, V17, P1491, DOI 10.1111/j.1523-1739.2003.00059.x; Wilson CJ, 2004, MAMMAL REV, V34, P211, DOI 10.1111/j.1365-2907.2004.00038.x	13	136	145	2	87	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 18	2005	436	7053					927	928		10.1038/436927a	http://dx.doi.org/10.1038/436927a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955XQ	16107828				2022-12-28	WOS:000231263900030
J	Sutton, MD; Briggs, DEG; Siveter, DJ; Siveter, DJ				Sutton, MD; Briggs, DEG; Siveter, DJ; Siveter, DJ			Silurian brachiopods with soft-tissue preservation	NATURE			English	Article							HEREFORDSHIRE; ENGLAND; FOSSIL; LOPHOPHORE; ARTHROPOD	Articulated' rhynchonelliformean(1) brachiopods are abundant shelly fossils, but the direct fossil record of their soft parts was hitherto confined to a single pyritized trace possibly representing a lophophore(2). Anatomical knowledge of extinct rhynchonelliformeans relies heavily on analogies to extant species; these analogies are untested for stem-group clades. The Silurian Herefordshire (UK) Konservat-Lagerstatte(3) ( about 425 Myr BP) yields exceptionally preserved three-dimensional fossils that provide unrivalled insights into the palaeobiology of a variety of invertebrates(4-9). The fossils are preserved as calcitic void in-fills in carbonate concretions within a volcaniclastic horizon(10), and are reconstructed digitally(11). Here we describe a stem-group rhynchonelliformean specimen from this deposit; it most probably belongs in the order Orthida. A robust ridged pedicle with distal rootlets is preserved, together with a lophophore and other soft-tissue structures. The pedicle morphology is novel, urging caution in inferring stem-group rhynchonelliformean anatomy from that of crown-group species. Smaller brachiopods are attached to the specimen; these include a probable atrypide, with pedicle and marginal setae preserved.	Univ London Imperial Coll Sci Technol & Med, Dept Earth Sci & Engn, London SW7 2AZ, England; Yale Univ, Dept Geol & Geophys, New Haven, CT 06520 USA; Univ Leicester, Dept Geol, Leicester LE1 7RH, Leics, England; Univ Oxford, Dept Earth Sci, Oxford OX1 3PS, England; Univ Museum Nat Hist, Geol Collect, Oxford OX1 3PW, England	Imperial College London; Yale University; University of Leicester; University of Oxford; University of Oxford	Sutton, MD (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Earth Sci & Engn, London SW7 2AZ, England.	m.sutton@imperial.ac.uk	Sutton, Mark/A-4189-2010					BARTELS C, 2002, METALLA, V9, P123; BASSETT MG, 1984, SPEC PAP PALAEONTOL, V32, P237; Briggs DEG, 2004, P ROY SOC B-BIOL SCI, V271, P131, DOI 10.1098/rspb.2003.2593; Briggs DEG, 1996, NATURE, V382, P248, DOI 10.1038/382248a0; BROMLEY RG, 1973, LETHAIA, V6, P349, DOI 10.1111/j.1502-3931.1973.tb01203.x; Cohen BL, 2003, PALAEONTOLOGY, V46, P59, DOI 10.1111/1475-4983.00287; DAVIDSON T, 1874, PALAEONTOL SOC MONOG, V4, P103; EMIG CC, 1992, LETHAIA, V25, P291, DOI 10.1111/j.1502-3931.1992.tb01398.x; Orr PJ, 2000, J GEOL SOC LONDON, V157, P173, DOI 10.1144/jgs.157.1.173; RACHEBOEUF PR, 1990, LETHAIA, V23, P341, DOI 10.1111/j.1502-3931.1990.tb01367.x; Richardson Joyce R., 1997, P441; ROWELL AJ, 1985, J PALEONTOL, V59, P1227; Rudwick M.J.S., 1970, LIVING FOSSIL BRACHI; Siveter DJ, 2004, NATURE, V431, P978, DOI 10.1038/nature02928; Siveter DJ, 2003, SCIENCE, V302, P1749, DOI 10.1126/science.1091376; Sutton MD, 2002, P ROY SOC B-BIOL SCI, V269, P1195, DOI 10.1098/rspb.2002.1986; Sutton MD, 2001, P ROY SOC B-BIOL SCI, V268, P2355, DOI 10.1098/rspb.2001.1788; Sutton MD, 2001, NATURE, V410, P461, DOI 10.1038/35068549; SUTTON MD, 2001, PALEONTOL ELECT, V4; WALCOTT CD, 1888, P US NATL MUS, V11, P480; Williams A., 1997, TREATISE INVERTEBRAT, V1, P7; Williams Alwyn, 1997, P321; WILLIAMS CARLSON S. J., 2000, TREATISE INVERTEBR H, P1; Zhang ZF, 2004, ACTA PALAEONTOL POL, V49, P259	24	47	49	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 18	2005	436	7053					1013	1015		10.1038/nature03846	http://dx.doi.org/10.1038/nature03846			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955XQ	16107847				2022-12-28	WOS:000231263900049
J	Johnson, CM; Beard, BL				Johnson, CM; Beard, BL			Biogeochemical cycling of iron isotopes	SCIENCE			English	Editorial Material							FE ISOTOPE; FRACTIONATION; CONSTRAINTS; EARTH; ROCKS		Univ Wisconsin, Dept Geol & Geophys, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Johnson, CM (corresponding author), Univ Wisconsin, Dept Geol & Geophys, 1215 W Dayton St, Madison, WI 53706 USA.	clarkj@geology.wisc.edu						Anbar AD, 2005, GEOCHIM COSMOCHIM AC, V69, P825, DOI 10.1016/j.gca.2004.06.012; Beard BL, 2004, REV MINERAL GEOCHEM, V55, P319, DOI 10.2138/gsrmg.55.1.319; Beard BL, 1999, SCIENCE, V285, P1889, DOI 10.1126/science.285.5435.1889; Beard BL, 2004, GEOCHIM COSMOCHIM AC, V68, P4727, DOI 10.1016/j.gca.2004.04.023; Brantley SL, 2004, GEOCHIM COSMOCHIM AC, V68, P3189, DOI 10.1016/j.gca.2004.01.023; Bullen TD, 2001, GEOLOGY, V29, P699, DOI 10.1130/0091-7613(2001)029<0699:DOSAII>2.0.CO;2; Butler IB, 2005, EARTH PLANET SC LETT, V236, P430, DOI 10.1016/j.epsl.2005.05.022; Croal LR, 2004, GEOCHIM COSMOCHIM AC, V68, P1227, DOI 10.1016/j.gca.2003.09.011; Fantle MS, 2004, EARTH PLANET SC LETT, V228, P547, DOI 10.1016/j.epsl.2004.10.013; Johnson C. M, 2004, REV MINERAL GEOCHEM, V55; Johnson CM, 2005, GEOCHIM COSMOCHIM AC, V69, P963, DOI 10.1016/j.gca.2004.06.043; Johnson CM, 2003, CONTRIB MINERAL PETR, V144, P523, DOI 10.1007/s00410-002-0418-x; Kump L, 2005, SCIENCE, V307, P1058, DOI 10.1126/science.1107482; Levasseur S, 2004, EARTH PLANET SC LETT, V224, P91, DOI 10.1016/j.epsl.2004.05.010; Rouxel OJ, 2005, SCIENCE, V307, P1088, DOI 10.1126/science.1105692; Schauble EA, 2004, REV MINERAL GEOCHEM, V55, P65, DOI 10.2138/gsrmg.55.1.65; Sevenet N, 2003, CLIN EXP MED, V3, P1, DOI 10.1007/s102380300008; Skulan JL, 2002, GEOCHIM COSMOCHIM AC, V66, P2995, DOI 10.1016/S0016-7037(02)00902-X; Welch SA, 2003, GEOCHIM COSMOCHIM AC, V67, P4231, DOI 10.1016/S0016-7037(03)00266-7; Yamaguchi KE, 2005, CHEM GEOL, V218, P135, DOI 10.1016/j.chemgeo.2005.01.020	20	46	51	1	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 12	2005	309	5737					1025	1027		10.1126/science.1112552	http://dx.doi.org/10.1126/science.1112552			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955MN	16099969				2022-12-28	WOS:000231230100029
J	Chanda, B; Asamoah, OK; Blunck, R; Roux, B; Bezanilla, F				Chanda, B; Asamoah, OK; Blunck, R; Roux, B; Bezanilla, F			Gating charge displacement in voltage-gated ion channels involves limited transmembrane movement	NATURE			English	Article							SHAKER K+ CHANNEL; POTASSIUM CHANNEL; SODIUM-CHANNELS; ELECTRIC-FIELD; FREE-ENERGY; S4 SEGMENT; SENSOR; PORE; ELECTROSTATICS; MELITTIN	Voltage-gated ion channels are responsible for generating electrical impulses in nerves and other excitable cells. The fourth transmembrane helix (S4) in voltage-gated channels is the primary voltage-sensing unit that mediates the response to a changing membrane electric field(1,2). The molecular mechanism of voltage sensing, particularly with respect to the magnitude of the transmembrane movement of S4, remains controversial(3-5). To determine the extent of this transmembrane movement, we use fluorescent resonance energy transfer between the S4 domain and a reference point in the lipid bilayer. The lipophilic ion dipicrylamine distributes on either side of the lipid bilayer depending on the membrane potential, and is used here as a resonance-energy-transfer acceptor from donor molecules attached to several positions in the Shaker K+ channel. A voltage-driven transmembrane movement of the donor should produce a transient fluorescence change because the acceptor also translocates as a function of voltage. In Shaker K+ channels no such transient fluorescence is observed, indicating that the S4 segment does not translocate across the lipid bilayer. Based on these observations, we propose a molecular model of voltage gating that can account for the observed 13e gating charge with limited transmembrane S4 movement.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90025 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Anesthesiol, Los Angeles, CA 90025 USA; Cornell Univ, Weill Med Coll, Dept Physiol & Biophys, New York, NY 10021 USA; Ctr Estudios Cient, Valdivia, Chile	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cornell University	Bezanilla, F (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, 650 Charles E Young Dr S, Los Angeles, CA 90025 USA.	fbezanil@ucla.edu	Blunck, Rikard/L-4226-2013; Blunck, Rikard/AAM-3078-2020	Blunck, Rikard/0000-0003-4484-2907; Blunck, Rikard/0000-0003-4484-2907; Chanda, Baron/0000-0003-4954-7034				Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; Ahern CA, 2004, TRENDS NEUROSCI, V27, P303, DOI 10.1016/j.tins.2004.03.008; Asamoah OK, 2003, NEURON, V37, P85, DOI 10.1016/S0896-6273(02)01126-1; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; BOLAND LM, 1994, BIOPHYS J, V66, P694, DOI 10.1016/S0006-3495(94)80843-4; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; Cha A, 1999, NATURE, V402, P809, DOI 10.1038/45552; Cha A, 1998, J GEN PHYSIOL, V112, P391, DOI 10.1085/jgp.112.4.391; Chanda B, 2002, J GEN PHYSIOL, V120, P629, DOI 10.1085/jgp.20028679; Cuello LG, 2004, SCIENCE, V306, P491, DOI 10.1126/science.1101373; Glauner KS, 1999, NATURE, V402, P813, DOI 10.1038/45561; Gonzalez C, 2001, P NATL ACAD SCI USA, V98, P9617, DOI 10.1073/pnas.171306298; GONZALEZ JE, 1995, BIOPHYS J, V69, P1272, DOI 10.1016/S0006-3495(95)80029-9; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; Islas LD, 2001, J GEN PHYSIOL, V117, P69, DOI 10.1085/jgp.117.1.69; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; KEMPF C, 1982, J BIOL CHEM, V257, P2469; Laine M, 2003, NEURON, V39, P467, DOI 10.1016/S0896-6273(03)00468-9; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; LONG SB, 2000, SCIENCE         0707; Nina M, 1997, J PHYS CHEM B, V101, P5239, DOI 10.1021/jp970736r; Roux B, 1997, BIOPHYS J, V73, P2980, DOI 10.1016/S0006-3495(97)78327-9; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; Starace DM, 2004, NATURE, V427, P548, DOI 10.1038/nature02270; Starace DM, 1997, NEURON, V19, P1319, DOI 10.1016/S0896-6273(00)80422-5; TOSTESON MT, 1981, BIOPHYS J, V36, P109, DOI 10.1016/S0006-3495(81)84719-4; Yang NB, 1996, NEURON, V16, P113, DOI 10.1016/S0896-6273(00)80028-8; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	31	217	225	0	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 11	2005	436	7052					852	856		10.1038/nature03888	http://dx.doi.org/10.1038/nature03888			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953XG	16094369				2022-12-28	WOS:000231116500047
J	Faleschini, E; Zennaro, F; Ventura, A; Tonini, G				Faleschini, E; Zennaro, F; Ventura, A; Tonini, G			An unusual case of growth retardation	LANCET			English	Editorial Material							PRIMARY HYPOTHYROIDISM		Childrens Inst IRCCS Burlo Garofolo, Dept Paediat, Trieste, Italy; Childrens Inst IRCCS Burlo Garofolo, Dept Radiol, Trieste, Italy	IRCCS Burlo Garofolo; IRCCS Burlo Garofolo	Tonini, G (corresponding author), Childrens Inst IRCCS Burlo Garofolo, Dept Paediat, Via Istria 65, Trieste, Italy.	tonini@burio.trieste.it		Ventura, Alessandro/0000-0002-4657-1760				CHAN A W, 1990, British Journal of Neurosurgery, V4, P107, DOI 10.3109/02688699008992708; EHTRIM PU, 1998, PEDIATR NEUROSURG, V28, P195; MINDERMANN T, 1995, NEUROSURGERY, V36, P259, DOI 10.1227/00006123-199502000-00004; NISHI Y, 1989, ACTA PAEDIATR SCAND, V78, P136, DOI 10.1111/j.1651-2227.1989.tb10904.x; Sarlis NJ, 1997, J CLIN ENDOCR METAB, V82, P808, DOI 10.1210/jc.82.3.808	5	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 6	2005	366	9484					520	520		10.1016/S0140-6736(05)67065-1	http://dx.doi.org/10.1016/S0140-6736(05)67065-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	952RD	16084262				2022-12-28	WOS:000231022300035
J	Dotto, GP; Cotsarelis, G				Dotto, GP; Cotsarelis, G			Developmental biology - Rac1 up for epidermal stem cells	SCIENCE			English	Editorial Material							HAIR FOLLICLE; EXPRESSION; DIFFERENTIATION; SKIN; RHO		Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland; Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Univ Penn, Sch Med, Dept Dermatol, Kligman Labs, Philadelphia, PA 19104 USA	University of Lausanne; Harvard University; Massachusetts General Hospital; University of Pennsylvania	Dotto, GP (corresponding author), Univ Lausanne, Inst Biochem, Chemin Bovaresses 155, CH-1066 Epalinges, Switzerland.	cotsarel@mail.med.upenn.edu						Arnold I, 2001, CURR BIOL, V11, P558, DOI 10.1016/S0960-9822(01)00154-3; Benitah SA, 2005, SCIENCE, V309, P933, DOI 10.1126/science.1113579; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Chiariello M, 2001, NAT CELL BIOL, V3, P580, DOI 10.1038/35078555; GROSSI M, IN PRESS P NATL ACAD; Huang ZD, 2004, MOL CELL BIOL, V24, P1582, DOI 10.1128/MCB.24.4.1582-1594.2004; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; Okuyama R, 2004, J INVEST DERM SYMP P, V9, P248, DOI 10.1111/j.1087-0024.2004.09308.x; Potten CS, 2002, J INVEST DERMATOL, V119, P888, DOI 10.1046/j.1523-1747.2002.00020.x; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Waikel RL, 2001, NAT GENET, V28, P165, DOI 10.1038/88889; Xu XW, 2003, AM J PATHOL, V163, P969, DOI 10.1016/S0002-9440(10)63456-6	13	11	11	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 5	2005	309	5736					890	891		10.1126/science.1117192	http://dx.doi.org/10.1126/science.1117192			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953SS	16081726				2022-12-28	WOS:000231101400033
J	Joanicot, M; Ajdari, A				Joanicot, M; Ajdari, A			Applied physics - Droplet control for microfluidics	SCIENCE			English	Editorial Material							MONODISPERSE DOUBLE EMULSIONS		Rhodia Lab Future, F-33608 Pessac, France; Ecole Super Phys & Chim Ind Ville Paris, F-75005 Paris, France	UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)	Joanicot, M (corresponding author), Rhodia Lab Future, 178 Ave Docteur Schweitzer, F-33608 Pessac, France.	mathieu.joanicot@eu.rhodia.com; armand.ajdari@espci.fr						Dendukuri D, 2005, LANGMUIR, V21, P2113, DOI 10.1021/la047368k; Dreyfus R, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.144505; GUILLOT P, UNPUB; Jensen K, 2004, LAB CHIP, V4, p31N, DOI 10.1039/b409797c; Link DR, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.054503; LORENCEAU E, IN PRESS LANGMUIR; Nieves A. F., 2005, ADV MATER, V17, P680; Okushima S, 2004, LANGMUIR, V20, P9905, DOI 10.1021/la0480336; Song H, 2003, ANGEW CHEM INT EDIT, V42, P768, DOI 10.1002/anie.200390203; Stone HA, 2004, ANNU REV FLUID MECH, V36, P381, DOI 10.1146/annurev.fluid.36.050802.122124; Tan YC, 2004, LAB CHIP, V4, P292, DOI 10.1039/b403280m; Thorsen T, 2001, PHYS REV LETT, V86, P4163, DOI 10.1103/PhysRevLett.86.4163; Thorsen T, 2002, SCIENCE, V298, P580, DOI 10.1126/science.1076996; Tice JD, 2004, ANAL CHIM ACTA, V507, P73, DOI 10.1016/j.aca.2003.11.024; Utada AS, 2005, SCIENCE, V308, P537, DOI 10.1126/science.1109164; Zheng B, 2003, J AM CHEM SOC, V125, P11170, DOI 10.1021/ja037166v	16	297	324	2	196	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 5	2005	309	5736					887	888		10.1126/science.1112615	http://dx.doi.org/10.1126/science.1112615			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953SS	16081724				2022-12-28	WOS:000231101400031
J	Schenkl, S; van Mourik, F; van der Zwan, G; Haacke, S; Chergui, M				Schenkl, S; van Mourik, F; van der Zwan, G; Haacke, S; Chergui, M			Probing the ultrafast charge translocation of photoexcited retinal in bacteriorhodopsin	SCIENCE			English	Article							SPECTROSCOPY; CHROMOPHORE; DYNAMICS; ISOMERIZATION; STATE; TRANSITIONS; EXCITATION; RESOLUTION; PROTEINS; EVENTS	The ultrafast evolution of the electric field within bacteriorhodopsin was measured by monitoring the absorption changes of a tryptophan residue after excitation of retinal. The Trp absorption decreases within the first 200 femtoseconds and then recovers on time scales typical for retinal isomerization and vibrational relaxation. A model of excitonic coupling between retinal and tryptophans shows that the signal reflects a gradual rise of the retinal difference dipole moment, which precedes and probably drives isomerization. The results suggest an intimate connection between the progressive dipole moment change and the retinal skeletal changes reported over the same time scale.	Ecole Polytech Fed Lausanne, Lab Ultrafast Spect, Inst Sci & Ingn Chim, FSB BSP, CH-1015 Lausanne, Switzerland; Vrije Univ Amsterdam, Fac Sci, NL-1081 HV Amsterdam, Netherlands	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Vrije Universiteit Amsterdam	Chergui, M (corresponding author), Ecole Polytech Fed Lausanne, Lab Ultrafast Spect, Inst Sci & Ingn Chim, FSB BSP, CH-1015 Lausanne, Switzerland.	majed.chergui@epfl.ch	Haacke, Stefan/B-5554-2013	Haacke, Stefan/0000-0002-6969-4667				Callis PR, 1997, METHOD ENZYMOL, V278, P113; DOBLER J, 1988, CHEM PHYS LETT, V144, P215, DOI 10.1016/0009-2614(88)87120-3; DOIG SJ, 1991, J PHYS CHEM-US, V95, P6372, DOI 10.1021/j100169a054; EFTINK MR, 1990, J PHYS CHEM-US, V94, P3469, DOI 10.1021/j100372a022; Gonzalez-Luque R, 2000, P NATL ACAD SCI USA, V97, P9379, DOI 10.1073/pnas.97.17.9379; Groma GI, 2004, P NATL ACAD SCI USA, V101, P7971, DOI 10.1073/pnas.0306789101; Herbst J, 2002, SCIENCE, V297, P822, DOI 10.1126/science.1072144; HORNG ML, 1995, J PHYS CHEM-US, V99, P17311, DOI 10.1021/j100048a004; HUANG JY, 1989, J PHYS CHEM-US, V93, P3314, DOI 10.1021/j100345a086; Kennis JTM, 2002, J PHYS CHEM B, V106, P6067, DOI 10.1021/jp014681b; Kobayashi T, 2001, NATURE, V414, P531, DOI 10.1038/35107042; LEWIS A, 1978, P NATL ACAD SCI USA, V75, P549, DOI 10.1073/pnas.75.2.549; Luecke H, 1999, J MOL BIOL, V291, P899, DOI 10.1006/jmbi.1999.3027; MATHIES R, 1976, P NATL ACAD SCI USA, V73, P2169, DOI 10.1073/pnas.73.7.2169; MATHIES RA, 1988, SCIENCE, V240, P777, DOI 10.1126/science.3363359; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; SALEM L, 1975, NATURE, V258, P526, DOI 10.1038/258526a0; TSUDA M, 1980, NATURE, V287, P351, DOI 10.1038/287351a0; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230; WARSHEL A, 1981, ACCOUNTS CHEM RES, V14, P284, DOI 10.1021/ar00069a004; Xu D, 1996, BIOPHYS J, V70, P453, DOI 10.1016/S0006-3495(96)79588-7; Zhong Q, 1996, J AM CHEM SOC, V118, P12828, DOI 10.1021/ja961058+	22	118	120	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 5	2005	309	5736					917	920		10.1126/science.1111482	http://dx.doi.org/10.1126/science.1111482			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953SS	16081732				2022-12-28	WOS:000231101400041
J	Brem, RB; Storey, JD; Whittle, J; Kruglyak, L				Brem, RB; Storey, JD; Whittle, J; Kruglyak, L			Genetic interactions between polymorphisms that affect gene expression in yeast	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; COMPLEX TRAIT; EPISTASIS; DROSOPHILA	Interactions between polymorphisms at different quantitative trait loci (QTLs) are thought to contribute to the genetics of many traits, and can markedly affect the power of genetic studies to detect QTLs(1). Interacting loci have been identified in many organisms(1-5). However, the prevalence of interactions(6-8), and the nucleotide changes underlying them(9,10), are largely unknown. Here we search for naturally occurring genetic interactions in a large set of quantitative phenotypes - the levels of all transcripts in a cross between two strains of Saccharomyces cerevisiae(7). For each transcript, we searched for secondary loci interacting with primary QTLs detected by their individual effects. Such locus pairs were estimated to be involved in the inheritance of 57% of transcripts; statistically significant pairs were identified for 225 transcripts. Among these, 67% of secondary loci had individual effects too small to be significant in a genome-wide scan. Engineered polymorphisms in isogenic strains confirmed an interaction between the mating-type locus MAT and the pheromone response gene GPA1. Our results indicate that genetic interactions are widespread in the genetics of transcript levels, and that many QTLs will be missed by single-locus tests but can be detected by two-stage tests that allow for interactions.	Fred Hutchinson Canc Res Ctr, Program Computat Biol, Seattle, WA 98109 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; Infect Dis Res Inst, Seattle, WA 98104 USA; Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA; Princeton Univ, Dept Ecol & Evolutionary Biol, Carl Icahn Lab, Princeton, NJ 08544 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Princeton University; Princeton University	Brem, RB (corresponding author), Fred Hutchinson Canc Res Ctr, Program Computat Biol, 1100 Fairview Ave N,M2-B876, Seattle, WA 98109 USA.	rbrem@fhcrc.org; leonid@genomics.princeton.edu	Storey, John/B-5282-2011	Storey, John/0000-0001-5992-402X	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002913] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH059520] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01 HG002913] Funding Source: Medline; NIMH NIH HHS [R37 MH059520] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BARDWELL L, 1994, DEV BIOL, V166, P363, DOI 10.1006/dbio.1994.1323; Brem RB, 2005, P NATL ACAD SCI USA, V102, P1572, DOI 10.1073/pnas.0408709102; Brem RB, 2002, SCIENCE, V296, P752, DOI 10.1126/science.1069516; Broman KW, 2003, BIOINFORMATICS, V19, P889, DOI 10.1093/bioinformatics/btg112; Caicedo AL, 2004, P NATL ACAD SCI USA, V101, P15670, DOI 10.1073/pnas.0406232101; Carlborg O, 2004, NAT REV GENET, V5, P618, DOI 10.1038/nrg1407; Csank C, 2002, METHOD ENZYMOL, V350, P347, DOI 10.1016/S0076-6879(02)50973-3; Gibson G, 2004, GENETICS, V167, P1791, DOI 10.1534/genetics.104.026583; HAGEN DC, 1984, J MOL BIOL, V178, P835, DOI 10.1016/0022-2836(84)90314-0; Kroymann J, 2005, NATURE, V435, P95, DOI 10.1038/nature03480; Leamy LJ, 2005, HEREDITY, V94, P316, DOI 10.1038/sj.hdy.6800637; Lynch M., 1998, GENETICS ANAL QUANTI; Montooth KL, 2003, GENETICS, V165, P623; Rawson PD, 2002, P NATL ACAD SCI USA, V99, P12955, DOI 10.1073/pnas.202335899; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Schadt EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01434; Shook DR, 1999, GENETICS, V153, P1233; Storey JD, 2005, PLOS BIOL, V3, P1380, DOI 10.1371/journal.pbio.0030267; Storey JD, 2003, ANN STAT, V31, P2013, DOI 10.1214/aos/1074290335; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Yvert G, 2003, NAT GENET, V35, P57, DOI 10.1038/ng1222; Zeitlinger J, 2003, CELL, V113, P395, DOI 10.1016/S0092-8674(03)00301-5	25	243	252	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 4	2005	436	7051					701	703		10.1038/nature03865	http://dx.doi.org/10.1038/nature03865			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	951XA	16079846	Green Accepted			2022-12-28	WOS:000230964500044
J	Eisen, GM; Weinberg, DS				Eisen, GM; Weinberg, DS			Narative review: Screening for colorectal cancer in patients with a first-degree relative with colonic neoplasia	ANNALS OF INTERNAL MEDICINE			English	Review							COMPUTED TOMOGRAPHIC COLONOGRAPHY; FECAL-OCCULT-BLOOD; VIRTUAL COLONOSCOPY; FAMILY-HISTORY; BARIUM ENEMA; AVERAGE-RISK; ASYMPTOMATIC ADULTS; DISEASE PREVENTION; RANDOMIZED-TRIAL; CT COLONOGRAPHY	Many patients and providers are aware that colorectal cancer (CRC) "runs in families." A patient with 1 first-degree relative with CRC has approximately twice the personal risk for CRC as a similar person without this family history. Colorectal cancer is the third most common type of cancer in the United States. When providers neglect to collect information on family history, they may fail to appropriately tailor recommendations for screening for CRC for many patients. This review considers the existing data and summarizes an evidence-based approach to the common clinical problem of how and when to implement screening for CRC in a patient with a family history of colonic neoplasia. The authors discuss the varying risks for CRC given the patient's age, health habits, and personal and family histories. In the context of a clinical case that focuses on the effect of a single affected first-degree relative, the authors weigh the risks and benefits of various screening alternatives; and briefly address chemoprevention, genetic testing, and future directions in screening for CRC.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Oregon Hlth & Sci Univ, Portland, OR USA	Fox Chase Cancer Center; Oregon Health & Science University	Weinberg, DS (corresponding author), Fox Chase Canc Ctr, 333 Cottman Ave, Philadelphia, PA 19111 USA.	david.weinberg@fccc.edu						Ahlquist DA, 2000, GASTROENTEROLOGY, V119, P1219, DOI 10.1053/gast.2000.19580; Alberts DS, 2000, NEW ENGL J MED, V342, P1156, DOI 10.1056/NEJM200004203421602; Arguedas MR, 2001, ALIMENT PHARM THER, V15, P631, DOI 10.1046/j.1365-2036.2001.00969.x; Baron JA, 2003, NEW ENGL J MED, V348, P891, DOI 10.1056/NEJMoa021735; Barrison AF, 2003, AM J GASTROENTEROL, V98, P1410, DOI 10.1016/S0002-9270(03)00256-9; Berg AO, 2002, ANN INTERN MED, V137, P834, DOI 10.7326/0003-4819-137-10-200211190-00013; Blakeborough A, 1997, CLIN RADIOL, V52, P142, DOI 10.1016/S0009-9260(97)80108-0; Bond JH, 2000, AM J GASTROENTEROL, V95, P3053; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Burt RW, 1996, PREVENTION EARLY DET, P171; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Chung DC, 2003, ANN INTERN MED, V138, P560, DOI 10.7326/0003-4819-138-7-200304010-00012; Cotton PB, 2004, JAMA-J AM MED ASSOC, V291, P1713, DOI 10.1001/jama.291.14.1713; Cram P, 2003, ARCH INTERN MED, V163, P1601, DOI 10.1001/archinte.163.13.1601; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Dong SM, 2001, J NATL CANCER I, V93, P858, DOI 10.1093/jnci/93.11.858; Eisen GM, 2000, GASTROINTEST ENDOSC, V51, P777, DOI 10.1053/ge.2000.v51.age516777; Fletcher RH, 2002, JAMA-J AM MED ASSOC, V287, P3127, DOI 10.1001/jama.287.23.3127; FUCHS CS, 1994, NEW ENGL J MED, V331, P1669, DOI 10.1056/NEJM199412223312501; Giardiello FM, 1997, JAMA-J AM MED ASSOC, V278, P1278, DOI 10.1001/jama.278.15.1278; Giardiello FM, 2001, GASTROENTEROLOGY, V121, P198, DOI 10.1053/gast.2001.25581; Giovannucci E, 1998, ANN INTERN MED, V129, P517, DOI 10.7326/0003-4819-129-7-199810010-00002; Houlston RS, 2001, GASTROENTEROLOGY, V121, P282, DOI 10.1053/gast.2001.26265; Howe GR, 1997, CANCER CAUSE CONTROL, V8, P215, DOI 10.1023/A:1018476414781; Hyman J, 1998, CANCER EPIDEM BIOMAR, V7, P291; Iannaccone R, 2004, GASTROENTEROLOGY, V127, P1300, DOI 10.1053/j.gastro.2004.08.025; Imperiale TF, 2000, NEW ENGL J MED, V343, P169, DOI 10.1056/NEJM200007203430302; Imperiale TF, 2004, NEW ENGL J MED, V351, P2704, DOI 10.1056/NEJMoa033403; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Johnson CD, 2003, GASTROENTEROLOGY, V125, P311, DOI 10.1016/S0016-5085(03)00894-1; Kinzler KW, 1998, GENETIC BASIS HUMAN, P565; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; Ladabaum U, 2004, CLIN GASTROENTEROL H, V2, P554, DOI 10.1016/S1542-3565(04)00247-2; Lieberman DA, 2000, NEW ENGL J MED, V343, P162, DOI 10.1056/NEJM200007203430301; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; Martinez ME, 1998, CANCER EPIDEM BIOMAR, V7, P163; McCullough ML, 2003, CANCER CAUSE CONTROL, V14, P1, DOI 10.1023/A:1022591007673; MULLER AD, 1995, ARCH INTERN MED, V155, P1741, DOI 10.1001/archinte.155.16.1741; Murff HJ, 2004, AM J PREV MED, V27, P239, DOI 10.1016/j.amepre.2004.05.003; Mysliwiec PA, 2004, ANN INTERN MED, V141, P264, DOI 10.7326/0003-4819-141-4-200408170-00006; Nanda K, 1999, OBSTET GYNECOL, V93, P880, DOI 10.1016/S0029-7844(98)00424-4; *NAT COMPR CANC NE, COL CANC SCREEN GUID; Noshirwani KC, 2000, GASTROINTEST ENDOSC, V51, P433, DOI 10.1016/S0016-5107(00)70444-5; Patterson RE, 1997, CANCER CAUSE CONTROL, V8, P786, DOI 10.1023/A:1018443724293; Pickhardt PJ, 2003, AM J ROENTGENOL, V181, P799, DOI 10.2214/ajr.181.3.1810799; Pickhardt PJ, 2004, ANN INTERN MED, V141, P352, DOI 10.7326/0003-4819-141-5-200409070-00009; Pickhardt PJ, 2003, NEW ENGL J MED, V349, P2191, DOI 10.1056/NEJMoa031618; Pignone M, 2002, ANN INTERN MED, V137, P132, DOI 10.7326/0003-4819-137-2-200207160-00015; Pineau BC, 2003, GASTROENTEROLOGY, V125, P304, DOI 10.1016/S0016-5085(03)00885-0; Rex DK, 1997, GASTROENTEROLOGY, V112, P17, DOI 10.1016/S0016-5085(97)70213-0; RIS LA, 1994, NIH PUB, V94; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sandler RS, 2003, NEW ENGL J MED, V348, P883, DOI 10.1056/NEJMoa021633; Sandler RS, 2004, ANN INTERN MED, V140, P224, DOI 10.7326/0003-4819-140-3-200402030-00014; Schatzkin A, 2000, NEW ENGL J MED, V342, P1149, DOI 10.1056/NEJM200004203421601; Schroy PC, 2002, AM J GASTROENTEROL, V97, P1031, DOI 10.1111/j.1572-0241.2002.05624.x; Schroy PC, 2005, J CLIN GASTROENTEROL, V39, P298, DOI 10.1097/01.mcg.0000155129.31208.0d; Seeff LC, 2004, CANCER-AM CANCER SOC, V100, P2093, DOI 10.1002/cncr.20276; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; Slattery ML, 2004, PREV MED, V38, P276, DOI 10.1016/j.ypmed.2003.11.009; Smith RA, 2004, CA-CANCER J CLIN, V54, P41, DOI 10.3322/canjclin.54.1.41; Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405; Sonnenberg A, 1999, AM J GASTROENTEROL, V94, P2268; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; Suleiman S, 2002, GASTROENTEROLOGY, V122, P78, DOI 10.1053/gast.2002.29689; Tagore Kuldeep S, 2003, Clin Colorectal Cancer, V3, P47, DOI 10.3816/CCC.2003.n.011; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; Wagner JL, 1996, PREVENTION EARLY DET, P321; Weisburger JH, 2002, EUR J CANCER PREV, V11, pS1; Wiesner R, 2003, GASTROENTEROLOGY, V124, P91, DOI 10.1053/gast.2003.50016; Winawer S, 2003, GASTROENTEROLOGY, V124, P544, DOI 10.1053/gast.2003.50044; Winawer SJ, 1996, NEW ENGL J MED, V334, P82, DOI 10.1056/NEJM199601113340204; WINAWER SJ, 1993, NEW ENGL J MED, V328, P901, DOI 10.1056/NEJM199304013281301; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; Winawer SJ, 2000, NEW ENGL J MED, V342, P1766, DOI 10.1056/NEJM200006153422401	76	11	12	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 2	2005	143	3					190	198		10.7326/0003-4819-143-3-200508020-00005	http://dx.doi.org/10.7326/0003-4819-143-3-200508020-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	951TM	16061917				2022-12-28	WOS:000230953900004
J	Baglietto, L; English, DR; Gertig, DM; Hopper, JL; Giles, GG				Baglietto, L; English, DR; Gertig, DM; Hopper, JL; Giles, GG			Does dietary folate intake modify effect of alcohol consumption on breast cancer risk? Prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							WOMEN; PREVENTION; VEGETABLES; NUTRIENTS; DISEASE; FRUITS	Objective To evaluate the effect of dietary folate intake on the relation between alcohol consumption and breast cancer risk. Design Prospective cohort study. Setting Melbourne, Australia. Participants 17 447 Anglo-Australian women resident in Melbourne, aged 40-69 years at recruitment in 1990-4, and followed up until 31 December 2003. Main outcome measure Invasive breast cancers diagnosed during follow-up and ascertained through the Victorian cancer registry. Results 537 invasive breast cancers were diagnosed. Compared with lifetime abstainers, the hazard ratio for breast cancer in women who consumed an average of 40 g or more of alcohol daily at baseline was 1.41 (95% confidence interval 0.90 to 2.23). No direct association was found between dietary folate intake and risk of breast cancer, but a high folate intake mitigated the excess risk associated with alcohol. The estimated hazard ratio of an alcohol consumption of 40 g/day or more was 2.00 (1.14 to 3.49) for women with intakes of 200 mu g/day of folate and 0.77 (0.33 to 1.80) for 400 mu g/day of folate (P=0.04 for interaction between alcohol and folate). Conclusions An adequate dietary intake of folate might protect against the increased risk of breast cancer associated with alcohol consumption.	Canc Council Melbourne, Canc Epidemiol Ctr, Carlton, Vic 3053, Australia; Univ Melbourne, Ctr Genet Epidemiol, Melbourne, Vic, Australia	University of Melbourne	Baglietto, L (corresponding author), Canc Council Melbourne, Canc Epidemiol Ctr, 100 Drummond St, Carlton, Vic 3053, Australia.	laura.baglietto@cancervic.org.au	English, Dallas/AAH-5005-2019; Gertig, Dorota/Z-1087-2019; Baglietto, Laura/AAB-9051-2019	English, Dallas/0000-0001-7828-8188; Giles, Graham/0000-0003-4946-9099; Baglietto, Laura/0000-0002-8193-7529				ABRAHAM B, 2000, INTERIM EVALUATION V; Akaike H, 1973, P 2 INT S INF THEOR, P267, DOI DOI 10.1007/978-1-4612-1694-0_15; Beral V, 2002, BRIT J CANCER, V87, P1234, DOI 10.1038/sj.bjc.6600596; *EXP PAN FOL FORT, 1994, 117 SESS NHMRC SYDN; Fairfield KM, 2002, JAMA-J AM MED ASSOC, V287, P3116, DOI 10.1001/jama.287.23.3116; Freudenheim JL, 1996, JNCI-J NATL CANCER I, V88, P340, DOI 10.1093/jnci/88.6.340; Giovannucci E, 2004, J NUTR, V134, p2475S, DOI 10.1093/jn/134.9.2475S; GRAHAM S, 1991, AM J EPIDEMIOL, V134, P552, DOI 10.1093/oxfordjournals.aje.a116129; Holland B, 1993, MCCANCE WIDDOWSONS C; Ireland P, 1994, Asia Pac J Clin Nutr, V3, P19; Kim Y, 1999, NUTR REV, V57, P314; Kim YI, 1999, J NUTR BIOCHEM, V10, P66, DOI 10.1016/S0955-2863(98)00074-6; Lewis J., 1995, NUTTAB95 NUTR DATA T; Mason J B, 1996, Oncology (Williston Park), V10, P1727; Mason JB, 1996, ONCOLOGY HUNTINGT, V10, P1743; Mason JB, 1996, ONCOLOGY, V10, P1742; Metz J, 2002, MED J AUSTRALIA, V176, P90, DOI 10.5694/j.1326-5377.2002.tb04306.x; Negri E, 2000, J NATL CANCER I, V92, P1270, DOI 10.1093/jnci/92.15.1270-a; POLS R, 1992, IS THERE SAFE LEVEL; Poschl G, 2004, ALCOHOL ALCOHOLISM, V39, P155, DOI 10.1093/alcalc/agh057; Rohan TE, 2000, J NATL CANCER I, V92, P266, DOI 10.1093/jnci/92.3.266; Ronco A, 1999, NUTR CANCER, V35, P111, DOI 10.1207/S15327914NC352_3; ROYSTON P, 1994, J R STAT SOC C-APPL, V43, P429, DOI 10.2307/2986270; Seitz HK, 2001, ALCOHOL CLIN EXP RES, V25, p137S, DOI 10.1097/00000374-200105051-00024; Sellers TA, 2004, CANCER CAUSE CONTROL, V15, P113, DOI 10.1023/B:CACO.0000019471.97208.c6; Sellers TA, 2001, EPIDEMIOLOGY, V12, P420, DOI 10.1097/00001648-200107000-00012; Shrubsole MJ, 2001, CANCER RES, V61, P7136; Singletary KW, 2001, JAMA-J AM MED ASSOC, V286, P2143, DOI 10.1001/jama.286.17.2143; Smith-Warner SA, 1998, JAMA-J AM MED ASSOC, V279, P535, DOI 10.1001/jama.279.7.535; Zhang SM, 1999, JAMA-J AM MED ASSOC, V281, P1632, DOI 10.1001/jama.281.17.1632	30	71	72	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 8	2005	331	7520					807	+		10.1136/bmj.38551.446470.06	http://dx.doi.org/10.1136/bmj.38551.446470.06			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	974BC	16087654	Green Published, Bronze			2022-12-28	WOS:000232565300018
J	Gans, J; Wolinsky, M; Dunbar, J				Gans, J; Wolinsky, M; Dunbar, J			Computational improvements reveal great bacterial diversity and high metal toxicity in soil	SCIENCE			English	Article							SPECIES ABUNDANCE; REASSOCIATION; PATTERNS; MODELS; DNA	The complexity of soil bacterial. communities has thus far confounded effective measurement. However, with improved analytical methods, we show that the abundance distribution and total diversity can be deciphered. Reanalysis of reassociation kinetics for bacterial community DNA from pristine and metal-polluted soils showed that a power law best described the abundance distributions. More than one million distinct genomes occurred in the pristine soil, exceeding previous estimates by two orders of magnitude. Metal pollution reduced diversity more than 99.9%, revealing the highly toxic effect of metal contamination, especially for rare taxa.	Los Alamos Natl Lab, Biosci Div, Los Alamos, NM 87501 USA	United States Department of Energy (DOE); Los Alamos National Laboratory	Gans, J (corresponding author), Los Alamos Natl Lab, Biosci Div, Los Alamos, NM 87501 USA.							Adami C, 1998, FROM ANIM ANIMAT, P221; Allen AP, 2001, ECOL LETT, V4, P1, DOI 10.1046/j.1461-0248.2001.00194.x; Bevington P. R., 2003, DATA REDUCTION ERROR, DOI 10.2307/2284752; Breitbart M, 2002, P NATL ACAD SCI USA, V99, P14250, DOI 10.1073/pnas.202488399; BRITTEN RJ, 1968, SCIENCE, V161, P529, DOI 10.1126/science.161.3841.529; Chave J, 2002, AM NAT, V159, P1, DOI 10.1086/324112; DAAE FL, COMMUNICATION; FRONTIER S, 1985, OCEANOGR MAR BIOL, V23, P253; HUGHES RG, 1986, AM NAT, V128, P879, DOI 10.1086/284611; Kotz S., 2001, LAPLACE DISTRIBUTION; Narang R, 2004, MICROB ECOL, V47, P396, DOI 10.1007/s00248-003-1026-7; PEARSON WR, 1977, NUCLEIC ACIDS RES, V4, P1727, DOI 10.1093/nar/4.6.1727; PRESTON FW, 1962, ECOLOGY, V43, P185, DOI 10.2307/1931976; Sandaa RA, 1999, FEMS MICROBIOL ECOL, V30, P237, DOI 10.1111/j.1574-6941.1999.tb00652.x; SMITH MJ, 1975, P NATL ACAD SCI USA, V72, P4805, DOI 10.1073/pnas.72.12.4805; Sole RV, 2000, PHYSICA A, V286, P337, DOI 10.1016/S0378-4371(00)00304-6; TOKESHI M, 1993, ADV ECOL RES, V24, P111, DOI 10.1016/S0065-2504(08)60042-2; TORSVIK V, 1990, APPL ENVIRON MICROB, V56, P782, DOI 10.1128/AEM.56.3.782-787.1990; Wilson JB, 1996, J ECOL, V84, P527, DOI 10.2307/2261475	19	804	904	11	425	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 26	2005	309	5739					1387	1390		10.1126/science.1112665	http://dx.doi.org/10.1126/science.1112665			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TX	16123304				2022-12-28	WOS:000231543300048
J	Blackstock, O				Blackstock, O			Curing stigma - The limits of antiretrovial access	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Montefiore Med Ctr, Program Primary Care & Social Med, New York, NY 10467 USA	Montefiore Medical Center	Blackstock, O (corresponding author), Montefiore Med Ctr, Program Primary Care & Social Med, New York, NY 10467 USA.								0	9	9	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 25	2005	353	8					752	752		10.1056/NEJMp058198	http://dx.doi.org/10.1056/NEJMp058198			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	957YK	16120853				2022-12-28	WOS:000231409300002
J	Bal, SK; Hollingworth, GR				Bal, SK; Hollingworth, GR			10-minute consultation - Red eye	BRITISH MEDICAL JOURNAL			English	Article							NONVALVULAR ATRIAL-FIBRILLATION; ORAL ANTICOAGULANT TREATMENT; EUROPEAN STROKE PREVENTION; INTRACEREBRAL HEMORRHAGE; INTRACRANIAL HEMORRHAGE; BLEEDING COMPLICATIONS; ANTITHROMBOTIC THERAPY; SECONDARY PREVENTION; CEREBRAL-HEMORRHAGE; DECISION-ANALYSIS		Univ Ottawa, Fac Med, Dept Family Med, Ottawa, ON K1N 5C8, Canada	University of Ottawa	Bal, SK (corresponding author), Univ Ottawa, Fac Med, Dept Family Med, Ottawa, ON K1N 5C8, Canada.	sharon_k_bal@yahoo.ca						Aithal GP, 1999, LANCET, V353, P717, DOI 10.1016/S0140-6736(98)04474-2; Albers GW, 2003, LANCET, V362, P1691; Anderson DC, 1998, JAMA-J AM MED ASSOC, V279, P1273; Arakawa S, 1998, STROKE, V29, P1806, DOI 10.1161/01.STR.29.9.1806; BABIKIAN VL, 1988, STROKE, V19, P407, DOI 10.1161/str.19.3.407b; Bae HG, 1999, CEREBROVASC DIS, V9, P102, DOI 10.1159/000015906; Berger C, 2001, STROKE, V32, P1330, DOI 10.1161/01.STR.32.6.1330; Butler AC, 1998, BRIT J HAEMATOL, V103, P1064; CALANDRE L, 1984, ARCH NEUROL-CHICAGO, V41, P1152, DOI 10.1001/archneur.1984.04050220046013; DAWSON I, 1993, STROKE, V24, P1655, DOI 10.1161/01.STR.24.11.1655; Dennis MS, 2003, CEREBROVASC DIS, V16, P9, DOI 10.1159/000069935; Diener HC, 1996, J NEUROL SCI, V143, P1, DOI 10.1016/S0022-510X(96)00308-5; Fang MC, 2004, CARDIOL CLIN, V22, P47, DOI 10.1016/S0733-8651(03)00115-2; FOGELHOLM R, 1992, J NEUROL NEUROSUR PS, V55, P1121, DOI 10.1136/jnnp.55.12.1121; FURLAN AJ, 1979, ANN NEUROL, V5, P367, DOI 10.1002/ana.410050410; Go AS, 2000, CIRCULATION, V102, P11, DOI 10.1161/01.CIR.102.1.11; Gonzalez-Duarte A, 1998, STROKE, V29, P1802, DOI 10.1161/01.STR.29.9.1802; Greenberg SM, 1999, NEUROLOGY, V53, P1135, DOI 10.1212/WNL.53.5.1135; Higashi MK, 2002, JAMA-J AM MED ASSOC, V287, P1690, DOI 10.1001/jama.287.13.1690; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; Kidwell CS, 2002, STROKE, V33, P95, DOI 10.1161/hs0102.101792; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; LAU J, 1983, MED DECIS MAKING, V3, P39, DOI 10.1177/0272989X8300300110; Laupacis A, 1998, CHEST, V114, p579S, DOI 10.1378/chest.114.5_Supplement.579S; LOWENTHAL A, 1990, STROKE, V21, P1122; Molina CA, 2001, STROKE, V32, P1079, DOI 10.1161/01.STR.32.5.1079; MOULIN T, 1998, CEREBROVASC DIS, P1472; O'Donnell HC, 2000, NEW ENGL J MED, V342, P240, DOI 10.1056/NEJM200001273420403; OKADA Y, 1989, STROKE, V20, P598, DOI 10.1161/01.STR.20.5.598; Palareti G, 1996, LANCET, V348, P423, DOI 10.1016/S0140-6736(96)01109-9; PASSERO S, 1995, STROKE, V26, P1185; PESSIN MS, 1993, NEUROLOGY, V43, P1298, DOI 10.1212/WNL.43.7.1298; PHILLIPS SJ, 1989, AM J HYPERTENS, V2, P493, DOI 10.1093/ajh/2.6.493; Rosand J, 2004, ARCH INTERN MED, V164, P880, DOI 10.1001/archinte.164.8.880; Sandercock P, 1997, LANCET, V349, P1569; Stollberger C, 2003, STROKE, V34, pE217, DOI 10.1161/01.STR.0000099071.46210.3A; Tabrizi AR, 2001, SURGERY, V129, P645, DOI 10.1067/msy.2001.108610; Thomson R, 2000, LANCET, V355, P956, DOI 10.1016/S0140-6736(00)90012-6; Tsushima Y, 2003, AM J NEURORADIOL, V24, P88; WEHLINGER C, 2001, STROKE, V32, P2246; Wijdicks EFM, 1998, NEUROSURGERY, V42, P769, DOI 10.1097/00006123-199804000-00053; WINTZEN AR, 1984, ANN NEUROL, V16, P553, DOI 10.1002/ana.410160505; Woo D, 2004, STROKE, V35, P1703, DOI 10.1161/01.STR.0000130855.70683.c8	43	3	3	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	AUG 20	2005	331	7514					438	438D		10.1136/bmj.331.7514.438	http://dx.doi.org/10.1136/bmj.331.7514.438			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958WB	16110072	Bronze, Green Published			2022-12-28	WOS:000231477800018
J	Uchino, S; Kellum, JA; Bellomo, R; Doig, GS; Morimatsu, H; Morgera, S; Schetz, M; Tan, I; Bouman, C; Macedo, E; Gibney, N; Tolwani, A; Ronco, C				Uchino, S; Kellum, JA; Bellomo, R; Doig, GS; Morimatsu, H; Morgera, S; Schetz, M; Tan, I; Bouman, C; Macedo, E; Gibney, N; Tolwani, A; Ronco, C		BEST Kidney Investigators	Acute renal failure in critically ill patients - A multinational, multicenter study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTINUOUS VENOVENOUS HEMOFILTRATION; INTENSIVE-CARE PATIENTS; ACUTE DIALYSIS; EPIDEMIOLOGY; MORTALITY; THERAPY; MANAGEMENT; OUTCOMES; ILLNESS; MODELS	Context Although acute renal failure (ARF) is believed to be common in the setting of critical illness and is associated with a high risk of death, little is known about its epidemiology and outcome or how these vary in different regions of the world. Objectives To determine the period prevalence of ARF in intensive care unit (ICU) patients in multiple countries; to characterize differences in etiology illness severity, and clinical practice; and to determine the impact of these differences on patient outcomes. Design, Setting, and Patients Prospective observational study of ICU patients who either were treated with renal replacement therapy (RRT) or fulfilled at least 1 of the predefined criteria for ARF from September 2000 to December 2001 at 54 hospitals in 23 countries. Main Outcome Measures Occurrence of ARF, factors contributing to etiology, illness severity, treatment, need for renal support after hospital discharge, and hospital mortality. Results Of 29 269 critically ill patients admitted during the study period, 1738 (5.7%; 95% confidence interval [CI], 5.5%-6.0%) had ARF during their ICU stay, including 1260 who were treated with RRT. The most common contributing factor to ARF was septic shock (47.5%; 95% Cl, 45.2%-49.5%). Approximately 30% of patients had preadmission renal dysfunction. Overall hospital mortality was 60.3% (95% Cl, 58.0%-62.6%). Dialysis dependence at hospital discharge was 13.8% (95% Cl, 11.2%-16.3%) for survivors. Independent risk factors for hospital mortality included use of vasopressors (odds ratio [OR], 1.95; 95% Cl, 1.50-2.55; P<.001), mechanical ventilation (OR, 2.11; 95% Cl, 1.58-2.82; P<.001), septic shock (OR, 1.36; 95% Cl, 1.03-1.79; P=.03), cardiogenic shock (OR, 1.41; 95% Cl, 1.05-1.90; P=.02), and hepatorenal syndrome (OR, 1.87; 95% Cl, 1.07-3.28; P=.03). Conclusion In this multinational study; the period prevalence of ARF requiring RRT in the ICU was between 5% and 6% and was associated with a high hospital mortality rate.	Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15261 USA; Austin Hosp, Dept Intens Care, Melbourne, Vic 3084, Australia; Austin Hosp, Dept Surg, Melbourne, Vic 3084, Australia; Univ Sydney, Dept Med, Sydney, NSW 2006, Australia; Royal N Shore Hosp, Sydney, NSW, Australia; Univ Hosp Charite, Dept Nephrol, Berlin, Germany; Univ Ziekenhuis Gasthuisberg, Dienst Intens Geneeskunde, Louvain, Belgium; Pamela Youde Nethersole Eastern Hosp, Dept Anaesthesia, Intens Care Unit, Hong Kong, Hong Kong, Peoples R China; Univ Amsterdam, Acad Med Ctr, Adult Intens Care Unit, NL-1105 AZ Amsterdam, Netherlands; Univ Sao Paulo, Sch Med, Div Nephrol, Sao Paulo, Brazil; Univ Alberta, Div Crit Care Med, Edmonton, AB, Canada; Univ Alabama Birmingham, Dept Med, Div Nephrol, Birmingham, AL 35294 USA; St Bortolo Hosp, Vicenza, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Sydney; Royal North Shore Hospital; University of Sydney; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; KU Leuven; University Hospital Leuven; Pamela Youde Nethersole Eastern Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Universidade de Sao Paulo; University of Alberta; University of Alabama System; University of Alabama Birmingham; ULSS 8 Berica; Ospedale San Bortolo di Vicenza	Kellum, JA (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, 3550 Terrace St, Pittsburgh, PA 15261 USA.	kellumja@ccm.upmc.edu	Macedo, Etienne/D-4659-2012; Kellum, John/AAP-3072-2020; Kellum, John A/HCH-2944-2022; Ronco, Cyril/ABA-9149-2021; MORIMATSU, Hiroshi/B-2236-2011	Macedo, Etienne/0000-0002-3669-6519; Kellum, John/0000-0003-1995-2653; Kellum, John A/0000-0003-1995-2653; Ronco, Cyril/0000-0002-9023-5940; MORIMATSU, Hiroshi/0000-0002-6744-0508; Doig, Gordon/0000-0003-2141-7000; NOIRI, Eisei/0000-0002-9515-7582; GIBNEY, NOEL/0000-0003-3376-0535; Bellomo, Rinaldo/0000-0002-1650-8939; Ronco, Claudio/0000-0002-6697-4065				Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Bouman CSC, 2002, CRIT CARE MED, V30, P2205, DOI 10.1097/00003246-200210000-00005; Brivet FG, 1996, CRIT CARE MED, V24, P192, DOI 10.1097/00003246-199602000-00003; Chertow GM, 1998, J AM SOC NEPHROL, V9, P692; CHERTOW GM, 1995, ARCH INTERN MED, V155, P1505, DOI 10.1001/archinte.155.14.1505; Cole L, 2000, AM J RESP CRIT CARE, V162, P191, DOI 10.1164/ajrccm.162.1.9907016; de Mendonca A, 2000, INTENS CARE MED, V26, P915, DOI 10.1007/s001340051281; Douma CE, 1997, J AM SOC NEPHROL, V8, P111; Fiaccadori E, 2000, KIDNEY INT, V58, P283, DOI 10.1046/j.1523-1755.2000.00164.x; Guerin C, 2000, AM J RESP CRIT CARE, V161, P872, DOI 10.1164/ajrccm.161.3.9809066; Hamel MB, 1997, ANN INTERN MED, V127, P195, DOI 10.7326/0003-4819-127-3-199708010-00003; Kellum JA, 2002, INTENS CARE MED, V28, P29, DOI 10.1007/s00134-001-1159-4; Kresse S, 1999, KIDNEY INT, V56, pS75, DOI 10.1046/j.1523-1755.56.s72.7.x; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Liano F, 1996, KIDNEY INT, V50, P811, DOI 10.1038/ki.1996.380; Mehta RL, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000014692.19351.52; Mehta RL, 2001, KIDNEY INT, V60, P1154, DOI 10.1046/j.1523-1755.2001.0600031154.x; Paganini EP, 1996, AM J KIDNEY DIS, V28, pS81, DOI 10.1016/S0272-6386(96)90084-0; Parker RA, 1998, AM J KIDNEY DIS, V32, P432, DOI 10.1053/ajkd.1998.v32.pm9740160; Phu NH, 2002, NEW ENGL J MED, V347, P895, DOI 10.1056/NEJMoa020074; Ronco C, 2000, LANCET, V356, P26, DOI 10.1016/S0140-6736(00)02430-2; Ronco C, 2001, NEPHROL DIAL TRANSPL, V16, P1555, DOI 10.1093/ndt/16.8.1555; SCHAEFER JH, 1991, INTENS CARE MED, V17, P19, DOI 10.1007/BF01708404; Schiffl H, 2002, NEW ENGL J MED, V346, P305, DOI 10.1056/NEJMoa010877; Silvester W, 2001, CRIT CARE MED, V29, P1910, DOI 10.1097/00003246-200110000-00010; TURNEY JH, 1990, Q J MED, V74, P83	26	2828	3076	6	100	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	2005	294	7					813	818		10.1001/jama.294.7.813	http://dx.doi.org/10.1001/jama.294.7.813			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955LI	16106006	Bronze			2022-12-28	WOS:000231227000021
J	Eddy, DM; Schlessinger, L; Kahn, R				Eddy, DM; Schlessinger, L; Kahn, R			Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes	ANNALS OF INTERNAL MEDICINE			English	Article							PRIMARY-PREVENTION; LIFE-STYLE; CARDIOVASCULAR EVENTS; MYOCARDIAL-INFARCTION; TYPE-2; PRAVASTATIN; ARCHIMEDES; MELLITUS; MEN; NEPHROPATHY	Background: Lifestyle modification can forestall diabetes in high-risk people, but the long-term cost-effectiveness is uncertain. Objective: To estimate the effects of the lifestyle modification program used in the Diabetes Prevention Program (DPP) on health and economic outcomes. Design: Cost-effectiveness analysis using the Archimedes model. Data Sources: Published basic and epidemiologic studies, clinical trials, and Kaiser Permanente administrative data. Target Population: Adults at high risk for diabetes (body mass index > 24 kg/m(2), fasting plasma glucose level of 5.2725 to 6.9375 mmol/L [95 to 125 mg/dL] 2-hour glucose tolerance test result of 7.77 to 11.0445 mmol/L [140 to 199 mg/dL]). Time Horizon: 5 to 30 years. Perspective: Patient, health plan, and societal. Interventions: No prevention, DPP's lifestyle modification program, lifestyle modification begun after a person develops diabetes, and metformin. Measurements: Diagnosis and complications of diabetes. Results of Base-Case Analysis: Compared with no prevention program, the DPP lifestyle program would reduce a high-risk person's 30-year chances of getting diabetes from about 72% to 61%, the chances of a serious complication from about 38% to 30%, and the chances of dying of a complication of diabetes from about 13.5% to 11.2%. Metformin would deliver about one third the long-term health benefits achievable by immediate lifestyle modification. Compared with not implementing any prevention program, the expected 30-year cost/quality-adjusted life-year (QALY) of the DIPP lifestyle intervention from the health plan's perspective would be about $143 000. From a societal perspective, the cost/QALY of the lifestyle intervention compared with doing nothing would be about $62 600. Either using metformin or delaying the lifestyle intervention until after a person develops diabetes would be more cost-effective, costing about $35 400 or $24 500 per QALY gained, respectively, compared with no program. Compared with delaying the lifestyle program until after diabetes is diagnosed, the marginal cost-effectiveness of beginning the DPP lifestyle program immediately would be about $201 800. Results of Sensitivity Analysis: Variability and uncertainty deriving from the structure of the model were tested by comparing the model's results with the results of real clinical trials of diabetes and its complications. The most critical element of uncertainty is the effectiveness of the lifestyle program, as expressed by the 95% CI of the DPP study. The most important potentially controllable factor is the cost of the lifestyle program. Compared with no program, lifestyle modification for high-risk people can be made cost-saving over 30 years if the annual cost of the intervention can be reduced to about $100. Limitations: Results depend on the accuracy of the model. Conclusions: Lifestyle modification is likely to have important effects on the morbidity and mortality of diabetes and should be recommended to all high-risk people. The program used in the DPP study may be too expensive for health plans or a national program to implement. Less expensive methods are needed to achieve the degree of weight loss seen in the DPP.	Kaiser Permanente, Archimedes Project, Oakland, CA USA; Amer Diabet Assoc, Alexandria, VA USA	Kaiser Permanente; American Diabetes Association	Eddy, DM (corresponding author), 1426 Crystal Lake Rd, Aspen, CO 81611 USA.	eddyaspen@yahoo.com						[Anonymous], 1991, JAMA, V265, P3255; Benjamin SM, 2003, DIABETES CARE, V26, P645, DOI 10.2337/diacare.26.3.645; Blumenthal JA, 2000, ARCH INTERN MED, V160, P1947, DOI 10.1001/archinte.160.13.1947; Buchanan TA, 2002, DIABETES, V51, P2796, DOI 10.2337/diabetes.51.9.2796; Chiasson JL, 2002, LANCET, V359, P2072, DOI 10.1016/S0140-6736(02)08905-5; Coffey JT, 2002, DIABETES CARE, V25, P2238, DOI 10.2337/diacare.25.12.2238; Colhoun HM, 2004, LANCET, V364, P685, DOI 10.1016/S0140-6736(04)16895-5; Collins R, 2002, LANCET, V360, P23, DOI 10.1016/S0140-6736(02)09328-5; DEFRONZO RA, 1995, NEW ENGL J MED, V333, P541, DOI 10.1056/NEJM199508313330902; Diabet Prevention Program Res Grp, 2003, DIABETES CARE, V26, P2518, DOI 10.2337/diacare.26.9.2518; DPP Res Grp, 2002, DIABETES CARE, V25, P2165; Eddy DM, 2003, DIABETES CARE, V26, P3102, DOI 10.2337/diacare.26.11.3102; Eddy DM, 2003, DIABETES CARE, V26, P3093, DOI 10.2337/diacare.26.11.3093; EDDY DM, 1992, FAST PRO SOFTWARE ME; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; Gavin JR, 1997, DIABETES CARE, V20, P1183; Gerstein HC, 2000, LANCET, V355, P253; Gold MR, 1996, COST EFFECTIVENESS H; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; Herman WH, 2005, ANN INTERN MED, V142, P323, DOI 10.7326/0003-4819-142-5-200503010-00007; Herman WH, 2003, DIABETES CARE, V26, P36; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; Lewis SJ, 1998, ANN INTERN MED, V129, P681, DOI 10.7326/0003-4819-129-9-199811010-00002; Parving HH, 2001, NEW ENGL J MED, V345, P870, DOI 10.1056/NEJMoa011489; PEDERSEN TR, 1994, LANCET, V344, P1383; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Schlessinger L, 2002, J BIOMED INFORM, V35, P37, DOI 10.1016/S1532-0464(02)00006-0; SCHLESSINGER L, 2004, TECHNICAL REPORT A B; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Yusuf S, 2000, NEW ENGL J MED, V342, P145	37	232	234	0	24	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 16	2005	143	4					251	264		10.7326/0003-4819-143-4-200508160-00006	http://dx.doi.org/10.7326/0003-4819-143-4-200508160-00006			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955PA	16103469				2022-12-28	WOS:000231237100002
J	Routy, JP				Routy, JP			Valproic acid: a potential role in treating latent HIV infection	LANCET			English	Editorial Material							CD4(+) T-CELLS; REPLICATION		McGill Univ, Royal Victoria Hosp, Ctr Hlth, Div Hematol, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital	Routy, JP (corresponding author), McGill Univ, Royal Victoria Hosp, Ctr Hlth, Div Hematol, Montreal, PQ H3A 1A1, Canada.	routyjp@muhchem.mcgill.ca						CHOMONT N, 2005, 3 IAS C HIV PATH TRE; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1999, NAT MED, V5, P651, DOI 10.1038/9498; DiCenzo R, 2004, ANTIMICROB AGENTS CH, V48, P4328, DOI 10.1128/AAC.48.11.4328-4331.2004; Klass CM, 2005, BLOOD, V105, P4028, DOI 10.1182/blood-2004-09-3569; Lehrman G, 2004, JAIDS-J ACQ IMM DEF, V36, P1103, DOI 10.1097/00126334-200408150-00015; Lehrman G, 2005, LANCET, V366, P549, DOI 10.1016/S0140-6736(05)67098-5; Marchion DC, 2005, CANCER RES, V65, P3815, DOI 10.1158/0008-5472.CAN-04-2478; Moog C, 1996, J GEN VIROL, V77, P1993, DOI 10.1099/0022-1317-77-9-1993; Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880; Ylisastigui L, 2004, AIDS, V18, P1101, DOI 10.1097/00002030-200405210-00003; Younes SA, 2003, J EXP MED, V198, P1909, DOI 10.1084/jem.20031598	12	19	19	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 13	2005	366	9485					523	524		10.1016/S0140-6736(05)67074-2	http://dx.doi.org/10.1016/S0140-6736(05)67074-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955LL	16099272				2022-12-28	WOS:000231227300004
J	Cawkwell, MJ; Nguyen-Manh, D; Woodward, C; Pettifor, DG; Vitek, V				Cawkwell, MJ; Nguyen-Manh, D; Woodward, C; Pettifor, DG; Vitek, V			Origin of brittle cleavage in iridium	SCIENCE			English	Article							BOND-ORDER; SCREW DISLOCATIONS; TEMPERATURE; SIMULATION; BEHAVIOR; FRACTURE	Iridium is unique among the face-centered cubic metals in that it undergoes brittle cleavage after a period of plastic deformation under tensile stress. Atomistic simulation using a quantum-mechanically derived bond-order potential shows that in iridium, two core structures for the screw dislocation are possible: a glissile planar core and a metastable nonplanar core. Transformation between the two core structures is athermal and leads to exceptionally high rates of cross slip during plastic deformation. Associated with this athermal cross slip is an exponential increase in the dislocation density and strong work hardening from which brittle cleavage is a natural consequence.	Univ Penn, Dept Mat Sci & Engn, Philadelphia, PA 19104 USA; EURATOM, Culham Sci Ctr, European Atom Energy Community UK Atom Energy Aut, Abingdon OX14 3DB, Oxon, England; USAF, Res Lab, Wright Patterson AFB, OH 45433 USA; Northwestern Univ, Dept Mat Sci & Engn, Evanston, IL 60208 USA; Univ Oxford, Dept Mat, Oxford OX1 3PH, England	University of Pennsylvania; Culham Science Centre; Euratom; UK Atomic Energy Authority; United States Department of Defense; United States Air Force; US Air Force Research Laboratory; Northwestern University; University of Oxford	Cawkwell, MJ (corresponding author), Univ Penn, Dept Mat Sci & Engn, 3231 Walnut St, Philadelphia, PA 19104 USA.	cawkwell@seas.upenn.edu						ADAMESKU R, 1994, J MATER SCI LETT, V13, P865, DOI 10.1007/BF00273232; Balk TJ, 2001, PHILOS MAG A, V81, P1507, DOI 10.1080/01418610108214360; BROOKES CA, 1970, J I MET, V98, P27; CAWKWELL MJ, UNPUB; Duesbery M. S., 1989, DISLOCATIONS SOLIDS, V8, P67; ESCAIG B, 1968, J PHYS-PARIS, V29, P225, DOI 10.1051/jphys:01968002902-3022500; Girshick A, 1998, PHILOS MAG A, V77, P981, DOI 10.1080/01418619808221223; HAASEN P, 1965, Z METALLKD, V56, P832; HECKER SS, 1978, METALL TRANS A, V9, P481, DOI 10.1007/BF02646403; Hirth J. P., 1972, THEORY DISLOCATIONS; Horsfield AP, 1996, PHYS REV B, V53, P12694, DOI 10.1103/PhysRevB.53.12694; Hull D., 2011, INTRO TC DISLOCATION, V5th, DOI DOI 10.1016/B978-0-08-096672-4.00001-3; KOEHLER JS, 1952, PHYS REV, V86, P52, DOI 10.1103/PhysRev.86.52; Lu G, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.144103; Mrovec M, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.094115; Panfilov P, 2000, IRIDIUM, P27; PANFILOV P, 1994, J MATER SCI LETT, V13, P137, DOI 10.1007/BF00416826; Panfilov P., 1991, PLATINUM MET REV, V35, P196; PETTIFOR DG, 1989, PHYS REV LETT, V63, P2480, DOI 10.1103/PhysRevLett.63.2480; Rao S, 1998, PHILOS MAG A, V77, P231, DOI 10.1080/01418619808214240; Read W.T., 1953, DISLOCATIONS CRYSTAL; REID CN, 1972, METALL TRANS, V3, P2257, DOI 10.1007/BF02643240; VITEK V, 1992, PROG MATER SCI, V36, P1, DOI 10.1016/0079-6425(92)90003-P; Woodward C, 2004, PHILOS MAG, V84, P401, DOI 10.1080/14786430310001611626	24	75	80	2	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 12	2005	309	5737					1059	1062		10.1126/science.1114704	http://dx.doi.org/10.1126/science.1114704			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955MN	16099981				2022-12-28	WOS:000231230100041
J	Longini, IM; Nizam, A; Xu, SF; Ungchusak, K; Hanshaoworakul, W; Cummings, DAT; Halloran, ME				Longini, IM; Nizam, A; Xu, SF; Ungchusak, K; Hanshaoworakul, W; Cummings, DAT; Halloran, ME			Containing pandemic influenza at the source	SCIENCE			English	Article							RANDOMIZED CONTROLLED-TRIAL; AVIAN INFLUENZA; ASIAN INFLUENZA; EPIDEMIC; PREVENTION; MODEL; TRANSMISSION; ZANAMIVIR; VIROLOGY; SPREAD	Highly pathogenic avian influenza A (subtype H5N1) is threatening to cause a human pandemic of potentially devastating proportions. We used a stochastic influenza simulation model for rural Southeast Asia to investigate the effectiveness of targeted antiviral prophylaxis, quarantine, and pre-vaccination in containing an emerging influenza strain at the source. If the basic reproductive number (R-o) was below 1.60, our simulations showed that a prepared response with targeted antivirals would have a high probability of containing the disease, In that case, an antiviral agent stockpile on the order of 100,000 to 1 million courses for treatment and prophylaxis would be sufficient. If pre-vaccination occurred, then targeted antiviral prophylaxis. could be effective for containing strains with an R-o as high as 2.1. Combinations of targeted antiviral prophylaxis, pre-vaccination, and quarantine could contain strains with an R-o as high as 2.4.	Emory Univ, Rollins Sch Publ Hlth, Dept Biostat, Atlanta, GA 30322 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; Minist Publ Hlth, Nonthaburi, Thailand	Emory University; Rollins School Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Ministry of Public Health - Thailand	Longini, IM (corresponding author), Emory Univ, Rollins Sch Publ Hlth, Dept Biostat, 1518 Clifton Rd NE, Atlanta, GA 30322 USA.	longini@sph.emory.edu	Chen, Chien Ku/C-6128-2008		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM070749] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI32042] Funding Source: Medline; NIGMS NIH HHS [U01-GM070749] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antia R, 2003, NATURE, V426, P658, DOI 10.1038/nature02104; Cauchemez S, 2004, STAT MED, V23, P3469, DOI 10.1002/sim.1912; CHAMRAATHRITHIR.A, 1995, NATL MIGRATION SURVE; DAVIS LE, 1970, AM J EPIDEMIOL, V92, P240, DOI 10.1093/oxfordjournals.aje.a121203; ELVEBACK LR, 1976, AM J EPIDEMIOL, V103, P152, DOI 10.1093/oxfordjournals.aje.a112213; Enserink M, 2004, SCIENCE, V306, P2016, DOI 10.1126/science.306.5704.2016; Faust K, 1999, SOC NETWORKS, V21, P311; Ferguson NM, 2004, SCIENCE, V304, P968, DOI 10.1126/science.1096898; Fitzner K. A., 1999, Hong Kong Medical Journal, V5, P87; Guest P, 1994, Asian Pac Migr J, V3, P531; Halloran ME, 1999, EPIDEMIOL REV, V21, P73, DOI 10.1093/oxfordjournals.epirev.a017990; Halloran ME, 2002, VACCINE, V20, P3254; Hayden FG, 1999, ANTIMICROBIAL, P1344; Hayden FG, 2000, NEW ENGL J MED, V343, P1282, DOI 10.1056/NEJM200011023431801; Hayden FG, 2001, PHILOS T R SOC B, V356, P1877, DOI 10.1098/rstb.2001.1007; Hill AN, 2003, MATH BIOSCI, V181, P85, DOI 10.1016/S0025-5564(02)00129-3; JORDAN WS, 1961, AM REV RESPIR DIS, V83, P29; KILBOURNE ED, 1975, INFLUENZA VIRUSES IN; Laver G, 2001, SCIENCE, V293, P1776, DOI 10.1126/science.1063817; LONGINI IM, 1978, MATH BIOSCI, V38, P141, DOI 10.1016/0025-5564(78)90023-8; Longini IM, 2004, AM J EPIDEMIOL, V159, P623, DOI 10.1093/aje/kwh092; Mills CE, 2004, NATURE, V432, P904, DOI 10.1038/nature03063; Monto AS, 2005, NEW ENGL J MED, V352, P323, DOI 10.1056/NEJMp048343; Monto AS, 1999, JAMA-J AM MED ASSOC, V282, P31, DOI 10.1001/jama.282.1.31; National Statistical Office, POP HOUS CENS 2000; RVACHEV LA, 1985, MATH BIOSCI, V75, P3, DOI 10.1016/0025-5564(85)90064-1; SHARRAR RG, 1969, B WORLD HEALTH ORGAN, V41, P361; Stohr K, 2005, NEW ENGL J MED, V352, P405, DOI 10.1056/NEJMe048344; Stohr K, 2004, SCIENCE, V306, P2195, DOI 10.1126/science.1108165; Ungchusak K, 2005, NEW ENGL J MED, V352, P333, DOI 10.1056/NEJMoa044021; Webby RJ, 2003, SCIENCE, V302, P1519, DOI 10.1126/science.1090350; Webster RG, 2001, SCIENCE, V293, P1773; Welliver R, 2001, JAMA-J AM MED ASSOC, V285, P748, DOI 10.1001/jama.285.6.748; YANG Y, 0409 EM U DEP BIOST	34	827	862	4	113	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 12	2005	309	5737					1083	1087		10.1126/science.1115717	http://dx.doi.org/10.1126/science.1115717			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955MN	16079251				2022-12-28	WOS:000231230100048
J	Ma'ayan, A; Jenkins, SL; Neves, S; Hasseldine, A; Grace, E; Dubin-Thalere, B; Eungdamrong, NJ; Weng, GZ; Ram, PT; Rice, JJ; Kershenbaum, A; Stolovitzky, GA; Blitzer, RD; Iyengar, R				Ma'ayan, A; Jenkins, SL; Neves, S; Hasseldine, A; Grace, E; Dubin-Thalere, B; Eungdamrong, NJ; Weng, GZ; Ram, PT; Rice, JJ; Kershenbaum, A; Stolovitzky, GA; Blitzer, RD; Iyengar, R			Formation of regulatory patterns during signal propagation in a mammalian cellular network	SCIENCE			English	Article							LONG-TERM POTENTIATION; SMALL-WORLD NETWORKS; TRANSCRIPTION; HIPPOCAMPUS; PROTEIN; MEMORY; LOOP; PHOSPHATASE; DYNAMICS; ELEMENT	We developed a model of 545 components (nodes) and 1259 interactions representing signaling pathways and cellular machines in the hippocampal CA1 neuron. Using graph theory methods, we analyzed ligand-induced signal flow through the system. Specification of input and output nodes allowed us to identify functional modules. Networking resulted in the emergence of regulatory motifs, such as positive and negative feedback and feedforward loops, that process information. Key regulators of plasticity were highly connected nodes required for the formation of regulatory motifs, indicating the potential importance of such motifs in determining cellular choices between homeostasis and plasticity.	Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Biol Chem, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; Columbia Univ, Dept Biol Sci, New York, NY 10029 USA; IBM Corp, Thomas J Watson Res Ctr, Yorktown Hts, NY 10598 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Columbia University; International Business Machines (IBM)	Iyengar, R (corresponding author), Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA.	Ravi.Iyengar@mssm.edu	Ma'ayan, Avi/AAG-3131-2019; Yang, Chen/G-1379-2010	Ma'ayan, Avi/0000-0002-6904-1017; Rice, John/0000-0001-8280-8529; Ram, Prahlad/0000-0003-4739-3166; Jenkins, Sherry/0000-0003-1730-0977	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072853, R01GM054508, F31GM065065, P50GM071558, T32GM062754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA015863] Funding Source: NIH RePORTER; NIDA NIH HHS [DA15863, R01 DA015863] Funding Source: Medline; NIGMS NIH HHS [F31 GM065065, GM-54508, T32 GM062754, R01 GM054508-12, P50 GM071558-020007, P50 GM071558, R01 GM072853, P50 GM071558-030007, R01 GM054508, R01 GM072853-01, GM-62754, P50 GM071558-01A20007, GM-65065, GM-072853] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amaral LAN, 2000, P NATL ACAD SCI USA, V97, P11149, DOI 10.1073/pnas.200327197; Angeli D, 2004, P NATL ACAD SCI USA, V101, P1822, DOI 10.1073/pnas.0308265100; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Bhalla US, 2002, SCIENCE, V297, P1018, DOI 10.1126/science.1068873; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blitzer RD, 1998, SCIENCE, V280, P1940, DOI 10.1126/science.280.5371.1940; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Caldarelli G, 2004, EUR PHYS J B, V38, P183, DOI 10.1140/epjb/e2004-00020-6; HVALBY O, 1987, EXPERIENTIA, V43, P599, DOI 10.1007/BF02126343; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; Jordan JD, 2000, CELL, V103, P193, DOI 10.1016/S0092-8674(00)00112-4; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Kashtan N, 2004, BIOINFORMATICS, V20, P1746, DOI 10.1093/bioinformatics/bth163; Katsuki H, 1997, J NEUROPHYSIOL, V77, P3013, DOI 10.1152/jn.1997.77.6.3013; Lahav G, 2004, NAT GENET, V36, P147, DOI 10.1038/ng1293; Mangan S, 2003, P NATL ACAD SCI USA, V100, P11980, DOI 10.1073/pnas.2133841100; Mangan S, 2003, J MOL BIOL, V334, P197, DOI 10.1016/j.jmb.2003.09.049; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; Pittenger C, 2002, NEURON, V34, P447, DOI 10.1016/S0896-6273(02)00684-0; Siegelbaum S A, 1991, Curr Opin Neurobiol, V1, P113, DOI 10.1016/0959-4388(91)90018-3; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918	22	236	240	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 12	2005	309	5737					1078	1083		10.1126/science.1108876	http://dx.doi.org/10.1126/science.1108876			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955MN	16099987	Green Accepted			2022-12-28	WOS:000231230100047
J	McElroy, K; Lee, J; Slezak, JA; Lee, DH; Eisaki, H; Uchida, S; Davis, JC				McElroy, K; Lee, J; Slezak, JA; Lee, DH; Eisaki, H; Uchida, S; Davis, JC			Atomic-scale sources and mechanism of nanoscale electronic disorder in Bi2Sr2CaCu2O8+delta	SCIENCE			English	Article							INHOMOGENEITY; GAP; SUPERCONDUCTIVITY	The randomness of dopant atom distributions in cuprate high-critical temperature superconductors has long been suspected to cause nanoscale electronic disorder. In the superconductor Bi2Sr2CaCu2O8+delta, we identified populations of atomic-scale impurity states whose spatial densities follow closely those of the oxygen dopant atoms. We found that the impurity-state locations are strongly correlated with all manifestations of the nanoscale electronic disorder. This disorder occurs via an unanticipated mechanism exhibiting high-energy spectral weight shifts, with associated strong superconducting coherence peak suppression but very weak scattering of low-energy quasi-particles.	Cornell Univ, Dept Phys, Atom & Solid State Phys Lab, Ithaca, NY 14850 USA; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Natl Inst Adv Ind Sci & Technol, Tsukuba, Ibaraki 3058568, Japan; Univ Tokyo, Dept Phys, Tokyo 1138656, Japan	Cornell University; University of California System; University of California Berkeley; National Institute of Advanced Industrial Science & Technology (AIST); University of Tokyo	Davis, JC (corresponding author), Cornell Univ, Dept Phys, Atom & Solid State Phys Lab, Ithaca, NY 14850 USA.	jcdavis@ccmr.cornell.edu	mcelroy, kyle/D-1816-2013; Eisaki, Hiroshi/F-6317-2018	Eisaki, Hiroshi/0000-0002-8299-6416; McElroy, Kyle/0000-0003-4799-2820				Attfield JP, 1998, NATURE, V394, P157, DOI 10.1038/28120; Bobroff J, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.157002; Capriotti L, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.014508; Cava RJ, 1998, NATURE, V394, P126, DOI 10.1038/28044; Cren T, 2001, EUROPHYS LETT, V54, P84, DOI 10.1209/epl/i2001-00232-4; EDWARDS HL, 1995, PHYS REV LETT, V75, P1387, DOI 10.1103/PhysRevLett.75.1387; Eisaki H, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.064512; Grebille D, 1996, ACTA CRYSTALLOGR B, V52, P628, DOI 10.1107/S0108768196004673; Hanaguri T, 2004, NATURE, V430, P1001, DOI 10.1038/nature02861; Howald C, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.100504; Kaneshita E, 2004, J PHYS SOC JPN, V73, P3223, DOI 10.1143/JPSJ.73.3223; Kinoda G, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.224509; Kohsaka Y, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.097004; Lang KM, 2002, NATURE, V415, P412, DOI 10.1038/415412a; Loram JW, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.060502; Maekawa S., 2004, PHYS TRANSITION META; Martin I, 2001, PHYSICA C, V357, P46, DOI 10.1016/S0921-4534(01)00192-7; Matsuda A, 2003, PHYSICA C, V388, P207, DOI 10.1016/S0921-4534(02)02378-X; McElroy K, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.197005; McElroy K, 2003, NATURE, V422, P592, DOI 10.1038/nature01496; Miyakawa N, 1998, PHYS REV LETT, V80, P157, DOI 10.1103/PhysRevLett.80.157; Pan SH, 2001, NATURE, V413, P282, DOI 10.1038/35095012; QUE WM, 1992, PHYS REV B, V46, P14772, DOI 10.1103/PhysRevB.46.14772; SCALAPINO DJ, IN PRESS P 7 INT C S; Wang QH, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.020511; Wang QH, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.054501; Wang ZQ, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.064509; Zhu JX, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.057004; Zhu LY, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.060503	29	368	370	1	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 12	2005	309	5737					1048	1052		10.1126/science.1113095	http://dx.doi.org/10.1126/science.1113095			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955MN	16099978				2022-12-28	WOS:000231230100038
J	Boyd, CM; Darer, J; Boult, C; Fried, LP; Boult, L; Wu, AW				Boyd, CM; Darer, J; Boult, C; Fried, LP; Boult, L; Wu, AW			Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases - Implications for pay for performance	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVERSE DRUG EVENTS; ELDERLY-PATIENTS; ATRIAL-FIBRILLATION; MEDICAL-MANAGEMENT; AMERICAN-COLLEGE; OSTEOARTHRITIS; POLYPHARMACY; PREFERENCES; ADHERENCE; PITFALLS	Context Clinical practice guidelines (CPGs) have been developed to improve the quality of health care for many chronic conditions. Pay-for-performance initiatives assess physician adherence to interventions that may reflect CPG recommendations. Objective To evaluate the applicability of CPGs to the care of older individuals with several comorbid diseases. Data Sources The National Health Interview Survey and a nationally representative sample of Medicare beneficiaries (to identify the most prevalent chronic diseases in this population); the National Guideline Clearinghouse (for locating evidence-based CPGs for each chronic disease). Study Selection Of the 15 most common chronic diseases, we selected hypertension, chronic heart failure, stable angina, atrial fibrillation, hypercholesterolemia, diabetes mellitus, osteoarthritis, chronic obstructive pulmonary disease, and osteoporosis, which are usually managed in primary care, choosing CPGs promulgated by national and international medical organizations for each. Data Extraction Two investigators independently assessed whether each CPG addressed older patients with multiple comorbid diseases, goals of treatment, interactions between recommendations, burden to patients and caregivers, patient preferences, life expectancy, and quality of life. Differences were resolved by consensus. For a hypothetical 79-year-old woman with chronic obstructive pulmonary disease, type 2 diabetes, osteoporosis, hypertension, and osteoarthritis, we aggregated the recommendations from the relevant CPGs. Data Synthesis Most CPGs did not modify or discuss the applicability of their recommendations for older patients with multiple comorbidities. Most also did not comment on burden, short- and long-term goals, and the quality of the underlying scientific evidence, nor give guidance for incorporating patient preferences into treatment plans. if the relevant CPGs were followed, the hypothetical patient would be prescribed 12 medications (costing her $406 per month) and a complicated nonpharmacological regimen. Adverse interactions between drugs and diseases could result. Conclusions This review suggests that adhering to current CPGs in caring for an older person with several comorbiclities may have undesirable effects. Basing standards for quality of care and pay for performance on existing CPGs could lead to inappropriate judgment of the care provided to older individuals with complex comorbiclities and could create perverse incentives that emphasize the wrong aspects of care for this population and diminish the quality of their care. Developing measures of the quality of the care needed by older patients with complex comorbidities is critical to improving their care.	Johns Hopkins Univ, Ctr Aging & Hlth, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Div Geriatr Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Div Gerontol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Div Gen Internal Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Hlth Policy & Management, Baltimore, MD 21205 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; Johns Hopkins Univ, Roger C Lipitz Ctr Integrated Hlth Care, Baltimore, MD 21205 USA; Midatlantic Permanente Med Grp, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Permanente Medical Groups	Boyd, CM (corresponding author), Johns Hopkins Univ, Ctr Aging & Hlth, 2024 E Monument St,Suite 2-700, Baltimore, MD 21205 USA.	cyboyd@jhmi.edu	Wu, Albert/AAJ-4780-2021		DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA [T32PE010025] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG021334, T32AG000120] Funding Source: NIH RePORTER; NIA NIH HHS [P30 AG021334, T32-AG00120] Funding Source: Medline; BHP HRSA HHS [5-T32-PE10025] Funding Source: Medline	DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); BHP HRSA HHS		*3 REP EXP PAN DET, EV TERATM HIGH BLOOD; *7 REP JOINT NAT C, DET EV TREATM HIGH B; Altman RD, 2000, ARTHRITIS RHEUM-US, V43, P1905; *AM COLL PHYS WEB, MARK FORC NOW PUSH P; American Diabetes Association, 2002, Diabetes Care, V25, P202, DOI 10.2337/diacare.25.1.202; American Diabetes Association Clinical Practice Recommendations, 2001, DIABETES CARE S1, V24, pS1; ANDERSON G, 2002, CHRONIC CONDITIIONS; [Anonymous], 2005, DIABETES CARE, V28, pS4; Arauz-Pacheco Carlos, 2004, Diabetes Care, V27 Suppl 1, pS65; Brown AF, 2003, J AM GERIATR SOC, V51, P665, DOI 10.1034/j.1600-0579.2003.00211.x; Cluzeau FA, 1999, INT J QUAL HEALTH C, V11, P21, DOI 10.1093/intqhc/11.1.21; Colwell John A, 2004, Diabetes Care, V27 Suppl 1, pS72; Current estimates from the National Health Interview Survey, 1994, VITAL HLTH STAT, V10, P1; Elwyn G, 2003, BMJ-BRIT MED J, V327, P864, DOI 10.1136/bmj.327.7419.864; Field TS, 2004, J AM GERIATR SOC, V52, P1349, DOI 10.1111/j.1532-5415.2004.52367.x; Findley LJ, 2002, BRIT MED J, V324, P1466, DOI 10.1136/bmj.324.7352.1466; Flaherty JH, 2000, J GERONTOL A-BIOL, V55, pM554, DOI 10.1093/gerona/55.10.M554; Fong DS, 2004, DIABETES CARE, V27, P2540, DOI 10.2337/diacare.27.10.2540; Franz MJ., 2004, DIABETES CARE S1, V27, pS36; Fried TR, 2002, J GERONTOL B-PSYCHOL, V57, pS348, DOI 10.1093/geronb/57.6.S348; Fuster V, 2001, J AM COLL CARDIOL, V38, P1231, DOI 10.1016/S0735-1097(01)01587-X; Garber AM, 2005, HEALTH AFFAIR, V24, P174, DOI 10.1377/hlthaff.24.1.174; Gavin JR, 2000, DIABETES CARE, V23, pS4; GIBBONS RJ, ACC AHA 2002 GUIDELI; Gijsen R, 2001, J CLIN EPIDEMIOL, V54, P661, DOI 10.1016/S0895-4356(00)00363-2; Glynn RJ, 1999, J CLIN EPIDEMIOL, V52, P781, DOI 10.1016/S0895-4356(99)00055-4; Goldstein DE, 2004, DIABETES CARE, V27, P1761, DOI 10.2337/diacare.27.7.1761; GOULDING M, 2005, TRENDS PRESCRIBED ME; Graham ID, 2000, INT J TECHNOL ASSESS, V16, P1024, DOI 10.1017/S0266462300103095; Gray SL, 2001, ANN PHARMACOTHER, V35, P539, DOI 10.1345/aph.10295; Greer AL, 2002, INT J TECHNOL ASSESS, V18, P747, DOI 10.1017/S0266462302000569; Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E; Gurwitz JH, 2004, ARCH INTERN MED, V164, P1957, DOI 10.1001/archinte.164.18.1957; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; Haffner Steven M, 2004, Diabetes Care, V27 Suppl 1, pS68; Haire-Joshu Debra, 2004, Diabetes Care, V27 Suppl 1, pS74; HAYWARD RSA, 1995, JAMA-J AM MED ASSOC, V274, P570, DOI 10.1001/jama.274.7.570; HOCHBERG MC, 1995, ARTHRITIS RHEUM, V38, P1541, DOI 10.1002/art.1780381104; HOCHBERG MC, 1995, ARTHRITIS RHEUM, V38, P1535, DOI 10.1002/art.1780381103; Hofer TP, 2004, J GEN INTERN MED, V19, P646, DOI 10.1007/s11606-004-0058-0; Hofer TP, 1999, JAMA-J AM MED ASSOC, V281, P2098, DOI 10.1001/jama.281.22.2098; Hoffman C, 1996, JAMA-J AM MED ASSOC, V276, P1473, DOI 10.1001/jama.276.18.1473; HUNT SA, ACC AHA GUIDELINES E; Institute of Medicine, 2001, CROSSING QUALITY CHA; Juurlink DN, 2003, JAMA-J AM MED ASSOC, V289, P1652, DOI 10.1001/jama.289.13.1652; KROENKE LTCK, 1990, J AM GERIATR SOC, V38, P31, DOI 10.1111/j.1532-5415.1990.tb01593.x; Masoudi FA, 2003, AM HEART J, V146, P250, DOI 10.1016/S0002-8703(03)00189-3; Mayfield JA, 2004, DIABETES CARE, V27, pB39, DOI 10.2337/diacare.27.suppl_2.B39; Medpac, 2020, REP C MED PAYM POL; Mojtabai R, 2003, HEALTH AFFAIR, V22, P220, DOI 10.1377/hlthaff.22.4.220; MOLITCH ME, 2004, DIABETES CARE S1, V27, pS79, DOI DOI 10.2337/DIACARE.27.5.1240-A; *NAT OST FDN, PHYS GUID PREV TREAT; *NCQA, HLTH PLAN EMPL DAT I; *PARTN SOL, MED COSTS PREV CHRON; Pauwels R A, 2001, Respir Care, V46, P798; Protheroe J, 2000, BRIT MED J, V320, P1380, DOI 10.1136/bmj.320.7246.1380; Safran DG, 1998, MED CARE, V36, P728, DOI 10.1097/00005650-199805000-00012; Schmader KE, 1998, AGE AGEING, V27, P493, DOI 10.1093/ageing/27.4.493; Schnitzer TJ, 2002, J PAIN SYMPTOM MANAG, V23, pS24, DOI 10.1016/S0885-3924(02)00372-X; Shaneyfelt TM, 1999, JAMA-J AM MED ASSOC, V281, P1900, DOI 10.1001/jama.281.20.1900; Shiffman RN, 2003, ANN INTERN MED, V139, P493, DOI 10.7326/0003-4819-139-6-200309160-00013; Sigal RJ, 2006, DIABETES CARE, V29, P1433, DOI 10.2337/dc06-9910; Snow V, 2004, ANN INTERN MED, V141, P562, DOI 10.7326/0003-4819-141-7-200410050-00014; Sperl-Hillen J, 2000, Jt Comm J Qual Improv, V26, P615; Tinetti ME, 2004, NEW ENGL J MED, V351, P2870, DOI 10.1056/NEJMsb042458; Tinetti ME, 2004, AM J MED, V116, P179, DOI 10.1016/j.amjmed.2003.09.031; Townsend A, 2003, BRIT MED J, V327, P837, DOI 10.1136/bmj.327.7419.837; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; Walter LC, 2004, JAMA-J AM MED ASSOC, V291, P2466, DOI 10.1001/jama.291.20.2466; Walter LC, 2001, JAMA-J AM MED ASSOC, V285, P2750, DOI 10.1001/jama.285.21.2750; Wenger NS, 2003, ANN INTERN MED, V139, P740, DOI 10.7326/0003-4819-139-9-200311040-00008; Yarnall KSH, 2003, AM J PUBLIC HEALTH, V93, P635, DOI 10.2105/AJPH.93.4.635; 2004, 4 ANN DIS MAN OUTC S; 2002, 2 ANN DIS MAN OUTC S	74	1608	1633	6	192	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	2005	294	6					716	724		10.1001/jama.294.6.716	http://dx.doi.org/10.1001/jama.294.6.716			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	953IA	16091574				2022-12-28	WOS:000231068600025
J	Decosas, J; Boillot, F				Decosas, J; Boillot, F			Surveillance of HIV and tuberculosis drug resistance	LANCET			English	Editorial Material							PREVALENCE		Plan, W Africa Reg Off, Accra, Ghana; Alter Sante Int & Dev, Montpellier, France; Int Union TB & Lung Dis, TB Div, Paris, France		Decosas, J (corresponding author), Plan, W Africa Reg Off, Accra, Ghana.	josef.decosas@plan-international.org						Bayer R, 1991, Law Med Health Care, V19, P222; Boillot F, 1997, INT J TUBERC LUNG D, V1, P493; Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009; Laszlo A, 2002, INT J TUBERC LUNG D, V6, P748; Nelson LJ, 2005, LANCET, V366, P488, DOI 10.1016/S0140-6736(05)67062-6; UNAIDS/WHO, 2000, GUID 2 GEN HIV SURV; Van Deun A, 2005, INT J TUBERC LUNG D, V9, P355; World Health Organization, 2004, GUID HIV SURV TUB PA	8	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 6	2005	366	9484					438	439		10.1016/S0140-6736(05)67039-0	http://dx.doi.org/10.1016/S0140-6736(05)67039-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	952RD	16084238				2022-12-28	WOS:000231022300009
J	Smyth, A				Smyth, A			Multiresistant pulmonary infection in cystic fibrosis - prevention is better than cure	LANCET			English	Editorial Material							PSEUDOMONAS-AERUGINOSA; BACTERIA		Univ Nottingham, Div Child Hlth, Nottingham NG5 1PB, England; City Hosp Nottingham, Dept Pediat, Nottingham NG5 1PB, England	University of Nottingham; Nottingham University Hospital NHS Trust; Nottingham City Hospital	Smyth, A (corresponding author), Univ Nottingham, Div Child Hlth, Nottingham NG5 1PB, England.	Alan.Smyth@nottingham.ac.uk		Smyth, Alan/0000-0001-5494-5438				Aaron SD, 2005, LANCET, V366, P463, DOI 10.1016/S0140-6736(05)67060-2; Al-Aloul M, 2004, THORAX, V59, P334, DOI 10.1136/thx.2003.014258; Cheng K, 1996, LANCET, V348, P639, DOI 10.1016/S0140-6736(96)05169-0; ELBORN JS, 1991, THORAX, V46, P881, DOI 10.1136/thx.46.12.881; ELPHICK HE, 2005, COCHRANE DB SYST REV, V2, P2007, DOI DOI 10.1002/14651858.CD0022007.PUB2; Rasmussen TB, 2005, J BACTERIOL, V187, P1799, DOI 10.1128/JB.187.5.1799-1814.2005; Stewart PS, 2001, LANCET, V358, P135, DOI 10.1016/S0140-6736(01)05321-1; Taccetti G, 2005, EUR RESPIR J, V26, P458, DOI 10.1183/09031936.05.00009605; Tan KHV, 2003, AM J RESP CRIT CARE, V167, P819, DOI 10.1164/rccm.200109-012CC; *UK CYST FIBR TRUS, 2002, ANT TREATM CYST FIBR; *UK CYST FIBR TRUS, 2005, UK CYST FIBR DAT ANN; UK Cystic Fibrosis Trust Infection Control Group, 2004, PSEUD AER INF PEOPL; VanDevanter DR, 2005, PEDIATR PULM, V39, P504, DOI 10.1002/ppul.20220	13	6	6	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 6	2005	366	9484					433	435		10.1016/S0140-6736(05)67037-7	http://dx.doi.org/10.1016/S0140-6736(05)67037-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	952RD	16084235				2022-12-28	WOS:000231022300006
J	Horodecki, M; Oppenheim, J; Winter, A				Horodecki, M; Oppenheim, J; Winter, A			Partial quantum information	NATURE			English	Article							CURRENT SITUATION; ENTANGLEMENT; CAPACITY	Information - be it classical(1) or quantum(2) - is measured by the amount of communication needed to convey it. In the classical case, if the receiver has some prior information about the messages being conveyed, less communication is needed(3). Here we explore the concept of prior quantum information: given an unknown quantum state distributed over two systems, we determine how much quantum communication is needed to transfer the full state to one system. This communication measures the partial information one system needs, conditioned on its prior information. We find that it is given by the conditional entropy - a quantity that was known previously, but lacked an operational meaning. In the classical case, partial information must always be positive, but we find that in the quantum world this physical quantity can be negative. If the partial information is positive, its sender needs to communicate this number of quantum bits to the receiver; if it is negative, then sender and receiver instead gain the corresponding potential for future quantum communication. We introduce a protocol that we term 'quantum state merging' which optimally transfers partial information. We show how it enables a systematic understanding of quantum network theory, and discuss several important applications including distributed compression, noiseless coding with side information, multiple access channels and assisted entanglement distillation.	Univ Cambridge, Dept Appl Math & Theoret Phys, Cambridge CB3 0WA, England; Univ Gdansk, Inst Theoret Phys & Astrophys, PL-80952 Gdansk, Poland; Univ Bristol, Dept Math, Bristol BS8 1TW, Avon, England	University of Cambridge; Fahrenheit Universities; University of Gdansk; University of Bristol	Oppenheim, J (corresponding author), Univ Cambridge, Dept Appl Math & Theoret Phys, Cambridge CB3 0WA, England.	j.oppenheim@damtp.cam.ac.uk	Winter, Andreas/C-4185-2016; Winter, Andreas/K-4200-2019; Oppenheim, Jonathan/E-1518-2017	Winter, Andreas/0000-0001-6344-4870; Winter, Andreas/0000-0001-6344-4870; Oppenheim, Jonathan/0000-0002-8993-412X	Engineering and Physical Sciences Research Council [GR/S82169/01] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		AHN C, 2004, ORGQUANTPH0403042; BENNETT CH, 1993, PHYS REV LETT, V70, P1895, DOI 10.1103/PhysRevLett.70.1895; Cerf NJ, 1997, PHYS REV LETT, V79, P5194, DOI 10.1103/PhysRevLett.79.5194; DEVETAK I, 2004, PHYS REV LETT, V93; DiVincenzo DP, 1999, LECT NOTES COMPUT SC, V1509, P247; Einstein A, 1935, PHYS REV, V47, P0777, DOI 10.1103/PhysRev.47.777; GROISMAN B, 2004, ORGQUANTPH0410091; Horodecki M, 2005, PHYS REV A, V71, DOI 10.1103/PhysRevA.71.062307; HORODECKI R, 1994, PHYS LETT A, V194, P147, DOI 10.1016/0375-9601(94)91275-0; Lieb E. H., 1973, Journal of Mathematical Physics, V14, P1938, DOI 10.1063/1.1666274; Schrodinger E, 1935, NATURWISSENSCHAFTEN, V23, P807, DOI 10.1007/BF01491891; SCHUMACHER B, 1995, PHYS REV A, V51, P2738, DOI 10.1103/PhysRevA.51.2738; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI DOI 10.1002/J.1538-7305.1948.TB01338.X; Shor P, 2002, QUANTUM CHANNEL CAPA; Slepian D., 1971, IEEE T INFORM THEORY, V19, P461; SMOLIN JA, 2005, ORGQUANTPH0505038; Terhal BM, 2002, J MATH PHYS, V43, P4286, DOI 10.1063/1.1498001; WEHRL A, 1978, REV MOD PHYS, V50, P221, DOI 10.1103/RevModPhys.50.221; WYNER AD, 1975, IEEE T INFORM THEORY, V21, P294, DOI 10.1109/TIT.1975.1055374; YARD J, 2005, CAPACITY THEOREMS 1	23	269	269	2	40	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 4	2005	436	7051					673	676		10.1038/nature03909	http://dx.doi.org/10.1038/nature03909			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	951XA	16079840	Green Submitted			2022-12-28	WOS:000230964500037
J	Padma, TV				Padma, TV			Strength in numbers	NATURE			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 28	2005	436	7050					492	493						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	949LE	16089007				2022-12-28	WOS:000230788800047
J	Watson, FL; Puttmann-Holgado, R; Thomas, F; Lamar, DL; Hughes, M; Kondo, M; Rebel, VI; Schmucker, D				Watson, FL; Puttmann-Holgado, R; Thomas, F; Lamar, DL; Hughes, M; Kondo, M; Rebel, VI; Schmucker, D			Extensive diversity of Ig-superfamily proteins in the immune system of insects	SCIENCE			English	Article							GENOMIC ANALYSIS; AXON GUIDANCE; DROSOPHILA; RECEPTOR; DSCAM; EXPRESSION; DIVERSIFICATION; HEMOCYTES; PATTERN; GENES	The extensive somatic diversification of immune receptors is a hallmark of higher vertebrates. However, whether molecular diversity contributes to immune protection in invertebrates is unknown. We present evidence that Drosophila immune-competent cells have the potential to express more than 18,000 isoforms of the immunoglobulin (Ig)-superfamily receptor Down syndrome cell adhesion molecule (Dscam). Secreted protein isoforms of Dscam were detected in the hemolymph, and hemocyte-specific loss of Dscam impaired the efficiency of phagocytic uptake of bacteria, possibly due to reduced bacteria[ binding. Importantly, the molecular diversity of Dscam transcripts generated through a mechanism of alternative splicing is highly conserved across major insect orders, suggesting an unsuspected molecular complexity of the innate immune system of insects.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol,Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Schmucker, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol,Dept Neurobiol, Boston, MA 02115 USA.	dietmar_schmucker@dfci.harvard.edu		Rebel, Vivienne/0000-0002-3862-3903	NINDS NIH HHS [1RO1-NS46747-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS046747] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agaisse H, 2003, DEV CELL, V5, P441, DOI 10.1016/S1534-5807(03)00244-2; Azumi K, 2003, IMMUNOGENETICS, V55, P570, DOI 10.1007/s00251-003-0606-5; Cannon JP, 2004, CURR BIOL, V14, pR465, DOI 10.1016/j.cub.2004.06.009; Cuthbertson BJ, 2002, IMMUNOGENETICS, V54, P442, DOI 10.1007/s00251-002-0487-z; Daly H.V., 1998, INTRO INSECT BIOL DI; Du Pasquier L, 2004, IMMUNOL REV, V198, P233, DOI 10.1111/j.0105-2896.2004.00122.x; EZEKOWITZ A, 2003, INNATE IMMUNITY; Goto A, 2001, BIOCHEM J, V359, P99, DOI 10.1042/0264-6021:3590099; Graveley BR, 2004, RNA, V10, P1499, DOI 10.1261/rna.7105504; Holz A, 2003, DEVELOPMENT, V130, P4955, DOI 10.1242/dev.00702; Hummel T, 2003, NEURON, V37, P221, DOI 10.1016/S0896-6273(02)01183-2; Meister M, 2004, CURR OPIN IMMUNOL, V16, P10, DOI 10.1016/j.coi.2003.11.002; Meister M, 1997, BIOESSAYS, V19, P1019, DOI 10.1002/bies.950191112; Neves G, 2004, NAT GENET, V36, P240, DOI 10.1038/ng1299; Pancer Z, 2000, P NATL ACAD SCI USA, V97, P13156, DOI 10.1073/pnas.230096397; Pancer Z, 2004, NATURE, V430, P174, DOI 10.1038/nature02740; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Ramet M, 2001, IMMUNITY, V15, P1027, DOI 10.1016/S1074-7613(01)00249-7; SAMAKOVLIS C, 1990, EMBO J, V9, P2969, DOI 10.1002/j.1460-2075.1990.tb07489.x; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; Tzou P, 2002, CURR OPIN MICROBIOL, V5, P102, DOI 10.1016/S1369-5274(02)00294-1; Zhan XL, 2004, NEURON, V43, P673, DOI 10.1016/j.neuron.2004.07.020; Zhang SM, 2004, SCIENCE, V305, P251, DOI 10.1126/science.1088069	23	520	539	7	98	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 16	2005	309	5742					1874	1878		10.1126/science.1116887	http://dx.doi.org/10.1126/science.1116887			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	965ZN	16109846				2022-12-28	WOS:000231989500055
J	Santer, BD; Wigley, TML; Mears, C; Wentz, FJ; Klein, SA; Seidel, DJ; Taylor, KE; Thorne, PW; Wehner, MF; Gleckler, PJ; Boyle, JS; Collins, WD; Dixon, KW; Doutriaux, C; Free, M; Fu, Q; Hansen, JE; Jones, GS; Ruedy, R; Karl, TR; Lanzante, JR; Meehl, GA; Ramaswamy, V; Russell, G; Schmidt, GA				Santer, BD; Wigley, TML; Mears, C; Wentz, FJ; Klein, SA; Seidel, DJ; Taylor, KE; Thorne, PW; Wehner, MF; Gleckler, PJ; Boyle, JS; Collins, WD; Dixon, KW; Doutriaux, C; Free, M; Fu, Q; Hansen, JE; Jones, GS; Ruedy, R; Karl, TR; Lanzante, JR; Meehl, GA; Ramaswamy, V; Russell, G; Schmidt, GA			Amplification of surface temperature trends and variability in the tropical atmosphere	SCIENCE			English	Article							SATELLITE; RADIOSONDE	The month-to-month variability of tropical temperatures is larger in the troposphere than at Earth's surface. This amplification behavior is similar in a range of observations and climate model simulations and is consistent with basic theory. On multidecadal time scales, tropospheric amplification of surface warming is a robust feature of model simulations, but it occurs in only one observational data set. Other observations show weak, or even negative, amplification. These results suggest either that different physical mechanisms control amplification processes on monthly and decadal time scales, and models fail to capture such behavior or (more plausibly) that residual errors in several observational data sets used here affect their representation of long-term trends.	Lawrence Livermore Natl Lab, Program Climate Model Diag & Intercomparison, Livermore, CA 94550 USA; Natl Ctr Atmospher Res, Boulder, CO 80303 USA; Remote Syst Sensing, Santa Rosa, CA 95401 USA; NOAA, Air Resources Lab, Silver Spring, MD 20910 USA; UK Met Off, Hadlet Ctr Climate Predict & Res, Exeter EX1 3PB, Devon, England; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; NOAA, Geophys Fluid Dynam Lab, Princeton, NJ 08542 USA; Univ Washington, Dept Atmospher Sci, Seattle, WA 98195 USA; NASA, Goddard Inst Space Studies, New York, NY 10025 USA; NOAA, Natl Climat Data Ctr, Asheville, NC 28801 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; National Center Atmospheric Research (NCAR) - USA; National Oceanic Atmospheric Admin (NOAA) - USA; Met Office - UK; Hadley Centre; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; National Oceanic Atmospheric Admin (NOAA) - USA; University of Washington; University of Washington Seattle; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; National Center Atmospheric Research (NCAR) - USA; National Oceanic Atmospheric Admin (NOAA) - USA	Santer, BD (corresponding author), Lawrence Livermore Natl Lab, Program Climate Model Diag & Intercomparison, Livermore, CA 94550 USA.	santer1@llnl.gov	Dixon, Keith W/L-7120-2015; Schmidt, Gavin/D-4427-2012; Taylor, Karl E/F-7290-2011; Santer, Ben/ABA-1099-2021; Thorne, Peter/F-2225-2014; Jones, Gareth/H-8022-2013; Gleckler, Peter/H-4762-2012; Wehner, Michael/F-7841-2015; Santer, Benjamin D/F-9781-2011; Thorne, Peter W/R-6823-2017; Klein, Stephen A/H-4337-2016; Ramaswamy, Venkatachalam/AAJ-6265-2021; Fu, Qiang/W-5836-2019; Collins, William D/J-3147-2014; Wigley, Tom M.L./B-4705-2008; Lanzante, John R./G-7643-2019	Dixon, Keith W/0000-0003-3044-326X; Schmidt, Gavin/0000-0002-2258-0486; Taylor, Karl E/0000-0002-6491-2135; Thorne, Peter/0000-0003-0485-9798; Gleckler, Peter/0000-0003-2816-6224; Wehner, Michael/0000-0001-5991-0082; Thorne, Peter W/0000-0003-0485-9798; Klein, Stephen A/0000-0002-5476-858X; Ramaswamy, Venkatachalam/0000-0002-1984-6423; Collins, William D/0000-0002-4463-9848; Lanzante, John R./0000-0002-1736-7170; Ruedy, Reto/0000-0002-1270-1088				Christy JR, 2003, J ATMOS OCEAN TECH, V20, P613, DOI 10.1175/1520-0426(2003)20<613:EEOVOM>2.0.CO;2; FREE M, IN PRESS J GEOPHYS R; Fu Q, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL022266; Fu Q, 2004, NATURE, V429, P55, DOI 10.1038/nature02524; Gaffen DJ, 2000, SCIENCE, V287, P1242, DOI 10.1126/science.287.5456.1242; Gillett NP, 2000, CLIM DYNAM, V16, P49, DOI 10.1007/PL00007921; Hansen J, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001143; Hegerl GC, 2002, J CLIMATE, V15, P2412, DOI 10.1175/1520-0442(2002)015<2412:IOPOCV>2.0.CO;2; Hurrell JW, 1998, J CLIMATE, V11, P945, DOI 10.1175/1520-0442(1998)011<0945:DIORTT>2.0.CO;2; Jones PD, 2003, J CLIMATE, V16, P206, DOI 10.1175/1520-0442(2003)016<0206:HALSSA>2.0.CO;2; Lanzante JR, 2003, J CLIMATE, V16, P241, DOI 10.1175/1520-0442(2003)016<0241:THOMRT>2.0.CO;2; Mears CA, 2005, SCIENCE, V309, P1548, DOI 10.1126/science.1114772; Mears CA, 2003, J CLIMATE, V16, P3650, DOI 10.1175/1520-0442(2003)016<3650:AROTMC>2.0.CO;2; Meehl GA, 2000, B AM METEOROL SOC, V81, P413, DOI 10.1175/1520-0477(2000)081<0413:AITTIE>2.3.CO;2; Ramaswamy V., 2001, CLIMATE CHANGE 2001; RANDEL WJ, UNPUB; Santer BD, 2003, SCIENCE, V301, P479, DOI 10.1126/science.1084123; Santer BD, 2003, SCIENCE, V300, P1280, DOI 10.1126/science.1082393; Santer BD, 2000, SCIENCE, V287, P1227, DOI 10.1126/science.287.5456.1227; Santer BD, 1996, NATURE, V382, P39, DOI 10.1038/382039a0; Seidel DJ, 2004, J CLIMATE, V17, P2225, DOI 10.1175/1520-0442(2004)017<2225:UISOLC>2.0.CO;2; Sherwood SC, 2005, SCIENCE, V309, P1556, DOI 10.1126/science.1115640; Smith TM, 2005, J CLIMATE, V18, P2021, DOI 10.1175/JCLI3362.1; STONE PH, 1979, J ATMOS SCI, V36, P415, DOI 10.1175/1520-0469(1979)036<0415:ALRRAT>2.0.CO;2; Tett SFB, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2000JD000028; Thorne PW, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015717; THORNE PW, IN PRESS J GEOPHYS R; THORNE PW, IN PRESS B AM MET SO; WALLACE JM, 2000, RECONCILING OBSERVAT; Wentz FJ, 2000, NATURE, V403, P414, DOI 10.1038/35000184	30	225	227	1	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 2	2005	309	5740					1551	1556		10.1126/science.1114867	http://dx.doi.org/10.1126/science.1114867			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	962EY	16099951	Green Accepted, Green Submitted			2022-12-28	WOS:000231715000047
J	Locatelli, F; De Stefano, P				Locatelli, F; De Stefano, P			T-cell depletion to prevent GVHD after unrelated-donor marrow transplantation	LANCET			English	Editorial Material							VERSUS-HOST-DISEASE; IMMUNE RECONSTITUTION; LEUKEMIA REACTIONS; RECIPIENTS; IMPACT		Policlin San Matteo, IRCCS, I-27100 Pavia, Italy	IRCCS Fondazione San Matteo; University of Pavia	Locatelli, F (corresponding author), Policlin San Matteo, IRCCS, I-27100 Pavia, Italy.	f.locatelli@smatteo.pv.it						Andre-Schmutz I, 2002, LANCET, V360, P130, DOI 10.1016/S0140-6736(02)09413-8; Barrett AJ, 1996, BRIT J HAEMATOL, V93, P754, DOI 10.1046/j.1365-2141.1996.d01-1713.x; Ferrara JLM, 2003, INT J HEMATOL, V78, P181, DOI 10.1007/BF02983793; HOROWITZ MM, 1990, BLOOD, V75, P555; KEEVER CA, 1989, BLOOD, V73, P1340; KERNAN NA, 1986, BLOOD, V68, P770; KERNAN NA, 1993, NEW ENGL J MED, V328, P593, DOI 10.1056/NEJM199303043280901; Kolb HJ, 2004, BLOOD, V103, P767, DOI 10.1182/blood-2003-02-0342; Locatelli F, 1998, HAEMATOLOGICA, V83, P550; Locatelli F, 2004, BEST PRACT RES CL HA, V17, P479, DOI 10.1016/j.beha.2004.06.0054; MARANINCHI D, 1987, LANCET, V2, P175; MARMONT AM, 1991, BLOOD, V78, P2120, DOI 10.1182/blood.V78.8.2120.bloodjournal7882120; Parkman R, 1997, IMMUNOL REV, V157, P73, DOI 10.1111/j.1600-065X.1997.tb00975.x; Wagner JE, 2005, LANCET, V366, P733, DOI 10.1016/S0140-6736(05)66996-6; Zecca M, 2002, BLOOD, V100, P1192, DOI 10.1182/blood-2001-11-0059	15	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 27	2005	366	9487					692	694		10.1016/S0140-6736(05)66997-8	http://dx.doi.org/10.1016/S0140-6736(05)66997-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958UV	16125569				2022-12-28	WOS:000231474600005
J	Munakata, Y; Kodera, T; Saito, T; Sasaki, T				Munakata, Y; Kodera, T; Saito, T; Sasaki, T			Rheumatoid arthritis, type 1 diabetes, and Graves' disease after acute parvovirus B19 infection	LANCET			English	Editorial Material									Tohoku Univ, Grad Sch Med, Dept Rheumatol & Hematol, Sendai, Miyagi 9808574, Japan	Tohoku University	Munakata, Y (corresponding author), Tohoku Univ, Grad Sch Med, Dept Rheumatol & Hematol, Sendai, Miyagi 9808574, Japan.	mnkt@mail.tains.tohoku.ac.jp						Kasuga A, 1996, ANN INTERN MED, V125, P700, DOI 10.7326/0003-4819-125-8-199610150-00030; Murai C, 1999, ANN RHEUM DIS, V58, P130, DOI 10.1136/ard.58.2.130; Oguz F, 2002, J PAEDIATR CHILD H, V38, P358, DOI 10.1046/j.1440-1754.2002.00789.x; Takahashi Y, 1998, P NATL ACAD SCI USA, V95, P8227, DOI 10.1073/pnas.95.14.8227; Takasawa N, 2004, J IMMUNOL, V173, P4675, DOI 10.4049/jimmunol.173.7.4675	5	33	33	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 27	2005	366	9487					780	780		10.1016/S0140-6736(05)67184-X	http://dx.doi.org/10.1016/S0140-6736(05)67184-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958UV	16125597				2022-12-28	WOS:000231474600036
J	Class, C; Goldstein, SL				Class, C; Goldstein, SL			Evolution of helium isotopes in the Earth's mantle	NATURE			English	Article							HE-3/HE-4 RATIOS; OCEANIC BASALTS; VOLCANIC-ROCKS; EXCESS HE-3; PLUMES; GEOCHEMISTRY; CONSTRAINTS; SYSTEMATICS; CONVECTION; MODEL	Degassing of the Earth's mantle through magmatism results in the irreversible loss of helium to space, and high He-3/He-4 ratios observed in oceanic basalts have been considered the main evidence for a 'primordial' undegassed deep mantle reservoir. Here we present a new global data compilation of ocean island basalts, representing upwelling 'plumes' from the deep mantle, and show that island groups with the highest primordial signal ( high He-3/He-4 ratios) have striking chemical and isotopic similarities to mid-ocean-ridge basalts. We interpret this as indicating a common history of mantle trace element depletion through magmatism. The high He-3/He-4 in plumes may thus reflect incomplete degassing of the deep Earth during continent and ocean crust formation. We infer that differences between plumes and the upper-mantle source of ocean-ridge basalts reflect isolation of plume sources from the convecting mantle for similar to 1-2 Gyr. An undegassed, primordial reservoir in the mantle would therefore not be required, thus reconciling a long-standing contradiction in mantle dynamics.	Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA; Columbia Univ, Dept Earth & Environm Sci, Palisades, NY 10964 USA	Columbia University; Columbia University	Class, C (corresponding author), Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA.	class@ldeo.columbia.edu		Class, Cornelia/0000-0002-3429-4049				ABEDINI AA, 2004, EOS T AGU, V85; Albarede F, 1998, CHEM GEOL, V145, P413, DOI 10.1016/S0009-2541(97)00152-6; ALLEGRE CJ, 1987, EARTH PLANET SC LETT, V81, P127, DOI 10.1016/0012-821X(87)90151-8; Allegre CJ, 1996, GEOPHYS RES LETT, V23, P3555, DOI 10.1029/96GL03373; Anderson DL, 1998, P NATL ACAD SCI USA, V95, P9087, DOI 10.1073/pnas.95.16.9087; Ballentine CJ, 2002, PHILOS T ROY SOC A, V360, P2611, DOI 10.1098/rsta.2002.1083; Coltice N, 1999, EARTH PLANET SC LETT, V174, P125, DOI 10.1016/S0012-821X(99)00258-7; CRAIG H, 1975, EARTH PLANET SC LETT, V26, P125, DOI 10.1016/0012-821X(75)90079-5; CREAGER KC, 1984, J GEOPHYS RES, V89, P3031, DOI 10.1029/JB089iB05p03031; Davies GF, 1999, EARTH PLANET SC LETT, V166, P149, DOI 10.1016/S0012-821X(99)00007-2; DZIEWONSKI AM, 1987, SCIENCE, V236, P37, DOI 10.1126/science.236.4797.37; FARLEY KA, 1992, EARTH PLANET SC LETT, V111, P183, DOI 10.1016/0012-821X(92)90178-X; FARLEY KA, 1995, J GEOPHYS RES-SOL EA, V100, P3829, DOI 10.1029/94JB02913; FARLEY KA, 1995, GEOLOGY, V23, P531, DOI 10.1130/0091-7613(1995)023<0531:RCOSSI>2.3.CO;2; GOLDSTEIN SL, 1984, EARTH PLANET SC LETT, V70, P221, DOI 10.1016/0012-821X(84)90007-4; Graham DW, 2002, REV MINERAL GEOCHEM, V47, P247, DOI 10.2138/rmg.2002.47.8; GRAHAM DW, 1992, EARTH PLANET SC LETT, V110, P121, DOI 10.1016/0012-821X(92)90043-U; Grand SP., 1997, GSA TODAY, V7, P1; Hanyu T, 1997, NATURE, V390, P273, DOI 10.1038/36835; Harper CL, 1996, SCIENCE, V273, P1814, DOI 10.1126/science.273.5283.1814; HART SR, 1992, SCIENCE, V256, P517, DOI 10.1126/science.256.5056.517; HART SR, 1984, NATURE, V309, P753, DOI 10.1038/309753a0; Hauri EH, 1996, J GEOPHYS RES-SOL EA, V101, P11793, DOI 10.1029/95JB03346; HOFMANN AW, 1986, EARTH PLANET SC LETT, V79, P33, DOI 10.1016/0012-821X(86)90038-5; Hofmann AW, 1997, NATURE, V385, P219, DOI 10.1038/385219a0; HOFMANN AW, 1982, EARTH PLANET SC LETT, V57, P421, DOI 10.1016/0012-821X(82)90161-3; KELLOGG LH, 1990, EARTH PLANET SC LETT, V99, P276, DOI 10.1016/0012-821X(90)90116-F; KURZ MD, 1982, NATURE, V297, P43, DOI 10.1038/297043a0; KURZ MD, 1983, EARTH PLANET SC LETT, V66, P388, DOI 10.1016/0012-821X(83)90154-1; Lassiter JC, 2004, GEOCHEM GEOPHY GEOSY, V5, DOI 10.1029/2004GC000711; Lehnert K, 2000, GEOCHEM GEOPHY GEOSY, V1, DOI 10.1029/1999GC000026; LUPTON JE, 1975, EARTH PLANET SC LETT, V26, P133, DOI 10.1016/0012-821X(75)90080-1; Montelli R, 2004, SCIENCE, V303, P338, DOI 10.1126/science.1092485; Moreira M, 2001, EARTH PLANET SC LETT, V189, P49, DOI 10.1016/S0012-821X(01)00340-5; Morgan JP, 1999, EARTH PLANET SC LETT, V170, P215, DOI 10.1016/S0012-821X(99)00114-4; Mukhopadhyay S, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2002GC000342; ONIONS RK, 1979, J GEOPHYS RES, V84, P6091, DOI 10.1029/JB084iB11p06091; ONIONS RK, 1983, NATURE, V306, P429, DOI 10.1038/306429a0; PARMAN SW, 2004, EOS T AGU, V85; Porcelli D, 2002, REV MINERAL GEOCHEM, V47, P411, DOI 10.2138/rmg.2002.47.11; PORCELLI D, 1995, GEOCHIM COSMOCHIM AC, V59, P4921, DOI 10.1016/0016-7037(95)00336-3; Salters VJM, 2004, GEOCHEM GEOPHY GEOSY, V5, DOI 10.1029/2003GC000597; STAUDACHER T, 1982, EARTH PLANET SC LETT, V60, P389, DOI 10.1016/0012-821X(82)90075-9; Stuart FM, 2003, NATURE, V424, P57, DOI 10.1038/nature01711; Sun S.S., 1989, GEOLOGICAL SOC, V42, P313, DOI [10.1144/GSL.SP.1989.042.01.19, DOI 10.1144/GSL.SP.1989.042.01.19]; Tolstikhin I, 2005, PHYS EARTH PLANET IN, V148, P109, DOI 10.1016/j.pepi.2004.05.011; van der Hilst RD, 1999, SCIENCE, V283, P1885, DOI 10.1126/science.283.5409.1885; Wood BJ, 2001, EARTH PLANET SC LETT, V188, P59, DOI 10.1016/S0012-821X(01)00294-1; ZINDLER A, 1986, EARTH PLANET SC LETT, V79, P1, DOI 10.1016/0012-821X(86)90034-8	49	144	148	2	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 25	2005	436	7054					1107	1112		10.1038/nature03930	http://dx.doi.org/10.1038/nature03930			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	958AK	16121171				2022-12-28	WOS:000231416600035
J	Kennedy, T; Jones, R; Darnley, S; Seed, P; Wessely, S; Chalder, T				Kennedy, T; Jones, R; Darnley, S; Seed, P; Wessely, S; Chalder, T			Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							UK POPULATION; EPIDEMIOLOGY; DISORDERS; SYMPTOMS; ANXIETY; PAIN	Objective To assess the efficacy of cognitive behaviour therapy delivered in primary care for treating irritable bowel syndrome. Design Randomised controlled trial. Setting 10 general practices in London. Participants 149 patients with moderate or severe irritable bowel syndrome resistant to the antispasmodic mebeverine. Interventions Cognitive behaviour therapy delivered by trained primary care nurses plus 270 mg mebeverine taken thrice daily compared with mebeverine treatment alone. Main outcome measures Primary measures were patients' scores on the irritable bowel syndrome symptom severity scale. Secondary measures were scores on the work and social adjustment scale and the hospital anxiety and depression scale. Results Of 334 referred patients, 72 were randomised to mebeverine plus cognitive behaviour therapy and 77 to mebeverine alone. Cognitive behaviour therapy had considerable initial benefit on symptom severity compared with mebeverine alone, with a mean reduction in score of 68 points (95% confidence interval 103 to 33), with the benefit persisting at three months and six months after therapy (mean reductions 71 points (109 to 32) and 11 points (20 to 3)) but not later. Cognitive behaviour therapy also showed significant benefit on the work and social adjustment scale that was still present 12 months after therapy (mean reduction 2.8 points (5.2 to 0.4)), but had an inconsistent effect on the hospital anxiety and depression scale. Conclusion Cognitive behaviour therapy delivered by primary care nurses offered additional benefit over mebeverine alone up to six months, although the effect had waned by 12 months. Such therapy may be useful for certain patients with irritable bowel syndrome in primary care.	Kings Coll London, Guys Kings & St Thomas Sch Med, Dept Gen Practice & Primary Care, London SE11 6SP, England; Kings Coll London, Inst Psychiat, London WC2R 2LS, England	University of London; King's College London; University of London; King's College London	Jones, R (corresponding author), Kings Coll London, Guys Kings & St Thomas Sch Med, Dept Gen Practice & Primary Care, London SE11 6SP, England.	roger.jones@kcl.ac.uk	Seed, Paul T/C-4435-2008; Wessely, Simon C/A-8713-2008; Chalder, Trudie/A-5717-2011	Seed, Paul T/0000-0001-7904-7933; Chalder, Trudie/0000-0003-0775-1045; Wessely, Simon Charles/0000-0002-6743-9929				BINDER DA, 1983, INT STAT REV, V51, P279, DOI 10.2307/1402588; Boyce PM, 2003, AM J GASTROENTEROL, V98, P2209, DOI 10.1016/S0002-9270(03)00749-4; Drossman D., 1990, GASTR INT, V3, P159; Drossman DA, 2003, GASTROENTEROLOGY, V125, P19, DOI 10.1016/S0016-5085(03)00669-3; Francis CY, 1997, ALIMENT PHARM THERAP, V11, P395, DOI 10.1046/j.1365-2036.1997.142318000.x; FRISON L, 1992, STAT MED, V11, P1685, DOI 10.1002/sim.4780111304; HARVEY RF, 1983, LANCET, V1, P632; Jones RH, 1999, ALIMENT PHARM THER, V13, P1419; Kennedy TM, 1998, GUT, V43, P770, DOI 10.1136/gut.43.6.770; Kennedy TM, 2000, INT J CLIN PRACT, V54, P647; Kennedy TM, 2000, BRIT J SURG, V87, P1658, DOI 10.1046/j.1365-2168.2000.01596.x; KENNEDY TM, IN PRESS HLTH TECHNO; KETTELL J, 1992, BRIT J GEN PRACT, V42, P459; LANG PJ, 1970, J ABNORM PSYCHOL, V76, P220, DOI 10.1037/h0029875; MANNING AP, 1978, BRIT MED J, V2, P653, DOI 10.1136/bmj.2.6138.653; Marks I, 1986, BEHAV PSYCHOTHERAPY; Muller-Lissner SA, 2001, ALIMENT PHARM THER, V15, P1655, DOI 10.1046/j.1365-2036.2001.01094.x; OWENS DM, 1995, ANN INTERN MED, V122, P107, DOI 10.7326/0003-4819-122-2-199501150-00005; Poynard T, 2001, ALIMENT PHARM THER, V15, P355, DOI 10.1046/j.1365-2036.2001.00937.x; Talley NJ, 2002, LANCET, V360, P555, DOI 10.1016/S0140-6736(02)09712-X; Thompson WG., 1989, GASTROENTEROL INT, V2, P92; VANDULMEN AM, 1995, PSYCHOL MED, V25, P1011, DOI 10.1017/S0033291700037508; WHORWELL PJ, 1987, GUT, V28, P423, DOI 10.1136/gut.28.4.423; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	24	92	94	1	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	AUG 20	2005	331	7514					435	437		10.1136/bmj.38545.505764.06	http://dx.doi.org/10.1136/bmj.38545.505764.06			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958WB	16093252	Green Published, Bronze			2022-12-28	WOS:000231477800017
J	Mutton, P; Peacock, K				Mutton, P; Peacock, K			Neonatal hearing screens: Wessex re-visited	LANCET			English	Editorial Material									Childrens Hosp Westmead, Deafness Ctr, Westmead, NSW 2145, Australia	University of Sydney	Mutton, P (corresponding author), Childrens Hosp Westmead, Deafness Ctr, Westmead, NSW 2145, Australia.	patrim@chw.edu.au						FORTNUM HM, 2001, BMJ-BRIT MED J, V323, P535; Kennedy C, 2005, LANCET, V366, P660, DOI 10.1016/S0140-6736(05)67138-3; Kennedy CR, 1998, LANCET, V352, P1957; Mehl AL, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.1.e4; Moeller MP, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.3.e43; Mohr PE, 2000, INT J TECHNOL ASSESS, V16, P1120, DOI 10.1017/S0266462300103162; Yoshinaga-Itano C, 1998, PEDIATRICS, V102, P1161, DOI 10.1542/peds.102.5.1161	7	1	1	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 20	2005	366	9486					612	613		10.1016/S0140-6736(05)67116-4	http://dx.doi.org/10.1016/S0140-6736(05)67116-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958EB	16112284				2022-12-28	WOS:000231426400006
J	Pusey, PN				Pusey, PN			Freezing and melting: Action at grain boundaries	SCIENCE			English	Editorial Material							2 DIMENSIONS; PHASE-BEHAVIOR; SUSPENSIONS; TRANSITION; SPHERES; ENTROPY; ORDER		Univ Edinburgh, Sch Phys, SUPA, Edinburgh EH9 3JZ, Midlothian, Scotland	University of Edinburgh	Pusey, PN (corresponding author), Univ Edinburgh, Sch Phys, SUPA, Mayfield Rd, Edinburgh EH9 3JZ, Midlothian, Scotland.	p.n.pusey@ed.ac.uk						ACKERSON BJ, 1993, NATURE, V365, P11, DOI 10.1038/365011a0; ALDER BJ, 1957, J CHEM PHYS, V27, P1208, DOI 10.1063/1.1743957; Alsayed AM, 2005, SCIENCE, V309, P1207, DOI 10.1126/science.1112399; de Villeneuve VWA, 2005, SCIENCE, V309, P1231, DOI 10.1126/science.1113207; FRENKEL D, 1993, PHYS WORLD, V6, P24, DOI 10.1088/2058-7058/6/2/24; Gasser U, 2001, SCIENCE, V292, P258, DOI 10.1126/science.1058457; Kosterlitz JM, 1973, J PHYS C SOLID STATE, V6, P1181, DOI 10.1088/0022-3719/6/7/010; NELSON DR, 1979, PHYS REV B, V19, P2457, DOI 10.1103/PhysRevB.19.2457; PUSEY PN, 1986, NATURE, V320, P340, DOI 10.1038/320340a0; Senff H, 1999, J CHEM PHYS, V111, P1705, DOI 10.1063/1.479430; Weeks ER, 2000, SCIENCE, V287, P627, DOI 10.1126/science.287.5453.627; YOUNG AP, 1979, PHYS REV B, V19, P1855, DOI 10.1103/PhysRevB.19.1855; YOUNG DA, 1974, J CHEM PHYS, V60, P1254, DOI 10.1063/1.1681190; Zahn K, 1999, PHYS REV LETT, V82, P2721, DOI 10.1103/PhysRevLett.82.2721	14	38	40	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 19	2005	309	5738					1198	1199		10.1126/science.1116597	http://dx.doi.org/10.1126/science.1116597			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	957TE	16109873				2022-12-28	WOS:000231395400033
J	Chisari, FV				Chisari, FV			Unscrambling hepatitis C virus-host interactions	NATURE			English	Editorial Material							INFECTION; REPLICATION; CHIMPANZEES; ESCAPE; RESPONSES; EFFICACY; PROTEASE; IMMUNITY; CULTURE; GENOME	The human suffering exacted by the hepatitis C virus is enormous. Hundreds of thousands of people die each year from liver failure and cancer caused by this infection. There is no vaccine, and the available antiviral drugs are toxic, expensive and only partly effective. Progress has been hindered by the absence of cell culture and small-animal models of the infection. Nonetheless, recent advances have yielded several promising new antiviral drugs and enhanced the prospects of developing a vaccine. The recent development of a robust in vitro hepatitis C virus infection system will aid this search.	Scripps Res Inst, La Jolla, CA 92037 USA	Scripps Research Institute	Chisari, FV (corresponding author), Scripps Res Inst, La Jolla, CA 92037 USA.	fchisari@scripps.edu	Chisari, Francis V/A-3086-2008	Chisari, Francis/0000-0002-4832-1044				Alter HJ, 2000, SEMIN LIVER DIS, V20, P17, DOI 10.1055/s-2000-9505; Alter MJ, 1999, J HEPATOL, V31, P88, DOI 10.1016/S0168-8278(99)80381-X; Alter MJ, 2002, HEPATOLOGY, V36, pS93, DOI 10.1053/jhep.2002.36389; Alter MJ, 1996, EUR J GASTROEN HEPAT, V8, P319, DOI 10.1097/00042737-199604000-00005; ALTER MJ, 1997, HEPATOLOGY S1, V26, P62; Bartenschlager R, 2002, NAT REV DRUG DISCOV, V1, P911, DOI 10.1038/nrd942; Bassett SE, 2001, HEPATOLOGY, V33, P1479, DOI 10.1053/jhep.2001.24371; Bigger CB, 2004, J VIROL, V78, P13779, DOI 10.1128/JVI.78.24.13779-13792.2004; Bowen DG, 2005, J EXP MED, V201, P1709, DOI 10.1084/jem.20050808; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Foy E, 2005, P NATL ACAD SCI USA, V102, P2986, DOI 10.1073/pnas.0408707102; Foy E, 2003, SCIENCE, V300, P1145, DOI 10.1126/science.1082604; Hoofnagle JH, 2002, HEPATOLOGY, V36, pS21, DOI 10.1053/jhep.2002.36227; Kato T, 2003, GASTROENTEROLOGY, V125, P1808, DOI 10.1053/j.gastro.2003.09.023; Kato T, 2001, J MED VIROL, V64, P334, DOI 10.1002/jmv.1055; Lamarre D, 2003, NATURE, V426, P186, DOI 10.1038/nature02099; Lanford RE, 2002, VIROLOGY, V293, P1, DOI 10.1006/viro.2001.1316; Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016; Lohmann V, 1996, J HEPATOL, V24, P11; McHutchison John G, 2003, Clin Liver Dis, V7, P149, DOI 10.1016/S1089-3261(02)00077-6; Meyer-Olson D, 2004, J EXP MED, V200, P307, DOI 10.1084/jem.20040638; Mondelli MU, 2001, ANTIVIR RES, V52, P153, DOI 10.1016/S0166-3542(01)00180-2; Moradpour D, 2004, J VIROL, V78, P13278, DOI 10.1128/JVI.78.23.13278-13284.2004; Neumann AU, 1998, SCIENCE, V282, P103, DOI 10.1126/science.282.5386.103; Nevens F, 2003, HEPATOLOGY, V38, P1289, DOI 10.1053/jhep.2003.50474; Pawlotsky JM, 2003, ANTIVIR RES, V59, P1, DOI 10.1016/S0166-3542(03)00088-3; Penin F, 2004, HEPATOLOGY, V39, P5, DOI 10.1002/hep.20032; Rehermann B, 2005, NAT REV IMMUNOL, V5, P215, DOI 10.1038/nri1573; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Sarnow P, 2003, J VIROL, V77, P2801, DOI 10.1128/JVI.77.5.2801-2806.2003; SHIMIZU YK, 1994, J VIROL, V68, P1494, DOI 10.1128/JVI.68.3.1494-1500.1994; Shoukry NH, 2004, ANNU REV MICROBIOL, V58, P391, DOI 10.1146/annurev.micro.58.030603.123836; Spaulding A, 1999, PREV MED, V28, P92, DOI 10.1006/pmed.1998.0418; Strader DB, 2004, HEPATOLOGY, V39, P1147, DOI 10.1002/hep.20119; Sulkowski MS, 2000, CLIN INFECT DIS, V30, pS77, DOI 10.1086/313842; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Wieland SF, 2005, J VIROL, V79, P9369, DOI 10.1128/JVI.79.15.9369-9380.2005; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102	39	180	210	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 18	2005	436	7053					930	932		10.1038/nature04076	http://dx.doi.org/10.1038/nature04076			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955XQ	16107831	Bronze			2022-12-28	WOS:000231263900033
J	Verma, S; Marsden, PA				Verma, S; Marsden, PA			Nitric oxide-eluting polyurethanes - Vascular grafts of the future?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									St Michaels Hosp, Div Cardiac Surg, Toronto, ON M5B 1W8, Canada; St Michaels Hosp, Div Nephrol, Toronto, ON M5B 1W8, Canada; Univ Toronto, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto	Verma, S (corresponding author), St Michaels Hosp, Div Cardiac Surg, 30 Bond St, Toronto, ON M5B 1W8, Canada.		Marsden, Philip A/B-1441-2012					Jun HW, 2005, BIOMACROMOLECULES, V6, P838, DOI 10.1021/bm049419y; Loscalzo J, 2001, CIRC RES, V88, P756, DOI 10.1161/hh0801.089861; Sata M, 2002, NAT MED, V8, P403, DOI 10.1038/nm0402-403; Verma S, 2003, CIRCULATION, V108, P2054, DOI 10.1161/01.CIR.0000089191.72957.ED; Wilcox JN, 1997, ARTERIOSCL THROM VAS, V17, P2479, DOI 10.1161/01.ATV.17.11.2479	5	23	28	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 18	2005	353	7					730	731		10.1056/NEJMcibr052030	http://dx.doi.org/10.1056/NEJMcibr052030			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955UW	16107627				2022-12-28	WOS:000231254100014
J	Blazquez, MA				Blazquez, MA			The right time and place for making flowers	SCIENCE			English	Editorial Material							ARABIDOPSIS; CONSTANS; SIGNALS		Univ Politecn Valencia, CSIC, Inst Biol Mol & Celular Plantas, Valencia 46022, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universitat Politecnica de Valencia; CSIC-UPV - Instituto de Biologia Molecular y Celular de Plantas (IBMCP)	Blazquez, MA (corresponding author), Univ Politecn Valencia, CSIC, Inst Biol Mol & Celular Plantas, Valencia 46022, Spain.	clarkj@geology.wisc.edu	Blazquez, Miguel A/B-1495-2008	Blazquez, Miguel A/0000-0001-5743-0448				Abe M, 2005, SCIENCE, V309, P1052, DOI 10.1126/science.1115983; An HL, 2004, DEVELOPMENT, V131, P3615, DOI 10.1242/dev.01231; Ayre BG, 2004, PLANT PHYSIOL, V135, P2271, DOI 10.1104/pp.104.040592; BERNIER G, 1993, PLANT CELL, V5, P1147, DOI 10.1105/tpc.5.10.1147; HUANG T, 2005, SCIENCE         0811, DOI DOI 10.1126/SCIENCE.1117768; Kardailsky I, 1999, SCIENCE, V286, P1962, DOI 10.1126/science.286.5446.1962; Kobayashi Y, 1999, SCIENCE, V286, P1960, DOI 10.1126/science.286.5446.1960; Komeda Y, 2004, ANNU REV PLANT BIOL, V55, P521, DOI 10.1146/annurev.arplant.55.031903.141644; Ratcliffe OJ, 1999, DEVELOPMENT, V126, P1109; Sessions A, 2000, SCIENCE, V289, P779, DOI 10.1126/science.289.5480.779; Simpson GG, 2002, SCIENCE, V296, P285, DOI 10.1126/science.296.5566.285; Ueki S, 2001, BIOESSAYS, V23, P1087, DOI 10.1002/bies.10027; Valverde F, 2004, SCIENCE, V303, P1003, DOI 10.1126/science.1091761; Wigge PA, 2005, SCIENCE, V309, P1056, DOI 10.1126/science.1114358; Yanovsky MJ, 2003, NAT REV MOL CELL BIO, V4, P265, DOI 10.1038/nrm1077; ZEEVAART JAD, 1976, ANNU REV PLANT PHYS, V27, P321, DOI 10.1146/annurev.pp.27.060176.001541	16	33	38	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 12	2005	309	5737					1024	1025		10.1126/science.1117203	http://dx.doi.org/10.1126/science.1117203			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955MN	16099968				2022-12-28	WOS:000231230100028
J	Urton, G; Brezine, CJ				Urton, G; Brezine, CJ			Khipu accounting in ancient Peru	SCIENCE			English	Article								Khipu are knotted-string devices that were used for bureaucratic recording and communication in the Inka Empire. We recently undertook a computer analysis of 21 khipu from the Inka administrative center of Puruchuco, on the central coast of Peru. Results indicate that this khipu archive exemplifies the way in which census and tribute data were synthesized, manipulated, and transferred between different accounting levels in the Inka administrative system.	Harvard Univ, Dept Anthropol, Cambridge, MA 02138 USA	Harvard University	Urton, G (corresponding author), Harvard Univ, Dept Anthropol, Cambridge, MA 02138 USA.							de la Vega Garcilaso, 1966, ROYAL COMMENTARIES I; DEPRIMEGLIO CR, 1964, SERIACION COMO POSIB; Mackey Carol, 1970, THESIS U CALIFORNIA; SALOMON F, 2004, CORD KEEPERS KHIPUS, P252	4	37	38	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 12	2005	309	5737					1065	1067		10.1126/science.1113426	http://dx.doi.org/10.1126/science.1113426			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	955MN	16099983				2022-12-28	WOS:000231230100043
J	Bringmann, H; Hyman, AA				Bringmann, H; Hyman, AA			A cytokinesis furrow is positioned by two consecutive signals	NATURE			English	Article							SAND DOLLAR EGGS; CAENORHABDITIS-ELEGANS EMBRYO; C-ELEGANS; MITOTIC APPARATUS; SPINDLE MIDZONE; CELL-DIVISION; PROTEIN; RNAI; EMBRYOGENESIS; ORGANIZATION	The position of the cytokinesis furrow in a cell determines the relative sizes of its two daughter cells as well as the distribution of their contents. In animal cells, the position of the cytokinesis furrow is specified by the position of the mitotic spindle(1). The cytokinesis furrow bisects the spindle midway between the microtubule asters, at the site of the microtubule-based midzone, producing two daughter cells. Experiments in some cell types have suggested that the midzone positions the furrow(2,3), but experiments in other cells have suggested that the asters position the furrow(4,5). One possibility is that different organisms and cell types use different mechanisms to position the cytokinesis furrow. An alternative possibility is that both asters and the midzone contribute to furrow positioning(6,7). Recent work in C. elegans has suggested that centrosome separation and the midzone are implicated in cytokinesis(8). Here we examine the relative contributions of different parts of the mitotic spindle to positioning of the cytokinesis furrow in the C. elegans zygote. By spatially separating the spindle midzone from one of the asters using an ultraviolet laser, we show that the cytokinesis furrow is first positioned by a signal determined by microtubule asters, and then by a second signal that is derived from the spindle midzone. Thus, the position of the cytokinesis furrow is specified by two consecutive furrowing activities.	Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany	Max Planck Society	Bringmann, H (corresponding author), Max Planck Inst Mol Cell Biol & Genet, Pfotenhauer Str 108, D-01307 Dresden, Germany.	bringman@mpi-cbg.de	Hyman, Tony/F-1923-2011; Hyman, Anthony A/B-3917-2017	Hyman, Anthony A/0000-0003-3664-154X				Bonaccorsi S, 1998, J CELL BIOL, V142, P751, DOI 10.1083/jcb.142.3.751; Canman JC, 2003, NATURE, V424, P1074, DOI 10.1038/nature01860; Canman Julie C, 2004, J Cell Biol, V166, P943, DOI 10.1083/jcb.200409019; Cao LG, 1996, MOL BIOL CELL, V7, P225, DOI 10.1091/mbc.7.2.225; Dechant R, 2003, DEV CELL, V4, P333, DOI 10.1016/S1534-5807(03)00057-1; Grill SW, 2001, NATURE, V409, P630, DOI 10.1038/35054572; Grill SW, 2003, SCIENCE, V301, P518, DOI 10.1126/science.1086560; HIRAMOTO Y, 1956, EXP CELL RES, V11, P630, DOI 10.1016/0014-4827(56)90171-9; Jantsch-Plunger V, 2000, J CELL BIOL, V149, P1391, DOI 10.1083/jcb.149.7.1391; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kennedy S, 2004, NATURE, V427, P645, DOI 10.1038/nature02302; Mishima M, 2004, NATURE, V430, P908, DOI 10.1038/nature02767; Piekny AJ, 2002, J CELL SCI, V115, P2271; Raich WB, 1998, MOL BIOL CELL, V9, P2037, DOI 10.1091/mbc.9.8.2037; RAPPAPORT R, 1961, J EXP ZOOL, V148, P81, DOI 10.1002/jez.1401480107; RAPPAPORT R, 1985, J EXP ZOOL, V235, P217, DOI 10.1002/jez.1402350208; RAPPAPORT R, 1985, J EXP ZOOL, V234, P167, DOI 10.1002/jez.1402340120; RAPPAPORT R, 1996, CYTOKINESIS ANIMAL; Schumacher JM, 1998, J CELL BIOL, V143, P1635, DOI 10.1083/jcb.143.6.1635; Severson AF, 2002, CURR BIOL, V12, P2066, DOI 10.1016/S0960-9822(02)01355-6; Shelton CA, 1999, J CELL BIOL, V146, P439, DOI 10.1083/jcb.146.2.439; Simmer F, 2002, CURR BIOL, V12, P1317, DOI 10.1016/S0960-9822(02)01041-2; Sonnichsen B, 2005, NATURE, V434, P462, DOI 10.1038/nature03353; Verbrugghe KJC, 2004, CURR BIOL, V14, P1755, DOI 10.1016/j.cub.2004.09.055; Wang YL, 2001, CELL STRUCT FUNCT, V26, P633, DOI 10.1247/csf.26.633	25	166	182	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 4	2005	436	7051					731	734		10.1038/nature03823	http://dx.doi.org/10.1038/nature03823			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	951XA	16079852	Green Published			2022-12-28	WOS:000230964500050
J	Czeisler, CA; Walsh, JK; Roth, T; Hughes, RJ; Wright, KP; Kingsbury, L; Arora, S; Schwartz, JRL; Niebler, GE; Dinges, DF; Black, JE; Bogan, RK; Bonnet, MH; Carskadon, MA; Cook, JS; Corser, BC; Erman, MK; Feldman, NT; Ferguson, JM; Furman, Y; Hardy, SC; Harsh, JR; Hirshkowitz, M; Hull, SG; Mahajan, VK; Pegram, GV; Pinto, J; Richardson, GS; Rosenberg, R; Rosenthal, MH; Schmidt, MH; Schweitzer, PK; Seiden, D; Wagner, DR; Wells, CC; Wyatt, JK; Zammit, GK				Czeisler, CA; Walsh, JK; Roth, T; Hughes, RJ; Wright, KP; Kingsbury, L; Arora, S; Schwartz, JRL; Niebler, GE; Dinges, DF; Black, JE; Bogan, RK; Bonnet, MH; Carskadon, MA; Cook, JS; Corser, BC; Erman, MK; Feldman, NT; Ferguson, JM; Furman, Y; Hardy, SC; Harsh, JR; Hirshkowitz, M; Hull, SG; Mahajan, VK; Pegram, GV; Pinto, J; Richardson, GS; Rosenberg, R; Rosenthal, MH; Schmidt, MH; Schweitzer, PK; Seiden, D; Wagner, DR; Wells, CC; Wyatt, JK; Zammit, GK		US Modafinil Shift Work Sleep Diso	Modafinil for excessive sleepiness associated with shift-work sleep disorder	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DAYTIME SLEEPINESS; RANDOMIZED-TRIAL; DOSE-RESPONSE; PERFORMANCE; DEPRIVATION; WAKEFULNESS; NIGHT; PATHOPHYSIOLOGY; CONSEQUENCES; RESTRICTION	BACKGROUND: Patients with shift-work sleep disorder chronically have excessive sleepiness during night work and insomnia when attempting to sleep during the day. We evaluated the use of modafinil for treating sleepiness in patients with this disorder. METHODS: In a three-month, double-blind trial, we randomly assigned 209 patients with shift-work sleep disorder to receive either 200 mg of modafinil or placebo before the start of each shift. Assessments were performed with the use of the nighttime Multiple Sleep Latency Test, the Clinical Global Impression of Change, the Psychomotor Vigilance Test, diaries of patients, and daytime polysomnography. After randomization, we conducted monthly assessments. RESULTS: Treatment with modafinil, as compared with placebo, resulted in a modest improvement from baseline in mean (+/-SEM) nighttime sleep latency (the interval between the time a person attempts to fall asleep and the onset of sleep) (1.7+/-0.4 vs. 0.3+/-0.3 minutes, respectively; P=0.002), and more patients had improvement in their clinical symptoms (74 percent vs. 36 percent, respectively; P<0.001). Patients who were receiving modafinil also had a reduction in the frequency and duration of lapses of attention during nighttime testing of their performance on the Psychomotor Vigilance Test (change from baseline, a reduction in lapse frequency of 2.6 vs. an increase of 3.8, respectively; P<0.001), and proportionally fewer patients reported having had accidents or near accidents while commuting home (29 percent vs. 54 percent, respectively; P<0.001). Despite these benefits, patients treated with modafinil continued to have excessive sleepiness and impaired performance at night. Modafinil did not adversely affect daytime sleep as compared with placebo. Headache was the most common adverse event. CONCLUSIONS: Treatment with 200 mg of modafinil reduced the extreme sleepiness that we observed in patients with shift-work sleep disorder and resulted in a small but significant improvement in performance as compared with placebo. However, the residual sleepiness that was observed in the treated patients underscores the need for the development of interventions that are even more effective.	Harvard Univ, Sch Med, Div Sleep Med, Boston, MA USA; Brigham & Womens Hosp, Dept Med, Div Sleep Med, Boston, MA 02115 USA; St Lukes Hosp, Sleep Med Res Ctr, Chesterfield, MO USA; Henry Ford Hosp, Sleep Disorders Res Ctr, Detroit, MI 48202 USA; Cephalon, Frazer, PA USA; Univ Colorado, Dept Integrat Physiol, Sleep & Chronobiol Lab, Boulder, CO 80309 USA; Integris SW & Baptist Med Ctr, Oklahoma City, OK USA; Univ Penn, Sch Med, Dept Psychiat, Div Sleep & Chronboiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Sleep & Resp Neurobiol, Philadelphia, PA 19104 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Saint Luke's Hospital - Missouri; Henry Ford Health System; Henry Ford Hospital; Teva Pharmaceutical Industries; Cephalon Inc.; University of Colorado System; University of Colorado Boulder; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Czeisler, CA (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, 221 Longwood Ave,Suite 438, Boston, MA 02115 USA.	caczeisler@hms.harvard.edu	Dinges, David/P-7183-2019; Wyatt, James K/F-1785-2011	Czeisler, Charles Andrew/0000-0002-7408-1849; Sahota, Pradeep/0000-0002-6137-4861				Akerstedt T, 2003, OCCUP MED-OXFORD, V53, P89, DOI 10.1093/occmed/kqg046; Akerstedt T, 2005, SLEEP, V28, P9; AKERSTEDT T, 1982, SLEEP, V5, pS95, DOI 10.1093/sleep/5.S2.S95; American Academy of Sleep Medicine, 2005, ICSD INT CLASS SLEEP; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Axelsson J, 2004, INT ARCH OCC ENV HEA, V77, P121, DOI 10.1007/s00420-003-0482-1; Becker PM, 2000, NEUROLOGY, V54, P1166; Beers TM, 2000, MON LABOR REV, V123, P33; Black JE, 2005, SLEEP, V28, P464, DOI 10.1093/sleep/28.4.464; CARSKADON MA, 1987, NEUROSCI BIOBEHAV R, V11, P307, DOI 10.1016/S0149-7634(87)80016-7; CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/sleep/9.4.519; Dinges DF, 1997, SLEEP, V20, P267; Doran SM, 2001, ARCH ITAL BIOL, V139, P253; Dorrian J., 2005, THESIS, P39; Drake CL, 2004, SLEEP, V27, P1453, DOI 10.1093/sleep/27.8.1453; Guy W, 1976, ECDEU ASSESSMENT MAN, DOI DOI 10.1037/E591322011-001; Knutsson A, 2003, OCCUP MED-OXFORD, V53, P103, DOI 10.1093/occmed/kqg048; Leproult R, 2003, AM J PHYSIOL-REG I, V284, pR280, DOI 10.1152/ajpregu.00197.2002; Mitler MM, 1997, NEW ENGL J MED, V337, P755, DOI 10.1056/NEJM199709113371106; Mitler MM, 1998, ANN NEUROL, V43, P88; MITLER MM, 2000, PRINCIPLES PRACTICE, P1251; MUEHLBACH MJ, 1995, SLEEP, V18, P22, DOI 10.1093/sleep/18.1.22; Ohayon MM, 2002, J PSYCHOSOM RES, V53, P577, DOI 10.1016/S0022-3999(02)00438-5; Pack AI, 2001, AM J RESP CRIT CARE, V164, P1675, DOI 10.1164/ajrccm.164.9.2103032; Powell NB, 1999, LARYNGOSCOPE, V109, P1648, DOI 10.1097/00005537-199910000-00019; Richardson GS, 1996, J CLIN NEUROPHYSIOL, V13, P17, DOI 10.1097/00004691-199601000-00003; Saper CB, 2001, TRENDS NEUROSCI, V24, P726, DOI 10.1016/S0166-2236(00)02002-6; Van Dongen HPA, 2003, SLEEP, V26, P117, DOI 10.1093/sleep/26.2.117; Van Dongen HPA, 2004, SLEEP, V27, P423; Van Dongen HPA, 2004, SLEEP, V27, P600; WALSH JK, 1990, PSYCHOPHARMACOLOGY, V101, P271, DOI 10.1007/BF02244139; Wright KP, 2001, P NATL ACAD SCI USA, V98, P14027, DOI 10.1073/pnas.201530198; Zisapel N, 2001, CNS DRUGS, V15, P311, DOI 10.2165/00023210-200115040-00005	34	241	252	1	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 4	2005	353	5					476	486		10.1056/NEJMoa041292	http://dx.doi.org/10.1056/NEJMoa041292			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	951OB	16079371				2022-12-28	WOS:000230939000007
J	Jaar, BG; Coresh, J; Plantinga, LC; Fink, NE; Klag, MJ; Levey, AS; Levin, NW; Sadler, JH; Kliger, A; Powe, NR				Jaar, BG; Coresh, J; Plantinga, LC; Fink, NE; Klag, MJ; Levey, AS; Levin, NW; Sadler, JH; Kliger, A; Powe, NR			Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	36th Annual Meeting of the American-Society-of-Nephrology	NOV 12-17, 2003	SAN DIEGO, CA	Amer Soc Nephrol			RESIDUAL RENAL-FUNCTION; LONG-TERM CAPD; ADJUSTED MORTALITY-RATES; QUALITY-OF-LIFE; SURVIVAL; MODALITY; ADEQUACY; COMORBIDITY; CLEARANCE; THERAPY	Background: The influence of type of dialysis on survival of patients with end-stage renal disease (ESRD) is controversial. Objective: To compare risk for death among patients with ESRD who receive peritoneal dialysis or hemodialysis. Design: Prospective cohort study. Setting: 81 dialysis clinics in 19 U.S. states. Patients: 1041 patients starting dialysis (274 patients receiving peritoneal dialysis and 767 patients receiving hemodialysis) at baseline. Measurements: Patients were followed for up to 7 years and censored at transplantation or loss to follow-up. Cox proportional hazards regression stratified by clinic was used to compare the risk for death with peritoneal dialysis versus hemodialysis. Results: Twenty-five percent of patients undergoing peritoneal dialysis and 5% of hemodialysis patients switched type of dialysis. After adjustment, the risk for death did not differ between patients undergoing peritoneal dialysis and those undergoing hemodialysis during the first year (relative hazard, 1.39 [95% CI, 0.64 to 3.06]), but the risk became significantly higher among those undergoing peritoneal dialysis in the second year (relative hazard, 2.34 [CI, 1.19 to 4.59]). After stratification, the survival rate was no different for patients who had the highest propensity of being initially treated with peritoneal dialysis. Results were consistent with adjustment based on a propensity score model and in sensitivity analyses that used as-treated models and models in which switches in type of dialysis were treated as treatment failures. Results were similar but stronger in analyses that were restricted to patients who were treated only in clinics offering both types of dialysis. Limitations: Patients were not randomly assigned to their initial type of dialysis. Also, more patients undergoing peritoneal dialysis than hemodialysis switched type of dialysis over time, and the reason for switching was often a consequence of the technique. Conclusions: The risk for death in patients with ESRD undergoing dialysis depends on dialysis type. Further studies are needed to evaluate a possible survival benefit of a timely change from peritoneal dialysis to hemodialysis.	Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Sch Publ Hlth, Baltimore, MD 21218 USA; Johns Hopkins Univ, Independent Dialysis Fdn, Baltimore, MD 21218 USA; Renal Res Inst, New York, NY USA; Hosp St Raphael, New Haven, CT USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Renal Research Institute; Hospital Saint Raphael	Jaar, BG (corresponding author), Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, 2024 E Monument St,Suite 2-500, Baltimore, MD 21205 USA.	bjaar@jhmi.edu	Kliger, Alan/AAN-6653-2021; Jaar, Bernard/B-1917-2009	Jaar, Bernard/0000-0003-1210-7115	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008365] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059616, T32DK007024] Funding Source: NIH RePORTER; AHRQ HHS [HS08365] Funding Source: Medline; NHLBI NIH HHS [HL62985] Funding Source: Medline; NIDDK NIH HHS [DK59616, DK07024] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Athienites NV, 2000, SEMIN DIALYSIS, V13, P320, DOI 10.1046/j.1525-139x.2000.00095.x; Bargman JM, 2001, J AM SOC NEPHROL, V12, P2158, DOI 10.1681/ASN.V12102158; BLOEMBERGEN WE, 1995, J AM SOC NEPHROL, V6, P177; Churchill DN, 1998, J AM SOC NEPHROL, V9, P1285; Collins AJ, 1999, AM J KIDNEY DIS, V34, P1065, DOI 10.1016/S0272-6386(99)70012-0; Enia G, 2001, NEPHROL DIAL TRANSPL, V16, P1459, DOI 10.1093/ndt/16.7.1459; Fenton SSA, 1997, AM J KIDNEY DIS, V30, P334, DOI 10.1016/S0272-6386(97)90276-6; Foley RN, 1998, J AM SOC NEPHROL, V9, P267; Ganesh SK, 2003, J AM SOC NEPHROL, V14, P415, DOI 10.1097/01.ASN.0000043140.23422.4F; HELD PJ, 1994, KIDNEY INT, V45, P1163, DOI 10.1038/ki.1994.154; Kim S S, 1994, Adv Perit Dial, V10, P282; Kimak E, 2000, CLIN CHEM LAB MED, V38, P421, DOI 10.1515/CCLM.2000.061; Korevaar JC, 2003, KIDNEY INT, V64, P2222, DOI 10.1046/j.1523-1755.2003.00321.x; Kraus MA, 1996, ADV PERIT D, V12, P89; Kronenberg F, 2003, KIDNEY INT, V63, pS113, DOI 10.1046/j.1523-1755.63.s84.23.x; Lee SW, 1998, PERITON DIALYSIS INT, V18, P435; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Li PKT, 2003, ANN INTERN MED, V139, P105, DOI 10.7326/0003-4819-139-2-200307150-00010; Locatelli F, 2004, J AM SOC NEPHROL, V15, pS25, DOI 10.1097/01.ASN.0000093239.32602.04; Locatelli F, 2001, J AM SOC NEPHROL, V12, P2411, DOI 10.1681/ASN.V12112411; Mattana J, 1997, J AM SOC NEPHROL, V8, P1342; Menon MK, 2001, NEPHROL DIAL TRANSPL, V16, P2207, DOI 10.1093/ndt/16.11.2207; Miskulin DC, 2002, AM J KIDNEY DIS, V39, P324, DOI 10.1053/ajkd.2002.30552; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Rubin HR, 2004, JAMA-J AM MED ASSOC, V291, P697, DOI 10.1001/jama.291.6.697; Schafer JL, 1999, STAT METHODS MED RES, V8, P3, DOI 10.1191/096228099671525676; Stack AG, 2003, KIDNEY INT, V64, P1071, DOI 10.1046/j.1523-1755.2003.00165.x; Suda T, 2000, NEPHROL DIAL TRANSPL, V15, P396, DOI 10.1093/ndt/15.3.396; Takeda K, 1998, AM J KIDNEY DIS, V32, P482, DOI 10.1053/ajkd.1998.v32.pm9740166; Tanna MM, 2000, AM J KIDNEY DIS, V36, P1175, DOI 10.1053/ajkd.2000.19832; Termorshuizen F, 2003, J AM SOC NEPHROL, V14, P2851, DOI 10.1097/01.ASN.0000091585.45723.9E; Termorshuizen F, 2003, AM J KIDNEY DIS, V41, P1293, DOI 10.1016/S0272-6386(03)00362-7; *US REN DAT SYST, 1999, US REN DAT SYST 1999; *US REN DAT SYST, 2003, US REN DAT SYST 2003; Van Biesen W, 2000, J AM SOC NEPHROL, V11, P116, DOI 10.1681/ASN.V111116; Winkelmayer WC, 2002, J AM SOC NEPHROL, V13, P2353, DOI 10.1097/01.ASN.0000025785.41314.76; Wolfe RA, 1999, NEW ENGL J MED, V341, P1725, DOI 10.1056/NEJM199912023412303; Wu AW, 2004, J AM SOC NEPHROL, V15, P743, DOI 10.1097/01.ASN.0000113315.81448.CA; Xue JL, 2002, KIDNEY INT, V61, P741, DOI 10.1046/j.1523-1755.2002.00176.x	39	238	245	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 2	2005	143	3					174	183		10.7326/0003-4819-143-3-200508020-00003	http://dx.doi.org/10.7326/0003-4819-143-3-200508020-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	951TM	16061915				2022-12-28	WOS:000230953900002
J	Welch, HG; Woloshin, S; Schwartz, LM				Welch, HG; Woloshin, S; Schwartz, LM			Skin biopsy rates and incidence of melanoma: population based ecological study	BRITISH MEDICAL JOURNAL			English	Article							HISTOPATHOLOGIC DIAGNOSIS; INCREASED SURVEILLANCE; PROSTATE-CANCER; EPIDEMIC; NEUROBLASTOMA; CARCINOMA; SEXTANT	Objectives To describe changes in skin biopsy rates and to determine their relation to changes in the incidence of melanoma. Design Population based ecological study. Setting Nine geographical areas of the United States. Participants Participants of the Surveillance Epidemiology and End Results (SEER) programme aged 65 and older. Main outcome measures For the period 1986 to 2001, annual skin biopsy rates for each surveillance area from Medicare claims and incidence rates for melanoma for the same population. Results Between 1986 and 2001 the average biopsy rate across the nine participating areas increased 2.5-fold among people aged 65 and older (2847 to 7222 per 100 000 population). Over the same period the average incidence of melanoma increased 2.4-fold (45 to 108 per 100 000 population). Assuming that the occurrence of true disease was constant, the extra number of melanoma cases that were diagnosed after carrying out 1000 additional biopsies was 12.6 (95% confidence interval 11.2 to 14.0). After controlling for a potential increase in the true occurrence of disease, 1000 additional biopsies were still associated with 6.9 (3.1 to 10.8) extra melanoma cases diagnosed. Stage specific analyses suggested that 1000 biopsies were associated with 4.4 (2.1 to 6.8) extra cases of in situ melanoma diagnosed and 2.3 (0.0 to 4.6) extra cases of local melanoma, but not with the incidence of advanced melanoma. Mortality from melanoma changed little during the period. Conclusion The incidence of melanoma is associated with biopsy rates. That the extra cases diagnosed were confined to early stage cancer while mortality remained stable suggests overdiagnosis-the increased incidence being largely the result of increased diagnostic scrutiny and not an increase in the incidence of disease.	Dept Vet Affairs Med Ctr, VA Outcomes Grp, White River Jct, VT 05009 USA	VA Outcomes Group	Welch, HG (corresponding author), Dartmouth Coll Sch Med, Ctr Evaluat Clin Sci, Hanover, NH 03755 USA.	H.Gilbert.Welch@dartmouth.edu		Welch, H. Gilbert/0000-0002-3448-1207	NIA NIH HHS [P01 AG019783-05, P01 AG19783-01, P01 AG019783] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG019783] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], SURV RES PROGR; Arnold PM, 2001, UROL ONCOL, V6, P91; Babaian RJ, 2000, J UROLOGY, V163, P152, DOI 10.1016/S0022-5347(05)67993-1; Beddingfield FC, 2003, ONCOLOGIST, V8, P459, DOI 10.1634/theoncologist.8-5-459; BURTON RC, 1994, MELANOMA RES, V4, P107, DOI 10.1097/00008390-199404000-00005; BURTON RC, 1993, INT J CANCER, V55, P765, DOI 10.1002/ijc.2910550512; Corona R, 1996, J CLIN ONCOL, V14, P1218, DOI 10.1200/JCO.1996.14.4.1218; Durkan GC, 2002, BJU INT, V89, P33, DOI 10.1046/j.1464-410X.2002.02555.x; Eskew LA, 1997, J UROLOGY, V157, P199, DOI 10.1016/S0022-5347(01)65322-9; Farmer ER, 1996, HUM PATHOL, V27, P528, DOI 10.1016/S0046-8177(96)90157-4; Fleshner N, 2002, UROLOGY, V60, P93, DOI 10.1016/S0090-4295(02)01625-4; Florez A, 2004, INT J DERMATOL, V43, P405, DOI 10.1111/j.1365-4632.2004.02004.x; HIATT RA, 1986, PREV MED, V15, P652, DOI 10.1016/0091-7435(86)90070-8; *NAT CANC I, 2004, SURV RES PROGR; Schilling FH, 2002, NEW ENGL J MED, V346, P1047, DOI 10.1056/NEJMoa012277; Sone S, 1998, LANCET, V351, P1242, DOI 10.1016/S0140-6736(97)08229-9; Spouge AR, 1996, J ULTRAS MED, V15, P763; Swerlick RA, 1997, MAYO CLIN PROC, V72, P559, DOI 10.4065/72.6.559; Swerlick RA, 1996, ARCH DERMATOL, V132, P881, DOI 10.1001/archderm.132.8.881; Weinstock MA, 1997, ARCH DERMATOL, V133, P953, DOI 10.1001/archderm.133.8.953; Woods WG, 2002, NEW ENGL J MED, V346, P1041, DOI 10.1056/NEJMoa012387; Zahl PH, 2004, BMJ-BRIT MED J, V328, P921, DOI 10.1136/bmj.38044.666157.63	22	220	222	0	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	SEP 3	2005	331	7515					481	484B		10.1136/bmj.38516.649537.E0	http://dx.doi.org/10.1136/bmj.38516.649537.E0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	963RA	16081427	Green Published, Bronze			2022-12-28	WOS:000231820400014
J	Andersen, LO				Andersen, LO			Historical keywords - Imagination	LANCET			English	Editorial Material									Univ Copenhagen, Med Museion, DK-1168 Copenhagen, Denmark	University of Copenhagen	Andersen, LO (corresponding author), Univ Copenhagen, Med Museion, DK-1168 Copenhagen, Denmark.	lars_ole_andersen@hotmail.com		Andersen, Lars Ole/0000-0001-5805-6806					0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 27	2005	366	9487					709	709		10.1016/S0140-6736(05)67163-2	http://dx.doi.org/10.1016/S0140-6736(05)67163-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958UV	16125577				2022-12-28	WOS:000231474600014
J	Bendor, D; Wang, XQ				Bendor, D; Wang, XQ			The neuronal representation of pitch in primate auditory cortex	NATURE			English	Article							HARMONIC COMPLEX TONES; TONOTOPIC ORGANIZATION; MONGOLIAN GERBIL; PERIODICITY; PERCEPTION; MONKEY; CONNECTIONS; FREQUENCY; SALIENCE; NOISE	Pitch perception is critical for identifying and segregating auditory objects(1), especially in the context of music and speech. The perception of pitch is not unique to humans and has been experimentally demonstrated in several animal species(2,3). Pitch is the subjective attribute of a sound's fundamental frequency (f(0)) that is determined by both the temporal regularity and average repetition rate of its acoustic waveform. Spectrally dissimilar sounds can have the same pitch if they share a common f(0). Even when the acoustic energy at f(0) is removed ('missing fundamental') the same pitch is still perceived(1). Despite its importance for hearing, how pitch is represented in the cerebral cortex is unknown. Here we show the existence of neurons in the auditory cortex of marmoset monkeys that respond to both pure tones and missing fundamental harmonic complex sounds with the same f(0), providing a neural correlate for pitch constancy(1). These pitch-selective neurons are located in a restricted low-frequency cortical region near the anterolateral border of the primary auditory cortex, and is consistent with the location of a pitch-selective area identified in recent imaging studies in humans(4,5).	Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Lab Auditory Neurophysiol, Baltimore, MD 21025 USA	Johns Hopkins University	Bendor, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Lab Auditory Neurophysiol, Baltimore, MD 21025 USA.	dbendor@bme.jhu.edu; xwang@bme.jhu.edu		Bendor, Daniel/0000-0001-6621-793X	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [F31DC006528, R01DC003180] Funding Source: NIH RePORTER; NIDCD NIH HHS [F31 DC006528, R01 DC003180] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Cariani PA, 1996, J NEUROPHYSIOL, V76, P1698, DOI 10.1152/jn.1996.76.3.1698; Cedolin L, 2005, J NEUROPHYSIOL, V94, P347, DOI 10.1152/jn.01114.2004; EPPLE G, 1968, FOLIA PRIMATOL BASEL, V8, P40; Fay R. R., 1988, HEARING VERTEBRATES; Fishman YI, 1998, BRAIN RES, V786, P18, DOI 10.1016/S0006-8993(97)01423-6; GOLDSTEIN JL, 1973, J ACOUST SOC AM, V54, P1496, DOI 10.1121/1.1914448; HEFFNER H, 1976, J ACOUST SOC AM, V59, P915, DOI 10.1121/1.380951; Langner G, 1997, J COMP PHYSIOL A, V181, P665, DOI 10.1007/s003590050148; Lu T, 2001, NAT NEUROSCI, V4, P1131, DOI 10.1038/nn737; McAlpine D, 2004, J NEUROPHYSIOL, V92, P1295, DOI 10.1152/jn.00034.2004; Moore B., 2003, INTRO PSYCHOL HEARIN; MOREL A, 1993, J COMP NEUROL, V335, P437, DOI 10.1002/cne.903350312; MOREL A, 1992, J COMP NEUROL, V318, P27, DOI 10.1002/cne.903180104; PANTEV C, 1989, SCIENCE, V246, P486, DOI 10.1126/science.2814476; Patterson RD, 2002, NEURON, V36, P767, DOI 10.1016/S0896-6273(02)01060-7; Penagos H, 2004, J NEUROSCI, V24, P6810, DOI 10.1523/JNEUROSCI.0383-04.2004; POLLACK I, 1968, J ACOUST SOC AM, V43, P308, DOI 10.1121/1.1910780; Pressnitzer D., 2001, PHYSL PSYCHOPHYSICAL, P97; Rauschecker JP, 2004, J NEUROPHYSIOL, V91, P2578, DOI 10.1152/jn.00834.2003; RITSMA RJ, 1962, J ACOUST SOC AM, V34, P1224, DOI 10.1121/1.1918307; Schouten J. F., 1940, P K NED AKAD WETENSC, V43, P991; Schulze H, 2002, EUR J NEUROSCI, V15, P1077, DOI 10.1046/j.1460-9568.2002.01935.x; Schulze H, 1997, J COMP PHYSIOL A, V181, P651, DOI 10.1007/s003590050147; SCHWARZ DWF, 1990, J NEUROPHYSIOL, V64, P282, DOI 10.1152/jn.1990.64.1.282; Suga N., 1994, COGNITIVE NEUROSCIEN, P295; TOMLINSON RWW, 1988, J ACOUST SOC AM, V84, P560, DOI 10.1121/1.396833; Warrier CM, 2004, BRAIN, V127, P1616, DOI 10.1093/brain/awh183; WHITFIELD IC, 1980, J ACOUST SOC AM, V67, P644, DOI 10.1121/1.383889; Yost WA, 1998, J ACOUST SOC AM, V104, P2349, DOI 10.1121/1.423746; ZATORRE RJ, 1988, J ACOUST SOC AM, V84, P566, DOI 10.1121/1.396834	30	395	406	5	79	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 25	2005	436	7054					1161	1165		10.1038/nature03867	http://dx.doi.org/10.1038/nature03867			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	958AK	16121182	Green Accepted			2022-12-28	WOS:000231416600047
J	Richards, TA; Cavalier-Smith, T				Richards, TA; Cavalier-Smith, T			Myosin domain evolution and the primary divergence of eukaryotes	NATURE			English	Article							RNA-POLYMERASE-II; PHYLOGENETIC ANALYSIS; CLASSIFICATION; TREE; PROTEINS; SEQUENCE; DATABASE; PROTOZOA; AMOEBOZOA; RELATIVES	Eukaryotic cells have two contrasting cytoskeletal and ciliary organizations. The simplest involves a single cilium-bearing centriole, nucleating a cone of individual microtubules ( probably ancestral for unikonts: animals, fungi, Choanozoa and Amoebozoa). In contrast, bikonts ( plants, chromists and all other protozoa) were ancestrally biciliate with a younger anterior cilium, converted every cell cycle into a dissimilar posterior cilium and multiple ciliary roots of microtubule bands. Here we show by comparative genomic analysis that this fundamental cellular dichotomy also involves different myosin molecular motors. We found 37 different protein domain combinations, often lineage-specific, and many previously unidentified. The sequence phylogeny and taxonomic distribution of myosin domain combinations identified five innovations that strongly support unikont monophyly and the primary bikont/unikont bifurcation. We conclude that the eukaryotic cenancestor ( last common ancestor) had a cilium, mitochondria, pseudopodia, and myosins with three contrasting domain combinations and putative functions.	Nat Hist Museum, Dept Zool, London SW7 5BD, England; Univ Oxford, Dept Zool, Oxford OX1 3PS, England	Natural History Museum London; University of Oxford	Richards, TA (corresponding author), Univ Exeter, Sch Biol & Chem Sci, Washington Singer Labs, Perry Rd, Exeter EX4 4QG, Devon, England.	thomr@nhm.ac.uk		Richards, Thomas/0000-0002-9692-0973				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bahler M, 2000, BBA-MOL CELL RES, V1496, P52, DOI 10.1016/S0167-4889(00)00008-2; BALDAUF SL, 1993, P NATL ACAD SCI USA, V90, P11558, DOI 10.1073/pnas.90.24.11558; Bapteste E, 2002, MOL BIOL EVOL, V19, P972, DOI 10.1093/oxfordjournals.molbev.a004156; Bapteste E, 2002, P NATL ACAD SCI USA, V99, P1414, DOI 10.1073/pnas.032662799; Bass D, 2005, PROTIST, V156, P149, DOI 10.1016/j.protis.2005.03.001; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Berney C, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-13; Bolivar I, 2001, MOL BIOL EVOL, V18, P2306, DOI 10.1093/oxfordjournals.molbev.a003777; Cavalier-Smith T, 2002, INT J SYST EVOL MICR, V52, P297, DOI 10.1099/00207713-52-2-297; Cavalier-Smith T, 2004, P ROY SOC B-BIOL SCI, V271, P1251, DOI 10.1098/rspb.2004.2705; Cavalier-Smith T, 2004, EUR J PROTISTOL, V40, P21, DOI 10.1016/j.ejop.2003.10.001; Cavalier-Smith T, 2003, EUR J PROTISTOL, V39, P338, DOI 10.1078/0932-4739-00002; Cavalier-Smith T, 2003, PROTIST, V154, P341, DOI 10.1078/143446103322454112; CAVALIERSMITH T, 1991, BIOSYSTEMS, V25, P25, DOI 10.1016/0303-2647(91)90010-I; D'Aquino JA, 2003, J BACTERIOL, V185, P4081, DOI 10.1128/JB.185.14.4081-4086.2003; Dacks JB, 2002, MOL BIOL EVOL, V19, P830, DOI 10.1093/oxfordjournals.molbev.a004140; Felsenstein J., 1995, PHYLIP; Furusawa T, 2000, BIOCHEM BIOPH RES CO, V270, P67, DOI 10.1006/bbrc.2000.2377; GOODSON HV, 1993, P NATL ACAD SCI USA, V90, P659, DOI 10.1073/pnas.90.2.659; Hirt RP, 1999, P NATL ACAD SCI USA, V96, P580, DOI 10.1073/pnas.96.2.580; Hodge T, 2000, J CELL SCI, V113, P3353; Kudryavtsev A, 2005, PROTIST, V156, P215, DOI 10.1016/j.protis.2005.03.003; Kull FJ, 1998, J MUSCLE RES CELL M, V19, P877, DOI 10.1023/A:1005489907021; Lang BF, 2002, CURR BIOL, V12, P1773, DOI 10.1016/S0960-9822(02)01187-9; Leipe DD, 2002, J MOL BIOL, V317, P41, DOI 10.1006/jmbi.2001.5378; Marchler-Bauer A, 2003, NUCLEIC ACIDS RES, V31, P383, DOI 10.1093/nar/gkg087; Matsuzaki M, 2004, NATURE, V428, P653, DOI 10.1038/nature02398; Milyutina IA, 2001, GENE, V272, P131, DOI 10.1016/S0378-1119(01)00556-X; Minotto L, 2000, EXP PARASITOL, V95, P54, DOI 10.1006/expr.2000.4507; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502; Sellers J. R., 1999, MYOSINS; Simpson AGB, 2004, CURR BIOL, V14, pR693, DOI 10.1016/j.cub.2004.08.038; Stechmann A, 2003, CURR BIOL, V13, pR665, DOI 10.1016/S0960-9822(03)00602-X; Stechmann A, 2002, SCIENCE, V297, P89, DOI 10.1126/science.1071196; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Thompson RF, 2002, ANAT RECORD, V268, P276, DOI 10.1002/ar.10160; Titus MA, 1999, CURR BIOL, V9, P1297, DOI 10.1016/S0960-9822(00)80051-2; Tuxworth RI, 2001, CURR BIOL, V11, P318, DOI 10.1016/S0960-9822(01)00097-5	41	299	319	2	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 25	2005	436	7054					1113	1118		10.1038/nature03949	http://dx.doi.org/10.1038/nature03949			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	958AK	16121172				2022-12-28	WOS:000231416600036
J	Valdes, AM; Andrew, T; Gardner, JP; Kimura, M; Oelsner, E; Cherkas, LF; Aviv, A; Spector, TD				Valdes, AM; Andrew, T; Gardner, JP; Kimura, M; Oelsner, E; Cherkas, LF; Aviv, A; Spector, TD			Obesity, cigarette smoking, and telomere length in women	LANCET			English	Article							OXIDATIVE STRESS	Obesity and smoking are important risk factors for many age-related diseases. Both are states of heightened oxidative stress, which increases the rate of telomere erosion per replication, and inflammation, which enhances white blood cell turnover. Together, these processes might accelerate telomere erosion with age. We therefore tested the, hypothesis that increased body mass and smoking are associated with shortened telomere length in white blood cells. We investigated 1122 white women aged 18-76 years and found that telomere length decreased steadily with age at a mean rate of 27 bp per year. Telomeres of obese women were 240 bp shorter than those of lean women (p=0.026). A dose-dependent relation with smoking was recorded (p=0.017), and each pack-year smoked was equivalent to an additional 5 bp of telomere length lost (18%) compared with the rate in the overall cohort. Our results emphasise the pro-ageing effects of obesity and cigarette smoking.	St Thomas Hosp, Twin Res & Genet Epidemiol Unit, London, England; Univ Med & Dent New Jersey, Hypertens Res Ctr, Newark, NJ 07103 USA	Guy's & St Thomas' NHS Foundation Trust; Rutgers State University New Brunswick; Rutgers State University Medical Center	Spector, TD (corresponding author), St Thomas Hosp, Twin Res & Genet Epidemiol Unit, London, England.	tim.spector@kcl.ac.uk	Spector, Tim D/F-6533-2012; Andrew, Toby/O-8868-2017	Valdes, Ana M./0000-0003-1141-4471; Andrew, Toby/0000-0001-8838-4384; Cooper, Cyrus/0000-0003-3510-0709	NATIONAL INSTITUTE ON AGING [R01AG021593] Funding Source: NIH RePORTER; NIA NIH HHS [AG021593] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Wellcome Trust(Wellcome TrustEuropean Commission)		Andrew T, 2001, Twin Res, V4, P464, DOI 10.1375/1369052012803; AVIV A, TELOMERES HUMAN AGIN; Beltowski J, 2003, ATHEROSCLEROSIS, V170, P21, DOI 10.1016/S0021-9150(03)00236-3; Benetos A, 2001, HYPERTENSION, V37, P381, DOI 10.1161/01.HYP.37.2.381; Burke A, 2003, PROG CARDIOVASC DIS, V46, P79, DOI 10.1016/S0033-0620(03)00076-8; Dandona P, 2004, TRENDS IMMUNOL, V25, P4, DOI 10.1016/j.it.2003.10.013	6	1021	1051	3	73	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 20	2005	366	9486					662	664		10.1016/S0140-6736(05)66630-5	http://dx.doi.org/10.1016/S0140-6736(05)66630-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958EB	16112303				2022-12-28	WOS:000231426400030
J	van den Bent, MJ				van den Bent, MJ			Surgical resection improves outcome in metastatic epidural spinal cord compression	LANCET			English	Editorial Material									Daniel den Hoed Oncol Ctr, Neurooncol Unit, NL-3008 AE Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute	van den Bent, MJ (corresponding author), Daniel den Hoed Oncol Ctr, Neurooncol Unit, NL-3008 AE Rotterdam, Netherlands.	m.vandenbent@erasmusmc.nl		van den Bent, Martin/0000-0001-5710-5127				GILBERT RW, 1978, ANN NEUROL, V3, P40, DOI 10.1002/ana.410030107; Helweg-Larsen S, 2000, INT J RADIAT ONCOL, V46, P1163, DOI 10.1016/S0360-3016(99)00333-8; Patchell RA, 2005, LANCET, V366, P643, DOI 10.1016/S0140-6736(05)66954-1; Sundaresan N, 2002, SPINE, V27, P1802, DOI 10.1097/00007632-200208150-00021; YOUNG RF, 1980, J NEUROSURG, V53, P741, DOI 10.3171/jns.1980.53.6.0741	5	20	20	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 20	2005	366	9486					609	610		10.1016/S0140-6736(05)66955-3	http://dx.doi.org/10.1016/S0140-6736(05)66955-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958EB	16112282				2022-12-28	WOS:000231426400004
J	Scholz, H; Franz, M; Heberlein, U				Scholz, H; Franz, M; Heberlein, U			The hangover gene defines a stress pathway required for ethanol tolerance development	NATURE			English	Article							ALCOHOL TOLERANCE; OXIDATIVE STRESS; DROSOPHILA; EXPRESSION; OCTOPAMINE; RESISTANCE; ADDICTION; OXIDANTS; BRAIN	Repeated alcohol consumption leads to the development of tolerance, simply defined as an acquired resistance to the physiological and behavioural effects of the drug. This tolerance allows increased alcohol consumption, which over time leads to physical dependence and possibly addiction(1-3). Previous studies have shown that Drosophila develop ethanol tolerance, with kinetics of acquisition and dissipation that mimic those seen in mammals. This tolerance requires the catecholamine octopamine, the functional analogue of mammalian noradrenaline(4). Here we describe a new gene, hangover, which is required for normal development of ethanol tolerance. hangover flies are also defective in responses to environmental stressors, such as heat and the free-radical-generating agent paraquat. Using genetic epistasis tests, we show that ethanol tolerance in Drosophila relies on two distinct molecular pathways: a cellular stress pathway defined by hangover, and a parallel pathway requiring octopamine. hangover encodes a large nuclear zinc-finger protein, suggesting a role in nucleic acid binding. There is growing recognition that stress, at both the cellular and systemic levels, contributes to drug- and addiction-related behaviours in mammals. Our studies suggest that this role may be conserved across evolution.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Neurosci, San Francisco, CA 94143 USA; Univ Wurzburg, Biozentrum, D-97074 Wurzburg, Germany	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Wurzburg	Scholz, H (corresponding author), Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.	henrike.scholz@biozentrum.uni-wuerzburg.de; ulrike@itsa.ucsf.edu	Scholz, Henrike/ABE-1063-2020		NIAAA NIH HHS [R01 AA010035] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010035] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ARKING R, 1991, DEV GENET, V12, P362, DOI 10.1002/dvg.1020120505; BRAND AH, 1993, DEVELOPMENT, V118, P401; Fadda F, 1998, PROG NEUROBIOL, V56, P385, DOI 10.1016/S0301-0082(98)00032-X; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560; Le A. D., 1996, PHARM TOXIC, P251; LEGRAIN P, 1990, EMBO J, V9, P2775, DOI 10.1002/j.1460-2075.1990.tb07465.x; Min KT, 1997, CURR BIOL, V7, P885, DOI 10.1016/S0960-9822(06)00378-2; MLODZIK M, 1992, METHODS NEUROSCIENCE, V9, P397; Monastirioti M, 1996, J NEUROSCI, V16, P3900; Moore MS, 1998, CELL, V93, P997, DOI 10.1016/S0092-8674(00)81205-2; Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570; PIPER PW, 1995, FEMS MICROBIOL LETT, V134, P121, DOI 10.1016/0378-1097(95)00431-9; Scholz H, 2000, NEURON, V28, P261, DOI 10.1016/S0896-6273(00)00101-X; Schwaerzel M, 2003, J NEUROSCI, V23, P10495, DOI 10.1523/jneurosci.23-33-10495.2003; Singh CM, 2000, ALCOHOL CLIN EXP RES, V24, P1127, DOI 10.1111/j.1530-0277.2000.tb02075.x; Sun AY, 2001, ALCOHOL CLIN EXP RES, V25, p237S, DOI 10.1097/00000374-200105051-00038; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; TABAKOFF B, 1986, ANN EMERG MED, V15, P1005, DOI 10.1016/S0196-0644(86)80119-6; Torroja L, 1999, CURR BIOL, V9, P489, DOI 10.1016/S0960-9822(99)80215-2; Walter HJ, 1999, NEUROCHEM INT, V35, P95, DOI 10.1016/S0197-0186(99)00050-9; WEBER KE, 1990, GENETICS, V125, P585; WILKE N, 1994, EXS, V71, P49	23	95	98	0	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 11	2005	436	7052					845	847		10.1038/nature03864	http://dx.doi.org/10.1038/nature03864			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953XG	16094367	Green Accepted			2022-12-28	WOS:000231116500045
J	Hviid, A; Wohlfahrt, J; Stellfeld, M; Melbye, M				Hviid, A; Wohlfahrt, J; Stellfeld, M; Melbye, M			Childhood vaccination and nontargeted infectious disease hospitalization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNIZATION; SURVIVAL; RISK; GUINEA; HEALTH	Context It has been hypothesized that multiple-antigen vaccines, such as measles-mumps-rubella vaccine, or aggregated vaccine exposure could lead to immune dysfunction, resulting in nontargeted infectious diseases as a result of an "overload" mechanism. Objective To evaluate the relationship between routinely administered childhood vaccines (Haemophilus influenzae type b; diphtheria-tetanus-inactivated poliovirus; diphtheria-tetanus-acellular pertussis-inactivated poliovirus; whole-cell pertussis; measles-mumps-rubella; oral poliovirus) and hospitalization for nontargeted infectious diseases. Design, Setting, and Participants Population-based cohort comprising all children born in Denmark from 1990 through 2001 (N = 805 206). Longitudinal information was collected on type and number of vaccine doses received and hospitalization with infectious diseases, specifically acute upper respiratory tract infection, viral and bacterial pneumonia, septicemia, viral central nervous system infection, bacterial meningitis, and diarrhea. Main Outcome Measures Rate ratios for each type of infectious disease according to vaccination status. Results During 2 900 463 person-years of follow-up, 84 317 cases of infectious disease hospitalization were identified. Out of 42 possible associations (6 vaccines and 7 infectious disease categories), the only adverse association was for Haemophilus influenzae type b vaccine and acute upper respiratory tract infection (rate ratio, 1.05; 95% confidence interval, 1.01-1.08 comparing vaccinated participants with unvaccinated participants). This one adverse association of 42 possible outcomes was within the limits of what would be expected by chance alone and the effect was not temporal or dose-response. When considering aggregated vaccine exposure, we found no adverse associations between an increasing number of vaccinations and infectious diseases. Conclusion These results do not support the hypotheses that multiple-antigen vaccines or aggregated vaccine exposure increase the risk of nontargeted infectious disease hospitalization.	Statens Serum Inst, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark; Statens Serum Inst, Dept Med, DK-2300 Copenhagen, Denmark	Statens Serum Institut; Statens Serum Institut	Hviid, A (corresponding author), Statens Serum Inst, Dept Epidemiol Res, Artillerivej 5, DK-2300 Copenhagen, Denmark.	aii@ssi.dk	Hviid, Anders/AAH-4319-2020	Hviid, Anders/0000-0002-7509-9127; melbye, mads/0000-0001-8264-6785				Andersen TF, 1999, DAN MED BULL, V46, P263; [Anonymous], 2002, IMMUNIZATION SAFETY; BLACK SB, 1991, AM J DIS CHILD, V145, P746; Breiman RF, 2004, LANCET, V364, P2204, DOI 10.1016/S0140-6736(04)17593-4; BURSTEIN JL, 1994, PEDIATR EMERG CARE, V10, P138, DOI 10.1097/00006565-199406000-00004; DAVIDSON M, 1991, AM J DIS CHILD, V145, P750; GRIFFIN MR, 1992, PEDIATRICS, V89, P640; Hills, 1993, STAT MODELS EPIDEMIO; Hviid A, 2004, NEW ENGL J MED, V350, P1398, DOI 10.1056/NEJMoa032665; Knudsen LB, 1998, DAN MED BULL, V45, P320; Kristensen I, 2000, BRIT MED J, V321, P1435, DOI 10.1136/bmj.321.7274.1435; Lehmann D, 2005, INT J EPIDEMIOL, V34, P138, DOI 10.1093/ije/dyh262; Madsen KM, 2002, NEW ENGL J MED, V347, P1477, DOI 10.1056/NEJMoa021134; MADSEN KM, 2004, THESIS AARHUS U AARH; MALIG C, 1996, 66 IIVRS; Miller E, 2003, ARCH DIS CHILD, V88, P222, DOI 10.1136/adc.88.3.222; Otto S, 2000, J INFECTION, V41, P172, DOI 10.1053/jinf.2000.0718; Vaugelade J, 2004, BRIT MED J, V329, P1309, DOI 10.1136/bmj.38261.496366.82; *WHO, 2004, TASK FORC ROUT INF V	19	16	19	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	2005	294	6					699	705		10.1001/jama.294.6.699	http://dx.doi.org/10.1001/jama.294.6.699			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	953IA	16091572				2022-12-28	WOS:000231068600023
J	Avenell, A; Campbell, MK; Cook, JA; Hannaford, PC; Kilonzo, MM; McNeill, G; Milne, AC; Ramsay, CR; Seymour, DG; Stephen, AI; Vale, LD				Avenell, A; Campbell, MK; Cook, JA; Hannaford, PC; Kilonzo, MM; McNeill, G; Milne, AC; Ramsay, CR; Seymour, DG; Stephen, AI; Vale, LD		Writing Grp MAVIS Trial	Effect of multivitamin and multimineral supplements on morbidity from infections in older people (MAVIS trial): pragmatic, randomised, double blind, placebo controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY-TRACT INFECTIONS; IMMUNE-RESPONSES; ELDERLY SUBJECTS; VITAMIN-E; IMPACT	Objective To examine whether supplementation with multivitamins and multiminerals influences self reported days of infection, use of health services, and quality of life in people aged 65 or over. Design Randomised, placebo controlled trial, with blinding of participants, outcome assessors, and investigators. Setting Communities associated with six general practices in Grampian, Scotland. Participants 910 men and women aged 65 or over who did not take vitamins or minerals. Interventions Daily multivitamin and multimineral supplementation or placebo for one year. Main outcome measures Primary outcomes were contacts with primary care for infections, self reported days of infection, and quality of life. Secondary outcomes included antibiotic prescriptions, hospital admissions, adverse events, and compliance. Results Supplementation did not significantly affect contacts with primary care and days of infection per person (incidence rate ratio 0.96, 95% confidence interval 0.78 to 1.19 and 1.07, 0.90 to 1.27). Quality of life was not affected by supplementation. No statistically significant findings were found for secondary outcomes or subgroups. Conclusion Routine multivitamin and multimineral supplementation of older people living at home does not affect self reported infection related morbidity.	Univ Aberdeen, Sch Med, Hlth Serv Res Unit, Aberdeen AB25 2ZD, Scotland; Univ Aberdeen, Sch Med, Dept Gen Practice & Primary Care, Foresterhill Hlth Ctr, Aberdeen AB25 2AY, Scotland; Univ Aberdeen, Hlth Econ Res Unit, Aberdeen AB25U, Scotland; Univ Aberdeen, Sch Med, Dept Environm & Occupat Med, Liberty Safe Work Res Ctr, Aberdeen AB25 2ZP, Scotland; Univ Aberdeen, Sch Med, Dept Med & Therapeut, Aberdeen AB25 2ZD, Scotland	University of Aberdeen; University of Aberdeen; University of Aberdeen; University of Aberdeen; University of Aberdeen	Avenell, A (corresponding author), Univ Aberdeen, Sch Med, Hlth Serv Res Unit, Aberdeen AB25 2ZD, Scotland.	a.avenell@abdn.ac.uk	Hannaford, Philip C/B-7867-2012; Campbell, Marion/ABB-7063-2020; Cook, Jonathan/A-3474-2012; Cook, Jonathan/Z-5970-2019; Ramsay, Craig/AAD-8249-2021; Cook, Jonathan/D-3648-2015	Ramsay, Craig/0000-0003-4043-7349; Cook, Jonathan/0000-0002-4156-6989; Vale, Luke/0000-0001-8574-8429; Campbell, Marion/0000-0001-5386-4097; McNeill, Geraldine/0000-0003-0373-650X; Kilonzo, Mary/0000-0002-3450-4536				[Anonymous], NATL DIET NUTR SURVE; Barringer TA, 2003, ANN INTERN MED, V138, P365, DOI 10.7326/0003-4819-138-5-200303040-00005; CHANDRA RK, 1992, LANCET, V340, P1124, DOI 10.1016/0140-6736(92)93151-C; Chandra RK, 2002, NUTR RES, V22, P5, DOI 10.1016/S0271-5317(01)00366-9; CHAVANCE M, 1993, INT J VITAM NUTR RES, V63, P11; El-Kadiki A, 2005, BMJ-BRIT MED J, V330, P871, DOI 10.1136/bmj.38399.495648.8F; Girodon F, 1997, ANN NUTR METAB, V41, P98, DOI 10.1159/000177984; Girodon F, 1999, ARCH INTERN MED, V159, P748, DOI 10.1001/archinte.159.7.748; Glezen WP, 2000, JAMA-J AM MED ASSOC, V283, P499, DOI 10.1001/jama.283.4.499; Graat JM, 2002, JAMA-J AM MED ASSOC, V288, P715, DOI 10.1001/jama.288.6.715; Kind P, 1999, 172 CTR HLTH EC; LAMBERT D, 1992, TECHNOMETRICS, V34, P1, DOI 10.2307/1269547; Lesourd B, 1999, P NUTR SOC, V58, P85, DOI 10.1079/PNS19990013; McNeill G, 2002, BRIT J NUTR, V88, P555, DOI 10.1079/BJN2002706; Medical Research Council, 1998, MRC GUID GOOD CLIN P; Meydani SN, 2004, JAMA-J AM MED ASSOC, V292, P828, DOI 10.1001/jama.292.7.828; Ramos EJB, 2005, NUTRITION, V21, P269, DOI 10.1016/j.nut.2004.06.021; Scrimshaw NS, 1997, AM J CLIN NUTR, V66, P464; *SPSS, 2001, SPSS BAS 11 0 WIND U; *STAT, 2003, STAT STAT SOFTW 8 0; *STAT, 2003, STAT STAT SOFTW REL; SUTTON A, ASSESSING CONCERNS R; SUTTON A, ROLE MULTIVITAMINS M; WARE JE, 2002, SCORE VERSION 2 SFI2; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; 1995, MORBIDITY STAT GEN P; 1991, DIETARY REFERENCE VA; 1998, NATL DIET NUTR SURVE; NUTR ASSESSMENT QUES	29	61	62	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 6	2005	331	7512					324	327		10.1136/bmj.331.7512.324	http://dx.doi.org/10.1136/bmj.331.7512.324			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955WZ	16081445	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000231259800019
J	Martinez-Sansigre, A; Rawlings, S; Lacy, M; Fadda, D; Marleau, FR; Simpson, C; Willott, CJ; Jarvis, MJ				Martinez-Sansigre, A; Rawlings, S; Lacy, M; Fadda, D; Marleau, FR; Simpson, C; Willott, CJ; Jarvis, MJ			The obscuration by dust of most of the growth of supermassive black holes	NATURE			English	Article							ACTIVE GALACTIC NUCLEI; X-RAY; RADIO; LUMINOSITY; REDSHIFT; FREQUENCY; EVOLUTION; EMISSION; COUNTS; QUASAR	Supermassive black holes underwent periods of exponential growth during which we see them as quasars in the distant Universe. The summed emission from these quasars generates the cosmic X-ray background, the spectrum of which has been used to argue that most black-hole growth is obscured(1,2). There are clear examples of obscured black-hole growth in the form of 'type-2' quasars(3-5), but their numbers are fewer than expected from modelling of the X-ray background. Here we report the direct detection of a population of distant type-2 quasars, which is at least comparable in size to the well-known unobscured type-1 population. We selected objects that have mid-infrared and radio emissions characteristic of quasars, but which are faint at near-infrared and optical wavelengths. We conclude that this population is responsible for most of the black-hole growth in the young Universe and that, throughout cosmic history, black-hole growth occurs in the dusty, gas-rich centres of active galaxies.	Univ Oxford, Dept Phys, Oxford OX1 3RH, England; Natl Res Council Canada, Herzberg Inst Astrophys, Victoria, BC V9E 2E7, Canada; Univ Durham, Dept Phys, Durham DH1 3LE, England; CALTECH, Spitzer Sci Ctr, Pasadena, CA 91125 USA	University of Oxford; National Research Council Canada; Durham University; California Institute of Technology	Martinez-Sansigre, A (corresponding author), Univ Oxford, Dept Phys, Keble Rd, Oxford OX1 3RH, England.	a.martinez-sansigre1@physics.oxford.ac.uk		Marleau, Francine/0000-0002-1442-2947; Willott, Chris/0000-0002-4201-7367				Alexander DM, 2005, MON NOT R ASTRON SOC, V357, pL16, DOI 10.1111/j.1745-3933.2005.08621.x; Alexander DM, 2005, NATURE, V434, P738, DOI 10.1038/nature03473; ANTONUCCI R, 1993, ANNU REV ASTRON ASTR, V31, P473, DOI 10.1146/annurev.aa.31.090193.002353; Baker JC, 2002, ASTROPHYS J, V568, P592, DOI 10.1086/339033; Barger AJ, 2005, ASTRON J, V129, P578, DOI 10.1086/426915; BROADHURST T, 1995, APJ, V450, P41; Bruzual G, 2003, MON NOT R ASTRON SOC, V344, P1000, DOI 10.1046/j.1365-8711.2003.06897.x; Chapman SC, 2005, ASTROPHYS J, V622, P772, DOI 10.1086/428082; Cirasuolo M, 2003, MON NOT R ASTRON SOC, V346, P447, DOI 10.1046/j.1365-2966.2003.07105.x; Condon JJ, 2003, ASTRON J, V125, P2411, DOI 10.1086/374633; Croom SM, 2004, MON NOT R ASTRON SOC, V349, P1397, DOI 10.1111/j.1365-2966.2004.07619.x; Fabian AC, 1999, MON NOT R ASTRON SOC, V308, pL39, DOI 10.1046/j.1365-8711.1999.03017.x; LACY M, IN PRESS ASTROPHYS J; LAWRENCE A, 1991, MON NOT R ASTRON SOC, V252, P586, DOI 10.1093/mnras/252.4.586; Marleau FR, 2004, ASTROPHYS J SUPPL S, V154, P66, DOI 10.1086/422584; MILLER P, 1993, MON NOT R ASTRON SOC, V263, P425, DOI 10.1093/mnras/263.2.425; Norman C, 2002, ASTROPHYS J, V571, P218, DOI 10.1086/339855; PEI YCC, 1992, ASTROPHYS J, V395, P130, DOI 10.1086/171637; RAWLINGS S, 1990, MNRAS, V243, P14; ROWANROBINSON M, 1991, NATURE, V351, P719, DOI 10.1038/351719a0; ROWANROBINSON M, 1995, MON NOT R ASTRON SOC, V272, P737; Serjeant S, 1998, MON NOT R ASTRON SOC, V298, P321, DOI 10.1046/j.1365-8711.1998.01522.x; Simpson C, 1998, MON NOT R ASTRON SOC, V297, pL39, DOI 10.1046/j.1365-8711.1998.01678.x; Simpson C, 2005, MON NOT R ASTRON SOC, V360, P565, DOI 10.1111/j.1365-2966.2005.09043.x; Treister E, 2004, ASTROPHYS J, V616, P123, DOI 10.1086/424891; Willott CJ, 2000, MON NOT R ASTRON SOC, V316, P449, DOI 10.1046/j.1365-8711.2000.03447.x; Wolf C, 2003, ASTRON ASTROPHYS, V408, P499, DOI 10.1051/0004-6361:20030990; Worsley MA, 2004, MON NOT R ASTRON SOC, V350, P207, DOI 10.1111/j.1365-2966.2004.07634.x; YU Q, MON NOT R ASTRON SOC, P965; ZAKAMSKA NL, CANDIDATE TYPE 2 QUA, V3; Zheng W, 2004, ASTROPHYS J SUPPL S, V155, P73, DOI 10.1086/424385	32	159	159	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 4	2005	436	7051					666	669		10.1038/nature03829	http://dx.doi.org/10.1038/nature03829			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	951XA	16079838	Green Submitted			2022-12-28	WOS:000230964500035
J	Marshall, GN; Schell, TL; Elliott, MN; Berthold, SM; Chun, CA				Marshall, GN; Schell, TL; Elliott, MN; Berthold, SM; Chun, CA			Mental health of Cambodian refugees 2 decades after resettlement in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTTRAUMATIC-STRESS-DISORDER; INTERNATIONAL DIAGNOSTIC INTERVIEW; NATIONAL-COMORBIDITY-SURVEY; INDO-CHINESE REFUGEES; PSYCHIATRIC-DISORDERS; 12-MONTH PREVALENCE; BHUTANESE REFUGEES; BOSNIAN REFUGEES; ASYLUM SEEKERS; PTSD SYMPTOMS	Context Little is known about the long-term mental health of trauma-exposed refugees years after permanent resettlement in host countries. Objective To assess the prevalence, comorbidity, and correlates of psychiatric disorders in the US Cambodian refugee community. Design, Setting, and Participants A cross-sectional, face-to-face interview conducted in Khmer language on a random sample of households from the Cambodian community in Long Beach, Calif, the largest such community in the United States, between October 2003 and February 2005. A total of 586 adults aged 35 to 75 years who lived in Cambodia during the Khmer Rouge reign and immigrated to the United States prior to 1993 were selected. One eligible individual was randomly sampled from each household, with an overall response rate (eligibility screening and interview) of 87% (n = 490). Main Outcome Measures Exposure to trauma and violence before and after immigration (using the Harvard Trauma Questionnaire and Survey of Exposure to Community Violence); weighted past-year prevalence rates of posttraumatic stress disorder (PTSD) and major depression (using the Composite International Diagnostic Interview version 2.1); and alcohol use disorder (by the Alcohol Use Disorders Identification Test). Results All participants had been exposed to trauma before immigration. Ninety-nine percent (n=483) experienced near-death due to starvation and 90% (n=437) had a family member or friend murdered. Seventy percent (n=338) reported exposure to violence after settlement in the United States. High rates of PTSD (62%,weighted) major depression (51%, weighted), and low rates of alcohol use disorder were found (4%, weighted). PTSD and major depression were highly comorbid in this population (n = 209; 42%, weighted) and each showed a strong dose-response relationship with measures of traumatic exposure. In bivariate analyses, older age, having poor English-speaking proficiency, unemployment, being retired or disabled, and living in poverty were also associated with higher rates of PTSD and major depression. Following multivariate analyses, premigration trauma remained associated with PTSD (odds ratio [OR], 2.08; 95% Cl, 1.37-3.16) and major depression (OR, 1.56; 95% Cl, 1.24-1.97); postmigration trauma with PTSD (OR, 1.65; 95% Cl, 1.21-2.26) and major depression (OR, 1.45; 95% Cl, 1.12-1.86); and older age with PTSD (OR, 1.76; 95% Cl, 1.46-2.13) and major depression (OR, 1.47; 95% Cl, 1.15-1.89). Conclusion More than 2 decades have passed since the end of the Cambodian civil war and the subsequent resettlement of refugees in the United States; however, this population continues to have high rates of psychiatric disorders associated with trauma.	RAND Corp, Santa Monica, CA 90407 USA; Program Torture Victims, Los Angeles, CA USA; Calif State Univ Long Beach, Long Beach, CA 90840 USA	RAND Corporation; California State University System; California State University Long Beach	Marshall, GN (corresponding author), RAND Corp, 1776 Main St,POB 2138, Santa Monica, CA 90407 USA.	grantm@rand.org		Chun, Chi-Ah/0000-0002-1902-450X	NIAAA NIH HHS [R01AA013818] Funding Source: Medline; NIMH NIH HHS [R01MH059555] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059555] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA013818] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Allden K, 1996, AM J PUBLIC HEALTH, V86, P1561, DOI 10.2105/AJPH.86.11.1561; Allden K., 1998, HARVARD TRAUMA MANUA; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ANDREWS G, 1995, AUST NZ J PSYCHIAT, V29, P124, DOI 10.3109/00048679509075901; Andrews G, 1998, SOC PSYCH PSYCH EPID, V33, P80, DOI 10.1007/s001270050026; [Anonymous], 1997, COMP INT DIAGN INT C; Babor T.F., 1992, GUIDELINES USE PRIMA; Berman SL, 1996, AM J ORTHOPSYCHIAT, V66, P329, DOI 10.1037/h0080183; Caetano R, 1998, ALCOHOL HEALTH RES W, V22, P233; Chan S., 2004, SURVIVORS CAMBODIAN; Chilcoat HD, 1998, ADDICT BEHAV, V23, P827, DOI 10.1016/S0306-4603(98)00069-0; CONIGRAVE KM, 1995, ADDICTION, V90, P1349, DOI 10.1046/j.1360-0443.1995.901013496.x; Culbertson FM, 1997, AM PSYCHOL, V52, P25, DOI 10.1037/0003-066X.52.1.25; DAVANZO CE, 1994, J STUD ALCOHOL, V55, P420, DOI 10.15288/jsa.1994.55.420; de Jong JTVM, 2001, JAMA-J AM MED ASSOC, V286, P555, DOI 10.1001/jama.286.5.555; Eisenman DP, 2003, JAMA-J AM MED ASSOC, V290, P627, DOI 10.1001/jama.290.5.627; Feigelman S, 2000, J ADOLESCENT HEALTH, V27, P202, DOI 10.1016/S1054-139X(99)00124-X; Fernandez William G, 2004, Ann Emerg Med, V43, pE1, DOI 10.1016/j.annemergmed.2003.09.012; FLAHERTY JA, 1988, J NERV MENT DIS, V176, P257; Food and Agriculture Organization of the United Nations, FAO STAT DAT; *HARV PROGR REF TR, HARV TRAUM QUEST; Hinton D, 2000, GEN HOSP PSYCHIAT, V22, P437, DOI 10.1016/S0163-8343(00)00102-X; Hollifield M, 2002, JAMA-J AM MED ASSOC, V288, P611, DOI 10.1001/jama.288.5.611; Iacopino V, 1999, JAMA-J AM MED ASSOC, V282, P479, DOI 10.1001/jama.282.5.479; Jaranson JM, 2004, AM J PUBLIC HEALTH, V94, P591, DOI 10.2105/AJPH.94.4.591; Keller AS, 2003, LANCET, V362, P1721, DOI 10.1016/S0140-6736(03)14846-5; Kessler R.C., 1998, MENTAL HLTH US 1998, P99; Kessler RC, 2000, B WORLD HEALTH ORGAN, V78, P464; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kessler RC, 2000, J CLIN PSYCHIAT, V61, P4; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Laban CJ, 2004, J NERV MENT DIS, V192, P843, DOI 10.1097/01.nmd.0000146739.26187.15; LYNCH JF, 1989, BORDER KHMER DEMOGRA; MOLLICA RF, 1992, J NERV MENT DIS, V180, P111, DOI 10.1097/00005053-199202000-00008; Mollica RF, 1998, BRIT J PSYCHIAT, V173, P482, DOI 10.1192/bjp.173.6.482; MOLLICA RF, 1993, JAMA-J AM MED ASSOC, V270, P581, DOI 10.1001/jama.270.5.581; Mollica RH, 2001, JAMA-J AM MED ASSOC, V286, P546, DOI 10.1001/jama.286.5.546; Neugebauer R, 1999, AM J PUBLIC HEALTH, V89, P1473, DOI 10.2105/AJPH.89.10.1473; North CS, 2002, JAMA-J AM MED ASSOC, V288, P633, DOI 10.1001/jama.288.5.633; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P1390, DOI 10.1176/appi.ajp.161.8.1390; Pham PN, 2004, JAMA-J AM MED ASSOC, V292, P602, DOI 10.1001/jama.292.5.602; Regier DA, 1998, ARCH GEN PSYCHIAT, V55, P109, DOI 10.1001/archpsyc.55.2.109; Reinert DF, 2002, ALCOHOL CLIN EXP RES, V26, P272, DOI 10.1111/j.1530-0277.2002.tb02534.x; Richters JE., 1990, SURVEY EXPOSURE COMM; ROBINS LN, 1988, ARCH GEN PSYCHIAT, V45, P1069; ROGLER LH, 1992, J NERV MENT DIS, V180, P215, DOI 10.1097/00005053-199204000-00001; Rummel R.J., 1994, DEATH GOVT; Sabin M, 2003, JAMA-J AM MED ASSOC, V290, P635, DOI 10.1001/jama.290.5.635; Scarpa A, 2001, J INTERPERS VIOLENCE, V16, P36, DOI 10.1177/088626001016001003; Scholte WF, 2004, JAMA-J AM MED ASSOC, V292, P585, DOI 10.1001/jama.292.5.585; Shrestha NM, 1998, JAMA-J AM MED ASSOC, V280, P443, DOI 10.1001/jama.280.5.443; Southwick SM, 1997, AM J PSYCHIAT, V154, P173; Stewart SH, 1996, PSYCHOL BULL, V120, P83, DOI 10.1037/0033-2909.120.1.83; Takeuchi DT, 1998, AM J PSYCHIAT, V155, P1407, DOI 10.1176/ajp.155.10.1407; Turner SW, 2003, BRIT J PSYCHIAT, V182, P444, DOI 10.1192/bjp.182.5.444; *UN HIGH COMM REF, 2004 GLOB REF TRENDS; US Committee for Refugees, 1992, REF REP, V13; Ustun TB, 2002, BRIT J PSYCHIAT, V181, P181, DOI 10.1192/bjp.181.3.181; Van Ommeren M, 2001, ARCH GEN PSYCHIAT, V58, P475, DOI 10.1001/archpsyc.58.5.475; Weine SM, 1998, AM J PSYCHIAT, V155, P562, DOI 10.1176/ajp.155.4.562; Willis BM, 2000, JAMA-J AM MED ASSOC, V284, P612, DOI 10.1001/jama.284.5.612; WITTCHEN HU, 1994, J PSYCHIAT RES, V28, P57, DOI 10.1016/0022-3956(94)90036-1; WITTCHEN HU, 1991, BRIT J PSYCHIAT, V159, P645, DOI 10.1192/bjp.159.5.645; YEE BWK, 1987, J PSYCHOACTIVE DRUGS, V19, P77, DOI 10.1080/02791072.1987.10472382	64	393	395	1	59	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	2005	294	5					571	579		10.1001/jama.294.5.571	http://dx.doi.org/10.1001/jama.294.5.571			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	951NN	16077051	Bronze			2022-12-28	WOS:000230937500017
J	Unal, B; Critchley, JA; Capewell, S				Unal, B; Critchley, JA; Capewell, S			Modelling the decline in coronary heart disease deaths in England and Wales, 1981-2000: comparing contributions from primary prevention and secondary prevention	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RISK-FACTOR CHANGES; MORTALITY; POPULATION; SCOTLAND; SMOKING; TRENDS; CARE	Objective To investigate whether population based primary prevention (risk factor reduction in apparently healthy people) might be more powerful than current government initiatives favouring risk factor reduction in patients with coronary heart disease (CHD) (secondary prevention). Design, setting, and participants The IMPACT model was used to synthesise data for England and Wales describing CHD patient numbers, uptake of specific treatments, trends in major cardiovascular risk factors, and the mortality benefits of these specific risk factor changes in healthy people and in CHD patients. Results Between 1981 and 2000, CHD mortality rates fell by 54%, resulting in 68 230 fewer deaths in 2000. Overall smoking prevalence declined by 35% between 1981 and 2000, resulting in approximately 29 715 (minimum estimate 20 035, maximum estimate 44 6,75) fewer deaths attributable to smoking cessation: approximately 5035 in known CHD patients and approximately 24 680 in healthy people. Population total cholesterol concentrations fell by 4.2%, resulting in approximately 5770 fewer deaths attributable to dietary changes (1205 in CHD patients and 4565 in healthy people) plus 2135 fewer deaths attributable to statin treatment (1990 in CHD patients, 145 in people without CHD). Mean population blood pressure fell by 7.7%, resulting in approximately 5870 fewer deaths attributable to secular falls in blood pressure (520 in CHD patients and 5345 in healthy people) plus approximately 1890 fewer deaths attributable to antihypertensive treatments in people without CHD. Approximately 45 370 fewer deaths were thus attributable to reductions in the three major risk factors in the population: some 36 625 (81%) in people without recognised CHD and 8745 (19%) in CHD patients. Conclusions Compared with secondary prevention, primary prevention achieved a fourfold larger reduction in deaths. Future CHD policies should prioritise population-wide tobacco control and healthier diets.	Dokuz Eylul Univ, Sch Med, Dept Publ Hlth, TR-35340 Izmir, Turkey; Univ Liverpool, Liverpool Sch Trop Med, Int Hlth Grp, Liverpool L3 5QA, Merseyside, England; Univ Liverpool, Div Publ Hlth, Liverpool L69 3GB, Merseyside, England	Dokuz Eylul University; Liverpool School of Tropical Medicine; University of Liverpool; University of Liverpool	Unal, B (corresponding author), Dokuz Eylul Univ, Sch Med, Dept Publ Hlth, TR-35340 Izmir, Turkey.	belgin.unal@deu.edu.tr	Unal, Belgin/E-7064-2017; Shao, Ruitai/AAU-7642-2021	Unal, Belgin/0000-0002-4354-8266; Critchley, Julia/0000-0002-5248-4188				Bonow RO, 2002, CIRCULATION, V106, P3140, DOI 10.1161/01.CIR.0000048067.86569.E1; Boyle R, 2004, HEART, V90, P3, DOI 10.1136/hrt.2004.037523; BRIGGS A, 1994, HEALTH ECON, V3, P95, DOI 10.1002/hec.4730030206; *BRIT HEART FDN ST, 2005, COR HEART DIS STAT; *CA DEP HLTH TOB C, CAL TOB CONTR UPD; Capewell S, 1999, HEART, V81, P380, DOI 10.1136/hrt.81.4.380; Capewell S, 2001, LANCET, V358, P1213, DOI 10.1016/S0140-6736(01)06343-7; Capewell S, 2000, CIRCULATION, V102, P1511, DOI 10.1161/01.CIR.102.13.1511; Critchley J, 2004, CIRCULATION, V110, P1236, DOI 10.1161/01.CIR.0000140668.91896.AE; Critchley JA, 2003, JAMA-J AM MED ASSOC, V290, P86, DOI 10.1001/jama.290.1.86; *DEP HLTH ENGL, 2004, CHOOS HLTH MAK HLTH; Doll R, 2004, BMJ-BRIT MED J, V328, P1519, DOI 10.1136/bmj.38142.554479.AE; DOWSE GK, 1995, BRIT MED J, V311, P1255, DOI 10.1136/bmj.311.7015.1255; EBRAHIM S, 1999, COCHRANE DB SYST REV; Emberson J, 2004, EUR HEART J, V25, P484, DOI 10.1016/j.ehj.2003.11.012; Hunink MGM, 1997, JAMA-J AM MED ASSOC, V277, P535, DOI 10.1001/jama.277.7.535; Kendall Cyril W C, 2004, Curr Atheroscler Rep, V6, P492, DOI 10.1007/s11883-004-0091-9; Law M, 1999, BRIT MED J, V318, P1471, DOI 10.1136/bmj.318.7196.1471; Rose G., 1992, STRATEGY PREVENTIVE; Unal B, 2005, AM J PUBLIC HEALTH, V95, P103, DOI 10.2105/AJPH.2003.029579; Unal B, 2004, CIRCULATION, V109, P1101, DOI 10.1161/01.CIR.0000118498.35499.B2; UNAL B, APPENDICES IMPACT CH; United States Department of Health and Human Services, 2000, HLTH PEOPL 2010, V1; Vartiainen E, 2000, INT J EPIDEMIOL, V29, P49, DOI 10.1093/ije/29.1.49	24	195	203	1	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 17	2005	331	7517					614	617		10.1136/bmj.38561.633345.8F	http://dx.doi.org/10.1136/bmj.38561.633345.8F			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	967EK	16107431	Green Accepted, Green Published, Bronze			2022-12-28	WOS:000232074100022
J	Tuske, S; Sarafianos, SG; Wang, XY; Hudson, B; Sineva, E; Mukhopadhyay, J; Birktoft, JJ; Leroy, O; Ismail, S; Clark, AD; Dharia, C; Napoli, A; Laptenko, O; Lee, J; Borukhov, S; Ebright, RH; Arnold, E				Tuske, S; Sarafianos, SG; Wang, XY; Hudson, B; Sineva, E; Mukhopadhyay, J; Birktoft, JJ; Leroy, O; Ismail, S; Clark, AD; Dharia, C; Napoli, A; Laptenko, O; Lee, J; Borukhov, S; Ebright, RH; Arnold, E			Inhibition of bacterial RNA polymerase by streptolydigin: Stabilization of a straight-bridge-helix active-center conformation	CELL			English	Article							II ELONGATION COMPLEX; STRUCTURAL BASIS; BETA-SUBUNIT; TRANSCRIPTION ELONGATION; RANDOM MUTAGENESIS; CRYSTAL-STRUCTURE; MECHANISM; RESISTANCE; INITIATION; DNA	We define the target, mechanism, and structural basis of inhibition of bacterial RNA polymerase (RNAP) by the tetramic acid antibiotic streptolydigin (Stl). Stl binds to a site adjacent to but not overlapping the RNAP active center and stabilizes an RNAP-active-center conformational state with a straight-bridge helix. The results provide direct support for the proposals that alternative straight-bridge-helix and bent-bridge-helix RNAP-active-center conformations exist and that cycling between straight-bridge-helix and bent-bridge-helix RNAP-active-center conformations is required for RNAP function. The results set bounds on models for RNAP function and suggest strategies for design of novel antibacterial agents.	Rutgers State Univ, Dept Chem & Biol Chem, Piscataway, NJ 08855 USA; Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ USA; Rutgers State Univ, Waksman Inst, Piscataway, NJ USA; Howard Hughes Med Inst, Piscataway, NJ USA; Univ Med & Dent New Jersey, Dept Cell Biol, Stratford, NJ 08084 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center	Ebright, RH (corresponding author), Rutgers State Univ, Dept Chem & Biol Chem, Piscataway, NJ 08855 USA.	ebright@mbcl.rutgers.edu; arnold@cabm.rutgers.edu	Borukhov, Sergei/AAF-3195-2019; Sineva, Elena/A-5267-2008; Ebright, Richard/O-3321-2019	Borukhov, Sergei/0000-0002-3517-3003; Sineva, Elena/0000-0003-2307-0581; Ebright, Richard/0000-0001-8915-7140; Sarafianos, Stefan G/0000-0002-5840-154X	Howard Hughes Medical Institute Funding Source: Medline; NIAID NIH HHS [AI27690, R37 AI027690-16, R37 AI027690-13, R37 AI027690-15, R37 AI027690, R37 AI027690-14] Funding Source: Medline; NIGMS NIH HHS [R01 GM041376-17, R01 GM054098, R37 GM041376, R01 GM041376, R01 GM021589, GM54098, R01 GM054098-05, GM41376, R01 GM041376-14, GM21589, R01 GM041376-16, P01 GM066671, P01 GM066671-02, R01 GM041376-15, GM66671] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027690, R37AI027690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM066671, R01GM054098, R01GM021589, R37GM041376, R01GM041376] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adelman K, 2004, MOL CELL, V14, P753, DOI 10.1016/j.molcel.2004.05.017; Armache KJ, 2003, P NATL ACAD SCI USA, V100, P6964, DOI 10.1073/pnas.1030608100; Artsimovitch I, 2004, CELL, V117, P299, DOI 10.1016/S0092-8674(04)00401-5; Artsimovitch I, 2003, SCIENCE, V302, P650, DOI 10.1126/science.1087526; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bar-Nahum G, 2005, CELL, V120, P183, DOI 10.1016/j.cell.2004.11.045; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bushnell DA, 2004, SCIENCE, V303, P983, DOI 10.1126/science.1090838; Bushnell DA, 2003, P NATL ACAD SCI USA, V100, P6969, DOI 10.1073/pnas.1130601100; Bushnell DA, 2002, P NATL ACAD SCI USA, V99, P1218, DOI 10.1073/pnas.251664698; Campbell EA, 2001, CELL, V104, P901, DOI 10.1016/S0092-8674(01)00286-0; Campbell EA, 2005, EMBO J, V24, P674, DOI 10.1038/sj.emboj.7600499; CASSANI G, 1971, NATURE-NEW BIOL, V230, P197, DOI 10.1038/newbio230197a0; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; Christie GE, 1996, J BACTERIOL, V178, P6991, DOI 10.1128/jb.178.23.6991-6993.1996; Cramer P, 2002, CURR OPIN STRUC BIOL, V12, P89, DOI 10.1016/S0959-440X(02)00294-4; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Darst SA, 2001, CURR OPIN STRUC BIOL, V11, P155; Ebright RH, 2000, J MOL BIOL, V304, P687, DOI 10.1006/jmbi.2000.4309; Epshtein V, 2002, MOL CELL, V10, P623, DOI 10.1016/S1097-2765(02)00640-8; FRALICK JA, 1994, J BACTERIOL, V176, P6404, DOI 10.1128/jb.176.20.6404-6406.1994; GERBER PR, 1995, J COMPUT AID MOL DES, V9, P251, DOI 10.1007/BF00124456; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Guajardo R, 1998, J MOL BIOL, V281, P777, DOI 10.1006/jmbi.1998.1988; HEISLER LM, 1993, J BIOL CHEM, V268, P25369; HERMES JD, 1989, GENE, V84, P143, DOI 10.1016/0378-1119(89)90148-0; HERMES JD, 1990, P NATL ACAD SCI USA, V87, P696, DOI 10.1073/pnas.87.2.696; Holmes SF, 2003, J BIOL CHEM, V278, P35597, DOI 10.1074/jbc.M304496200; Iwata Y, 2005, ANGEW CHEM INT EDIT, V44, P1532, DOI 10.1002/anie.200462300; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kettenberger H, 2003, CELL, V114, P347, DOI 10.1016/S0092-8674(03)00598-1; Kettenberger H, 2004, MOL CELL, V16, P955, DOI 10.1016/j.molcel.2004.11.040; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; LANDICK R, 1990, GENE DEV, V4, P1623, DOI 10.1101/gad.4.9.1623; Laptenko O, 2003, METHOD ENZYMOL, V371, P219; LEE VJ, 1980, J ANTIBIOT, V33, P408, DOI 10.7164/antibiotics.33.408; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCLURE WR, 1980, J BIOL CHEM, V255, P1610; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; Mukhopadhyay J, 2004, MOL CELL, V14, P739, DOI 10.1016/j.molcel.2004.06.010; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Naryshkin N, 2000, CELL, V101, P601, DOI 10.1016/S0092-8674(00)80872-7; Niu W, 1996, CELL, V87, P1123, DOI 10.1016/S0092-8674(00)81806-1; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Sambrook J., 2001, MOL CLONING LAB MANU; Sarafianos SG, 1999, P NATL ACAD SCI USA, V96, P10027, DOI 10.1073/pnas.96.18.10027; SEVERINOV K, 1995, J BIOL CHEM, V270, P23926, DOI 10.1074/jbc.270.41.23926; Severinov K, 1997, J BIOL CHEM, V272, P24137, DOI 10.1074/jbc.272.39.24137; SIDDHIKOL C, 1969, J BACTERIOL, V99, P151, DOI 10.1128/JB.99.1.151-155.1969; Sosunov V, 2003, EMBO J, V22, P2234, DOI 10.1093/emboj/cdg193; TANG H, 1994, GENE DEV, V8, P3058, DOI 10.1101/gad.8.24.3058; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; VASSYLYEVA M, 2002, ACTA CRYSTALLOGR D, V50, P760; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; Westover KD, 2004, CELL, V119, P481, DOI 10.1016/j.cell.2004.10.016; Westover KD, 2004, SCIENCE, V303, P1014, DOI 10.1126/science.1090839; YANG XF, 1995, J BIOL CHEM, V270, P23930, DOI 10.1074/jbc.270.41.23930; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3; Yuzenkova J, 2002, J BIOL CHEM, V277, P50867, DOI 10.1074/jbc.M209425200; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	61	153	165	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 26	2005	122	4					541	552		10.1016/j.cell.2005.07.017	http://dx.doi.org/10.1016/j.cell.2005.07.017			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	959YI	16122422	Green Accepted, Bronze			2022-12-28	WOS:000231555100010
J	Maisel, WH				Maisel, WH			Safety issues involving medical devices - Implications of recent implantable cardioverter-defibrillator malfunctions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PACEMAKERS		Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiovasc, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Maisel, WH (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiovasc, 185 Pilgrim Rd,Baker 4, Boston, MA 02215 USA.	wmaisel@bidmc.harvard.edu						*ADVAMED, ADVAMED SUPP PROMPT; Bardy GH, 2005, NEW ENGL J MED, V352, P225, DOI 10.1056/NEJMoa043399; Blot WJ, 2005, CIRCULATION, V111, P2850, DOI 10.1161/CIRCULATIONAHA.104.511659; BURDITT GM, 1995, FOOD DRUG LAW J, P197; *GUID CORP, GUID CARD RHTHM MAN; *ICD, 2005, MED DEV DIAGN INSTR, V31, P5; Levine PA, 2002, PACE, V25, P1667, DOI 10.1046/j.1460-9592.2002.01667.x; Maisel WH, 2004, PACE, V27, P437, DOI 10.1111/j.1540-8159.2004.00460.x; Maisel WH, 2004, ANN INTERN MED, V140, P296, DOI 10.7326/0003-4819-140-4-200402170-00012; Maisel WH, 2002, JAMA-J AM MED ASSOC, V287, P839; Maisel WH, 2002, PACE, V25, P1670, DOI 10.1046/j.1460-9592.2002.01670.x; Maisel WH, 2001, JAMA-J AM MED ASSOC, V286, P793, DOI 10.1001/jama.286.7.793; Maisel William H, 2005, Am J Ther, V12, P183, DOI 10.1097/01.mjt.0000155117.55919.43; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; *MEDTR, MEDTR CRM PROD PERFM; MEIER B, 2005, NY TIMES        0524, P1; MIROWSKI M, 1980, NEW ENGL J MED, V303, P322, DOI 10.1056/NEJM198008073030607; Monsein LH, 1997, RADIOLOGY, V205, P1; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; MUNSEY RR, 1995, FOOD DRUG LAW J, P163; ONEILL WW, 1995, NEW ENGL J MED, V333, P414, DOI 10.1056/NEJM199508173330703; Pilot LR, 1998, FOOD DRUG LAW J, V53, P267; Pritchard WF, 1997, RADIOLOGY, V205, P27, DOI 10.1148/radiology.205.1.9314955; *ST JUD MED, 1 QUART 2005 AN PRES; *ST JUD MED, ST JUD MED PROD PERF; *ST JUD MED, ST JUD MED ANN ICD S; Stanton MS, 2002, JAMA-J AM MED ASSOC, V287, P839, DOI 10.1001/jama.287.7.839; *US DEP HHS, CTR DEV RAD HLTH CDR; *US FDA, FDA STAT GUID CORP W; *US FDA, FDA ENF REP IND; *US FDA, MEDTR ISS NOT REG CE; PHYS COMMUNICATIONS	32	67	68	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 24	2005	294	8					955	958		10.1001/jama.294.8.955	http://dx.doi.org/10.1001/jama.294.8.955			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	957JM	16118386				2022-12-28	WOS:000231366100026
J	Hawker, CJ; Wooley, KL				Hawker, CJ; Wooley, KL			The convergence of synthetic organic and polymer chemistries	SCIENCE			English	Review							LIVING RADICAL POLYMERIZATION; CROSS-LINKED NANOPARTICLES; HYBRID BLOCK-COPOLYMERS; CLICK CHEMISTRY; QUANTUM DOTS; POLYPHENYLENE DENDRIMERS; DENDRONIZED POLYMERS; IN-VIVO; ARCHITECTURES; CYCLOADDITION	Several recent conceptual advances, which take advantage of the design criteria and practical techniques of molecular-level control in organic chemistry, allow preparation of well-defined polymers and nanostructured materials. Two trends are clear: the realization that synthesis of complex macromolecules poses major challenges and opportunities and the expectation that such materials will exhibit distinctive properties and functions. Polymer synthesis methods now being developed will yield well-defined synthetic macromolecules that are capable of mimicking many of the features of proteins (for example, three-dimensional folded structure) and other natural materials. These macromolecules have far-reaching potential for the study of molecular-level. behavior at interfaces, in thin films, and in solution, while also enabling the development of encapsulation, drug-delivery, and nanoscale-patterning technologies.	Univ Calif Santa Barbara, Dept Mat, Mat Res Lab, Santa Barbara, CA 93106 USA; Washington Univ, Ctr Mat Innovat, St Louis, MO 63130 USA; Washington Univ, Dept Chem, St Louis, MO 63130 USA; Univ Calif Santa Barbara, Dept Chem, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; Washington University (WUSTL); Washington University (WUSTL); University of California System; University of California Santa Barbara	Hawker, CJ (corresponding author), Univ Calif Santa Barbara, Dept Mat, Mat Res Lab, Santa Barbara, CA 93106 USA.	hawker@mrl.ucsb.edu; klwooley@artsci.wustl.edu	Hawker, Craig J/G-4971-2011; Wooley, Karen/AAX-2259-2020; Wooley, Karen L/D-4399-2015	Hawker, Craig J/0000-0001-9951-851X; Wooley, Karen/0000-0003-4086-384X; Wooley, Karen L/0000-0003-4086-384X				Becker ML, 2005, BIOMACROMOLECULES, V6, P220, DOI 10.1021/bm049551y; Becker ML, 2004, BIOCONJUGATE CHEM, V15, P699, DOI 10.1021/bc049946e; Becker ML, 2003, CHEM COMMUN, P180, DOI 10.1039/b209557b; Behanna HA, 2005, J AM CHEM SOC, V127, P1193, DOI 10.1021/ja044863u; Bes L, 2003, MACROMOLECULES, V36, P2493, DOI 10.1021/ma0211986; Cheng JY, 2004, NAT MATER, V3, P823, DOI 10.1038/nmat1211; de Loos F, 2005, CHEM COMMUN, P60, DOI 10.1039/b412067a; Elemans JAAW, 2003, J MATER CHEM, V13, P2661, DOI 10.1039/b304972h; Gibbs JM, 2005, J AM CHEM SOC, V127, P1170, DOI 10.1021/ja046931i; Haddleton DM, 2000, BIOMACROMOLECULES, V1, P152, DOI 10.1021/bm005531u; Halford B, 2005, CHEM ENG NEWS, V83, P30; Helms B, 2004, J AM CHEM SOC, V126, P15020, DOI 10.1021/ja044744e; Joralemon MJ, 2004, BIOMACROMOLECULES, V5, P903, DOI 10.1021/bm0344710; Kang YJ, 2005, ANGEW CHEM INT EDIT, V44, P409, DOI 10.1002/anie.200461119; Klok HA, 2005, J POLYM SCI POL CHEM, V43, P1, DOI 10.1002/pola.20527; Larson DR, 2003, SCIENCE, V300, P1434, DOI 10.1126/science.1083780; Link AJ, 2004, J AM CHEM SOC, V126, P10598, DOI 10.1021/ja047629c; Malkoch M, 2005, MACROMOLECULES, V38, P3663, DOI 10.1021/ma047657f; Mei Y, 2004, J AM CHEM SOC, V126, P3472, DOI 10.1021/ja039583d; Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274; Mihov G, 2005, BIOCONJUGATE CHEM, V16, P283, DOI 10.1021/bc049839k; Mihov G, 2004, J ORG CHEM, V69, P8029, DOI 10.1021/jo048998u; Murthy KS, 2003, J MATER CHEM, V13, P2785, DOI 10.1039/b304166b; Nelson JC, 1997, SCIENCE, V277, P1793, DOI 10.1126/science.277.5333.1793; Opsteen JA, 2005, CHEM COMMUN, P57, DOI 10.1039/b412930j; Reynhout IC, 2005, CHEM COMMUN, P602, DOI 10.1039/b413973a; Rostovtsev VV, 2002, ANGEW CHEM INT EDIT, V41, P2596, DOI 10.1002/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4; Ryu DY, 2005, SCIENCE, V308, P236, DOI 10.1126/science.1106604; Shin K, 2002, NANO LETT, V2, P933, DOI 10.1021/nl0256560; Shklyarevskiy IO, 2005, J AM CHEM SOC, V127, P1112, DOI 10.1021/ja0431096; Shu LJ, 2001, ANGEW CHEM INT EDIT, V40, P4666, DOI 10.1002/1521-3773(20011217)40:24<4666::AID-ANIE4666>3.0.CO;2-1; Temple K, 2003, ADV MATER, V15, P297, DOI 10.1002/adma.200390071; Tomalia DA, 2002, J POLYM SCI POL CHEM, V40, P2719, DOI 10.1002/pola.10301; Tsarevsky NV, 2004, MACROMOLECULES, V37, P9308, DOI 10.1021/ma048207q; Velonia K, 2002, J AM CHEM SOC, V124, P4224, DOI 10.1021/ja017809b; Verma A, 2005, CHEM COMMUN, P303, DOI 10.1039/b410889b; Watson KJ, 2001, J AM CHEM SOC, V123, P5592, DOI 10.1021/ja0156845; Wooley KL, 2000, J POLYM SCI POL CHEM, V38, P1397, DOI 10.1002/(SICI)1099-0518(20000501)38:9<1397::AID-POLA1>3.0.CO;2-N; Wu XY, 2003, NAT BIOTECHNOL, V21, P41, DOI 10.1038/nbt764; Yoshida M, 2005, MACROMOLECULES, V38, P334, DOI 10.1021/ma048722o; Zhang Q, 2002, NANO LETT, V2, P1051, DOI 10.1021/nl025653n	41	1116	1138	10	662	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 19	2005	309	5738					1200	1205		10.1126/science.1109778	http://dx.doi.org/10.1126/science.1109778			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	957TE	16109874				2022-12-28	WOS:000231395400034
J	Vaccarino, V; Rathore, SS; Wenger, NK; Frederick, PD; Abramson, JL; Barron, HV; Manhapra, A; Mallik, S; Krumholz, HM				Vaccarino, V; Rathore, SS; Wenger, NK; Frederick, PD; Abramson, JL; Barron, HV; Manhapra, A; Mallik, S; Krumholz, HM		Natl Registry Myocardial Infarctio	Sex and racial differences in the management of acute myocardial infarction, 1994 through 2002	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRACTICE GUIDELINES COMMITTEE; ASSOCIATION TASK-FORCE; GENDER-DIFFERENCES; NATIONAL REGISTRY; REPERFUSION THERAPY; ACC/AHA GUIDELINES; AMERICAN-COLLEGE; RACE-DIFFERENCES; TEMPORAL TRENDS; WOMEN	Background: Although increased attention has been paid to sex and racial differences in the management of myocardial infarction, it is unknown whether these differences have narrowed over time. Methods: With the use of data from the National Registry of Myocardial Infarction, we examined sex and racial differences in the treatment of patients who were deemed to be "ideal candidates'' for particular treatments and in deaths among 598,911 patients hospitalized with myocardial infarction between 1994 and 2002. Results: In the unadjusted analysis, sex and racial differences were observed for rates of reperfusion therapy (for white men, white women, black men, and black women: 86.5, 83.3, 80.4, and 77.8 percent, respectively; P<0.001), use of aspirin (84.4, 78.7, 83.7, and 78.4 percent, respectively; P<0.001), use of beta-blockers (66.6, 62.9, 67.8, and 64.5 percent; P<0.001), and coronary angiography (69.1, 55.9, 64.0, and 55.0 percent; P<0.001). After multivariable adjustment, racial and sex differences persisted for rates of reperfusion therapy (risk ratio for white women, black men, and black women: 0.97, 0.91, and 0.89, respectively, as compared with white men) and coronary angiography (relative risk, 0.91, 0.82, and 0.76) but were attenuated for the use of aspirin (risk ratio, 0.97, 0.98, and 0.94) and beta-blockers (risk ratio, 0.98, 1.00, and 0.96); all risks were unchanged over time. Adjusted in-hospital mortality was similar among white women (risk ratio, 1.05; 95 percent confidence interval, 1.03 to 1.07) and black men (risk ratio, 0.95; 95 percent confidence interval, 0.89 to 1.00), as compared with white men, but was higher among black women (risk ratio, 1.11; 95 percent confidence interval, 1.06 to 1.16) and was unchanged over time. Conclusions: Rates of reperfusion therapy, coronary angiography, and in-hospital death after myocardial infarction, but not the use of aspirin and beta-blockers, vary according to race and sex, with no evidence that the differences have narrowed in recent years.	Emory Univ, Dept Med, Div Cardiol, Sch Med, Atlanta, GA 30306 USA; Emory Univ, Dept Med, Div Gen Med, Sch Med, Atlanta, GA 30306 USA; Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA; Yale Univ, Dept Med, Sect Cardiovasc Med, Sch Med, New Haven, CT 06520 USA; Yale Univ, Div Hlth Policy & Adm, Dept Epidemiol & Publ Hlth, Sch Med, New Haven, CT 06520 USA; Yale Univ, Robert Wood Johnson Clin Scholars Program, Sch Med, New Haven, CT 06520 USA; Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT USA; Ovat Res Grp, San Francisco, CA USA; Genentech Inc, San Francisco, CA USA; Hackley Hosp, Spring Lake, MI USA	Emory University; Emory University; Emory University; Rollins School Public Health; Yale University; Yale University; Yale University; Yale University; Roche Holding; Genentech	Vaccarino, V (corresponding author), Emory Univ, Dept Med, Div Cardiol, Sch Med, 1256 Briarcliff Rd,Suite 1N, Atlanta, GA 30306 USA.	viola.vaccarino@emory.edu	, Harlan/AAI-2875-2020; , Viola/AAW-5600-2020	Frederick, Paul/0000-0002-7936-5488	AHRQ HHS [R01HS10407, R01 HS010407] Funding Source: Medline; NCRR NIH HHS [K12RR17643, K12 RR017643] Funding Source: Medline; NHLBI NIH HHS [K24 HL077506, K24HL077506] Funding Source: Medline; NIGMS NIH HHS [T32 GM007205-35, GM07205, T32 GM007205] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS010407] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K12RR017643] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL077506] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007205] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnold AL, 2001, AM J CARDIOL, V88, P1037, DOI 10.1016/S0002-9149(01)01987-7; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; Bach PB, 2004, NEW ENGL J MED, V351, P575, DOI 10.1056/NEJMsa040609; Bradley EH, 2004, JAMA-J AM MED ASSOC, V292, P1563, DOI 10.1001/jama.292.13.1563; Canto JG, 2000, NEW ENGL J MED, V342, P1094, DOI 10.1056/NEJM200004133421505; Chen J, 2001, NEW ENGL J MED, V344, P1443, DOI 10.1056/NEJM200105103441906; Department of Health Human Services Washington DC. Healthy People 2010 (Group) and United States Government Printing Office., 2000, HLTH PEOPL 2010; Epstein AM, 2003, MED CARE, V41, P1240, DOI 10.1097/01.MLR.0000093423.38746.8C; Escarce JJ, 2004, AM J PUBLIC HEALTH, V94, P1795, DOI 10.2105/AJPH.94.10.1795; Every NR, 1999, J AM COLL CARDIOL, V33, P1886, DOI 10.1016/S0735-1097(99)00113-8; Gan SC, 2000, NEW ENGL J MED, V343, P8, DOI 10.1056/NEJM200007063430102; GILES WH, 1995, ARCH INTERN MED, V155, P318, DOI 10.1001/archinte.155.3.318; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; Hannan EL, 1999, MED CARE, V37, P68, DOI 10.1097/00005650-199901000-00010; Heidenreich PA, 2001, AM J MED, V110, P165, DOI 10.1016/S0002-9343(00)00712-9; Institute of Medicine Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care, 2003, UNEQUAL TREATMENT CO, DOI DOI 10.17226/12875; KOSTIS JB, 1994, CIRCULATION, V90, P1715, DOI 10.1161/01.CIR.90.4.1715; Kudenchuk PJ, 1996, AM J CARDIOL, V78, P9, DOI 10.1016/S0002-9149(96)00218-4; McLaughlin TJ, 1996, ARCH INTERN MED, V156, P799, DOI 10.1001/archinte.156.7.799; MCLAUGHLIN TJ, 1996, ARCH INTERN MED, V156, P1920; Miller TD, 2001, J AM COLL CARDIOL, V38, P690, DOI 10.1016/S0735-1097(01)01413-9; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; Rathore SS, 2004, ANN INTERN MED, V141, P635, DOI 10.7326/0003-4819-141-8-200410190-00011; ROGERS WJ, 1994, CIRCULATION, V90, P2103, DOI 10.1161/01.CIR.90.4.2103; Rogers WJ, 2000, J AM COLL CARDIOL, V36, P2056, DOI 10.1016/S0735-1097(00)00996-7; Ryan TJ, 1999, J AM COLL CARDIOL, V34, P890, DOI 10.1016/S0735-1097(99)00351-4; Ryan TJ, 1996, CIRCULATION, V94, P2341, DOI 10.1161/01.CIR.94.9.2341; Schulman KA, 1999, NEW ENGL J MED, V340, P1130; Spencer F, 2001, AM HEART J, V142, P594, DOI 10.1067/mhj.2001.117776; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; Stone PH, 1996, JAMA-J AM MED ASSOC, V275, P1104, DOI 10.1001/jama.275.14.1104; van Lennep JER, 2000, EUR HEART J, V21, P911, DOI 10.1053/euhj.1999.1941; Weitzman S, 1997, AM J CARDIOL, V79, P722, DOI 10.1016/S0002-9149(96)00857-0; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; Yarzebski J, 1996, AM HEART J, V131, P43, DOI 10.1016/S0002-8703(96)90049-6; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	37	418	421	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 18	2005	353	7					671	682		10.1056/NEJMsa032214	http://dx.doi.org/10.1056/NEJMsa032214			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955UW	16107620	Green Accepted			2022-12-28	WOS:000231254100005
J	Rubin, LJ; Badesch, DB				Rubin, LJ; Badesch, DB			Evaluation and management of the patient with pulmonary arterial hypertension	ANNALS OF INTERNAL MEDICINE			English	Review							INHALED NITRIC-OXIDE; CONTINUOUS INTRAVENOUS EPOPROSTENOL; CLINICAL-PRACTICE GUIDELINES; PROGRESSIVE SYSTEMIC-SCLEROSIS; PLACEBO-CONTROLLED TRIAL; LONG-TERM TREATMENT; PROSTACYCLIN ANALOG; LUNG TRANSPLANTATION; ATRIAL SEPTOSTOMY; DOUBLE-BLIND	Increased pressure in the pulmonary circulation, or pulmonary hypertension, is a common disorder that may complicate various cardiopulmonary conditions, including severe obstructive airways disease and left ventricular dysfunction. An increase in pulmonary arterial pressure that is not due to coexistent cardiopulmonary disease, known as pulmonary arterial hypertension, may occur in the absence of a demonstrable cause (idiopathic or familial); as a complication of systemic conditions, such as connective tissue disease, HIV infection, or chronic liver disease; or as a result of the use of fenfluramine anorexigens, amphetamines, or cocaine. The development of disease-specific therapies for pulmonary arterial hypertension over the past decade underscores the importance of diagnosing pulmonary hypertension early in the course of the condition and implementing a treatment strategy that is based on the condition's cause and severity. In this review, the authors present approaches to the diagnosis and management of pulmonary arterial hypertension, using a hypothetical case to highlight the key management points.	Univ Calif San Diego, Med Ctr, 9300 Campus Pt Dr,M-C 7381, La Jolla, CA 92037 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA	University of California System; University of California San Diego; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Rubin, LJ (corresponding author), Univ Calif San Diego, Med Ctr, 9300 Campus Pt Dr,M-C 7381, La Jolla, CA 92037 USA.							Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; AHN HS, 1991, ADV EXP MED BIOL, V308, P191; Atwood CW, 2004, CHEST, V126, p72S, DOI 10.1378/chest.126.1_suppl.72S; Atz AM, 1999, ANESTHESIOLOGY, V91, P307, DOI 10.1097/00000542-199907000-00041; Azarian R, 1997, J NUCL MED, V38, P980; Badalian SS, 2000, J REPROD MED, V45, P149; Badesch DB, 2000, ANN INTERN MED, V132, P425, DOI 10.7326/0003-4819-132-6-200003210-00002; Badesch DB, 2004, CHEST, V126, p35S, DOI 10.1378/chest.126.1_suppl.35S; Bailey CL, 2000, AM J RESP CRIT CARE, V162, P1974, DOI 10.1164/ajrccm.162.5.2003045; Barst RJ, 2004, AM J RESP CRIT CARE, V169, P441, DOI 10.1164/rccm.200307-957OC; Barst RJ, 1996, NEW ENGL J MED, V334, P296, DOI 10.1056/NEJM199602013340504; Barst RJ, 2003, J AM COLL CARDIOL, V41, P2119, DOI 10.1016/S0735-1097(03)00463-7; BARST RJ, 1994, ANN INTERN MED, V121, P409, DOI 10.7326/0003-4819-121-6-199409150-00003; Battle RW, 1996, CHEST, V110, P1515, DOI 10.1378/chest.110.6.1515; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; Bharani Anil, 2003, Indian Heart J, V55, P55; Bossone E, 1999, J AM COLL CARDIOL, V33, P1662, DOI 10.1016/S0735-1097(99)00055-8; BRANER DAV, 1993, AM J PHYSIOL, V264, pH252, DOI 10.1152/ajpheart.1993.264.1.H252; BRECKER SJD, 1994, BRIT HEART J, V72, P384; Castro M, 1996, MAYO CLIN PROC, V71, P543, DOI 10.4065/71.6.543; Channick RN, 2001, LANCET, V358, P1119, DOI 10.1016/S0140-6736(01)06250-X; Christie JD, 2003, CHEST, V124, P1232, DOI 10.1378/chest.124.4.1232; CHRISTMAN BW, 1992, NEW ENGL J MED, V327, P70, DOI 10.1056/NEJM199207093270202; Cohen AH, 1996, J CLIN INVEST, V97, P172, DOI 10.1172/JCI118386; Decoene C, 2001, CAN J ANAESTH, V48, P584, DOI 10.1007/BF03016836; Denton CP, 1997, BRIT J RHEUMATOL, V36, P239; Du Lingling, 2003, New England Journal of Medicine, V348, P500, DOI 10.1056/NEJMoa021650; Eddahibi S, 2001, J CLIN INVEST, V108, P1141, DOI 10.1172/JCI12805; Elkayam U, 1998, CARDIAC PROBLEMS PRE, P183; FAGAN KA, 2004, PULMONARY CIRCULATIO, P181; Fedullo PF, 2001, NEW ENGL J MED, V345, P1465, DOI 10.1056/NEJMra010902; FUSTER V, 1984, CIRCULATION, V70, P580, DOI 10.1161/01.CIR.70.4.580; Galie N, 2004, J AM COLL CARDIOL, V43, p81S, DOI 10.1016/j.jacc.2004.02.038; Galie N, 2002, J AM COLL CARDIOL, V39, P1496, DOI 10.1016/S0735-1097(02)01786-2; Galie N, 1996, EUR J CLIN INVEST S1, V26, P273; Ghofrani HA, 2003, AM J RESP CRIT CARE, V167, P1139, DOI 10.1164/rccm.200210-1157BC; Ghofrani HA, 2002, ANN INTERN MED, V136, P515, DOI 10.7326/0003-4819-136-7-200204020-00008; GHOFRANI HA, 2004, CHEST; GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402; Gladwin MT, 2004, NEW ENGL J MED, V350, P886, DOI 10.1056/NEJMoa035477; Grunig E, 2000, CIRCULATION, V102, P1145, DOI 10.1161/01.CIR.102.10.1145; Hanson KA, 1998, AM J PHYSIOL-LUNG C, V275, pL931, DOI 10.1152/ajplung.1998.275.5.L931; Hinderliter AL, 1997, CIRCULATION, V95, P1479; Hoeper MM, 2000, J AM COLL CARDIOL, V35, P176, DOI 10.1016/S0735-1097(99)00494-5; Hoeper MM, 2000, NEW ENGL J MED, V342, P1866, DOI 10.1056/NEJM200006223422503; Hoeper MM, 2004, J AM COLL CARDIOL, V43, p48S, DOI 10.1016/j.jacc.2004.02.010; Hoeper MM, 2003, EUR RESPIR J, V22, P330, DOI 10.1183/09031936.03.00008003; Humbert M, 2004, EUR RESPIR J, V24, P353, DOI 10.1183/09031936.04.00028404; Kim H, 2000, EUR RESPIR J, V15, P640, DOI 10.1034/j.1399-3003.2000.15d04.x; King MA, 1998, AM J ROENTGENOL, V170, P955, DOI 10.2214/ajr.170.4.9530043; Kuo PC, 1997, CHEST, V112, P980, DOI 10.1378/chest.112.4.980; Lepore JJ, 2002, AM J CARDIOL, V90, P677, DOI 10.1016/S0002-9149(02)02586-9; LOVE PE, 1990, ANN INTERN MED, V112, P682, DOI 10.7326/0003-4819-112-9-682; MCCAFFREY R M, 1964, Obstet Gynecol Surv, V19, P567, DOI 10.1097/00006254-196408000-00001; McGoon M, 2004, CHEST, V126, p14S, DOI 10.1378/chest.126.1_suppl.14S; McLaughlin VV, 2002, CIRCULATION, V106, P1477, DOI 10.1161/01.CIR.0000029100.82385.58; Mehta NJ, 2000, CHEST, V118, P1133, DOI 10.1378/chest.118.4.1133; Mendeloff EN, 2002, ANN THORAC SURG, V73, P209, DOI 10.1016/S0003-4975(01)03082-X; Michelakis E, 2002, CIRCULATION, V105, P2398, DOI 10.1161/01.CIR.0000016641.12984.DC; Morris TA, 1996, CHEST, V110, P399, DOI 10.1378/chest.110.2.399; Nishimura T, 2003, CIRCULATION, V108, P1640, DOI 10.1161/01.CIR.0000087592.47401.37; OGATA M, 1993, JPN CIRC J, V57, P63, DOI 10.1253/jcj.57.63; Okano Y, 1997, LANCET, V349, P1365, DOI 10.1016/S0140-6736(97)24019-5; Olschewski H, 2000, ANN INTERN MED, V132, P435, DOI 10.7326/0003-4819-132-6-200003210-00003; Olschewski H, 2002, NEW ENGL J MED, V347, P322, DOI 10.1056/NEJMoa020204; Opravil M, 1997, AM J RESP CRIT CARE, V155, P990, DOI 10.1164/ajrccm.155.3.9117037; OWENS GR, 1983, CHEST, V84, P546, DOI 10.1378/chest.84.5.546; PETITPRETZ P, 1994, CIRCULATION, V89, P2722, DOI 10.1161/01.CIR.89.6.2722; Petkov V, 2003, J CLIN INVEST, V111, P1339, DOI 10.1172/JCI200317500; Pielsticker EJ, 2001, J HEART LUNG TRANSPL, V20, P1297, DOI 10.1016/S1053-2498(01)00348-5; Pietra GG, 2004, J AM COLL CARDIOL, V43, p25S, DOI 10.1016/j.jacc.2004.02.033; Rafanan AL, 2001, CHEST, V120, P894, DOI 10.1378/chest.120.3.894; Rich S, 2000, CHEST, V117, P870, DOI 10.1378/chest.117.3.870; Rich S, 1999, J AM COLL CARDIOL, V34, P1184, DOI 10.1016/S0735-1097(99)00320-4; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; Rich S, 1998, CHEST, V114, P787, DOI 10.1378/chest.114.3.787; RICH S, 1992, NEW ENGL J MED, V327, P76, DOI 10.1056/NEJM199207093270203; Rothman A, 1999, AM J CARDIOL, V84, P682, DOI 10.1016/S0002-9149(99)00416-6; Rubens C, 2001, CHEST, V120, P1562, DOI 10.1378/chest.120.5.1562; Rubin LJ, 2002, NEW ENGL J MED, V346, P896, DOI 10.1056/NEJMoa012212; Rubin LJ, 1997, NEW ENGL J MED, V336, P111, DOI 10.1056/NEJM199701093360207; RYAN KL, 1988, CHEST, V93, P1180, DOI 10.1378/chest.93.6.1180; Sandoval J, 2001, CLIN CHEST MED, V22, P547, DOI 10.1016/S0272-5231(05)70291-4; Sandoval J, 2001, AM J RESP CRIT CARE, V164, P1682, DOI 10.1164/ajrccm.164.9.2106076; Sandoval J, 1998, J AM COLL CARDIOL, V32, P297, DOI 10.1016/S0735-1097(98)00238-1; Sastry BKS, 2004, J AM COLL CARDIOL, V43, P1149, DOI 10.1016/j.jacc.2003.10.056; SCHRADER BJ, 1992, J AM COLL CARDIOL, V19, P1060, DOI 10.1016/0735-1097(92)90295-X; Shapiro SM, 1997, J AM COLL CARDIOL, V30, P343, DOI 10.1016/S0735-1097(97)00187-3; Simonneau G, 2002, AM J RESP CRIT CARE, V165, P800, DOI 10.1164/ajrccm.165.6.2106079; Sitbon O, 2002, J AM COLL CARDIOL, V40, P780, DOI 10.1016/S0735-1097(02)02012-0; SITBON O, 1995, AM J RESP CRIT CARE, V151, P384, DOI 10.1164/ajrccm.151.2.7842196; Steen V, 2003, ARTHRITIS RHEUM, V48, P516, DOI 10.1002/art.10775; Stewart R, 2001, CHEST, V119, P973, DOI 10.1378/chest.119.3.973; Swensen SJ, 1996, AM J ROENTGENOL, V167, P937, DOI 10.2214/ajr.167.4.8819387; Tanaka E, 2002, J RHEUMATOL, V29, P282; Thomson JR, 2000, J MED GENET, V37, P741, DOI 10.1136/jmg.37.10.741; Tuder RM, 1999, AM J RESP CRIT CARE, V159, P1925, DOI 10.1164/ajrccm.159.6.9804054; UNGERER RG, 1983, AM J MED, V75, P65, DOI 10.1016/0002-9343(83)91169-5; Weiss BM, 1998, J AM COLL CARDIOL, V31, P1650, DOI 10.1016/S0735-1097(98)00162-4; Wilkens H, 2001, CIRCULATION, V104, P1218, DOI 10.1161/hc3601.096826; 2004, CHEST S, V125, pS1	101	101	112	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 16	2005	143	4					282	292		10.7326/0003-4819-143-4-200508160-00009	http://dx.doi.org/10.7326/0003-4819-143-4-200508160-00009			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955PA	16103472	Green Published			2022-12-28	WOS:000231237100005
J	Johnson, D; Krsek, M; Wellington, EMH; Stott, AW; Cole, L; Bardgett, RD; Read, DJ; Leake, JR				Johnson, D; Krsek, M; Wellington, EMH; Stott, AW; Cole, L; Bardgett, RD; Read, DJ; Leake, JR			Soil invertebrates disrupt carbon flow through fungal networks	SCIENCE			English	Article							ARBUSCULAR MYCORRHIZAL FUNGI		Univ Aberdeen, Sch Biol Sci, Aberdeen AB24 3UU, Scotland; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; NERC, Life Sci Mass Spectrometry Facil, Lancaster Environm Ctr, Lancaster LA1 4AP, England; Ctr Ecol & Hydrol, Banchory AB31 4BW, Kincardine, Scotland; Univ Lancaster, Inst Environm & Nat Sci, Lancaster LA1 4YQ, England; Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England	University of Aberdeen; University of Warwick; Lancaster University; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); UK Centre for Ecology & Hydrology (UKCEH); Lancaster University; University of Sheffield	Johnson, D (corresponding author), Univ Aberdeen, Sch Biol Sci, Aberdeen AB24 3UU, Scotland.	D.Johnson@abdn.ac.uk	Johnson, David/N-3193-2013; Read, David/C-2454-2013; STOTT, ANDREW/I-7920-2012	Wellington, ELizabeth/0000-0002-4329-0699; Leake, Jonathan/0000-0001-8364-7616	Natural Environment Research Council [NER/J/S/2002/00652] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Gange A, 2000, TRENDS ECOL EVOL, V15, P369, DOI 10.1016/S0169-5347(00)01940-6; Leake JR, 2004, CAN J BOT, V82, P1016, DOI [10.1139/B04-060, 10.1139/b04-060]; MCGONIGLE TP, 1988, P R SOC EDINB B, V94, P2; OLSSON PA, 1995, MYCOL RES, V99, P623, DOI 10.1016/S0953-7562(09)80723-5; Staddon PL, 2003, SCIENCE, V300, P1138, DOI 10.1126/science.1084269; van der Heijden MGA, 1998, NATURE, V396, P69, DOI 10.1038/23932	6	113	124	4	135	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 12	2005	309	5737					1047	1047		10.1126/science.1114769	http://dx.doi.org/10.1126/science.1114769			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955MN	16099977				2022-12-28	WOS:000231230100037
J	Linnerooth-Bayer, J; Mechler, R; Pflug, G				Linnerooth-Bayer, J; Mechler, R; Pflug, G			Refocusing diaster aid	SCIENCE			English	Article								With new modeling techniques for estimating and pricing the risks of natural disasters, the donor community is now in a position to help the poor cope with the economic repercussions of disasters by assisting before they happen. Such assistance is possible with the advent of novel insurance instruments for transferring catastrophe risks to the global financial markets. Donor-supported risk-transfer programs not only would leverage limited disaster-aid budgets but also would free recipient countries from depending on the vagaries of postdisaster assistance. Both donors and recipients stand to gain, especially because the instruments can be closely coupled with preventive measures.	Int Inst Appl Syst Anal, A-2361 Laxenburg, Austria	International Institute for Applied Systems Analysis (IIASA)	Linnerooth-Bayer, J (corresponding author), Int Inst Appl Syst Anal, A-2361 Laxenburg, Austria.		Pflug, Georg/D-9323-2017	Pflug, Georg/0000-0001-8215-3550; /0000-0003-2239-1578; Bayer, Joanne/0000-0003-3084-2471				AUFFRET P, 2003, 2963 WORLD BANK GROU; EMBRECHTS P, 1997, MODELING EXTREME EVE; GEMAN H, 1999, INSURANCE WEATHER DE; Gurenko E., 2004, CATASTROPHE RISK REI, P3; HESS U, 2005, CLIMATE RISK WEATHER, P295; IPCC, 2001, ADV CLIM CHANG RES; Kuzak D., 2004, CATASTROPHE RISK REI, P41; Linnerooth-Bayer J., 2003, INSURANCE RELATED AC; Linnerooth-Bayer J., 2000, GENEVA PAP RISK INS, V25, P203, DOI [10.1111/1468-0440.00060, DOI 10.1111/1468-0440.00060]; LINNEROOTHBAYER.J, 2004, OECD C CAT RISKS INS; LINNEROOTHBAYER.J, UNPUB CLUMSY SOLUTIO; Mechler R., 2004, NATURAL DISASTER RIS; MECHLER R, IN PRESS COST BENEFI; Mills E, 2005, SCIENCE, V309, P1040, DOI 10.1126/science.1112121; MORRIS J, 2005, FT COM FINANCIA 0510; MunichRe, 2005, NAT DIS ACC COUNTR I; Parsons T, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002667; POLLNER J, 2000, MANAGING CATASTROPHI; Telford J, 2004, DISASTER RISK MANAGE, V8; UNISDR, 2005, WORLD C DIS RED KOB; VARANGIS P, 2005, CLIMATE RISK WEATHER, P279; World Bank, 2003, RISK FIN DIS; *WORLD BANK, 2005, WORLD BANK NEWS 0524	23	94	98	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 12	2005	309	5737					1044	1046		10.1126/science.1116783	http://dx.doi.org/10.1126/science.1116783			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955MN	16099976				2022-12-28	WOS:000231230100036
J	Lu, YH; Conrad, R				Lu, YH; Conrad, R			In situ stable isotope probing of methanogenic archaea in the rice rhizosphere	SCIENCE			English	Article							MICROBIAL COMMUNITY DYNAMICS; FIELD SOIL; PADDY FIELDS; CARBON FLOW; ROOTS; METHANE; LINKING; CH4; MICROORGANISMS; PHOTOSYNTHATES	Microorganisms living in anoxic rice soils contribute 10 to 25% of global methane emissions. The most important carbon source for CH4 production is plant-derived carbon that enters soil as root exudates and debris. Pulse labeling of rice plants with (CO2)-C-13 resulted in incorporation of C-13 into the ribosomal RNA of Rice Cluster I Archaea in the soil, indicating that this archaeal group plays a key role in CH4 production from plant-derived carbon. This group of microorganisms has not yet been isolated but appears to be of global environmental importance.	China Agr Univ, Coll Resources & Environm Sci, Beijing 100094, Peoples R China; Max Planck Inst Terr Microbiol, Karl von Frisch Str, D-35043 Marburg, Germany	China Agricultural University; Max Planck Society	Conrad, R (corresponding author), Max Planck Inst Terr Microbiol, Karl von Frisch Str, D-35043 Marburg, Germany.	conrad@staff.uni-marburg.de	Lu, Yahai/A-5030-2013	Lu, Yahai/0000-0002-1702-9868				Bodelier PLE, 2000, NATURE, V403, P421, DOI 10.1038/35000193; Boschker HTS, 1998, NATURE, V392, P801, DOI 10.1038/33900; Butler JL, 2003, APPL ENVIRON MICROB, V69, P6793, DOI 10.1128/AEM.69.11.6793-6800.2003; Chin KJ, 1999, APPL ENVIRON MICROB, V65, P2341; Conrad R, 1999, FEMS MICROBIOL ECOL, V30, P147, DOI 10.1111/j.1574-6941.1999.tb00643.x; Erkel C, 2005, FEMS MICROBIOL ECOL, V53, P187, DOI 10.1016/j.femsec.2004.12.004; Griffiths RI, 2004, J MICROBIOL METH, V58, P119, DOI 10.1016/j.mimet.2004.03.011; Grosskopf R, 1998, APPL ENVIRON MICROB, V64, P4983; Hogberg P, 2001, NATURE, V411, P789, DOI 10.1038/35081058; Inubushi K, 2003, GLOBAL CHANGE BIOL, V9, P1458, DOI 10.1046/j.1365-2486.2003.00665.x; Jeon CO, 2003, P NATL ACAD SCI USA, V100, P13591, DOI 10.1073/pnas.1735529100; King JY, 2002, SOIL BIOL BIOCHEM, V34, P173, DOI 10.1016/S0038-0717(01)00164-X; Lehmann-Richter S, 1999, ENVIRON MICROBIOL, V1, P159; Lelieveld J, 1998, TELLUS B, V50, P128, DOI 10.1034/j.1600-0889.1998.t01-1-00002.x; Lu YH, 2004, FEMS MICROBIOL ECOL, V48, P179, DOI 10.1016/j.femsec.2004.01.004; Lu YH, 2005, ENVIRON MICROBIOL, V7, P326, DOI 10.1111/j.1462-2920.2005.00697.x; Lueders T, 2004, ENVIRON MICROBIOL, V6, P60, DOI 10.1046/j.1462-2920.2003.00535.x; Lueders T, 2001, ENVIRON MICROBIOL, V3, P194, DOI 10.1046/j.1462-2920.2001.00179.x; LYNCH JM, 1990, PLANT SOIL, V129, P1, DOI 10.1007/BF00011685; Manefield M, 2002, APPL ENVIRON MICROB, V68, P5367, DOI 10.1128/AEM.68.11.5367-5373.2002; Minoda T, 1996, J GEOPHYS RES-ATMOS, V101, P21091, DOI 10.1029/96JD01710; Paustian K, 1997, GEODERMA, V79, P227, DOI 10.1016/S0016-7061(97)00043-8; Radajewski S, 2000, NATURE, V403, P646, DOI 10.1038/35001054; Rangel-Castro JI, 2005, ENVIRON MICROBIOL, V7, P828, DOI 10.1111/j.1462-2920.2005.00756.x; Singh BK, 2004, TRENDS MICROBIOL, V12, P386, DOI 10.1016/j.tim.2004.06.008; Treonis AM, 2004, SOIL BIOL BIOCHEM, V36, P533, DOI 10.1016/j.soilbio.2003.10.015; van der Gon HACD, 2002, P NATL ACAD SCI USA, V99, P12021, DOI 10.1073/pnas.192276599; Wang JS, 2004, GLOBAL BIOGEOCHEM CY, V18, DOI 10.1029/2003GB002180; Wardle DA, 2004, SCIENCE, V304, P1629, DOI 10.1126/science.1094875	29	224	267	15	431	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 12	2005	309	5737					1088	1090		10.1126/science.1113435	http://dx.doi.org/10.1126/science.1113435			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955MN	16099988				2022-12-28	WOS:000231230100049
J	Kao, H; Shan, SJ; Dragert, H; Rogers, G; Cassidy, JF; Ramachandran, K				Kao, H; Shan, SJ; Dragert, H; Rogers, G; Cassidy, JF; Ramachandran, K			A wide depth distribution of seismic tremors along the northern Cascadia margin	NATURE			English	Article							SUBDUCTION ZONE; SOUTHWEST JAPAN; ASEISMIC SLIP; SILENT SLIP; EARTHQUAKES; MODEL; DEEP; DEFORMATION; REFLECTIONS; WASHINGTON	The Cascadia subduction zone is thought to be capable of generating major earthquakes with moment magnitude as large as M-w = 9 at an interval of several hundred years(1-3). The seismogenic portion of the plate interface is mostly offshore and is currently locked, as inferred from geodetic data(4-6). However, episodic surface displacements - in the direction opposite to the long-term deformation motions caused by relative plate convergence across a locked interface - are observed about every 14 months with an unusual tremor-like seismic signature(7-9). Here we show that these tremors are distributed over a depth range exceeding 40 km within a limited horizontal band. Many occurred within or close to the strong seismic reflectors above the plate interface where local earthquakes are absent, suggesting that the seismogenic process for tremors is fluid-related. The observed depth range implies that tremors could be associated with the variation of stress field induced by a transient slip along the deeper portion of the Cascadia interface or, alternatively, that episodic slip is more diffuse than originally suggested.	Geol Survey Canada, Pacific Geosci Ctr, Sidney, BC V8L 1B9, Canada	Natural Resources Canada; Lands & Minerals Sector - Natural Resources Canada; Geological Survey of Canada	Kao, H (corresponding author), Geol Survey Canada, Pacific Geosci Ctr, 9860 W Saanich Rd, Sidney, BC V8L 1B9, Canada.	hkao@nrcan.gc.ca						Adam J, 2004, TECTONICS, V23, DOI 10.1029/2002TC001475; Atwater B., 1997, US GEOLOGICAL SURVEY; ATWATER BF, 1987, SCIENCE, V236, P942, DOI 10.1126/science.236.4804.942; BROAN KM, 2003, EOS S, V84; Calvert AJ, 2004, NATURE, V428, P163, DOI 10.1038/nature02372; CALVERT AJ, 1990, GEOLOGY, V18, P1091, DOI 10.1130/0091-7613(1990)018<1091:DHARFA>2.3.CO;2; CASSIDY JF, 1993, J GEOPHYS RES-SOL EA, V98, P4407, DOI 10.1029/92JB02696; CLOWES RM, 1987, CAN J EARTH SCI, V24, P31, DOI 10.1139/e87-004; Dragert H, 2001, SCIENCE, V292, P1525, DOI 10.1126/science.1060152; DRAGERT H, 1995, GEOPHYS RES LETT, V22, P755, DOI 10.1029/95GL00469; HYNDMAN RD, 1988, J GEOPHYS RES-SOLID, V93, P13391, DOI 10.1029/JB093iB11p13391; Hyndman RD, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB001710; Kao H, 2004, GEOPHYS J INT, V157, P589, DOI 10.1111/j.1365-246X.2004.02276.x; Katsumata A, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL015981; LINDE AT, 1989, GEOPHYS RES LETT, V16, P1305, DOI 10.1029/GL016i011p01305; Mazzotti S, 2004, B SEISMOL SOC AM, V94, P1954, DOI 10.1785/012004032; Miller MM, 2002, SCIENCE, V295, P2423, DOI 10.1126/science.1071193; Nedimovic MR, 2003, NATURE, V424, P416, DOI 10.1038/nature01840; Obara K, 2002, SCIENCE, V296, P1679, DOI 10.1126/science.1070378; PEACOCK SM, 1990, SCIENCE, V248, P329, DOI 10.1126/science.248.4953.329; Ramachandran K, 2005, J GEOPHYS RES-SOL EA, V110, DOI 10.1029/2004JB003258; Rogers G, 2003, SCIENCE, V300, P1942, DOI 10.1126/science.1084783; Satake K., 2003, J GEOPHYS RES, V108; SAVAGE JC, 1991, SCIENCE, V252, P101, DOI 10.1126/science.252.5002.101; SHIMAZAKI K, 1980, GEOPHYS RES LETT, V7, P279, DOI 10.1029/GL007i004p00279; Szeliga W, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020824; THATCHER W, 1982, NATURE, V299, P12, DOI 10.1038/299012a0; von Huene R, 2004, GEOLOGY, V32, P913, DOI 10.1130/G20563.1; Wang K, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB001227; Wang T, 2004, APPL PHYS LETT, V85, P43, DOI 10.1063/1.1766404	30	159	165	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 11	2005	436	7052					841	844		10.1038/nature03903	http://dx.doi.org/10.1038/nature03903			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953XG	16094366				2022-12-28	WOS:000231116500044
J	Ren, ZY; Ingle, S; Takahashi, E; Hirano, N; Hirata, T				Ren, ZY; Ingle, S; Takahashi, E; Hirano, N; Hirata, T			The chemical structure of the Hawaiian mantle plume	NATURE			English	Article							INTERSHIELD GEOCHEMICAL DIFFERENCES; SCIENTIFIC DRILLING PROJECT; HOSTED MELT INCLUSIONS; ISOTOPIC EVOLUTION; KOOLAU VOLCANO; MAUNA-LOA; LAVAS; VARIABILITY; ABUNDANCES; MINERALS	The Hawaiian - Emperor volcanic island and seamount chain is usually attributed to a hot mantle plume, located beneath the Pacific lithosphere, that delivers material sourced from deep in the mantle to the surface(1-5). The shield volcanoes of the Hawaiian islands are distributed in two curvilinear, parallel trends ( termed 'Kea' and 'Loa'), whose rocks are characterized by general geochemical differences(2-5). This has led to the proposition that Hawaiian volcanoes sample compositionally distinct, concentrically zoned, regions of the underlying mantle plume(4,5). Melt inclusions, or samples of local magma 'frozen' in olivine phenocrysts during crystallization, may record complexities of mantle sources(6), thereby providing better insight into the chemical structure of plumes. Here we report the discovery of both Kea- and Loa-like major and trace element compositions in olivine-hosted melt inclusions in individual, shield-stage Hawaiian volcanoes - even within single rock samples. We infer from these data that one mantle source component may dominate a single lava flow, but that the two mantle source components are consistently represented to some extent in all lavas, regardless of the specific geographic location of the volcano. We therefore suggest that the Hawaiian mantle plume is unlikely to be compositionally concentrically zoned. Instead, the observed chemical variation is probably controlled by the thermal structure of the plume.	Tokyo Inst Technol, Dept Earth & Planetary Sci, Meguro Ku, Tokyo 1528551, Japan; Japan Agcy Marine Earth Sci & Technol, Inst Frontier Res Earth Evolut, Kanagawa 2370061, Japan	Tokyo Institute of Technology; Japan Agency for Marine-Earth Science & Technology (JAMSTEC)	Ren, ZY (corresponding author), Tokyo Inst Technol, Dept Earth & Planetary Sci, Meguro Ku, 2-12-1 Ookayama, Tokyo 1528551, Japan.	zyren@jamstec.go.jp	HIRANO, NAOTO/F-6009-2016; Takahashi, Eiichi/B-4883-2017	HIRANO, NAOTO/0000-0003-3491-0312; Takahashi, Eiichi/0000-0002-6500-1827; Hirano, Naoto/0000-0003-0980-3929				Abouchami W, 2005, NATURE, V434, P851, DOI 10.1038/nature03402; Blichert-Toft J, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2002GC000340; Eisele J, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2002GC000339; Farnetani CG, 2002, EARTH PLANET SC LETT, V196, P1, DOI 10.1016/S0012-821X(01)00597-0; FREY FA, 1994, GEOCHIM COSMOCHIM AC, V58, P1441, DOI 10.1016/0016-7037(94)90548-7; FREY FA, 1993, PHILOS T R SOC A, V342, P121, DOI 10.1098/rsta.1993.0009; Gaetani GA, 2000, EARTH PLANET SC LETT, V183, P27, DOI 10.1016/S0012-821X(00)00260-0; GARCIA MO, 1995, GEOPHYS MONOGR SER, V92, P219; Gasperini D, 2000, NATURE, V408, P701, DOI 10.1038/35047049; Hauri E, 2002, CHEM GEOL, V183, P115, DOI 10.1016/S0009-2541(01)00374-6; Hauri EH, 1996, NATURE, V382, P415, DOI 10.1038/382415a0; HIROSE K, 1993, EARTH PLANET SC LETT, V114, P477, DOI 10.1016/0012-821X(93)90077-M; Hofmann AW, 1996, J GEOPHYS RES-SOL EA, V101, P11831, DOI 10.1029/95JB03701; Huang S, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2002GC000322; Lassiter JC, 1998, EARTH PLANET SC LETT, V164, P483, DOI 10.1016/S0012-821X(98)00240-4; Lassiter JC, 1996, J GEOPHYS RES-SOL EA, V101, P11769, DOI 10.1029/96JB00181; Maclennan J, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2000JB000142; MORGAN WJ, 1971, NATURE, V230, P42, DOI 10.1038/230042a0; Norman MD, 2002, CHEM GEOL, V183, P143, DOI 10.1016/S0009-2541(01)00376-X; Norman MD, 1998, J ANAL ATOM SPECTROM, V13, P477, DOI 10.1039/a707972i; Pertermann M, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2000JB000118; Putirka K, 1999, J GEOPHYS RES-SOL EA, V104, P2817, DOI 10.1029/1998JB900048; Ren ZY, 2004, J PETROL, V45, P2067, DOI 10.1093/petrology/egh076; REN ZY, IN PRESS J PETROL; Rhodes M, 2004, GEOCHEM GEOPHY GEOSY, V5, DOI 10.1029/2003GC000622; Slater L, 2001, J PETROL, V42, P321, DOI 10.1093/petrology/42.2.321; Sobolev AV, 2000, NATURE, V404, P986, DOI 10.1038/35010098; Sobolev AV, 1996, PETROLOGY+, V4, P209; Sun S.-S., 1989, GEOLOGICAL SOC LONDO, V42, P323, DOI [10.1144/GSL.SP.1989.042.01.19, DOI 10.1144/GSL.SP.1989.042.01.19]; Takahahshi E, 1998, EARTH PLANET SC LETT, V162, P63, DOI 10.1016/S0012-821X(98)00157-5; Takahashi E, 2002, GEOPH MONOG SERIES, V128, P403; Tanaka R, 2002, GEOPH MONOG SERIES, V128, P311; WEST HB, 1987, EARTH PLANET SC LETT, V84, P211, DOI 10.1016/0012-821X(87)90087-2	33	90	107	2	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 11	2005	436	7052					837	840		10.1038/nature03907	http://dx.doi.org/10.1038/nature03907			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953XG	16100780				2022-12-28	WOS:000231116500043
J	Sheikh, A; Walker, S				Sheikh, A; Walker, S			10-minute consultation - Anaphylaxis	BRITISH MEDICAL JOURNAL			English	Article									Univ Edinburgh, GP Sect, Div Community Hlth Sci, Edinburgh EH8 9DX, Midlothian, Scotland; Natl Resp Training Ctr, Warwick, England	University of Edinburgh	Sheikh, A (corresponding author), Univ Edinburgh, GP Sect, Div Community Hlth Sci, Edinburgh EH8 9DX, Midlothian, Scotland.	aziz.sheikh@ed.ac.uk	Sheikh, Aziz/D-2818-2009	Sheikh, Aziz/0000-0001-7022-3056					0	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	AUG 6	2005	331	7512					330	330		10.1136/bmj.331.7512.330	http://dx.doi.org/10.1136/bmj.331.7512.330			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955WZ	16081446	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000231259800021
J	Jayaraman, KS				Jayaraman, KS			Wellcome funding	NATURE			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 28	2005	436	7050					489	489						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	949LE	16089006				2022-12-28	WOS:000230788800044
J	Spinewine, A; Swine, C; Dhillon, S; Franklin, BD; Tulkens, PM; Wilmotte, L; Lorant, V				Spinewine, A; Swine, C; Dhillon, S; Franklin, BD; Tulkens, PM; Wilmotte, L; Lorant, V			Appropriateness of use of medicines in elderly inpatients: qualitative study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IN-HOSPITAL INPATIENTS; INTERNAL-MEDICINE; OLDER PATIENTS; HEALTH-CARE; GERIATRICS; PHYSICIAN; BEHAVIOR	Objectives To explore the processes leading to inappropriate use of medicines for elderly patients admitted for acute care. Design Qualitative study with semistructured interviews with doctors, nurses, and pharmacists; focus groups with inpatients; and observation on die ward by clinical pharmacists for one month. Setting Five acute wards for care of the elderly in Belgium. Participants 5 doctors, 4 nurses, and 3 pharmacists from five acute wards for the interviews; all professionals and patients on two acute wards for the observation and 17 patients (from the same two wards) for the focus groups. Results Several factors contributed to inappropriate prescribing, counselling, and transfer of information on medicines to primary care. Firstly, review of treatment was driven by acute considerations, the transfer of information on medicines from primary to secondary care was limited, and prescribing was often not tailored to elderly patients. Secondly, some doctors had a passive attitude towards learning: they thought it would take too long to find the information they needed about medicines and lacked self directed learning. Finally, a paternalistic doctor-patient relationship and difficulties in sharing decisions about treatment between prescribers led to inappropriate use of medicines. Several factors, such as the input of geriatricians and good communication between members of the multidisciplinary geriatric team, led to better use of medicines. Conclusions In this setting, improvements targeted at the abilities of individuals, better doctor-patient and doctor-doctor relationships, and systems for transferring information between care settings will increase the appropriate use of medicines in elderly people.	Catholic Univ Louvain, Sch Pharm, Ctr Clin Pharm, B-1200 Brussels, Belgium; Mt Godinne Univ Hosp, Dept Geriatr Med, B-5530 Yvoir, Belgium; Univ Hertfordshire, Sch Pharm, Hatfield AL10 9AB, Herts, England; Hammersmith Hosp NHS Trust, Acad Pharm Unit, London W12 0HS, England; Catholic Univ Louvain, Clin Univ St Luc, B-1200 Brussels, Belgium; Catholic Univ Louvain, Sch Publ Hlth, B-3000 Louvain, Belgium	Universite Catholique Louvain; Universite Catholique Louvain; Universite Catholique Louvain Hospital; University of Hertfordshire; Imperial College London; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain	Spinewine, A (corresponding author), Catholic Univ Louvain, Sch Pharm, Ctr Clin Pharm, B-1200 Brussels, Belgium.	anne.spinewine@facm.ucl.ac.be	; Tulkens, Paul/B-2087-2015	/0000-0002-2663-332X; Franklin, Bryony/0000-0002-2892-1245; Tulkens, Paul/0000-0002-7121-3623				Al-Rashed SA, 2002, BRIT J CLIN PHARMACO, V54, P657, DOI 10.1046/j.1365-2125.2002.01707.x; Britten N, 2000, BMJ-BRIT MED J, V320, P484, DOI 10.1136/bmj.320.7233.484; BURNS JMA, 1992, AGE AGEING, V21, P178, DOI 10.1093/ageing/21.3.178; Cook DJ, 2004, LANCET, V363, P1224, DOI 10.1016/S0140-6736(04)15955-2; Dean B, 2002, QUAL SAF HEALTH CARE, V11, P340, DOI 10.1136/qhc.11.4.340; Dean B, 2002, LANCET, V359, P1373, DOI 10.1016/S0140-6736(02)08350-2; Department of Health, SINGL ASS PROC; Dickinson D, 2003, BRIT MED J, V327, P861, DOI 10.1136/bmj.327.7419.861-a; Gafni A, 1998, SOC SCI MED, V47, P347, DOI 10.1016/S0277-9536(98)00091-4; Hanlon JT, 2000, ANN PHARMACOTHER, V34, P360, DOI 10.1345/aph.19140; KROENKE LTCK, 1990, J AM GERIATR SOC, V38, P31, DOI 10.1111/j.1532-5415.1990.tb01593.x; Larson EB, 2001, ANN INTERN MED, V134, P997, DOI 10.7326/0003-4819-134-10-200105150-00013; Mangione-Smith R, 2002, HEALTH SERV RES, V37, P1603, DOI 10.1111/1475-6773.10482; Mays N, 2000, BMJ-BRIT MED J, V320, P50, DOI 10.1136/bmj.320.7226.50; Mold F, 2003, HEALTH SOC CARE COMM, V11, P405, DOI 10.1046/j.1365-2524.2003.00443.x; National Service Framework for Older People, 2001, MED OLD PEOPL IMPL M; OWENS NJ, 1990, J AM GERIATR SOC, V38, P1082, DOI 10.1111/j.1532-5415.1990.tb01369.x; Rathore SS, 2003, AM J MED, V114, P307, DOI 10.1016/S0002-9343(02)01531-0; Rochon PA, 1999, JAMA-J AM MED ASSOC, V282, P113, DOI 10.1001/jama.282.2.113; Rolfe IE, 2002, MED EDUC, V36, P345, DOI 10.1046/j.1365-2923.2002.01170.x; Schmader KE, 2004, AM J MED, V116, P394, DOI 10.1016/j.amjmed.2003.10.031; Strauss A., 1990, BASICS QUALITATIVE R; Thomas DC, 2003, ANN INTERN MED, V139, P628, DOI 10.7326/0003-4819-139-7-200310070-00037; Tomlin Z, 1999, BMJ-BRIT MED J, V318, P1532, DOI 10.1136/bmj.318.7197.1532	24	66	69	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 22	2005	331	7522					935	938		10.1136/bmj.38551.410012.06	http://dx.doi.org/10.1136/bmj.38551.410012.06			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	979UR	16093254	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000232970900020
J	Metzger, E; Wissmann, M; Yin, N; Muller, JM; Schneider, R; Peters, AHFM; Gunther, T; Buettner, R; Schule, R				Metzger, E; Wissmann, M; Yin, N; Muller, JM; Schneider, R; Peters, AHFM; Gunther, T; Buettner, R; Schule, R			LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription	NATURE			English	Article							COMPLEX; COACTIVATOR; FHL2	Gene regulation in eukaryotes requires the coordinate interaction of chromatin-modulating proteins with specific transcription factors such as the androgen receptor(1). Gene activation and repression is specifically regulated by histone methylation status at distinct lysine residues(2). Here we show that lysine-specific demethylase 1 (LSD1; also known as BHC110)(3) co-localizes with the androgen receptor in normal human prostate and prostate tumour. LSD1 interacts with androgen receptor in vitro and in vivo, and stimulates androgen-receptor-dependent transcription. Conversely, knockdown of LSD1 protein levels abrogates androgen-induced transcriptional activation and cell proliferation. Chromatin immunoprecipitation analyses demonstrate that androgen receptor and LSD1 form chromatin-associated complexes in a ligand-dependent manner. LSD1 relieves repressive histone marks by demethylation of histone H3 at lysine 9 (H3-K9), thereby leading to de-repression of androgen receptor target genes. Furthermore, we identify pargyline as an inhibitor of LSD1. Pargyline blocks demethylation of H3-K9 by LSD1 and consequently androgen-receptor-dependent transcription. Thus, modulation of LSD1 activity offers a new strategy to regulate androgen receptor functions. Here, we link demethylation of a repressive histone mark with androgen-receptor-dependent gene activation, thus providing a mechanism by which demethylases control specific gene expression.	Univ Freiburg Klinikum, Univ Frauenklin, D-79106 Freiburg, Germany; Univ Freiburg Klinikum, Zentrum Klin Forsch, D-79106 Freiburg, Germany; Max Planck Inst Immunbiol, D-79108 Freiburg, Germany; Novartis Res Fdn, Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; Univ Klinikum Bonn, Inst Pathol, D-53127 Bonn, Germany	University of Freiburg; University of Freiburg; Max Planck Society; Friedrich Miescher Institute for Biomedical Research; Novartis; University of Bonn	Schule, R (corresponding author), Univ Freiburg Klinikum, Univ Frauenklin, Breisacherstr 66, D-79106 Freiburg, Germany.	roland.schuele@uniklinik-freiburg.de		Gunther, Thomas/0000-0003-3903-9490; Peters, Antoine/0000-0002-0311-1887				Eimer S, 2002, EMBO J, V21, P5787, DOI 10.1093/emboj/cdf561; Glass CK, 2000, GENE DEV, V14, P121; Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599; Hakimi MA, 2003, J BIOL CHEM, V278, P7234, DOI 10.1074/jbc.M208992200; Kang ZG, 2002, J BIOL CHEM, V277, P48366, DOI 10.1074/jbc.M209074200; Metzger E, 2003, EMBO J, V22, P270, DOI 10.1093/emboj/cdg023; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Muller JM, 2002, EMBO J, V21, P736, DOI 10.1093/emboj/21.4.736; ONEILL TE, 1992, J MOL BIOL, V223, P67, DOI 10.1016/0022-2836(92)90716-W; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Shatkina L, 2003, MOL CELL BIOL, V23, P7189, DOI 10.1128/MCB.23.20.7189-7197.2003; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003	16	1270	1395	8	133	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 15	2005	437	7057					436	439		10.1038/nature04020	http://dx.doi.org/10.1038/nature04020			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	964AS	16079795				2022-12-28	WOS:000231849100059
J	Woodall, AA; Sandbach, EJ; Woodward, CM; Aveyard, P; Merrington, G				Woodall, AA; Sandbach, EJ; Woodward, CM; Aveyard, P; Merrington, G			The partial smoking ban in licensed establishments and health inequalities in England: modelling study	BRITISH MEDICAL JOURNAL			English	Article									Telford & Wrekin Primary Care Trust, Telford TF1 5RY, Shrops, England; Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England; Borough Telford & Wrekin Council, Telford TF3 4LE, Shrops, England	University of Birmingham	Woodall, AA (corresponding author), Telford & Wrekin Primary Care Trust, Telford TF1 5RY, Shrops, England.	alan.woodall@telfordpct.nhs.uk		Woodall, Alan/0000-0003-2933-0508; Aveyard, Paul/0000-0002-1802-4217				*BRIT MED ASS, 2005, BOOZ FAGS FOOD; Department of Health, 2004, CHOOS HLTH MAK HLTH; Jamrozik K, 2005, BRIT MED J, V330, P812, DOI 10.1136/bmj.38370.496632.8F; Raine R, 2004, BRIT MED J, V329, P1247, DOI 10.1136/bmj.329.7477.1247; Wiltshire S, 2003, HEALTH EDUC RES, V18, P292, DOI 10.1093/her/cyf031	5	9	9	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	SEP 3	2005	331	7515					488	489		10.1136/bmj.38576.467292.EB	http://dx.doi.org/10.1136/bmj.38576.467292.EB			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	963RA	16113033	Green Published, Bronze			2022-12-28	WOS:000231820400016
J	McGarvey, EL; Brenin, DR				McGarvey, EL; Brenin, DR			Myths about cancer might interfere with screening decisions	LANCET			English	Editorial Material							CARCINOMA IN-SITU; BREAST-CANCER; RACIAL-DIFFERENCES; ATTITUDES; WOMEN		Dept Psychiat Med, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Surg, Charlottesville, VA 22908 USA	University of Virginia	McGarvey, EL (corresponding author), Dept Psychiat Med, Charlottesville, VA 22908 USA.	rel8s@virginia.edu		Brenin, David/0000-0003-2589-121X				Bazargan M, 2004, PREV MED, V39, P465, DOI 10.1016/j.ypmed.2004.05.003; Breen N, 2001, J NATL CANCER I, V93, P1704, DOI 10.1093/jnci/93.22.1704; Cady B, 1998, J SURG ONCOL, V69, P60, DOI 10.1002/(SICI)1096-9098(199810)69:2<60::AID-JSO2>3.0.CO;2-3; Denberg TD, 2005, PATIENT EDUC COUNS, V57, P280, DOI 10.1016/j.pec.2004.07.015; Desai MM, 1999, INT J PSYCHIAT MED, V29, P29, DOI 10.2190/0C63-U15V-5NUR-TVXE; Donovan RJ, 2004, MED J AUSTRALIA, V181, P23, DOI 10.5694/j.1326-5377.2004.tb06153.x; Feig SA, 2000, RADIOL CLIN N AM, V38, P653, DOI 10.1016/S0033-8389(05)70192-5; Feig SA, 2005, BREAST J, V11, pS3, DOI 10.1111/j.1075-122X.2005.217161.x; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Hsia J, 2000, PREV MED, V31, P261, DOI 10.1006/pmed.2000.0697; McGarvey EL, 2003, ETHNIC HEALTH, V8, P71, DOI 10.1080/13557850303556; *NCI, 2005, GEN BREAST OV CANC; Ogedegbe G, 2005, J NATL MED ASSOC, V97, P162; Paskett ED, 2004, CANCER-AM CANCER SOC, V101, P2650, DOI 10.1002/cncr.20671; Pirraglia PA, 2004, J WOMENS HEALTH, V13, P731, DOI 10.1089/jwh.2004.13.731; Shavers VL, 2002, ANN EPIDEMIOL, V12, P248, DOI 10.1016/S1047-2797(01)00265-4; Smart CR, 1997, CA-CANCER J CLIN, V47, P134, DOI 10.3322/canjclin.47.3.134; *US BUR CENS, 1990, FOR BORN RES POP EST; Wu Tsu-Yin, 2005, Health Care Women Int, V26, P225, DOI 10.1080/07399330590917780; Yen MF, 2003, EUR J CANCER, V39, P1746, DOI 10.1016/S0959-8049(03)00260-0	20	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 27	2005	366	9487					700	702		10.1016/S0140-6736(05)67156-5	http://dx.doi.org/10.1016/S0140-6736(05)67156-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	958UV	16125574				2022-12-28	WOS:000231474600010
J	Connolly, SR; Hughes, TP; Bellwood, DR; Karlson, RH				Connolly, SR; Hughes, TP; Bellwood, DR; Karlson, RH			Community structure of corals and reef fishes at multiple scales	SCIENCE			English	Article							SPECIES ABUNDANCE DISTRIBUTIONS; NEUTRAL THEORY; BIODIVERSITY; POPULATION; RESILIENCE; PATTERNS; COMPETITION; ECOSYSTEMS; DIVERSITY	Distributions of numerical abundance and resource use among species are fundamental aspects of community structure. Here we characterize these patterns for tropical reef fishes and corals across a 10,000-kilometer biodiversity gradient. Numerical abundance and resource-use distributions have similar shapes, but they emerge at markedly different scales. These results are consistent with a controversial null hypothesis regarding community structure, according to which abundance distributions arise from the interplay of multiple stochastic environmental and demographic factors. Our findings underscore the importance of robust conservation strategies that are appropriately scaled to the broad suite of environmental processes that help sustain biodiversity.	James Cook Univ N Queensland, Dept Marine Biol, Ctr Coral Reef Biodivers, Townsville, Qld 4811, Australia; Univ Delaware, Dept Biol Sci, Newark, DE 19716 USA	James Cook University; University of Delaware	Connolly, SR (corresponding author), James Cook Univ N Queensland, Dept Marine Biol, Ctr Coral Reef Biodivers, Townsville, Qld 4811, Australia.		Hughes, Terry P/L-4721-2013; Connolly, Sean R./E-7773-2011	Hughes, Terry P/0000-0002-5257-5063; Connolly, Sean R./0000-0003-1537-0859				Bellwood DR, 2005, ECOL LETT, V8, P643, DOI 10.1111/j.1461-0248.2005.00763.x; Bellwood DR, 2003, ECOL LETT, V6, P281, DOI 10.1046/j.1461-0248.2003.00432.x; Bellwood DR, 2004, NATURE, V429, P827, DOI 10.1038/nature02691; Bellwood DR, 2001, SCIENCE, V292, P1532, DOI 10.1126/science.1058635; Engen S, 1996, J THEOR BIOL, V178, P325, DOI 10.1006/jtbi.1996.0028; Engen S, 1996, MATH BIOSCI, V132, P169, DOI 10.1016/0025-5564(95)00054-2; Fisher RA, 1943, J ANIM ECOL, V12, P42, DOI 10.2307/1411; Hubbell Stephen P., 2001, V32, pi; Hughes TP, 2005, TRENDS ECOL EVOL, V20, P380, DOI 10.1016/j.tree.2005.03.022; Hughes TP, 2003, SCIENCE, V301, P929, DOI 10.1126/science.1085046; MACARTHUR RH, 1957, P NATL ACAD SCI USA, V43, P293, DOI 10.1073/pnas.43.3.293; Magurran AE, 2003, NATURE, V422, P714, DOI 10.1038/nature01547; May R.M., 1975, P81; McGill BJ, 2003, ECOL LETT, V6, P766, DOI 10.1046/j.1461-0248.2003.00491.x; McGill BJ, 2003, NATURE, V422, P881, DOI 10.1038/nature01583; Mouquet N, 2003, AM NAT, V162, P544, DOI 10.1086/378857; NEE S, 1991, P ROY SOC B-BIOL SCI, V243, P161, DOI 10.1098/rspb.1991.0026; Pachepsky E, 2001, NATURE, V410, P923, DOI 10.1038/35073563; PRESTON FW, 1962, ECOLOGY, V43, P185, DOI 10.2307/1931976; Sole RV, 2002, PHILOS T R SOC B, V357, P667, DOI 10.1098/rstb.2001.0992; Taper ML, 1996, AM NAT, V147, P1072, DOI 10.1086/285893; TILMAN D, 1994, ECOLOGY, V75, P2, DOI 10.2307/1939377; Tilman D, 2004, P NATL ACAD SCI USA, V101, P10854, DOI 10.1073/pnas.0403458101; Tokeshi M., 1999, SPECIES COEXISTENCE; Volkov I, 2003, NATURE, V424, P1035, DOI 10.1038/nature01883; Wainwright PC, 2004, BIOL J LINN SOC, V82, P1, DOI 10.1111/j.1095-8312.2004.00313.x; Williamson M, 2005, J ANIM ECOL, V74, P409, DOI 10.1111/j.1365-2656.2005.00936.x; Wootton JT, 2005, NATURE, V433, P309, DOI 10.1038/nature03211	28	112	119	3	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 26	2005	309	5739					1363	1365		10.1126/science.1113281	http://dx.doi.org/10.1126/science.1113281			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TX	16123298				2022-12-28	WOS:000231543300041
J	Julius, D; Basbaum, AI				Julius, D; Basbaum, AI			A neuropeptide courier for delta-opioid receptors?	CELL			English	Editorial Material							SUBSTANCE-P; SECRETION; PAIN	The delta-opioid receptor and the precursor protein of a neuropeptide, substance P, are colocalized in the large dense-core vesicles of pain-sensing neurons. In this issue of Cell, Guan et al. (2005) report that trafficking of the delta-opioid receptor to these vesicles depends on its physical interaction with the substance P domain of its precursor polyprotein (protachykinin). Moreover, in mice lacking this precursor, the contribution of the delta-opioid receptor to pain processing is dramatically altered. These observations suggest a new role for peptide precursors as sorting signals in vesicular transport.	Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, WM Keck Fdn Ctr Integrat Neurosci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Julius, D (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA.							Acosta CG, 1999, J NEUROSCI, V19, P8337; Bao L, 2003, NEURON, V37, P121, DOI 10.1016/S0896-6273(02)01103-0; Basbaum AI, 1999, CURR BIOL, V9, pR429, DOI 10.1016/S0960-9822(99)80273-5; Cahill CM, 2001, J NEUROSCI, V21, P7598, DOI 10.1523/JNEUROSCI.21-19-07598.2001; Cao YQ, 1998, NATURE, V392, P390, DOI 10.1038/32897; De Felipe C, 1998, NATURE, V392, P394, DOI 10.1038/32904; Guan JS, 2005, CELL, V122, P619, DOI 10.1016/j.cell.2005.06.010; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; NAWA H, 1983, NATURE, V306, P32, DOI 10.1038/306032a0; Potrebic S, 2003, J NEUROSCI, V23, P10988	10	8	8	0	3	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 26	2005	122	4					496	498		10.1016/j.cell.2005.08.009	http://dx.doi.org/10.1016/j.cell.2005.08.009			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	959YI	16122418	Bronze			2022-12-28	WOS:000231555100005
J	Lee, MCS; Orci, L; Hamamoto, S; Futai, E; Ravazzola, M; Schekman, R				Lee, MCS; Orci, L; Hamamoto, S; Futai, E; Ravazzola, M; Schekman, R			Sar1p N-terminal helix initiates membrane curvature and completes the fission of a COPII vesicle	CELL			English	Article							ENDOPLASMIC-RETICULUM; COATED VESICLE; CARGO SELECTION; SACCHAROMYCES-CEREVISIAE; BIOLOGICAL-MEMBRANES; TRANSPORT VESICLES; BAR DOMAINS; PROTEIN; ER; GTPASE	Secretory proteins traffic from the ER to the Golgi via COPII-coated transport vesicles. The five core COPII proteins (Sar1p, Sec23/24p, and Sec13/31p) act in concert to capture cargo proteins and sculpt the ER membrane into vesicles of defined geometry. The molecular details of how the coat proteins deform the lipid bilayer into vesicles are not known. Here we show that the small GTPase Sar1p directly initiates membrane curvature during vesicle biogenesis. Upon GTP binding by Sar1p, membrane insertion of the N-terminal amphipathic alpha helix deforms synthetic liposomes into narrow tubules. Replacement of bulky hydrophobic residues in the a helix with alanine yields Sar1p mutants that are unable to generate highly curved membranes and are defective in vesicle formation from native ER membranes despite normal recruitment of coat and cargo proteins. Thus, the initiation of vesicle budding by Sar1p couples the generation of membrane curvature with coat-protein assembly and cargo capture.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94702 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94702 USA; Univ Med Ctr, Dept Cell Physiol & Metab, CH-1121 Geneva, Switzerland	University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of Geneva	Schekman, R (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94702 USA.	schekman@berkeley.edu		Lee, Marcus/0000-0002-4973-0915; Futai, Eugene/0000-0002-0879-6117				Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; Antonny B, 2001, NAT CELL BIOL, V3, P531, DOI 10.1038/35078500; Aridor M, 2001, J CELL BIOL, V152, P213, DOI 10.1083/jcb.152.1.213; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bi XP, 2002, NATURE, V419, P271, DOI 10.1038/nature01040; Chernomordik LV, 2003, ANNU REV BIOCHEM, V72, P175, DOI 10.1146/annurev.biochem.72.121801.161504; Farsad K, 2003, CURR OPIN CELL BIOL, V15, P372, DOI 10.1016/S0955-0674(03)00073-5; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Futai E, 2004, EMBO J, V23, P4146, DOI 10.1038/sj.emboj.7600428; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Huang MD, 2001, J CELL BIOL, V155, P937, DOI 10.1083/jcb.200106039; Kalab P, 2002, SCIENCE, V295, P2452, DOI 10.1126/science.1068798; KUBALEK EW, 1994, J STRUCT BIOL, V113, P117, DOI 10.1006/jsbi.1994.1039; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; Kurihara T, 2000, MOL BIOL CELL, V11, P983, DOI 10.1091/mbc.11.3.983; Lederkremer GZ, 2001, P NATL ACAD SCI USA, V98, P10704, DOI 10.1073/pnas.191359398; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Malaisse W J, 1979, Methods Achiev Exp Pathol, V9, P112; Matsuoka K, 2001, P NATL ACAD SCI USA, V98, P13705, DOI 10.1073/pnas.241522198; Matsuoka K, 2000, METHODS, V20, P417, DOI 10.1006/meth.2000.0955; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; McMahon HT, 2004, CURR OPIN CELL BIOL, V16, P379, DOI 10.1016/j.ceb.2004.06.009; Miller E, 2002, EMBO J, V21, P6105, DOI 10.1093/emboj/cdf605; Miller EA, 2003, CELL, V114, P497, DOI 10.1016/S0092-8674(03)00609-3; Mossessova E, 2003, CELL, V114, P483, DOI 10.1016/S0092-8674(03)00608-1; Owen DJ, 2004, ANNU REV CELL DEV BI, V20, P153, DOI 10.1146/annurev.cellbio.20.010403.104543; Pathre P, 2003, EMBO J, V22, P4059, DOI 10.1093/emboj/cdg390; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; SHEETZ MP, 1974, P NATL ACAD SCI USA, V71, P4457, DOI 10.1073/pnas.71.11.4457; Shimoni Y, 2000, J CELL BIOL, V151, P973, DOI 10.1083/jcb.151.5.973; Shimoni Y, 2002, METHOD ENZYMOL, V351, P258; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644; Zimmerberg J, 2004, CURR BIOL, V14, pR250, DOI 10.1016/j.cub.2004.02.060	39	357	367	0	42	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 26	2005	122	4					605	617		10.1016/j.cell.2005.07.025	http://dx.doi.org/10.1016/j.cell.2005.07.025			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	959YI	16122427	Bronze			2022-12-28	WOS:000231555100015
J	Pomerening, JR; Kim, SY; Ferrell, JE				Pomerening, JR; Kim, SY; Ferrell, JE			Systems-level dissection of the cell-cycle oscillator: Bypassing positive feedback produces damped oscillations	CELL			English	Article							XENOPUS EGG EXTRACTS; M-PHASE CONTROL; PROTEIN-KINASE; NEGATIVE FEEDBACK; OOCYTE EXTRACTS; ACTIVATION; CDC2; MODEL; PHOSPHORYLATION; MITOSIS	The cell-cycle oscillator includes an essential negative-feedback loop: Cdc2 activates the anaphase-promoting complex (APC), which leads to cyclin destruction and Cdc2 inactivation. Under some circumstances, a negative-feedback loop is sufficient to generate sustained oscillations. However, the Cdc2/APC system also includes positive-feedback loops, whose functional importance we now assess. We show that short-circuiting positive feedback makes the oscillations in Cdc2 activity faster, less temporally abrupt, and damped. This compromises the activation of cyclin destruction and interferes with mitotic exit and DNA replication. This work demonstrates a systems-level role for positive-feedback loops in the embryonic cell cycle and provides an example of how oscillations can emerge out of combinations of subcircuits whose individual behaviors are not oscillatory. This work also underscores the fundamental similarity of cell-cycle oscillations in embryos to repetitive action potentials in pacemaker neurons, with both systems relying on a combination of negative and positive-feedback loops.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Pomerening, JR (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, 269 W Campus Dr,CCSR 3160, Stanford, CA 94305 USA.	pomereni@stanford.edu		Pomerening, Joseph/0000-0003-4120-9081	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T90DK070090] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061276] Funding Source: NIH RePORTER; NIDDK NIH HHS [T90 DK70090] Funding Source: Medline; NIGMS NIH HHS [R01 GM61276] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barkai N, 2000, NATURE, V403, P267, DOI 10.1038/35002258; Berridge MJ, 2001, NOVART FDN SYMP, V239, P52; Cross FR, 2002, MOL BIOL CELL, V13, P52, DOI 10.1091/mbc.01-05-0265; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; GABRIELLI BG, 1992, J BIOL CHEM, V267, P1969; GOLDBETER A, 1991, P NATL ACAD SCI USA, V88, P9107, DOI 10.1073/pnas.88.20.9107; Goldbeter A, 2002, NATURE, V420, P238, DOI 10.1038/nature01259; Goldbeter A., 1996, BIOCH OSCILLATIONS C; GOODWIN BRIAN C., 1965, ADVANCE ENZYME REGULAT, V3, P425, DOI 10.1016/0065-2571(65)90067-1; GRIFFITH JS, 1968, J THEOR BIOL, V20, P202, DOI 10.1016/0022-5193(68)90189-6; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; Hartley RS, 1996, DEV BIOL, V173, P408, DOI 10.1006/dbio.1996.0036; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; Igoshin OA, 2004, P NATL ACAD SCI USA, V101, P15760, DOI 10.1073/pnas.0407111101; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; Lorca T, 1998, EMBO J, V17, P3565, DOI 10.1093/emboj/17.13.3565; Marlovits G, 1998, BIOPHYS CHEM, V72, P169, DOI 10.1016/S0301-4622(98)00132-X; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MINSHULL J, 1989, J CELL SCI, P77; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NAVE CR, 2005, RELAXATION OSCILLATO; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NOVAK B, 1993, J CELL SCI, V106, P1153; Pomerening JR, 2003, NAT CELL BIOL, V5, P346, DOI 10.1038/ncb954; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Reynolds AR, 2003, NAT CELL BIOL, V5, P447, DOI 10.1038/ncb981; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; Ruoff P, 1999, J BIOL RHYTHM, V14, P469, DOI 10.1177/074873099129001037; Sha W, 2003, P NATL ACAD SCI USA, V100, P975, DOI 10.1073/pnas.0235349100; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; TANG ZH, 1993, EMBO J, V12, P3427, DOI 10.1002/j.1460-2075.1993.tb06017.x; Thron CD, 1996, BIOPHYS CHEM, V57, P239, DOI 10.1016/0301-4622(95)00075-5; Tyson JJ, 1999, BIOPHYS J, V77, P2411, DOI 10.1016/S0006-3495(99)77078-5; Walter SA, 2000, MOL BIOL CELL, V11, P887, DOI 10.1091/mbc.11.3.887; Walter SA, 1997, MOL BIOL CELL, V8, P2157, DOI 10.1091/mbc.8.11.2157	52	266	266	1	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 26	2005	122	4					565	578		10.1016/j.cell.2005.06.016	http://dx.doi.org/10.1016/j.cell.2005.06.016			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	959YI	16122424	Bronze			2022-12-28	WOS:000231555100012
J	Silber, MH				Silber, MH			Chronic insomnia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIOR THERAPY; DOUBLE-BLIND; NONPHARMACOLOGIC TREATMENT; REBOUND INSOMNIA; LONG-TERM; PRACTICE PARAMETERS; TREATMENT EFFICACY; CLINICAL-TRIAL; SELF-HELP	A 46-year-old woman has difficulty in falling asleep and staying asleep. The problem started after the birth of her second child 15 years earlier in association with mild post-partum depression. Despite having had no recurrence of depression and no major psychosocial stressors, the patient requires two hours tofall asleep most nights, and on the occasions that she falls asleep rapidly, she wakes at 2 a. m. and cannot reinitiate sleep. Her bedtime is 11 p. m., andshe has found that going to bed later does not allow her to fall asleep more easily. She has no symptoms of sleep-disordered breathing or the restless legssyndrome and is otherwise well. How should her case be managed?	Mayo Clin, Coll Med, Mayo Sleep Disorders Ctr, Rochester, MN 55902 USA; Mayo Clin, Coll Med, Dept Neurol, Rochester, MN 55902 USA	Mayo Clinic; Mayo Clinic	Silber, MH (corresponding author), Mayo Clin, Coll Med, Mayo Sleep Disorders Ctr, 200 1st SW, Rochester, MN 55902 USA.	msilber@mayo.edu						American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS; American Sleep Disorders Association International Classification of Sleep Disorders, 1997, INT CLASS SLEEP DIS; Aslan S, 2002, SLEEP, V25, P677, DOI 10.1093/sleep/25.6.666; Baillargeon L, 2003, CAN MED ASSOC J, V169, P1015; Baillargeon L, 1998, CAN FAM PHYSICIAN, V44, P73; Bootzin R.R., 1991, STIMULUS CONTROL INS, P19, DOI [10.1007/978-1-4757-9586-8_2, DOI 10.1007/978-1-4757-9586-8_2]; Canaday BR, 1996, PHARMACOTHERAPY, V16, P687; Chesson AL, 1999, SLEEP, V22, P1128, DOI 10.1093/sleep/22.8.1128; Edinger JD, 2003, SLEEP, V26, P177, DOI 10.1093/sleep/26.2.177; Edinger JD, 2001, JAMA-J AM MED ASSOC, V285, P1856, DOI 10.1001/jama.285.14.1856; Elie R, 1999, J CLIN PSYCHIAT, V60, P536, DOI 10.4088/JCP.v60n0806; Espie CA, 2001, BEHAV RES THER, V39, P45, DOI 10.1016/S0005-7967(99)00157-6; GREENBLATT DJ, 1987, NEW ENGL J MED, V317, P722, DOI 10.1056/NEJM198709173171202; Hajak G, 2001, J CLIN PSYCHIAT, V62, P453, DOI 10.4088/JCP.v62n0609; Hauri P., 1992, CASE STUDIES INSOMNI, P65, DOI DOI 10.1007/978-1-4757-9586-8_5; Hauri PJ, 1997, SLEEP, V20, P1111, DOI 10.1093/sleep/20.12.1111; Holbrook AM, 2000, CAN MED ASSOC J, V162, P225; Jacobs GD, 2004, ARCH INTERN MED, V164, P1888, DOI 10.1001/archinte.164.17.1888; Kaynak H, 2004, SLEEP MED, V5, P15, DOI 10.1016/j.sleep.2003.06.006; Krystal AD, 2003, SLEEP, V26, P793, DOI 10.1093/sleep/26.7.793; Littner M, 2003, SLEEP, V26, P754, DOI 10.1093/sleep/26.6.754; MCCLUSKY HY, 1991, AM J PSYCHIAT, V148, P121; MENDELSON WB, 1992, J CLIN PSYCHIAT, V53, P4; Meoli AL, 2005, J CLIN SLEEP MED, V1, P173; Mimeault V, 1999, J CONSULT CLIN PSYCH, V67, P511, DOI 10.1037/0022-006X.67.4.511; MONTI JM, 1994, PHARMACOPSYCHIATRY, V27, P166, DOI 10.1055/s-2007-1014298; Morgan K, 2003, BRIT J GEN PRACT, V53, P923; Morgenthaler Timothy I, 2002, Sleep Med, V3, P323, DOI 10.1016/S1389-9457(02)00007-2; Morin CM, 2004, AM J PSYCHIAT, V161, P332, DOI 10.1176/appi.ajp.161.2.332; MORIN CM, 1994, AM J PSYCHIAT, V151, P1172; Morin CM, 1999, JAMA-J AM MED ASSOC, V281, P991, DOI 10.1001/jama.281.11.991; Morin CM, 1999, SLEEP, V22, P1134, DOI 10.1093/sleep/22.8.1134; MURTAGH DRR, 1995, J CONSULT CLIN PSYCH, V63, P79, DOI 10.1037/0022-006X.63.1.79; NIERENBERG AA, 1994, AM J PSYCHIAT, V151, P1069; Nowell PD, 1997, JAMA-J AM MED ASSOC, V278, P2170; Perlis M. L., 2005, PRINCIPLES PRACTICE, V4, P714, DOI [10.1016/B0-72-160797-7/50067-7, DOI 10.1016/B0-72-160797-7/50067-7]; Perlis ML, 2004, J CLIN PSYCHIAT, V65, P1128; RIEDEL BW, 1995, PSYCHOL AGING, V10, P54, DOI 10.1037/0882-7974.10.1.54; Rogers NL, 2003, SLEEP, V26, P1058; ROTH T, 1991, J CLIN PSYCHIAT, V52, P38; ROTH T, 1980, PSYCHOPHARMACOLOGY, V70, P231, DOI 10.1007/BF00427879; ROTHSCHILD AJ, 1992, J CLIN PSYCHIAT, V53, P69; SCHARF MB, 1994, J CLIN PSYCHIAT, V55, P192; Silva JACE, 1996, SLEEP, V19, P412, DOI 10.1093/sleep/19.5.412; Smith MT, 2002, AM J PSYCHIAT, V159, P5, DOI 10.1176/appi.ajp.159.1.5; Soldatos CR, 1999, INT CLIN PSYCHOPHARM, V14, P287; SPIELMAN AJ, 1987, PSYCHIAT CLIN N AM, V10, P541; SPIELMAN AJ, 1987, SLEEP, V10, P45; TURNER RM, 1982, BEHAV RES THER, V20, P33, DOI 10.1016/0005-7967(82)90006-7; VOGEL GW, 1992, J CLIN PHARMACOL, V32, P647, DOI 10.1002/j.1552-4604.1992.tb05776.x; Voshaar RCO, 2004, EUR NEUROPSYCHOPHARM, V14, P301, DOI 10.1016/S0924-977X(03)00192-5; Walsh JK, 2000, SLEEP MED, V1, P41, DOI 10.1016/S1389-9457(99)00006-4; Walsh JK, 1998, HUM PSYCHOPHARM CLIN, V13, P191, DOI 10.1002/(SICI)1099-1077(199804)13:3<191::AID-HUP972>3.0.CO;2-X; Walsh JK, 2000, CLIN NEUROPHARMACOL, V23, P17, DOI 10.1097/00002826-200001000-00004; Walsh JK, 1999, SLEEP, V22, P371; Walsh JK, 2000, SLEEP, V23, P1087, DOI 10.1093/sleep/23.8.1h; Zammit G, 2005, SLEEP, V28, pA228; Zemlan FP, 2005, J CLIN PSYCHIAT, V66, P384, DOI 10.4088/JCP.v66n0316	58	83	91	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 25	2005	353	8					803	810		10.1056/NEJMcp043762	http://dx.doi.org/10.1056/NEJMcp043762			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	957YK	16120860				2022-12-28	WOS:000231409300009
J	Hunt, LM				Hunt, LM			Health research: what's culture got to do with it?	LANCET			English	Editorial Material									Michigan State Univ, Dept Anthropol, E Lansing, MI 48824 USA; Michigan State Univ, Julian Samora Res Inst, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	Hunt, LM (corresponding author), Michigan State Univ, Dept Anthropol, E Lansing, MI 48824 USA.	huntli@msu.edu						Carrillo JE, 1999, ANN INTERN MED, V130, P829, DOI 10.7326/0003-4819-130-10-199905180-00017; Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P1226, DOI 10.1001/archpsyc.61.12.1226; HARWOOD A, 1994, THEORETICAL CONCEPTU, P3; Hunt LM, 2004, SOC SCI MED, V59, P973, DOI 10.1016/j.socscimed.2003.12.009; Krieger N, 2001, PUBLIC HEALTH REP, V116, P419, DOI 10.1016/S0033-3549(04)50070-5; O'Connor B B, 1996, J Assoc Nurses AIDS Care, V7 Suppl 1, P41, DOI 10.1016/S1055-3290(96)80006-9; SANTIAGOIRIZARR.V, 2001, MED ETHNICITY CONSTR; STANFIELD JH, 1993, RACE ETHNICITY RES M, P3	8	17	17	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 20	2005	366	9486					617	618		10.1016/S0140-6736(05)67118-8	http://dx.doi.org/10.1016/S0140-6736(05)67118-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	958EB	16112287				2022-12-28	WOS:000231426400009
J	Chen, C; Ouyang, W; Grigura, V; Zhou, Q; Carnes, K; Lim, H; Zhao, GQ; Arber, S; Kurpios, N; Murphy, TL; Cheng, AM; Hassell, JA; Chandrashekar, V; Hofmann, MC; Hess, RA; Murphy, KM				Chen, C; Ouyang, W; Grigura, V; Zhou, Q; Carnes, K; Lim, H; Zhao, GQ; Arber, S; Kurpios, N; Murphy, TL; Cheng, AM; Hassell, JA; Chandrashekar, V; Hofmann, MC; Hess, RA; Murphy, KM			ERM is required for transcriptional control of the spermatogonial stem cell niche	NATURE			English	Article							SERTOLI-CELLS; RECEPTOR CXCR4; SELF-RENEWAL; MICE LACKING; GERM-CELLS; GENE; CHEMOKINE; PEA3; SPERMATOGENESIS; MAINTENANCE	Division of spermatogonial stem cells(1) produces daughter cells that either maintain their stem cell identity or undergo differentiation to form mature sperm. The Sertoli cell, the only somatic cell within seminiferous tubules, provides the stem cell niche through physical support and expression of surface proteins and soluble factors(2,3). Here we show that the Ets related molecule(4) (ERM) is expressed exclusively within Sertoli cells in the testis and is required for spermatogonial stem cell self-renewal. Mice with targeted disruption of ERM have a loss of maintenance of spermatogonial stem cell self-renewal without a block in normal spermatogenic differentiation and thus have progressive germ-cell depletion and a Sertoli-cell-only syndrome. Microarray analysis of primary Sertoli cells from ERM-deficient mice showed alterations in secreted factors known to regulate the haematopoietic stem cell niche. These results identify a new function for the Ets family transcription factors in spermatogenesis and provide an example of transcriptional control of a vertebrate stem cell niche.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Obstet & Gynecol, St Louis, MO 63110 USA; Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA; Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA; Univ Illinois, Dept Vet Biosci, Urbana, IL 61802 USA; Univ Texas, SW Med Sch, Cecil H & Ida Green Ctr Reprod Biol Sci, Dallas, TX 75390 USA; Univ Basel, Biozentrum, Dept Cell Biol, CH-4056 Basel, Switzerland; Friedrich Miescher Inst, CH-4058 Basel, Switzerland; McMaster Univ, Inst Mol Biol & Biotechnol, Hamilton, ON L8S 4K1, Canada; So Illinois Univ, Sch Med, Dept Physiol, Carbondale, IL 62901 USA; Univ Dayton, Dept Biol, Dayton, OH 45469 USA	Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Roche Holding; Genentech; Washington State University; University of Illinois System; University of Illinois Urbana-Champaign; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Basel; Friedrich Miescher Institute for Biomedical Research; McMaster University; Southern Illinois University System; Southern Illinois University; University of Dayton	Murphy, KM (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.	murphy@pathbox.wustl.edu	Lim, Hyunjung J/D-5343-2011; Ouyang, Wenjun/ABA-8763-2020	Lim, Hyunjung J/0000-0003-2191-666X; Ouyang, Wenjun/0000-0002-1811-5864; Chen, Chen/0000-0001-9159-4489; Arber, Silvia/0000-0002-6261-250X; Hess, Rex/0000-0003-2649-3563; Hofmann, Marie-Claude/0000-0002-4899-8039	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K02HD054607, R01HD044543] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD044543-02, R01 HD044543, K02 HD054607] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arber S, 2000, CELL, V101, P485, DOI 10.1016/S0092-8674(00)80859-4; Buaas FW, 2004, NAT GENET, V36, P647, DOI 10.1038/ng1366; Choong ML, 2004, CYTOKINE, V25, P239, DOI 10.1016/j.cyto.2003.11.002; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; Christensen JL, 2004, PLOS BIOL, V2, P368, DOI 10.1371/journal.pbio.0020075; Colvin JS, 2001, CELL, V104, P875, DOI 10.1016/S0092-8674(01)00284-7; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; DEFRANCA LR, 1994, ANAT REC, V240, P225; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Griswold MD, 1998, SEMIN CELL DEV BIOL, V9, P411, DOI 10.1006/scdb.1998.0203; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; KARL AF, 1990, METHOD ENZYMOL, V190, P71; Kiger AA, 2000, NATURE, V407, P750, DOI 10.1038/35037606; Kubota H, 2003, P NATL ACAD SCI USA, V100, P6487, DOI 10.1073/pnas.0631767100; Livet J, 2002, NEURON, V35, P877, DOI 10.1016/S0896-6273(02)00863-2; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Molyneaux KA, 2003, DEVELOPMENT, V130, P4279, DOI 10.1242/dev.00640; MONTE D, 1994, ONCOGENE, V9, P1397; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; OuladAbdelghani M, 1996, J CELL BIOL, V135, P469, DOI 10.1083/jcb.135.2.469; Ouyang W, 1999, P NATL ACAD SCI USA, V96, P3888, DOI 10.1073/pnas.96.7.3888; Raible F, 2001, MECH DEVELOP, V107, P105, DOI 10.1016/S0925-4773(01)00456-7; Sassone-Corsi P, 2002, SCIENCE, V296, P2176, DOI 10.1126/science.1070963; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Tran J, 2000, NATURE, V407, P754, DOI 10.1038/35037613	26	249	276	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 18	2005	436	7053					1030	1034		10.1038/nature03894	http://dx.doi.org/10.1038/nature03894			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955XQ	16107850	Green Accepted			2022-12-28	WOS:000231263900053
J	Jorgensen, R; Merrill, AR; Yates, SP; Marquez, VE; Schwan, AL; Boesen, T; Andersen, GR				Jorgensen, R; Merrill, AR; Yates, SP; Marquez, VE; Schwan, AL; Boesen, T; Andersen, GR			Exotoxin A-eEF2 complex structure indicates ADP ribosylation by ribosome mimicry	NATURE			English	Article							PSEUDOMONAS-AERUGINOSA; CRYSTAL-STRUCTURE; DIPHTHERIA-TOXIN; CONFORMATIONAL-CHANGES; CLOSTRIDIUM-BOTULINUM; CATALYTIC MECHANISM; TRANSFER-RNA; DOMAIN; RECOGNITION; ACID	The bacteria causing diphtheria, whooping cough, cholera and other diseases secrete mono-ADP-ribosylating toxins that modify intracellular proteins. Here, we describe four structures of a catalytically active complex between a fragment of Pseudomonas aeruginosa exotoxin A (ETA) and its protein substrate, translation elongation factor 2 (eEF2). The target residue in eEF2, diphthamide (a modified histidine), spans across a cleft and faces the two phosphates and a ribose of the non-hydrolysable NAD(+) analogue, beta TAD. This suggests that the diphthamide is involved in triggering NAD(+) cleavage and interacting with the proposed oxacarbenium intermediate during the nucleophilic substitution reaction, explaining the requirement of diphthamide for ADP ribosylation. Diphtheria toxin may recognize eEF2 in a manner similar to ETA. Notably, the toxin-bound beta TAD phosphates mimic the phosphate backbone of two nucleotides in a conformational switch of 18S rRNA, thereby achieving universal recognition of eEF2 by ETA.	Aarhus Univ, Ctr Struct Biol, Dept Mol Biol, DK-8000 Aarhus, Denmark; Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada; Univ Guelph, Dept Chem, Guelph, ON N1G 2W1, Canada; NCI, Med Chem Lab, Canc Res Ctr, NIH, Frederick, MD 21702 USA	Aarhus University; University of Guelph; University of Guelph; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Andersen, GR (corresponding author), Aarhus Univ, Ctr Struct Biol, Dept Mol Biol, Gustav Wieds Vej 10C, DK-8000 Aarhus, Denmark.	rmerrill@uoguelph.ca; gra@mb.au.dk	Merrill, Rod/M-8313-2014; Marquez, Victor/AAP-3549-2021; Jørgensen, René/P-5619-2014	Jørgensen, René/0000-0003-0672-466X; Boesen, Thomas/0000-0002-5633-6844; Schwan, Adrian/0000-0003-3362-9633; Andersen, Gregers Rom/0000-0001-6292-3319	NATIONAL CANCER INSTITUTE [Z01BC006176] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armstrong S, 2004, BIOCHEMISTRY-US, V43, P183, DOI 10.1021/bi034772u; Armstrong S, 2002, J BIOL CHEM, V277, P46669, DOI 10.1074/jbc.M206916200; Beattie BK, 1996, BIOCHEMISTRY-US, V35, P15134, DOI 10.1021/bi961985t; Bell CE, 1997, PROTEIN SCI, V6, P2084; Bell CE, 1996, BIOCHEMISTRY-US, V35, P1137, DOI 10.1021/bi9520848; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHIRON MF, 1994, J BIOL CHEM, V269, P18167; Collier RJ, 2001, TOXICON, V39, P1793, DOI 10.1016/S0041-0101(01)00165-9; Corda D, 2003, EMBO J, V22, P1953, DOI 10.1093/emboj/cdg209; DeLano W.L, 2002, PYMOL USERS MANUA; DOUGLAS CM, 1987, J BACTERIOL, V169, P4967, DOI 10.1128/jb.169.11.4967-4971.1987; Evans HR, 2003, J BIOL CHEM, V278, P45924, DOI 10.1074/jbc.M307719200; Han S, 1999, NAT STRUCT BIOL, V6, P932, DOI 10.1038/13300; Han SI, 2001, J MOL BIOL, V305, P95, DOI 10.1006/jmbi.2000.4292; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jorgensen R, 2004, J BIOL CHEM, V279, P45919, DOI 10.1074/jbc.M406218200; Jorgensen R, 2003, NAT STRUCT BIOL, V10, P379, DOI 10.1038/nsb923; Jorgensen R, 2002, ACTA CRYSTALLOGR D, V58, P712, DOI 10.1107/S0907444902003001; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; Li M, 1996, P NATL ACAD SCI USA, V93, P6902, DOI 10.1073/pnas.93.14.6902; Liu SH, 2003, MOL CELL, V12, P603, DOI 10.1016/j.molcel.2003.08.003; LUKAC M, 1988, BIOCHEMISTRY-US, V27, P7629, DOI 10.1021/bi00420a009; Lyczak JB, 2000, MICROBES INFECT, V2, P1051, DOI 10.1016/S1286-4579(00)01259-4; MARQUEZ VE, 1986, J MED CHEM, V29, P1726, DOI 10.1021/jm00159a027; Mattos-Guaraldi AL, 2003, MEM I OSWALDO CRUZ, V98, P987, DOI 10.1590/S0074-02762003000800001; Menetrey J, 2002, J BIOL CHEM, V277, P30950, DOI 10.1074/jbc.M201844200; Ogle JM, 2001, SCIENCE, V292, P897, DOI 10.1126/science.1060612; Parikh SL, 2004, BIOCHEMISTRY-US, V43, P1204, DOI 10.1021/bi035907z; Spahn CMT, 2004, EMBO J, V23, P1008, DOI 10.1038/sj.emboj.7600102; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; VANNESS BG, 1980, J BIOL CHEM, V255, P717; Wedekind JE, 2001, J MOL BIOL, V314, P823, DOI 10.1006/jmbi.2001.5195; WEISS MS, 1995, BIOCHEMISTRY-US, V34, P773, DOI 10.1021/bi00003a010; Yates SP, 2005, BIOCHEM J, V385, P667, DOI 10.1042/BJ20041480; Yates SP, 2005, ANAL BIOCHEM, V340, P41, DOI 10.1016/j.ab.2005.01.051; Yates SP, 2001, J BIOL CHEM, V276, P35029, DOI 10.1074/jbc.M105002200; Zhou GC, 2004, J AM CHEM SOC, V126, P5690, DOI 10.1021/ja038159+	38	100	103	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 18	2005	436	7053					979	984		10.1038/nature03871	http://dx.doi.org/10.1038/nature03871			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955XQ	16107839				2022-12-28	WOS:000231263900041
J	Woolf, SH; Chan, ECY; Harris, R; Sheridan, SL; Braddock, CH; Kaplan, RM; Krist, A; O'Connor, AM; Tunis, S				Woolf, SH; Chan, ECY; Harris, R; Sheridan, SL; Braddock, CH; Kaplan, RM; Krist, A; O'Connor, AM; Tunis, S			Promoting informed choice: Transforming health care to dispense knowledge for decision making	ANNALS OF INTERNAL MEDICINE			English	Article							PROSTATE-SPECIFIC ANTIGEN; RISK COMMUNICATION; CONTROLLED-TRIAL; SELF-MANAGEMENT; PATIENTS WISH; PATIENT; INFORMATION; AIDS; PHYSICIANS; MEDICINE	Ours is an era in which patients seek greater engagement in health care choices, increasing the demand for high-quality information about clinical options. Providing support for informed choice is not straightforward, however, because of challenges faced by clinicians, health systems, and consumers. Greater use of written or electronic tools can help to clarify choices for patients, but decision aids cannot replace the human element in facilitating informed choice. The ideal solution is to couple information with high-quality decision counseling to help patients understand the potential risks, benefits, and uncertainties of clinical options and to assist them in selecting the option that best accommodates their personal preferences. Decision counseling can be offered by 3 types of providers: clinicians who lack formal informed-choice training ("usual care"), clinicians with formal informed-choice training, or trained third parties who function as impartial decision counselors. Controlled studies are needed to determine which model is best, but none appears to be ideal. The health care system cannot truly support informed decision making without correcting the underlying obstacles that impede patient access to needed information. New information technology solutions, training programs, and reimbursement schemes are necessary. Patient demand for guidance will only increase as clinical options multiply and the world of information continues its rapid growth. Today's health care system is unprepared for the convergence of these 2 burgeoning domains, and the need to address systemic deficiencies will grow more urgent over time.	Virginia Commonwealth Univ, Dept Family Med, W Hosp, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Epidemiol & Community Hlth, W Hosp, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Woolf, SH (corresponding author), Virginia Commonwealth Univ, Dept Family Med, W Hosp, 1200 E Broad St,POB 980251,MCV Stn, Richmond, VA 23298 USA.	swoolf@vcu.edux	KAPLAN, Robert/AAK-7342-2021; Tao, Youyou/D-2367-2014					Bacon Francis, 1605, PROFICIENCE ADVANCEM; Barry MJ, 2002, ANN INTERN MED, V136, P127, DOI 10.7326/0003-4819-136-2-200201150-00010; Berwick D, 2000, Clin Leadersh Manag Rev, V14, P250; BILLINGS J, 2004, HLTH AFF MILLWOOD S; Birkmeyer NJO, 2002, SPINE, V27, P1361, DOI 10.1097/00007632-200206150-00020; BLACKHALL LJ, 1995, JAMA-J AM MED ASSOC, V274, P820, DOI 10.1001/jama.274.10.820; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469; Bogardus ST, 1999, JAMA-J AM MED ASSOC, V281, P1037, DOI 10.1001/jama.281.11.1037; Braddock CH, 1999, JAMA-J AM MED ASSOC, V282, P2313, DOI 10.1001/jama.282.24.2313; Briss P, 2004, AM J PREV MED, V26, P67, DOI 10.1016/j.amepre.2003.09.012; Brodie M, 2000, HEALTH AFFAIR, V19, P255, DOI 10.1377/hlthaff.19.6.255; Bruera E, 2002, CANCER-AM CANCER SOC, V94, P2076, DOI 10.1002/cncr.10393; Cassell, 1994, NATURE SUFFERING GOA; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P101; Chan ECY, 2003, J COMMUN HEALTH, V28, P393, DOI 10.1023/A:1026072022853; Chan ECY, 2003, AM J PUBLIC HEALTH, V93, P779, DOI 10.2105/AJPH.93.5.779; Charles C, 1999, SOC SCI MED, V49, P651, DOI 10.1016/S0277-9536(99)00145-8; Cohen LM, 2003, JAMA-J AM MED ASSOC, V289, P2113, DOI 10.1001/jama.289.16.2113; *COMM CONS UN BOAR, 2002, CAR COV TOO LITTL TO; Commonwealth Fund, 2004, 1 REP REC COMM FUNDS; Cooper-Patrick L, 1999, JAMA-J AM MED ASSOC, V282, P583, DOI 10.1001/jama.282.6.583; Cotler SJ, 2001, AM J GASTROENTEROL, V96, P2730, DOI 10.1111/j.1572-0241.2001.04132.x; Coulter A, 1997, J Health Serv Res Policy, V2, P112; Coulter A., 2002, AUTONOMOUS PATIENT E; Covinsky KE, 2000, J AM GERIATR SOC, V48, pS187, DOI 10.1111/j.1532-5415.2000.tb03131.x; *CTR INF THER, 2005, INF THER; Cuervo LG, 2003, BMJ-BRIT MED J, V327, P65, DOI 10.1136/bmj.327.7406.65; *DARTM MED CTR, 2005, DARTM CTR SHAR DEC M; Davidoff F, 2000, ANN INTERN MED, V132, P996, DOI 10.7326/0003-4819-132-12-200006200-00012; Deber RB, 1996, ARCH INTERN MED, V156, P1414, DOI 10.1001/archinte.156.13.1414; Devereaux PJ, 2001, BMJ-BRIT MED J, V323, P1218, DOI 10.1136/bmj.323.7323.1218; EDDY DM, 1982, NEW ENGL J MED, V307, P343, DOI 10.1056/NEJM198208053070604; Edwards A, 2003, PATIENT EDUC COUNS, V50, P33, DOI 10.1016/S0738-3991(03)00077-6; *FDN INF MED DEC M, 2005, FDN INF MED DEC MAK; Feldman-Stewart Deb, 2000, Health Expect, V3, P46, DOI 10.1046/j.1369-6513.2000.00082.x; Ferguson T, 2000, BRIT MED J, V321, P1129, DOI 10.1136/bmj.321.7269.1129; Frosch DL, 1999, AM J PREV MED, V17, P285, DOI 10.1016/S0749-3797(99)00097-5; Frosch DL, 2003, J GEN INTERN MED, V18, P781, DOI 10.1046/j.1525-1497.2003.20911.x; GABEL JR, 2004, HLTH AFF MILLWOOD S; Godolphin W, 2001, Health Expect, V4, P235, DOI 10.1046/j.1369-6513.2001.00144.x; Gwyn Richard, 2003, Health Expect, V6, P242, DOI 10.1046/j.1369-6513.2003.00245.x; Hayden M, 2002, ANN INTERN MED, V136, P161, DOI 10.7326/0003-4819-136-2-200201150-00016; Hibbard JH, 2003, MED CARE, V41, pI61; HIBBARD JH, 2004, HLTH AFF MILLWOOD S; *HLTH DIAL, 2005, COLLABORATIVECARE NE; *HLTH DIAL SERV CO, 2005, HLTH DIAL SUPP DEC M; Holmes-Rovner Margaret, 2000, Health Expect, V3, P182, DOI 10.1046/j.1369-6513.2000.00093.x; *I MED, 2004, HLTH LIT PRESCR END; Impicciatore P, 1997, BMJ-BRIT MED J, V314, P1875, DOI 10.1136/bmj.314.7098.1875; Institute of Medicine, 2002, SPEAK HLTH ASS HLTH; Institute of Medicine, 2001, CROSSING QUALITY CHA; Kaplan RM, 2004, J HEALTH PSYCHOL, V9, P29, DOI 10.1177/1359105304036100; Kaplan RM, 2003, QUAL LIFE RES, V12, P3, DOI 10.1023/A:1023547632545; KASSIRER JP, 1995, NEW ENGL J MED, V332, P52, DOI 10.1056/NEJM199501053320110; KASSIRER JP, 1981, NEW ENGL J MED, V305, P1465, DOI 10.1056/NEJM198112103052409; KEMPER D, 2002, INFORMATION THERAPY; Kennedy ADM, 2002, JAMA-J AM MED ASSOC, V288, P2701, DOI 10.1001/jama.288.21.2701; Kim SP, 2001, CANCER INVEST, V19, P684, DOI 10.1081/CNV-100106143; Kravitz RL, 2001, BRIT MED J, V323, P584, DOI 10.1136/bmj.323.7313.584; Laine C, 1996, JAMA-J AM MED ASSOC, V275, P152, DOI 10.1001/jama.275.2.152; LEWIN SA, 2003, COCHRANE LIB; Lomas S J, 2001, Healthc Pap, V2, P38; LOMAS SJ, 2001, HEALTHC PAP, V2, P69; Mazur DJ, 1997, J GEN INTERN MED, V12, P114, DOI 10.1046/j.1525-1497.1997.00016.x; McKinstry B, 2000, BRIT MED J, V321, P867, DOI 10.1136/bmj.321.7265.867; McNutt RA, 2004, JAMA-J AM MED ASSOC, V292, P2516, DOI 10.1001/jama.292.20.2516; Merenstein D, 2004, JAMA-J AM MED ASSOC, V291, P15, DOI 10.1001/jama.291.1.15; Miller N, 2000, B MED LIBR ASSOC, V88, P11; Misselbrook D, 2001, BRIT J GEN PRACT, V51, P276; Morgan MW, 2000, J GEN INTERN MED, V15, P685, DOI 10.1046/j.1525-1497.2000.91139.x; National Institutes of Health Consensus Development Panel, 2001, J NATL CANC I MONOGR, P5; Norris SL, 2002, DIABETES CARE, V25, P1159, DOI 10.2337/diacare.25.7.1159; Nuovo J, 2002, JAMA-J AM MED ASSOC, V287, P2813, DOI 10.1001/jama.287.21.2813; O'Connor AM, 1999, BRIT MED J, V319, P731, DOI 10.1136/bmj.319.7212.731; O'Connor AM, 2003, BMJ-BRIT MED J, V327, P736, DOI 10.1136/bmj.327.7417.736; O'Connor AM, 2004, HLTH AFF MILLWOOD S; OConnor AM, 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001431, DOI 10.1002/14651858.CD001431]; *OTT HLTH RES I, 2005, OTT PERS DEC GUID; *OTT HLTH RES I, 2005, COCHR INV PAT DEC AI; Perkins HS, 2002, J GEN INTERN MED, V17, P48, DOI 10.1046/j.1525-1497.2002.01032.x; Pignone M, 2005, J GEN INTERN MED, V20, P185, DOI 10.1111/j.1525-1497.2005.40208.x; REISER SJ, 1993, JAMA-J AM MED ASSOC, V269, P1012, DOI 10.1001/jama.269.8.1012; ROBINSON A, 2001, QUAL HLTH CARE S1, V10, P34; Schapira MM, 2001, MED DECIS MAKING, V21, P459, DOI 10.1177/02729890122062811; Schwartz LM, 1997, ANN INTERN MED, V127, P966, DOI 10.7326/0003-4819-127-11-199712010-00003; Sheridan SL, 2004, AM J PREV MED, V26, P56, DOI 10.1016/j.amepre.2003.09.011; Sheridan SL, 2003, J GEN INTERN MED, V18, P884, DOI 10.1046/j.1525-1497.2003.21102.x; Sieber WJ, 2000, CONTROL CLIN TRIALS, V21, p233S, DOI 10.1016/S0197-2456(00)00084-2; Teno JM, 2002, J AM GERIATR SOC, V50, P496, DOI 10.1046/j.1532-5415.2002.50116.x; Teutsch C, 2003, MED CLIN N AM, V87, P1115, DOI 10.1016/S0025-7125(03)00066-X; Towle A, 1999, BRIT MED J, V319, P766, DOI 10.1136/bmj.319.7212.766; Volk RJ, 2000, J FAM PRACTICE, V49, P425; WAGNER EH, 1995, MED CARE, V33, P765, DOI 10.1097/00005650-199508000-00002; WENNBERG JF, 2002, HLTH AFF MILLWOOD S; Wills CE, 2003, PATIENT EDUC COUNS, V50, P285, DOI 10.1016/S0738-3991(03)00051-X; Woloshin S, 2001, MED DECIS MAKING, V21, P382, DOI 10.1177/0272989X0102100505; Woolf SH, 1997, J FAM PRACTICE, V45, P205; Woolf SH, 2001, J UROLOGY, V166, P244, DOI 10.1016/S0022-5347(05)66136-8; Yedidia MJ, 2003, JAMA-J AM MED ASSOC, V290, P1157, DOI 10.1001/jama.290.9.1157	99	222	228	0	23	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 16	2005	143	4					293	300		10.7326/0003-4819-143-4-200508160-00010	http://dx.doi.org/10.7326/0003-4819-143-4-200508160-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	955PA	16103473				2022-12-28	WOS:000231237100006
J	Wigge, PA; Kim, MC; Jaeger, KE; Busch, W; Schmid, M; Lohmann, JU; Weigel, D				Wigge, PA; Kim, MC; Jaeger, KE; Busch, W; Schmid, M; Lohmann, JU; Weigel, D			Integration of spatial and temporal information during floral induction in Arabidopsis	SCIENCE			English	Article							LATE-FLOWERING MUTANTS; GENE-EXPRESSION; TARGET GENES; CONSTANS; TIME; ACTIVATION; THALIANA; PROTEIN; ROLES	Flowering of Arabidopsis is regulated by several environmental and endogenous signals. An important integrator of these inputs is the FLOWERING LOCUS T (FT) gene, which encodes a small, possibly mobile protein. A primary response to floral. induction is the activation of FT RNA expression in leaves. Because flowers form at a distant site, the shoot apex, these data suggest that FT primarily controls the timing of flowering. Integration of temporal and spatial information is mediated in part by the bZIP transcription factor FD, which is already expressed at the shoot apex before floral. induction. A complex of FT and FD proteins in turn can activate flora[ identity genes such as APETALA1 (AP1).	Max Planck Inst Dev Biol, Dept Mol Biol, D-72076 Tubingen, Germany; Max Planck Inst Dev Biol, Arbeitsgrp Lohmann, D-72076 Tubingen, Germany; Max Planck Inst Dev Biol, Arbeitsgrp Schmid, D-72076 Tubingen, Germany; Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA	Max Planck Society; Max Planck Society; Max Planck Society; Salk Institute	Wigge, PA (corresponding author), Max Planck Inst Dev Biol, Dept Mol Biol, D-72076 Tubingen, Germany.	philip.wigge@bbsrc.ac.uk; weigel@weigelworld.org	Lohmann, Jan/T-3776-2019; Schmid, Markus/I-4384-2015; Wigge, Philip/B-3333-2010; Weigel, Detlef/AAR-3312-2021; Busch, Wolfgang/B-8593-2008; Wigge, Philip Anthony/ABD-5113-2021; Weigel, Detlef/GSJ-0799-2022; Weigel, Detlef/C-1418-2008	Lohmann, Jan/0000-0003-3667-187X; Schmid, Markus/0000-0002-0068-2967; Busch, Wolfgang/0000-0003-2042-7290; Wigge, Philip Anthony/0000-0003-4822-361X; Weigel, Detlef/0000-0002-2114-7963; Weigel, Detlef/0000-0002-2114-7963	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		An HL, 2004, DEVELOPMENT, V131, P3615, DOI 10.1242/dev.01231; Aukerman MJ, 2003, PLANT CELL, V15, P2730, DOI 10.1105/tpc.016238; Ayre BG, 2004, PLANT PHYSIOL, V135, P2271, DOI 10.1104/pp.104.040592; Banfield MJ, 2000, J MOL BIOL, V297, P1159, DOI 10.1006/jmbi.2000.3619; Cardon GH, 1997, PLANT J, V12, P367, DOI 10.1046/j.1365-313X.1997.12020367.x; He YH, 2005, TRENDS PLANT SCI, V10, P30, DOI 10.1016/j.tplants.2004.11.003; Henderson IR, 2004, DEVELOPMENT, V131, P3829, DOI 10.1242/dev.01294; IZAWA T, 1993, J MOL BIOL, V230, P1131, DOI 10.1006/jmbi.1993.1230; Kardailsky I, 1999, SCIENCE, V286, P1962, DOI 10.1126/science.286.5446.1962; KNOTT JAMES E., 1934, PROC AMER SOC HORT SCI, V31, P152; Kobayashi Y, 1999, SCIENCE, V286, P1960, DOI 10.1126/science.286.5446.1960; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; Koornneef M, 1998, GENETICS, V148, P885; Lemon WJ, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r67; MANDEL MA, 1995, NATURE, V377, P522, DOI 10.1038/377522a0; Parcy F, 1998, NATURE, V395, P561, DOI 10.1038/26903; Pnueli L, 2001, PLANT CELL, V13, P2687, DOI 10.1105/tpc.13.12.2687; RuizGarcia L, 1997, PLANT CELL, V9, P1921, DOI 10.1105/tpc.9.11.1921; Samach A, 2000, SCIENCE, V288, P1613, DOI 10.1126/science.288.5471.1613; Schmid M, 2003, DEVELOPMENT, V130, P6001, DOI 10.1242/dev.00842; Schmid M, 2005, NAT GENET, V37, P501, DOI 10.1038/ng1543; Schwab R, 2005, DEV CELL, V8, P517, DOI 10.1016/j.devcel.2005.01.018; Suarez-Lopez P, 2001, NATURE, V410, P1116, DOI 10.1038/35074138; Takada S, 2003, PLANT CELL, V15, P2856, DOI 10.1105/tpc.016345; Valverde F, 2004, SCIENCE, V303, P1003, DOI 10.1126/science.1091761; Yanovsky MJ, 2002, NATURE, V419, P308, DOI 10.1038/nature00996; ZEEVAART JAD, 1976, ANNU REV PLANT PHYS, V27, P321, DOI 10.1146/annurev.pp.27.060176.001541	27	999	1128	10	233	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 12	2005	309	5737					1056	1059		10.1126/science.1114358	http://dx.doi.org/10.1126/science.1114358			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955MN	16099980				2022-12-28	WOS:000231230100040
J	Gallo, E; Fender, R; Kaiser, C; Russell, D; Morganti, R; Oosterloo, T; Heinz, S				Gallo, E; Fender, R; Kaiser, C; Russell, D; Morganti, R; Oosterloo, T; Heinz, S			A dark jet dominates the power output of the stellar black hole Cygnus X-1	NATURE			English	Article							ACTIVE GALACTIC NUCLEI; X-RAY; RELATIVISTIC JETS; LOW/HARD STATE; RADIO-SOURCES; SPECTRUM; STARS; X-1; GALAXIES; BINARIES	Black holes undergoing accretion are thought to emit the bulk of their power in the X-ray band by releasing the gravitational potential energy of the infalling matter(1). At the same time, they are capable of producing highly collimated jets of energy and particles flowing out of the system with relativistic velocities(2). Here we show that the 10-solar-mass (10 M(.)) black hole in the X-ray binary Cygnus X-1 (refs 3 - 5) is surrounded by a large-scale (similar to 5 pc in diameter) ring-like structure that appears to be inflated by the inner radio jet(6). We estimate that in order to sustain the observed emission of the ring, the jet of Cygnus X-1 has to carry a kinetic power that can be as high as the bolometric X-ray luminosity of the binary system. This result may imply that low-luminosity stellar-mass black holes as a whole dissipate the bulk of the liberated accretion power in the form of 'dark', radiatively inefficient relativistic outflows, rather than locally in the X-ray-emitting inflow.	Univ Amsterdam, Astron Inst Anton Pannekoek, NL-1098 SJ Amsterdam, Netherlands; Univ Amsterdam, Ctr High Energy Astrophys, NL-1098 SJ Amsterdam, Netherlands; Univ Southampton, Sch Phys & Astron, Southampton SO17 1BJ, Hants, England; Netherlands Fdn Res Astron, NL-7990 AA Dwingeloo, Netherlands; MIT, Ctr Space Res, Cambridge, MA 02139 USA	University of Amsterdam; University of Amsterdam; University of Southampton; Massachusetts Institute of Technology (MIT)	Gallo, E (corresponding author), Univ Amsterdam, Astron Inst Anton Pannekoek, Kruislaan 403, NL-1098 SJ Amsterdam, Netherlands.	egallo@science.uva.nl		Gallo, Elena/0000-0001-5802-6041; Heinz, Sebastian/0000-0002-8433-8652; Russell, David/0000-0002-3500-631X				Blandford RD, 2001, PROG THEOR PHYS SUPP, P182, DOI 10.1143/PTPS.143.182; BOWYER S, 1965, SCIENCE, V147, P394, DOI 10.1126/science.147.3656.394; CASTOR J, 1975, ASTROPHYS J, V200, pL107, DOI 10.1086/181908; Di Salvo T, 2001, ASTROPHYS J, V547, P1024, DOI 10.1086/318396; Fender RP, 2000, MON NOT R ASTRON SOC, V312, P853, DOI 10.1046/j.1365-8711.2000.03219.x; Fender RP, 2003, MON NOT R ASTRON SOC, V343, pL99, DOI 10.1046/j.1365-8711.2003.06950.x; FENDER RP, IN PRESS COMPACT STE; Frank J., 2002, ACCRETION POWER ASTR, V3rd; Gallo E, 2003, MON NOT R ASTRON SOC, V344, P60, DOI 10.1046/j.1365-8711.2003.06791.x; GIES DR, 1986, ASTROPHYS J, V304, P371, DOI 10.1086/164172; HERRERO A, 1995, ASTRON ASTROPHYS, V297, P556; Hughes P.A., 1991, BEAMS JETS ASTROPHYS; HUNTER DA, 1990, ASTRON J, V99, P846, DOI 10.1086/115378; Kaiser CR, 1997, MON NOT R ASTRON SOC, V286, P215, DOI 10.1093/mnras/286.1.215; Lestrade JF, 1999, ASTRON ASTROPHYS, V344, P1014; Livio M, 2003, ASTROPHYS J, V593, P184, DOI 10.1086/375872; Longair M.S., 1992, HIGH ENERGY ASTROPHY, V2nd; LOTZ W, 1967, ASTROPHYS J, VS 14, P207, DOI 10.1086/190154; Malzac J, 2004, MON NOT R ASTRON SOC, V351, P253, DOI 10.1111/j.1365-2966.2004.07772.x; Marti J, 1996, ASTRON ASTROPHYS, V306, P449; MCCLINTOCK JE, IN PRESS COMPACT STE; Mirabel IF, 1999, ANNU REV ASTRON ASTR, V37, P409, DOI 10.1146/annurev.astro.37.1.409; MIRABEL IF, 1994, NATURE, V371, P46, DOI 10.1038/371046a0; Mirabel IF, 2003, SCIENCE, V300, P1119, DOI 10.1126/science.1083451; Sharpless S., 1959, ASTROPHYS J        S, V4, P257; Smith DA, 2002, ASTROPHYS J, V565, P195, DOI 10.1086/324539; Stirling AM, 2001, MON NOT R ASTRON SOC, V327, P1273, DOI 10.1046/j.1365-8711.2001.04821.x; URRY CM, 1995, PUBL ASTRON SOC PAC, V107, P803, DOI 10.1086/133630	30	241	241	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 11	2005	436	7052					819	821		10.1038/nature03879	http://dx.doi.org/10.1038/nature03879			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953XG	16094361				2022-12-28	WOS:000231116500038
J	Holden, PJP				Holden, PJP			The London attacks - A chronicle - Improvising in an emergency	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	15	15	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 11	2005	353	6					541	543		10.1056/NEJMp058179	http://dx.doi.org/10.1056/NEJMp058179			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	953ST	16093459	Bronze			2022-12-28	WOS:000231101500001
J	Harvey, S; Harrison, DA; Singer, M; Ashcroft, J; Jones, CM; Elbourne, D; Brampton, W; Williams, D; Young, D; Rowan, K				Harvey, S; Harrison, DA; Singer, M; Ashcroft, J; Jones, CM; Elbourne, D; Brampton, W; Williams, D; Young, D; Rowan, K		PAC-Man Study Collaboration	Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial	LANCET			English	Article							RIGHT-HEART CATHETERIZATION; KNOWLEDGE; TIME; FAILURE; DEATH	Background Over the past 30 years the pulmonary artery catheter (PAC) has become a widely used haemodynamic monitoring device in the management of critically ill patients, though doubts exist about its safety. Our aim was, therefore, to ascertain whether hospital mortality is reduced in critically ill patients when they are managed with a PAC. Methods We did a randomised controlled trial to which we enrolled 1041 patients from 65 UK intensive care units. We assigned individuals to management with (n=519) or without (n=522) a PAC. The timing of insertion and subsequent clinical management were at the discretion of the treating clinician. Intensive care units decided a priori to have the option of using an alternative cardiac output-monitoring device in control patients. Findings 1014 patients were eligible for analysis. We noted no difference in hospital mortality between patients managed with or without a PAC (68% [346 of 506] vs 66% [333 of 507], p=0.39; adjusted hazard ratio 1.09, 95% CI 0.94-1.27). We noted complications associated with insertion of a PAC in 46 of 486 individuals in whom the device was placed, none of which was fatal. Interpretation Our findings indicate no clear evidence of benefit or harm by managing critically ill patients with a PAC. Efficacy studies are needed to ascertain whether management protocols involving PAC use can result in improved outcomes in specific groups if these devices are not to become a redundant technology.	Intens Care Natl Audit & Res Ctr, London, England; UCL, Dept Med, London, England; UCL, Wolfson Inst Biomed Res, London, England; London Sch Hyg & Trop Med, London WC1, England; Gloucestershire Hosp NHS Trust, Cheltenham, Glos, England; Dumfries & Galloway Acute & Matern Hosp NHS Trust, Dumfries, Scotland; John Radcliffe Hosp NHS Trust, Oxford, England	Intensive Care National Audit & Research Centre; University of London; University College London; University of London; University College London; University of London; London School of Hygiene & Tropical Medicine; Gloucestershire Hospitals NHS Foundation Trust	Singer, M (corresponding author), UCL, Middlesex Hosp, Bloomsbury Inst Intens Care Med, London W1T 3AA, England.	m.singer@ucl.ac.uk	Singer, Mervyn/J-4425-2012; Young, John D/M-9756-2016; Singer, Mervyn/Q-6142-2019; Harrison, David A/O-4355-2018	Singer, Mervyn/0000-0002-1042-6350; Singer, Mervyn/0000-0002-1042-6350; Harrison, David A/0000-0002-9002-9098; Harvey, Sheila/0000-0001-7604-8607; Young, John Duncan/0000-0002-6838-4835	National Institute for Health Research [97/08/03] Funding Source: researchfish; Department of Health [97/08/03] Funding Source: Medline	National Institute for Health Research(National Institute for Health Research (NIHR)); Department of Health		[Anonymous], 2002, ANESTHESIOL CLIN N A; Audit Commission, CRIT SUCC PLAC EFF E; Briggs AH, 2001, HEALTH ECON, V10, P179, DOI 10.1002/hec.584; Claxton K, 2002, LANCET, V360, P711, DOI 10.1016/S0140-6736(02)09832-X; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; Coulter TD, 1999, CLIN CHEST MED, V20, P249, DOI 10.1016/S0272-5231(05)70140-4; Dalen JE, 1996, JAMA-J AM MED ASSOC, V276, P916, DOI 10.1001/jama.276.11.916; Gnaegi A, 1997, CRIT CARE MED, V25, P213, DOI 10.1097/00003246-199702000-00003; GORE JM, 1987, CHEST, V92, P721, DOI 10.1378/chest.92.4.721; IBERTI TJ, 1994, CRIT CARE MED, V22, P1674; IBERTI TJ, 1990, JAMA-J AM MED ASSOC, V264, P2928, DOI 10.1001/jama.264.22.2928; Kern JW, 2002, CRIT CARE MED, V30, P1686, DOI 10.1097/00003246-200208000-00002; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MACKIRDY FN, 1997, CLIN INTENSIVE CARE, V8, P97; MCCABE CJ, 1998, EFFECTIVE HLTH CARE, V4, P1; Neill H, 2004, BRIT J ANAESTH, V92, p616P; *NHS EX, 1997, INT HIGH DEP CAR DAT; NICE, 2004, GUID METH TECHN APPR; Rhodes A, 2002, INTENS CARE MED, V28, P256, DOI 10.1007/s00134-002-1206-9; Richard C, 2003, JAMA-J AM MED ASSOC, V290, P2732; ROBIN ED, 1988, CHEST, V93, P1059, DOI 10.1378/chest.93.5.1059-a; ROBIN ED, 1987, CHEST, V92, P727, DOI 10.1378/chest.92.4.727; *SCOTT INT CAR SOC, 2004, ANN REP; Singer M, 2004, LANCET, V364, P545, DOI 10.1016/S0140-6736(04)16815-3; STEVENS KJ, INCREMENTAL COST EFF; Taylor RW, 1997, CRIT CARE MED, V25, P910; Thompson SG, 2000, BRIT MED J, V320, P1197, DOI 10.1136/bmj.320.7243.1197; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/s001340050156; Vincent JL, 1998, CRIT CARE MED, V26, P1283, DOI 10.1097/00003246-199807000-00035; ZION MM, 1990, CHEST, V98, P1331, DOI 10.1378/chest.98.6.1331	30	642	679	0	24	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 6	2005	366	9484					472	477		10.1016/S0140-6736(05)67061-4	http://dx.doi.org/10.1016/S0140-6736(05)67061-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	952RD	16084255				2022-12-28	WOS:000231022300028
J	Nielsen, NR; Zhang, ZF; Kristensen, TS; Netterstrom, B; Schnohr, P; Gronbaek, M				Nielsen, NR; Zhang, ZF; Kristensen, TS; Netterstrom, B; Schnohr, P; Gronbaek, M			Self reported stress and risk of breast cancer: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							LIFE EVENTS; HORMONE; WOMEN; COPENHAGEN; MORTALITY	Objective To assess the relation between self reported intensity and frequency of stress and first time incidence of primary breast cancer. Design Prospective cohort study with 18 years of follow-up. Setting Copenhagen City heart study, Denmark. Participants The 6689 women participating in the Copenhagen City heart study were asked about their perceived level of stress at baseline in 1981-3. These women were followed until 1999 in the Danish nationwide cancer registry, with < 0.1% loss to follow-up. Main outcome measure First time incidence of primary breast cancer. Results During follow-up 251 women were diagnosed with breast cancer. After adjustment for confounders, women with high levels of stress had a hazard ratio of 0.60 (95% confidence interval 0.37 to 0.97) for breast cancer compared with women with low levels of stress. Furthermore, for each increase in stress level on a six point stress scale an 8% lower risk of,primary breast cancer was found (hazard ratio 0.92,0.85 to 0.99). This association seemed to be stable over time and was particularly pronounced in women receiving hormone therapy. Conclusion High endogenous concentrations of oestrogen are a known risk factor for breast cancer, and impairment of oestrogen synthesis induced by chronic stress may explain a lower incidence of breast cancer in women with high stress. Impairment of normal body function should not, however, be considered a healthy response, and the cumulative health consequences of stress may be disadvantageous.	Natl Inst Publ Hlth, DK-1399 Copenhagen, Denmark; Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA; Natl Inst Occupat Hlth, Copenhagen, Denmark; Hillerod Hosp, Clin Occupat Med, Hillerod, Denmark; Bispebjerg Univ Hosp, Epidemiol Res Unit, Copenhagen City Heart Study, Copenhagen, Denmark	University of California System; University of California Los Angeles; University of Copenhagen; University of Copenhagen; Bispebjerg Hospital	Nielsen, NR (corresponding author), Natl Inst Publ Hlth, Oster Farimagsgrade 5A, DK-1399 Copenhagen, Denmark.	nrn@niph.dk	Rod, Naja/B-9411-2015	Rod, Naja/0000-0002-6400-5105; Zhang, Zuo-Feng/0000-0002-4669-3995; Gronbaek, Morten Klocker/0000-0002-8473-6474				Achat H, 2000, INT J EPIDEMIOL, V29, P622, DOI 10.1093/ije/29.4.622; Appleyard M., 1989, SCAND J SOC MED, V41, P1; Birk AM, 2002, AP FIRE SCI, V4, P3; Breen KM, 2004, ENDOCRINOLOGY, V145, P692, DOI 10.1210/en.2003-1114; Duijts SFA, 2003, INT J CANCER, V107, P1023, DOI 10.1002/ijc.11504; Ferin M, 1999, J CLIN ENDOCR METAB, V84, P1768, DOI 10.1210/jc.84.6.1768; HALBREICH U, 1997, NEUROLOGY S7, V48, P16; HANKINSON S, 2002, TXB CANC EPIDEMIOLOG, P301; Helgesson O, 2003, EUR J CANCER PREV, V12, P377, DOI 10.1097/00008469-200310000-00006; Johansen C, 1997, BRIT J CANCER, V75, P144, DOI 10.1038/bjc.1997.24; Kroenke CH, 2004, AM J EPIDEMIOL, V159, P1019, DOI 10.1093/aje/kwh148; Lillberg K, 2003, AM J EPIDEMIOL, V157, P415, DOI 10.1093/aje/kwg002; Lillberg K, 2001, INT J CANCER, V91, P888, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1138>3.0.CO;2-D; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; NEGROVILAR A, 1993, ENVIRON HEALTH PERSP, V101, P59, DOI 10.2307/3431377; Olsen AH, 2005, BMJ-BRIT MED J, V330, P220, DOI 10.1136/bmj.38313.639236.82; Olsen AH, 2003, BRIT J CANCER, V88, P362, DOI 10.1038/sj.bjc.6600712; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Protheroe D, 1999, BRIT MED J, V319, P1027, DOI 10.1136/bmj.319.7216.1027; Rivier C, 1995, ANN NY ACAD SCI, V771, P187, DOI 10.1111/j.1749-6632.1995.tb44680.x; Rothman K., 1998, MODERN EPIDEMIOLOGY, P253; SAPOLSKY R, 1998, WHY ZEBRAS DONT GET, P101; Truelsen T, 2003, STROKE, V34, P856, DOI 10.1161/01.STR.0000062345.80774.40	23	71	75	0	15	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	SEP 10	2005	331	7516					548	550A		10.1136/bmj.38547.638183.06	http://dx.doi.org/10.1136/bmj.38547.638183.06			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	965GX	16103031	Green Published, Bronze			2022-12-28	WOS:000231939700017
J	Zinkel, SS; Hurov, KE; Ong, C; Abtahl, FM; Gross, A; Korsmeyer, SJ				Zinkel, SS; Hurov, KE; Ong, C; Abtahl, FM; Gross, A; Korsmeyer, SJ			A role for proapoptotic BID in the DNA-damage response	CELL			English	Article							NORMAL HUMAN FIBROBLASTS; CHECKPOINT KINASE ATR; IONIZING-RADIATION; CASEIN KINASE-2; STRAND BREAKS; BLM HELICASE; S-PHASE; PHOSPHORYLATION; REPAIR; P53	The BCL-2 family of apoptotic proteins encompasses key regulators proximal to irreversible cell damage The BH3-only members of this family act as sentinels interconnecting specific death signals to the core apoptotic pathway. Our previous data demonstrated a role for BH3-only BID in maintaining myeloid homeostasis and suppressing leukemogenesis. In the absence of Bid, mice accumulate chromosomal aberrations and develop a fatal myeloproliferative disorder resembling chronic myelomonocytic leukemia. Here, we describe a role for BID in preserving genomic integrity that places BID at an early point in the path to determine the fate of a cell. We show that BID plays an unexpected role in the intra-S phase checkpoint downstream of DNA damage distinct from its proapoptotic function. We further demonstrate that this role is mediated through BID phosphorylation by the DNA-damage kinase ATM. These results establish a link between proapoptotic Bid and the DNA-damage response.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Howard Hughes Med Inst, Boston, MA 02115 USA; Weizmann Inst Sci, Dept Regulat Biol, IL-7610 Rehovot, Israel	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; Weizmann Institute of Science	Zinkel, SS (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Howard Hughes Med Inst, Boston, MA 02115 USA.	sandra.zinkel@vanderbilt.edu	Gross, Atan/ABC-2640-2020	zinkel, sandra/0000-0002-2818-9795	NATIONAL CANCER INSTITUTE [R37CA050239, K08CA098394, P01CA092625] Funding Source: NIH RePORTER; NCI NIH HHS [CA098394, P01 CA92625, R37 CA50239] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andegeko Y, 2001, J BIOL CHEM, V276, P38224; Andreassen PR, 2004, GENE DEV, V18, P1958, DOI 10.1101/gad.1196104; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Baus F, 2003, EMBO J, V22, P3992, DOI 10.1093/emboj/cdg387; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cha RS, 2002, SCIENCE, V297, P602, DOI 10.1126/science.1071398; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; D'Andrea AD, 2003, GENE DEV, V17, P1933, DOI 10.1101/gad.1128303; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Frei C, 2000, J CELL SCI, V113, P2641; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; HAWLEY RG, 1994, ONCOGENE, V9, P1; Jacks T, 2002, CELL, V111, P923, DOI 10.1016/S0092-8674(02)01229-1; Kalb R, 2004, RADIAT RES, V161, P318, DOI 10.1667/RR3138; Kamer I, 2005, CELL, V122, P593, DOI 10.1016/j.cell.2005.06.014; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; Langland G, 2002, CANCER RES, V62, P2766; Loizou JI, 2004, CELL, V117, P17, DOI 10.1016/S0092-8674(04)00206-5; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; Nakatani Y, 2003, METHOD ENZYMOL, V370, P430; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; O'Neill T, 2000, J BIOL CHEM, V275, P22719, DOI 10.1074/jbc.M001002200; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sarkaria JN, 1998, CANCER RES, V58, P4375; Sarno S, 2002, PHARMACOL THERAPEUT, V93, P159, DOI 10.1016/S0163-7258(02)00185-7; Sarno S, 2001, FEBS LETT, V496, P44, DOI 10.1016/S0014-5793(01)02404-8; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 2000, ONCOGENE, V19, P6176, DOI 10.1038/sj.onc.1203971; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zinkel SS, 2003, GENE DEV, V17, P229, DOI 10.1101/gad.1045603	53	183	195	0	5	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 26	2005	122	4					579	591		10.1016/j.cell.2005.06.022	http://dx.doi.org/10.1016/j.cell.2005.06.022			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	959YI	16122425	Bronze			2022-12-28	WOS:000231555100013
J	Markel, H				Markel, H			The search for effective HIV vaccines	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CD4(+) T-CELLS; GASTROINTESTINAL-TRACT; INFECTION; DEPLETION		Univ Michigan, Sch Med, Ctr Hist Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Markel, H (corresponding author), Univ Michigan, Sch Med, Ctr Hist Med, Ann Arbor, MI 48109 USA.							Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874; Li QS, 2005, NATURE, V434, P1148, DOI 10.1038/nature03513; Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501; Mehandru S, 2004, J EXP MED, V200, P761, DOI 10.1084/jem.20041196; Shilts R, 1987, BAND PLAYED, P451	5	37	41	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 25	2005	353	8					753	757		10.1056/NEJMp058146	http://dx.doi.org/10.1056/NEJMp058146			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	957YK	16120854				2022-12-28	WOS:000231409300003
J	Sanai, N; Alvarez-Buylla, A; Berger, MS				Sanai, N; Alvarez-Buylla, A; Berger, MS			Mechanisms of disease: Neural stem cells and the origin of gliomas	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SUBCORTICAL WHITE-MATTER; ACUTE MYELOID-LEUKEMIA; GROWTH-FACTOR RECEPTOR; AVIAN-SARCOMA VIRUS; ADULT HUMAN BRAIN; NEURONAL PRECURSORS; NERVOUS-SYSTEM; SUBVENTRICULAR ZONE; SUBEPENDYMAL PLATE; PROGENITOR CELLS		Univ Calif San Francisco, Dept Neurol Surg, Brain Tumor Res Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dev Stem Cell Biol Program, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Sanai, N (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, Brain Tumor Res Ctr, 505 Parnassus Ave,M-779,Campus Box 0112, San Francisco, CA 94143 USA.	sanain@neurosurg.ucsf.edu		Alvarez-Buylla, Arturo/0000-0003-4426-8925				Aboody KS, 2001, P NATL ACAD SCI USA, V98, P777; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P6890, DOI 10.1073/pnas.1131491100; Altaba ARI, 2004, CANCER LETT, V204, P145, DOI 10.1016/S0304-3835(03)00451-8; Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; ARMSTRONG RC, 1992, J NEUROSCI, V12, P1538; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Bai CB, 2002, DEVELOPMENT, V129, P4753; Bailey P, 1926, CLASSIFICATION TUMOR; Ben-Hur T, 1998, J NEUROSCI, V18, P5777, DOI 10.1523/jneurosci.18-15-05777.1998; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; BRUSTLE O, 1995, J NEURO-ONCOL, V24, P57, DOI 10.1007/BF01052659; BUICK RN, 1979, BLOOD, V54, P95; Caporaso GL, 2003, MOL CELL NEUROSCI, V23, P693, DOI 10.1016/S1044-7431(03)00103-9; Chekenya M, 2002, J NEUROCYTOL, V31, P507, DOI 10.1023/A:1025795715377; Chenn A, 2002, SCIENCE, V297, P365, DOI 10.1126/science.1074192; COONS SW, 1995, CANCER RES, V55, P1569; COPELAND DD, 1977, ACTA NEUROPATHOL, V38, P1, DOI 10.1007/BF00691268; COPELAND DD, 1975, J NEUROPATH EXP NEUR, V34, P340, DOI 10.1097/00005072-197507000-00004; DAHLSTRAND J, 1992, CANCER RES, V52, P5334; Dahmane N, 2001, DEVELOPMENT, V128, P5201; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Doetsch F, 2002, NEURON, V36, P1021, DOI 10.1016/S0896-6273(02)01133-9; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; ERIKSSON PS, 2004, NATURE, V427, P740; Fidler PS, 1999, J NEUROSCI, V19, P8778, DOI 10.1523/JNEUROSCI.19-20-08778.1999; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Globus J.H., 1944, J NEUROPATH EXP NEUR, V3, P1; Globus JH, 1942, ARCH PATHOL, V34, P674; Goings GE, 2004, BRAIN RES, V996, P213, DOI 10.1016/j.brainres.2003.10.034; Greaves M F, 1982, J Cell Physiol Suppl, V1, P113; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; HAMBURGER AW, 1977, SCIENCE, V197, P461, DOI 10.1126/science.560061; Hammoud MA, 1996, J NEURO-ONCOL, V27, P65, DOI 10.1007/BF00146086; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Holland EC, 2000, AM J PATHOL, V157, P1031, DOI 10.1016/S0002-9440(10)64615-9; HOPEWELL JW, 1975, J PATHOL, V117, P101, DOI 10.1002/path.1711170208; Jin K, 2003, MOL CELL NEUROSCI, V24, P171, DOI 10.1016/S1044-7431(03)00159-3; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Kenney AM, 2000, MOL CELL BIOL, V20, P9055, DOI 10.1128/MCB.20.23.9055-9067.2000; KIM SU, 1985, J NEUROIMMUNOL, V8, P255, DOI 10.1016/S0165-5728(85)80066-7; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Koos W T, 1985, Acta Neurochir Suppl (Wien), V35, P1; Kornblum HI, 1998, J NEUROSCI RES, V53, P697, DOI 10.1002/(SICI)1097-4547(19980915)53:6<697::AID-JNR8>3.3.CO;2-M; KRAUS JA, 1995, J NEUROPATH EXP NEUR, V54, P91, DOI 10.1097/00005072-199501000-00011; Lacroix M, 2001, J NEUROSURG, V95, P190, DOI 10.3171/jns.2001.95.2.0190; LANTOS PL, 1976, EXPERIENTIA, V32, P1467, DOI 10.1007/BF01937439; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; Leon SP, 1996, CANCER-AM CANCER SOC, V77, P362, DOI 10.1002/(SICI)1097-0142(19960115)77:2<362::AID-CNCR20>3.0.CO;2-Z; Li L, 2003, J CELL BIOCHEM, V88, P24, DOI 10.1002/jcb.10312; Linskey ME, 1997, J NEURO-ONCOL, V34, P5, DOI 10.1023/A:1005751018617; Lois C, 1996, SCIENCE, V271, P978, DOI 10.1126/science.271.5251.978; Luzzati F, 2003, P NATL ACAD SCI USA, V100, P13036, DOI 10.1073/pnas.1735482100; Machold R, 2003, NEURON, V40, P189, DOI 10.1016/S0896-6273(03)00593-2; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Marino S, 2000, GENE DEV, V14, P994; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Nunes MC, 2003, NAT MED, V9, P439, DOI 10.1038/nm837; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Palma V, 2005, DEVELOPMENT, V132, P335, DOI 10.1242/dev.01567; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Pietsch T, 1997, CANCER RES, V57, P2085; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; PRINGLE NP, 1992, DEVELOPMENT, V115, P535; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; Roy NS, 1999, J NEUROSCI, V19, P9986, DOI 10.1523/jneurosci.19-22-09986.1999; SALSBURY AJ, 1975, CANCER TREAT REV, V2, P55, DOI 10.1016/S0305-7372(75)80015-6; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Sasaki H, 1999, DEVELOPMENT, V126, P3915; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; Seidman KJN, 1997, BRAIN RES, V753, P18, DOI 10.1016/S0006-8993(96)01481-3; SELL S, 1994, LAB INVEST, V70, P6; Shapiro J R, 1991, Basic Life Sci, V57, P243; Shoshan Y, 1999, P NATL ACAD SCI USA, V96, P10361, DOI 10.1073/pnas.96.18.10361; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sutton L N, 1992, Neurosurg Clin N Am, V3, P821; TOHYAMA T, 1992, LAB INVEST, V66, P303; Traiffort E, 1999, EUR J NEUROSCI, V11, P3199, DOI 10.1046/j.1460-9568.1999.00777.x; Uhrbom L, 2002, CANCER RES, V62, P5551; VALTZ NLM, 1991, NEW BIOL, V3, P364; VICK NA, 1977, ACTA NEUROPATHOL, V40, P63, DOI 10.1007/BF00688574; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; Weinstein DE, 1996, BRAIN RES, V743, P11, DOI 10.1016/S0006-8993(96)00979-1; Yokota N, 2002, INT J CANCER, V101, P198, DOI 10.1002/ijc.10559	93	739	788	5	48	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 25	2005	353	8					811	822		10.1056/NEJMra043666	http://dx.doi.org/10.1056/NEJMra043666			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	957YK	16120861				2022-12-28	WOS:000231409300010
J	Brandon, AD; Humayun, M; Puchtel, IS; Leya, I; Zolensky, M				Brandon, AD; Humayun, M; Puchtel, IS; Leya, I; Zolensky, M			Osmium isotope evidence for an s-process carrier in primitive chondrites	SCIENCE			English	Article							EARLY SOLAR-SYSTEM; NEUTRON-CAPTURE; ABUNDANCES; NUCLEOSYNTHESIS; METEORITES; DIAMOND	Osmium extracted from unequilibrated bulk chondrites has isotope anomalies consistent with an insoluble s-process carrier, termed Os(i) here. Osmium from metamorphosed bulk chondrites does not have isotope anomalies, implying that the Os(i) carrier was destroyed by metamorphism. The isotopic homogeneity of metamorphosed bulk chondrites is consistent with extremely effective mixing of presolar grains from varied sources in the nebula. Osmium in the Os(i) carrier is likely from nucleosynthetic sites with a neutron density about two to four times as high as that of the average solar s-process Os.	NASA, Lyndon B Johnson Space Ctr, Houston, TX 77058 USA; Florida State Univ, Natl High Magnet Field Lab, Tallahassee, FL 32310 USA; Florida State Univ, Dept Geol Sci, Tallahassee, FL 32310 USA; Univ Maryland, Dept Geol, College Pk, MD 20742 USA; Univ Bern, Inst Phys, CH-3012 Bern, Switzerland	National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; State University System of Florida; Florida State University; State University System of Florida; Florida State University; University System of Maryland; University of Maryland College Park; University of Bern	Brandon, AD (corresponding author), NASA, Lyndon B Johnson Space Ctr, Mail Stop KR, Houston, TX 77058 USA.	alan.d.brandon1@jsc.nasa.gov	, Igor/ABA-2434-2020; Humayun, Munir/A-1247-2007	Humayun, Munir/0000-0001-8516-9435; Zolensky, Michael/0000-0002-3181-1303				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; Becker H, 2003, CHEM GEOL, V196, P43, DOI 10.1016/S0009-2541(02)00406-0; Becker H, 2003, NATURE, V425, P152, DOI 10.1038/nature01975; BECKER H, 2004, LUNAR PLANET SCI, V35, P1310; Beer H, 1997, ASTROPHYS J, V474, P843, DOI 10.1086/303480; Chen JH, 2004, LUNAR PLANET SCI, VXXXV, P1431; CROAT TK, 2005, LUNAR PLANET SCI, V36, P1507; Dauphas N, 2002, ASTROPHYS J, V565, P640, DOI 10.1086/324597; Gallino R, 1998, ASTROPHYS J, V497, P388, DOI 10.1086/305437; Grady MM, 2002, METEORIT PLANET SCI, V37, P713, DOI 10.1111/j.1945-5100.2002.tb00851.x; HUSS GR, 1990, NATURE, V347, P159, DOI 10.1038/347159a0; HUSS GR, 1995, GEOCHIM COSMOCHIM AC, V59, P115, DOI 10.1016/0016-7037(94)00376-W; HUSS GR, 1997, AIP C P, V402, P721; KAPPELER F, 1991, ASTROPHYS J, V366, P605, DOI 10.1086/169596; KAPPELER F, 1990, ASTROPHYS J, V354, P630, DOI 10.1086/168720; KASHIV Y, 2001, LUNAR PLANET SCI, V32, P2192; Leya I, 2003, GEOCHIM COSMOCHIM AC, V67, P529, DOI 10.1016/S0016-7037(02)01091-8; MCCULLOCH MT, 1978, ASTROPHYS J, V220, pL15, DOI 10.1086/182628; Nakamura T., 2001, LUN PLAN SCI C, VXXXII, P1621; Nittler LR, 2003, EARTH PLANET SC LETT, V209, P259, DOI 10.1016/S0012-821X(02)01153-6; PALME H, 1993, LANDOLDTBORNSTEIN GR, V3, P196; Papanastassiou D. A., 2004, LUNAR PLANET SCI, VXXXV, P1828; Schonbachler M, 2003, EARTH PLANET SC LETT, V216, P467, DOI 10.1016/S0012-821X(03)00547-8; TAKAHASHI K, 1987, ATOM DATA NUCL DATA, V36, P375, DOI 10.1016/0092-640X(87)90010-6; Walker RJ, 2002, GEOCHIM COSMOCHIM AC, V66, P4187, DOI 10.1016/S0016-7037(02)01003-7; Yin QZ, 2002, NATURE, V415, P881, DOI 10.1038/415881a; Zinner E, 1998, ANNU REV EARTH PL SC, V26, P147, DOI 10.1146/annurev.earth.26.1.147	27	89	91	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 19	2005	309	5738					1233	1236		10.1126/science.1115053	http://dx.doi.org/10.1126/science.1115053			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	957TE	16109878	Green Submitted			2022-12-28	WOS:000231395400043
J	Gillette, MU; Sejnowski, TJ				Gillette, MU; Sejnowski, TJ			Biological clocks coordinately keep life on time	SCIENCE			English	Editorial Material							MAMMALIAN CIRCADIAN CLOCK; CELL-CYCLE		Univ Illinois, Dept Cell & Dev Biol, Urbana, IL 61801 USA; Univ Illinois, Program Neurosci, Urbana, IL 61801 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Diego	Gillette, MU (corresponding author), Univ Illinois, Dept Cell & Dev Biol, Urbana, IL 61801 USA.	terry@salk.edu	Sejnowski, Terrence/AAV-5558-2021					Cross FR, 2002, MOL BIOL CELL, V13, P52, DOI 10.1091/mbc.01-05-0265; Destexhe A, 2003, PHYSIOL REV, V83, P1401, DOI 10.1152/physrev.00012.2003; Dijk DJ, 2004, AVIAT SPACE ENVIR MD, V75, pA119; Dudley CA, 2003, SCIENCE, V301, P379, DOI 10.1126/science.1082795; Ivleva NB, 2005, EMBO J, V24, P1202, DOI 10.1038/sj.emboj.7600606; Kaasik K, 2004, NATURE, V430, P467, DOI 10.1038/nature02724; Klevecz RR, 2004, P NATL ACAD SCI USA, V101, P1200, DOI 10.1073/pnas.0306490101; Leloup JC, 2004, J THEOR BIOL, V230, P541, DOI 10.1016/j.jtbi.2004.04.040; Lowrey PL, 2004, ANNU REV GENOM HUM G, V5, P407, DOI 10.1146/annurev.genom.5.061903.175925; Matsuo T, 2003, SCIENCE, V302, P255, DOI 10.1126/science.1086271; Panda Satchidananda, 2003, Novartis Found Symp, V253, P73; Reick M, 2001, SCIENCE, V293, P506, DOI 10.1126/science.1060699; Rutter J, 2002, ANNU REV BIOCHEM, V71, P307, DOI 10.1146/annurev.biochem.71.090501.142857; Tischkau SA, 2004, NEURON, V43, P539, DOI 10.1016/j.neuron.2004.07.027; Zheng BH, 2001, CELL, V105, P683, DOI 10.1016/S0092-8674(01)00380-4	15	41	43	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 19	2005	309	5738					1196	1198		10.1126/science.1111420	http://dx.doi.org/10.1126/science.1111420			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	957TE	16109872				2022-12-28	WOS:000231395400032
J	van Enk, SJ; Kimble, HJ				van Enk, SJ; Kimble, HJ			Comment on "Quantum state transfer between matter and light"	SCIENCE			English	Editorial Material								Matsukevich and Kuzmich (Reports, 22 October 2004, p. 663) claim to have produced several types of nearly maximally entangled states involving photons and atomic ensembles. We show that their experimental evidence is insufficient to support these claims, that their comparisons to a previous experiment are misleading, and that their sweeping assertions related to quantum networks are unjustified.	Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA; CALTECH, Norman Bridge Lab 12 33, Pasadena, CA 91125 USA	Alcatel-Lucent; Lucent Technologies; AT&T; California Institute of Technology	van Enk, SJ (corresponding author), Bell Labs, Lucent Technol, Room 1D-428,600-700 Mt Ave, Murray Hill, NJ 07974 USA.							Blinov BB, 2004, NATURE, V428, P153, DOI 10.1038/nature02377; Duan LM, 2001, NATURE, V414, P413, DOI 10.1038/35106500; Matsukevich DN, 2004, SCIENCE, V306, P663, DOI 10.1126/science.1103346	3	6	6	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 19	2005	309	5738								10.1126/science.1110603	http://dx.doi.org/10.1126/science.1110603			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	957TE	16109867				2022-12-28	WOS:000231395400023
J	Tagliaferri, G; Goad, M; Chincarini, G; Moretti, A; Campana, S; Burrows, DN; Perri, M; Barthelmy, SD; Gehrels, N; Krimm, H; Sakamoto, T; Kumar, P; Meszaros, PI; Kobayashi, S; Zhang, B; Angelini, L; Banat, P; Beardmore, AP; Capalbi, M; Covino, S; Cusumano, G; Giommi, P; Godet, O; Hill, JE; Kennea, JA; Mangano, V; Morris, DC; Nousek, JA; O'Brien, PT; Osborne, JP; Pagani, C; Page, KL; Romano, P; Stella, L; Wells, A				Tagliaferri, G; Goad, M; Chincarini, G; Moretti, A; Campana, S; Burrows, DN; Perri, M; Barthelmy, SD; Gehrels, N; Krimm, H; Sakamoto, T; Kumar, P; Meszaros, PI; Kobayashi, S; Zhang, B; Angelini, L; Banat, P; Beardmore, AP; Capalbi, M; Covino, S; Cusumano, G; Giommi, P; Godet, O; Hill, JE; Kennea, JA; Mangano, V; Morris, DC; Nousek, JA; O'Brien, PT; Osborne, JP; Pagani, C; Page, KL; Romano, P; Stella, L; Wells, A			An unexpectedly rapid decline in the X-ray afterglow emission of long gamma-ray bursts	NATURE			English	Article							BATSE	'Long' gamma-ray bursts (GRBs) are commonly accepted to originate in the explosion of particularly massive stars, which give rise to highly relativistic jets. Inhomogeneities in the expanding flow result in internal shock waves that are believed to produce the gamma-rays we see(1,2). As the jet travels further outward into the surrounding circumstellar medium, 'external' shocks create the afterglow emission seen in the X-ray, optical and radio bands(1,2). Here we report observations of the early phases of the X-ray emission of five GRBs. Their X-ray light curves are characterised by a surprisingly rapid fall-off for the first few hundred seconds, followed by a less rapid decline lasting several hours. This steep decline, together with detailed spectral properties of two particular bursts, shows that violent shock interactions take place in the early jet outflows.	Osserv Astron Brera, INAF, I-23807 Merate, Italy; Univ Leicester, Dept Phys & Astron, Leicester LE1 7RH, Leics, England; Univ Milano Bicocca, I-20126 Milan, Italy; Penn State Univ, Dept Astron & Astrophys, University Pk, PA 16802 USA; ASI Sci Data Ctr, I-00044 Frascati, Italy; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Univ Space Res Assoc, Columbia, MD 21044 USA; CNR, Washington, DC 20418 USA; Univ Texas, Dept Astron, Austin, TX 78712 USA; Univ Nevada, Dept Phys, Las Vegas, NV 89154 USA; Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA; Ist Astrofis Spaziale & Com, INAF, I-90146 Palermo, Italy; Osserv Astron Roma, INAF, I-00040 Monte Porzio Catone, Italy	Istituto Nazionale Astrofisica (INAF); University of Leicester; University of Milano-Bicocca; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Agenzia Spaziale Italiana (ASI); National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Universities Space Research Association (USRA); University of Texas System; University of Texas Austin; Nevada System of Higher Education (NSHE); University of Nevada Las Vegas; Johns Hopkins University; Istituto Nazionale Astrofisica (INAF); Istituto Nazionale Astrofisica (INAF)	Tagliaferri, G (corresponding author), Osserv Astron Brera, INAF, Via Bianchi 46, I-23807 Merate, Italy.	tagliaferri@merate.mi.astro.it	Gehrels, Neil/D-2971-2012; Kennea, Jamie/AAF-2090-2019; Covino, Stefano/AAQ-5188-2021; Barthelmy, Scott D/D-2943-2012; Tagliaferri, Gianpiero/ABD-7556-2021; Campana, Sergio/AAL-6012-2020; giommi, paolo/L-1006-2018	Kennea, Jamie/0000-0002-6745-4790; Covino, Stefano/0000-0001-9078-5507; Tagliaferri, Gianpiero/0000-0003-0121-0723; Campana, Sergio/0000-0001-6278-1576; giommi, paolo/0000-0002-2265-5003; Perri, Matteo/0000-0003-3613-4409; Romano, Patrizia/0000-0003-0258-7469; Cusumano, Giancarlo/0000-0002-8151-1990; Beardmore, Andrew/0000-0001-5186-5950; Goad, Michael/0000-0002-2908-7360; Mangano, Vanessa/0000-0003-4262-8616				Akerlof C, 1999, NATURE, V398, P400, DOI 10.1038/18837; BARTHELMY S, IN PRESS SPACE SCI R; BERGER E, 2005, IN PRESS ASTROPHYS J; Burenin RA, 1999, ASTRON ASTROPHYS, V344, pL53; Burrows DN, 2005, ASTROPHYS J, V622, pL85, DOI 10.1086/429666; BURROWS DN, IN PRESS SPACE SCI R; Campana S, 2005, ASTROPHYS J, V625, pL23, DOI 10.1086/430883; FORD LA, 1995, ASTROPHYS J, V439, P307, DOI 10.1086/175174; Fox DW, 2003, ASTROPHYS J, V586, pL5, DOI 10.1086/374683; Frontera F, 1998, ASTROPHYS J, V493, pL67, DOI 10.1086/311132; Giblin TW, 1999, ASTROPHYS J, V524, pL47, DOI 10.1086/312285; Hill JE, 2004, P SOC PHOTO-OPT INS, V5165, P217, DOI 10.1117/12.505728; HULLINGER D, 2005, 3038 GCN; Kumar P, 2000, ASTROPHYS J, V541, pL51, DOI 10.1086/312905; Kumar P, 2000, ASTROPHYS J, V535, P152, DOI 10.1086/308847; McMahon E, 2004, MON NOT R ASTRON SOC, V354, P915, DOI 10.1111/j.1365-2966.2004.08245.x; Meszaros P, 1997, ASTROPHYS J, V476, P232, DOI 10.1086/303625; Meszaros P, 2001, ASTROPHYS J, V556, pL37, DOI 10.1086/322934; Piran T, 2004, REV MOD PHYS, V76, P1143, DOI 10.1103/RevModPhys.76.1143; Piro L, 2005, ASTROPHYS J, V623, P314, DOI 10.1086/428377; Piro L, 1998, ASTRON ASTROPHYS, V331, pL41; Ramirez-Ruiz E, 2002, MON NOT R ASTRON SOC, V337, P1349, DOI 10.1046/j.1365-8711.2002.05995.x; REES MJ, 2005, IN PRESS ASTROPHYS J; ROMING PW, IN PRESS SPACE SCI R; Sari R, 1999, ASTROPHYS J, V517, pL109, DOI 10.1086/312039; SATO G, 2005, 2987 GCN; SCHADY P, 2005, 3039 GCN; Vietri M, 2000, ASTROPART PHYS, V14, P211, DOI 10.1016/S0927-6505(00)00119-5; Zhang B, 2004, INT J MOD PHYS A, V19, P2385, DOI 10.1142/S0217751X0401746X	30	230	234	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 18	2005	436	7053					985	988		10.1038/nature03934	http://dx.doi.org/10.1038/nature03934			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955XQ	16107840				2022-12-28	WOS:000231263900042
J	Jin, MH; Li, SH; Moghrabi, WN; Sun, H; Travis, GH				Jin, MH; Li, SH; Moghrabi, WN; Sun, H; Travis, GH			Rpe65 is the retinoid isomerase in bovine retinal pigment epithelium	CELL			English	Article							VERTEBRATE VISUAL CYCLE; BINDING-PROTEIN; MEMBRANE-RECEPTOR; HEK293S CELLS; LECITHIN; ACYLTRANSFERASE; IDENTIFICATION; ESTERS; ISOMEROHYDROLASE; ESTERIFICATION	The first event in light perception is absorption of a photon by an opsin pigment, which induces isomerization of its 11-cis-retinaldehyde chromophore. Restoration of light sensitivity to the bleached opsin requires chemical regeneration of 11-cis-retinaldehyde through an enzymatic pathway called the visual cycle. The isomerase, which converts an all-trans-retinyl ester to 11-cis-retinol, has never been identified. Here, we performed an unbiased cDNA expression screen to identify this isomerase. We discovered that the isomerase is a previously characterized protein called Rpe65. We confirmed our identification of the isomerase by demonstrating catalytic activity in mammalian and insect cells that express Rpe65. Mutations in the human RPE65 gene cause a blinding disease of infancy called Leber congenital amaurosis. Rpe65 with the Leber-associated C330Y and Y368H substitutions had no isomerase activity. Identification of Rpe65 as the isomerase explains the phenotypes in rpe65(-/-) knockout mice and in humans with Leber congenital amaurosis.	Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Travis, GH (corresponding author), Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA.	travis@jsei.ucla.edu	Travis, Gabriel Harvey/AIF-1062-2022	Travis, Gabriel Harvey/0000-0003-4020-9493	NEI NIH HHS [R01 EY015844, R01 EY015844-04] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY015844] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229; BAVIK CO, 1991, J BIOL CHEM, V266, P14978; BAVIK CO, 1992, J BIOL CHEM, V267, P23035; Bok D, 2003, BIOCHEMISTRY-US, V42, P6090, DOI 10.1021/bi0342416; Brueggemann LI, 2002, J GEN PHYSIOL, V119, P593, DOI 10.1085/jgp.20018495; Chen YM, 2003, VISION RES, V43, P3037, DOI 10.1016/j.visres.2003.08.001; Choo DW, 1998, FEBS LETT, V440, P195, DOI 10.1016/S0014-5793(98)01459-8; CRABB JW, 1991, J BIOL CHEM, V266, P16674; Gollapalli DR, 2003, BIOCHEMISTRY-US, V42, P11824, DOI 10.1021/bi035227w; Gollapalli DR, 2003, BIOCHEMISTRY-US, V42, P5809, DOI 10.1021/bi0341004; HAMSDORF K, 1979, HDB SENSORY PHYSL, V7, P45; Hanein S, 2004, HUM MUTAT, V23, P306, DOI 10.1002/humu.20010; HARNEL CP, 1993, J BIOL CHEM, V268, P15751; HUBBARD R, 1958, J GEN PHYSIOL, V41, P501, DOI 10.1085/jgp.41.3.501; INTRES R, 1994, J BIOL CHEM, V269, P25411; Kloer DP, 2005, SCIENCE, V308, P267, DOI 10.1126/science.1108965; Ma JX, 2001, INVEST OPHTH VIS SCI, V42, P1429; Ma JX, 1999, FEBS LETT, V452, P199, DOI 10.1016/S0014-5793(99)00606-7; MACDONALD PN, 1988, J BIOL CHEM, V263, P12478; Mata NL, 2004, J BIOL CHEM, V279, P635, DOI 10.1074/jbc.M310042200; Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1; Moiseyev G, 2003, BIOCHEMISTRY-US, V42, P2229, DOI 10.1021/bi026911y; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Ruiz A, 1999, J BIOL CHEM, V274, P3834, DOI 10.1074/jbc.274.6.3834; SAARI JC, 1989, J BIOL CHEM, V264, P8636; SAARI JC, 1988, J BIOL CHEM, V263, P8084; SAARI JC, 1987, J BIOL CHEM, V262, P7618; SAARI JC, 1993, BIOCHEM J, V291, P697, DOI 10.1042/bj2910697; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHWEMER J, 1985, MOL MECHANISMS PHOTO, P303; SHI YQ, 1993, BIOCHEMISTRY-US, V32, P1257, DOI 10.1021/bi00056a009; Thompson DA, 2000, INVEST OPHTH VIS SCI, V41, P4293; Tsilou E, 1997, ARCH BIOCHEM BIOPHYS, V346, P21, DOI 10.1006/abbi.1997.0276; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; Wenzel A, 2001, J NEUROSCI, V21, P53, DOI 10.1523/JNEUROSCI.21-01-00053.2001; Winston A, 1998, BIOCHEMISTRY-US, V37, P2044, DOI 10.1021/bi971908d; Xue LL, 2004, CELL, V117, P761, DOI 10.1016/j.cell.2004.05.016; Yzer S, 2003, J MED GENET, V40, P709, DOI 10.1136/jmg.40.9.709; Znoiko SL, 2002, INVEST OPHTH VIS SCI, V43, P1604	39	337	347	4	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 12	2005	122	3					449	459		10.1016/j.cell.2005.06.042	http://dx.doi.org/10.1016/j.cell.2005.06.042			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	955UZ	16096063	Green Accepted, Bronze			2022-12-28	WOS:000231254400015
J	Meshorer, E; Misteli, T				Meshorer, E; Misteli, T			Splicing misplaced	CELL			English	Editorial Material							TRANSLATION		NCI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Meshorer, E (corresponding author), NCI, NIH, Bethesda, MD 20892 USA.			Meshorer, Eran/0000-0003-4777-986X				Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Denis MM, 2005, CELL, V122, P379, DOI 10.1016/j.cell.2005.06.015; Gaspari M, 2004, BBA-BIOENERGETICS, V1659, P148, DOI 10.1016/j.bbabio.2004.10.003; Iborra FJ, 2004, J CELL SCI, V117, P5713, DOI 10.1242/jcs.01538; ITALIANO JE, 2002, PLATELETS, P21; Jensen TH, 2003, MOL CELL, V11, P1129, DOI 10.1016/S1097-2765(03)00191-6; Ruegsegger U, 2001, CELL, V107, P103, DOI 10.1016/S0092-8674(01)00505-0; Shin C, 2004, NAT REV MOL CELL BIO, V5, P727, DOI 10.1038/nrm1467; Yong JS, 2004, TRENDS CELL BIOL, V14, P226, DOI 10.1016/j.tcb.2004.03.010	9	12	13	0	3	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 12	2005	122	3					317	318		10.1016/j.cell.2005.07.016	http://dx.doi.org/10.1016/j.cell.2005.07.016			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	955UZ	16096050	Bronze			2022-12-28	WOS:000231254400001
J	Wilson, WH; Schroeder, DC; Allen, MJ; Holden, MTG; Parkhill, J; Barrell, BG; Churcher, C; Harnlin, N; Mungall, K; Norbertczak, H; Quail, MA; Price, C; Rabbinowitsch, E; Walker, D; Craigon, M; Roy, D; Ghazal, P				Wilson, WH; Schroeder, DC; Allen, MJ; Holden, MTG; Parkhill, J; Barrell, BG; Churcher, C; Harnlin, N; Mungall, K; Norbertczak, H; Quail, MA; Price, C; Rabbinowitsch, E; Walker, D; Craigon, M; Roy, D; Ghazal, P			Complete genome sequence and lytic phase transcription profile of a Coccolithovirus	SCIENCE			English	Article							EMILIANIA-HUXLEYI; CELL-DEATH; PHOSPHATE TRANSPORTER; VIRUSES; APOPTOSIS; CERAMIDE; PHYCODNAVIRIDAE; PHYTOPLANKTON; LIMITATION; NITROGEN	The genus Coccolithovirus is a recently discovered group of viruses that infect the globally important marine calcifying microalga Emiliania huxleyi. Among the 472 predicted genes of the 407,339-base pair genome are a variety of unexpected genes, most notably those involved in biosynthesis of ceramide, a sphingolipid known to induce apoptosis. Uniquely for algal viruses, it also contains six RNA polymerase subunits and a novel promoter, suggesting this virus encodes its own transcription machinery. Microarray transcriptomic analysis reveals that 65% of the predicted virus-encoded genes are expressed during lytic infection of E. huxleyi.	Plymouth Marine Lab, Plymouth PL1 3DH, Devon, England; Marine Biol Assoc UK, Plymouth PL1 2PB, Devon, England; Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; Univ Edinburgh, Coll Med, Scottish Ctr Genom Technol & Informat, Edinburgh EH16 4SB, Midlothian, Scotland	Plymouth Marine Laboratory; Marine Biological Association United Kingdom; Wellcome Trust Sanger Institute; University of Edinburgh	Wilson, WH (corresponding author), Plymouth Marine Lab, Prospect Pl, Plymouth PL1 3DH, Devon, England.	whw@pml.ac.uk	Allen, Michael J/C-1248-2011; Schroeder, Declan C./O-9131-2019; Parkhill, Julian/G-4703-2011; Quail, michael/ABE-6131-2020; Holden, Matthew TG/K-6449-2014	Allen, Michael J/0000-0001-8504-7171; Schroeder, Declan C./0000-0001-5991-2838; Parkhill, Julian/0000-0002-7069-5958; Holden, Matthew TG/0000-0002-4958-2166; Ghazal, Peter/0000-0003-0035-2228				Berges JA, 1998, LIMNOL OCEANOGR, V43, P129, DOI 10.4319/lo.1998.43.1.0129; BERHE A, 1995, EUR J BIOCHEM, V227, P566, DOI 10.1111/j.1432-1033.1995.tb20426.x; Berhe A, 2001, BIOCHEM BIOPH RES CO, V287, P837, DOI 10.1006/bbrc.2001.5664; Bidle KD, 2004, NAT REV MICROBIOL, V2, P643, DOI 10.1038/nrmicro956; Brussaard CPD, 1997, J PHYCOL, V33, P980, DOI 10.1111/j.0022-3646.1997.00980.x; CHARLSON RJ, 1987, NATURE, V326, P655, DOI 10.1038/326655a0; Delaroque N, 2001, VIROLOGY, V287, P112, DOI 10.1006/viro.2001.1028; Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208; GALLI I, 1992, NUCLEIC ACIDS RES, V20, P3333, DOI 10.1093/nar/20.13.3333; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; Iyer LM, 2001, J VIROL, V75, P11720, DOI 10.1128/JVI.75.23.11720-11734.2001; La Scola B, 2003, SCIENCE, V299, P2033; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Raoult D, 2004, SCIENCE, V306, P1344, DOI 10.1126/science.1101485; Sandaa RA, 2001, VIROLOGY, V290, P272, DOI 10.1006/viro.2001.1161; Schroeder DC, 2002, ARCH VIROL, V147, P1685, DOI 10.1007/s00705-002-0841-3; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Van Etten JL, 2003, ANNU REV GENET, V37, P153, DOI 10.1146/annurev.genet.37.110801.143915; Van Etten JL, 2002, ARCH VIROL, V147, P1479, DOI 10.1007/s00705-002-0822-6; WESTBROEK P, 1993, GLOBAL PLANET CHANGE, V8, P27, DOI 10.1016/0921-8181(93)90061-R; WESTBROEK P, 1989, J PROTOZOOL, V36, P368, DOI 10.1111/j.1550-7408.1989.tb05528.x; WESTBROEK P, 1994, HAPTOPHYTE ALGAE, V51, P321; Wilson WH, 2002, J MAR BIOL ASSOC UK, V82, P369, DOI 10.1017/S002531540200560X; WILSON WH, 2005, VIRUS TAXONOMY, P163; WILSON WR, UNPUB	27	210	224	3	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 12	2005	309	5737					1090	1092		10.1126/science.1113109	http://dx.doi.org/10.1126/science.1113109			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955MN	16099989				2022-12-28	WOS:000231230100050
J	Paradise, JL; Campbell, TF; Dollaghan, CA; Feldman, HM; Bernard, BS; Colborn, DK; Rockette, HE; Janosky, JE; Pitcairn, DL; Kurs-Lasky, M; Sabo, DL; Smith, CG				Paradise, JL; Campbell, TF; Dollaghan, CA; Feldman, HM; Bernard, BS; Colborn, DK; Rockette, HE; Janosky, JE; Pitcairn, DL; Kurs-Lasky, M; Sabo, DL; Smith, CG			Developmental outcomes after early or delayed insertion of tympanostomy tubes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							1ST 3 YEARS; PERSISTENT OTITIS-MEDIA; HEARING-LOSS; LANGUAGE; AGE; CHILDREN; SPEECH; LIFE; PREVALENCE; DISORDER	BACKGROUND: To prevent later developmental impairments, myringotomy with the insertion of tympanostomy tubes has often been undertaken in young children who have persistent otitis media with effusion. We previously reported that prompt as compared with delayed insertion of tympanostomy tubes in children with persistent effusion who were younger than three years of age did not result in improved developmental outcomes at three or four years of age. However, the effect on the outcomes of school-age children is unknown. METHODS: We enrolled 6350 healthy infants younger than 62 days of age and evaluated them regularly for middle-ear effusion. Before three years of age, 429 children with persistent middle-ear effusion were randomly assigned to have tympanostomy tubes inserted either promptly or up to nine months later if effusion persisted. We assessed developmental outcomes in 395 of these children at six years of age. RESULTS: At six years of age, 85 percent of children in the early-treatment group and 41 percent in the delayed-treatment group had received tympanostomy tubes. There were no significant differences in mean (+/-SD) scores favoring early versus delayed treatment on any of 30 measures, including the Wechsler Full-Scale Intelligence Quotient (98+/-13 vs. 98+/-14); Number of Different Words test, a measure of word diversity (183+/-36 vs. 175+/-36); Percentage of Consonants Correct-Revised test, a measure of speech-sound production (96+/-2 vs. 96+/-3); the SCAN test, a measure of central auditory processing (95+/-15 vs. 96+/-14); and several measures of behavior and emotion. CONCLUSIONS: In otherwise healthy children younger than three years of age who have persistent middle-ear effusion within the duration of effusion that we studied, prompt insertion of tympanostomy tubes does not improve developmental outcomes at six years of age.	Childrens Hosp Pittsburgh, Dept Pediat, Pittsburgh, PA 15213 USA; Childrens Hosp Pittsburgh, Dept Audiol, Pittsburgh, PA 15213 USA; Childrens Hosp Pittsburgh, Dept Commun Disorders, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Family Med & Clin Epidemiol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Paradise, JL (corresponding author), Childrens Hosp Pittsburgh, Dept Pediat, 3705 5th Ave, Pittsburgh, PA 15213 USA.	jpar@pitt.edu		Feldman, Heidi/0000-0002-4435-0913	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026026, R01HD042080] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000084] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR000084, M01RR00084] Funding Source: Medline; NICHD NIH HHS [R01 HD026026-10A2S1, R01 HD042080-03, HD26026, R01 HD042080, R01 HD042080-02, HD42080, R01 HD026026-08, R01 HD026026-09, R01 HD026026-09S1, R01 HD042080-01, R01 HD026026-09S2, R01 HD026026-10A2] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abidin RR., 1995, PSYCHOL ASSESSMENT R; Achenbach T., 1991, INTEGRATIVE GUIDE 19; Ah-Tye C, 2001, PEDIATRICS, V107, P1251, DOI 10.1542/peds.107.6.1251; *AM AC OT HEAD NEC, 2000, AM AC OT B, V10; *AM SPEECH LANG HE, TYP DEGR CONF HEAR L; American Speech and Hearing Association, 1979, ASHA, V21, P283; [Anonymous], 1995, PEDIATRICS, V95, P152; Brown R., 1973, 1 LANGUAGE EARLY STA; Cacace AT, 1998, J SPEECH LANG HEAR R, V41, P355, DOI 10.1044/jslhr.4102.355; De Beer BA, 2004, ANN OTO RHINOL LARYN, V113, P438, DOI 10.1177/000348940411300604; Dollaghan C, 1998, J SPEECH LANG HEAR R, V41, P1136, DOI 10.1044/jslhr.4105.1136; Dollaghan CA, 1999, J SPEECH LANG HEAR R, V42, P1432, DOI 10.1044/jslhr.4206.1432; Dunn L.M., 2007, PEABODY PICTURE VOCA; Feldman HM, 2003, J SPEECH LANG HEAR R, V46, P273, DOI 10.1044/1092-4388(2003/022); Glutting JJ, 1997, PSYCHOL ASSESSMENT, V9, P295, DOI 10.1037/1040-3590.9.3.295; Gravel JS, 1996, ACTA OTO-LARYNGOL, V116, P219, DOI 10.3109/00016489609137827; Johnston LC, 2004, PEDIATRICS, V114, pE58, DOI 10.1542/peds.114.1.e58; Keith R. W., 1986, SCAN SCREENING TEST; LILDHOLDT T, 1983, ACTA OTO-LARYNGOL, P1; MCCALL RB, 1989, PEDIATR ANN, V18, P287, DOI 10.3928/0090-4481-19890501-05; MILLER JF, 1991, RESEARCH ON CHILD LANGUAGE DISORDERS : A DECADE OF PROGRESS, P211; MILLER JF, 1981, J SPEECH HEAR RES, V24, P154, DOI 10.1044/jshr.2402.154; OWINGS MF, 1998, VITAL HLTH STAT, V139, P19; Paradise J L, 1992, Adv Pediatr, V39, P157; Paradise JL, 1997, PEDIATRICS, V99, P318, DOI 10.1542/peds.99.3.318; Paradise JL, 2003, PEDIATRICS, V112, P265, DOI 10.1542/peds.112.2.265; PARADISE JL, 1976, ANN OTO RHINOL LARYN, V85, P20, DOI 10.1177/00034894760850S206; PARADISE JL, 1981, PEDIATRICS, V68, P869; Paradise JL, 2000, PEDIATRICS, V105, P1119, DOI 10.1542/peds.105.5.1119; Paradise JL, 2001, NEW ENGL J MED, V344, P1179, DOI 10.1056/NEJM200104193441601; Paradise JL, 2003, PEDIATR INFECT DIS J, V22, P309; Rosenfeld RM, 2004, PEDIATRICS, V113, P1412, DOI 10.1542/peds.113.5.1412; Sabo Diane L., 2003, Ear and Hearing, V24, P38, DOI 10.1097/01.AUD.0000051988.23117.91; SCHAPPERT SM, 1999, VITAL HLTH STAT, V143, P13; SHRIBERG LD, 1993, J SPEECH HEAR RES, V36, P105, DOI 10.1044/jshr.3601.105; STOOL SE, 1994, AHCPR PUBLICATION; Tomblin JB, 2003, J SPEECH LANG HEAR R, V46, P1283, DOI 10.1044/1092-4388(2003/100); VENTRY IM, 1980, J SPEECH HEAR DISORD, V45, P143, DOI 10.1044/jshd.4502.143; VERHULST FC, 1994, J ABNORM CHILD PSYCH, V22, P531, DOI 10.1007/BF02168936; Wechsler D., 1991, WISC 3 WECHSLER INTE	40	78	82	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 11	2005	353	6					576	586		10.1056/NEJMoa050406	http://dx.doi.org/10.1056/NEJMoa050406			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	953ST	16093466	Green Accepted			2022-12-28	WOS:000231101500008
J	Turi, L; Sheu, WS; Rossky, PJ				Turi, L; Sheu, WS; Rossky, PJ			Characterization of excess electrons in water-cluster anions by quantum simulations	SCIENCE			English	Article							NEGATIVELY CHARGED WATER; HYDRATED ELECTRON; ABSORPTION-SPECTRUM; SOLVATION DYNAMICS; INTERNAL STATES; SPECTROSCOPY; SURFACE; FEMTOSECOND; BULK	Water-cluster anions can serve as a bridge to understand the transition from gaseous species to the bulk hydrated electron. However, debate continues regarding how the excess electron is bound in (H(2)O)(n)(-), as an interior, bulklike, or surface electronic state. To address the uncertainty, the properties of (H(2)O)(n)(-) clusters with 20 to 200 water molecules have been evaluated by mixed quantum-classical simulations. The theory reproduces every observed energetic, spectral, and structural trend with cluster size that is seen in experimental photoelectron and optical absorption spectra. More important, surface states and interior states each manifest a characteristic signature in the simulation data. The results strongly support assignment of surface-bound electronic states to the water-cluster anions in published experimental studies thus far.	Univ Texas, Inst Theoret Chem, Dept Chem & Biochem, Austin, TX 78712 USA; Eotvos Lorand Univ, Dept Chem Phys, H-1518 Budapest, Hungary; Fu Jen Catholic Univ, Dept Chem, Taipei 242, Taiwan	University of Texas System; University of Texas Austin; Eotvos Lorand University; Fu Jen Catholic University	Rossky, PJ (corresponding author), Univ Texas, Inst Theoret Chem, Dept Chem & Biochem, Austin, TX 78712 USA.	rossky@mail.utexas.edu	Turi, László/A-1811-2012	Turi, László/0000-0001-8238-7816				Ayotte P, 1997, J CHEM PHYS, V106, P811, DOI 10.1063/1.473167; Ayotte P, 1999, J CHEM PHYS, V110, P6268, DOI 10.1063/1.478531; BARNETT RN, 1988, J CHEM PHYS, V88, P4429, DOI 10.1063/1.453801; BARNETT RN, 1990, J CHEM PHYS, V93, P6226, DOI 10.1063/1.458992; Bragg AE, 2004, SCIENCE, V306, P669, DOI 10.1126/science.1103527; COE JV, 1990, J CHEM PHYS, V92, P3980, DOI 10.1063/1.457805; Coe JV, 2001, INT REV PHYS CHEM, V20, P33, DOI 10.1080/01442350010008589; Gai HD, 1996, J CHEM PHYS, V105, P8835, DOI 10.1063/1.472612; HABERLAND H, 1984, BER BUNSEN PHYS CHEM, V88, P270, DOI 10.1002/bbpc.19840880322; Hammer NI, 2004, SCIENCE, V306, P675, DOI 10.1126/science.1102792; HAMMER NI, IN PRESS J PHYS CH A; HART EJ, 1962, J AM CHEM SOC, V84, P4090, DOI 10.1021/ja00880a025; Jordan KD, 2004, SCIENCE, V306, P618, DOI 10.1126/science.1104678; Jordan KD, 2003, ANNU REV PHYS CHEM, V54, P367, DOI 10.1146/annurev.physchem.54.011002.103851; Jungwirth P, 2002, J PHYS CHEM B, V106, P6361, DOI 10.1021/jp020242g; LONG FH, 1990, PHYS REV LETT, V64, P1469, DOI 10.1103/PhysRevLett.64.1469; MAKOV G, 1994, J PHYS CHEM-US, V98, P3459, DOI 10.1021/j100064a030; MIGUS A, 1987, PHYS REV LETT, V58, P1559, DOI 10.1103/PhysRevLett.58.1559; Nicolas C, 2003, J CHEM PHYS, V118, P9689, DOI 10.1063/1.1570407; Paik DH, 2004, SCIENCE, V306, P672, DOI 10.1126/science.1102827; Peslherbe GH, 2000, CHEM PHYS, V258, P201, DOI 10.1016/S0301-0104(00)00106-3; ROSSKY PJ, 1988, J PHYS CHEM-US, V92, P4277, DOI 10.1021/j100326a009; SCHWARTZ BJ, 1994, J CHEM PHYS, V101, P6902, DOI 10.1063/1.468319; Silva C, 1998, PHYS REV LETT, V80, P1086, DOI 10.1103/PhysRevLett.80.1086; Sremaniak LS, 1996, J PHYS CHEM-US, V100, P1350, DOI 10.1021/jp951593g; STAIB A, 1995, J CHEM PHYS, V103, P2642, DOI 10.1063/1.470524; Tauber MJ, 2003, J AM CHEM SOC, V125, P1394, DOI 10.1021/ja021134a; Turi L, 2002, J CHEM PHYS, V117, P6186, DOI 10.1063/1.1503308; Verlet JRR, 2005, SCIENCE, V307, P93, DOI 10.1126/science.1106719; WALLQVIST A, 1988, J PHYS CHEM-US, V92, P1721, DOI 10.1021/j100318a006; WEBSTER F, 1991, COMPUT PHYS COMMUN, V63, P494, DOI 10.1016/0010-4655(91)90272-M	33	213	217	2	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 5	2005	309	5736					914	917		10.1126/science.1115808	http://dx.doi.org/10.1126/science.1115808			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953SS	16081731				2022-12-28	WOS:000231101400040
J	Braig, M; Lee, S; Loddenkemper, C; Rudolph, C; Peters, AHFM; Schlegelberger, B; Stein, H; Dorken, B; Jenuwein, T; Schmitt, CA				Braig, M; Lee, S; Loddenkemper, C; Rudolph, C; Peters, AHFM; Schlegelberger, B; Stein, H; Dorken, B; Jenuwein, T; Schmitt, CA			Oncogene-induced senescence as an initial barrier in lymphoma development	NATURE			English	Article							HISTONE H3; TUMOR-CELLS; LYSINE 9; P53; METHYLATION; HP1; METHYLTRANSFERASE; HETEROCHROMATIN; PROLIFERATION; INACTIVATION	Acute induction of oncogenic Ras provokes cellular senescence involving the retinoblastoma (Rb) pathway, but the tumour suppressive potential of senescence in vivo remains elusive. Recently, Rb-mediated silencing of growth-promoting genes by heterochromatin formation associated with methylation of histone H3 lysine 9 (H3K9me) was identified as a critical feature of cellular senescence, which may depend on the histone methyltransferase Suv39h1. Here we show that E mu-N-Ras transgenic mice harbouring targeted heterozygous lesions at the Suv39h1, or the p53 locus for comparison, succumb to invasive T-cell lymphomas that lack expression of Suv39h1 or p53, respectively. By contrast, most N-Ras-transgenic wild-type ('control') animals develop a non-lymphoid neoplasia significantly later. Proliferation of primary lymphocytes is directly stalled by a Suv39h1-dependent, H3K9me-related senescent growth arrest in response to oncogenic Ras, thereby cancelling lymphomagenesis at an initial step. Suv39h1-deficient lymphoma cells grow rapidly but, unlike p53-deficient cells, remain highly susceptible to adriamycin-induced apoptosis. In contrast, only control, but not Suv39h1-deficient or p53-deficient, lymphomas senesce after drug therapy when apoptosis is blocked. These results identify H3K9me-mediated senescence as a novel Suv39h1-dependent tumour suppressor mechanism whose inactivation permits the formation of aggressive but apoptosis-competent lymphomas in response to oncogenic Ras.	Charite Univ Med Berlin Haematol Oncol, D-13353 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Res Inst Mol Pathol, A-1030 Vienna, Austria; Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; Hannover Med Sch, Inst Cell & Mol Pathol, D-30625 Hannover, Germany; Charite Univ Med Berlin, Dept Pathol, D-12200 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Friedrich Miescher Institute for Biomedical Research; Hannover Medical School; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schmitt, CA (corresponding author), Charite Univ Med Berlin Haematol Oncol, D-13353 Berlin, Germany.	clemens.schmitt@charite.de	Lee, Soyoung/T-6669-2019; Lee, Soyoung/AHC-5032-2022; Schmitt, Clemens A/S-9479-2017	Lee, Soyoung/0000-0002-4614-2931; Schmitt, Clemens A/0000-0002-4731-2226; Peters, Antoine/0000-0002-0311-1887				Ait-Si-Ali S, 2004, EMBO J, V23, P605, DOI 10.1038/sj.emboj.7600074; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Chang BD, 1999, CANCER RES, V59, P3761; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Frank O, 2004, BLOOD, V104, P3543, DOI 10.1182/blood-2004-03-0852; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Hamrouni A, 2003, J EXP MED, V197, P601, DOI 10.1084/jem.20021945; HAUPT Y, 1992, ONCOGENE, V7, P981; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Kim KC, 2003, CANCER RES, V63, P7619; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Leone G, 2003, CLIN IMMUNOL, V109, P89, DOI 10.1016/S1521-6616(03)00207-9; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nguyen CT, 2002, CANCER RES, V62, P6456; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Rane SG, 2002, MOL CELL BIOL, V22, P644, DOI 10.1128/MCB.22.2.644-656.2002; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6	31	913	951	2	68	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 4	2005	436	7051					660	665		10.1038/nature03841	http://dx.doi.org/10.1038/nature03841			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	951XA	16079837				2022-12-28	WOS:000230964500034
J	Kim, S; Poursine-Laurent, J; Truscott, SM; Lybarger, L; Song, YJ; Yang, LP; French, AR; Sunwoo, JB; Lemieux, S; Hansen, TH; Yokoyama, WM				Kim, S; Poursine-Laurent, J; Truscott, SM; Lybarger, L; Song, YJ; Yang, LP; French, AR; Sunwoo, JB; Lemieux, S; Hansen, TH; Yokoyama, WM			Licensing of natural killer cells by host major histocompatibility complex class I molecules	NATURE			English	Article							NK CELLS; HEMATOPOIETIC TRANSPLANTS; T-CELLS; MHC; RECEPTORS; MICE; CYTOTOXICITY; EXPRESSION; REJECTION; PEPTIDE	Self versus non-self discrimination is a central theme in biology from plants(1) to vertebrates, and is particularly relevant for lymphocytes that express receptors capable of recognizing self-tissues and foreign invaders. Comprising the third largest lymphocyte population, natural killer (NK) cells recognize and kill cellular targets and produce pro-inflammatory cytokines. These potentially self-destructive effector functions can be controlled by inhibitory receptors for the polymorphic major histocompatibility complex (MHC) class I molecules that are ubiquitously expressed on target cells(2-4). However, inhibitory receptors are not uniformly expressed on NK cells, and are germline-encoded by a set of polymorphic genes that segregate independently from MHC genes(5,6). Therefore, how NK-cell self-tolerance arises in vivo is poorly understood. Here we demonstrate that NK cells acquire functional competence through 'licensing' by self-MHC molecules. Licensing involves a positive role for MHC-specific inhibitory receptors and requires the cytoplasmic inhibitory motif originally identified in effector responses. This process results in two types of self-tolerant NK cells - licensed or unlicensed - and may provide new insights for exploiting NK cells in immunotherapy. This self-tolerance mechanism may be more broadly applicable within the vertebrate immune system because related germline-encoded inhibitory receptors are widely expressed on other immune cells.	Washington Univ, Sch Med, Dept Med, Howard Hughes Med Inst,Div Rheumatol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Otolaryngol, St Louis, MO 63110 USA; Univ Quebec, Inst Armand Frappier, INRS, Laval, PQ H7V 1B7, Canada	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Quebec; Institut national de la recherche scientifique (INRS)	Yokoyama, WM (corresponding author), Washington Univ, Sch Med, Dept Med, Howard Hughes Med Inst,Div Rheumatol, St Louis, MO 63110 USA.	yokoyama@wustl.edu		Sunwoo, John/0000-0002-8393-4196	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI034385, R01AI051345, R01AI033903] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI051345, R01 AI033903, R37 AI034385] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andersson M, 1998, J IMMUNOL, V161, P6475; Bakker ABH, 2000, IMMUNITY, V13, P345, DOI 10.1016/S1074-7613(00)00034-0; Barao I, 2003, BIOL BLOOD MARROW TR, V9, P727, DOI 10.1016/j.bbmt.2003.09.002; Bennett M, 1995, Semin Immunol, V7, P121, DOI 10.1006/smim.1995.0016; Biron CA, 1999, ANNU REV IMMUNOL, V17, P189, DOI 10.1146/annurev.immunol.17.1.189; BIX M, 1991, NATURE, V349, P329, DOI 10.1038/349329a0; Brennan J, 1996, J EXP MED, V184, P2085, DOI 10.1084/jem.184.6.2085; Doucey MA, 2004, NAT IMMUNOL, V5, P328, DOI 10.1038/ni1043; Furukawa H, 1999, HUM IMMUNOL, V60, P32, DOI 10.1016/S0198-8859(98)00097-4; Furukawa H, 2002, J IMMUNOL, V169, P126, DOI 10.4049/jimmunol.169.1.126; Hanke T, 1999, IMMUNITY, V11, P67, DOI 10.1016/S1074-7613(00)80082-5; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; Kim S, 2002, NAT IMMUNOL, V3, P523, DOI 10.1038/ni796; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; Lybarger L, 2003, J BIOL CHEM, V278, P27105, DOI 10.1074/jbc.M303716200; Lybarger L, 2003, IMMUNITY, V18, P121, DOI 10.1016/S1074-7613(02)00509-5; Moretta L, 2000, IMMUNOL TODAY, V21, P420, DOI 10.1016/S0167-5699(00)01673-X; Murase K, 2004, SCIENCE, V303, P1516, DOI 10.1126/science.1093586; Nakamura MC, 1999, J EXP MED, V189, P493, DOI 10.1084/jem.189.3.493; Nakamura MC, 1997, J EXP MED, V185, P673, DOI 10.1084/jem.185.4.673; Parham P, 2003, NAT REV IMMUNOL, V3, P108, DOI 10.1038/nri999; Raulet DH, 2001, ANNU REV IMMUNOL, V19, P291, DOI 10.1146/annurev.immunol.19.1.291; Ruggeri L, 2002, SCIENCE, V295, P2097, DOI 10.1126/science.1068440; Sentman C L, 1995, Semin Immunol, V7, P109, DOI 10.1006/smim.1995.0015; Starr TK, 2003, ANNU REV IMMUNOL, V21, P139, DOI 10.1146/annurev.immunol.21.120601.141107; Trowsdale J, 2001, IMMUNITY, V15, P363, DOI 10.1016/S1074-7613(01)00197-2; Vance RE, 1998, J EXP MED, V188, P1841, DOI 10.1084/jem.188.10.1841; Yokoyama WM, 2003, NAT REV IMMUNOL, V3, P304, DOI 10.1038/nri1055; Yu YYL, 2002, J IMMUNOL, V168, P3145, DOI 10.4049/jimmunol.168.7.3145	30	978	1011	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 4	2005	436	7051					709	713		10.1038/nature03847	http://dx.doi.org/10.1038/nature03847			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	951XA	16079848				2022-12-28	WOS:000230964500046
J	Brewer, RD; Swahn, MH				Brewer, RD; Swahn, MH			Binge drinking and violence	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ALCOHOL; RISK; INJURIES; TRENDS		Ctr Dis Control & Prevent, Alcohol Team,Div Adult & Community Hlth, Emerging Invest & Analyt Methods Branch, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA; Ctr Dis Control & Prevent, Etiol & Surveillance Branch, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Brewer, RD (corresponding author), CDC, Alcohol Team, Natl Ctr Chron Dis Prevent & Hlth Promot, MS K-67,4770 Buford Hwy NE, Atlanta, GA 30341 USA.	bbrewer1@cdc.gov						Babor TF, 2003, ALCOHOL NO ORDINARY; Barry R., 2004, Morbidity and Mortality Weekly Report, V53, P452; *CDCP, ALC REL DIS IMP SOFT; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P866; CHALOUPKA F, 2004, REDUCING UNDERAGE DR; FAGAN J, 1990, CRIME JUSTICE, V13, P241, DOI 10.1086/449177; Fleming MF, 1997, JAMA-J AM MED ASSOC, V277, P1039, DOI 10.1001/jama.277.13.1039; FOEGE WH, 1987, NEW ENGL J MED, V316, P1407, DOI 10.1056/NEJM198705283162210; GREENFIELD TK, 2003, 131 ANN M AM PUBL HL; Grunbaum Jo Anne, 2004, Morbidity and Mortality Weekly Report, V53, P1; Iyasu S, 2002, JAMA-J AM MED ASSOC, V288, P2717, DOI 10.1001/jama.288.21.2717; Macdonald S, 2005, ADDICT BEHAV, V30, P103, DOI 10.1016/j.addbeh.2004.04.016; Markowitz S, 2000, J HEALTH ECON, V19, P271, DOI 10.1016/S0167-6296(99)00025-9; Naimi TS, 2003, JAMA-J AM MED ASSOC, V289, P70, DOI 10.1001/jama.289.1.70; *NAT CTR STAT AN, 2003, ALC INV FAT MOT VEH; National Institute on Alcohol Abuse and Alcoholism, 2004, NIAAA NEWSLETTER WIN; Quinlan KP, 2005, AM J PREV MED, V28, P346, DOI 10.1016/j.amepre.2005.01.006; Roizen J, 1997, Recent Dev Alcohol, V13, P7; Serdula MK, 2004, AM J PREV MED, V26, P294, DOI 10.1016/j.amepre.2003.12.017; SLOAN FA, 1995, J LAW ECON, V38, P49, DOI 10.1086/467325; Swahn MH, 2004, ADDICT BEHAV, V29, P959, DOI 10.1016/j.addbeh.2004.02.043; *US DEP JUST, 2000, DRINK AM MYTHS REAL; *US PREV SERV TASK, 2004, SCREEN ALC MIS; Vinson DC, 2003, J STUD ALCOHOL, V64, P358, DOI 10.15288/jsa.2003.64.358; Wechsler H, 2002, J AM COLL HEALTH, V50, P203, DOI 10.1080/07448480209595713; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20	26	95	102	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	2005	294	5					616	618		10.1001/jama.294.5.616	http://dx.doi.org/10.1001/jama.294.5.616			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	951NN	16077057				2022-12-28	WOS:000230937500023
J	Alexander, LM; Inchley, J; Todd, J; Currie, D; Cooper, AR; Currie, C				Alexander, LM; Inchley, J; Todd, J; Currie, D; Cooper, AR; Currie, C			The broader impact of walking to school among adolescents: seven day accelerometry based study	BRITISH MEDICAL JOURNAL			English	Article							PHYSICAL-ACTIVITY		Univ Edinburgh, Child & Adolescent Hlth Res Unit, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Bristol, Dept Exercise & Hlth Sci, Bristol BS8 1TH, Avon, England	University of Edinburgh; University of Bristol	Alexander, LM (corresponding author), Univ Edinburgh, Child & Adolescent Hlth Res Unit, Edinburgh EH8 9AG, Midlothian, Scotland.	Leslie.Alexander@ed.ac.uk	Cooper, Ashley/D-9956-2014	Cooper, Ashley/0000-0001-8644-3870; Currie, Dorothy/0000-0001-7321-9394; Inchley, Joanna/0000-0001-8322-8817				Cooper AR, 2003, AM J PREV MED, V25, P273, DOI 10.1016/S0749-3797(03)00205-8; Freedson PS, 1998, MED SCI SPORT EXER, V30, P777, DOI 10.1097/00005768-199805000-00021; Metcalf B, 2004, BMJ-BRIT MED J, V329, P832, DOI 10.1136/bmj.38169.688102.F71; *MTI HLTH SERV, 2005, ACT US MAN MOD 7164; Tudor-Locke C, 2001, SPORTS MED, V31, P309, DOI 10.2165/00007256-200131050-00001	5	105	107	1	13	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	NOV 5	2005	331	7524					1061	1062		10.1136/bmj.38567.382731.AE	http://dx.doi.org/10.1136/bmj.38567.382731.AE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	983DL	16107430	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000233211200022
J	Rauh, NR; Schmidt, A; Bormann, J; Nigg, EA; Mayer, TU				Rauh, NR; Schmidt, A; Bormann, J; Nigg, EA; Mayer, TU			Calcium triggers exit from meiosis II by targeting the APC/C inhibitor XErp1 for degradation	NATURE			English	Article							CYTOSTATIC FACTOR ARREST; XENOPUS EGG EXTRACTS; PROTEIN KINASE-II; METAPHASE; DESTRUCTION; UBIQUITIN; ANAPHASE; COMPLEX; FERTILIZATION; BINDING	Vertebrate eggs awaiting fertilization are arrested at metaphase of meiosis II by a biochemical activity termed cytostatic factor (CSF)(1,2). This activity inhibits the anaphase-promoting complex/ cyclosome (APC/C), a ubiquitin ligase that triggers anaphase onset and mitotic/meiotic exit by targeting securin and M-phase cyclins for destruction(3,4,5). On fertilization a transient rise in free intracellular calcium(6) causes release from CSF arrest and thus APC/C activation. Although it has previously been shown that calcium induces the release of APC/C from CSF inhibition through calmodulin-dependent protein kinase II ( CaMKII)(7,8), the relevant substrates of this kinase have not been identified. Recently, we characterized XErp1 (Emi2), an inhibitor of the APC/C and key component of CSF activity in Xenopus egg extract(9). Here we show that calcium-activated CaMKII triggers exit from meiosis II by sensitizing the APC/C inhibitor XErp1 for polo-like kinase 1 (Plx1)-dependent degradation. Phosphorylation of XErp1 by CaMKII leads to the recruitment of Plx1 that in turn triggers the destruction of XErp1 by phosphorylating a site known to serve as a phosphorylation-dependent degradation signal. These results provide a molecular explanation for how the fertilization-induced calcium increase triggers exit from meiosis II.	Max Planck Inst Biochem, Independent Res Grp, D-82152 Martinsried, Germany; Max Planck Inst Biochem, Dept Cell Biol, D-82152 Martinsried, Germany	Max Planck Society; Max Planck Society	Mayer, TU (corresponding author), Max Planck Inst Biochem, Independent Res Grp, Klopferspitz 18, D-82152 Martinsried, Germany.	mayer@biochem.mpg.de		Mayer, Thomas/0000-0001-6954-2287; nigg, erich/0000-0003-4835-5719				BUSA WB, 1985, J CELL BIOL, V100, P1325, DOI 10.1083/jcb.100.4.1325; COLBRAN RJ, 1988, J BIOL CHEM, V263, P18145; Desai A, 1999, METHOD CELL BIOL, V61, P385; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Fuchs SY, 2004, ONCOGENE, V23, P2028, DOI 10.1038/sj.onc.1207389; Funabiki H, 2000, CELL, V102, P411, DOI 10.1016/S0092-8674(00)00047-7; HOLLOWAY SL, 1993, CELL, V73, P13393; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; LORCA T, 1991, EMBO J, V10, P2087, DOI 10.1002/j.1460-2075.1991.tb07741.x; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Ohsumi K, 2004, P NATL ACAD SCI USA, V101, P12531, DOI 10.1073/pnas.0405300101; Salah SM, 2000, CHROMOSOMA, V109, P27, DOI 10.1007/s004120050409; Schmidt A, 2005, GENE DEV, V19, P502, DOI 10.1101/gad.320705; Stemmann O, 2001, CELL, V107, P715, DOI 10.1016/S0092-8674(01)00603-1; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Tung JJ, 2005, P NATL ACAD SCI USA, V102, P4318, DOI 10.1073/pnas.0501108102; Tunquist BJ, 2003, GENE DEV, V17, P683, DOI 10.1101/gad.1071303; Zachariae W, 2005, DEV CELL, V8, P301, DOI 10.1016/j.devcel.2005.02.004	22	175	184	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 13	2005	437	7061					1048	1052		10.1038/nature04093	http://dx.doi.org/10.1038/nature04093			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AU	16127448	Green Submitted			2022-12-28	WOS:000232496100050
J	Binder, WD; Fifer, MA; King, ME; Stone, JR; Harris, NL; Das, S				Binder, WD; Fifer, MA; King, ME; Stone, JR; Harris, NL; Das, S			A man with loss of consciousness while jogging - Hypertrophic cardiomyopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SUDDEN CARDIAC DEATH; IMPLANTABLE CARDIOVERTER; PRIMARY-CARE; SYNCOPE; RISK; FIBROSIS; PATIENT; PROGNOSIS; DIAGNOSIS; PATHOLOGY		Massachusetts Gen Hosp, Emergency Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pediat Cardiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pediat, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University	Binder, WD (corresponding author), Massachusetts Gen Hosp, Emergency Serv, Boston, MA 02114 USA.							Alboni P, 2001, J AM COLL CARDIOL, V37, P1921, DOI 10.1016/S0735-1097(01)01241-4; [Anonymous], 2001, ANN EMERG MED, V37, P771, DOI 10.1067/mem.2001.114838; Benditt DG, 2004, CURR PROB CARDIOLOGY, V29, P152, DOI 10.1016/j.cpcardiol.2003.12.002; Bergfeldt L, 2003, HEART, V89, P353, DOI 10.1136/heart.89.3.353; Booth CM, 2004, JAMA-J AM MED ASSOC, V291, P870, DOI 10.1001/jama.291.7.870; Crilley JG, 2003, J AM COLL CARDIOL, V41, P1776, DOI 10.1016/S0735-1097(02)03009-7; DAVIES MJ, 1995, HISTOPATHOLOGY, V26, P493, DOI 10.1111/j.1365-2559.1995.tb00267.x; DAY SC, 1982, AM J MED, V73, P15, DOI 10.1016/0002-9343(82)90913-5; Edlow JA, 2000, NEW ENGL J MED, V342, P29, DOI 10.1056/NEJM200001063420106; Elliott PM, 2000, J AM COLL CARDIOL, V36, P2212, DOI 10.1016/S0735-1097(00)01003-2; Fatkin D, 2002, PHYSIOL REV, V82, P945, DOI 10.1152/physrev.00012.2002; Fenton AM, 2000, ANN INTERN MED, V133, P714, DOI 10.7326/0003-4819-133-9-200011070-00014; Frenneaux MP, 2004, HEART, V90, P570, DOI 10.1136/hrt.2003.020529; Heaven DJ, 2000, CRIT CARE MED, V28, pN116, DOI 10.1097/00003246-200010001-00002; Hughes SE, 2004, HISTOPATHOLOGY, V44, P412, DOI 10.1111/j.1365-2559.2004.01835.x; Jayatilleke I, 2004, AM J CARDIOL, V93, P1192, DOI 10.1016/j.amjcard.2004.01.057; Kapoor WN, 2000, NEW ENGL J MED, V343, P1856, DOI 10.1056/NEJM200012213432507; Lim DS, 2001, CIRCULATION, V103, P789, DOI 10.1161/01.CIR.103.6.789; Linzer M, 1997, ANN INTERN MED, V126, P989, DOI 10.7326/0003-4819-126-12-199706150-00012; Lombardi R, 2002, ACTA PAEDIATR, V91, P10, DOI 10.1080/080352502762457842; Maron BJ, 2000, CIRCULATION, V102, P858; Maron BJ, 2003, NEW ENGL J MED, V349, P1064, DOI 10.1056/NEJMra022783; Maron BJ, 2004, CIRCULATION, V109, P2807, DOI 10.1161/01.CIR.0000128363.85581.E1; Maron BJ, 2003, J AM COLL CARDIOL, V42, P882, DOI 10.1016/S0735-1097(03)00855-6; Maron BJ, 2003, J AM COLL CARDIOL, V41, P974, DOI 10.1016/S0735-1097(02)02976-5; MARON BJ, 1994, J AM COLL CARDIOL, V24, P880, DOI 10.1016/0735-1097(94)90844-3; MARON BJ, 1995, CIRCULATION, V91, P1596, DOI 10.1161/01.CIR.91.5.1596; Maron BJ, 2000, NEW ENGL J MED, V342, P365, DOI 10.1056/NEJM200002103420601; MARON BJ, 1980, CIRCULATION, V62, P218, DOI 10.1161/01.CIR.62.2.218; MARTIN GJ, 1984, ANN EMERG MED, V13, P499, DOI 10.1016/S0196-0644(84)80511-9; Monserrat L, 2003, J AM COLL CARDIOL, V42, P873, DOI 10.1016/S0735-1097(03)00827-1; MORROW AG, 1975, CIRCULATION, V52, P88, DOI 10.1161/01.CIR.52.1.88; Nishimura RA, 2004, NEW ENGL J MED, V350, P1320, DOI 10.1056/NEJMcp030779; NISHIMURA RA, 2004, NEW ENGL J MED, V351, P1038; Ommen SR, 2004, CURR PROB CARDIOLOGY, V29, P239, DOI 10.1016/j.cpcardiol.2004.01.001; Patel R, 2001, CIRCULATION, V104, P317, DOI 10.1161/hc2801.094031; Safar P, 2002, CRIT CARE MED, V30, pS140, DOI 10.1097/00003246-200204001-00004; Sarasin FP, 2001, AM J MED, V111, P177, DOI 10.1016/S0002-9343(01)00797-5; SIGWART U, 1995, LANCET, V346, P211, DOI 10.1016/S0140-6736(95)91267-3; SILVERSTEIN MD, 1982, JAMA-J AM MED ASSOC, V248, P1185, DOI 10.1001/jama.248.10.1185; Soteriades ES, 2002, NEW ENGL J MED, V347, P878, DOI 10.1056/NEJMoa012407; Spirito P, 2000, NEW ENGL J MED, V342, P1778, DOI 10.1056/NEJM200006153422403; Spirito P, 1997, NEW ENGL J MED, V336, P775, DOI 10.1056/NEJM199703133361107; Takagi E, 1999, J AM COLL CARDIOL, V33, P206, DOI 10.1016/S0735-1097(98)00555-5; Tsybouleva N, 2004, CIRCULATION, V109, P1284, DOI 10.1161/01.CIR.0000121426.43044.2B; Varnava AM, 2000, HEART, V84, P476, DOI 10.1136/heart.84.5.476	46	3	3	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 25	2005	353	8					824	832		10.1056/NEJMcpc059021	http://dx.doi.org/10.1056/NEJMcpc059021			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	957YK	16120863				2022-12-28	WOS:000231409300013
J	Louie, T				Louie, T			Occupational hazards	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Med & Dent New Jersey, New Brunswick, NJ 08903 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Louie, T (corresponding author), Univ Med & Dent New Jersey, New Brunswick, NJ 08903 USA.								0	9	9	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 25	2005	353	8					757	759		10.1056/NEJMp058012	http://dx.doi.org/10.1056/NEJMp058012			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	957YK	16120855				2022-12-28	WOS:000231409300004
J	Vaillancourt, FH; Yeh, E; Vosburg, DA; O'Connor, SE; Walsh, CT				Vaillancourt, FH; Yeh, E; Vosburg, DA; O'Connor, SE; Walsh, CT			Cryptic chlorination by a non-haem iron enzyme during cyclopropyl amino acid biosynthesis	NATURE			English	Article							2-HIS-1-CARBOXYLATE FACIAL TRIAD; GENE-CLUSTER; PHYTOTOXIN CORONATINE; ACTIVATION; OXYGENASES; DIOXYGENASE; COMPLEX	Enzymatic incorporation of chlorine, bromine or iodine atoms occurs during the biosynthesis of more than 4,000 natural products(1). Halogenation can have significant consequences for the bioactivity of these products so there is great interest in understanding the biological catalysts that perform these reactions. Enzymes that halogenate unactivated aliphatic groups have not previously been characterized. Here we report the activity of five proteins - CmaA, CmaB, CmaC, CmaD and CmaE - in the construction of coronamic acid (CMA; 1-amino-1-carboxy-2-ethylcyclopropane), a constituent of the phytotoxin coronatine synthesized by the phytopathogenic bacterium Pseudomonas syringae(2). CMA derives from L-allo-isoleucine, which is covalently attached to CmaD through the actions of CmaA, a non-ribosomal peptide synthetase module, and CmaE, an unusual acyltransferase. We show that CmaB, a member of the non-haem Fe2+, alpha-ketoglutarate-dependent enzyme superfamily, is the first of its class to show halogenase activity, chlorinating the gamma-position of L-allo-isoleucine. Another previously undescribed enzyme, CmaC, catalyses the formation of the cyclopropyl ring from the gamma-Cl-L-allo-isoleucine product of the CmaB reaction. Together, CmaB and CmaC execute gamma-halogenation followed by intramolecular gamma-elimination, in which biological chlorination is a cryptic strategy for cyclopropyl ring formation.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvey Mudd Coll, Dept Chem, Claremont, CA 91711 USA	Harvard University; Harvard Medical School; Claremont Colleges; Harvey Mudd College	Walsh, CT (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	christopher_walsh@hms.harvard.edu	Vosburg, David/P-3944-2019	Vosburg, David/0000-0003-3424-5471; Yeh, Ellen/0000-0003-3974-3816				Armstrong RN, 2000, BIOCHEMISTRY-US, V39, P13625, DOI 10.1021/bi001814v; Buell CR, 2003, P NATL ACAD SCI USA, V100, P10181, DOI 10.1073/pnas.1731982100; Bugg TDH, 2001, CURR OPIN CHEM BIOL, V5, P550, DOI 10.1016/S1367-5931(00)00236-2; Chang ZX, 2002, GENE, V296, P235, DOI 10.1016/S0378-1119(02)00860-0; COOK GK, 1994, J AM CHEM SOC, V116, P1855, DOI 10.1021/ja00084a029; Couch R, 2004, J BACTERIOL, V186, P35, DOI 10.1128/JB.186.1.35-42.2004; ENTSCH B, 1976, J BIOL CHEM, V251, P2550; Gerlt JA, 2001, ANNU REV BIOCHEM, V70, P209, DOI 10.1146/annurev.biochem.70.1.209; Gribble GW, 2004, J CHEM EDUC, V81, P1441, DOI 10.1021/ed081p1441; Guenzi E, 1998, J BIOL CHEM, V273, P32857, DOI 10.1074/jbc.273.49.32857; HAIGLER BE, 1990, J BACTERIOL, V172, P457, DOI 10.1128/JB.172.1.457-464.1990; Hausinger RP, 2004, CRIT REV BIOCHEM MOL, V39, P21, DOI 10.1080/10409230490440541; Hegg EL, 1997, EUR J BIOCHEM, V250, P625, DOI 10.1111/j.1432-1033.1997.t01-1-00625.x; Koehntop KD, 2005, J BIOL INORG CHEM, V10, P87, DOI 10.1007/s00775-005-0624-x; KOJIMA T, 1993, J AM CHEM SOC, V115, P11328, DOI 10.1021/ja00077a035; MASSEY V, 1994, J BIOL CHEM, V269, P22459; Mayer JM, 1998, ACCOUNTS CHEM RES, V31, P441, DOI 10.1021/ar970171h; McCarthy AA, 2001, STRUCTURE, V9, P637, DOI 10.1016/S0969-2126(01)00622-0; Molnar-Perl I, 2001, J CHROMATOGR A, V913, P283, DOI 10.1016/S0021-9673(00)01200-0; PARRY RJ, 1994, CAN J CHEM, V72, P86, DOI 10.1139/v94-014; PARRY RJ, 1991, J AM CHEM SOC, V113, P1849, DOI 10.1021/ja00005a069; Price JC, 2003, BIOCHEMISTRY-US, V42, P7497, DOI 10.1021/bi030011f; Rohde JU, 2003, SCIENCE, V299, P1037, DOI 10.1126/science.299.5609.1037; Ryle MJ, 2002, CURR OPIN CHEM BIOL, V6, P193, DOI 10.1016/S1367-5931(02)00302-2; Schofield CJ, 1999, CURR OPIN STRUC BIOL, V9, P722, DOI 10.1016/S0959-440X(99)00036-6; Vaillancourt FH, 1998, J BIOL CHEM, V273, P34887, DOI 10.1074/jbc.273.52.34887; Vaillancourt FH, 2005, P NATL ACAD SCI USA, V102, P10111, DOI 10.1073/pnas.0504412102; Yeh E, 2004, CHEMBIOCHEM, V5, P1290, DOI 10.1002/cbic.200400077; Yeh E, 2005, P NATL ACAD SCI USA, V102, P3960, DOI 10.1073/pnas.0500755102; YOUNG SA, 1992, J BACTERIOL, V174, P1837, DOI 10.1128/jb.174.6.1837-1843.1992	30	239	250	3	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 25	2005	436	7054					1191	1194		10.1038/nature03797	http://dx.doi.org/10.1038/nature03797			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	958AK	16121186				2022-12-28	WOS:000231416600053
J	Vincenti, F; Larsen, C; Durrbach, A; Wekerle, T; Nashan, B; Blancho, G; Lang, P; Grinyo, J; Halloran, PF; Solez, K; Hagerty, D; Levy, E; Zhou, WJ; Natarajan, K; Charpentier, B				Vincenti, F; Larsen, C; Durrbach, A; Wekerle, T; Nashan, B; Blancho, G; Lang, P; Grinyo, J; Halloran, PF; Solez, K; Hagerty, D; Levy, E; Zhou, WJ; Natarajan, K; Charpentier, B		Belatacept Study Grp	Costimulation blockade with belatacept in renal transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLOMERULAR-FILTRATION-RATE; CONTAINING TRIPLE THERAPY; KIDNEY-TRANSPLANTATION; MYCOPHENOLATE-MOFETIL; LYMPHOPROLIFERATIVE DISORDER; MONOCLONAL-ANTIBODY; CYCLOSPORINE WITHDRAWAL; CREATININE CLEARANCE; SERUM CREATININE; RECIPIENTS	Background: Renal transplantation is the standard of care for patients with end-stage renal disease. Although maintenance immunosuppression with calcineurin inhibitors yields excellent one-year survival, it is associated over the long term with high rates of death and graft loss, owing in part to the adverse renal, cardiovascular, and metabolic effects of these agents. The use of potentially less toxic agents, such as belatacept, a selective blocker of T-cell activation, may improve outcomes. Methods: We randomly assigned renal-transplant recipients to receive an intensive or a less-intensive regimen of belatacept or cyclosporine. All patients received induction therapy with basiliximab, mycophenolate mofetil, and corticosteroids. The primary objective was to demonstrate the noninferiority of belatacept over cyclosporine in the incidence of acute rejection at six months (with an upper bound of the 95 percent confidence interval around the treatment difference of less than 20 percent). Results: At six months, the incidence of acute rejection was similar among the groups: 7 percent for intensive belatacept, 6 percent for less-intensive belatacept, and 8 percent for cyclosporine. At 12 months, the glomerular filtration rate was significantly higher with both intensive and less-intensive belatacept than it was with cyclosporine (66.3, 62.1, and 53.5 ml per minute per 1.73 m(sup 2), respectively), and chronic allograft nephropathy was less common with both regimens of belatacept than with cyclosporine (29 percent, 20 percent, and 44 percent, respectively). Lipid levels and blood-pressure values were similar or slightly lower in the belatacept groups, despite the greater use of lipid-lowering and antihypertensive medications in the cyclosporine group. Conclusions: Belatacept, an investigational selective costimulation blocker, did not appear to be inferior to cyclosporine as a means of preventing acute rejection after renal transplantation. Belatacept may preserve the glomerular filtration rate and reduce the rate of chronic allograft nephropathy.	Emory Univ, Sch Med, Emory Transplant Ctr, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Surg, Atlanta, GA 30322 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Le Kremlin Bicetre Hosp, INSERM, U542, Nephrol Unit, Le Kremlin Bicetre, France; Med Univ Vienna, Vienna Gen Hosp, Dept Surg, Div Transplantat, Vienna, Austria; Hannover Med Sch, Klin Viszeral & Transplantat Chirurg, Hannover, Germany; Hop Hotel Dieu, Nephrol Unit, Nantes, France; Hop Henri Mondor, Serv Nephrol & Transplantat, F-94010 Creteil, France; Univ Barcelona, Hosp Univ Bellvitge, Dept Med, Barcelona, Spain; Univ Alberta, Dept Med, Edmonton, AB, Canada; Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB, Canada; Bristol Myers Squibb Co, Pharmaceut Res Inst, Princeton, NJ 08543 USA	Emory University; Emory University; University of California System; University of California San Francisco; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Medical University of Vienna; Hannover Medical School; Nantes Universite; CHU de Nantes; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; University of Alberta; University of Alberta; Bristol-Myers Squibb	Larsen, C (corresponding author), Emory Univ, Sch Med, Emory Transplant Ctr, Rm 5105 WMB,1639 Pierce Dr, Atlanta, GA 30322 USA.	clarsen@emory.org	Larsen, Christian P./B-6906-2012; Nashan, Björn/H-9087-2019; Halloran, Philip F/J-1390-2012	Larsen, Christian P./0000-0001-6573-2649; Nashan, Björn/0000-0001-7587-9935; Halloran, Philip F/0000-0003-1371-1947; Wekerle, Thomas/0000-0001-5159-2796				Abramowicz D, 2002, TRANSPLANTATION, V74, P1725, DOI 10.1097/01.TP.0000038729.43731.F6; Abrams JR, 2000, J EXP MED, V192, P681, DOI 10.1084/jem.192.5.681; AMLOT PL, 1995, TRANSPLANTATION, V60, P748, DOI 10.1097/00007890-199510150-00023; Boubenider S, 1997, J NEPHROL, V10, P136; Burdmann EA, 2003, SEMIN NEPHROL, V23, P465, DOI 10.1016/S0270-9295(03)00090-1; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Dantal J, 1998, LANCET, V351, P623, DOI 10.1016/S0140-6736(97)08496-1; EVANS RW, 1985, NEW ENGL J MED, V312, P553, DOI 10.1056/NEJM198502283120905; Flechner SM, 2004, AM J TRANSPLANT, V4, P1776, DOI 10.1111/j.1600-6143.2004.00627.x; Gaspari F, 1998, CURR OPIN NEPHROL HY, V7, P675, DOI 10.1097/00041552-199811000-00009; Gaspari F, 2004, AM J TRANSPLANT, V4, P1826, DOI 10.1111/j.1600-6143.2004.00579.x; Herzig KA, 2003, TRANSPL INT, V16, P529, DOI 10.1007/s00147-003-0596-0; JELLIFFE RW, 1973, ANN INTERN MED, V79, P604, DOI 10.7326/0003-4819-79-4-604; Jensik SC, 1998, TRANSPLANT P, V30, P1216, DOI 10.1016/S0041-1345(98)00216-4; Johnson RWG, 2001, TRANSPLANTATION, V72, P777, DOI 10.1097/00007890-200109150-00007; Kasiske BL, 2004, AM J TRANSPLANT, V4, P905, DOI 10.1111/j.1600-6143.2004.00450.x; Kode R, 2003, CLIN TRANSPLANT, V17, P369, DOI 10.1034/j.1399-0012.2003.00061.x; Kreis H, 2000, TRANSPLANTATION, V69, P1252, DOI 10.1097/00007890-200004150-00009; Kremer JM, 2003, NEW ENGL J MED, V349, P1907, DOI 10.1056/NEJMoa035075; Larsen CP, 2005, AM J TRANSPLANT, V5, P443, DOI 10.1111/j.1600-6143.2005.00749.x; Lawen JG, 2003, TRANSPLANTATION, V75, P37, DOI 10.1097/00007890-200301150-00007; Lebranchu Y, 2002, AM J TRANSPLANT, V2, P48, DOI 10.1034/j.1600-6143.2002.020109.x; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; Miller LW, 2002, AM J TRANSPLANT, V2, P807, DOI 10.1034/j.1600-6143.2002.20902.x; Nankivell BJ, 2004, TRANSPLANTATION, V78, P242, DOI 10.1097/01.tp.0000128167.60172.cc; NANKIVELL BJ, 1995, TRANSPLANTATION, V59, P1683, DOI 10.1097/00007890-199506270-00007; Nankivell Brian J., 2003, New England Journal of Medicine, V349, P2326, DOI 10.1056/NEJMoa020009; Ojo AO, 2000, KIDNEY INT, V57, P307, DOI 10.1046/j.1523-1755.2000.00816.x; Opelz G, 2004, AM J TRANSPLANT, V4, P222, DOI 10.1046/j.1600-6143.2003.00325.x; Pescovitz M, 2004, AM J TRANSPLANT, V4, P251; PORT FK, 1993, JAMA-J AM MED ASSOC, V270, P1339, DOI 10.1001/jama.270.11.1339; Racusen LC, 1999, KIDNEY INT, V55, P713, DOI 10.1046/j.1523-1755.1999.00299.x; RUSSELL JD, 1992, TRANSPLANTATION, V54, P656, DOI 10.1097/00007890-199210000-00018; Sayegh MH, 1998, NEW ENGL J MED, V338, P1813, DOI 10.1056/NEJM199806183382506; SWINNEN LJ, 1990, NEW ENGL J MED, V323, P1723, DOI 10.1056/NEJM199012203232502; VELLA AT, 1995, IMMUNITY, V2, P261, DOI 10.1016/1074-7613(95)90050-0; Vincenti F, 2001, TRANSPLANTATION, V71, P1282, DOI 10.1097/00007890-200105150-00017; WALKER RC, 1995, J HEART LUNG TRANSPL, V14, P214; Wolfe RA, 1999, NEW ENGL J MED, V341, P1725, DOI 10.1056/NEJM199912023412303; 2003, UNITED NETWORK ORGAN	41	659	691	0	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 25	2005	353	8					770	781		10.1056/NEJMoa050085	http://dx.doi.org/10.1056/NEJMoa050085			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	957YK	16120857	Green Submitted, Green Published			2022-12-28	WOS:000231409300006
J	Firth, S				Firth, S			End-of-life: a Hindu view	LANCET			English	Editorial Material											Firth, S (corresponding author), 24 W End Terrace, Winchester SO2 5EN, Hants, England.	Shirley.rolles@which.net						BASHAM AL, 1966, CONCISE ENCY LIVING, P244; CRAWFORD SC, 1995, DILEMMAS LIFE DEATH, P129; CRAWFORD SC, 1995, DILEMMAS LIFE DEATH, P111; CRAWFORD SC, 1988, HINDUISM TODAY, P109; Crawford SC, 1995, DILEMMAS LIFE DEATH, P113; CRAWFORD SC, 1995, DILEMMAS LIFE DEATH, P110; FIRTH S, 2001, WIDER HORIZONS CARE, P66; FIRTH S, 1997, DYING DEATH BEREAVEM, P58; FIRTH S, 1997, DYING DEATH BEREAVEM, P33; FIRTH S, 1997, DYING DEATH BEREAVEM, P121; FIRTH S, 2001, WIDER HORIZONS CARE, P63; FIRTH S, 1997, DYING DEATH BEREAVEM, P60; Flood Galvin, 1996, INTRO HINDUISM, P36; Gordon DR, 1997, SOC SCI MED, V44, P1433, DOI 10.1016/S0277-9536(96)00198-0; JUSTICE C, 1997, DYING GOOD DEATH PIL, P230; Justice C, 1997, DYING GOOD DEATH PIL; Kakar S., 1987, INNER WORLD PSYCHOAN; KANE VP, 1974, HIST DHARMASHASTRA, V2, P926; Knipe D., 1977, RELIG ENCOUNTERS DEA; Ng LF, 2000, PALLIATIVE MED, V14, P163, DOI 10.1191/026921600669696020; OSIS K, 1997, HOUR DEATH, P92; PARRY J, 1982, DEATH REGENERATION L, P84; PARRY J, 1982, DEATH REGENERATION L, P82; PARRY J, 1982, DEATH REGENERATION L, P85; Weightman S., 1978, HINDUISM VILLAGE SET; YOUNG K, 1995, HINDU ETHICS PURITY, P16; YOUNG K, 1995, HINDU ETHICS PURITY; ZAEHNER RC, 1966, HINDUISM, P11; 1983, 13 PRINCIPAL UPANISH	29	44	44	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 20	2005	366	9486					682	686		10.1016/S0140-6736(05)67141-3	http://dx.doi.org/10.1016/S0140-6736(05)67141-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	958EB	16112306				2022-12-28	WOS:000231426400033
J	Rees, J				Rees, J			ABC of asthma - Prevalence	BRITISH MEDICAL JOURNAL			English	Review							SYMPTOMS		Guys Kings & St Thomass Sch Med, London SE1 9RT, England	University of London; King's College London	Rees, J (corresponding author), Guys Kings & St Thomass Sch Med, London SE1 9RT, England.	john.rees@kcl.ac.uk						Anderson HR, 2004, BRIT MED J, V328, P1052, DOI 10.1136/bmj.38057.583727.47; Basagana X, 2004, AM J EPIDEMIOL, V160, P178, DOI 10.1093/aje/kwh186; PEAT JK, 1994, BMJ-BRIT MED J, V308, P1591, DOI 10.1136/bmj.308.6944.1591; Siersted HC, 1996, THORAX, V51, P503, DOI 10.1136/thx.51.5.503; Toelle BG, 2004, BRIT MED J, V328, P386, DOI 10.1136/bmj.328.7436.386; Wills-Karp M, 2004, NAT REV GENET, V5, P376, DOI 10.1038/nrg1326	6	14	14	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	AUG 20	2005	331	7514					443	445		10.1136/bmj.331.7514.443	http://dx.doi.org/10.1136/bmj.331.7514.443			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958WB	16110074	Green Published			2022-12-28	WOS:000231477800023
J	Jha, AK; Fisher, ES; Li, ZH; Orav, EJ; Epstein, AM				Jha, AK; Fisher, ES; Li, ZH; Orav, EJ; Epstein, AM			Racial trends in the use of major procedures among the elderly	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-REVASCULARIZATION PROCEDURES; 1ST NATIONAL-HEALTH; CARDIAC REVASCULARIZATION; SYMPTOMATIC PATIENTS; MEDICAL PROCEDURES; CAROTID STENOSIS; DIAGNOSTIC-TESTS; DISPARITIES; RATES; RACE	Background: Differences in the use of major procedures according to patients' race are well known. Whether national and local initiatives to reduce these differences have been successful is unknown. Methods: We examined data for men and women enrolled in Medicare from 1992 through 2001 on annual age-standardized rates of receipt of nine surgical procedures previously shown to have disparities in the rates at which they were performed in black patients and in white patients. We also examined data according to hospital-referral region for three of the nine procedures: coronary-artery bypass grafting (CABG), carotid endarterectomy, and total hip replacement. Results: Nationally, in 1992, the rates of receipt for all the procedures examined were higher among white patients than among black patients. The difference between the rates among whites and blacks increased significantly between 1992 and 2001 for five of the nine procedures, remained unchanged for three procedures, and narrowed significantly for one procedure. We examined rates of CABG, carotid endarterectomy, and total hip replacement in 158 hospital-referral regions (79 hospital-referral regions for black men and white men and 79 for black women and white women) with an adequate number of persons for each procedure. We found that in the early 1990s, whites had higher rates for these procedures than blacks in every hospital-referral region. By 2001, the difference between whites and blacks (both men and women) in the rates of these procedures narrowed significantly in 22 hospital-referral regions, widened significantly in 42, and were not significantly changed in the remaining hospital-referral regions. At the end of the study period, we found no hospital-referral region in which the difference in rates between whites and blacks was eliminated for men or women with regard to any of these three procedures. Conclusions: For the decade of the 1990s, we found no evidence, either nationally or locally, that efforts to eliminate racial disparities in the use of high-cost surgical procedures were successful.	Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Gen Med, Boston, MA 02115 USA; Boston Vet Affairs Hlth Syst, Boston, MA USA; White River Junct VA Med Ctr, Outcomes Grp, White River Jct, VT USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Dartmouth College	Jha, AK (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 665 Huntington Ave, Boston, MA 02115 USA.				NATIONAL INSTITUTE ON AGING [P01AG019783] Funding Source: NIH RePORTER; NIA NIH HHS [P01AG19783, P01 AG019783-05, P01 AG019783] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON JJ, 1988, AM J EPIDEMIOL, V128, P179, DOI 10.1093/oxfordjournals.aje.a114939; Anderson PL, 2004, J VASC SURG, V39, P10, DOI 10.1016/j.jvs.2003.07.020; [Anonymous], 1996, DARTMOUTH ATLAS HLTH; BAICKER K, 2004, HLTH AFF; BRAVEMAN P, 1994, NEW ENGL J MED, V331, P444, DOI 10.1056/NEJM199408183310706; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; Canto JG, 2000, NEW ENGL J MED, V342, P1094, DOI 10.1056/NEJM200004133421505; *DEP HLTH HUM SERV, IN EL RAC DISP; Epstein AM, 2000, NEW ENGL J MED, V343, P1537, DOI 10.1056/NEJM200011233432106; Epstein AM, 2003, MED CARE, V41, P1240, DOI 10.1097/01.MLR.0000093423.38746.8C; Epstein AM, 2001, NEW ENGL J MED, V344, P1471, DOI 10.1056/NEJM200105103441911; ESCARCE JJ, 1993, AM J PUBLIC HEALTH, V83, P948, DOI 10.2105/AJPH.83.7.948; Escarce JJ, 2004, AM J PUBLIC HEALTH, V94, P1795, DOI 10.2105/AJPH.94.10.1795; Flum DR, 2002, ARCH SURG-CHICAGO, V137, P799, DOI 10.1001/archsurg.137.7.799; GITTELSOHN AM, 1991, AM J PUBLIC HEALTH, V81, P1435, DOI 10.2105/AJPH.81.11.1435; Hannan EL, 1999, MED CARE, V37, P68, DOI 10.1097/00005650-199901000-00010; Institute of Medicine Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care, 2003, UNEQUAL TREATMENT CO, DOI DOI 10.17226/12875; Kressin NR, 2001, ANN INTERN MED, V135, P352, DOI 10.7326/0003-4819-135-5-200109040-00012; Laouri M, 1997, J AM COLL CARDIOL, V29, P891, DOI 10.1016/S0735-1097(96)00434-2; Mahomed NN, 2003, J BONE JOINT SURG AM, V85A, P27, DOI 10.2106/00004623-200301000-00005; MORT EA, 1994, ARCH INTERN MED, V154, P761, DOI 10.1001/archinte.154.7.761; Peterson ED, 1997, NEW ENGL J MED, V336, P480, DOI 10.1056/NEJM199702133360706; Schneider EC, 2001, ANN INTERN MED, V135, P328, DOI 10.7326/0003-4819-135-5-200109040-00009; Skinner J, 2003, NEW ENGL J MED, V349, P1350, DOI 10.1056/NEJMsa021569; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; TEPPER S, 1993, AM J EPIDEMIOL, V137, P1081, DOI 10.1093/oxfordjournals.aje.a116611; Trivedi AN, 2005, HEALTH AFFAIR, V24, P388, DOI 10.1377/hlthaff.24.2.388; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; 1998, DARTMOUTH ATLAS HLTH	29	250	251	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 18	2005	353	7					683	691		10.1056/NEJMsa050672	http://dx.doi.org/10.1056/NEJMsa050672			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955UW	16107621	Bronze			2022-12-28	WOS:000231254100006
J	Magid, DJ; Wang, YF; Herrin, J; McNamara, RL; Bradley, EH; Curtis, JP; Pollack, CV; French, WJ; Blaney, ME; Krumholz, HM				Magid, DJ; Wang, YF; Herrin, J; McNamara, RL; Bradley, EH; Curtis, JP; Pollack, CV; French, WJ; Blaney, ME; Krumholz, HM			Relationship between time of day, day of week, timeliness of reperfusion, and in-hospital mortality for patients with acute ST-segment elevation myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY ANGIOPLASTY; NATIONAL REGISTRY; IMMEDIATE ANGIOPLASTY; DELAY; PERFORMANCE; THERAPY	Context Understanding how door-to-drug and door-to-balloon times vary by time of day and day of week can inform the design of interventions to improve the timeliness of reperfusion therapy. Objective To determine the pattern of door-to-drug and door-to-balloon times by time of day and day of week and whether this pattern may affect mortality. Design, Setting, and Participants Cohort study of 68439 patients with ST-segment elevation myocardial infarction (STEMI) treated with fibrinolytic therapy and 33 647 treated with percutaneous coronary intervention (PCI) from 1999 through 2002. We classified patient hospital arrival period into regular hours (weekdays, 7 AM-5 Pm) and off-hours (weekdays 5 PM-7 Am and weekends). Main Outcome Measures Geometric mean door-to-drug time for fibrinolytic therapy and door-to-balloon time for PCI and all-cause in-hospital mortality. All outcomes were adjusted for patient and hospital characteristics. Results Most fibrinolytic therapy (67.9%) and PCI patients (54.2%) were treated during off-hours. Door-to-drug times were slightly longer during off-hours (34.3. minutes) than regular hours (33.2 minutes; difference, 1.0 minute; 95% confidence interval [CI], 0.7-1.4; P<.001). In contrast, door-to-balloon times were substantially longer during off-hours (116.1 minutes) than regular hours (94.8 minutes; difference, 21.3 minutes; 95% Cl, 20.5-22.2; P<.001). A lower percentage of patients met guideline recommended times for door-to-balloon during off-hours (25.7%) than regular hours (471%; P<.001). Door-to-balloon times exceeding 120 minutes occurred much more commonly during off-hours (41.5%) than regular hours (27.7%; P<.001). Longer off-hours cloor-to-balloon times were primarily due to a longer interval between obtaining the electrocardiogram and patient arrival at the catheterization laboratory (off-hours, 69.8 minutes vs regular hours, 49.1 minutes; P<.001). This pattern was consistent across all hospital subgroups examined. Furthermore, patients presenting during off-hours had significantly higher adjusted in-hospital mortality than patients presenting during regular hours (odds ratio, 1.07; 95% Cl, 1.01-1.14; P=.02). Conclusions Presentation during off-hours was common and was associated with substantially longer times to treatment for PCI but not for fibrinolytic therapy. To achieve the best outcomes, hospitals providing PCI during off-hours should commit to doing so in a timely manner.	Yale Univ, Sch Med, Cardiovasc Sect, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Div Hlth Policy & Adm, New Haven, CT 06520 USA; Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06520 USA; Yale New Haven, Ctr Outcomes Res & Evaluat, New Haven, CT USA; Penn Hosp, Philadelphia, PA 19107 USA; Harbor UCLA Med Ctr, Torrance, CA 90509 USA; Genentech Inc, San Francisco, CA 94080 USA; Univ Colorado, Hlth Sci Ctr, Dept Emergency Med, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Dept Prevent Med, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Dept Biometr, Denver, CO USA; Kaiser Permanente, Clin Res Unit, Denver, CO USA	Yale University; Yale University; Yale University; Yale University; University of Pennsylvania; Pennsylvania Medicine; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Roche Holding; Genentech; Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Kaiser Permanente	Krumholz, HM (corresponding author), Yale Univ, Sch Med, Cardiovasc Sect, Dept Internal Med, 333 Cedar St,POB 208088, New Haven, CT 06520 USA.	harlan.krumholz@yale.edu	, Harlan/AAI-2875-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072575] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL072575] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AM HOSP ASS, 1998, ANN SURV HOSP DAT DO; Angeja BG, 2002, AM J CARDIOL, V89, P1156, DOI 10.1016/S0002-9149(02)02296-8; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; Antman Elliott M, 2004, J Am Coll Cardiol, V44, P671, DOI 10.1016/j.jacc.2004.07.002; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Berger AK, 2000, AM HEART J, V139, P985, DOI 10.1067/mhj.2000.105703; Berger PB, 1999, CIRCULATION, V100, P14, DOI 10.1161/01.CIR.100.1.14; Bland JM, 1996, BRIT MED J, V312, P1079; Bradley EH, 2004, MED CARE, V42, P591, DOI 10.1097/01.mlr.0000128006.27364.a9; Cannon CP, 2000, JAMA-J AM MED ASSOC, V283, P2941, DOI 10.1001/jama.283.22.2941; Cannon CP, 2000, J AM COLL CARDIOL, V35, p376A; De Luca G, 2004, CIRCULATION, V109, P1223, DOI 10.1161/01.CIR.0000121424.76486.20; Every NR, 1999, J AM COLL CARDIOL, V33, P1886, DOI 10.1016/S0735-1097(99)00113-8; Garot P, 1997, AM J CARDIOL, V79, P1527, DOI 10.1016/S0002-9149(97)00186-0; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; Goldberg RJ, 1998, AM J CARDIOL, V82, P259, DOI 10.1016/S0002-9149(98)00342-7; Goldstein H, 1995, MULTILEVEL STAT MODE, DOI 10.1002/9780470973394; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; HAND MM, 1994, ANN EMERG MED, V23, P311; King G, 2000, AM J POLIT SCI, V44, P347, DOI 10.2307/2669316; ONEILL W, 1986, NEW ENGL J MED, V314, P812, DOI 10.1056/NEJM198603273141303; *SMG MARK GROUP, 2002, MARK OV; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Zahn R, 1999, AM HEART J, V138, P1111, DOI 10.1016/S0002-8703(99)70077-3; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002	26	330	343	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	2005	294	7					803	812		10.1001/jama.294.7.803	http://dx.doi.org/10.1001/jama.294.7.803			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955LI	16106005	Bronze			2022-12-28	WOS:000231227000020
J	Tappin, DM; Lumsden, MA; Gilmour, WH; Crawford, F; McIntyre, D; Stone, DH; Webber, R; MacIndoe, S; Mohammed, E				Tappin, DM; Lumsden, MA; Gilmour, WH; Crawford, F; McIntyre, D; Stone, DH; Webber, R; MacIndoe, S; Mohammed, E			Randomised controlled trial of home based motivational interviewing by midwives to help pregnant smokers quit or cut down	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NICOTINE; COTININE; SMOKING; ENGLAND; HEALTH	Objective To determine whether motivational interviewing-a behavioural therapy for addictions-provided at home by specially trained midwives helps pregnant smokers to quit. Design Randomised controlled non-blinded trial analysed by intention to treat. Setting Clinics attached to two maternity hospitals in Glasgow. Participants 762/1684 pregnant women who were regular smokers at antenatal booking: 351 in intervention group and 411 in control group. Interventions All women received standard health promotion information. Women in the intervention group were offered motivational interviewing at home. All interviews were recorded. Main outcome measures Self reported smoking cessation verified by plasma or salivary cotinine concentration. Results 17/351 (4.8%) women in the intervention group stopped smoking (according to self report and serum cotinine concentration < 13.7 ng/ml) compared with 19/411(4.6%) in the control group. Fifteen (4.2%) women in the intervention group cut down (self report and cotinine concentration less than half that at booking) compared with 26 (6.3%) in the control group. Fewer women in the intervention group reported smoking more (18 (5.1%) v 44 (10.7%); relative risk 0.48, 95% confidence interval 0.28 to 0.81). Birth weight did not differ significantly (mean 3078 g v 3048 g). Conclusion Good quality motivational interviewing did not significantly increase smoking cessation among pregnant women.	Univ Glasgow, Div Dev Med, Dept Child Hlth, Paediat Epidemiol & Community Hlth Unit, Glasgow G3 8SJ, Lanark, Scotland; Univ Glasgow, Div Dev Med, Sect Obstet & Gynaecol, Glasgow G31 2ER, Lanark, Scotland; Univ Glasgow, Div Community Based Sci, Sect Publ Hlth & Hlth Policy, Glasgow G12 8RZ, Lanark, Scotland; NHS Hlth Scotland, Publ Hlth Project, Glasgow G3 7LS, Lanark, Scotland; Int Non Govt Coalit Tobacco, London SW8 4WS, England; Yorkhill Hosp, Dept Haematol, Glasgow G3 8SJ, Lanark, Scotland	University of Glasgow; University of Glasgow; University of Glasgow	Tappin, DM (corresponding author), Univ Glasgow, Div Dev Med, Dept Child Hlth, Paediat Epidemiol & Community Hlth Unit, Glasgow G3 8SJ, Lanark, Scotland.	goda11@udcf.gla.ac.uk						Adams EK, 1997, JAMA-J AM MED ASSOC, V278, P2058; Bryant TN, 2000, STAT CONFIDENCE; CARSTAIRS V, 1989, BRIT MED J, V299, P886, DOI 10.1136/bmj.299.6704.886; Chandola T, 2004, ADDICTION, V99, P770, DOI 10.1111/j.1360-0443.2004.00756.x; Coleman T, 2004, BMJ-BRIT MED J, V328, P965, DOI 10.1136/bmj.328.7446.965; Cuzick J, 1997, STAT MED, V16, P1017, DOI 10.1002/(SICI)1097-0258(19970515)16:9<1017::AID-SIM508>3.0.CO;2-V; Dempsey D, 2002, J PHARMACOL EXP THER, V301, P594, DOI 10.1124/jpet.301.2.594; DiClemente C.C., 2002, MOTIVATIONAL INTERVI, V2nd ed., P201; FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x; Hegaard HK, 2003, ACTA OBSTET GYN SCAN, V82, P813, DOI 10.1034/j.1600-0412.2003.00221.x; Hughes EG, 2000, FERTIL STERIL, V74, P498, DOI 10.1016/S0015-0282(00)00687-7; Jarvis MJ, 2003, NICOTINE TOB RES, V5, P349, DOI 10.1080/1462220031000094213; LUMLEY J, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001055.PUB2; Moyers T, 2003, BEHAV COGN PSYCHOTH, V31, P177, DOI 10.1017/S1352465803002054; *NHS CTR REV DISS, 1998, EFFECTIVENESS MATTER, V3, P1; Owen L, 1998, BRIT MED J, V317, P728, DOI 10.1136/bmj.317.7160.728; *ROYAL COLL PHYS, 1992, SMOK YOUNG REP WORK, P103; *SCOTL HLTH, 1997, SCOTT HLTH SURV 1995; Stead LF, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000146.pub3; Stephenson J, 1998, BMJ-BRIT MED J, V316, P611, DOI 10.1136/bmj.316.7131.611; Tappin DM, 2000, HEALTH EDUC RES, V15, P491, DOI 10.1093/her/15.4.491; Townsend P., 1988, INEQUALITIES HLTH; WINDSOR RA, 1993, AM J PUBLIC HEALTH, V83, P201, DOI 10.2105/AJPH.83.2.201; Wisborg K, 2000, OBSTET GYNECOL, V96, P967, DOI 10.1016/S0029-7844(00)01071-1; Wright CM, 2001, BMJ-BRIT MED J, V323, P1280, DOI 10.1136/bmj.323.7324.1280	25	61	62	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 13	2005	331	7513					373	+		10.1136/bmj.331.7513.373	http://dx.doi.org/10.1136/bmj.331.7513.373			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	956SK	16096304	Green Published			2022-12-28	WOS:000231319900012
J	Vats, A; Bielby, RC; Tolley, NS; Nerem, R; Polak, JM				Vats, A; Bielby, RC; Tolley, NS; Nerem, R; Polak, JM			Stem cells	LANCET			English	Review							SKELETAL MYOBLAST TRANSPLANTATION; POROUS ALGINATE SCAFFOLDS; CENTRAL-NERVOUS-SYSTEM; BONE-MARROW; IN-VITRO; ENDOTHELIAL-CELLS; MYOCARDIAL-INFARCTION; PROGENITOR CELLS; MULTILINEAGE DIFFERENTIATION; HUMAN BLASTOCYSTS	Stem cells derived from adult and embryonic sources have great therapeutic potential, but much research is still needed before their clinical use becomes commonplace. There is debate about whether adult stem cells can be used instead of those derived from embryos. Rationalisation is needed but can be exercised only once the various cells have been carefully compared and contrasted under appropriate experimental conditions. Some characteristics that might help resolve the issue of cell source can already be applied to the debate. Accessibility is important; some adult cells, such as neural stem cells, are difficult to obtain, at least from living donors. Other factors include the frequency and abundance of adult stem cells and their numbers and potency, which might decline with age or be affected by disease. For embryonic stem cells, ethical concerns have been raised, and the proposed practice of therapeutic cloning tends to be misrepresented in the lay media. For both adult and embryonic stem cells, stability, potential to transmit harmful pathogens or genetic mutations, and risk of forming unwanted tissues or even teratocarcinomas have yet to be fully assessed.	Univ London Imperial Coll Sci Technol & Med, Tissue Engn & Regenerat Med Ctr, London, England; St Marys Hosp, Imperial Coll Sch Med, London, England; Georgia Inst Technol, Parker H Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA	Imperial College London; Imperial College London; University System of Georgia; Georgia Institute of Technology	Vats, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, Chelsea & Westminster Hosp, Fac Med, Tissue Engn & Regenerat Med Ctr, London SW10 9NH, England.	a.vats@imperial.ac.uk						Agency for Healthcare Research and Quality, HCUPNET HEALTHC COST; Alexandre H, 2001, INT J DEV BIOL, V45, P457; Ali NN, 2002, TISSUE ENG, V8, P541, DOI 10.1089/107632702760240463; Alison M, 1998, CURR OPIN CELL BIOL, V10, P710, DOI 10.1016/S0955-0674(98)80111-7; Alison MR, 2000, NATURE, V406, P257, DOI 10.1038/35018642; *ALZH ASS, STAT ALZH DIS; *AM HEART ASS, 2002, HEART DIS STROK STAT; ANDERSON JM, 1994, PROB GEN SURG, V11, P101; Arai AE, 2003, J AM COLL CARDIOL, V41, p371A; Assady S, 2001, DIABETES, V50, P1691, DOI 10.2337/diabetes.50.8.1691; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Balconi G, 2000, ARTERIOSCL THROM VAS, V20, P1443, DOI 10.1161/01.ATV.20.6.1443; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; BARD DR, 1972, NATURE, V236, P314, DOI 10.1038/236314a0; BARNARD C N, 1967, South African Medical Journal, V41, P1271; Bielby RC, 2004, TISSUE ENG, V10, P1518, DOI 10.1089/ten.2004.10.1518; BINDERMA.I, 1974, J CELL BIOL, V61, P427, DOI 10.1083/jcb.61.2.427; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bonner-Weir S, 2000, P NATL ACAD SCI USA, V97, P7999, DOI 10.1073/pnas.97.14.7999; Bonner-Weir S, 2002, J PATHOL, V197, P519, DOI 10.1002/path.1158; BONNERWEIR S, 1993, DIABETES, V42, P1715, DOI 10.2337/diabetes.42.12.1715; Bradley JA, 2002, NAT REV IMMUNOL, V2, P859, DOI 10.1038/nri934; Campagnoli C, 2001, BLOOD, V98, P2396, DOI 10.1182/blood.V98.8.2396; Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471-4914(01)02016-0; Chan J, 2005, STEM CELLS, V23, P93, DOI 10.1634/stemcells.2004-0138; Chapekar MS, 2000, J BIOMED MATER RES, V53, P617, DOI 10.1002/1097-4636(2000)53:6<617::AID-JBM1>3.0.CO;2-C; Chen SS, 2003, STEM CELLS, V21, P281, DOI 10.1634/stemcells.21-3-281; CHEN TL, 1983, ENDOCRINOLOGY, V112, P1739, DOI 10.1210/endo-112-5-1739; CHEN TL, 1983, CALCIFIED TISSUE INT, V35, P806, DOI 10.1007/BF02405127; Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623-200308000-00017; Chien KR, 2004, NATURE, V428, P607, DOI 10.1038/nature02500; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; Coraux C, 2005, AM J RESP CELL MOL, V32, P87, DOI 10.1165/rcmb.2004-0079RC; Cowan CA, 2004, NEW ENGL J MED, V350, P1353, DOI 10.1056/NEJMsr040330; Davani S, 2003, CIRCULATION, V108, P253, DOI 10.1161/01.cir.0000089186.09692.fa; Domm C, 2002, OSTEOARTHR CARTILAGE, V10, P13, DOI 10.1053/joca.2001.0477; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Draper JS, 2002, J ANAT, V200, P249, DOI 10.1046/j.1469-7580.2002.00030.x; Drukker M, 2002, P NATL ACAD SCI USA, V99, P9864, DOI 10.1073/pnas.142298299; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Fairchild PJ, 2004, TRENDS IMMUNOL, V25, P465, DOI 10.1016/j.it.2004.07.005; FRIEDENSTEIN AJ, 1974, TRANSPLANTATION, V17, P331, DOI 10.1097/00007890-197404000-00001; Gerecht-Nir S, 2004, BIOTECHNOL BIOENG, V88, P313, DOI 10.1002/bit.20248; Ghostine S, 2002, CIRCULATION, V106, pI131, DOI 10.1161/01.cir.0000032889.55215.f1; Glicklis R, 2000, BIOTECHNOL BIOENG, V67, P344, DOI 10.1002/(SICI)1097-0290(20000205)67:3<344::AID-BIT11>3.0.CO;2-2; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Goodell MA, 2001, ANN NY ACAD SCI, V938, P208; Grimshaw MJ, 2001, OSTEOARTHR CARTILAGE, V9, P357, DOI 10.1053/joca.2000.0396; GRUSBY MJ, 1993, P NATL ACAD SCI USA, V90, P3913, DOI 10.1073/pnas.90.9.3913; Hagege AA, 2003, LANCET, V361, P491, DOI 10.1016/S0140-6736(03)12458-0; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Hench L. L., 1996, CLIN PERFORMANCE SKE; Hench LL, 1998, BIOMATERIALS, V19, P1419, DOI 10.1016/S0142-9612(98)00133-1; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Hutmacher DW, 2000, BIOMATERIALS, V21, P2529, DOI 10.1016/S0142-9612(00)00121-6; Hwang WS, 2004, SCIENCE, V303, P1669, DOI 10.1126/science.1094515; Jakob M, 2003, CONNECT TISSUE RES, V44, P173, DOI 10.1080/03008200390215836; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kang HJ, 2004, LANCET, V363, P751, DOI 10.1016/S0140-6736(04)15689-4; Kaufman DS, 2001, P NATL ACAD SCI USA, V98, P10716, DOI 10.1073/pnas.191362598; Kawada H, 2004, BLOOD, V104, P3581, DOI 10.1182/blood-2004-04-1488; Kim M, 2002, CLIN CANCER RES, V8, P22; KORTESIDIS A, 2005, BLOOD           0127; Kuethe F, 2004, INT J CARDIOL, V97, P123, DOI 10.1016/j.ijcard.2004.05.002; Lee DA, 2003, ACTA ORTHOP SCAND, V74, P6, DOI 10.1080/00016470310013581; Levenberg S, 2002, P NATL ACAD SCI USA, V99, P4391, DOI 10.1073/pnas.032074999; Levenberg S, 2003, P NATL ACAD SCI USA, V100, P12741, DOI 10.1073/pnas.1735463100; Lian JB, 1998, J CELL BIOCHEM, P62, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<62::AID-JCB10>3.0.CO;2-S; Liechty KW, 2000, NAT MED, V6, P1282, DOI 10.1038/81395; Lindvall O, 2001, Lancet, V358 Suppl, pS48; MACKENZIE TS, 2001, BLOOD, V98, pA238; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MARTIN GR, 1975, P NATL ACAD SCI USA, V72, P1441, DOI 10.1073/pnas.72.4.1441; Martin MJ, 2005, NAT MED, V11, P228, DOI 10.1038/nm1181; McCloskey KE, 2003, ENDOTHELIUM-J ENDOTH, V10, P329, DOI 10.1080/10623320390272325; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Menasche P, 2003, J AM COLL CARDIOL, V41, P1078, DOI 10.1016/S0735-1097(03)00092-5; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; Mummery C, 2002, J ANAT, V200, P233, DOI 10.1046/j.1469-7580.2002.00031.x; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Narayan KMV, 2003, JAMA-J AM MED ASSOC, V290, P1884, DOI 10.1001/jama.290.14.1884; *NAT I DIAB DIG KI, 2003, NAT DIAB STAT FACT S; *NAT I NEUR DIS ST, PARK DIS BACKGR; Noguchi H, 2003, DIABETES, V52, P1732, DOI 10.2337/diabetes.52.7.1732; Odorico JS, 2001, STEM CELLS, V19, P193, DOI 10.1634/stemcells.19-3-193; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Orlic D, 2003, ANN NY ACAD SCI, V996, P152, DOI 10.1111/j.1749-6632.2003.tb03243.x; Ourednik J, 2002, NAT BIOTECHNOL, V20, P1103, DOI 10.1038/nbt750; Overturf K, 1997, AM J PATHOL, V151, P1273; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Pei M, 2002, BIOCHEM BIOPH RES CO, V294, P149, DOI 10.1016/S0006-291X(02)00439-4; Petersen M, 2003, DIABETES CARE, V26, P917; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Planat-Benard V, 2004, CIRCULATION, V109, P656, DOI 10.1161/01.CIR.0000114522.38265.61; Poulsom R, 2002, J PATHOL, V197, P441, DOI 10.1002/path.1176; RATNER BD, 1996, BIOMATERIALS SCI INT, P283; Reinecke H, 2004, CIRC RES, V94, pE56, DOI 10.1161/01.RES.0000125294.04612.81; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; Reyes M, 2001, ANN NY ACAD SCI, V938, P231; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Ros JE, 2003, J PATHOL, V200, P553, DOI 10.1002/path.1379; Ryan EA, 2001, DIABETES, V50, P710, DOI 10.2337/diabetes.50.4.710; Sanders GT, 1986, AMPUTATION PROSTHETI; Schachinger V, 2003, J AM COLL CARDIOL, V41, p404A; Schulze D, 2000, IMECHE CONF TRANS, V2000, P97; Scorsin M, 2000, J THORAC CARDIOV SUR, V119, P1169, DOI 10.1067/mtc.2000.104865; Snyder EY, 2004, J NEUROSCI RES, V76, P157, DOI 10.1002/jnr.20033; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; Sottile V, 2003, CLONING STEM CELLS, V5, P149, DOI 10.1089/153623003322234759; SPECTOR M, 1992, ORTHOP CLIN N AM, V23, P211; Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593; THOMSON JA, 1995, P NATL ACAD SCI USA, V92, P7844, DOI 10.1073/pnas.92.17.7844; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tian L, 1997, BIOL REPROD, V57, P561, DOI 10.1095/biolreprod57.3.561; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Vunjak-Novakovic Gordana, 2003, Novartis Found Symp, V249, P34; Weiss S, 1998, J NEUROBIOL, V36, P307, DOI 10.1002/(SICI)1097-4695(199808)36:2<307::AID-NEU14>3.0.CO;2-A; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Wilmut I, 2004, BMJ-BRIT MED J, V328, P415, DOI 10.1136/bmj.328.7437.415; Wilmut I, 2003, ONCOL RES, V13, P303; Wong M, 2003, BONE, V33, P685, DOI 10.1016/S8756-3282(03)00242-4; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568; Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	127	124	142	0	24	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 13	2005	366	9485					592	602		10.1016/S0140-6736(05)66879-1	http://dx.doi.org/10.1016/S0140-6736(05)66879-1			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955LL	16099296				2022-12-28	WOS:000231227300032
J	Ling, HF; Gao, JF; Zhao, KD; Jiang, SY; Mu, DS				Ling, HF; Gao, JF; Zhao, KD; Jiang, SY; Mu, DS			Comment on "Molybdenum isotope evidence for widespread anoxia in mid-proterozoic oceans"	SCIENCE			English	Editorial Material									Nanjing Univ, Dept Earth Sci, State Key Lab Mineral Deposits Res, Nanjing 210093, Peoples R China	Nanjing University	Ling, HF (corresponding author), Nanjing Univ, Dept Earth Sci, State Key Lab Mineral Deposits Res, Nanjing 210093, Peoples R China.	hfling@public1.ptt.js.cn	Gao, Jianfeng/E-5537-2010; Gao, Jianfeng/L-7385-2019	Gao, Jianfeng/0000-0002-0553-025X; Gao, Jianfeng/0000-0002-0553-025X				Arnold GL, 2004, SCIENCE, V304, P87, DOI 10.1126/science.1091785; Barling J, 2004, EARTH PLANET SC LETT, V217, P315, DOI 10.1016/S0012-821X(03)00608-3; Barling J, 2001, EARTH PLANET SC LETT, V193, P447, DOI 10.1016/S0012-821X(01)00514-3; BERTINE KK, 1973, GEOCHIM COSMOCHIM AC, V37, P1415, DOI 10.1016/0016-7037(73)90080-X; EMERSON SR, 1991, MAR CHEM, V34, P177, DOI 10.1016/0304-4203(91)90002-E; Morford JL, 1999, GEOCHIM COSMOCHIM AC, V63, P1735, DOI 10.1016/S0016-7037(99)00126-X; Siebert C, 2003, EARTH PLANET SC LETT, V211, P159, DOI 10.1016/S0012-821X(03)00189-4	7	11	14	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 12	2005	309	5737								10.1126/science.1108737	http://dx.doi.org/10.1126/science.1108737			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955MN	16099965				2022-12-28	WOS:000231230100019
J	Cosman, F; Nieves, J; Zion, M; Woelfert, L; Luckey, M; Lindsay, R				Cosman, F; Nieves, J; Zion, M; Woelfert, L; Luckey, M; Lindsay, R			Daily and cyclic parathyroid hormone in women receiving alendronate	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURE; OSTEOPOROSIS; THERAPY; RISK; MEN; ESTROGEN; MASS; TERIPARATIDE	BACKGROUND: We evaluated whether patients with osteoporosis treated with long-term alendronate have a response to parathyroid hormone treatment and whether short, three-month cycles of parathyroid hormone therapy could be as effective as daily administration. METHODS: We randomly assigned 126 women with osteoporosis who had been taking alendronate for at least 1 year to continued alendronate plus parathyroid hormone (1-34) subcutaneously daily, continued alendronate plus parathyroid hormone (1-34) subcutaneously daily for three 3-month cycles alternating with 3-month periods without parathyroid hormone, or alendronate alone for 15 months. RESULTS: In both parathyroid hormone groups, bone formation indexes rose swiftly. Among the women who were receiving cyclic parathyroid hormone, bone formation declined during cycles without parathyroid hormone and increased again during cycles with parathyroid hormone. Bone resorption increased in both parathyroid hormone groups but increased progressively more in the daily-treatment group than in the cyclic-therapy group. Spinal bone mineral density rose 6.1 percent in the daily-treatment group and 5.4 percent in the cyclic-therapy group (P<0.001 for each parathyroid hormone group as compared with the alendronate group and no significant difference between parathyroid hormone groups). One woman in the daily-treatment group, two in the cyclic-therapy group, and four in the alendronate group had new or worsening vertebral deformities. CONCLUSIONS: This study suggests that a regimen of three-month cycles of parathyroid hormone alternating with three-month cycles without parathyroid hormone causes the early phase of action of parathyroid hormone (characterized by pure stimulation of bone formation) to be dissociated from the later phase (activation of bone remodeling). The early phase may be more important to the increase in spinal bone mineral density. In patients with persistent osteoporosis after prior alendronate treatment, both daily treatment and cyclic treatment with parathyroid hormone increase spinal bone mineral density.	Helen Hayes Hosp, Clin Res Ctr, W Haverstraw, NY 10993 USA; Columbia Univ, Mailman Sch Publ Sch, Dept Epidemiol, New York, NY USA; Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY USA; St Barnabas Osteoporosis & Metab Bone Dis Ctr, Livingston, NJ USA; Mt Sinai Med Ctr, Dept Med, New York, NY 10029 USA	Columbia University; Columbia University; Icahn School of Medicine at Mount Sinai	Cosman, F (corresponding author), Helen Hayes Hosp, Reg Bone Ctr, Route 9W,, W Haverstraw, NY 10993 USA.	cosmanf@helenhayeshosp.org		Nieves, Jeri/0000-0001-8593-343X	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039191] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39191] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975; BLACK DM, 1991, J BONE MINER RES, V6, P883; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897; Cosman F, 2001, J BONE MINER RES, V16, P925, DOI 10.1359/jbmr.2001.16.5.925; Cosman F, 1998, J BONE MINER RES, V13, P1051, DOI 10.1359/jbmr.1998.13.6.1051; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; Dempster DW, 2001, J BONE MINER RES, V16, pS179; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P2124; Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725; Finkelstein JS, 1998, JAMA-J AM MED ASSOC, V280, P1067, DOI 10.1001/jama.280.12.1067; Guglielmi G, 2003, MED RAD DIA IMG, P101; Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344; HODSMAN AB, 1993, BONE, V14, P523, DOI 10.1016/8756-3282(93)90190-L; JERGAS M, 1995, VERTEBRAL FRACTURE O, P163; Kurland ES, 2000, J CLIN ENDOCR METAB, V85, P3069, DOI 10.1210/jc.85.9.3069; Lane NE, 2000, J BONE MINER RES, V15, P944, DOI 10.1359/jbmr.2000.15.5.944; Lindsay R, 2003, J BONE MINER RES, V18, pS54; Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140-6736(97)02342-8; McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503; MELTON LJ, 1993, OSTEOPOROSIS INT, V3, P113, DOI 10.1007/BF01623271; NEER R, 2002, J BONE MINER RES  S1, V19, pS98; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; NELSON D, 1990, J BONE MINER RES, V5, P707; Orwoll E, 2003, J BONE MINER RES, V18, P9, DOI 10.1359/jbmr.2003.18.1.9; Roe EB, 1999, J BONE MINER RES, V14, pS137; SLOVIK DM, 1986, J BONE MINER RES, V1, P377; SMITHBINDMAN R, 1991, J BONE MINER RES, V6, P25; STEMARIE LG, 2001, END SOC 83 ANN M DEN, P125	31	177	188	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 11	2005	353	6					566	575		10.1056/NEJMoa050157	http://dx.doi.org/10.1056/NEJMoa050157			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	953ST	16093465				2022-12-28	WOS:000231101500007
J	Sharp, D				Sharp, D			Novel pain relief via marine snails	LANCET			English	Editorial Material							ZICONOTIDE; DRUGS		The Lancet, London NW1 7BY, England		Sharp, D (corresponding author), The Lancet, London NW1 7BY, England.							Bonnemain B, 2005, EVID-BASED COMPL ALT, V2, P25, DOI 10.1093/ecam/neh057; COUSINS MJ, 2002, 10 WORLD C PAIN SAN; Duda TF, 2004, SCIENCE, V303, P955, DOI 10.1126/science.303.5660.955; *EUR MED EV AG, 2005, PRIALT EUR PUBL ASS; Fegan D, 1997, LANCET, V349, P1672, DOI 10.1016/S0140-6736(05)62639-6; Livett BG, 2004, CURR MED CHEM, V11, P1715, DOI 10.2174/0929867043364928; Miljanich GP, 2004, CURR MED CHEM, V11, P3029, DOI 10.2174/0929867043363884; Penn RD, 2000, PAIN, V85, P291, DOI 10.1016/S0304-3959(99)00254-7; Sollod BL, 2005, PEPTIDES, V26, P131, DOI 10.1016/j.peptides.2004.07.016; Staats PS, 2004, JAMA-J AM MED ASSOC, V291, P63, DOI 10.1001/jama.291.1.63; Stix G, 2005, SCI AM, V292, P79	11	10	10	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 6	2005	366	9484					439	440		10.1016/S0140-6736(05)67040-7	http://dx.doi.org/10.1016/S0140-6736(05)67040-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	952RD	16084239				2022-12-28	WOS:000231022300010
J	Cukierman, T; Gatt, ME; Hiller, N; Chajek-Shaul, T				Cukierman, T; Gatt, ME; Hiller, N; Chajek-Shaul, T			Clinical problem-solving: A fractured diagnosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PRIMARY SJOGRENS-SYNDROME; RENAL TUBULAR-ACIDOSIS; BONE-DISEASE; OSTEOMALACIA; INVOLVEMENT		Hadassah Hebrew Univ Med Ctr, Dept Med, IL-91240 Jerusalem, Israel	Hebrew University of Jerusalem	Chajek-Shaul, T (corresponding author), Hadassah Hebrew Univ Med Ctr, Dept Med, POB 24035, IL-91240 Jerusalem, Israel.	chajek@hadasssah.org.il						Anselmino M, 1997, DIGEST DIS SCI, V42, P113, DOI 10.1023/A:1018845323765; BINGHAM CT, 1993, AM J MED, V95, P519, DOI 10.1016/0002-9343(93)90335-M; Bossini N, 2001, NEPHROL DIAL TRANSPL, V16, P2328, DOI 10.1093/ndt/16.12.2328; Fulop M, 2004, ARCH INTERN MED, V164, P905, DOI 10.1001/archinte.164.8.905; HAJJAJHASSOUNI N, 1995, REV RHUM, V62, P529; Krieger NS, 2004, CURR OPIN NEPHROL HY, V13, P423, DOI 10.1097/01.mnh.0000133975.32559.6b; Lamberg-Allardt CJE, 2001, J BONE MINER RES, V16, P2066, DOI 10.1359/jbmr.2001.16.11.2066; NETO JTM, 1991, CLIN EXP RHEUMATOL, V9, P625; Okada M, 2001, INTERNAL MED, V40, P829, DOI 10.2169/internalmedicine.40.829; RUSSELL JA, 1994, MUSCLE NERVE, V17, P578, DOI 10.1002/mus.880170603; Soriano JR, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000023430.92674.E5; TOVEY FI, 1992, J GASTROEN HEPATOL, V7, P639, DOI 10.1111/j.1440-1746.1992.tb01498.x; VITALI C, 1993, ARTHRITIS RHEUM, V36, P340, DOI 10.1002/art.1780360309; VITALI C, 1991, SCAND J RHEUMATOL, V20, P132, DOI 10.3109/03009749109165289; Wiederkehr M, 2001, SWISS MED WKLY, V131, P127	15	7	9	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 4	2005	353	5					509	514		10.1056/NEJMcps040047	http://dx.doi.org/10.1056/NEJMcps040047			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	951OB	16079375				2022-12-28	WOS:000230939000011
J	Domack, E; Duran, D; Leventer, A; Ishman, S; Doane, S; McCallum, S; Amblas, D; Ring, J; Gilbert, R; Prentice, M				Domack, E; Duran, D; Leventer, A; Ishman, S; Doane, S; McCallum, S; Amblas, D; Ring, J; Gilbert, R; Prentice, M			Stability of the Larsen B ice shelf on the Antarctic Peninsula during the Holocene epoch	NATURE			English	Article							QUATERNARY GLACIAL HISTORY; SEDIMENTARY RECORD; CLIMATE; MARGIN; SHEET	The stability of the Antarctic ice shelves in a warming climate has long been discussed(1), and the recent collapse of a significant part, over 12,500 km(2) in area, of the Larsen ice shelf off the Antarctic Peninsula(2,3) has led to a refocus toward the implications of ice shelf decay for the stability of Antarctica's grounded ice(4-6). Some smaller Antarctic ice shelves have undergone periodic growth and decay over the past 11,000 yr ( refs 7 - 11), but these ice shelves are at the climatic limit of ice shelf viability(12) and are therefore expected to respond rapidly to natural climate variability at century to millennial scales(8-11). Here we use records of diatoms, detrital material and geochemical parameters from six marine sediment cores in the vicinity of the Larsen ice shelf to demonstrate that the recent collapse of the Larsen B ice shelf is unprecedented during the Holocene. We infer from our oxygen isotope measurements in planktonic foraminifera that the Larsen B ice shelf has been thinning throughout the Holocene, and we suggest that the recent prolonged period of warming in the Antarctic Peninsula region(13,14), in combination with the long-term thinning, has led to collapse of the ice shelf.	Hamilton Coll, Dept Geosci, Clinton, NY 13323 USA; Colgate Univ, Dept Geol, Hamilton, NY 13346 USA; So Illinois Univ, Dept Geol, Carbondale, IL 62901 USA; Univ Barcelona, Dept Stratig Paleontol & Marine Geosci, E-08028 Barcelona, Spain; Hamilton Coll, Dept Phys, Clinton, NY 13323 USA; Queens Univ, Dept Geog, Kingston, ON K7L 3N6, Canada; Univ New Hampshire, Dept Earth Sci, Durham, NH 03824 USA	Hamilton College; Colgate University; Southern Illinois University System; Southern Illinois University; University of Barcelona; Hamilton College; Queens University - Canada; University System Of New Hampshire; University of New Hampshire	Domack, E (corresponding author), Hamilton Coll, Dept Geosci, Clinton, NY 13323 USA.	edomack@hamilton.edu	Amblas, David/A-5482-2015	Amblas, David/0000-0002-6248-5512; Leventer, Amy/0000-0001-9401-0987				Brachfeld S, 2003, GEOLOGY, V31, P749, DOI 10.1130/G19643.1; CLAPPERTON CM, 1982, QUATERNARY RES, V18, P243, DOI 10.1016/0033-5894(82)90074-6; De Angelis H, 2003, SCIENCE, V299, P1560, DOI 10.1126/science.1077987; DOANE SS, 2003, THESIS HAMILTON COLL; Domack EW, 2003, ANTARCT RES SER, V79, P205; DOMACK EW, 1995, ANTARCT SCI, V7, P159, DOI 10.1017/S0954102095000228; DORMACK EW, 1999, GEOL SOC AM BULL, V111, P1517; Evans J, 2005, QUATERNARY SCI REV, V24, P741, DOI 10.1016/j.quascirev.2004.10.007; Frank M, 2002, PALEOCEANOGRAPHY, V17, DOI 10.1029/2000PA000606; Gilbert R, 2003, ANTARCT RES SER, V79, P195; Gilbert R, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2002GC000441; Hjort C, 2001, ANTARCT SCI, V13, P296, DOI 10.1017/S0954102001000426; Ishman SE, 2003, ANTARCT RES SER, V79, P239; JACOBS SS, 1979, SCIENCE, V203, P439, DOI 10.1126/science.203.4379.439; King HS, 2003, SOAP COSMET, V79, P30; MacAyeal DR, 2003, J GLACIOL, V49, P22, DOI 10.3189/172756503781830863; MERCER JH, 1978, NATURE, V271, P321, DOI 10.1038/271321a0; Morris EM, 2003, ANTARCT RES SER, V79, P61; Nicholls KW, 2003, J GEOPHYS RES-OCEANS, V108, DOI 10.1029/2002JC001713; NORRIS RD, 1998, GEOSCI J, V2, P88; Pahnke K, 2003, SCIENCE, V301, P948, DOI 10.1126/science.1084451; Pudsey CJ, 2001, GEOLOGY, V29, P787, DOI 10.1130/0091-7613(2001)029<0787:FSOASI>2.0.CO;2; Rignot E, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020697; Scambos T, 2003, ANTARCT RES SER, V79, P79; Scambos TA, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020670; SCAMBOS TA, 2001, J GLACIOL, V154, P516; SCHEIDER WA, 1979, WATER AIR SOIL POLL, V12, P171, DOI 10.1007/BF01047121; Shepherd A, 2003, SCIENCE, V302, P856, DOI 10.1126/science.1089768; Vaughan DG, 1996, NATURE, V379, P328, DOI 10.1038/379328a0	29	224	233	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 4	2005	436	7051					681	685		10.1038/nature03908	http://dx.doi.org/10.1038/nature03908			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	951XA	16079842				2022-12-28	WOS:000230964500039
